<SEC-DOCUMENT>0001387131-14-000771.txt : 20140305
<SEC-HEADER>0001387131-14-000771.hdr.sgml : 20140305
<ACCEPTANCE-DATETIME>20140305171047
ACCESSION NUMBER:		0001387131-14-000771
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140305
DATE AS OF CHANGE:		20140305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		14670188

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123113.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="text-align: left; text-indent: 0pt; font: 12pt Wingdings; vertical-align: top; width: 5%"><FONT STYLE="font: 12pt Wingdings 2">S</FONT></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-size: 12pt; vertical-align: bottom; font-weight: bold; width: 90%"><FONT STYLE="font-size: 12pt">ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF        THE SECURITIES EXCHANGE ACT OF 1934</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0pt; font-weight: bold"><B>For the fiscal year
ended December 31, 2013</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B><B>Commission File Number 000-16731</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>TherapeuticsMD, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Exact Name of Registrant as Specified in
Its Charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Nevada</b></font></td>
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>87-0233535</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>(State or Other Jurisdiction of<BR>
 Incorporation or Organization)</i></font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>(I.R.S. Employer Identification No.)</i></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>6800 Broken Sound Parkway NW&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Third Floor&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Boca Raton, Florida 33487&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(561) 961-1900&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Address, including zip code, and telephone
number,&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>including area code, of Principal Executive
Offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Title of
        Each Class</b></P></td>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><b>Name of
        Each Exchange on Which Registered</b></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Common Stock, par value $0.001 per share</font></td>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">NYSE MKT</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in"><B>Securities registered
pursuant to Section 12(g) of the Act: </B>None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </FONT><FONT STYLE="font-family: Times New Roman">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Times New Roman">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </FONT><FONT STYLE="font-family: Times New Roman">&#9744;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Times New Roman">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes </FONT><FONT STYLE="font-family: Times New Roman">&#9746;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </FONT><FONT STYLE="font-family: Times New Roman">&#9746;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
No </FONT><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be
contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. </FONT><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act. (Check one):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Calibri, Helvetica, Sans-Serif">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp;&nbsp;</font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Accelerated filer </font><FONT STYLE="font-family: Times New Roman">&#9746;</FONT></td>
    <TD STYLE="width: 10%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;Non-accelerated filer </font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD STYLE="font-size: 10pt; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company </font><FONT STYLE="font-family: Times New Roman">&#9744;</FONT></td>
    <TD>&nbsp;</TD></tr>
<tr>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller reporting company)</font></td>
    <TD STYLE="padding-bottom: 12pt; font-size: 12pt; text-align: justify"></td>
    <TD>&nbsp;</TD></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;Yes&nbsp;<FONT STYLE="font-family: Times New Roman">&#9744;</FONT>&nbsp;&nbsp;No&nbsp;<FONT STYLE="font-family: Times New Roman">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The aggregate market value
of common stock held by nonaffiliates of the registrant (91,907,740 shares) based on the closing price of the registrant&rsquo;s
common stock as reported on NYSE MKT on June&nbsp;28, 2013, which was the last business day of the registrant&rsquo;s most recently
completed second fiscal quarter, was $278,462,272. For purposes of this computation, all officers, directors, and 10% beneficial
owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers,
directors, or 10% beneficial owners are, in fact, affiliates of the registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of March 3, 2014,
there were outstanding 145,017,060 shares of the registrant&rsquo;s common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Documents Incorporated by Reference</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Portions of the registrant&rsquo;s
definitive Proxy Statement for its 2014 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual
Report on Form 10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120
days of the registrant&rsquo;s fiscal year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ANNUAL REPORT ON FORM 10-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fiscal Year Ended December 31, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; MARGIN: 0px"></P>
<P STYLE="text-align: center; text-indent: 0pt; margin: 0px; font: 10pt Times New Roman, Times, Serif"></P>
<P STYLE="margin: 0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A001">PART
      I</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; width: 10%; font-family: Times New Roman, Times, Serif"><A HREF="#A002">Item
      1.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; width: 80%; font-family: Times New Roman, Times, Serif"><A HREF="#A002"><I>Business</I></A></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; width: 5%; font-family: Times New Roman, Times, Serif; vertical-align: bottom">1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A003">Item
      1A.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A003">Risk Factors</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">25</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A004">Item
      1B.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A004">Unresolved Staff
    Comments</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">46</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A005">Item
      2.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A005">Properties</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">46</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A006">Item
      3.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A006">Legal Proceedings</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">46</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A007">Item
      4.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A007">Mine Safety
    Disclosures</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">46</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A008">PART
      II</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A009">Item
      5.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A009">Market for the
    Registrant&rsquo;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">47</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A010">Item
      6.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A010">Selected Financial
    Data</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A011">Item
      7.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A011">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">50</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A012">Item
      7A.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A012">Quantitative
    and Qualitative Disclosures about Market Risk</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">60</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A013">Item
      8.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A013">Financial Statements
    and Supplementary Data</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">60</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A014">Item
      9.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A014">Changes in and
    Disagreements with Accountants on Accounting and Financial Disclosure</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">60</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A015">Item
      9A.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A015">Controls and
    Procedures</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">60</TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A015a">Item 9B.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><P STYLE="margin: 0"><I><A HREF="#A015a">Other
                                         Information</A></I></P>


</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A016">PART
      III</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A017">Item
      10.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A017">Directors, Executive
    Officers, and Corporate Governance</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A018">Item
      11.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A018">Executive Compensation</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A019">Item
      12.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A019">Security Ownership
    of Certain Beneficial Owners and Management and Related Stockholder Matters</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A020">Item
      13.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A020">Certain Relationships
    and Related Transactions, and Director Independence</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A021">Item
      14.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A021">Principal Accountant
    Fees and Services</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A022">PART
      IV</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><A HREF="#A023">Item
      15.</A></TD>
    <TD STYLE="text-align: left; text-indent: 0pt; font-family: Times New Roman, Times, Serif"><I><A HREF="#A023">Exhibits and
    Financial Statement Schedules</A></I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0pt; font-family: Times New Roman, Times, Serif; vertical-align: bottom">62</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">vitaMedMD<SUP>&reg;</SUP>,
TherapeuticsMD<SUP>&reg;</SUP>, and BocaGreenMD<SUP>&reg;</SUP> are registered trademarks of our company. This Annual Report
also contains trademarks and trade names of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report
includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys,
government agency sources, filings of public companies in our industry, and internal company surveys. Industry publications
and surveys generally state that the information contained therein has been obtained from sources believed to be reliable.
Although we believe the foregoing industry and market data to be reliable at the date of the report, this information could
provide to be inaccurate as a result of a variety of matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Statement Regarding Forward-Looking Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">This Annual Report on Form
10-K contains forward-looking statements that involve substantial risks and uncertainties. For example, statements regarding our
operations, financial position, business strategy, product development, and other plans and objectives for future operations, and
assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales
are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &ldquo;Business&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; as well as in this
Annual Report generally. These statements are generally accompanied by words such as &ldquo;intend,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;potential(ly),&rdquo; &ldquo;continue,&rdquo; &ldquo;forecast,&rdquo; &ldquo;predict,&rdquo;
&ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
or the negative of such terms or other comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have based these forward-looking
statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected
in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure
you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently
be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual
results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that
could cause or contribute to such differences include, but are not limited to, research and product development uncertainties,
regulatory policies and approval requirements, competition from other similar businesses, market and general economic factors,
and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated
financial statements and notes thereto included in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have identified some of
the important factors that could cause future events to differ from our current expectations and they are described in this Annual
Report in the section entitled &ldquo;Risk Factors&rdquo; that you should review carefully. Please consider our forward-looking
statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize,
or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake,
and specifically decline any obligation to update any forward-looking statements or to publicly announce the results of any revisions
to any statements to reflect new information or future events or developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="A001"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="A002"></A>Item 1.&#9;<I>Business</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Our Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are a women&rsquo;s health
care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused
on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical
products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health
risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing
these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating
equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products.
Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability
alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well
as over-the-counter, or OTC, vitamins and cosmetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have obtained U.S. Food
and Drug Administration, or FDA, approval of our Investigational New Drug, or IND, applications to conduct clinical trials for
four of our hormone therapy drug candidates: TX&nbsp;12-001HR, our oral combination of progesterone and estradiol; TX&nbsp;12-002HR, our oral
progesterone alone; TX&nbsp;12-003HR, our oral estradiol alone; and TX&nbsp;12-004HR, our suppository estradiol alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Hormone Therapy Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The menopause hormone therapy
market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies.
On November 27, 2013, the Drug Quality and Security Act became law and the FDA was given additional oversight over compounding pharmacies.
We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically
referred to as bioidenticals, when produced and sold by compounding pharmacies are not monitored or easily measured. We estimate
the non-FDA approved compounded bioidentical hormone therapy combination sales of estradiol and progesterone products sold by compounding
pharmacies approximate $1.5 billion per year and the FDA-approved market approximates $625 million per year. Our phase 3 trials
are intended to establish an indication of the safety and efficacy of our bioidentical drug candidates at specific dosage levels.
We intend our hormone therapy drug candidates, if approved, to provide hormone therapies with well characterized safety and efficacy
profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved
compounded bioidentical market. This is based on our belief that our drug candidates will offer advantages in terms of demonstrated
safety and efficacy consistency in the hormone dose, lower patient cost as a result of insurance coverage, and improved access
as a result of availability from major retail pharmacy chains than custom order or formulation by individual compounders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Pipeline of our Hormone Therapy Drug Candidates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-001HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-001HR, our combination
estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms
due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal dryness, for post-menopausal women with
an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&rsquo;s
body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen
and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time
a combination product of estradiol and progesterone the biologically identical or bioidentical to the estradiol and progesterone
produced by the ovaries, would be approved for use in a single combined product. According to Source Healthcare Analytics, the
total FDA-approved market for menopause-related combination estrogen/progestin was approximately $625 million in U.S. sales for
the 12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-002HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-002HR is a natural
progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut
oil. The product would be chemically identical to the hormones that naturally occur in a woman&rsquo;s body. We believe it
will be similarly effective to traditional treatments, but may be effective at lower dosages. According to Source
Healthcare Analytics, the total FDA-approved market for oral progestin was approximately $364 million in U.S. sales for the
12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-003HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-003HR is a natural estradiol
formulation. This hormone therapy drug candidate would be chemically identical to the hormones that naturally occur in a woman&rsquo;s
body. We currently do not have plans to further develop this hormone therapy drug candidate. According to Source Healthcare Analytics,
the total FDA-approved market for oral estradiol was approximately $130 million in U.S. sales for the 12 months ended December&nbsp;31,
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX-12-004HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-004HR is a vaginal suppository
estradiol drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings
that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments
for VVA because of an early onset of action with less systemic exposure inferring a greater probability of dose administration
to the target tissue and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments.
According to Source Healthcare Analytics, the total FDA-approved market for VVA treatment was approximately $1 billion in U.S.
sales for the 12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Preclinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Based upon
leveraging our hormone platform technology, we have seven preclinical projects that include development of our proposed
combination estradiol and progesterone and progesterone-alone products in a topical cream and transdermal patch form. We plan
to advance these projects into the next stages of development as financial and personnel resources become available. We are
also evaluating various other indications for our hormone technology, including oral contraception, treatment of preterm
birth, and premature ovarian failure. According to South Healthcare Analytics, the total FDA-approved menopause-related
market for estrogen alone and in combination was approximately $3.3 billion in U.S. sales for the 12 months ended December
31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Current Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As we continue the clinical
development of our hormone therapy drug candidates, we continue to market our prescription and over-the-counter dietary supplement
and cosmetic product lines, consisting of prenatal vitamins, iron supplements, vitamin D supplements, natural menopause relief
products, and cosmetic stretch mark creams under our vitaMedMD<SUP>&reg;</SUP> brand name and duplicate formulations of our prescription
prenatal vitamin products, also referred to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD<SUP>&reg;</SUP> Prena1&trade;
name. All of our prenatal vitamins are gluten-, sugar-, and lactose-free. We believe our product attributes result in greater consumer
acceptance and satisfaction than competitive products while offering the highest quality and patented ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Industry and Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Health Care and Pharmaceutical
Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">According to EvaluatePharma&reg;
World Preview report, the pharmaceutical industry experienced an unprecedented decline in worldwide prescription drug sales in
2012. Worldwide prescription drug sales fell by 1.6% to $714 billion in 2012, with the United States representing about 36% of
the market. Loss of patent protection on a number of blockbuster brands and fiscal austerity affecting Eurozone countries (compounded
by a weak euro compared to the dollar) contributed to this unprecedented contraction. In total, $38 billion of sales were lost
as a result of expired patent protection, including drugs such as Lipitor and Plavix. According to the report, this anomaly is
not expected to continue and sustained sales growth should start returning at the end of 2013 at an average rate of 3.8% per annum
between 2012 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In terms of numbers of new
drug approvals in the United States, 2012 was the best year since 1997 when the Pfizer drug, Lipitor, was approved. But perhaps
more important than the large number of approvals in 2012 (45 versus 35 in 2011), quality was also significantly better than in
previous years, as judged by analysts&rsquo; consensus expectations of sales five-year post launch. Looking ahead, EvaluatePharma
expects this positive dynamic to continue, with 2013 being another good year for new drug approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Women&rsquo;s Health Care
Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">According GBI Research (a
provider of industry-leading business intelligence solutions on a global basis) report &ldquo;Women&rsquo;s Health Therapeutic
Market through 2018&rdquo;, the women&rsquo;s health therapeutics market is one of the most attractive markets in the global pharmaceutical
industry. Hormone therapy, gynecological disorders, and musculoskeletal disorders in women are the prime areas of focus in the
women&rsquo;s health therapeutics market. The women&rsquo;s health therapeutics market in the United States was valued at $12.5
billion in 2011. Revenues are projected to increase to $15.1 billion in 2018 at a compound and growth rate of 2.7%. This can be
attributed to the launch of new drug molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Hormone Therapy Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Menopause is the spontaneous
and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. It is defined as the
final menstrual period and is confirmed when a woman has not had her period for 12 consecutive months. Hormone therapy is the only
government-approved treatment in the United States and Canada for relief of menopausal symptoms. These symptoms are caused by the
reduced levels of circulating estrogen as the ovarian production shuts down. The symptoms include hot flashes, night sweats, sleep
disturbances, and vaginal dryness. According to Source Healthcare Analytics, prescriptions for hormone therapy products for the
treatment of menopause symptoms or prevention of osteoporosis generated total sales of over $3.8 billion on over 36 million prescriptions
for the 12 months ended December 31, 2013. Oral hormone therapy accounted for $1.8 billion on 23 million prescriptions over the
same time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Prescriptions for menopausal
hormone therapy in the United States dropped significantly following the Women&rsquo;s Health Initiative, or WHI, study in 2002
that found that subjects using estrogen plus synthetic progestin had, among other things, a greater incidence of coronary heart
disease, breast cancer, stroke, and pulmonary embolism. A number of additional studies regarding the benefits and risks of hormone
therapy have been conducted over the last decade since the WHI results were first published. In general, recommendations for hormone
therapy use are to be judged on an individual basis, and the FDA recommends that women with moderate to severe menopausal symptoms
who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">There were approximately 41.7
million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly (2.8%) to 42.9 million
in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures. These women are the
target market for hormone therapy to treat menopausal related symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Hormone Therapy Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Estrogen (with
or without a progestin) is the most effective treatment for menopause-related vasomotor symptoms according to the North
American Menopause Society, or NAMS. Sales of total oral, transdermal and suppositories for Estrogen (with and without
a progestin) hormone therapy products were approximately $3.3 billion for the 12 months ended December 31, 2013. That was up
approximately 7% over the comparable time period from the prior year according to Source Healthcare Analytics. The three
primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a
variety of forms, including oral tablets or capsules, skin patches, gels, emulsion, or vaginal suppositories and creams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Estrogen-Only Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Estrogen therapies are used
for vasomotor symptoms (hot flashes and night sweats) of menopause that are a direct result of the decline in estrogen levels associated
with ovarian shutdown at menopause. Estrogen therapy has been used to manage these symptoms for more than 50 years. Estrogen is
a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such
as estradiol. Based upon the age demographic for all women receiving prescriptions for estrogen therapy and the average age range
during which women experience vasomotor symptoms, we believe that estrogen is primarily used for the treatment of vasomotor symptoms,
but also prescribed for the prevention of osteoporosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Estrogen-only therapy, or
ET, is used primarily in women who have had a hysterectomy and are undergoing a surgical menopause, as those women do not require
a progestin to protect the uterine endometrium from proliferation. Approximately 600,000 women undergo a hysterectomy each year
in the United States according to the United States Centers for Disease Control and Prevention. Sales of ET were approximately
$2.7 billion for the 12-month period ended December 31, 2013, according to Source Healthcare Analytics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">ET is also used for vulvar
and vaginal atrophy, which has a variety of indications, including vaginal dryness, vaginal itching and irritation, painful intercourse,
painful urination, and other symptoms. Sales of ET for vulvar and vaginal atrophy were approximately $1 billion for the 12-month
period ended December 31, 2013, according to Source Healthcare Analytics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Estrogen therapy is approved
for the prevention of osteoporosis. Multiple studies conducted on various estrogen compositions, including studies published in
the Journal of the American Medical Association in 2002, Osteoporosis International in 2000, The Lancet in 2002, Maturitas in 2008,
and Climacteric in 2005, demonstrated efficacy based on increases in bone mineral density. Epidemiological and some fracture prevention
studies, such as the study published in the New England Journal of Medicine in 1980, also have demonstrated a decrease in bone
fractures as a result of estrogen therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Progestin-Only Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Progestins include the naturally
occurring hormone progesterone and a number of synthetic progestin compounds that have progestational activity. These agents are
used for a variety of indications and conditions, but most often, progestins are used either alone or in combination with an estrogen
for hormonal contraception and to prevent endometrial hyperplasia from unopposed estrogen in hormone therapy. Progestins alone
are also used to treat women with secondary amenorrhea in order to create withdrawal bleeding in these women who have not had regular
menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis. Progesterone has also been used to
prevent threatened or recurrent pregnancy loss and for the prevention of preterm birth. Progestins have also been used in fertility
treatments. Progestins have also been used as a palliative measure for metastatic endometrial carcinoma and in the treatment of
renal and breast carcinoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Estrogen/Progestin Combination
Products</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Progestins are used in
combination with estrogen in post-menopausal women with uteruses to avoid an increase in the incidence of endometrial
hyperplasia. This is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an
increased incidence of uterine, or endometrial, cancer. Studies have shown that, after one year, the incidence of endometrial
hyperplasia is less than 1% in women taking estrogen/progestin combinations, in contrast to up to 20% in women taking
estrogen alone. In accordance with FDA recommendations, doctors typically recommend that a menopausal or post-menopausal
woman who has a uterus take estrogen plus a progestin, either as a combination drug or as two separate drugs. Source
Healthcare Analytics estimates that sales of FDA-approved estrogen/progestin combinations were approximately $625 million in
the United States for the 12-month period ended December31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Limitations of Existing
Estrogen/Progestin Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The most commonly prescribed
progestin is a synthetic progestin (medroxyprogesterone acetate), which can cause some women to experience painful vaginal bleeding,
breast tenderness, and bloating and may reduce cardio-protective benefits potentially associated with estrogen therapy by limiting
the estrogen&rsquo;s ability to raise HDL cholesterol and LDL cholesterol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">A widely prescribed naturally
occurring progesterone is known as Prometrium<SUP>&reg;</SUP> (progesterone USP), sold by AbbVie Inc., a spinoff of Abbott Laboratories.
Natural progesterone is used in combination with estrogen for hormone therapy; however, we believe there are currently no FDA-approved
hormone therapy combination products with natural progesterone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Prenatal Vitamin Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">According to the American
Pregnancy Association, approximately six million women become pregnant each year, resulting in approximately four million births.
Of these women, over 75% receive prenatal care during the first trimester, and most doctors encourage taking a prenatal vitamin
as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy
and during postnatal lactation that provide nutrients recognized by the various health organizations as helpful for a healthy pregnancy
outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">There are hundreds of prenatal
vitamins available, with both prescription and OTC (non-prescription) choices. According to Source Healthcare Analytics, there
were approximately 7.7 million prescriptions for prenatal vitamins sold for a total of approximately $314 million for the 12 months
ended July 31, 2013, with sales between branded and generic products split nearly evenly. According to the 2012 Gallup Target Market
Report on Prenatal Vitamins, supplement use has been fairly constant overall between 2008 and 2011. However, shifts have occurred
in terms of types used, with the trend toward OTC prenatal vitamins and away from prescription prenatal vitamins. During this same
period, the use of OTC products surpassed the use of prescription products, largely driven by increased use among women currently
pregnant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Business Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are a women&rsquo;s health
care product company focused on creating and commercializing products targeted exclusively for women, including products specifically
for pregnancy, childbirth, nursing, pre-menopause, menopause, and post-menopause. We intend to use our current prescription and
over-the-counter dietary supplement and cosmetic product lines, consisting of prenatal vitamins, iron supplements, vitamin D supplements,
natural menopause relief products, and stretch mark creams, as the foundation of our business platform. If approved and commercialized,
our hormone therapy drug candidates will allow us to enter the $3.8&nbsp;billion hormone therapy market, based on 2013 total sales
of the hormone therapy market, according to Source Healthcare Analytics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our current product line is
marketed and sold by a direct national sales force that calls on health care providers in the OB/GYN market space, as well as through
our website to consumers who have been referred to our website by physicians. We market our prescription prenatal vitamins, over-the-counter
dietary supplements, and other products under our vitaMedMD brand name and duplicate formulations of our prescription prenatal
vitamin products, also referred to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD brand name. We believe that our
vitaMedMD brand name has become a recognized name for high quality women&rsquo;s health care, while our BocaGreenMD products provide
physicians, women, and payors with a lower cost alternative for prenatal supplements. We intend to leverage our existing relationships
and distribution system to introduce our hormone therapy drug candidates, if approved, which will enable us to provide a comprehensive
line of women&rsquo;s health care products all under one brand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our sales model focuses on
the &ldquo;4Ps&rdquo;: patient, provider, pharmacist, and payor. We market and sell our current dietary supplement and cosmetic
products primarily through a direct national sales force of approximately 30 full-time professionals that calls on health care
providers in the OB/GYN market space as well as through our website directly to consumers. In addition, our products allow health
care providers to offer an alternative to patients to meet their individual nutritional and financial requirements related to co-payment
and cost-of-care considerations and help patients realize cost savings over competing products. We also believe that our combination
of branded, generic, and over-the-counter lines offers physicians, women, and payors cost-effective alternatives for top-quality
care. We supply our prescription dietary supplement products to consumers through retail pharmacies. We market our over-the-counter
products either directly to consumers via our website and phone sales followed by direct shipment to their homes or offices or
through physicians who then re-sell them to their patients. Our fully staffed customer care center uses current customer relationship
management software to respond to health care providers, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails,
and live-chat. We also facilitate repeat customer orders for our non-prescription products through our website&rsquo;s auto-ship
feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As health care becomes increasingly
consumer driven, patients are seeking more information, control, and convenience, which places additional time and financial pressures
on physicians, and as a result, physicians are looking for improved ways to provide better service to their patients. A recent
study by IMS Health Inc. concluded that physicians desire fewer but more encompassing relationships with companies that can provide
more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients.
Our goal is to meet this challenge by focusing on the opportunities in women&rsquo;s health, specifically the OB/GYN market, to
provide a better customer experience for physician, payor, and patient through the following means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">We believe we will offer physicians a comprehensive product line of women&rsquo;s health care products,
including our hormone therapy drug candidates, if approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Our hormone therapy drug candidates are designed to use the lowest effective dose for the shortest
duration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">We believe the attributes of our dietary supplements will result in greater consumer acceptance and
satisfaction than competitive products while offering the highest quality products incorporating patented ingredients, such as
Quatrefolic&reg;, chelated iron, FOLMAX&trade;, FelPlus&trade; , and pur-DAH&trade;. All of our prenatal vitamins are gluten-sugar-and lactose-free.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">We strive to improve our existing products and develop new products to generate additional revenue
through our existing sales channels.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">We believe health care providers are able to offer alternatives to patients that meet the patient&rsquo;s
individual nutritional and financial requirements and help patients realize cost savings over competing products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Health care provider practices that choose to dispense our OTC products directly to their patients
through their offices could earn revenue from the sale of the products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Improved patient education, a high level of patient compliance, and reduced cost of products all result
in lower cost of care for payors and improved outcomes for patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our goal is to become the
women&rsquo;s health care company recommended by health care providers to all patients by becoming the new standard in women&rsquo;s
health with a complete line of products, all under one quality brand. Key elements of our strategy to achieve this goal are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Exclusive Focus on Women&rsquo;s
Health Issues</I>. We plan to focus exclusively on women&rsquo;s health issues to enable us to build long-term relationships with
women as they move through their life cycles of birth control, pregnancy, child birth, and pre- and post- menopause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Focus on Hormone Therapy
Products</I>. We plan to focus on the development, clinical trials, and commercialization of hormone therapy products designed
to (1) alleviate the systems of and reduce the health effects resulting from menopause-related hormone deficiencies, including
hot flashes, osteoporosis, and vaginal dryness, and (2) demonstrate equivalent clinical efficacy at lower doses, enabling an enhanced
side effect profile compared with competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Penetrate Bioidentical
Market with FDA-approved Products</I>. As we are not aware of any current FDA-approved bioidentical hormone therapy combination
products, we believe that our hormone therapy drug candidate for combined estradiol and progesterone, if approved by the FDA, will
provide a safer and more effective alternative to non-FDA approved compounded bioidentical hormone therapy products, at a lower
price to patients due to insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Marketing Emphasis</I>.
We plan to maintain an emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that
are receptive to the data and savings we provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Multiple Distribution Channels</I>.
We are pursuing multiple distribution channels, including physicians and pharmacies, through our sales force and our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Geographical Expansion</I>.
We plan to expand our geographic market and sales team to cover the entire country by increasing our current 36 sales territories
to 60 sales territories in the next 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Introducing New Products</I>.
We plan to introduce a new prescription prenatal vitamin product under our branded vitaMedMD name and our generic Prena1 name in
the first quarter of 2014, as well as the development of our hormone therapy drug candidates consisting of a (1) bioidentical oral
combination of progesterone and estradiol product, (2) an oral progesterone product, and (3) a suppository vulvar and vaginal atrophy
estradiol product. Early pharmacokinetic, or PK, studies of our combination estradiol and progesterone drug candidate demonstrate
that the product is bioequivalent to the reference listed drug (based on the criterion that the 90% confidence interval on the
test-to-reference ratio is contained entirely within the interval 0.800 to 1.250).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Current Product Lines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We offer a wide range of products
targeted for women&rsquo;s health specifically associated with pregnancy, child birth, nursing, post-child birth, and menopause,
including prescription and over-the-counter prenatal vitamins, iron supplements, vitamin D supplements, natural menopause relief
products, and stretch mark creams under our vitaMedMD brand name and duplicate formulations of our prescription prenatal vitamin
products, referred to as &ldquo;generic&rdquo; formulations, under our BocaGreenMD Prena1 name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In March 2012, we launched
our first prescription-only prenatal vitamin, vitaMedMD Plus Rx, with subsequent launches of our second prescription-only prenatal
vitamin, vitaMedMD One Rx, in April 2012 and our third prescription-only prenatal vitamin, vitaMedMDRediChew&trade;, Rx in May
2012. In the fourth quarter 2012, our BocaGreenMD Prena1 line brand was launched and our first products include three prescription
products Prena1 Plus, Prena1, and Prena1 Chew, which are duplicate, or &ldquo;generic&rdquo; formulations, of our vitaMedMD-branded
prescription prenatals. In the first quarter of 2014, we will introduce vitaPearl, a prescription prenatal vitamin. This &ldquo;complete
prenatal in one tiny pearl&rdquo; features a unique, proprietary combination of FOLMAX&trade;, FePlus&trade;, and pur-DHA&trade;.
Our product line is detailed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Plus (Prenatal
Women&rsquo;s Multivitamin + DHA&trade;) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD</I> Plus Prenatal
is a once-daily, two pill combo pack that contains a complete multivitamin with 16 essential vitamins and minerals and 300 mg of
plant based DHA, and is Vegan and Kosher certified. Based on recent medical and scientific research, we have optimized many of
the nutrients found in <I>vitaMedMD</I> Plus. All minerals, including iron, zinc, and copper, are chelated to improve absorption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD One Prenatal
Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD</I> One is a
single-dose daily multivitamin that provides 14 vitamins and minerals and 200 mg of vegetarian, plant-based DHA. Each convenient,
easy-to-swallow softgel also features 975 mcg of folic acid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Plus Rx Prenatal
Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Plus Rx</I> is
a once-daily, two pill combo prescription-only product containing one prenatal vitamin tablet with Quatrefolic<SUP>&reg;</SUP>,
the fourth generation folate, and one plant-based DHA 300 mg capsule. Quatrefolic<SUP>&reg;</SUP> is a registered trademark of
Gnosis S.P.A. All minerals, including iron, zinc, and copper, are chelated to improve absorption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD One Rx Prenatal
Multivitamin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD</I> <I>One Rx</I>
is a prescription-only product with a single-dose daily multivitamin that provides 14 vitamins and minerals, Quatrefolic<SUP>&reg;</SUP>,
and 200 mg of plant-based DHA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD RediChew&trade;
Rx Prenatal Multivitamin </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD</I> <I>RediChew</I>&trade;
<I>Rx</I> is a prescription-only, easy-to-chew, small, vanilla-flavored chewable tablet containing Quatrefolic, vitamin D3 to promote
healthy birth weight, vitamin B2 to support bone, muscle, and nerve development, and vitamin B6 and vitamin B12 to help relieve
nausea and morning sickness. We believe <I>vitaMedMD RediChew Rx</I> is an excellent option for women who have difficulty swallowing
tablets or softgels, or are experiencing nausea and morning sickness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Iron 21/7</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Iron 21/7</I>
is an iron replacement supplement with a 3-weeks-on/1-week-off dosing schedule intended to maximize absorption and enhance tolerability.
It is formulated with 150 mg of chelated iron to help improve tolerability and limit typical side effects associated with iron
replacements. Each easy-to-swallow single tablet serving also includes 800 mcg of folic acid, plus vitamins C and B12, and succinic
acid to aid in absorption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Menopause Relief
with Lifenol<SUP>&reg;</SUP> Plus Bone Support</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Menopause Relief
with Lifenol<SUP>&reg;</SUP> Plus Bone Support</I> offers a natural treatment for hot flashes, night sweats, and mood disturbances.
Each single tablet dosage delivers 120 mg of Lifenol<SUP>&reg;</SUP>, a well-studied female hops extract recognized for its potency
and support in alleviating hot flashes, plus plant phytoestrogens. It also includes calcium and vitamin D3 for added bone support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Vitamin D3 50,000
IU and Vitamin D3 2,000 IU</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Vitamin D3 50,000
IU and Vitamin D3 2,000 IU</I> are dietary supplements provided in a small, easy-to-swallow gel capsule that help replenish and
maintain beneficial levels of vitamin D in the body. Sustaining adequate levels of vitamin D in the body is essential to bone health,
enhancing the absorption of calcium and phosphorus. Vitamin D3, also known as cholecalciferol, is considered the most preferred
form of vitamin D as it is the most active form of the nutrient. We believe <I>vitaMedMD</I> <I>Vitamin D3 50,000 IU and Vitamin
D3 2,000 IU</I> are ideal for pregnant, breastfeeding, and menopausal women to sustain adequate levels of vitamin D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Signature Collection
Stretch Mark Body Cream </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>vitaMedMD Signature Collection
Stretch Mark Body Cream</I> contains naturally derived ingredients, including peptides, shea butter, sweet almond oil, and fruit
extracts. This combination of ingredients hydrates, soothes, and pampers skin to make it softer, smoother, and younger-looking.
It helps reduce the appearance of stretch marks, scars, and other skin irregularities by hydrating and replenishing the skin&rsquo;s
moisture, diminishing the look of fine lines and wrinkles, and encouraging the fading of age spots and sun spots. <I>vitaMedMD
Stretch Mark Body Cream</I> is hypoallergenic, paraben-free, and non-comedogenic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1 Plus</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1 Plus</I>
is a prescription-only, comprehensive single-dose dietary supplement containing one prenatal tablet with 16 vitamins and minerals,
plus one softgel with 300 mg of plant-based life&rsquo;s DHA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1</I>
is a prescription-only, convenient single-dose softgel with 14 vitamins, minerals and 200 mg of plant-based DHA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1 Chew</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>BocaGreenMD Prena1 Chew</I>
is a prescription-only, single daily easy-to-chew, vanilla-flavored, chewable tablet well-suited for women planning a pregnancy
and those with difficulty swallowing tablets or capsules or when nausea or morning sickness make taking tablets or capsules difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">All <I>BocaGreenMD</I> Prena1
multivitamins contain a combination of folic acid and Quatrefolic and are available by prescription only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Hormone Therapy Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have obtained FDA
approval of our IND applications to conduct clinical trials for four of our proposed products: TX 12-001HR, our oral
combination of progesterone and estradiol; TX 12-002HR, our oral progesterone alone; TX 12-003HR, our oral estradiol alone;
and TX 12-004HR, our estradiol alone vaginal suppository.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-001HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-001HR, our
combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe
vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal dryness, for
post-menopausal women with an intact uterus. The drug candidate is chemically identical to the hormones that naturally occur
in a woman&rsquo;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen (where the
combination of estrogen and progesterone are taken together in one product daily). If approved by the FDA, we believe this
would represent the first time a combination product of estradiol and progesterone, the biologically identical or
bioidentical to the estradiol and progesterone produced by the ovaries, would be approved for use in a single combined
product. According to Source Healthcare Analytics, the total FDA-approved market for menopause-related
combination estrogen/progestin was approximately $625 million in U.S. sales for the 12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We conducted a PK study of
Therapeutics&rsquo;<I> </I>TX 12-001HR to demonstrate that our drug candidate is bioequivalent to the reference listed drug based
on the criterion that the 90% confidence interval on the test-to-reference ratio is contained entirely within the interval 80%
to 125%. The study compared our combined capsule TX 12-001HR of 2 mg estradiol and 200 mg of progesterone to 2 mg of Estrace<SUP>&reg;</SUP>
and 200 mg of Prometrium<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The study compared the mean
plasma concentrations for free estradiol between TX 12-001HR and Estrace<SUP>&reg;</SUP> in 62 female test subjects. When the results
of a single dose-fed study were compared over 48 hours by the test drug versus reference drug, the ratio was 0.93 with the standard
deviation within the subject being 0.409 for an upper 95% confidence bound of -0.089. The maximum plasma concentration levels of
free estradiol showed drug versus reference drug ratio was 0.88 with the standard deviation within the subject being 0.344 for
an upper 95% confidence bound of -0.040 over 48 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The study also compared the
mean plasma concentrations for progesterone between TX 12-001HR and Prometrium<SUP>&reg;</SUP> in 62 female test subjects. When
the results were compared over 48 hours of the test drug verses reference drug, the ratio was 1.05 with the standard deviation
within the subject being 0.956 for an upper 95% confidence bound of -0.542. The maximum plasma concentration levels of progesterone
showed drug versus reference drug ratio as 1.16 with the standard deviation within the subject being 1.179 for an upper 95% confidence
bound of -0.785 over 48 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We believe these data are
sufficient to demonstrate the bioequivalence of TX 12-001HR to Estrace<SUP>&reg;</SUP> and Prometrium<SUP>&reg;</SUP> based on
the criteria for demonstrating bioequivalence established in connection with the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On September 5, 2013, we began
enrollment of patients in the REPLENISH Trial, a phase 3 clinical trial designed to measure the safety and effectiveness in treating
the symptoms of menopause and protecting the endometrium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-002HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-002HR is a natural
progesterone formulation without the potentially allergenic component of peanut oil. The product would be chemically
identical to the hormones that naturally occur in a woman&rsquo;s body. We believe it will be similarly effective to
traditional treatments, but may demonstrate efficacy at lower dosages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In January 2014, we
began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness in
treating secondary amenorrhea. According to Source Healthcare Analytics, the total FDA-approved market for oral progestin was
approximately $364 million in U.S. sales for the 12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-003HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-003HR is a natural estradiol
formulation. This hormone therapy drug candidate would be chemically identical to the hormones that naturally occur in a woman&rsquo;s
body. We currently do not have plans to further develop this hormone therapy drug candidate. According to Source Healthcare Analytics,
the total FDA-approved market for oral estradiol was approximately $130 million in U.S. sales for the 12 months ended December
31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>TX 12-004HR</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">TX 12-004HR is a
vaginal suppository estradiol drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal
women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be as effective as
the traditional treatments for VVA and that it will have an added advantage of being a simple, easier to use dosage form
versus traditional VVA treatments. In August 2013, we initiated a phase 1 clinical trial for VVA, designed to measure the
effect of TX 12-004HR on certain clinical endpoints, including a study candidate&rsquo;s pH levels, vaginal cytology, and
most bothersome symptom of VVA, out of the symptoms identified in FDA guidance. Based upon our phase 1 results, we believe we
have a rapidly acting product that differs substantially from the reference listed drug Vagifem&reg; sold by Novo Nordisk.
According to Source Healthcare Analytics, the total FDA-approved market for VVA treatment was approximately $1 billion
in U.S. sales for the 12 months ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Preclinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Based upon leveraging our
hormone platform technology, we have seven preclinical projects that include development of our proposed combination estradiol
and progesterone and progesterone-alone products in a topical cream and transdermal patch form. We plan to advance these projects
into the next stages of development as financial and personnel resources become available. We are also evaluating various other
indications for our hormone technology, including oral contraception, treatment of preterm birth, and premature ovarian failure.
According to South Healthcare Analytics, the total FDA-approved menopause-related market for estrogen alone and in combination
was approximately $3.3 billion in U.S. sales for the 12 months ended December 31, 2013.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Sales and Marketing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Although our direct national
sales force is similar to that of a traditional pharmaceutical company in that sales representatives call on OB/GYN practices to
provide education and sampling, we believe our sales representatives are more customer centric in their sales approach by offering
physicians more than just differences in our products from the competition; they are also able to offer an array of partnering
opportunities to promote efficiency and cost savings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our national rollout strategy
has been to focus first on the largest metropolitan areas in the United States. In order to accelerate the sales ramp in a new
territory, we employ a national sales/large practice sales effort to identify key practices in new or expanding markets. Concurrent
with our provider sales effort, we work with commercial insurance payors for partnerships in which the payor can support the prescribing
and/or recommendation of our products for the benefit of patient, physician, and payor with an end result of providing better outcomes
for all three constituents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">At the forefront of our sales
approach is the philosophy that the physician should recommend or prescribe products based only on what is best for the patient.
In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having
an assortment of high-quality product options that can be recommended or prescribed by both the physician and payor is the foundation
of providing valuable options to the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We believe our sales force
has developed strong relationships and partnerships in the OB/GYN market to sell our current products. We have also established
relationships with some of the largest OB/GYN practices their respective markets. By delivering additional products through the
same sales channel, we believe we can leverage our already deployed assets to increase our sales and achieve profitability. We
intend to leverage and grow our current marketing and sales organization to commercialize our drug candidates in the United States
assuming the successful completion of the FDA regulatory process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Online Commerce</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">A vast majority of our over-the-counter
product sales are completed online. The Internet has continued to increase its influence over communication, content, and commerce.
We believe several factors will contribute to this continuing increase, including convenience, expanded range of available products
and services, improved security and electronic payment technology, increased access to broadband Internet connections and widespread
consumer confidence and acceptance of the Internet as a means of commerce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Retail Commerce</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The vast majority of our prescription
product sales are completed through the traditional pharmacy distribution network. Although online and mail order pharmacy commerce
continues to grow, the majority of products are still purchased directly by the consumer locally at traditional stores. As this
division of our business expands, we will continue to employ strategies that help us reduce inefficiencies in this channel and
develop relationships that allow our products to be differentiated from the competition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The pharmaceutical industry
is subject to intense competition and is characterized by extensive research efforts and rapid technological change. Competition
in our industry occurs in a variety of areas, including developing and bringing new products to market before others, developing
new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower
cost, and developing new products to provide benefits superior to those of existing products. There are many companies, including
generic manufacturers, drug compounding pharmacies, and large pharmaceutical companies, that have significantly greater financial
and other resources than we do. In addition, academic and other research institutions could be engaged in research and development
efforts for the indications targeted by our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Seasonality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The specialty pharmaceutical
industry is not subject to seasonal sales fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Products in Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We introduced our branded
prescription products in the first and second quarters of 2012 and introduced our first prescription generic product line in the
fourth quarter of 2012. Our market objective is to develop an entire suite of products that are condition-specific and geared to
the women&rsquo;s health sector. Our focus is to introduce products in which we use proprietary or patented molecules or ingredients
that will differentiate our products from the competition. We currently have numerous products in development, including our hormone
therapy drug candidates as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Raw Materials for Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We acquire all raw materials
and ingredients for our proprietary products from a group of third-party suppliers specializing in raw material manufacturing,
processing, and specialty distribution. Our primary manufacturer maintains multiple supply and purchasing relationships throughout
the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Availability of and Dependence Upon Suppliers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We currently obtain approximately
98% of our vitaMedMD products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer
specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and
functional foods in the dietary supplement category. As a result, we are dependent on Lang for the manufacture of most of our products.
We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. Although we anticipate
continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services.
We have experienced no difficulties in obtaining the products we need in the amounts we require and do not anticipate those issues
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Manufacturing of Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our vitamin products are manufactured
in accordance with FDA&rsquo;s current Good Manufacturing Practice, or cGMPs, for dietary supplements. In addition, we employ an
outside third party to enforce rigorous quality audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">All of our manufacturing is
performed by third-party manufacturers. In addition to manufacturing substantially all of our products, Lang also provides a variety
of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review,
and packaging production. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang
as our third-party manufacturer for most of our products. In the event our relationship with Lang terminates for any reason, there
are a number of other manufacturers available to us. Accordingly, we do not believe that such termination would have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We use third-party manufacturers
to source key raw materials and manufacture and package our products. The FDA must approve the manufacturing facility for compliance
with the FDA&rsquo;s cGMP regulations before a New Drug Application, or NDA, for a new drug is approved. Accordingly, we intend
to engage only those third-party contract manufacturers that have consistently shown the ability to satisfy these requirements
for our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Quality Control for Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">A quality assurance team establishes
process controls and documents and tests every stage of the manufacturing process to ensure we meet product specifications and
that our finished dietary supplements contain the correct ingredients, purity, strength, and composition in compliance with FDA
regulations. We test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards,
including quantitative and qualitative assay and microbial and heavy metal contamination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our manufacturers&rsquo; quality
and production standards are designed to meet or exceed current FDA regulations. To ensure the highest quality, our manufacturing
operations are audited by AIB International, Inc., or AIB, among others, for independent cGMP certification. AIB is an independent,
not-for-profit organization that offers programs and services to augment and support the work of regulatory officials around the
country, including standards development, product testing and certification, and onsite audits and inspections. The manufacturing
facilities we primarily use are also ISO 9001 certified, which is a family of standards related to quality management systems and
are designed to help organizations ensure they meet the needs of customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Distribution of our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We use a variety of distribution
channels dependent upon product type. We sell our prescription dietary supplement products to patients through their pharmacies.
Since the launch of our prescription products, in addition to third-party logistics providers, we use some of the same national
and regional distributors as other pharmaceutical companies, including Cardinal, McKesson, AmerisourceBergen, H.D. Smith, and Smith
Drug. Wholesaler product inventory is monitored daily and sales out is monitored weekly. National and regional retail chain pharmacies
are also an area of focus to make sure our products are purchased and dispensed properly. We sell our OTC products directly to
consumers via our website and phone sales and the products are shipped directly from us to the consumer&rsquo;s home or office.
In a few instances, we sell OTC product to physicians who then sell the products directly to their patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Customer Service </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our goal is 100% customer
satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal,
we maintain a fully staffed customer care center that uses current customer relationship management software to respond to health
care providers, pharmacies, and consumers and accept orders for non-prescription products via incoming and outgoing telephone calls,
e-mails, and live-chat. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships
and facilitate repeat visits and purchases. We also facilitate repeat customer orders through our auto-ship feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our representatives receive
regular training so that they can effectively and efficiently field questions from current and prospective customers and are also
trained not to answer questions that should be directed to a customer&rsquo;s physician. Having a quality customer care center
allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead
generation, and customer retention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Our Return Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We sell our prescription products
through third-party logistics providers, major distributors, and pharmacies, all of whom may return a product within six months
prior to or after the expiration date of the product. Once customers buy a product from the pharmacy, the product may not be returned.
Non-prescription customers may return or exchange our products for any reason by returning the product within 30 days of receipt.
We will refund the entire purchase price, less shipping. The customer is responsible for the cost of returning the products to
us, except in cases in which the product is being returned because of a defect or an error made in our order fulfillment. If the
purchased product exceeded a 30-day supply, the unused product must be returned to receive the full refund. All unopened OTC products
may be exchanged for different products; the customer will be responsible for the difference in price if the replacement product
is more expensive or we will refund the difference if the replacement product is less expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Quality Guarantee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We proudly stand behind the
quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under
our quality guarantee, we</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">ensure the potency and quality of our vitamin products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">help health care providers and payors by delivering information on patient compliance and satisfaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">provide a 30-day money back guarantee for all of our OTC products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">ensure a safe, secure online shopping experience through our encrypted website.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We value frequent communication
with and feedback from our customers in order to continue to improve our offerings and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">Our product development
programs are concentrated in the area of advanced hormone therapy pharmaceutical products. We engage in programs to provide
alternatives to the non-FDA approved compounded bioidentical market for hormone therapy. Our programs seek to bring new
products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing
hormone therapy alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">We intend our hormone therapy
drug candidates, if approved, to provide an alternative to the non-FDA approved compounded bioidentical market based on our belief
that our drug candidates will offer advantages in terms of proven safety, efficacy, and stability, lower patient cost as a result
of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order
or formulation by individual compounders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">Our research and
development expenses were $13.6 million in 2013, $4.5 million in 2012, and $0.1 million in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our success depends, in part,
on our ability to obtain patents, maintain trade secret protection, and operate without infringing the proprietary rights of others.
Our intellectual property portfolio is one of the means by which we attempt to protect our competitive position. We rely primarily
on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products and to maintain
our competitive position. We are diligently seeking ways to protect our intellectual property through various legal mechanisms
in relevant jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have filed several
provisional patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our hormone therapy
drug candidates. We intend to file additional patent applications when appropriate; however, we may not file any such
applications or, if filed, the patents may not be issued. We hold multiple U.S. trademark registrations and have
numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of
ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all of the
areas in which it is used. Federally registered trademarks have a perpetual life as long as they are maintained and renewed
on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the
trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us
certain benefits in marketing our products. We intend to actively protect our intellectual property with patents, trademarks,
trade secrets, or other legal avenues for the protection of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We intend to aggressively
prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by expiration or otherwise, of any
one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive
and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully
challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter
or discontinue the development of our products or pay licensing fees to take into account patent rights of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">OPERA is our patented information
technology platform used in our business. We believe the deployment of OPERA&trade; and the further development and deployment
of related technology creates a sustainable competitive advantage in clinical development and product improvement. We are actively
filing new patent application, when appropriate, that reflects incremental developments in our technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As we continue to develop
proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine
our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that
will enable us to gain patent protection for these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">While we seek broad coverage
under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor
to avoid infringement claims. In addition, patents expire and we cannot provide any assurance that any patents will be issued from
our pending application or that any potentially issued patents will adequately protect our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceuticals, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and
its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including
federal and state consumer protection laws, laws protecting the privacy of health-related information, and laws prohibiting unfair
and deceptive acts and trade practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Pharmaceutical Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The process required by the
FDA before a new drug product may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">completion or reference of extensive preclinical laboratory tests and preclinical animal studies,
all performed in accordance with the FDA&rsquo;s Good Laboratory Practice, or GLP, regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">submission to the FDA of an IND, which the FDA must allow to become effective before human clinical
trials may begin and must be updated annually;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy
of the drug candidate for each proposed indication; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">submission to the FDA of an NDA after completion of all pivotal clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">An IND is a request for authorization
from the FDA to administer an investigational drug product to humans. We currently have effective INDs for all of our hormone therapy
drug candidates, although we have no current plans to conduct clinical trials for TX 12-003HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Clinical trials involve the
administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with
current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent
for their participation in any clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be
submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&rsquo;s Institutional
Review Board, or IRB, before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements
governing the reporting of ongoing clinical trials and clinical trial results to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Clinical trials are usually
conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety
and find the potential dosing range. After a safe dose has been established, the drug is administered to small populations of sick
patients (Phase 2) to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess
safety. Phase 3 clinical trials are usually multi-center, double-blind controlled trials in hundreds or even thousands of subjects
at various sites to assess as fully as possible both the safety and effectiveness of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FDA, the IRB, or the clinical
trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects
are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified
experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews
unblended data from clinical trials and provides authorization for whether or not a trial may move forward at designated check
points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business
objectives and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Assuming successful completion
of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information
is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application
includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as
well as positive findings, together with detailed information relating to the product&rsquo;s chemistry, manufacturing, controls
and proposed labeling, among other things.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Once the NDA submission has
been accepted for filing, the FDA&rsquo;s goal is to review applications within 10 months of filing. However, the review process
is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application
to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is
not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">After the FDA evaluates the
NDA and conducts inspections of manufacturing facilities in which the drug product will be formulated and its active pharmaceutical
ingredient, or API, will be produced, it may issue an approval letter or, instead, a Complete Response Letter. An approval letter
authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response
Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete
Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant,
expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional
information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could
also approve the NDA with a REMS plan to mitigate risks, which could include medication guides, physician communication plans,
or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and
specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include
Phase 4 clinical trials and surveillance to further assess and monitor the product&rsquo;s safety and effectiveness after commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">After regulatory approval
of a drug product is obtained, we are required to comply with a number of post-approval requirements. As a holder of an approved
NDA, we would be required to report, among other things, certain adverse reactions and production problems to the FDA, to provide
updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any
of our products. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval to ensure and
preserve the long-term stability of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance
with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. In addition, changes to the manufacturing
process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented.
FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We rely, and expect to continue
to rely, on third parties for the production of clinical and commercial quantities of our drug candidates. Future FDA and state
inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt
production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems
with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or
holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial
action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes
to a product&rsquo;s approved labeling, including the addition of new warnings and contraindications, and also may require the
implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation,
may be established, or the FDA&rsquo;s policies may change, which could delay or prevent regulatory approval of our products under
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our hormone therapy drug candidates
may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in
which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored
to the medical needs of an individual patient. The medications created by the compounding pharmacy are technically &ldquo;new drugs&rdquo;
subject to the new drug approval requirements of the FDCA. However, FDA&rsquo;s 2002 Compliance Policy Guide 460.200 states that
FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding
pharmacies act more akin to traditional drug manufacturers. FDA does not exercise the same authority to regulate compounding pharmacies
as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated with
compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>505(b)(2) Applications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We intend to submit NDAs for
our hormone therapy drug candidates, assuming that the clinical data justify submission, under section 505(b)(2) of the FDCA. Section
505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted
by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon published
literature and the FDA&rsquo;s findings of safety and effectiveness based on certain pre-clinical or clinical studies conducted
for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change
from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the
referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. In regards to
TX 12-001HR, we are required to conduct phase 3 studies for vasomotor symptoms versus placebo and an endometrial protection study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Phase 3 clinical trials for
secondary amenorrhea versus placebo will be required for TX 12-002HR. TX&nbsp;12-003HR would be required to undergo phase 3 studies
of vasomotor symptoms compared to placebo, though we currently do not have plans to continue development of this drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As part of our submission,
we intend to certify that all of the patents for approved products referenced in the NDA for each of the hormone therapy drug candidates
as listed in the FDA&rsquo;s Orange Book have expired and that we will not be compelled to certify that any patent is invalid,
unenforceable, or will not be infringed by the new product. If, in fact, this assessment is incorrect, it can have a serious and
significant adverse effect on our ability to obtain FDA approval or market our new product. If we are compelled to certify that
a patent is invalid, unenforceable, or not infringed, then the holder of that patent can initiate a patent infringement suit against
us and the FDA is precluded from approving our product for 30 months or until a court decision or settlement finding that the patent
is invalid, unenforceable or not infringed, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Marketing Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">A 505(b)(2) NDA applicant
may be eligible for its own regulatory exclusivity period, such as three-year exclusivity. The first approved 505(b)(2) NDA applicant
for a particular condition of approval, or change to a marketed product, such as a new extended release formulation for a previously
approved product, may be granted three-year Hatch-Waxman exclusivity if one or more clinical studies, other than bioavailability
or bioequivalence studies, was essential to the approval of the application and was conducted/sponsored by the applicant. Should
this occur, the FDA would be precluded from making effective any other application for the same condition of use or for a change
to the drug product that was granted exclusivity until after that three-year exclusivity period has run. Additional exclusivities
may also apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Additionally, the 505(b)(2)
NDA applicant may have relevant patents in the Orange Book, and if it does, it can initiate patent infringement litigation against
those applicants that challenge such patents, which could result in a 30-month stay delaying those applicants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Dietary Supplement and
Cosmetic Regulation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our currently marketed products
are regulated as dietary supplements and cosmetics. The processing, formulation, safety, manufacturing, packaging, labeling, advertising,
and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal
Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Generally, our nutritional
product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that appear
to have beneficial impact based upon scientific literature and input from physicians; however, we are generally prohibited from
making disease treatment and prevention claims in the promotion of our products that use these formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The Dietary Supplement Health
and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling,
manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United
States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. &ldquo;New&rdquo; dietary ingredients
(<I>i.e.</I>, dietary ingredients that were &ldquo;not marketed in the United States before October 15, 1994&rdquo;) must be the
subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &ldquo;present in the food
supply as an article used for food&rdquo; without being &ldquo;chemically altered.&rdquo; A new dietary ingredient notification
must provide the FDA evidence of a &ldquo;history of use or other evidence of safety&rdquo; establishing that use of the dietary
ingredient &ldquo;will reasonably be expected to be safe.&rdquo; A new dietary ingredient notification must be submitted to the
FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient
notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a
determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification
of new dietary ingredients. FDA guidance is not mandatory and companies are free to use an alternative approach if the approach
satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&rsquo;s
&ldquo;current thinking&rdquo; on the topic discussed in the guidance, including its position on enforcement. The draft guidance
on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the
dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such
action would have material adverse impact on our business and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FDA or other agencies
could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers
that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the
products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated
reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based
in part on such reports, the FDA has issued public warnings to consumers to stop using certain third party dietary supplement products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FDCA permits &ldquo;statements
of nutritional support&rdquo; to be included in labeling for dietary supplements without premarket approval. Such statements must
be submitted to the FDA within 30 days of marketing. Such statements may describe how a particular dietary ingredient affects the
structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body
structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure,
mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific
evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of
nutritional support is an unacceptable drug claim, conventional food claim, or an unauthorized version of a &ldquo;health claim,&rdquo;
or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading,
we would be prevented from using the claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, DSHEA provides
that so-called &ldquo;third-party literature,&rdquo; such as a reprint of a peer-reviewed scientific publication linking a particular
dietary ingredient with health benefits, may be used &ldquo;in connection with the sale of a dietary supplement to consumers&rdquo;
without the literature being subject to regulation as labeling. The literature (1) must not be false or misleading; (2) may not
&ldquo;promote&rdquo; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available
scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements;
and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of
these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject
our product to regulatory action as an illegal drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In June 2007, pursuant to
the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing,
packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose
significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA
is conducting inspections of dietary supplement manufacturers pursuant to these requirements. There remains considerable uncertainty
with respect to the FDA&rsquo;s interpretation of the regulations and their actual implementation in manufacturing facilities.
In addition, the FDA&rsquo;s interpretation of the regulations will likely change over time as the agency becomes more familiar
with the industry and the regulations. The failure of a manufacturing facility to comply with the cGMP regulations renders products
manufactured in such facility &ldquo;adulterated,&rdquo; and subjects such products and the manufacturer to a variety of potential
FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the
manufacturing of dietary ingredients contained in dietary supplements will be subject to similar or even more burdensome manufacturing
requirements, which will likely increase the costs of dietary ingredients and will subject suppliers of such ingredients to more
rigorous inspections and enforcement. The FSMA will also require importers of food, including dietary supplements and dietary ingredients,
to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FDA has broad authority
to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or
Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting
of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice
initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory
powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and
regulatory powers include the FDA&rsquo;s ability to order mandatory recalls, administratively detain domestic products, require
certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke
manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without
judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our cosmetic products, such
as our topical creams, are also subject to regulation by the FDA. Such products and their ingredients do not require premarket
approval prior to sale, but are subject to specific labeling regulations. While the FDA has not promulgated specific cGMPs for
the manufacture of cosmetics, the FDA has provided guidelines for cosmetic manufacturers to follow to ensure that their products
are neither misbranded nor adulterated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FTC exercises jurisdiction
over the advertising of dietary supplements and cosmetics. In recent years, the FTC has instituted numerous enforcement actions
against companies for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading
advertising claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In recent years, the FTC has
instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims
and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent
decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of
consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &ldquo;free&rdquo;
offers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are also subject to regulation
under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing,
packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of
California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any
such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in
California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to
cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against
non-compliant parties and can result in substantial costs and fines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Other U.S. Health Care
Laws and Compliance Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are also subject to additional
health care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal
and state health care laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">The federal health care anti-kickback statute prohibits, among other things, persons from knowingly
and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce
or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which
payment may be made under federal health care programs, such as Medicare and Medicaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">The Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding
regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed
under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial
relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims
to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">The federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or
qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government
claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay
money to the federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil
liability for executing a scheme to defraud any health care benefit program and also imposes obligations, including mandatory contractual
terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">The federal false statements statute prohibits knowingly and willfully falsifying, concealing, or
covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care
benefits, items, or services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply
to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party
payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Efforts to ensure that our
business arrangements with third parties comply with applicable health care laws and regulations could be costly. Although we believe
that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will
conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable
fraud and abuse or other health care laws and regulations. If our past or present operations, including activities conducted by
our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply
to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party
payor programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians,
providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to
criminal, civil, or administrative sanctions, including exclusion from government funded health care programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Many aspects of these laws
have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety
of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations
are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause
us to incur significant legal expenses, divert our management&rsquo;s attention from the operation of our business, and damage
our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, from time to
time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal,
state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such
as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future
laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when
it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products
to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements,
increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation,
additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The growth and demand for
eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers.
These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">There is currently great uncertainty
in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal
privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities
in a number of states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of
companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New
legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our
business, or a change in application of existing laws and regulations to the Internet and commercial online services could result
in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As of December 31, 2013, we
had 69 full-time employees, four of whom are executive officers. Additionally, from time to time, we hire temporary contract employees.
None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We
have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Our History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On October 3, 2011, we changed
our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD, LLC, a Delaware limited liability
company, or VitaMed, pursuant to which (1) all outstanding membership units of VitaMed were exchanged for shares of our common
stock (2) all outstanding VitaMed options and warrants were exchanged and converted into options and warrants to purchase shares
of our common stock, and (3) VitaMed became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMed would
become the sole focus of our company and services previously performed relative to the aforementioned licensing agreement were
discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We were incorporated in Utah
in 1907 under the name Croff Mining Company. Prior to 2008, Croff&rsquo;s operations consisted entirely of oil and natural gas
leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced
its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or
the Exchange Act. As a result of the spin-off, Croff was a &ldquo;shell company&rdquo; under the rules of the Securities and Exchange
Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&rsquo;s Minority Health Network, Inc. as
a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders
of America&rsquo;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to
acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles
of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&rsquo;s Minority
Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011,
we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated
debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum
Health Network for commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are a Nevada corporation.
We maintain our principal executive offices at 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, Florida 33487. Our telephone
number is (561) 961-1900. We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmd.com</I>, <I>www.vitamedmdrx.com</I>,
and <I>www.bocagreenmd.com</I>. The information contained on our websites or that can be accessed through our websites is not incorporated
by reference into this Annual Report or in any other report or document we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We file reports with the SEC,
including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required
by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K, and all amendments to those reports, as soon as reasonably practicable after we electronically file
such material with, or furnish it to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The public may read and copy
any materials we file with, or furnish to, the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington, DC
20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The
SEC maintains an Internet site (<I>www.sec.gov</I>) that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets
forth certain information regarding our executive officers as of December 31, 2013:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-align: center"><B>Name</B></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 6%; border-bottom: Black 1pt solid; text-align: center"><B>Age</B></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 53%; border-bottom: Black 1pt solid; text-align: center"><B>Position</B></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">Robert G. Finizio&#9;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">43</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">John C.K. Milligan, IV&#9;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">51</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: justify">President and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">Daniel A. Cartwright&#9;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">56</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: justify">Chief Financial Officer, Vice President of Finance, and Treasurer</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">Mitchell L. Krassan&#9;</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: center">48</TD>
    <TD>&nbsp;</TD>
<TD STYLE="text-align: justify">Executive Vice President and Chief Strategy Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Robert G. Finizio</I> has
served as Chief Executive Officer and a director of our company since October 2011. As co-founder of VitaMed, Mr.
Finizio served as its Chief Executive Officer and a director from April 2008 to October 2011. Mr. Finizio has 16 years of successful
early stage company development experience in the health care industry. Mr. Finizio co-founded and served from August 2001 to February
2008 as President of Care Fusion, LLC and then as Chief Executive Officer of CareFusion, Inc., which was acquired by Cardinal Health,
Inc. Mr. Finizio&rsquo;s early business experience was with Omnicell, Inc. (formerly known as Omnicell Technologies, Inc.) and
Endoscopy Specialists, Inc. in the healthcare IT and surgical space, respectively. Mr. Finizio earned a B.A. from the University
of Miami.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>John C.K. Milligan, IV</I>
has served as President, Secretary, and a director of our company since October 2011. From December 2008 to October 2011, Mr. Milligan
served as President and Director of VitaMed. Prior to VitaMed, Mr. Milligan co-founded CareFusion, LLC, serving as President and
General Manager from August 2001 to February 2008, and then as President and Chief Operating Officer of CareFusion, Inc. From 1997
to 2001, Mr.&nbsp;Milligan was Vice President, Sales and Operations for Omnicell, Inc., a provider of pharmaceutical supply chain
management systems and services. Prior to Omnicell, Mr. Milligan also held executive management positions at Serving Software Inc.
and HBO &amp; Co., both subsequently acquired by McKesson Corporation. Mr. Milligan is a graduate of the U.S. Naval Academy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Daniel A. Cartwright</I>
has served as Chief Financial Officer, Vice President of Finance, and Treasurer of our company since October 2011. From July 2011
to October 2011, Mr. Cartwright served as Chief Financial Officer of VitaMed. From May 1996 to July 2011, Mr. Cartwright served
as Chief Financial Officer and Executive Vice President of Circle F Ventures, LLC, an Arizona venture capital firm that made investments
in more than 50 companies. During the same period, Mr. Cartwright served as Chief Financial Officer and Treasurer of Fleming Securities,
formerly a registered broker dealer involved with raising capital for public and private companies. From 1993 to 1996, Mr. Cartwright
served as Chief Financial Officer of American Wireless Systems, Inc., a provider of entertainment video services. Mr. Cartwright
currently serves as a member of the board of directors of Primetrica, Inc., a private information research company for the telecommunications
industry, and formerly served on the board of directors of Antenna Technologies Company, Inc. and WEB Corp. Mr. Cartwright earned
his B.S. in Accounting from Arizona State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Mitchell L. Krassan</I>
has served as Executive Vice President and Chief Strategy Officer of our company since October 2011. From April 2010 to October
2011, Mr. Krassan served as Chief Strategy and Performance Officer of VitaMed. Mr. Krassan has been a partner with EquiMark Limited,
a private investment partnership, since October 1997. From November 1994 to July 1997, Mr. Krassan served as Chief Financial Officer
and Chief Operating Officer of The Reich Group/Telespectrum Worldwide, a fully integrated direct marketing firm that provided clients
expertise in market research and analysis, strategic planning, marketing, creative, and production services, telemarketing and
database development. The Reich Group became a leading company in a roll-up and $180 million initial public offering of Telespectrum
Worldwide. Mr. Krassan earned a B.S. in Accounting from University of Maryland, received his certification as a CPA in the state
of Maryland, and earned his M.B.A. in Management from New York University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Non-Executive Officers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Dr. Brian
Bernick</I> has served as Chief Clinical Officer of our company since November 2012 and has served as a director of our
company since October 2011. Dr. Bernick also has served as the Chief Medical Officer of our company from February 2012 until
2013. As co-founder of VitaMed, Dr. Bernick served on VitaMed&rsquo;s board of directors from April 2008. Dr. Bernick is a
practicing and board certified obstetrician/gynecologist with 20 years of clinical medical experience. Dr. Bernick is the
past Chairman of the Department of Obstetrics and Gynecology at Boca Raton Regional Hospital and has served as a member of
its Medical Executive Board. He has served on the board of directors of the Palm Beach Medical Society and VitalMD Group
Holding, LLC, the largest physician-owned and managed group of obstetricians/gynecologists in Florida covering more than 250
physicians/practices. Dr. Bernick is an Associate Professor of Medicine at Florida Atlantic University and provides medical
education in conjunction with Emory University and Florida Atlantic University School of Nursing and Medicine. Dr. Bernick
earned a B.A. in economics from Northwestern University and a doctorate in medicine from the University of Chicago Medical
School. He completed his residency at the University of Pennsylvania.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Julia Amadio </I>has served
as Chief Product Officer of our company since January 16, 2012. Ms. Amadio has a 25-year background in general management and leading
pharmaceutical marketing and product development organizations. From June 2011 to January 2012, Ms. Amadio was President of JMA
Consulting, LLC, her own consulting company that she formed in 2008. From June 2009 to May 2011, she served as Global Vice President
of Marketing for MeadWestvaco Healthcare Division. Previously, Ms. Amadio was President of a start-up, Patients&rsquo; &amp; Consumers&rsquo;
Pharma, in 2007. She was Vice President of Marketing &amp; Marketing Services with Daiichi Pharmaceutical from 2004 to 2006; Vice
President of Aventis Pharmaceutical from 1997 to 2004; Senior Director, New Products Women&rsquo;s Health at Wyeth from 1991 to
1997; and started her career at J&amp;J&rsquo;s McNeil Pharmaceutical. Ms. Amadio is an active member and leader in the Healthcare
Businesswomen&rsquo;s Association. She was an adjunct lecturer at St. Joseph&rsquo;s University in the pharmaceutical MBA program
and authored a chapter on Marketing, Market Research and insights in the book Pharmaceutical Development for Woman (Wiley &amp;
Sons). Ms. Amadio earned a B.S. in Accounting from St. Joseph&rsquo;s University and a Masters in Business Administration from
Drexel University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Dr. Joel
Krasnow</I> has served as the Chief Scientific Officer of our company since December 2013. Dr.&nbsp;Krasnow has 15 years
of pharmaceutical industry experience in clinical development and medical affairs. Mr.&nbsp;Krasnow was Chief Safety Officer
for Intarcia Therapeutics in 2013. From 2010 to 2012, Dr. Krasnow served as Vice-President and Chief Medical Officer of
Eisai Pharmaceuticals, Frontier Business Unit. He led the Actemra&reg; (tocilizumab) and Boniva&reg; (ibandronate
sodium) development teams at Roche Pharmaceuticals, resulting in several global product approvals between 2006 to 2010. From
2004 to 2006, Dr. Krasnow led the global development team at Novartis for Zometa&reg; (zoledronic acid), resulting in multiple
regulatory approvals. Dr. Krasnow&rsquo;s experience as a Medical Director in women&rsquo;s health includes the development
of contraceptive, hormone replacement, and fertility treatments while at Organon. In a medical affairs capacity
at Pharmacia/Pfizer, Dr. Krasnow worked with Activella&reg; (estradiol/norethindrone acetate), Vagifem&reg; (estradiol
vaginal tablets), Depo-Provera (medroxyprogesterone acetate injectable suspension), and Detrol&reg; (tolterodine tartrate).
Dr. Krasnow pursued his residency training in OB-GYN at the University of Chicago; a fellowship in Reproductive
Endocrinology at Baylor College of Medicine; and was on faculty in the Department of Obstetrics, Gynecology and Reproductive
Sciences at the University of Pittsburgh from 1991 to 1996. After receiving a Masters of Business Administration from the
University of Pittsburgh, Dr. Krasnow worked in the healthcare practice at Deloitte Consulting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Dr.
Sebastian Mirkin</I></FONT> has served as the Chief Medical Officer of our company since November 2013. Dr.&nbsp;Mirkin has
more than 15 years of experience and leadership in clinical development and medical affairs in Women&rsquo;s Health in global
pharmaceutical companies. From October 2009 to November 2013, Dr. Sebastian was Clinical Lead and Global Clinical Lead of
Women&rsquo;s Health, Clinical Research at Pfizer. From October 2005 to October 2009, he was Director and Senior Director,
Clinical Research, Women&rsquo;s Health at Wyeth, and from October 2004 to October 2005 was Global Lead Medical Services,
Women&rsquo;s Health at Organon. Dr Mirkin oversaw the development and successful marketing authorization of several novel
medicines, including Duavee&reg;, Conbriza&reg;, Lybrel&reg;, and Premarin Vaginal Cream&reg; in the United States, Europe,
and Japan. Dr. Mirkin holds a Doctor in Medicine degree from National University, Argentina. Trained in Obstetrics/Gynecology,
Dr. Mirkin completed his fellowship in Reproductive Medicine at The Jones Institute of Reproductive Medicine in Norfolk,
Virginia, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Jason Spitz </I>has served
as Vice President - Marketing of our company since December 2011. Mr. Spitz has a 24-year career in marketing, advertising, and
general management experience in pharmaceutical and biopharmaceutical markets. From June 2008 to December 2010, Mr. Spitz served
as Managing Director, Oncology &amp; Hematology at Beacon Healthcare Communications, a company specializing in pharmaceutical and
health care advertising. From September 2004 to June 2008, he served as General Manager, Canada and Commercial Strategy and Development
at MGI Pharma (later acquired by Eisai, Inc.), a company specializing in oncology and cancer supportive care products. From February
2004 to September 2004, he served as Vice President of Marketing and Sales at Aesgen, Inc., a company specializing in cancer products
and drug delivery systems that was acquired by MGI Pharma. Mr. Spitz began his career at Schering Plough as a sales representative,
rising within the organization over 15 years to lead a global pharmaceutical franchise. Mr. Spitz earned his Bachelor of Business
Administration in Marketing from The University of Texas at Austin and his Master of Business Administration in Pharmaceutical
Studies from Fairleigh Dickinson University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Michael Donegan</I> has
served as Vice President &ndash; Finance of our company since April 2013. Mr. Donegan has a 23-year background in accounting and
finance. From August 2012 to April 2013, Mr. Donegan served as an independent consultant exclusively for our company, where he
conceptualized, designed and executed our Sarbanes-Oxley 404 compliance program. From August 2007 to August 2012, Mr. Donegan served
as an independent consultant designing and implementing Sarbanes-Oxley 404 compliance programs for various non-accelerated filers
and executed on pre-designed Sarbanes-Oxley 404 compliance programs for certain large accelerated filers. From January 2005 to
August 2007, Mr. Donegan served as an independent consultant exclusively for Tyco International, where he enhanced and executed
the Sarbanes-Oxley 404 compliance model with their corporate headquarters group. From November 2001 to December 2004, Mr. Donegan
was Manager of Financial Systems at Tyco International at its global headquarters. From 1994 to 2001, Mr. Donegan held various
positions in the global consolidation/SEC Reporting group at Sensormatic Electronics Corporation culminating with the acquisition
of Sensormatic Electronics Corporation by Tyco International in the fall of 2001 when he was the Manager of Financial Systems.
Mr. Donegan began his career at Ernst &amp; Young, LLP where he worked in both the audit and tax departments. Mr. Donegan earned
his Bachelor of Science in Accounting and his Master of Accounting from the University of Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Christian Bloomgren </I>has
served as Vice President - Sales of our company since June 2011. Mr.&nbsp;Bloomgren has 14 years of leadership experience in the
pharmaceutical, bio-technology, and diagnostic industry. From 2005 to 2011, Mr. Bloomgren served as Region Manager at ViaCell,
Inc., a biotechnology company dedicated to enabling the widespread application of human cells as medicine, later acquired by PerkinElmer,
Inc. While at ViaCell, Mr. Bloomgren built a successful national sales channel and helped lead the Specialty Diagnostics business.
From 2000 to 2002, Mr. Bloomgren served as a specialty Account Manager at Eli Lilly &amp; Co. and from 2002 to 2005 as District
Manager at KV Pharmaceutical. Mr.&nbsp;Bloomgren served as an Officer in the United States Air Force and holds a Bachelor of Science
degree from California State University and a Master of Science degree from Troy State University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Marlan Walker </I>has served
as Corporate and Intellectual Property Counsel since June 2013. Mr. Walker&rsquo;s experience is focused in the life science industries,
including long-term portfolio strategy and management, patent preparation and prosecution, contract negotiation and drafting, life-cycle
management, and Hatch-Waxman. After law school, he took a position at Greenberg Traurig LLP in August 2005. In March of 2009, he
moved to Luce Forward Hamilton &amp; Scripps. Mr. Walker accepted an in-house position as Intellectual Property Counsel for Medicis
Pharmaceutical Corp. in June 2011, which was acquired by Valeant Pharmaceutical International, Inc. in December 2012. In February
2013, Mr. Walker accepted a position at Kilpatrick Townsend &amp; Stockton, but chose to move in-house again in June 2013, when
he accepted a position at our company. Mr. Walker graduated from Arizona State University&rsquo;s Sandra Day O&rsquo;Conner College
of Law with his J.D. in 2004, and an LL.M. in Intellectual Property Law at The George Washington University Law School in 2005.
He holds a Master&rsquo;s Degree in Molecular Biology and a Bachelor of Science degree, both earned from Brigham Young University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="A003"></A>Item 1A. <I>Risk Factors</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Investing in our common stock involves a high
degree of risk. You should carefully consider the following risk factors, together with all of the information included in this
Annual Report before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below
are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial,
also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results
of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and
you may lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We have incurred significant operating losses
since inception and anticipate that we will incur continued losses for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have incurred recurring
net losses, including net losses of $28 million, $35, and $13 million for the years ended December 31, 2013, 2012, and 2011, respectively.
As of December 31, 2013, we had an accumulated deficit of approximately $81 million. We have generated limited revenue and have
funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We expect
to incur substantial additional losses over the next several years as our research, development, and clinical trial activities
increase, especially those related to our hormone therapy drug candidates. As a result, we may never achieve or maintain profitability
unless we successfully commercialize our products, in particular, our hormone therapy drug candidates. If we are unable to make
required payments under any of our obligations for any reason, our creditors may take actions to collect their debts, including
foreclosing on our intellectual property that collateralizes our obligations. If we continue to incur substantial losses and are
unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable
prices, refinance existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater
financial resources in a transaction that might be unfavorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our independent registered public accounting
firm, in its audit reports related to our financial statements for the years ended December 31, 2012 and 2011, expressed substantial
doubt about our ability to continue as a going concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As a result of our continued
losses, our independent registered public accounting firm has included an explanatory paragraph in its reports on our financial
statements for the years ended December 31, 2012 and 2011, expressing substantial doubt as to our ability to continue as a going
concern. The inclusion of a going concern explanatory paragraph in the report of our independent registered public accounting firm
may make it more difficult for us to secure additional financing or enter into strategic relationships on terms acceptable to us,
if at all, and may materially and adversely affect the terms of any financing that we might obtain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We currently derive all of our revenue from
sales of our women&rsquo;s health care products, and our failure to maintain or increase sales of these products would have a material
adverse effect on our business, financial condition, results of operations, and growth prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We currently derive all of
our revenue from sales of women&rsquo;s health care products, including prenatal and women&rsquo;s multi-vitamins, iron supplements,
vitamin D supplements, natural menopause relief, and scar reduction creams. While sales of our vitamin products grew from 2010
through 2013, we cannot assure you that such sales will continue to grow. In addition to other risks described herein, our ability
to maintain or increase existing product sales is subject to a number of risks and uncertainties, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the presence of new or existing competing products, including generic copies of our prescription dietary
supplement products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">any supply or distribution problems arising with any of our manufacturing and distribution strategic
partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changed or increased regulatory restrictions or regulatory actions by the FDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes in health care laws and policy, including changes in requirements for rebates, reimbursement,
and coverage by federal health care programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the impact or efficacy of any price increases we may implement in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes to our label and labeling, including new safety warnings or changes to our boxed warning,
that further restrict how we market and sell our products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">acceptance of our products as safe and effective by physicians and patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If revenue from sales of our
existing prescription and over-the-counter dietary supplements and cosmetics does not continue or increase, we may be required
to reduce our operating expenses or to seek to raise additional funds, which could have a material adverse effect on our business,
financial condition, results of operations, and growth prospects, or we may not be able to commence or continue clinical trials
to seek approval for and commercialize our hormone therapy drug candidates or any other products we may choose to develop in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If our products do not have the effects
intended or cause undesirable side effects, our business may suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Although many of the ingredients
in our current dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human
consumption, they also contain innovative ingredients or combinations of ingredients. Although we believe all of these products
and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects
if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have
the effect intended if they are not taken in accordance with certain instructions, which include certain dietary restrictions.
Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or
will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop
or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business,
financial condition, results of operations, and prospects would be harmed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our future success will depend in large
part on our ability to commercialize our hormone therapy drug candidates designed to alleviate the symptoms of and reduce the health
risks resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our future success will depend
in large part on our ability to successfully develop and commercialize our hormone therapy drug candidates designed to alleviate
the symptoms of and reduce the health risks resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness.
We have submitted IND applications for our four hormone therapy drug candidates, which the FDA has made effective and which permit
us to conduct clinical testing on these proposed products. We intend to clinically test three of those drug candidates. However,
we may not be able to complete the development of these drug candidates, the results of the clinical trials may not be sufficient
to support NDA for any of them, and even if we believe the results of our clinical trials are sufficient to support any NDA that
we submit, the FDA may disagree and may not approve our NDA. In addition, even if the FDA approves one or more of our NDAs, it
may do so with restrictions on the intended uses that may make commercialization of the product or products financially untenable.
The failure to commercialize or obtain necessary approval for any one or more of these products would substantially harm our prospects
and our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may not be able to complete the development
and commercialization of our hormone therapy drug candidates if we fail to obtain additional financing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We need substantial amounts
of cash to complete the clinical development of our hormone therapy drug candidates. Our existing cash and cash equivalents will
not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster
than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.
We do not currently have any committed external source of funds. We will attempt to raise additional capital from the issuance
of equity or debt securities, collaborations with third parties, licensing of rights to these products, or other means, or a combination
of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management
and may divert a disproportionate amount of their attention away from our day-to-day activities, which may adversely affect our
ability to conduct our day-to-day operations. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms,
we may be required to take one or more of the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">significantly delay, scale back, or discontinue our product development and commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">seek collaborators for our hormone therapy drug candidates at an earlier stage than otherwise would
be desirable or on terms that are less favorable than might otherwise be the case; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">license, potentially on unfavorable terms, our rights to our hormone therapy drug candidates that
we otherwise would seek to develop or commercialize ourselves.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Debt financing, if available,
may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new
securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise
additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms
that may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing discovery, development,
and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We have no experience as a company in bringing
a drug to regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have never obtained regulatory
approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive
review or may conclude, after review of our data, that our applications are insufficient to obtain regulatory approval of any of
our hormone therapy drug candidates. The FDA may also require that we conduct additional clinical or manufacturing validation studies,
which may be costly and time-consuming, and submit that data before it will reconsider our applications. Depending on the extent
of these or any other FDA required studies, approval of any NDA that we submit may be significantly delayed, possibly for years,
or may require us to expend more resources than we have available or can secure. Any delay or inability in obtaining regulatory
approvals would delay or prevent us from commercializing our hormone therapy drug candidates, generating revenue from these proposed
products, and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed,
may not be considered sufficient by the FDA to approve any NDA we submit. If any of these outcomes occur, we may be forced to abandon
our planned NDAs for one or more of our hormone therapy drug candidates, which would materially adversely affect our business and
could potentially cause us to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Clinical trials involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Three hormone therapy drug
candidates are currently in various stages of clinical testing. We have recently begun phase 3 clinical trial of our estradiol
and progesterone combination and our progesterone alone drug candidates. Clinic trials are expensive, can take many years to complete,
and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process as a result of inadequate performance
of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later
stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical
trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials
as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical
trials may not be successful or may be more expensive or time-consuming than we currently expect. If clinical trials for any of
our hormone therapy drug candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve
that drug and we would not be able to commercialize it, which will have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Delays in clinical trials are common for
many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory
approval and commence product sales as currently contemplated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We may experience delays in
clinical trials for our hormone therapy drug candidates. Our planned clinical trials might not begin on time; may be interrupted,
delayed, suspended, or terminated once commenced; might need to be redesigned; might not enroll a sufficient number of patients;
or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining regulatory approval to commence a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites
by the FDA or other regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">imposition of a clinical hold because of safety or efficacy concerns by DSMB, the FDA, or IRB, or
us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in reaching agreement on acceptable terms with prospective contract research organizations,
or CROs, and clinical trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining required institutional review board approval at each site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in identifying, recruiting, and training suitable clinical investigators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in recruiting suitable patients to participate in a trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in having patients complete participation in a trial or return for post-treatment follow-up;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">clinical sites dropping out of a trial to the detriment of enrollment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">time required to add new sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays resulting from negative or equivocal findings of DSMB for a trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Patient enrollment, a significant
factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing
clinical trials, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug being studied
in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.
Any of these delays in completing our clinical trials could increase our costs, slow down our product development and approval
process, and jeopardize our ability to commence product sales and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be required to suspend or discontinue
clinical trials because of adverse side effects or other safety risks that could preclude approval of our hormone therapy drug
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our clinical trials may be
suspended or terminated at any time for a number of reasons. A clinical trial may be suspended or terminated by us, our collaborators,
the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from
using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue
the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An institutional review board
may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend
or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition,
regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the
clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety
risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop,
the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these
proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of
operations, and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We rely on third parties to conduct our
research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful
in obtaining regulatory approval for, or in commercializing our hormone therapy drug candidates if these third parties do not successfully
carry out their contractual duties or meet expected deadlines.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I></I></B></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We do not have the resources
to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various
third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our
on-going clinical programs for our hormone therapy drug candidates, as well as for the execution of our clinical studies. Although
we control only certain aspects of our CROs&rsquo; activities, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve
us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner,
or that the results will be reproducible. We and our CROs are required to comply with the FDA&rsquo;s cGCPs, which are regulations
and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic
inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable
cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform
additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine
that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of
our hormone therapy drug candidates to a statistically significant degree, our clinical trials will require an adequately large
number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly,
if our CROs fail to comply with these regulations or recruit a sufficient number of patients, we may be required to repeat clinical
trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, we do not employ
the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control
whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may
also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting
clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical
programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they
need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere
to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated,
and we may not be able to obtain regulatory approval for or successfully commercialize our hormone therapy drug candidates that
we seek to develop. As a result, our financial results and the commercial prospects for our hormone therapy drug candidates that
we seek to develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed or ended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We typically engage one or
more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships
with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources
and expertise in an attempt to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation
of clinical trial data for submission with an NDA for each of our hormone therapy drug candidates. If any of our relationships
with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially
reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management
time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which
can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly.
Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges
or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition,
results of operations, or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Future legislation, regulations, and policies
adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical
trials for our hormone therapy drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The FDA has established regulations,
guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change
in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing
clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical
trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical
trials for our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, the FDA&rsquo;s
policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval
of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements. If we are
slow or unable to adapt to such changes, our business, prospects, and ability to achieve or sustain profitability would be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Even if we obtain regulatory approval for
our hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products
may face future development and regulatory difficulties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Even if we obtain regulatory
approval for one or more of our hormone therapy drug candidates in the United States, the FDA may still impose significant restrictions
on a product&rsquo;s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially
costly post-approval studies, including Phase 4 clinical trials or post-market surveillance. As a condition to granting marketing
approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval
clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side
effects or efficacy of a product. For example, the labeling for our hormone therapy drug candidates, if approved, may include restrictions
on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority,
including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information,
and compliance with FDA-approved Risk Evaluation and Mitigation Strategies, or REMS, programs. If approved, our hormone therapy
drug candidates will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution,
safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&rsquo;s
exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory
review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of
approved products. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies,
whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed
products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved,
and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our
products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our
approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects
or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information,
including information about product misuse, may lead government agencies, professional societies, and practice management groups
or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or
the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The holder of an approved
NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications
in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional
material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of clinical
trial results on publicly available databases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, manufacturers
of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory
authorities for compliance with the FDA&rsquo;s cGMPs regulations. If we or a regulatory agency discovers previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is
manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring
recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes
to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring
that we establish a REMS. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable
federal and state laws. The distribution of product samples to physicians must comply with the requirements of the Prescription
Drug Marketing Act. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions
of the Social Security Act, the False Claims Act, and similar state laws. Pricing and rebate programs must comply with the Medicaid
rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements
apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws.
If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any
of the following actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">conduct an investigation into our practices and any alleged violation of law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">issue warning letters or untitled letters asserting that we are in violation of the law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">seek an injunction or impose civil or criminal penalties or monetary fines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">suspend or withdraw regulatory approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">require that we suspend or terminate any ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">refuse to approve pending applications or supplements to applications filed by us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">suspend or impose restrictions on operations, including costly new manufacturing requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">seize or detain products, refuse to permit the import or export of products, or require us to initiate
a product recall; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">exclude us from providing our products to those participating in government health care programs,
such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The occurrence of any of the
foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability
to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our dependence upon third parties for the
manufacture and supply of our existing women&rsquo;s health care products and our hormone therapy drug candidates may cause delays
in, or prevent us from, successfully developing, commercializing, and marketing our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We do not currently have nor
do we plan to build the infrastructure or capability internally to manufacture our existing women&rsquo;s health care products.
For example, we depend on Lang to supply approximately 98% of our vitaMedMD products. We also rely on third-party contract manufacturing
organizations, or CMOs to supply our hormone therapy drug candidates for use in the conduct of our clinical trials. We rely on
these third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory
requirements. We do not have long-term contracts for the commercial supply of our products or our hormone therapy drug candidates.
We intend to pursue long-term manufacturing agreements, but we may not be able to negotiate such agreements on acceptable terms,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, regulatory requirements
could pose barriers to the manufacture of our products, including our hormone therapy drug candidates. Our third-party manufacturers
are required to comply with cGMP regulations. As a result, the facilities used by any of our current or future manufacturers must
be approved by the FDA. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product
under their own name, are responsible for manufacturing even though that manufacturing is conducted by a third-party CMO. All of
our existing products are and our hormone therapy drug candidates, if approved, will be manufactured by CMOs. These CMOs are required
by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. If our manufacturers
cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA
and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing
facilities. If these facilities are not approved for the commercial manufacture of our existing products or our hormone therapy
drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and significant
delays of up to several years in obtaining approval for our hormone therapy drug candidates. In addition, our manufacturers will
be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with
cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations could
result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals,
operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any
of which could have a material adverse impact on our business, financial condition, results of operations, and prospects. Finally,
we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products
and proposed products or otherwise do not satisfactorily perform according to the terms of their agreements with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If any supplier of the product
for our hormone therapy drug candidates experiences any significant difficulties in its respective manufacturing processes, does
not comply with the terms of the agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing
needs, we could experience significant interruptions in the supply of our hormone therapy drug candidates, which could impair our
ability to supply our hormone therapy drug candidates at the levels required for our clinical trials and commercialization and
prevent or delay their successful development and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The commercial success of our existing products
and our hormone therapy drug candidates that we develop, if approved in the future, will depend upon gaining and retaining significant
market acceptance of these products among physicians and payors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Physicians may not prescribe
our products, including any of our hormone therapy drug candidates, if approved by the appropriate regulatory authorities for marketing
and sale, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our
hormone therapy drug candidates, by physicians, patients, and payors, will depend on a number of factors, many of which are beyond
our control, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the clinical indications for which our hormone therapy drug candidates are approved, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">acceptance by physicians and payors of each product as safe and effective treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the cost of treatment in relation to alternative treatments, including numerous generic drug products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the relative convenience and ease of administration of our products in the treatment of the symptoms
for which they are intended;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the availability and efficacy of competitive drugs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the effectiveness of our sales force and marketing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the extent to which the product is approved for inclusion on formularies of hospitals and managed
care organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the availability of adequate reimbursement by third parties, such as insurance companies and other
health care payors, or by government health care programs, including Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">limitations or warnings contained in a product&rsquo;s FDA-approved labeling; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">prevalence and severity of adverse side effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Even if the medical community
accepts that our products are safe and efficacious for their approved indications, physicians may not immediately be receptive
to the use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. We cannot
assure you that any labeling approved by the FDA will permit us to promote our products as being superior to competing products.
If our products, including, in particular our hormone therapy drug candidates, if approved, do not achieve an adequate level of
acceptance by physicians and payors, we may not generate sufficient or any revenue from these products and we may not become profitable.
In addition, our efforts to educate the medical community and third-party payors on the benefits of our products may require significant
resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our products, including our hormone therapy
drug candidates if approved, face significant competition from branded and generic products, and our operating results will suffer
if we fail to compete effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Development and awareness
of our brand will depend largely upon our success in increasing our customer base. The dietary supplement and pharmaceutical industries
are intensely competitive and subject to rapid and significant technological change. Our products, including any hormone therapy
drug candidates that are approved, face intense competition, including from major multinational pharmaceutical and dietary supplement
companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. Many of these companies have
greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing
organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and
marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license
novel compounds that could make the products that we sell or develop obsolete. As a result, our competitors may succeed in commercializing
products before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results
of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non FDA-approved
compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Reimbursement may not be available for our
products, which could make it difficult for us to sell our products profitably.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Market acceptance and sales
of our products, including any hormone therapy drug candidates, will depend on coverage and reimbursement policies and may be affected
by health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors generally do not
cover over-the-counter products, and coverage for vitamins and dietary supplements varies. We cannot be sure that coverage and
reimbursement will be available for our products, including any hormone therapy drug candidates, if approved. We also cannot be
sure that the amount of reimbursement available, if any, will not reduce the demand for, or the price of, our products. If reimbursement
is not available or is available only at limited levels, we may not be able to successfully compete through sales of our existing
dietary supplement products or successfully commercialize our hormone therapy drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Specifically, in both the
United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health
care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription
Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare
covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain
others and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition,
this legislation provided authority for limiting the number of certain outpatient drugs that will be covered in any therapeutic
class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional
pressure to contain and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we
receive for our products, including our hormone therapy drug candidates, if approved, and could seriously harm our business. While
the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment
limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar
reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In March 2010, the Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively,
PPACA, became law in the United States. The goal of PPACA is to reduce the cost of health care and substantially change the way
health care is financed by both governmental and private insurers. Among other measures, PPACA imposes increased rebates on manufacturers
for certain covered drug products reimbursed by state Medicaid programs. While we cannot predict the full effect PPACA will have
on federal reimbursement policies in general or on our business specifically, the PPACA may result in downward pressure on drug
reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals
will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The availability of generic
products at lower prices than branded products may also substantially reduce the likelihood of reimbursement for branded products,
such as our hormone therapy drug candidates, if approved. We expect to experience pricing pressures in connection with the sale
of our products generally due to the trend toward managed health care, the increasing influence of health maintenance organizations,
and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our
products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our
business will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Product liability lawsuits could divert
our resources, result in substantial liabilities and reduce the commercial potential of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We face an inherent risk of
product liability claims as a result of the marketing of our current products and the clinical testing of our hormone therapy drug
candidates despite obtaining appropriate informed consents from our clinical trial participants, and we will face an even greater
risk if we obtain FDA approval and commercialize our hormone therapy drug candidates in the United States or other additional jurisdictions
or if we engage in the clinical testing of proposed new products or commercialize any additional products. For example, we may
be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing,
marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a
failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also
be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims,
we may incur substantial liabilities or be required to limit commercialization of our existing products or hormone therapy drug
candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the
merits or eventual outcome, product liability claims may result in any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to commercialize our products or hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial
is completed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">labeling, marketing, or promotional restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">product recalls or withdrawals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">decreased demand for our products or products that we may develop in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">loss of revenue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">initiation of investigations by regulators;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">costs to defend the related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a diversion of management&rsquo;s time and our resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">substantial monetary awards to trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">exhaustion of any available insurance and our capital resources; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a decline in our stock price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Although we maintain general
liability insurance of up to $10 million in the aggregate and clinical trial liability insurance of $10 million in the aggregate
for our hormone therapy drug candidates, this insurance may not fully cover potential liabilities. The cost of any product liability
litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain
sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent
or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our business may be affected by unfavorable
publicity or lack of consumer acceptance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are highly dependent upon
consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer
acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other
publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may
not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry
or any of our particular products and may not be consistent with earlier favorable research or publicity. A future research report
or publicity that is perceived by our consumers as less than favorable or that may question earlier favorable research or publicity
could have a material adverse effect on our ability to generate revenue. Adverse publicity in the form of published scientific
research, statements by regulatory authorities or otherwise, whether or not accurate, that associates consumption of our product
or any other similar product with illness or other adverse effects, or that questions the benefits of our product or a similar
product, or that claims that such products do not have the effect intended could have a material adverse effect on our business,
reputation, financial condition, or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we use hazardous and biological materials
in a manner that causes injury or violates applicable law, we may be liable for damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our research and development
activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials.
In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the United States
govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for
use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors)
comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future.
We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way
existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws,
we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability
as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized
with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous
materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines
and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain
compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations
may impair our research, development and production efforts, which adversely affect our business, financial condition, results
of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We are subject to extensive and costly government
regulation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The products we currently
market, including the vitamins and cosmetic creams, and the pharmaceutical products we are developing and planning to develop in
the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers
for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its
Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our
products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents.
The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates
the processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and
cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development,
pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval,
advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions.
If any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments,
whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding
than corresponding U.S. regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Government regulation substantially increases
the cost and risk of researching, developing, manufacturing, and selling products. Our failure to comply with these regulations
could result in, by way of example, significant fines, criminal and civil liability, product seizures, recalls, withdrawals, withdrawals
of approvals, and exclusion and debarment from government programs. Any of these actions, including the inability of our hormone
therapy drug candidates to obtain and maintain regulatory approval, would have a materially adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We are subject to additional federal and
state laws and regulations relating to our business, and our failure to comply with those laws could have a material adverse effect
on our results of operations and financial conditions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are subject to additional
health care regulation and enforcement by the federal government and the states in which we conduct our business. The laws that
may affect our ability to operate include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the federal health care program Anti-Kickback Statute, which prohibits, among other things, persons
from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or
to induce either the referral of an individual for, or the purchase, order, or recommendation of, any good or service for which
payment may be made under government health care programs such as the Medicare and Medicaid programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">federal false claims laws that prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that
are false or fraudulent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">federal criminal laws that prohibit executing a scheme to defraud any health care benefit program
or making false statements relating to health care matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws
that may apply to items or services reimbursed by any third-party payor, including commercial insurers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Further, the recently enacted
PPACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes.
A person or entity can now be found guilty of fraud or false claims under PPACA without actual knowledge of the statute or specific
intent to violate it. In addition, PPACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims
statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion
from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any
violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could
result in a material adverse effect on our reputation, business, results of operations, and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">PPACA also imposes new reporting
requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments to health care providers
and ownership of their stock by health care providers. Failure to submit required information may result in civil monetary penalties
of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &ldquo;knowing failures&rdquo;), for
all payments, transfers of value, or ownership or investment interests that are not reported. Manufacturers were required to begin
data collection on August 1, 2013 and will be required to report such data to CMS by March 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, there has been
a recent trend of increased federal and state regulation of payments made to physicians for marketing. Some states, such as California,
Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts,
compensation, and other remuneration to physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The scope and enforcement
of these laws is uncertain and subject to change in the current environment of health care reform, especially in light of the lack
of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these laws. Federal or
state regulatory authorities may challenge our current or future activities under these laws. Any such challenge could have a material
adverse effect on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review
of us, regardless of the outcome, would be costly and time-consuming.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we are not successful in attracting and
retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our ability to compete in
the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial,
scientific, and medical personnel. In order to induce valuable employees to remain with us, we have, among other things, provided
stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected
by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers
from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams
may terminate their employment with us on short notice. We do not have employment agreements with a number of our key employees.
As a result, most employees are employed on an at-will basis, which means that any of these employees could leave our employment
at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers
or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends
on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Any failure to adequately expand a direct
sales force will impede our growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We expect to be substantially
dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our direct sales
force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills
and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our
success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive
as expected, and we may be unable to hire sufficient numbers of qualified individuals in the future in the markets in which we
do business. While there presently exists a high rate of unemployment, if we are unable to hire and develop sufficient numbers
of productive sales personnel our business prospects could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Other pharmaceutical companies
with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and longer histories
than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics
may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality
personnel, our ability to commercialize drug candidates will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our success is tied to our distribution
channels.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We sell our prescription dietary
supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally
sell products to retail pharmacies, hospitals, and other institutional customers. However, over 98% of our product shipments since
inception were to only three customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. Our business
would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially
favorable terms to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>A failure to maintain optimal inventory
levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our ability to maintain optimal
inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances,
our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials,
if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level
of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not
have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products
in the future, each of which could have a material adverse effect on our business, financial condition, results of operations,
and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our success depends on how efficiently we
respond to changing consumer preferences and demand.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our success depends, in part,
on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely
or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our
inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings
depends upon a number of factors, including our ability to achieve the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">accurately anticipate customer needs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">innovate and develop new products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">successfully commercialize new products in a timely manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">competitively price our products in the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">procure and maintain products in sufficient volumes and in a timely manner; and</TD></TR>                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD STYLE="text-align: left">differentiate our product
offerings from those of our competitors.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If we do not introduce new
products, make enhancements to existing products, or maintain the appropriate inventory levels to meet customers&rsquo; demand
in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may initiate product recalls or withdrawals,
or may be subject to regulatory enforcement actions that could negatively affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We may be subject to product
recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness
or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of
any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence
in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products
would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially
and adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We will need to grow our organization, and
we may experience difficulties in managing this growth, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As of December 31, 2013, we
had 69 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base
for managerial, operational, financial, and other resources and, depending on our commercialization strategy, we may further expand
our employee base for sales and marketing resources. Future growth would impose significant added responsibilities on members of
management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management
may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount
of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may
result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees
and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial
resources from other projects, such as the development of additional drug candidates. If we are unable to effectively manage our
expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not
be able to implement our business strategy. Our future financial performance and our ability to commercialize our hormone therapy
drug candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth
in our organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our employees may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are exposed to the risk
of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations,
to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations,
to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing,
and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements.
Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result
in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against
us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to our Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Another party could develop hormone therapy
products and obtain FDA regulatory exclusivity in the United States before we do, potentially preventing our ability to commercialize
our hormone therapy drug candidates and other products in development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We plan to seek to obtain
market exclusivity for our hormone therapy drug candidates and any other drug candidates we develop in the future. To the extent
that patent protection is not available or has expired, FDA marketing exclusivity may be the only available form of exclusivity
available for these proposed products. Marketing exclusivity can delay the submission or the approval of certain marketing applications.
Potentially competitive products may also be seeking marketing exclusivity and may be in various stages of development, including
some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted,
nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It
is possible that competing products may obtain FDA approval with marketing exclusivity before we do, which could delay our ability
to submit a marketing application or obtain necessary regulatory approvals, result in lost market opportunities with respect to
our hormone therapy drug candidates, and materially adversely affect our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If our efforts to protect the proprietary
nature of the intellectual property covering our hormone therapy drug candidates and other products are not adequate, we may not
be able to compete effectively in our market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our commercial success will
depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to
maintain adequate protection of other intellectual property for our hormone therapy drug candidates and other products. If we do
not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive
advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical
companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and
legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue
to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in
patent laws in the United States, such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of
our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of
some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter
significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights
from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable
patents or are effectively maintained as trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">These risks include the possibility
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the patent applications that we have filed may fail to result in issued patents in the United States
or in foreign countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">patents issued or licensed to us or our partners may be challenged or discovered to have been issued
on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the scope of any patent protection may be too narrow to exclude competitors from developing or designing
around these patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">we or our licensors were not the first to make the inventions covered by each of our issued patents
and pending patent applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">we or our licensors were not the first inventors to file patent applications for these technologies
in the United States or were not the first to file patent applications directed to these technologies abroad;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during
the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">future drug candidates may not be patentable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">others will claim rights or ownership with regard to patents and other proprietary rights that we
hold or license;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">delays in development, testing, clinical trials, and regulatory review may reduce the period of time
during which we could market our drug candidates under patent protection; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">we may fail to timely apply for patents on our technologies or products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">While we apply for patents
covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or
have received patents in our areas of product development. These entities&rsquo; applications, patents, and other intellectual
property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could
call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture,
or commercialize our hormone therapy drug candidates. In addition, if third parties file patent applications in the technologies
that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings
with the USPTO or foreign patent regulatory authorities to determine our rights in the
technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged during in the courts or in
post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent
claims or adverse changes to the scope of the claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">If we, our licensors, or strategic
partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies
may be dissuaded from collaborating with us. In such event, our ability to commercialize our hormone therapy drug candidates or
future product candidates, if approved, may be threatened, we could lose our competitive advantage, and the competition we face
could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, mechanisms exist
in much of the world permitting some form of challenge by generic drug marketers to our patents prior to, or immediately following,
the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &ldquo;at
risk&rdquo; launches to challenge relevant patent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our business also may rely
on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached,
it could adversely impact our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we are sued for infringing intellectual
property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our commercial success depends,
in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other
agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S.
issued patents and pending applications that exist in the areas of hormone therapy, including compounds, formulations, treatment
methods, and synthetic processes, that may be applied towards the synthesis of hormones. Patent applications are confidential when
filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain
unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently
unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related
to the use or manufacture of our products or drug candidates. Therefore, we cannot ever know with certainty the nature or existence
of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market
our drug candidates as planned or that we or our licensors&rsquo; and partners&rsquo; patents will not be opposed or litigated
by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations,
methods of manufacture, or methods of treatment related to the use or manufacture of any of our drug candidates, the holders of
any such patent may be able to block our ability to develop and commercialize the applicable drug candidate unless we obtained
a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances
that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have a
material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">There is a substantial amount
of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe
its patents or other proprietary rights, we could face a number of risks that could adversely affect our business, financial condition,
results of operations, and prospects, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">infringement and other intellectual property claims, which would be costly and time-consuming to defend,
whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital, and
divert management&rsquo;s attention from our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">substantial damages for past infringement, which we may have to pay if a court determines that our
products or technologies infringe a competitor&rsquo;s patent or other proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a court prohibiting us from selling or licensing our technologies or future products unless the third
party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">if a license is available from a third party, we may have to pay substantial royalties or lump sum
payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">redesigning our products so they do not infringe, which may not be possible or may require substantial
monetary expenditures and time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are party from time to
time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that
our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will
assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those
claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot
be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating
to our drug candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our
partners to curtail or cease the development of some or all of our drug candidates, which could adversely affect our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be required to file lawsuits or take
other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Competitors may infringe our
patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other
resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual
property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, in an infringement
proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the
other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology
in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents,
or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications,
or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation
of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the United States
or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount
of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information
could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public
announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our
common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we are unable to protect the confidentiality
of certain information, the value of our products and technology could be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive
position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees,
independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored
by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims
that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming,
and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets,
know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing
us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our
business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We may be subject to claims that our employees
have wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As is common in the pharmaceutical
industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend
against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property
rights, which could adversely affect our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Risks Related to Ownership of Our Common
Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>The market price of our common stock may
be highly volatile, and you could lose all or part of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The trading price of our common
stock on NYSE MKT is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the
price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which
include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">any delay in commencement of our phase 3 clinical trials for our hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">adverse results or delays in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">any delay in filing our NDAs for our hormone therapy drug candidates and any adverse development or
perceived adverse development with respect to the FDA&rsquo;s review of the NDAs, including the FDA&rsquo;s issuance of a &ldquo;refusal
to file&rdquo; letter or a request for additional information;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes in laws or regulations applicable to our products or proposed products, including clinical
trial requirements for approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">unanticipated serious safety concerns related to the use of our hormone therapy drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing
clinical trial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to obtain adequate clinical supply for our hormone therapy drug candidates or the inability
to do so at acceptable prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">adverse regulatory decisions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the introduction of new products or technologies offered by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the effectiveness of our or our potential strategic partners&rsquo; commercialization efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">developments concerning our sources of manufacturing supply and any commercialization strategic partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment
community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">disputes or other developments relating to proprietary rights, including patents, litigation matters,
and our ability to obtain patent protection for our technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the inability to effectively manage our growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">actual or anticipated variations in quarterly operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the failure to meet or exceed the estimates and projections of the investment community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the overall performance of the U.S. equity markets and general political and economic conditions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments
by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">additions or departures of key scientific or management personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">sales of our common stock by us or our stockholders in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">significant lawsuits, including patent or stockholder litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes in the market valuations of similar companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">the trading volume of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">increases in our common stock available for sale upon expiration of lock-up agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">effects of natural or man-made catastrophic events or other business interruptions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">other events or factors, many of which are beyond our control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, the stock market
in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors
may negatively affect the market price of our common stock, regardless of our actual operating performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our principal stockholders and management
own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">At December 31, 2013, our
executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 77% of
our common stock on an as converted basis. These stockholders may be able to determine the outcome of all matters requiring stockholder
approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents,
or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition
proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If we fail to maintain proper internal controls,
our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Pursuant to Section 404 of
the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal
control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation
report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control
over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the
effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley
Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating
results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business.
If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business,
our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly,
we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>We do not intend to pay dividends on our
common stock so any returns will be limited to the value of our stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have never declared or
paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development,
operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.
Any return to stockholders will be limited to the value of their stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Some provisions of our charter documents
and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would
be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Provisions in our articles
of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire
us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult
to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">authorizing the issuance of &ldquo;blank check&rdquo; preferred stock that could be issued by our
board of directors to increase the number of outstanding shares and thwart a takeover attempt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">prohibiting cumulative voting in the election of directors, which would otherwise allow less than
a majority of stockholders to elect director candidates; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">advance notice provisions in connection with stockholder proposals that may prevent or hinder any
attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In addition, we are subject
to Nevada&rsquo;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits
an &ldquo;interested stockholder&rdquo; from entering into a &ldquo;combination&rdquo; with a company, unless certain conditions
are met. An &ldquo;interested stockholder&rdquo; is a person who, together with affiliates and associates, beneficially owns (or
within the prior two years, did beneficially own) 10% or more of the corporation&rsquo;s capital stock entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A004"></A>Item&nbsp;1B.&nbsp;</TD><TD STYLE="text-align: justify"><I>Unresolved Staff Comments</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A005"></A>Item 2.</TD><TD STYLE="text-align: justify"><I>Properties</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our corporate headquarters
is located in Boca Raton, Florida, where we lease 17,686 square feet of space. The primary functions performed at this location
are executive, administrative, accounting, treasury, marketing, and human resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We believe that our current
facility is in good working order and is capable of supporting our operations for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A006"></A>Item 3.</TD><TD STYLE="text-align: justify"><I>Legal Proceedings</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">From time to time, we are
involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding
that we believe would have a material effect on our business or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A007"></A>Item 4.</TD><TD STYLE="text-align: justify"><I>Mine Safety Disclosures</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="A008"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A009"></A>Item 5.</TD><TD STYLE="text-align: justify"><I>Market
for the Registrant&rsquo;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Market Information on Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Since April 23,
2013, our common stock has been listed on the NYSE MKT under the symbol &ldquo;TXMD.&rdquo; Prior to that time, our common
stock was quoted on the OTCQB. The following table sets forth for the periods indicated the high and low bid or sales prices
of our common stock on the OTCQB and the NYSE MKT, as applicable. The below quotations reflect inter-dealer prices, without
retail mark-up, mark-down or commission, and may not represent actual transactions. Prices listed in 2011 are historic prices
that have been adjusted to reflect the 1:100 reverse split that was effective on October 3, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; text-indent: -10pt; padding-left: 10pt">Fourth Quarter&#9;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">5.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Third Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Second Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.73</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Third&nbsp;&nbsp;quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.61</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.84</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">First&nbsp;&nbsp;quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Fourth quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.51</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Third&nbsp;&nbsp;quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Second quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">First quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On March 3, 2014, the
closing sale price of our common stock was $6.75 per share. On March 3, 2014, there were approximately 324 record holders
and approximately 3,103 beneficial owners of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Historically, we have not
paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable
future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments
of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as
well as other factors deemed relevant by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Performance Graph</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The following line
graph compares cumulative total shareholder return for the five years ended December&nbsp;31, 2013 for (i) our common stock;
(ii) NASDAQ Pharmaceutical Index; and (iii) Peer Group (includes: Acorda Therapeutics, Inc., AMAG Pharmaceuticals, Inc.,
Amarillo Biosciences Inc., Arena Pharmaceuticals, Inc., Avanir Pharmaceuticals, Inc., Cadence Pharmaceuticals Inc., Dendreon
Corporation, Dyax Corporation, Exelixis, Inc., Halozyme Therapeutics, Inc., Orexigen Therapeutics, Inc., Spectrum
Pharmaceuticals, Inc., and VIVUS Inc.). The graph assumes $100 invested on December 31, 2009 and includes reinvestment of
dividends. Measurement points are at the last trading day of the fiscal years ended December 31, 2009, 2010, 2011, 2012, and
2013. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="txmd-10k123113_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The following line graph
compares cumulative total shareholder return for the period beginning when we became listed on the NYSE MKT exchange (April
23, 2013) and ended December 31, 2013 for (i) our common stock; (ii) NASDAQ Pharmaceutical Index; and (iii) our Peer Group
(includes: Acorda Therapeutics, Inc., AMAG Pharmaceuticals, Inc., Amarillo Biosciences Inc., Arena Pharmaceuticals,
Inc., Avanir Pharmaceuticals, Inc., Cadence Pharmaceuticals Inc., Dendreon Corporation, Dyax Corporation, Exelixis, Inc.,
Halozyme Therapeutics, Inc., Orexigen Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and VIVUS Inc.). The graph assumes
$100 invested on December 31, 2009 and includes reinvestment of dividends. Measurement points are April 23, 2013 and the
last trading day of the fiscal years ended December 31, 2013. The stock price performance on the following graph is not
necessarily indicative of future stock price performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="txmd-10k123113_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The performance graphs shall
not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that
section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act
or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A010"></A>Item 6.</TD><TD STYLE="text-align: justify"><I>Selected Financial Data</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The following table sets forth
selected consolidated financial and other data as of and for the periods indicated. You should read the following information together
with the more detailed information contained in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and our consolidated financial statements and the related notes included elsewhere in this Annual Report.
The consolidated statements of operations for the years ended December 31, 2013, 2012, and 2011 and the consolidated balance sheet
data as of December 31, 2013, 2012, and 2011 are derived from our audited consolidated financial statements included in this Annual
Report. The consolidated statements of operations for the year ended December 31, 2010, and the consolidated balance sheet data
as of December 31, 2010, are derived from the audited consolidated financial statements of VitaMed, our predecessor, included in
this Annual Report. The consolidated statements of operations for the period April 2, 2009 (inception) through December 31, 2009,
and the consolidated balance sheet data as of December 31, 2009, are derived from the audited consolidated financial statements
of AMHN, Inc., our predecessor, not included in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="text-align: center; margin-bottom: 0"><B></B></P>

<P STYLE="text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Restated)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Restated)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center">(in thousands, except share data)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations Data:<B> </B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left; padding-left: 10pt; text-indent: -10pt">Revenue, net</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,088</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,242</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">221</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,816</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,470</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,141</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">556</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">205</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Sales, general, and administration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,070</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">58</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">56</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">55</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">23</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">32,624</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">18,618</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,568</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,423</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,498</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,293</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,611</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,972</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,486</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(28,419</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(35,120</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(12,913</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(2,867</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(1,288</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 2.5pt">Net loss per share, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.22</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.38</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.21</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.07</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.05</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,516</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,424</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Consolidated Balance Sheet Data (at end of period)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">62,016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Total stockholders surplus (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,433</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,712</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">964</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">484</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Other Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Capital expenditures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Working Capital (deficit) (end of period)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">52,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,914</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">361</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A011"></A>Item 7.</TD><TD STYLE="text-align: justify"><I>Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>You should read the
following discussion and analysis in conjunction with the information set forth under &ldquo;Selected Consolidated Financial
and Other Data&rdquo; and our consolidated financial statements and the notes to those financial statements included
elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that
involve risks and uncertainties. See &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo; Our actual results may
differ materially from those contained in or implied by any forward-looking statements as a result of various factors,
including the risks and uncertainties described under &ldquo;Risk Factors&rdquo; elsewhere in this Annual Report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We are a women&rsquo;s health
care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused
on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical
products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health
risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing
these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating
equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products.
Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability
alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well
as over-the-counter, or OTC, vitamins and cosmetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of Years Ended December 31,
2013, 2012, and 2011:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Year ended December 31, 2013 compared
with year ended December 31, 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">(000s)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Revenue</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">8,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">4,958</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,006</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 22pt; text-indent: -10pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,660</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Financing Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,504</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,504</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">739</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Other income (expense) net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Beneficial conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(6,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,717</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,419</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,120</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,701</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Revenue for year
ended December 31, 2013 increased by approximately $4,958,000, or 130%, compared with the year ended December 31, 2012.
This increase was directly attributable to additional products sold and an increase in the average sales price of
each product, increase in the number of physicians writing prescriptions for our products, the productivity of our sales
force, and the new prescription products introduced in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Cost
of Goods Sold</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Cost of goods sold increased
by approximately $611,000, or 45%, for the year ended December 31, 2013 compared with the year ended December 31, 2012. Our gross
margins increased to 78% in 2013 compared to 65% in 2012. The gross margin change was primarily attributable to the increase in average
sales price of products sold and product mix of prescription and OTC products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Operating
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our principal operating costs
included the following items as a percentage of total operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended<BR>December 31,</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Human resource costs</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; text-align: right">33</TD>
<TD STYLE="width: 1%; text-align: left">%</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 15%; text-align: right">39</TD>
<TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Sales and marketing, excluding human resource costs</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">15</TD>
<TD STYLE="text-align: left">%</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">24</TD>
<TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Production design and development costs</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">41</TD>
<TD STYLE="text-align: left">%</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">24</TD>
<TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Professional fees and consulting</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">4</TD>
<TD STYLE="text-align: left">%</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">6</TD>
<TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Other</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">7</TD>
<TD STYLE="text-align: left">%</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">7</TD>
<TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Operating expenses
increased by approximately $14,006,000, or 75%, for the year ended December 31, 2013 from year ended December 31, 2012 as a
result of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">(000s)</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; width: 80%; text-indent: -10pt">Increase in product research and development costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 15%">9,059</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in sales and marketing, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">582</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in professional and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Increase in all other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,006</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and
development costs increased by approximately $9,059,000, primarily as a result of the commencement of phase 3 clinical trials
for TX&nbsp;12-001HR as well as the preparation for phase 3 clinical trials for TX&nbsp;12-002HR, and phase 3
clinical trials for TX&nbsp;12-004HR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Human resource related
costs, including salaries and benefits, increased by approximately $3,333,000, primarily as a result of an increase in amortization
of non-cash compensation totaling approximately $3,152,000 related to employee stock options issued during 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sales and marketing costs
increased approximately $582,000, primarily as a result of expanded marketing, advertising, education, and training. In addition,
we increased spending in the areas of travel, product samples, and commissions. We also incurred added costs associated with our
new product distribution channels introduced in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financing Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Financing costs
increased approximately $1,504,000 resulting from the amortization of costs associated with warrants granted in 2013
in connection with a $10,000,000 revolving line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Interest expense decreased
approximately $739,000, primarily as a result of the retirement of debt issued during 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Year ended December 31, 2012 compared
with year ended December 31, 2011</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">(000s)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Revenue</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,818</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,088</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,730</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,348</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,618</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,568</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,050</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 22pt; text-indent: -10pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,148</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,721</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,308</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,918</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Beneficial conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,717</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,717</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,841</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,120</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,913</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(22,207</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenue for year ended
December 31, 2012 increased by $1,730,000, or 83%, from the year ended December 31, 2011. This increase was directly attributable
to the introduction of our prescription prenatal product line and the use of various pharmaceutical distribution sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Consistent with our increase
in revenue, cost of goods sold increased by $401,000, or 42%, for the year ended December 31, 2012 compared with the year ended
December 31, 2011. Our gross margins increased to 65% in 2012 compared to 55% in 2011. This change is primarily attributed to the
fact that our 2012 revenue consisted of prescription and OTC products in contrast to revenue in prior years that consisted exclusively
of OTC products. Our prescription products offer more favorable margins than those of our OTC products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our principal operating
costs included the following items as a percentage of total operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended<BR>December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Human resource costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">39</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">48</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Sales and marketing, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Production design and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Professional fees and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Operating expenses increased
by $12,050,000, or 184%, for year ended December 31, 2012 from year ended December 31, 2011 as a result of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">(000s)</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; width: 80%; text-indent: -10pt">Increase in product research and development costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 15%">4,385</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in sales and marketing, excluding human resource costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,238</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in professional and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">719</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Increase in all other operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">553</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,050</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">During 2012 we began the
development of drug candidates designed to alleviate the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. The increase in our product
research and development costs was primarily attributable to these hormone therapy drug candidates, which contain estradiol
and progesterone alone or in combination, with the aim of providing clinical efficacy at lower doses, thereby enabling an
enhanced side effect profile compared with competing products. We have obtained FDA acceptance of our IND applications to
conduct clinical trials for four drug candidates and have commenced or intend to commence clinical trials for three of those
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Human resource related costs,
including salaries and benefits, increased by approximately $4,155,000, primarily as a result of an increase in amortization of
non-cash compensation totaling approximately $1,678,000 related to employee stock options issued during 2012 and 2011, and an increase
of  19 employees in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Sales and marketing costs increased approximately
$2,238,000, primarily as a result of expanded marketing, advertising, education, and training. In addition, we increased spending
in the areas of travel, product samples, and commissions. We also incurred added costs associated with our new product distribution
channels introduced in 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Professional fees
increased approximately $719,000 primarily because of an increase in legal fees of approximately $442,000 arising from
contract and patent services, costs related to our September 2012 private placement, and public filings. We incurred
additional accounting and audit costs of approximately $101,000 as a result of SEC reporting and additional requirements
related to Sarbanes-Oxley. Consulting costs also increased by approximately $176,000 as a result of the introduction of new
pharmacy-sold products, as well as enhanced SEC reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Loss on Extinguishment of Debt</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In February 2012, we issued
promissory notes in the aggregate of approximately $2,700,000 and granted warrants for the purchase of an aggregate of 9,000,000
shares of our common stock, or the February 2012 Funding. In connection with the February 2012 Funding, we received $1,000,000
and the surrender of certain other promissory notes totaling $1,700,000. We determined that the resulting modification of these
notes was substantial in accordance with Accounting Standards Certification 470-50, <I>Modifications and Extinguishments</I>. As
such, the modification was accounted for as an extinguishment and restructuring of the debt and the fair value of the warrants
granted of approximately $10,505,000 was recognized as loss on the extinguishment of debt. The relative fair value of the promissory
notes was estimated to be $1,500,000 by calculating the present value of future cash flows discounted at a market rate of return
for comparable debt instruments. We recognized a reduction in loss of extinguishment of debt in the amount of $197,000, which represented
the difference between the net carrying amount of the February 2012 Funding and its fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Beneficial
Conversion Feature</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Beneficial conversion feature
of approximately $6,717,000 consisted of non-cash costs associated with the conversion of approximately $1,055,000 in debt into
2,775,415 shares of our common stock. As a result of this conversion, we recognized $6,717,000 in non-cash costs related to a beneficial
conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Interest expense increased
approximately $1,841,000, primarily as a result of amortization of debt discount associated with promissory notes we issued during
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Year ended December 31, 2011 compared
with year ended December 31, 2010</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1pt solid">(000s)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Revenue</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,088</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">1,242</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">846</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Cost of goods sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,568</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,553</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,015</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 22pt; text-indent: -10pt">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,427</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,867</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,560</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,390</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(96</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-0-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(96</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,913</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,867</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,046</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Revenue for year ended December
31, 2011 increased by $846,000, or approximately 68.1%, from the year ended December 31, 2010. This increase was directly attributable
to the increase in the number of sales territories and the associated increase in number of sales people in those territories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Cost of goods sold increased
$391,000, or approximately 70.3%, for the year ended December 31, 2011 compared with the year ended December 31, 2010. Approximately
96.9% of this increase was due to an increase in the amount of product sold and approximately 3.1% of the increase was related
to product mix. Our costs of individual products did not change for year ended December 31, 2011 compared with 2010.&emsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Operating Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our principal operating
costs included the following items as a percentage of total operating expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year Ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Human resource costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">48</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">48</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Sales and marketing, excluding human resources cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Professional fees and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Product design and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Operating expenses increased
by $3,015,000, or 84%, for year ended December 31, 2011 from year ended December 31, 2010 as a result of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">(000s)</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; width: 80%; text-indent: -10pt">Increase in human resource costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 15%">1,411</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in sales and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,094</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in professional and consulting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Increase in product design and development costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Increase in all other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,015</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Human resource related costs
increased by approximately $1,411,000 primarily due to the addition of employees in 2011. We had 49 employees at December 31, 2011,
which increased from 25 for the comparable date in the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Sales and marketing costs
increased $1,094,000 because of the increase in both sales territories and sales personnel during 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Professional fees increased
approximately $318,000, primarily due to an increase in legal fees arising from contract and patent services as well as due diligence
related to our merger with VitaMed in October 2011. We incurred additional accounting and audit costs related to audits for 2010
and 2011 as required by our merger with VitaMed. Consulting cost also increased as a result of opening new sales territories and
the additional resources needed to complete the merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">During 2011, we made improvements
to products and packaging, which increased costs by a nominal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Rent and occupancy costs increased
slightly as a result of repairs and maintenance and other ancillary costs. Non-cash compensation costs increased as a result of
the additional options granted in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Loss on Extinguishment of Debt</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On October 18, 2011, we and
two noteholders entered into debt conversion agreements and converted the $210,000 principal amount of their convertible notes
into 20,000,000 shares of our common stock valued at $7,600,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other Expense, net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Other non-operating expense
increased by $96,000 for the year ended December 31, 2011 over the prior fiscal year, primarily as a result of the addition of
interest expense not incurred during 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We have funded our operations
primarily through the private placement of equity, debt securities, and public offerings of our common stock. For the three year
period ending December 31, 2013, we received $12 million in net proceeds from the issuance of debt securities and $88 million in
net proceeds from the issuance of shares of our common stock. As of December 31, 2013, we had cash and cash equivalents totaling
$54 million, however, changing circumstances may cause
us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected
because of circumstances beyond our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We believe that our existing
cash and cash equivalents will allow us to fund our operating plan through at least the next 12 months. If our available cash
and cash equivalents are insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities
or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest
of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences
that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic
alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be
favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We need substantial amounts
of cash to complete the clinical development of our hormone therapy drug candidates. The following table sets forth the primary
sources and uses of cash for each of the periods set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Summary of Sources and (Uses) of Cash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 18pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Net cash flows used in operating activities</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&#36;&nbsp;</TD><TD STYLE="width: 13%; text-align: right">(20,768,069</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&#36;&nbsp;</TD><TD STYLE="width: 13%; text-align: right">(12,737,326</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&#36;&nbsp;</TD><TD STYLE="width: 13%; text-align: right">(4,966,596</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Net cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">(583,561</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">(272,506</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">(37,636</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Net cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">73,989,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">14,436,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">4,707,714</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The use of cash in all periods
resulted primarily from our net loss adjusted for non-cash charges and changes in components of working capital. The increase of
$8 million in cash used in operating activities for the year ended December 31, 2013 in comparison to prior year was due primarily
to research and development, sales, general and administrative costs. These were offset by $9 million in sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The increase of $8
million in cash used in operating activities for the year ended December 31, 2012  compared with the comparable period
in the prior year was due to research and development, and sales, general and administrative costs. These were
offset by $4 million in sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The use of cash in all
periods reflects patent costs, security deposits, and purchase of property and equipment. The increase of $300,000 in cash
used in investing activities for the year ended December 31, 2013 compared with the comparable period in the prior year
was due to patent costs and purchase of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The increase of $200,000
in cash used in investing activities for the year ended December 31, 2012 compared with the comparable period in the prior year was due to patent costs and purchase of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Financing activities represent
the principal source of our cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our financing activities for
the year ended December 31, 2013 provided net cash of $74 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On March 14, 2013, we entered
into an underwriting agreement. The net proceeds to us from this offering was approximately $45 million, after deducting underwriting
discounts and commissions and other offering expenses. In addition, under the terms of the underwritten offering, we granted the
underwriters a 30-day option to purchase additional shares of our common stock. On April 12, 2013, the underwriters exercised their
option to purchase 1,954,587 shares of our common stock, and we received net proceeds of approximately $3 million after deducting
underwriting discounts and commissions and other offering expenses. On September 25, 2013, we entered into an underwriting agreement.
The net proceeds to us from this offering was approximately $30 million, after deducting underwriting discounts and commissions
and other offering expenses. In March 2013, we repaid approximately $5 million in notes and credit lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our financing activities for
the year ended December 31, 2012 provided net cash of $14 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In September 2012, we
entered into a Securities Purchase Agreement with multiple investors, relating to the issuance and sale of our common stock
in a private placement to raise approximately $8 million in net proceeds. During 2012, we issued notes in the aggregate
amount of approximately $9 million to multiple parties, of which approximately $2 million was repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our financing
activities for the year ended December 31, 2011 provided net cash of $5 million. During 2011, we entered into a securities
purchase agreement with an investor, relating to the issuance and sale of our common stock in a private placement to raise
approximately $1 million in net proceeds. Our predecessor company sold membership units prior to our merger for
approximately $1 million of net proceeds. In 2011, we issued notes in the aggregate amount of approximately $3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Critical Accounting Estimates and New Accounting
Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Critical Accounting Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The preparation of financial
statements in accordance with accounting principles generally accepted in the United States requires us to make estimates and assumptions
that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate to be critical
if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">it requires assumptions to be made that were uncertain at the time the estimate was made, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">changes in the estimate or different estimates that could have been selected could have a material
impact on our results of operations or financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We base our estimates and
judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in
the industry, information provided by our customers, and information available from other sources. Actual results may differ from
these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as
those that we believe are most critical to our financial condition and results of operations and that require our most subjective
and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense and income taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Revenue
Recognition.</I><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><U> </U>We recognize revenue on arrangements
in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive
evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Over-the-Counter Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Prescription Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U></U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We sell our name brand and generic prescription
products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of
sales discounts, chargebacks, and rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We accept returns of unsalable product
from customers within a return period of six months prior to and following product expiration. Our prescription products currently
have a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently
cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition
of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription
products are dispensed through patient prescriptions or expiration of the right of return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We maintain various rebate programs in
an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate
program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end
user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Research
and Development Expense. </I><FONT STYLE="font-style: normal">We rely on the services of external contract research organizations,
or CRO&rsquo;s, to facilitate our clinical studies. Certain of these CRO&rsquo;s require us to make payments based on agreed-upon
terms, which may include payments in advance of a study starting date. We capitalize these advance payments into prepaid expense
when paid. We expense these nonrefundable advance payments for goods and services that will be used in future R&amp;D activities
when the activity has been performed rather than when the payment is made. As a result, we amortize certain of these amounts based
on factors relating to the progress of our clinical studies. These factors include successful enrollment of patients, expected
duration of studies, and completion of clinical trial milestones. On a quarterly basis we re-assess the factors by which these
advanced payments are expensed. If these factors change we adjust these prepaid balances accordingly.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Share-Based
Compensation.</I> We periodically issue stock options and warrants to employees and non-employees in non-capital
raising transactions for services and for financing costs. We account for stock option and warrant grants issued and vesting
to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of
the awards are measured on the date of grant and recognized over the vesting period. We account for stock option and warrant
grants issued and vesting to non-employees in accordance with the authoritative guidance of the Financial Accounting
Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the
date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity
instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a
straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option
grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement
date. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the
expected term that stock options and warrants will be outstanding prior to exercise and the associated volatility. We
estimate the fair value of options granted using the Black-Scholes-Merton valuation model. The expected life of the options
used in this calculation is the period the options are expected to be outstanding and has been determined based on the
simplified method in accordance with guidance provided by SEC Staff Accounting Bulletin 07 (ASC 718-10-S99). Expected stock
price volatility is based on the historical volatility of the stock of peer entities whose stock prices were publicly
available for a period approximating the expected life. We use the historical volatility of peer entities due to the lack of
sufficient historical data or our stock prices. The risk-free interest rate is based on the implied yield available on US
Treasury zero-coupon issues approximating the expected life. We believe that these assumptions are &quot;critical
accounting estimates&quot; because significant changes in the assumptions used to develop the estimates could materially
affect key financial measures including net income/(loss).</P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>Income Taxes</I>. As part
of the process of preparing our consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions
in which we operate. We determine provision for income taxes using the asset and liability approach to account for income taxes.
We record current liability for the estimated taxes payable for the current year. We record deferred tax assets and liabilities
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates
in effect for the year in which the timing differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of changes in tax rates or tax laws is recognized in the provision for income taxes in the period that includes
the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount more-likely-than-not
to be realized. Changes in valuation allowances will flow through the statement of operations unless related to deferred tax assets
that expire unutilized or are modified through translation, in which case both the deferred tax asset and related valuation allowance
are similarly adjusted. Where a valuation allowance was established through purchase accounting for acquired deferred tax assets,
any future change will be credited or charged to income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The determination of our provision
for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws.
In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain.
In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain
positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized
with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and
regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex
judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable,
the final determination could be materially different than that which is reflected in our provision for income taxes and recorded
tax assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><U>New Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In July, 2013, the FASB issued Accounting
Standards Update, or ASU, No. 2013-11, <I>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating
Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force)</I>,<I>
</I>or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized
tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax
benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward,
a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should
be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures.
The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December
15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In July 2012, the FASB issued ASU No. 2012-02,
<I>Testing Indefinite-Lived Intangible Assets for Impairment</I>,<I> </I>or ASU 2012-02. ASU 2012-02 gives entities an option to
first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely
than not that the long-lived intangible assets are impaired. If, based on its qualitative assessment, an entity concludes that it
is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative
impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU
2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with
early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In December 2011, the FASB issued ASU No.
2011-11, <I>Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities</I>, or ASU 2011-11<I>.</I> ASU 2011-11
enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of
financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are
offset on the statement of financial position. Entities are required to provide both net and gross information for these assets
and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial
statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting
periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material
impact on our financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We do not believe there would have been
a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting
standards been adopted in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">As of December 31, 2013,
2012 and 2011 we had no material off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In the ordinary course of
business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal
and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and
suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for
losses suffered or incurred by the indemnified parties with respect to our drug candidates, use of such drug candidates, or other
actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification
provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification
provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have
no liabilities recorded for these provisions as of December 31, 2013, 2012 or 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">In the normal course of business,
we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims,
environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess
the claim. If, in our opinion, we have incurred a probable loss as set forth by accounting principles generally accepted in the
United States, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Effects of Inflation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">For each of the fiscal years
ended December 31, 2013, 2012, and 2011, our business and operations have not been materially affected by inflation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">A summary of contractual cash
obligations as of December 31, 2013 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Payments Due By Period</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="13" STYLE="text-align: center">(in thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: center; padding-bottom: 1pt; padding-left: 10pt">&nbsp;</TD>
<TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Total</B></TD>
<TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Less than 1 Year</B></TD>
<TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD>
<TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>1-3 Years</B></TD>
<TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD>
<TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>4-5 Years</B></TD>
<TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 38%; text-align: left; padding-left: 10pt; text-indent: -10pt">Operating Lease Obligations</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: center; padding-left: 5.4pt">1,766</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: center">316</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: center">1,147</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: center">303</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Seasonality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The specialty pharmaceutical
industry component of women&rsquo;s health is not subject to seasonal sales fluctuation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A012"></A>Item&nbsp;7A.&nbsp;</TD><TD STYLE="text-align: justify"><I>Quantitative and Qualitative Disclosures about Market
Risk</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We had cash and cash equivalents
totaling $54 million as of December 31, 2013<FONT STYLE="color: #252525">. </FONT>We hold our cash in money market funds and the
primary objective of our investment policy is to preserve principal and maintain proper liquidity to meet operating needs<FONT STYLE="color: #252525">.
</FONT>Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to
any single issue, issuer or type of investment<FONT STYLE="color: #252525">. </FONT>Our primary exposure to market risk is interest
rate sensitivity, which is affected by changes in the general level of U.S. interest rates<FONT STYLE="color: #252525">. </FONT>To
minimize this risk, we intend to maintain a portfolio that may include cash, cash equivalents and investment securities available-for-sale
in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper,
all with various maturity dates<FONT STYLE="color: #252525">. </FONT> Due to the low risk profile of our investments, an immediate
100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We do not hold or issue derivatives,
derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our
cash equivalents and investment securities have significant risk of default or illiquidity. We made this determination based on
discussions with our investment advisors and a review of our holdings. While we believe our cash equivalents and investment securities
do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse
changes in market value. All of our investments are held at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A013"></A>Item 8.</TD><TD STYLE="text-align: justify"><I>Financial Statements and Supplementary Data</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Reference is made to the financial
statements, the notes thereto, and the report thereon, commencing on page F-1 of this Annual Report, which financial statements,
notes, and report are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 36pt; text-align: left"><A NAME="A014"></A>Item 9.</TD><TD STYLE="text-align: justify"><I>Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A015"></A>Item&nbsp;9A.&nbsp;</TD><TD STYLE="text-align: justify"><I>Controls and Procedures</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Evaluation of Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">We maintain disclosure controls
and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act
of 1934, as amended, is recorded, processed, summarized and reported within the specified time periods, and that such information
is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures
(as defined in the Securities Exchange Act of 1934 Rules 13a-15(f) or 15d-15(f)) as of the end of the period covered by this Annual
Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December
31, 2013, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the
reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified
in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and
Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Management&rsquo;s Annual Report on Internal
Control over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f)
and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting
principles generally accepted in the United States of America. Internal control over financial reporting includes those policies
and procedures that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the Company&rsquo;s assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">provide reasonable assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting principles, and that the Company&rsquo;s receipts and expenditures
are being made only in accordance with authorizations of the Company&rsquo;s management and directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: left">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use, or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The management assessed the
effectiveness of our internal control over financial reporting as of December 31, 2013. In making this assessment, the management
used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&mdash;Integrated
Framework. The Management&rsquo;s assessment included an evaluation of the design of the Company&rsquo;s internal control over
financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on the
management&rsquo;s assessment, we believe that our internal controls over financial reporting were effective as of December 31,
2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Rosenberg Rich Baker Berman
&amp; Company, an independent registered public accounting firm , has audited the consolidated financial statements included in
this Annual Report; and, as part of its audit, has issued an attestation report, included herein, on the effectiveness of our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Changes in Internal Control over Financial
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">There was no change in our
internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Inherent Limitations on Effectiveness of Controls</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Our
management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented
or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration
of the degree of compliance with policies or procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A015a"></A>Item&nbsp;9B.&nbsp;</TD><TD STYLE="text-align: justify"><I>Other Information</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="A016"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A017"></A>Item&nbsp;10.&nbsp;</TD><TD STYLE="text-align: justify"><I>Directors, Executive Officers, and Corporate Governance</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The information required by
this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement
to be filed pursuant to Regulation 14A of the Exchange Act for our 2014 Annual Meeting of Stockholders<B>. </B>The information
required by this Item relating to our executive officers is included under the caption &ldquo;Executive Officers&rdquo; within
Item 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A018"></A>Item&nbsp;11.&nbsp;</TD><TD STYLE="text-align: justify"><I>Executive Compensation</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the
Exchange Act for our 2014 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A019"></A>Item&nbsp;12.&nbsp;</TD><TD STYLE="text-align: justify"><I>Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The information required by
this Item is incorporated by reference to the definitive Proxy Statement to be filed pursuant to Regulations 14A of the Exchange
Act for our 2014 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A020"></A>Item&nbsp;13.&nbsp;</TD><TD STYLE="text-align: justify"><I>Certain Relationships and Related Transactions, and Director
Independence</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The information required by
this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the
Exchange Act for our 2014 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A021"></A>Item&nbsp;14.&nbsp;</TD><TD STYLE="text-align: justify"><I>Principal Accountant Fees and Services</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">The information required by
this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regular 14A of the Exchange
Act for our 2014 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="A022"></A>PART IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD NOWRAP STYLE="width: 36pt; text-align: left"><A NAME="A023"></A>Item&nbsp;15.&nbsp;</TD><TD STYLE="text-align: justify"><I>Exhibits and Financial Statement Schedules</I></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">(a)</TD><TD STYLE="text-align: justify"><B>Financial Statements and Financial Statements Schedules</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: left">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of this
Annual Report.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: left">No financial statement schedules are included because such schedules are not applicable, are not required,
or because required information is included in the consolidated financial statements or notes thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt; text-align: left">(b)</TD><TD STYLE="text-align: justify"><B>Exhibits</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><b>Exhibit</b></P></td>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><b>Date</b></P></td>
    <TD STYLE="width: 68%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><b>Description</b></P></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 6, 2009</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&rsquo;s Minority Health Network, Inc., and the Major Shareholders<sup>(1)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">June 11, 2010</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.<sup>(2)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2.3</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 25, 2007</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization<sup>(3)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">2.4</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 18, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC<sup>(4)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 15, 2009</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Articles of Amendment to Articles of Incorporation (to change name to AMHN, Inc.)<sup>(5)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 27, 2009</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Certificate of Merger of AMHN Acquisition Corp., with and into America&rsquo;s Minority Health Network, Inc.<sup>(6)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.3</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">December 27, 2007</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Articles of Amendment to Articles of Incorporation of Croff Enterprises, Inc. (to increase authorized common shares from 20,000,000 to 50,000,000)<sup>(3)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.4</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 20, 2010</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<sup>(7)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.5</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 20, 2010</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<sup>(7)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.6</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">August 29, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment and Restatement of Articles of Incorporation of AMHN, Inc. (to change name and increase authorized shares)<sup>(8)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">3.7</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Bylaws of AMHN, Inc.<sup>(9)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">4.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 26, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Securities Purchase Agreement<sup> (10)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">4.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Certificate of Common Stock<sup>(11)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">November 9, 2010</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Demand Promissory Note to Philip M. Cohen for $210,000<sup>(12)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">April 18, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Promissory Note to First Conquest Investment Group, L.L.C. for $105,000<sup>(12)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.3</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">April 18, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Promissory Note to Energy Capital, LLC for $105,000<sup>(12)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.4</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">May 7, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Sales Representative Agreement between AMHN, Inc. and Mann Equity, LLC<sup>(12)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.5</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">July 9, 2009</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Lease Agreement between Liberty Property Limited Partnership and VitaMedMD, LLC<sup>(13)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.6</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 8, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Stock Purchase Agreement between AMHN, Inc. and Pernix Therapeutics, LLC<sup>(14)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.7</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 8, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Lock-Up Agreement between AMHN, Inc. and Pernix Therapeutics, LLC<sup>(14)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.8</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant<sup> (13)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.9</font>&#42;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Non-Qualified Stock Option Agreement<sup> (13)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.10</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Convertible Promissory Note<sup>(15)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.11</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">September 20, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Financing Agreement between Lang Naturals, Inc. and VitaMedMD, LLC<sup>(16)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.12</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 18, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Debt Conversion Agreement between the Company and Energy Capital, LLC<sup>(17)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.13</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 18, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Debt Conversion Agreement between the Company and First Conquest Investment Group, LLC<sup>(17)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.14</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 23, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement among VitaMedMD, LLC, the Company, and Lang Naturals, Inc.<sup>(17)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.15</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 23, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Warrant to Lang Naturals, Inc.<sup>(17)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.16</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">October 23, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Lock-Up Agreement between the Company and Lang Naturals, Inc. <sup>(17)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">10.17</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">November 3, 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Software License Agreement between vitaMedMD, LLC and Pernix Therapeutics, LLC<sup>(18)</sup></font></td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 11%; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><b>Exhibit</b></P></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 21%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><b>Date</b></P></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; border-bottom: Black 0.5pt solid"><b>Description</b></P></td></tr>

<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 11%; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.18</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 21%"><font style="font: 10pt Times New Roman, Times, Serif">November 2011</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; width: 68%"><font style="font: 10pt Times New Roman, Times, Serif">Form of Promissory Note<sup> (19)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.19</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">February 24, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Note Purchase Agreement among the Company, Plato &amp; Associates, Inc., and Steven G. Johnson<sup>(20)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.20</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">February 24, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Secured Promissory Note<sup>(20)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.21</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">February 24, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Security Agreement among the Company, Plato &amp; Associates, Inc., and Steven G. Johnson<sup>(20)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.22</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">February 24, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Common Stock Purchase Warrant<sup>(20)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.26</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">April 17, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Master Services Agreement between the Company and Sancilio and Company, Inc.<sup>(21)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.27</font>&#42;&#42;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">May 17, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement between the Company and Sancilio and Company, Inc.<sup> (21)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.28</font>&#42;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">November 8, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Form of Employment Agreement<sup>(22)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.29</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">January 31, 2013</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Multiple Advance Revolving Credit Note, issued to Plato &amp; Associates, LLC<sup>(23)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.30</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">January 31, 2013</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Warrant, issued to Plato &amp; Associates, LLC<sup>(23)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.31</font>&#42;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">May 8, 2013</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio<sup>(24)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.32</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">May 7, 2013</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement between the Company and Sancilio and Company, Inc.<sup> (24)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.33</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">May 16, 2013</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Lease between the Company and 6800 Broken Sound LLC<sup>(25)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.34&#42;</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Amended and Restated 2012 Stock Incentive Plan<sup>(26)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">10.35&#42;</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2009 Long Term Incentive Compensation Plan, as amended<sup>(27)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">21.00</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2012</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Subsidiaries of the Company<sup>(21)</sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">23.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">March
    5, 2014</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif"><A HREF="ex23-1.htm#Exhibits">Consent of Rosenberg Rich Baker Berman &amp; Company</A><sup></sup></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">31.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">March
    5, 2014</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex31-1.htm"><font style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</font></A></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">31.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">March
    5, 2014</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex31-2.htm"><font style="font: 10pt Times New Roman, Times, Serif">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</font></A></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">32.1</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">March
    5, 2014</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex32-1.htm"><font style="font: 10pt Times New Roman, Times, Serif">Certification
    pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></A></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">32.2</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">March
    5, 2014</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><A HREF="ex32-2.htm"><font style="font: 10pt Times New Roman, Times, Serif">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></A></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">101.INS &dagger;</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Instance Document</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><font style="font: 10pt Times New Roman, Times, Serif">101.SCH &dagger;</font> </td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Taxonomy Extension Schema Document</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL &dagger;</FONT></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Taxonomy Extension Calculation Linkbase Document</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF &dagger;</FONT></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Taxonomy Extension Definition Linkbase Instance Document</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB &dagger;</FONT></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Taxonomy Extension Label Linkbase Instance Document</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE &dagger;</FONT></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
Taxonomy Extension Presentation Linkbase Instance Document</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*</TD><TD STYLE="text-align: left">Indicates a contract with management or compensatory plan or arrangement. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">**</TD><TD STYLE="text-align: left">Certain information in this exhibit has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&dagger;</TD><TD STYLE="text-align: left">Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part
of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed
not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability
under those sections.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(1)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(2)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(3)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on
May 1, 2008 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(4)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(5)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2009 filed with the Commission on
November 16, 2009 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(6)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-K for the year ended December 31, 2009 filed with the Commission on
March 17, 2010 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(7)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2010 filed with the Commission on August
3, 2010 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(8)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on September
12, 2011 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(9)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29,
2010 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(10)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on October 2, 2012 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(11)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(12)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2011 filed with the Commission on May
19, 2011 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(13)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(14)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on September 14, 2011 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(15)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K/A filed with the Commission on November 22, 2011 and incorporated
herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(16)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K/A filed with the Commission on February 2, 2012 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(17)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(18)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2011 filed with the Commission on
November 7, 2011 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(19)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on November 23, 2011 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(20)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(21)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2012 filed with the Commission on August
9, 2012 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(22)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2012 filed with the Commission on
November 13, 2012 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(23)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein
by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(24)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2013 filed with the Commission on May
10, 2013 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(25)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2013 filed with the Commission on August
7, 2013 and incorporated herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(26)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated
                                                                       herein by reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><SUP>(27)</SUP></TD><TD STYLE="text-align: left">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October
                                                                       15,                                                                        2013 and
                                                                       incorporated                                                                                                   herein by
                                                                       reference.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -0.5in"></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>THERAPEUTICSMD, INC.</B></TD>
</TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"></TD>
    <TD STYLE="vertical-align: top; width: 46%">/<I>s</I>/<I> Robert G. Finizio</I></TD>
</TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Robert G. Finizio<BR>Chief Executive Officer</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0">Date:
March 5, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the date indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Signature</u></b></font></td>
    <td style="width: 41%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Capacity</u></b></font></td>
    <td style="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>Date</u></b></font></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert G. Finizio</i></font></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, Director</font><br>
<font style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</font></td>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
    5, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ John C.K. Milligan, IV</i></font></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">President, Secretary, Director</font></td>
    <TD ROWSPAN="2" STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
    5, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">John C.K. Milligan, IV</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Daniel A. Cartwright</i></font></td>
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Chief Financial Officer, Treasurer&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Principal Financial and Accounting Officer)</P></td>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
    5, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Tommy G. Thompson</i></font></td>
    <TD ROWSPAN="2" STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chairman</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></td>
    <TD STYLE="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
    5, 2014</FONT></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Tommy G. Thompson</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Brian Bernick</i></font></td>
    <TD ROWSPAN="2" STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
        5, 2014</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Brian Bernick</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Cooper C. Collins</i></font></td>
    <TD ROWSPAN="2" STYLE="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;March
        5, 2014&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Cooper C. Collins</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Robert V. LaPenta, Jr.</i></font></td>
    <TD ROWSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></td>
    <td rowspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;March
        5, 2014</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Robert V. LaPenta, Jr.</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Nicholas Segal</i></font></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;Director&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
        5, 2014</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Nicholas Segal</font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Jules Musing</i></font></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;Director&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
        5, 2014</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Jules Musing</font></td></tr>
<tr>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Randall Stanicky</i></font></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;Director&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td>
    <td rowspan="2" style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;March
        5, 2014&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Randall Stanicky</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="width: 93%; text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="width: 7%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Page</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#LegalMatters">Reports of Independent Registered Public Accounting Firm</A></td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-2</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#B001">Consolidated Balance Sheets as of December 31, 2013 and 2012</A></td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-4</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#B002">Consolidated Statements of Operations for the years ended December 31, 2013, 2012 and 2011</A></td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-5</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#B003">Consolidated Statements of Stockholders&rsquo; Equity for the years ended December 31, 2013, 2012 and 2011</A></td>
    <td nowrap style="background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-6</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><A HREF="#B004">Consolidated Statements of Cash Flows for the years ended December 31, 2013, 2012 and 2011</A></td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-7</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <TD NOWRAP STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="background-color: white; text-indent: -10pt; padding-left: 10pt"><A HREF="#B005">Notes to Consolidated Financial Statements</A></td>
    <td nowrap style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">F-8</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 71; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white"><A NAME="LegalMatters"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">To
the Board of Directors and</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><BR>
<FONT STYLE="background-color: white">Stockholders of TherapeuticsMD, Inc.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
have audited the accompanying consolidated balance sheets of TherapeuticsMD, Inc. as of December 31, 2013 and 2012, and the related
consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows for each of the years in the three
year period ended December 31, 2013. TherapeuticsMD Inc.&#8217;s management is responsible for these consolidated financial statements.
Our responsibility is to express an opinion on these consolidated financial statements based on our audits</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">In
our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position
of TherapeuticsMD, Inc. as of December 31, 2013 and 2012, and the results of its operations and its cash flows for each of the
years in the three year period ended December 31, 2013 in conformity with accounting principles generally accepted in the United
States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), TherapeuticsMD
Inc.&#8217;s internal control over financial reporting as of December 31, 2013, based on criteria established in Internal Control&#8212;Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated March 5,
2014 expressed an unqualified opinion on the effectiveness of TherapeuticsMD, Inc.&#8217;s internal control over financial reporting.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">/s/
Rosenberg Rich Baker Berman &amp; Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Somerset,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
5, 2014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-2</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white"><A NAME="LegalProceedings"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">To
the Board of Directors and</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><BR>
<FONT STYLE="background-color: white">Stockholders of TherapeuticsMD, Inc.</FONT></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
have audited TherapeuticsMD, Inc.&#8217;s internal control over financial reporting as of December 31, 2013, based on criteria
established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO). TherapeuticsMD Inc.&#8217;s management is responsible for maintaining effective internal control over financial
reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying
Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on
the Company&#8217;s internal control over financial reporting based on our audit.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an
understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and
evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing
such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for
our opinion.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">A
company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s
assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">In
our opinion, TherapeuticsMD, Inc. maintained, in all material respects, effective internal control over financial reporting as
of December 31, 2013, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO).</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">We
have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated
balance sheets and the related consolidated statements of operations, stockholders&#8217; equity (deficit), and cash flows of
TherapeuticsMD, Inc., and our report dated March 5, 2014 expressed an unqualified opinion on those consolidated financial statements.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">/s/
Rosenberg Rich Baker Berman &amp; Company</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">Somerset,
New Jersey</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: white">March
5, 2014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-3</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="B001"></A><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; padding-left: 22pt; text-indent: -10pt">Cash</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">54,191,260</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,553,474</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Accounts
    receivable, net of allowance for doubtful accounts of $26,555 and $42,048, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,690,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,043,618</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,615,210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,477,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">751,938</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 33pt; text-indent: -10pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,403,346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,635,047</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Fixed assets, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">65,673</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Other Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Prepaid expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">953,655</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">665,588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">239,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Security deposit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">135,686</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,949</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,551,729</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,225,159</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 44pt; text-indent: -10pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,016,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,925,879</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,114,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,641,366</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,602,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,144,752</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,601,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">833,654</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,317,986</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,619,772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Long-Term Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Notes payable, net of debt discount of $0 and $1,102,680, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,589,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Accrued interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,068</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total long-term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,739,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 44pt; text-indent: -10pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,317,986</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,359,007</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Commitments and Contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Stockholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Common stock - par value $0.001; 250,000,000 shares authorized; 144,976,757 and 99,784,982 issued and outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,785</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,086,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,580,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(80,532,626</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,113,313</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,698,407</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,433,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 44pt; text-indent: -10pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,016,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,925,879</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="B002"></A>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt">Revenues, net</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">8,775,598</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">3,818,013</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2,088,177</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Cost of goods sold</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,959,597</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,348,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">947,112</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,816,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,469,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,141,065</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Sales, general, and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,014,837</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,069,701</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,406,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,551,263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,492,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,241</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,145</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,260</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,845</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 33pt; text-indent: -10pt">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,624,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,618,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,568,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,808,244</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,148,423</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,427,218</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Other income and (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">Miscellaneous income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,544</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,392</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,234</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,503,922</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,165,981</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,905,409</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(64,380</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Loan guaranty costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,944</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,036</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,159</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,307,864</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,390,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt; padding-bottom: 1pt">Beneficial conversion feature</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,716,504</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 22pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,611,069</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,971,812</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,486,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Loss before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,419,313</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,120,235</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,913,365</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,419,313</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(35,120,235</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,913,365</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Net loss per share, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.22</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.38</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.21</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Weighted average number of common shares
    outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">127,569,731</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">91,630,693</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">62,516,461</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="B003"></A><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY (DEFICIT)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2013, 2012
AND 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Additional</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center">Common Stock</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Paid in</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Accumulated</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Shares</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Amount</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Capital</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Total</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Balance, December 31, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">55,487,321</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="text-align: right">55,487</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="text-align: right">4,988,637</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="text-align: right">(4,079,713</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="text-align: right">964,411</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">165,879</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">166</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(255,919</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(255,753</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Shares issued in private placement, net of cost</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,551,589</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,552</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,701,448</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,707,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Shares issued in exchange for debt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">21,681,958</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">21,682</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,217,455</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,239,137</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Shares issued for exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">92,057</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">92</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">17,158</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">17,250</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Options issued as compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">183,355</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">183,355</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for services</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">190,280</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">190,280</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for loan guaranty costs-related parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">93,969</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">93,969</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for financing costs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">45,362</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">45,362</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for financing costs-related parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">9,338</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">9,338</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued as compensation-related party</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,158</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,158</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,913,365</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,913,365</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Balance, December 31, 2011</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">82,978,804</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">82,979</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">15,198,241</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(16,993,078</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,711,858</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Shares issued in private placement, net of cost</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,953,489</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,954</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,891,531</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,895,485</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Shares issued in exchange for debt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,775,415</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,775</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,051,882</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,054,657</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Shares issued for exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,931,788</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,932</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">189,068</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">191,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Shares issued for exercise of warrants</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,145,486</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,145</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,093,855</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,102,000</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Options issued as compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,832,061</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,832,061</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for financing costs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,014,784</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,014,784</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for services</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,563,620</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,563,620</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued as compensation-related party</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">36,284</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">36,284</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for cash</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">400</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">400</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Cancellation of warrants issued for loan guaranty costs-related parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(7,830</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(7,830</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Beneficial ownership feature</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">6,716,504</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">6,716,504</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,120,235</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(35,120,235</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 10pt; text-indent: -10pt">Balance, December 31, 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">99,784,982</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">99,785</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">50,580,400</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(52,113,313</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">(1,433,128</TD>
    <TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Shares issued in private placements, net of cost</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">45,116,352</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">45,117</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">78,605,236</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">78,650,353</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Shares issued for exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">75,423</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">75</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">30,835</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">30,910</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Employee Share Based Compensation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,254,083</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,254,083</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for financing costs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,711,956</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,711,956</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued for services</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">867,262</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">867,262</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants issued as compensation-related party</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">36,284</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">36,284</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,419,313</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,419,313</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><B>Balance, December 31, 2013</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">144,976,757</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">144,977</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">135,086,056</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(80,532,626</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,698,407</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="B004"></A><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; text-align: center">Year Ended December, 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left; padding-left: 33pt; text-indent: -10pt">Net loss</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(28,419,313</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(35,120,235</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(12,913,365</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 44pt; text-indent: -10pt">Adjustments to reconcile net loss to net cash flows used
    in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Effect of merger and recapitalization pursuant to execution
    of Security Exchange Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(255,753</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,883</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,686</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,262</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Provision for doubtful accounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,493</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,548</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Loss on extinguishment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,307,864</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,390,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Beneficial conversion feature</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,716,504</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,102,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,604,240</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,719</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,207,238</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,868,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Amortization of deferred financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,451,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Stock based expense for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,630</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Loan guaranty costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 55pt; text-indent: -10pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,068,619</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(728,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,409</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,592</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,027,137</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,996</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,386,319</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(346,822</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(565,706</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">472,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,334,855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,144,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt">Accrued expenses and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,875,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">639,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,535</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 66pt; text-indent: -10pt; padding-bottom: 1pt">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(150,068</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Net cash flows used in operating
    activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(20,768,069</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,737,326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,966,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Patent costs, net of abandoned costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(439,034</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,101</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,870</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt">Payment of security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(103,737</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40,790</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(66,405</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,766</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Net cash flows used in investing
    activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(583,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(272,506</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(37,636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from sale of common stock,
    net of costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,650,353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,895,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds bank line of credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from exercise of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from notes and loans payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,684,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from sale of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from notes and loans payable-related
    parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Proceeds from sale of membership
    units, net of expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">707,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Repayment of bank line of credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(300,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Repayment of notes payable-related
    party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(200,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,696</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 33pt; text-indent: -10pt; padding-bottom: 1pt">Repayment of notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,691,847</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,850,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Net cash flows provided by financing
    activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">73,989,416</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,436,885</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,707,714</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,637,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,427,053</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(296,518</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cash, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,553,474</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">126,421</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">422,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cash, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,191,260</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,553,474</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">126,421</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="13" STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">SUPPLEMENTAL DISCLOSURES OF CASH FLOW
    INFORMATION:</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">212,853</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,253</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">696</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="13" STYLE="text-align: center; padding-left: 10pt; text-indent: -10pt">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING
    ACTIVITIES:</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Warrants issued for financing</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,711,956</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,509,537</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">148,668</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Warrants issued for services</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">462,196</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,532,228</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">190,280</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Warrants exercised in exchange for
    debt and accrued interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,102,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Shares issued in exchange for debt
    and accrued interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,054,658</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">849,137</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Notes payable issued for accrued
    interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,123</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part
of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="B005"></A><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
1 &ndash; THE COMPANY</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized
on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless
the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as &ldquo;our company,&rdquo;
&ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Nature of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&rsquo;s healthcare product
company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on
conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy
pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of
and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and
vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or
in combination, with the aim of providing equivalent efficacy at lower doses, thereby enabling an enhanced side effect
profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables
the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture (through third
parties) and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and
cosmetics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Agreement and Plan of Merger with VitaMed</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2011, we entered into an Agreement
and Plan of Merger with VitaMed and our newly formed wholly owned subsidiary. In connection with the acquisition, our subsidiary
merged with and into VitaMed with VitaMed surviving the merger. The merger became effective upon the filing of the Certificate
of Merger with the Secretary of State of the State of Delaware on October 4, 2011. In preparation for and prior to the closing
of the Merger, we completed the following required corporate actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">a
                                         reverse split of our 16,575,209 issued and outstanding shares of our common stock, par
                                         value $0.001 per share, or the Common Stock, on a ratio of 1-for-100. As a result of
                                         the reverse split, each share of Common Stock outstanding on the July&nbsp;28, 2011 record
                                         date, without any action on the part of the holder thereof, became one one-hundredth
                                         of a share of Common Stock. The reverse split decreased the number of outstanding shares
                                         of our Common Stock by approximately 99%, resulting in 165,856 shares outstanding after
                                         the reverse split. The effectuation of the reverse split did not result in a change in
                                         the relative equity position or voting power of our shareholders;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">an
                                         increase in the number of shares of our Common Stock authorized for issuance to 250,000,000;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">a
                                         change in the name of our company to TherapeuticsMD, Inc.; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">an
                                         amendment to our 2009 Long Term Incentive Compensation Plan to increase the number of
                                         shares of our Common Stock reserved for issuance thereunder to 25,000,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the effective date of the merger, we acquired
100% of VitaMed in exchange for shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Exchange of Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the effective date of the merger, all outstanding
membership units of VitaMed were exchanged for shares of our Common Stock. In addition, all outstanding options and warrants to
purchase VitaMed membership units were exchanged for and converted into options and warrants to purchase shares of our Common Stock.
Pursuant to the conversion ratio in the merger, we issued 58,407,331 shares of our Common Stock in exchange for the outstanding
VitaMed membership units, reserved an aggregate of 10,119,796 shares of our Common Stock for issuance upon the exercise of the
VitaMed options, and reserved an aggregate of 1,472,916 shares of our Common Stock for issuance upon the exercise of the warrants.
After giving effect to the reverse split, and taking into consideration the 58,407,331 shares issued in exchange for the membership
units, the number of shares of our Common Stock issued and outstanding as of the effective date of the merger was 58,573,187, of
which the former members of VitaMed owned approximately 99%. All shares of our Common Stock issued in exchange for the VitaMed
membership units and issuable upon exercise of the options and warrants were subject to a lock-up agreement for a period of 18
months from the effective date of the merger, and on a limited basis for 12 months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><U>NOTE
2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Principles of Consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Cash</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">We
maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses
related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting
from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no
limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per
depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured
limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal; letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal; letter-spacing: 0pt"><U>Trade
Accounts Receivable and Allowance for Doubtful Accounts</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal; letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <FONT STYLE="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt"><U>Inventories</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">Inventories
represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using
the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed
in <U>Revenue Recognition</U>) are recorded as deferred costs and are included in inventory, until such time as the related deferred
revenue is recognized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Fixed Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Equipment</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <FONT STYLE="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Leasehold
Improvements</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt"><U>Intangible</U> </FONT><U>Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt"><I><U>Patent
and Trademarks</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">We have
adopted the provisions of </FONT>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <FONT STYLE="letter-spacing: -0.15pt">350,
<I>Intangible-Goodwill and Other</I>,<I> </I>or </FONT>ASC 350<FONT STYLE="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </FONT>In accordance with ASC 350, <FONT STYLE="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted
in the year ended December 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Impairment of Long-Lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property and
equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying
values may not be recoverable. Such events or circumstances include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">significant
                                         declines in an asset&rsquo;s market price;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">significant
                                         deterioration in an asset&rsquo;s physical condition;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">significant
                                         changes in the nature or extent of an asset&rsquo;s use or operation;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">significant
                                         adverse changes in the business climate that could impact an asset&rsquo;s value, including
                                         adverse actions or assessments by regulators; </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">accumulation
                                         of costs significantly in excess of original expectations related to the acquisition
                                         or construction of an asset;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">current-period
                                         operating or cash flow losses combined with a history of such losses or a forecast that
                                         demonstrates continuing losses associated with an asset&rsquo;s use; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">expectations
                                         that it is more likely than not that an asset will be sold or otherwise disposed of significantly
                                         before the end of its previously estimated useful life.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&rsquo;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future
cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a
loss for the difference between the assets&rsquo; fair value and respective carrying value. We determine the fair value of the
assets using an &ldquo;income approach&rdquo; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected
selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships,
market conditions, and available external information about future trends. We believe our current assumptions and estimates are
reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting
in the need for an impairment charge in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Fair Value of Financial Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts
payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered
Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short-
and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which
would be considered Level 3 inputs under the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <I>Fair Value Measurements
and Disclosures. </I> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets
and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities recorded in the consolidated
balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 54pt; text-align: left"><B>Level 1</B></TD><TD STYLE="text-align: justify">unadjusted quoted prices in active markets for identical
assets or liabilities;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left"><B>Level 2</B></TD><TD STYLE="text-align: justify">quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left"><B>Level 3</B></TD><TD STYLE="text-align: justify">unobservable inputs for the asset or liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 81; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, 2012, and 2011, we had
no assets or liabilities that were valued at fair value on a recurring basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt"><U>Income
Taxes</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="letter-spacing: 0pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the advent of the Merger, we determined
that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because
of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4,
2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <I>Income Taxes</I>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating
to open tax returns that were considered to be uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Share-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2004, the FASB issued ASC 718,
<I>Compensation &ndash; Stock Compensation</I>,<I> </I>or<I> </I>ASC 718. Under ASC 718, companies are required to measure the
compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial
statements over the period during which employees are required to provide services. Share-based compensation arrangements include
options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase
plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any,
over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,
an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the
expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of
the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&ldquo;instruments&rdquo;)
issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC
505, <I>Equity Based Payments to Non-Employees</I>,<I> </I>or ASC 505<I>, </I>defines the measurement date and recognition period
for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b)
the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the
instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&rsquo;s requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Debt Discounts</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Revenue Recognition</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <I>Revenue Recognition</I>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Over-the-Counter Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <FONT STYLE="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</FONT>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Prescription Products</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #252525">We sell our name
brand and generic prescription products </FONT>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product from
customers within a return period of six months prior to and following product expiration. Our prescription products currently have
a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot
reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue
on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products
are dispensed through patient prescriptions or expiration of the right of return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an effort
to maintain<I> </I>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program
is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We
estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,
on a quarterly basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Shipping and Handling Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt"><U>Advertising Costs</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31,
2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&amp;D, expenses
include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&amp;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based
compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity
expenses include regulatory consulting and legal counsel. We charge internal R&amp;D activities and other activity expenses to
operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting
date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the
activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed
in future R&amp;D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively.
We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those
costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Earnings Per Share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS, in
accordance with ASC 260, <I>Earnings Per Share</I>, which requires the computation and disclosure of two EPS amounts: basic and
diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We
compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options
and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our
Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these
periods because their effect would have been anti-dilutive due to the net loss reported by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal"><U>Use
of Estimates</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Recently Issued Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July, 2013, the FASB issued
Accounting Standards Update, or ASU, No. 2013-11, <I>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when
a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues
Task Force)</I>,<I> </I>or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation
of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.
An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating
loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized
tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new
recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning
after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2012, the FASB issued ASU No. 2012-02,
<I>Testing Indefinite-Lived Intangible Assets for Impairment</I>,<I> </I>or ASU 2012-02. ASU 2012-02 gives entities an option to
first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely
than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it
is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative
impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU
2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with
early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
<I>Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities</I>, or ASU 2011-11<I>.</I> ASU 2011-11 enhances
current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial
position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset
on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities
in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared
on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on
or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our
financial position or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Reclassifications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain 2012 amounts have been reclassified to conform
to current year presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 85; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 3 &ndash; INVENTORY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2013</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2012</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Finished
    product</FONT></TD><TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">621,679</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">1,124,739</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Raw
    material</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">250,943</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">380,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Deferred
    costs</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">170,996</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">110,471</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">TOTAL
    INVENTORY</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">1,043,618</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">1,615,210</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 4 &ndash; OTHER CURRENT ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: normal 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2013</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2012</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Prepaid
    R&amp;D costs</FONT></TD><TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">1,267,588</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="width: 3%; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">189,375</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Prepaid
    consulting</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">530,596</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">432,216</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Deferred
    financing costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">260,022</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9472;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Other
    receivable &ndash; related party</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">249,981</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9472;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Prepaid
    other</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">169,528</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">127,403</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Prepaid
    guaranty costs</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9472;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2,944</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">TOTAL
    OTHER CURRENT ASSETS</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2,477,715</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">751,938</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 5 &ndash; FIXED ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2013</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">2012</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Equipment</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">108,458</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">67,668</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Furniture
    and fixtures</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">46,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">46,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Leasehold
    improvements</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9472;</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">11,980</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">155,083</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">126,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">Accumulated
    depreciation</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">(93,765</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">(60,600</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">TOTAL
    FIXED ASSETS</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">61,318</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">65,673</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2013, 2012, and 2011 was $45,145, $27,484 and $25,686, respectively. In December 2013, accumulated depreciation was reduced
by $11,980 associated with leasehold improvements of our previously leased office property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 6 &ndash;PREPAID EXPENSE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid R &amp; D costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">824,221</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">953,655</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid manufacturing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">899,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Accreted prepaid costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">TOTAL PREPAID EXPENSE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,750,455</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">953,655</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 7 &ndash; INTANGIBLE ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of&nbsp;December&nbsp;31, 2013&nbsp;and&nbsp;December&nbsp;31,
2012:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&nbsp;31,
    2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross<BR>
    Carrying<BR> Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<BR>
    Amortization</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net<BR>
    Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<BR>
    Average<BR> Amortization<BR> Period&nbsp;(yrs.)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>Amortizing intangible assets:</B></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">OPERA&reg; software patent</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">31,951</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(499</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">31,452</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">15.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Development
    costs for corporate website</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(89,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt"><B>Non-amortizing
                                         intangible assets:</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><P STYLE="margin: 0 0 0 12pt; text-indent: -12pt">Hormone therapy drug candidate patents</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">572,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">572,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Multiple
    trademarks for vitamins/supplements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">n/a</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 24pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">755,748</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(90,160</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">665,588</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross<BR> Carrying<BR> Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<BR> Amortization</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net<BR> Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR> Average<BR> Amortization<BR> Period&nbsp;(yrs.)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Amortizing intangible assets:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left; padding-left: 10pt; text-indent: -10pt">OPERA &reg; software patent</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">23,722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">23,722</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Development costs for corporate website</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(77,159</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Non-amortizing intangible assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Hormone therapy drug candidate patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Multiple trademarks for vitamins/supplements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,055</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,055</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">316,714</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(77,159</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">239,555</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 87; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">The intangible asset related
to development costs for corporate website is amortized over 36 months, which is the prescribed life for software and website development
costs. The intangible asset related to OPERA&reg; is amortized using the straight-line method over the estimated remaining useful
life of 16 years, which is the life of the intellectual property patents.&nbsp;&nbsp;During the year ended December 31, 2013, there
was no impairment recognized. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Amortization expense was $13,001,
$28,776, $29,159 for the years ended December 31, 2013, 2012, and 2011, respectively. Estimated amortization expense for the next
five years is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Year Ending December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Estimated Amortization</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">2014</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">4,080</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">1,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">1,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">1,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#36;&nbsp;</TD><TD STYLE="text-align: right">1,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 8 &ndash; OTHER CURRENT LIABILITIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued payroll and commission costs</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">941,313</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">397,210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued financing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">850,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued vacation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,899</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Allowance for wholesale distributor fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,303</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,784</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued legal and accounting expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued lab research</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">536,574</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued clinical trial costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Allowance for coupons and returns</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126,233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,002</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses<sup>(1)</sup></font></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">230,088</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">70,759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">&nbsp;TOTAL OTHER CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,601,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">833,654</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 36pt; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><SUP>(1) </SUP>In June 2008, we declared and paid a special
dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed
by certain shareholders at December 31, 2013 and 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 9 &ndash; NOTES PAYABLE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of Multiple Advance
Revolving Credit Note</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2013, we entered into a
business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the
Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal
amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the
Revolving Credit Note at our request, which advances were of a revolving nature and were able to be,made, repaid, and made
from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in
which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the
Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any,
was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each
of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid
$401,085, including accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31,
2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a
warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (see NOTE 10 for more
details).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Borrowing under Business Loan Agreement
and Promissory Note, as amended</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were
required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers
of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.
The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.
We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the
extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013. On November 13, 2012, the outstanding balance
of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with
the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited
Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.
In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. The amended bank line of credit
required a personal guarantee and cash collateral limited to $100,000, which was provided by Reich Family Limited Partnership.
On April 25, 2013, we re-paid $100,735, which represented the principal and interest that was due under the amended bank line of
credit. On May 1, 2013, the amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled,
and the cash collateral was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013, 2012, and
2011, we paid $735, $7,366, and $5,650, respectively, of interest expense, which are included in interest expense on the accompanying
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance of Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February 2012, we issued 6%
promissory notes in the aggregate principal amount of $900,000, due March 1, 2012. As discussed below in <U>Issuance and Settlement
of February 2012 Notes</U>, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Settlement of February 2012
Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2012, we issued promissory
notes, the February 2012 Notes, to an individual and an entity, or the Parties, both of which are stockholders of our company,
in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of 9,000,000
shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received an aggregate
of $1,000,000 of new funding from the Parties upon issuance of the February 2012 Notes and related warrants and surrender by the
Parties of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the aggregate accrued
interest of $15,124 (collectively known as the &ldquo;Prior Notes&rdquo;). Under the February 2012 Notes, we borrowed an additional
$3,000,000 from the Parties during March, April, and May 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We granted 5,685,300 warrants in
consideration of the modification of the Prior Notes and 3,314,700 warrants with the February Funding. We determined that the
resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Modifications
and Extinguishments.&nbsp;</I></FONT>As such the modification was accounted for as an extinguishment and restructuring of
the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed (see <U>Warrant Activity
During 2012 </U>in NOTE 10 for more details). The fair value of the Prior Notes was estimated by calculating the present
value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741,
resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented
the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair
value as of the date of the modification on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we settled an aggregate amount
of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase
8,145,486 shares of our Common Stock. As discussed below in <U>Issuance and Payment of June 2012 Notes</U>, the remaining balance
of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the
June 2012 Notes (see NOTE 10 for more details).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of June 2012 Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we issued secured promissory
notes, or the June 2012 Notes, to the Parties in the principal amounts of $2,347,128 and $2,344,719, respectively, pursuant to
the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the Parties surrendered the remaining balance of
the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively, which sums included principal and accrued
interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding from the Parties, or the June Funding.
The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest
at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June
2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein.
We also granted warrants to purchase an aggregate of 7,000,000 shares of our Common Stock in connection with the June Funding.
On March 21, 2013, we repaid $4,882,019, including accrued interest, leaving a balance of $21,595 in accrued interest as of March
31, 2013 on the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance and Payment of Additional Notes
in 2012</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August and September 2012, we issued 6%
promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were
paid in full in October 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we issued a 6% promissory
note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Conversion of July 2011 Secured Notes </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed issued two senior secured
promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security agreement under which VitaMed
pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon the merger and bore interest at the
rate of 6% per annum, were due on the one year anniversary thereof, and were convertible into shares of our Common Stock at our
option. We were permitted to satisfy the obligation underlying the Secured Notes by delivering such number of shares of our Common
Stock calculated by dividing the then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the
&ldquo;Share Price&rdquo; meant the lower of the most recent price at which we offered and sold shares of our Common Stock (not including
any shares of our Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities)
or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement
to convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of $1,054,647
into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial conversion feature
of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial statements. For the years ended
December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Issuance of VitaMed Promissory Notes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory notes,
or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, we granted warrants
to purchase an aggregate of 613,718 shares of our Common Stock. The VitaMed Notes were assumed by us upon the merger and bore interest
at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time
as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon
the closing of the Funding in July 2011, as more fully described above in <U>Conversion of July 2011 Secured Notes</U>, two of
the VitaMed Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Notes in the aggregate
of $300,000 were extended. In October 2011, one of the VitaMed Notes for $50,000 was paid in full, and, by mutual agreement, certain
of the VitaMed Notes in the aggregate amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share,
which represented the fair value of the shares of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held
by an unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.
Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate amount
of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes in full, including
$5,341 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September and October 2011, VitaMed issued
convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible Notes bore interest
at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt Conversion Agreements with
the holders of VitaMed Convertible Notes, pursuant to which we converted the principal and accrued interest of the VitaMed Convertible
Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common
Stock on the date of conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended
by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&nbsp;Finizio in full, including $888
in accrued interest. Mr. Milligan&rsquo;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&rsquo;s
promissory note in full, including $1,519 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2012 and 2011,
we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>NOTE 10 &ndash; STOCKHOLDERS&rsquo;
EQUITY</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">At December
31, 2013, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred
stock were outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Common Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">At December
31, 2013, we had </FONT>250,000,000 shares of Common Stock<FONT STYLE="letter-spacing: -0.15pt"> authorized for issuance, of which
</FONT>144,976,757<FONT STYLE="letter-spacing: -0.15pt"> shares of our Common Stock were issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2013</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a shelf registration statement
previously filed with the Securities and Exchange Commission, or the SEC, on March 14, 2013, we entered into an underwriting agreement
with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating
to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share,
and the Jefferies Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement
at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting
discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement,
we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The
offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional
1,954,587 shares of our Common Stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18,
2013 and received proceeds of approximately $3.1 million, net of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2013, we entered into an underwriting
agreement with Stifel, Nicolaus &amp; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel
Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering
was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting
agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting
underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013 certain individuals exercised their
right to purchase shares of our Common Stock. Options to purchase an aggregate of 75,423 shares of our Common Stock were exercised
for approximately $31,000. These shares of our Common Stock were issued in part in reliance upon an exemption from the registration
provisions of the Securities Act of 1933, or the Act, provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2012, certain individuals exercised
their right to purchase shares of our Common Stock. These shares were issued in reliance upon an exemption from the registration
provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Options to purchase an aggregate
                                         of 1,691,393 shares of our Common Stock were exercised for $191,000.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Using
                                         the cashless exercise feature, options to purchase an aggregate of 240,395 shares of
                                         our Common Stock were exercised.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During June 2012, we settled $3,102,000 in
principal and accrued interest of the February 2012 Notes in exchange for the Parties&rsquo; exercise of a portion of the related warrants
for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration
provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. During June 2012, we and
the Parties also agreed to convert a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012,
totaling $1,054,647, into 2,775,415 shares of our Common Stock at $0.38 per share. The shares were issued in reliance upon an exemption
from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we entered into a Securities
Purchase Agreement with multiple investors, relating to the issuance and sale of our Common Stock in a private placement. The private
placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of our Common Stock at $2.15 per share,
for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies served as our exclusive placement
agent. Jefferies&rsquo; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses of the
investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. The shares were
issued in reliance upon the exemptions from registration under the Act provided by Section 4(a)(2) and Rule 506 of Regulation D
promulgated thereunder. The shares were issued directly by us and did not involve a public offering. The investors were &ldquo;accredited
investors&rdquo; as that term is defined in Rule 501 of Regulation D and acquired our Common Stock for investment only and not with
a present view toward, or for resale in connection with, the public sale or distribution thereof. Pursuant to the terms of the
Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares, which we filed on
November 27, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Issuances During 2011</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">In December
2011, </FONT>a former director of VitaMed, <FONT STYLE="letter-spacing: -0.15pt">exercised options to purchase 92,057 shares of
our Common Stock for an aggregate exercise price of $17,250.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October and November 2011, we converted
principal and accrued interest in the aggregate of $849,137 into shares of our Common Stock totaling 20,266,822 and 1,415,136,
respectively (as more fully described in NOTE 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 5, 2011, we entered into a Stock
Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company, or Pernix. Pursuant to the terms of the
Stock Purchase Agreement, Pernix agreed to purchase 2,631,579 shares of our Common Stock at a purchase price of $0.38 per share
for a total purchase price of $1,000,000. Pernix is a related party. For further details, see NOTE 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 3, 2011, we effected a reverse split
of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100, resulting in 165,856 shares issued and
outstanding thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Warrants </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2013, we had warrants outstanding
to purchase an aggregate of 14,293,499 shares of our Common Stock with a weighted-average contractual remaining life of 3.9 years,
and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 93; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate and the term of the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2013</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2013, we granted warrants to purchase
1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE
9). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised
prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the
date of the issuance using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At
December 31, 2013, $260,022 was reported as deferred financing costs included in other current assets in the accompanying consolidated
balance sheet and is being amortized over the life of the Plato Note. As of December 31, 2013, $1,451,934 was recorded as financing
costs on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we entered into a consulting agreement
with Sancilio &amp; Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug
Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval
for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy. In connection with the agreement,
SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant
to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI
a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">283,333 shares were earned on May 11, 2013 upon successful filing
of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment
of vulvar and vaginal atrophy; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013. The
fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the
vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the
entire $405,066 as non-cash compensation in the accompanying consolidated financial statements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">283,333 shares vested on June 30, 2013. The fair value of $462,196
for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility
of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. At December 31, 2013 we had $154,068 recorded as prepaid expense-short
term and $308,128 recorded as prepaid expense-long term in the accompanying consolidated financial statements. During the year
ended December 31, 2013, we recorded $77,034 as non-cash compensation in the accompanying consolidated financial statements; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">283,334 shares will vest upon the receipt by us of any final FDA
approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2012</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2012, we issued an aggregate of
5,685,300 Warrants in connection with the modification of certain existing promissory notes, or the Modification Warrants, and
warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection with the issuance of the February
2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable
at $0.38 per share. The Modification Warrants have a fair value of $10,505,247, and the February 2012 Warrants have a fair value
of $6,124,873. Fair value was determined on the date of the issuance using a term of five years; a volatility of 44.5%; risk free
rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment
of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647
was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining
unamortized debt discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2012, we issued an aggregate of 31,000
Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the issuance using a
term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; we recorded $29,736 as consulting
expense in the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2012, we issued an aggregate of 1,300,000
Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided
are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug
development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing
efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property
and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and
(c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The
Warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility
of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2013, we had $360,528 reported as prepaid expense-short
term and $593,127 recorded as prepaid expense-long term. During the year ended December 31, 2013 and the year ended December 31,
2012, we recorded $360,528 and $218,045, respectively as non-cash compensation in the accompanying consolidated financial statements.
The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process
will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we granted aggregate of 7,000,000
Warrants in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 9). Of the June 2012 Warrants
issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June
2012 Warrants of $9,424,982 was determined on the date of the issuance using a term of five years; a volatility of 44.64%; risk
free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined
by using the relative fair value calculation method on the date of the issuance. Of the $1,649,890, $547,210 was amortized to interest
expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, we amortized the remaining unamortized
debt discount of $1,102,680 to interest expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued an aggregate of 1,500
Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the issuance using a
term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded
as consulting expense in the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Warrant Activity During 2011</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 500 Warrants with
a fair value of $338 to an unrelated individual for consulting services covered under a three-month agreement. The Warrants were
valued on the date of the issuance using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield
of 0%. The Warrants vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation
and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2011, we issued 600,000 Warrants
with a fair value of $133,045 to an officer of our company for services performed. The Warrants were valued on the date of the
issuance using an exercise price of $0.38; a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield
of 0%. The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares
for month 44). For the years ended December 31, 2013, 2012 and 2011, we recognized $36,284, $36,284 and $7,158, as non-cash compensation
in the accompanying consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 184,211 Warrants
with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Warrants were
valued on the date of the issuance using an exercise price of $0.38; a term of five years; volatility of 41.04%; risk free rate
of 1.08%; and a dividend yield of 0%. For the year ended December 31, 2011, the $25,980 fair value was recorded as financing expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">In December 2011, VitaMed
entered into a two-year consulting agreement with an entity providing help to evaluate improvements to existing products and new
products as well as services, including research, design, compliance, scientific and regulatory affairs, and commercialization
of products. As compensation, the consultant received 800,000 fully vested and non forfeitableWarrants. The Warrants were valued
on the date of the issuance using an exercise price of $0.38; a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%;
and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $177,394 at the date of grant and
was amortized to research and development expense over the life of the agreement which is when the research and development activities
were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $71,688, $95,582 and $10,124, respectively,
in research and development expenses related to this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed also entered into a one-year
consulting agreement with the same consultant, whereby Consultant would assist in the design, development, and distribution efforts
of VitaMed&rsquo;s initial product offering. As compensation, the Consultant received 200,000 fully vested non forfeitable VitaMed Warrants
(or a Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at
$12,548 using an exercise price of $0.41; a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend
yield of 0%. The Warrant vested immediately. The fair value of the warrants was $12,548 at the date of grant and was amortized
to research and development expense over the life of the agreement which is when the research and development activities were performed.
During the years ended December 31, 2013, 2012 and 2011, we recognized $0, $6,936 and $5,612 respectively, in research and development
expenses related to this agreement. In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate of $500,000
with 500,000 accompanying VitaMed Warrants (or Warrants for an aggregate of 613,718 shares of our Common Stock taking into account
the merger). The VitaMed Warrants were valued on the date of the issuance using an exercise price of $0.41; a term of five years;
a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Warrants vested
immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount
and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited
LP (See NOTE 9 for more details). In consideration for the personal guarantees and cash collateral, VitaMed issued an aggregate
of 499,998 VitaMed Warrants (or Warrants for an aggregate of 613,713 shares of our Common Stock taking into account the merger).
The ten-year Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of
$0.24 per share. On November 13, 2012, the outstanding balance was repaid in full and business loan agreement was amended to reflect
a $100,000 bank line of credit. As part of the amended line of credit, the personal guarantees and cash collateral were removed
for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Warrants, Warrants previously issued to Mr. Finizio and Mr.
Milligan were amended to reflect the amount vested prior to the date of the amended line of credit (179,000 each). At December
31, 2013, an aggregate of 562,571 Warrants were vested. The Warrants, with a fair value of $93,969 ($86,139 after adjusting for
the effect of the amended line of credit ), were valued on the date of the issuance using a term of 10 years; a volatility of 47.89%;
risk free rate of 3.48%; and a dividend yield of 0%. For the years ended December 31, 2013, 2012 and 2011, $2,944, $45,036 and
$38,159, respectively was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Summary of our Warrant activity and related information for
2011-2013</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Number
of Shares Under Warrants</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted
Average Exercise Price</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual
Life in Years</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Aggregate
Intrinsic Value</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2010</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="width: 36%; padding-left: 22pt; text-indent: -10pt">Issued</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: right">3,057,627</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">$</TD>
<TD STYLE="width: 11%; text-align: right">0.36</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 11%; text-align: right">7.9</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="width: 1%; text-align: left">$</TD>
<TD STYLE="width: 11%; text-align: right">3,483,691</TD>
<TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#9472;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2011</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">3,057,627</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">0.36</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">7.9</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">3,483,691</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Issued</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">17,332,500</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">1.26</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">4.3</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">31,891,150</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">(8,145,486</TD>
<TD STYLE="text-align: left">)</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">0.38</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: right">(51,142</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">0.24</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2012</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">12,193,499</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">1.63</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">17,971,994</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Issued</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">2,100,000</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">2.72</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">4.8</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">5,232,500</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&#9472;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#9472;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">&nbsp;</TD>
<TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance
at December 31, 2013</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,293,499</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">1.79</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">3.9</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">48,932,777</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Vested
and Exercisable at December 31, 2013</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,764,710</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">1.81</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: right">3.9</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
<TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="text-align: left">$</TD>
<TD STYLE="text-align: right">46,840,559</TD>
<TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2013, we had warrants outstanding
with exercise prices ranging from $0.24 to $3.20 per share. As of December 31, 2013, unamortized costs associated with warrants
totaled approximately $1,599,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are
set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; padding-left: 10pt; text-indent: -10pt">Weighted average fair value</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">2.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.72-1.04</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.91-3.48</font></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44.64-44.81</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39.13-51.83</font></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-10</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated volatility is a measure of the
amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is
an average of the historical volatility of the stock prices of peer entities whose stock prices were publicly available. Our
calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We
used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during
2011-2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 98; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Options to Purchase Common Stock of the
Company</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, we adopted the 2009 Long Term Incentive
Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our
company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options
and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger, no awards had been issued
under the 2009 Plan. As of December 31, 2013 there were 13,632,742 shares of our Common Stock issued under the 2009 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2012, we adopted the 2012 Stock
Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as
an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of
our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2013, there
were 2,650,000 shares issued under the 2012 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions
used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.61-2.23</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.91-2.54</font></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.77-46.01</font></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37.92-40.48</font></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.5-6.25</font></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt">Dividend yield</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">0.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated
volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award.
Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices
were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the
term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our
stock price. The average expected life is based on the contractual term of the option using the simplified method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of activity under the 2009 and 2012 Plans and related
information for 2011-2013 follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Number
    of Shares Under Options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted
    Average Exercise Price</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Weighted
    Average Remaining Contractual Life in Years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Aggregate
    Intrinsic Value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&#9472;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; padding-left: 22pt; text-indent: -10pt">Granted<SUP>(1)</SUP></TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">10,682,218</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">0.16</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">7.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">14,188,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(92,057</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&#9472;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#9472;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,590,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,067,649</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,121,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,737,530</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,931,788</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&#9472;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(46,135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,733,488</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26,804,117</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,583,677</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,920,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75,423</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 22pt; text-indent: -10pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(608,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance
    at December 31, 2013</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,632,742</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.44</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">58,878,132</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Vested
    and Exercisable at December 31, 2013</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,282,627</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">.80</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">48,321,930</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><SUP>(1)</SUP>This includes (i) VitaMed Options
granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to
conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and
October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted
between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options
were reflected in the replacement Options including the number of shares vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, our outstanding options
had exercise prices ranging from $0.10 to $4.67 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation expense for options
recognized in our results for the years ended December&nbsp;31, 2013, 2012, and 2011 ($3,200,655, $1,832,061, and $183,355, respectively)
is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant
and revised in subsequent periods if actual forfeitures differ from the estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, total unrecognized estimated
compensation expense related to unvested options granted prior to that date was approximately $3,921,000, which is expected to
be recognized over a weighted-average period of 1.3 years. No tax benefit was realized due to a continued pattern of operating
losses. At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to unvested options granted prior
to that date was approximately $4,391,000 and $244,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2013, we issued a restricted stock
unit, or the RSU, under our 2012 Plan to an officer for the purchase of 50,000 shares of our Common Stock. The RSU will vest on
April 1, 2014 and has a fair value of $233,500. As of December 31, 2013, we recorded $53,428 of non-cash compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 11 &ndash; INCOME TAXES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the years ended
December 31, 2013, 2012 and 2011, there was no provision for income taxes, current or deferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At December 31,
2013, we have a federal net operating loss carry forward of approximately $37,000,000 available to offset future taxable
income through 2033.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At December 31,
2013, 2012, and 2011, we have state net operating loss carryforwards of approximately $35,000,000 available to offset future
losses through 2033. We established valuation allowances equal to the full amount of the deferred tax assets because of the
uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will
be able to recover the deferred tax assets. We consider all available evidence, both positive and negative,
including historical levels of income, expectations and risks associated with estimates of future taxable income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our deferred tax asset and liability as presented
in the accompanying consolidated financial statements consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 22pt; text-indent: -10pt">Net operating losses</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">14,773,537</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">5,920,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">748,404</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">R&amp;D Credit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">547,511</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">186,346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Total deferred income tax asset </TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,321,048</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,107,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">748,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,321,048</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,107,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(748,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our provision for income taxes differs from
applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting
certain expenses for financial statement purposes but not for federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 10pt; text-indent: -10pt">Federal statutory tax rate</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">35.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">35.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">35.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">State tax rate, net of federal tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0-</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Adjustment in valuation allowances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32.4</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18.2</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.8</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Permanent and other differences</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8.4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22.3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29.2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Provision (Benefit) for Income Taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-0-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>NOTE 12 &ndash; RELATED PARTIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Loan Guaranty</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited
Limited Partnership. See NOTES 9 and 10 for more details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Loans from Affiliates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory notes,
or the VitaMed Notes, in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the
affiliate notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments,
LLC, which is owned by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Promissory
Notes were paid in full including $5,341 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These
promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio
was paid in full, including $888 in accrued interest. Mr. Milligan&rsquo;s VitaMed Promissory Note was extended to October 15,
2012. On October 4, 2012 this VitaMed Notes was paid in full including $1,519 in accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Lock Up Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by the terms of the merger agreement
with VitaMed dated July 18, 2011, we entered into Lock-Up Agreements with stockholders covering the aggregate of 70,000,000 shares
of our Common Stock issued pursuant to the merger or reserved for issuance pursuant to stock options and warrants. Each stockholder
agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause
any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder&rsquo;s
aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month
period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Purchases by Related Parties</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013, 2012, and 2011, we sold our products
to Dr. Brian Bernick, a director of our company, in the amounts of $0, $2,632 and $20,669, respectively, while $0, $1,272 and $0
of receivables related thereto remained outstanding at December 31, 2013, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal"><U>Agreements with Pernix Therapeutics,
LLC</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2012, Cooper C. Collins, President
and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. We closed a stock
purchase agreement with Pernix on October 5, 2011. From time to time, we have entered into agreements with Pernix in the normal
course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors.
During the years ended December 31, 2013, 2012, and 2011, we made purchases of approximately $0, $404,000 and $19,000, respectively,
from Pernix. At December 31, 2013, 2012, and 2011, there were amounts due Pernix of approximately $46,000, $308,000 and 19,000
outstanding, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, there were amounts due to
us from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement, in the amounts
of $249,981 and $0 for the periods ending December 31, 2013 and December 31, 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal"><U>Warrants
assigned to Related Party</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">In June 2012,
a warrant to purchase 100,000 shares of our Common Stock was assigned to the son of the Chairman of our board of directors by a
non-affiliated third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 13 - BUSINESS CONCENTRATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We purchase our products from several suppliers
with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and
2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We sell our prescription dietary supplement
products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products
to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health,
Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December
31, 2013, 2012, and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2013 and 2012,
64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three customers:
AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers in prior years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><U>NOTE 14 &ndash; COMMITMENTS AND CONTINGENCIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Operating Lease</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease administrative office space in Boca
Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018.
The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and
sales tax, for a total future minimum payments over the life of the lease of $1,899,414.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 4 -->
    <DIV STYLE="margin-top: 3pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THERAPEUTICSMD, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The straight line rental expense related to
our current lease totaled $180,894 for the six months ended December 31, 2013 offset by rent income of $32,963. The rental expense
related to our prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 and
$122,752 for the years ended December 31, 2012 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2013, future minimum rental payments are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; padding-left: 10pt">Years Ending December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: center; padding-left: 0pt">2014</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">316,039</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 0pt">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-left: 0pt">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">382,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-left: 0pt">2017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">393,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-left: 0pt">2018</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">302,748</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Total minimum lease payments</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,766,252</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Noncancelable sub-lease income</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,956</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net minimum lease payments</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,727,296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 15 &ndash; SELECTED QUARTERLY FINANCIAL
DATA (UNAUDITED)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years&nbsp;2013&nbsp;and&nbsp;2012&nbsp;is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">2013 Quarters</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">(In thousands, except per share)</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">1<SUP>st</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">2<SUP>nd</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">3<SUP>rd</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">4th</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,863</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,396</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,376</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,009</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,673</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,361</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Loss per common share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.05</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">2012 Quarters</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">(In thousands, except per share)</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">1<SUP>st</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">2<SUP>nd</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">3<SUP>rd</SUP></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: center">4th</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">722</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">819</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,241</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">447</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">729</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">908</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(13,290</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(11,850</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,727</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: -10pt">Loss per common share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.16</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>NOTE 16_ &ndash; SUBSEQUENT EVENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On January 6,
2014, options for 390,000 shares of stock were granted to certain members of our Board of Directors under the 2012 Plan for
their services to be rendered in 2014. The options were granted for a period of 10 years at an exercise price equal to the
closing price at the date of grant, and vest on December 31, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">F-34</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF ROSENBERG RICH BAKER BERMAN & CO.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-10k_123113.htm">TherapeuticsMD, Inc. 10-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U><A NAME="Exhibits"></A>Exhibit
23.1</U></B></FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B>&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">We
consent to the incorporation by reference in the registration statements (Nos. 333-185156, 333-186189, 333-193558) on Form S-3
and (No. 333-191730) on Form S-8 of TherapeuticsMD, Inc. of our report dated March 5, 2014, relating to our audits of the consolidated
financial statements as of December 31, 2013 and 2012 and for each of the three years in the period ended December 31, 2013, and
the effectiveness of internal control over financial reporting as of December&nbsp;31, 2013, which appear in the Annual Report
on Form 10-K of TherapeuticsMD, Inc. for the year ended December 31, 2013.</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><I>/s/
Rosenberg Rich Baker Berman &amp; Company</I></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Somerset,
NJ</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">March
5, 2014</FONT></P>



<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<A HREF="txmd-10k_123113.htm">TherapeuticsMD, Inc. 10-K</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 31.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Certification of Chief Executive Officer
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Robert G. Finizio, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">1. I have reviewed this annual report
on Form 10-K of TherapeuticsMD, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Robert G. Finizio</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:
March 5, 2014 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123113.htm">TherapeuticsMD, Inc.</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex31-2"></A><B><U>Exhibit 31.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Certification of Chief Financial Officer
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Daniel A. Cartwright, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">1. I have reviewed this annual report
on Form 10-K of TherapeuticsMD, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">2. Based on my knowledge, this report
does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">3. Based on my knowledge, the financial
statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">4. The registrant&rsquo;s other certifying
officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) Designed such disclosure
controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Designed such internal
control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">c) Evaluated the effectiveness
of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">d) Disclosed in this report
any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most
recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">5. The registrant&rsquo;s other certifying
officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">a) All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">b) Any fraud, whether or
not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
over financial reporting.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer, Vice President of Finance, and Treasurer </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:
March 5, 2014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123113.htm">TherapeuticsMD, Inc.</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex32-1"></A><B><U>Exhibit 32.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Section 1350 Certification of Chief
Executive Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">In connection with the Annual Report
on Form 10-K of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2012, as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert G. Finizio, Chief Executive Officer of the Company,
certify, to the best of my knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley
Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Robert G. Finizo</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert G. Finizio</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD>&nbsp;</TD>
<TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
5, 2014 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10k_123113.htm">TherapeuticsMD, Inc.</A></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><A NAME="ex32-2"></A><B><U>Exhibit 32.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Section 1350 Certification of Chief
Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">In connection with the Annual Report
on Form 10-K of TherapeuticsMD, Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2012, as filed with the Securities
and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Daniel A. Cartwright, Chief Financial Officer, Vice President
of Finance, and Treasurer of the Company, certify, to the best of my knowledge and belief, pursuant to 18 U.S.C. &sect; 1350, as
adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: 24.5pt">(2) The information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Daniel A. Cartwright</I></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Daniel A. Cartwright</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer, Vice President of Finance, and Treasurer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">March
5, 2014 </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<HR NOSHADE SIZE="2" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>txmd-10k123113_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd-10k123113_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%.`G$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBN6\6^);_2KS3-&T2S
MANM:U0R"W^TEE@B6-<L\A7G`R.!R<T`=317$W_BCQ'H/AZV_M;2K"?7[R_CL
M+2&RG<P3,P!\PDKN10`Y((/W>O/$>F>*/$NG>+=/\/\`BZSTE'U5)GL;C3))
M"N8P&,;AQG."3NX'08H`[JBO-/AQ\3+KQ3:WDFNP6=DZVQU"V$!8`VHD>-BV
MXGE6C.2./F'`K&3XN:^/"_B_4[C2[&*XTE;*:SB(?!CNB"@D&[)8*P)Q@$YH
M`]DHKS_P+XYU/7]>N]%U+^Q;R2"T6Z^WZ)<-+;C<VT1MNY#]^IZ&K/ACQK>:
MUXEDM;F*V33;V*6;298U8/*D4IC<L22#D;'4@#AN]`';T5XS<?%O7[?7-8`B
M\/36=AJS:='IHG==1N,2!`T:Y*MU]!T/I70:O\1K[2=4\;0_V?#/!H$=FT.T
M/N;SE!9I",_*N<\#.`>M`'HU%<)%XTU/3/A_>>(=:CTK4)HB!;'1)GDANBY"
MHHW`LIW,`>OK[5`WBOQ=H&L:6/%>GZ*FF:K>)90OI\\C26\KABH?<,-DC&1C
M')H`]"HKSKPY\0]0U7Q1X@TR^L8(;:UNKNVT^:/=^\:WV[U?)^\0ZL,8X#>G
M/0:1XH\[X=6OBG5%1,Z<+VX6!3@83<P4$D_3F@#I:*\PN?'/C/2-&M_%>LZ-
MH\/AR587E@BGE-Y;I(R@,V5"G&X94#.?2DU'Q]KQ^)6H>'+"[\+65G9/;+G5
M9I$FN?-16(BPV&(SC&.X]:`/4**Y;Q;XEO\`2KS3-&T2SANM:U0R"W^TEE@B
M6-<L\A7G`R.!R<UE:OXK\4>'=)T0ZO8:4NH7VN6^FR&VD=X6BD!)D0'#*V00
M`<XQGF@#OJ*X[Q1XOO-!UBYMH;>"6&#0;O5/G!W-)$5VKD'`4Y.>,UE>%_B5
M/?>!M5U?6K>V34]-A2>6WM<A9$EB66#`8D@L&"]>H-`'HU%>36/Q-\0'0K27
M4+#3DU'_`(2M=`N5B#^6%QEF4%L[NH&3COCM73^*?%U[H.KW5K!!;R10:#=Z
MF/,#;C)$5VKD'[IR<\9]Z`.RHK#T+7OMO@?3_$&I&&#S=/2\N"ORHF4#,1D\
M`<]36+X1\5:SKL>HVM_;6EMJ0MHKVRCV.J^3,A,?F`DG<K!E;&.G`%`';45Y
MIX8\2?$'4_'&I:'J4?AA8-(:#[>]LMP&994+KY18X)&.=P'XT>$OB+JNM0>%
M+O4+.UCM-<:[@=X58>5/&S&,9+'AD1NQY'84`>ET5YSXD^(&J:5H'C'6;*VL
MI;71KB&SM"X8^;*6192Q!&0IDVX&.5.3Z;'@76=<UNWO+C5]1\,7L2E%A?09
MGD"M@EA(6)P>4P![^U`'745Y>OB3XD?\+"'A=H_"F?LG]H&0+<?\>_F^7C.?
M]9[8Q[UH-XH\9:Y?:DWA32](.G:=>/:/)J4LJR731XWB,*N%YRH))&1^%`'H
M%%>3Z]\1_$G_``KNT\<^'K;1AI9@4W<%[YKS+*91$53:5!`8]3C(&:ZF[UGQ
M)HOA2%]7727\07=VEI:I9B0P,\C@*2&(8[5W,V#T4T`=?17GNJ^/[^P^$5UX
MICMK4ZM:$07$#!O*2<3"&08SG`))'/IS7H$;%XD8]6`-`#J*\9\)?%O7]:O-
M&>\B\/3P:K>?95L;"=_MML,M^\D1B1L`7)/'&#WK2TCQ[XFUSQQ?:7;W?A*V
MLK/5Y+$VMU-(M]-%&WS-&H;#$J#CC&0?2@#U2BO+U\2?$C_A80\+M'X4S]D_
MM`R!;C_CW\WR\9S_`*SVQCWK>\.>+KW6;+Q;/-!;H=&U*ZLX`@;YTB4$%LGD
MDYSC%`'945X]??%'Q`+S0+6VE\,6)OM"AU6XFU:62&,L[$&.,AN#QD`Y[^E6
MM1^*NL0:/X/U"UT)"VLQ7-S=6SDEUA@4,WEX(R67++GV]>`#U>BN=TWQ%)J/
MC"^TN/R'L8M/MKN&9`=S^:TG?.",*N./6NBH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M8LL;R/&LB-)'C>H8$KGID=J`'T444`%%8]KXM\-WWG?9/$.DW'D1--+Y5[&_
MEQK]YVP>%'<G@5L`@@$'(/>@`HHHH`*Y3Q?X:U/5+_2M:T&^@M=8TLR^2+I6
M:&9)%PR.%.<<*<C.,=*ZNB@#B-0\+^)->\/VAU35K"'7[*_CO[26S@<6\3*`
M/+(+;G4Y?))'WNG'*:5X8\1:CXFT[Q!XPNM*>YTR.5;*VTM)!&K2`*SLSG).
MT8QC%=J)HC.8!(GG!0YCW#<%)(!QZ9!_*GT`>20_"75$\'>&]'_M&VBN+)[B
MVU"6)FVSV4TK.\:_+G<1LZXQSSZW/$?PTU+5XO':6MS91#7QIXLU<L!&+<+G
M?A>,X(&,UZ'_`&KIW]G_`-H?VA:_8O\`GY\Y?+ZX^]G'7CZTP:YI)U9M*&J6
M1U)0"UG]H3S@,`\IG=T(/3O0!0N]!-CX4OM-\,6UAIUW+;ND!2(11K(00'(5
M3T)ST-<=;?":YT.^T"_T?Q)JES/I5PF+?5+KS(%@*E)5C55^0E3QV['UKT^H
M[>X@N[:*YMIHYH)5#QRQL&5U/(((X(/K0!YC_P`*MO(8M?O[633H_$$^N/JF
MF7VUMT2%E;RI&`W;3\X(&1\V>>E;"^$_$-GXH\5ZYIUYIL<VKI9_9TG1Y$!B
MCV.L@&.#V(.?;U[JB@#S.R^&%W/X>\26VIW]K:7VMR13[-*C:.VLY8L%7C4G
M))8`L>,X'2KJ^%?%?B#5-,?Q??:,]AI=XMY!%IL4JO/*@(1I"YPN,YVC([5W
M]%`'GD?P\O8]&U^)+VW34;K79]8T^<*2(2^`%?C/*[E;'9C6]I/A;ROAQ;>%
M=2D5_P#B7?8KAX&.#E-I*D@'Z9%=+10!YD_@?QAJ^CP>%M?U?2)O#D(A1Y;>
M&47=TD94A7);:I)49(R:U[+P#;#XAZ_XCU.STV\AO?LK60EA#R6[11[6(W+A
M<D*05/;MBNOO;VTTZTDN[ZZAM;:/!>:>0(BY.!ECP.2!6?8^*_#FJ7:6FGZ_
MI5W<ODK#;WD<CM@9.%!)/'-`&7XO\-:GJE_I6M:#?06NL:69?)%TK-#,DBX9
M'"G..%.1G&.E4M4\*^(?$?A:*#6=2TU-;M[^*_M9;6V;R('CQA<,VYA]_DX^
M]TXKN*CGGAM;>6XN)8X8(D+R22,%5%`R22>``.<T`>>GP7XHUL:M?>)-1TL:
MC<Z/<:5:P:?&X@B$O5V9_F)R%]A@U''\-;TWWA5Y+R!;2QL+:WU>!&8BZ>V`
M,.WCD!\DDXXQP>E>B+>6SS10K<0M++&98T#@ET&`6`[@;EYZ?,/6HGU73H[&
M6^DO[5+.(LLEPTRB-"I*L"V<`@@@^A!H`X$_#:^DT768#?6L5]/XEDUZPF"&
M18CN4H'!QS@$''KWJ3_A"_$^M_VM?>)=2TP:A<Z//I5M!I\;B"(2]79G^9CD
M+QT&#77OXI\/1V]I</KVEK!>%A;2&\C"SE3A@ASAL$X..AK0DNK>)X$DGB1[
MAMD*LX!D;!;"^IP">.P)H`\VM/"/CJ?P(_A+5+O08K/R+>SCGL6F\WR%($NX
MNI!8H,#``R3TJ]I/PYO/#OC+3=;L/$.I:C$L,MK>IK%T9G\D@%1$0HQAU!(/
M'T[]Q/J-C:W<%K<7MO%<W!Q##)*JO(?]D$Y/0]*BU#6M*TF2"/4M3L[-[@E8
M5N9UC,I&,A0Q&>HZ>HH`QM#\-W6F>./%6NS30M;ZN;3R(T)W((HBC;LC')/&
M,\5S=A\.=3L?A58>'5N;$ZUIMV+VSN&#&%95G,BD\!AE25.!QN/7OZ-%<P3R
M31PS1R/"P254<$HQ4,`P'0[64\]B#WJ6@#S[5?`-]?\`PAN/"J7-JNJ706:>
M=BWE-.9A-(<XS@MD#CICBM/P+HVN:);WEOJ^G>&+*)BC0IH,+QAFP0QD#`9/
M"8(]_:NNHH`YC_A&[K_A:)\4&:'['_8HTX19/F>9YWF$],;<8'7.>U8H\+^,
MM#U'48O#&J:0-*U*[DO'&H12O-:O)C=Y>UMK`MDX.,9[\UZ#10!Y_JWPX+?!
M]O`^CW$:OMC`GN"0&83+(['`)YPV![@=*T/%_@^\\6ZOI6[5KK3M-L5EF+V$
M_E7)G.%0AMI`4*9`><_-77221PQ/+*ZI&BEF=C@*!U)/84JL&4,I!4C(([T`
M>4W?PKU=?"GBSPY9ZR+JTU:6"ZM9]1E9YQ,K(9?-8+R&\M<$#/J/7N_#"^)T
ML9%\4?V1]H#@0_V9YNS9C^+S.<YSTK8EN(('A2::.-IG\N)78`R-@MM7/4X5
MC@=@3VH:X@2YCMFFC6>16=(BP#,JX#$#J0-RY/;</6@#S#PU\+;WPSH_AZ2R
M?38]>TZ\=KNYC5E6[MG=MT;,%!)VE2,@@%1]:32/`7B;0_'%]JEO:>$KFRO-
M7DOC=74,C7T,4C?,L;!<*0I..<9)]:]4J."X@NHS);S1S1AF3=&P8;E8JPR.
MX((([$$4`<Y_PC=U_P`+1/B@S0_8_P"Q1IPBR?,\SSO,)Z8VXP.N<]JP+OP9
MXLL-0UR'PUJ>CP:5KEQ)<7/VNW=IK=W0*QCP=K9()^;&/>O1J*`/-S\*;.;Q
M)I\M\EI?Z/9^'ETA8[E-TOF*^1(!C`.TGD$$&I].\$ZX+_P5=ZMJ%I<R>'TO
M(9W4N3<)(GEQGD?>V@;LGKGDUZ#10!Q/A#P7>^&?$NK73W4,NF2P16]A&N?,
MAC5Y&V-QC"[]H(/0#TY[:BB@`HJ.>>&V@>>XE2*)!EI)&"JH]23THM[B"[@2
M>VFCFA<962-@RM]"*`)***KWU_9Z99R7E_=P6EK'C?-/((T7)`&6/`R2!^-`
M%BBH;2\M;^UCNK.YAN;>0926%PZ,/4$<&IJ`"BBJMMJ5A>SSP6M[;3S0-MFC
MBE5FC/HP!X/UH`M4444`%%%%`!1110`4444`%%%%`!1110`445GFYN/[4\II
M(XH@=JQNAS+D`[@V<9'(QC^E`&A16=]MG765M,HT;9R#"Z%1C/#$[7[#`Z<_
M2J=AJ]T;&6[OY(U:*W,TEM]DDA=2!D\LQW`<C(%`&[15&RNII+F:VN#&98T2
M3,:E1M?=@<D\C:>?Y5+>WL=A")95<J6V_*!G//\`A0!9HJM'?VLD*R^?&JD#
M.YP"I/8\]>OY4\W=LN[=<1#:=K9<<'T/Y&@":N-U+PYXUNM2N)['Q\+*U=R8
MK8:/#)Y2]EW,<M]376&[MEW;KB(;3M;+C@^A_(T&[MEW;KB(;3M;+C@^A_(U
M<)N#NK?-)_F%CB1X5\?Y_P"2E?\`E"@_QJA:^'?$,EXT-C<3:/J46?M6K-$)
MEFSZ!N)=QYYQLZ<=#Z*;NV7=NN(AM.ULN.#Z'\C0;NV7=NN(AM.ULN.#Z'\C
M6RQ4TFK+[E^BU^9#@FT^QQ/_``BOC_\`Z*5_Y0H/\:V/#NC>)M-O)9-;\6#6
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MAM.ULN.#Z'\C0!YQ??\`"5+'9-<:A<V-JD;-;R1:==WLV[S9-GFK"ZG(A\G/
MF!@6W9YZUO%-EKVJZ!/H2Q:O+<27VIES&TJ(\3Q736Z&0$*4R85VD[<@*1V/
MJ!N[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[6RXX/H?R-`'"(NJ(+P:0NL?8?[
M-L?+%X;@R#-S-]HV^;\_F^7T[_ZOMMJ<^6=3T8:?_P`)'<VOR%;:?[=#Y?[U
MMTLDLF-V.<QRDY55VC!`;M#=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?
M0_D:`/*AHNJCX4-H_P#9MYDZ`+CR_*.[S_LWE>3LZ[MWS8QG-;=Y%<SWWC+2
MH;2]2]O[N*6RN/L;F%2+:!1*)2/+^1U)QNS\AP*[HW=LN[=<1#:=K9<<'T/Y
M&@W=LN[=<1#:=K9<<'T/Y&@`MKJ&[B:2!]R+(\9.TCYE8JPY]P1FO+;"Q\06
MGA3="FKPW%AX4LGM+9/-13>+YVY2@^\_$8*=P1D=,>I&[MEW;KB(;3M;+C@^
MA_(T&[MEW;KB(;3M;+C@^A_(T`<YI$YB\0W*ZFNJ_P!IRS3)'MCNFLQ!O)B(
M.#"K;%7).&SD=\5U-0F[MEW;KB(;3M;+C@^A_(T&[MEW;KB(;3M;+C@^A_(T
M`345";NV7=NN(AM.ULN.#Z'\C0;NV7=NN(AM.ULN.#Z'\C0!-7#2^%_'KRNR
M?$<1HS$J@T.`A1Z9+9KLS=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?0_
MD:N%1PVM\TG^8FCS+Q)X:\:VVDI<7WC"?6K6&\M99;"#1$5Y%6XC8D&/+?+C
M=P#G;4$RZEK>LZ+!HZZIIMS'=22&]N-&F"0#[-,NX^:BJ>6``)ZL*]4-W;+N
MW7$0VG:V7'!]#^1H-W;+NW7$0VG:V7'!]#^1HE4<I<SM]R_+8+'$_P#"*^/_
M`/HI7_E"@_QJ34-$\26W@'Q3:ZIKKZ_<W&G3I;+'IZP.K&)QM"H3N))&._YU
MV1N[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[6RXX/H?R-5*M*2LTON2_)!8X:6
MVU;2/$:26>GSW$5GHUX+-@IVEY)(#'"3C@@HPZ<*`>QJ*TL[K1X)+76K*ZM5
MBEANK*XTM9M1`E\MHWR!#D$A=QRN/WF0V3QWQN[9=VZXB&T[6RXX/H?R-!N[
M9=VZXB&T[6RXX/H?R-9#.,DO;Z/Q#X<U'5M.NLFRO[>0VMG+,`S2P>66"*WE
M[E0MAN!R,\9K,FTWQ/';0BVTJ.==,C:X@66Y,+JS3F588U",KE8DCBY91\Q&
M>2:]&-W;+NW7$0VG:V7'!]#^1H-W;+NW7$0VG:V7'!]#^1H`XO7$N5A\11>5
M>&XU5(VL)X[)W%NHC11N(&%*2!I,,0?FXSBK>N6E_JOBS0;C2IX5M6TZ\66Z
M>V,\91VMB`"&4!F`)4DD?*>#74F[MEW;KB(;3M;+C@^A_(T&[MEW;KB(;3M;
M+C@^A_(T`>?VVC7^B7>I/IZZEMBUG3H(!ERLEOY-K%*Y'\8"[\L<X*$\$&LD
MIXF2Z%M:?VU%:SF$S1XO'>VD6[M0R^?-(^\>4\I)0*I4-UP<>K&[MEW;KB(;
M3M;+C@^A_(T&[MEW;KB(;3M;+C@^A_(T`<++I^KGQ4R)-K*V7]L);?+/,4^R
M?V>I8Y)Z><@&_J&+88%CF*\BUFXT+3TE&IPW,=U>1)<C[6Q55G*P^9'#(A<,
M@4AW.T`9/#<]^;NV7=NN(AM.ULN.#Z'\C0;NV7=NN(AM.ULN.#Z'\C0!P.F7
M&OW%DEQ?QZ@GB"334?34*7"VPE-HI<7"K^[#>=YG$G/W<<U'IC:U;S6L\FH:
MG=06VH))>0C3+R$JC0SJV/->0S+YC1G"$JNT$#&*]"-W;+NW7$0VG:V7'!]#
M^1H-W;+NW7$0VG:V7'!]#^1H`\BCTW5TD\2ZI)#XB74[O2[T:>XENC^\2:\"
M+M!VKB-H2@(`R<I\V378W0N6UC4%O8=5FG,+#3([6:YBAD3[.-PD>,B-9"_F
M`,^"/D*\UUAN[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[6RXX/H?R-`'F.DP:X
M_B;3(I4U"XTRWOX;B*2>VNE\K=;WJ2!FG=W."(ADD#YEP`&&=WQU;ZF]VUSI
MD-VTT?A_54BEME8LLS"`QA2O(<E3M`Y.TXZ5V)N[9=VZXB&T[6RXX/H?R-!N
M[9=VZXB&T[6RXX/H?R-`'$W46L6>L2VJMJDFCC['+<RAIGE.X7`D$;+\WWUM
MRRKT#'@9K`@M_$=I8P+]JOM,LEN+N6%AI=W=3&5KRX;+I"Z_*8S&1O5E.2?3
M/JIN[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[6RXX/H?R-`'->&?[475;I=1^W
MFU*L=.,^>(=_(E_Z:9QC=SL"_P`6^NKJ$W=LN[=<1#:=K9<<'T/Y&@W=LN[=
M<1#:=K9<<'T/Y&@":BH3=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?0_D
M:`(=4M[VZTR>#3[X6-VZXCN3")?+.>NTD`\9ZUBV6B^*8-)O[:Z\7K=7LVW[
M-=G3(T^SXZ_(#A\^_3WKH#=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?0
M_D:5A-7.(ET7Q!I\UK=:_J\GB.RA=F,<6FJC0L1A7V1Y,F.1P"1NS]+VG6&H
M74>LS:3+)HT5XD0MGFM/F652WF2^2^/O`HOS8/R9QTSU)N[9=VZXB&T[6RXX
M/H?R-!N[9=VZXB&T[6RXX/H?R-3[-<UR/9KFYCG[+1?%,&DW]M=>+UNKV;;]
MFNSID:?9\=?D!P^??I[U6\1Z;K)\"P637G]HZJE[9,;H6F`Q6[B;>8D/15&3
M@CA2<CMU)N[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[6RXX/H?R-4E8M*QPVO:
M5K6G0Q&#466&ZFDN=1N+6QN96\[$:Q^7%!*)%3"MD;F&?O`Y)J-&\0GQ'I\M
MWJURMN?LP@,>C79%PA2/S?-"OY<+,^__`%J$H".>#CO3=VR[MUQ$-IVMEQP?
M0_D:#=VR[MUQ$-IVMEQP?0_D:8SF=`L-6E^&%O;O=7D6MW6F#=->,SR17#1`
M9(;D8;''J#GDDUC7MQK0TO5K'2=->VM;;0+E+5(=.E@N+6X$:!(HY=VV7)W$
M&-<`HO)/7OS=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?0_D:`..UR#5X
M)!!9O?NXLU.FLKSL#>$N6^T%>/+P8\!_E^\`,A16#XIO-?L?#MY&DFK1W%M<
MZM/+<)YH18#;W;P?O.F!F+`!^5E4<$"O3S=VR[MUQ$-IVMEQP?0_D:#=VR[M
MUQ$-IVMEQP?0_D:`,3PY]K-]?DF[.G&.'ROMAD\SSOG\W&_^#'EXQ\N=V.*Z
M&H3=VR[MUQ$-IVMEQP?0_D:#=VR[MUQ$-IVMEQP?0_D:`)J*A-W;+NW7$0VG
M:V7'!]#^1H-W;+NW7$0VG:V7'!]#^1H`FHJ$W=LN[=<1#:=K9<<'T/Y&IJ`"
MBBB@`HHHH`*IFS=[TRO<2-`-K+#D8WY//3/I@9QUXJY10!5^Q!KP7,LTDI0D
MQ(X7;&2,'&`#T)ZDTU=-C,DDD\LER[HT>Z4*-J'JHV@<<#KSQ5RB@"O:VBVH
M;][)*[8!>3&<#H.`!@4W48TDT^XWHK;8V89&<'!YJU5>_P#^0?<_]<F_D:`,
M_P`.?\@^3_KJ?Y"MBL?PY_R#Y/\`KJ?Y"MB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHK,=#'J@N)
M6=U+^7&R2G"9`RI3H>1G/)Y[8H`TZ*R9!-#KT&3(D,I8#;.SA\*3AD(P@'/(
MZX'KBJ<-W=QVOVE!(\LMA)<2(TA8+*,84`\#JPXX^6@#HJKW_P#R#[G_`*Y-
M_(U5TXNEW<0AY)(1''(KO(7.YMVX9/;A3CIS3M9EFBT]_)CW[\J_!.%(.3Q0
M!7\.?\@^3_KJ?Y"MBL/0)&33Y-L,DG[W^$KZ#U(_R:UC-(-V+:4X.!@KS[CY
MO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=B
MVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.
M:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@K
MS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S
M2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X
M^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X
M.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`F
MHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8
M*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V
M+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\
MYH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE
M.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#
M-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[
MCYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#
M=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;
M_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!
M@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ
M$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\
M^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:
M4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH
M`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#
M@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(
M-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CY
MO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=B
MVE.#@8*\^X^;_.:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.
M:#-(-V+:4X.!@KS[CYO\YH`FHJ$S2#=BVE.#@8*\^X^;_.:FH`****`"BBB@
M`JN+*V%\U[Y*?:"@3?M&0!GOC/?]!5BB@"&.TMHIY)X[>))I/OR*@#-]3U-.
MCMX(6D:*&-&D.YRJ@;CZGUJ2B@".&WAMDV011Q)DG:BA1D]3Q4=__P`@^Y_Z
MY-_(U8JO?_\`(/N?^N3?R-`&?X<_Y!\G_74_R%;%8_AS_D'R?]=3_(5L4`%%
M%%`!1110`4444`%%%%`!1110`444C,%4LQ`4#))Z"@!:*:CI+&LD;*Z,`RLI
MR"#T(-.H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBN.\0>/[;3]0.BZ):2:WKQX^QVQ^6+WE?H@_
M7Z9S5PIRF[10-V(_B-:V][%X>MKN"*>WDU4AXI4#*V+6X(R#P>0#^%<I>>']
M%T^73;FRTBPMKA-5L`LL-LB,N;J('!`SR"1^->D7VB6_B+2K&/7+=EGB*SE;
M:ZDC\J;85;:Z%6(P[#W!Z51B\`^'XKB"?RM0D:"5)D$VJ74BAT8,I*M(0<,`
M>0>E0P.FHHHH`****`"H6N[=;M;4SQBX92RQ[OF('M^-35EEPFJM'"LI=W62
M5'A)3&,;@^,`\=,GITH`OK<P/<-`L\9F49:,.-P'N.M16VI6%Y(8[6]MIW`W
M%8I58@>N`?>J"3I=:ZD9MKB)+5G\MC;R*LCD'<=V-NW!/4\D_3,%M;W*6%QI
M]E-<O;I:M%$]S%Y;(^,*%^5=PQGGGMS0!N0W$-PI:":.502I*,&`(ZCBH[__
M`)!]S_UR;^1JKIRL]U/<!)(X6CCC5'0H0R[MQP>>X'X4[68II=/?R9-FS+/R
M1E0#D<4`5_#G_(/D_P"NI_D*V*P]`$QT^3RI(U_>_P`2%NPSW'M6L5N?FVRQ
M#GY<Q$X'O\W/:@":BH2MS\VV6(<_+F(G`]_FY[4%;GYMLL0Y^7,1.![_`#<]
MJ`)J*A*W/S;98AS\N8B<#W^;GM05N?FVRQ#GY<Q$X'O\W/:@":BH2MS\VV6(
M<_+F(G`]_FY[4%;GYMLL0Y^7,1.![_-SVH`FHJ$K<_-MEB'/RYB)P/?YN>U4
M]6U2'1-.GO\`4=0M;6UCY,DJ'`'/'WN3TQC\J:3;L@-*N;\0>//#OAN86U[?
MA[YN%L[93+,Q[#:O3\<5S4=YXN^(7F-IT[^'?#C']W=F+%Y=+ZJ"?D7_`&NO
M?V'3^'_!NF>%X772K>WCF<Y>YDB+S29Z[W+9)/X#KQ6_LX4_XCN^R_5BO?8Q
M%\;>*=0^;1_A]J#0G[LFHW4=H?8E#DU5N]4\1ZFZ6'B32HM(MI>4BBN!,+LC
MDH7'``')3JP]@P/H)6Y^;;+$.?ES$3@>_P`W/:JVHZ;_`&I936ERT312$8_=
MG*XY!!#9#`X((Q@BJA7A&2?(OQO^=B9Q<HM)G&:'XCL]'\3P^'C?6ZQ7*-(M
MO+*%,#=@F>H8G[GXCBO0JYF]\#:/J.B'2;RSM9X,EE>6(F4,>K[]V=YXY&.G
M3'`Y<W^N_#.>*VU2ZDU/PM(X2+4I4,DUCG@++@C<O3YO_K"JJ*%>5Z>_;OZ>
M?E^8H)PBDSTZBJT4DES`L]M=6\D,H#Q.J%E*'D'(;GMS3RMS\VV6(<_+F(G`
M]_FY[5QFA-14)6Y^;;+$.?ES$3@>_P`W/:@K<_-MEB'/RYB)P/?YN>U`$U%0
ME;GYMLL0Y^7,1.![_-SVH*W/S;98AS\N8B<#W^;GM0!-14)6Y^;;+$.?ES$3
M@>_S<]J"MS\VV6(<_+F(G`]_FY[4`345"5N?FVRQ#GY<Q$X'O\W/:@K<_-ME
MB'/RYB)P/?YN>U`$U%0E;GYMLL0Y^7,1.![_`#<]J"MS\VV6(<_+F(G`]_FY
M[4`345"5N?FVRQ#GY<Q$X'O\W/:@K<_-MEB'/RYB)P/?YN>U`$U%0E;GYMLL
M0Y^7,1.![_-SVH*W/S;98AS\N8B<#W^;GM0!-14)6Y^;;+$.?ES$3@>_S<]J
M"MS\VV6(<_+F(G`]_FY[4`345"5N?FVRQ#GY<Q$X'O\`-SVH*W/S;98AS\N8
MB<#W^;GM0!-14)6Y^;;+$.?ES$3@>_S<]J"MS\VV6(<_+F(G`]_FY[4`345"
M5N?FVRQ#GY<Q$X'O\W/:@K<_-MEB'/RYB)P/?YN>U`$U%0E;GYMLL0Y^7,1.
M![_-SVH*W/S;98AS\N8B<#W^;GM0!-14)6Y^;;+$.?ES$3@>_P`W/:@K<_-M
MEB'/RYB)P/?YN>U`$U%0E;GYMLL0Y^7,1.![_-SVH*W/S;98AS\N8B<#W^;G
MM0!-14)6Y^;;+$.?ES$3@>_S<]J"MS\VV6(<_+F(G`]_FY[4`345"5N?FVRQ
M#GY<Q$X'O\W/:@K<_-MEB'/RYB)P/?YN>U`$U%0E;GYMLL0Y^7,1.![_`#<]
MJ"MS\VV6(<_+F(G`]_FY[4`345"5N?FVRQ#GY<Q$X'O\W/:@K<_-MEB'/RYB
M)P/?YN>U`$U%0E;GYMLL0Y^7,1.![_-SVH*W/S;98AS\N8B<#W^;GM0!-14)
M6Y^;;+$.?ES$3@>_S<]J"MS\VV6(<_+F(G`]_FY[4`345"5N?FVRQ#GY<Q$X
M'O\`-SVH*W/S;98AS\N8B<#W^;GM0!-14)6Y^;;+$.?ES$3@>_S<]J"MS\VV
M6(<_+F(G`]_FY[4`345"5N?FVRQ#GY<Q$X'O\W/:@K<_-MEB'/RYB)P/?YN>
MU`$U-:1$*AG52QPH)QD^@KB?$/CN2SU1]"\/6ZZUKQ/_`![0H1';CUF?=A>W
M_P!;(I-'\$:A)JL7B'Q1J::CK,9W01*C"VL_41ID9/3YCSQZ\UM[&T>:;MV[
MO_@>8K]C3\5Z-XAUV2WL=.UA-+TIU/VV:$'[4WHL9Z*",Y/7ZU?\/>&=(\+:
M>++2;1((SR[]7E;^\S'DFM$K<_-MEB'/RYB)P/?YN>U!6Y^;;+$.?ES$3@>_
MS<]JEU)./)T_K<+$U%0E;GYMLL0Y^7,1.![_`#<]JFK,84444`%%%%`!2;5#
M%MHW$`$XY('3^9_.EHH`****`"J]_P#\@^Y_ZY-_(U8JO?\`_(/N?^N3?R-`
M&?X<_P"0?)_UU/\`(5L5C^'/^0?)_P!=3_(5L4`%%%%`!1110`445C^)?$EA
MX5T:34;]F*@A(H4&9)I#T1!W)_\`KTXQ<GRK<!/$WB?3O"FE&_U!V.YMD,$8
MW23N>B(O<URVC>%=1\4ZE%XD\;1+E#NL-%SNBM!V:0?Q2?7I^06;PQX7U#4M
M8'B[Q:H.J,/]!L,YCT^,]`/60]S_`)'>5T.2HKEAOU?Z+_/]!;[ATHHHKF&%
M%%%`!4=Q;PW5O);W$22PRJ4>-URK*>"".XJ2B@#S2UDE^%FM1:?<2,_@[4)=
MMK,YR=.F;GRV)_Y9GL>W?N3Z7UJGJFEV>M:7<:;J$*S6MPA21&[C^A'4'L:X
MSP7J-YX>UA_`NN3&6:"/S-*O'_Y>K8?PG_;3H1Z#VR>F7[Z//]I;^:[^O?[^
MXMCOZ***YAA1110`4444`%%0W-W;647FW5Q%!'TWRN%'YFJ-WXET.PLH;VZU
M>RBM9F*Q3-.NUR.H!SSC%%Q71J45D2>*O#\.GP7\NM6"6=PQ6&=KA0CD<$`Y
MYQW]*SQK]]J[R2Z`VGO8QN4%U,6D$Y'79M(`4'C=DY(/&.3+FEN3*<8ZMG3T
M5G:/JG]J6TIDB\FYMY3!<1!MP1P`>#@9!5E8'`X(X'2M&FG?5%)IJZ"BBBF,
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHJM>O=?V=</IJP2W?EL8!,Q$;/CC<1SC/I32N!#K&M:;
MH&G2:AJMY%:VL?5Y#U/H!U)]AS65X4\2WGB<75X=%N+#2\K]CGN6Q)<CG+>7
MCY5Z8.><UE:1X`DN=2CUSQE>KK.K+S%#MQ:VGM&G<_[1]N_-=S6L_9Q7*M7W
MZ?+_`(/W"U*UKIUE8R7$EI:00/<R&6=HHPIE<]68CJ?<U9HHK)MO<84444@"
MBBB@`HHHH`****`"JHO2UZ8$MY613M>88VJV`0,9ST/7&*M5G/#/)JNX0Q1H
MFUC<*S!G'/R$8P>G<\9'%`$WV]%O$MGAEC\PE8Y&`VN0"2!SGH">0!Z4V+4X
M96?*O&BH9%=\8=!U88.<?7%0Q0ZBVL//<QVS6XRL.V9LHOKMV<L3C/S<#IWS
M!%HC&U-M/L$<=H]G$48DE&QDG@8/RCU^M`&C:WBW1=?*DB=,$I)C.#T/!/!Q
M2:C(D>GW&]U7=&RC)QDX/%,LK6:.>6YN!&)I$2,B-BPVKNP<D#GYCV_.DU:V
M2YT^3>6'E@R#'J`:`*OAS_D'R?\`74_R%;%8>@0K+I\FXR#][_#(R]AZ'WK6
M-M&V[+2_,<G$K#\N>.O2@":BH3;1MNRTOS')Q*P_+GCKTH-M&V[+2_,<G$K#
M\N>.O2@":BH3;1MNRTOS')Q*P_+GCKTJ.Z%K:VT]S<SO%`@,LDC3LJH`"2<Y
MX'6@"'6]:L/#VD7&J:E.(;6!=S-W/H`.Y)X`KCO"^C:AXGUF/QGXFA,14?\`
M$HTUN1:1GI(P[R-U]OR`H:382?$S7AK^H1S)X7LY2=-LY';_`$J0''GL">%Z
MX'_U\^E&VC;=EI?F.3B5A^7/'7I73+]RN1?$]_+R_P`_N[BW)J*A-M&V[+2_
M,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*YADU%0FVC;=EI?F.3B5A^7/'7I0
M;:-MV6E^8Y.)6'Y<\=>E`$U%0FVC;=EI?F.3B5A^7/'7I0;:-MV6E^8Y.)6'
MY<\=>E`$U%0FVC;=EI?F.3B5A^7/'7I0;:-MV6E^8Y.)6'Y<\=>E`$U<OXY\
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M'V81VB%2'QDDE\84<<C/45)I_@K2[32GL+Q[K5DDF$\CZE,9F:0#`//`_`5M
MK901Q^7&'1,\*DC*![``\#GH*QU'JSGY#XOUGP_"\(M?#VHM,?,23%WMCYQ@
MC"[NE+/X0FU30K73];U_4;J:&1I)+BV86IESGAE3C:,]*Z$VT;;LM+\QR<2L
M/RYXZ]*#;1MNRTOS')Q*P_+GCKTHMW#E74Q!X(\.MH]II4^FI<VEHS/"EPS2
M%2QR3DG/-7U\/:*MA#8C2;'[)"28H3;J40GJ0",#-7#;1MNRTOS')Q*P_+GC
MKTH-M&V[+2_,<G$K#\N>.O2BR'9%:71-)GM([272[*2VCSY<+VZ%$SUPN,"L
M9="U'17DAT&WTYK"1S(EM-(T`MR?O!=J,"I.3C`QD\XQCHC;1MNRTOS')Q*P
M_+GCKTH-M&V[+2_,<G$K#\N>.O2E*"EN3*$9+4YBY\'7D]B#;^(;W3]2:=KF
M6>TP(Y'957#1G.Y55%`!/;WIVH:CXG\.Z=8'^S3XBV(POI[8K#+GLRQ=#QV!
M_*NE-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*.5+8?*EL5+36[&Z
M>U@:46U[<P"X2RN2$G"'U0G(QR#[@UHU@Z[X-T/Q&%;4K0R3H<QW"R,LD1SG
MY6!R!D].GM5#4'\2Z;X@C$%@NI:%<-&A\JY=+BV/0L=S89<DGC'Z4[M;A=K<
MZVBL^UN=-U&2ZCM+Y9W@E,<ZQ7))B<9RI`/R]^/\*M&VC;=EI?F.3B5A^7/'
M7I3*)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+
M2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2
M@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L
M/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M
M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N
M>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\Q
MR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J
M*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$
MK#\N>.O2@VT;;LM+\QR<2L/RYXZ]*`)J*A-M&V[+2_,<G$K#\N>.O2JFJ7>F
M:192WNIWHM+8'+22W#(`>>!S^@ZTTFW9`:-8OB3Q5H_A2Q6ZU:Z$7F$K#$HW
M23-Z(HY)Y'L,C.*YO3_%FI>*M5A'AO1ISHAF!N-4OY9(5D3/(A3.X\$X/`SU
M%=C/I-C=7$5Q/;B2:%B\4C,2T1/78<Y7/MCMZ5HZ?LY)5%\NO_`%>^QPOV?Q
M?\0/^/SSO#'AYO\`E@C?Z;<KZ,?^68/IU[<CFNZTG2;+0]*M],TZ$0VENNR-
M,DX'7J>3R2:G-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]**E5R7*E
M9=@2)J*A-M&V[+2_,<G$K#\N>.O2@VT;;LM+\QR<2L/RYXZ]*R&345";:-MV
M6E^8Y.)6'Y<\=>E!MHVW9:7YCDXE8?ESQUZ4`345";:-MV6E^8Y.)6'Y<\=>
ME!MHVW9:7YCDXE8?ESQUZ4`345";:-MV6E^8Y.)6'Y<\=>E34`%%%%`!1110
M`4444`%%%%`!5>__`.0?<_\`7)OY&K%5[_\`Y!]S_P!<F_D:`,_PY_R#Y/\`
MKJ?Y"MBL?PY_R#Y/^NI_D*V*`"BBB@`KS/5)I?B;XBDT&RD9?"VFRC^T[E#@
M7DHY$"$?PCJ3_P#6S>\9:Y?ZQJR^"/#<Q34+A-VH7J\BQ@/7_@;#@#W[9!'6
MZ%H=AX<T:VTK381%;6Z[5'=CW8GN2>2:Z8_N8\[^)[>7G_E]_86Y=@ABMH(X
M((UCBC4(B(,!5`P`!Z5)117,,****`"BBB@`JIJ&IV>EVXGO9UB0MM48)9CZ
M*HR6/L!69=^,_#UEK4&C2ZG$VHS2B%;>(&1@QZ!MH.W\<5CC4;FX\=3?VCIT
MUE`D+6VGR3NI6=@Y,C+@\;AY>!U(4^AQ$YV5T9SGRJZ.KT_4[+58#-93B55;
M:PP59#Z,IP5/L151?$^B2:P-(BU.VFU$AB+:)P[_`"C)!QT.!T-8L5DE_P"/
MK>ZMYYU2QM7^U"&4JCR$@1)(!PV%,IP>F0>_._IN@Z1HQ<Z;IMK:LY)=HH@K
M,3ZGJ:(2<E<(2<E<Q](UKQ'KMS<A]`DT;3S"PAN;N16G,G13Y0Z`=<$_C3M&
M\(/9B[?6=9O=<FO(O*G6[($&WN%B'"_K73T55NY7+W,^?0M,GT2;1C8P)I\T
M9B:"-`B[2.P'2N4^'M_=:;-?>"=5E+WVCX-K*W6XM#_JW^J\*?3@>M=W7#?$
M/3;JU%EXQTF(OJ>BDO)&O6XM3_K(S^&2/3G'-=%%J2=)]=O7I_D-Z:G<T54T
MS4;75]+M=1LI!);7,:RQMZ@C//H?:K=8M-.S&%%%%(`HHHH`****`"BBB@`H
MHHH`P9/".E?\)(GB*V@-OJ:JP9XG*)/D8_>*/O>OKP/2JWASQ!K%Q<76G>(]
M(-A>6J[S=0Y-I.F<`HYZ'_9//\AT]5=2TVTU?3I]/OX%GM9UV21MD9'X=*5N
MQ-NQ:HKC%BNOAWX=?RAJ>O6,=P,1Y5I;2#'..[A2.GH>P%=-I.K66N:5;ZGI
MTPFM+A=T;@$9YP>#T(((_"A/H-/H7:***8PHHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`**:[K&A=V"JHR68X`%<S+\0_"RZQ;Z3!JL=Y?7$HB6*S4S8)
M.,L5!``[Y/%5&$I_"KA<TO$NLOH.AR7\5LMS*)H84B:7RPS2RI&,MM;`!<'H
M>E<K?^/->TW3KJ_N/#NFF&VA>:01ZM(6*J"3@&W`)P/45L>/=/U?4M`ABTB)
M9WCOK:>>W^4/+''*KD(S,JAOE!Y/.".]<CK=AXDU/0-1L(?">I++=6LL*,]Q
M:!0S*0"<3DXYJ0.]\-^)K'Q592WNG1W0M5D*)+/"8Q-QG<F>2O/6LG_A7FEW
MGB";6=<GN-9G\PM;0WC`PVRDY"I&../4Y]>O-=>````,`=J*T51Q;=/2_P#6
MXK=Q``H````X`':EHHK,84444`%%%%`!1110`4444`%%%%`!1110`4444`%9
MYN;C^U/*:2.*(':L;H<RY`.X-G&1R,8_I6A5,V;O>F5[B1H!M98<C&_)YZ9]
M,#..O%`"0W4SZO<6DBQB..&.1"N<_,SCD_\``1^?>L^PU>Z-C+=W\D:M%;F:
M2V^R20NI`R>68[@.1D"KT>FM'J;WWVZY9G`5HV$>S:"Q"\+G`+'OGU)IZZ;&
M9)))Y9+EW1H]TH4;4/51M`XX'7GB@!ME=327,UM<&,RQHDF8U*C:^[`Y)Y&T
M\_RHU:Y2VT^3>&/F`QC'J0:FM;1;4-^]DE=L`O)C.!T'``P*;J,:2:?<;T5M
ML;,,C.#@\T`9N@3+%I\FX2'][_#&S=AZ#VK6-S&N[*R_*<'$3'\N.>G6LWPY
M_P`@^3_KJ?Y"MB@"$W,:[LK+\IP<1,?RXYZ=:Y7QMXR;0K:/3M)@>Z\0WS&*
MRMO+/7O(>/NKR?\`ZV2-3Q7XGL_">BO?W0:65B([:VCY>XE/W44>I_05C^"O
M"]Y;7$_B;Q&5F\1:@OS@<K:1=1"GICOZGUZG>E!17M)[=%W?^7<3[(M^#O#M
MMX3TF2.22:ZU*XD\V_O&B<M/*<Y.<<J.<?XFNC-S&N[*R_*<'$3'\N.>G6IJ
M*RG-SDY2W&0FYC7=E9?E.#B)C^7'/3K0;F-=V5E^4X.(F/Y<<].M1W^I6.E6
MK76H7<%K`O62:0(OTR>]8.I>++F33;&Z\,:/+KOVT/Y4L<@BA0*<9=FZ<YP,
M<X-0VD)M(Z(W,:[LK+\IP<1,?RXYZ=:QM;\:>'_#K"/5-06"8XVP^6S2/DD`
MA0,D9!YZ54U3P[JWB6UL1?ZU=:5'Y0^UVFFN!O<]?WI&[';&.:W(-&TZWEMY
MQ:1/=00K`ES(@>;8!P"Y^8_GW-&O05V]C`U?7/%#:H+70M$@^R`(6U"^9]AS
MU"QJ-YQCKTIVH>&8]2\0'4[[6-9>WAD0PV$)>.%&'?"C+\@G.>_TKJZ*+=PY
M>Y0B@TZUNKBZAL4BN)6_?2QVI#R'U)"Y;IUY[4Z]2QOK:2VO;07,!.UXI;8R
M*WX$$$<=:NT4RBE:QV&FVWV:RLQ;01G`B@MBJ@GT"C'XBIS<QKNRLORG!Q$Q
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M!G!&0>XH`Z\W,:[LK+\IP<1,?RXYZ=:#<QKNRLORG!Q$Q_+CGIUJIH6LPZ_I
M,>H00S0(\DD9BG"[T:.1HV!VDC[RGH36@S*BEF(50,DDX`%`$1N8UW967Y3@
MXB8_EQSTZT&YC7=E9?E.#B)C^7'/3K7/7OQ%\&Z>2)_$FG$CJ(IA*1^"9JGI
M_P`3]!UC4+>TTF#5;\3R+&)X+"3RDR>K,P&`.I/I6JH56K\KL*Z.M-S&N[*R
M_*<'$3'\N.>G6@W,:[LK+\IP<1,?RXYZ=:HZ_=:Q:::'T/3H;^\,@7RYI_*5
M5YRQ/?'''O7+_8/B=J7^OUK0M&0]/L5JUPX'OYG&?I1"ES*[DE_7WA<[8W,:
M[LK+\IP<1,?RXYZ=:S-6\6:#H.?[5U2"S(Z+,2K-UY4=6'!Y&:K>'/#FHZ-<
M37.H^)=1U>65`NV<*D2<YRJ`<'\:OW?AW1+_`%%=1O-)L;B\50BSS0*[@#I@
MD>YI6@I6;NO+_@AJ<I)\5]+NRT?AW2M8U^0<;K*T81@_[3L!CZX-=3I&J7=[
MI,5SJ6F3:==L2)+7F8IR<?,HP<@9XZ9Q6HJJBA54*H&``,`4M.<H-6A&WSN_
M\OP!7//&^'%EJ,[S>*=:UK7B'_U$I>*`=<8CC`].H.*Z[3--T?0H&ATO3([.
M,':PM[4KN^I`^;IUYK5HHG6J35I/3\/N"R(3<QKNRLORG!Q$Q_+CGIUH-S&N
M[*R_*<'$3'\N.>G6IJ*R&0FYC7=E9?E.#B)C^7'/3K0;F-=V5E^4X.(F/Y<<
M].M344`0FYC7=E9?E.#B)C^7'/3K0;F-=V5E^4X.(F/Y<<].M344`0FYC7=E
M9?E.#B)C^7'/3K0;F-=V5E^4X.(F/Y<<].M344`0FYC7=E9?E.#B)C^7'/3K
M0;F-=V5E^4X.(F/Y<<].M344`0FYC7=E9?E.#B)C^7'/3K0;F-=V5E^4X.(F
M/Y<<].M344`0FYC7=E9?E.#B)C^7'/3K0;F-=V5E^4X.(F/Y<<].M344`0FY
MC7=E9?E.#B)C^7'/3K4U5-2U&'2[,W$P=OF")'&,M(Y.%51ZD_AW.!6;::_<
M?;(8-4TW[$+AMD,BSB52V,A6X&TG''4$\9SC,N23LR7))V9NT445104444`%
M%%%`!1110`57O_\`D'W/_7)OY&K%5[__`)!]S_UR;^1H`S_#G_(/D_ZZG^0J
MQKFMV'AW1[C5-3G$-K`N6/=CV4#N3T`K*T_6-/T?PY>:C?W<4%I;R,9)&;@$
M`<>YSQCKFN7T^TF\::@OBWQ0AM=#LE:XTS2Y?[JC/VB5>YQR!V_GM3IIKGGI
M%?U9?UH)LN^%=%O_`!)K*>-?$L!CEP1I.G/R+.(_QL/^>C=?;\@/0*Y73?&)
M\3VM^?#NGW+F*+=;7=]"T5M._8`_>([]/RHL?#^LZGI%_9^+]3AO$O0H^S6*
M&%(`#DA7&'8'C.>PQW-9U*KJ._3IV0D^QHZEXHTW3]-N;R)GU'[-(L4D&G@3
MRAST7:IX//?%9QG\3^)/#V^TC/AF[>XP#=(L\GDX^\%Z*Q)Z'ICW%;.C:#I7
MAZS^R:380VD).6$:\L?5CU)]S6C46;W"S>YS]OX1L9-,M+36F;7)+:1I5GU!
M5=MQZ\8QCT'-;R(D:*D:JJ*,!5&`!3J*$K#22"BJUQJ-C9L%N;RW@8\@2RJI
M/YFLZ7QCX8@QYOB/2$STW7T0S_X]5J$GLAFU15>ROK34K**\LKF*YMI1E)8G
M#*P]B*XZ;XP>!(I#'_;@DD[+%;3/D^@(3%5"E4FVHQ;MY"NCN:*X:'XL>'+J
M>.*UAU:?>P0-'I\A&3VZ5F^*=*T[5/B#=C4;"UO!%I5H8Q<0K)LS+<YQD'&<
M#\A2G2G3^-6!.YZ717CUOL\)^,K";P_X76ZEN-/NDDM[!(X2<26Y#,<`8'3V
MW5W&A>(?$FJ:FL&H^#IM+L]I+74M]&^&[#8.3GU[4U2DX\VEO5!<ZFBL+Q)>
M^)+1;<>'=(M+]G+>:US<^4(L8QQCYL\_2L#[;\4I>4TCPU!G@":YE;'O\O:G
M&BY*]TOF@N=Y16+X<_X2CR)_^$G_`+'\[</)_LSS=NW'.[S.<Y]*S=:TOQM=
MZK*^D^(["PT\A3&C6/FR`X&023@Y.3^5)4US<KD@N=97G5F?^$&^)<E@WR:)
MXE<SV_/RPW@^^OMO&"/?`'2K/_"*>/9O]?\`$8JIZI#H\*X^C9S6AXB\(W&N
M^!?['N=0>YU2!1+;W[*(V%PG*/A>%]..Q/>MH*$'RN2:>CM?3SU2V$SK**\B
M\&>'[OQ?H"WEUXV\507<4C07UK%>A&AF4\KG;P.A^AQ72P?#*VBN(YY?%/BN
MZ>-PP\_5"<X.<'`''^-*=&$&XRGJO(=V=Q02`,G@50UG1[/7M*FTV_61K:;&
M\1R-&>"".5(/4"N2'P;\"D[IM'DG?^_)>3D_^AUE!4VO?;7HK_J@U.WCN;>5
MML<\;MZ*X)K@4\3>*;V>\>VNM'@@BO;FWCCET^61@L4SQ@EA.H).S/0=:Z#1
M?`/A?P[J`O\`2='AMKH*4$@9F(!ZXR37/Q^&?%-E->I;6NC3P2WMS<1O)J$L
M;%99GD`*B!@"`^.IZ5,U&_N/3^O49=T'QW:`ZE:>)M;T2TOK2Z$2CS!;>9&8
MHW#;'D8]789SCY:Z;2M<TK78I)=*U&UO8XVVNUO*'"GT.*YG0/`EH3J5WXFT
M31+J]N[L2H?+%SY<8BC0+O>-3U1CC&/FKK++3;#3(VCL+*VM48Y98(EC!/J0
M!5/V?+I>_P"`M3'U/QYX6T?4);#4-<M+>ZBQOB=CE<C(SCV(K-_X6WX$_P"A
MA@_[]2?_`!-=3/I6G7,IEN+"UED;J\D*L3^)%/\`L-I_SZP?]^Q5)T;:I_>O
M\@U&V&I6>IZ;#J-E.LUI,GF1RKG#+Z\UQS?&7P`K$'7QD''%I.?_`&2NZ50J
MA5`"@8`'04M3%TTWS)OYV_1AJ<1;?%WP/>745M:ZR\TTKA$1;.?))./[E=1K
M6KVVA:5-J-VL[0Q8RL$32.<G`PHY[U?HHDZ=URIV]?\`@(-3@_\`A;&C/Q!I
M/B"=NZQ::Y('KS6IH'C>/Q!J7V.+P]X@M$*%Q=7MB8H3CMNSU]L=JZBBJE.E
M:RC^(:G!>)[*X\-27-SX.\,2/J^IIMDNK;8(XRI!!=&8+DY;G'XUDW?C[QUH
M6A1WNN>#[2W4,J2737P"9;@9C7>R^_->ITUT61&1U#(PP589!%0I15K17X_Y
MB<>QS_@W6-4US2&OM2&E8=_W!TZX,R[<#.XG^+.>E>;^%_$>AP^$M(BEUG3H
MY(K&!)$>Z0%&$8!!&>"*])U+PA9W&EK9:5<W&A;)S<*^ED0Y<C!W`##`^GL*
MQ=!MK`^'G_M46\UXH(U22Y"EO-'WMY/;TSQMQCC%8U:K3O8SG4<%L87A/P/:
M>)M#?4YO$>N&TN+Z\:.UM+_9;;?M,N"H4<YZYSSNKTZTTZWL]+BTY%:2VBB$
M(69C(64#&&+9SQZURUIXBO-#\*Z=-/HNL:FLCRJGV.'S95A#MY3."0<E-GOU
MS5R\\>Z'IFC6.J:F;RQM[PL$6>TDWIM.#O4`[?;U[5JZTI12;T1:E'<T[+PS
MH.G8^Q:+IUL1WAM44_F!6I7.7'CWPQ::38ZI<:M''97V[[-(T;_O-IPW&,C!
M]11>^//#&GZ39ZI<ZM$EE>!C;RA';S-OWL``GCZ5+G?5L?-'N='17,WOC_PU
M8Z/8ZK-?L;2_W?972WD8R;>HP%R/QQ1>>-[*WTBQU*VTW6-0AO=WDI96+._R
M_P!Y3C;GMGK2YD',NYTU%<Q>^*-332K"\TWPIJ=W)=AB;:8I`\&.GF9)QGM1
M?7OC*;2K"72]'TVVO90QNH;ZZ+B`_P`(!0?-WZ4<R#F1T]%<Q?Z?XPU#2[!(
M-=L-*OE#?;'M[/ST8\8V"0\`<]>N:+[PE=ZKINGVM]XHUA);92)IK&1;8W).
M.6`!QC&,#U-%WV"[['3$@`DG`'4FJ5]K.EZ7'')J&I6=HD@RC7$ZQAOH21GK
M6/?^`M`U:PT^SU6"XOX[!2L37%U(6.<9+$,-QX[U=;PGX>DM+2UFT6QG@LT,
M=ND\"R"-3U`W`T:A[Q7UGQAI.EV5O)'>VUQ<7H`L(DE!%PQ(48(S\N2,GTJE
M=WVLZ):3:M=:DEY!;H9;FV%NJ*(QRQC(^8$#)&XMG&.,Y&[=Z'IMYIPL)+.%
M8$39$(T"F$=MF!\I&!C'H*S/^$<O[HBWU/5X[G3P03$EIY<DH!SB1]Q!![A5
M7/TXK.:FVK&<U4;7*-U+QUI6FV-A>-!J-Q%?1F2#[/9NQ(XZC`P>>AHU+QFF
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MO+:ZO[VXTC&V&:XW?:5QM8MG`,F"2&XYX[U&\C^(9[2UMK.]ABBNH;B>:YM9
M(`@C<.%7>`6)*@?+D8)YZ9Z^BH=--W(E23E<****T-0HHHH`*S'0QZH+B5G=
M2_EQLDIPF0,J4Z'D9SR>>V*TZKBRMA?->^2GV@H$W[1D`9[XSW_04`5H&D'B
M"[B,LC)]FB<*QX4EY,X'0<`#\*SH;N[CM?M*"1Y9;"2XD1I"P648PH!X'5AQ
MQ\M;":981W7VI+&V6X)+>:L2A\GJ<XSDY-31V\$+2-%#&C2'<Y50-Q]3ZT`4
M=.+I=W$(>22$1QR*[R%SN;=N&3VX4XZ<UR?CG1M,UWQEX8L]56.6#R+UU@D`
MQ(P,!'OD<GCMD=":[J&WAMDV011Q)DG:BA1D]3Q6)XG\,:3K\,=UJ-O))/8Q
MR-;R1W$D10G:3]QAGE%/.>E3)75D3--QLCSCQEX0TC3M8T"YT3P]9W.I2W91
M;`%8A<`1.=Q)Z;.&]#QG.!5CPYX8\;:'J#W]OH6E-?RC9+>ZGJ<MQ,R$@XRH
MP.G85U/ACPCI2WJ:W+]LN=2MY7$,]S>S2^6"A7`#-@\.P&03R>:[6M*4O9QY
M6D_O(A3LM3.U4:R^FW*Z3]BBOC@027)9HQSR6``/3^?MSR#:)\3I<[O%VDP<
MX'E:>&R/7YN_M7H%%5"JX*R2^:3_`#-+''Z+H'C"PU1;K5?%_P#:L*;E^S?8
MX[='!!P254D$'!X_/UO>)?#UYXBCAC35]2TQ87)SIM[Y+2@_WCL)&,#`'J:Z
M*BAU9.7-U]$@L>?'X66S[_M.M>(;S)X^T:PYW>YP@YZ5T'A[PO:>%HKI-+@?
M_2'#.9[V20MC//S`X//;K^`KH:*<J]22M)Z!9'+ZKX%\/ZSJ4^HZAH%C=7<N
MT-+)(V6"C`SQP<`#^O%">!/#,._R_">A-D\;[=&R.?5#CM7444O;5+6YG]X6
M15@A:T@$%I:6T4,9Q''&VQ0O/8+@?3WIRK-$'$5O`H+9&)",^Y^7KTJQ16=Q
MD):Y^;;%$>?ES*1D>_R\=JYS6O",FK:S)JD6I7EC.T$=N5MI(MKHC2,I(DA?
M!S(W0]_:NIHH`Y;2/",FD:S_`&H=2O+^=('MXENY(E54=D9CB.%><QIU)[UT
M9:Y^;;%$>?ES*1D>_P`O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,
MI&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A
M+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`/--6:?P-\1(];6.
M-=%U]UM;P>80L5R/]7*>/EW#@_B2:]%+7/S;8HCS\N92,CW^7CM5+Q#H=IXD
MT&\TB^7,%U&4)'53U##W!P?PK`^'NMW=YIESH>L-_P`3O19!:W63S*N/W<H]
M0R]^Y!/>NB7[RGS]5H_3H_T^X6S.L+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY
M<RD9'O\`+QVJ:BN<9"6N?FVQ1'GY<RD9'O\`+QVH+7/S;8HCS\N92,CW^7CM
M4U%`$):Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'
MGY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_+QVH+
M7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1D>_P`O':@M<_-MBB//RYE(
MR/?Y>.U344`0EKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$):
MY^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'
MO\O':J-WH]E>WBWESHVFW%U$1Y4TR!G4#T8H2.W2M2B@"$M<_-MBB//RYE(R
M/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`K2I+*"'MK>0!OE#N>GK]W@]*#')M"
MK:VY5&!C!?`'7G[O!Z59HH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'
MO\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_`"\=JFHH`A+7
M/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]
M_EX[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>
M?ES*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\`+QVJ
M:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS
M\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%K
MGYML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>
M_P`O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<
M_-MBB//RYE(R/?Y>.U3444`%%%%`!1110`4444`%%0I=V\ET]LD\;3Q@,T8;
MD`^U1VVI6%Y(8[6]MIW`W%8I58@>N`?>@"U5>_\`^0?<_P#7)OY&I(;B&X4M
M!-'*H)4E&#`$=1Q4=_\`\@^Y_P"N3?R-`&?X<_Y!\G_74_R%;%8_AS_D'R?]
M=3_(5L4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!7`>.K>;PWK%GX\T^)G^RJ+?584',UJ3]['=D//TZ\"N_IDT,=Q!)!,BR12
M*4=&&0RD8(-:4JG)*_3KZ":N-MKF&\M8;JVD66"9!)'(IR&4C((_"I:\\\&S
MR>$/$=QX%OY&-JVZYT69SG?"3EHL_P!Y#G\,]!BO0Z*M/DE9;=/0$[A11168
MPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@#+M'`OFA@64QJ[-(LL)'ELWS?*^,')/09Z]15.VM[E+"XT^RFN7M
MTM6BB>YB\MD?&%"_*NX8SSSVYK?"JI8A0"QR2!U/3^@I:`,W3E9[J>X"21PM
M''&J.A0AEW;C@\]P/PIVLQ32Z>_DR;-F6?DC*@'(XK0JO?\`_(/N?^N3?R-`
M&7H$;/I\FV:2/][_``A?0>H/^16L89#NQ<RC)R,!>/8?+_G%9OAS_D'R?]=3
M_(5L4`0F&0[L7,HR<C`7CV'R_P"<4&&0[L7,HR<C`7CV'R_YQ4U%`$)AD.[%
MS*,G(P%X]A\O^<4&&0[L7,HR<C`7CV'R_P"<5-10!"89#NQ<RC)R,!>/8?+_
M`)Q089#NQ<RC)R,!>/8?+_G%344`0F&0[L7,HR<C`7CV'R_YQ089#NQ<RC)R
M,!>/8?+_`)Q4U%`$)AD.[%S*,G(P%X]A\O\`G%!AD.[%S*,G(P%X]A\O^<5-
M10!"89#NQ<RC)R,!>/8?+_G%!AD.[%S*,G(P%X]A\O\`G%344`0F&0[L7,HR
M<C`7CV'R_P"<4&&0[L7,HR<C`7CV'R_YQ4U%`$)AD.[%S*,G(P%X]A\O^<4&
M&0[L7,HR<C`7CV'R_P"<5-10!"89#NQ<RC)R,!>/8?+_`)Q089#NQ<RC)R,!
M>/8?+_G%344`0F&0[L7,HR<C`7CV'R_YQ089#NQ<RC)R,!>/8?+_`)Q4U%`$
M)AD.[%S*,G(P%X]A\O\`G%!AD.[%S*,G(P%X]A\O^<5-10!ROC;PI-XBT??9
MW3Q:O92"ZTZ?Y1Y4J_PYQ]UNAS['M3_!OB'_`(2O0!=F6:WOHI##>6Q"AK>9
M>&3!'3N,\XQ[UT]>=^*K.Y\&>(CXWTJ%I;&51'KEI'U>,=)U']Y>_M^)KHI_
MO(^R>_3_`"^?Y^HGIJ=\89#NQ<RC)R,!>/8?+_G%!AD.[%S*,G(P%X]A\O\`
MG%-LKVVU*Q@O;.9)K:=`\<B'(93T-6*YVK:,9"89#NQ<RC)R,!>/8?+_`)Q0
M89#NQ<RC)R,!>/8?+_G%344`0F&0[L7,HR<C`7CV'R_YQ089#NQ<RC)R,!>/
M8?+_`)Q4U%`$)AD.[%S*,G(P%X]A\O\`G%!AD.[%S*,G(P%X]A\O^<5-10!"
M89#NQ<RC)R,!>/8?+_G%!AD.[%S*,G(P%X]A\O\`G%344`0F&0[L7,HR<C`7
MCV'R_P"<4&&0[L7,HR<C`7CV'R_YQ4U%`$)AD.[%S*,G(P%X]A\O^<4&&0[L
M7,HR<C`7CV'R_P"<5-10!"89#NQ<RC)R,!>/8?+_`)Q089#NQ<RC)R,!>/8?
M+_G%344`0F&0[L7,HR<C`7CV'R_YQ089#NQ<RC)R,!>/8?+_`)Q4U%`$)AD.
M[%S*,G(P%X]A\O\`G%!AD.[%S*,G(P%X]A\O^<5-10!"89#NQ<RC)R,!>/8?
M+_G%!AD.[%S*,G(P%X]A\O\`G%344`0F&0[L7,HR<C`7CV'R_P"<4&&0[L7,
MHR<C`7CV'R_YQ4U%`$)AD.[%S*,G(P%X]A\O^<4&&0[L7,HR<C`7CV'R_P"<
M5-10!"89#NQ<RC)R,!>/8?+_`)Q089#NQ<RC)R,!>/8?+_G%344`0F&0[L7,
MHR<C`7CV'R_YQ089#NQ<RC)R,!>/8?+_`)Q4U%`$)AD.[%S*,G(P%X]A\O\`
MG%!AD.[%S*,G(P%X]A\O^<5-10!"89#NQ<RC)R,!>/8?+_G%!AD.[%S*,G(P
M%X]A\O\`G%344`0F&0[L7,HR<C`7CV'R_P"<4&&0[L7,HR<C`7CV'R_YQ4U%
M`$)AD.[%S*,G(P%X]A\O^<4&&0[L7,HR<C`7CV'R_P"<5-10!"89#NQ<RC)R
M,!>/8?+_`)Q089#NQ<RC)R,!>/8?+_G%344`0F&0[L7,HR<C`7CV'R_YQ089
M#NQ<RC)R,!>/8?+_`)Q4U%`$)AD.[%S*,G(P%X]A\O\`G%3444`%%%%`!111
M0`4444`%%!.!DU3MK\3Q23/!)#`%WI(^,.F,[N"<?0\T`7*KW_\`R#[G_KDW
M\C26MXMT77RI(G3!*28S@]#P3P<4FHR)'I]QO=5W1LHR<9.#Q0!1\.?\@^3_
M`*ZG^0K8K"T"Y@AL766>-&,I.&<`XP*U?M]G_P`_<'_?P4`6**K_`&^S_P"?
MN#_OX*/M]G_S]P?]_!0!8HJO]OL_^?N#_OX*/M]G_P`_<'_?P4`6**K_`&^S
M_P"?N#_OX*/M]G_S]P?]_!0!8HJO]OL_^?N#_OX*/M]G_P`_<'_?P4`6**K_
M`&^S_P"?N#_OX*/M]G_S]P?]_!0!8HJO]OL_^?N#_OX*/M]G_P`_<'_?P4`6
M**K_`&^S_P"?N#_OX*/M]G_S]P?]_!0!8HJO]OL_^?N#_OX*/M]G_P`_<'_?
MP4`6**K_`&^S_P"?N#_OX*/M]G_S]P?]_!0!8HJO]OL_^?N#_OX*/M]G_P`_
M<'_?P4`6**K_`&^S_P"?N#_OX*/M]G_S]P?]_!0!8I&571D=0RL,$$9!%0?;
M[/\`Y^X/^_@H^WV?_/W!_P!_!0!YT#-\*=9;*R2>"KZ7((RQTN5C_P"BB?R^
MOWO2HY8YHDECD1XW`974Y#`]"#WJK<RZ9>6LMM<RVLT$JE)(Y'4JRGJ"*\NT
MO18+>;4=+2\NFTFVNF-IITLN[[-Z.&')!.63D[>OWLX[(16)W=I+?S_X/Y_G
ME4FJ:NSUZBN5\*^)4OOMMA=7D$TE@ZQFY\Q07R,[6']\=R.#GUR!T7V^S_Y^
MX/\`OX*YJD'"3BS2,E)718HJO]OL_P#G[@_[^"C[?9_\_<'_`'\%0,L457^W
MV?\`S]P?]_!1]OL_^?N#_OX*`+%%5_M]G_S]P?\`?P4?;[/_`)^X/^_@H`L4
M57^WV?\`S]P?]_!1]OL_^?N#_OX*`+%%5_M]G_S]P?\`?P5%<:SI=JF^XU*S
MA7^]).JC]30E?8"[17-W7Q`\'V8)F\2Z6<=1'<K(?R4DUE2^(-8N[M=1LR(K
M9/\`564@`\].YD.,JQ[8^[WSDBMX8:I/I;U,YU(PW9W-%<8WQ7\&0L8KK6%M
MKA#MD@EA</&PZJ<*1D'T)%)_PMOP)_T,,'_?J3_XFE]6K?R/[F7S+N=I17%_
M\+;\"?\`0PP?]^I/_B:KGXS>``2/[?Z?].<__P`13^K5_P"1_<PNCO**X,_&
M;P$1\FMM(W9$LY\G_P`<IO\`PN3P9_S^7G_@#+_\31]5K_R/[F',COJ*X`_&
M/PF?]2VHS^OEV,G'UR!2?\+B\-_PVNL,>RBP?)H^JUOY6',CT"BO/?\`A;^C
M?]`3Q'_X+C_C2'XO:>3^Z\+>*Y5_OIIHP?S>CZM5_E#F1Z'17G?_``MJ!^(?
M!_BHOZ26*H/S+T?\+4D_Z$SQ#_WZ3_XJCZM5[?B@NCT2D!!)`(R.OM7G,OQ+
MU-HB!X5O+)6X^U74BM'"/[[*N20.N./<CK4)N)-!W:Q:W!ENVP9C*V?MQ/16
MP.IZ*0/EZ`;<J=(8.<DVS.=:,&D^IZ;17G?_``L'Q.W$?@.0N>F_5X%'XGM1
M_P`)SXT_Z)_!_P"%#;?X5G]7GW7_`(%'_,TNCT2BO._^$Q\<O\R^#M-C!_A?
M6XB1]2!BC_A*O'LO">&=%A([RZNK`_E1]7EW7WK_`#"YZ)17G?\`PDGQ!_Z`
MOAT?]Q*C^V?B/_S[^$/_``+EH]@_YE]Z"YZ)17G?]I?$R3YDD\#PCIMDGG8_
M7(H^V?$R3Y6U#P-$#_'&UPQ'X$XH]A_>7WA<]$HKSOS/B/\`]!WPA_WQ+_C1
MY/Q";D^+O#BD\E5MB0/89-'L5_.OQ_R"YZ)17G?V/Q]+]_QSHD&.GE6*MGZ[
MC1_9GCIN#\1=,4'C<NFQ$CW&6H]C'^=?C_D%_([^YN8;.VDN;F58H8U+.[G`
M4#O5+2-<L]:BD:V\Q'B.'AF39(H/W25/8CD'ZCJ"!PUUI6OVB+=:OXMB\16L
M+;S:I9QV[(1_RT`0GS"/[I^HY`!NZ)#)K&LVU]ILNRWMC^]O$.1*IY,*]F!X
MR>B\8^;IJL/3]FY<U_Z\]3)U)*:C;0[ZBBBN,V"BBB@`HHHH`0YP<8SVS63%
M8275O>130QVT4Z20F.)V(;.1OP0,9YZ=<]:UZ*`*5E:S1SRW-P(Q-(B1D1L6
M&U=V#D@<_,>WYTFK6R7.GR;RP\L&08]0#5ZJ]_\`\@^Y_P"N3?R-`&-HNG6M
MW9O)/%O82%0=Q'&!Z&M'^Q-._P"??_Q]O\:K^'/^0?)_UU/\A6Q0!G_V)IW_
M`#[_`/C[?XT?V)IW_/O_`./M_C6A10!G_P!B:=_S[_\`C[?XT?V)IW_/O_X^
MW^-:%%`&?_8FG?\`/O\`^/M_C1_8FG?\^_\`X^W^-:%%`&?_`&)IW_/O_P"/
MM_C1_8FG?\^__C[?XUH44`9_]B:=_P`^_P#X^W^-']B:=_S[_P#C[?XUH44`
M9_\`8FG?\^__`(^W^-07FAVQM7%K`%FXVDN?7GJ?2M>B@#,AT2R$$8E@S)M&
M\[VZXY[T_P#L33O^??\`\?;_`!K0HH`S_P"Q-._Y]_\`Q]O\:/[$T[_GW_\`
M'V_QK0HH`S_[$T[_`)]__'V_QH_L33O^??\`\?;_`!K0HH`S_P"Q-._Y]_\`
MQ]O\:/[$T[_GW_\`'V_QK0HH`S_[$T[_`)]__'V_QH_L33O^??\`\?;_`!K0
MHH`S_P"Q-._Y]_\`Q]O\:/[$T[_GW_\`'V_QK0HH`S_[$T[_`)]__'V_QK)U
MSPC;7T4;V(DMKI6VF:*4JQC/WER<\'CW'48-=-151DXN\1-)Z,X75_A7HEU(
MMWHTD^A:DB[5N;)N&'HZ'AA^1]ZR5E\3^&<QZ]X8_MVU7I?Z.Y\PC_:A)SG_
M`'<"O4**U5=M6FN9>?\`GN%NQP&F^-?A_J+F(ZA'97"G#P7[/;NA]#O(&?H:
MZFVL-%O(Q):F&=",AHIRPQ]0:L:CHNE:NFS4M-L[Q>F+B!9,?F*YB?X2>!;A
M]YT".-\Y#0S2QX/MM84?N'W7W/\`R#4Z7^Q-._Y]_P#Q]O\`&D;1M-52S0``
M#))D;C]:Y3_A3W@__GVO?_`^;_XJG+\'?`^5:;2))W7HTUY,WX??Q1RT/YG]
MW_!#4T[V_P#!NG`_;=4TV`CJ)+T`_ENSV-<]-\0/`(D,-BUUJ<XZQ6%O-(?S
MX'ZUTEE\/_"&GD&W\-Z:&'1I+=9"/Q;)KH(8(K>,1PQ)%&.BHH4#\!1>@NC?
MW+_,-3S<Z[JFH<:+\.-58'^/4[@6@'O@DDT?\(UX^U3_`%UUH.B1MT^S1R7,
MJ_7>=I/TKTRBCVR7PP2_'\]/P"QYS'\)S<<ZMXNUV[]4@E6W1OJH!_G5^V^$
M7@BW;>^C?:9>\ES<22%OJ"V/TKMZ*'B:O25O33\@LCG8/`?A2V&(-`L(_P#=
MB`-9\W@Z>+4$M=/G%OHL@S(H8^9!URD1[*>.OW><=MO945,:]2+NF*4(RW1C
MQ>%=#@B6*/38511@`9_QI_\`PC6C?]`^+]?\:U:*SYGW*,K_`(1K1O\`H'Q?
MK_C4HT/3@`!;8`_VV_QK0HI7`S_[$T[_`)]__'V_QH_L33O^??\`\?;_`!K0
MHH`S_P"Q-._Y]_\`Q]O\:/[$T[_GW_\`'V_QK0HH`S_[$T[_`)]__'V_QH_L
M33O^??\`\?;_`!K0HH`S_P"Q-._Y]_\`Q]O\:/[$T[_GW_\`'V_QK0HH`S_[
M$T[_`)]__'V_QK&L_!EC:ZU)/Y3-9(O^C0-(2L!.-VP=1GGJ3@<#`XKJ:*I2
ME%-)[B:3,_\`L33O^??_`,?;_&C^Q-._Y]__`!]O\:T**D9G_P!B:=_S[_\`
MC[?XT?V)IW_/O_X^W^-:%%`&?_8FG?\`/O\`^/M_C1_8FG?\^_\`X^W^-:%%
M`&?_`&)IW_/O_P"/M_C1_8FG?\^__C[?XUH44`9_]B:=_P`^_P#X^W^-']B:
M=_S[_P#C[?XUH44`9_\`8FG?\^__`(^W^-']B:=_S[_^/M_C6A10!G_V)IW_
M`#[_`/C[?XTFBV4EA9-#(JJ?,+`*>,'']<UHT4`%%%%`!1110`445#-=VUO)
M%'/<11/*=L:NX4N>.`#UZC\Z`)J*S[:YN)+^1)I(T7D+`4(8`$_,&S\P((Z#
MBJ5AJ]T;&6[OY(U:*W,TEM]DDA=2!D\LQW`<C(%`&M>';;.YNOLR*"SR@+E1
MC_:R!^(-8]U=7DNF1P2NT4LMO/*TBJ,E5QM!!'!(89X]<8JSY:ZHTMAJ(#M#
MY<X\EGB');;T;)(*GOV!P*;J\%I;Z3Y4@G<<I&WG.6!(/5BV2/8D^E`&+I&H
MW`TNXDB+Q_9X1=%`H/FDC[G(_P!GM@\BMV>YG74MHN"J"5$"A04PV,ACC(;K
MCD#E?6J>D6L`LQ)<P3!EDRFU'PRD#&0.&''?(K2DBLVN3</%,9%89PDFTL.A
MVCAB,=<''%`%^BH3<QKNRLORG!Q$Q_+CGIUH-S&N[*R_*<'$3'\N.>G6@":B
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M28)YP=HX/UQQZ\T`58;V=[Z)R[F*:XEM_*VC";-WS9QGG9ZXY%&G7MQ)>)#/
MYYD>%I)$>+:L3`J-JG`W`[CSSTZU:5+2*YDN!%-YF<'Y)",^H'3MR0/2B%;6
MT:5D2X+$X9F61R>O`)SQUZ<4`7:*A-S&N[*R_*<'$3'\N.>G6@W,:[LK+\IP
M<1,?RXYZ=:`)J*A-S&N[*R_*<'$3'\N.>G6@W,:[LK+\IP<1,?RXYZ=:`)J*
MA-S&N[*R_*<'$3'\N.>G6@W,:[LK+\IP<1,?RXYZ=:`)J*A-S&N[*R_*<'$3
M'\N.>G6@W,:[LK+\IP<1,?RXYZ=:`)J*A-S&N[*R_*<'$3'\N.>G6@W,:[LK
M+\IP<1,?RXYZ=:`*ADN%UB.%+GS58%IHBH`B3G:1@9R3@<GG!QTJ#3KVYN)(
M"SL1=VQN%5T&(2"H"\8/\7<YX/-2QVEC;7DUW&MX)6D+28:8JS$8SMSM/`],
M#CVJ18;.`3A([A=^48J)<C.?NG^$=?NX%`%:*_N%TB:9W+RB[>!6VC@><8P<
M#T&/RJWITLK_`&F&5WD:WF\L2.`"XVJV>`!_%C@=JAALK"TAGA2.Z,;M\ZN9
MI,DDDD9SWR<C_"K,+6]K$8XTGVJV"3&[DGUR02W3KS0!:HJ$W,:[LK+\IP<1
M,?RXYZ=:#<QKNRLORG!Q$Q_+CGIUH`FHJ$W,:[LK+\IP<1,?RXYZ=:#<QKNR
MLORG!Q$Q_+CGIUH`FHJ$W,:[LK+\IP<1,?RXYZ=:#<QKNRLORG!Q$Q_+CGIU
MH`FHJ$W,:[LK+\IP<1,?RXYZ=:#<QKNRLORG!Q$Q_+CGIUH`FHJ$W,:[LK+\
MIP<1,?RXYZ=:#<QKNRLORG!Q$Q_+CGIUH`S7O+BTEOG$YNHK:W:20;0-D@&0
MBX'<9."21D>M36DER;BXM7G:1E2.1960<;BV5&,#C;Q]1G--M;*PT_S1"EWM
M)*LC--(I+')."2#DYY'KUYJ06]G%;2P*MTJ%@&*F7?[88?-CCL<8X[T`5/MM
MVW@P7ZS`7(L?.,FP'+;,].G7VK:0DHI/4BLHZ;IRZ>UAY=Y]E4[3&))SQ@C:
M#G)7';I5R%H+2'RD%R5C./G620]^YR2/_K4`6J*A-S&N[*R_*<'$3'\N.>G6
M@W,:[LK+\IP<1,?RXYZ=:`)J*A-S&N[*R_*<'$3'\N.>G6@W,:[LK+\IP<1,
M?RXYZ=:`)J*A-S&N[*R_*<'$3'\N.>G6@W,:[LK+\IP<1,?RXYZ=:`)J*A-S
M&N[*R_*<'$3'\N.>G6@W,:[LK+\IP<1,?RXYZ=:`)J9*&:)@DGEG^_@''KUI
MAN8UW967Y3@XB8_EQSTZU#>BUO+6:VN8YVA;Y'54D&?Q7G'';C\Z`*,5Y<O:
MPH+AF6XN3%#=*J[C'L+;^FW)*D`XQR#1+?7?]CQ7"R;'6Z6%R4&7'GB,GT&1
MD]._:K/V:S2U>W*WC1A\Y9IF8'_98Y(Z=CC\Z2ZM+"YA2&6.Z\N%@`L1F09S
MD'Y<;L%<YYP?K0`NJR7$,:O;W.R9B%AAVC$K^AR"<8YXQC!-:-94]A82RI+(
MM]YD">2KI).#CZ@\YQR><\9/2KYN8UW967Y3@XB8_EQSTZT`345";F-=V5E^
M4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N
M8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_E
MQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`35!>';;.
MYNOLR*"SR@+E1C_:R!^(-*;F-=V5E^4X.(F/Y<<].M5K^*TOX?)N8[AD20-A
M!(IW#.#E<$],^G3VH`JK=7LL-I`\C032QRRF14&<*1M!!&`2&!(QV.,4XWUS
M(FBSAO+2[=1)&5YYB=L$GW`_*IGM[,P+"ZW3+"V`296;G.?FZL/Q(Z#TJ2ZT
MJUO)(I)1,#%_J_+N)(PO49`5@,X)&>N#B@""_GN+>_MBDDJ0NZ(S,$,7)QM_
MO[CV[9(^E:E5VLH7N5N'\QG7&`96*C'?;G;GWQFK%`!1110`4444`4X;-UNG
MFEN))5#?N48C"#'/0`D]>I/%"Z;&9)))Y9+EW1H]TH4;4/51M`XX'7GBKE%`
M%>UM%M0W[V25VP"\F,X'0<`#`J62*.9=LL:.H.<,H(S3Z*`$50BA5`"@8``X
M`I:**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHIAFB$PA,B"5E+!-PW$#J<>E1F]M569C<P@0\2DR#]W_`+WI^-`$]%0FZMPK
ML;B(!$\QCO'RIS\Q]!P>?8TJ7,$CR(DT;-'C>%8$KD9&?3B@"6BJK:E8(L+/
M>VRK-_JB95`D_P!WGG\*F2X@D>1(YHV:(XD"L"4/OZ4`2454MM3L;Q)7M[N&
M1821(0X^3!(Y]!P<'OVJ5KRV5(7:YA"38\IBXP^1D;?7CTH`FHJ/[1`;@VXF
MC\X+N,>X;@/7'7%--U;J^PW$0??Y>TN,[\9V_7'./2@":BF+-$[E%D1G'50P
M)':H1J-B98HA>VYDE4-&GFKEP>A`SR*`+-%5'U73HHQ))?VJ(6*AFF4`D=1G
M/44#5=.9F47]J65/,($RY"XSNZ],'.:`+=%16]U;W<?F6T\4T><;HW##\Q3!
M?V9:91=P$P#,H\P?NQZMZ?C0!8HIBRQMC;(IRNX8/;U^E0Q:C8SPR30WMO)%
M&,NZ2J54>Y!XH`LT5674;)H%G6\MS"S;1()5VD^F<XS5AF5%+,0J@9))P`*`
M%HJ#[;:_9?M7VF'[/C/F^8-F/KTJ>@`HJM_:%EY+3?;+?RE;8S^:NT-TQG/6
MI&N8$FCB::,2R#*(6&6'L.]`$M%1075O=!S;SQ3!&VMY;AMI]#CH:EH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`P[BQU`ZJ-0C\HA)D58MF',7W3\^[&/G=L$=AWJ!M
M+G\N\C%G+Y!?S(T$D>\2;MVY">V></\`RKHZ*`.:GT_4C%=+]G21[RQ%LS*Z
MJ(V'F<L/3YQ]W/.>*<=*O4NYVC3]W<3^7(=X`,)CC!;UR"C`#K\U='5&34=F
MJ1V9B/EL,&;/`<@D+CZ*3GW'7-`&5-I]['=Z;)%;2E(5E5Q$T7&YU(SO[8!Z
M<U9L[":)[^,VI6VD#[8W=3N9B2=K#D*<G[W(-(WB`K;WDOV4?Z/+Y>PR@$?-
MMW.,?(O?//'-2R:UY<=Z_D*WV:S%U\LH(?._@$#_`&.OOTH`AV7-WHMP)K.>
MXCE0&*WN5C$@)SUY"X'RD9YX.>:SYM)OI]&LK9M/1I/L)M&\QTS`V`-_?(.,
M\'/3\-6/74:>[BDAV>0N4PV3)A48@#'_`$T4?C44NOR1O81M;0))=!RPEN@@
M4JP7`.WYCSP..E`#$TRY_MU)6MHQ''<-/]JW#<X,93;CKQGZ8`I)=)N)]2=V
MC(B:^,H<,,A?L^P,/^!5H6&I_;9+I?*$?D.R;3("_!QEE_ASU'7(Q5"/Q)(-
M.^U7%B(R]H]U"BS;@ZJ`2"=HP?F'8T`-DL=1:%)XX`EXSRQ/AQ\B2?QCL<%5
M..N/?BGR6%S%X@62&VE:T^S1Q`HT87Y2_#;OF'4?=J[_`&I\SQ^3B87"0*C-
MC>&`;<#CLI8_\!(]ZJC7+B:>&*VL%D=VGR&GVX$4@0D?*<DYSCCZT`5AI5R=
M'>U6V(5)X?)20H75%D4G)'!``XSSCKS4=WIE^\VN1QVTICNHV$)#1!"?*51U
M^<'((["KD7B)+C4+>WACA\N:!)PTLX1R&W<*F/F(V\\]Z4>(<Z.M^;7#&W:=
MHO,Z84,!G'<$<XH`DL+6X:ZN+J2W^R"6!(A$64G<I;YCM)'\0[]JRIM(OY])
MCM19+%-;6DD)D$BGSV,>W`]B>23CD"MVSU"2:66WN;<07$<:RE5DWJ58D`@X
M']T]JR(/%IFTR6[^R1#8(CQ<@H/,;;AGV_*PZD8X%`&I;6LT-]./+_<"+;$^
MX<Y).W';&<?3%8<>D:A-HRPFR^SRPZ=):E"Z$S.RK@\'&/E/4]ZTWU]T0XM8
MY'"0,!%/N5C+(4&&QSC&<]\]JMC55:ZAC6(M%*X02`],H7!(_#'UQ0!G16E\
MLEI<O923B..2)X9GB#`L5PWRX7&`1ZX]:UF\^2WN8FME&WY8QO!$@VCGD'')
M(P1V]ZSI?$#)+8HL-OMN][(TMR$!4,`I'R\E@P(%$FO3"TOYXK)'-F7W1O<;
M7VKG)(VD@G&0.X(YH`S[G2KR;PK<VCZ6LEQ+*S1)NC+)G^-CPH;K]WU^M=)'
M-++O#6S(HC4X8C)8@Y7TXXY!(Y/I69'KLYU*&RFM;:*1XEE8&[YP2W"C:-W"
MY/3K4NEZS)??9A<6@MS=0F>';+O!4;<YX&#\PH`R(;"_8M<3:&@D,V]H#)&$
M(*%1MP3]T8R3R<G'I3CH5XB6MM]FAEV1VW^DE@/+,1R5QUY[8]375T4`87AR
MPN[)9!=0^7^ZBC7<5)^4'(&W^`9XS\W)S6[110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%9TNB6,T[7#1`7)E67[0%7S`01@!L=,#&/3-:-%`&>=*4O+(+NZ$
MCC:K[QF,>@XY'US44F@6DB;!).BM%Y,JH^!*G/#<?[3=,'FM6B@#.?1;5YA*
M6D!^T"XP&`&0@4+T^[\H./44DFCQO-;RQW5S"\`<`QE?F#,&(.5/<#IBM*B@
M"I#IZ0W$LYFFD=QM'F,#L7T''\\U2B\.6L=BUJ]Q<S+Y#6Z-(R[HXR`"%P`.
MPZ@]*V**`*?]G0_VDE]ND\Q8]FW/RG&<''K@D9]#58Z##YD3Q7=U"T;2G,;+
M\PD?>P.5Z9';!K5HH`S4T6&&[CGMYYX%2)(?)0KL95S@'()_B/>F/H%J]JEO
MYLXC6T^R<,.5QC)X^]CO^G2M6B@"G::=':%W,TT\SJ$:64@L5&<#@`8&3VJH
M?#MJ+-;:.:XB58XDW(RY)C;*MR,;N.N/Z5KT4`9IT:%I/,DGN))/W.78KD^6
MY=<X'J>?;TI9=&@D@N8O-G43R"3<K`&-@01M./4=\_EQ6C10!GSZ3'+/:RQW
M$]NULAC00E0"IVY!R#_='3%#Z1#*EVLL\[_:8FA)9AE$(Y"\?SS6A10!GG2D
M^WB[2ZN(SY:Q-&I7:ZKG&<C/\1Z$4W3M&ATX18GGG,,?E1&9@?+3C@8`]![\
M5I44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
5110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>txmd-10k123113_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd-10k123113_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`%V`HH#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HI&(52Q.`!DUP?
MA_Q1XM\3SVVLZ=I6EKX8GEV(+B:1+QHP^TS`8V8P"0IY..O-`'>T5Y^WBCQE
MKE]J3>%-+T@Z=IUX]H\FI2RK)=-'C>(PJX7G*@DD9'X5B:U\7K]=!\*ZMHFG
M6TB:K#=7-W%<%B8DME#2JA&.<!\$C'`XYH`];HKS;XA_$FZ\-:597N@6]I?+
M);K?SM-N*BV9T12I4CYF:08)XPK=:R_%7Q1UO1/&&OZ?;-X<CL=&BBD,5_.\
M=S=[X@Y6'!P2"<8QZ>O`!Z[17&^(O%>J6^A:0VBV4(UK58C-#:W@+"-5A,K[
MPI!X^5,YP&<5G^+_`(A7.F>!M!U[1!8;M7NK>!)-0+"&%9$9BSD$$`;>?3F@
M#T*BO)9/BEK4'@;Q/JCVVD75[HLEO$EW8RM+97+2L@.TY#':&Y&>I'-;4_C7
M6Y_'[Z!I\&CQ0VHB::*_G>.XNT=0=UOQM(7D'.<D=J`/0**X?5/$GBC4?$>I
M:)X1L=++:8L7VJ[U1Y1&9)!N"(J#)(7!)SW_`#Q-1^*&KCPI;7.GZ5:#73KX
MT*XM)9&>-)OFSAA@D'"X/;=WQ0!ZG17(Z=XQ?5M<\/P6L*+9ZIIDUXXD!\V-
MT:,;.N!@LP(P>13?$7B37!XDC\->&+&RFU$V9O)KC4'=8($W;%!V`EF)#<9'
MW?R`.PHKRW4?B9K.D>$_%3WVGV">(_#S6R2QQN[V\HF*!9!G#8^8G;G(P.>:
MZCP1K>JZSIES<ZMJ/AR]*2`(^A3/+&@VY(<L3AO;TH`ZJBN"\/\`BCQ;XGGM
MM9T[2M+7PQ/+L07$TB7C1A]IF`QLQ@$A3R<=>:M^'/%U[K-EXMGF@MT.C:E=
M6<`0-\Z1*""V3R2<YQB@#LJ*\CG^+&JVFI>&Q<6=@NG76CVNIZI,=RF)9I1%
ME,M@!693\V>,\UM>*_'^HZ+XXT?1K"SMIK&6\M;._EEW;T>X+;`A!P"%1F.0
M>JT`>A45QOASQ=>ZS9>+9YH+=#HVI75G`$#?.D2@@MD\DG.<8JEX9\=:CK7B
M?1-+N+>U2*^\-QZO*\:L&$K.%VKECA>O7)]Z`._HKBO&WC"^\/W<4.F06\_V
M>W;4-1$JLQ2U5U4[<$88@N1G(_=MQ57XD^*/%'A?06\0Z"FBS:5!$C3B\65I
M6+NJJ4"D#'S#J?6@#OZ*X";Q-XLTK7/"NAZO%HK7VL/>":2T$IC011AH]NX@
MY)/.?3CUHB\=ZA<?#RQU2*TMTU^[NTTT6D@.Q;KS?+<8#$E0%=\9S@=10!W]
M%>5ZSX]\3?\`"P=5\-Z3=^$K)+'[.L9UJ:2.2X>5`V$VMS@G&,=QUS75^.]2
M\2Z-X?FU3PZNDL+*&6XNUU`2',:(6Q'L(^;@]2!0!U-%>;V?C7Q3:^#=-U75
M;#2KK4=;FMX]*MK`RHN)EW9E+;MNT9)QD<=>]6;7Q1XLT[Q':>'_`!)9Z*EW
MJL-P^F7%C)*8O,C4-Y<@89Z'.X8]`*`._HKS3PQXD^(.I^.-2T/4H_#"P:0T
M'V][9;@,RRH77RBQP2,<[@/QK4B\:WDGCH:>8K;^PGNI--CN`K>8;M(UD(W9
MV[?]8F,9#(>>U`';T5RVB^)KO4_'WBC0)885MM(6U,+J#O<RQEVW<X]`,`?C
M63\1O&FJ^&-3\/Z=I4FBV[ZHT^^ZUAV2"(1JI&64C&=V._.!WH`[^BO);_XI
MZS'X#M-7@M=)AO)];_LG[1/*S63*-V9U8$'R\KU]B>:T;GQ%X[C\"7&OVMUX
M,OGM?/GEDM))Y8'@C0'"$'F3<'!R<=/>@#TFBO+X_''BZQ\+^&]6U:WT1FUW
M4[*"%;19<);SH6)8,?OC'8D?6M_Q1XNO=!UBZMH8()(8-!N]3^<'<9(BNU<@
M_=.3GC/O0!V-%>5^!OB1K>O:WI6GZD-`NUU*U>YSH\[L]D%53BX1B=I)8+UZ
MU'X>^*NJZMX$UK6;O3[2WO[:RDO[)%#&*:(,Z<_-DE7C(;!'WEZ9H`]8HJ*V
ME,UK#*P`9T5B![C-2T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`C*'4JPR",$5P/ASPOXQ\,26VC6>KZ5)X:MY2\;S02->+&9-WD_>VXP
M2-W4>G`KOZ*`//AX7\9:'J.HQ>&-4T@:5J5W)>.-0BE>:U>3&[R]K;6!;)P<
M8SWYI+/X:KI5[X)2RFB>PT".\2Y$N0\YGCP648(^\22"1@'CI7H5%`'DDGPF
MU1_`_B#16U&VEO+UX+:QED9ML%E#,'CC)VYW`;NQYP,]ZZ>P\"PI\1?$'B74
M;;3[N.^%L;+S(@\MNT<>Q_O+\N<#D'GOTKM**`.'\1>!+SQ/XM&I7&O:CIEG
M;6@@M/[*NO)FW,Q,I<E3P<1@`'^'M6$WPMU,^%].\.RWEG=Z?IWB%-0A^T[F
M:2TRQ:.0;<%R7?\`V3[9KU6B@#S+6_AMJ5QX:\5^'=)N+"WTK4Y(+C3H&W*+
M60.K2H0`0$)0$;>A8\59\6^"?$7BJY2PFOM'CT=9(Y8[H6SB_MBI4XB?.T9P
M?FZX/0UZ)10!PVI>&_%.G>)]1UGPE?:4%U7ROMEMJB2LJ,BE?,C*'J5P"".<
M=>E4C\-+B/2])B2_ADOH_$D>O:C.R%1,^6+A%YQU``]O>O1J*`.)L/!5YIOQ
M&;6X+F#^QS#.4ML$2133-&7QQC:2A;KD%CZ\2>(_#>O_`/"2Q^)?"U[81ZC]
MC^Q3VVHK(8)DW[E/R'(926['KVYKLJ*`/,-6^&FJ:MX2\41W-_92>(O$#V[S
M3*CQVZ"%D*(H^9L`*>>IS[5W^F:)IFCV;6NG:=9V<3\R):PK$KMC&2%`R?>M
M"B@#@/#GA?QCX8DMM&L]7TJ3PU;REXWF@D:\6,R;O)^]MQ@D;NH].!4%WX,\
M66&H:Y#X:U/1X-*URXDN+G[7;NTUN[H%8QX.ULD$_-C'O7HU%`'GB_#,#64#
MW$<NDCPM_8)5R1*6$@8/P,8Q[\'M5.U^&VL#0]!2^U&UN-7M]?@U?4KDEL2K
M$I4*GR\G:$'(`ZGZ^GT4`><W?@SQ98:AKD/AK4]'@TK7+B2XN?M=N[36[N@5
MC'@[6R03\V,>]5[OP)XHT7Q'I&J>$;K1Y!8Z)'I#+JWFC<JN6W#RQU/'?UKT
MZB@#SJ_^&MYXCUW5=4UGQ%J=BUTJ6\<&CW?E1F!4`VR!DRV7:0XY&&I;_P`"
MZWJ'P9_X0R>]LFU!$B@2X!<1F*.964GC(/EJ!CU[XYKT2B@#EM?\,W>K>-O"
MFN0S0K!H[71G1R=SB6,*-N!C@CG..#699^!;VU^(<^J^=9_V";E]2BME#"5;
MQXEB9B,;2N-[9SG+=.]=Y10!Y7K7@+Q-_P`+"U;Q)I%IX2O4OOL[1C6H9'DM
MVB0+E-J_*21G.>P]*]`\2Z;-K/A75]+MVC6>]LIK>-I"0H9T*@G`)QD^AK4H
MH`XJ]\$W=SX(\.Z7;Z@EMJNA"UDM[D*6C,L*!""N02C#<,>A_"F:5X8\1:CX
MFT[Q!XPNM*>YTR.5;*VTM)!&K2`*SLSG).T8QC%=Q10!RVD>&[[3/&?BW7?-
MMW35Q:_9H]S94PQ%#OXXRQ[9X_*N,;X/:FFA6\T7BK4GU^&=+\0SW6=/^UA]
M[,(P@(!);D<\YQVKURB@#SP^&?&6F_$75M?T:;06L-7-J+F.\,WFHL2!#LVC
M&?O$$^W2M+Q;X*'BCQ5X8U"XCLKC3M,:Y^U6UTF_S1(BA<*00<,H/./7M78T
M4`>4ZS\-=>N_"$.A6USI4\6G:V+_`$Z.]\QHS:@-B"48)X+D8&05`'%=#9>'
M=<D^'6LZ!?VOAZQO+J"X@MH](C>*V19(\`L",@[BQ.!TQWKM:*`.*U'P/<7W
MP_T+0TO(8=2T<6DMO<F,O&)H%`SC@X.&'XUG'P7XHUL:M?>)-1TL:C<Z/<:5
M:P:?&X@B$O5V9_F)R%]A@UZ-10!Y_P"'/`%SX8O?#=WIO]GV[P6/V/6DB4JM
MV=@VR+@#<X<'E@"0QY%9$GPJU-/A=I_A^VO[1-9LH[F'[00WE2Q3NY>,G&[&
M&4]/O(*]7HH`BMHC!:PQ,02B*I(]ABI:**`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.-U+X
MA#3M2N+,>$/%EUY+E//M=,WQ28[JVX9'O57_`(6=_P!2-XU_\%/_`-G7>45N
MITK:P_$5F>>0_$"^M&6XNM+N]3AO5\ZWMM)@\Z:W7CAAD;EP1ENS9'0C$_\`
MPL[_`*D;QK_X*?\`[.NOL](L-/NKJYM+5(IKI]\SK_$?Z#))P.,DGJ2:NU4Z
MM%O2'XDQ4DM6<_H?B%O%-G>K'I>NZ*\8V![^S$+Y8'#1AMRMC'<$=,@YKFX=
M4URR\(WNI-K-W?W2ZVMC&LT5NH$:Z@("!MC499."3GGD;:]$K-.@Z8;!K$VW
M^C-=_;2GF-S-YWG[LYS_`*SYL=.V,<5A)INZ5BSGKWQ[]CE>Q.F22ZI'<20M
M;P+-,N$6)V8-%$S?=GCQE0,G!(ZU8B\7W5W!JLT&EQ0I8-"@^WW+P,[R10R!
M641LR,!*5Q@G<`,?,=NK<>&M*N6N7:&:.2XG^T22P7,L,F_8J9#HP9<K&@(!
M`./K3H_#NEQVMU;"!V2[9'G,D\CN[(B(K%RQ;<!&GS9SD9ZY-2!SNG^/;G5+
MN.QM=&_TS;<><D\LD"QM"(&('F1!R"+A<$HO3I@Y$MI\0+;4M3M(-.T^]NK:
M80>9.EM.?*,R)(F2L9C`"2*6+.I'H:L'P'I0U>"\B,Z1K'.LR&XE9YGD$"[S
M(7W9VVZ@C^+)SWSJR>'].DO8+M5N(98=NT6UW+"C;<;0Z(P5P,8PP(QQTH`Y
M+4_B%J2Z/X>NM+TFT:?5[:&Z9;JZ8+"KSV\6T;4)8YN!SQC!.&^Z=5?%%TES
M>VCVD;:B+^*PAMVN?W)E:U2X8"01;@H!?DJ2=O09"BZ_@OP_)D/8L1Y30J/M
M$O[M"Z/A/F^3#QHPVXVE<C%66\-Z6T-S$89?])D2:607,@D,BQK&KB3=N5MJ
M*,@@]3U)R`8/B/Q3K&G:;JRI8VEI<6FFS7`EDNB2TBP&3,*F/$JAOE.XH>"=
MN,99J6OZI;66EI%<8N8]0MX+URBGS$>YCB&1C`WJY?C&,5MW'A#1KP2+>0W-
MTKP&W*W-[/*%0QF)BH9SM8H2"XPQW$DDDFK4V@Z7</(\EHI>2:"=V#$%GA8-
M&20?X2H_+G-`',Z;JNK102:K<:C<7D4FN3:?]C,,6R./[6\"%"JALJ-I)9FX
M5OK70>++ZXTSP;KE_9R>7=6NGW$T+[0=KK&Q4X/!P0.M%KX8TRPNI[JTBE6>
M2:2X'FW$LL<<KEBSK&S%4)+MG:!U-6I-*M[G0GTB\,EU;2VQMIC+(=\J%=K;
MF!SDC/(YYH`PSXOFBU&Z@DTX?9+6_MK"2Y\_YF>=(BI";>@:90>1QR,\@:>@
M:M<:Y9+J)M8(M/N$26RD2=GDEC89RZ%%"'&"`"W7G&*D?P_I<AG+6N?/NH;R
M3]XWS31;/+;KQCRH^!P=O(.3DL=!L=-O'N;7[4C."OE&\F:%03GY8BQ1>G91
MW]30!IT444`%%%%`&7K^M#0=-^V?V;J6H_.$\C3K?SI><\[<C@8ZUR__``L[
M_J1O&O\`X*?_`+.N\HK6$H)>]&_S%J>7'Q;K'B3Q#=Q6<NO>';:VM8&%O=6,
M$<LCN\N7Q(CG;A%`P1R&J72_'M_I,FI6.H:;XD\0O!>>7'<V.G))M0PPOM<H
M$7.YV[9QBNPU7PCH^M:A]OO([H7/E+"7M[Z>#**6*@B-U!P7;KZFK6C:%I^@
M6\T&G1RHL\OG2F6XDF9WVJN2TC,?NJHZ]JE2CS7:T[`<K_PL[_J1O&O_`(*?
M_LZO:MX@OK?7]`>W$L5A/8W-W>6TT063:K6X!.>59!*Q('H1SQ7756ET^UFU
M&"_DBW7,$4D,;[CPDA0N,=#DQIU]/<TYR@_AC;Y@<'>>-9K/PO!<7&KV=O>R
MZA?"-[F2*(20V]Q*!&-W!R%CCSU^;.<\UMSW]S)J]K=3:K=V>DSR0_8VMHX6
MAN-X7"2LR,REF.!M*@A@`=U;&FZ!I>CK$NGV:0+$CI&%).U7?>P&3W8Y/X>E
M06OA72+.XBE@AN`L(40P-=S-!%M`"[(2QC4C`P0HQ68S`TW5=6B@DU6XU&XO
M(I-<FT_[&88MD<?VMX$*%5#94;22S-PK?6H]+\>0W47B&ZAO[74UMK:2_MH+
M66.1TC3<OED+SD[$;GG,I&>*Z.V\*Z1:7$\\4$VZ>629E>ZE=%DD+%V1&8K&
M27;E0.IJZ-)L%:U86L8-I"T$''W(V"@I]#M7C_9'I0!EZ=<W]KKL&GW=Y+?+
M=V;W?F-$BK"R-&I1=H'RGS,@-D_*W)[<;+XE\0+I'B6^M;^]FDLFU0,)[)4@
MM4A,PA,3^4!(V4C!!9^^<'@][9>'K'3KM;FS:YC<`JP:X>0,G.$^<MM4$Y`7
M&,8'&14AT+36TB]THVW^A7IG-Q%O;Y_.9FDYSD9+MT(QGC%`&%=^+[VU%Q;_
M`-G6WVZ!8)/)ENI/WD<HDV[?+A=FDS$^453P"<FJ<?Q%:YL-2O;;22T.G:9)
M?S>;,T3;D>XC,84ID'=;GD@<,<@$8/2W?AS2[V>6>:W<3RI%&98YY(W`CW[-
MK*P*D>:_*X)W'-0Q>$-"@M;ZVCL=L-];O;7*^:_SQL\KLOWN,M-*<C!^;V&`
M#.C\8W`N;B.ZTI(8[;4(;":1;G?\TPC,14;!G_7)NSC&3@MC-07GC]-*U:XM
MM3M(TM$\\QW5J\TRD11R2,')A5`VV-LHKL0>/>N@?P_I<AG+6N?/NH;R3]XW
MS31;/+;KQCRH^!P=O(.3F)_"VC2:@+U[1GF$CRJK32&-7='1R(]VP%ED?/'.
M<G)`(`,O4O%][I$-K'>:0K:A=EY(+:T>>Y!A39N9C'`2K?O`,;2N<?-S39?&
MLK:=>W%MI+>=!?6=E'!=2F$LUPL!!?Y"8]IGP1@GY3ZX&J?"VEFS%K_IVP2&
M1'&H7'F1D@`A)-^]%P!\JD+[42>%='EDBDEMYG>-H7!>ZE.YX2IC=LM\[`JO
MS-DG&"2*`.;TGQQ>OI&D:GKMM!;)<Z/<ZI(;.8NACB6%LE63<&/FM\H8XQU;
M/&GJ7B76-+LX)[C2+`O*S'R(;R>:4Q@+AE2.V8L?F.X8VK\OS'/&E:>%M&L?
M*$%H0L,4L,2/,[K''*4+HJLQ`4^6F%`P,8`&32#PKI0ACB*7;+'(9$+WT[,N
M<90,7R(SM&8\[3CI0!2\(>()/$3ZM=B1FL_.MVM$90"D4EI!+@XZ\R,><]?2
ML[3O%FJ-,ED+-+ZYFN=5*O),(5CCMKH1JIPAS\KJ,]<J,]21TVD:%IN@V[0:
M9;>1$PC!7>S9V1I$OWB>B1H/PSU)--M_#^EVMRES#:[94-P5;S&.//D$DO!/
M\3*#[8XP*`.8NO&T^I:?:7>C1^7;->Z;%-,[#>!</`Y385((,4P!;.06XZ9"
MP?$B*>SFU(:1>#28XQ<_;#!,B_9\J"^9(E4L-V[:C-E0Q!)`4[J^#]"2*TB2
MS98[06XA03R!1Y!4Q$C=ABNU>3DD#!)%/C\+:3'=BX6.Y.&#K`UY,T"L#D$0
ME_+!!&>%Z\T`:&GW,EYI\%S+!Y#2KO\`+WABH/3)'&<8SCOW/6K-5[*RM].M
M$M;2/RX$SL3<2%R<X&>@YX'0=!5B@`HHHH`*YD^,@/$/]D?\(YXB(\_R?MHL
M#]FZXW;\_=]\5TU%)B=SC]4\?KIEY>6Q\,>(Y1;;_P#2EL#]G;:"<A\_=XZX
MI8=9U33;[2_MUP;^/5)A#Y=O;@>0Y4L&7')C&#DMD@8.>#GKB`P((!!X(-9F
MG^'M,TNY,]I`ZOM*IOF>18E_NQJS$(.!PH`X'H*EQE=69#C)M-,S3XR`\0_V
M1_PCGB(CS_)^VBP/V;KC=OS]WWQ6KIVKC4;V_MA87]M]CD$?FW,!C2;K\T9_
MB7CK]/6M&BJU+29YKX8\8:C#X6M=;U2YU'4+62RB>=[BP,3"ZD:-4CA"1*9$
M)<\@/VP6S@:DGQ`:.RMMVB7HU&=Y`+4VEWAECV%W7]QYA7]ZH!,:@G(R,9KJ
M(-&T^WT6'1XK<"PAA6&.$L3M10`HR3GC`YSFJG_"+:8;(6K-J+*',BRMJ=RT
MR$@`A93)O4'`^4,![<FF,CT+Q#-KE]?QC3GMK>T:-"T[E92SPQ2@&,K\I`E(
M()X*CU.,Q?$+?V@MU>ZC=V<$FI/I]O:I8&2)BLJQ#S7"L5+MRA+(,..#@UT>
MGZ59Z69S:I(&N&1YGDE>1I&6-8P2S$DG:BC/?&3DDFH+CP]I=U?K>S6[&59%
MEVB9UC:12"KM&#L9@57#$$C`Q0!E0^+;B>W9DTZ)9IM2GTVR1[D@321-,&+$
M(=B[82W1CU&.F:S^/HQI^MW2:?O.E::UXZ^=C?(LEQ$\8.W@!K=OF[YZ>N^V
M@::=/DL1`Z023R7)\N9T<2N[.S*X(9269CP1C.!Q4%[X3T34;8VUS9DPM;M;
M.J32)OC.<JVUANY)/.<$DCF@"GIWBM[R^ABGL4@@N+^[T^"03EV>2!I<DKM`
M`*PL<YX/'O735AZ+X8M=(EFG+M/<275S<*Y+!4\Z5I"`FXKD!MN[&2!^%;E`
M!1110`4444`%%%%`!1110`5F.ACU07$K.ZE_+C9)3A,@94IT/(SGD\]L5IU7
M%E;"^:]\E/M!0)OVC(`SWQGO^@H`HR":'7H,F1(92P&V=G#X4G#(1A`.>1UP
M/7%4X;N[CM?M*"1Y9;"2XD1I"P648PH!X'5AQQ\M;D=I;13R3QV\232??D5`
M&;ZGJ:=';P0M(T4,:-(=SE5`W'U/K0!1TXNEW<0AY)(1''(KO(7.YMVX9/;A
M3CIS4NIW4]I:B6WC#L&^;*D@+@Y/%68;>&V39!%'$F2=J*%&3U/%1W__`"#[
MG_KDW\C0!6L+^>^M3*L$896VG,A`)QR>AQU%6RUS\VV*(\_+F4C(]_EX[5F^
M'/\`D'R?]=3_`"%;%`$):Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[
M5-10!"6N?FVQ1'GY<RD9'O\`+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%
M$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'O\O':
M@M<_-MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92
M,CW^7CM4U%`$):Y^;;%$>?ES*1D>_P`O':@M<_-MBB//RYE(R/?Y>.U344`0
MEKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1
MD>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'O\O':@M<_-MB
MB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_`"\=J"US\VV*(\_+F4C(]_EX
M[5-10!"6N?FVQ1'GY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.U344`0EKGYML4
M1Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1D>_R\=J
M"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'O\`+QVH+7/S;8HCS\N9
M2,CW^7CM4U%`$):Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"
M6N?FVQ1'GY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&
M1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1D>_P`O':@M<_-M
MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7C
MM4U%`$):Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1
M'GY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_`"\=
MJ"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'O\O':@M<_-MBB//RYE
M(R/?Y>.U344`0EKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$)
M:Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9
M'O\`+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1D>_R\=J"US\VV
M*(\_+F4C(]_EX[5-10!"6N?FVQ1'GY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.
MU344`0EKGYML41Y^7,I&1[_+QVH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$
M>?ES*1D>_P`O':@M<_-MBB//RYE(R/?Y>.U344`0EKGYML41Y^7,I&1[_+QV
MH+7/S;8HCS\N92,CW^7CM4U%`$):Y^;;%$>?ES*1D>_R\=J"US\VV*(\_+F4
MC(]_EX[5-10!"6N?FVQ1'GY<RD9'O\O':@M<_-MBB//RYE(R/?Y>.U344`0E
MKGYML41Y^7,I&1[_`"\=J"US\VV*(\_+F4C(]_EX[5-10!&IF+D-'&%SP0Y)
MQSVQ]*DHHH`****`"BBB@`HHHH`****`"J]__P`@^Y_ZY-_(U8JO?_\`(/N?
M^N3?R-`&?X<_Y!\G_74_R%;%8_AS_D'R?]=3_(5L4`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1158WT(O!:_.7[L$)53P<%N@)!SB@"S15=;ZW:Z^SASYG(&48!B.H#8P2,=`
M:BL]5M;Y0T!F*%/,$CV\B(5]0S*`>OK0!=JO?_\`(/N?^N3?R-+;7<-VK&%F
M.TX(9"I_(@<>_>DO_P#D'W/_`%R;^1H`S_#G_(/D_P"NI_D*V*Q_#G_(/D_Z
MZG^0K8H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`***QM2\7>'-'R-0US3[=A_`]PN__`+YSG]*J,7)VBK@;-%>;MX@B\:J;
MNSO'73(9"L"P2%7+J?\`6.1R#W5>PP3DD;>J\,:Q<:G;W$-TN^:T<1-<HN$F
MX_1A_$!P#]<#:IAITX<S,HU8RDXHWJ***YS4****`"LT^9_:S)!#+&V5>63>
MIC=>1R,YW<=AV'-:5%`&2AN[C6PUS82I;P%A;R;HRN<8+GYMPST`QWYZ\00Z
M9+]FNK2WCN+2T:W>%8YIO,.XC"LIW-M`&>./IQ6[10!0L(9OM,]U-$T)DCCC
M$;,#C9NYX)'.[]!TI-9M?M.GO\^WRLR=,YP#Q6A5>_\`^0?<_P#7)OY&@#+T
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M`'H!@]R<8'7CVJ2)+>Z@6>&9Y(I@)%>.=BK`\@@@].>W%>;?\),WB?5_M,]A
MJ-KIJ.%TUKNV,4<K;?F89ZO][&?X1QSNI]IX6N/$MZ\<.L:K8Z!'O\V*SN/*
M2:8D9"\$[?O;L<;CQSNKK>$48<TY6_K\S%5;SY+':ZOKF@:(K'5=8@LRQW;9
M;LJQ^BYSWZ`5R\GQ0\.W3O'HMKKNMR%NFG6TI&?JQ7`^G%;&D_#;PAHS"2VT
M.VDFSDS7(,[D^N7S@_3%=2B+&@1%"J.``,`5C>A'9-_A_G^9KJ>>G6?'NK;A
MIOA"+34<Y$VJZDW_`*+C.Y>O2E_X1?Q_J1)U#QG;Z<KG+Q:9:EOP#R'(Z]J]
M"HH]O;X8I?*_YW"QP?\`PJK3KL?\3O7-?UC/WH[J_81GV"KC`_&M2P^'/@_3
M!_HF@6:,#D.P+N/HS$D?G7444I8BK)6<G8+(P=4\*VFH3K<0SSV<_"220M]^
M/^Y@Y`ZG!'*]NI!V+2TM[&TCM;6)8H(EVHB]`*FHK-SDTHMZ($DG<****D84
M444`%%%%`!1110`57O\`_D'W/_7)OY&K%5[_`/Y!]S_UR;^1H`S_``Y_R#Y/
M^NI_D*V*Q_#G_(/D_P"NI_D*V*`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BHKBX@M+
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MJ(@PJ@<``=A3Z*RN[6&%%%%(`HHHH`****`"BBB@`HHHH`****`"BBLYFG35
M`TTTR1;MD2JH,;`@?>[AL@\\#IZT`:-%9QDN%UB.%+GS58%IHBH`B3G:1@9R
M3@<GG!QTJE%JMPEM]K?S)5EL7O!&5`\LKM^08YYW=R>AH`WJKW__`"#[G_KD
MW\C5>PEG^USVTTK3;(XY1(R@?>W97@#IM^O(IVK7*6VGR;PQ\P&,8]2#0!5\
M.?\`(/D_ZZG^0K8K#T"98M/DW"0_O?X8V;L/0>U:QN8UW967Y3@XB8_EQSTZ
MT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^
M4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N
M8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_E
MQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=
MV5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<]
M.M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@X
MB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345"
M;F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/
MY<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967
MY3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`
M345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X
M.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8U
MW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQS
MTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5
ME^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M
M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8
M_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F
M-=V5E^4X.(F/Y<<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<
M<].M!N8UW967Y3@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M!N8UW967Y3
M@XB8_EQSTZT`345";F-=V5E^4X.(F/Y<<].M176I6ME;37-U(T,$`)DD>-@J
M@9R<XZ<=>E`$>K:M;Z/:>?/N=V.R*%.7E?LJC^O0`$G`%<G>_$.YM8X;"'0+
MJ[\03DB&SMR3$P&/G,I``49&<C(/;&"<2;6]1\8^(5UCP[I,DFCV<+PM=W&Y
M?MF3G$"XXP0?F.`>`V,#'0:)I\E]?0ZK>P75M!:OFVA:!UD=R"-[#&0N"1CO
MGGL*[U1I4X7J;]OT,7*?/9+0K6W@/4/$,\=_X\U$7Y4[X]*M24M(3[CK(1ZG
MW'(KNX((;6!(+>)(H8QM2.-0JJ/0`=*:;F-=V5E^4X.(F/Y<<].M!N8UW967
MY3@XB8_EQSTZUR5*LI[[=NAJE8FHJ$W,:[LK+\IP<1,?RXYZ=:#<QKNRLORG
M!Q$Q_+CGIUK,9-14)N8UW967Y3@XB8_EQSTZT&YC7=E9?E.#B)C^7'/3K0!-
M14)N8UW967Y3@XB8_EQSTZT&YC7=E9?E.#B)C^7'/3K0!-14)N8UW967Y3@X
MB8_EQSTZT&YC7=E9?E.#B)C^7'/3K0!-14)N8UW967Y3@XB8_EQSTZT&YC7=
ME9?E.#B)C^7'/3K0!-14)N8UW967Y3@XB8_EQSTZT&YC7=E9?E.#B)C^7'/3
MK0!-14:S*SE0),@XYC8#OWQ[=?\`&I*`"BBB@`HHHH`*J_8(OMQN27/`PA=M
MH;G+;<XSTYQGBK5%`%*'2K6WO)+N(3++(Y=_](D*L2,9*[MO3VXP,=*EAL;:
M`R%(_P#6<,&8L,>@!/`]AQ5BB@"&VM(;1"L*L`3DEG+'\R2<>W:H]1C233[C
M>BMMC9AD9P<'FK55[_\`Y!]S_P!<F_D:`,_PY_R#Y/\`KJ?Y"MBL?PY_R#Y/
M^NI_D*V*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBLW7M>T[PUH\^J:I.(;:(?5G/95'<GTII.3LMP)=6
MU:PT/3)]1U*Y2WM(5W/(_P#(#N3V`Y-<%;Z7J?Q,N8M0UV*6P\+(PDM-+)VR
M7F.DDV.B]PO_`.LRZ/H&I>-]2@\2>+8#!8Q-YFF:*W*Q^DDP_B?T!Z?I7HM=
M#:H:1UEW[>GGY_<+<9%%'!"D,,:1Q(H5$10%4#H`!T%/HHKF&%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%5[_P#Y
M!]S_`-<F_D:L57O_`/D'W/\`UR;^1H`S_#G_`"#Y/^NI_D*V*Q_#G_(/D_ZZ
MG^0K8H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHK)\1^(]-\+:1)J6IS;(5^5$49>5ST51W)_SQ3C%R=EN`[Q!X
M@T[PQH\VJ:I.(K>,<`<L[=E4=R?2N0T#P]J/BW5H?%?BZ`QI&=VEZ0W*VR]I
M)!WD/OT_(!?#_AO4?$VL1>+/&$'EO&<Z9I+<I9KV=QWD/!]OR"^A5T.2HKEA
M\75_HOU8MPHHHKF&%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`5"UW;K=K:F>,7#*66/=\Q`]OQJ:LLN$U5HX5E+NZR2H\)
M*8QC<'Q@'CID].E`&B)8VE:(2(9%`+(#R`>A(_`_E4%MJ5A>2&.UO;:=P-Q6
M*56('K@'WJA;31CQ+<[8+A4>!(P_V9U0NK2%OFVX[CG.#GC-06UO<I87&GV4
MUR]NEJT43W,7ELCXPH7Y5W#&>>>W-`&Y#<0W"EH)HY5!*DHP8`CJ.*CO_P#D
M'W/_`%R;^1JKIRL]U/<!)(X6CCC5'0H0R[MQP>>X'X4[68II=/?R9-FS+/R1
ME0#D<4`5_#G_`"#Y/^NI_D*V*P]`C9]/DVS21_O?X0OH/4'_`"*UC#(=V+F4
M9.1@+Q[#Y?\`.*`)J*A,,AW8N91DY&`O'L/E_P`XH,,AW8N91DY&`O'L/E_S
MB@":BH3#(=V+F49.1@+Q[#Y?\XH,,AW8N91DY&`O'L/E_P`XH`FHJ$PR'=BY
ME&3D8"\>P^7_`#B@PR'=BYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/E_S
MB@PR'=BYE&3D8"\>P^7_`#B@":BH3#(=V+F49.1@+Q[#Y?\`.*##(=V+F49.
M1@+Q[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y?\`.*`)
MJ*A,,AW8N91DY&`O'L/E_P`XH,,AW8N91DY&`O'L/E_SB@":BH3#(=V+F49.
M1@+Q[#Y?\XH,,AW8N91DY&`O'L/E_P`XH`FHJ$PR'=BYE&3D8"\>P^7_`#BL
MS5M<TG1$9M4UZ"RR=P6:6-6QZ*",G]3Q347)V0&S17GTGQ3T.YD>/15UW6GW
M=--L-X7VRR@8]^>E!\6^,;LDZ=X$U,HS9#7=];VQ4?0J3W'OQ6WU:KU5O5I?
MF*Z/0:0D#J0,\<UY\=7^);[BOA6TC&<[3J<9)'HOR<?CZ55:>]\0R.^NQFWN
M+=]HT]9,_9'_`+VX`$MW5^P(VGDDW#"RD]6ODT_R(J55!79Z917G>C_$32H[
MR71M:UX07D;@0W,B*D<Z\_Q%=H8'@\X)'&.0.\5#*F^.\D*/AE9=A&/;CI6-
M6E.D[21<9*2NBQ14)AD.[%S*,G(P%X]A\O\`G%!AD.[%S*,G(P%X]A\O^<5F
M,FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y?\XH`FHJ$PR'=BYE&3
MD8"\>P^7_.*##(=V+F49.1@+Q[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(
M=V+F49.1@+Q[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y
M?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y?\XH`FHJ$PR'=B
MYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.
M*##(=V+F49.1@+Q[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+
MQ[#Y?\XH`FHJ$PR'=BYE&3D8"\>P^7_.*##(=V+F49.1@+Q[#Y?\XH`FHJI=
MR)9VLUS<WSPP)\[.VS"#T^[_`/7Z5Q>I^/YK6W:*WTO4YM3NY=FG6JHI\X8)
MRS;<1@=2&Y`Q_M8TIT9U/A0G)+1G2>)_%.G>%--^UWS,\DAV6]M$-TMQ)V5%
M[G^5<]X?\+ZCK&L1^*_&"*;]>;#30=T5@OJ?[TGJ>WY8E\.^"KS^TCXD\3WH
MN_$,@Q'Y8!ALD_YYQ`@^O+=?U)[$PR'=BYE&3D8"\>P^7_.*TE.--<M/5]7^
MB_SZAON345"89#NQ<RC)R,!>/8?+_G%!AD.[%S*,G(P%X]A\O^<5SC)J*A,,
MAW8N91DY&`O'L/E_SB@PR'=BYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/
ME_SB@PR'=BYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/E_SB@PR'=BYE&3
MD8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/E_SB@PR'=BYE&3D8"\>P^7_.*`)J
M*A,,AW8N91DY&`O'L/E_SB@PR'=BYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`
MO'L/E_SB@PR'=BYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/E_SB@PR'=B
MYE&3D8"\>P^7_.*`)J*A,,AW8N91DY&`O'L/E_SB@PR'=BYE&3D8"\>P^7_.
M*`)J*A,,AW8N91DY&`O'L/E_SB@PR'=BYE&3D8"\>P^7_.*`)J*C6-E<L9I&
M!.=I"X'7CI_G%24`%%%%`!1110`4FU0Q;:-Q`!..2!T_F?SI:*`"BBB@`JO?
M_P#(/N?^N3?R-6*KW_\`R#[G_KDW\C0!G^'/^0?)_P!=3_(5L5C^'/\`D'R?
M]=3_`"%;%`!1110`4444`%%%5=0U"VTNR>[NY-D:\<#)8GHJCJ23P`*:3;L@
M+5%9>F:_9:E8O<EOLK0G$\5PP5H3_M<XP>Q!P:R-2^)?@W2B5N/$%H[@XV6Q
M,[9],(#S5JC4;Y5%W%=6N=717!_\+/CN^-'\*^)-1STD2R\N(_\``F/]*/\`
MA(/B'?\`_'GX,LK!3T?4-1#Y^JH,BK^K5%\5EZM(+H[RBN$_LWXG7O\`Q\>(
M-`TW/>RLGFQ]/,-)_P`('K]W_P`A3X@ZW)GK]A2.T_+:#CO^GI1[*"WFOQ?Z
M!<[MF"J68@`#))[5S&L^)3*[6&B3Q/..)[I<.EO[#LSGT[#D]@<P?"/PO,P;
M4SJ6JN#G=?7\CY/X$"K5QX)MM(M@_ABTBMBO^LL]Y6.8>N3G:X]>_0]B-*2H
M*2NV_EI^9%3GY7R[E:;XCQZ<(K*\T;5+O52I/DZ=:F59`.-ZG/`Y'!Y'3G@F
M/^W?B'K'&E^%K+2(FZ3ZM=;VQZ^7'R#[&NFT+0ETM&N+AUGU"88EF`X4?W$]
M%'YD\GVV*4ZE*,O<C?UO^7^8XJ5ES;G`_P#""^(M7Y\1^-]1=#UMM+1;1![%
MADL/K6EI7PT\(:0_F0Z);S3]3-=YG<GUR^<'Z8KK**S>(J-6O9>6GY%60V.-
M(D5(T5$48"J,`4ZBBL1A61J_ARQUF:*:<RQ2H-K/`^PR1]XV/=?R(YP1DYUZ
M*J,G%WBQ-)Z,HW>C:9?Z<-/N]/M9[-5"K!)$I10!@8&.,=L=*XV7X>7N@,US
MX&UJ;36!W?V;=L9K.3VP<LF?49_"O0**N%:<-$].W0+(X33OB,MI?1Z3XQTY
M]!U%SM260[K6<^J2]!]#T]<UW0(8`@@@\@CO574M+L=8L9+'4;2*ZMI!AHI5
MW`^_L?>N$/AWQ+X#)F\*3OJ^BKR^BWDG[R)?^F$A_P#03^I-7RTZOP^Z^W3[
M^GS^\-4>C45SWAGQGI'BJ-TLY7AOH>+BQN5\N>$CJ&4_S'%=#6,H2@^62LQA
M1114@%%%%`!1110`4444`%%%%`!1110`4444`%'2J&LZWIOA_39-0U6[CM;6
M/J[GJ?0#J3[#FN#\OQ!\3CF<7.A>$FY$7W;K4%]_[B'T[CUSD:TZ3DN9Z1[_
M`-;L38NO^(I/%^M6VD>$[7^TCI]R);R\>399QX!&PM@[VYR,="`>>:MV6F76
MOW*0O;W%E!;2JT\DBE)%D4Y"1GU]7'&.A.<CL]+TJQT73XK#3;6.UM8AA(HQ
M@#W]SZD\FKE;?6N6/)36GXF<J4924GN%%%%<AJ%%%%`!1110`4444`%%%%`!
M1110`4444`%%<)XCO]8?QC/I]GK5UI]M!86\X6WB@;<[R3J23)&QZ1KTQWJO
MI.OW>E>*K>UUOQ,TMC<6-Q)F_%O$%D1X0NUD1.SOP<]/:FDWH@/0Z*PE\:^%
M'=43Q/HK,QP`+^(DG_OJM2_U"STJRDO=0NH;6UCQOEF<*JY.!DGW(%-PDG9H
M"S17-?\`"P_!W_0S:7_X$K_C5O3/%WAW6;P6FFZW875R06$44ZLQ`ZX%4Z51
M*[B_N%=&U15#4M;TG1A&=4U2RL1+GR_M5PD6_'7&XC.,C\ZH?\)OX2_Z&C1/
M_!A%_P#%4E3FU=(=S>HKS1]=U#7-<UB32O%4R:=;W206_P!@6VEC8>1$['<T
M;DG>[#KVQVK9\'W^J2Z]J^GW^J3ZA%!:VL\33QQ*REVG5A^[101^[7J/6H:M
MHP.RHHHH`****`"BBB@`HHHH`*KW_P#R#[G_`*Y-_(U8JO?_`/(/N?\`KDW\
MC0!G^'/^0?)_UU/\A6Q6/X<_Y!\G_74_R%;%`!15/4M5T_1[4W6I7MO:0#_E
MI/($'T&>IKC'^)AU9V@\':!?ZZX.W[25\BU4^\C]?ICGUK2%&<]8K3OT^\5S
MOZQM<\6Z!X;C+:OJUM:G&1&SYD(]D&6/X"N8_P"$9\;^(<-X@\4+I5LW6RT-
M"C8]YF^;/TR*V-#^'GA?P_()K32HI+O.XW5U^^E+>NYLX/TQ6G)2C\<K^G^;
M_P""%V8__"QM1UCY?"GA#5-15ONW5V!:P'W#-]X>W!JO+IWC22?^V?$2Z=-%
M"N$L=/#LUN#G=(,_?;'!`YQG;W#>D44XXA0=X12_%_UZ(F4.969YK;^$=-\;
M7EKJ&H6<<VF6I)CD;.;HD$8&/^68SG/<CCC)/<:;X>T;1@!IFE65G[P0*A/U
M(&36ETHJ:N(G4>KT[!3IJ"L@HHHK`L****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@#FO$W@;2?$TB7<@ELM5AY@U&T;RYXSVY'WA['\,5SX\3>)_!
M!\GQ;9MJNE+PNM6$660>LT0Z?4<?4UZ+1UK:-9VY9JZ_+T?3\A6*.DZSINNV
M*7NE7L-W;-T>)LX/H1U!]CS5MIHEF2%I$$K@E4+#+`8R0.^,C\Q7C7CZ/P+I
M"ZM?Z+XB_L3Q'%!*/+TJX*>;*%.$=%R`2W'8@]:>VE65U<1ZDMMXDNA$/W=^
MFH73X'/*'S=Y')Y4$')QUI58PA9ZI/NA.26Y[+17E_A#XF^';/0+BSU+6I'O
M+*>ZVB=WDDGB$TAC".W^L.W:H&23BM-?BSH^T/)HWB**-A\LCZ:VT_0@FFL/
M5DKJ+'='>T5Q^E?$WPWJ^IP:=;RWJ7<[;$CFLY$PWH3C`K=UOQ!I/ARTCNM8
MOH[2"201*\F<%B"<<>P-3*E4C)1<7=A=&G17+P_$?P9./D\2Z:.<?/.$_GBM
MC3M=TC6"XTO5;&^,?+BUN$EV_7:3BE*E..LDT%T:%%<YXP\2#0=+Q:75BNJ2
MS6\4$-P=Q(DF2,ML#*S`!B>".G6L/^VO&'_01T/_`,%4W_R346L,[^BL7PEK
M\7B;PKINK)+`\EQ;QM.L#96.4J"Z=3C!)&#S7.:Q\8?!^C74]I)=74]S!(T3
MQ06KY#J<%<L`"<CL:TA2J3=HIMB;2.]KD/$GCRWTN^&BZ/:R:SX@D'R65N>(
MO]J5NB#Z\_3.:X77?%?C_P`6RBUT3PSK.EZ0_P!Z7:(;F9?9WXCR.XS]3G%>
MBZ5X8@\+^&YK?PQ8VMO?R1[@]X6?S)<=977YFYST_"M_8QI6=35OI?\`,5[[
M&1HW@2YOM2CU_P`:W2:IJJ_-!:J/]%L_9%_B/^T?3U&:[NN#_L/XD7W_`!]>
M+]-TX'JMCIPE_(R']:OZ-X/U/3]5AO[_`,8:SJ+1YS`Y1(7R".4`]\]?3TI5
M;2UE->BO_E8$6O%^LZCI$&EIIAM4GO;W[.9+F)I511#+(3M5U)/[L#KWKG9O
M%/B;3GM9[V\T62U:\MX)E2PDB(229(R0QG8#`;/(/2M[QCH5_J_]DW.F+;/<
MZ?=M,4NIWB1D:&2,C*JW.74_=['D9KE'T'5?%,:V$R^')[%;J![P6^JO.WEI
M*KLNWR1R0I')'6N73J4>EVU]:7N[[+=03[<;O*D#8SZXJE?^)=!TJX^SZCK>
MFV<^`WE7%TD;8]<,0<4S1/"^A^'/._L?3+>S,^/,,2X+8SC/YG\Z=?\`AG0-
M4NC<ZAH>FWEP0%,MQ:1R.0.@R036B]GS=;?B+4K?\)OX2_Z&C1/_``81?_%5
MKV=]::C:I=6-U!=6[YV302!T;!P<$<'FLC_A"/"7_0KZ)_X+XO\`XFM>SL;3
M3K5+6QM8+6W3.R&",(BY.3@#@<T3]G;W+_,-3*?QIX5BD:.3Q-HR.I*LK7\0
M((Z@C=5<_$+P<&*GQ-I60<<72X_/-6)/!?A661I)/#.C.[DLS-81$DGJ2=M3
M)X6\/1[?+T'2TVXV[;.,8QZ<5?[CS_`-3G/&IEN?$>B68O;V&VDL[N9EM+R6
M#>RO;A23&RDX#MUXYKG+K4H?"&K:+J4^H:R]JUV\4\;WUS="13;S%1Y;.P)W
MA#TXQ7;^)?#5[K.I:??V&I6]G-:0S0D3VC3JZR&,]I$P08AW/6J5AX/U:+7-
M-O[_`%JRGBL9GF6*#3GB9V,4D?+&9L#$A/3M6*M?49-HGC^RU[58K&TT?756
M0,?M4UBR0K@$\L3QG&!QUK2\1:EKFG0P'0_#_P#;$LC$2*;Q+<1#C!);K]!Z
M5M45;E#FNHZ=G_2$<)]L^*%Y_J=*\-Z<#_S]7$LS#_O@8S_A6_X;MO$MO'<'
MQ'J%C=2.5,2V<!C6,<Y!).3V_+WK<HIRJ\RLHI!8Y36_!,FN:K+=R^*/$%I;
MN%`L[&[$,8P,'HN2#R3]:S_^%2>&9?\`C]DU6^Z9^TZC*<^N<$=:[NBFL15B
MK1E8+(X"Z\%ZCI>K*WAJRTW^S5L(;1(;J]EC:,QR3/P?+DW`^;W.>#3;7P/=
MZKX@M[OQ3I>C365O:S1QPI</<YD=XB&P\2`8$;#O]ZNGU75KJ*^33=-CA>[:
M+SI))R=D*9P"0.6)(.!D?=//3,5EK[P79L-;>TM[@QF6*9'VQS*"`V`W*L"5
MR,G[P.>H&'M??WU)YXWY1\?@SPK#(LD7AK1DD0AE9;"(%2.A!VUKW-K;WEN]
MO=013PO]Z.5`RMWY!X-!NK=41VGB"N,JQ<88>H]:E!!`(.0:MSD]6RS)_P"$
M5\._]`'2_P#P#C_PJ:TT+2+"<3V>E6-O,`0)(;=$8`^X&:T**'.3ZA8HZEHF
MDZR(QJFF65\(L^6+JW679GKC<#CH*S_^$(\)?]"OHG_@OB_^)K>HIJI-*R86
M.%;P#=V6HW\F@ZAI>G6-W,LPM/[*+")A&B'!29!@[-WW>I-:OAKPU>Z-J6H7
M]_J5O>37<,,($%HT"HL9D/>1\DF4]QTKI:*AN^K`****`"BBB@`JDMY,^I-;
MI''Y4?#EI,/D@$$+CE>HSGK]*NU1DM;B;4%:1X_L\>'3]W\^[G(W9Z=.W.>M
M`#XKQI-2GLVA*>5$D@8MG<&9AT[?<]>_:J\6L1LK2RHJ0&!KF)P^=T:XR2,#
M'4=SUIT5C>)K$MZUU`T<B+&8A`00JEBOS;^OS<G'..@IL.C1K"T,SK)$(&MH
ME";=D;8R"<G)X'ITZ4`6+.\>XEEAFB6*:,*^U7W?*V=IS@<\'CV[U@>*-0UA
M=:TG1M+-K'#?PW+W4\T3.T:)Y8&P!@,DR=\CIQ6_9VCP/)+-*LLSA4+JFT;5
MSM&,GU/Y]JYOQ?I6NS:SI&LZ*UD1IT5PMQ%=2O&)%?RSQM1L\(WIS@\\BIE>
MVA,[\KY=S!UGQ%JOP[^P2S,-5TBYG:*8>2%N5D*'8%8,$VDKSE<@9Y-5XO$G
MBWQ9/Y$6L>'_``Q`QP46ZCN[S\L[1^A%6#H>L^.M5T^37-,TZ'0+*X=IK3[6
M\KSMY;!6X0#&64CD'AL@YK:'PG\#JP(T"+(.>9Y3_P"S5MAYJ$/>6M]]]/OM
MWW,X*=M3,TGP9X'34C-J.K1>(=74D-)J5ZL[*1U`CS@`>A!Q7:6^MZ(9?LEM
MJ>GF2/*^3'<)E<=MH/&*S)_A]X4GBE0:':0M*I4R6Z>5(,]<,N"/P[<=*PQ\
M&/!T;K);P7UO(IXDBO9`WIUS3<W4LZDB_>1VBZQI;RF)-2LVD4X*"=20?3&:
M%UC3'E:)-2LVD4X*"=20?3&:Y;0/A7X9\-ZW!J^GQW8NX-VPR3EA\RE3D=^"
M:-2^%GAR\N8;JP^V:)=Q.S"XTF802'<,$$X/'7ICJ:A)<R5]!^\=2NL:8\S0
MKJ-HTJDAD$ZD@CL1FLB]\3/-K$FC:*D$]U%")IKF1]T,(+,H4A3DOE3\O''.
M>U<G:?`S0;"[6[L]>\1VURN=LT-W&CC(P<,(\\@G\ZR;?P[/\-/%-VNB0ZMJ
M%E<V<+L)[26=9)-\H8>9!$=A`"'D'[Y_!5(VC>,KLB3G;0]$L/$,T>K+I&L1
M0Q7+P-<17,38AE5656&&.58%QQR,<Y[5L_VA9;W3[9;[T.UE\U<J?0\\5Y4F
ME7GC[Q?9OJD6L:9;6EG.Z-;03VOE2%H@`)98U+%E,F0`.%'X[$/P3\)0.'1M
M2\P=9!=E6/KR`.M*FKQ7,QP<[:GH!N[9=VZXB&T[6RXX/H?R-59]>T:U+"XU
M:PA*'#"2Y1=I]\FL70_ASX6\.:C%J.F::T5Y&&"S-<2L>1@\%B.A]*I6WPC\
M$VU[]I71ED;)(2:5Y$Y_V6)!_&G&U_>*O+L;,OC?PI"VQ_$ND!L[=OVV,G/T
MS5W5=>TO1=.N-0U"]BAM;;'FORVW)P!@9.<]L5S>F_"GPAI.KQZE:Z:?-CSM
MCDD,D>3WVMGUX]..]7]*\#V&CZR-3MM0U9GRQ,,UZ[Q,6!!)4]>O?T%-N-U9
M>NO_```O(R3\9O`./EUQG;LJV<^2?0?)7,6^JR>-=>UNZT>?6+B!+E%A`U*Y
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MT^XNTER0=I&YR`<X]>*Z_P`*Z;XRTB2WT_4'T1]%@5E5HI;A[G')7+/P><9]
MNE$_9I>XV_56_5@I/JCK#=VR[MUQ$-IVMEQP?0_D:X&X^)-^E[=PV^BV,B07
M,T`W:A+YA$<K1EV1+=]H)0D9-86E_#+QRVM;M9\<:FNF$N2++5I_.'7;C<FW
MTS6AX,N[/PKI-UIFN3O97R7UQYEQJ&8_MIWG]ZCOCS-PQR,G\ZBLXPC>#O\`
M(SG4<5>QUGACQ='KMA?7%XEG9M:7(@8QW?FQL#$D@8.53@A\=/X33]0\>^$M
M+#&[\1:<K+U1)UD<?\!7)_2N5T'PW)XBOM>:[1X/#%W?EVTNYL3&;IQ'%^^#
MG#!2R@C'7!JYX:^$FB^&]874TN;BYF4,!&Z1K%SGDJJ\D=CFJIN#5YI_A_7X
M%J4FD[&CHGQ+\.^(=5-CI[W3*(S(+J6`QPD#L&;!S^%96K^/YM2U>+2O!FIZ
M#/,8GDFENVE8(%Q]W8,$^G/-=%HO@7PWX?O3>Z;IB1W9!!G>1Y'YZ\L3BMNU
MLK2R0I:6L-NAZK%&$'Z4^=*5XQT\]?\`(?O=3QW2)O%'BV[FBU7Q#XBLK=$)
MW06<6GQ[NR"0DMSV)'8^E=/X'M_$&C6]S9WL%E:6?SN'NM2:[G\\X`W'@;?E
M.0,?SKT*BG.K.:LWIY)+\@4?,\]M?"VHSPZPFMZKH6+ZVEMW%G8I&R2R`_.7
M)W$CG@]<5>B\01V4*V=SI]ZEY"!$T,-NSQ[@,864#RP#@XW,ON!TKM**PG#G
MW9$J2D>>Z=X+7[/=1ZWJEC=V<OG,NF36L3Q6<LCE_E<_,<$MZ9]L5SNE?"W5
M]!FN'T[QN+!54[8[7*1F8G@.C,RXX/;^5>R45M"I."M%NWX?<5R(\QM=4^*&
MD!DOK?0-92(X9H[H02,?3)PH/!ZJ*>WQ/"":#Q+X,U6TC0[6*1"ZBW<\%L`=
MC7I=%"DM+K]!\K[GEMIX]^%NKLZW5I86SA<%;[3T&1Z9P1^%;>B^(OAK8"2Z
MTB]\/:>TBA7,8CMF8#G!!"DUUUSI]E>?\?5G;S_]=8@W\Q6:?!OA<MN/AO1]
MV,9^PQ9_]!I\^EFV*TCA?'.L>"M9M$NM.NM'O?$236[695LRR&.9'\L.JL5W
M`,H)X^;GC-7KC3_$MO8R7:PZ=/(B%_L22.K'C.T28()_X"/PKH3X`\-1Q3_8
MM*MK*>50%G@C`:-@0RLO8$,`?PI#8^)I@;61M,AC8;6O8I)"^/58BN%/IEV`
M]ZPJRF[<IG/VEU8X/PG'XMU+PAI=C!JFC>&=)@LXE>6V99KF7Y!EC_"A;!/]
MX'/6NH\/:!X(T&YN-0CU.UU#4XE+W&H7MZL\R@=223\G?D`5LZ1X$\,Z$EPN
MGZ5%']IA,$Y9F?S(SU4Y)X/>K>F>%M!T;S3IVD65L94\N0QP@%U]">XKH=>H
MURJR7E_5W\S1)]2K;>.O#%X+LVNLVT_V2(S3",EB$'4C`^;Z#)JMIOQ!T35X
M;V6Q6^E6TA,K9M63S.ORINQEC@X'>NCMK&TLE*VMK!`#U$487/Y5/6.H]3D]
M,\;OJD-^\?A[5;4VT1>-;]4@,S\XC&6X8X/6C3/$VO7D-^]]X:BTYH(B;=9=
M4B?SI.<(VT?)TZFNLHHL^X6?<\[OM:UZ^MEA\0Z19Z;IJW4:W;1WZS;D.[Y6
M`'"[@F<]LYXS5KQ!-;:2MA=Z=;QMJ,<R&"*#:KRQ`@RJ.@VE-W7C=M[XKN2`
MRE6`((P0>]4K#1M+TIY'T[3;.S:7_6&W@6,O]=H&:SE3;=[F<J3<D[F#IGCV
MRN[>_EU#3-3TA;"/S)VO;?"XYX4J3N/!X`S6EI'BWP_KT3R:9JUM<*F-X#[6
M7/3(.".AK:K.NM!TJ]M;NVGT^`Q7B;+@(FPR+Z$K@_K6FIIJ6S=VR[MUQ$-I
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MEM;^ZN698RLP,:!0"S,5SP,KP.26'3J*H\2R:/*B>)9K"W@ER(KR-C''N`SL
M8,3@D`D')S@C@XRG.*=B74BG:YT)N[9=VZXB&T[6RXX/H?R-!N[9=VZXB&T[
M6RXX/H?R-8<GC?1#HUQJEC-+J=O!*(7%A$96WG&``/J.>E0+K7B/6O#S76BZ
M,-.O3/L2/6@4_=X^_M3)SDXP?0T^9#YD=&;NV7=NN(AM.ULN.#Z'\C61KOC'
M0O#EJL^H7R@.YCC2)3([L/X0%SS]:IR>%KS7/#T>G^*-5EN)?.,LC6!-NC+C
M`C..67GO[5M:1HFFZ%IT.GZ;:);VL))C0$G!/4Y.3GD\T:AJSG[_`,2ZU?Z3
M977AK3[4&XW"5M7E,!ML'"[HQ\QS@G@]![TNI:1J>LV%C'>^+'TV6%2EZ-+8
M1B1SZ,V67&#77446[AR]SE;C26L&@NM-U&*XNK>W6SF&HW)S.JDE2\@!*N"7
MYVG.3QTQ7E\,:?KD_P!K\5QZ=</`#'#:I,7C@R?F)8[2S':.PP%Z=37945/)
M&]Q>SC>]CF-3\(^$-5M[6"_T^SDBL4\F%?,*>4O]W@CTZ'WJ/5?!OA?5+>S@
MN,PIIZ>1`(+QH_*'8<-UX[\\5U=%5RHKE78Y/5?#%M>6UG#;>*-7TS[#&(%^
MS7P`;_KH#G<W!ZTFK6&O^1:)I'C"&V:UB$4XN[:.7SW_`+S-P5/!X`]:ZVBC
ME0N5')ZM?>*[.*T_LQM"O#'$$O#<2M$S3=]N,@`X/!Y_*DUCQ1K>E1VAA\.)
MJ.Z(&[:WU"-?(E[H`PRW0\\=*ZVBBWF%O,XL%/$^IWB:G;L(;01(MC(X(1VC
M#LS!3AF!;;WQL..ISI>'G>VU74M)1W>TMHX9H=[%C'YF\&/)YP/+!`[;\=,`
M7=2T*/4+D745Y=6-V%$9GM2F70$D*P=64X).,C(R<'DU8TW3(-+@:.)I)'D;
M?+-*VYY6P!EC]`!@8``P`!6:A)3N9QA)3YKZ%VBBBM38****`"BBB@`HHHH`
M*KW_`/R#[G_KDW\C5BJ]_P#\@^Y_ZY-_(T`9_AS_`)!\G_74_P`A6Q6/X<_Y
M!\G_`%U/\A6Q0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%5;K3+"^M)+6[LK>>WD.7BEB5E8^I!&#5
MJB@#FY?"-E8+#-X>M+.PN8&9@JQ[8Y0P`96V\C.U3GG!4<'D%L?A^YU>ZAF\
M16NGM!;$M%9QL;A"Y&-[,Z+G`)`&WC.<GC'345')&]R'3BW>Q%;VT%I"(;:&
M.&)>B1H%4?@*EHHJRPHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"J]__P`@^Y_ZY-_(U8JO?_\`(/N?^N3?R-`&?X<_Y!\G
M_74_R%;%8_AS_D'R?]=3_(5L4`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!F6R&'42\K.[
MSE@DBRED9020"O0$`]OSYK.M!=Z7:S1SK++J$=D\BN+R69)"H')#\*2?;U]Z
MW(;*VM[B>XBA199B"[A0">`,9`Z<?J:=!:6UJ'%O;Q0ASN?RT"[CZG'6@"GI
MQ=+NXA#R20B..17>0N=S;MPR>W"G'3FG:S+-%I[^3'OWY5^"<*0<GBKD-O#;
M)L@BCB3).U%"C)ZGBH[_`/Y!]S_UR;^1H`R]`,PT^3RHXV_>_P`3E>PSV/M6
ML6N?FVQ1'GY<RD9'O\O':LWPY_R#Y/\`KJ?Y"MB@"$M<_-MBB//RYE(R/?Y>
M.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<
MRD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_`"\=JFHH
M`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F
M4C(]_EX[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;
M;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\`
M+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;
M8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX
M[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES
M*1D>_P`O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_+QVJ:B@
M"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS\N9
M2,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYM
ML41Y^7,I&1[_`"\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\
MO':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<_-M
MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7C
MM06N?FVQ1'GY<RD9'O\`+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?E
MS*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`
M(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE
M(R/?Y>.U!:Y^;;%$>?ES*1D>_P`O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGY
MML41Y^7,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R
M\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV
M*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_`"\=JFHH`A+7/S;8HCS\N92,CW^7
MCM06N?FVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7
M,I&1[_+QVJ:B@"$M<_-MBB//RYE(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`
MA+7/S;8HCS\N92,CW^7CM06N?FVQ1'GY<RD9'O\`+QVJ:B@"$M<_-MBB//RY
ME(R/?Y>.U!:Y^;;%$>?ES*1D>_R\=JFHH`A+7/S;8HCS\N92,CW^7CM06N?F
MVQ1'GY<RD9'O\O':IJ*`(2US\VV*(\_+F4C(]_EX[4%KGYML41Y^7,I&1[_+
MQVJ:B@"-3,7(:.,+G@AR3CGMCZ5)110`4444`%%%%`!1110`4444`%5[_P#Y
M!]S_`-<F_D:L57O_`/D'W/\`UR;^1H`S_#G_`"#Y/^NI_D*V*Q_#G_(/D_ZZ
MG^0K8H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHJM;W\%UYGEEPJ<[G0JK#&=RD]1[B
M@"S5>_\`^0?<_P#7)OY&EMKN&[5C"S':<$,A4_D0./?O27__`"#[G_KDW\C0
M!G^'/^0?)_UU/\A6Q6/X<_Y!\G_74_R%;%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(V
M=IP,G'0]ZQXH);NQO+>))K:!XG@19'5MK<KE<$D`<]?08`K9HH`H6$,WVF>Z
MFB:$R1QQB-F!QLW<\$CG=^@Z4_4K'^T+=8O,\O#AL[<]B/ZU;5E895@0"1P>
MXZTM`&'!X;B"'SYG+YX\L@#'XBI/^$<L_P#GI/\`]]#_``K75E895@0"1P>X
MZTM`&/\`\(Y9_P#/2?\`[Z'^%'_".6?_`#TG_P"^A_A6Q10!C_\`".6?_/2?
M_OH?X4?\(Y9_\])_^^A_A6Q10!C_`/".6?\`STG_`.^A_A2/X<M=C;)9M^/E
MW$8S[\5L*RNH96#*1D$'(-+0!B1>&X/+'G2R&3N4(`_44_\`X1RS_P">D_\`
MWT/\*UU974,K!E(R"#D&EH`Q_P#A'+/_`)Z3_P#?0_PH_P"$<L_^>D__`'T/
M\*V**`,?_A'+/_GI/_WT/\*/^$<L_P#GI/\`]]#_``K8I&944LQ"J!DDG``H
M`R/^$<L_^>D__?0_PIDOAN#RSY,L@D[%R"/T%;=(S*BEF(50,DDX`%`&.GAR
MUV+OEFWX^;:1C/MQ2_\`".6?_/2?_OH?X5L44`8__".6?_/2?_OH?X4?\(Y9
M_P#/2?\`[Z'^%;%%`&/_`,(Y9_\`/2?_`+Z'^%'_``CEG_STG_[Z'^%;%(S*
M@RS`#(&2?6@#(_X1RS_YZ3_]]#_"HY/#<6^/RIG"9^?<021[<?6MRD9E099@
M!D#)/K0!D?\`".6?_/2?_OH?X4?\(Y9_\])_^^A_A6Q10!C_`/".6?\`STG_
M`.^A_A1_PCEG_P`])_\`OH?X5L44`8__``CEG_STG_[Z'^%'_".6?_/2?_OH
M?X5L4A95(!8`L<#)ZF@#(_X1RS_YZ3_]]#_"HV\-Q?:%VS/Y./F!(W9]CC'I
M6Y2%E4@%@"QP,GJ:`,C_`(1RS_YZ3_\`?0_PH_X1RS_YZ3_]]#_"MBB@#'_X
M1RS_`.>D_P#WT/\`"C_A'+/_`)Z3_P#?0_PK8HH`Q_\`A'+/_GI/_P!]#_"C
M_A'+/_GI/_WT/\*V*3<NXKN&X#)&><?Y%`&1_P`(Y9_\])_^^A_A4:^&XOM#
M;IG\G'R@$;L^YQCUK<I-R[BNX;@,D9YQ_D4`9'_".6?_`#TG_P"^A_A1_P`(
MY9_\])_^^A_A6Q10!C_\(Y9_\])_^^A_A1_PCEG_`,])_P#OH?X5L44`8_\`
MPCEG_P`])_\`OH?X4?\`".6?_/2?_OH?X5L4@96+`,"5."`>E`&1_P`(Y9_\
M])_^^A_A4<?AN+?)YLSE,_)M(!`]^/I6Y2!E8L`P)4X(!Z4`9'_".6?_`#TG
M_P"^A_A1_P`(Y9_\])_^^A_A6Q10!C_\(Y9_\])_^^A_A1_PCEG_`,])_P#O
MH?X5L44`8_\`PCEG_P`])_\`OH?X4?\`".6?_/2?_OH?X5L4A95(!8`L<#)Z
MF@#'?PY:[&V2S;\?+N(QGWXIL7AN#RQYTLAD[E"`/U%;=(652`6`+'`R>IH`
MR/\`A'+/_GI/_P!]#_"C_A'+/_GI/_WT/\*V**`,?_A'+/\`YZ3_`/?0_P`*
M/^$<L_\`GI/_`-]#_"MBB@#'_P"$<L_^>D__`'T/\*/^$<L_^>D__?0_PK8I
M"RA@I8;B"0,\G_.:`,67PW!Y9\F602=BY!'Z"G)X<M=B[Y9M^/FVD8S[<5LT
MA90P4L-Q!(&>3_G-`&1_PCEG_P`])_\`OH?X4?\`".6?_/2?_OH?X5L44`8_
M_".6?_/2?_OH?X4?\(Y9_P#/2?\`[Z'^%;%%`&/_`,(Y9_\`/2?_`+Z'^%'_
M``CEG_STG_[Z'^%;%)N7<5W#<!DC/./\B@#&?P^L95[2>1)5.=SD'^0K:HI-
MR[BNX;@,D9YQ_D4`+1110`4444`%%%%`!6):G4+6_O9;JVA*&%7\Q)"2[9?"
MC*CM@8SQQR<\;=(RJPPP!&0>1W'(H`Q;J*)+RR@:*X,^49KE(G95PV<9`(4L
M<@].#SVIP/D:Q<W$=O\`((GW,L+1;G^3`)/$A.#AATZ=ZV:1E5AA@",@\CN.
M10!BW4427EE`T5P9\HS7*1.RKALXR`0I8Y!Z<'GM3+*&7^T9C+#,JXN1.^TK
MOS(#%@C[WR9QCITX-;U%`'/6BPG0)(3:LJK=2E(YK&1P`9693LP#]TCGM^&*
MV=/5TTVU65&200H&5WW%3@9!/<^]6**`&R;_`"V\O;OP=N[IGMFL6Q%_!%?1
M7$$<3/,JQR)(7+,R*"W*C.#DY]B,<9.Y2%58@D`E3D9'0]*`,J2%1KMJ8;?[
M@Q(ZPLI"[&QF3HXZ#9U!Y[52TI;F*V<-%+"\EO!$Q9-I-QEQ(W/7JIST..,U
MT=(55B"0"5.1D=#TH`R-D`U^*.."XC>/YFF\I]C_`"$!-V-H4#G&0-P'?-5=
M*A9;27[9;SK%]E@$R^4V7F!;S#@#+9^7)&0?>NBHH`YHQF3PII\7V61KF.!4
M5'MGWAPF"`V!Y9ST<\?6NEHHH`K:C`+K2[NW+%!+"Z%@I8C*D9P.OTK.T]`+
M(6Z6L5NDL_\`RRMS`'4`%F,9Y7.-O/L>];5)M4L&P-P&`<<@?Y`H`R$A4ZU<
MNL#+"8G$CQPO$2WR=3_RT)P<,O3&.]1Z65.FK:)#+$K7<WR20M'B,R,XX8#@
MK@?C6Y2;5+!L#<!@''('^0*`.?G0RS:H+&"ZBN%MID4F)U$TC<[MS#!P>%YZ
M$XXJ*[@63P_JRBTG\F0M]DA6%P>8E`^0#(^?<>1UY]ZZ:B@#'O\`;<W-C+#;
MLTF]&R;=U<+O7/SG&S`R2IY8<5L444`4]469M/<0??W)GY2V4W#=P.3\N>!4
M%DK&"T@:!(0FYRD:;%P"0OR]5SD-CMC%:=)M4,6P-Q&"<<D?Y)H`YUH7$=^T
M%JP@:6$D1V[1AU$I,@\L\L=O5A][/`XJ[IZ2>3!`Z,BB664*PQB/>WEC';@J
M0.VVM:H;F6.UMYKIUSL0LVT9)`R<>_?\Z`,!%1[.[>UMKN.,20*T#P2`M&LF
M7;##+,R[LXR2`,\G%+<1;-(MFEMKAI$O0\2)"[E(Q<!@=J@XQ&._/;VI8=2O
MYM+N8EF/VZ)T.Z2+RF9&P3M5P!GAP,\?+R3S4L>HW+WEL_GL;62,*H")DR<Y
MWC.1VQMXZY[4`6)DWZ];2109('[R00LA`VMC,G1AD@;.H//:M:N4EUN\_LBS
MFBN5,S:7-<2D*I_>*J8)&..2>.E7EU&ZDN8;=9=KV\WEW7R@E\MA>W&1\W&#
MTH`O:O:QWMEY#VZ3,[!4+QAQ&3P7Y!`P,G].].6*))%@5,6]M#M"!<CD8`Q[
M*.G^U6)!>ZI/;7[I<R>8MP\<8<0@;5D(.SONVC^/C-7IY);JQMI+>6=1)\\A
M@V),Q4KSAN"!CD=^!TXH`I3VP/AC4HVM)"&W_9XXK=U#$Q@`B+DH-V>#W&[O
M6Q+)'=;W99C`D!8J$97.X=APP8`'CK\U4Y;RY35-%6*[#VER&#JT8#OB-F#$
M]N@X`']*H+K%W%)<R"Y@=9(9I2OE@?9V1U0;B#D\9SG^[VH`F14>TAD%I<"U
M>\+36IMW'EIY1``0C)&[83@8R3Z9I^QX3X?>YAN'NXPHF98GD"?N74Y(!`^9
MAG_`4+J-XFA:Q)]J6>6SWB&Y5%&[$8;.!P2"2/PIW]I7:7%\'E'EBX2*'Y1\
MIV1L1[YW,?PH`M6\>-?FDC@VQF-@[K"T>6RF-Q/$A.#AAT`([UJUC6]]<RW0
MM&E'G022F<J!@H/N`^A(=3Q_=-9MGJ&J2:';7;74K,Y627<(`^S;D[`.,9Q]
M[!QGO0!IZA$7UBW;[-)(1Y95PI(&'.<-T3`.3G[PXYQ3[I4FLIY9(UD\R4!`
M]L9P`IP/E7GL2#VSFLR^N]0AFU"6+4I#%%I_VJ-#%'C+;P/X<X&T'K]:='/>
M^;8V_P#:,MLAAED8R)#D[2@`.T%0,$],&@"=T\J707EMKG[1&5$GR/+Y8\IU
M(+`$?>89/?KT'$]\T7V1[F:UDN=\V(XUC9QP"H+!0<KU;D'J.^*C;4[F?3M)
M8N+62^P'DP#Y?[MFX!XR2,<U6MM3NX[V*`SI);6XF#NJ*!*B&,;N.FW>V<8&
M5/%`#I()UN+1$6XFVQ6@AF>,Y&V0^:6)'RDIC(.">E6K80QZ_J&()]DD$>YF
M@<J[!I"PW$8/#+_(=*+G4)ET6W=99%N+A@HDC@,I7N3M4'L#VQG%9]YK%_.F
MGM9/*DTMM*YACA#[ID*C:V1E5R6!/'X4`:VB1M%;3#RO+0RYC`B,2D;5Y6,\
MH,Y&/4$]ZTZYJ+4=0/B5[=YF%N)Q$594$>/*#D!OO;\\\\8S5_6KTQZ4L]I?
M+$\F/)9%5_-)'R@9XP?7TR<CK0!')!(OB%9XV8H'WS%X6&U/**[1(>"N=IVC
MH<G--U*(RZ4I^SF6YE+2(ODEF!(.`''^K;H-YX&*2]OI8K^PC>[B$,VV.6/"
M%'+=NN[)[8&,=:GUJ],6E+/:WRQ/)CR615?S21E0,\8/KZ9.1UH`A*3#7VD,
M4@VW&\RE/E\CR,8W=/\`6=NO?%-U)8VLHO.@N6FN-Y$D43OY&['S84'#*,`'
M&<CTS45[J-TMY'&+J#:#`C6VP-YPD;#-GK@#.,>ASFG6M[?/8:H)KT-/!=&*
M.2*-%P-JG"ACCN>I-`$OE3GQ`6\F3(N=WF[./(\C&-W3_6?P]>^*;9K`L6LQ
M"VE$+3;E$UI(ZN/+1<[2,O\`,IR!R>O?-:&CW1O=)M[AIDF9E(:1!@$@D']1
M5Z@"EI*/'IR*\9C.Y\*<CC><8!^Z,8(7L..U6I0K1.'W;2ISMSG'MCG\J?10
M!S5NJ_V;;)]CN/LJ7\QEA:V<?NV,I3Y2,D99#P./P-:-@LIM+5+Q6+P6B><I
M&[,A7!Z=2,'_`+ZK4I`JJ20`"QR<#J>E`',SVP/AC4HVM)"&W_9XXK=U#$Q@
M`B+DH-V>#W&[O6Q+)'=;W99C`D!8J$97.X=APP8`'CK\U7Z0*JDD``L<G`ZG
MI0!SB*CVD,@M+@6KWA::U-NX\M/*(`"$9(W;"<#&2?3-/V/"?#[W,-P]W&%$
MS+$\@3]RZG)`('S,,_X"NAHH`RM*CV7MZR0>7"VW:5A:%2=SY^0]3R,MT;(]
M*OW8B-J_GH[Q8RRHK,2/3"\GZ=ZFHH`Y@JH\,Z/YEM=&>`VPV"WD+(4=-Y*@
M=@IYQ].M:]QLGCO))$#QA/*57A,H/&2=@Y;D@$?[-:%(JJHPH`&2>!W/)H`Y
M>Z@NO[.A1;64DP72PJJ$[92P,38_@&-V,_=!QFM>\:)H[N:>&6>*/:@BB4LS
MD$$X"\D$D`CI\ISQFM*D55484`#)/`[GDT`<Q=03'3H!##/(&M[GRE\EAY<[
M,#&,,`5"_,`2```/45?G$,?B2*0P3MNMI4E<0.Z\F,J,X(Z*W']3SLT4`9FB
M1M%;3#RO+0RYC`B,2D;5Y6,\H,Y&/4$]Z3Q%$LV@WB&*65VB<1I&C.2Y4A>%
M]_7@=:U**`,:]>"XO[,K!="1S&XG$$F(U#9"],*6Z'./EZ]JDNE2:RGEDC63
MS)0$#VQG`"G`^5>>Q(/;.:U:155%"J`J@8``P`*`,%T\J707EMKG[1&5$GR/
M+Y8\IU(+`$?>89/?KT'$]\T7V1[F:UDN=\V(XUC9QP"H+!0<KU;D'J.^*V*1
M55%"J`J@8``P`*`.=D@G6XM$1;B;;%:"&9XSD;9#YI8D?*2F,@X)Z5*RP)JF
MJK]FE*2VT8+26DDJ.X:3/;Y\;EX!Z<#IQO44`4M)1X].17C,9W/A3D<;SC`/
MW1C!"]AQVJ[110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!3719%VNH93V(R*=10!#+:6T^_SK>*3
M>H1]Z`[E&2`<]1R?SH%I;"5)1;Q"1%VH^P94>@/85-10!7-G9HDY-M`JR@^=
M\@`<=]WK^--,FGI%]J9[98YF5O.)4!VX"G/<],4W4X)KJQ>W@V`RD(Q==RA2
M?FR,C/&1U[UDR:=?"R\EX3++;W+/;RPE5&&&<[7)^4;F7!.<#CM0!HM!HT;W
M2O%8*[+ON`50$KUR_MWR:=>1Z4PB%Y]E`MBLJ+(P`3.54X].H'N/45E7&DWD
MYOHHH1$+FW979F4QM(4V@K_$O0`]L=*6XT^]OKAKB2T\H$VL?E-(I)6.8LS<
M'&,'Z^U`&O-;Z;)>PO/#:-=@;HF=5+@*<Y7//!/;I4<5UH[)-<0SV)61@LLB
M.F&8]`Q'4GWJE8Z?>+-%+<IEXBT*L6!)C52%8^[$Y_&J%GIE\FB6L,MG<BZM
MBOEDO!\IV[>,<%>3][+<T`;\SZ790):3-9P0R@JL+E55QT("GKU_6GLM@7:%
MQ;%V99&0A<ENBL1Z_+P?]GVK/OK>Z&H6,ZV`NE6WDBD564*K,4Y^8CCY3TS5
M2+1+N*"2-@))([.W6)RV`TT3,P]\9V_G0!N[[)+ER&MUG<B-SD!F(7<%/<\'
M./2J5NF@/:2&V736MHSOD,8C**1W..!CUJ'[!=.-/E:(^;]J>XG!9<INC<`<
M=<95>,]*S(](U";1EA-E]GEATZ2U*%T)F=E7!X.,?*>I[T`="DVF7I^22SG,
MZ&/Y65O,5>J^X&>GO[U7,.@+);VQCTP./G@B*QYY/51]1V]*IPV%[)-:SM!*
MCP02@&9H]V\M&5!V<8(5AP.G6JSZ;?N)XOL!/VFQ2$2M(F(7!?)/.>-PZ9H`
MW[V;3T5;>_EM0LO"QSLH#^P!Z]13#<:5#,T)FLXY8(R"FY0T:<$\=AP">W2L
MW6](NM0F@$)^1+26-R=N')V80YY`.#R.1ZU5GTW4';642TF"74)\D;XMF?*5
M<'^+.01UQ0!T,;648V1&W46^$VKM'E9`P/;(Q0@LHVCE06ZL[,$<;06+?,P!
M[DX)/TSVK);3KM);R5(<F:Y3C<!NCV1C=^!4\>F?:I[6PN(M1E5H]MI$TDD!
MW`[FDY/N,'?[8:@"REWI$L;SI<6+H95+2!T(\S&!D_WN`!WJ*>;090+*XDTU
MQ`#B"1HSY>T<_*>F!GZ"L>STR^31+6&6SN1=6Q7RR7@^4[=O&."O)^]EN:MW
M^E7,YU%DMT+S::L*%2`#)\^0/3[PYH`N_:-"V6[BXT]1M,4#K(@P.A5"#QVZ
M5<GLK2ZA2*XM8)HDY59(PP'T!K"6VOEGLIGTV:<)%+$ZRO"""Q3!.W`Q\IZ`
MFMK3+:2RTNUMI7WR11*C-ZD"@"065JK1,MM"&B79&1&,HOH/0>U1Q:7I\,4L
M45A:QQR@"1%A4!P.F1CGK5NB@!$18T"(H50,``8`I:**`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
;`"BBB@`HHHH`****`"BBB@`HHHH`****`/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>txmd-20131231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:txmd="http://therapeuticsmd.com/20131231">
    <link:schemaRef xlink:href="txmd-20131231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-04-01to2012-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-04-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-20_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-19to2013-04-20_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-19</xbrli:startDate>
        <xbrli:endDate>2013-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-24</xbrli:startDate>
        <xbrli:endDate>2013-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:PrivatePlacementAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:PrivatePlacementAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2011-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-11-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-10-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-11-01to2011-11-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-11-01</xbrli:startDate>
        <xbrli:endDate>2011-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-03to2011-10-05_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-03</xbrli:startDate>
        <xbrli:endDate>2011-10-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-05_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-27to2011-07-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-27</xbrli:startDate>
        <xbrli:endDate>2011-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_SancilioAndCompanyWarrants3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrants3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-01to2012-02-29_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_ModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-01</xbrli:startDate>
        <xbrli:endDate>2012-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividualsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:June2012NotesWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividuals1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnaffiliatedIndividuals1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_WarrantsIssuedToOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedEntityForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedEntityForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsIssuedToUnrelatedEntityForConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-12-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-06-01</xbrli:startDate>
        <xbrli:endDate>2011-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_MrFinizioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrFinizioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_MrMilliganMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrMilliganMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:ReichFamilyLimitedLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_MrFinizioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrFinizioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_MrMilliganMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrMilliganMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_ReichFamilyLimitedLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:ReichFamilyLimitedLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:VestedNonForfeitableVitaMedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-30</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-24</xbrli:startDate>
        <xbrli:endDate>2013-02-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-12</xbrli:startDate>
        <xbrli:endDate>2013-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-03-01</xbrli:startDate>
        <xbrli:endDate>2011-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-18</xbrli:startDate>
        <xbrli:endDate>2012-03-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-11-13_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:ReichFamilyLimitedLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-12</xbrli:startDate>
        <xbrli:endDate>2012-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-11-12to2012-11-13_custom_MrMilliganMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:MrMilliganMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-11-12</xbrli:startDate>
        <xbrli:endDate>2012-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-02-28_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-24to2013-04-25_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-24</xbrli:startDate>
        <xbrli:endDate>2013-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-29_custom_IssuanceOfPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:IssuanceOfPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_February2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-03-01to2012-05-31_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-03-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-02-24_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-02-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-02-23to2012-02-24_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-02-23</xbrli:startDate>
        <xbrli:endDate>2012-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_February2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:February2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012Notes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012Notes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012Notes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-21_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-24to2013-04-25_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-24</xbrli:startDate>
        <xbrli:endDate>2013-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_custom_NotesIssuedInAugustAndSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInAugustAndSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-10-31_custom_NotesIssuedInAugustAndSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInAugustAndSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-09-30_custom_NotesIssuedInSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-10-31_custom_NotesIssuedInSeptember2012Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedInSeptember2012Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-19_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-18</xbrli:startDate>
        <xbrli:endDate>2012-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotes1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotes1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotes2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotes2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-01</xbrli:startDate>
        <xbrli:endDate>2011-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-03</xbrli:startDate>
        <xbrli:endDate>2012-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-30_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-09-30to2011-10-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-09-30</xbrli:startDate>
        <xbrli:endDate>2011-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_NotesIssuedToVariousPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToVariousPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_NotesIssuedToParty1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToParty1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-03to2012-10-04_custom_NotesIssuedToParty2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToParty2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-03</xbrli:startDate>
        <xbrli:endDate>2012-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_NotesIssuedToVariousPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToVariousPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_NotesIssuedToVariousPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToVariousPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-28_custom_AgreementAndPlanMergerVitaMedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-29_custom_AgreementAndPlanMergerVitaMedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-07-27to2011-07-29_custom_AgreementAndPlanMergerVitaMedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-07-27</xbrli:startDate>
        <xbrli:endDate>2011-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-10-03to2011-10-04_custom_AgreementAndPlanMergerVitaMedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-10-03</xbrli:startDate>
        <xbrli:endDate>2011-10-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">txmd:AgreementAndPlanMergerVitaMedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-10-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EquipmentMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EquipmentMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_DeferredRevenueConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:DeferredRevenueConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_DeferredRevenueConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:DeferredRevenueConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_NotesIssuedToPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:NotesIssuedToPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:StockPurchaseAgreementWithPernixTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-06-30_custom_NonAffiliatedThirdPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">txmd:NonAffiliatedThirdPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-10-01to2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-10-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-01-01to2012-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-01-01</xbrli:startDate>
        <xbrli:endDate>2012-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2011-01-01to2011-12-31_custom_VitaMedPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:VitaMedPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2011-01-01</xbrli:startDate>
        <xbrli:endDate>2011-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-18to2013-03-21_custom_June2012NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:June2012NotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-18</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-07-31_custom_July2011SecuredNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:July2011SecuredNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-03-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-03-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2011-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2011-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-01-06_us-gaap_SubsequentEventMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPUnit">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>txmd:Unit</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="N">
      <xbrli:measure>txmd:Number</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2013-01-01to2013-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2013-01-01to2013-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2013-01-01to2013-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2013-01-01to2013-12-31">2013-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2013-01-01to2013-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2013-01-01to2013-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2013-01-01to2013-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2013-01-01to2013-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2013-01-01to2013-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2013-01-01to2013-12-31">Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2013-01-01to2013-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2013-01-01to2013-12-31">2013</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat contextRef="AsOf2013-06-28" unitRef="USD" decimals="0">278462272</dei:EntityPublicFloat>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">62016393</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5925879</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54698407</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-1433128</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-80532626</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-52113313</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">135086056</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">50580400</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">144977</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">99785</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">7317986</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">7359007</us-gaap:Liabilities>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3739235</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">150068</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">15124</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2013-03-21_custom_June2012NotesMember" unitRef="USD" decimals="0">21595</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LongTermNotesPayable contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3589167</us-gaap:LongTermNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">7317986</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">3619772</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3601189</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">833654</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1602580</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1144752</us-gaap:DeferredRevenue>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2114217</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1641366</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">62016393</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5925879</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2551729</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1225159</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">135686</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">31949</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">23722</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1750455</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">953655</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">61318</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">65673</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">59403346</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4635047</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2477715</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">751938</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1043618</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1615210</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1690753</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">714425</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54191260</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1553474</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">126421</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">422939</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26555</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">42048</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1102680</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2012-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-07-28" unitRef="Shares" decimals="INF">16575209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-07-29" unitRef="Shares" decimals="INF">165856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-07-28_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">16575209</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2011-07-29_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">165856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-12-31" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2010-12-31_CommonStockMember" unitRef="Shares" decimals="INF">55487321</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">82978804</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-07-28" unitRef="Shares" decimals="INF">16575209</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-07-29" unitRef="Shares" decimals="INF">165856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-07-28_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">16575209</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2011-07-29_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">165856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">27234</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherNonoperatingIncome contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">34544</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3001</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">6392</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-25808244</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-16148423</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-5427218</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">32624245</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">18618323</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">6568283</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">58145</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">56260</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">54845</us-gaap:DepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">13551263</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">4492362</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">107241</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2012-01-01to2012-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">6936</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2011-01-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">5612</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">19014837</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">14069701</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">6406197</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">6816001</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2469900</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">1617000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">447000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">1646000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">729000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">1141065</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1157000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">2396000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">386000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">908000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsSold contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1959597</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1348113</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">947112</us-gaap:CostOfGoodsSold>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8775598</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3818013</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">2081000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">819000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">2295000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">1036000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">2088177</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">1537000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">2863000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">722000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">1241000</us-gaap:SalesRevenueNet>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">127569731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">91630693</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2011-01-01to2011-12-31" unitRef="Shares" decimals="INF">62516461</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-04-01to2013-06-30" unitRef="USDPShares" decimals="INF">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-04-01to2012-06-30" unitRef="USDPShares" decimals="INF">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-07-01to2013-09-30" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-07-01to2012-09-30" unitRef="USDPShares" decimals="INF">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2011-01-01to2011-12-31" unitRef="USDPShares" decimals="INF">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-03-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-10-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-01-01to2012-03-31" unitRef="USDPShares" decimals="INF">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2012-10-01to2012-12-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-35120235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-04-01to2013-06-30" unitRef="USD" decimals="0">-6009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-04-01to2012-06-30" unitRef="USD" decimals="0">-11850000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-07-01to2013-09-30" unitRef="USD" decimals="0">-7673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-07-01to2012-09-30" unitRef="USD" decimals="0">-4253000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-12913365</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2011-01-01to2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-12913365</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-35120235</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-03-31" unitRef="USD" decimals="0">-6376000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-10-01to2013-12-31" unitRef="USD" decimals="0">-8361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-01-01to2012-03-31" unitRef="USD" decimals="0">-13290000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2012-10-01to2012-12-31" unitRef="USD" decimals="0">-5727000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-35120235</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-12913365</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2611069</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-18971812</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-7486147</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="USD" decimals="0">1054647</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2011-10-01to2011-11-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">849137</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">6716504</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-10307864</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-7390000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">10307864</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <txmd:LoanGuarantyCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2944</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">45036</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">38159</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">2944</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2012-01-01to2012-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">45036</txmd:LoanGuarantyCosts>
    <txmd:LoanGuarantyCosts contextRef="From2011-01-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">38159</txmd:LoanGuarantyCosts>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1165981</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1905409</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">64380</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">33204</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-12-31_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">21453</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_NotesIssuedToVariousPartiesMember" unitRef="USD" decimals="0">6344</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-12-31_custom_NotesIssuedToVariousPartiesMember" unitRef="USD" decimals="0">2390</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">735</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2012-01-01to2012-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">7366</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2011-01-01to2011-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">5650</us-gaap:InterestExpense>
    <us-gaap:DebtIssuanceCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1503922</us-gaap:DebtIssuanceCosts>
    <us-gaap:DebtIssuanceCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtIssuanceCosts contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-1931788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">92057</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">1931788</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-92057</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">191000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">17250</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">92</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17158</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">1932</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">189068</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">75</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2011-12-01to2011-12-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">17250</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">21681958</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">2775415</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1054657</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">8239137</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">21682</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8217455</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">2775</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1051882</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">5551589</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">3953489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45116352</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">29411765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF">13750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">3953489</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2011-10-03to2011-10-05_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="Shares" decimals="INF">2631579</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">7895485</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">1707000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">5552</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1701448</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">3954</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7891531</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45117</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">78605236</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_custom_JefferiesLLCMember" unitRef="USD" decimals="0">45400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USD" decimals="0">30200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">7895485</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2011-10-03to2011-10-05_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="Shares" decimals="INF">165879</txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares>
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">255753</txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement>
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement contextRef="From2011-01-01to2011-12-31_CommonStockMember" unitRef="USD" decimals="0">-166</txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement>
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">255919</txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54698407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-1433128</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">-1711858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2010-12-31_CommonStockMember" unitRef="USD" decimals="0">55487</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2011-12-31_CommonStockMember" unitRef="USD" decimals="0">82979</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2010-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4988637</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">15198241</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2010-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-4079713</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2011-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-16993078</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2010-12-31" unitRef="USD" decimals="0">964411</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2012-12-31_CommonStockMember" unitRef="USD" decimals="0">99785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50580400</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2012-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-52113313</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">144977</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">135086056</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-80532626</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">7158</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7158</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsCompensationRelatedParty contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36284</txmd:WarrantsIssuedAsCompensationRelatedParty>
    <txmd:WarrantsIssuedAsFinancingCostRelatedParties contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">9338</txmd:WarrantsIssuedAsFinancingCostRelatedParties>
    <txmd:WarrantsIssuedAsFinancingCostRelatedParties contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9338</txmd:WarrantsIssuedAsFinancingCostRelatedParties>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">13014784</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">45362</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">45362</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">13014784</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForFinancingCosts contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancingCosts>
    <txmd:WarrantsIssuedForLoanGuarantyCostsRelatedParties contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">93969</txmd:WarrantsIssuedForLoanGuarantyCostsRelatedParties>
    <txmd:WarrantsIssuedForLoanGuarantyCostsRelatedParties contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">93969</txmd:WarrantsIssuedForLoanGuarantyCostsRelatedParties>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">867262</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1563620</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">190280</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">190280</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1563620</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">867262</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1832061</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">183355</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2011-01-01to2011-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">183355</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1832061</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2012-06-18to2012-06-19_custom_February2012NotesMember" unitRef="Shares" decimals="INF">8145486</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3102000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31_CommonStockMember" unitRef="USD" decimals="0">8145</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3093855</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="USD" decimals="0">3102000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">400</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">400</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-7830</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-7830</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">6716504</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="From2012-01-01to2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6716504</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3254083</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3254083</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">636917</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">338457</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">22630</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1451934</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">25980</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3207238</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1868345</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">190513</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">53428</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1102680</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1604240</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">28719</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-15493</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">40548</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">1500</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10262</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">28776</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">29159</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">47883</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">27484</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">25686</us-gaap:Depreciation>
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-255753</txmd:EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-150068</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2875320</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">639157</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">594535</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:DeferredRevenueAdditions contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-457828</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-1144752</us-gaap:DeferredRevenueAdditions>
    <us-gaap:DeferredRevenueAdditions contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">472851</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1334855</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">188876</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">565706</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1386319</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-42281</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">346822</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-571592</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1027137</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-29996</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1068619</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">728253</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">16409</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">40790</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">66405</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">28766</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForDeposits contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">103737</us-gaap:PaymentsForDeposits>
    <us-gaap:PaymentsForDeposits contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsForDeposits contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">439034</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">206101</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">8870</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-20768069</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-12737326</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-4966596</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-583561</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">-272506</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-37636</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">212853</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">17253</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">696</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2013-04-24to2013-04-25_custom_June2012NotesMember" unitRef="USD" decimals="0">21595</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-06-01to2012-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">2160</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">5341</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-06-01to2012-06-30_custom_NotesIssuedToParty1Member" unitRef="USD" decimals="0">888</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2012-10-03to2012-10-04_custom_NotesIssuedToParty2Member" unitRef="USD" decimals="0">1519</us-gaap:InterestPaid>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">52637786</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1427053</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">-296518</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">73989416</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">14436885</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">4707714</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">4691847</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1850000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-01to2012-10-31_custom_NotesIssuedInAugustAndSeptember2012Member" unitRef="USD" decimals="0">1600000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-01to2012-10-31_custom_NotesIssuedInSeptember2012Member" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">50000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2012-10-03to2012-10-04_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-03-18to2013-03-21_custom_June2012NotesMember" unitRef="USD" decimals="0">4882019</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">200000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">100696</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">300000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2011-01-01to2011-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">299220</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-04-24to2013-04-25_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100735</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">707000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">400</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">8700000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">2684160</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">191000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">17250</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2012-01-01to2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2012-11-12to2012-11-13_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-02-01to2013-02-28_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">7895485</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <txmd:WarrantsExercisedInExchangeForDebtAndAccruedInterest contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">3102000</txmd:WarrantsExercisedInExchangeForDebtAndAccruedInterest>
    <txmd:WarrantsIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">462196</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForServices contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1532228</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForServices contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">190280</txmd:WarrantsIssuedForServices>
    <txmd:WarrantsIssuedForFinancing contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedForFinancing contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">2509537</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedForFinancing contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">148668</txmd:WarrantsIssuedForFinancing>
    <us-gaap:NotesIssued1 contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">15123</us-gaap:NotesIssued1>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 3 &amp;#150; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Inventory&#13;consists of the following:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;621,679&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,124,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    material&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;250,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Deferred&#13;    costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;170,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;110,471&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    INVENTORY&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,043,618&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,615,210&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 4 &amp;#150; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    R&amp;#38;D costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,267,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;189,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;530,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;432,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Deferred&#13;    financing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;260,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Other&#13;    receivable &amp;#150; related party&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;249,981&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;169,528&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;127,403&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Prepaid&#13;    guaranty costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    OTHER CURRENT ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2,477,715&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;751,938&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 5 &amp;#150; FIXED ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;108,458&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;67,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Furniture&#13;    and fixtures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;46,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Leasehold&#13;    improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;11,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;155,083&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;126,273&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Accumulated&#13;    depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;(93,765&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;(60,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    FIXED ASSETS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;61,318&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;65,673&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense for the years ended December&#13;31, 2013, 2012, and 2011 was $45,145, $27,484 and $25,686, respectively. In December 2013, accumulated depreciation was reduced&#13;by $11,980 associated with leasehold improvements of our previously leased office property.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 7 &amp;#150; INTANGIBLE ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The following table sets forth&#13;the gross carrying amount and accumulated amortization of our intangible assets as of&amp;#160;December&amp;#160;31, 2013&amp;#160;and&amp;#160;December&amp;#160;31,&#13;2012:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;December&amp;#160;31,&#13;    2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;Carrying&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Amortization&lt;br /&gt;Period&amp;#160;(yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortizing intangible assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; width: 40%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;OPERA&amp;#174; software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(499&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;31,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;15.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Development&#13;    costs for corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(89,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-amortizing&#13;    intangible assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 12pt; text-indent: -12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks for vitamins/supplements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 24pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;755,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(90,160&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;665,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;December&amp;#160;31,&#13;    2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;Carrying&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Amortization&lt;br /&gt;Period&amp;#160;(yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 40%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;OPERA&#13;    &amp;#174; software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;23,722&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;23,722&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Development&#13;    costs for corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(77,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;14,584&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;180,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;180,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks for vitamins/supplements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;21,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;21,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;316,714&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(77,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;239,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The intangible asset related&#13;to development costs for corporate website is amortized over 36 months, which is the prescribed life for software and website development&#13;costs. The intangible asset related to OPERA&amp;#174; is amortized using the straight-line method over the estimated remaining useful&#13;life of 16 years, which is the life of the intellectual property patents.&amp;#160;&amp;#160;During the year ended December 31, 2013, there&#13;was no impairment recognized. &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;Amortization expense was $13,001,&#13;$28,776, $29,159 for the years ended December 31, 2013, 2012, and 2011, respectively. Estimated amortization expense for the next&#13;five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Year Ending December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Estimated&#13;    Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; width: 81%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;4,080&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 8 &amp;#150; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    payroll and commission costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;941,313&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;397,210&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    financing costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;850,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    vacation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;256,920&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;114,899&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Allowance&#13;    for wholesale distributor fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;306,303&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;107,784&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    legal and accounting expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;224,550&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;90,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    lab research&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;536,574&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accrued&#13;    clinical trial costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;129,208&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Allowance&#13;    for coupons and returns&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;126,233&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;53,002&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&#13;    accrued expenses&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;230,088&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;70,759&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;TOTAL&#13;    OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;3,601,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;833,654&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"&gt;&lt;sup&gt;(1) &lt;/sup&gt;In June 2008, we declared&#13;and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which&#13;$41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 13 - BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We purchase our products from several suppliers&#13;with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and&#13;2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We sell our prescription dietary supplement&#13;products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products&#13;to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health,&#13;Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December&#13;31, 2013, 2012, and 2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2013 and&#13;2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three&#13;customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers&#13;in prior years.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&lt;u&gt;NOTE 14 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Operating Lease&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We lease administrative office space in Boca&#13;Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018.&#13;The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and&#13;sales tax, for a total future minimum payments over the life of the lease of $1,899,414.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The straight line rental expense related to&#13;our current lease totaled $180,894 for the six months ended December 31, 2013 offset by rent income of $32,963. The rental expense&#13;related to our prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 and&#13;$122,752 for the years ended December 31, 2012 and 2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2013, future minimum rental payments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Years&#13;    Ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; width: 77%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 18%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;316,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;371,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;382,377&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;393,848&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;302,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Total&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,766,252&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Noncancelable&#13;    sub-lease income&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(38,956&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Net&#13;    minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1,727,296&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 15 &amp;#150; SELECTED QUARTERLY FINANCIAL&#13;DATA (UNAUDITED)&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years&amp;#160;2013&amp;#160;and&amp;#160;2012&amp;#160;is&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&#13;    Quarters&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-style: italic; text-indent: -10pt; padding-left: 10pt; width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(In&#13;    thousands, except per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4th&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,537&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,081&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,295&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,863&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    profit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,157&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,617&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,646&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,396&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,376&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,009&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,673&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Loss&#13;    per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2012&#13;    Quarters&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-style: italic; text-indent: -10pt; padding-left: 10pt; width: 40%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(In&#13;    thousands, except per share)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; width: 2%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: center; width: 11%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4th&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; width: 1%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;722&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;819&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,036&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,241&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Gross&#13;    profit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;386&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;447&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;729&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;908&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&#13;    loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(13,290&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(11,850&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4,253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(5,727&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Loss&#13;    per common share, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.16&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue on arrangements in accordance&#13;with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price is fixed or determinable, persuasive evidence&#13;of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We generate OTC revenue from product sales&#13;primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of&#13;loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include&#13;shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive&#13;the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. &lt;font style="color: #252525"&gt;We&#13;provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.&#13;&lt;/font&gt;We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;We sell our name&#13;brand and generic prescription products &lt;/font&gt;primarily through drug wholesalers and retail pharmacies. We recognize revenue from&#13;prescription product sales, net of sales discounts, chargebacks, and rebates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable product from&#13;customers within a return period of six months prior to and following product expiration. Our prescription products currently have&#13;a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot&#13;reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue&#13;on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products&#13;are dispensed through patient prescriptions or expiration of the right of return.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We maintain various rebate programs in an&#13;effort to maintain&lt;i&gt; &lt;/i&gt;a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate&#13;program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end&#13;user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted&#13;if necessary, on a quarterly basis.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense all shipping and handling costs&#13;as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances&#13;and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal; letter-spacing: 0pt"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal; letter-spacing: 0pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations&#13;due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide&#13;an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,&#13;and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write&#13;off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection&#13;efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance&#13;for doubtful accounts when received. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does not&#13;accurately reflect bad debts; adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories&#13;represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using&#13;the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed&#13;in &lt;u&gt;Revenue Recognition&lt;/u&gt;) are recorded as deferred costs and are included in inventory, until such time as the related deferred&#13;revenue is recognized.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Equipment&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We state equipment at cost, net of accumulated&#13;depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair&#13;costs to operating expense as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line method&#13;over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Leasehold&#13;Improvements&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We state&#13;improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining&#13;term of the lease.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily&#13;of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts&#13;payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered&#13;Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short-&#13;and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which&#13;would be considered Level 3 inputs under the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities that&#13;are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value Measurements&#13;and Disclosures. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets&#13;and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets and liabilities recorded in the consolidated&#13;balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font-size: 10pt; margin-bottom: 0px"&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td style="width: 36pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 54pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Level 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in&#13;    active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Level 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets&#13;    or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through&#13;    market corroboration, for substantially the full term of the financial instrument; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="text-align: justify; vertical-align: top"&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Level 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the&#13;    asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2013, 2012, and 2011, we had&#13;no assets or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;&lt;u&gt;Income&#13;Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With the advent of the Merger, we determined&#13;that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because&#13;of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4,&#13;2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for income taxes under the asset&#13;and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.&#13;We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which&#13;the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities&#13;of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the&#13;amount that will more likely than not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,&#13;we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in&#13;an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest&#13;amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in&#13;the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize both interest and penalties related&#13;to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating&#13;to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our tax returns are subject to review by the&#13;Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2004, the FASB issued ASC 718,&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or&lt;i&gt; &lt;/i&gt;ASC 718. Under ASC 718, companies are required to measure the&#13;compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial&#13;statements over the period during which employees are required to provide services. Share-based compensation arrangements include&#13;options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase&#13;plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any,&#13;over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,&#13;an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the&#13;expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of&#13;the award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments (&amp;#147;instruments&amp;#148;)&#13;issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC&#13;505, &lt;i&gt;Equity Based Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;, &lt;/i&gt;defines the measurement date and recognition period&#13;for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b)&#13;the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the&#13;instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize the compensation expense for all&#13;share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize&#13;the compensation expense on a straight-line basis over the employee&amp;#146;s requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred from parties that are providing&#13;long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based&#13;on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the&#13;related debt using the effective interest rate method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense advertising costs when incurred.&#13;Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31,&#13;2012, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Use&#13;of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our consolidated financial statements have&#13;been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation&#13;of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,&#13;liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including&#13;those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions&#13;that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying&#13;values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material&#13;amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;December&#13;    31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Finished&#13;    product&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;621,679&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 15%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,124,739&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Raw&#13;    material&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;250,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;380,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;Deferred&#13;    costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;170,996&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;110,471&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;TOTAL&#13;    INVENTORY&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,043,618&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;1,615,210&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font: normal 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible&lt;/u&gt; &lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patent&#13;and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have&#13;adopted the provisions of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350,&#13;&lt;i&gt;Intangible-Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs,&#13;net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once&#13;a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.&#13;If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment&#13;annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted&#13;in the year ended December 31, 2013.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">170996</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">110471</us-gaap:DeferredCostsCurrent>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">250943</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">380000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">621679</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1124739</us-gaap:InventoryFinishedGoods>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">169528</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">127403</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">260022</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1451934</us-gaap:DeferredFinanceCostsCurrentNet>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">530596</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">432216</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1267588</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">189375</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidGuarantyCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">2944</txmd:PrepaidGuarantyCostsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">155083</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">126273</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_EquipmentMember" unitRef="USD" decimals="0">67668</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31_EquipmentMember" unitRef="USD" decimals="0">108458</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">46625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">46625</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2012-12-31_LeaseholdImprovementsMember" unitRef="USD" decimals="0">11980</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31_LeaseholdImprovementsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">93765</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">60600</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <txmd:PrepaidAccreditedCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">27234</txmd:PrepaidAccreditedCostsNoncurrent>
    <txmd:PrepaidAccreditedCostsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">899000</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DividendsPayableAmountPerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.40</us-gaap:DividendsPayableAmountPerShare>
    <txmd:UnclaimedDividends contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">41359</txmd:UnclaimedDividends>
    <txmd:UnclaimedDividends contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">41359</txmd:UnclaimedDividends>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" id="Foot-00-0" decimals="0">230088</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2012-12-31" unitRef="USD" id="Foot-00-1" decimals="0">70759</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">126233</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">53002</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">129208</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:AccruedLabResearchCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">536574</txmd:AccruedLabResearchCurrent>
    <txmd:AccruedLabResearchCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">224550</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">90000</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">306303</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">107784</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">256920</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">114899</us-gaap:AccruedVacationCurrent>
    <txmd:AccruedFinancingCostsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">850000</txmd:AccruedFinancingCostsCurrent>
    <txmd:AccruedFinancingCostsCurrent contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">941313</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">397210</us-gaap:AccruedSalariesCurrent>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6107207</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">748404</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">547511</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">186346</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">14773537</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">5920861</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">748404</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2011-01-01to2011-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2011-01-01to2011-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2011-01-01to2011-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <txmd:MonthlyBaseRentOfLeases contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30149</txmd:MonthlyBaseRentOfLeases>
    <us-gaap:LeaseAndRentalExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">106315</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">60168</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">122752</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">180894</us-gaap:LeaseAndRentalExpense>
    <us-gaap:RentalIncomeNonoperating contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">32963</us-gaap:RentalIncomeNonoperating>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2013-01-01to2013-12-31_custom_JefferiesLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:StockExpectedToIssuedDuringPeriodShares contextRef="From2013-03-19to2013-03-20_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">4411765</txmd:StockExpectedToIssuedDuringPeriodShares>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2013-04-19to2013-04-20_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">1954587</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodValueNewIssues1 contextRef="From2013-04-19to2013-04-20_custom_JefferiesLLCMember" unitRef="USD" decimals="0">3100000</txmd:StockIssuedDuringPeriodValueNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1 contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">240395</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2013-06-01to2013-06-30_custom_February2012NotesMember" unitRef="Shares" decimals="INF">2775415</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-10-01to2011-10-31_custom_VitaMedPromissoryNotesMember" unitRef="Shares" decimals="INF">20266822</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-11-01to2011-11-30_custom_VitaMedPromissoryNotesMember" unitRef="Shares" decimals="INF">1415136</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2012-06-18to2012-06-19_custom_July2011SecuredNotesMember" unitRef="N" decimals="INF">2775415</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-10-01to2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="N" decimals="INF">266822</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="From2011-09-30to2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="N" decimals="INF">1415136</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2013-06-30_custom_February2012NotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2012-06-19_custom_July2011SecuredNotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2011-10-30_custom_VitaMedPromissoryNotesMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USDPShares" decimals="INF">0.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForCash contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">8500001</us-gaap:StockIssuedDuringPeriodValueIssuedForCash>
    <us-gaap:LegalFees contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">52016</us-gaap:LegalFees>
    <txmd:PrivatePlacementFees contextRef="From2013-09-01to2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USD" decimals="0">552500</txmd:PrivatePlacementFees>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2011-07-27to2011-07-28">1 for 100</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2011-07-27to2011-07-29_custom_AgreementAndPlanMergerVitaMedMember">1 for 100</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">14293499</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2013-01-01to2013-12-31">P3Y10M24D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <txmd:UnamortizedCostsOfWarrants contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1599000</txmd:UnamortizedCostsOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-12-31_us-gaap_MinimumMember" unitRef="USDPUnit" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-12-31_us-gaap_MaximumMember" unitRef="USDPUnit" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-12-31_us-gaap_WeightedAverageMember" unitRef="USDPUnit" decimals="INF">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USDPUnit" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPUnit" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USDPUnit" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="USDPUnit" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USDPUnit" decimals="INF">2.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants1Member" unitRef="USDPUnit" decimals="INF">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants2Member" unitRef="USDPUnit" decimals="INF">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="USDPUnit" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="USDPUnit" decimals="INF">0.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USDPUnit" decimals="INF">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USDPUnit" decimals="INF">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USDPUnit" decimals="INF">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.36</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-05-11_custom_SancilioAndCompanyWarrants1Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Shares" decimals="INF">283333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-12-31_custom_SancilioAndCompanyWarrants3Member" unitRef="Shares" decimals="INF">283334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="Shares" decimals="INF">5685300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="Shares" decimals="INF">3314700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Shares" decimals="INF">31000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Shares" decimals="INF">1300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Shares" decimals="INF">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants1Member" unitRef="Shares" decimals="INF">6000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrants2Member" unitRef="Shares" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Shares" decimals="INF">1500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="Shares" decimals="INF">500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="Shares" decimals="INF">600000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="Shares" decimals="INF">36284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="Shares" decimals="INF">36284</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="Shares" decimals="INF">7158</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="Shares" decimals="INF">184211</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Shares" decimals="INF">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Shares" decimals="INF">613718</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Shares" decimals="INF">93969</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-24_custom_February2012NotesMember" unitRef="Shares" decimals="INF">3314700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="Shares" decimals="INF">5685300</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesMember" unitRef="Shares" decimals="INF">9000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2012-06-30_custom_NonAffiliatedThirdPartyMember" unitRef="Shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2013-10-31</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrants1Member">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2019-01-31</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="Pure" decimals="INF">0.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="Pure" decimals="INF">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="Pure" decimals="INF">0.0223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="Pure" decimals="INF">0.0108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.0156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.4077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.3335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.4601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.4576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember" unitRef="Pure" decimals="INF">0.4450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember" unitRef="Pure" decimals="INF">0.4450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="Pure" decimals="INF">0.4481</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="Pure" decimals="INF">0.4471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember" unitRef="Pure" decimals="INF">0.4464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="Pure" decimals="INF">0.4478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="Pure" decimals="INF">0.5183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="Pure" decimals="INF">0.4594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="Pure" decimals="INF">0.4104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.3944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Pure" decimals="INF">0.4789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.3792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants2Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-02-01to2012-02-29_custom_February2012NotesMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-02-01to2012-02-29_custom_ModificationWarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-05-01to2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-06-18to2012-06-19_custom_June2012NotesWarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">260022</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2013-01-01to2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">1532228</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">547210</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">28719</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">77034</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-01-01to2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">360528</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2012-01-01to2012-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">218045</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2011-01-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="USD" decimals="0">15</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2011-01-01to2011-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="USD" decimals="0">36284</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2012-01-01to2012-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="USD" decimals="0">36284</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <txmd:ClassOfWarrantOrRightExpenseRecognized contextRef="From2013-01-01to2013-12-31_custom_WarrantsIssuedToOfficersMember" unitRef="USD" decimals="0">7158</txmd:ClassOfWarrantOrRightExpenseRecognized>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2013-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">308128</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">593127</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">593127</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">154068</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">360528</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2013-12-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">360528</us-gaap:PrepaidExpenseCurrent>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1711956</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants1Member" unitRef="USD" decimals="0">405066</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2013-06-30_custom_SancilioAndCompanyWarrants2Member" unitRef="USD" decimals="0">462196</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USD" decimals="0">10505247</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-02-29_custom_ModificationWarrantsMember" unitRef="USD" decimals="0">6124873</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-05-31_custom_WarrantsIssuedToUnaffiliatedEntityMember" unitRef="USD" decimals="0">1532228</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">9424982</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="USD" decimals="0">338</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2011-10-31_custom_WarrantsIssuedToOfficersMember" unitRef="USD" decimals="0">133045</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="USD" decimals="0">25980</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">12548</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">30993</txmd:ClassOfWarrantOrRightFairValueOfWarrantsOrRights>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="AsOf2012-02-29_custom_February2012NotesMember" unitRef="USD" decimals="0">859647</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">197383</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <txmd:NumbersOfUnaffiliatedIndividuals contextRef="AsOf2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="N" decimals="INF">5</txmd:NumbersOfUnaffiliatedIndividuals>
    <txmd:NumbersOfUnaffiliatedIndividuals contextRef="AsOf2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="N" decimals="INF">3</txmd:NumbersOfUnaffiliatedIndividuals>
    <us-gaap:ProfessionalFees contextRef="From2012-03-01to2012-03-31_custom_WarrantsIssuedToUnaffiliatedIndividualsMember" unitRef="USD" decimals="0">29736</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2012-06-01to2012-06-30_custom_WarrantsIssuedToUnaffiliatedIndividuals1Member" unitRef="USD" decimals="0">1656</us-gaap:ProfessionalFees>
    <txmd:RemainingAmortizationOfFinancingCostsAndDiscounts contextRef="From2012-01-01to2012-12-31_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">1102680</txmd:RemainingAmortizationOfFinancingCostsAndDiscounts>
    <txmd:AgreementCoverPeriod contextRef="From2011-12-01to2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember">P3M</txmd:AgreementCoverPeriod>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2011-12-31_custom_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" unitRef="USD" decimals="0">323</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <txmd:DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights contextRef="From2011-10-01to2011-10-31_custom_WarrantsIssuedToOfficersMember">The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44).</txmd:DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights>
    <txmd:DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights contextRef="From2011-03-01to2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember">Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end.</txmd:DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights>
    <txmd:FinancingExpense contextRef="From2011-01-01to2011-12-31_custom_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" unitRef="USD" decimals="0">25980</txmd:FinancingExpense>
    <txmd:AmortizationResearchAndDevelopmentExpense contextRef="From2011-12-01to2011-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">12548</txmd:AmortizationResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.3915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.3913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-29_custom_IssuanceOfPromissoryNotesMember" unitRef="USD" decimals="0">900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-24_custom_February2012Notes1Member" unitRef="USD" decimals="0">1358014</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1357110</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-06-19_custom_June2012Notes1Member" unitRef="USD" decimals="0">2347128</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-06-19_custom_June2012Notes2Member" unitRef="USD" decimals="0">2344719</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-09-30_custom_NotesIssuedInAugustAndSeptember2012Member" unitRef="USD" decimals="0">1600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2012-09-30_custom_NotesIssuedInSeptember2012Member" unitRef="USD" decimals="0">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-07-31_custom_July2011SecuredNotes1Member" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-07-31_custom_July2011SecuredNotes2Member" unitRef="USD" decimals="0">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">534160</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-12-31_custom_NotesIssuedToVariousPartiesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2011-12-31_custom_NotesIssuedToPartiesMember" unitRef="USD" decimals="0">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_MrFinizioMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_MrMilliganMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_MrFinizioMember" unitRef="USD" decimals="0">179000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_MrMilliganMember" unitRef="USD" decimals="0">179000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_ReichFamilyLimitedLPMember" unitRef="USD" decimals="0">179000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2011-03-31_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2012-11-13_custom_VitaMedPromissoryNotesMember" unitRef="USD" decimals="0">299220</us-gaap:LineOfCredit>
    <txmd:WarrantsIssuedDuringPeriodShares contextRef="From2011-03-01to2011-03-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="Shares" decimals="INF">613713</txmd:WarrantsIssuedDuringPeriodShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2013-01-01to2013-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">13632742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">2650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2013-01-01to2013-12-31_custom_LongTermIncentiveCompensationPlan2009Member">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2013-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2013-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">15632742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">13733488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">10590161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2010-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">3921000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">4391000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">244000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">233500</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember">2014-04-01</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2013-01-01to2013-12-31">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <txmd:FairValueOfWarrantsByRelativeFairValueCalculationMethod contextRef="AsOf2012-06-19_custom_June2012NotesWarrantsMember" unitRef="USD" decimals="0">1649890</txmd:FairValueOfWarrantsByRelativeFairValueCalculationMethod>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfDebt contextRef="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">401085</us-gaap:RepaymentsOfDebt>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.06</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0302</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod contextRef="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.0235</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2013-01-30to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">Interest payments were due and payable on the tenth day following the end of each calendar quarter</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2011-03-01to2011-03-31_custom_VitaMedPromissoryNotesMember">The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityInterestRateDescription contextRef="From2012-03-18to2012-03-19_custom_VitaMedPromissoryNotesMember">Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:LineOfCreditFacilityDecreaseForgiveness1 contextRef="From2012-11-12to2012-11-13_custom_MrMilliganMember" unitRef="USD" decimals="0">100000</us-gaap:LineOfCreditFacilityDecreaseForgiveness1>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes1Member" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-03-01to2012-05-31_custom_February2012Notes1Member" unitRef="USD" decimals="0">3000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-02-23to2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2012-06-18to2012-06-19_custom_June2012Notes2Member" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentFairValue contextRef="AsOf2012-02-24_custom_February2012Notes2Member" unitRef="USD" decimals="0">1517741</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt contextRef="AsOf2012-06-19_custom_February2012NotesMember" unitRef="USD" decimals="0">3102000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="AsOf2012-06-19_custom_July2011SecuredNotesMember" unitRef="USD" decimals="0">1054647</us-gaap:LongTermDebt>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012NotesMember" unitRef="USD" decimals="0">2691847</txmd:RemainingSurrenderValueOfNotes>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012Notes1Member" unitRef="USD" decimals="0">1347128</txmd:RemainingSurrenderValueOfNotes>
    <txmd:RemainingSurrenderValueOfNotes contextRef="AsOf2012-06-19_custom_February2012Notes2Member" unitRef="USD" decimals="0">1344719</txmd:RemainingSurrenderValueOfNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-06-30_custom_VitaMedPromissoryNotesMember" unitRef="Pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2012-06-19_custom_June2012NotesMember" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-10-31_us-gaap_ConvertibleNotesPayableMember" unitRef="Pure" decimals="INF">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2011-07-31_custom_July2011SecuredNotesMember" unitRef="Pure" decimals="INF">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2011-06-01to2011-06-30_custom_VitaMedPromissoryNotesMember">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier&#13;of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory&#13;note(s) issued in an amount of not less than $1,000,000, or the Funding.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2012-06-18to2012-06-19_custom_June2012NotesMember">Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.</us-gaap:DebtInstrumentInterestRateTerms>
    <txmd:DebtInstrumentRemainingFaceAmount contextRef="AsOf2012-06-30_custom_VitaMedPromissoryNotesMember_us-gaap_DirectorMember" unitRef="USD" decimals="0">100000</txmd:DebtInstrumentRemainingFaceAmount>
    <txmd:NumberOfWarrantsVested contextRef="From2013-01-01to2013-12-31_custom_VestedNonForfeitableVitaMedWarrantsMember" unitRef="N" decimals="INF">562571</txmd:NumberOfWarrantsVested>
    <txmd:PercentageDecreaseInHoldingDueToMerger contextRef="From2011-07-27to2011-07-29_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Pure" decimals="INF">0.99</txmd:PercentageDecreaseInHoldingDueToMerger>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Pure" decimals="INF">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="From2011-10-03to2011-10-04_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">58407331</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember" unitRef="Shares" decimals="INF">70000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember_us-gaap_OptionMember" unitRef="Shares" decimals="INF">10119796</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2011-10-04_custom_AgreementAndPlanMergerVitaMedMember_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1472916</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AdvertisingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">11739</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">19480</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">65944</us-gaap:AdvertisingExpense>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">29926241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">25926987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2011-01-01to2011-12-31" unitRef="Shares" decimals="INF">13647788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_EquipmentMember_us-gaap_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_EquipmentMember_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2011-01-01to2011-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_ProductConcentrationRiskMember" unitRef="Pure" decimals="INF">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_us-gaap_ProductConcentrationRiskMember" unitRef="Pure" decimals="INF">0.63</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2011-01-01to2011-12-31_us-gaap_ProductConcentrationRiskMember" unitRef="Pure" decimals="INF">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_custom_DeferredRevenueConcentrationRiskMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2012-01-01to2012-12-31_custom_DeferredRevenueConcentrationRiskMember" unitRef="Pure" decimals="INF">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">302748</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">393848</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">382377</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">371240</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">316039</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <txmd:OperatingLeasesNetFutureMinimumPaymentsDue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1727296</txmd:OperatingLeasesNetFutureMinimumPaymentsDue>
    <txmd:OperatingLeasesFutureMinimumSubleaseRentals contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">38956</txmd:OperatingLeasesFutureMinimumSubleaseRentals>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1766252</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <txmd:DescriptionOfLockInPeriod contextRef="From2011-10-03to2011-10-04_custom_AgreementAndPlanMergerVitaMedMember">Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18&#13;months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder&#13;agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares&#13;reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble&#13;Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.</txmd:DescriptionOfLockInPeriod>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2013-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">0</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2012-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">1272</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2011-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">0</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">46000</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">308000</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:DueFromOfficersOrStockholders contextRef="AsOf2011-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">19000</us-gaap:DueFromOfficersOrStockholders>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2013-01-01to2013-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2012-01-01to2012-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">2632</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2011-01-01to2011-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">20669</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2012-01-01to2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">404000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2011-01-01to2011-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">19000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <txmd:LegalFeeReimbursement contextRef="From2013-01-01to2013-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">249981</txmd:LegalFeeReimbursement>
    <txmd:LegalFeeReimbursement contextRef="From2012-01-01to2012-12-31_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USD" decimals="0">0</txmd:LegalFeeReimbursement>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1997</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1997</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1997</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">1997</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">4080</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-90160</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-77159</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">-499</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">-89661</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">-77159</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31452</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">2082</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">23722</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">14584</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">755748</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">316714</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">572726</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">59328</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">180194</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">21055</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">665588</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">239555</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">572726</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2013-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">59328</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">180194</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2012-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">21055</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P15Y9M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-01-01to2012-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2013-01-01to2013-12-31_us-gaap_InternetDomainNamesMember">P0Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2012-01-01to2012-12-31_us-gaap_InternetDomainNamesMember">P1Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">14293499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2012-12-31_WarrantMember" unitRef="Shares" decimals="INF">12193499</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3057627</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2010-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-51142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-8145486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">17332500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">3057627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2013-12-31_WarrantMember" unitRef="USD" decimals="0">48932777</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_WarrantMember" unitRef="USD" decimals="0">17971994</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">3483691</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">2.72</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">1.26</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.36</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.38</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USDPUnit" decimals="INF">0.24</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="USD" decimals="0">5232500</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">31891150</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">3483691</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">13764710</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPUnit" decimals="INF">1.81</txmd:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue contextRef="AsOf2013-12-31_WarrantMember" unitRef="USD" decimals="0">46840559</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-46135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-608750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">5121250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">2583677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" id="Foot-01-0" decimals="INF">10682218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-01-06_us-gaap_SubsequentEventMember_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" id="Foot-01-1" decimals="INF">0.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="AsOf2013-12-31_EmployeeStockOptionMember">P7Y2M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="AsOf2012-12-31_EmployeeStockOptionMember">P7Y8M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember">P7Y7M6D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1737530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">4920981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" id="Foot-01-2" decimals="INF">14188484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USD" decimals="0">58878132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2012-12-31_EmployeeStockOptionMember" unitRef="USD" decimals="0">26804117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2011-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">14067649</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2012-01-01to2012-12-31_EmployeeStockOptionMember">P9Y8M12D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember">P9Y9M18D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1 contextRef="From2011-01-01to2011-12-31_us-gaap_EmployeeStockOptionMember" id="Foot-01-3">P7Y7M6D</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">11282627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2013-01-01to2013-12-31_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2013-12-31_EmployeeStockOptionMember" unitRef="USD" decimals="0">48321930</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <txmd:ClassOfWarrantOrRighstContractualLifeGrants contextRef="From2013-01-01to2013-12-31_WarrantMember">P4Y9M18D</txmd:ClassOfWarrantOrRighstContractualLifeGrants>
    <txmd:ClassOfWarrantOrRighstContractualLifeGrants contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember">P4Y3M18D</txmd:ClassOfWarrantOrRighstContractualLifeGrants>
    <txmd:ClassOfWarrantOrRighstContractualLifeGrants contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember">P7Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeGrants>
    <txmd:ClassOfWarrantOrRighstContractualLife contextRef="AsOf2013-12-31_WarrantMember">P3Y10M24D</txmd:ClassOfWarrantOrRighstContractualLife>
    <txmd:ClassOfWarrantOrRighstContractualLife contextRef="AsOf2011-12-31_us-gaap_WarrantMember">P7Y10M24D</txmd:ClassOfWarrantOrRighstContractualLife>
    <txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable contextRef="AsOf2013-12-31_WarrantMember">P3Y10M24D</txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable>
    <txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrants1Member">Black-Scholes Model</txmd:ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Pure" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">P10Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4464</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4481</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.3913</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.5183</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0072</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2012-01-01to2012-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0104</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0091</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2011-01-01to2011-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0348</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">2.83</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2012-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">2.05</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2011-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.16</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityAmountOutstanding contextRef="AsOf2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">0</us-gaap:LineOfCreditFacilityAmountOutstanding>
    <txmd:SharePrice1 contextRef="AsOf2013-12-31_custom_JefferiesLLCMember" unitRef="USDPShares" decimals="INF">1.58</txmd:SharePrice1>
    <txmd:SharePrice1 contextRef="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USDPShares" decimals="INF">2.23</txmd:SharePrice1>
    <txmd:SharePrice1 contextRef="AsOf2011-10-05_custom_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" unitRef="USDPShares" decimals="INF">0.38</txmd:SharePrice1>
    <us-gaap:SharePrice contextRef="AsOf2013-12-31_custom_JefferiesLLCMember" unitRef="USDPShares" decimals="INF">1.70</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USDPShares" decimals="INF">2.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-09-30_us-gaap_PrivatePlacementMember" unitRef="USDPShares" decimals="INF">2.15</us-gaap:SharePrice>
    <txmd:DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-12-31_LeaseholdImprovementsMember" unitRef="USD" decimals="0">11980</txmd:DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">665588</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">239555</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">755748</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">316714</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2013-01-01to2013-12-31">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">-0.223</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2011-01-01to2011-12-31" unitRef="Pure" decimals="INF">-0.292</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.324</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2012-01-01to2012-12-31" unitRef="Pure" decimals="INF">-0.182</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2011-01-01to2011-12-31" unitRef="Pure" decimals="INF">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2012-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:DebtConversionConvertedInstrumentNonCash contextRef="From2012-01-01to2012-12-31" unitRef="USD" decimals="0">1054658</txmd:DebtConversionConvertedInstrumentNonCash>
    <txmd:DebtConversionConvertedInstrumentNonCash contextRef="From2011-01-01to2011-12-31" unitRef="USD" decimals="0">849137</txmd:DebtConversionConvertedInstrumentNonCash>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;We&#13;maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses&#13;related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting&#13;from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no&#13;limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per&#13;depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured&#13;limits.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July, 2013, the FASB issued&#13;Accounting Standards Update, or ASU, No. 2013-11, &lt;i&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when&#13;a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues&#13;Task Force)&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation&#13;of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.&#13;An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating&#13;loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized&#13;tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new&#13;recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning&#13;after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, the FASB issued ASU No. 2012-02,&#13;&lt;i&gt;Testing Indefinite-Lived Intangible Assets for Impairment&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASU 2012-02. ASU 2012-02 gives entities an option to&#13;first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely&#13;than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it&#13;is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative&#13;impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU&#13;2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with&#13;early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, the FASB issued ASU No. 2011-11,&#13;&lt;i&gt;Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities&lt;/i&gt;, or ASU 2011-11&lt;i&gt;.&lt;/i&gt; ASU 2011-11 enhances&#13;current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial&#13;position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset&#13;on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities&#13;in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared&#13;on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on&#13;or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our&#13;financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We do not believe there would have been a material&#13;effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards&#13;been adopted in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;NOTE 10 &amp;#150; STOCKHOLDERS&amp;#146;&#13;EQUITY&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;At December&#13;31, 2013, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred&#13;stock were outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;At December&#13;31, 2013, we had &lt;/font&gt;250,000,000 shares of Common Stock&lt;font style="letter-spacing: -0.15pt"&gt; authorized for issuance, of which&#13;&lt;/font&gt;144,976,757&lt;font style="letter-spacing: -0.15pt"&gt; shares of our Common Stock were issued and outstanding.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to a shelf registration statement&#13;previously filed with the Securities and Exchange Commission, or the SEC, on March 14, 2013, we entered into an underwriting agreement&#13;with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating&#13;to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share,&#13;and the Jefferies Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement&#13;at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting&#13;discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement,&#13;we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The&#13;offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional&#13;1,954,587 shares of our Common Stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18,&#13;2013 and received proceeds of approximately $3.1 million, net of expenses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 25, 2013, we entered into an underwriting&#13;agreement with Stifel, Nicolaus &amp;#38; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel&#13;Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering&#13;was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting&#13;agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting&#13;underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2013 certain individuals exercised their&#13;right to purchase shares of our Common Stock. Options to purchase an aggregate of 75,423 shares of our Common Stock were exercised&#13;for approximately $31,000. These shares of our Common Stock were issued in part in reliance upon an exemption from the registration&#13;provisions of the Securities Act of 1933, or the Act, provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2012&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2012, certain individuals exercised&#13;their right to purchase shares of our Common Stock. These shares were issued in reliance upon an exemption from the registration&#13;provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;                                                                                                                                                                                                                                                                                                                                                                                                               &lt;tr style="vertical-align: top"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Options to purchase an aggregate&#13;                                         of 1,691,393 shares of our Common Stock were exercised for $191,000.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Using&#13;                                         the cashless exercise feature, options to purchase an aggregate of 240,395 shares of&#13;                                         our Common Stock were exercised.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During June 2012, we settled $3,102,000 in&#13;principal and accrued interest of the February 2012 Notes in exchange for the Parties&amp;#146; exercise of a portion of the related warrants&#13;for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration&#13;provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. During June 2012, we and&#13;the Parties also agreed to convert a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012,&#13;totaling $1,054,647, into 2,775,415 shares of our Common Stock at $0.38 per share. The shares were issued in reliance upon an exemption&#13;from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, we entered into a Securities&#13;Purchase Agreement with multiple investors, relating to the issuance and sale of our Common Stock in a private placement. The private&#13;placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of our Common Stock at $2.15 per share,&#13;for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies served as our exclusive placement&#13;agent. Jefferies&amp;#146; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses of the&#13;investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. The shares were&#13;issued in reliance upon the exemptions from registration under the Act provided by Section 4(a)(2) and Rule 506 of Regulation D&#13;promulgated thereunder. The shares were issued directly by us and did not involve a public offering. The investors were &amp;#147;accredited&#13;investors&amp;#148; as that term is defined in Rule 501 of Regulation D and acquired our Common Stock for investment only and not with&#13;a present view toward, or for resale in connection with, the public sale or distribution thereof. Pursuant to the terms of the&#13;Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares, which we filed on&#13;November 27, 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2011&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;In December&#13;2011, &lt;/font&gt;a former director of VitaMed, &lt;font style="letter-spacing: -0.15pt"&gt;exercised options to purchase 92,057 shares of&#13;our Common Stock for an aggregate exercise price of $17,250.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October and November 2011, we converted&#13;principal and accrued interest in the aggregate of $849,137 into shares of our Common Stock totaling 20,266,822 and 1,415,136,&#13;respectively (as more fully described in NOTE 9).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 5, 2011, we entered into a Stock&#13;Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company, or Pernix. Pursuant to the terms of the&#13;Stock Purchase Agreement, Pernix agreed to purchase 2,631,579 shares of our Common Stock at a purchase price of $0.38 per share&#13;for a total purchase price of $1,000,000. Pernix is a related party. For further details, see NOTE 12&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 3, 2011, we effected a reverse split&#13;of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100, resulting in 165,856 shares issued and&#13;outstanding thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Warrants &lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2013, we had warrants outstanding&#13;to purchase an aggregate of 14,293,499 shares of our Common Stock with a weighted-average contractual remaining life of 3.9 years,&#13;and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The valuation methodology used to determine&#13;the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,&#13;including volatility of the stock price, the risk-free interest rate and the term of the warrant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2013, we granted warrants to purchase&#13;1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE&#13;9). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised&#13;prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the&#13;date of the issuance using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At&#13;December 31, 2013, $260,022 was reported as deferred financing costs included in other current assets in the accompanying consolidated&#13;balance sheet and is being amortized over the life of the Plato Note. As of December 31, 2013, $1,451,934 was recorded as financing&#13;costs on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2013, we entered into a consulting agreement&#13;with Sancilio &amp;#38; Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug&#13;Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval&#13;for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy. In connection with the agreement,&#13;SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant&#13;to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI&#13;a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;1.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;283,333 shares were earned on May 11, 2013 upon successful filing&#13;of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment&#13;of vulvar and vaginal atrophy; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013. The&#13;fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the&#13;vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the&#13;entire $405,066 as non-cash compensation in the accompanying consolidated financial statements;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;2.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;283,333 shares vested on June 30, 2013. The fair value of $462,196&#13;for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility&#13;of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. At December 31, 2013 we had $154,068 recorded as prepaid expense-short&#13;term and $308,128 recorded as prepaid expense-long term in the accompanying consolidated financial statements. During the year&#13;ended December 31, 2013, we recorded $77,034 as non-cash compensation in the accompanying consolidated financial statements; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font-size: 10pt"&gt;3.&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;283,334 shares will vest upon the receipt by us of any final FDA&#13;approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2012&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2012, we issued an aggregate of&#13;5,685,300 Warrants in connection with the modification of certain existing promissory notes, or the Modification Warrants, and&#13;warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection with the issuance of the February&#13;2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable&#13;at $0.38 per share. The Modification Warrants have a fair value of $10,505,247, and the February 2012 Warrants have a fair value&#13;of $6,124,873. Fair value was determined on the date of the issuance using a term of five years; a volatility of 44.5%; risk free&#13;rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment&#13;of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647&#13;was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining&#13;unamortized debt discount.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2012, we issued an aggregate of 31,000&#13;Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the issuance using a&#13;term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; we recorded $29,736 as consulting&#13;expense in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2012, we issued an aggregate of 1,300,000&#13;Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided&#13;are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug&#13;development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing&#13;efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property&#13;and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and&#13;(c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The&#13;Warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility&#13;of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2013, we had $360,528 reported as prepaid expense-short&#13;term and $593,127 recorded as prepaid expense-long term. During the year ended December 31, 2013 and the year ended December 31,&#13;2012, we recorded $360,528 and $218,045, respectively as non-cash compensation in the accompanying consolidated financial statements.&#13;The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process&#13;will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2012, we granted aggregate of 7,000,000&#13;Warrants in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 9). Of the June 2012 Warrants&#13;issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June&#13;2012 Warrants of $9,424,982 was determined on the date of the issuance using a term of five years; a volatility of 44.64%; risk&#13;free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined&#13;by using the relative fair value calculation method on the date of the issuance. Of the $1,649,890, $547,210 was amortized to interest&#13;expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, we amortized the remaining unamortized&#13;debt discount of $1,102,680 to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2012, we issued an aggregate of 1,500&#13;Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the issuance using a&#13;term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded&#13;as consulting expense in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Warrant Activity During 2011&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 500 Warrants with&#13;a fair value of $338 to an unrelated individual for consulting services covered under a three-month agreement. The Warrants were&#13;valued on the date of the issuance using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield&#13;of 0%. The Warrants vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation&#13;and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2011, we issued 600,000 Warrants&#13;with a fair value of $133,045 to an officer of our company for services performed. The Warrants were valued on the date of the&#13;issuance using an exercise price of $0.38; a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield&#13;of 0%. The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares&#13;for month 44). For the years ended December 31, 2013, 2012 and 2011, we recognized $36,284, $36,284 and $7,158, as non-cash compensation&#13;in the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 184,211 Warrants&#13;with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Warrants were&#13;valued on the date of the issuance using an exercise price of $0.38; a term of five years; volatility of 41.04%; risk free rate&#13;of 1.08%; and a dividend yield of 0%. For the year ended December 31, 2011, the $25,980 fair value was recorded as financing expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"&gt;In December 2011, VitaMed&#13;entered into a two-year consulting agreement with an entity providing help to evaluate improvements to existing products and new&#13;products as well as services, including research, design, compliance, scientific and regulatory affairs, and commercialization&#13;of products. As compensation, the consultant received 800,000 fully vested and non forfeitableWarrants. The Warrants were valued&#13;on the date of the issuance using an exercise price of $0.38; a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%;&#13;and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $177,394 at the date of grant and&#13;was amortized to research and development expense over the life of the agreement which is when the research and development activities&#13;were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $71,688, $95,582 and $10,124, respectively,&#13;in research and development expenses related to this agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2011, VitaMed also entered into a one-year&#13;consulting agreement with the same consultant, whereby Consultant would assist in the design, development, and distribution efforts&#13;of VitaMed&amp;#146;s initial product offering. As compensation, the Consultant received 200,000 fully vested non forfeitable VitaMed Warrants&#13;(or a Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at&#13;$12,548 using an exercise price of $0.41; a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend&#13;yield of 0%. The Warrant vested immediately. The fair value of the warrants was $12,548 at the date of grant and was amortized&#13;to research and development expense over the life of the agreement which is when the research and development activities were performed.&#13;During the years ended December 31, 2013, 2012 and 2011, we recognized $0, $6,936 and $5,612 respectively, in research and development&#13;expenses related to this agreement. In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate of $500,000&#13;with 500,000 accompanying VitaMed Warrants (or Warrants for an aggregate of 613,718 shares of our Common Stock taking into account&#13;the merger). The VitaMed Warrants were valued on the date of the issuance using an exercise price of $0.41; a term of five years;&#13;a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Warrants vested&#13;immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount&#13;and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2011, VitaMed entered into a business&#13;loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.&#13;Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited&#13;LP (See NOTE 9 for more details). In consideration for the personal guarantees and cash collateral, VitaMed issued an aggregate&#13;of 499,998 VitaMed Warrants (or Warrants for an aggregate of 613,713 shares of our Common Stock taking into account the merger).&#13;The ten-year Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of&#13;$0.24 per share. On November 13, 2012, the outstanding balance was repaid in full and business loan agreement was amended to reflect&#13;a $100,000 bank line of credit. As part of the amended line of credit, the personal guarantees and cash collateral were removed&#13;for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Warrants, Warrants previously issued to Mr. Finizio and Mr.&#13;Milligan were amended to reflect the amount vested prior to the date of the amended line of credit (179,000 each). At December&#13;31, 2013, an aggregate of 562,571 Warrants were vested. The Warrants, with a fair value of $93,969 ($86,139 after adjusting for&#13;the effect of the amended line of credit ), were valued on the date of the issuance using a term of 10 years; a volatility of 47.89%;&#13;risk free rate of 3.48%; and a dividend yield of 0%. For the years ended December 31, 2013, 2012 and 2011, $2,944, $45,036 and&#13;$38,159, respectively was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;u&gt;Summary of our Warrant activity and related information for&#13;2011-2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;&lt;td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&#13;of Shares Under Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&#13;Average Exercise Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;Weighted Average Remaining Contractual&#13;Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&#13;Intrinsic Value&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2010&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="width: 36%; padding-left: 22pt; text-indent: -10pt"&gt;Issued&lt;/td&gt;&#13;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 11%; text-align: right"&gt;3,057,627&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 11%; text-align: right"&gt;0.36&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 11%; text-align: right"&gt;7.9&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 11%; text-align: right"&gt;3,483,691&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2011&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;3,057,627&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;7.9&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;3,483,691&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Issued&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;17,332,500&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;1.26&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;31,891,150&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;(8,145,486&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(51,142&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;0.24&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;12,193,499&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;1.63&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;17,971,994&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Issued&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;2,100,000&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;2.72&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;4.8&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;5,232,500&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Balance&#13;at December 31, 2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,293,499&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;1.79&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;48,932,777&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Vested&#13;and Exercisable at December 31, 2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,764,710&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;1.81&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right"&gt;46,840,559&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2013, we had warrants outstanding&#13;with exercise prices ranging from $0.24 to $3.20 per share. As of December 31, 2013, unamortized costs associated with warrants&#13;totaled approximately $1,599,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value per share of&#13;warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are&#13;set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; padding-left: 10pt; text-indent: -10pt"&gt;Weighted average fair value&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2.05&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.72-1.04&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.91-3.48&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.64-44.81&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39.13-51.83&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-10&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The risk-free interest rate assumption is based&#13;upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimated volatility is a measure of the&#13;amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is&#13;an average of the historical volatility of the stock prices of peer entities whose stock prices were publicly available. Our&#13;calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We&#13;used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during&#13;2011-2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Options to Purchase Common Stock of the&#13;Company&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2009, we adopted the 2009 Long Term Incentive&#13;Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our&#13;company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options&#13;and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation&#13;rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described&#13;in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger, no awards had been issued&#13;under the 2009 Plan. As of December 31, 2013 there were 13,632,742 shares of our Common Stock issued under the 2009 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 23, 2012, we adopted the 2012 Stock&#13;Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as&#13;an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of&#13;our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2013, there&#13;were 2,650,000 shares issued under the 2012 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The valuation methodology used to determine&#13;the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions&#13;including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions&#13;used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.91-2.54&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37.92-40.48&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The risk-free interest rate assumption is based&#13;upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated&#13;volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award.&#13;Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices&#13;were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the&#13;term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our&#13;stock price. The average expected life is based on the contractual term of the option using the simplified method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of activity under the 2009 and 2012 Plans and related&#13;information for 2011-2013 follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number&#13;    of Shares Under Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&#13;    Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&#13;    Average Remaining Contractual Life in Years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&#13;    Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2010&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 36%; padding-left: 22pt; text-indent: -10pt"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;10,682,218&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0.16&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;7.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;14,188,484&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(92,057&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,590,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14,067,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,121,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,737,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,788&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(46,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Balance at December 31, 2012&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,733,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26,804,117&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,583,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,920,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,423&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 22pt; text-indent: -10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(608,750&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Balance&#13;    at December 31, 2013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,632,742&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;58,878,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Vested&#13;    and Exercisable at December 31, 2013&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,282,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;48,321,930&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"&gt;&lt;div style="font-size: 1pt; border-top: Black 1pt solid; width: 25%"&gt;&lt;/div&gt;&lt;/div&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;(1)&lt;/sup&gt;This includes (i) VitaMed Options&#13;granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to&#13;conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and&#13;October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted&#13;between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options&#13;were reflected in the replacement Options including the number of shares vested.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2013, our outstanding options&#13;had exercise prices ranging from $0.10 to $4.67 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Share-based compensation expense for options&#13;recognized in our results for the years ended December&amp;#160;31, 2013, 2012, and 2011 ($3,200,655, $1,832,061, and $183,355, respectively)&#13;is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant&#13;and revised in subsequent periods if actual forfeitures differ from the estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2013, total unrecognized estimated&#13;compensation expense related to unvested options granted prior to that date was approximately $3,921,000, which is expected to&#13;be recognized over a weighted-average period of 1.3 years. No tax benefit was realized due to a continued pattern of operating&#13;losses. At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to unvested options granted prior&#13;to that date was approximately $4,391,000 and $244,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2013, we issued a restricted stock&#13;unit, or the RSU, under our 2012 Plan to an officer for the purchase of 50,000 shares of our Common Stock. The RSU will vest on&#13;April 1, 2014 and has a fair value of $233,500. As of December 31, 2013, we recorded $53,428 of non-cash compensation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review the carrying values of property and&#13;equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying&#13;values may not be recoverable. Such events or circumstances include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         declines in an asset&amp;#146;s market price;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         deterioration in an asset&amp;#146;s physical condition;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         changes in the nature or extent of an asset&amp;#146;s use or operation;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         adverse changes in the business climate that could impact an asset&amp;#146;s value, including&#13;                                         adverse actions or assessments by regulators; &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;accumulation&#13;                                         of costs significantly in excess of original expectations related to the acquisition&#13;                                         or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;current-period&#13;                                         operating or cash flow losses combined with a history of such losses or a forecast that&#13;                                         demonstrates continuing losses associated with an asset&amp;#146;s use; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expectations&#13;                                         that it is more likely than not that an asset will be sold or otherwise disposed of significantly&#13;                                         before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If impairment indicators are present, we determine&#13;whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#146;s carrying value for recoverability.&#13;This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent&#13;of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future&#13;cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective&#13;carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment&#13;in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.&#13;In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected&#13;timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a&#13;loss for the difference between the assets&amp;#146; fair value and respective carrying value. We determine the fair value of the&#13;assets using an &amp;#147;income approach&amp;#148; based upon a forecast of all the expected discounted future net cash flows associated&#13;with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected&#13;selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships,&#13;market conditions, and available external information about future trends. We believe our current assumptions and estimates are&#13;reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting&#13;in the need for an impairment charge in future periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid R&amp;#38;D costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;1,267,588&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;189,375&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid consulting&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530,596&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;432,216&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Deferred financing costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,022&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Other receivable &amp;#150; related party&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,981&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,528&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;127,403&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid guaranty costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,944&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,477,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;751,938&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Equipment&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;108,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;67,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,980&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,083&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(93,765&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(60,600&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;61,318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;65,673&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;Estimated amortization expense for the next&#13;five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Estimated Amortization&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 80%; text-align: left"&gt;2014&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;4,080&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left"&gt;2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left"&gt;2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,997&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation between taxes computed at&#13;the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(22.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29.2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Provision (Benefit) for Income Taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of December 31, 2013, future minimum rental payments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; border-bottom: Black 1pt solid; padding-left: 10pt"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 76%; text-align: center; padding-left: 0pt"&gt;2014&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;316,039&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: center; padding-left: 0pt"&gt;2015&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: center; padding-left: 0pt"&gt;2016&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: center; padding-left: 0pt"&gt;2017&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;393,848&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: center; padding-left: 0pt"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;302,748&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,766,252&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Noncancelable sub-lease income&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(38,956&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Net minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,727,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years&amp;#160;2013&amp;#160;and&amp;#160;2012&amp;#160;is&#13;as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,537&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,295&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,863&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,157&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,646&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,396&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,376&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,009&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,673&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,361&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;(In thousands, except per share)&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; border-bottom: Black 1pt solid; text-align: center"&gt;4th&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;722&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;819&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;386&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;447&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;729&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;908&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,850&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,253&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,727&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued payroll and commission costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;941,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;397,210&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued financing costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;256,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,899&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;306,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;107,784&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued lab research&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;536,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,208&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;230,088&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;70,759&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"&gt;&amp;#160;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,601,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;833,654&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;div style="text-align: left; margin-left: 36pt; margin-top: 3pt; margin-bottom: 3pt"&gt;&lt;div style="font-size: 1pt; border-top: Black 1pt solid; width: 25%"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"&gt;&lt;sup&gt;(1) &lt;/sup&gt;In June 2008, we declared and paid a special&#13;dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed&#13;by certain shareholders at December 31, 2013 and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2014-03-03" unitRef="Shares" decimals="INF">145017060</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;NOTE&#13;1 &amp;#150; THE COMPANY&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;TherapeuticsMD, Inc., a Nevada corporation,&#13;or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized&#13;on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless&#13;the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as &amp;#147;our company,&amp;#148;&#13;&amp;#147;we,&amp;#148; &amp;#147;our,&amp;#148; or &amp;#147;us.&amp;#148;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Nature of Business&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are a women&amp;#146;s healthcare product&#13;company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on&#13;conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy&#13;pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of&#13;and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and&#13;vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or&#13;in combination, with the aim of providing equivalent efficacy at lower doses, thereby enabling an enhanced side effect&#13;profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables&#13;the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture (through third&#13;parties) and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and&#13;cosmetics.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Agreement and Plan of Merger with VitaMed&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 18, 2011, we entered into an Agreement&#13;and Plan of Merger with VitaMed and our newly formed wholly owned subsidiary. In connection with the acquisition, our subsidiary&#13;merged with and into VitaMed with VitaMed surviving the merger. The merger became effective upon the filing of the Certificate&#13;of Merger with the Secretary of State of the State of Delaware on October 4, 2011. In preparation for and prior to the closing&#13;of the Merger, we completed the following required corporate actions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;a&#13;                                         reverse split of our 16,575,209 issued and outstanding shares of our common stock, par&#13;                                         value $0.001 per share, or the Common Stock, on a ratio of 1-for-100. As a result of&#13;                                         the reverse split, each share of Common Stock outstanding on the July&amp;#160;28, 2011 record&#13;                                         date, without any action on the part of the holder thereof, became one one-hundredth&#13;                                         of a share of Common Stock. The reverse split decreased the number of outstanding shares&#13;                                         of our Common Stock by approximately 99%, resulting in 165,856 shares outstanding after&#13;                                         the reverse split. The effectuation of the reverse split did not result in a change in&#13;                                         the relative equity position or voting power of our shareholders;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;an&#13;                                         increase in the number of shares of our Common Stock authorized for issuance to 250,000,000;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;a&#13;                                         change in the name of our company to TherapeuticsMD, Inc.; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;an&#13;                                         amendment to our 2009 Long Term Incentive Compensation Plan to increase the number of&#13;                                         shares of our Common Stock reserved for issuance thereunder to 25,000,000.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On the effective date of the merger, we acquired&#13;100% of VitaMed in exchange for shares of our Common Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Exchange of Securities&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On the effective date of the merger, all outstanding&#13;membership units of VitaMed were exchanged for shares of our Common Stock. In addition, all outstanding options and warrants to&#13;purchase VitaMed membership units were exchanged for and converted into options and warrants to purchase shares of our Common Stock.&#13;Pursuant to the conversion ratio in the merger, we issued 58,407,331 shares of our Common Stock in exchange for the outstanding&#13;VitaMed membership units, reserved an aggregate of 10,119,796 shares of our Common Stock for issuance upon the exercise of the&#13;VitaMed options, and reserved an aggregate of 1,472,916 shares of our Common Stock for issuance upon the exercise of the warrants.&#13;After giving effect to the reverse split, and taking into consideration the 58,407,331 shares issued in exchange for the membership&#13;units, the number of shares of our Common Stock issued and outstanding as of the effective date of the merger was 58,573,187, of&#13;which the former members of VitaMed owned approximately 99%. All shares of our Common Stock issued in exchange for the VitaMed&#13;membership units and issuable upon exercise of the options and warrants were subject to a lock-up agreement for a period of 18&#13;months from the effective date of the merger, and on a limited basis for 12 months thereafter.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;NOTE&#13;2 &amp;#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances&#13;and transactions have been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;We&#13;maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses&#13;related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting&#13;from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no&#13;limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per&#13;depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured&#13;limits.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal; letter-spacing: 0pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal; letter-spacing: 0pt"&gt;&lt;u&gt;Trade&#13;Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal; letter-spacing: 0pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations&#13;due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide&#13;an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,&#13;and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write&#13;off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection&#13;efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance&#13;for doubtful accounts when received. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does not&#13;accurately reflect bad debts; adjustments to these reserves may be required.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories&#13;represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using&#13;the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed&#13;in &lt;u&gt;Revenue Recognition&lt;/u&gt;) are recorded as deferred costs and are included in inventory, until such time as the related deferred&#13;revenue is recognized.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Equipment&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We state equipment at cost, net of accumulated&#13;depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair&#13;costs to operating expense as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line method&#13;over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Leasehold&#13;Improvements&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We state&#13;improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining&#13;term of the lease.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible&lt;/u&gt; &lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patent&#13;and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have&#13;adopted the provisions of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350,&#13;&lt;i&gt;Intangible-Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs,&#13;net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once&#13;a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.&#13;If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment&#13;annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted&#13;in the year ended December 31, 2013.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review the carrying values of property and&#13;equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying&#13;values may not be recoverable. Such events or circumstances include the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         declines in an asset&amp;#146;s market price;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         deterioration in an asset&amp;#146;s physical condition;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         changes in the nature or extent of an asset&amp;#146;s use or operation;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;significant&#13;                                         adverse changes in the business climate that could impact an asset&amp;#146;s value, including&#13;                                         adverse actions or assessments by regulators; &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;accumulation&#13;                                         of costs significantly in excess of original expectations related to the acquisition&#13;                                         or construction of an asset;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;current-period&#13;                                         operating or cash flow losses combined with a history of such losses or a forecast that&#13;                                         demonstrates continuing losses associated with an asset&amp;#146;s use; and&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;expectations&#13;                                         that it is more likely than not that an asset will be sold or otherwise disposed of significantly&#13;                                         before the end of its previously estimated useful life.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If impairment indicators are present, we determine&#13;whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#146;s carrying value for recoverability.&#13;This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent&#13;of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future&#13;cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective&#13;carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment&#13;in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.&#13;In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected&#13;timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a&#13;loss for the difference between the assets&amp;#146; fair value and respective carrying value. We determine the fair value of the&#13;assets using an &amp;#147;income approach&amp;#148; based upon a forecast of all the expected discounted future net cash flows associated&#13;with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected&#13;selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships,&#13;market conditions, and available external information about future trends. We believe our current assumptions and estimates are&#13;reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting&#13;in the need for an impairment charge in future periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily&#13;of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts&#13;payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered&#13;Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short-&#13;and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which&#13;would be considered Level 3 inputs under the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities that&#13;are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value Measurements&#13;and Disclosures. &lt;/i&gt; The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets&#13;and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets and liabilities recorded in the consolidated&#13;balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td style="width: 36pt"&gt;&lt;/td&gt;&lt;td style="width: 54pt; text-align: left"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unadjusted quoted prices in active markets for identical&#13;assets or liabilities;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;quoted prices for similar assets or liabilities in active&#13;markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,&#13;for substantially the full term of the financial instrument; and&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify"&gt;&#13;&lt;td&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2013, 2012, and 2011, we had&#13;no assets or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;&lt;u&gt;Income&#13;Taxes&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="letter-spacing: 0pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With the advent of the Merger, we determined&#13;that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because&#13;of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4,&#13;2011.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We account for income taxes under the asset&#13;and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to&#13;differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.&#13;We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which&#13;the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities&#13;of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the&#13;amount that will more likely than not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,&#13;we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in&#13;an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest&#13;amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in&#13;the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize both interest and penalties related&#13;to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating&#13;to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our tax returns are subject to review by the&#13;Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2004, the FASB issued ASC 718,&#13;&lt;i&gt;Compensation &amp;#150; Stock Compensation&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or&lt;i&gt; &lt;/i&gt;ASC 718. Under ASC 718, companies are required to measure the&#13;compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial&#13;statements over the period during which employees are required to provide services. Share-based compensation arrangements include&#13;options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase&#13;plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any,&#13;over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,&#13;an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the&#13;expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of&#13;the award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Equity instruments (&amp;#147;instruments&amp;#148;)&#13;issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC&#13;505, &lt;i&gt;Equity Based Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;, &lt;/i&gt;defines the measurement date and recognition period&#13;for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b)&#13;the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the&#13;instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize the compensation expense for all&#13;share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize&#13;the compensation expense on a straight-line basis over the employee&amp;#146;s requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred from parties that are providing&#13;long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based&#13;on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the&#13;related debt using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue on arrangements in accordance&#13;with ASC 605, &lt;i&gt;Revenue Recognition&lt;/i&gt;. We recognize revenue only when the price is fixed or determinable, persuasive evidence&#13;of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Over-the-Counter Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We generate OTC revenue from product sales&#13;primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of&#13;loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include&#13;shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive&#13;the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. &lt;font style="color: #252525"&gt;We&#13;provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.&#13;&lt;/font&gt;We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="color: #252525"&gt;We sell our name&#13;brand and generic prescription products &lt;/font&gt;primarily through drug wholesalers and retail pharmacies. We recognize revenue from&#13;prescription product sales, net of sales discounts, chargebacks, and rebates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable product from&#13;customers within a return period of six months prior to and following product expiration. Our prescription products currently have&#13;a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot&#13;reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue&#13;on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products&#13;are dispensed through patient prescriptions or expiration of the right of return.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We maintain various rebate programs in an effort&#13;to maintain&lt;i&gt; &lt;/i&gt;a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program&#13;is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We&#13;estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,&#13;on a quarterly basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense all shipping and handling costs&#13;as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We expense advertising costs when incurred.&#13;Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31,&#13;2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;#38;D, expenses&#13;include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research&#13;sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based&#13;compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity&#13;expenses include regulatory consulting and legal counsel. We charge internal R&amp;#38;D activities and other activity expenses to&#13;operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting&#13;date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the&#13;activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed&#13;in future R&amp;#38;D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively.&#13;We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those&#13;costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies&#13;progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We calculate earnings per share, or EPS, in&#13;accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and&#13;diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We&#13;compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive&#13;shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options&#13;and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our&#13;Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these&#13;periods because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Use&#13;of Estimates&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our consolidated financial statements have&#13;been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation&#13;of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,&#13;liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including&#13;those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions&#13;that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying&#13;values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material&#13;amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July, 2013, the FASB issued&#13;Accounting Standards Update, or ASU, No. 2013-11, &lt;i&gt;Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when&#13;a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues&#13;Task Force)&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation&#13;of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.&#13;An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating&#13;loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized&#13;tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new&#13;recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning&#13;after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2012, the FASB issued ASU No. 2012-02,&#13;&lt;i&gt;Testing Indefinite-Lived Intangible Assets for Impairment&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASU 2012-02. ASU 2012-02 gives entities an option to&#13;first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely&#13;than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it&#13;is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative&#13;impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU&#13;2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with&#13;early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, the FASB issued ASU No. 2011-11,&#13;&lt;i&gt;Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities&lt;/i&gt;, or ASU 2011-11&lt;i&gt;.&lt;/i&gt; ASU 2011-11 enhances&#13;current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial&#13;position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset&#13;on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities&#13;in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared&#13;on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on&#13;or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our&#13;financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We do not believe there would have been a material&#13;effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards&#13;been adopted in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain 2012 amounts have been reclassified to conform&#13;to current year presentation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;#38;D, expenses&#13;include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research&#13;sites, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based&#13;compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity&#13;expenses include regulatory consulting and legal counsel. We charge internal R&amp;#38;D activities and other activity expenses to&#13;operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting&#13;date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the&#13;activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed&#13;in future R&amp;#38;D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively.&#13;We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those&#13;costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies&#13;progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We calculate earnings per share, or EPS, in&#13;accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and&#13;diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We&#13;compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive&#13;shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options&#13;and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our&#13;Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these&#13;periods because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Certain 2012 amounts have been reclassified to conform&#13;to current year presentation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <txmd:PrepaidExpensesDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 6 &amp;#150;PREPAID EXPENSE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid R &amp;#38; D costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;824,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;953,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;899,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Accreted prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;27,234&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,750,455&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;953,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</txmd:PrepaidExpensesDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid R &amp;#38; D costs&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;824,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;953,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;899,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Accreted prepaid costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;27,234&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9472;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,750,455&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;953,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">824221</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">953655</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="background-color: white"&gt;The following table sets forth&#13;the gross carrying amount and accumulated amortization of our intangible assets as of&amp;#160;December&amp;#160;31, 2013&amp;#160;and&amp;#160;December&amp;#160;31,&#13;2012:&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;December&amp;#160;31,&#13;    2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;Carrying&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Amortization&lt;br /&gt;Period&amp;#160;(yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Amortizing intangible assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; width: 40%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;OPERA&amp;#174; software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;31,951&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(499&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;31,452&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;15.8&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Development&#13;    costs for corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(89,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Non-amortizing&#13;    intangible assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 12pt; text-indent: -12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;572,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks for vitamins/supplements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;59,328&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 24pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;755,748&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(90,160&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;665,588&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;December&amp;#160;31,&#13;    2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Gross&lt;br /&gt;Carrying&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;br /&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;br /&gt;Amount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Weighted-&lt;br /&gt;Average&lt;br /&gt;Amortization&lt;br /&gt;Period&amp;#160;(yrs.)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 40%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;OPERA&#13;    &amp;#174; software patent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;23,722&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;23,722&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Development&#13;    costs for corporate website&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;91,743&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(77,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;14,584&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;1.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Non-amortizing&#13;    intangible assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Hormone&#13;    therapy drug candidate patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;180,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;180,194&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Multiple&#13;    trademarks for vitamins/supplements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;21,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;21,055&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;316,714&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;(77,159&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;239,555&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 9 &amp;#150; NOTES PAYABLE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Multiple Advance&#13;Revolving Credit Note&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 31, 2013, we entered into a&#13;business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the&#13;Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal&#13;amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the&#13;Revolving Credit Note at our request, which advances were of a revolving nature and were able to be,made, repaid, and made&#13;from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in&#13;which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the&#13;Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any,&#13;was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each&#13;of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid&#13;$401,085, including accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31,&#13;2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a&#13;warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (see NOTE 10 for more&#13;details).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Borrowing under Business Loan Agreement&#13;and Promissory Note, as amended&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2011, VitaMed entered into a business&#13;loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were&#13;required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers&#13;of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.&#13;The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.&#13;We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the&#13;extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013. On November 13, 2012, the outstanding balance&#13;of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with&#13;the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited&#13;Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.&#13;In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. The amended bank line of credit&#13;required a personal guarantee and cash collateral limited to $100,000, which was provided by Reich Family Limited Partnership.&#13;On April 25, 2013, we re-paid $100,735, which represented the principal and interest that was due under the amended bank line of&#13;credit. On May 1, 2013, the amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled,&#13;and the cash collateral was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013, 2012, and&#13;2011, we paid $735, $7,366, and $5,650, respectively, of interest expense, which are included in interest expense on the accompanying&#13;consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance of Promissory Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January and February 2012, we issued 6%&#13;promissory notes in the aggregate principal amount of $900,000, due March 1, 2012. As discussed below in &lt;u&gt;Issuance and Settlement&#13;of February 2012 Notes&lt;/u&gt;, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory&#13;notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Settlement of February 2012&#13;Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 24, 2012, we issued promissory&#13;notes, the February 2012 Notes, to an individual and an entity, or the Parties, both of which are stockholders of our company,&#13;in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of 9,000,000&#13;shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received an aggregate&#13;of $1,000,000 of new funding from the Parties upon issuance of the February 2012 Notes and related warrants and surrender by the&#13;Parties of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the aggregate accrued&#13;interest of $15,124 (collectively known as the &amp;#147;Prior Notes&amp;#148;). Under the February 2012 Notes, we borrowed an additional&#13;$3,000,000 from the Parties during March, April, and May 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We granted 5,685,300 warrants in&#13;consideration of the modification of the Prior Notes and 3,314,700 warrants with the February Funding. We determined that the&#13;resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, &lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Modifications&#13;and Extinguishments.&amp;#160;&lt;/i&gt;&lt;/font&gt;As such the modification was accounted for as an extinguishment and restructuring of&#13;the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed (see &lt;u&gt;Warrant Activity&#13;During 2012 &lt;/u&gt;in NOTE 10 for more details). The fair value of the Prior Notes was estimated by calculating the present&#13;value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741,&#13;resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented&#13;the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair&#13;value as of the date of the modification on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 19, 2012, we settled an aggregate amount&#13;of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase&#13;8,145,486 shares of our Common Stock. As discussed below in &lt;u&gt;Issuance and Payment of June 2012 Notes&lt;/u&gt;, the remaining balance&#13;of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the&#13;June 2012 Notes (see NOTE 10 for more details).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of June 2012 Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 19, 2012, we issued secured promissory&#13;notes, or the June 2012 Notes, to the Parties in the principal amounts of $2,347,128 and $2,344,719, respectively, pursuant to&#13;the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the Parties surrendered the remaining balance of&#13;the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively, which sums included principal and accrued&#13;interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding from the Parties, or the June Funding.&#13;The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest&#13;at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June&#13;2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein.&#13;We also granted warrants to purchase an aggregate of 7,000,000 shares of our Common Stock in connection with the June Funding.&#13;On March 21, 2013, we repaid $4,882,019, including accrued interest, leaving a balance of $21,595 in accrued interest as of March&#13;31, 2013 on the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Additional Notes&#13;in 2012&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August and September 2012, we issued 6%&#13;promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were&#13;paid in full in October 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2012, we issued a 6% promissory&#13;note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Conversion of July 2011 Secured Notes &lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2011, VitaMed issued two senior secured&#13;promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security agreement under which VitaMed&#13;pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon the merger and bore interest at the&#13;rate of 6% per annum, were due on the one year anniversary thereof, and were convertible into shares of our Common Stock at our&#13;option. We were permitted to satisfy the obligation underlying the Secured Notes by delivering such number of shares of our Common&#13;Stock calculated by dividing the then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the&#13;&amp;#147;Share Price&amp;#148; meant the lower of the most recent price at which we offered and sold shares of our Common Stock (not including&#13;any shares of our Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities)&#13;or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement&#13;to convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of $1,054,647&#13;into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial conversion feature&#13;of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial statements. For the years ended&#13;December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying&#13;consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance of VitaMed Promissory Notes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2011, VitaMed issued promissory notes,&#13;or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, we granted warrants&#13;to purchase an aggregate of 613,718 shares of our Common Stock. The VitaMed Notes were assumed by us upon the merger and bore interest&#13;at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time&#13;as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon&#13;the closing of the Funding in July 2011, as more fully described above in &lt;u&gt;Conversion of July 2011 Secured Notes&lt;/u&gt;, two of&#13;the VitaMed Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Notes in the aggregate&#13;of $300,000 were extended. In October 2011, one of the VitaMed Notes for $50,000 was paid in full, and, by mutual agreement, certain&#13;of the VitaMed Notes in the aggregate amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share,&#13;which represented the fair value of the shares of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held&#13;by an unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.&#13;Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate amount&#13;of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes in full, including&#13;$5,341 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September and October 2011, VitaMed issued&#13;convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible Notes bore interest&#13;at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt Conversion Agreements with&#13;the holders of VitaMed Convertible Notes, pursuant to which we converted the principal and accrued interest of the VitaMed Convertible&#13;Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common&#13;Stock on the date of conversion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 4% promissory notes&#13;to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended&#13;by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&amp;#160;Finizio in full, including $888&#13;in accrued interest. Mr. Milligan&amp;#146;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&amp;#146;s&#13;promissory note in full, including $1,519 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2012 and 2011,&#13;we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;u&gt;Summary of our Warrant activity and related information for&#13;2011-2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Shares Under Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2010&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt; width: 40%"&gt;Issued&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;3,057,627&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;0.36&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;7.9&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;3,483,691&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2011&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,057,627&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.36&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.9&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3,483,691&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Issued&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;17,332,500&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.26&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31,891,150&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(8,145,486&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.38&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(51,142&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.24&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12,193,499&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.63&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;17,971,994&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Issued&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,100,000&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.72&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.8&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,232,500&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;14,293,499&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.79&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;48,932,777&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Vested and Exercisable at December 31, 2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;13,764,710&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.81&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.9&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;46,840,559&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <txmd:ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value per share of&#13;warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are&#13;set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;2011&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt; width: 49%"&gt;Weighted average fair value&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;2.83&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;2.05&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 13%"&gt;0.16&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Risk-free interest rate&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.72-1.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.91-3.48&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.64-44.81&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39.13-51.83&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Term (in years)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font-size: 10pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Dividend yield&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</txmd:ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of activity under the 2009 and 2012 Plans and related&#13;information for 2011-2013 follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Number of Shares Under Options&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2010&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt; width: 40%"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;10,682,218&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;0.16&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;7.6&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; width: 11%"&gt;14,188,484&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(92,057&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.19&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2011&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,590,161&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.16&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.6&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;14,067,649&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5,121,250&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.80&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.7&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,737,530&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,931,788&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0.13&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#9472;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(46,135&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2012&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;13,733,488&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.16&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.7&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26,804,117&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,583,677&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.31&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;9.8&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,920,981&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Exercised&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(75,423&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="text-indent: -10pt; padding-left: 22pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(250&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt"&gt;Cancelled&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;(608,750&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Balance at December 31, 2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;15,632,742&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.44&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.2&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;58,878,132&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: rgb(204,238,255); vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Vested and Exercisable at December 31, 2013&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.5pt double; text-align: right"&gt;11,282,627&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;.80&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.5&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;48,321,930&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;(1)&lt;/sup&gt;This includes (i) VitaMed Options&#13;granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to&#13;conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and&#13;October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted&#13;between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options&#13;were reflected in the replacement Options including the number of shares vested.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The assumptions&#13;used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.61-2.23&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.91-2.54&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.77-46.01&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37.92-40.48&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.5-6.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2013-12-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">35000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2012-12-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">35000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2011-12-31_us-gaap_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">35000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2013-12-31_us-gaap_InternalRevenueServiceIRSMember" unitRef="USD" decimals="0">37000000</us-gaap:OperatingLossCarryforwards>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2091809</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">189375</txmd:AdvancePaymentsForFutureResearchAndDevelopmentActivities>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">6107207</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2011-12-31" unitRef="USD" decimals="0">748404</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 12 &amp;#150; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Loan Guaranty&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2011, VitaMed entered into a business&#13;loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.&#13;Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited&#13;Limited Partnership. See NOTES 9 and 10 for more details.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Loans from Affiliates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2011, VitaMed issued promissory notes,&#13;or the VitaMed Notes, in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the&#13;affiliate notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments,&#13;LLC, which is owned by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Promissory&#13;Notes were paid in full including $5,341 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2011, we issued 4% promissory notes&#13;to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These&#13;promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio&#13;was paid in full, including $888 in accrued interest. Mr. Milligan&amp;#146;s VitaMed Promissory Note was extended to October 15,&#13;2012. On October 4, 2012 this VitaMed Notes was paid in full including $1,519 in accrued interest.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Lock Up Agreements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As required by the terms of the merger agreement&#13;with VitaMed dated July 18, 2011, we entered into Lock-Up Agreements with stockholders covering the aggregate of 70,000,000 shares&#13;of our Common Stock issued pursuant to the merger or reserved for issuance pursuant to stock options and warrants. Each stockholder&#13;agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause&#13;any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder&amp;#146;s&#13;aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month&#13;period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;u&gt;Purchases by Related Parties&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During 2013, 2012, and 2011, we sold our products&#13;to Dr. Brian Bernick, a director of our company, in the amounts of $0, $2,632 and $20,669, respectively, while $0, $1,272 and $0&#13;of receivables related thereto remained outstanding at December 31, 2013, 2012 and 2011, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Agreements with Pernix Therapeutics,&#13;LLC&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 29, 2012, Cooper C. Collins, President&#13;and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. We closed a stock&#13;purchase agreement with Pernix on October 5, 2011. From time to time, we have entered into agreements with Pernix in the normal&#13;course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors.&#13;During the years ended December 31, 2013, 2012, and 2011, we made purchases of approximately $0, $404,000 and $19,000, respectively,&#13;from Pernix. At December 31, 2013, 2012, and 2011, there were amounts due Pernix of approximately $46,000, $308,000 and 19,000&#13;outstanding, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, there were amounts due to&#13;us from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement, in the amounts&#13;of $249,981 and $0 for the periods ending December 31, 2013 and December 31, 2012, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Warrants&#13;assigned to Related Party&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;In June 2012,&#13;a warrant to purchase 100,000 shares of our Common Stock was assigned to the son of the Chairman of our board of directors by a&#13;non-affiliated third party.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2014-01-01to2014-01-06_us-gaap_SubsequentEventMember_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate contextRef="From2014-01-01to2014-01-06_us-gaap_SubsequentEventMember_us-gaap_EmployeeStockOptionMember">2014-12-31</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 11 &amp;#150; INCOME TAXES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;For the years ended&#13;December 31, 2013, 2012 and 2011, there was no provision for income taxes, current or deferred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At December 31,&#13;2013, we have a federal net operating loss carry forward of approximately $37,000,000 available to offset future taxable&#13;income through 2033.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;At December 31,&#13;2013, 2012, and 2011, we have state net operating loss carryforwards of approximately $35,000,000 available to offset future&#13;losses through 2033. We established valuation allowances equal to the full amount of the deferred tax assets because of the&#13;uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will&#13;be able to recover the deferred tax assets. We consider all available evidence, both positive and negative,&#13;including historical levels of income, expectations and risks associated with estimates of future taxable income.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our deferred tax asset and liability as presented&#13;in the accompanying consolidated financial statements consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 22pt; text-indent: -10pt"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;14,773,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;5,920,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;748,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;R&amp;#38;D Credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;547,511&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Total deferred income tax asset &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;748,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Deferred Income Tax Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our provision for income taxes differs from&#13;applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting&#13;certain expenses for financial statement purposes but not for federal income tax purposes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation between taxes computed at&#13;the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Federal statutory tax rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;35.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Adjustment in valuation allowances&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;Permanent and other differences&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(22.3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29.2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Provision (Benefit) for Income Taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our deferred tax asset and liability as presented&#13;in the accompanying consolidated financial statements consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Deferred Income Tax Assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 22pt; text-indent: -10pt"&gt;Net operating losses&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;14,773,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;5,920,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;748,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;R&amp;#38;D Credit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;547,511&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;186,346&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Total deferred income tax asset &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;748,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(15,321,048&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(6,107,207&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(748,404&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"&gt;Deferred Income Tax Assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2013-01-01to2013-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 16_ &amp;#150; SUBSEQUENT EVENTS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"&gt;On January 6,&#13;2014, options for 390,000 shares of stock were granted to certain members of our Board of Directors under the 2012 Plan for&#13;their services to be rendered in 2014. The options were granted for a period of 10 years at an exercise price equal to the&#13;closing price at the date of grant, and vest on December 31, 2014. &lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2 contextRef="From2012-01-01to2012-12-31" unitRef="Shares" decimals="INF">1691393</txmd:StockIssuedDuringPeriodSharesStockOptionsExercised2>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>txmd-20131231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aIps7xRiXgen8uHY31MOa+LGbOdwZ56CZlBvGV2bZmKnyMrB8MEjCs/E4LW0VcE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-roles="http://fasb.org/us-roles/2013-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:txmd="http://therapeuticsmd.com/20131231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20131231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" id="ConsolidatedStatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssets" id="FixedAssets">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpense" id="PrepaidExpense">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000013 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000015 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000024 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" id="FixedAssetsTables">
	  <link:definition>00000026 - Disclosure - FIXED ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" id="PrepaidExpenseTables">
	  <link:definition>00000027 - Disclosure - PREPAID EXPENSE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000028 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000031 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" id="CompanyDetailsNarrative">
	  <link:definition>00000034 - Disclosure - THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000036 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000037 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" id="FixedAssetsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - FIXED ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" id="FixedAssetsDetails">
	  <link:definition>00000039 - Disclosure - FIXED ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" id="PrepaidExpenseDetails">
	  <link:definition>00000040 - Disclosure - PREPAID EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000042 - Disclosure - INTANGIBLE ASSETS (Details )</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000043 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" id="OtherCurrentLiabilitiesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000046 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" id="NotesPayableDetailsNarrative1">
	  <link:definition>00000047 - Disclosure - NOTES PAYABLE (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
	  <link:definition>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000055 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000056 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000057 - Disclosure - INCOME TAXES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000058 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000059 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" id="SelectedQuarterlyFinancialDataDetails">
	  <link:definition>00000062 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20131231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20131231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20131231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20131231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelNicolausAndCompanyMember" name="StifelNicolausAndCompanyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012NotesMember" name="February2012NotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VitaMedPromissoryNotesMember" name="VitaMedPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" name="StockPurchaseAgreementWithPernixTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleAdvanceRevolvingCreditNoteMember" name="MultipleAdvanceRevolvingCreditNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants1Member" name="SancilioAndCompanyWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants2Member" name="SancilioAndCompanyWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrants3Member" name="SancilioAndCompanyWarrants3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ModificationWarrantsMember" name="ModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" name="WarrantsIssuedToUnaffiliatedIndividualsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedEntityMember" name="WarrantsIssuedToUnaffiliatedEntityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrantsMember" name="June2012NotesWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrants1Member" name="June2012NotesWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesWarrants2Member" name="June2012NotesWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" name="WarrantsIssuedToUnaffiliatedIndividuals1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" name="WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToOfficersMember" name="WarrantsIssuedToOfficersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" name="WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_VestedNonForfeitableVitaMedWarrantsMember" name="VestedNonForfeitableVitaMedWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MrFinizioMember" name="MrFinizioMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MrMilliganMember" name="MrMilliganMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReichFamilyLimitedLPMember" name="ReichFamilyLimitedLPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IssuanceOfPromissoryNotesMember" name="IssuanceOfPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012Notes1Member" name="February2012Notes1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_February2012Notes2Member" name="February2012Notes2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012Notes1Member" name="June2012Notes1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012Notes2Member" name="June2012Notes2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_June2012NotesMember" name="June2012NotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedInAugustAndSeptember2012Member" name="NotesIssuedInAugustAndSeptember2012Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedInSeptember2012Member" name="NotesIssuedInSeptember2012Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotesMember" name="July2011SecuredNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotes1Member" name="July2011SecuredNotes1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_July2011SecuredNotes2Member" name="July2011SecuredNotes2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToVariousPartiesMember" name="NotesIssuedToVariousPartiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToParty1Member" name="NotesIssuedToParty1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToParty2Member" name="NotesIssuedToParty2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AgreementAndPlanMergerVitaMedMember" name="AgreementAndPlanMergerVitaMedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredRevenueConcentrationRiskMember" name="DeferredRevenueConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NotesIssuedToPartiesMember" name="NotesIssuedToPartiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonAffiliatedThirdPartyMember" name="NonAffiliatedThirdPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LoanGuarantyCosts" name="LoanGuarantyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ConsolidatedStatementsOfStockholdersEquityDeficitAbstract" name="ConsolidatedStatementsOfStockholdersEquityDeficitAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" name="EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" name="EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" name="WarrantsIssuedForLoanGuarantyCostsRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForFinancingCosts" name="WarrantsIssuedForFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedAsFinancingCostRelatedParties" name="WarrantsIssuedAsFinancingCostRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedAsCompensationRelatedParty" name="WarrantsIssuedAsCompensationRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" name="EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForFinancing" name="WarrantsIssuedForFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForServices" name="WarrantsIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" name="WarrantsExercisedInExchangeForDebtAndAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtConversionConvertedInstrumentNonCash" name="DebtConversionConvertedInstrumentNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_InventoryAbstract" name="InventoryAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" name="ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PercentageDecreaseInHoldingDueToMerger" name="PercentageDecreaseInHoldingDueToMerger" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DescriptionOfLockInPeriod" name="DescriptionOfLockInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" name="AdvancePaymentsForFutureResearchAndDevelopmentActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidGuarantyCostsCurrent" name="PrepaidGuarantyCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" name="DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchDevelopmentCostsNoncurrent" name="PrepaidResearchDevelopmentCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsNoncurrent" name="PrepaidManufacturingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidAccreditedCostsNoncurrent" name="PrepaidAccreditedCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnclaimedDividends" name="UnclaimedDividends" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedFinancingCostsCurrent" name="AccruedFinancingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedLabResearchCurrent" name="AccruedLabResearchCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RemainingSurrenderValueOfNotes" name="RemainingSurrenderValueOfNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtInstrumentRemainingFaceAmount" name="DebtInstrumentRemainingFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrivatePlacementAxis" name="PrivatePlacementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_PrivatePlacementDomain" name="PrivatePlacementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SharePrice1" name="SharePrice1" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockExpectedToIssuedDuringPeriodShares" name="StockExpectedToIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" name="StockIssuedDuringPeriodSharesStockOptionsExercised2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" name="StockIssuedDuringPeriodSharesStockOptionsExercised1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrivatePlacementFees" name="PrivatePlacementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnamortizedCostsOfWarrants" name="UnamortizedCostsOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" name="ClassOfWarrantOrRightFairValueOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" name="ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExpenseRecognized" name="ClassOfWarrantOrRightExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" name="FairValueOfWarrantsByRelativeFairValueCalculationMethod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" name="RemainingAmortizationOfFinancingCostsAndDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumbersOfUnaffiliatedIndividuals" name="NumbersOfUnaffiliatedIndividuals" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" name="DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AgreementCoverPeriod" name="AgreementCoverPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingExpense" name="FinancingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AmortizationResearchAndDevelopmentExpense" name="AmortizationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedDuringPeriodShares" name="WarrantsIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfWarrantsVested" name="NumberOfWarrantsVested" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateTimeItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsActivityAndRelatedInformationAbstract" name="WarrantsActivityAndRelatedInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSharesUnderWarrantAbstract" name="NumberOfSharesUnderWarrantAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" nillable="true" xbrli:periodType="duration" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="us-types:perUnitItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLife" name="ClassOfWarrantOrRighstContractualLife" nillable="true" xbrli:periodType="instant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeGrants" name="ClassOfWarrantOrRighstContractualLifeGrants" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExercises" name="ClassOfWarrantOrRighstContractualLifeExercises" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" name="ClassOfWarrantOrRighstContractualLifeExpirations" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" name="ClassOfWarrantOrRighstContractualLifeForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" name="ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ActivityUnderLtipAbstract" name="ActivityUnderLtipAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOptionsAbstract" name="NumberOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="instant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredIncomeTaxAssetsAbstract" name="DeferredIncomeTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LegalFeeReimbursement" name="LegalFeeReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MonthlyBaseRentOfLeases" name="MonthlyBaseRentOfLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLeasesFutureMinimumSubleaseRentals" name="OperatingLeasesFutureMinimumSubleaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OperatingLeasesNetFutureMinimumPaymentsDue" name="OperatingLeasesNetFutureMinimumPaymentsDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateTimeItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>txmd-20131231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20131231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20131231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20131231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20131231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20131231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20131231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20131231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20131231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20131231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20131231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20131231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20131231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20131231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20131231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20131231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20131231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20131231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20131231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20131231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20131231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20131231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20131231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20131231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20131231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20131231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20131231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20131231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20131231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaapDebtIssuanceCosts" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="1100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:calculationArc order="1200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="1300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="1400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="1500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="1600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="1700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaapDeferredRevenueAdditions" />
      <link:calculationArc order="1800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDeferredRevenueAdditions" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:calculationArc order="1900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:calculationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="loc_us-gaapPaymentsForDeposits" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForDeposits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000026 - Disclosure - FIXED ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000027 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000036 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000037 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidGuarantyCostsCurrent" xlink:label="loc_txmdPrepaidGuarantyCostsCurrent" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsCurrent" xlink:to="loc_txmdPrepaidGuarantyCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - FIXED ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000040 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="loc_txmdPrepaidAccreditedCostsNoncurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:to="loc_txmdPrepaidAccreditedCostsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details )" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000044 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="loc_txmdAccruedFinancingCostsCurrent" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedFinancingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedLabResearchCurrent" xlink:label="loc_txmdAccruedLabResearchCurrent" />
      <link:calculationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedLabResearchCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="900" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000056 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000057 - Disclosure - INCOME TAXES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000058 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000059 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:label="loc_txmdOperatingLeasesNetFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:calculationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txmdOperatingLeasesNetFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:label="loc_txmdOperatingLeasesFutureMinimumSubleaseRentals" />
      <link:calculationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_txmdOperatingLeasesNetFutureMinimumPaymentsDue" xlink:to="loc_txmdOperatingLeasesFutureMinimumSubleaseRentals" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>txmd-20131231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20131231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20131231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20131231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20131231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20131231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20131231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20131231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20131231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20131231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20131231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20131231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20131231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20131231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20131231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20131231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20131231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20131231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20131231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20131231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20131231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20131231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20131231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20131231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20131231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20131231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20131231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20131231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20131231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:label="loc_txmdWarrantsIssuedForLoanGuarantyCostsRelatedParties_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForLoanGuarantyCostsRelatedParties_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="loc_txmdWarrantsIssuedForFinancingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForFinancingCosts_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="loc_txmdWarrantsIssuedAsCompensationRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsCompensationRelatedParty_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000026 - Disclosure - FIXED ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000027 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRestructuringPlanAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementAndPlanMergerVitaMedMember" xlink:label="loc_txmdAgreementAndPlanMergerVitaMedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringPlanDomain" xlink:to="loc_txmdAgreementAndPlanMergerVitaMedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PercentageDecreaseInHoldingDueToMerger" xlink:label="loc_txmdPercentageDecreaseInHoldingDueToMerger_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPercentageDecreaseInHoldingDueToMerger_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionOfLockInPeriod" xlink:label="loc_txmdDescriptionOfLockInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDescriptionOfLockInPeriod_80" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdvertisingExpense_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000036 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000037 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - FIXED ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_txmdDecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000040 - Disclosure - PREPAID EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_150" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_150" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_150" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000044 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="loc_txmdIssuanceOfPromissoryNotesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdIssuanceOfPromissoryNotesMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes1Member" xlink:label="loc_txmdFebruary2012Notes1Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes1Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes2Member" xlink:label="loc_txmdFebruary2012Notes2Member_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes2Member_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes1Member" xlink:label="loc_txmdJune2012Notes1Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes1Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes2Member" xlink:label="loc_txmdJune2012Notes2Member_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes2Member_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesMember" xlink:label="loc_txmdJune2012NotesMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012NotesMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_440" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_440" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDescription_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDescription_440" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_440" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_440" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAmountOutstanding" xlink:label="loc_us-gaapLineOfCreditFacilityAmountOutstanding_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityAmountOutstanding_440" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_440" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_440" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCredit_440" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_440" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_440" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1_440" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense_440" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_440" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_440" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_440" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_440" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_440" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_440" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_440" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_440" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_440" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="loc_txmdRemainingSurrenderValueOfNotes_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRemainingSurrenderValueOfNotes_440" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_440" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_440" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid_440" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="loc_txmdNotesIssuedInAugustAndSeptember2012Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInAugustAndSeptember2012Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="loc_txmdNotesIssuedInSeptember2012Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInSeptember2012Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotesMember" xlink:label="loc_txmdJuly2011SecuredNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="loc_txmdJuly2011SecuredNotes1Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes1Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="loc_txmdJuly2011SecuredNotes2Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes2Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="loc_txmdNotesIssuedToVariousPartiesMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToVariousPartiesMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount_260" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementAxis" xlink:label="loc_txmdPrivatePlacementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_txmdPrivatePlacementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdPrivatePlacementDomain" xlink:to="loc_us-gaapPrivatePlacementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSharePrice1_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodValueNewIssues1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodValueNewIssues1_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments_240" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_240" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementFees" xlink:label="loc_txmdPrivatePlacementFees_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPrivatePlacementFees_240" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_240" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash_240" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_240" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaapWeightedAverageMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapWeightedAverageMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ModificationWarrantsMember" xlink:label="loc_txmdModificationWarrantsMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdModificationWarrantsMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="loc_txmdJune2012NotesWarrantsMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrantsMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="loc_txmdJune2012NotesWarrants1Member_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants1Member_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="loc_txmdJune2012NotesWarrants2Member_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants2Member_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:label="loc_txmdWarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_380" xlink:type="arc" order="381" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToOfficersMember" xlink:label="loc_txmdWarrantsIssuedToOfficersMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToOfficersMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:label="loc_txmdWarrantsIssuedToUnrelatedEntityForConsultingServicesMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnrelatedEntityForConsultingServicesMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VestedNonForfeitableVitaMedWarrantsMember" xlink:label="loc_txmdVestedNonForfeitableVitaMedWarrantsMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdVestedNonForfeitableVitaMedWarrantsMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember_610" xlink:type="arc" order="612" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember_620" xlink:type="arc" order="622" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember_630" xlink:type="arc" order="632" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_700" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_700" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_700" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_700" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdUnamortizedCostsOfWarrants_700" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_700" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_700" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_700" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights_700" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_700" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_700" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_700" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_700" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_700" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet_700" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_700" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_700" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized_700" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapPrepaidExpenseCurrent_700" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent_700" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_700" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod_700" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts_700" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_700" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="loc_txmdNumbersOfUnaffiliatedIndividuals_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdNumbersOfUnaffiliatedIndividuals_700" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapProfessionalFees_700" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_700" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementCoverPeriod" xlink:label="loc_txmdAgreementCoverPeriod_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdAgreementCoverPeriod_700" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FinancingExpense" xlink:label="loc_txmdFinancingExpense_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdFinancingExpense_700" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="loc_txmdAmortizationResearchAndDevelopmentExpense_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdAmortizationResearchAndDevelopmentExpense_700" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_700" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_700" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_700" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_700" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_700" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_700" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_us-gaapLineOfCredit_700" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="loc_txmdWarrantsIssuedDuringPeriodShares_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdWarrantsIssuedDuringPeriodShares_700" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfWarrantsVested" xlink:label="loc_txmdNumberOfWarrantsVested_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdNumberOfWarrantsVested_700" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_700" xlink:to="loc_txmdLoanGuarantyCosts_700" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_140" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="loc_txmdWarrantsActivityAndRelatedInformationAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsActivityAndRelatedInformationAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLife" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLife_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_40" xlink:type="arc" order="32" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="loc_txmdActivityUnderLtipAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdActivityUnderLtipAbstract_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdNumberOptionsAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_40" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_40" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000056 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000057 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000058 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="loc_txmdNotesIssuedToPartiesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToPartiesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="loc_txmdNonAffiliatedThirdPartyMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdNonAffiliatedThirdPartyMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRestructuringPlanAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementAndPlanMergerVitaMedMember" xlink:label="loc_txmdAgreementAndPlanMergerVitaMedMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringPlanDomain" xlink:to="loc_txmdAgreementAndPlanMergerVitaMedMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCredit_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPaid_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionOfLockInPeriod" xlink:label="loc_txmdDescriptionOfLockInPeriod_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDescriptionOfLockInPeriod_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="loc_us-gaapDueFromOfficersOrStockholders_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOfficersOrStockholders_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LegalFeeReimbursement" xlink:label="loc_txmdLegalFeeReimbursement_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdLegalFeeReimbursement_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000059 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="loc_txmdDeferredRevenueConcentrationRiskMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdDeferredRevenueConcentrationRiskMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_20" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>txmd-20131231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_JefferiesLLCMember" xlink:label="txmd_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC (Underwriters)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="txmd_StifelNicolausAndCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelNicolausAndCompanyMember_lbl" xml:lang="en-US">Stifel, Nicolaus &amp; Company (Underwriters)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="txmd_February2012NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012NotesMember" xlink:to="txmd_February2012NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012NotesMember_lbl" xml:lang="en-US">February 2012 Notes/ Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementAxis" xlink:label="txmd_PrivatePlacementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrivatePlacementAxis_lbl" xml:lang="en-US">Private Placement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="txmd_VitaMedPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaMedPromissoryNotesMember" xlink:to="txmd_VitaMedPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VitaMedPromissoryNotesMember_lbl" xml:lang="en-US">VitaMed Promissory Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_lbl" xml:lang="en-US">Stock Purchase Agreement With Pernix Therapeutics LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">Sancilio &amp; Company Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="txmd_SancilioAndCompanyWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants1Member_lbl" xml:lang="en-US">Sancilio &amp; Company Warrants 1st Installments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="txmd_SancilioAndCompanyWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants2Member_lbl" xml:lang="en-US">Sancilio &amp; Company Warrants 2nd Installments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="txmd_SancilioAndCompanyWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrants3Member_lbl" xml:lang="en-US">Sancilio &amp; Company Warrants 3rd Installments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ModificationWarrantsMember" xlink:label="txmd_ModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ModificationWarrantsMember" xlink:to="txmd_ModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ModificationWarrantsMember_lbl" xml:lang="en-US">Modification Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Individuals</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="txmd_June2012NotesWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrantsMember" xlink:to="txmd_June2012NotesWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrantsMember_lbl" xml:lang="en-US">June 2012 Notes/Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="txmd_June2012NotesWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants1Member" xlink:to="txmd_June2012NotesWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrants1Member_lbl" xml:lang="en-US">June 2012 Notes/Warrants 1st Issue</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="txmd_June2012NotesWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants2Member" xlink:to="txmd_June2012NotesWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesWarrants2Member_lbl" xml:lang="en-US">June 2012 Notes/Warrants 2nd Issue</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_lbl" xml:lang="en-US">Warrants Issued to Unaffiliated Individuals</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:label="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:to="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_lbl" xml:lang="en-US">Warrants Issued to Unrelated Individual for Consulting Services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToOfficersMember" xlink:label="txmd_WarrantsIssuedToOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToOfficersMember" xlink:to="txmd_WarrantsIssuedToOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToOfficersMember_lbl" xml:lang="en-US">Warrants Issued Officers</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:label="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:to="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember_lbl" xml:lang="en-US">Warrants Issued to Unrelated Entity for Consulting Services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VestedNonForfeitableVitaMedWarrantsMember" xlink:label="txmd_VestedNonForfeitableVitaMedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VestedNonForfeitableVitaMedWarrantsMember" xlink:to="txmd_VestedNonForfeitableVitaMedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_VestedNonForfeitableVitaMedWarrantsMember_lbl" xml:lang="en-US">Vested non forfeitable VitaMed Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="txmd_MrFinizioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrFinizioMember" xlink:to="txmd_MrFinizioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MrFinizioMember_lbl" xml:lang="en-US">Mr. Finizio</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="txmd_MrMilliganMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrMilliganMember" xlink:to="txmd_MrMilliganMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MrMilliganMember_lbl" xml:lang="en-US">Mr. Milligan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="txmd_ReichFamilyLimitedLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReichFamilyLimitedLPMember" xlink:to="txmd_ReichFamilyLimitedLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReichFamilyLimitedLPMember_lbl" xml:lang="en-US">Reich Family Limited LP</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock unit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="txmd_IssuanceOfPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IssuanceOfPromissoryNotesMember" xlink:to="txmd_IssuanceOfPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IssuanceOfPromissoryNotesMember_lbl" xml:lang="en-US">Issuance of 6% Promissory Notes (January and February 2012)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes1Member" xlink:label="txmd_February2012Notes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes1Member" xlink:to="txmd_February2012Notes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012Notes1Member_lbl" xml:lang="en-US">February 2012 Notes Issued To Individual And Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes2Member" xlink:label="txmd_February2012Notes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes2Member" xlink:to="txmd_February2012Notes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_February2012Notes2Member_lbl" xml:lang="en-US">February 2012 Notes Issued To Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes1Member" xlink:label="txmd_June2012Notes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes1Member" xlink:to="txmd_June2012Notes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012Notes1Member_lbl" xml:lang="en-US">June 2012 Notes Issued To Individual And Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes2Member" xlink:label="txmd_June2012Notes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes2Member" xlink:to="txmd_June2012Notes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012Notes2Member_lbl" xml:lang="en-US">June 2012 Notes Issued To Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesMember" xlink:label="txmd_June2012NotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesMember" xlink:to="txmd_June2012NotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_June2012NotesMember_lbl" xml:lang="en-US">June 2012 Notes (secured promissory notes)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:to="txmd_NotesIssuedInAugustAndSeptember2012Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member_lbl" xml:lang="en-US">6% Notes issued in August and September 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="txmd_NotesIssuedInSeptember2012Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInSeptember2012Member" xlink:to="txmd_NotesIssuedInSeptember2012Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedInSeptember2012Member_lbl" xml:lang="en-US">6% Notes issued in September 2012</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotesMember" xlink:label="txmd_July2011SecuredNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotesMember" xlink:to="txmd_July2011SecuredNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotesMember_lbl" xml:lang="en-US">VitaMed July 2011 Secured Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="txmd_July2011SecuredNotes1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes1Member" xlink:to="txmd_July2011SecuredNotes1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotes1Member_lbl" xml:lang="en-US">VitaMed July 2011 First Secured Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="txmd_July2011SecuredNotes2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes2Member" xlink:to="txmd_July2011SecuredNotes2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_July2011SecuredNotes2Member_lbl" xml:lang="en-US">VitaMed July 2011 Second Secured Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Brian Bernick</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">VitaMed Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="txmd_NotesIssuedToVariousPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToVariousPartiesMember" xlink:to="txmd_NotesIssuedToVariousPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToVariousPartiesMember_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio And Mr. Milligan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="txmd_NotesIssuedToParty1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty1Member" xlink:to="txmd_NotesIssuedToParty1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToParty1Member_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="txmd_NotesIssuedToParty2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty2Member" xlink:to="txmd_NotesIssuedToParty2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToParty2Member_lbl" xml:lang="en-US">Notes Issued to Mr. Milligan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementAndPlanMergerVitaMedMember" xlink:label="txmd_AgreementAndPlanMergerVitaMedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementAndPlanMergerVitaMedMember" xlink:to="txmd_AgreementAndPlanMergerVitaMedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AgreementAndPlanMergerVitaMedMember_lbl" xml:lang="en-US">Agreement and Plan of Merger with VitaMed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="us-gaap_RestructuringPlanAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringPlanAxis" xlink:to="us-gaap_RestructuringPlanAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringPlanAxis_lbl" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Revenue - Prescription dietary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Net Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="txmd_DeferredRevenueConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="txmd_NotesIssuedToPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToPartiesMember" xlink:to="txmd_NotesIssuedToPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_NotesIssuedToPartiesMember_lbl" xml:lang="en-US">Notes Issued to Mr. Finizio And Mr. Milligan</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="txmd_NonAffiliatedThirdPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAffiliatedThirdPartyMember" xlink:to="txmd_NonAffiliatedThirdPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonAffiliatedThirdPartyMember_lbl" xml:lang="en-US">Non-affiliated third party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">OPERA&#174; software patent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development costs for corporate website</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone therapy drug candidate patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple trademarks for vitamins/supplements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $26,555 and $42,048, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, net of debt discount of $0 and $1,102,680, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 250,000,000 shares authorized; 144,976,757 and 99,784,982 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income and (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="us-gaap_DebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCosts" xlink:to="us-gaap_DebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtIssuanceCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="txmd_LoanGuarantyCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_LoanGuarantyCosts_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_lbl" xml:lang="en-US">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_lbl" xml:lang="en-US">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in private placement, net of cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Shares issued in exchange for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Shares issued in exchange for debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Options issued as compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:label="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:to="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties_lbl" xml:lang="en-US">Warrants issued for loan guaranty costs-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Employee Share Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="txmd_WarrantsIssuedForFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancingCosts" xlink:to="txmd_WarrantsIssuedForFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForFinancingCosts_lbl" xml:lang="en-US">Warrants issued for financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:to="txmd_WarrantsIssuedAsFinancingCostRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties_lbl" xml:lang="en-US">Warrants issued as financing costs-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:to="txmd_WarrantsIssuedAsCompensationRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty_lbl" xml:lang="en-US">Warrants issued as compensation-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Cancellation of warrants issued for loan guaranty costs-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount_lbl" xml:lang="en-US">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_2_lbl" xml:lang="en-US">Beneficial conversion feature</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock based expense for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LoanGuarantyCosts_2_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs, net of abandoned costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="us-gaap_PaymentsForDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDeposits" xlink:to="us-gaap_PaymentsForDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForDeposits_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from notes and loans payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from sale of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from notes and loans payable-related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of membership units, net of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of notes payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="txmd_WarrantsIssuedForFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForFinancing_lbl" xml:lang="en-US">Warrants issued for financing</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForServices" xlink:label="txmd_WarrantsIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantsIssuedForServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:to="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_lbl" xml:lang="en-US">Warrants exercised in exchange for debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtConversionConvertedInstrumentNonCash" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtConversionConvertedInstrumentNonCash" xlink:to="txmd_DebtConversionConvertedInstrumentNonCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash_lbl" xml:lang="en-US">Shares issued in exchange for debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes payable issued for accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_InventoryAbstract" xlink:label="txmd_InventoryAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_InventoryAbstract" xlink:to="txmd_InventoryAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_InventoryAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsAbstract_2_lbl" xml:lang="en-US">Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense, Current [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued and Newly Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:to="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsAndContingenciesTablesAbstract" xlink:to="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of quarterly unaudited summary information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PercentageDecreaseInHoldingDueToMerger" xlink:label="txmd_PercentageDecreaseInHoldingDueToMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PercentageDecreaseInHoldingDueToMerger" xlink:to="txmd_PercentageDecreaseInHoldingDueToMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PercentageDecreaseInHoldingDueToMerger_lbl" xml:lang="en-US">Percentage decrease in holding due to merger</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Percentage of holding acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Shares issued in exchange for outstanding membership units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares reserved for future isssuance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionOfLockInPeriod" xlink:label="txmd_DescriptionOfLockInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionOfLockInPeriod" xlink:to="txmd_DescriptionOfLockInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DescriptionOfLockInPeriod_lbl" xml:lang="en-US">Description of lock in period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_lbl" xml:lang="en-US">Advance payments for future research and development activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished Product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw Material</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid R&amp;D costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Other receivables-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidGuarantyCostsCurrent" xlink:label="txmd_PrepaidGuarantyCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidGuarantyCostsCurrent" xlink:to="txmd_PrepaidGuarantyCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidGuarantyCostsCurrent_lbl" xml:lang="en-US">Prepaid guaranty costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Decrease accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Fixed Assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsAbstract_3_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xml:lang="en-US">Prepaid R&amp;D costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidAccreditedCostsNoncurrent" xlink:to="txmd_PrepaidAccreditedCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent_lbl" xml:lang="en-US">Accreted prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_2_lbl" xml:lang="en-US">TOTAL PREPAID EXPENSE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Weighted Average Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2014</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends Payable, amount per share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_UnclaimedDividends" xlink:label="txmd_UnclaimedDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnclaimedDividends" xlink:to="txmd_UnclaimedDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnclaimedDividends_lbl" xml:lang="en-US">Unclaimed dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="txmd_AccruedFinancingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedFinancingCostsCurrent" xlink:to="txmd_AccruedFinancingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedFinancingCostsCurrent_lbl" xml:lang="en-US">Accrued financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedLabResearchCurrent" xlink:label="txmd_AccruedLabResearchCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedLabResearchCurrent" xlink:to="txmd_AccruedLabResearchCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedLabResearchCurrent_lbl" xml:lang="en-US">Accrued lab research</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Stated interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xml:lang="en-US">Description of interest payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAmountOutstanding" xlink:label="us-gaap_LineOfCreditFacilityAmountOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityAmountOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAmountOutstanding_lbl" xml:lang="en-US">Revolving credit outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per unit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of lines of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_2_lbl" xml:lang="en-US">Proceeds from lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="us-gaap_LineOfCreditFacilityDecreaseForgiveness1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:to="us-gaap_LineOfCreditFacilityDecreaseForgiveness1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityDecreaseForgiveness1_lbl" xml:lang="en-US">Line of credit facility decrease forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Acrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Fair value of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Recognized loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Aggregate principal and accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Amount of shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="txmd_RemainingSurrenderValueOfNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingSurrenderValueOfNotes" xlink:to="txmd_RemainingSurrenderValueOfNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RemainingSurrenderValueOfNotes_lbl" xml:lang="en-US">Remaining balance of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Description of interest rate terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_2_lbl" xml:lang="en-US">Acrued interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US">Numbers of shares converted for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_3_lbl" xml:lang="en-US">Value of debt converted to shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Numbers of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="txmd_DebtInstrumentRemainingFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtInstrumentRemainingFaceAmount" xlink:to="txmd_DebtInstrumentRemainingFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtInstrumentRemainingFaceAmount_lbl" xml:lang="en-US">Aggregate remaining principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrivatePlacementAxis_2_lbl" xml:lang="en-US">PrivatePlacementAxis [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SharePrice1" xlink:label="txmd_SharePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharePrice1" xlink:to="txmd_SharePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharePrice1_lbl" xml:lang="en-US">Share price to underwritters (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period,value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Additional period for purchase share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xml:lang="en-US">Total Additional common stock issued under shelf registration statement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under shelf registration statement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under shelf registration statement,value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_lbl" xml:lang="en-US">Numbers of options to purchase shares of common stock exercised for cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Options to purchase shares of common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_lbl" xml:lang="en-US">Numbers of options to purchase shares of common stock, cashless exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Number of shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementFees" xlink:label="txmd_PrivatePlacementFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementFees" xlink:to="txmd_PrivatePlacementFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrivatePlacementFees_lbl" xml:lang="en-US">Transaction cash fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees and expenses paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForCash_lbl" xml:lang="en-US">Aggregate purchase price of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="txmd_UnamortizedCostsOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnamortizedCostsOfWarrants_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares purchased forfeit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_lbl" xml:lang="en-US">Valuation method of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_lbl" xml:lang="en-US">Non-cash compensation recongised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expense-short term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expense-long term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:to="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_lbl" xml:lang="en-US">Fair value of warrants by relative fair value calculation method</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:to="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Remaining amortization deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumbersOfUnaffiliatedIndividuals" xlink:to="txmd_NumbersOfUnaffiliatedIndividuals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals_lbl" xml:lang="en-US">Number of unaffiliated individuals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:to="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_lbl" xml:lang="en-US">Description of vesting period of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementCoverPeriod" xlink:label="txmd_AgreementCoverPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementCoverPeriod" xlink:to="txmd_AgreementCoverPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AgreementCoverPeriod_lbl" xml:lang="en-US">Agreement covering period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FinancingExpense" xlink:label="txmd_FinancingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingExpense" xlink:to="txmd_FinancingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingExpense_lbl" xml:lang="en-US">Financing expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationResearchAndDevelopmentExpense" xlink:to="txmd_AmortizationResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Amortization research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Minimum volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Maximum volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Minimum risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Maximum risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="txmd_WarrantsIssuedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedDuringPeriodShares" xlink:to="txmd_WarrantsIssuedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedDuringPeriodShares_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfWarrantsVested" xlink:label="txmd_NumberOfWarrantsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfWarrantsVested" xlink:to="txmd_NumberOfWarrantsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfWarrantsVested_lbl" xml:lang="en-US">Number of warrants vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Numbers of options oustanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Number of shares purchased</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_lbl" xml:lang="en-US">Vesting date</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_lbl" xml:lang="en-US">Fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="txmd_WarrantsActivityAndRelatedInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:to="txmd_WarrantsActivityAndRelatedInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsActivityAndRelatedInformationAbstract_lbl" xml:lang="en-US">Warrant activity and related information</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesUnderWarrantAbstract" xlink:to="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xml:lang="en-US">Number of shares under warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_4_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLife" xlink:label="txmd_ClassOfWarrantOrRighstContractualLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLife" xlink:to="txmd_ClassOfWarrantOrRighstContractualLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLife_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLife" xlink:to="txmd_ClassOfWarrantOrRighstContractualLife_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLife_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="txmd_ActivityUnderLtipAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ActivityUnderLtipAbstract" xlink:to="txmd_ActivityUnderLtipAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ActivityUnderLtipAbstract_lbl" xml:lang="en-US">Activity under the LTIP</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOptionsAbstract" xlink:label="txmd_NumberOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOptionsAbstract" xlink:to="txmd_NumberOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOptionsAbstract_lbl" xml:lang="en-US">Number Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (Benefit) for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Transaction amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="us-gaap_DueFromOfficersOrStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOfficersOrStockholders" xlink:to="us-gaap_DueFromOfficersOrStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOfficersOrStockholders_lbl" xml:lang="en-US">Receivables outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LegalFeeReimbursement" xlink:label="txmd_LegalFeeReimbursement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalFeeReimbursement" xlink:to="txmd_LegalFeeReimbursement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LegalFeeReimbursement_lbl" xml:lang="en-US">Legal fee reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MonthlyBaseRentOfLeases" xlink:label="txmd_MonthlyBaseRentOfLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MonthlyBaseRentOfLeases" xlink:to="txmd_MonthlyBaseRentOfLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MonthlyBaseRentOfLeases_lbl" xml:lang="en-US">Monthly Base rent of leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="us-gaap_RentalIncomeNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalIncomeNonoperating_lbl" xml:lang="en-US">Rental Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2014</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2018</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:label="txmd_OperatingLeasesFutureMinimumSubleaseRentals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:to="txmd_OperatingLeasesFutureMinimumSubleaseRentals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_OperatingLeasesFutureMinimumSubleaseRentals_lbl" xml:lang="en-US">Noncancelable sub-lease income</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:label="txmd_OperatingLeasesNetFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:to="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Net minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Exercise period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_lbl" xml:lang="en-US">Date awards vest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLife" xlink:to="txmd_ClassOfWarrantOrRighstContractualLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLife_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants exercised in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants expired in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants cancelled or forfeited in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_doc" xml:lang="en-US">The exercise price of each class of warrants exercised in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_doc" xml:lang="en-US">The exercise price of each class of warrants expired in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_doc" xml:lang="en-US">The exercise price of each class of warrants cancelled or forfeited in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_doc" xml:lang="en-US">The exercise price of each class of warrants granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_doc" xml:lang="en-US">The exercise price of each class of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LoanGuarantyCosts" xlink:to="txmd_LoanGuarantyCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LoanGuarantyCosts_doc" xml:lang="en-US">The expense incurred for loan guaranty costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MonthlyBaseRentOfLeases" xlink:to="txmd_MonthlyBaseRentOfLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MonthlyBaseRentOfLeases_doc" xml:lang="en-US">Base monthly rent of operating leases, as stipulated in leasing agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidGuarantyCostsCurrent" xlink:to="txmd_PrepaidGuarantyCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidGuarantyCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of the unamortized carrying amount of the contractual right to remit fees, as compensation in exchange for having a guarantee provided, which will be charged against earnings over the life of the guarantee. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards granted in the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForFinancing_doc" xml:lang="en-US">Warrants issued in the period for financing in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForServices_doc" xml:lang="en-US">Warrants issued in the period for services in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants granted during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidAccreditedCostsNoncurrent" xlink:to="txmd_PrepaidAccreditedCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidAccreditedCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of accredited contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_doc" xml:lang="en-US">The value of the effect of merger and recapitalization pursuant to the execution of a security exchange agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares_doc" xml:lang="en-US">Number of shares issued during the period as a result of the merger and recapitalization pursuant to secuirty exchnage agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:to="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancingCosts" xlink:to="txmd_WarrantsIssuedForFinancingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForFinancingCosts_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:to="txmd_WarrantsIssuedAsFinancingCostRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedAsFinancingCostRelatedParties_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:to="txmd_WarrantsIssuedAsCompensationRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedAsCompensationRelatedParty_doc" xml:lang="en-US">Increase in additional paid in capital due to warrants issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices_doc" xml:lang="en-US">Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:to="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest_doc" xml:lang="en-US">Refers to amount of warrants ecercised in exchange for debt and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount_doc" xml:lang="en-US">Refers to amount of effect of merger and recapitalization pursuant to execution of security exchange agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:to="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock_doc" xml:lang="en-US">Disclosure of schedule of weighted average fair value per share and valuation assumptions of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnclaimedDividends" xlink:to="txmd_UnclaimedDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnclaimedDividends_doc" xml:lang="en-US">Amount of dividend which have been paid by the entity but not claimed by the shareholder</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedFinancingCostsCurrent" xlink:to="txmd_AccruedFinancingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedFinancingCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for financing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedLabResearchCurrent" xlink:to="txmd_AccruedLabResearchCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedLabResearchCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for lab research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_doc" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xml:lang="en-US">Refers to numbers of share expected to be issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodValueNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodValueNewIssues1_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelNicolausAndCompanyMember_doc" xml:lang="en-US">Stifel Nicolaus And company Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1_doc" xml:lang="en-US">Number of shares issued during the period as a result of an cashless exercise feature.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementFees" xlink:to="txmd_PrivatePlacementFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrivatePlacementFees_doc" xml:lang="en-US">Refers to fees and expense regarding private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012NotesMember" xlink:to="txmd_February2012NotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012NotesMember_doc" xml:lang="en-US">February 2012 Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrivatePlacementAxis" xlink:to="txmd_PrivatePlacementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrivatePlacementAxis_doc" xml:lang="en-US">A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VitaMedPromissoryNotesMember" xlink:to="txmd_VitaMedPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VitaMedPromissoryNotesMember_doc" xml:lang="en-US">VitaMed Promissory Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:to="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember_doc" xml:lang="en-US">Stock Purchase Agreement With Pernix Therapeutics LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnamortizedCostsOfWarrants" xlink:to="txmd_UnamortizedCostsOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnamortizedCostsOfWarrants_doc" xml:lang="en-US">Refers to unamortized costs associated with warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights_doc" xml:lang="en-US">Refers to fair value of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:to="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpenseRecognized_doc" xml:lang="en-US">Refers to non cash compensation expenses of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xml:lang="en-US">Multiple Advance Revolving Credit Note Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants1Member" xlink:to="txmd_SancilioAndCompanyWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants1Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants2Member" xlink:to="txmd_SancilioAndCompanyWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants2Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrants3Member" xlink:to="txmd_SancilioAndCompanyWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrants3Member_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:to="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RemainingAmortizationOfFinancingCostsAndDiscounts_doc" xml:lang="en-US">Refers to remaining amortization deferred financing costs during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumbersOfUnaffiliatedIndividuals" xlink:to="txmd_NumbersOfUnaffiliatedIndividuals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumbersOfUnaffiliatedIndividuals_doc" xml:lang="en-US">Refers to numbers of entities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ModificationWarrantsMember" xlink:to="txmd_ModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ModificationWarrantsMember_doc" xml:lang="en-US">Modification Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividualsMember_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Individuals Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:to="txmd_WarrantsIssuedToUnaffiliatedEntityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedEntityMember_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Entity Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrantsMember" xlink:to="txmd_June2012NotesWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrantsMember_doc" xml:lang="en-US">June 2012 Notes Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants1Member" xlink:to="txmd_June2012NotesWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrants1Member_doc" xml:lang="en-US">June 2012 Notes Warrants 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesWarrants2Member" xlink:to="txmd_June2012NotesWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesWarrants2Member_doc" xml:lang="en-US">June 2012 Notes Warrants 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_doc" xml:lang="en-US">Warrants Issued To Unaffiliated Individuals 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:to="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights_doc" xml:lang="en-US">Refers to description of warrants and rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementCoverPeriod" xlink:to="txmd_AgreementCoverPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AgreementCoverPeriod_doc" xml:lang="en-US">This item provides the agreement covering period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingExpense" xlink:to="txmd_FinancingExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingExpense_doc" xml:lang="en-US">Refers to financing expense related to debt during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AmortizationResearchAndDevelopmentExpense" xlink:to="txmd_AmortizationResearchAndDevelopmentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AmortizationResearchAndDevelopmentExpense_doc" xml:lang="en-US">Refers to amortization research and development expenseduring the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedDuringPeriodShares" xlink:to="txmd_WarrantsIssuedDuringPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedDuringPeriodShares_doc" xml:lang="en-US">Numbers of shares warrants for common stock issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfWarrantsVested" xlink:to="txmd_NumberOfWarrantsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfWarrantsVested_doc" xml:lang="en-US">Refers to numbers of warrants vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:to="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember_doc" xml:lang="en-US">Warrants Issued To Unrelated Individual For Consulting Services Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToOfficersMember" xlink:to="txmd_WarrantsIssuedToOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToOfficersMember_doc" xml:lang="en-US">Warrants Issued To Officers Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:to="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember_doc" xml:lang="en-US">Warrants Issued To Unrelated Entity For Consulting Services Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_VestedNonForfeitableVitaMedWarrantsMember" xlink:to="txmd_VestedNonForfeitableVitaMedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_VestedNonForfeitableVitaMedWarrantsMember_doc" xml:lang="en-US">Vested Non Forfeitable VitaMed Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrFinizioMember" xlink:to="txmd_MrFinizioMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MrFinizioMember_doc" xml:lang="en-US">MrFinizio Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MrMilliganMember" xlink:to="txmd_MrMilliganMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MrMilliganMember_doc" xml:lang="en-US">MrMilligan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReichFamilyLimitedLPMember" xlink:to="txmd_ReichFamilyLimitedLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReichFamilyLimitedLPMember_doc" xml:lang="en-US">ReichFamily Limited LP Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate_doc" xml:lang="en-US">Date which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue_doc" xml:lang="en-US">Refers to fair value of awards on equity-based plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:to="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod_doc" xml:lang="en-US">Refers to fair value of awards by a calculation method.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IssuanceOfPromissoryNotesMember" xlink:to="txmd_IssuanceOfPromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IssuanceOfPromissoryNotesMember_doc" xml:lang="en-US">Issuance Of Promissory Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RemainingSurrenderValueOfNotes" xlink:to="txmd_RemainingSurrenderValueOfNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RemainingSurrenderValueOfNotes_doc" xml:lang="en-US">Refers to amount of remaining surrender value of notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes1Member" xlink:to="txmd_February2012Notes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012Notes1Member_doc" xml:lang="en-US">Refers to amount of remaining surrender value of notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_February2012Notes2Member" xlink:to="txmd_February2012Notes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_February2012Notes2Member_doc" xml:lang="en-US">February 2012 Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes1Member" xlink:to="txmd_June2012Notes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012Notes1Member_doc" xml:lang="en-US">June 2012 Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012Notes2Member" xlink:to="txmd_June2012Notes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012Notes2Member_doc" xml:lang="en-US">June 2012 Notes 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_June2012NotesMember" xlink:to="txmd_June2012NotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_June2012NotesMember_doc" xml:lang="en-US">June 2012 Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:to="txmd_NotesIssuedInAugustAndSeptember2012Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedInAugustAndSeptember2012Member_doc" xml:lang="en-US">Notes Issued In August And September 2012 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedInSeptember2012Member" xlink:to="txmd_NotesIssuedInSeptember2012Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedInSeptember2012Member_doc" xml:lang="en-US">Notes Issued In September 2012 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotesMember" xlink:to="txmd_July2011SecuredNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotesMember_doc" xml:lang="en-US">July 2011 Secured Notes Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes1Member" xlink:to="txmd_July2011SecuredNotes1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotes1Member_doc" xml:lang="en-US">July 2011 Secured Notes 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_July2011SecuredNotes2Member" xlink:to="txmd_July2011SecuredNotes2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_July2011SecuredNotes2Member_doc" xml:lang="en-US">July 2011 Secured Notes 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtInstrumentRemainingFaceAmount" xlink:to="txmd_DebtInstrumentRemainingFaceAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtInstrumentRemainingFaceAmount_doc" xml:lang="en-US">Refers to balance amount of debt instrument at time of issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToVariousPartiesMember" xlink:to="txmd_NotesIssuedToVariousPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToVariousPartiesMember_doc" xml:lang="en-US">Notes Issued to Various Parties Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty1Member" xlink:to="txmd_NotesIssuedToParty1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToParty1Member_doc" xml:lang="en-US">Notes Issued To Party 1 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToParty2Member" xlink:to="txmd_NotesIssuedToParty2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToParty2Member_doc" xml:lang="en-US">Notes Issued To Party 2 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PercentageDecreaseInHoldingDueToMerger" xlink:to="txmd_PercentageDecreaseInHoldingDueToMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PercentageDecreaseInHoldingDueToMerger_doc" xml:lang="en-US">Refers to percentage decrease in holding due to merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DescriptionOfLockInPeriod" xlink:to="txmd_DescriptionOfLockInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DescriptionOfLockInPeriod_doc" xml:lang="en-US">Refers to description of lock in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AgreementAndPlanMergerVitaMedMember" xlink:to="txmd_AgreementAndPlanMergerVitaMedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AgreementAndPlanMergerVitaMedMember_doc" xml:lang="en-US">Agreement And Plan Merger VitaMed Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_doc" xml:lang="en-US">Deferred Revenue Concentration Risk Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:to="txmd_OperatingLeasesFutureMinimumSubleaseRentals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLeasesFutureMinimumSubleaseRentals_doc" xml:lang="en-US">Amount of required minimum rental payments for sub leases having an initial or remaining non-cancelable letter-terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:to="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_doc" xml:lang="en-US">Net amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToPartiesMember" xlink:to="txmd_NotesIssuedToPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NotesIssuedToPartiesMember_doc" xml:lang="en-US">Notes Issued To Parties Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LegalFeeReimbursement" xlink:to="txmd_LegalFeeReimbursement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LegalFeeReimbursement_doc" xml:lang="en-US">Refers to reimbursment of legal fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonAffiliatedThirdPartyMember" xlink:to="txmd_NonAffiliatedThirdPartyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonAffiliatedThirdPartyMember_doc" xml:lang="en-US">Non Affiliated Third Party Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights_doc" xml:lang="en-US">Refers to valuation method of warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharePrice1" xlink:to="txmd_SharePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharePrice1_doc" xml:lang="en-US">Price of a single share of a number of saleable stocks of a company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_doc" xml:lang="en-US">Decrease amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtConversionConvertedInstrumentNonCash" xlink:to="txmd_DebtConversionConvertedInstrumentNonCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtConversionConvertedInstrumentNonCash_doc" xml:lang="en-US">The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:to="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities_doc" xml:lang="en-US">Carrying amount of advance payments made for future research and development activiites to be expensed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate_doc" xml:lang="en-US">Date the equity-based award vests, in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:to="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period for cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:to="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member_3_lbl" xml:lang="en-US">WarrantsIssuedToUnaffiliatedIndividuals1Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NotesIssuedToPartiesMember" xlink:to="txmd_NotesIssuedToPartiesMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NotesIssuedToPartiesMember_3_lbl" xml:lang="en-US">NotesIssuedToPartiesMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCosts" xlink:to="us-gaap_DebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCosts_2_lbl" xml:lang="en-US">Debt Issuance Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:to="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement_3_lbl" xml:lang="en-US">EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueAdditions_2_lbl" xml:lang="en-US">Deferred Revenue, Additions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForDeposits" xlink:to="us-gaap_PaymentsForDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForDeposits_2_lbl" xml:lang="en-US">Payments for Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForServices_3_lbl" xml:lang="en-US">WarrantsIssuedForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_InventoryAbstract" xlink:to="txmd_InventoryAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_InventoryAbstract_2_lbl" xml:lang="en-US">InventoryAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_2_lbl" xml:lang="en-US">Advertising Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_2_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xml:lang="en-US">PrepaidResearchDevelopmentCostsNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_3_lbl" xml:lang="en-US">IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable_3_lbl" xml:lang="en-US">ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLife" xlink:to="txmd_ClassOfWarrantOrRighstContractualLife_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLife_4_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLife</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeGrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExpirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeForfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeVestedAndExercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:to="txmd_OperatingLeasesFutureMinimumSubleaseRentals_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLeasesFutureMinimumSubleaseRentals_3_lbl" xml:lang="en-US">OperatingLeasesFutureMinimumSubleaseRentals</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:to="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OperatingLeasesNetFutureMinimumPaymentsDue_3_lbl" xml:lang="en-US">OperatingLeasesNetFutureMinimumPaymentsDue</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>txmd-20131231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.0a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20131231\txmd_123113.xfr; Date: 2014%2D03%2D05T19:52:44 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80010000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20131231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20131231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20131231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20131231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20131231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20131231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssets" xlink:href="txmd-20131231.xsd#FixedAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20131231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20131231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20131231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20131231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20131231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20131231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20131231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20131231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20131231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20131231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:href="txmd-20131231.xsd#FixedAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20131231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20131231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20131231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20131231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:href="txmd-20131231.xsd#CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20131231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20131231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20131231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#FixedAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:href="txmd-20131231.xsd#FixedAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20131231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20131231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20131231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:href="txmd-20131231.xsd#NotesPayableDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20131231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20131231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20131231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20131231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20131231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20131231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20131231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:href="txmd-20131231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaapDebtIssuanceCosts" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:label="loc_txmdConsolidatedStatementsOfStockholdersEquityDeficitAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdConsolidatedStatementsOfStockholdersEquityDeficitAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:label="loc_txmdWarrantsIssuedForLoanGuarantyCostsRelatedParties" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForLoanGuarantyCostsRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForFinancingCosts" xlink:label="loc_txmdWarrantsIssuedForFinancingCosts" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedForFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsFinancingCostRelatedParties" xlink:label="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsFinancingCostRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedAsCompensationRelatedParty" xlink:label="loc_txmdWarrantsIssuedAsCompensationRelatedParty" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsIssuedAsCompensationRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:label="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdEffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="loc_us-gaapDeferredRevenueAdditions" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapDeferredRevenueAdditions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForDeposits" xlink:label="loc_us-gaapPaymentsForDeposits" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="loc_txmdWarrantsIssuedForFinancing" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedForServices" xlink:label="loc_txmdWarrantsIssuedForServices" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:label="loc_txmdWarrantsExercisedInExchangeForDebtAndAccruedInterest" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsExercisedInExchangeForDebtAndAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtConversionConvertedInstrumentNonCash" xlink:label="loc_txmdDebtConversionConvertedInstrumentNonCash" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdDebtConversionConvertedInstrumentNonCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaapNotesIssued1" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapNotesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_InventoryAbstract" xlink:label="loc_txmdInventoryAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdInventoryAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssets" xlink:title="00000011 - Disclosure - FIXED ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="loc_txmdPrepaidExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseCurrentAbstract" xlink:to="loc_txmdPrepaidExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapOtherLiabilitiesCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000024 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsTables" xlink:title="00000026 - Disclosure - FIXED ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000027 - Disclosure - PREPAID EXPENSE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseCurrentAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000028 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaapNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncontrollingInterestAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:label="loc_txmdScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_txmdScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_txmdCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRestructuringPlanAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementAndPlanMergerVitaMedMember" xlink:label="loc_txmdAgreementAndPlanMergerVitaMedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringPlanDomain" xlink:to="loc_txmdAgreementAndPlanMergerVitaMedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PercentageDecreaseInHoldingDueToMerger" xlink:label="loc_txmdPercentageDecreaseInHoldingDueToMerger" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPercentageDecreaseInHoldingDueToMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionOfLockInPeriod" xlink:label="loc_txmdDescriptionOfLockInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDescriptionOfLockInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:label="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_txmdAdvancePaymentsForFutureResearchAndDevelopmentActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000036 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000037 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidGuarantyCostsCurrent" xlink:label="loc_txmdPrepaidGuarantyCostsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidGuarantyCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - FIXED ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_txmdDecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdDecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsDetails" xlink:title="00000039 - Disclosure - FIXED ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000040 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrepaidAccreditedCostsNoncurrent" xlink:label="loc_txmdPrepaidAccreditedCostsNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdPrepaidAccreditedCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative" xlink:title="00000044 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapOtherLiabilitiesCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_UnclaimedDividends" xlink:label="loc_txmdUnclaimedDividends" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdUnclaimedDividends" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapOtherLiabilitiesCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedFinancingCostsCurrent" xlink:label="loc_txmdAccruedFinancingCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdAccruedFinancingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedLabResearchCurrent" xlink:label="loc_txmdAccruedLabResearchCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdAccruedLabResearchCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_IssuanceOfPromissoryNotesMember" xlink:label="loc_txmdIssuanceOfPromissoryNotesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdIssuanceOfPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes1Member" xlink:label="loc_txmdFebruary2012Notes1Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012Notes2Member" xlink:label="loc_txmdFebruary2012Notes2Member" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012Notes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes1Member" xlink:label="loc_txmdJune2012Notes1Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012Notes2Member" xlink:label="loc_txmdJune2012Notes2Member" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012Notes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesMember" xlink:label="loc_txmdJune2012NotesMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJune2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityAmountOutstanding" xlink:label="loc_us-gaapLineOfCreditFacilityAmountOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityAmountOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:label="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityDecreaseForgiveness1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingSurrenderValueOfNotes" xlink:label="loc_txmdRemainingSurrenderValueOfNotes" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRemainingSurrenderValueOfNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1" xlink:title="00000047 - Disclosure - NOTES PAYABLE (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInAugustAndSeptember2012Member" xlink:label="loc_txmdNotesIssuedInAugustAndSeptember2012Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInAugustAndSeptember2012Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedInSeptember2012Member" xlink:label="loc_txmdNotesIssuedInSeptember2012Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedInSeptember2012Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotesMember" xlink:label="loc_txmdJuly2011SecuredNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes1Member" xlink:label="loc_txmdJuly2011SecuredNotes1Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_July2011SecuredNotes2Member" xlink:label="loc_txmdJuly2011SecuredNotes2Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdJuly2011SecuredNotes2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToVariousPartiesMember" xlink:label="loc_txmdNotesIssuedToVariousPartiesMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToVariousPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementAxis" xlink:label="loc_txmdPrivatePlacementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_txmdPrivatePlacementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementDomain" xlink:label="loc_txmdPrivatePlacementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrivatePlacementAxis" xlink:to="loc_txmdPrivatePlacementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrivatePlacementDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SharePrice1" xlink:label="loc_txmdSharePrice1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSharePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_PrivatePlacementFees" xlink:label="loc_txmdPrivatePlacementFees" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdPrivatePlacementFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="loc_us-gaapWeightedAverageMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_February2012NotesMember" xlink:label="loc_txmdFebruary2012NotesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFebruary2012NotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants1Member" xlink:label="loc_txmdSancilioAndCompanyWarrants1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants2Member" xlink:label="loc_txmdSancilioAndCompanyWarrants2Member" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_SancilioAndCompanyWarrants3Member" xlink:label="loc_txmdSancilioAndCompanyWarrants3Member" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrants3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ModificationWarrantsMember" xlink:label="loc_txmdModificationWarrantsMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividualsMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividualsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedEntityMember" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrantsMember" xlink:label="loc_txmdJune2012NotesWarrantsMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants1Member" xlink:label="loc_txmdJune2012NotesWarrants1Member" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_June2012NotesWarrants2Member" xlink:label="loc_txmdJune2012NotesWarrants2Member" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdJune2012NotesWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:label="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnaffiliatedIndividuals1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:label="loc_txmdWarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnrelatedIndividualForConsultingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToOfficersMember" xlink:label="loc_txmdWarrantsIssuedToOfficersMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:label="loc_txmdWarrantsIssuedToUnrelatedEntityForConsultingServicesMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsIssuedToUnrelatedEntityForConsultingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VestedNonForfeitableVitaMedWarrantsMember" xlink:label="loc_txmdVestedNonForfeitableVitaMedWarrantsMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdVestedNonForfeitableVitaMedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_UnamortizedCostsOfWarrants" xlink:label="loc_txmdUnamortizedCostsOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdUnamortizedCostsOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightFairValueOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightValuationMethodOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExpenseRecognized" xlink:label="loc_txmdClassOfWarrantOrRightExpenseRecognized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpenseRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:label="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdFairValueOfWarrantsByRelativeFairValueCalculationMethod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_RemainingAmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdRemainingAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumbersOfUnaffiliatedIndividuals" xlink:label="loc_txmdNumbersOfUnaffiliatedIndividuals" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdNumbersOfUnaffiliatedIndividuals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:label="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdDescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementCoverPeriod" xlink:label="loc_txmdAgreementCoverPeriod" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdAgreementCoverPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_FinancingExpense" xlink:label="loc_txmdFinancingExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdFinancingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AmortizationResearchAndDevelopmentExpense" xlink:label="loc_txmdAmortizationResearchAndDevelopmentExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdAmortizationResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsIssuedDuringPeriodShares" xlink:label="loc_txmdWarrantsIssuedDuringPeriodShares" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsIssuedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfWarrantsVested" xlink:label="loc_txmdNumberOfWarrantsVested" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdNumberOfWarrantsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LoanGuarantyCosts" xlink:label="loc_txmdLoanGuarantyCosts" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdLoanGuarantyCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WarrantsActivityAndRelatedInformationAbstract" xlink:label="loc_txmdWarrantsActivityAndRelatedInformationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsActivityAndRelatedInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLife" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLife" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLife" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLife" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLife_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLife_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ActivityUnderLtipAbstract" xlink:label="loc_txmdActivityUnderLtipAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdActivityUnderLtipAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdNumberOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000056 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="loc_txmdDeferredIncomeTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000057 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000058 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_VitaMedPromissoryNotesMember" xlink:label="loc_txmdVitaMedPromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdVitaMedPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToPartiesMember" xlink:label="loc_txmdNotesIssuedToPartiesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToPartiesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty1Member" xlink:label="loc_txmdNotesIssuedToParty1Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NotesIssuedToParty2Member" xlink:label="loc_txmdNotesIssuedToParty2Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdNotesIssuedToParty2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrFinizioMember" xlink:label="loc_txmdMrFinizioMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrFinizioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MrMilliganMember" xlink:label="loc_txmdMrMilliganMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdMrMilliganMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ReichFamilyLimitedLPMember" xlink:label="loc_txmdReichFamilyLimitedLPMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdReichFamilyLimitedLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_StockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:label="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdStockPurchaseAgreementWithPernixTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_NonAffiliatedThirdPartyMember" xlink:label="loc_txmdNonAffiliatedThirdPartyMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_txmdNonAffiliatedThirdPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaapRestructuringPlanAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRestructuringPlanAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaapRestructuringPlanDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringPlanAxis" xlink:to="loc_us-gaapRestructuringPlanDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_AgreementAndPlanMergerVitaMedMember" xlink:label="loc_txmdAgreementAndPlanMergerVitaMedMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringPlanDomain" xlink:to="loc_txmdAgreementAndPlanMergerVitaMedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DebtInstrumentRemainingFaceAmount" xlink:label="loc_txmdDebtInstrumentRemainingFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDebtInstrumentRemainingFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DescriptionOfLockInPeriod" xlink:label="loc_txmdDescriptionOfLockInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdDescriptionOfLockInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DueFromOfficersOrStockholders" xlink:label="loc_us-gaapDueFromOfficersOrStockholders" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDueFromOfficersOrStockholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_LegalFeeReimbursement" xlink:label="loc_txmdLegalFeeReimbursement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_txmdLegalFeeReimbursement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000059 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="loc_txmdDeferredRevenueConcentrationRiskMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdDeferredRevenueConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_MonthlyBaseRentOfLeases" xlink:label="loc_txmdMonthlyBaseRentOfLeases" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdMonthlyBaseRentOfLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RentalIncomeNonoperating" xlink:label="loc_us-gaapRentalIncomeNonoperating" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRentalIncomeNonoperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesFutureMinimumSubleaseRentals" xlink:label="loc_txmdOperatingLeasesFutureMinimumSubleaseRentals" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_txmdOperatingLeasesFutureMinimumSubleaseRentals" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_OperatingLeasesNetFutureMinimumPaymentsDue" xlink:label="loc_txmdOperatingLeasesNetFutureMinimumPaymentsDue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_txmdOperatingLeasesNetFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000062 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20131231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FIXED ASSETS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump">$ 155,083<span></span></td>
        <td class="nump">$ 126,273<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="num">(93,765)<span></span></td>
        <td class="num">(60,600)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, net</a></td>
        <td class="nump">61,318<span></span></td>
        <td class="nump">65,673<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump">108,458<span></span></td>
        <td class="nump">67,668<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and Fixtures</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="nump">46,625<span></span></td>
        <td class="nump">46,625<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 11,980<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EI5AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
        <td class="nump">13,733,488<span></span></td>
        <td class="nump">10,590,161<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
        <td class="nump">2,583,677<span></span></td>
        <td class="nump">5,121,250<span></span></td>
        <td class="nump">10,682,218<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
        <td class="num">(75,423)<span></span></td>
        <td class="num">(1,931,788)<span></span></td>
        <td class="num">(92,057)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
        <td class="num">(250)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Cancelled</a></td>
        <td class="num">(608,750)<span></span></td>
        <td class="num">(46,135)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
        <td class="nump">15,632,742<span></span></td>
        <td class="nump">13,733,488<span></span></td>
        <td class="nump">10,590,161<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable</a></td>
        <td class="nump">11,282,627<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
        <td class="nump">$ 1.16<span></span></td>
        <td class="nump">$ 0.16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
        <td class="nump">$ 3.31<span></span></td>
        <td class="nump">$ 2.8<span></span></td>
        <td class="nump">$ 0.16<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.13<span></span></td>
        <td class="nump">$ 0.19<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
        <td class="nump">$ 1.44<span></span></td>
        <td class="nump">$ 1.16<span></span></td>
        <td class="nump">$ 0.16<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable</a></td>
        <td class="nump">$ 0.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Options outstanding, beginning</a></td>
        <td class="text">7 years 8 months 12 days<span></span></td>
        <td class="text">7 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1', window );">Granted</a></td>
        <td class="text">9 years 9 months 18 days<span></span></td>
        <td class="text">9 years 8 months 12 days<span></span></td>
        <td class="text">7 years 7 months 6 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Options outstanding, ending</a></td>
        <td class="text">7 years 2 months 12 days<span></span></td>
        <td class="text">7 years 8 months 12 days<span></span></td>
        <td class="text">7 years 7 months 6 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
        <td class="text">6 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
        <td class="nump">$ 26,804,117<span></span></td>
        <td class="nump">$ 14,067,649<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Granted</a></td>
        <td class="nump">$ 4,920,981<span></span></td>
        <td class="nump">$ 1,737,530<span></span></td>
        <td class="nump">$ 14,188,484<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
        <td class="nump">58,878,132<span></span></td>
        <td class="nump">26,804,117<span></span></td>
        <td class="nump">14,067,649<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
        <td class="nump">$ 48,321,930<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AggregateIntrinsicValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOptionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_NumberOptionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards granted in the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerms1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WeightedAverageExercisePriceAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WeightedAverageRemainingContractualLifeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBLCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 28, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 29, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 05, 2011

</div>
          <div>Stock Purchase Agreement With Pernix Therapeutics LLC</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Private placement</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Apr. 20, 2013

</div>
          <div>Jefferies LLC (Underwriters)</div>
        </th>
        <th class="th">
          <div>Mar. 20, 2013

</div>
          <div>Jefferies LLC (Underwriters)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Jefferies LLC (Underwriters)</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Stifel, Nicolaus &amp; Company (Underwriters)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,631,579<span></span></td>
        <td class="nump">3,953,489<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,411,765<span></span></td>
        <td class="nump">13,750,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.70<span></span></td>
        <td class="nump">$ 2.40<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharePrice1', window );">Share price to underwritters (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.58<span></span></td>
        <td class="nump">$ 2.23<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Number of shares issued during the period,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 78,650,353<span></span></td>
        <td class="nump">$ 7,895,485<span></span></td>
        <td class="nump">$ 1,707,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="nump">$ 7,895,485<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 45,400,000<span></span></td>
        <td class="nump">$ 30,200,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Additional period for purchase share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockExpectedToIssuedDuringPeriodShares', window );">Total Additional common stock issued under shelf registration statement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,411,765<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under shelf registration statement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,954,587<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodValueNewIssues1', window );">Additional common stock issued under shelf registration statement,value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2', window );">Numbers of options to purchase shares of common stock exercised for cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,691,393<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options to purchase shares of common stock, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,910<span></span></td>
        <td class="nump">191,000<span></span></td>
        <td class="nump">17,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,250<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1', window );">Numbers of options to purchase shares of common stock, cashless exercise</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">240,395<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Number of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,102,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,102,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Amount of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,145,486<span></span></td>
        <td class="nump">8,145,486<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(6,716,504)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,054,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">849,137<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,775,415<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,415,136<span></span></td>
        <td class="nump">266,822<span></span></td>
        <td class="nump">20,266,822<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrivatePlacementFees', window );">Transaction cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">552,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">52,016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash', window );">Aggregate purchase price of common stock sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,500,001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
        <td class="text">1 for 100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to additonal period for purchase of shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AdditionalPeriodForPurchaseShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrivatePlacementFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fees and expense regarding private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrivatePlacementFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_SharePrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockExpectedToIssuedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to numbers of share expected to be issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_StockExpectedToIssuedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_StockIssuedDuringPeriodSharesNewIssues1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of an cashless exercise feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_StockIssuedDuringPeriodSharesStockOptionsExercised1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period for cash.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_StockIssuedDuringPeriodSharesStockOptionsExercised2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodValueNewIssues1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_StockIssuedDuringPeriodValueNewIssues1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LegalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityReverseStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued as consideration for cash for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`J>8[^.@(``+8E```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VM]NVC`4!O#[27N'R+<3
M,;;CK)N`7NS/Y59IW0-XR8%$)'9DNQV\_9S05E7%J-"0]MT00>QS/ASI=Y.S
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M.21(#@62HP#)H4%RE"`YWH/DN`+)\0$DAYBC!$$15:"0*E!,%2BH"A15!0JK
M`L55@0*K0)%5HL@J4625*+)*%%DEBJP215:)(JM$D56BR"I19%4HLBH4616*
MK`I%5H4BJT*15:'(JE!D52BR*A19"Q19"Q19"Q19"Q19"Q19"Q19"Q19"Q19
M"Q19"Q19-8JL&D56C2*K1I%5H\BJ4635*+)J%%DUBJP:1=821=821=821=;R
M?\D:TU0,\>GSWQ_*5.:5L8P0]QV%"[]*/11]K7-C/-4_HD_S0Q</\+SVJ1QI
MNN;&NR&D.2-/YY_"XR#1N'LVI$+D8TM/HT3'1G*>.J89I?,;OI@)HG$*JJ;Z
M2&\^35VM_@```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?
M<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````",DL].PS`,QN](
MO$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4
M'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBR
MBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'
MJC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB
M8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%
M#U1?````__\#`%!+`P04``8`"````"$`+@T\IX<"``!/)0``&@`(`7AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````O)K-;IM`%(7WE?H.:/8QOO.7I`K.)JJ4;9L^`(*Q
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M#5F.-T@.VSK0.>RR@E4E[$06G,CW9-_H>^0;80-"("`T&Q`:`L*PG6R@E0V[
MR@TL<\L&A(6`L&Q`6`@(QP:$@X!PN3/FTOP.Y8Y?-)5C5T^A_9JF_!P0\WV^
M]<I7PT@-VSG0.)X=R1Y&LK"!)1A8;$(()(1F$T)#0F@V(30DA&$3PD!"&':=
M&UCHEDT("PEAV82PD!!N44+,VR87.LQ#;SLI#O;M?M'<27G'*5RDG`_+\R?,
M8O8*X05B<\K!WX9=3+"6A(T%@5@0-A8$8D&S<UC#'#9TZT#O&':5&UCFEIW#
M%N:P8[>C#K:CFMWA:-CA6'8F6YC);E%HSL"^@',>^L-PV*Q[=BI[G,KY/IA_
M%<&E8E<Y+')A`T(@(#0;$!H"0K,!H2$@#-LZ!GK'L@%A(2`<N_5RL/42-J\$
M\LJP>65@"%HVKRSDE6/SRD%>>;9W//2.7Q02,9T.^661R][Q^1AM&M.]@L2P
M0P]FGK!Y*9"7PN:E8%ZRU\K,BU5>O0:U^0T``/__`P!02P,$%``&``@````A
M`#1"<2K$!```8A(```\```!X;"]W;W)K8F]O:RYX;6R4F%]3VEP0QN\[T^_`
MY/XMD/!''+43X*AGBH&28/7J3`I1,@T)D\2JW_[=@.!SLFE&KW#!\V3WV=]N
M,CG[_K*)&G^#-`N3^-QH?VL9C2!>)JLP?CPW%M[E?R=&(\O]>.5'21R<&Z]!
M9GR_^/KE[#E)__Q.DC\-$HBS<V.=Y]O39C-;KH.-GWU+MD%,OSPDZ<;/*4P?
MF]DV#?Q5M@Z"?!,US5:KU]SX86SL%4[3CV@D#P_A,A@GRZ=-$.=[D32(_)S2
MS];A-C,NSA["*+C=5]3PMUO'WU#>+Y'1B/PL%ZLP#U;G1I?"Y#G0ODB?ML.G
M,*)?!U;+,IH7QR)G:6,5//A/4>Y1>0=U\LOLF&:O^,_"BMLP>,[>#Q5AX^57
M&*^2Y^)?R=K78V11`L^[GWZ%JWQ-O[=:K>-WUT'XN,X/7Y)\$_1W#M)U=I^-
M>%?>P1%%G5(BSL/\5<EX[WZ84`L+UR55UC8:Z6E(?Z1RU2X21Y71U'&G$SFV
M/3%60WMB.R.AW&LA/!<D3)`P/R&A9CZH6*"R\_J?B;@>Y7,C',]5TTLUG0E0
MZ8!*IS877<7UIJ!"OA]-Z7Y"962C+SU0V3&!%7G70HVF-S/;N8<+]S#_?OG*
M[N+FQI[?%U6[\LJ1EW)D.YZR1Z/IPO%0!@LX*<M(YY;,F\ZU"V.R@_*)*64[
M5Z/%?$X'E>VZ.@"]/E3:;I5/7\H[PH>?HDUR=+G-V)O-Q<R68R7N9L)QL<>]
M`1YDQ$G'LYTK.9P(?LT^S=S[-1EF>IT3:0_E1'I28%?[VL0PQIRI)UPUL^]M
M2@!:TL<I:3.HB+_1C^OI9"SFKA(_%]+#[O1Q.-J,)>D024)Y]IV>*<+49C3-
MQ60WUS-[7BX1\6DS?H8+5SK"=8E?V@>.-[<]28L"BT6:V@PGRO9&>OL)MIUQ
MH>-)YTHXHY+5R!6MR])V<L5$C(K-]'-!)8CYY%Y=2H=VE+0G:HSI(&DF(\U=
M#%VRO$!;%).A58*LF8RU^HDD4HY[]@3),QEYQYE4GO\["C(\B<"9##B=V?V4
M58@@?B;##T>TXC#BM[^]X2HK36K%>0319""R@:U00")-1J3N`<SM3@F]1#!-
M!F;%%%;D@E1:C$H<QHK#B*+%4*R=#(6%()<6Y[)V-)#+`7)I,2[A-J7&0>Z'
M4:8</TWI`>MO`/D,$%*+05H_)\3F<4Z*YZ#CAJ:@-//O<_*6#1[%YEIL2^J0
MO`U*A8K67@:K-BEUCEA:IQFR53I8B]9?!FIYY'@9'>PK!<S'TDU2ZRXDTL'&
M4O!1'93`W=-AK/+Q/]B*G'9P!U%0RD-O+FZ`0@R3P5W48:#6ZV@)(:@=!JKV
M'*"96XP.)#30W&'4UNM@0@/-(09NU6X[&.V@0P/-(09NO8Z6D.808[A>"'="
M%UFFH-3[&B'PN4NI'1<+!1\745A4%]M%P2=DM)*P65V&<TU)BDX>MV47>T5!
M*1OM7O3>;+Z^N]@J"CZ@@UG@XNTRA"NST#S%E=MEY)8>5$O#!'D,M#P8N?]X
M;GW3`YTN+E\*2F[4WZ2QL!Z"2\&GA!"7'L)+04FH_DE8$T)\>QS?\J.P9C98
M-,"6]7;\-G=4TGN(I1\MZ05)\5&\8=B5W3R\'KKX'P``__\#`%!+`P04``8`
M"````"$`'J#M=;P%``!`%@``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;)2876^K1A"&[ROU/R#N;=A=6""*<Q1`:8_42E75CVN"L8UBC`7DX_S[SC(8
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MV;>?^@K\T5C;8I>]'KL_Z_=?BW)_Z*#</CA2QNZV/]*BS2&C$&:-,O+Z"`+@
MMU65JC4@(]E'__>]W':'C2WDV@]<P0"WGHNV>RI52-O*7]NNKOY%B"E18Q`^
M!/%`_?`Y7QK$04&]OS3KLH?[IGZWH&G@DNTY4RW([B#PQ1C*&*U^YA34J2"/
M*LK&AFX'$RV4Y^TA".Z=-\AH/B#Q'&&42"Z$\JRBIMH;#L@=-4,B=,W_7X2+
M-`4K:9>H,;X!L4>MW!`R)X2!I',D",<H1*RX1:R"H3<T;4$TANV3$B,"I1KE
M2THD7Q+I-8*(A\LLS[2"-S9D9E06NE1:C(CL.R0,`M^/IJSU]A*=$"$+729H
MC%0GN!N&3&LU(AY6UG+Q"C;$&_T9(Q+TXEGDPX_1XPDAA!>RF7B=B+R`L:FQ
MB'9YBW8%&]JGL-@UB*!V&3+INH:[1">X)Z/(-8J7Z@1C'G.E/Y:&B`]N$:]@
MVO*A4?$8$:C[V%AFRW])I-<((EZ-;.V&>/WFHF`C\]Z8$\P\(I>N<9D7"K-M
M".*Y,@K,ZJ0Z(@%A6N\1^=$M\A5LR)]*BO(1&>0+WV=<&N5)=,3S(BZDT7VI
M3C`WX-[4?$0\@\&\//D];<@W&B,>&-3OA\PS_"44D%R:74\!+]0B4.UJ6BUN
M'(:SC=PLC;:(!P:U"RZYQ[6+X^V2,"R4+!3<J$]*&.G+D&LKC'I08VVY!QR"
MQ(-Q.X\9,NAAQ?W0#;EG+)&$0DS"&O'F+D@DW^,!9]/5J`TUWY;;P&D(O\?;
M2V@.779M8@Z5^!))KT:A#M206^X`1Z)>B,AHXY@A,S23Y\^+0(#9?$A)`"FB
M:8U3Y6K"+5>.\Y`HG^X->`=2^VRX2Z%RJ+J8M0\"H'\LH#];`U<9ZD#-N>4.
M<"H2!U-J!@?ZY%PQWX7L&4S"D+ENXBI#3:AYM]P$3D=BPLA@S)`95C)C$O9N
M1JD2@XE<WW.-I9121GI"VR12"VKF+;>`$Y)8,!HE9OH47?%HO@8(X$&AC'F2
MTA"P0?4G?U2]FGG+U>.$).J-214S9*YU2#(PER*YP@U"::0AI5`@8*>G[?6(
M"W[30.YI.I`C(X'QP%QU,3"#"QE`K[FFB>MQJ(F;)C.?3V9MKX4+>F`&@5PR
MV`M/?8#S@#(LC`(6:KO]'DHI%'@PP+UI&T!=0',L;RBN:*,4T[0<7"!S<1%Z
M+!+F`TLR!!H@`?L_EPNC-5,*,1XQ(3Y[..!J3BY>&#UM^#`R'0\,/E6N^"<^
M<#P/T&<^"/2%#VCA&WPHFOI@VJ(;"H)0U#]AKN`HR1P2W`"$4=+4!/ATAZ;-
MI,:A5@1U["-@K5]_VE%G53,3TQ4&$PAAPS`>^/`X(PPH&2(A%#$I8/T8`T>=
MYTUS7W*?24].<=`.'MCA@595-/LB*8['ULKK5W48QR&1X[OC0>$C5V=!QOLQ
M'"#VIVW.^`&<WYVS??%[UNS+4VL=BQV$=-<!R&KP!!!?=/6Y/T9[KCLXN>O_
M/<!);0$G6.X:X%U==Y<7<&%G//M]^`\``/__`P!02P,$%``&``@````A`%<4
M</)2%@``Y+T``!D```!X;"]W;W)K<VAE971S+W-H965T-#8N>&ULI-U;<]I(
MM\;Q^UVUOX/+]V,CP(!=2=YJSN?S^<[CD,0UL4D9SV3>;[^7:`G3+47_Y>RY
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MN<K?A)4>]M]E`^3_%T^/X;$AN^3^W^.?/Q\_OW[[>%DH7=V4<X5`^,6?N\-K
M\S$L>7GQ\/?A=?^TLNCXB$Y%\E&1HFQ]]//\5;YR$]R4WE%%UG?<%/GSK<I[
M-Z44%9$_XR(W5\7\3;GRG@=4CJK(GU&5?/XJ*.;>\W`D8G;/RMZ)BOS&K@T*
M<1GY2[PM-^_=ED">&;LQ;T_1[VQ,_!0%9SOF_1MSVC.WIX?T&QN3EZP<'U/^
M_[,Q^7AC)*3Q_OV-C2G$$2B\';UY>7C*`!7BP[;P]E@*[]ZQA=-CD;_\_B%7
MD.T^[MCP+W&9X/UY+L9/4/%W$G!M!ZKCN%>_?[W_].%E__-"NHD\3X<?]V%O
M"N["RO&(9\>GTQCXJR%0QKZPB@G+?+R4'26CVT$&[G\^E2K!A^M_9*Q]B$PU
M:3Q1BT4XL(9EZ_Z"AEU@Q\M0-.,%9RL.;MT5MV(3EVW'93-^J1.;^)>Z_H*>
MOZ!O%[QMW"`6&>L9QB9>SRA></9+E;S[B,:QB7]IXB^8^@MF_H)YO.!M/=[3
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M<U/.><>@B2+J(N_P,5%(`WE5&;X6*`:YDO=,F)20EG/>(6924II$*3$MY[R#
MS*3D-/G84H(JYV[NX6I2DII$*5%-;GA*5I,H):Y)E)I7?\/3`EOQ@F92$GN^
M.J<;R#F4TPW"UXX%>9F:W17"WW*Z@K^@YB^H^PL:=L'Y,5BJ>,=.,\UXPU,K
MS7A'3CO->$-/1V&Z"M-3F+["#%+,K=<`APHS4IBQPDP49JHP,X69*\Q"898*
MLU*8M<)L%&:K,,9H4#6)RCFO#9HHA.<1*^>\0\A$P<Q&*6%-5DI):SGGI=6D
MQ#6)4O*:1"F!3:*4Q)9S_GB9$MDD2LEL.>>-(28EM.7`[YHIJ2T'?HM.B6T2
MI>3V'#D#O5SF<@;Z[`$^U,X`[R^H^0OJ_H*&7?!VDM3T%[3\!6U_0<=?T/47
M]/P%?7_!P%\P]!>,_`5C?\'$7S#U%\S\!7-_P<)?L/07K/P%ZWC!V\E6HD=N
MTHR7NFV:\7JD,1I4C5%\/FBB`^'M:3;1D7"V)'$HF,2Q8!('@TD<#29Q.)C$
M\6`2!X1)'!$F<4B8Q#%A$@>%.3\JG&C)!<YW1"O4\AKK[)I'.?!&[JHULJ_?
MKHNXKV!K*.HH&BB:*%HHVB@Z*+HH>BCZ*`8HABA&*,8H)BBF*&8HYB@6*)8H
M5BC6*#8HMBB,8<*I,QP[P[DS'#S#R3,</</9,QP^P^DS'#_#^3,<0,,)-!Q!
MDYE!9VB7NU#O&-I#_?%2+M.<ANURX)W!5ZW)&MI1U%$T4#11M%"T4710=%'T
MK"@=KT(%.?N?VPW[6&2`8HABA&*,8H)BBF*&8HYB@6*)8H5BC6*#8HO"&"8<
M.U/C*AP\P\DS'#W#V3,</L/I,QP_$^4O8\0RG#_#`32<0,,1-)D9=,9V>6/!
M.\;V4/MCNW<MI6I-QIZJH:BC:*!HHFBA:*/HH.BBZ%D1!)7CZ)Z[\J\7];'$
M`,7074G^JG#3^,,[XQIAE3&*"8HIBID5\0XI7.7D[8-G_P6)+9]CS06*)8H5
MBC6*#8HM"F.8<`P-Y]!P$`TGT7`4#6?1<!@-I]%P'$V4QXP1S'`B#4?21)G,
M6A%'TF1FTAGKY5U-SE@?WN8JX6VN\+?\,=^[156U)N.!U%#44310-%&T4+11
M=%!T4?22HAQX%RS[2>.)`8IA4I0#[Z+G*&F\]8Q13%!,4<R2HAQXMRGF2>-M
MZP+%$L4*Q1K%!L46A3%,.'N&PV<X?8;C9SA_A@-H.(&&(V@X@R8EA-[!9#B#
MAD-H4E+HKXA#:#)3Z`ST\@9=9Z#/OLT5:G^`]^[I5:W)&N!1U%$T4#11M%"T
M472L*!]?CMN7GNZEEBZ!'JZCCV*`8HABA&*,8H)BBF*&8HYB@6*)8H5BC6*#
M8HO"&":<.5/C*IPZP[$SG#O#P3.</!-%+V.@,5'XL@C'SW#^#`?0<`(-1]!D
M9M`9V`-YM?Z.D?W(O:$][[T3HQJAC/U98U)GTF#29-)BTHZ(';^+N2#GOZ6N
MPT6Z3'I,^DP&3(9,1DS&3"9,IDQF3.9,%DR63%9,UDPV3+9,9#9(&-^/EQE1
MD_DA;!1Y-(I`RGP17I<BDC*!A.O$H<QZ[(I8&D4NC2*8,NF$MUD139F%PG44
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MP63)9,5DS63#9,M$F@#F2)H`FYK"*`(I)P&\+D4DY22`Z\2AM(?-C;R-O^!G
MQ<2IM*90"(K)^9UQ++/JQ+G,&*^D"?`V*Y(I38#K*+(I3<#6L8_KUK[EX326
MN$T@G/MTW@1T<Q;#SXU)G`SX[\Z,4,:>JS&I,VDP:3)I,6DSZ3#I,NF=2/A*
MOW#EM=G^Z<>_?*T_8#)D,F(R9C)A,CV1XZG-5=$[L9R=?O[+1SQGLF"R9+)B
MLF:R8;)E(FW`)C$C9-(&V"B2*.<"7$>113D7X#J*-,JY0%S''C0%[R:_](`8
M_/*HD1,!-F]Q_'4=12:-(I32`WA[%+&4'I!5Q^T!<O`X/0!.!$+N7PCRW[T9
M?B18]B7*&I,ZDT9$;*L+RF&S.W6ZXV<F-5&T4+1Y0SI,NDQZ3/I,!DR&3$9,
MQDPF3*9,9A&)7LT=7]&X3_.<BRR8+)FLG$W)W][F_5MA:T?861;NQFY0;'E#
M9.RW(8N._92=(D,_YM`H@BA#/]>)HRCR-&7'NP(I0S_7B>.854<12!G]>5V*
M2,IM`*ZC"*6,_EQ'$4OY>"JNDQU,=_0/)_.=GP'`Z&_G_LD)QNE)+N?]]W&&
M'Q$JH[\],(]7,KQ!N>8(.7N3_]R(U",AC_6THAOO#*.18KPCKLFDQ:3-I,.D
MRZ3'I,]D$)'3P%`N>,_0D(N,F(R93)A,F<R8S)DLF"R9K)BLF6R8;"-BG\6T
M1B,=0#$35V'B.)Z'S0N2M`!>ER*0T@*XCB*2\NJ?ZRA"*2<`7$<12[D(Q'7B
M8&;M9T4TI07PNK+#Z;:`<+;>.UJ`G=SGM@#O<*D&%F6U@.0<07^`KSM5TMI$
M(Q(9>[3)I,6DS:3#I,NDQZ3/9,!DR&04D5,C2;3I,1>9,)DRF3&9,UDP63)9
M,5DSV3#91N37^U]:0#)&7A;E+(!-36'B.&:$3>X#\+H4B93[`%Q'D4DY"^`Z
MBE3*60#74>12S@*XCB*9T@*X3G8XW1803@4\;P'*^P!V!J';"KQY0=7PX]SI
M6A"2.E=I,&E&Y->!:G&1-I,.DRZ3'I,^DP&3(9,1DS&3"9,IDQF3.9,%DR63
M%9,UDPV3+1-I!I@C:09L:@JC"*0T`UY7',FLIJ((I9P/\+H4L93S`:ZC"*:<
M#W`=133EA@#74813;@ADU7&;03A=\+P9P"4A.[OPO`GXGY]=E0\E>+LB%`2E
MFUO_ZQ!J+KG-W13]CX2L.Z14+%2\BT:-"&0<2TTF+29M)ATF728])GTF`R9#
M)B,F8R83)E,F,R;S$PEO#R8N@2VB']N7`N5"R7O5O'1^?E.Z\8ZUU:G\VP5*
MK\2:R8;)EHD,_(H9O@H3AS`C0'(AB->E"*)<".(ZBBC*P,]U%&&4@9_K*.(H
M`S_74012!GZNHXBD#/Q9==R!/YP(^(Z!W\X;/!_XRWGO)GPUP,F%-29U)@TF
M328M)FTF'29=)CTF?28#)D,F(R9C)A,FTXC883GMWM&,B\R9+)@LF:R8K)EL
MF&R92!/`J,FK?VOL[K5O#71OO,G]X',2%&XJN<![>X?T`%Z5(I#2`[B.(I+2
M`[B.(I32`[S'+A\![O5]N1+$ZXIS:7=SOE"4CR7V!D:Y$G2^+C&"O,]+D![`
MZU)$4WI`5AVG!X1??/>.'G#D_KN!O(=1C5#&JXH:DSJ3!I,FDQ:3-I,.DRZ3
M'I,^DP&3(9,1DS&3"9,IDQF3.9,%DR63%9,UDPV3+1/Y8J.L":#VRPD5>92O
M-;)U[`@6?52LURGB1%IC;\_YHZ4BDO*M1KS-BE#*=QIQ'44LY1N-G,<N$P<2
M][V,(IA&D4P31S/J%,=5^?M0D4VC"*=\EU'6_G&[0#B-3'\FD+>SSIPS@8+W
M,*H1LH^T6+H-*D7O5D'-(4$E91)4W2%IGZK3B$1&MVDR:3%I,^DPZ3+I,>DS
M&3`9,ADQ&3.91,0>"RE/\]0!:4_SC-<R9[)@LF2R8K)FLF&R92(=(&L*:-P!
MV,1AS,B1?*\=UU'D43H`UU$D4CH`UU%D4CJ`K6./S^`7'8#7I8BE=`"NHPBF
M=(#S;2Y6*OE<XGPB.YIN!Y#!_#T=(.3>>4#!F\53S5MT?D3Y;_FI12;:\S(T
ME+P3IWI*%>_":X-)DTF+29M)ATF728])G\F`R9#)B,F8R83)E,F,R9S)@LF2
MR8K)FLF&R9:)=(%DUKR4R/>;LHGS>)Y9OXXBD?+UIKPN12:-(I32!7A=BEA*
M%[!UXK$HR/O7P12QE+,`WAI%,(TBF=(#SK<X']S<>F_\EG.`K*UQ.T`X@^P=
MYP!VPIF4/[UAO^Q_57`UGS4K[?C:I,:DSJ3!I,FDQ:3-I,.DRZ3'I,]DP&3(
M9,1DS&3"9,IDQF3.9,%DR63%9,UDPV3+1#H`9DTZ`!M%(.4\@.LH(BGG`5Q'
M$4KI`%Q'$4OI`+;.J0.4R_[4=+D2Q.M2)%/.`[B.(IO2`[A.=CK=+B"=_SU=
M(.3^>8`W;ZN:MRCC-46-29U)@TF328M)FTF'29=)CTF?R8#)D,F(R9C)A,F4
MR8S)G,F"R9+)BLF:R8;)EHET`<R:=`$VBD!*%^`ZBDA*%^`ZBE!*%[!U[.A=
MN;DM^1><C2*5T@3.RP2WY4+%&]"D!_`6*W(I/8#K*)(I/8#K9&?3[0'A=+/S
M,P'=[("\G:7FGA%XIU#5",GVGDX;DM>$;"'[//X1Y`JY<J7D%:I'A2)4+AS?
MW.#>L6JDK,P[F6TR:3%I,^DPZ3+I,>DS&3`9,ADQ&3.9,)DRF3&9,UDP63)9
M,5DSV3#9,I%^P%-'TS+IQ43N#W.=.)+GV?;K*"(I_8#7I0BE]`.NHXBE-`1;
M)SHK2!V.I"7PRA31E);`=13AE);`=;+CZ;:$</K9;[0$.VO-;0G>-:IJ'J>V
MU9C4F328-)FTF+29=)ATF?28])D,F`R9C)B,F4R83)G,F,R9+)@LF:R8K)EL
MF&R92#O`K,GI`1M%(.7T@.LH(BGMP-:QPV\A.'ZMI_M"3VX3\+H4J93S`ZZC
MR*5T`ZZC2*9T`ZZCR*9T`ZZ3G4ZW&X1SRWZC&]@I:6XW\%XA5/-9\]:B6P9(
MZEREP:3)I,6DS:3#I,NDQZ3/9,!DR&3$9,QDPF3*9,9DSF3!9,EDQ63-9,-D
MRT2Z`09)N@&;FL(H$BDWC7E=<29M-Z@$Q9MBQ1M"I!O8.EE&D4KI!KP]BEQ*
M-^`ZBF1*-^`ZBFQ*-^`ZV>ETNT$XX>R\&V3/'\[;^6EN%_#>&5J-4,:I9(U)
MG4F#29-)BTF;28=)ETF/29_)@,F0R8C)F,F$R93)C,F<R8+)DLF*R9K)ALF6
MB72!K`FC\1M(V2@"*><$7">.9'2Y)74R59Q):_)I;RZ7+L#K4J12N@#74>12
MNH"M<WI<*1/`%,F4+L#;H\BF=`&NDYU.MPN$4\[>T07L##6W"WAO_:SFLZ:Q
M1><"2.I<I<&DR:3%I,VDPZ3+I,>DSV3`9,ADQ&3,9,)D&I%`IL#;SXC/>7>-
M9EQDSF3!9,EDQ63-9,-DRT2:`.9(3@78U!1&$4@Y%>!U*2(I38#K*$(I38#K
M*&(I38#K*((I38#K**(I38#KQ.$\B]7;&9?3`PKAA+/S'A#>.)8IY9<7V:<$
MQ]_SWT7DSRJ.4-8I`9,ZDP:3)I,6DS:3#I,NDQZ3/I,!DR&3$9,QDPF3:0HI
M%[U)BK,4]'9L'U]AS)DLF"R9K)BLF6R8;)D8HS!5A:DIC"*31A%*HTBE4<32
M*')I%,$TBF0:132-(IM&$4ZC2*=1Q-.DY?/\?;)N2PAGJ9VW!.@$=E*;<UI0
M]+X/JUJPJ'1\D9>7C]I(O(/($8%\8X'W#JZZ`TJW7N8;T8\S>DV328M)FTF'
M29=)CTF?R8#)D,F(R3@B\5-<\L;M"9>8,IDQF3-9,%DR63%9,]DPV3*1T=\F
M+./X-W$*LTQ-42>.8E8=11YE].=M5B121G^NH\BDC/Y<1Y%*&?VYCB*7,OK;
M.G&DDG/%%+F4L3]K:^S(?WWXMMN]UN]?[S]]>-J]?-W5=M^_'RX>]G\_AZ<#
M>1FV3XLO7G9?/EZN@[M-<'F=6"X?OG0G'["7]I.!_&2<]I-J_JY:3/F-6OZN
MEK:\GK^KIRTWLH*TY=7@KIZVWG9PUTM;+ALZ3%L^"NYF:<OGP=WRN/SZM),.
MGS[\N/^Z&]R_?'U\/EQ\WWV1_9B[*LMYU<OCU_`<R_[C=?]#]N_EQ9_[U]?]
MT_&OWW;WGW<O(1#\9;]_C?\A._OZY_[EK^-S]>G_!````/__`P!02P,$%``&
M``@````A`./1R6%E"P``<$T``!D```!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&ULG-S9<N+($@;@^Q-QWH'@O@T")):P/2'V?=_O:"S;Q!CD`'I[^\FB5*!*
MR?I%ST6/G?Y(5*7*1`*AQW]^[S\2/YWC:><>GI+&0SJ9<`Y;]V5W>'M*SJ;U
M;X5DXG3>'%XV'^[!>4K^<4[)?Y[__[_'7^[QW].[XYP3E.%P>DJ^G\^?I53J
MM'UW]IO3@_OI'.@OK^YQOSG3K\>WU.GSZ&Q>+@_:?Z0RZ;25VF]VAZ3,4#K&
MR>&^ONZV3M7=_M@[A[-,<G0^-F?:_M/[[O.DLNVW<=+M-\=_?WQ^V[K[3TKQ
M??>Q._^Y)$TF]MM2Z^W@'C??/VC<OXW<9JMR7WX)I-_OMD?WY+Z>'RA=2FYH
M<,S%5#%%F9X?7W8T`C'MB:/S^I2TC9)=-?+)U//C98;F.^?7R?=SXO3N_FH<
M=R_=W<&AZ:8=)7;!=]?]5]#6BPC1@U.!1]<ONV!X3+PXKYL?'^>Q^ZOI[-[>
MS[2_31J2&%GIY4_5.6UI2BG-0\84F;;N!VT`_9O8[\3:H"G9_+[\_]?NY?S^
ME,Q:#V8^G36()[X[IW-])U(F$]L?I[.[7TAD>*EDDHR7)$=;[_T]\Y`IF(9I
MW9&%GN^R*=8URU]L2MY+0@M<C2<;>QQ%-1DT(/5H&GG,63#HB>1<T@_JX>9#
M+F/F"_?,ID'3*//<YO,O9D*L`IGF-A<9\\'(I>_9*<9U3N@'-:B_6"&TL"\;
M(]:#E^;^C<G0TI!9;FN$LA1,,V<5\G>L5[5*,K>I^8L9SJBY$3]<!Q5[O635
MG(@?U,-C3VU*%O*E+U0WY\WSX]']E:!N2POV]+D1O=LHB<RJ(\CZO?:(KUH$
M]0:1Q19IGI(T/U3])VIL/Y_SN>QCZB?UHJUGRD%CZ**BA&@\(FV5!VHR0/]>
MG\<J9/0L=654EH8*1#RHJ8QZ4$L%?`\RBOHSM:7QCYJ-J*.$2MOE@1X/]'E@
MH`*^+>%C'BJCGF?$`V,>F/#`5`;HW^O<YG,Y?<0S]:";82.>*Z&V9,$#2QF@
M?Z_/8_&972FCLJQ5P/<@/@EVR"ID6V=?%Z%*;'N+3MN<0&9O(6K(M\TI*J9K
M1=&K@591X:^MJG"$%H6CMJ>L`K>!LO5="8HL(]4@R1?T/5F3Q#^B?,[433W,
MY'73"#,L3S/,L#RM$)-F>=I!PT?>"1(^\FX(,=DZZ<4P_1AF$#16D8U\&#1Y
MD]7=*&BL(MNCXZ#)FVP&)T%C%5E7FP9-8'MF0<.6X#PH^+Y:!`G?5\L08EKZ
M"EP%36".UT$3F!O;#B*^R;97GEK9L/U@>P7J-X$-LKT2]:.\;V1:1Z$#1*VC
MB-=H\5H=W5G$H[3.P@,5'JCR0$T&M(W,L>FOQS"-,,.FK1G#M,(,6[[M&*83
MPW1CF%Z(,5DA],,,.S0:!(U59"U@&,.,8IAQ##.)8:8QS"R&F<<PBQAF&<.L
M8IAUT.1-ME9M.PRQA6B7XR"O"+42L])ZA[.]PM31[25+:Q9T%J@UB^@F(;36
M)'B@P@-5'JC)@#S'%T?M=1YH\$"3!UHJ<#OJR9ML%MK*J$.E#@]T>:#'`WT>
M&/#`D`=&*A"Q:6-EU*9->&#*`S,>F//`@@>6*N#?$G8PL8IAUF&&3;9M*Z2&
M9)<#$6]MW/:\[2V.2T1;E72V?<>J%)I>XGQG"'F#M=6R-+1-M[,(O6HJ4%2A
MJ$%1AZ(!11.*%A1M*#I0=*'H0=&'8@#%$(H1%&,H)E!,H9A!,8=B`<42BA44
M:RAL&Q-<=38N.SNR[K2V06_<W=$VA'Y*TE'\M27D,^R5NRQ-5-N`H@I%#8JZ
M%-;EK3+#2HO_]/;5@#F:_AST24H@10NF:$/1@:(+14\*.5@S9$/["`S@<PRA
M&$$QAF(BQ=<CF<(4,RCF4"R@6$*Q@F(MA3?8;(Z6J;Y$;1OFL+V"\Q9ZR+ZW
M*SA)9,5I#8/>JK^C80C-&D:6C;$L3?Y2J#FK:!1R[)"KXA=&X;*^]7FJ^D58
MH=;\(+0;U*6(Z%L-?XZP)VG"%"THVE!TH.A"T8.B#\4`BB$4(RGDO@_9KV.8
M8>+/$+93IC#%#(HY%`LHEE+(H1HA9;J"*=90V#8F7KU%+'3;*[@HXE5<.-$:
M!GUX<T?#$)HW#'Z$(4WX4U\^U:I`486B!D4=B@8432A:4+2AZ$#1E<(P"I<V
MG'Y(LS<A>S!%'XH!%$,H1E",H9A(X1LL>R=P"E/,H)A#L8!B"<4*BK447P_6
MMF$.NXP)KCD[LNBTGD&?WVL](][[\>)1O'>PCV?*TD3U#BBJ4-2@J$/1@*()
M14L*]9I#5V7P0ZLVS-&!H@M%#XH^%`,HAE",H!A#,8%B"L4,BCD4"RB64*R@
M6$-AVYC@JK,K.$MDW6GMPZ"/[K3^$?T6_86SQF'Q=T,]%-4Y,*EB4L.DCDD#
MDR8F+8_(!I+)TZ?4!FNH;9RE@TD7DQXF?4P&F`P]XG5-&K&190=#(XUD++I"
MBBV7L2[286:"MV6*R0R3.28+3):8K#!9>R1B=NDJ(U&_3\F(6J/+C+"IQ##1
M%:EW%?IT\)ZN(CCO*NQCZ;(A4<1(*YA4,:EA4L>D@4D3DY9'BMZI1I:=W[5Q
MB@XF74QZF/0Q&6`RQ&3DD:\F98Q33#"98C+#9([)`I,E)BM,UA[Y:MZHF<`2
MHV:"38PZI&\61.71FXFX%,I_63`X1)%73FF?O%CLK+5L2.1O)B9K.!7/R/;[
MS<H;EIEF>:HQ\M1"#'N1K&/2P*2)2<LC<DRA0VKC+!U,NICT,.EC,L!DB,G(
M(]Y+;<A;CF.<9(+)5'N>0JYH9-D;^#.<9([)`I,E)BM,UIA06PD6&RL`:BO8
MJ(+T%RW/$U:0-Z.W%7%%U!UM15Y`Y6\K1=8QRN)K-'0<XZTBZA?%PNW"*/EV
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ML(E1C]14HO+H345<]>8_)KE\`S)+47#.(Z^6\Q^<Y+/LN*(LOE6+N@LD59RE
MADD=DP8F34Q:F+0QZ6#2Q:2'21^3`29#3$:8C#&9A)!\CKWP3D,0.T:883+'
M9(')$I,5)FM,J,'`4J(&@TTEAHFN2;W!B.O;_`T&]!5Y.9S65W+L_?NR(9%\
MB<D8=/,$=EY4T821SW!0]4#N\C:G563+HW;]\Y='F75,&I@T,6EATL:D@TD7
MDQXF?4P&'E'[CU]8.<0I1IB,,9E@,L5DALD<DP4F2X_(>3/IDE3]W&B%4ZPQ
MH4:"+TE5)4C'&=>KS5D-T>F/RB/.!`L%=AA(1RG^,J9/\FZ'#WH'$9?-W=%!
MY%5V6@?A9YEENLL,/#*!1-RK!F2I85+'I(%)$Y,6)FU,.IAT,>EATL=D@,D0
MDQ$F8TPFF$PQF6$RQV2!R1*3E4>^OGA]C9-0-X%%0H<EV%1BF.B"E$U%WAQ*
MW@1F[QS?G(KS\7%*;-T?XL9/]*'T\^,U[-V62MR7BNZ<05\%9'\I9TKTM<!@
MO)(IT9<#@_%JID1?$0S&Q1.$Q<M&B6Z]$?1MHT2W5@G&NT:)[I\2C`^,$MWO
M)!B?&26Z/PG%4]>!T>VN/C=O3F]S?-L=3HD/YY5F)?T@[A=TE#?,DK^<W<_+
MW7.^NV>ZT=7EQW>ZLYE#7X!-/Q!^==VS^D4\P?5>:<__`0``__\#`%!+`P04
M``8`"````"$`_G$$V24,``!16P``&0```'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6R<W%ESVL@:!N#[4W7^`\5]``F$@(HS-:!]7\YR33"VJ3'&!60R\^^G
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MVZQ_'J[^W3F\['[Z^\UCLGE;L[W-CA,_`M]WNS\X#1]Y$WMS_^;=WND(%/O.
MX_II^>/U6.U^!NO-\\N1'6Z+;1'?L-GCW\[ZL&)[E)7IF1:OM-J]LA5@?W>V
M&QX-MD>6?YU^_MP\'E\>NL-QS[('0X/QSO?UX>AM>,EN9_7C<-QM_R_0:8O.
M14Q9A/V410RK-S(M>_*9*D-9A2VWJ6+VS(EE6.-/K,M85F$_FRK&Y]?%EE78
M3UGE%W8+^XR=]BW[V:R*_?E5F<HJ!L^&V/LF:[OST!CG`WS9K:;5,T:#S^Q4
MH]FKQF5;S/'G#XYQWACVCT_OV+[([NFCX"R/RV]?][N?'=:_L&T\O"]Y;V7,
M^"*:#X&([/EC\=&G@GT<>)7?>9F'+MM"%O@#^RC_^<T>VU_[?[*/WTJ:N3#L
M[[,9&U/5+&[K&*IP&L$_CWS1+FWP1(/XF''A-PV:!0<M9F*JBPY;#-V`2)CK
M'3&F=>+&-)N0T(:4-F2T(1<-[._SSK1'(W5]B^9-%W.SP\O&-.M2W18F1Z"^
M%==E^RQ8YW2Q7DU)5WO7VH2(:QZB9EWF3</5!I@#=2,7MX8<-N=6#`EQ;XD]
M49?CW9*Q2?:,+PS;/Y>#,B9U@A9CDVT*6\S`4M<G:C/D$Q>W&+(Z20NQ2([2
M6S.>DCK9K;$MLLIYFR'+*EJ,38Y6V69(G>K6D"KUK;#MRQHK,6:G5R7&O),<
MLG.*/L[\74J<:<."-CBTP:4-'FWP18.:.=*K!BW&)MD-6\Q@3#)WAXEOS7A*
M#DYRATGO,-D=)K_#%+?&MH?JMI=WF.H.4[>9RWY68C<BL=/'C6LE;K1A01L<
MVN#2!H\V^*+A<G(-:$-(&R+:$-.&A#:D3<-51VJ13C)K3'.VR&E#01M*VE#1
MAOJJ03D4[`I0Z0'TAX+KAR[K8"[G`;+V<T'8XL[D$H+3=<U""/MT,64,Q!\U
MDPXF+ER.!X4/10!%"$4$10Q%`D4*109%#D4!10E%!46M$TIZV2V(DM[[SE_\
M723%-KG"F`NCB[$04Q%C]POI5AW]RRZL[T'A0Q%`$4(101%#D4"10I%!D4-1
M0%%"44%1ZX027S:2H,17W_ER36)+KG7F@NA2VPA^)TNZ;D?SFMN\]F&W[D'A
M0Q%`$4(101%#D4"10I%!D4-10%%"44%1ZX225W;W_XF\<DWR2FY5YH+H\MJ(
MMKQJ7G.;US[.*Q0^%`$4(101%#$4"10I%!D4.10%%"44%12U3BAY9<-^G\@K
MUR2OY/YN+H@NKT*(BUO3:K^ZO<.X<$D>%#X4`10A%!$4,10)%"D4&10Y%`44
M)105%+5.*/GEP_N?"/")DP1?!GY.-U]S:>3=U]BR+7-`1E46JAF-IFS(VR(7
MR(Z"IE-[,IK2\6!7&LWGQ5/*&&-K8I';11\7"3`),8DPB3%),$DQR3#),2DP
M*3&I,*FU1(TT'V2_GI?17_/RJ2K:*9.`S*711UK4D>:C2%^CCR(MC#;2UV7:
M(PV+!'*C-,L),8DPB3%),$DQR3#),2DP*3&I,*FU1(TT'W"_CO1]HQ"&&*=7
M!M/HY,Q<(DT,%I@XF+B8>)CXDLC+G_'0L&QR<@D4,IQ:P]&$D!`O*,(DQB3!
M),4DPR3'I,"DQ*221!Z`Z<@P[#&Y!*@58PSMTU7J>0!6C38?U+^.-NBMQ1R`
M&FER=.>&0-I(0^+@*BXF'B8^)H$D8BC0[!EDAX>X1(1)C$F"28I)ADF.28%)
MB4DEB1QE[9&+T%IYV>Q=;M?4%+.L*2F^LX/F;R.7TQ,R9C8W!-*F&1('5W$Q
M\3#Q)1'[<]`;DMGN`)<(,8DPB3%),$DQR3#),2DP*3&I)&G2;)&]7RNOL^^Y
M7>84U#SS^9'K7OG./(MI%:5WGM`19/X]019Z;9X%&8MO0TW&UF!H7=;T=)OI
MR#*-F5JC">D57848]L!F@R7GL]"IBH=7QE>KM$TF!@JQ)RWK$N(%19C$F"28
MI)ADF.28%)B4F%22B",]LD:G0Z`>QUHQPP'[.C#[<S9JMOGDR76VP16'F&M1
M,TU'F?DW%5&F(7%P%1<3#Q,?DP"3$),(DQB3!),4DPR3'),"DQ*3JH78$]+#
MU2WH,C"A1IK/KUQ'^L[N6DS+J-&^7.'(X3S=W,V)+`Q('$Q<3#Q,?$P"3$),
M(DQB3!),4DPR3'),"DQ*2<3-WZCMWJ_"56HM48/-)V)^(=AB_D8--KDZF/,O
ME:,^&Q('5W$Q\3#Q,0DP"3&),(DQ23!),<DPR3$I))%#L^SJS)J0V[P25ZDP
MJ;5$#3:?H?F%8(N)'378EY."[+%ULS^RQX;$X?^C0?_Q<#'Q,/$Q"3`),8DP
MB3%),$DQR3#),2DD$<$>BF\ZGB]Z3T>ZQ%4J3&HM48)MT@G%^RY%3F^C(R'D
M0SJ72'?GB(DCB>P-QE-C."577BZNXF'B8Q)@$F(281)CDF"28I)ADF-28%)B
M4F%2:XD:;#ZC]OD>VQ03<6J/349EYA)I@WT]Y3<<3(W+W>WI@^[(&LU)CG<&
M:E?@JL)FWQU1@8=7P\<DP"3$),(DED1N\>WV)+A&BDF&28Y)@4F)285)K25J
MHEDH?R71_&VTJZ93,*9`VD1#XL@JX@B;HP&;S%,CZ^+E>)CXF`28A)A$F,28
M))BDF&28Y)@4F)285)C46J+FFDXIWGD)TC*U."5=Y-R$\X8+3!Q)1*[9=1L?
MKJ3!A@OR\()\3`),0DPB231;%.,J"28I)ADF.28%)B4F%2:UEJC!9MWIKW38
M_&VDPQ[2FT93(&V'#8F#J[B8>)CXF`28A)*(U$X,-K<P(?LEPB3&"THP23')
M,,DQ*3`I,:DPJ;5$#3:=;M1/R?#G<M!`C^FXM43:0-_.1-Y,,\HR(B)?QC;[
MMMV`+,IM612MX[48$C4?DP"3$)-($K%-QL`:C4?D5CO&51),4K(@94[N=->2
MX2*Y4H1]!YA]GT@]5Q:X2(E)A4FM)6JB/S?):+9,,H[I)*-$VD3C249<Q<7$
MP\3'),`DQ"221,399$\B&-'O1\6X2J)4,5@)@YXC4X688_9T$G*(,E4,VDR.
MUZ7`I,2DPJ36$C70=(H1=-$M4XMC,LPV-^&\X0(3!Q,7$P\3'Y,`DQ"32)*/
MOD(5XQ())BE82H9+Y)@4F)285)C46J)&F4XJ@BBW3"9.Z9>:3#A3N,#$P<3%
MQ,/$QR201/2JEL7_IYEZV@UQD0B3&),$DQ23#),<DP*3$I,*DUI+U#SSF;KK
MD6F09S&QQT;?SL_/L*?D1#;GSWK3S_XM,'$P<3'Q,/$Q"221>38'!KG\#G&-
M"),8DP23%),,DQR3`I,2DPJ36DN4./.G0REQOF_X[O0V,LI!)_;F$NDNH3%Q
M,'$Q\3#Q,0DD$5^.G)S^HP4Y-X6X2H1)C$F"28I)ADF.28%)B4F%2:TE:K#I
M#**^GV;/;Z6C'.SAF>HY>"Z1$FB3]&R+-J36<3!Q,?$P\3$),`DQB3"),4DP
M23'),,DQ*3`I,:DPX4\._OCD+R(MG@PL'H>Z7>^?UXOUZ^NAL]K]X$_]Y7<N
MY];S$XE_'_''4Y+VA3%CCR&];8^,&7MRYVU[8<S*MO:Y.9NWUC=G[.%MMW4<
M<\:>X7;;[IHS]BBWVW;/G+$GNK'V_GD#V`.-WY?/ZW2Y?]Z\'3JOZR>VZ8.>
MS485]^*1R.*7X^[]]+#8[[LC>Y3QZ9\O[-'5:_9\U4&/X:?=[MC\PA=P?ACV
MMW\```#__P,`4$L#!!0`!@`(````(0#.6_-@HR,``-X^`0`9````>&PO=V]R
M:W-H965T<R]S:&5E=#0Y+GAM;*2=67/;QK:%WV_5_0\JO4<B.%-E^U1SGN?Y
M39%E6Q7;<DG*2?+O[P8!D,0&A&\SUP^.`WY<W0!Z]>(&P.:'__S]X_O5?Q]?
M7I^>?WZ\]FYRUU>//Q^>/S_]_/KQ>K5L_U:]OGI]N__Y^?[[\\_'C]?_/+Y>
M_^?3__[/A[^>7_YX_?;X^'8E"C]?/UY_>WO[=7=[^_KP[?''_>O-\Z_'G_+*
ME^>7'_=O\K\O7V]??[T\WG\^O.G']]M\+E>^_7'_]/,Z4+A[L6@\?_GR]/#8
M?'[X\\?CS[=`Y.7Q^_V;]/_UV].OUTCMQX-%[L?]RQ]__OKMX?G'+Y'X_>G[
MT]L_!]'KJQ\/=[VO/Y]?[G__+OO]MU>\?XBT#_^3D/_Q]/#R_/K\Y>U&Y&Z#
MCB;WN79;NQ6E3Q\^/\D>^(?]ZN7QR\=KY]VY;;%X??OIP^$(K9\>_WH]^_?5
MZ[?GOSHO3Y^'3S\?Y7#+B?)/P>_/SW_X:.^SOTG>?)MX=_MP"J8O5Y\?O]S_
M^?UM_OQ7]_'IZ[<W.=\EV25_S^X^_]-\?'V00RHR-_F2K_3P_%TZ(']?_7CR
MQX8<DON_#__]Z^GSV[>/UX7R3:F2*WB"7_W^^/K6?O(EKZ\>_GQ]>_ZQ"2`O
ME`I$\J&(_#<4R1=OBOE2I7J)2B%4*1Y5O/Q-OEKR2N4+^B*]/NQ0^5SETAVJ
MA"+RWVB'\C=>,7=)1\1BAX[(?R.-RDW%R]4*%?N1K84BGAR<4.5?G!]/#FEP
MED_'-N]=?H;\@17HR#_^']V1<Q/(G(Y-H73I\?6B8Y/W31,,2QEVEQ[A?.0`
M_Q_1/LG1M@[]X]@_#?Y"X:9:*A7+U0M.=#X:_?G3P/T79SH?C=R\')WHH!0N
M/;0%.:*'$U0XJ?R+SA0CF>+IT/K],A[:8G1HBV<VO'B8%",?%D_[\J_FE6AG
M2J?AYE7,)_HVF'</TWCS_NW^TX>7Y[^N)!SET+S^NO>CUKOSI:,)/)ANCU/Z
M>S.Z3.6^BO-E/E[+OLID_2HY]-]/E5KQP^U_)3H>0J:>9+PXT8@(/R=\V:;>
MT-(;VGI#1V_H!AOD[V/7RM5\O.%>]*8SQJO%F7[$1)T;Z`W#8(/\?6Q)[>`H
M(B*-<:1Q>DNB<Y.(B=XTU1MFT8:3BFIX'A&1QB+8('\?^UK6>[Q,,DIVI677
M>L,FVG#6CC[ZVXB).K<+-LC?Q\ZIAO=)(G'<7,J@5#+N.":CIEUB#+IP$)[W
M)ME6.##/(=W6<:B>]BJIDQB^+AR_Y];2RL?A>]R+Q&!UX6@-/C@=+)LR7)/]
M.8[84Z=UZ^$8/M_UI$XXB,^:#T=Q]MO"D7WVML1(=N%0KAX^$A[V+!RX9UL2
M`]4E1JH[#M7C43P?F+<R7QXG34F&V*29_FDWFAM]VI\;(]UZM.%T3-5\U$@2
M!84TDTBE&I^Q6@$2/\)J4FX;F(Z!Z8:,?!CR)_^B)Q^_X[WI)54JN4J<Z2=4
M<DIE8%`9)AEU\$9(C)-$):=&_B3)5'.Y^!Y-0^9X7')E1<R2*JJW\R2A1\,B
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M?X8&9I3&J$\,XS1&66&29*HZ&:=IS&G`'&J[F8&9&YA%&J,\OC0PJS1&S5[K
M-$:=]TT:HSXY;-,8-39V!F:?QJBQX9P%JEN@T(3G%JOJCW`N-&8<4N/,I9BU
MFM-0BENK.34:78I=DU"*7Y-0BF&34(ICDU"*99-0BF?+5;UW*:9-0FFNS:G1
MY%)L6TE`*;XMZ\LX+L6X22C%N4DHQ;I)*,6[22C%O$DHS;V>SLLT^WK*OB[-
MO]YI?HL%HESRC@5B=A#Z="P(]8:&WM#4&UK!AE/-W-8;.GI#5V_HZ0U]O6&@
M-PSUAI'>,-8;)M&&4R%<*:D3,HV8J'J>Z0USO6&A-RSUAI7>L-8;-M&&C*YM
M(R;JVDYOV.L-SB6VU!-;PE-\.H$N/,=G6Q(GV27.LDN<9G<\SQE[Y1+GWB5.
MODN<?9<X_2YQ_EUB`+CC"(@.H4N<;Y<XX2YQQMWQE)]V+/'ASQV'P3FDY\GC
MT#B'=*0FAHL[CI?CCIR/CMB$(/>N+I@0?%H^09\5)U5/?;JI!XR,H^/E4K57
M#22:2+20:"/10:*+1`^)/A(#)(9(C)`8(S%!8HK$#(DY$@LDEDBLD%@CL4%B
MB\0.B3T2SC'"KG-L.\>^<VP\Q\YS;#W'WG-L/L?N<VP_Q_YS;$#'#G1L0<<>
M=&Q"QRYT;$/'/G1L1,=.=&Q%E^G%6.3),P471)Y/?[R6:[;'.*MZJA"O!TSY
M<+-![C74"D5]R:X1(!FIV$2BA40;B0X2721Z2/21&"`Q1&*$Q!B)"1)3)&9(
MS)%8(+%$8H7$&HD-$ELD=DCLD7".D=!V&9YR;#O'OG-L/,?.<VP]Q]YS;#['
M[G-L/\?^<VQ`QPYT;$'''G1L0L<N=&Q#QSYT;$3'3G1L19?IQ5CFR4-CL<RS
MW0CQWZ6S3UU@K@?,N0FKGB[XDHPBFDBTD&@CT4&BBT0/B3X2`R2&2(R0&",Q
M06**Q`R).1(+))9(K)!8([%!8HO$#HD]$LXQDN([Y2G78!7VG6/C.7:>8^LY
M]IYC\SEVGV/[.?:?8P,Z=J!C"SKVH&,3.G:A8QLZ]J%C(SIVHF,KNDPOQL)/
MGE;\%^'GOTN'G[KT6@^8\_!3)FP@T42BA40;B0X2W8CPGYC+W^1RM?,_ZFYH
M+X)/5;':\3X2`R2&2(R0&$>$OUNYFX+:D4GT\KL[,HV(X+B4U!"812^_*S!'
M8H'$$HE51!RZ&7^(9'W^FKI<OXE>>[?_6R1V2.PC(OTL.!>]_FXO''O-L=G<
MT6WO=.3HM7=>/SHM>+VH[\4>?1:\GE=7BMS19>_O*'O+'<WU3B_86N[H+5^B
M<'.Z71Q\@X*-Y<!9CJWE8M[*W22.)IO+L;L<V\NQO]S18.^?N9C/Y"N&^N0?
MO99^S(]&\U_V;BJGQR]B:2;?W(FE6?8M?)_6*:;FP'K`5(++EZ5:+:>?VVP$
M1$;.-9%H(=%&HH-$%XD>$GTD!D@,D1@A,49B@L04B1D2<R062"R16"&Q1F*#
MQ!:)'1)[))QC)'1=AJ<<V\ZQ[QP;S['S'%O/L?<<F\^Q^QS;S['_'!O0L0,=
M6]"Q!QV;T+$+'=O0L0\=&]&Q$QU;T65Z,19YGCRR?4'F'?!XZ%7RZA-./80R
M_-=@I,E(BY$V(QU&NB$2Y'BU)"FNGE[KL4@_)I*O%N1/O)@8(#'D9D9)$?5A
M:1PC"@6OF/C*P22.>(G]G<8`K^`?$75(9B&2,0SFC"QB#4E'DPTM66454RFG
MJ:QCB+_'\B=^?C9Q1(9!_/7ML2/^Q\S$R[OLE_<Q]:"/<7WYHJOOUH_7P3BL
M>"7U<5.^YGH.%,KYQ-=R(N<%$FE$9+SP0VNUF$\\%AL9+P.)C!<@LEI+XF@Z
M@_'D2['G.U0KU,JGC^Y!.65PGE/62^M,Y+V,T>HB]X6[G4^9!UQDORR=N`%+
M\@"C^$>=:N7`-).ZN`G+7J'BZ0%A,*$SN%"^>QN<AZS=,OC014;,THF<F,5$
M5LQB3G9,JROC*2C?8K@D!7T\GH)5_:7ZNA=`&3UL,-)DI,5(FY$.(UU&>HST
M&1DP,F1DQ,B8D0DC4T9FC,P963"R9&3%R)J1#2-;1G:,[!F17$2O230R8S"D
MK!+!.@9+.H,G)2&Y+8,KG<&6DI'<EL&8$I*!3BE8'T">UU.W+R0BN26#,YW!
MFA*1W);!G)*1K&.PIS/X4S*2VS(X5-:Y8)ULC\8STO]R_?D*0ME71[W@N_BQ
MISOSZE-./80R,S+0R4":K-)BI,U(AY$N(SU&^B$2>L@KZI4.!JPQ9&3$R)B1
M"2-31F:,S!E9,+)D9,7(FI$-(UM&=HSL&9&$1!M)0C+3,#`&/SJ#(24AN3\&
M2TH-R3H&4TI"LH[!F)*0@4[D;EF^4A5_!F,Z@S,E(;G'!F\Z@SDE(;DM@STE
M(5G'8%!9]XEU#!9UV1Z-)Z3_W?H+$C+X*KYT\_3]A[RZZUWW%^244C,C_AJ,
M-!EI,=)FI,-(EY%>B`3768JY4JZL/D/V6600%RGG/?U!=,@B(T;&L7;*7KY8
MK:CKNA-6F<94O%(AG\^K66'&*G-&%K&&:L5\L::7Z5NRRHJ1-2,;1K9'Y'!C
M7S]CM,M^>1^^'%ZP*Q1R1?6,M00C&DR"D1F#"Z5T#'3":Z*E6E5]'I98)"(R
MX?$:9%$-$RD:N;<&$TK1R#J1#]_O363#C`E,`O%\K[V*Y]5*RO!2-')OXE;T
M9-XHY8OJH3+)1!:*N[$@S^LI1TLBLHK!C7)=E74,?I2:D74,CI2:D75.GCP%
MU^ETQ1-13OLEB>CCZKIJ\NYB`&4,J(:_#G5V:#89:3'29J3#2)>17@I2S:M!
MV4^!3N?E<+=DD((D=(8ID-(9,3).01)-32S0U`+-4B#5Z3DCBQ0DT>EE"J2:
M6C&R9F23@B1ZLTV%U"W?70JDNKQ/0:J)Y^Q<"J6$)"[1?K+Z+C-I'DWLOD0F
M*Z7Y-*EDL*K4DLG6DD<IS:[Z*!G<*FOY)EO3.FENK>HU624^6<GD6,E/5C(Y
M5C*4E0R>E0QE'8-G)4-9Q^!:R5#627/MZ<S&,]1?HN*"JC)8T2)>59ZD#S%0
M]W]@(3L@&XPT&6DQTF:DPTB7D5Z(>%[U<&M"'HHN5:OGW\10'Q7[K#E(TRQD
M:`Y9<\3(.-EL\?`PPN')!O\O=1EADO*&JF*F*4Q%,3/NVYR114I+Y>*Q[_(/
M]439DC57C*P9V:3TK%(Y/Y^JVMHFWE#RJOF,-^RX$_N$9K$D3[Z<_5&=D"(6
M_2RIS(S!]%+$!CIG-O)RL=[I)W0,DX!<Z]6JA5HQIJK,*64N[T\T*YSUM1*W
MO.YK-$G(#'Z\**<F3[D.S"U'$T.63C07G/5.%CC)L(&D.+=\\=P@B<ZJT>20
MM3^&R4&N$G-;T?20U99A1I`\Y[8,<X+D.>M$\T!ZG^-Y[B^_<4&>!ZMUQ/-<
MF:'NX9(>#4::C+08:3/28:3+2"]$SNQ#>8Y'::`TY;>KO-9O*HV&W+<1(V/5
M5.Y&+PH[483\O%XQT9FI@BHWL2#-Y0JMW]1U@AEW;L[((MGP64+)/RN)AI>L
MNF)DS<@FT3<OWK=JHF];]9;:3?@(<#0?RZ%7QW'''=DK5?F=.3D?:CQ)?./`
ME/AFQN!QB>]`)W*-#"KY+8NS/\GQ+B4VMQW9_J1;DJ^[G?])[K=A'I"".][?
MPDTQ]GFL)J=2'\]H9DB?C(/'AON&?8IF@RR=:#*(]KMZ$S^<N5)BW$B,\_'D
MZ4%RFV6BZ2%K%PSS@>0VMQ7-"%EM&:8`R6UNRS`)2&ZS3F3[]#['<]M?\^."
MW`Z6"#G/[:*^JU'W<!V1!B--1EJ,M!GI,-)EI!<BD6/4/;`^*PRR%8:L,&)D
MG-W()/OE:?;+,VY_SL@BNY$E*ZP863.RR>['-OOE'3>PSU:0`$4?28`R8S";
M!&B@\\[PE;#D=B*OO:=A,)H$8W8_(INESVQ1"')?([-EZ42.>V]_#':3YYFR
M]R<R7%8_P'5RQ9GWU^`[N>+,.@;W2=*QCL%_DG2L$[DP_?C%D\Y?,N2"I`M6
M&#E/NJI^>*4N%UWQBC,B359I,=)FI,-(EY$>(WU&!HP,&1DQ,F9DPLB4D5F(
MA$^-I#WL-&>5!2/+6$.E8B6O?P9DQ2)K1C:,;!G9,;)G1,(0?21AR$S#P!@,
M*8'(;1DL*1=\6<=@2GFNB74,MI2;LZQC,*94@X%.^%28?/%7/_(BV<A-&:PI
MWX:)-56MZ"\M2D)R2P9O2D*R3N3.]$0*/J$8_"E/^G);!H?*D[Y9.O&$]!<A
MN2`A@S5+SA,R7U6W%>K^[\S+/=GWAT$C),Z/5TE=DVJF,*JA%B-M1CJ,=!GI
M,=)G9,#(D)$1(V-&)HQ,&9DQ,F=DP<B2D14C:T8VC&P9V3&R9T0BTK"(D(%)
M<Z1RF]2+W);!DG*'E'4,II2ZD74,MI2[H*QC,*8\_,LZD37##XS%DB>_`Z&^
M,V/PIEPQY;8,[I249!V#/R4E6<?@4*DC6<?@4:DC62?;I;&4E-_"OB0E#[A^
M^E?=H*^'T'D&*L<U&&DRTF*DS4B'D6Z(!&-;5@62>S'QH=UCD3XC`T:&C(P8
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MI(^K8K*@'A2KYP,H,R<1:;)*BY$V(QU&NHST0B2H-U,75V"1`2/#6#N52DY?
ML1FQQIB1"2-31F8A$AR40EF^.*Z^8S&/$7FOFEA*8,'-+!E9,;)F9,/(EI'=
M$3G\;():.F%_?/7]KTJXD`F.:R5EP=H8D+8<;0,)@P$E%-''4CPR8_"@%(^L
M$[DP8^J14&0=@Q$E%%G'8$8)1=8QV%%"D74B0V8=G\B268S!E!**W!^#+244
M6<=@3`G%+)UX*/JK-5Q0/`:+.XC\\<M-<L$Q?K6QGL<5(!J,-!EI,=)FI,-(
MEY$>(WU&!HP,0R28$+U2,5=603-BD3$C$T:FL:ZD9=X,B3DWLV!DR<B*D34C
M&T:VC.P8V3,B=2,:3>I&9@QN=`8[2D1R6P9#2MW(.@9+2MW(.@93RO55UHEL
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MLF%D>T0."]?JM1IWV2_OCR^_/W$Y`V/PH=QW1*]*.#)CL**$(^L8S"CAR#H&
M.THXLH[!D!*.K&.PI(0CZQA,*>'(.@9;RGU'UC$84RZQLH[!FE(_LH[!G%(_
M9NG$P]%?1.`\'+_)1XF"/&[TMU>\?[C[_$_S\?7A\:=LE)^E]I?T#[ZXD@_6
M'C@/R6I!W4&IAU#&QY,&(TU&6HRT&>DPTF6DQTB?D0$C0T9&C(P9F3`R963&
MR)R118B$UY?+LKI[33T=MF25%2-K1C:,;!G9,;)G1$I)7@S$X$=)2]8Q.%*N
MMK*.P9-RM95U#*Z4JZVL8_"E7&UE'8,SG<&:DI;<EL&<DI:L8["GI"7K1`;-
MF/,E+5G'8%%)2]8QF%32,DLGGI;^0@3_(BV#]0OB::DJ]7H>%SEH,-)DI,5(
MFY$.(UU&>HST&1DP,F1DQ,B8D0DC4T9FC,P963"R#)$P4+U<OJQ_M6/%*FM&
M-HQL&=DQLF=$TA*])A=>F3$84FI+UC%84FI+UC&84FI+UC'84FI+UC$84VI+
MUC%84]*2=0SFE+1D'8,])2U9QV!024O6,5A4TI)U#":5M,S2B:>EO^#`>5I"
M31FL3W">DI7DXSM9BQ@<:M-&'I$F(RU&VHQT&.DRTF.DS\B`D2$C(T;&C$P8
MF3(R8V3.R(*1)2,K1M:,;!C9,K)C9,^(I"0:25*2&8,A)259QV!)24G6,9A2
M4I)U#+:4E&0=@S$E)5G'8$U)R4`G^+Q7+=7*R5\0,S1E,*<SN%-"DG?+X$\)
M2=8Q.%1"DG4,'I60S-*)AZ2_)L$%(1DL87`>DM6">FJCGL=U#AJ,-!EI,=)F
MI,-(EY$>(WU&!HP,&1DQ,F9D<D3\>VSJXOKT^.*[M]!FC,P963"R9&3%R)J1
MS1$YW'6,/]F]/;[X[A'9,;)G1((1_27!R(S!A!*,K&.PH00CZQB,*,'(.@8K
M2C"RCL&,$HRL8["C!"/KG`SY[@B3\I%U#,:49&0=@S4E&5G'8$Y)1M8YV?/]
MXY/MTE@R^G<A+TC&`ZX?;57?/JB'4,;EZ08C349:C+09Z3#29:3'2)^1`2-#
M1D:,C!F9A$CP*39?JQ34Q?0I:\P8F3.R8&3)R(J1-2.;$(ENCNKE^+<LL6-D
MSXAS!L9@16?PHC.8T1G<Z`QV=`8_.H,AG<&1SF!)9_"D,YC2&5SI#+9TD2\S
MIE=GL*8S>-,9S.D,[G0&>SJ#/YW!H"YR:-;QR79I/"#]U07.2T?_V9TR/KM3
M"!8EB)>0>B&Z$,KH:8.1)B,M1MJ,=!CI,M)CI,_(@)$A(R-&QHQ,&)DR,F-D
MSLB"D24C*T;6C&P8V3*R8V2?@E2+ZI$ER<NL=4*")^[J!L9@2<E+;LM@2LE+
MUDFS954_3"^)R4H&:TIBLH[!G)*8K&.PIR0FZQ@,*HG).@:+2F*RCL&DDIBL
M8["I)";K&(SJLIT:3TP)O5AB9M^1+/BX*BF+>I6=$,I,RD`G`VFR2HN1-B,=
M1KJ,]!CI,S)@9,C(B)$Q(Q-&IHS,&)DSLF!DR<B*D34C&T:V*4BUJ-;=V*5`
MJFC?,R))B59R=0/3,#`&3TIER?TQN%(J2]8Q^%(J2]8Q.%,J2]8Q>%,J2]8Q
MN%,J2]8Q^%,J2]8Q.%0J2]8Q>%0J2]8QN%0J2]9)\^G)@O&<]-<?.*\L(2>#
MY0JD"\?OH5:+>E6!0M::!L&3.XPT&6DQTF:DPTB7D1XC?48&C`P9&3$R9F3"
MR)21&2-S1A:,+!E9,;)F9,/(EI$=(WM&)"71:Y*2S#0,C,&1DI)!6^'U^E)-
M/V,LU23WQF!)J259QV!*J259QV!+J259QV!,J259QV!-J259QV!.J259QV!/
MJ259QV!0J259QV!1J26S=.(9*>5<+"-MWYPL^&_3-:5ZN*,>0AD%8X.1)B,M
M1MJ,=!CI,M)CI,_(@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6C&P8V3*R8V3/
MB&1E8,@,KTE6,F,PI%Q[91V#)24M`YWP3F^^5%3/.4@]R2T9/"GU).L87"GU
M).L8?"GU).L8G"GU).L8O"GU).L8W"GU).L8_"GU).L8'"KU).MD>S2>E?YZ
M!!?4D\'R!?%Z\E2J'HK%>B&`0@\42B4O7U87G1HQIEBLY64)YOA3@\T8XN4J
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MP\B6D1TC>T8D&=%(4CTRTS`P!D?*E59NR^!)J1]9Q^!*J1]9Q^!+24G6,3A3
MZD?6,7A3ZD?6B=P91K_\\*W^Z5LI'UG&8$\I'UG'8%`I'UG'8%$I'UDGVZ3Q
MD/27'+@@)(,5"N(AJ:Z0U`M9RQB$(8E(DU5:C+09Z3#29:3'2)^1`2-#1D:,
MC!F9,#)E9,;(G)$%(TM&5HRL&=DPLF5DQ\B>$0E)-)*$)#,-`V-PI(0DMV7P
MI(0DZQA<*2').@9?2DBRCL&9$I*L8_"FA"3K1.[TO*HL+BH%]DVAYN5K9W_4
MQ"V9R:H&MTIFLH[!KY*9K&-PK&0FZV1[-IZ9_@H$%V1FL&!!/#,37PK)6M4@
MS$Q$F@5$6HRT&>DPTF6DQTB?D0$C0T9&C(P9F3`R963&R)R1!2-+1E:,K!G9
M,+)E9,?(GA')3'2)9"8S#0-C<*1D)K=E\*1D)NL87"F9R3H&7TIFLH[!F9*9
MK&/PIF0FZT3NC&5FZ5!?AG^IWX67S&15@ULE,UG'X%?)3-8Q.%8RDW6R/1O/
M3'^-@PLR,U@2(9:9)76'H%[`=1,:C#09:3'29J3#2)>1'B-]1@:,#!D9,3)F
M9,+(E)$9(W-&%HPL&5DQLF9DP\B6D1TC>T8D,]%KDIG,&`PIMRE9QV!)N4W)
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M5Y?%8'6$\^I2'DZ-/[U:#Z',U,15%IJLT@J1\&G;2BUQ+[N-1`>)+G>DQTB?
MD0$C0T9&C(P9F3`R963&R)R1!2-+1E:,K!G9,+)E9,?(GA&)3'21,YA1(I-U
M#':4R&2=R)$9DX-$9J`3^+IPN'P8GV(D,;DI@RLE,5DG\F4XS:1UQ^!+"4QN
MRN!,"4S6,7C31>8,=DON;N;SZC*AB\R9<2(B<V8<G,B<&4ADS@S$8$[)1CXT
MV?:,9Z/$W"79Z..ZHE3%?+T80!G#O\%(DY$6(VU&.HQT&>DQTF=DP,B0D1$C
M8T8FC$P9F3$R9V3!R)*1%2-K1C:,;!G9,;)G1.(1O2;QR(S!D%)1LH[!DE)1
MLDYDRF"R+'N%BJ>^8B;QR#(&5TH\LH[!EU)0LH[!F5)0LH[!FU)0LH[!G1*0
MK&/PIQ20K&-PJ!20K&/PJ!2063KQD/37)KB@@`R6,A#YX_<6JR4U?.O%K/4.
M@D=Z&&DRTF*DS4B'D2XC/4;ZC`P8&3(R8F3,R(21*2,S1N:,+!A9,K)B9,W(
MAI$M(SM&]HQ(2*+7)"29:1@8@R.EAN2V#)Z4&I)U(E<&05HJYTL5=0-(KKJR
MC,&6<M65=0S&E"*2=0S6E"*2=0SFE"*2=0SVE*NLK&,PJ%QE91V#1:629)UL
MD\9#4NJ]2T+2Q^.59"UQD35@RH<'E/,UO;)=HWC^>K&4TU\";L:`0M4KJ0=K
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M>7O^)6?Q^NKWY[>WYQ^'?WY[O/_\^.(#`G]Y?GZ+_D=.Z.U?SR]_'$;$I_\3
M````__\#`%!+`P04``8`"````"$`6@_:5/$$```)%0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6R4F,N.JT80AO>1\@Z(_3$TF(LMVT<#:)(C)5(4
MY;+&N&VC`=H"YO;VJ:8P0Q=.8V]&`WP4]5=U\>/>?/\H"^.-UTTNJJW)%K9I
M\"H3A[PZ;<V__WK^%II&TZ;5(2U$Q;?F)V_,[[N??]J\B_JE.7/>&A"A:K;F
MN6TO:\MJLC,OTV8A+KR"*T=1EVD+A_7):BXU3P_=365A.;;M6V6:5R9&6-?W
MQ!#'8Y[Q1&2O):]:#%+S(FTA_^:<7YIKM#*[)UR9UB^OEV^9*"\08I\7>?O9
M!36-,EO_.%6B3O<%Z/Y@RS2[QNX.)N'+/*M%(X[M`L)9F.A4\\I:61!IMSGD
MH$"6W:CY<6L^L77BN*:UVW0%^B?G[\WH?Z,YB_=?ZOSP6UYQJ#;T279@+\2+
M1'\<Y"FXV9K<_=QUX(_:./!C^EJT?XKW7WE^.K?0;@\426'KPV?"FPPJ"F$6
MCB<C9:*`!."O4>9R:4!%TH^MZ<"#\T-[WIJNO_`"VV6`&WO>M,^Y#&D:V6O3
MBO)?A%@?"H.X?9#E$(0Y"R?TF.?/1[$PHTY@DK;I;E.+=P-6#3RSN:1R#;(U
M1+XJPSP&K?\G%33*($\RRM:$Y0XJ&NC/VR[TEAOK#6J:]4PT99A*Q%="%E"&
M348G+,AW2!KJ.$[Z=ANNN4E8YG:-&N$)B#TDZY!$IH1+D&2*!.$014D6^G9_
MLA+NULF06^AY0]RN*A$RT*R!\5P5B:>(KQ*)CE#2A^?<G[Z$:?KDR1$R?K=*
M7,<.'/>K<)W`>$RPT`_=)2E!HA`KVV-?!5"2A^D:)R]7MPO3KU\P\B8J(E#+
M%R$3H(B5PVS;5HEX3"S=U91(QH2S7(Y#*")\580^>0G3Y$E](V2@AL,"\@,Z
MBS<856"B(Y3\@T?RES#)GY'21L@H^:NYQ;-$HB.4[*6'DQ?D_!*2-Q$5WDK-
M,4)FU2TA>T'KCU<U&A,=H2A8J0KTZT?")'-&<HN0T>06SQ*)CE"R9S"OCS>@
MNXOHF'2@A[`%RX5/ACSNKVN$)EI$U2'-[.&%Q-`"P6V&60U].@\]I,DSGD<2
M+:)*D>9'I#!G]KW*T#-5+71M]=!82^@3\XUO0,1E$BVBJI%62-3,3SA#`U7%
M?+D0.G4/H4TX'KSAQR]Y-+N>&0N>:+G;K!F$&6O1SWI'DR'Q)Y]M,N361`W,
M]5TG6$[Z@8Q6@PY1^R%]\?%^H)NJ_2"?#9'\9@<MFCSC>231(JH4Z9%$2@`Y
MS+0%G565,IF3J?V&/EDX,9M"!$FTB"I&6B81<\><H-&J8B9S@E"_QG!,R$LN
M9CK'[D8IT2*J%FF>(RTS#4&K535,Y@2A?M;];MA5QX^9SK)["3I$E2`=="3A
MOF];AKZK2B&^%_60=DQT_MU+T2&*%&D=8RGZ;G0T>6MY9%E'/83=\-RE0[Z!
MXQ[0:$RTB"J`>/N,@*FG!PYYI48.0KV`&[[1`UH!&.,VH@J`!?%`!R1-.N"3
M`D<.0N.'AS[Y!HYO0*23B19111`CG^G"#0,/R$LG@DTEJ11_K#JN"U--9KHG
MQC(G"N;M&W>><&.FY/6)Q[PH&B,3KW)7R8'?",/98<?KR9%;&N1\!#MAW;:1
M-5R`C:A+>N*_I_4IKQJCX$<(:2^D#]6XE84'K;ATVT%[T<(65/?O&;8<.6S$
MV`N`CT*TUP-XL#5L8N[^`P``__\#`%!+`P04``8`"````"$`SOQ*SY$%``"0
M&```&0```'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6R4F5]OHS@4Q=]7VN^`
M>"_$!@*)DHP*5G='VI%6J_WS3(F3H(80`6TZWWZON81P#26D#],F_')SSK7-
M,9[5M\_L:'S(HDSST]IDULPTY"G)M^EIOS;_^?OE*3"-LHI/V_B8G^3:_"E+
M\]OFUU]6E[QX*P]25@94.)5K\U!5YZ5ME\E!9G%IY6=Y@BN[O,CB"EX6>[L\
M%S+>UA_*CC:?S>9V%J<G$RLLBRDU\MTN3:3(D_=,GBHL4LAC7('^\I">RVNU
M+)E2+HN+M_?S4Y)G9RCQFA[3ZF==U#2R9/E]?\J+^/4(OC^9&R?7VO6+7ODL
M38J\S'>5!>5L%-KWO+`7-E3:K+8I.%!M-PJY6YO/;"EX8-J;5=V@?U-Y*3M_
M&^4AO_Q6I-L_TI.$;L,XJ1%XS?,WA7[?JK?@PW;OTR_U"/Q9&%NYB]^/U5_Y
MY7>9[@\5#+<'CI2QY?:GD&4"'84R%O=4I20_@@#XU\A2-36@(_%G_?N2;JO#
MVG3FEN?/'`:X\2K+ZB55)4TC>2^K//L/(=:4PB*\*>*">KS.7<OEGA],J&*C
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MN*<CHHOH#HE\_Q'Y"M;D^_K41^:+SM6K(T($'3X%S/7<8$XMBM$JQ(`*\,[=
M<?Q&HV#=@$>_.D1FU,!]1(PBQ,#B$0,*U@UHO0N1&36`2#,"'F.N-@G%:`TB
MGT%43Q^`FM8-:(LO;*!F";M\:`E39G"9"\*,K@*F8FSR+*IIW<0M6C`"&J@Q
MX?ASUV?Z0FZ8[E!I@RE&$3H0*N^F>\!T[`8!-%I;"@RA$7W1?42,(M2"RKSI
M%C`ANTG<3P.&D(MQ8,UO=W&\%Y'K,\OI]?_Z^:$HI^*A30^(5[0VAWI1P!!"
M\=S2@SHBUYG%>^*[GR?FJ'*5=M/;CME(VZZG@-IZ@SWX_B]W0"VB]J(@3EM`
MHKT^5(+J5VDW73]F(]6O=2YD"(WJOR*H7]\#BM$25+]*N^GZ,1NI_MXM]!J@
M2ARS?&UE1XQ>UY>%(-='9HZ*N>G*,12I<FW80W9-3E0>])Y`KM>'ID6]ID5;
M8@BAG5<YU]&OGJT<"+3Q703#=(0[0SNY`[W#80.-SJ!^RFKS4(Q6(5;X0SE<
MT]KMI[>3;J`Q"P-($&@Q)P:@FT]JXJ$<YOCP2>93[Q[:0%T306]2#4+ZGF@0
MNGFE1D!4=V*-3RBN:'TT]"7=0,0(N_41XVP`TA`Q@'2'C-I0Z==9'W=L8%:2
M\>@\<N.^B/<#->C;Z$,]&V,(-0$M>\"$HND3LNMH-Z&0(]0="TU?=!\1HPBU
M\%!"JQ.KWG32-CYA`\UQ8^0O?+98:"D>$<9Q`V>^T#HA&F2X$]3#0RG-!U*Z
MO[81PCVVQP<>A*.F#B(."Q:,>;<UBWE!&<TF]?!04O,I2=U`*-`-%@[W?6WI
M1X1A@V,E"*./%37Q4&C#H6U_,NFAW4`XF=QYX,X\3]]R-,SP3&D&8BS;T0,>
M`./Y:":+O8SD\5@:2?ZN#G<YS.;VW?;@^9FKDT7M_1`.I.O36[N]`.?!YW@O
M?\3%/CV5QE'NH.3,\F$Y%7BBC"^J_%R?RK[F%9P$UW\>X.1?PGGHS`)XE^?5
M]05\L=W^7\+F?P```/__`P!02P,$%``&``@````A`*=0T2]H!```]PX``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-#4N>&ULE%?;;N(Z%'T?Z?Q#E/<A<>X@
M8-2$])R19J31T;D\AV`@:A*C.)3V[V<[.TYMTV%H'QHP:ZVL??%M^>6EJ:UG
MVO&*M2N;S%S;HFW)=E5[6-G__O/X.;$MWA?MKJA92U?V*^7VE_4?GY87UCWQ
M(Z6]!0HM7]G'OC\M'(>71]H4?,9.M(5?]JQKBAZ^=@>'GSI:[`924SN>ZT9.
M4U2MC0J+[AX-MM]7)=VP\MS0MD>1CM9%#_[YL3IQJ=:4]\@U1?=T/GTN67,"
MB6U55_WK(&I;3;GX>FA95VQKB/N%!$4IM8<O5_)-57:,LWT_`SD'C5['/'?F
M#BBME[L*(A!IMSJZ7]D/9)&3P';6RR%!_U7TPI7/%C^RRY]=M?M6M12R#742
M%=@R]B2@7W=B",C.%?MQJ,"/SMK1?7&N^[_9Y2]:'8X]E#N$B$1@B]WKAO(2
M,@HR,R\42B6KP0#\MYI*M`9DI'@9GI=JUQ]7MA_-PMCU"<"M+>7]8R4D;:L\
M\YXU_R.(C%(HXHTB\'Q'Y`;1'XGP'(G$FWE)2,)(O/X&,QB9\/S8*T%V"!B>
M][W2P8P-!=@4?;%>=NQB05=#3OBI$'.$+$!-9AY-3[7X52F@!D+D0:@,6I!E
M#OWSO([B:.D\0\W+$9,B!J;LA/%T1"81HL!"=B,'WBB^P<DE1+07A#3%!554
MXWJ_DZ1]`8:>4:SY0:B;2Q$#E9KL&P%F$C'9EP._I.028;H'*_>[%^"5#5*3
M,S](#/>(B8;2S`/B$U\'9`@8YCCF7F7X\]@CKL[(%8:6>4C1_=X%V/0^UU^4
M(B8>O">A"W\Z($.`XET.O&4D-.+-)<3,/,R!^]T+L.$^-,REB$'W7AC-/0.0
M(4!QKS(("9*YD9!<86B9CW3O8B[[L!;?[GU!,F,@>H)3Q&`,OAOYKI'-#`%*
M#"J#N'&<!+IDKC"T&&(]AMO>!=CT;BP0*6+&_'M!:!8H0X#B767,K]LM5PB:
M=7$:49;2V]8%V+1N9#5%#%H/_2B,C21F"%"LRX$;C2\A9N///^)>@$WWAKD4
M,>B>>-#WQIJ4(4!Q+P=NN)<0TSV!/K\_^0/:]&\N^"-(!A!YOE&?;$0H$6B<
MT'==HQMSE:(U#Q$;F=(]PT8<B^/.;^;O0-1CB>)8GVWI"!IG`?A*S&*,"$(@
MP],^$L4&;*,)Q6X<FFO3;W7TJ,4&J$1]>\X0W"[5G2Z*#0/I",*MSH]<0A(#
MDHT0M6ZHC*3$A[EF='.N<O00Q#YX?PBX:Y)X.'J*0TY*KH:RZZ'-]5"N#>F>
MQ.ZF>!+-%$`G??14AYNDGF^C(U*X%XBU@,"Z\M8WB;G)O:%@YHZ'NXDHA\0=
M8]2:YC?>&?#(VM#N0#-:U]PJV5G<!P(X%$RC>%=)R0(.DL`WQC?B#O/.^`/Q
MX0?_G5\@-'GM<28QN':<B@/]7G2'JN563?=@PYW%D-T.+R[XI6>GX4"\93U<
M.(:/1[A@4JBX.P/PGK%>?A'!3E?6]4\```#__P,`4$L#!!0`!@`(````(0"I
M"Q$X50(``)D%```9````>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;(R4VX[:
M,!"&[ROU'2S?;YP0$A9$6"T@VI6Z4E7U<&T<AUC$<62;T]MW'`,E@+;<0!S_
M\_F?\4S&+WM9H2W71J@ZPU$08L1KIG)1KS+\Z^?BZ1DC8VF=TTK5/,,';O#+
MY/.G\4[IM2DYMP@(M<EP:6TS(L2PDDMJ`M7P&G8*I26UL-0K8AK-:=X&R8KT
MPC`EDHH:>\)(/\)012$8GRNVD;RV'J)Y12WX-Z5HS(DFV2,X2?5ZTSPQ)1M`
M+$4E[*&%8B39Z&U5*TV7%>2]C_J4G=CMX@8O!=/*J,(&@"/>Z&W.0S(D0)J,
M<P$9N+(CS8L,OT:C61^3R;BMSV_!=^;B&9E2[;YHD7\3-8=BPS6Y"U@JM7;2
MM]R]@F!R$[UH+^"[1CDOZ*:R/]3N*Q>KTL)M)Y"0RVN4'^;<,"@H8()>XDA,
M56``?I$4KC.@('3?_N]$;LL,QVF0#,(X`CE:<F,7PB$Q8AMCE?SC1=$1Y2&]
M(R0&]\?]7M![3J(D_3^%>$=M@G-JZ62LU0Y!T\"9IJ&N!:,1D%UF,=3G?F:0
MDHMY=4%M**@-W,9VD@[B,=E""=E1,[W5]+J*V:TB_B<AX.]L$E*_-/FQ.2>&
M)#`ZFXO[2??HJ=?T+S1I5S'[2-'Q!@<][LV),PSLL[=TT.^>//6:85O6,+C:
MG?G=^\X[OD#RN"\GOO9U73.O25M?_2A.AEW?,'^.<6_?^_+3Y9NOH2O^3O5*
MU`95O(!JA,$`1D'[V?(+JYJVR9;*PDRTCR5\`CET8!B`N%#*GA9N>L\?U<E?
M````__\#`%!+`P04``8`"````"$`#,23378"``!>!@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6R455UOVC`4?9^T_V#YO7$2(`%$J(I0MTJ;-$W[
M>#:.0ZS&<62;`O]^US:DZ:A:^D)B[O$Y]YY[[2QN#[)!3UP;H=H")U&,$6^9
M*D6[+?#O7_<W4XR,I6U)&]7R`A^YP;?+SY\6>Z4?3<VY1<#0F@+7UG9S0@RK
MN:0F4AUO(5(I+:F%I=X2TVE.2[])-B2-XXQ(*EH<&.;Z&@Y558+QM6([R5L;
M2#1OJ(7\32TZ<V:3[!HZ2?7CKKMA2G9`L1&-L$=/BI%D\X=MJS3=-%#W(1E3
M=N;VBPMZ*9A61E4V`CH2$KVL>49F!)B6BU)`!<YVI'E5X+MDOLHQ62Z\/W\$
MWYO!.S*UVG_1HOPF6@YF0YM<`S9*/3KH0^G^@LWD8O>];\`/C4I>T5UC?ZK]
M5RZVM85N3Z`@5]>\/*ZY86`HT$3IQ#$QU4`"\(ND<),!AM"#?^Y%:>L"C[)H
MDL>C!.!HPXV]%XX2([8S5LF_`92<J`))>B*!YXDD2:-T.DDFV?LL)&3D"UQ3
M2Y<+K?8(A@8T34?=""9S8'Z](BC%8>\<V&^!9`UTX6F9Y>F"/(%U[(1976*>
M$01$>V50&RH[3T?0F;<S<)L`AU&?P2@9_9=!P(P'F*Q'O,@`:(89O*WLP`5.
M?=5IG(Q[2F_-*H0S'Q['T[@/OU"$I*Y7=."!XJ2G#(HAG'O%9#;+^_`+19BO
MZQ4=>*#X;%M0#.'W%+./*#KP0/&YB*`8PN\IYA]1=."!XK2W+2B&<.CC*ZZ&
M*R*<H(YN^7>JMZ(UJ.$53&0<Y>"1#A=$6%C5^1.S418.MG^MX1[G<)SB","5
M4O:\<%=0_V58_@,``/__`P!02P,$%``&``@````A`*,%]O"Y`@``#P<``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S@N>&ULE)5=;YLP%(;O)^T_6+XO!A((
MB4*J)JA;I4V:IGU<.\8$JX"1[33MO]\Q#BPD79O=D-CGY>$]YYC#\O:YKM`3
M5UK()L6!YV/$&R9ST>Q2_//'_4V"D3:TR6DE&Y[B%Z[Q[>KCA^5!JD==<FX0
M$!J=XM*8=D&(9B6OJ?9DRQN(%%+5U,!2[8AN%:=Y=U-=D=#W8U)3T6!'6*AK
M&+(H!..99/N:-\9!%*^H`?^Z%*WN:36[!E=3];AO;YBL6T!L127,2P?%J&:+
MAUTC%=U6D/=S,*6L9W>+"WPMF)):%L8#''%&+W.>DSD!TFJ9"\C`EATI7J3X
M+EAD$2:K95>?7X(?],E_I$MY^*1$_D4T'(H-;;(-V$KY:*4/N=V"F\G%W?==
M`[XIE/."[BOS71X^<[$K#70[@H1L7HO\)>.:04$!XX6=#28K,`!75`M[,J`@
M]+G[/8C<E"F>Q%XT\R<!R-&6:W,O+!(CMM=&UK^=*+"F!DAXA$S!_3$>>F$2
M!5'\/H4X1UV"&35TM53R@.#0P#-U2^T1#!9`[C-S/H9<_Y4JV+.0.TM),9QV
MR$)#>YY6\72^)$]04W;4K"\UP5BQZ14V:XO-3C8(^!U,0RE.3;_>AMZ;%5MO
M/77M-H`]F`W/C%PJ)F>2[%(R2P;*R.SD?\Q:<8H!/GB+(W_@=E59.TW<E7DZ
M2Y+).+XYC8>S:3(=Q[-1/(J3>(B/?,-IN+[(5CSV'?JS@>M\.PU<_^8V5FS>
M561O*4;NX;VZWKT5C]W'T=GA7#N-JWH0S).SKFQ<_(WL8$#9I[RN<-[=`'+O
M9\W5CF]X56G$Y-X.EQ`Z/NP.<^\NM"?[;'\-\[";'F0(P#QJZ8Y_I6HG&HTJ
M7@#2]V;@2KF)YA9&MMU4V$H#DZC[6\*'A\/[Z'L@+J0T_0(>3(9/V>H/````
M__\#`%!+`P04``8`"````"$`;*=Z+N@"```W"0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6R4EEUOVC`4AN\G[3]8N6^^($Y`0%6HNE7:I&G:Q[5)
M'&(UB2/;E/;?[]CFRV%%X08P?O+F/:\=G\SNWYH:O5(A&6_G7N2''J)MS@O6
M;N;>[U]/=YF'I")M06K>TKGW3J5WO_C\:;;CXD56E"H$"JV<>Y52W30(9%[1
MADB?=[2%F9*+AB@8BDT@.T%)82YJZB`.0QPTA+6>59B*(1J\+%E.'WF^;6BK
MK(B@-5'@7U:LDP>U)A\BUQ#QLNWN<MYT(+%F-5/O1M1#33Y]WK1<D'4-=;]%
M8Y(?M,W@0KYAN>"2E\H'N<`:O:QY$DP"4%K,"@85Z-B1H.7<>XBFJRCT@L7,
M!/2'T9T\^XUDQ7=?!"N^L99"VK!.>@76G+]H]+G0?\'%P<753V8%?@A4T))L
M:_63[[Y2MJD4+'<"%>G"IL7[(Y4Y)`HR?IQHI9S78``^4</TUH!$R)OYWK%"
M57,OSOPX2Z($`X_65*HGIC4]E&^EXLU?2T5[+:L2[U5&8'\_'P]6":PE4^$C
M460Q$WR'8-O`/65']":,IJ#\_Y*@%LT^:-A<`F8EK,/K`B?Q+'B%[/(]L[QD
M>L3JDAB=D`!\'<U!R</-:1B2]="9N5'/G&6PL1XE29CU@)4#Q#A.3X#C#*(:
M[DS#KK-XDO6<628USNXFHQ0G+K!R`!SB,#P"CK/Q+<XT[#K#R?BH:Q9]:1GK
M#$>CJ.=\Y<PG^*/$8*,/3TS#KJ\X[`6RM`S<_;3>KO/5-<+)#-_B3<.N-YR<
M=HG-S#(VLRC,QDD_M',`IQB?YAUCZ2W&--PWU@_-,M="NT8XWG1W&WQR:+CO
MK1^:96QH8PQ'8V\Y/YYW?$UN\:5AUU<<INY]EY:YEMDUPO$&7>J&T`SMNKO<
M:GOHW%Y_.^KFJ,O<GWO1).N?';;UV<;0D0W]3L2&M1+5M(2G*_13>)2$;7QV
MH'AG&L&:*^A7YF<%+R@4ND3H`UQRK@X#W5J/KSR+?P```/__`P!02P,$%``&
M``@````A`#LJI?*5`@``S@8``!D```!X;"]W;W)K<VAE971S+W-H965T-#`N
M>&ULE)5=;YLP%(;O)^T_6+XO'R:0#X543:INE59IFO9Q[8`)5C%&MM.T_W['
M=L)"4FWLAN#P^/7[GF/,\O95-.B%*<UEF^,XB#!B;2%+WNYR_./[P\T,(VUH
M6])&MBS';TSCV]7'#\N#5,^Z9LP@4&AUCFMCND48ZJ)F@NI`=JR%)Y54@AH8
MJEVH.\5HZ2:))B11E(6"\A9[A84:HR&KBA?L7A9[P5KC111KJ`'_NN:=/JF)
M8HR<H.IYW]T44G0@L>4--V].%"-1+!YWK51TVT#NUWA"BY.V&US)"UXHJ65E
M`I`+O='KS/-P'H+2:EER2&#+CA2K<GP7+S89#E=+5Y^?G!WTV3W2M3Q\4KS\
MPEL&Q88VV09LI7RVZ&-I_X+)X=7L!]>`KPJ5K*+[QGR3A\^,[VH#W4XAD,VU
M*-_NF2Z@H"`3D-0J%;(!`W!%@MN=`06AK^[WP$M3YS@AP82DTUD,/-HR;1ZX
MU<2HV&LCQ2]/Q4<MKT*.*@G8/SXG`9FE<9K]6R7TEES">VKH:JGD`<&N@35U
M1^T>C!>@_'XDR&+9.PN[*6!60QM>5EF:+<,7J%UQ9-;7#!D2FVLB^8.$X*LW
M!Y''F[,P5!:C,W/3X=)KSTS.F2&Q^1LQ\`8+C?=FX1R#=N^-S";#E=>>R5Q9
M9V1"2#P$-N?`/$VR-.V!@3.(-]Z9A8?.DFC>Z[JVKSTS]<[F\RB*AL#&`W#M
MXZ5)CPR\P78?[\W"%][BBZ77GO'>R)0D%U7=^.=CK&7_8\W"E]8N^K7VC&]H
M/$VCR5G#7&'AS+(JGGBWH_Y(\B]L1W?LB:H=;S5J6`6ECH(IQ%/^0/(#(SOW
M@FZE@7/$W=;PW6#P]D8!P)64YC2P1U[_)5K]!@``__\#`%!+`P04``8`"```
M`"$`ISFR5YL"``!;!@``&0```'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R,
M55MOFS`8?9^T_V#YO9A+(1>%5$U0MTJK-$V[/#O&@%7`R'::]M_O,PXT)%O;
M%\#V\?$YW\6L;IZ;&CUQI85L4QQX/D:\93(7;9GB7S_OKN88:4/;G-:RY2E^
MX1K?K#]_6AVD>M05YP8!0ZM37!G3+0G1K.(-U9[L>`LKA50--3!4)=&=XC3O
M-S4U"7T_(0T5+78,2_41#ED4@O%,LGW#6^-(%*^I`?VZ$IT>V!KV$;J&JL=]
M=\5DTP'%3M3"O/2D&#5L>5^V4M%=#;Z?@VO*!NY^<$'?"*:DEH7Q@(XXH9>>
M%V1!@&F]R@4XL&%'BA<IO@V6V34FZU4?G]^"'_3)-]*5/'Q1(O\F6@[!AC39
M!.RD?+30^]Q.P69RL?NN3\!WA7)>T'UM?LC#5R[*RD"V8S!D?2WSEXQK!@$%
M&B^,+1.3-0B`)VJ$K0P("'WNWP>1FRK%4>+%,S\*`(YV7)L[82DQ8GMM9//'
M@8(CE2,)CR37H/ZX'GKA/`[BY'T6XA3U!C-JZ'JEY`%!T<"9NJ.V!(,E,`_.
MG([1Z_^L@D=+<FM94@S5#BXTI.=IG<3S%7F"F+(C9G.)"::([8"P`;2TV<D$
M`;VC:`C%J>A_IV'09L%6V\"Z<1/`/8H-SX1<(J(S2'8)F;T:GHB-IF)MA".H
MP+=%VTV`.]$8!=%4Y<9A(&FCCV2*V+Z+R-Y"3%S`,1\/N06G&$+TJBQ>3+5M
M'";IBR7PP^0LP-O3]7`^FYUY@W:W9[C]X2(XX7>Z73.[6F^X*OF6U[5&3.YM
MHX9P[C@[WB&WH:V2L_D-W"U])Y)Q`7J[HR5_H*H4K48U+X#2]V;0S,K=#FY@
M9-=WV$X:Z.K^LX)+G$-M^QZ`"RG-,("#R?A;6/\%``#__P,`4$L#!!0`!@`(
M````(0`4Q)A'"`4``*$5```9````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM
M;)2878^J2!"&[S?9_T"X'[$;`3'JR<AD=D^RFVPV^W&-V"H9H0TPX\R_WVJJ
M%:KAL'`SCOKP\G95=17V^MMG=K$^1%&F,M_8;#:W+9$G\I#FIXW]]U^O3TO;
M*JLX/\07F8N-_25*^]OVYY_6-UF\E6<A*@L4\G)CGZOJNG*<,CF++"YG\BIR
M^.8HBRRNX&UQ<LIK(>)#?5%V<?A\[CM9G.8V*JR*,1KR>$P3\2*3]TSD%8H4
MXA)7X+\\I]?RKI8E8^2RN'A[OSXE,KN"Q#Z]I-57+6I;6;+Z?LIE$>\OL.Y/
MMHB3NW;]IB.?I4DA2WFL9B#GH-'NFD,G=$!INSZDL`(5=JL0QXW]S%81#VUG
MNZX#]$\J;F7K?ZL\R]LO17KX+<T%1!ORI#*PE_)-H=\/ZB.XV.E<_5IGX(_"
M.HAC_'ZI_I2W7T5Z.E>0;@]6I!:V.GR]B#*!B(+,C'M**9$7,`!_K2Q5I0$1
MB3_KUUMZJ,X;V_5G7C!W&>#67I35:ZHD;2MY+RN9_8L0TU(HPK4(O&H1OI@M
MN!<LIZBX6@5>[RI\K!4'EU5'Z26NXNVZD#<+2@^,E]=8%3);@?`]/+B81\!^
M%"\(E!)Y5BH;&_8,A**$)']L?7^^=CX@,8EF=EV&42*Z$RJ?8._A$<+6]MB?
MNKL5!2LK*I7*VPX_`.V'-V[<MTNX#4*<0(3&.U$PE$OKQKYO+'F'S*+-&.:&
M".(-1,9[4_#&AH4_@N+[S9HQ<,CX=3J?PCDS,QH1(`B8%SZ\$V>P4<8[4[`9
M-?>AB\Z0@=LW[BD1#1'$FS_%FX+-J"WHG7?(!'74`L\+%DL*1&W`97[`&@7B
M+)CB3,&F,X_>>(<,.O-]SUN:SMH`=T//:Q2(,S4;6SUC>#\JV'36K!CSB<Q`
MS-K`4,S"*<X4;#IK5HS.D!F(61L8BAF#R=4.FFJT+GPV'+SZ*NK1;?4F]*BA
MH>TPB)#<,M6$1R>WIO]OMVIHT!^V_GZ$^E/->KP_;.VTSYG5QQ#")'L!#[A/
M=TY$"+:<L[#1H.Y4MQ[O#GL[=6=6($-HR%V;&'0'\6V[&UF#ZBJS!CLN$>I/
M8%VF$1M":!0G#0SU-`?^(`C--/#-B:&A07^C9P:;-#1JFL;/]YOZT7NX/16\
MT.5F;]8J6`:<S7_4F]FDL5'3IK=.;MMSH==;&QCR-FEPL+[)8>S,G88&\XHZ
M_0BMNTGC@V'KIW5G/M]IJ/_F>E^@3C]"_'%CA@S/CIHV<VO6G8:PK%P6>L8"
M(@)P-^#-4R+U-FEN<.SWM/,URK@G-+3`!]!%V#Q=8N#(]\VO#6I+]?;1#9GC
M)*"VS.V@H7O(%I[A.R+`4,A4WQ[O#;L\]1;00;7C")%:\LU6T@LUP:7Q`ZFV
MQW$C@ZNK:.FYO+F#3B]"Q"M=3J1U^A'J<]+(4#_=.R/#J/R=AOIOKBMP],C@
MDT9&3=/X=4>&AK`.0Q8LC)D7#0`T=I-&!L=F3^O0V`([#:&WIV78^>$;46+@
MQR.?-#1JVHQ<9P?C1,!?MGR^--Q'6@2_9PMOV71-&KA)\P).N<Q-X?N=#=PS
M#(*FM^FRZX.:\D6/>"*&9SV9*$XB$I=+:27R79UV<6BJCT\?)W'/7!V;&)_O
MX(2N/LYR'E_``=DU/HG?X^*4YJ5U$4>0G,\"V`X%'K'AFTI>ZQ.FO:S@:*S^
M]PQ'H0*.9>8S@(]25O<WZM#G<;BZ_0\``/__`P!02P,$%``&``@````A`*/N
M)&LZ!```\P\``!D```!X;"]W;W)K<VAE971S+W-H965T-3(N>&ULE%?1CJ)*
M$'V_R?X#X7V`1E`PZF:$G7LWV4TV-W=WGQ%;)0.TH7&<^?M;10MV-R[B/#@*
MIP_G5%5W48O/[T5NO-&*9ZQ<FL1R3(.6*=MFY7YI_OSOY2DP#5XGY3;)64F7
MY@?EYN?5I[\69U:]\@.EM0$,)5^:A[H^SFV;IP=:)-QB1UK"G1VKBJ2&G]7>
MYL>*)MMF49';KN-,[2+)2E,PS*LQ'&RWRU(:L_14T+(6)!7-DQKT\T-VY"U;
MD8ZA*Y+J]71\2EEQ!(I-EF?U1T-J&D4Z_[HO695L<O#]3KPD;;F;'SWZ(DLK
MQMFNMH#.%D+[GD,[M(%IM=AFX`##;E1TMS2?R3PF4]->+9H`_<KHF4O?#7Y@
MY[^K;/LM*RE$&_*$&=@P]HK0KUN\!(OMWNJ7)@,_*F-+=\DIK_]EYW]HMC_4
MD&X?'*&Q^?8CICR%B`*-Y?K(E+(<!,"G4618&A"1Y+WY?\ZV]6%I3J:6/W,F
M!.#&AO+Z)4-*TTA/O&;%;P$B%RI!XEY(/%!_N>]:;N`3?WJ?Q1:*&H-Q4B>K
M1<7.!E0-/),?$ZQ!,@?FUIG0T7G]DU7PB"3/R+(TH=S!!8?\O*V"8+*PWR"F
MZ06S[F.(BHA:!`80:6/I@@UZ.]$0"EGT[32TVA",VEK6M;@`W)U85Q/21TPT
M2-R'S(*.11$[>40L@J$Z)&U!X'6\3536`@/)ZO1/541T%Q$/(13U\)CQH4;P
MTH30=,H\SU>UK04F;(K$M?0JB=3;CA?*?]<(B_J0P8Y%KF%0+,`6&V\!P9H%
M7[<@,/#PSN;UR8VPJ(\(7&T_Q'W,E471/WU$/X)U_5=>44`"0TC0),%1$Q0-
MWHW_=%=1/'M$,8)5Q0'1-*T%9BCB=Q'Q$$)1CUU;.A*'3Q<$W]NP`C.D_BXB
M'D(HZL-'U"-8C;WGZ=4B,&VU!%;@*'_^ER>MLB-UQ<PB\AX.PZ"W(E97A!91
M'N%X\@K%+8%>/CY9#5KSZVM=:'T!M88=R_/<4-:CM8+HQH*I-[`@[BV8A,25
M8W0]YU2SV`]'5R81W5,YC7M'V04DUV;OI(IN@+0BB6]`9![5!O;.\39$IY5M
M!*27,P&2;6@*(W(7$@]"5`O8/\=;$-T6/KN&T>_J9*@EBZYR'Q(/0E0+$*P'
M+"!:VSF]DX((4+MSB$7<+T^]W:*#<'=KH%ACFEC>3-X?>(1<EZBVL*V.SXQH
MPG)Q>?T#08!:6W`@^$$@RYEI'11'`PB6M,`+M(J->QB?!*/.`&S`X_V)=JWZ
MTU]G8')"N9"7:WFZ&BBZ`=)V&$Y@?9[KRZM(DYBQQ`A2T&I/(YKGW$C9"><G
M%]Y(NJO=;/?LXLN[=GV-,Q]>M[L;,'(=DSW]GE3[K.1&3G=`Z5@S2$<EAC;Q
MHV;'9O#9L!J&K>;K`89K"B.'8P%XQUC=_L`'X+#83$ZK_P$``/__`P!02P,$
M%``&``@````A`.$:JUKV`P``G0X``!D```!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&ULE%==CYLX%'U?J?\!\3Z`^0@0):DFT-FMU$K5:ML^$W`2-(`1)I.9
M?[_WXD"QZ1":AR38YQ[.N;[^VGQ\+0OMA38\9]56)X:E:[1*6997IZW^_;^G
MAT#7>)M465*PBF[U-\KUC[L/?VVNK'GF9TI;#1@JOM7/;5NO39.G9UHFW&`U
MK:#GR)HR:>&Q.9F\;FB2=4%E8=J6M3++)*]TP;!NEG"PXS%/:<S22TFK5I`T
MM$A:T,_/><U[MC)=0E<FS?.E?DA960/%(2_R]JTCU;4R77\^5:Q)#@7X?B5N
MDO;<W<.$OLS3AG%V;`V@,X70J>?0#$U@VFVR'!Q@VK6&'K?Z(UG'Q-7-W:9+
MT(^<7OGHO\;/[/IWDV=?\HI"MF&<<`0.C#TC]'.&31!L3J*?NA'XUF@9/2:7
MHOV77?^A^>G<PG![X`B-K;.WF/(4,@HTANTA4\H*$`#?6IEC:4!&DM?N]YIG
M[7FK.RO#\RV'`%P[4-X^Y4BI:^F%MZS\*4#D1B5([!N)"^IO_2O##CSBK>ZS
MF$)19S!.VF2W:=A5@ZJ!=_(ZP1HD:V#NG0D=@]?WK()')'E$EJT.Y0XN.(S/
MRRX(O(WY`CE-;YC]%$-D1-0C,(%(&X\:3-`[B(94C$7_?AAZ;0A&;3WK7C0`
M]R#65H1,$8X"B:<0/QA8)+&.+!8S[+Y;.[UH#((J&6D,@M7`WV5G+S`P:(,/
M!1'=1<1S",D%O&9YRA&\U2%%@[(@\!7U`D-(T)6+)?=&L[WQ>[V28LCQ<L4(
M5A031=->8.#=@RLUWW<1\1Q"4K^2U2^K&@RZ5S4",^?B+B*>0T@N?-G%_$1%
ML#P&KJMD>"\P?=6L##>4/OZG!T>I)#6"6-+'G43$<D1HS$5(;G&['ZVE\VX1
M++L-@E\KB)CA`M.[M0S'<;RQ>F51BE2\:_G^&*\LN+&*=_R0C//Y2X_D,_P3
MGPA6?-J*[KW`C&LRL-5Q7(")?X,)PJ$>)`\$#@'+!ZM#*RZ(DLW]#32VH91O
M=!\2ST)D"[@]CNIMV1I!Q*8ZO[7<0+-6!,\,))YED:W@=CJR,C]UB-A\Q_O+
M=*6X@?K)0PQ?GL?DTX-2AI$28ANV,P'%$Y#GC*=,&(Y#9).XV2XW*;;FL<GI
M`D$$J#=I&:[GKV9F?#0-6%E27I2BCJ<!ENM+AM^97U`8?V`6T<K\FJP2<,)'
MT+CB@E#9I*,E(+PKS#&)41.W`7%8+FESHA$M"JZE[((G?1N.+4/K<`MYM/&8
MJ;3O\7:"[>;0`9>#.CG1KTESRBNN%?0(E);AP_&@$=<+\="RNCNB'U@+UX+N
M[QFN@10.QY8!X"-C;?^`+\!K37?&W_T/``#__P,`4$L#!!0`!@`(````(0"_
M->2IJ@8``!P>```9````>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*R9;8^C
M-A#'WU?J=XAXOPDVS]%F3POFVI-:J:KZ\)HE)$&;A`C8V[MOWS$VK#WF@$B]
M%Y<-_#SX[QG/3/#CIV^7\^IK43=E==U99&U;J^*:5_OR>MQ9?__U^2&T5DV;
M7??9N;H6.^M[T5B?GG[^Z?&]JE^;4U&T*[!P;7;6J6UOV\VFR4_%)6O6U:VX
MPIU#55^R%K[6QTUSJXMLWPVZG#?4MOW-)2NOEK"PK9?8J`Z',B]8E;]=BFLK
MC-3%.6MA_LVIO#6]M4N^Q-PEJU_?;@]Y=;F!B9?R7+;?.Z/6ZI)OOQRO59V]
MG$'W-^)F>6^[^V*8OY1Y7375H5V#N8V8J*DYVD0;L/3TN"]!`5_V55T<=M8S
MV:8.L39/C]T"_5,6[XWR]ZHY5>^_U.7^M_):P&J#G[@'7JKJE:-?]OP2#-X8
MHS]W'OBC7NV+0_9V;O^LWG\MRN.I!7=[H(@+V^Z_LZ+)847!S)IZW%)>G6$"
M\/_J4O+0@!7)OG6?[^6^/>TLQU][@>T0P%<O1=-^+KE):Y6_-6UU^5=`G:+!
M")5&')B]N$_=-7%MG]N8&.?*<?#9CW.6C`.KW:3ALQ_W,6?S>1NAN5M"EK79
MTV-=O:\@+D%5<\MXE),MV.K73E@85O-'BPFKR(T\<RL["S84K%,#$?#U*8S(
MX^8K>"V73&PRB$AZ@KN(FV7X0JI<V("`006L_O^@@EOA*OKGQ^("/'201751
MB4DX"&&]U0\C0:A;27N$1[DJ"X))E34>T+T/.`RAJTPVC-!<8L%`K`V"?'TJ
MR2S!9HFT)[`<>.YR.1S>6;`RPU3#R-$G&PM&E>,A)#$1I)C-$FE/8#VP7Y;K
MX3#6XR(]@E'UH,DFLP2;)=*>P'+\>^1P>"[:!#,E9Y9@LT3:$UA.<(\<#F/O
M>,@[@@FZ]$:<P''<$&WD1$-L+[*)CY(<$XBZ*#AFTQ[!BGC#@G-UP&O:#TI=
MGQGX."P.!58L&"&.>J'C!X$N/U$)CU`HCK9.,)4@MA]22M`"I0(A)%+VM:_D
M0RW]`:3JG4Y_',8BD818,$+D0^"Y%&<+#2"10P+L8J8A$;4]])!4`&[7LJC)
MG$!CLUQ.1V,]:#5C";E=2#X8#DF&^Q])%`<;6\"D`X,CDO""K(3DM(LZ&FN*
M]""*)22=Y-MA@.,LT1'7)P[:JDP2D[ML8`Q1O!PO%R6*]W2A(@*2N</S'1JX
MJ#8G.C.:7YC.C":85#(C`<CK\G)=HHJKNB(;[?B8"$CJ(C2D/D7[(9&,Z@N4
M?-@\D@Z(X2TP?(<J3NMURZ5&"`IH8L8)F478/)(.B"&*U^CEKA(57755&*$M
M$?-?1*`\$N5K3;Q(^Z?OPD2C[34Q/":L32Q1*DV,Q"&OV(JX[C?'DCI&1*E7
M=;H!FEDL(:'363NH_B;:?;I&*95IMTWAJ;R_L((17LH5J3/Y411^39^#>\3.
MY,Z:6/E$(F()0`.J<@S?1_&?#H\PPI*7[^5R1+%7Y9@M/!%0'Y8NDIN@^]-A
MRS1ZS'OB:2,QR:OV<F6BQJO*1G*C@'HOH$!+>`L$^W'"CVP>20<$NXJB;H-O
M,@>N34=@-TI/CV&`PB.6T,3,DWF$S2/I@!CB[FH[J'AKH'K+3(\24D5!]XZR
MXBB$ZC@;@5".2@?$$`:35,-P<6JD?*#>6IFI44*Z1I0<DE$([4HV"J&%2"6T
M,%72N[J3CM;UFKE%0KI>5!>340@YGHU"AE[1#)G)A<(,5*_.[$%.Z]+,Y-*9
MU+-'9*,P2T8@A+!Y)!T0(UCO:E+XSU20!6LTO-!Q<7&.):1Z#,TXF4?8/)(.
MB"$*-2<SOC([DI'4(B"_Z[RH']HN(;A)IBK#7QL'OHOR+I/,Q.*D`V+(0HW(
M\L0RTI,8/1<5D%#HPH_B*$0[*-$0$CB!YZ`?$TQ'7!*&;H@23RJ9I3GEKGZ%
M+NE7)"1^\7AA&(0$O_%--&;<X4QCQAV>2F8DH=S5K=`EW8J$I`M#A\+;#^2@
M1#(3`<CFD71`<(SR]F1YFNQH.+4(/E[7FY<2\Q(S+Z7:)>T5%)Q;:7/J]@WO
M2^X\(.GLZ$E=?>W5'7?$$N)-[)`C(QNGB@\*%E"<DYB7^($;3[=@:UAF<8`F
M3G\N17TLDN)\;E9Y]<8/QSQ(3\/5X>#NF?+QZ'H,!WK=Z1>ZSN@6CC),_MFQ
MX02P.\1#(T!R?S:X&6[!V=PM.Q:_9_6QO#:K<W&`Z=GK``I(+4[WQ)>VNG7G
M5R]5"Z=RW9\G.(4MX.3(7@-\J*JV_\(783C7??H/``#__P,`4$L#!!0`!@`(
M````(0!X&>[]K`,``'<+```9````>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM
M;)166X_:/!!]K]3_$.6]N4)N`JJ%D+;2]TE5U<NS20Q8F\11;);=?]]QC$/B
M["Z4!T(.Q\=S9L:7Q>?GJC2><,L(K9>F:SFF@>N<%J0^+,U?/[-/D6DPCNH"
ME;3&2_,%,_/SZN.'Q9FVC^R(,3=`H69+\\AYD]@VRX^X0LRB#:[AGSUM*\3A
MM3W8K&DQ*KI!56E[CA/8%2*U*162]AX-NM^3'*<T/U6XYE*DQ27B$#\[DH8I
MM2J_1ZY"[>.I^933J@&)'2D)?^E$3:/*DV^'FK9H5X+O9W>&<J7=O4SD*Y*W
ME-$]MT#.EH%./<=V;(/2:E$0<"#2;K1XOS0?W"2+3'NUZ/+SF^`S&_PVV)&>
MO[2D^(_4&)(-91(%V%'Z**C?"@'!8'LR.NL*\+TU"KQ'IY+_H.>OF!R.'*H]
M!T/"5U*\I)CED%"0L;RY4,II"0'`MU$1T1F0$/3</<^DX,>EZ0?6/'1\%^C&
M#C.>$2%I&OF)<5K]D23W(B5%O(N(#]'+_[W(BN;S61"%H/+.R-EE)#S52-\*
M72?V;PP$V2YN>%X&!N].!/]V?'A>^$.?TPAMF:<N[2GB:+5HZ=F`5H9,L`:)
MA>$F(*;R+17Z"KQ5`,B\$'D0*DL3UB#DED'3/*UB/U[83U#I_,)93SGNF+%1
M#%%6(9OJP%8',@G`=S]QX%XGML%D[Q2J.G3Z>D<I0X(L#*E0U@JX3N1IT4\9
MOD9)IY0P&JML%45-G$E@Z#">.?V@D4/HU_L="O+(H0YL="#5@:T.9!(8!WNM
M\BA86"+#8+O&"\6B?F.MJ\J(<4L3LM)7/(J#/A]=WZPE)^P:T9M'?A"&8\9F
MR)B['NP.UYS*WALR7">(/,_5:R4IKAL/@@GTBF9#(3]VX-/',DH(.!\FY/W^
M%.1Q%N*9UFUKR8'I^TQI>=K<9*0W&5O%Z!M6`==I(V_VNF78<.ZW+,BZ9;_7
ME867G/<LWV2D-QE;Q>@M*^!J.9Z]83G\%\N"#!MS>-V&)LAF@J039#M!LB$R
MZD)QC]+.@^O1=?=Y(%3&M9JLB[7DN*-#P]'7:4]2N4XGR':"P`6ERUNW?4MW
M\L(A3[X*MP>\P67)C)R>Q&5"[!0]*N\YZ^ARS]%PN/\\^*(>&KYV$SB=7L&]
M9/T:?^,EL,%.^:F7P+8ZQ1_"!(H&N-U/#/>>!AWP_Z@]D)H9)=Z#%<<2Y6KE
MS4F^<-ITY_R.<KCQ=#^/<,'%<,(Z%I#WE'+U(B;HK\RKOP```/__`P!02P,$
M%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL
M[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.`
M`<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U
M]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO
M7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:J
MU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67
M"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-
M\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R
M[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;
M=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ
M-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0
M]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"
ME]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]
MN\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY
M9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-R
MYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'J
MV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(
M2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-
M;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,
M]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q
M509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6
M]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UH
MW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[A
MO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:O
MI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:
MSCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:
MFNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P
M5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6
MH0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV
M]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&
M9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%
ML3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-
M.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#
M70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=
M-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:
MKS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>
M2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%
M&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&A
MAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`FJ$>#2`.``"@D0``
M#0```'AL+W-T>6QE<RYX;6SL77EOX]81_[]`OP/!M$4#U*9.6W(L!VNMV2ZP
MW0;9+5J@*0J*HFQF>2@DM6NGZ'?O#,]YXO5(/HE<)#6:E2AQYC?'F^M1Y.VW
MS[8E?3(\WW2=E3R^',F2X>CNUG0>5_+?/Z@7"UGR`\W9:I;K&"OYQ?#E;^]^
M^YM;/WBQC/=/AA%(0,+Q5_)3$.QO%,77GPQ;\R_=O>'`)SO7L[4`WGJ/BK_W
M#&WKXTFVI4Q&HRO%UDQ'CBC<V#H/$5OS/A[V%[IK[[7`W)B6&;R$M&3)UF_>
M/#JNIVTL@/H\GFEZ0CM\DR-OF[KG^NXNN`1RBKO;F;J11[E4E@I0NKMU#K9J
M![ZDNP<G6,F3])`4??)FNY*O9"D2>>UN`<0??CJXP3>_B_[YZD]??37ZS]??
M_.M[8_OO'_Z8_^R'KV4E84-H@@VJ:5Z.*LG"QQ%E)9;@[G;G.ID@TPFH";5U
M\]%Q/SLJ?@;.`.+AU^YN_9^E3YH%1\8(3W<MUY,"L#+(%QYQ--N(OK'6+'/C
MF?BUG6:;UDMT>(('0L>(OV>;8"8\J$0<SLMG@V@2F18(@Y%IBD>H3#:(I.'!
M:IFT'PMD8GC-ZWEUT1_#*Y2B6BYAO/)^D=-A%UZIK0@?[W&SDE458LAX-$*U
M4H.=B-ER/0)^9V-V-3^;9%-UJEX+E8SQQ;S=D.%4%:G*&H;JJ^O79U.G>&9E
MTL5A^%PK`!><6"V:L'0KUO>UBG_G\),S)S2A%F.\(Z3,!/YP^67Q\8-I&[[T
MSO@L?>_:FH/*I8DM_#:3EY'\@=I)/(O4!<23'@SR]R_VQK4*U:T_:9X/I718
M9H75$F.`(NW$"7`RQS\DVL'`S"(4;P$D/Q@K="M1H54*7EGFHQ.9RC_LH7?2
M/7,?H`F*[%0<5QJOP91TZ!U"EW=*&D6HHCP,U9T%!:E8B@W8%D6XKGV(N*9E
MI9WD=(Z]%ARYNX6F-C`\1X4W4OSZP\L>.BT'^F\TD!)]K^;;CY[V,H[B`M\)
MOFN96T3QN`[[NSB\K*\>U/5#R)<@XT510E15U]<G(/IPOUR+1[I>+D43G:CP
M)YCHJSG^"2:JPO_6PG0:+Z29*)`I/2DP<1XSNKQ>+I>+\=5BL5C.IN/9+%3R
M)O9HT]D:SP:.:(2I*8]@#@B6T\7R:@)`1K-%R.JL"*8`X'H^7\S'R\D,_A]&
MLM,C$*W3N=RW50F"GJQ*$/1DU7`DH`B(_/%*@>EHSVN5(.C)J@1!3U:]%AR!
MKWNW*D'0DU4)@IZL&@ZR!:Y5V'7H>:T2!#U9E2#HR:K"BL\X`B][MRI!T)-5
M"8)S6S5IJ]8/#VHXULQ79L+JXY@7%O'->85=(_2I&]?;PH@CV?,<SZ!'C([=
MW5K&+H".U#,?G_#?P-W#?S=N$,!FZMWMUM0>74>SX*62G)'\6W$F;#?#SO)*
M#IY,_2,P8P82D6XB%J?BD$:]&783L^O9Z'HVGUQ%#9L@UK:Q-0]V7KJ4=Z%?
M@AI1M_6"$QTZ*9/8';*)NH)6B,W'>49HZM#2G">`3R0NP7F&"!FSW25>&<D9
M?#*2$SAE)&?PR@A+IVAQ)9K<N@>XTN'8P*JZ&(VB(3XOGVJ"!'B!QQ2#(.?D
M]5E[2H%&:\]I*BO$E]S:N)_@7U@=%TA:<T9>SIH3"J2L.8-71M9O$NLRQ-/1
M!8;G`B1'^F:^W@X&,(I.3/`<!<$X/N$&8[3%R!WN6'%S?(Y$$<6'6XP"[9Y(
M]#:00%U%F3I.V5`!Z(9EO<><_,]=6@;`9.WN]GE'KE&""\?P(AZ\!`I?PO@Z
M?AFE_.@-\"H["2Y!*CE)TO9[Z^7=P=X8GAI>31:R"(^JP"=[=Q_6*MG[<*/&
M-L+9H!R1^<YS`T,/PJO=PHVN,CS3$CSCF!`/GB[\9R7\04_<^NC"'V9/A?8`
MO?3*'YR+F[](?\#K^F*G!A-0IZ["(Q(!3!@2!&"$/A#@=8BQ#L`]^T``G5N"
M`!PT0P!P*KRBRSH8DV@&/I"Q!/ZG8@DQ)I&287E"*<O"+_"OD%)EPF\G-9-X
M"XZ>J1G>5`#HQ+(LQ/858HC98:5E*H`W%2I0(>N*27GCLIC?FT)(T`4,F48@
M#%1I1)Q7DI@+/#,`U1JY%UB'$*?`4-0W!(#3"P1BB'%/^7=,,?24@:DW])2"
M*00F!Y]Q35!+,!FR)PR`IY=5D=4)8R9CG%$-!$)?$9)XPZ2O$$DQ]!4C,U-,
M^@J1!$)?$9):HJ\023'T%2.)*?H*D00":*27"$DMT5>(I!CZBI&9*:9]A4@"
MH:\(22R!OWD\I4<J=&P:#5')_'0,E^65ST+!0DG_?VRLYUWM)'5<UC4!K>3T
MJ'V*6D<P1MA,D5X:P6EXE3L.3Z4GUS-_ABX3?P*JPP'#D_$GPX&ITR.?/6W_
MP7B&7C3:>WK>=1*P!E/&'Z;KLM2$N7#]=,#"8>D:1=1*'G;UM9/Y(\]@I]NU
M'E(+`EVR;PPX8>H;`]H[QB#<#04M4\B2"41N[Q3M+E1-D#'K@F'K:/;CP0_,
MW4O#^($:BL?@`)1)(IWC:RM$V/4,#!&$C($A$JVC#E$?VS.AVNF"1;1>:!A*
MO;D#0&Y\I?5+;79"%DTS0RFW#J*.?XUUX;4W5:7CK[&NOKR&YD)L?&FR@H0;
MJ`ES'(,*C:PTFN$E8;3S:=QY"%>-6'2_6*^!W\F>SFO2'-C$CR<5>],]U9AD
M@Q[RY1"J7M%SCD8&*BM+<).VRD+W\=YP;4]-UW8R=6F+<'H\C*]"J(;;YXWP
MM?-Q8K]3`!R2LH:$A3I6E-)JT9'1"<UA-58KG@JH4&GCC#!NVIL[6WB==;.6
M?7)B5VNA4M)S,"H]WK(:W$H]`<!:_SNCLAIAH6YU`KU\.6[5,8Y4Z^Y+B"-U
M:9]-JJV*`$X=EZT5I@08#ERNU)*'V]PG6NF\3:Y!`\3CX6FU8W=.A7F7D/`N
M)YA@PQMP*KR3%!8HW.>ULH8]GS.7>0>CUSS<+\,[P%&R-BKOXJQWM'+?KGT#
MBQ"FUE752"\(:TI05H>LWY9.<&G:'7@`:`.OM&BI<T%6?:W,G0]8\).PME$*
MO+/*'W]Y<'F]@2^JYM3[94354T>$O`NWS;EL13;XG%L#=[C>(7Q;K4F/*'Q'
MH@ES9K+`VB^WNJM29:M8SQN-`,DNN29&]`9H$V4-QU),==O(4%PU344$X]A;
MI.4#XU)#`XI^E?1A@P9Z1HVV69-D2Y5M$X=F<*K'$R^A%GID8C$#+]^_#B(6
M$[N#I3?AOA5>?%S7)K1*%FTZ5>$!FS9^0@&-(?Y4M2K]JTP8PB89EV[+,"Y6
M$UG.D.4`09(\AH7LI$[?J3(X,[*ZP<%)X72,_\-R*9J9A"-K$T<GY'<ZP@&U
MNU8!8)PQ'M3Y]J0L-P/,JCQ3&C@[7+0J'`O-PJFQF@(,?UT1=Y74OVLJV.9#
MC%*54C&&%B[:X('YU)!6P,`6I.@K"!N54407[/1SF)T%LQY/W)FW2C]4GTRG
M5A->U>87,[7!)WR>24-5O@2L2T8G+;2:PSGII;-Y..GPGV-T1OP*7IZXH\Y#
MK3/DF=NQ)G!JTG;5O(0K0>>5U<2NHJ?6W=8C#:^,F]5$KZZ*BNZ;6WG%R1DG
M=!46+;DT!C)1L@]!5T*-ZPVH8J3:/7%:;:Y=C'U)/5X*M&ZTR";85E,SWM*W
MS!NJ%3M0;V"*F`$IN<PI6+R#W!FG/EP#M[E3G-2SRY3.>/89.H=\#"FL"+@6
M8A[NEZ%TL,6)R\`V#09-?PQ">--JO$0+&MX`C&$JR1CX,M[*K<93;/72RJ9)
MEST5/0"I94[OW,)_MY!B%;`5<JE"J*$2S\E&;\F1(N3A_8[@#D?D?O'LW>+3
M^R%)^*#BE3P9_5ZZD%[I2#2-\-C:;@ZF!0^>PJU&O%>5#O?H<.W[Z&!\<Z$J
M6NE5JA,,:(061.FFM(!"Y.\XD::T8/[:E!:PCVBA(Q%:<"O]QK1@VA33PKO+
M93+.("LUQ06GQ+18W<\Y=3\KLB/V(`07BLR#B]+*[(CI-9,1GI7;F%9F1S`<
MI04B-\65V1$0$EHS8-*45F9'L`*E!>[6E%9JQQFK^SFG[J\*[<CZ*MXTC0<7
MI979D?75*:>O4EJ9'5E?19&;XLKL"%2I[N&#IK0R.[)Q8L89)ZB,F1U9W<\Y
M=7\<45F/GW!Z?$0ELQV\(CK"*3./CB(JF=58+Y]R>GE$);,7Z]\S3O^.J&26
M`GI$HAE\P"]1:J,IJ]T9IW;OM6T2=5F'P3S#`P.>/JX?+`V?8Y(0PA*8"(3W
M&.*B]&3H'Z4U/.,E)<2N!TRC/(0>GO>6YFB!Z[U(>!_`E!QK]#DGN3^[;JHC
ME@)6ISR`_F)H6]-YE$`O<1)G%(0551,RZ5I@U8-W!6]"!LZ.T+#^AT/T)F3@
M[(@,&U2Q?N(A\\;9'U(+L;$44S</B;>F\]'8LI[#1@F<Q/-0>F<<`D]+_8]=
M4KB]S$4$GPR4TF!#1/B@G^.:\1T\""A1(E;:9.U@Z\'#\V^'@*@1SR)$\"8\
M/$0^F`$\PRVV)KN&$187"1?NS9F2.(HHG#3^H7D.KA9FZ1[Y:(E$V:U.H?K?
M/F=/B0KU'FCPC+KP^5%I/P"*VAH[[6`%'](/5W+V^J_ATQ'!F>)O?6=^<H.0
MQ$K.7K_%QT["*H:I`82;MSX\RA#^E0Z>N9+_^W!_O7S]H$XN%J/[Q<5L:LPO
MEO/[UQ?SV?K^]6MU.9J,UO\#E=F6X]\\CV<K^2D(]C>*XNM/AJWYE[:I>Z[O
M[H)+'9YFZ>YVIFXH_MZ#H.(_&49@6\ID-%HJ2\76P@?)`9$;WX)O>;&P,?CW
MV;&53-Y$\,/[70%L^!54(H3BX\.VWB.3N_\#``#__P,`4$L#!!0`!@`(````
M(0"BRV9[`8L``-/8`0`4````>&PO<VAA<F5D4W1R:6YG<RYX;6SLG=MR&U>6
MIN\G8MXA0Z$:RQ&@S(,DBBY;%10/-JLDDD-2=CLFYB())$F40`"%!$2SKOP.
MW3<=,1/A)YC;N?>C^$GF^]?:.\\@:5=)-S7=U5TBD+D/Z[S^M?;&5W_Z\7J4
M?,AF^7`R_OK1VM/51TDV[D\&P_'EUX_>G>VOO'R4Y/-T/$A'DW'V]:/;+'_T
MIU?_];]\E>?SA'?'^=>/KN;SZ9=??)'WK[+K-'\ZF69COKF8S*[3.7_.+K_(
MI[,L'>1763:_'GVQOKKZXHOK=#A^E/0GB_'\ZT>;JQM,O!@/_[;(=ORCK6?/
M'[WZ*A^^^FK^:G?27UQGXWG".I*]\7PXOTT.QCX!ZTZ>O#O=31Y__M47\U=?
M?:%7_+6U]>3M9#R_RGEGD`V:7^]F_:?)QEHO65]=VVA^^3:=/4U6-^S+9\TO
M_[P8/TW67W:_62QVNW.QS;$^:WX0]G>270[S^2QEUX?I==9\ZK.SJVR63K/%
M?-C/W^[VH$?_:?.A,-0.I)NE(QX99#\F?\ENF\]]MJK_67^^^:Q%AV(W9[?3
M]B+65E?^TARL>.,XFPTGXM<@V4WGK9>WX>C`N+H_2B^;HWQVD8[RUCL[B]F,
MS23[P[S/AG[(TMG2\3];65E;7]E8:XY\('$P$4J3[[/1:.7]>'(S3DZS-$?"
M!\E!GB^RV9^:KWUV.&E^5!WIN\EH,9ZGLUO6-NIXO7CVLSPYR::3V1P-2T[G
MZ7R1)V%;[3E_R/+FI&'M-DNR`UTO)[,V0[?[_8QE\/7`%[1DF./%^6C83_9'
MDW2^Y)&=R?4U.G8ZG_3?]Y+3JW26Y<G18FY6@4TT7ROX'Y@4Q&`?'6YMYK/]
M'^Y[W7C<_7*7WNX<'9X>O3G8W3[;VTU>;[_9/MS92TZ_W=L[.UUF)JIV8+VY
MG"AQVWF>S?,O6U^G^57S,V@O$Y8GLZR?#3^DYZ.LEXRS>3*Y2-+1:'*3COM9
M@O5*!I/%^?QB,4K2^`J//%Y_T7O^_+G9NL?/UGNKSS`TT'R:]>?##]FHQ>R#
M\8=L/.^0@J,Y-B+I!YU);0?-Q9Y-YBC2W<_L#W]$C/Q]VTES$)]H"8F.9]DT
M'0Z2[$?\0ENE#]":\>40(H49FH.?9JQ.%G^`VN3#EICZ#B:VU[OVV/U=Y.^;
M87H^'`WGPZS-Y(*AT_16W&RN<#>[R+!+`[@$)Q:M[^M\&)4S-0>J,^..!]],
MQI<K9]GL.KEKW8>3.:H:%EV(X"`[GR<##*B$5#+Y>-5E;:VWMKK>>_%R]6YQ
M^^R7GW_YN;ER2#1;R'B.YQFRNH1)MFP>N$[NV)L3X8X'9)"&<WF.W!:^@X_'
M#A&VP+SFPLQL74U&`T*<SY*]ORV0I)86(Z*!@[FL7+("T6;)AW2TR*#.T]75
MM3\F:ZL]?*3^+\G=!J:+^=5D-OQ[-OAC,I[$3X=R'V@+7F^RW$@&H[I\NO7G
M=\ZW]NQ9;VOS16_S^:9-M;75VWS)1R_7D^X%W,W3[<$`T9^,,06FJ\-QTD^G
M0TQ#DYXP>G&]&)EC&607P_XRA;2M%83/C/#-P5JLMKT\Y,T[S?PQ+HJP+R,T
M2D>?+S/[\KV9Q1_HP/YPC%4>LO]CV1@%E?]C^USQ5W_^/YO+WK[;B#<?WZTK
MW!AAJ>AE\^F&+/9*4;SWR99</O0-%YF'/OU`L;YCY57I[T7%*=6IN9#.Q[O7
MW/GH70NNA@NG9T0-;_<."16.]I.CX[V3[;,#'E@F0=7`H1UFDD5=9Q;AN90M
MEZ<3=QMYIV_=F9!H(:&7D\D@3W(L69,\W\PF.69^-KEHZ^+15$&@0LW@?MO>
M[30=94R-_>314<]4,!U<#\>6?BCD:$YXDN4$WOTK>W3`XD>3J12I^=QN-B4$
M&C(_ZB2#F%XK[OV[?=!\V&T!N6-]O<W'R@V-V'7K6XL"ADYZS?@D;/OSYI-O
M<8`$_^DXFRSRQ-]H/A.=V9*O@\V`MGUXU%I+\?:2P.?-)!TGEXM4*=YM]Q!O
MQ%AHE_TH%BZ&^56T5W+BS>6^AH,RR!BQ_H28T'+ZY"(CQ9BU>!C(7:774EK9
M,LXS(M8LF:<_MIWL(<%M%SOBYPE<=37O)>=I3L(AW@R&HP7Y27,;WV?#RROE
M+2E;2"^S9+RX/N=]="`8N-^GSZ=G1SM_^?;HS>[>R2F1P']_=W#V0_)D=V__
M8.?@;*F7"`;E5'%!<Z45KWFL"!>ON7._UR1:7.HUFS.\!@08CZ6^YRFR2MJ0
MSI.JV5F]]XW2OM[SYM[%!1F&R'R=S2XAN'B$_OJ.@M8FT\4L7PB4F$\02T)S
M4VY>*L+TO1_[5T3T6;)].<O,]#77^/%FBIMMSGCJ$5L(C>#3=$9B-L^2Z2CM
MVQJ+\%BZ_`^^_N!59)%4E@QVJ'1KW:TW'C:7QH=;L_XPS\3AR51L:YFL^G1+
M7EHVXY&/6<2?.5;H6BE?I[G_/IW)\&%Z/5[69'DV^S#LM\U+U[,`%DWKN3++
M/"XE>%<>U^1BUS`7'O<ML^'-5](\:;SQ6R=EA"I9:J^W,GN@LSMTOQ5RU!^/
M?&J:C-9K=:ZC'%5)N0E\:A+S02_%)31?;I)5S.]W("D[,GDXZ6ACXF*J0O,[
M!*%.IR9]6A!0_?&XI_M?NYZ.)K<9(:",3_(ZS?%IN).E*E&?ISG^1I.(]<>7
M+:OU6BUSJD>\.]NGWR;[;XZ^7QKQUG*F'3@FY/`FORM7&OQUD8=D'9>!/YF0
M9P'V"!!3S"!'HG^+_\F%C;80I9##,A@D"QM^Z`9GJD%FDT3;E7A39F]X']9T
M/)M\&*H4T@W/-<>/\9E!*O4@K?EH<RGV2D1AF@];M*%("3I4K47SN?:@`<9H
M&*GF>]7Q0W1J&UYF@'?,H2M,KO+$\$2+$BI@30M;*<"S$@UM+L?QL6Y\+@)+
M,7VQ^1SLBZ!E9?;ND>]X0!'J`R6O.79%6_9/CMXF!X??[9V>'1Q^DVSOG!U\
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M^AP>G>TE:\FO/_U[<L<BSCKJ^(!PR6'V(1VDV,89Q6);0B]!3.J/ZQ,@'`LK
MT_%M+\'Z)_.;27(#\CZZ32ALHSWYXCP?#H;I#&/22XBCTK?90#T#;][L:*I=
M\B8L5H9!I;#""]%A"I:ZGC(P\QBI^`Y#_3:]3=8VU/VP2FF2)7SG0SIV^'K2
M3[\A\Q_'KH3NW2#P<6\^ZI_3,6`8(U-_HK*[;B,7@SU-WHW!*=D=VR6&G!-N
M)18'W"BGG<G#P:Y>@T"])6MCB-$H%E03[3T'K9T/KRF8%<4@(E/(^>M/_VNR
M(#]Q2O1^_>E_ZZ.;+/Z++^V?T('/%_E3GFA*VJ%A<#(FKQ<Y7JN-7'X/M,,J
MTN2&=8Q__>D_\^0J2T?SJ[X^QA`.%H`SD1T7*J8[V63QW%-CK?@>\$80X/#O
MRAS#>U`M!=(1:]&^$4M0'=E"/ION:>Q`&"%"-[Z2ZA23L6;7@$9]_*XJ*\E\
MQD0YT3LY>R[6R8[-LDN5ARA')^E4!IP'Y46K2RLT*AU\4(HW2"BD$0(`+YHV
MW"93K,8UT(S:6Q@@[N.IV%M4JP>S!=@K@TMI85R1-XA=C46*BH,L'UY*(<18
MV/\!:-JF3/+;Z^E\<@W82HF>Q1)0+/K^E7,AF0WS]Q*-?#$R0E@``Z<FTY1I
M"Y<=]^&E,2])]B3JH\5`]+N:S$ER,/P259"F;#*=`-\/^4OS?DC!^]CO8'8K
M(7E*@XJ)10#9`P>0]SA/I%>#%'#Q:@A`+T5)E=&KDC483IP54/.23[*9*&Y]
M75)B^<S)]3GS*]UFA.'\ROB=#J_-#9HSUA*D:[!5D6QV`9B9]N&ULKD;4,/!
M)-?>M+`,MYV-J9CK)>":;$P>(6YCC3*]*KR1Q5PH'S315A'=YM5?J"/OE:P_
M@JV-?1IQ3`-XT5B2"M*;(XBVYH),6?]J/!E-+F]9&$NU52$QK#*IUCHP;DA`
M>"OWI5P!1R?GPTGZ(1V.O$F`[:H;KDVUIQ3`&="+J:9*UUBU"R(6(/CDR?QJ
M-EDPVOQJ.!NHL">8ZG/C/*D@ZG0.()Z<`XPIZ)%`6%4&O'R*Y/5G0X/8]`=,
M0DQDRBG44`9GK0`E^N\)J/D*^UJQ^GXV,S-Z=+;CAM^?-G7,9>_Z>:MIK(!M
M;0''P,ZBR5O'A(TYP=PWC=S1./GS`K.RAE/`@--8ARE!2!`$Q0]2NG$)"M\W
MNGTOPSO.;MQ674LX.OW:K=$=8<<4&594RFX?6?6"+H1@M,(7WCK,'>1-M+8E
MAKTYZ^,?^0)@\D/0O@"/NRD*4/DY,#G%/A=IC&NRF")*DBYD6^]!0?VU0T8V
ME,;`Y@91]348^BRS)C*^M!@COEC\4?AJQC_JSR>JC#QS>AL1D`WDR@VLS+$V
M!MC-OZ"_YN@#NE16Y'PU5DGG1N8D;.$XR,F-G@R^52;<8Q%TQLC<KB7^\G^;
M0I'RNDI1.-@I[37:C]BP1H_3YO/>^NI6C.6TT$IAIZCU^/.LK9(BLL-:=T:U
MOJ2=BM+^@B$=<!ZM3(PJ6L#:"I1965M=?9ILHSNL4%8]DKJV7I*`%#N:&X3'
MJ]5A:\L-[)8"_/)S:`U=8V1H1J4+?KM!98>P!/OA<AK>DB6(TWO+A/8PRR87
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MBMT_>.MH$+4;^6`(7FY<,HR\BO>B06R@:KF<(^=B:3ZE,%$AW,2:A4IES>5-
MT-T_Z/MHH!&#6EJYG$NMN?=B#8[A0@VS`W-YT`J)*6LVH0G)5%=,J(2TAKF=
M;G<LNAY6-.<)>);9^H@\B>+4:OL&!T8RM1;4L0K983PI-EOI@OG$>\>_:^5@
MDD7!6/+D8QO&[@8YJ'"%S:$D^/QE[]GJ9F]C8ZVP*>X,:EK79+WFJ!JU97LW
MZ^5"2UB27E*LO@Q21P:ZMD9#W59IS#HFKHEZX>\C8A*E-TX?:.AA?J$NK9E[
MSS;7>UMK_X2)HR#@X\SZ7GH`$Z)NI$.$JME97]L\?2^G;XR'5PK50SBA%]H\
M"<SJ8D-3W"PKJ/B>Y6*S+"A0?.N1U%VV(KGA.5;Z?'.CM_9R$_=_$?(A;0&^
M(6M$<8:75G72T9*6GX."*/;]B^TB061_DQ2FJV8HU?ALTM.4G$ZM,X4EAOVK
M4B>8F))U]=^O+*9(<.BV,!M,&N2G+]CZVLN$V$G'8"Q#$@WNHIZ+`;Z3L0,>
MI)X=WL:V<Z0FC,4PN$B)5LNDGKY[^W;[Y`>!E*<'WQP>T&&S?7A&663GZ-VA
M54B.:='?Z:B/A&*1!/`8+$X-O7?4%@U@6S>`[?=/>3S#W0T)?$VT=JH@8-.S
MGD$YX$;WR5JC],,A0[F^`AW,@0RMJ<0:R\C\'4G0JPNU/,`3.>7HW#WRG2W)
M;0RSBV*D1RN0F.12\9AP&&DLT$\(&$*[D#=(ZQ11'D)V$$+<_CGP7)*)O222
M9N8K>R%N:K$4'$('M@Q,L'H9272Y85)0#M2`U4`/[`K?\1\'TZ[!"G%S%'WH
M1),I$2S)\PNY<9.OW%`.6]98J0*/2W;!3GA"L;*JQ'`GEAC<=)%07!!:\+*(
M$"@ZGHQ7C`R@&^P1P%-,$LQ>T,,4B",7E56P5EJJS!S$XV#KII^>Q'IVH)$*
M]8&[P#:&>/F>A%)<SM)K=A9Q#7NX.>XJU'$(H/G-N@!.Z,,#J%H8+L`H9L_H
M,#=RQ3R.7DJ$23LW:EJD*0V%J^$T11"WITG9159@K)8Q;@B9@A/V;E_`@=KM
MS"=(*"#TXQ"X6H(5SE\P!Q2SM*A3`K`?\VANP5--U!_`F/02^0JB<I>PM)02
M8(M>LZA;)\69&V,APE$Y;[,;S]O$Q^N#S3AKJ#.-7^93H,>O'TV#GW[TZLPF
M*128M"X<[$F$*X+%`A["NPE0%T&$J<&`LP,>^XYU$%)HJ1:*CEZ[Q$/G879C
M!L6L0F50\7$!/.X0M1V-B?NS\`S=(94&&294(S.]S%;.TS[PI+Y$=%0SX]_W
M'38BI#:0$'GS5@-S0Y:P:V&F4\4I+\0B[CFGS`!:Q=$'0;-QE3B,87DDTYU(
M]B//27/4]3&Y!L?BOQT<<QK(@"K`",3I(O`T19=%3!&%?@[94O:VM4I6?8NU
MF:#H9+>@+)P='<_-F-QP7DCYPT7EB^H&<)8(&^/*#&.1*B+2/I+EM+'M#8BA
M!@MMVCE`B6;DB2LTD5]U6V$6OD(7O"U]SSPB_N@<ER"@I#^<<90"7X&A\S>"
M&$7Q,.@`LDLQY0AA2$$@1//#D,YES)@V2U>!;9>XITC>T*;[MG9SQ7O.V&SP
M-'%M0`OTGV/^7_YWP2P<"UY]],6KK]@1+)A=GG_]:']__;G^5Q_/]@DN_+DS
MJY\<(CPG$X!/?7L!0,DB?1A]\(6-/']UYA$H91RX)H2$T@<:@UV'I0A6WPZ9
MB*I\A#TWX"$'7H828\``2('E,BR"@HUJ.4@Q4`M=E#EY<;WMR$<)ZISCRFXE
M-1'8"MZ.#7]1'AZ.I^I:R2"/+;$2E5<8&Q:I>@C,VW^/707"6(#PRC@@0!'5
M=I%83(D_U.3A*CQ+;PJWCM2XELK02-SD%'&N")OC[4B%6B6$=%RGL_?TLZC"
MY)6:T$$-%,P#P+U7$[A\QJO67"&!*N'I^(Z674&:K>[$LO)\HDY^9B^P56H<
MM6-OR1/$3RU-"_RU58Q;`K5``+J$BNU<8W#7_@%Y.O%#%,D)"G-)`P1T;DW_
MD:8&P8<YTM390.R!"I$T3FCIO1Y!-Q4-&FW48F.G-GN8^OF0!&,!T*B@20.(
MOS'@*0:39^9X(<F13<8N.7O6*;Q^8G.[\\3G'AC*5,+FY"DEGAC/(M>R6TB2
MIAT433E2NO+T%Z(23G>8U757A$@I!--QJB!G48('-/JAN*K!&08^GF,83/^)
M-=@ONJ^SL"-P*3-V3H-X[E4BR`E<-Z("N8>*H#EW(7M1=@K&=C:WA#KZBLBS
M,P7&*JX0Q!2KKFB*ZF,Z=K""'R'4-56Q4HJM+)J?P9(U`CX:WWV!KJ]$5013
M(60D-=,R<S$PN24P;9==WJAQ19!D<G`M'^[V8"F/AI6'?B.;_A%*S+CA@>JO
M[(N`1"R(N#32VH,@1GF2F7QU4#1<?B)=[`[?VI[M(QJBJM;57<HQ8H)#D#6P
M@%+VNM&EOMRY(,.6(Z4#@`&D372W6$]0FNG+?I&`;GNT*#91..+NCMD@)V_D
MO\!"9LG^]NGK7@R9ZP_M</.'U:<8U)[=/MWI)1L<1FW3</CQC'DI-RO?<.[M
M9DB.)[)9I^@G$J57O=9$'V_'#Y7;C^3!$`H8+3[3"A(/_"!D4Y=8L[.=3H`L
MM#C1%_L<9`\NB7'<.N/SS`I;_![&`V(#W/%$R4OF".QL8"[#PHNP&"107@0P
MR]>!XR/+QKL@QS=\[I,K(\#`+UEV:<5+VS4:7B@]<!WRH<N@J<L5L,C:TRQD
MC"NK+L9RCA7E',(LEJ[&8C?]/QR].::0!N(SZ]<@&+VP\O@Y.6M&I3W*>KJ$
M%`F^4?R`XN,&:YG$D`S+"LP&Q$`:.4I.<=Q*TP-JH`!8&[`@V#-_LLRG7.LQ
M`]:9$2T&B@M)#;LD>C&"R7U1UE<8TP0Q-CJ#$?Q9W`0TMSL`WN#C!Q1?Y3!=
MRZ+;F+_"T`6:.%O#RBWV-3N'U>OH;#;[0%?&)2Y<@]]+4!$1&K*7DI!EG_MO
MH&E8V3*:GBJNJ\S18)9%A$;8BUAQ;S5O5D(F`ABU-A$A*;_C/Z*AM8N%Z)]B
M?S]K%1GK(^"[Z0CPBFMSF.G5+0<T37U#JG[G8`1]Q#FV&K$+.!%D3T(9$CLX
M7ENE$CR^#0';9'SGX+2'6>M`8Y)S*2OM46KR$OP)]2Q071`\26-(!6MS&H.B
M=3(M".-&3)0%B8XY+3%2*8K=11=;WEI@$0/C(F5$W,Q5"&S0HB%9.KT+UCL#
MD5/2I]BT#S9L#CM&]X2%(IR5-L/-`U)I?/I\M@A=`B4-6ZLQXSJ>KT2XG_]F
M`C1=@PCYU)&:"*$2!-/?A7*8D4T#C$-W)T=K):4!:14Y9'[H/,`2&'$'&;"_
M+*/Z[%@<4RPT2W@#ZM72PQKY87EGH;I&#IL%4`O+:B#/:/A>;09\;/<E^"KB
ML*R?@`#CE2M>9KEE(RCY)\5_MJ@]U3*->(`98F.]]#U=\H10!9#2$>5?-*-:
M0EK>*PU:,+:3&2DR<L]HROG-.PUHI9D!L&<RU[`8H@*1E:^*=%25)I+:8(<]
MHY/\06;CHHF&>TN#`:7MVK"I/99YLIB:\A<&WF3=?(?R4=0G=*PI[X>V&A?A
MMC)Z#O<*<VD#1CC-QH6&YJP<:.`U&B:SD0T=<,,!6R5:U)4XI:PY(49")4T1
M2+CD+/!@4%S;*:32E<,I8YX``I6]QU;WT/.1CFZN&"3D5W$3?UT,+J6WYDTC
M#VTFX-=PS0U[N5B89:K,[O+'5Z@@#/`+$!1:%SB_C)769-9;N)]+%_\(>PE4
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M[QF0M`AYYB!AQFLLU\V<HSLA&,K5M\=%-+-)D.><+EGQW*(D)*^.?\J5.\`4
M]Z:F08_319?*@JQ64BF#R)AXT9*D!?F&KE2$[#(.\_1:-6>S;$I#:9'U4`GQ
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M;%=#H@TZSNC&1C`U+V:4MQ5Q6-QHKE$>+`2MT+B4>@SNPBUCT3^HM=F2C9P6
MK!34]!`VQYH3:N`#J*K:4V62'[:HRAEC1SDT$U99-'-(79?.$\'KFQBGM8BR
MP3:!ECE^$NKW2XA2%\4[@3ZE[USK*:,6?27CBRWQ9);MRAHM(*<Y"(0#^U#Z
M"VO@0:*P"3)XF"_\D_FU%!H`2*^$>*Y\I6`@;$9DJ>[#>8)1H3$OUS\M!-@-
MB.V7&O\6,T:JZ<HKTNP2Z^%=^0S+Z,2&R/K/LE(F\ON/5IVDTA6BEQ2DW4Z"
MQ]<Z/R(=P+#`4F(2I/%O"XXS*L[2=2>R=,I$L>)N6X,:6'BM3#PH79/_3X)2
M4GZ29&"#&[,LQI-S]>6:K0]"&E[:^+P3JMGNC,-#],*"6:FV)!TH^IY":PTJ
MQ.W.#2$T92^$&6'"B9)ZL5_($JR%[*PO#K.IK:L>WSY:$#9;UZ+YJ\782[T,
M^[N(BO>IZ%0KO?996U>"U*=2.!<M4>!5?=@.#O-`X$AA%2O,B@&BC:9\+ZZ1
M\WD9Y[)(%P8T0O=50;.1BK]B?U'AI6>SR7EQ@-16RFE0L,8Y/6.\+7:J'<I,
M:`S$ZGT][B$[4W@G3^N.D2[!6[ZE1N%H_FJ[W9"U$<^$2M2+PT57%/SIB^JF
MN='5VKT>;!];*SGP^/BLZ]*S[XOS<:!)97K[U@Y*U1$`Y2!8Y]C%%WV)Q=YB
M`,H$%W2F4QP(X>/4SHFPW6F`*)("]R(@@IPZ#X5UUN,\`BY(#H@P"+*U\-5`
M&J5<KVMA@,)80SQ[LO&975P;\@"[W,V`C"*7L"EB.X9G2P($E,3H"H<"QVNM
M'!FC,H#G:9Y2:FHPL4*(@"POJBVE=*FN"543J`-<WM'`".B"JOXXS&)/;"9*
M1O4U><XHBS$H*-`!O2/C!K:@K`R?._=3>69",=QEQ@9,6$G92HUAW][\V0SU
MC$)%1U20V>;*]#<201A7R?6T*O/?%EA=N^-[T$8]UZ,8[[DOXW@D5H4^5(PQ
MI\0TP5.88`9;;]5J&3"'722N!719M$%6R2*;7QW_W+E#?B#3KUN^YO-1J,J7
M;-.XH3<=]_`0)J(IM6-`Q>:L.F+KA!/%X9H<U,_(\-12!D>3B@8I.,VRM1QK
MX8#3K'9!7MZU$K[5\"&"=SLC0+(3N+3MZSPV6ZZ+_O(0\$`!0;LBMOGLT\9@
ME.]-$LY*\_?Q(RJSG-UR<:&F2,ZET(&`0+KUA.OQL!<*-D:2@<[$G?)3<;:3
M-4C0>283E2_06HMV&9ED-.6P-D!`$:UHO+F.$%MAA+Q>R#%O5^>IZ6:Q?E"O
MNY=<UAT-,B6"JXJ5KG-0&SY8^/"*0K@F]263Q9M,L08\"Z$][?^(NW`E-O!\
M]0\4<LO23%B/L!.I8#`ABIV#W%L#'?K)_FU3;)'9^"MJ/9AZ%00HT,2)VO!H
MPGZ`RQ8.%CSVW43I#$UK1OX<P)_5A>Q21I/$F]L29-P+ZT1"6=!>)K0B$;K.
MISQR694E=<^JHZ)[2Q9I^^44Y6;J8SO:@U!A)?".T%.&*2/=CKWQ%I-4TD@>
MQ$@4:VU8B?FK(QQ\=1#)<X31S%!9'[&*!HCI@8@B\.A$3IYFL5,2`+(,OE03
MDEOSXCPF"3B#Z?P]8<*.PT>Z`\(?L\_#X4TVS37Q73.WUGLJT&WEM87Z.S0;
MQ?.%O\'Z%85E#BX^\];:?9I6XK$@):2;.F;N0U:,TL?KT'A5W8J?.;&[XJL?
MMY;SD=HU_J4Z4UI$_7@\[@8=VE+VD=@:Q#J>!"FD'$]',B#;)@6,7<LR,#$6
ME.;KJ:AJ_*'.2+Q%;LKHGJSVA-WK>1GPDYJGLWZ/%3JR:]"&C&SAULS4Q/X>
M^Z,C`&9^@C[[UA%<VO@-BW*?0O!H]V.V=P4@;4<8A%T((*%*\*!=8,?ML%5Q
MUE+8(Q"+H!;.*^CG:YJ?8';MKK204:D#B;,4`BET(](`)-<(:#AK;'9-J.=?
MQ4[4N(OP7''DEN+2F(5O4^*ELBYDO,$=JW1[*&^(B%AH-(=IQH$ZE&+A!:&!
MNJUD_JG6UX;TJ('U$OZ0.%*$B+2O)!+Q4K\`J,<0QK9:@+9:R&M*8^]73OOT
MHV;Y"BGM7(&#U5X,M%+0=#WAU`7S.(=K;R1O_3N%4OP0T71N>86]H)BB,[:5
M.;=8IJA.:R&&D6B=0M$([K3G$3]B)6D,/E"XV0<0>\VA_1=W[>C](A&IMGS9
M?FT(Y<[%(R8BCLEQ:0`]O?H]&/)K$;(X3TEFB'.5;Y_50ZZ[9^L(:9:'_WN4
MYYFX"LD_L6)=4:V@4/=Y=(:L!8;;_1"L(02`42RC<H6\!BYJG4@X$2-4U1\5
M^#)\4IG8(+G"X@0L&->+9..#GZ\^_[0^.%#FM6EHN!C3X/U#3O[M18/2\A@?
MR5[_2[GAR/`6<3^U.^Z0N(_$7W)_DD)'\:LIDYGIBC^TM"JX.$=8L<X5);*F
MA^+W-:1SK=%01X,M`KC[)`74UZ%+P7SA)$7\T2-325_:`'.GA(?2O6,K3\X_
M-YVF19.RL/UFPI.A?Z0CF-$JU$9F!+>J^'N,VI-A>*&R`8L[Y#R4)IR5ZX_]
M(9642[NKOFGK"]@<?JYF2VM1AR[)PEIAU^NME]@D.VLZ%9RH0V&RN\#7JA4$
M*C!AE,X..QLZ2B,^J`76/*?L/XB?@8+J<5@:,<4^V-JR?2W-8*D$%I>[.W.X
M02KP;,W8JA(NQ!5BO;GQIW92)5CRZ.LC@ZTGS,PV+86$"R$'=!EM)6R[5*>M
M?&;'TUW!RW[<'0LE<:M*#T-SE#'#-`/P04&IAVP*"\HR;0@)QY>QAAKCLW@U
M1?1@T(ATN'5WEX&_(VM;5OT<N;?H-T(5!HWH"T>[%XA$C3.>B!,<M!V<O251
M*U:"$Y5@S.W7\-B,W1S<X%`1?<7FD$J`6PTOHC;8+"6^4]ZY4``7`F,CBMTD
M>\S?3QS9EHVI/[(\?JA!)10/#`>0\.@G%V+(OT0P7WQJE[YTGY6L_B/9=^-O
MJ7<EI5#'`D2V&JW,[(7]"B(6,M9&%'#26T2'\H)X"D&CDY2:+5@+-DNA;TEN
M@DQ.0A.=2LBB-C)FL/`ZSV"6ST]\QTL&S7:&9AV0&KIZ4,!."W>$`;!+_W:D
MPAC^8^]=:S37WRDRL?\QX;)`K)%+C15YT`>[?337+T4I0`X-,BB-KJOC[*+0
M+/IH.-:FUH\V23N&L08JM40)A92%",UOGER)A+J.Q2^T-E_+!9SZU&I/=A)J
MJAH*Y1)7W;@$6T&T-/1,T3>E7(&)IC)/&@I<U#L%+S+V@R+XQO05OP%)=$]?
M@-_)$M=7&[08*]AE&T+)L)9G0Q$=4\K_JY?[M9,%#6%@S+HD0-"CWY3JA;MP
MP-8ZLL.Q<GJ$E'EJ/:","\1+E5JH2@N2@#P<F#J[O9!B("Y[T*V_1@K!?.=<
MCZ[=ZH@\P!YB$^\+\*W2`TGGC'KFV@U.O&P_-1205)N2HXOB_0/[*OY)1\2[
MT1CDRYV-&OZ$FL8^.M*RC55@"^J")$.W=B6"Y!/@%>B7\T:W/#U`-QQ^@+*>
MFVHX$^\(TGIA$Y8%X18?^%5JZ^>#])&/#R2&A.D?/-I<4RE)34T[I:[&G>*`
M5M@(V(4I;.&N7*3*K4C\.\W),9A!<0;\=Y@2=5F:T-M==G:?J4FSF9CV;:9!
M!5J9Q4<R^Q4#%BYCL5ME=;5H)HJIEQ^6!^Y/@9ZXB1CT[6[;5J%8%*@Z5UK,
MZ#/R968W=SAGN#"7@*";)<A`$-<HIMB5!=?Z<"4MS0-Q2I/=0D2M24Z.7ILQ
M/?"ZCNS4\$?IB6Z%@AX"<00C$-[%0TC%D%BY(8&*U42.$+YI53C"O*00L7@0
M3JEB<;,1UCJ<M%M_%F>S%<J&1;"K;,&E`?4;S(UC%';9#>;=>VRM&],-9IO0
MV$JTN5P!5T*/.=Q&'"90B#/FG*6P<T(RV(8&5FBHI71OB=!67]J1?%$L^"J,
MN]5FL:_ANFRK$3-=<?&`'$'44>*N[N%QU'A.S6`NS]\Q+NFJ'TYF8*IBV.`F
MRVIM"*>OJY+C%<N\8S/$SA@"2W748N"W$$WA*^ZWMD*B6@/%`M.UKHY%-I((
M118ZN5=<$B5$3K^LZ#+-!'8_DO>ZV1U)()F2N?A"2_D_-:SPR5!^W>E/<C?G
MB@J\>2Q**@P1F;UO2T<3Y-_@E)U#N*9=,%AS?1@5'#&YI>I)P^T9K\8(J$%S
MQ:Z#3&WU'BQ1*)7%T&098]&G:\H?+(169Z$9$R\P>1QWTI/A0X&?G/@1SHK&
M<=0)G#Q.!P;!R0E>JXYL-K/0/WU3M%Q8PMU8<[R)"*61LDM?O:G>:,%A*YSO
MC%"8<)<K5;2*>(,1ZL:E13&0+GH"0<.+Z^G!JF4*V0-76\ZP"Y8\=SK`TVJX
M^"TDMT,#E@G7DS`3^A`'V@F)(C@4GXI`TTLE9*PQC:X%E)`%_,&?00QJH:36
M;&3#YJ@*9.FPJ%;T7W957AK:24N=3CS.J6P3%-Z[C<JSOB@+SLNE5P<+#]#<
MDSSFRN_-C:U>\IB;@+>>/3.>/>8BS6<ON:S)2S_:BA>7D1WDL2CT;G!=.#7F
MC5[K(YK.(67S07X>HBQLC&Y;&SZ!I,5OU.Z2S83?J$WV0H]^DX^U%RH_:FL5
MCI/_EEY/_[A+\V5X6XRT6I/E\E9O]T?PTNBU_509\5<H8,F&%J<Z8!X03E_^
M*2PQ_+B&^5AD&O.[<W+$/YRV;G_I""M^TJ!X4>`.SXD^=@*R,KDPQ]@)4%^9
M[EPQ-V#2:)L@AE"+J'ZS(===1*;@"BUT[Y2NH-8/R\:*EX!$SS^6%>7B^&0>
M)T=Q31W33G&9*)8UU526H-?),?%+`0^,SU#+2\'GYG3G*!JSRR#N&+XXPZNR
M$?FI_W"#B!7O)R!^RD:FBAZ+P=5NFC%?F\J5'6'U*IV033V_3M]CZ/W'EJQ:
M(?:68)7=W#G@#D^IN@XR1+.F$^51SHK7%<[YKV9(JH0'+@:P+79;*JIRH^M,
MIC]VS/U89#YF]>.KQ7#"J_VGI4680F#+IK9S.\IAO4#A.$Y0ADAYT:;(WH/T
MWV+ZU"!)+%=`')+KXCF?LKR+,B2W1-TI)B(4L8JGPVKER:[3`?O#`ADJ7FP#
M!K#0('CW+=:,U7IO=6NM]W)U*YBIEUN]C<WGYI3N-%`/LD:.@OC]?I"5R)WS
M0:8-43=LF$+Z2\FN"%6!9A9<*6DI9A'?$A833(7P-E3TK%/+,-MPS89Y^PB2
MV!7_Q/*2F$M'JH((P3"B-$%8UO,K&;50UTXV29'='`F$;70?^0TTO&]EZ:"?
M'O+IE#Z\D>_BIP4LAR!*#-HFG^WO!JH@[>;LI/_U]C.AN*H/F%SJ;`5!,SXS
M1!MQ(&2`F;+D_1CLJ.42]M*9;B[*DV,$[%3&J^X#[D3'^L6-=+@5'X95>K'`
M3/;>\:F*S^)UZRJ3]1>?N'%SV58_/J8:;5>MBB_V+^;FWTSNA4CX41W++D"N
MH%YH?,R_M+BL'QZTGPAW$VV#>/&Z;R\4"J*HXB;\;/C*\I\-O^/G&RKAB0M?
M;<J!_U+Y[YQ4D>Q.Y><H"&W+:S6G_!J3!8Y30OQX*,/FDY#GDE+3ZSL'Z5C]
MJ3I$?NN8<I/@U&)*U^W33[F4^;<MLK@%47'G^E9O:_U%;_V90CTB1/Z]I=NY
M9<L(_%X\V^QMOGQYUY[EK#Q(]!Y,O<F_&`\JA9/1GI-CI+AUV"_;*Q"'J,,R
M?VPQ<K6MT.8%$"HLC$N#?)D?I>130K'0J>X'.4HOIE,U*P7S=&EI,%`Z&&W`
M-00A\74+2WI59+V5BR??,2NKVXM6O6ZDO!WTW@3`41AWP+HL3Y6[#N,D8R4<
M`NZ``L5[L,NB)-_3O>/O2LG>T2W%7Z?HLHOEMIJA^ZE9P&^VMX\]$R6P8TK7
M=[;BE.S*4^!;N(H"+8!6%BDM/P$>NXZ#'PCGC+6P@JZA#TH4]",6O>+LE,6R
M`98I(_D(O='OP\[JEDFA.K010M)]7L,C+9TOXFU/62/;ZIU(<LJQ+FC^,`PL
M7!'BX380R?'E1)SPM-0.=]/G4A]5CW:>.C<MXLN(NX1\H'(2W$.Z\L0XRR!D
MJIP&)T:TR`O_7+VCR(M6*!@!M)DBS[G5F6#.VI9K&@/WM/Z22WYH7?PICCW;
M62P;IINB[N$59(P-PN-7RXARB&3X"#8X-L^(N%Y,HC4';O?GZLF**U34[.=1
M8"T8D]U)B^P+`;0$HFB5BX8!(I<QE%,A'F@QQB_BK0.8'T0B'-MOQ1<G%&CL
M3LL#J(XL;9?*=<Q/K:%H7#+.$P\NRAWX#VK%Q%ATW*]V09?CHY#AEK]W4V4`
MIH_;I^]ZR>'DJ9G,%5G)PMPH#M"IV(\'LM7.CB1/SB93<'\.L'S^);5)#"O7
MG5G;C/1TC%TA`?`#7-R-2,/\:T\Y/6'0CV'.DR-,,>\@8&]T_&Q'%V`@A&K3
MA-'):3@*KK?U@)$@M<%"_:OZ!C"`"K)<66NY(0T@&"`W54[C/0P;MS9=)L;,
MG'$H/^Y/D+C/6U3\2'6*?[7VLG=14-V)%#]B9*`QPAR_CFE*<KG@AQ^MWNYI
M0X>'X=F6L"VJPJ:#%0'?B,(F9QVR>?AO;MO,5T78XFE?O:T'@K#IS[*&6X@G
MH8B$C6Q*!<N*I%<GYP:"<!-46'+I=3OV1<S(?[!YJEPJGL&:IQV'U<PNIV"@
M_^PM>;TZ',;2#SSXQ2R6`KF#`"-2ID@8BH+_<[==G(9>)BD5J\>-X<&56*2A
MGQ.$;"H62;M+?P][SC"PRZ5./JGLX4$8Z`C)"2D=S_0PPO`C?BXS1HVB$JZ'
M8ZK0PF`%H6G8%;M"UX_A%,CF&LVTBFZ7+:2ZJ>@@E3C[V<Y)++P5?BY<A8=P
M*'FX-V3L"$:79\3!-6F](+$MSX2RAM6NKZSR0,MD?D3'<R9?+L--.(/F$+"N
M^'63`*+QBLUMO^=`3#PH;F1K+?+_V_5_M',!^@;#+3G``+H5UQ^)WY!!(&!@
MN07`?L``4^9WD"I"Q--;T4GA`@FQ4"!=ML<SL0VKO%]/8FBF-C9AJ8DI@LC5
MD)94R.](#8G$??<.:N#*77EH>10D"V+I]*+IU>1(#;('^M5&ZU!']712M+H!
MWY/W/&$7;?N&3UNR^AO64^]J9"CV%.2=C*?K!E3!IW0XV!R^L"(J]Y"XIY6*
M'T[KREV%9'NF4]:19G:4?7X;;WVR(R?MK5@*HE_G?M"X8POWX]A506'2NMWU
MJW`MXXD&M[%6H,SBBH2FI6X9X%.EN/HQL"188`R6N3>``>4>NG!;+I8A^7ET
MLL2Z'+,\K?WAEKATYT7Q%SV)Z0M!:%E*^*TVN?`ECHK<89?7/GE"\-K;RD!>
M=4],R`C6UY01[!9X($&-771V='&A]C;9\6"KA?6\H9]#AW)(FC^9L5;9(DBC
M:-::]R-ZLI+[,5_[.!ZIN]&NNFN4FUJV+L0(73;5P"G>35=</U_M_Q?;@!7X
MO7"SW]6O#)"PJ,IOM.'N;+O=U(-YZA/A'@TTHEME*F4(,Z5H>C^S,M<U%]>B
MSX2])D+53ES8&:/WXB?SB%KI;8\(HO)`2D\HC^I0&18`\_Z;%O<TV2O<&N\6
MYZ?P6J'$DM@)=H7E(A"W%F*6J]?]R6@Q-U&C>1C4@L=BV*N*&U%E<6TH3E%:
M(0A*2#O(FVF)?N/&+Y4LR5=05<6>$A<D.&1&K!N-S[K61E">37GWF\H[<(V.
M`$$U(BP=/I>U)"[>+P3BQ%!/*7,!5!0V5$HES]1IXAW6TXLQHBZC9\6U',RS
M'[=L_:Z9R!5]0WRU'8RW%O$I#;FUCH3DY#S<XBB9(YZQ3+`"*Y?850">`^$%
MWSZ\*80$80!3J1EJ&B5!1!\X.-VWI\89?GS>/-DM4EEP@[RFA)F0G@`S&;(<
M?XK",AQDSUL``ZNZX+$1PES\O$0#!IN_V@G9I'**6`RJX-BL-[Q/9HPF!9FU
M?X:9E6'5,O[6(@X.O]L[/#LZ^<'M>'G*)?YVT^TVMV.I/:/YP.'1V5ZR80?_
M[Q_$LBT#F-`*J4C15MFZV[UPV73`-.=$@X;T4>H**.N1;7[_N/G!2>67HYK?
M[<;+GJR.V_SV[.AL^TVR=&>__/S+S\U7CLZ^W3M)=MZ=G$!2O,7IWMEI\QFC
MVC.CVD,>]Y:.*$C!]"ES#56INTEY+(O&;X7'!H7.C<:'-*JWA#377!`J&#^L
M3^=(O_['3\U7??W2+!R>ZNZ__O3O*-H(TPP3Z3N[;;X1EV,ZN>S+RP4V?8QQ
M[ER'L^XAY-T_^+>]W26<`J+&4,XY.:Z?`7>_I..V=C[COA]A?6X;O6MX_T6J
MW\K1?9J6^6%1;*(,.B=P].^6X2A_.HDT8.E/)P''=_YV59/H3[8V>ILOGC<_
M#K!O:3&>4-1_L;K:?,ZY<1<I=JL_014['X+#OZ\YSO$6$4,1OMWU]OC9\]X:
M_\>/=6[2:O?,2,4/=_9>O'Q1+XS:.=3"WC#`AEGW3JK8T`8O(KF<^U9SWQ9]
M?'"P=J>S_?23_6Q5E?8*H00Z3=69X3]3:`_2IW;!SPNIX]JEK66@CT_VCK</
M=I.]?SO>.SS=:U(WJLN>=S?UXJ4U]PGH"PGH`\>.+`EVIZ@+++?A<54GB;7:
M);O=BAH?*SO>%=ETZC3"2D.N67ZW:9U/N:S=LZV#P[/MPV\.7K_96Z+YM5]8
M(H2+V,:V@V1E<G8?D3?-"MP[WUG5'W*SD>PD@;]=RT?L*1OO`7$#GC#!)AHI
MY#4<R+1X,TH<05]<?S`V`.63BU]^CG+_R\^QU?27G]&CCB_6OVS[NO;;3<G\
M1C%\\T,K.<'DYN?;]N.]K4_+O;6^\IL_;*O-[PZS5K#R?6R&:3Z[[9W3S8^/
MK>'JEY^?W'*$KV7I6*VN'9&PMLC;BF>.CO=.MG_Y/Y1G+^;4YM3XJ)Z1YHQ/
MGFUM-3^KMNF:O%OU@G8J>B:4W-QDY^IX;;[VA-:]%R]"9E[:9UT)$23D82O_
ME@Q(UV@@@+-T2A%YMM"O1P,5#C2[[Z/%XE]_^H_F@L9?I,V/WBK4H`7.?^A6
M3?Y^"R6=POQ`ZCC_POINN\K#\U=/ME9[:R]:CJ8EDJU;:HT5R0-XL;G96WO>
M9$<W*B#E;0I!$B,<0V7+5NL[>*B,+S`'(V?7`FR\"$>$8@L9C\@63/'X'$8[
MYSD[321/60B7/&$0"V"&QM1>2+EKM5%8:ZLICVS7S]HO_U7(\M+Q1?P-RPMK
MXEE[$:L^Q4$%;2F>BM*_61ZGY2CBJ(<ANL4H;$\5=^\NK%2EARW!6=HYSQ/*
M'C%XG""J(*+$HZ&V'L\LEEH2=-MM:/1\&N(QT<'J*DT#C]=?]C8W"24>T\"%
MF)A2QL7H5LT!G(G"&']`G<BB'JHT(Y'8WD1&6C%MAJ+&RQ@TQYBV>>(^D']O
MROU_Y)WY<EO7M:=?!76+KJ:J0(08";;3JJ(H*I>)3"DB%;>KJ_^`2$AFFR+9
M'"P[3^-GR9/U]UMK3V<"05G*[52J[G5$X.#LO==>\ZB+$N6T]XC^0?;?`00+
MIRIW5*?&O'AY_/I358WZY>'>L\.7AR>'!PTCQ[7^PCFYMEHR-XGYR(6B>52Z
M@]:VD:18*#F%S.D;H&@R%2?"1YP`\G&WJAGQ-P_80_&QGQ<^VJ\.S[W*H.U4
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M]5TBW5_K\P62=1O):O^/8_>7\X_W)(QX]BT(BCB\5T,,,$'%/>8YDHX`%Z-D
M3(HH\)Y]8VBK0.A'LK(-!A+:=LTL8GFTH=;'=L.>/-L1[-,NK*B9?7F(H_VL
MVH*,>(4O6#RJ9>FUUL>6S2@-*=YVF/^H^["OXX;>+?NJW)$6((+D>#RA3YK;
M"I5K.FXJ[[%W*9]:/^-3>VUP@LNZ^%&=+H):(*33_04BM^91I.GP)\I!*/Y$
MZPHT*G]X`J^!,/!KK71_Z9N5@"2G0&]FT3TNBUDX1N_F0N%)+9CO,([$*!/]
M'P`V2317'SSF9!$8,9TH.M+^M"=S%";W>(3%@V^/;2%UQ!9`OEB^NS%"'$U,
M<YNL0G2]XU8I5,[(",,I,!`&2FCC((40QPUP"O7(<Z!%F3[.ZTSM+K^S&DU!
MT=U1&[!0$8=IL2(A$?Q"44,#<2OAV0+^HA'ZJK\(,1"\P1L3M-CM.0XRKZ73
M+=8AZ_C()6;]^3/N,(B#=@:>3QX@[.F&I)Z@PC#+0UD%$/"99Q?#"$RE@T!=
M-8_^P58(&->,[<F@[L`4`:):$`$ZXHXD2U.3AYSJCYCF+1"O*"X1\^'2?M$$
M,WX#9N.SVQ@/1J6XW+Q=+GOFX*<UM/:'(B_AJXY`MW&^3+8TGETQBN23H._(
M^DQVEM)17HJM[]&_W,Q?0PN<T=)(59`JP<'U`!I($%.C+D20_N'NK1`DSMAX
MC`QY81./0VW#,UKG!(&Q,0[(J'8Z&&U(>5`X)'CJP"[FI:]9P#.XZ=542)1J
M1;*G*-DP[1LNU)A8C`7#M=?\66R$P24B.?SJC)SL??)WQY*]-U<DL=PI[HJS
MQH7BGZ]^!#XT-3K_L+A$M)GWU54842BJSC4<T-$?+^^;Y3ET^@*7!''!EV14
MRP7YFKA%Z,2D!XM$GSN9$,X$OCN_HP$`M/^7&\A>:RTTT9''PYH"7;&D\Y<V
MP-9I4V)([#7*OO%@>U2(OYQJM7#SF'7&,PK.:7UDUQ`Y'IP[<!OC$62C48EX
MR9PM&)>.N8"W+[?<PF8"'S$G?F&\N((?$I[LIF7G44!J04CG]%YOS:M2&&]*
M',GN4>S:C&2M0_`U4H=*C1!4F>=+#XAG'PW&TV_L5.BWQL?S^YWS&3,\PJ'B
M"4W.6$.*9BF.$GM##1[M[O9'D+8V'I@F\E%3@1PQX*6!^.SH-4(`(!08RX/!
M1A.&ML#'P@_<;J4\4K",+Z^^V--*F\1EQZ_35AN1E*2A91Y";HZA;B1<&J>_
M5@<.N]'0*Z.YD954_I$K4#>=F]YWC$<H25)_1XHTD&3)8!$9H.W(P.\3.$UY
MJ^#A,_&D+/8C#%OA?E(`N>4!#NYY=UQ@\YCKPKM$_Q+T#X'=,-9U*H)6I?C>
M,MO-8+`SYBMGMV"H+'I4XKK:)::;Z,;+G<!H:3MKPNF56,2OB,BPBQ(YV^`6
M)'=B,Y>6PTB&N4ESPW3DG2H2]:86T(KB\#"?+N&B3FMZL([<3I<R(W1DYS\/
M0[7F-GR$IPX,=,@;U#=V^N,9[C]!=X.H(MH#"!.3I70X.&X">_#'Q,L2FPHM
M#(RLZL^)/QJ4`=;ZF2R-J&&R2]E*37>HN9.Z718H$M$:U5%+JE1"*.?PLB[9
M7ED]X<H1]S`,.\4'M)@/LM&R+>#VG&"TL>O2F[E;H&1-%NV!J&1!WA-SPSM`
MMY)/>JDK.^Q9_Z>"K?NOYQ)*,-3ICVU(4S3O*[`PC2Q`M=C95W+N&.F8"IHT
M0@>Y:3^TE%<[(A.S>9.N8(^X$N]RI:O1Y7FM$)V\@NU2O\96_\KG@"4KO7"4
MQKY*9*IOP3E%_HE2H8Z$8GQAVI0RUU'X%"S0/25U++DMI*U94:EE&()VSC5%
MB-;@/GJ:^$;J6"`[J]L1G%H15VZL>7][.'$FH#^)&,D"KC("[2B:(<'V,.]#
M,C[8[B+1"#O838Z0%<8(O];=F1FC+:)-,^R57U,7"&AZKZ-IDVP(*,Q4N@S'
M@!*F\WEZ#DA3W\T&=F)0L'F["H6BZR96BIHNK/1+:]92XI0VEI=+UV8`B^&Q
M!!+!Z=9RUJ0)HG?KU^'B=+#H&FQBAU^F&#0^EY!9H6UPF@8/*C@/C9G"P:S?
M@);+]]!0N-G!!JGP0YKV;<I^0;4C`H-%8'TU9(OI!4PD>&V=`PT_-9$@#B[I
M@(7A?5)M!/QL[&XHV.2V30/69Q[_,H;9=^^+2R/)ZL(O&JD.IM3AE?Y>F05@
M$M!2>LRTCX$7C61CXE6;&SCH*,YD/*:AV]%GQ<GMBL?]\7`B(.?7F>E0`<4+
M)#CZ@"%AJEZ1$A,M'*NQEH7\T)+2"`JWB^Z^KEAK/L-D9WM+XOJ/?[C#S5\P
MZZ^8M/Z=L62'EFO(![\H"?N>3$;)DUMBFHW]?!WAT1Z:0-):56+C:@540?'>
M$$2JNSZ0&Z3<?Z!H0E;WQ&PM,AMP0OV^LQ+7AF")4!_&,Q-O09DZZYFKI0&U
MKZ<,M$/N^^!.HN!>+<Y^[0454S38Q+&O<Z=/0?5NGY.5<%8KH^K4JEO&MVP-
M03T.$SK[B.[T<+`N?*IVI/?0^LHT\_>:3VS:6D`5><MP9M_\1.)TM-1#.T5A
MD8E8<O(Q)*TE?*4&PIHP('BF0[J?J#,*$C5T*A-1^R^D&6HM[8:&>BCD\W'`
MPQC9YU&K5$:?KN$KO[%E[;?;L+R=_GR&/&RWIIK`:T%D*R=V1A@;)>`?C-4&
M`F(]=2N02)UM\FAU8CV7$QZUG)OP[RH[_!T6`RPP13N[Q01*FX?T@LO&!)?*
MD>3KJB@-A8@=]X=4NLJORJ8++4I*6@@I).,G'*M-7^#2J::FV.:#DL:M"$3.
M)/?#\KND0Z`.)K5J;@F@D_ELA4_7W,O_/YD81?C0H&U<Q'2)!J/[2JS$E>V<
MO%/QB?5G:@\WV8GXV'99XB6.FR`&E%?!&IC)X\R/I,+7P.'<OYOI)7`EU+Y[
M6K%:'H)T5)Q(6:B=H315NJRFKFV;Q6+<URV2J*`6M&&A3J/XC5%_3/^GX6AN
M?,W^1)^B>6C-Q'B\,6`^-@1N8[Y(#<R.#5$+3^HY-ZM#M&*)OFC#"XA87Q4J
MMIW4V7?UH-A2D]:#.GMFJH(4T]#)J@!=&UN)"%=!0]=(L!BZS1YC6Y%UK3)[
MJE>=U-D3SEIL+9TU!OT$BP:PO?$9T=?""@BA90\,P^"(6O-;6A2IR$OX5(F0
MUKEJT*)#=7`4Q+-O0&+H5#X7[D4)GA<T]$$').H>,QB:5CH!T+T0Y92F(U8L
M<_GJG2(I*G##!DQ^_,;A`+<<E$42P[%\#GI3,E(-T4D)/?L@J4+D!.ZN)3QJ
MRFE3'C-WC>@(?W*?Q/+O;P08!+LRA=XYCMXPR]AL"XN\1$.G56!4A!CK[B3K
M:X4=#O0ZR2CA`AS$/5OMH=C^?`ZVB:Q7!6.I%;#<$7(_0M$P>]S@C=/=J2ZQ
M(5`!"4_XPC&5)+H6:Y?3ZFX6AA9+-=XO!#*7*(LK+M+M@)1I7_#;O6SBFFC3
M[B7HG&=GQGM(!/3^PSUA;KT@5Z3KV9()KW(^)KI#G:0PQ0A:6(]@>D77!"MP
M]Q@4;[2^V?K6]"R=3_:D,CVL)M`B4[B;+4R'^^W2W)P><52)58"#_C>^6UMM
MPN5RQ6$6EL=2]:4:I:4L@/KV/3Y`Z.Z$)FBV*:/M\FH>VE*[:;-_=4D>GH7\
M0*0_W^/LX#Q#-N]I#GYY+;>6'NWW8N@Y^&,TD(4PA68K/"@Z*\O0FT[9$H!6
M:%FHF--PJ4(1H_$:C[%EQ&-RCI3S*+_MN+\:SU&'"N<Y<C'Z5FWES.L\6%O9
M9$COP:(-Z6SP:N]@S)[5.PONI'WB[Q'?%2\4<N/$X_O,FW,:D[`\QS3UE%BU
MA6/AZ/B?;FZ5*,87-\LK.FSHY?8+>))2*,]E7[$01^ANFLGZQL6MH8/Q2D?I
MV-G!(`![OWWO/KD,`N?V/HU,FZL"`Q<>PU"U25F1YEX@,TL4!S:MV$_L2`D#
MURODV8UF*(M<;I41VRQA(Z<*CL-CG5<>J5,Z([\`W="1Z"R!EY+%&WMU-0?G
M7?$SG'?<F;E8.1KFK6]<O_VHN492';`^V0%F'C!T?$+($=LW(:?+H".]YBRQ
M%UM8<":]@(H*BKZ9O=O;A(=P05)E=$8E7JUX.A!10JG2!BIZD_Z!XR8)Q[_3
M\XX5D:"U6(DG@5+PY#Y1$;D.JB1SFQX4^\>J0ZTV^@YVYR<_)POL3,D"<(=K
MP21=5C16\ZHF9FJ*F"EA/JO1!'#,>`%GP^9L)^6E9^ION<@4"=4V,WH8>Z@K
M1QVZ(1@BK_=THO:K3CYUW6!$]O^T/QE.5UT72$$V[7AN]&S7&GBTNS/`;]@9
MXMS:^EDB;@852=\+/&F67+,Q0^F?]:?;$ZDYP%A-#NS'GO<&_JC!LXX8G&-1
MS,MS]X@(HA&*8.IU!4N+K=8SMT:VD`2!R>"TG3J(-L;C_DA;9EM24R93\BXX
M>=&2EM,D+OC[=MX00D5D*[+XUUFHFN2J_J;;\W$8[#\_<GQ;H,5F-"*03GS.
MEDJ1I&S]%*B9=90@S#JML]I+H9U':;0S<@J94[P"9UVH59;Y;*&6,W0FWV21
M9OB0I%J0?23WU$>SIEE,_"!+NL"\(VO1):34:QO2ZEYL)?2"7/$<8DMP,C=:
MN3$;9"E!0&I'1HI+U+E->%^X6=$F_Y<NAZ^+3E%B$*YY)/LOJ?MOK^'O(J/(
M+<.NPP.B^D)#8I^6(R@56A(S&B_T_*'"AV<=3XM`Q==S<3_=7T?E:VSHZ[FB
M4!<#\.)='IG2#5@$X$Q./)449%=?"HU\T'O&`+Q[JR9+:J#+_.S"6&.!F/IH
M"V1KX+"B[\,6I:2U;EL6\T;(-*V;3Z:]D?/6MM,8^VQ]:0,6&6=3JI3M.,A3
M$QV(UQ$)+//1:`4WD%I3DV#12DIB-E!5TT6^0H\)Y!&I.$L]8WS)-@4BB81U
M[3UR*4TGA"[O+VET38,?"VD7\?\F5+-VA0.-DE$3NC5-P-E>!R[TT[IEEIKQ
M,2[KV0LZ_&@,M.6%'$BIA[6C:%)P<7<VB/#",M/H3MO^,SHN7]+-ES8.IS_I
MD&>D.JN%GY!&*F(0VBU2HWFUP42(V"AE/1J?L7.;J5WQPQ#T#[+;L\E$2J6"
MU2`%\:;2.T'*TWA"AZ*FUR$8NV5,`<=K:?!*'XB;:16I`4W-=KD4M2<.&_?E
M7,JM&^,'JR$U'4]T\579UGC':JNL6X0E_<@SY(8&[9QL2O55TI4JINES36GV
M79A&GGQ@3(Y1NRE=2I&7LN+LI?LW62$!BDGH00;GUS%!IH;^=6;5A(W9D.AP
MRH"@)GD%;?_36<8?+8Y?\1JE*TF0#S)=MU@5^):*LRH;U7PO#=TVYIS+%^,>
M-K]]\\*H0UEC&>/`K>ZD-I8O,G9#R9U3=<:(YF?^'2%);:F26_WCMYAD"ZDV
MB'C.8(DV$K;LW)B-:U/3ZTN(RWX6Q[%-EVRT]?5MFU4T>+=UNW4$D+4ON'P1
M(V:F4(3Q>H5?:#KP3S-ACD]>[?_E/U^]?'[PYOB_]0[^^O;PY(?Z40](4<:U
M]4`-(Y4H:KE4OA"P=[SR-7GK2QMJ;QZ*^HI[+;68)DO41ZVHX<L<XCJ]\%8N
M#X:#D\EO$P^D6U@U_>*>9M`WC%[VY/"HU</W8Z8>M?N=;W0#I9!?#8?KRDV'
MRA_S#.<U*EZ:A_<W)%ZU2S^`G>E.L=&&N\>80.!%DH.K-GT8;)O;(J-D7+^.
MUT4:()61-EZ6;%L5CWN)E!5+FFK"/<3D.!0G0)VDC+GM8L/A,Z8`G'JH73!@
MLU:*$6CJ^&!?ZFWD>:Y,C`T!*L+--+2SY<TGPCOFV$J53+;JG]5*3W/T4E%J
M^@1]R%/IDH;)03"$@NIKOEN]%==G3Y.4S:A3E"=I">E57E02'A;A7O`JO$+P
M5O&'B&9&W;<40VH-VCE,\&S0ZVK%/;HFX?ZO\++K>X)@I^)/>K6Y`+64&.7&
M<+!3E(B9GF]/M6_4'=4<J\AET#LS;C;0RK(#\367BH!^DH!5O0)$M`Q?^2TY
M,=N;UEQ4*@&29S,8RNR$EX<41"FR=GGA=$PAN;FB7M<]@/3=&C#56+55*N#Q
M1I0XJT@+TQXJ&XH)/,HGHS`L(9O_[:ZMM%1P#RGBY(6NJ-XVBA45-(23^OYZ
M`RWHX>FPW6`PI(WN$SW6=1UQ@GKH>%S>2ZA>SGM`P9JLC4#I</(3@,B)KD:(
M&527L:F27@6BB)<^<JNU8ZO1'VPT00Y1RXZER>3P&^W+\').YRN9%@<^M68T
M^L\60=DKLW5N+500F!GP0^D)*,H/5L"34X8CN6J<DK;<19.P#M2LX=9X,,RH
M%=*M(EXT>/ZKTN:HU-`\AE$=WS&K&]/GZ)R<WP54X+W,X(S75B)XB.LU=&(Z
M^_V<RU?['+8EQ]Z#%:R/9%NC2B.(S+9:=OE/YUFCP6A<=:NOS;,44*LCUO9@
ME#'KZS.MDU)$9.+/$>YQ9`!U>9^32\<I(3Y[/ZS$TK+B(@?P*>HER^H6(W`;
M"P&:280H00N`IL4PRNH$A3V`??=K7!W+K$@^KSJ\S7EJZ)BY!O3>$&REOH1H
M17-4M$R2'`\*XLLB6^R0U7P<5912RNPIM""82IRJR3)B3H7.0^:NY.!PEX!%
M#'SQ&8IJ44;,\];O?K*Y>+(Y>F(BZ\T].L-T>Z9?OUE^N)=Z`7=[KA]^O+]0
MS5/03DSN-5A4FX;72(+(-XX$B'[`+W?EH&*^@AJXOP"8!=NO#<9UL);D#S(7
MQ[N/15P2BQU7ZX3XUL*@PB2E/]L$B8CR,70',JU!3Z,)Z<=D\*Q-4`TT"AA2
MN$WQ#L3,7&I(8@JN""AW5$'E:F3T!-KHR-YKI."&M$#9DNGLO`+=4JT1H83P
MOD:IC[&$&E]9+UU7G#-`ZE\#6:/Q5KT=*;S"G9A8Z6T!9"/Q>0Y\-R#9<C,N
MEQ^XV(Y`]]W5W8+Z\@]%N%N>5';P.^+;_V(75"?LPXK>&#/-JCIC*3VPP%U0
M)O^M&]8(`&]N>6[1`>;SK&F!-H0@=&OF&M,B</:I!%_V?%+FJA];S-%MB>1D
M=Q>B+`?/O4X^8LM.J0OX,3;!F)[)NY'0H.+&GN3E'0U(?Z!^VY\+#:5*JDXZ
M1+8UYV0Q*`D/+SF`QD?=2$#FV>J)^H5A=KN\41@7HUH[@B$Q*%C.@005=!6#
M33*0Q)PP+:]I7>'26;Q'I(>#A(]<J,M*9^8AC%R]]L2V-J;3D;::4T?-<^G=
M]M2/SQ2`:'Q$1I>N.OH!*IK3!J_<)H\#U:2H9NFVM.79K<'"MD:IRBY*V'SJ
M*+`..]2!DXX43/F*@F0*BL'E:TALJT!JV:?'O8AZFS%O(*6OK,U;`)3T2D/]
MQ*EAGI5H+/NA,Z1-#)"Y)6%&[I%4KO2E4KC,FP2ZRB.`RX<`^_O8SB+H;T-!
MM:*_B3TO3D/[AP;N"X-\"?.K75UR`/WBD@0!\VZ)6JT90\^&W=]=D8R%=<C/
M]%.^DJ\)JJZAOYOVX;CNCR*9.?:!E#SE&I7G1YN<PNUGR%RZ.PK5MLF<S.MA
M,7"3-/($`N,*+F27H9G]D@]:(^S;97K2&7F?9<VB<KA7D6VFX!>]U^6T:,F`
M;?%M-GH5PR!J@9R%`$@>925@&@)C&E[L%4$X4EKTKEV(;[5S5I=388;QA:)#
MC`VQ!0K2\!<W5#"V&KFM,"$#(&9)Y6@<[UH5B0,M!.PJXYA/:#([#JEH@8[8
M30,SDSS'@12C^]I/"MQ5HQ<,>NW(/6$75EJSV^Q8]2H?U1.//0VL+B`MN[&)
M?DX@KQ7Z_D5<@9[2R_N[\U.$H[4G7-#XBJ)8K#M*]T*KI=C25=F*P>W"3?D[
M'B*%CFTPS\&WD"DA":M1?T:V_'3G(?DGSA1$?\:/:KJ?QP[1Z%"SVIY..436
M^$H@@4&)&K$DX6,R=W_U[-5<VV"-Q/KH]['-6,-B+&X(@S:%0'UZC:0G"^#)
M$PE?,R%)>"U,4H8AQOUHFR@;Y*D'09TB0E'H`_B_<@XK%&^I7G37XE7#+3OU
MEB*DXAFY;G,XF_;GTQ0\[E@$[`^U+74J:T]2_][K;V]#FE2.`^]9QFWB(+$"
MPAB@@E4Y0_;^3JWZ/&^U<+I7>(%.-NF/&(-!C_8"$@T:#!+@4VPVGS)GKRY1
M.>)4;O54$F.-3:_'@UV/5[HZ7^4\Y'RJSH7'S0=/U(PF!"CIM=YS-7`O<,2<
M?_A1B!3W4'VM,[0!B)Z4N#K(GT*B%JMSW<F;?5]=7'V0\YT7LXE4LV]\JYH&
M).`D,(/:XFS/4&!_VCH^);4!+8K"^.6%B_26+\`?$\+^2U;4EAG<F[+(2=&/
M<\C+]!14!S8,;C/6R=T]%GIT/A[ROLYO?]IZC\&%($8U4!Z^)>`+Y[5-4Q?"
MC\,1&L`)J,=,\T;I=R-0AX2(C73<C?]0[N9:+0GATS4EPC8OTHI]7728COZ(
M<%%]ZXT1PV'Z16$EW-\TM\H##)^2\IND;2$<JZT0VWZK/"G0!HX1Q64D2V,V
MFE+_SC35X,2$L6J3-&ZG'@-M^SQ$-7E!A&9XP6[+<I"Z$FG0&A8$0SSD+`2Z
MQB.5(U8$^S3&98IB+CO`'K,M"C8Q14W_3E#U7OB+A"-*5;5D@V]9JXI[D\E@
MM/O-MSTRPFB@*'2+91[;@_F<+X1O2@`+#9A_/5>*&YO<_H9:N]98^\:(&3O;
MY.UIMP1)\;6(Q$VS]<`]"BZW+W[APP8\`XZ'0!</JU&_<X/$YE<V8X3/=<#N
M;/%87$&`F<"@]@PUOR/H2LF"=ZK7K2)4[#V1J67D.B*-RVH'.5D+1R:9=C+E
M#L:3<*B0X<ZAZF?AYE=O-?P`@9OTV-L&Y4*-H4\*$A)*K&DOT%246Z8@F)YO
MN'0LP!+;;(D#D>H'KA[O'\)@Q!9M[H+/R\`\O9/F:IYU$-QX)T`GZ<&&:W"+
MT:P//_#19K?)'_U<8S=>AT\-U26^L8913%,M+#4VUT('X8]8+Q*?OVQ1TJ)Y
M\-9SC*_>H41<]MX.CE$NEF?6A],6V#MC[$;*';#%7SS?0R2)8B`,D^P"?V4[
M)><%_Q=(*AX]75P#PURO?X=4]QQ)=O?S_<7/9($(D>+S"_IF7O^(NL/=M/&T
M=!%]P;@(.''&]TL-*^:D%NZP`X>4[RQ^N).DK\WQ]*LIP2I56OUGS+;DAUQ9
M#!3SCJZ^2\ZL6G%';.3,4`X#PDTB5=+J6?J4!J:6;?#BK"!GUE%M$\(N@T`\
MFS[(1WLP"FA)O:/!]C"+?4B*TXJQ1P:-W":&;W]R_3#\:U3%4[7KL#_?TP")
M?A^-.3>C.3U_QLG);O`CMU]YKQ"NM1'T/+FQAVXR6LIZ%#L!.81@AT?/XYKF
M23;BTQ?@8RL6NJJ-6%+FR]GYU<663YL&<95\(-9'?@SC=SXL.=;OP]%O(=Q/
M4J$)$76A@S&IF/3B*D?`MNCA$*C)6$!/\4R_%/,SF5L56;1KGO:W9[-T]/"N
M>%VA0B6^PKAH4LPLY]AEEG;5IF<%KEI*.[U:%U(7=GGN2(NTFP[F[=)N.!B.
M'I!VW\O%$!B_]@E/)BVZEXX.%EXRO<B\=!6/'E=KT'Y4K=.W=;]O#74[(.M:
M1OUR9B26[Z;+$6?VBC])Z/^B:YBT*AW#P63XP#6T*1T2D3*9:(`V`0WG^:(X
MX#722[46P1FZ=8M4NW/=2/R=?M&$=FAAD2ZWY3>:(Q\\=)]SF8,891$>6'7L
MLK5TS85]VL@&(YZVT3F^,&9)K+5CUR0A1F2NN3;3!-;U77"%P@95GBEEAIG!
M\+PD@O5-1?XZ\Y9$(/OO&DY+E@I51,Q.09;"^*2MXV$A^5LR*/15XU,8&!J@
ML7EY+J^8LT;;O27B%/E.P915ZF*K3!O:TPJ[I^&,0)I7@E:F;B73O^KGRDV5
MP@K2;%J5@6KOH]P;</D+VHNX%FP_]DKG<$4)`09G&K;;B\NXT?TI>A(`@7&4
M)%3M-JI[S;WM5B@1';M/AD00=A4`Q<Z680_5[^*&:T;:,[1ZVW'KZ4S-$F5T
MO(OBY&C-63\N5(%:T8]SO?:7VT3FNHE%W1'1$YQ)$]0=<8$5R[>_8*9.B_WY
MSA@5-5MO-8;:(K82;!\EMR:#:2N_Q$B3/-,)NHRTNMBJR@:=NQUNXH)*9PDX
M\$"?LL^2<7YMYDU4D*RYLPZ$8$L;\RGS`ZE^=B,SVV/6-2UF;II))W>BK*5X
MDMO4P[,;O:4->GE#V4TL2!#'EER,1:E7LC&KR]>Y+,PF]%F)<=L.3H/30/I_
M(B<T:--K.JK*,$,AQV1N83JCM.<^(.DUIN]^A@-AI4XU&<PELYL>A.%@6U*^
M&SF_E=S.TH[4YAUJ=T"\PD8),!>C%:YVNP`>:5=7&K0T/*GJ,=JX`9ZJP%\*
M(!Z\"NC=&(L7X"Z'JC\GPQ)AABEJ;E9.E_JB$KP/9K.,6AL3(0[(FX.?A+#(
MDWS9_+1F5I_)%B_G*@8[N[2#$ZZ4/T>^HN=<F=<$CA+:)S9>IPM%P27.I9X`
MYW]WWVM:A%B=,LTT!B0I!>G+NQ_/;\XHZB-PP'&DQ)KO0J_,GI3T]$=KSZC]
MI(^85X'@O+OYM4_#J<O[]_)86_\.WQ4^[*L+=`?W+-!26+`@,?:2WBQZ@A8;
M=UMI6_Q8/3&M\[*^=>>3'*[-X8[Z7JUTM["M/#C_'G<2#JHX61GTO%G*#ORV
MM_ENY06%W>E*LX%)D#;X/8[H86P.C+W@UG`:VCRE[846*<DCW2-4XP7$"O9Z
MHHXE'WI6?#E`BAMWEBOI=&4=DQM7?&5^FGO&>`,;9].M3$2BF%C4>,0HBKF8
MIFBTM-+JXJ[5+SL:3'=DK$6?=B81?=IP6.ZTLYOMP<YJ=M/EL(S&`P-(^E,S
M!++/\OH!XV%*P&4XVLE<3&*S]IMD/*QM!B259(6MX`PL<\^X>^$I[2SH_*WQ
MXHB^U,_B"]L1CA:P:@L;N:)N+O"0]BI4R&RBH-80)3&D"^X/"N#)Y84`'8-4
M";3\9*JX:5^%C9KZ+O-+>0Q]W;O%3\@&D4ORFV<DJF@!]E+QTR"SQ5RTTQ*-
MY2<N?MXBQ:O9<M'W5@F*Y^YLB7*@/,#5R"A*-!+TD?3RFJJ=/X]OK`=#7KES
MJOE@B)CV>S-)-9-L;5HU7K>B$,BP,(6`>VT_8*Q/\0/'B*8:U[(?J7!4,J%"
M[\X]4E#<\1I\9%U>,6OW,\`KI%"+5KKTYA.08H5JVG$F\GC)A9COAEEH3(._
MP64-9EL&442VMO>>QH[&G#X.+>[FI^3"^UV#MV%%9OU.,6=&5%-**<XZJ6D.
M;$3^O$*=4N*+0X"'Q2@*'5D<+,V)%'D4<L[[$B=--OA+G:Z2'JS?K*$A2R?G
M!,H`GLVW7<>I[K1AW!\&S5S;7V6L(Y9J&C3IA<2W*BI<F:=>T>.B!K="]GU!
M+-U1I*VI0(.E#SDE]X"9DC<<CC.R%^H&T5?3I0,3:HLNKY$JA=`-MD_EFEH#
MHG1JF@LW3`$WVH&@\M69!EX<,^E$EA[&HQZX0+\0`FP1T5+0-?J^O]`-0W4A
MQ%K55Z;#P7S<<;N[#_DZQ8,BKX^ACZ*?65?$$I($'T2"!KG,D&$1I,36,:3=
M:VUZQ)A*FOKCUU7U)LKLWV^9Q9`[E,T),H+$MI@)$NU(,E30;#(-B$(Z)J''
M>L>2JK%&6@E$3XGN[\.!5IU6B5:E3MN%']2C[K;+*)60K2&C$E1D3`6#LS>9
M!#3GB.=72)]D:<*U<O:?\^YA;Q/O`15ZL]PY0\S0".66A*G)V%4!GIBF=CSI
M"18C#^-%\`<:$1`;.8/NDI<V)E%X:-%>EBY9&NP'9A_R_,9XUA_-J=D._[`'
M-V@PS1R;+ZV\MBAU:;MI;X%##=G3B+ZB"=3M"$@1YZX+L0JC*MP$:S$I6DI]
M41:U%GIF=??;NL$5W#A-\<07#V6(E%C1@13@H'&J`+W,K!J,IW`0_')-OORR
M33>H76+L2L,ER".&U)`<Z='FU8=&%C>2)`(FA00$<','C[MAI+LI@"'^LI0/
M3=4.YQ_UI=4[6%2_].\KK*O8!HG7&/0\%S[`9,&]('R.@JITS*"'$9`^_1'7
MA<5(J*DCJ=3+"<FJ/#W7IF!M]N+2U?)>D+MU;W8VNZ)W!GD0=V!20R^-)0=^
M`0$2ZB=JH1[5,<R#K?#>6K^%D*.="#8"`U!>@USRD3#^J7RTX1GX0IRT5=!*
M$A>H&<3KIQB1D8PD]YH9'[N$ZX@N\GAT@WA2A*"FIRIJ>;QLN\R*Q\X1O#UE
MJ4!42VTG5O:)OK.V:.<;LZL+],/\+61?J,_3GG\7]][!%)G#J3>H_IABU9D&
M0:!%@1+9%\D1(7S7!X;H76=7[MB%AP15KJ\P85+96IAWT;`PTGQ;M^4T+;:;
M\`6'6QIW1#<;%($V(N<>-MR^9UZ)2CY=W9,*AV&$.U('LCL/-%O<I5-DI4PB
M^O_`HK!7ZS)$:I/&<4="18?#PPC;Z2#88BN)8.,@[@K!HM^5Q!K7S.),XG\1
M_S05:83OB`*>&`ZN9Y&P-#X2ZPKV1M[?D(<9`1_8@>%[=[0AT(4\B)0R3>8Q
MDZ-#7DV&I3I5RJLZ(QCO#B;M*A6=1&;KJU2?SPC\//^N?("\>CH"[RJ4(U\D
M47,<#5^4_I6#%QTPZ`\1[X*ZAJ!KCZW'YXX\XAYHMN*UH_FEN\=,!XA_5&R;
M^)8H]$Q[3G](+49UJ+STX;:VS(WX20J&JR<^SLP8BC=E;Z<O*1)P\FX*2X[%
M$&O^#,I28K_Y:PNKUD(*$-EP_(V4(?VK)3I=*0D88@UM#0>S=9QN"91!WZ@:
MO!=TXKK_X-D$A4`V`4QZV2[^^,!(Q(_-)4S>HW0U7>(]RI,<OC'7$TP=S36Q
MIJ%L5@*YALC.4[/\/O.XDXP%UQAMP>0!XT%6`^]S;#IE\D<O7'`A5=!+@NGJ
MXMPS,M</:J(RAE*:B)\HBJ7*^TY(((?YQ97A)ZZ0G#9<&5)M**R\**>$ZH!O
M$P]>4H<*<7NE_)\/]PMN^RY6G88,N`M)[QN^-BR-TZJMDFBMG\7R*E`LM8FU
M&0NNO\38*$*Y:(_8K_0&=-G;.G7YY>O>YG&L4=JU4W%U:&U+*V""XN`QNHN<
M_RJXZ([7/'>#+]79`H4ZX.L\L:^$^)+'Z8]NAI+26-$C&F4^:S&4.Z856(@I
MK19U?%=A8RU`?>=J)#=,R6+`@VSJ"VQ^4J;_+[C`M<O8,ZKQ[)D.SD.9D'YL
M&4IXM`O7A!I)05EX>`7QLL@KIOJ[6\HR^V#D(DY;KQ/-3?=VOP081<\_34A%
M[4FX]4ZSV:O(;II7F043![97'_--KHD6D1P>,6M>_.'FS`IF3"P)),`X-Q"+
MU]?/:'.=N^D%L<BI"T(Q8)6-+GU?\8`%B`);$S,+V.&)Y#RBKZ*9XX\Y@*O@
MZ6T.=VQFL(U(@;+V6NM&ZD@V)6MUNE-Z74S:X>6J.^Q0S]OJ:#:0!;NSW=[F
MQIQLK?%NZ/:V./L_]YZ$%PD:?5RX$(RZ"(+:(9[()?DH<9MB5-GW5U=5)SM=
M"<GCP>0QSA52'M9TN=$F=)=FD.0MD[$==;0Q*;`D5%6TM(9(-,$1>+UJ76]Q
M;T!Z,6D"EP)"%K+_LM+M^/XC:2!6*"<F%U`=:1YJVK1BM!3/+[E2.OVI%EV7
M*]F\Q7\:U6Y'J4+OV#.AWRIC*KX\S$G/I9K?QT+%/<P>.CC0@M)+N7V`2]T<
M;3S^9AGK*?>+*LN7M&X3`'_`#FXLN9=Z6AT28&?Z*"Z?O^%U6M87>Q:&;6%M
M)-]7\+=NUY\]M+K9^J?Q,(VDX`,5M"T;'^^+$Y$@T_ABQ58:$:'-U$^GOIU-
M*JV&DT:B[HJ7/^;9!BK\S1B*(6X`1$PRK8.S\=.]SZG@-595+71=LW[6I!%,
MJK$O-9;,>JD39A&PM14_15>5Q0OQ[56S)93^@#I"<D##J7H"DV]4ZA:J=Y+@
M8J!IF2!T1)TF&7(A+.JY.6+M\[9BCZ!8ZV>/\4=9@@+E@J)\_+<0EMY@_DGB
M'Y0#-4Z6Z#36'^=3U9'R37LY;OTQ%4UBYS1'Q7W3?')GQ)/;D^87N\,M<?_Z
M%W]+1</U;ZR(<XM(TGRWY:O99(L'Y@T*-`MNR^*3]5^=J!?))A`T^#^I?_V\
M4@U:_U;XHF!!:_5R0@,KT+2<'TM3NV*,G;7.23:2=$_HZ[+W]^6-.D[98U82
M>(+U1A(OI;A7EV?R?=*<E/0BY0&250@Z*N(E?Z'R@8+Q%T6]U*8&'AR@#J@_
M+,5^"<;V`LW78B4S@`V+W:;#Y'`+2`*IJ-S6;R3\3JV0@93="T(`%B<PN\4T
M[0*YM9>D=$`XA"%?\4+X4?MN\"H$\1,T%9RBI%E2]D;%6-YX^++8E[&IZR4"
M#IO04OH"T"K/N%EES6R40_CSXOQ"G-`W56:GL$#7'KVFC4LKME99Q&IPZ4SA
MET3U/'L/BF0#'+?6W,BXA8!?O+)ZVNK)U/$^O%&5_`+P[;V"P8J<E"]!<5WH
MV_HE%G:]Z0X-="GZ^;V.'3;V*PTG//C.9]<4R=3IXU##)+=1MHAP+\YH!0/>
MZ7SZD.XBN">,_.C<JMLB+U[OB;$:%<-?IJI;^XE_PI'!=J4+QT1:($O"L+_#
M@U/$D:Y^Q4HGMA0&>O!/QK<R#21'CJRR&&O>D$:P0:_3,80RQF)-/+(<QC&*
MR;M[7"O>08A%.`9=CEP!$V@IT^179@/:YQS5C#V?&^&N*Z5&^=;--4-^;Z"I
MV"5',L253$<E_6T^AGR\!)$]T1&(<\)._-\9DT,>2(*U`*=3F`-?:&+-6,*J
MQ-KL3S&1)7G.IE-Z^:ZIR1S=R-R>:G["6M3[4G_I*09FNX5'RX_"4_43`C<[
MX,).HU`AP<`P,S;(M73U=E98E-+SB*'&]+Y0]=/1&5XW=;.\E]*+0R8V,1!D
MW.'8IY2Q%U978=V[)?&E(-+M5QEC!<5.S<37<</)$@SHVS=)*02!^"JTLV*1
M.B'A+\@%(N/H+VA0%<[G8[O*3%$U(N()_X36'51PBBD18@57KX4AEG'JH3NW
ML;B!,/95IH7CFGP5]A*SFCQT*[K6;$[DFJZ05R6$->OD1JXF2__/*QINB]YQ
MS=SU?EK^VJ-Q;*3:D--2HU]1`Z,T>94A,UE\1KUZD]$VG?TBFPND7*),ZT@$
MD7WE5M9!HTYMV'#-<8`TOVK]=\MU!T`VV.X)V.EQ=YEWCVWUXM0<60J"6LC>
MHGWZ=;9\@9&Y=J\77728F%D555K4=X)><DJMNC[H4);<>:D'DDY1-JZH',AW
MC<X?N\U\,27[\5KU-FY^--N=AL+)%UCC9#75"7E[@,I+$4!#%QZ/!^.I%-N=
M6?TW$Y(C=[8F,_H$U+\:[PQV1UL\T-2AIUNSP6A:_\%TT/[Y2??E*.X;8"VM
MS_6>?ZHF6T&*0>_?0H<57ZIJ>Z[\%R05@F+>I?!?2X]MGNZ1NBR^.`!4`".P
MA6`U5#`F8RW,5$S&U#E54RW0R`O+Q%EF$5.[)>DIR$=GP@U.O8?&G9QVR5%7
MTQLDGY+4E'1<PXV'V&SOZ]'ASWOE?1:K]*Y!JD__9`&KX,$J1E<"JKN]"VK3
M)6K^QW]068=JC.9U??<??WCZQZ\T1W)S&$SLZE2Z36\)6=U];>O91[FI_D3T
MBIHW'`>;$[F_&UQOTSOEUU^_2?_(QF<S>B0POZ'ZN0&RW+O@^)K_?"4PV?AX
MEZQX!C;/GZ3(6;CGU`3GW?+NDS36G%&\/3<,J[O.MDT10S.KQ.MWR(2E%I46
M5F]=BT=1=8.?'H2JRS53^=3<H-(2H_X,"8$_EA:C$%[<E7P/N_WQ=*<_G0U3
M2LW2@XG[^3>>2D--S_D:1XOMQ6(*K^@G'M=UX6'KV69,.M81[&26NE!N<X>8
MRVB<\WZZ-FG`9)]L-/X\%D'584^H`3(?MH*_?8L*_$S2W$_G8>)(SB0`,EUT
M40%-JQ7GB@'ON!.[G1#@XWJ"P436>NIA%9_,:IK>D]OV!>/)PUV!O55ILSV$
M)?9;QBJO0I]7F5`/N7P)$F$M;$P&LQU9C2$H6J6XNZ<6K@BM@Z3-)[^`F#LI
ML7;G<5GE'H34:H"@S9&%@WW@Y>(Z<IM_]1^_5=.U70^U.]RD6S^&)TH\I86X
MC.<4?F[/0$%AW\90S97T39GKHW'%03U"T`23,D:9^17F6G8F871"+,HJQ>EV
MBU5YO-]C'C2].K/V73P@@+TK?Q\RKO"?F<LN9UXJ&!J\SGG$8?!"$<2B98D+
MOO+E].%XSSV$L5)YF6:WMG9D\,*<^\OB%O))6^\NAK$XUKW51H.]\2XC>25F
M8V:I!5_--L5-D6L?N:9=IW.\3#%'-(E_AUJQK>"4BT[^K>AF!`WE2H7[D;_C
MN#*@>@"?^B_`_9)&U61!8MGB\:$,G,T&?856Y?B&SB_5HY6N+M`NV(<WB/?A
M1\'!I682=K_-F)6GC0K;,(ZLM.F_!H(34GF=4QINCPB9RK52P>V&XG-8[0@-
M'P:]8R1$/ZUXC<Q'E#Q7;X[?Q@%AHM2D&@G)$5"QGD7"1)1;]GZIFM0M7A7G
MH:S@U;(B/WG6PY@K8]`3HV'KG5E+=-X845A#)ERGD\=.*72Z.>/"-]2<7\7@
M[]O;836!=K3_ZKN#WLG>_SPXKK.[0\970<LG(-SS\UM-(I(W_J%QDD,;)WFX
MXKTO`A3;^%^OROX,+@$?Y30SC(=1F<O29+VN!$FBC4(9<J^>AO:5?$$[=VMZ
MV3AV.],`7V*_F=#XT.:(52@'W^`-T0^6E7M0@*[%\L:Y]CBY\85&X)#%QQ@T
MSCG8J[ERX];#\(71-E9W_1[:-RL<S=+!T,`V;XTM;41?E>1]XV'?)K[K&\_^
MRQ4;=^X!%?BT"-MP[WMCT!SHG!Z@ZMJH`@TYBC0/[I-4-6(S9;C!,X8\H`,(
M15/QKHS!8>`OD93OEJ>,54L1(!I)N*^-2%/X%>W!4Q.,\%'UV*R,^`W=-)RG
M(MO8L/];\1L9JF*)[I:Z./^)`5(_7L%[W?D(TJDA%[(N.M]%;NB:7=NVU\.$
M+7M-("B\X(C"LR7'8)0[7G5UQ$"=DHL2:7RY9"@4?Y05*47<Y4)-0^WB'&G4
MTU[A+H-TL.&(_/&OW!;#X]TAIF6_#9"HXE\#Y5[!!)L78KO,#=<1/M>P57RE
MW'E0]!Z735D&`(0#;F$BI!J](Y_'N;,%4]HS)&D\>D04NHX#=9)Z8Y/ZGO?V
M;2I$_=L3$WWI_)%&X8.&E_7'E1E20_?Z(YN,QAY+*6AZQ3:Q#[>I'-_>:?QH
M9S+O3YI!ZFY8$#E8WM5?L[6]5?](U]O-0@E02?D*DT#@$A>_AN`0[@TBO=9=
MQH+![P.;+"!D68NP.UUG^#BTC<L/Q:XFJ%.67>3KB2RDSE@IO"E^2#1BN%H[
M^MB#HNTZ=$M^KB0S-,5["(TA`BT?@;$MA%KPK.0=I.<:F+_'#J!=]?'U.XTF
ME4D7$/;C-4$WO/MW=L3XZ@P8`X#(61`0%TCYQ)[I)FKG7=[J&?4<*NIRK+P(
M^\XOCS^L7^@Q]Y)?:V@@#AEWIY\%G;'^RSU+R+-D9$BXC7/7?[$Y9O9C_<,G
MC1R+S>%\T,@-VB1-HO[3UUB7BTM%7`0UCS46&%%_?'/>7'US-!HT'-N;H]WF
M!EXK3.M.@F>N1#^1+"??..HZR]OZBF\.7NZ='#SOO=Y[<W+85)/>A$JIU]97
MZ03?5I@<=/N@KC0R7>F!][]4ROB?/,N[+9Z=FIH5Q1CBR47%96=>KC(W_PW3
MS\/L$-W8)8SNQ_/K`8V_?&;&<8]<51`1LU>(4>:E-YB%KB:PR3VR',0RFNB#
M7?(5RF7@G7%23%*C8OV,=2!PTS,E6,M4M(E>LFC27BW1/NXNY'NG;\4_X:3F
MT5G^0DQ4%@8_CYXN9)I;2IL4]JD\UQJM5-*:!4%V94XOHVX>+#^+/WKV`@J4
M921&A`YOXUZ2\7SU*31Q>48QR67OF::S:%;\@D"D-2(-FM^[JZ"2IPP+,4$9
M=&+;I%%8FGO<OOO&1N+3J)C1CP6#B/5+1_GXE4QW`!_BBY17C2=#Z3[H/3>R
MN&,&50-5P(+D_W2#)ENGDV\DC>.R#G7@O#)A7-`4)(%'Q7V:+GPSPEWI3T\\
M29M\)>^_+E^!W!>F$CH#<5_FR*Q5X-'84!4-2!OQCF>Y,%2H8:B4WE1@?L"M
M#BA7D.<%8?F_TT1?&%O"O52+-^;S>2O8*Q4H5MC9M:1>OPJK.W`%B1W?&/"C
MMDUI&1$]R.NDNFD=]'AY1;;4V^O>7BRS;4BA/>E&8>H8T)=VX7[9@/R>.U)<
MA^G^<:^Z[#.N!UN'[F3F%#:3L2(HM(FMRB8<;2RHY5E#:@^)Z1/UP0KJ[1B=
M&ZT''VZ@OOTR/RMX9.I5K6'[8+1,"LM&%'KK:<O?*9^O1-^-66.+*Z:$97<`
MMGL4+J0Y6>%RL.5"=AG3HW12YK.[$9C=C`)3-"WC,ZGR^1:?D1JR#^>Q.P>7
M@/OM/?>@^R!+RZJ2(6`R(NF)QO[=?E4&UZWFNF5V1)<)WR:>G?@"8U,72UG.
M&'<=!]';H;1;M3%@`6J;I?#JS2:JL%E)<:-C;3Q&<7E&#_G**M?"J\*EM</?
M`XC=D#>W.2:^U1\EZS@9=+WAJ-(4)7G>GI/%1J(CR9=W&KN%RW,`'0`<(;C8
MML,CGJ;YN*=Q9+IQ:UVD07ML!HO\\0]W3__XAQRJ>QVR!C$1?NV5NAO-%NO/
M/K\W3(=?XTUL<;B80)5\@5MZ@PENYCE970U!%252@0$22.)I=E(O6#1VO*$2
M7LT9<V_L!N/:9K-:>0BT^Z.&\]FS#`/:"<]NZ_T8,$M&0P)5L8P+HWS#5#;G
M;<%@!66D!%LFR:9._QMHD7H(-(!:`3\Z)3?9.L.M#N!791899W08[U_)?N_M
M#\B#NJ`2"(7@-<O+<^)&PL7BYH/<J(:Q@<XY>->JAFS^)8`3WU?YF2LSQFOD
MC]4U-A4(]^7@].)I1D18*ANLZ!1?+4Z;R*R=38;E>5=4,5Q!8ISI"\1[SR(C
MW('^-_OK*APXO1&U2[IY>&5`DDO5US`\A:TZQ4>]'AX"-Z"=:=%:"\L2/Z,W
M<V3S(#M-NY;$J0R*$1_!.'0($=K'<V(%;K&&-NE`M/4GC4Z:`-1TPPXDJGDI
M/RY(DXTP-(RO.2*%_[@]DM+(F.VF^Y^)LH*I`XCS=Z)PN;I1@2NTD>"D"<6+
M:_ARB=U;W,'&%"AP:X:!E],5!/1`8&+OS&.F\C0:MY(?6\[L<@_@Q7TP)<)V
M)/[22%DN\OSC.]V[F>I&UB:$T>:IF[P[E^L0S".37M((\*9!-/J>3&3A*SJC
MVA7+X1E1MY4#C6BCN#OWL/&&VT%BQ]?&G^VVM7;CNFV!^J=H?BM9Q_>Q-@;?
M&JD?3I4E7VZS>0N3A4EV_@9)Q8A66&]N=*Q01,0(RC5UPELQ@I!`_B,M?7!,
M1([=Y`VB*4]:32:3]`QZ+(?AC'5N]^SM\>'1P?%Q;__5T?[!T<F;O9/#5T?'
M]<=4[L+6N*RWR>&-<'K0FS#N;?767$+^[\C%*O++B.I6XVM@-(8KYQC(SHRJ
M9+H[_Z;?VYGQ'^UTUQ4.>U<2L.'W&"HB51F)3)4X`ZV%V@+WR@A00^"N1B,N
MSU0BV/@U3UK:D"CB[)Q,WQOT+R&^4T\IK<EA0TY*-TM=8FP:MX0=_6!4TT*1
MXL<%%0R(H?QI]6F!`)D`G[;&NL@)ML`1D:R,G!8PH3G;7[FVY2#3<J98@'*:
M:]HZ7;"6WAG+._'@XW?E.&+_][P>=1EE]XW&=,#`?`U)-+\_CL/J<L*JZ6;Z
M0;^WCX%L4T/^DZCQ'7VN\'L-^KT]7G=^R^6=DI:[1+:B?VKY[T[_0E@$(.Y?
MX595_)A_R\6/(JS%N,:=73!@1C,*/3\9F=HI+)`7-:0_((-LEWI\Y8U'^:]7
MN8V\\LI?K(5%X66P(=K1VBY'\U6[U/.[._XD.![)/T4#XFG$/KK@;E.?:\#_
M[R64'<@E6#OO1OMINP?33.*X*$,MNW#Y,M*%2[OTG`6#>T-M(_;[W>')=["B
MX][>$>&05T<GAT=_.CC:;_%SREPX=P>-@7'?T@P`@4CC,1'BB7D]'[7V*T0/
MV(?0>4E1V++.,6%G%_J<G/L\HPX_N\?MH=H%B`TLGEV=+GIO:(\/?K^XP!MR
M9G-Z"U$Y&X?^?]Z7$_YK=5AE0,D6DL*DD[,C2,+M:D/?L<&&.,6YF0Y\>;RD
MRLC<5&$"U]PS`GS'4/;UO71T43Q&(>^3EB(Y<OE!GXD5?UA:%H]O#4Y"@UPO
M$4(QH5R7*GMS.MBT>\07JG$H8LMQL!@Y>6+[$\.#0RQ^08V"BNC)9R&O$!P4
M##_>?T2*61MB=#0V80R[S('W_;.<<I$H7YT,)PT$.Y%,I46Y1LUZ>P=M'286
MML-)@GU"@!RN$6/W_F[;%'R&Y*9MEI@DN:&9FJ%!9H?FJ:M7N!T1K16Y?&Y,
M"$%K%6KP9V._@]6[<=+QO;@STNZ5'9G^D0:JI7W2PW[(`"R!U+2)^C8K/W,6
MB[]NUA_3&%9T3C,N:G1H\QG?L(I=NLFW!I_$<\2YZWK9F*OW7(1XW0$8Z=9E
M/\#DNJ)3/ZAROG?@HY'+M]>I\\1P*Z[BX(R+U)\](O1FJ9T6:R==;,N?]_NK
M/[U)ZP1FL]8_5@1XO>6.#UX>["NV\]>W>V].#MZ\_*'WXO!H#_ZW][+W?.]D
MK[?Y]FCO[?-#G@EIPMF3\%?W=D"/N"S9M-K''19-$!Z1-#,UEOB[=N.M&BP3
M++AAV%@.D>+98@X3B/F>5!XV:ICUC]]`G_$_?OM_[%WI;AM'$GZ50;`!%<"2
M=5E>+Q`#M$0YW)5$+DEY$P2+!778%D!;6E)*;"`/L\^R3[;?5]4]TU/5,QSM
ME?PP$`0RIX_JJ[J.KZJQ]^3/W7_^H]TCR>)%&+>SEFP,:<NX?5BAN171"9?@
M?&(7$BG<S)\`F$/X"+'+`;X,3O/_QX"O@M,\A9D*?<&!^6O3%Y^,<_3MZ=;_
MM>E;5EC^Q-*V?__>GLP@L/JM`Q[HPXP`C4!8KFUC`PCQYV'@U6%$2HN]`Q>-
M=`*LH^Q`WM>XBV4C`GLS9T8/<MRKFP7=^:Z/[:UMQU8V\*,#\N-$[#:?"-@-
M=U\8Y/[]RPW@*W]O`?WX&8F.G_F!/0,8WF-#MK=V<@3N.,\\J78_3L]?30=_
M/A^<S8K!&_Q_:B=@^H"<`']_X-4YX%.`Z[7/@[\I#UO7\@CB$MX.HDJ&1[4Q
M??##19PM^=/>"ZNYJ]5-+"81B`M1-T)"U`4H5QPEB%?1!W@4HZQAM;\*XHLL
M%J--XP6+E[]I`)1WDM'F!0UF+(TK'N(BB5,Y(1)8(X+4EM'TN&%CIB%B0]!%
M'7->Q[\13$G9$1(&)%.4I[@0G0\R2)4.(E@TO5Z5++=@YZ>G_<D/Q>BXF`Y?
MGPV/AX=]K&[_\'!T+D)],1Z=#"G7%QMC0%(HM!N.?/\2V6Z0<O"&]G@%5]E>
M)E`OF"!9SLX1]+K%[1T-4KX<8]]Q`0WAO\%D\JCA927\T`]!]_TJ(>!X>?L1
M&B4>E>1&LTT-S[A!1QC:QDQLVAFJN4/YY%6G&W>*5ZRN^/@TEHQ.9ZEJ>QW-
MOAM,BL/SR81GI#^=#J`B-1&0MJC2>Y1C!2_FAG0\_!XBQR,:?7OSB9,H>#=+
MZ7@R&/>'1\7@^_'@;#KH1.1=_14!V^3P;-8_>SU\=3)X#)%P?<?-DZ<TG:9*
M18'2L[R/F;*#6F`)&I0*3:YT/,P`OWVZ3]X.8O!#B_Q:7^*38?_5\&1(@$_C
M%%(X9=X%<4J\P^:!J14#:3',I4.N[XP(H\0QM*.=SD:'?_IN='(TF$Q[!=CT
M<-:\^=,>HB$T1OVYAI.='^,-2@6S2K]3B6QR;K&8G0.;<:1`!#VQ;7T_LD7E
M_X$%VW:I83ZFO>`")K]M4ZZ@QD/[>51"HW0E1A)[!%,9\+S(BU,G6B3+U__K
M&,A#A(5<+&\8.?EV_N$&K%>"*G<EE)(/^4E`_[=?05&Z7?+'IQ(^2.DD<-A4
MVL3=D"#Z&T](.@>EQ8SH0^4(LI_:=GZR02/4$3<R#EV)QZQ/Y?W+5C-2(YVI
M+:N/NZENR])[QO:4CJU=<W8UUVN9#5=;VF>EU2'AV`-<2K@28JAODGO/=HZ+
M#':]TW'_#$SD2!.L%F=TF1!K[B[3[>(4+.Z]*/9>+H:A:ZM`TE[*($[8UH_J
MQ74?X1+=*N#4R];4X^)X1G0-V2%1BZ`'5!G#"@'12/5+X[0MV-,81SB#[!?X
MV"BAT+)V=<WL.&@.$A]]R93+0BR5@E):ZH+?Q2KS2P7GV-)3S7$88"_H`WHQ
M,!KHF/)CXD4,8#:B$24XR4U':`E73H6/"1L1K2M.QO9^E'A"0"PQ+1RG>O)L
MX=X7\`SD]@;P3`_"1)D6DOR#IEW!`V`91:\4\'JU-"5T2?6/VBTFC#!<UZJ@
MAM-=F5I_@]"9Z2-T#,]I8$J;'A6_<QP'XC^VXSU<X]3,J#I=%0.<)5$LBA]/
MD#@;3]5??UC]U>[7_M5/B@V+=FJQ;ZE1DZ>DU%22%R'BG9R1N_I`=VV*08`8
M_;"D.*U`\X'5BF<-33)GD"Z9E`#":W%)`SY<8Y:^:A2_X(5A/([Y\,$5*27;
MA]4UHJ)@)(?.9TOUGJNP8G^O=:!&>UND%V)'[>^)6A66ZINF!2(@<\6X+JP4
M44ZVJ<G\9PP/LC`,H/9;&:MRR(RU]FM=!(\*T3IZ1A#>EL5A"//K9[4B+9,@
MH3:CI^&.,'U+2%TCZ[YWCZZA2L4$90.-`K=M0W?7^P6.TX</XNN!W2FI:"MD
MB6E9G4HW?((D#+!XN09%?=2)RH8('3]@6TM<(@_?\<TG_NV:<9IFMX7*+U!&
MQ^P^[?T..F-+!RUSB6FXWCS!&;RB>A?UV?P08,(HUS.ER$[_$!8E&.(?T?)K
MKB*=]4N)O$+C#][&0B]'_LMH/)CT7VT!S?+V'I<,L!XXG;Z!,@-K/_@8TT$0
M%`4PIAU+#YXJU9M>1`\<X+!7\\]NM_3"FXRNA?![$3RM>..NH8$=Z6EMN9:%
MWFE<Z3KGJ2G_W;?A44C%NBK&\\^T38D+%TM5:=!V].<`A\^!_Z/E64)!K]S$
MK2>M>53"&<%G)!8A&%-<!S_NN)MT-IK!X=78LQW%L`QI06H:AME#A@8F$Z,B
M_Q#0/L"2BJ`I!RK.5^0%2]XLYD\TVM;$*=AA`9=)L9UBW*4:"&05##JHI'$&
M``HB(08HP"\AW&5_!UDP7D!G9,YOT`.S8IAO>(*CR5@N;H6-0JC+(`=E&#06
M.X?VV6@&`]&X_T.?UK&,/M5TB>X4;7K57NM7O!FY540(LEV+)$HD]^D4L<L`
M!SK9I.%=#M?$'&AF!*Y2;=MS'Y'.Y`:@*AAU51"#8G:[^(D*E`;6RAO:L#=#
M/+HM@C;GY#^$GY2C<UT@QR3Z?Y;O'WZ$K3)A@"4.^16::\:P"$@T,>SFC-$^
MMA&E+0"3[4>E395A1SAV*&B3'>H34HLR'#XZ33FMZ3X*00&C[3XJ00W4TA(O
MTC(.R\'7E.5J(R\VHE=&1(#KBZ6X:'@(W(II/R%^*C,K555]1#UZ`6:WN%2%
M[SW``]VGG`^1VTMC,@,`_7+3N1!2=&[;?QKWEEN_="[=$F5:2BAE<&!&24"+
MS!8,IY]LF*1"UZ$U5._8W\;J&LX%<+:[:@$_<NNZ53JZOKC'?`-^\R"8X39-
M*F@G]$?!U':'U9EG90Z),ZZBW"2(V6X`8W*`6T"MY`'R88OW2C-ZQ(0H.)HF
M&+U-Y&HES(I&6PHR[REPP'S"Y!)D-OP=;CM>`Q(U`Y4,_ZS>PW%=GI<>08D`
M8SPP$S(LE](>\TZ@<DDXW7D:KHT.$&C\[&LAC((5B01A:02=S]_1FX&^"__`
M#531>M!@=`3"EB7>J;VM;0`JH1RC/^3'2C(YJ60$<O8.MD7Z$HH(2<Q0Y(X0
MSO[E]?55@)L#T!B8-O04F!4E[--.V21]D[YC#=-L8NJRK5<9!(/6'<')3OX,
MKT1`I!7/*6:@M*(P9?X5]@1129PSIG=VAT*L":BE0[5TE*,4(8-OT,@?^<+U
M65Q3N-XODOS0H`UP<6E\A.GB'=0./A)FJ>J79J=UQ[-.TD>)7\6IHFAJ&ZT/
MM;5HO[Y+;4O'P,E+X@#9L]*2+2*L"(AI`0[;CY,**<SD,CQ/.)4XUP^P.@CG
MPGKQ13A;,3LO8`/V6+EZ9<!TV&VI;19V820K$XDR!";8ZM5[,A?A]1?0]S$G
M/92<C0?:-M/$)N7P@V5^</M`^$B47,YD<36,A`XZW`B0<!\0HW@7.&6(J"0/
M!6NC>3LPXAH_8^QQR6!85IH4YJNH!+#"!6(`."/,^DA>6\(OR9>P:9>K\$80
M/T840VG^9*.255'BDR0("GPJCD---*">=7&G*6-"9T!6U&^XC173V0F<`"<=
MAEJ]HD@89A\`8.P=B7X$'I51.Q*Y`]LL&SZ&#18[RHGS/>CPM;CMR(+)<'$+
M1D[,,(?(7=$Y0QD6<(K2_Q)1LMRWE42API$'Q)JS)+J2W1GK=(RB6:W=;=4C
M5.P,X=FV5\B$NJ>J.0Z)UKF`%8@Y)Y/A:[.PFVFXO;6X-015C>YVT+O*/$*@
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M"9OITFLVH@0C+#IKE!`:FRP&TWL\^[9X4IS=7.+-'MR6D@>,]J<[QNBW=SM&
M6EM))ZB.9[PO`BV!&9.N&7]1DSWS&\Z)N8'5)I@4W,49J^N4/N0@\G;K*JV!
M_8SK3Z>3\_G?IO:)S(%;[3+JE0(&4YGR^,8#HR?,UNGMJ39C?Y])!$$51ROQ
MRKAOU:<:9E'&B':O%PR!?X<@9MS>#%AC^BS!%MIF?WL-YJ<RX8D1B(HUK4^E
M*BH!Y2QNZ8@_U8GGDS9V_`%V40N<5<Y'H>HR:>R)[G/;P+]%&#)T@A81UR*)
M^79)1""GDDEB%7Z,JI^MGN3@DKZ0!\V;]DZ0;7$A7T1WCL;RK$16<?-RTO6B
M,=,D&98L-1W9>HM4-V5PR0(I<>K<*AA4G9ZPIGBQ`\@B[4*PLF<1M^OJ[T+F
M^4_J[\&,WU;_]!;IWY"84PYOTR!30ZB3CF*E1#PY_Y@$:5>F.C=YZZHV6BQ3
ML][3V(K="\9Z6);3-:$<UKF&K$*N1NR[-OCH_:Y&+NP8DA/3+5(ZF08<O"7`
M-C?B<VZX1=:5`X<Z1_IMF/XAN>FL=>WR#4"UJ(003-9@1G*)!HMB;:3(4G":
M1T`T("^L]].V%GMQ^47CAQ2[Y2J'-VO+;-Z0+G$=:9[S2B)D.*6MV@N`#883
M`&-$*!Y>ZLYY6!]A"Q,VZ@1@G`EUI&.R]>'2%J8*=,--N%"CBO]S@X6$Z\<M
MM:Y<W7+4U!IA%9JM!481-UO!'>U^C\$8[L-!'DKSIGK#D4J_K<:<#(``72-`
M)/.UG^(12MPK?/YDW)@(F5S;I),&X]TB%S9WO:U!A46YHK[]TG8']C*O:-GV
M@&??E*?N<-7S`0-MFXY6!($@XXTM#P%8?+OAKMQ<O0=T7[*0K2NY8&`S9$^W
M?ODMH&&[!%4!B/6VLB\F6"N@)1%KZ$BLC'-A:^N8'K\FP-C&+(GT=T2OE6-[
M,+F^A>4)<F:0)NQ4&#L?T%UR-H),W'+@Q-Q7,AO64W#@O-C?K^72@KL"6?WD
M+3MP3#B+-=H\>&UWY)T1>?_O((I3E,0#;]G9W`?6'3<Z2R#R.`A<90ET]HTW
MF]7(`O<($4P\&]R4-,Z51FO\^_G!D^<[^[%MVANMBX;^&]=-F54*!P@F`-&A
ML_H1>*8.QT[^<7D$PYZU!6HGMQ$SV%!YTH0Q;"A_!G,+S84Y>WRXO-*W9'.<
M)CKJX%O!SA870K:87H4%7[=K9ENQL?92Y5JK$&YGL&)CD8$CRPOO;UNPJQR\
MVPAOR:@;B#8&2HNV7=<==>:6QUIL>=4Q'_'>A6T@\6/$X)KR^L^K]2%*I%1I
M1*=H4,^]%40>(>WT9*VEU+`D&&PL/*3X]&'Q!TF;\>U7=SP62,CXU<O>[,L[
MM_0F]+'3^<ZMG=?J*`0NVO!RY]IZ#2<-W!VQ]^'Y-\$@J%5OB-A)`"EP5Q)!
M;5OO\4?U7B"'7LRP)4M*-!6^P><?ZI/M2U:B7^5E5$LYY),N`RY^*<")_>LN
MMKDW*!3%4ONMA^G<W]S&?\YR6HDHME(K1P,7BYSS29%'OKO]HB:LP$=M;[&U
M5.\`:B'>_8W%(WMQ#+EL$-<5@J6;OU\2-[18M)1(?/M(_)#EQYQ]2@H0-8+B
MDKL&K5:&E262C\L&7;54H4YRBE,`R:]7G'K[73&LL6"4+YJPJJT[02P[<;*;
M]L+A8D[?]]L(96)>QHFDS6G#[;3WRYM4.42P]#D-<)I<DC2"ETI`G_ETWXG5
ME,)X6FZLT1;*!5OC,P91<Q/I&=NB^'R#+.%VIY;%*AW,%NE%U/%!@Z#7"VI=
MB1:V+;3/U-X:F2,^M&=;C1;4#ON_MA"=VFD\VK'76@QIE0HC?H[V`3?A58'L
MN8^?#YN.?7*4`W/)'>48M%*4Z9(!FLO9,<J"SZ-2<I`O]Z+KL8T%._>\&WMN
M(C%NKZ;]]^5Y3/#V^%1*1)(JTD#3B,(Y>7L!Q6]/O';YMR>_/(^)T(%X^B"4
MA33R%#D_BNN9]T,0+57'<BIS/4J[N^\X/#5C^9)_2PF:.Z)2("="2O&Q"X(/
MM8UD:6IDN-G2N$)MJ^;5E,=@\6GW2JP[2<I6UTFP7Q.<^[E(_4IMMW):#F:H
MATPZ!"B+98[NY/*P_9=.*DCE2?Y?6ZPAZVMN3FS5*=.B$M\%\8I:`*P)])G2
MWFF+^A*MM[\O;AMD'#?3EVX"C9[$*8>,K;8T]V*H83^M20+0_1@<%&U1&FHO
MI2PL_H@JN6)(5YBQ;_8.HNAH:9:.D)7AU1QP0\E1B,,M#3D;XW$]3U][!KT)
M%A&F2`I5R/EL>PU?H3$B':+]V&T:&T^N(9-C`B$1U6T[ZY#L+JQ;8X>I#W#/
MMM\U]5<>#>'-+2YE5NYTK9.W)6(%"1^)7-FW%-N<6_9[E.<"GL)^/J+Q=2YL
M62QP]KNJN'B'82]1<9^N5O<O_R4`````__\#`%!+`P04``8`"````"$`GI,-
MURD#``!H"@``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)26VVZC,!"&
M[U?:=T#<-QS"(41)JD*WNY5VI=5J#]<.F&`5,++=IGW['=LTQ.30I!=MZ/S^
M_<UX,GAQ^]K4U@MFG-!V:7L3U[9PF]."M)NE_>?WP\W,MKA`;8%JVN*E_8:Y
M?;OZ_&FQI>R)5Q@+"QQ:OK0K(;JYX_"\P@WB$]KA%B(E90T2\,@V#N\81H5:
MU-2.[[J1TR#2VMIASB[QH&5)<GQ/\^<&MT*;,%PC`?R\(AU_=VOR2^P:Q)Z>
MNYN<-AU8K$E-Q)LRM:TFGS]N6LK0NH:\7[T`Y>_>ZN'`OB$YHYR68@)VC@8]
MS#EQ$@><5HN"0`:R[!;#Y=*^\^:9Y]O.:J$*])?@+=_[;/&*;K\R4GPG+89J
MPSG)$UA3^B2ECX7\%RQV#E8_J!/XR:P"E^BY%K_H]ALFFTK`<8>0D4QL7KS=
M8YY#1<%FXH?2*:<U`,!OJR&R-:`BZ%7]W9)"5$M[&DW"V)UZ(+?6F(L'(BUM
M*W_F@C;_M,CKK;2)WYM,@;Z/^Q-_%GIA]+&+HXE4@O=(H-6"T:T%70-[\@[)
M'O3FX"PSFT)]CF<&*<DU=W*16@IJ#L?QLHK"A?,"%<Q[27HH\4U%=JB8#A('
M\':,D/GUC'(1Y&);`V-D$J1:$NQ+3$5V3F$@PC[[B.?+)\5+&[P'M-C<.-62
M2-76C\)P5-YL/Q[X;C#;K3>P(+?+L:1XA#78JH-/M41CN;LM52S;CWF>ZT>S
M06%`0<M?#B7%(ZC$W#C5DD35ROMR,S7#V<FP`15=`R7%)E0\Y*HKI26QAG+U
MSPCLK,2`BZ^!D^(1G&?NG&I)H.!&X-GQF($C7VM[,^-\LTOQ"&?XFNM::<EQ
MG.,Q`R>Y!D>*1SBCADFUY&0_G0P;4!X,T<N+I-0CK&!T:+U&MY0?'N^I#T0F
MXFCVGS]'3\_K_:D5CZ92VFOZK@^")([B<#3:,D.4)/$L2&9#1YB$<OY>W&EP
M`S@XV_'([S4?$&HC+3I!J.\*^E7:H0W^@=B&M-RJ<0E3W9W$,':8OBGH!T$[
M]<I<4P%O>/6Q@AL=AO>I.P%Q2:EX?Y!WD=T=<?4?``#__P,`4$L#!!0`!@`(
M````(0!I.+FSI04``!D7```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
ME)C;;J-($(;O5]IW0-S'T$<@BC,:$V5WI!UIM=K#-<$X1C'&`G*8M]]JNI/N
M:F+&W"1Q_%'\7=55/_3-E[?F$+Q475^WQW5(5G$85,>RW=;'QW7XS]_W5VD8
M]$-QW!:']EBMPQ]5'WZY_?67F]>V>^KW534$$.'8K\/],)RNHZ@O]U53]*OV
M5!WAFUW;-<4`'[O'J#]U5;$=+VH.$8UC&35%?0QUA.ONDACM;E>7U5U;/C?5
M<=!!NNI0#*"_W]>G_CU:4UX2KBFZI^?35=DV)PCQ4!_JX<<8-`R:\OK;X['M
MBH<#K/N-\*)\CSU^F(1OZK)K^W8WK"!<I(5.UYQ%6021;F^V-:Q`I3WHJMTZ
M_$JN<T;#Z/9F3-"_=?7:.W\'_;Y]_:VKMW_4QPJR#752%7AHVR>%?MNJ?\'%
MT>3J^[$"?W;!MMH5SX?AK_;U]ZI^W`]0;@$K4@N[WOZXJ_H2,@IA5E2H2&5[
M``'P,VAJM34@(\7;^/NUW@[[=<CD2B0Q(X`'#U4_W-<J9!B4S_W0-O]IB)A0
M.@@U01BH-]_3%4T%$?+G42*M:%S@73$4MS==^QK`KH%[]J="[4%R#9'5RACD
MY_.5P9+4-5_51>.E0/=0CI=;1FZB%\A@:9#-%*&8R*<$LT@$\CXTPLI=C?/:
M%`QK"`.KC>$[;S3"'41B(I\CD#2XS^72%+P.(;:5QO&--QJ18TX%)QFA,L9(
M[B)$",83&P1I@P6ZVE1I^=E-^UY:=9&G46`!&XTDHT8BLS@17H)SET@(Y]2&
M0`I!C:MPOK`*]I1Y9=MHQ"B+.9,DQ=IS1$@B*+'I1=+D$FD*]J0E^,8;C6AI
ME"=)0FQ.QJ;*72(1)&-6.U*6+%&F8$^9#3O>=Z,1K4QD/&:,>WG-781+)F)N
MEX>T*<-SILE\017L:<N\K&E$:Y.$3<J)OA<RL1L1R<J6R%(P'B#<[A&=,HW`
M+O]H9#]C<P221F#87IZRD<8YXY/)JR*N0],%"11+^%O-A-%()IAT"*S.LX?Y
M@A(]TMT!Q^U(UZDSC"DIW#CU]F..",HR<5:<FM(7[S:B9SH29[>+$:<9DSHF
M9.K7U431!",9MSL6)VZ1,9"I,W`[U(TVS>@[4R%(0NV]1R0W88Q\2N'1P")8
MGIK0EZ=.SW.4.F]+;8@[\R6-B629E]X<,2*C(DW.Z5OD#.I1S&]9KW`;P\SU
M["R"T[?('<C4'ISY::KK3G]*"*?$CEA371<ADA,F[2*QO$460:8>P;V>W!C&
M["P90^F\F9AC!$P_$;;WL;Q%+D&F-N$TG<F>ZP-,QH2D=F.9[+E(RF#DV0;#
MZA:9!=&#WFT-X65F8QB=O(21))N.%1U&(_#8DB7)F>3117XQTMC,A.\7AIGK
MC%D$98]ZAG'9^\1X%;8U9_/H&AO&E3EY[C2,2:-(,R)M%V&=:M)?/`"I]@54
M9;M]C#[-S.O3C&DC`2_QMM&PO$7V0:?VX7BFD:>9>7FNQ;"$9939,8_U09P%
MZ5.T5UX[NHP^S<PU"<6(R.+X7'47V8=Z>_;EV<!&GF9`P<<CWW3WS3(X?XL,
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M50+3J]-'F_K#T)[&,[Z'=H`CR?'//1Q!5W``&*\`WK7M\/Y!'9Y^'&K?_@\`
M`/__`P!02P,$%``&``@````A`$`O5!65!```V1```!D```!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&ULE)C;;JLX%(;O1YIW0-PW8)MCE&2K.9]&&HWF<$V(
MDZ`"CH`T[=O/,DX(MO<N32^:8'_^65Z_E\$9_/C(4N.=%F7"\J&)>K9IT#QF
M^R0_#LU__IZ_!*915E&^CU*6TZ'Y24OSQ^CWWP975KR5)THK`Q3R<FB>JNK<
MMZPR/M$L*GOL3'/H.;`BBRJX+(Y6>2YHM*\'9:F%;=NSLBC)3:'0+[ZCP0Z'
M)*93%E\RFE="I*!I5$'\Y2DYEW>U+/Z.7!85;Y?S2\RR,TCLDC2I/FM1T\CB
M_NJ8LR+:I3#O#^1$\5V[OM#DLR0N6,D.50_D+!&H/N?0"BU0&@WV"<R`I]TH
MZ&%HOJ+^UC>MT:#.S[\)O9:M[T9Y8M=%D>RW24XAV6`3-V#'V!M'5WO>!(,M
M;?2\-N#/PMC30W1)J[_8=4F3XZD"MUV8$)]7?_\YI64,"069'G:Y4LQ2"`#^
M&UG"5P8D)/JH/Z_)OCH-3>+U7-\F"'!C1\MJGG!)TX@O9<6R_P2$;E)"!-]$
M"$1_Z\<]'+C(]9Y0<6XJ\-FH?#L$"+:>!WPV@Y^>AW<3\=LB3\\#*DND%-+R
M="R6\*>V>QI5T6A0L*L!)00.E.>(%R3J(U"^&RUL::S_E?-@.5=YY3)#$T($
M4TM8K>^CD'@#ZQV66'QCQCKC!41F)G>&KR@N/%4;9FK#7&U8J`U+M6&E-JSO
M#8_PD1S8YD[<`]NV&BS(99-0R*&4T)]7S#UOG.9YN\N.10.(-XG$<B03G?!]
M6V:F/V%L7V9F.A,2A9GK#%'"6>B([R@R2YWQ0H59Z4Q@*]-:ZXP2S48GU("W
M.N('36HD*V'?D:SDM4%@*_W:4CX*N):#KNLT-ZA7]5@PL",U+BO%,NDDIIW$
MK).8=Q*+3F+92:PZB74GL>DDME\1DJV0=LG6K^WD]-"$1=-8Y7K*KC46C%?O
M>SCPB*VNW(E$X-#5B*E$V`'2B%F;0"[Q-6(N$=C1-18281-/TUBVB0"%&K!J
M`SZ&US*U2MM`X/NN&S[JJU[^FS9!`A382,GHMDU@.PB0_]@O)#/AP?R$F9R6
MS0R4'60L$%]X24(]0Y,V@3Q')Z8R@72G9A*!X,5(S>*\380V[(5*FA=MP,>Z
M4<LVX#CZ+59M@`3Z/-9MP`L0$.ICL4U@QPLA#'FKV[8)A&!->FY#2$["6](3
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M.3K2/Z+BF.2ED=(#W,KN^;"W%.)L*BXJ=JY/-#M6P9FR_GJ"GQ`H'"3L'L`'
MQJK[!=S8:GZ4&/T/``#__P,`4$L#!!0`!@`(````(0!F4(17R`(``-D'```9
M````>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;)2576^;,!2&[R?M/UB^+V`(
M$**0JE75K=(F3=,^KATPP2I@9#M-^^]W;--`D[1+;I(0OWZ?<XZ/#\OKY[9!
M3TPJ+KH<$R_`B'6%*'FWR?'O7_=7<XR4IEU)&]&Q'+\PA:]7GS\M=T(^JIHQ
MC<"A4SFNM>X7OJ^*FK54>:)G':Q40K94PZ/<^*J7C)9V4]OX81`D?DMYAYW#
M0I[C(:J*%^Q.%-N6==J92-90#?&KFO?JU:TMSK%KJ7S<]E>%:'NP6/.&ZQ=K
MBE%;+!XVG9!TW4#>SV1&BU=O^W!DW_)""B4J[8&=[P(]SCGS,Q^<5LN20P:F
M[$BR*L<W9'%+`NROEK9`?SC;J<EOI&JQ^R)Y^8UW#*H-YV1.8"W$HY$^E.8O
MV.P?[;ZW)_!#HI)5=-OHGV+WE?%-K>&X8\C()+8H7^Z8*J"B8..%L7$J1`,!
MP"=JN6D-J`A]MM\[7NHZQU'BQ6D0$9"C-5/ZGAM+C(JMTJ+]ZT1DL'(FX6`"
MWX,)";UP'I,X^;^+[R*R"=Y135=+*78(N@:8JJ>F!\D"G$UF$=3G=&:0DMES
M8S;9K:!6<!Q/JRR:+?TG*&$Q:&Z/->%>X0-\'P%0IQ%\3#9BB!"C"3G>^]KH
M;IUF-M$D>\4;,MB<3S;B'(<VVS`@A^FZY<0N1R0)HNPT$\(ZGVG$$^9AHFXY
M=<R4A+/@-!-Z['RF$4^88^E<<=WRP)R'49J>9B:7,(UXPAPM'=,M#\PLFL_F
MIYGI)4PCGC!'2\=TRP,S"-/WF&;$3^[/Q]UKQ(8Y=F\\&_O$@9W&@4F:P-U^
MY]YDEY"-^(`<C]WBR$[CR%?1/(O'LW]S;6#27I"S51^BQY0<>A"YZT/2,`VS
M0[@;SFYV]73#OE.YX9U"#:M@%@1>"ITIW6AV#UKT=D:MA8:1:G_6\`IE,,`"
M#\25$/KUP0S__4MY]0\``/__`P!02P,$%``&``@````A`*."F22%`P````P`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-C`N>&ULE%9=;YLP%'V?M/^`>&_X
M2B")DE0EA*W2)DW3/IX=<!*K@)'M-.V_WS4.%$P'Z4L(YOCXGG.O[;NZ?\DS
MXQDS3FBQ-IV);1JX2&A*BN/:_/TKOIN;!A>H2%%&"[PV7S$W[S>?/ZTNE#WQ
M$\;"`(:"K\V3$.72LGARPCGB$UKB`KX<*,N1@%=VM'C),$JK27EFN;;M6SDB
MA:D8ENP6#GHXD`1'-#GGN!"*A.$,"8B?GTC):[8\N84N1^SI7-XE-"^!8D\R
M(EXK4M/(D^7CL:`,[3/0_>),45)S5R\]^IPDC')Z$!.@LU2@?<T+:V$!TV:5
M$E`@;3<8/JS-!V<9STUKLZK\^4/PA;?^&_Q$+U\82;^1`H/9D":9@#VE3Q+Z
MF,HAF&SU9L=5`GXP(\4'=,[$3WKYBLGQ)"#;,Q`D=2W3UPCS!`P%FHD[DTP)
MS2``^#5R(BL##$$OU?-"4G%:FYX_F06VYP#<V&,N8B(I32,Y<T'SOPKD7*D4
MB7LE@>>5Q'$G[GSFS/P/L'A7%G@V+#>',+U.]EN3;P[!4J94'D=(H,V*T8L!
M=0NR>8GD+G"6P%R;JZQH[/Z?VV"S)'F0+&L3-AP8R:%"GC<+UU]9SY#6Y(H)
MW\,$7<RVQL@L2N*H'G@C=KI3=C6BGA*W!BP0V2B%U+65OE\^M2`)EH)JUE`-
M`'>CT.T&LNTC`EO3%_4Q&LNNC_`T2-R'!/,FEHYDJ+.V9)E<#_;?L'0Y"7`M
MI;.I%D*H,%"1C1M:MK>CB&@4L1M%Q$.(CA,0:MN)80<D>&V"S8VZA?OF<%68
MH<(,.3"*B/J(A;MH,EFML^MC-*?C(43'`SCM;O=`@C4//+L;6Z@PL'[CDQ;;
M=A01*81?G1F>[4QU_:,,\1"BHQ^.M]OU2["N7SMZ0H4)JMB=P(>;0-LG6X48
M<"@:Y=B-<L1#B(X#P4<<D&#=`4U?J#!7!^;V?#'MELBV#?!MQ]>V4:2^#QBT
M:S,XMN\YL^X2<0?@ND$K"1WQLAULW73#1X`$Z^*][L*APEQ+UUWXVO>M^CZ@
M+1I%[$81T'G)2-]?1>E7G96Z]7/,CGB+LXP;"3W+KLF#\FU&FX;NP957GS8>
M.DNXH?OC$32`U;C53(`&K$1'_!VQ(RFXD>$#+&5/`MBL3+5PZD70LNI!]E1`
MZU7]/4&GC>'NMR<`/E`JZA=8V&IZ]\T_````__\#`%!+`P04``8`"````"$`
MKX2M4W4"``#L!@``&0```'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R4E4N/
MVC`4A?>5^A\L[R=.8(`!$48#$>U(K515?:R-XQ"+.(YL\_KWO;892F`*E$6(
MD\_'YQX_,G[>R0IMN#9"U2E.HA@C7C.5BWJ9XI\_Y@]/&!E+ZYQ6JN8IWG.#
MGR<?/XRW2J],R;E%H%";%)?6-B-"#"NYI"92#:_A3:&TI!::>DE,HSG-?2=9
MD4X<]XFDHL9!8:3OT5!%(1C/%%M+7ML@HGE%+?@WI6C,FYID]\A)JE?KYH$I
MV8#$0E3"[KTH1I*-7I>UTG110=V[Y)&R-VW?N)"7@FEE5&$CD"/!Z&7-0S(D
MH#09YP(J<+$CS8L4OR2CK(?)9.SS^27XUIS<(U.J[2<M\B^BYA`V3).;@(52
M*X>^YNX1="87O>=^`KYIE/."KBO[76T_<[$L+<QV#PIR=8WR?<8-@T!!)NIX
M&TQ58`"N2`JW,B`0NO/_6Y';,L7=?M0;Q-T$<+3@QLZ%D\2(K8U5\G>`$F?J
M*-(YB#R"^\/[3M1YZB6]_FT5$ASY`C-JZ62LU1;!HH$Q34/=$DQ&H.PJZT(^
M[U<&;ER?%]?)=P7:P&QL)L/X:4PV$"$[,--+IM,F9I=$]PS)+I'!WW$(E'"L
M`](YK>.Z?P>G&*XG_H=M=]/`0"1'IM\F9C>)[!K1<M_]'_<./G.?Q&UOT\#T
M_=QT!['_M9%90*X4F%TC6O9!Y/[P'7QN/VE[FP;FBK?932*[1K3<PQ:\W[V#
MS]V?AQ^80_B]=\._C<!YYD;ZATHH(!Q883\W=,F_4KT4M4$5+V#5QM$`-'0X
MKD+#JL;OVX6R<,SXVQ*^*APV=1P!7"AEWQKN0#Q^IR9_````__\#`%!+`P04
M``8`"````"$`\4[L;=("``!,"```&0```'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6R4EEUOFS`4AN\G[3\@WS=@PD<2A50EJ-ND39JF?5P[8()5P,AVFO;?
M[]A.:2!=1F\(#H]?WO/ZQ,[Z]JFIG4<J).-M@O#,0PYM<UZP=I^@7S_O;Q;(
MD8JT!:EY2Q/T3"6ZW7S\L#YR\2`K2I4#"JU,4*54MW)=F5>T(7+&.]K"DY*+
MAB@8BKTK.T%)828UM>M[7N0VA+7(*JS$%`U>EBRG&<\/#6V5%1&T)@K\RXIU
M\D6MR:?(-40\'+J;G#<=2.Q8S=2S$45.DZ^^[%LNR*Z&NI]P0/(7;3.XD&]8
M+KCDI9J!G&N-7M:\=)<N*&W6!8,*=.R.H&6"[O`JBY&[69M\?C-ZE&?WCJSX
M\9-@Q5?64@@;EDDOP([S!XU^*?17,-F]F'UO%N"[<`I:DD.M?O#C9\KVE8+5
M#J$@7=>J>,ZHS"%0D)GYH5;*>0T&X.HT3'<&!$*>S.>1%:I*T!S(18C#"'AG
M1Z6Z9UH3.?E!*M[\L10^:5D5_Z02@/W3<W^RBFLMF0HSHLAF+?C1@:Z!=\J.
MZ![$*U!^NR2H1;-W&C93P*R$97C<++&_=A\AN_S$I)?,B-A>$O,1DETB\:)_
MCPO6>_^0RG3_&H;PD=/[#Y9!KVMJ3"T#4?1,-"2V_R6R:\3`/5B9[E[#"0+M
MWEFP#(?>4LM$9FUP$,?S<!X/D>TY$BY];Q'A(9&=$W&P"+S7C`;N(:3I[C4\
M=C]*-K5,;-R'01SBD;/M.8`7T3P8*606@&N?T2LQ\`Z_N^G>-3SV/HHUM8SU
MCL.YC[W@M65-:VW/D0A[L>^-1+)SXEKRT7O<:WCL?F0MM8QU?_,/^P/F;?\#
MY%H!\7L*T/"P@-`;[1BI96SC>\-^WEYY!L>&UA[/LZUB#P2[779D3[\1L6>M
M=&I:0GMYLQB62]CCP`X4[\SVN.,*=G%S6\&I36'O]&8`EYRKEX$^</K_`9N_
M````__\#`%!+`P04``8`"````"$`.]=[42D#``"9"0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6R45EUOFS`4?9^T_X#\'CY#0J*0J@GK5FF3IFD?
MSPZ88!4PLIVF_?>[QH$&L]&6AP3,\?$Y]U[[LKEYJDKKD7!!61TCSW:11>J4
M9;0^QNC7S[M9A"PA<9WADM4D1L]$H)OMQP^;,^,/HB!$6L!0BQ@54C9KQQ%I
M02HL;-:0&M[DC%=8PB,_.J+A!&?MI*IT?-==.!6F-=(,:_X6#I;G-"4)2T\5
MJ:4FX:3$$O2+@C:B8ZO2M]!5F#^<FEG*J@8H#K2D\KDE15:5KN^/->/X4(+O
M)V^.TXZ[?1C15S3E3+!<VD#G:*%CSRMGY0#3=I-1<*#";G&2Q^C66R<1<K:;
M-CZ_*3F+JWM+%.S\F=/L*ZT)!!O2I!)P8.Q!0>\S-023G='LNS8!W[F5D1R?
M2OF#G;\0>BPD9#L$0\K7.GM.B$@AH$!C^Z%B2ED)`N#7JJBJ#`@(?FK_SS23
M18R"A1TNW<`#N'4@0MY118FL]"0DJ_YHD'>ATB3^A60.ZB_O?=N/0B]<O,[B
M:$6MP01+O-UP=K:@:&!-T6!5@MX:F#MG6D?O]7]6P:,BN54L,8)J!Q<"TO.X
M77G!QGF$F*87S&Z,\8:(?8=0`52TR=6``WI[T1"*:]'_3D.G38&5MHYUIP>`
MNQ?K&T+&B,"`)&/(,NI9!F*#]XA58*B.*VWSZ(6WC<I.8R!9O?Y%OW*+V+^*
M2*80`_6PS-M#K<`Q@M#TRD+7T+;3&,^+VC)Q[2`TQ+\&2"8``^FPM:ZEJ](.
M8.M/5XN:9%I8#A7N-*:S$-J1.[B"3S.C6O;FC'`$2880MU]R8&DQM#1M18%-
M*V8M:4QG90;I\.<#,^8>'4WP(L-L8D"FXS.PMWR//04V[(W.'(WI[47VT)P[
MSL/>F`(GNF^<9,D8LO)6U]=+E`?VU-?`U5D[G3T%-NV9A:@QG;V7FM&GP.1;
M:)>*?SQ7*]:M4'>*BO`CV9.R%%;*3JK-^;!W^]&^`]_ZZHPUQG?0F=L^YO0O
MH#,V^$B^87ZDM;!*D@.E:R]A!W#=6_6#9$W;GPY,0D]L;POX!"+0&5P;P#EC
MLGN`A9W^HVK[%P``__\#`%!+`P04``8`"````"$``J:'4<\)``#&0P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R<W%MSHDH7!N#[K^K[#Y;W.PHJ
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MG`H\N^;N@L$Q\6*_KC]WYY'SU;"W;^]GVM\Y&I(86>GECV6?-C2EU,R#GA,M
M;9P==8!^)O9;L39H2M:_W?^_MB_G]Z=DQGC(Y=,9C7CBAWTZU[:BR61B\WDZ
M._NY1)K7E&Q$]QK)4N^]Q_4'O9#3<L8=K=#VW*[0_W_?%<-KA!;XM2OWCJ?H
M3PH-^^^[HOG3(G[QFM$S#WDM7<SDXT^NEO%[HTSOO6,2BT+NZ>O\ZOJ#EDW?
MLX]H*<M6Q'[UQY2[MQ7]T@K]\O<3K.?]SM`OE\[$7[6T1MP9T:^+18^]^%,R
MD=R\M-;G]?/CT?E*4+6C-7/Z6(O:J95$RWY&RORYY.AW*4JY*5HQ13-/27H^
M9=^)"LNOYZ*6?4S]HEJP\4PY:#155'PA$E\T:_%`50;HYV4[AE946ZGY3[H:
MMIVZ+_SM-'B@R0,M'FCS0$<&9*D1G>]RT>.!/@\,_,"UZT9!5X<W](W?^1$/
MC&7@VI,)#TS]P,UV^#3.?.-O9RX#!;>6B@$N>&#)`RO>ANDM%(I?=R`?(;T$
MN:M)03?=2]'2O:Q?*E;*^@U_)?&7J=!BF?IC*ON!:W?8=%>"(L.(%23Y@KK3
MJI(H(])9,[6@8:(>%+POC2#A?6D&"=M.*RCX=MI!PK?3"1*CF%?GI1MB"JQN
M]&*8?@PS"#&\/\,PP_;E*,RP&C0.,7Q<DZ#)I]/J_$Q#3,Y0S2QH`O,\#YK`
MMA8QS#*&6848-H6F&32!/IM><MXF3?YF\$H9H*,.I0R(E[$,'9Y&EP/Q+*4<
M\$"%!RP>J,K`;2<UOJ=K09//L4RHQS"-&*898@RV.ELQ3#N&Z01-4<NIJ[,;
M-$:!F5Z88:N\'V;8'`Y"3)%5DV$,,XIAQC',)(:9QC"S&&8>PRQBF&4,LPJ:
M?(ZM,=,,008K;V8Y#%V/UI04I_<32HI'I[;02FKS0(4'+!ZHRL#U.*K&`W4>
M:/!`DP=:/-#F@0X/='F@QP-]'ACPP)`'1CPPYH$)#TS]P/5@*5#&9C',/&@"
M)6$19EA)6(895A)6OO&/^$PS$"G?1)051V\:[UAQ0M.+SLV1;5%C/2Y+0]N[
M'OVJY;("A05%%8H:%'4H&E`TH6A!T8:B`T47BAX4?2@&4`RA&$$QAF("Q12*
M&11S*!90+*%806&:F$1FG9+P]/G.'0DO]%.2CF0OR9S7V=%&69JHA(?"@J(*
M10V*.A0-*)I0M*!H0]&!HBN%X7X.I>6+:?ZVJH=`'X$![,00BA$4X]MNZ,6B
MKK,#J,DMR-`X^4BG<!LS*.:W&]%"-K)`8(G`"G;"-#&)S#8ET>D3V#L276B>
MZ.P=;5F:J$2'PH*B"D4-BCH4#2B:4+2@:$/1@:(+10^*/A0#*(90C*3(NR4I
M%Y)#8]C$!(HI%#,HYE`LH%A"L9)"3D=823%-V(89F7-*NM-YB3O276B6[@8_
MD)<F*MVAL*"H0E&#H@Y%`XHF%"THVE!TH.A"T8.B#\4`BB$4(RC&4$R@F$(Q
MD^+[/)O#)A90+*%806&:F)2CB)+O=$;\CGP7FN5[AAUGE:61\Y@UBO01+_N@
MH7(KM();XM6W]M:MH`M/Z)\*JA)$%)4:%'4H&E`TH6A!T8:B`T47BAX4?2@&
M4`REN'GM5O?;Z/;QL!T[AIN80#&]W4C8*^8,-C&'8@'%$HH5%*:)B9=PX;F@
MY+I&9WGN2':7LVS/LO.?90_)/:YK=&U01MWE%45H>9T#RP-9]X#/*++CA^KE
MX>N'!XS4,*ECTL"DB4D+DS8F'4RZF/0PZ6,R\(B_B_F9B2%N8H3)&),))E./
M>`4HD[V>('&ODIGA)N:8+#!98K+"A*X!$2G[E)2Y42BPM])T^8=\7(Y7RWUW
MZ8=&)UWOR7S!U<PW`J_S;INB:]_F9043"Y.J1^08Z5R\^T\M,C7<3!V3!B9-
M3%J8M#'I8-+%I(=)'Y,!)D-,1IB,,9E@,L5DALD<DP4F2TQ6F%`=D!D9D6Q4
M"Z*,>B`@KBGAES+JXLK/Z#/%XGK70%U@);;LH8BN5C"Q,*F&$7[Q52T,J;6C
MCDD#DR8F+4S:F'0PZ6+2PZ2/R0"3(28C3,:83#"98C+#9([)`I,E)BM,J##(
ME(S(-BH,448M#.(BD]O"`.J!O":%FK^<URMJ[-U^65SF[A["7!$[?J]@8F%2
MQ:1V(>*R:_:90MU[T#O.-7@I::B/IPU^K5@SJO66\NQL.AOX3*.M""UX*JYS
M:?_;F>QBTL.DC\D`DR$F(TS&F$PPF6(RPV2.R0*3)28K3"CS85Y1YD<9-?.I
M@MR3^8*K[Q#HDS[UA;6L2111FRJ86)A4,:E=2&CFRXYZ[Z+T//N0HQ'UY*;W
MH'QRU@CD=4L!F70A(-J*",U\.)/=2Q^_+0X]3/J8##`98C+"9(S)!),I)C-,
MYI@L,%EBLL*$,A^N!LK\**-FOK@LZ([7?'D5D?J:SZYH+8M[TM!K/B06;J6*
M20V3.B8-3)H>D=?2Z-EBL<#>&K44P0X_VG@+'4RZF/0PZ6,RP&2(R0B3,283
M3*:8S#"98[+`9(G)"A,J`S"#J`Q$&;4,B(N&[B@#\AJCVS*0Y[=IB?NC81F`
MQ,*M5#&I85+'I(%)$Y,6)FU,.A[QCEI"/A7MXD9ZF/0Q&6`RQ&3D$3D@0\OD
M^1'E&#<RP62*R0R3.28+3):8K#"A6@#3B&I!E)&U0'X;@;SK>6\?W^R*O=N=
M$AOG4WS30)'.T%VBUZ]!R(I[1%F\K)7HCN1@O*:5Z';@8+RKE>@6WV!\H)7H
MIMU@?*Z5Z!;:8+RLE^@>A6"\HI?H+I9@W-)+=#,+Q5.7`="7*'RLW^SN^OBV
M/9P2._N5AIY^$#?V'^77,,@_SLZ'>T_X#^=,7Y_@_OI.WY=AT^V^Z0?"KXYS
M]O\0&[A\`\?S?P```/__`P!02P,$%``&``@````A`!J95]6?`P``XPT``!D`
M``!X;"]W;W)K<VAE971S+W-H965T-3DN>&ULE)==C^HV$(;O*_4_1+D_^>(S
M"#C:8&U[I%:JJGY<F\2`M4D<V6;9_?>=B2%@LTU@+UCB/'G]SGAB#\OO'U7I
MO3.IN*A7?AQ$OL?J7!2\WJ_\O_]Z_3;W/:5I7=!2U&SE?S+E?U___-/R).2;
M.C"F/5"HU<H_:-TLPE#E!U91%8B&U7!G)V1%-5S*?:@:R6C1/E2581)%T["B
MO/:-PD(^HB%V.YXS(O)CQ6IM1"0KJ0;_ZL`;=5&K\D?D*BK?CLVW7%0-2&QY
MR?5G*^I[5;[XL:^%I-L2XOZ(QS2_:+<7=_(5SZ508J<#D`N-T?N8TS`-06F]
M+#A$@&GW)-NM_)=X0>*Q'ZZ7;8+^X>RD;KY[ZB!.OTA>_,9K!MF&=<(5V`KQ
MANB/`H?@X?#NZ==V!?Z07L%V]%CJ/\7I5\;W!PW+/8&(,+!%\4F8RB&C(!,D
M$U3*10D&X-.K.)8&9(1^M/]/O-"'E3^:!I-9-(H!][9,Z5>.DKZ7'Y46U;\&
MBL]21B0YBXS!_?E^$B3S23R9#JN$QE$;(*&:KI=2G#RH&IA3-11K,%Z`\B4R
MXZ.+]?]"A1A1Y`555CZ4.T2A8'W>UVD2+<-WR&E^9K)[)K:)S87`!*(LN1D(
MP6]G&E)Q:_KK9;AX0QB]750S,P#:G=G$,7)/C!R$W".S>:=BF1T]8Q;AE0_B
MG;<T<=*4&086JV.FW<QMWC:#!.DC+/<PS>.I1AAJ^\99FCB)RPS3YWZ0('V$
MY1[>KL?=(^SF?F1G-C-,',_;(H^"]+KH)O4N,'/6AKA`.NFFL*Q/G[&.L&M]
MW.FVSC+#]"5^D"!]A.5^]HQ[A(?*QC!][@<)TD=8[O'<OMD4^_<7A-W<NV5C
MF&O9S%)[<38N,'44B`N,K^^593U]QCK"KO5K.9JR,4Q?X@<)TD=8[F,XFA_/
M?$L/%<X9Z@M@&"&]B!T"'EH/%T]LCCA[PW?6/CM#U_*9.N_VYHY(YI'UYTB2
M\P-?9\6.!T^ZQ^,QY^)M/&-GB\QBPWP]M]E%AQ'2B]@1X&'W>`3F:.P_Q&(#
M]88PB)!>%3L$F.F)$)!VWVNG`C+HEQ&Z%E4Z<_:D>\)92>RY40,^OVA%3`"F
MIS8M9\7DGFU862HO%T?LEQ,X1KO1KI=_2;!9<\8S[/%Q/.QN0(O=T#W[G<H]
MKY57LAU(1L$,CEAIFG1SH473-KI;H:&Y;K\>X,<4@Q8S"@#>":$O%SA!]_-L
M_1\```#__P,`4$L#!!0`!@`(````(0#@/.*P.P0``)`0```8````>&PO=V]R
M:W-H965T<R]S:&5E=#$N>&ULE)A?CYLX%,7?5]KO@'AOP"0A,U&2:@#-;J5=
MJ>INVV<'G`0-8!8[DYEOO]<8"+ZD#'F9)N27XW/N]9^XF\]O>6:]LDJDO-C:
M9.;:%BMBGJ3%<6M___?YTX-M"4F+A&:\8%O[G0G[\^[WWS877KV($V/2`H5"
M;.V3E.7:<41\8CD5,UZR`CXY\"JG$MY61T>4%:-)_:4\<SS7]9V<IH6M%=;5
M%`U^.*0QBWA\SEDAM4C%,BK!OSBEI6C5\GB*7$ZKEW/Y*>9Y"1+[-$OE>RUJ
M6WF\_G(L>$7W&>1^(PL:M]KUFX%\GL85%_P@9R#G:*/#S(_.HP-*NTV20@)5
M=JMBAZW]1-816=G.;E,7Z$?*+J+WVA(G?OFC2I._TH)!M:%/DN[_81F+)4N@
M<[:E.K+G_$5]]0L\<F$040-J$/%?.\R3IT9QNF'ZK]LAG^NV?:VLA!WH.9/?
M^.5/EAY/$D9:0AE4-=;)>\1$#&V`L6;>4JG&/`,)^&OEJ9I/4$;ZIMVEB3QM
M[;D_6Z[<.0'<VC,AGU,E:5OQ64B>_]00::2TB->(P+\7_;D'PSTLR=*_0V7>
MJ"PZ%>)-M>+H6'7%(BKI;E/QBP7S%8R+DJK93]8@W)9'A^D*]JMZ0:&4R)-2
MV=JPT*`4`IKVNG,WSBNT)6Z(0!/PMR.(280MH7J@1*/>`P?<=I:ABGW+MSO9
M.E.P<M:J!OI!WXB'C`R)N4E$0V+1$895:-ETJPJ&Z=4KT;)3K2L2:`+:U!71
M-XGP0R(:(PSO,,QT[PK>VE"7SMG*=!9HHN_]P23"(8'216.$X1V6YG3O"C:]
M/YK.`DWTO1,TO\,A@LV/$89Y_Q[S"C;-$[2P`HT8[O&4'R+8_1AAN%_=XU[!
MR#U::X%&EO6FLB#^'/4FU)_WTV'K8X1A7?U0Z.V%XQN+@I'UZR:@EZM&^M8(
M6M'A$,'NQPC#_>,][A6,W*.!`XT8[M&:#H<($HG&",,]@9\#_>*K@V@.S\:;
M4'\+Y4#;2M`P1A`\B6XP.,DH8D91!]?D>43T,=??.CVTN00-,QY!Z_29080Q
MQ(R@3KCI$?1Y:$3`FQ#13-^>AW>A&\P@PE#FBI@1U$$W/8(^%HT(>"<BPZ/3
M0TL^O,%<_34_:X8R5\2,`-6Z(X*BS;7@H>TF()KI=^$Z=FTO_!B)&L2O]V1O
M];#P/6]U;::901U[O39,7-?ZL#3:@8P&ZE<\Y!W-HI%5;90LEBY9N3Y:7-&H
MCIE%'8*]+!_L3?K(-#*@#30@PV/50_M7>(-!I8A&$3.".@RG1]!'IQ$!;9T!
MW/AP&^:HQ.$-9A!A*'-%=`1]W].WEYQ51Q:R+!-6S,_J_D:@R=W3[D+:W!2[
M#^!J5](C^YM6Q[005L8.\%5WMH*)4NG+H7XC>5G?C?9<PJ6N?GF"FS^#>XD[
M`_C`N6S?J*MH]W\)N_\!``#__P,`4$L#!!0`!@`(````(0#=(:G1_0(``*0(
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;)2676^;,!2&[R?M/R#?
MEP_S'26I"E6W2JLT3?NX=L`$JX"1[33MO]\Q3D,@79?>)"%Y_/HYQP9G>?W<
M-M83%9+Q;H4\VT46[0I>LFZ[0K]^WETER)**="5I>$=7Z(5*=+W^_&FYY^)1
MUI0J"Q(ZN4*U4OW"<611TY9(F_>T@U\J+EJBX%)L'=D+2LIA4-LXV'4CIR6L
M0R9A(2[)X%7%"GK+BUU+.V5"!&V(`G]9LUZ^IK7%)7$M$8^[_JK@;0\1&]8P
M]3*$(JLM%O?;C@NR::#N9R\@Q6OV<'$6W[)"<,DK94.<8T3/:TZ=U(&D];)D
M4(%NNR5HM4(WWB)/D;->#OWYS>A>GGRV9,WW7P0KO[&.0K-AF?0";#A_U.A]
MJ;^"P<[9Z+MA`;X+JZ05V37J!]]_I6Q;*UCM$`K2=2W*EULJ"V@HQ-@XU$D%
M;T``7JV6Z9T!#2'/P_N>E:I>(3^RP]CU/<"M#97JCNE(9!4[J7C[QT#>(<J$
MX$.(#_:'W[&-D]`+H_^G.,9H*/"6*+)>"KZW8-/`G+(G>@MZ"TC6E?G0G[<K
M@Y+TF!L]:!@*M(35>%I'0;1TGJ"%Q8')SAD\)?)SPA\1!_R.DE#ZJ>3[<AJ&
M(I!U(A=/I\X,$YPR4R)_CYBXP427NVEXA2#[Z(:38#IS9IAH:*N'HSA,DBF1
M3X@D]>/P"$S4H+[+U30\5QMSAW7/#!,/:J'OANELT?-3(/`Q]D9@8@:[_G(S
M#<_-QEQC9AACAB/7Q>-.&H#<`.!W['SHO]VUZ"-N&IZZ1<%LN3+#'-R"-$V\
MX\3&S0"7N,4?<=/PU`TGZ73JS##&S8O2$,_D\PF`X\#]1]?T27?R''G_%M7P
MS"QU9V:&.6W*;,US0QSZF@;C?339:NE'Q#0\%YNM5F88<W_B((YC;W:;P$FD
M4PP1AU[JCTTU:N:@,<_AGFSI`Q%;UDFKH15L3]>.8;<*<\R8"\7[X7F[X0J.
MA^%C#?\&*#R,71O@BG/U>J$/LN/_B_5?````__\#`%!+`P04``8`"````"$`
MX"Q1+IP#``"!#```&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R<5UUO
MFS`4?9^T_X!X;_B&$"6IFJ!NDS9IFO;Q[(`)5@$CVVG:?[]KG!`,*>GVD@3[
M^'#.O=?VS?+^I2J-9\PXH?7*=&:V:>`ZI1FI]ROSU\_'N[EI<('J#)6TQBOS
M%7/S?OWQP_)(V1,O,!8&,-1\919"-`O+XFF!*\1GM,$US.2454C`(]M;O&$8
M9>VBJK1<VPZM"I':5`P+]AX.FN<DQ0E-#Q6NA2)AN$0"]/."-/S,5J7OH:L0
M>SHT=RFM&J#8D9*(UY;4-*IT\65?4X9V)?A^<7R4GKG;AQ%]15)&.<W%#.@L
M)73L.;9B"YC6RXR``QEV@^%\93XXB\1Q36N];`/TF^`C[_TV>$&/GQC)OI(:
M0[0A3S(#.TJ?)/1+)H=@L35:_=AFX#LS,IRC0RE^T.-G3/:%@'0'X$@:6V2O
M">8I1!1H9FX@F5):@@#X-"HB2P,B@E[:[R/)1+$RO7`61+;G`-S882X>B:0T
MC?3`!:W^*)!SHE(D[HG$!_6G>7?FS@,G"&^S6$I1:S!!`JV7C!X-J!IX)V^0
MK$%G`<S2F0?Q43HZKV]9!8^2Y$&RK$PH=UC.(3_/Z]#SEM8SQ#0]839CC*,C
MMF>$#*"D37H#%NCM1$,H^J*OI^&L38*EMC/K1@T`=R?6'0@9([P!)!E#HGG'
MHHGU=+'G"$^+EHL@$SV-H>=W_&UT-@H#2>M\A#IB>Q.13"$T%_":]X=<@E<F
MA*A3Y@:!KFVC,&%;+(X3>;$^O]7F8W]NZ_-)?SX,8O\2'4TW[*^^[O=%7R[2
M]8?>4+_"*/VN'3MS>^B@CW#FL1<-*!(%`"-=F"X)U$R$_V-"+AJ:N/"K$E*8
MJ$V"&\=NZ/K#3:E!`H#$\VB0BC[$\4(_BN9O[(5(-S*]!R1X:&#PZHW"7`]A
M:W%[$Y%,(;0TR.O\REDY[4(NNK63%6;*Q4U$,H707,2ZBVGU$CS,P26WJH@4
M1E,_VLU7,(,BFD)H^AVXGOIIF#;0H@<._,%9LCF!-`NZO.UM2#()T2W(B^V?
M*\E1U^'TI7`"35I1/!.09))%MR(OPIZ5&]E0UV;_9@B]83U!)R>+3M,W.I:N
M@?24R8YPQ--!E`G5\:F&J,)LC[>X++F1TH/LYEPX%[O1KM-\:!O-P?A&=J!M
M#]E-0`/8H#W^AMB>U-PH<0Z4]BR"4Y^I%E(]"-JT;=B."FC]VI\%M/H8&B![
M!N"<4G%^D$UJ]^=A_1<``/__`P!02P,$%``&``@````A`/XT7C[K$@``"&``
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK)Q=4QN[LH;O3]7Y#Q3W
M&_`7!E>27<&>[^^I?<ZY)N`DU`*<PL[*6O_^M"RU6ZUW`GC7O@GA4?<[TK2D
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M([ES6U%L\_7Y]3DI??IP_T`M,+?]Y&7]]>/IY]&BGXU.SS]]V-^@_WU8_]IZ
M_S_9?M_\2EX>[LN'YS7=;8J3B<"7S>8/8YK=&T3.Y^`=[R/0OIS<K[_>_GS<
M]9M?Z?KAV_<=A7M&+3(-6]S_O5IO[^B.DLS9>&:4[C:/5`'Z]^3IP70-NB.W
M?WT\'=.%'^YWWS^>3B[/9O.+R8C,3[ZLM[OXP4B>GMS]W.XV3_]GC?8M.HA,
MG`C]="+CL8B\XCAUCO33.4[?Y4=5V]>:?CJ_T>79:'IQ:2K]RO4NG=_\X/?.
MBM)PV5^0?AY5T6OG1S^YHK.SZ7@VO]K?WU>J.J*NL+^D^8_SG9Q=S6;3RZOY
MZZT<<5#-?YSK.]LYHGY@KRH=XGTA&7$G,/_AMKXK*"/N!2,*SY'5I4#:ZDI$
M1Q?OO$L<TY$$]?6[=&['SGXHKFYWMY\^O&Q^G=#\1K=Y^^/6S):CA5'C06C#
M>QB6OQN5-!R-RF<C\_&4_&G`;6DJ^?,3C<(/YW_2\+]S-C=H,](62[8P8]W(
MKD(0A2`.01*"-`19"/(0%"$H0U"%H`Y!$X(V!%T(>@^<4W@.,:+^_)^(D9$Q
M,>*[>\-`@A:$;,D6[+(*012".`1)"-(09"'(0U"$H`Q!%8(Z!$T(VA!T(>@]
MH`)"TP0$9$)SW?"3B\>(\:)GE!HC$ST";JS-B*:$PT"ZU";+@\DA*$`B(#&0
M!$@*)`.2`RF`E$`J(#60!D@+I`/2^T3%B&9FB)%971PYL1D9FAM?G]F<T6M1
M.Y@<H@8D`A(#28"D0#(@.9`"2`FD`E(#:8"T0#H@O4]4U"A`*FJOCRACO0\.
MW]0;2R[I:7P8/Y/1-!A!!R-V6P&)@,1`$B`ID`Q(#J0`4@*I@-1`&B`MD`Y(
M[Q,5"[J)1\3"6.M86#+VA\[XZB*(Q<'H$`L@$9`82`(D!9(!R8$40$H@%9`:
M2`.D!=(!Z7VB8D%3RQ&Q,-8Z%I:H6$Q&LR`6!Z-#+(!$0&(@"9`42`8D!U(`
M*8%40&H@#9`62`>D]XF*!77H(V)AK'4L+*%8\&U>`ED!B8#$0!(@*9`,2`ZD
M`%("J8#40!H@+9`.2.\3=>-I)ZINO-VKG)DMY>[[P]T?-QN[W1]X:$QH3V)W
M*D9$Q\.2\53B8<FED)4E^RO)!B=8F44'(PYL#"0!D@+)@.1`"B`ED`I(#:0!
MT@+I@/26V!ND0F1V_"I&`[&@1`<'8V^NH^&0/SP<NIP?(K1R:$Z#U'O0S_6$
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MIC-X##JD`FFMO)N_<E;T).2Z1HABASS'!%&*CAFB'!T+1"4Z5HAJ=&P0M>+H
M1RU8+7=BQ7>B5UHZ:F;'ZT?MC?G3;9#]^=,B>N;ZE0J6($N3D*:X^DL7A^A1
MR?6,$,7HF"!*T3%#E*-C@:A$QPI1C8X-HA8=.T2]<M3A,9O@(\)C]\QJ&K3(
M7T6:;%,8"XMH&I18`(K1,4&4.N1I98AR="P0E>A8(:K1L4'4HF.'J%>..A9F
M$WQ$+.R>6<7"HHE>_P2+PZ5Y94/AF4@L5HQ\Q_$\&&,16UVY]QS7LV!"C]E"
MAES"2*Z6,GKU:IFSFNEQ'ZR(\B&MR46P8"W82BI1,GJU$A5;<9.GLV"Q6K.%
M-+EA)%=K&8E5YQ"US[PU&LW.@J;URD?W%*KT,3W%F`>;#8LN:<LIR\UQL"Q9
MFG0\.4['AU&[8B1;Q(B1V=W\^>EZ-)\&*^Z8+<0I8232*2.QRAR:T50AU9P$
MT<W%T;/"/@"-*<619Z6*D6W,^.(*XNUDI)8-^TA;6D9BU3E$;3&WZ>(LN$F]
M<M'A-HF!(R8&FT=0$X-%\_UW"?MTP)**819P2#IIY*RHD_(=BME1K!)&TN%3
M1F*5H5:.5@4CT2H9B5:%6C5:-8Q$JV4D6AUJ]<I*Q\)D`(Z(A4T8D![?OYN1
MRRK0QL#KT\%,NG16:NA9QZG$(G)6U*=8/F9'L4H82?],&8E5AEHY6A6,1*MD
M)%H5:M5HU3`2K9:1:'6HU2LK%9[Q<6F8O;F>&1WRAXI#_@.3D72CR"%_J*!5
MPDBZ9,I(M#+4RM&J8"1:)2/1JE"K1JN&D6BUC$2K0ZU>6>E8F&3%^X?*V.8V
M_*'BD'Y*38(9>>FL_*'"2+I1Q,A.O[/Y>#X.UC<QFXA7PDBZ:,I(K#*'@L=4
M,,'GZ%@P$OF2D<A7C'Y?]9I-Q*MA)-HM(['J'`JJ'J16>N6H@VSR&WZ0S:Y\
M3,_(]R>FQS9%H@+OLB8TFKTY,MB(+IVC&I?6<2I]-G)64[N$FUU/QL%"*V8=
M<4H8R7!(64>L,H<N]?($XF[K1*MRGJ0+E"]1OF+TVYK7K"/2#2.I><M(K#J'
M].)Z`F'W:Z[#_A])QHPQ&>/0E)YUA\B/+H*1NF0KZ=LKAV9^E\$M#%N-]HNP
M^6PVGT)OL)7R'K,)7BYEH5<OESFKN=K#3(+6Y"ROK&#]RE;2YO)=E:C8RK;Y
M\G(VNPK:7+.V3`P-([E<RTBL.M:6!4BOK'2G,3F:<*Z@C<_A/=:_-C_H8?S6
MYT24:@BW,P[Y*3Q$*T01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J%=(Q,EF9
MUV+TKG>-YI/>8,?IT)6W!7'(S]DYI-\W3H(,1B16/*/&B!)$*:(,48ZH0%0B
MJA#5B!I$+:(.4>_0P-O'\7&IH[UYL.RU2:$K&=M+9^7ELE<.O?'V4:PD/%9^
M+ON@A*T$I8S,\N'PMAG>/HH5R^>,1*M`5#+2\L%RLA(KEJ\9B7R#J&6DY8/5
M0"=6+-\[9&^T'HVDI4;CZ]ESL^X*AYU%*JX6J;A:%+RE"IX2D9/W$J^Q0YY6
M@B@51S^NP98W$RN^,SEJ%8A*<?3DPW=LE5BQ?(U:#:)6'#UY>/LH5BS?*RT=
M5Y-I\6?9-^)J$S-JA6R1BJM%7BQ6]$`T'2*(:Y#FB\2*JQX[Y&DEB%)TS!#E
MZ%@@*M&Q0E2C8X.H%4<_8D%_Z\2*F]TK+1TQDWSQ(_9OO7T<VQ2."J1%*I`6
M>3=_Y1S]MX^(8H<\QP11BHX9HAP="T0E.E:(:G1L$+7BZ$<MV/1U8B51\^^7
MBIKY-EU%[?5QMC?7ST6'KFA5ZCV2@A7\TEGY*QEVE/5SQ&ARV`C&C,0J0:T4
MK3)&HI4S$JT"M4JTJAB)5LU(M!K4:M&J8R1:/:.]E@[/<1FB"6:('/)7E0ZI
M6%C'*VE-Q(Y2SYB16"6HE:)5QDBT<D:B5:!6B585(]&J&8E6@UHM6G6,1*MG
MM-?2L3![?7^">V.HV-2`/Y--+*+,J3=4)L$B8NFL_*0-(UJ$',88;MW9RF9#
MQI/Y.%BYQ6PA>8Z$D61#4D:O7BUS5N[M7/C&231X$BH8R95*1J]>J6*KW[:K
M9@MI5\-(KM8R$JO.H>%&],I!]X4PN_-&7\`TSL0BG;F%]XO.RL_<,I)]2,3(
MIC^'WB^RA3@EC&30I(S$*G,HR'X&ZZ-<'*5_XCMFMI(KEHSDBA4CVYC1='85
M)-UJMA"GAI%(MXS$JG.(&K-_H0PO&)6+CG>8F'DCWIB`F5CDOS5Q2`UT:^5E
M0B-GY;\U84?IR`DCZ>XI(['*4"M'JX*1:)6,1*M"K1JM&D:BU3(2K0ZU>F6E
M8Q$F8-Z(!69:)A;-:3H^3*>32;#Z73HK-?:LHY?YC)P5]2F>Z&)VE)Z7,)+^
MF3(2JPRU<K0J&(E6R4BT*M2JT:IA)%HM(]'J4*M75CH\QV5:J/>'.W*'U%"Q
M5FJH."3=*'*.:JB`5>*L/*V4D6AEJ)6C5<%(NG?)2+0JU*K1JF$D6BTCT>I0
MJU=6.A8F:W'$DL68!ZM[B_1C"EXPFN^IR%$-%8>D&T5LY:;?JXO1=3"UQVPB
M7@DCZ:(I(['*'`J>4T%J*4?'@I'(EXQ$OF+T^ZK7;")>#2/1;AF)5>=04/7@
MSO3*40?9I##\(!__@G%BLR!JK>H2(WJM&NPUE\Z1>B#/?BN'_!>,C-P";G0Q
M"W1BUI&.GC`2Z91UQ"ISZ(T7C*PEC@4CD2]1OF+TVYK7K"/2#2.1;AF)5><0
M35;^0PC";L-`T:<;K,-N]O1AV/UW1>]Z#S&QF0$5>8O>>,'H'-60MXYOO&!T
MCG1\C%F$34:7\_"O<&/6ED&2,)*AE+*0WT-A4Y0YJ^`%(RQ@79M5,.`%(U:B
M?%<E*K:R;1Y/KF?A"*A96]K<,)(VMXS$JF-M68#TRDIUFFF8[@F3=.][P;B7
MT0\*AZZD&DM$*T01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J%=(Q"G,^^_E\
M=D9KSV-/*,!TT-0BD\:5I>\TV+TOQ>HPK2.*$,6($D0IH@Q1CJA`5"*J$-6(
M&D0MH@Y1KY".W'$9(IH[P^660RH\^)?Q8B7AL5KDR"A"JQA1@BA%E"'*$16(
M2D05HAI1@ZA%U"'J%=+A.2YI,\6DC4,J/)-IN'$4*X[%"E&$*$:4($H198AR
M1`6B$E&%J$;4(&H1=8AZA71X3.[#7]"\OJ^G33B,'HN\0;!T5AY:(8H0Q8@2
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MFSUE&)F##W>>B*UL&$8#3?!]5!/,WO/]3=A;ZVV,0Q*%X/8MV4`V92M&7A08
M_38*;(!1H(WQ,4W`)?Y>@+K_87R$+QC90/(3*T:2GX@8_38*;.`-!GN@JSU%
M\FG]\FV]7#\^;D_N-C_-8:WT;=NG#P=L3Y*]F4X69DU`P8>2*97L[P^4S*AD
MO]$,2^:+?E^=D%\M^OW*..1CN@9]ZCET]0NZQOY3S-!G2H??TAY@R&=,)?N.
M$?C0!VQTG>L!G]7T<F$F4%2C,W8_#VG=T.4'KTX7'[2G&SQT?S]/%Y\IA'CA
M&W/?ASC=]<&;3FT;:@!]%+@P'[;@%>C;P(7YO@5+Z!/!A?D`<*AD3B5#P:6/
MF:AD*+STP0R5#%V'/KA;F,_I\#KTR1:5#*G19T%4,J1&7U<NS.=`J$8?62[,
M5T%80M]:+LR7E$,E<RH9JAM]`D8E0W6CSXRH9.@ZJ_&,[L%@W*@&-X,^]&'K
M8CE80M^W+J+!6J_HCIKO'[$]](T=E0S5FC[:HI*A6L=T'?.Q%JK15[$+\\T6
MEM#'L12?H3O:CV@PTPD,Z+,:31?FS`,L2:G$G&"`)70\P<*<1X`E=-C`PIPN
M@"6KT8RN,Q0%^F-]NLY0"?WI/5UGJ(3^D)ZN,U1"QP`MS%$66`,Z#6AA3K3`
M$CH4B-2&ICHZ5H9*AN8(.KZ$2H:F&SHB@TJ&KD-'[%!+A]3HD!8J&5*C@T"H
M9$B-SE-:F`-`L#UTK-+"G`.")72Z$MW1H9;2^3Q4,E0W.O2%2H;J1@>+4,G0
M=58T[0SUT!NZ_LV@QY)*EH,E=)X5]9RA.J^HSM%@G>E,'2H9JC,=TD(E0W6.
MZ3KF<!:\:W0*UL*<T8(E=!@616=?M_/#$X_.8?]Q^VU=W;Y\>WC>GCRNO]*C
M_V+_)RPO]B1W^\O._2G+E\V.3F"G51B=,$TG[J_I<.<+D^O\NMGL^!>Z]/GA
M#/]/_R\`````__\#`%!+`P04``8`"````"$`Q9[$"Z<'``#Y'P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6RLF6V/XC80Q]]7ZG=`O#_((PEHE].2
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MJ=MZW\U`;LX'2N>\G"_GH+1^V%4P`^;V25/N'Z=/YBJW[.E\_=`[Z.^J?&]'
M?T_:0_V>--7NM^I<@K=AG=@*/-?U5V::[1B"QG/2.NY7X(]FLBOWQ>NQ^[-^
M3\OJY=#!<KLP(S:QU>Y[6+9;\"C(S"R7*6WK(PP`_I^<*A8:X)'B6W]]KW;=
MX7%J6S//-):V!RK/9=O%%9.<3K:O;5>?_N%&II#B(I80@2N*+&:N9]@F]/E1
M$5N(P%6(F+X<R8W>'=$0KMC[A]K!T/JIPQ4[7-R<)MSM&WBRP<=&")NM;PC7
MNT:X%.W@BB.T9X[E>G[OV!L^,2&0^+JRB!)K=G.P<QX8?9R%15>L'YKZ?0*;
M%Y:^O10L%9@K)HL1QGL?8NY'(0>QQE2>F,SC%#P`T=3"/GE;VX[S,'^#V-X*
MFPVU,56+`"U8(#/94`>1#F(=)#I(=9#I(!^!.;AE\`T$_,_P#9-AOL%9;1!(
M9UF:(]`"FX0ZB'00ZR#10:J#3`?Y""B.@$W[,QS!9"`#*4'BJC/?<!L3-N$0
M20O5)!A,!N\0$A$2$Y(0DA*2$9*/B>(D2%`_PTE,!C;C[:TDC&YY:3`9O$1(
M1$A,2$)(2DA&2#XFBI<@'2M>NOXDP[3"K'MGX"0VG"P@60_Q83MZA`Q&V"PD
M)"(D)B0A)"4D(R0?$V7N,.@[YLZLU;ESLO"&3!(0$A(2$1(3DA"2$I(1DH^)
M,E&(RSLFRJS5B7)B05X>+;*GI8'!:%AD0B)"8D(20E)",D+R,5'F#AOWCKDS
M:W7NG,#<<5H!(2$A$2$Q(0DA*2$9(?F8*!.%LD69**\<9JRP[`[5]NNFAL6#
M);RRPVVH$'C=P$34^0MBR?ES8CD#"3EQX7$UQ(?E:>5&-!BA(V-"$D)20C)"
M<D[X@!27L`+J__ND5U&=@FCD%8'&;A'(9>Y]6UN&::M;)I(&@T^H3$)1*AL*
M9:U@R:0!*N>*C.HF5G"-B\XK(0*O%A@C)J_/X)&(VAN!;'C,#!%@.[XZW0"M
M%D/#$!%LWZ&AY6G/CPBM_-Z12\>T=5?&:"*3<8)(=I<BNME=AE:\.WOI6::A
M3B5'D[X[U9FL:+O#F;S&4YS)D0/!._C$=I;J"`)36,D0#!')G1DA8JOWMO9=
M`_ZI0C&:R%8)(JF=(I)6F4`N2S#XEF'YVF,A5QJJGF*EVQV>$I7>..PX4L/.
MU288F,)*QD&(2$9+A(@ONN4NEI8F%*.);)4@DMHI(FF5(>+:INGX2VTY<S2Y
M$E"L=KO#3:+4&[N)(S6@7/*R)ZSDHH>F0'+1(T0\H&QC81M:5HO11+9*$$GM
M%)&TRA!Q;=/P/%][B.1HTK=2HXF5>7>XB5>%RK[C2(LF+;,&[',//")MN>(A
M(KGB$2(139;CZF$9HXELE2"2VBDB:94AXMI+NJ5SM+@23*Q&O,-+O*14O,21
M%DQ:#`2FL)(+'B*2"QXAX@ONV@M7KQIB-)&M$D12.T4DK3*!_BL[B7%>B2=6
M4=[A*5Z`*I[B2(LG+:(#]FJMQY-`<LTCM!(9Q(+DI#U=8S21K1)$XW@BVIFP
M<F&SW\KCXX;JSF,EZ1V>XA6LXBF.M)C2/D4$T()YRI'K'B*2ZQXA$DG$6EBV
M%IPQFLA6"2*IG2*25ADBC%?#T+)#CA97XHE5J6,O]?6YQ[X3WU&?F[S6A6YD
M[<61%F9:"16(ADK:X@T=&3"1L')$VK(-PR=A)KJ3K1*JG:*0M,H0<6W/\%SR
M#!Q+*R%F72OD+8C(C[_9]!)J%2^0`]T.@6^[6@$3H)4,C5`@=URAT:H5K<R^
M]K(7AFGZVI1C%)=!EB"2_:6H=+._#*UX?[X-Z51+-CEJT_!D+_<T/%WY^OBE
MOOSH]7'T;M#+:%[FKPOC-VAA-4(A11%%,44)12E%&46Y@M1HNZ^$MV@)+Q!T
M@=LTH"BD**(HIBBA**4HHRA7D#IGO1AGZ<GR9Y"=[CQZ@/,W_1N"0#X\;$<;
M3<LL@;1"IX44113%%"44I11E%+'30S9Z&"H,@GN(GP;R4YI3V;R407D\MI-M
M_<I.^J#.6#\,F!]#;A8K^!@'`CKW5O"AZ@KW5_!=YPJWV'EF'T2ZDF7!G3Y%
MD#LVGH%J=\+E"CZ>T%Y"TUBQ3Q'T#GQG6+%/"?0.'+0^7>T=!GQ]O#"H*SH;
M&&Q_7JN-]<D!_6LW-LX*/F;3`6W<%7SH!3X?E.#@]5*\E+\7S4MU;B?'<@_+
M9?09K>%'M_Q')S+;<]W!D6N?Y`YPQ%["@9?!XG]?UQW^8!T,A_;K?P$``/__
M`P!02P,$%``&``@````A`!(NS^(*!0``&A@``!D```!X;"]W;W)K<VAE971S
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M2GD.#P`_G2+#I0$SDGS0[VMV:,X[-XQFX6H>S!>@=UY8W3QGF--UTK>ZX<5_
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M&NE78`"DFVZ'U'*Q+C0V%.`^'\S4Y/[00*6*8(;<H=C@R8H;@>#$@!Q=2.,)
MM[;B:5*7`ARH>!(AN4]S@R<K5`0]*_H-VX4TGJQ0@"\UU8@(R<TQ("^PH@&I
ME6D3A-`8T0`A\,/9\BX1@C$2NI#<G:6A.U900(2K4VC$0J#APB3*T4!EZ@09
MY$:M])Y"*S*06J[6A<:-"K5D6,WN]HD&*E4$&>0^_3QR2._;$/?Z8/O>)BNI
ME6J8`$(:3[B;!ZF1=E$43G@=A8(#`P!U(<G4\N<Q0S9EA89PC(8NI#&%.ULQ
M%<RC"3L*W\+*&N]"LBG#F2&TP@2IE4X9,1$JF+BS",9HH`103=I&2\-Q(;1"
M`ZD5(T8TA!HTQ/YJ2G<$"(9+3H3D[AA.#9$5&T@MF^I"XR47:=DP81O10*6*
M[M2P-)P:(MS:@[5^>UF06JF&"2"D\:1APR*^C[MH3(8N)+?)<&B(K,A`:L62
M@(7&DH8,\V#"THO&8.A"LB?#^2&R`@.I%4]&,$168""UDEJP0@:#X<P068&!
MU$HU(Q@B+1@F?)>@@4H5+1<,9X;8B@NDEJMUH?&"BQ4NW-Z>I%92:V%@."C$
M5C`@M5+-"(-8`X-)7R%HH%)%`$+:.2O#.2&VH@&IE6I&&L0:&@1K>*H[71JS
M@#)!6=F1X9`06[&`U(HC(PMBA05XG)MV\J&12AG!!=F4X<`06W&!U$HU(Q=B
M#1>FO(=HG%)$AX65X;@`%Z\6KU92R]6ZT``+[4UL>U%9L.K$?F-Y7CLI?\-;
MUA"N'OMH?P/\0./5>+QY:&^&O?X_<#-[24[LKZ0Z967MY.P(.7UZNU7MW6[[
MH>$7>%"XGN4-7,G2GV>X@V=P_>CCZ_W(>=-]@&_B7G^KO_\?``#__P,`4$L#
M!!0`!@`(````(0`XOOV[TC$``-8P`0`9````>&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;*R=6Y/;1I9NWT_$^0\*O4^I>*DJEL/V1+M(`B1!$F#,.>=9+9?;
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M'B:WC[,'9?GS\^<OZ_<NY>M7[_[V^<O'#__/!TU"*I]D&I+HWY!D=G]S]W`[
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M9S27=EF#50W6-6AJT-9@4X-M#78UZ&JPK\&A!L<:]#48:G`JP!OI28Y4-_\.
M1RZ-<Q2/[D\19&G32DB,B$V6-5C58%V#I@9M#38UV-9@5X.N!OL:'&IPK$%?
M@Z$&IP(8(3H;_3N$N#0_O-;_%D5S9PW\Y&/<J2$%W=N0IQ22+(&L0-8@#4@+
ML@'9@NQ`.I`]R`'D"-*##""GDAAIN@S\.Z2Y-#I97C[5A:!+UE)(L@:R`EF#
M-"`MR`9D"[(#Z4#V(`>0(T@/,H"<2F*LZ0ILK(U/@>-ER$6?Y<2#^E,@FB2E
M^IDMZ@I*0;'9$F0%L@9I0%J0#<@69`?2@>Q!#B!'D!YD`#F5Q+C0S.(*%R[:
MNO!D>E[[G*_O3R!+D!7(&J0!:4$V(%N0'4@'L@<Y@!Q!>I`!Y%02<^!U'KGB
MP+MH>^`]>=3EK"B"A^HRDH)2$8"L0-8@#4@+L@'9@NQ`.I`]R`'D"-*##""G
MDA@7.O%?X<)%6Q>>/,[2-.P)9`FR`EF#-"`MR`9D"[(#Z4#V(`>0(T@/,H"<
M2F(.O$[A5QQX%VT/O"=33;*+(EA419""4A&`K$#6(`U("[(!V8+L0#J0/<@!
MY`C2@PP@IY(8%VX'X0H9YW!K(R#IB$?ZB6A)M"):$S5$+=&&:$NT(^J(]D0'
MHB-13S00G0RR+MRRL5S"7YXBN1V<JC("FNJ<ETIC<CNK2B-'16-+HA71FJ@A
M:HDV1%NB'5%'M"<Z$!V)>J*!Z&20U>,6D5?H\6M.K2_B4?[)[9O)V#2C)Z(E
MT8IH3=00M40;HBW1CJ@CVA,=B(Y$/=%`=#+(NG"+PRM<A+5D/O`_N8U(Y\)>
M11[K4DE14>(R-XQH1;0F:HA:H@W1EFA'U!'MB0Y$1Z*>:"`Z&63UN%7@%7K"
MHK'4XY&YJ@`MW8ZPEYA=`*T9U1"U1!NB+=&.J"/:$QV(CD0]T4!T,LBZ<*O`
M*UR$16/IPJ.I)A'IJC)[O*U+)45%%TNWZ^[T/*93X(IH3=00M40;HBW1CJ@C
MVA,=B(Y$/=%`=#+(ZG%KQ2OT^*6EN:IX-"M6X^[>A0Y\@99$*Z(U44/4$FV(
MMD0[HHYH3W0@.A+U1`/1R2#KPJT52Q?N'LILX6[-ACLQ7W\;Q2\[C2>/[!7G
M$7=.4E0N(Z"5VT:V)[XU44/4$FV(MD0[HHYH3W0@.A+U1`.1[M47']NJ<ZO-
M4MT+<V>_.#5Z/#)7'*"E6E0'?D6T)FJ(6J(-T99H1]01[8D.1$>BGF@@.AED
M7;C59NG"E='T[N8;JLBO6]55+(:?)FDI6UZ,ZMM=.2HV7!*MB-9$#5%+M"':
M$NV(.J(]T8'H2-03#40G@XPY[>A:<Y>KZ!QN=P,"*JN(:$FT(EH3-40MT89H
M2[0CZHCV1`>B(U%/-!"=#+(NZMV`;ZXB=\71Q:*LHH#</\64KMXHR%&IBHA6
M1&NBAJ@EVA!MB79$'=&>Z$!T).J)!J*30=;<=1L%4VX4!*0NXH%_(EH2K8C6
M1`U12[0AVA+MB#JB/=&!Z$C4$PU$)X.LB^LV"J;<*`BH6OU47XEYRE'1V))H
M1;0F:HA:H@W1EFA'U!'MB0Y$1Z*>:"`Z&63UN-5Z.55XX8+C%_?F3.91L=1Y
MF@(MB59$:Z*&J"7:$&V)=D0=T9[H0'0DZHD&HI-!UH5;K5_APB_NC0N/W)FQ
MN*I47X1Y<JLINW99$JV(UD0-44NT(=H2[8@ZHCW1@>A(U!,-1">#K)[K-@K<
MMP?KB[Y'YJH"M`P-BZ@5T9JH(6J)-D1;HAU11[0G.A`=B7JB@>ADD'7AUJ%E
MJ10;!2^<P?P*UE1-0//B8A^0*B45TJ3^LLO2W>9QBN4P1<T>\U=B[%MV"]?R
M+;_P/OTZU[S/@,KW";34S8WPIG0AM.]@;%D8=E=>>#-<!KK+L?OLY9L)Z(6#
M%J+L0<M?H3!O65>5:P[:.=Q.M`,JJNF):$FT(EH3-40MT89H2[0CZHCV1`>B
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MC%H3-40MT89H2[0CZHCV1`>B(U%/-!"=#+)ZW)KF"CU^"63T>*2Y2#SP3S.@
M)=&*:$W4$+5$&Z(MT8ZH(]H3'8B.1#W10'0RR+IP2Y0K7(0537&_9^:1N:K,
M;^N[ICDJ&EL2K8C61`U12[0AVA+MB#JB/=&!Z$C4$PU$)X.L'K=8NT)/6-N5
M>CPR5Q6@Y0QH1;0F:HA:H@W1EFA'U!'MB0Y$1Z*>:"`Z&61=N(7I%2[".K9T
MX5%5*O6MT5F*RJ4"M&+4FJ@A:HDV1%NB'5%'M"<Z$!V)>J*!Z&20T3._;BO@
M'&ZW`@(J2X5H2;0B6A,U1"W1AFA+M"/JB/9$!Z(C44\T$)T,LB[JK8#+VT=S
MKO<#JDJEOO^9HU*I$*V(UD0-44NT(=H2[8@ZHCW1@>A(U!,-1">#K)[KUOMS
MKO<#,J7"]3ZC5D1KHH:H)=H0;8EV1!W1GNA`="3JB0:BDT'61;W>?Z%4N*R?
MI]5YWF6>W];W/W-4+I74,*(5H]9$#5%+M"':$NV(.J(]T8'H2-03#40G@ZR>
MZY;U<R[K`S*EXJ,*M&34BFA-U!"U1!NB+=&.J"/:$QV(CD0]T4!T,LBZN&Y9
M/^>R/B#W;81T0V9^6]__S%&Q+I9$*Z(U44/4$FV(MD0[HHYH3W0@.A+U1`/1
MR2"KY[IE_9S+^H"*NG@B6A*MB-9$#5%+M"':$NV(.J(]T8'H2-03#40G@ZR+
MZY;U<R[K`Y*+LE3RO4O_J_(<E4LE[0=$M&+4FJ@A:HDV1%NB'5%'M"<Z$!V)
M>J*!Z&20U>.6VU^_E)S[U7FY`Q:0*16LX9>,6A&MB1JBEFA#M"7:$75$>Z(#
MT9&H)QJ(3@99%VYM?84+OQ0W+M+JO"R5?,<ZE$J*BG6QG`.MB-9$#5%+M"':
M$NV(.J(]T8'H2-03#40G@XR>N^N6]>=PNZP/J"P5HB71BFA-U!"U1!NB+=&.
MJ"/:$QV(CD0]T4!T,LBZN&Y9[^Y:5M]P"JBZKU+?QL]1J52(5D1KHH:H)=H0
M;8EV1!W1GNA`="3JB0:BDT%6SW7+^CLNZP,J[ZL0+8E61&NBAJ@EVA!MB79$
M'=&>Z$!T).J)!J*30=9%O:POOH!VY9W\.R[Y`ZHF9_6=_!R5RXA+?D:MB1JB
MEFA#M"7:$75$>Z(#T9&H)QJ(3@99==<M^>^XY`_(7'&XY&?4BFA-U!"U1!NB
M+=&.J"/:$QV(CD0]T4!T,LBZJ)?\W_P;FSON!@1DJVA2W^3/4;F*?*["[XI1
M:Z*&J"7:$&V)=D0=T9[H0'0DZHD&HI-!UMQUNP%WW`T(J#C*3T1+HA71FJ@A
M:HDV1%NB'5%'M"<Z$!V)>J*!Z&20=5'O!IRK:')_XQX*?'F_^8X[`P$M\HW-
MIQ@U/S^/MKKWOXRO2G'>=9OD*/M>ZZ6Q>Z^3NZ]YJUPEWWEDWFJ(RM]+7L:H
M\U,0[)MQ"[1R;7A^,P\+]TO9%XZ;7]J5R\0[C\R;"5'^N%4W@I>A@?GZ^'R2
MH\Q;O:_725]]W,XM[9(IH/*MQJCBN,4H'K?[>J'@WLS]["LDGEM6;\8O(\R;
M"2L+?]RJNX++F,..MQQEC]MUD^9[3IH#*L]31$NB%=&:J"%JB39$6Z(=44>T
M)SH0'8EZHH'H9)!U44^:+]?8/2?&`=GUY:2^%Y:CTB6=:$6T)FJ(6J(-T99H
M1]01[8D.1$>BGF@@.AED]5PW,;[GQ#B@<GU)M"1:$:V)&J*6:$.T)=H1=41[
MH@/1D:@G&HA.!ED7;@I:7YF^[4DH]WXV6UZJ`JIFQO5]LAR5R\CG*LZ%*T:M
MB1JBEFA#M"7:$75$>Z(#T9&H)QJ(3@99==?-C.\Y,PZH.,I/1$NB%=&:J"%J
MB39$6Z(=44>T)SH0'8EZHH'H9)!U4<^,7[CB<#9\[U%5*O5]LAR52R4UC&C%
MJ#510]02;8BV1#NBCFA/="`Z$O5$`]')(*NG7@R\H(<K@'N/3*D`+1FU(EH3
M-40MT89H2[0CZHCV1`>B(U%/-!"=#+(NQM9";C/ZRNW,>ZZ,`JIJJ+Z!EJ-B
MP2R)5D1KHH:H)=H0;8EV1!W1GNA`="3JB0:BDT'&VT.],+Q<0^=PNP`+J*PA
MHB71BFA-U!"U1!NB+=&.J"/:$QV(CD0]T4!T,LBZ&%L7?].#MQ[""CAOPOP4
M4%5%];VU')6JB&A%M"9JB%JB#=&6:$?4$>V)#D1'HIYH(#H99,U=MTV@/UE7
MW_H,R%21CRK0DE$KHC510]02;8BV1#NBCFA/="`Z$O5$`]')(.OBNFV"!VX3
M!%252GW_+$?E4O&Y"F,K1JV)&J*6:$.T)=H1=41[H@/1D:@G&HA.!ED]UVT3
M/'";(*#B*#\1+8E61&NBAJ@EVA!MB79$'=&>Z$!T).J)!J*30=9%O4WPPL6?
M6P'N%H&^Q&%WU*;U3;(<E4LE-8QHQ:@U44/4$FV(MD0[HHYH3W0@.A+U1`/1
MR2"KY[JM@`=N!014[J@1+8E61&NBAJ@EVA!MB79$'=&>Z$!T).J)!J*30=9%
MO17@[EE\V]R,NP0/:;%?W`*;YEM@_BN".2J6S))H1;0F:HA:H@W1EFA'U!'M
MB0Y$1Z*>:"`Z&63-7;=+\,!=@H#,!8>[!(Q:$:V)&J*6:$.T)=H1=41[H@/1
MD:@G&HA.!ED78[L$WU9%W"=X\,A.VZ;YAFBHHA25JPAHE7/%J#510]02;8BV
M1#NBCFA/="`Z$O5$`]')(&-N<=T^P3G<[A,$5%81T9)H1;0F:HA:H@W1EFA'
MU!'MB0Y$1Z*>:"`Z&61=U/L$EZ=M"VX&!%252KX'[DLE1\4B6!*MB-9$#5%+
MM"':$NV(.J(]T8'H2-03#40G@ZR>ZS8#%MP,",B4"C<#&+4B6A,U1"W1AFA+
MM"/JB/9$!Z(C44\T$)T,LB[JS0`W;?NV&Z$+;A0$5)51_7V"')7+B!L%C%H3
M-40MT89H2[0CZHCV1`>B(U%/-!"=#++JKMLH6'"C("!31CZJ0$M&K8C61`U1
M2[0AVA+MB#JB/=&!Z$C4$PU$)X.LBWJCH/C&UI4W>!;<1`BH*J/Z^P0Y*I=1
MV$3(SUE?,6I-U!"U1!NB+=&.J"/:$QV(CD0]T4!T,LBJNVX38<%-A("*FGDB
M6A*MB-9$#5%+M"':$NV(.J(]T8'H2-03#40G@ZR+L4V$;[A)NN`60D!5#=5?
M-,A1N8;2WD-$*T:MB1JBEFA#M"7:$75$>Z(#T9&H)QJ(3@99;]=M(>B[J/7M
MG8!,#7$+@5$KHC510]02;8BV1#NBCFA/="`Z$O5$`]')(.O"+=;+K[:]L/CQ
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MEUBRL5F]R1JB]&#1^*:6$3TDM`K(_;XOY9HNJA/QF@V;B'+Z-J*<?I/3QS>Q
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MZ9-?&@+^/:B*SQW>3*MSS3:GB>-M%U'NK(LHOZ5]0"'S_*8Z(`<V.4:4$_<1
M7?P40XSRAVTV63Q.)G?5PNH4@\[OT8Z!Z_:('KE'%%!U`<:4R3<T9X&`<NVL
M0BYS`9[/JD7N.O98UL:L'BI-C,I%U494-APY-?CWE4\-5?_;G":/"WR\CE'[
M@)0Y-CPPZAA1?N-]1/E0#<QU,E'&\N3VNKTF'V\WFR*KBKV>:<6PLMH3RS6R
MBNR%Z7$,*R_2B>5B:1/+76PB*Z_3D17Y=HGE?%UB.=\^LB+?(;(BWS&QG*]/
M+.<;(BORG2+S^2J)8SM25T^])K?<@HJL*N+JA/B4PO+07$:F9Y/$02VWO@OW
M/)!T`I[/JH7C.H:Y!Q6G,!9R"LN]2K?OP31E*<>P5,O3ZKRTC1'%I$+C(23/
M'6H\I`[CQ]1X"!^SJ.?(BGP:#\BG\8!\&@_(I_%0QE7CX;HMJLDM]Z@BLYM4
M\^KZ(?&^J2WJP(SXP,)%?#IYG,T?Z1TMFY$>)#G%Y?$Q)MF'J8S\A?R^NMY*
M<DH4Y4ER8+E()1EQDIRRQ[8J>L1),O))<HJ[\`'D/83%J<_CP^3QL1JI&@DI
MF=Y(-1*NV_J:W'+O*[+J%%`=2HV$L$>6:T.G@,#RY4FG@,#\U'2J\YK^[_LW
M?]=;?Q>VX'0"0$,-!'2@@9#B+AQ'G>]]6*CVZ<U#M=FJ@9`219D:".A0`P%Q
M&@@F^_RFFA9H5*"11@62:U2DN`N?1J,BA/DC>#<=F0]K4*1<'!0ZK5XQO9_<
MNOCZFN]9=<VOAJ8&A0^SIX?`S.G!,U5J\<FQC9W2Y:8:%NA"PP)=:`RD+J)A
M64><K".?K"-.UI%/HA$GT<@GT8B35>23Q#*NJFRW0?3U:[3)K=]0*A=ID565
MS8E;V(LRE1V8J6S/5&67):*I)`:6NY!$Q$FB9\5$61(1)XG()XF(DT3DDT3$
M22+R22+B)!'Y)+&,JR2ZC:92XC?MF4UN_7Z5=>M95:"<N(6MKGRQTUG;LW+?
M+#+WS)4T(^,.:`PK)KURBR[D-K!<R'+K63'IE5O$R2WRR2WBY!;YY!9Q<HM\
M<HLXN44^N2WC*K=N>^7?X-;OTEBWGMG]M7EU5U,G7Q]6+JTCTQ.HXUE05V0?
MIR]1G:=)\^GXW"QDRQ4OM>A!:E-<,5*PS1;#PB5Y<O-030;E/B6*;U7NT:'<
M(T[N/0O99[@U%0/L;!S)-1!2\@N?1F,CA/E+\GSQ.)L^/%0;GAHM*1FOR6[/
MJ1XMTX?S\_S.N^?_]?&/\Y<(OGXK?7+K]['LT/&LFM97TR$-'1]FK]N>Z=E_
MT8>&3F!3/W1F#_?SA_KYKIK-A6RYVC5TT(.&3HJ[<+!UHO!A:5J_J$:^ADY*
M%-^JA@XZU-!!G(:.R3XV=-!(YQ`DU]!)<1<^C89."/-S_/G]0G\NYZXJ!@V=
ME(Q#QVTQU4.G7/W'H7-Y'W]RZ[>J['#Q3%\DB@=28P-,EPPPC0TPC00PC00P
MC00P:0>3:#")!I-H,(D&T_4!3&[!Y!9,(L&DK63V^C"Y<N?M'%_-P@.SWUB=
M8VF6PZ+%Y81L-<+6(ZP98>T(VXRP[0C;C;!NA.U'V&&$'4=8/\*&$7:RK#+F
M=ES*0GNAH"9^A\845&#EEU@G9-+CVQ9QT@,F/6#2`R8]8-(#)CU@T@,F/6#2
M`R8]8-(#)CU@PPB3GC*NTN.V0:[1X[=-K![/JH+"LG:2PHJ"`I,Q,!D#DS$P
M&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!DK667,[5%<8\SO:5ACGA6%\C29
M@*F@P*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'I*5NEQNP^E
MGF];G4[\)H:UYEGYU=9)B"N_VQJ9OMSJEB;3VTEU;9-#GTD1L13ET+,BDQR"
MR6%J&[)7\V`931$QNXPBDXR"R6AJ&[)7TU3Y31$QN_R6F2H?;B.A]/'2]<=O
M/-@#[UDU_\>6S\2'F?E_9%K$Y"V`>F$G(;YIF)U/;Q:5,ND)R<OE0&1Y'T)Z
M4MR%#N6HZO!6-Q:*_ZMV8^4OI8U'7?X"R]W+7XJ[T+TDFNYO;R;5'HN4ID3J
ML%+J]@^N4>KW&ZQ2SZK=@.I=Z*3HP\QN0&1Y32]_/L[LXLWGU5I6$D,Z#=<T
M&N;SZF"K[-"KO*:F48`DCO9:+8/D+C6]T*MTHE?I3$UCKW(WUFO])0D)3$W'
M>ZV<NE7^-4[]KH!UZIDMT[OJ!"*G/LR6:6"YNN34,[.]/K^KSG9RFIJ.?\[S
M+Q7D%+W*:6H:CZZ<CO9:G0[D-#6]T*N<HE<Y34UCKW(ZVFLUA9/3U'2\U\JI
M6WY?X]0OUZU3SVR=WO'4Z\-LG09FZM0S_4[%75[FDX?[*I5\HIGD(;WD(4[R
M/`L[:%5J24,3&4)J&4*<#'E6O/.JSF6G;%:I<$OJ:U3X);@RQC'RTV3B655>
M/&7Z,%M>@9GR\BQ<\G`S,_2F3?'QH1;+"KW)#'J3F4N]R4QJ<J$WR4)ODI6:
MQD,E69=ZDZC49+PWZVYZY9['.;[:\PC,3/C)EA.RU0A;C[!FA+4C;#/"MB-L
M-\*Z$;8?88<1=AQA_0@;1MC)LDJ/6UQ?45INF5S?&`[,_9/G!7?5].%IDL/B
M4).Q<FU_+@H9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QDE7&
MW.+Z&F-^,6Y.ANYOM;OG3^9]?>D!DQXPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I
M`9,>,.D!DQXPZ0&3GI)5>MSBNM1SX:>B+RSFIGZ=;LVEM7M9:]4<7#)36%%K
M8)())IE@D@DFF6"2"2:98)())IE@D@DFF6"2"2:98)())IDEJV2ZE7DI\R5C
M?B5OC875O:DU,-4:F/2`20^8](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`
M24_)*CUNE7V-'K\JMWH\<Q5=7+RJV:D**H45!04F8V`R!B9C8#(&)F-@,@8F
M8V`R!B9C8#(&)F-@,@8F8V`R5K+*F%M67V/,+\.M,<_LQ0M,!04F/6#2`R8]
M8-(#)CU@T@,F/6#2`R8]8-(#)CU@T@,F/6#24[)*CULAEWK^A8N77VQ;<YZY
MR4VNM?MJ\:1:2V%%K8%))IAD@DDFF&2"22:89()))IAD@DDFF&2"22:89())
M)IADEJR2Z1;4I<R7+EY^`6Z->69K#4RU!B8]8-(#)CU@T@,F/6#2`R8]8-(#
M)CU@T@,F/6#2`R8]8-)3LDJ/6T:7>OZ%6O,K<FO.LZK6L)WH'D%O5P*2"2:9
M8)())IE@D@DFF6"2"2:98)())IE@D@DFF6"2"2:98))9,BM3CXJW,E^HM7-\
MM<L1F*DULN6$;#7"UB.L&6'M"-N,L.T(VXVP;H3M1]AAA!U'6#_"AA%VLJS2
MXY;39:V]I,<OOTU!S=*2O+QX51OJ3Y,<EB]>9#*6TL4X&0.3,3`9`Y,Q,!D#
MDS$P&0.3,3`9`Y,Q,!D#DS$P&2M99<RML*\QYE?DUEBY2C]O+DD/F`H*3'K`
MI`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I*=DE1ZW9B[U?-OW!&9^
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M#3`Y15.=.-&%!").`K^F"PE$4]E"%[*%.-D:Z^*AVEJ0K;)II<:MI*]1XU?>
M5HUG5;E5]:%)B`^SY1:8*3?/P@WYZL-(26HR/O3"3>88EK\N)TNI:1SPLG2I
M-]E)32[T)F$A+/<F8:EI[$W"+O4F4:G)>&^5.[?,OL:=7Y9;=^52/<X6P33O
M`--Y$4QVP%0P8%(!)A5@.OY@.MA@.MA@.MA@.L)@FBV":;8(IMDBF&:+):OT
MN(5SJ>?;MSIF?@UNS:5U>3%6'GB12V%Q%$HFF&2"22:89()))IAD@DDFF&2"
M22:89()))IAD@DDFF&2"26;)K,SYE5L=Y_AJJR,PL]5!MIR0K4;8>H0U(ZP=
M89L1MAUANQ'6C;#]"#N,L.,(ZT?8,,).EE5ZW)JZK+475@)SOP8W!168V[S,
M\[?Z`0I/DQR6"XI,QL(R/W\=2\;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&
MP&0,3,9*5AESR^QKC/EEN356+M7#Q4O3"VSMDDD/XJ0'3'K`I`=,>L"D!TQZ
MP*0'3'K`I`=,>L"D!TQZP*2G9)4>M^HN]5RX>%WQ2]VY7\Q;BYZ9K8\05VQ8
MZ+3HX^SSOQ^J;]E*;`J+]2FQGA7I)!9,8E/;XA0PK58%<IW"8A=RC71R#2;7
MJ6W1!9X#7H3%+J0?Z:0?3/I'NZAF!AH1*2QVH1%1IJM&A%O&ER/BI5.L7_9;
MU9Y9U9X5;J0ZQ)4KML#TO/+X=N45<?**?/**.$GTK,@GB8B31.231,2I8)%/
MQA`G8\@G8XB3'N23GC*NTN-6Y-?H\2MXJ\<SN\;&\]HG<Q^F564T(6.!&6.>
MF37VR*,TV%02T84DH@M)3%W$MR*)B)-$Y)-$Q$DB\DDBXB01^201<9*(?))8
MQE42W4*]E'C>8+Z_48N7JLTO\:U.S^Q3;QZJ74%-:$)87KM*9V#ENCPR_^@'
M/1%D,9U.JITAE21:RB9ZD,T4E\^#(T\V"V%Q,P`_.I+NE"@.`>E&A]*-..GV
M+&1_N*GV+.0>C>0>R>4^Q5WX-!H.(2P<POEDL9@O*B$:("F9/E$U0-P&03E`
M7AH6?D/!#@O/J@?F5.]"P\*'V2H/S%2Y9Z;*YP_5+K#&16J:C]#(DPYC6#ZW
M:*B,-!T;*NF-N-L+^GU:==W64$F)BJ$26.Y00P5Q&BHI>VRKT8$XC0[DT^A`
MG(8"\DE\&5>)=_L,UXCW^Q)6O&?V?#"K3$E\"#/G@\#,^<`SLRT^=GI'4YT0
MT(4L(TZG]]1%/.B2B#C5._))(N(D$?DD$7&2B'R2B#A)1#Y)+.,JB6Y_H93X
M;?</G<#ZUPB!545=G<_DUC>U1>V9!E\\R)I$>_;24[!BNMQ4;M&%W`:6X^36
M,YTW8K=RBSBY13ZY19S<(I_<(DYND4]N$2>WR">W99QUJP=-6;<OG)G/\=4&
M46!V(QV/D]?#K<_^M7J+1VZ96#Z:J\3B!?ON\79R7RT#UBDJMVP2RSVTB6D*
MFK9'1L["X<U=N&#'MY\[W*7DN<,NL1RWC^Q_OF`S^3$V*HY7G]C%3S.DL'C!
MOKW7@Y^JZ\HI19W?:34LW`Y(6?(O#0N_8V+.V^Z//JK>;6W7OT=_FH0P4]N1
MY<+3L/#IM'/MKI-W^M6-'C-?/Y<T!N6&&A6A8;Y4:E0$IBO7Q5'APU3LYUO_
M]9-#MT6>.*8U*-"?!D7J+\9I4)CDCS?WQ8_B]9_5#L$AQNMF2\RA,8*^-$92
M7Q<^F\9("(O/KIT]W-7K>0V1E$M]5D/$[<)<,T3\KHT=(IZY\U/2,)]A3N?V
M3C22BDK0F2.P7&8:(IZ92_N\?LR;3AVI:>YU9$X7PW)Q:]R,-!T[FZ0W$N9T
ME4P-G)0HRM3`"2QWJ(&#.`V<E#VVU>!`G`8'\FEP($XC`?DDOHRKQ+O-EFO$
M^\T9*]XS>V[@G.[.A]ES0V"Y#"3>,S.9'YG3Q72YJ<X.Z$*6T<4F,G/=9YPD
M(I\D(I\D>E;DDT3$22+R22+B)!'Y)+&,JR2Z+9E2XK?-Z=P1K^=T@55%C3E=
M#,NC747MTYE'TD>F^6D^1SQ@`1_3E5?&L:+V/12G$ND.+)]*I#N\D_R$>-4L
MXJ0;^:0;<=*-?-*-..E&/NE&G'0CGW27<95NMWE3ZG[I>NXW>VS->F:WV?C$
M>7?VU9"P-1M8+CS5;&#A^C/3WXV9+Z@5+56RZ$$.4UP>)6,G9A^F(^5.S).;
MR9V]Z-KYA)2GM/%4*^7H7LH1)^6F+STJU":7?S22?R27_Q1WX;-I2(0P?T"G
M]XO;N9ZB83O5($G)>$5W&SC7#!*_X6,'2=@$,E?TD4E?"#/%'U@N0PV2P/Q$
M=GJG/RLX<CU'0XT1=*`QDN(N'$>5O@_3@7)C9'8SJ]8>&A4I43$JT*%&!>(T
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M;N;516=;)(H=[A++'7:)Y3>VCRQ,'!YNJD]SB`'%ISDFEI/WB5W\-$,*\Y_F
M;K%X6.AG0/6$+PHYO]-JM+C=G?KD\"\^U%Z/G\>9(K!JY5"]TR=M\IZ;FC-%
M8/HG^M#0\7'WX:'V^MWNE'^B.T85VV4:.NA!0R>P\H0R-G1\6%@YW'(K,.>)
M[U0C!_UIY*3^8IQ&CDFN&^=6HD8.&FGD(+E&3HK+9T=\&(V<$.:7"OICW>[O
M?56;J:<4=9YL52/';0_5(^<;GFDOAQPMGIGOFX:X@NFL@C@-#3"=0\`T$,`T
M$,`V(TRG",1)-)A$@TDTF-R"R2V8W())))BTE:S2YC:$:FW3A?NBQKN_??[R
M\4/[_/XOYQG"B]_<N/=[2V8"&-A"RX=T;9XO6.>^J<)B!4@FF&2"22:89())
M)IAD@DDFF&2"22:89()))IAD@DDFF&2"26;)*IENNZ>4^<*>SKV+KR_JGA5U
MI=,PF/2`20^8](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8])2LTN,V
M6J[1X^)K/9Y)3UE0U<T$&4MA14&!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,
M@<D8F(R!R1B8C)6L,N:V/:XQYK=)["G0,UM08"HH,.D!DQXPZ0&3'C#I`9,>
M,.D!DQXPZ0&3'C#I`9,>,.D!DYZ257K<[L4U>OQNA]7C6550U2I`!97"BH("
MDS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&2M99<SM2UQCS.]C
M6&.>V8("4T&!20^8](!)#YCT@$D/F/2`20^8](!)#YCT@$D/F/2`20^8])2L
MTN/V$4H];N8WO?NFV:#?DK#F/*MJK5K:J-926%%K8)())IE@D@DFF6"2"2:9
M8)())IE@D@DFF6"2"2:98)())IDELS+=XMK(?&$V>(ZOIAN!F5HC6T[(5B-L
M/<*:$=:.L,T(VXZPW0CK1MA^A!U&V'&$]2-L&&$GRRH];L5=UMI+>OP*W134
M@V=506'#-8?E@B*3L90NQLD8F(R!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,
M@<E8R2IC;AE]C3&_[+;&/'N<I97NT^0!3`4%)CU@T@,F/6#2`R8]8-(#)CU@
MT@,F/6#2`R8]8-(#)CU@TE,RK^?-YU^?G[\LWWYY^^/W'YX__>7YZ?FWWSZ_
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MUR;NB.CO7(Z^YHZ(_IC@R&L+'9#%Z/%8Z'`L1H_&0@=C,5H["QV*Q?B1T,#R
M>Y3U\5MH6/U_NLYHI6$@B**_4OP`-<DF6X,4*@H5+.@G5&RK*$9JP=_W3!=]
M2$_?FM[,9O;.9&_"9F>GFE49FZRYF+');@/C61G/D)>5NRG4E>6H1[Y!W%1Y
MB\',Q[*,C8]D&:Y]',MPG97K#-=9N<YPG97K#AL?VSIL?&3KX-K'M0ZN?50+
M(>"-2+*J@VM7@9:>\B6EV+1X76:.QU%H\9IY0+/!:[ZO$22$P74A9,%5(='3
M,HL^]B#14];TR'42/>7C3$%:,J1,THY;:\D0O@4W&[SF8V%!$C8^GB=L?#1/
M])3%W-8:7)>)T[%O":Y9G&HV<,VJ1$$:;"@&9@@V909R?)T&KLMLXA$"UZZ&
M#5R[%H84NA*&H+F>A?2X\C1P[;H3,NXJWL`U50J-`[BF_)T@(6*N834>N(+5
M>.#Z5>.!JU>-!ZY=-9%SY:JP87=&\;K"ADW^#(%K=H\SA&BS!YDA1+L\Y8_S
MH"+:;+@D-ICHO8B!GG^0QA/*R#7T3JS@F<U<Y>H5/+./Z#'"$K*F9\V88?.J
MGWMK-"9MW428[?](,_E_GOKYB6?DN-7%XH8P:A0)HL:0$%H$HQQI3^DH\XJJ
M4$U/&2C#J/#4])1T,BSJ?-"F,KD(C)6#9L>BP&A3L=NKJK\KA1Y&F;8`N5?D
M`62IR"/(DR)LOIOP7>\=MCA+^*X8&Y(E?%>,/=PB'4_DXR$A2T9>_'?M>W;]
MM=JNEZO=]NWS>_*QWO!"=WG.`\-D5V:ER\%^^.)%[VSR/.R9L3[\?%VO7M:[
M.)N3-\.P_SL@Y2]^AMW[X:5Q]@L``/__`P!02P,$%``&``@````A`'RTLC13
M"P``C3@``!D```!X;"]W;W)K<VAE971S+W-H965T,3<N>&ULK)M;;^)*$L??
M5]KO@'@_`1O,34F.)N#[1:O5V=UGAC@)FA!'P-R^_5:[N]R7/V'@:%YB\G-U
ME?WOKG97@V___+%[[7VK]X=M\W;7]VZ&_5[]MFD>MV_/=_W__!7],>OW#L?U
MV^/ZM7FK[_H_ZT/_S_M__N/V>[/_<GBIZV.//+P=[OHOQ^/[8C`X;%[JW?IP
MT[S7;W3FJ=GOUD?Z=_\\.+SOZ_5CVVCW.O"'P\E@M]Z^]:6'Q?X2'\W3TW93
MKYK-UUW]=I1.]O7K^DC7?WC9OA_8VVYSB;O=>O_EZ_L?FV;W3BX^;U^WQY^M
MTWYOMUFDSV_-?OWYE>[[AS=>;]AW^P^XWVTW^^;0/!UOR-U`7BC>\WPP'Y"G
M^]O'+=V!D+VWKY_N^I^\134:]0?WMZU`_]W6WP_&Y][AI?D>[[>/Q?:M)K6I
MGT0/?&Z:+\(T?12(&@^@==3VP+_VO<?Z:?WU]?COYGM2;Y]?CM3=`=V1N+'%
MX\]5?=B0HN3FQ@^$ITWS2A=`?WN[K1@:I,CZ1WO\OGT\OMSU1\.;L1],9Q[9
M]S[7AV.T%3[[O<W7P['9_4]:><J7].(K+W1D+Y.;8#H<M4[.-!RIAG3DAJ.+
M&HY50SJJAI.;J3><CZ9TU6<"TMGV?NG(`<G%F083U8".JH'G&0*=:3E5+>G(
MH2Z[-\K-]AKI>-6]S54[.G+`\]WFT7"3O2_&G>K8"^_.ZT8.?>!PE]V?Q\-%
M?+CJ#CT>+^*#:NE/;OQ9X`43,5[/=(?'0T9\N.QF!S)9VMQ;K8_K^]M]\[U'
M$QK=\N%]+:9';R'<<=;)\%T>?I2&E'_"RR?AYJY/W4P)=J"YX]O]>#:]'7RC
M?-\HFP>T\6R+)5N(Y!9N5RX(71"Y('9!XH+4!9D+<A<4+BA=4!E@0-)V^M*X
M^!WZ"C="7U;F@8$6W'?$9`MNLG)!Z(+(!;$+$A>D+LA<D+N@<$'I@LH`EIB4
M*K]#3.&&G@[68)W9ZCU(&X]FO&Y$3VR396?2*0PD!!(!B8$D0%(@&9`<2`&D
M!%*9Q!*;)H/?(;9P0Y/+^:E!&9U3NS/IU`82`HF`Q$`2("F0#$@.I`!2`JE,
M8JE-,[ZE]NE5#T^WPKH5E<5XD&1"S_9NO(YG<V?$=D;<;`4D!!(!B8$D0%(@
M&9`<2`&D!%*9Q-*0;OX*#86UK:$DOIYEET!60$(@$9`82`(D!9(!R8$40$H@
ME4DLP2C?KA!,6-N"2>+3LT\/NOG0&72=43?H@(1`(B`QD`1("B0#D@,I@)1`
M*I-8&M+$=H6&PMK64!+2D.59`ED!"8%$0&(@"9`42`8D!U(`*8%4)K$$HS7]
M%8():ULP29Q!YZXD.R-6=04D!!(!B8$D0%(@&9`<2`&D!%*9Q-)0E#M7B-B:
MVRHJ9(X[1"M$(:((48PH090BRA#EB`I$):+*0K9^8KGNECU^<$./EFL+'[GP
MI_4-C[0'44_2F'5&J+L\UU;<<(4H1!0ABA$EB%)$&:(<48&H1%19R%9;K.=-
MM<\O;D0M[>2\0M9HE58&6J%5B"A"%"-*$*6(,D0YH@)1B:BRD*V?6*-?H9]:
MTIM#4B)G2(Z<)[78BI`#5P])0"%:18AB1`FB%%&&*$=4("H151:R)14+\2LD
M5>MV4U*)C/&W%/LGKGZ`0K2*$,6($D0IH@Q1CJA`5"*J+&3K)Q;AIGYRW^A&
M[%D>7[:;+P\-+0EI(CR1ZB/:'U*[1G(I;TV>$LW:O>+6:BDV@86LXVZ*72D4
M^.U6DS_TG*$<:@,>RA&ZB1$ENJ'8Q"+/SKR=:@/VG*&;'%&A&RK/SIJEU`;L
MN;+<V!T@%O5F!YP0FK81.Z5E#6`I+1$I;:[>Q^Z<H(H'4WS5<-KU1^A)-->K
MV$BAF;:*%3(Z,D&K%'UE:)6CKP*M2O1565:VI&*-?X6DLB2P))5H8DL:N))*
MJ]&DTV\E]IEHB(_HT%52_M39<`K9:M:.>F\\G8Z"D;/+&K&1J3L$3+35F8`I
M6\F`P=P?SB;.J,W81L?+&>D;+!B=O<&2K62\Z7@V'CKCL6*3-IS=?:+B,+OO
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M:TU31F;$P/65L:^S$7.VTA$+=J\CEHSLB$[:5^SKHXAVWYZJ7[W@RN67*`=H
MRC(33Z&I^00+ALX::*FLS,13:$(NNR[")YBRFHM5(G]1&`R=Q5O$[K6&,2.=
M+\E%$=.+(F;L7D?,&>F(Q441RXLB5NR^C6CWK5LMNWG[5_/^T=+:6/'Y6$4K
M1*%Y<EPB6B$*$46(8D0)HA11ABA'5"`J$546LG45I>SE3R5?5KY6<G3%L#EZ
MG17*4C4T5%XA"A%%B&)$":(4488H1U0@*A%5%K(E%=7M%9(*<V>^D<@0:TGE
M@;`RT`I1B"A"%"-*$*6(,D0YH@)1B:BRD*V?J&ROT$\6PM:05+6Q.>T&0[?B
M$+\G<24%%*)5A"A&E"!*$66(<D0%HA)192%;4E&)7B&I+%PM224RQM_2![1"
M%"**$,6($D0IH@Q1CJA`5"*J+&3K)VI%4S_WZ7/1QHXO*TY+5HG,C1UE1?G!
MSZ.50A]O[&@#;A.AFQA1HAM^L+&C#=ASAFYR1(5N^,'&CC9@SY7EQNX`432:
M'7"^>*)OJV%.E<A9PSFEX%(UM-9PLJ%9/"FK8-S6JR-G8HG8B5G6C]WB*F8K
MO91*&.D%5WH^5*9;Z(<OA,K92H<J&.E0Y?E0E6YQ.I3=7Z(`NZ*_9+UF989$
M$U+?6!0[1>32EU;F_@(CG3^A0H'8^?MV']PX55FDF^A8H&+,5KJN21CI6*D;
MRQD<F6YR)E;.5CI6P4C'*G4L[0L*ATHWU%;FW5D=-W+KX_.)UIK;BQ>%G$1S
M)%\J*S/1&.DA&2I$B:8O/1BZA;!N:%AY;B',5CH)$D8Z8GHRHKL;E>F&9R+F
M;*4C%HQTQ/)T1*>XK'3#TQ'M3OPMA?`("V&%[*1TOV98*BLS*14R-SD860GN
M.75#Q+ZL$8!]*R_5B)BP>ZUTRLB.Z";H11%SMC(2E-WKB"4C.Z+ST*G8UT?W
M:/?MKPKABY8B(ZR#%;+SUG,G7&5EY:WT19L<_"`/E=4O=C38U_GG)%OI+$H4
M,B*F%T7,V-?9B#E;Z8@%1BPOBEBQKX\BVGWK%N/N,O.R30YZ'\5=_2A$RW<]
M??@S9XI<:BONR16B$%&$*$:4($H198AR1`6B$I%X,T>7>%)J^::-_+7_KMX_
MU\OZ]?70VS1?Q5LTM,BYO^VP?,7GP9\L1&U`FKAG1B-^^\<],U_0[Y1.M/"&
M"_$+G%-GZ$TB^K7(J3,^G6DG&C>*1_'IZ_Q3;<9TIETJ.&WHA:5/IWU1@U.>
M*/A)>W'K)^P_C1>?2/83ET17=.J"'H(%_7CUA#VI?E+TZ8)^=WC"?K:@G]<A
MIZ_%%^*;;SQ#7VLOQ#?7>(:^EEZ(;Y[Q#-5BBY#J%#Q#M=0B/7F&:J%%>?+,
M@R_4/2FO3_K2'A/&>?!)2%D=.EW[X).4M`E`;0;=*7H9['W]7)?K_?/V[=![
MK9]HF`_;/?&]?)U,_G-4^Z>?FR.]!=9NI;[0:W\UO7`R%+\`>VJ:(_\C`G0O
M$M[_'P``__\#`%!+`P04``8`"````"$`@`CT^S$$``!A$0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6R<6%UOXC@4?1]I_T.4]Q+L$%H04+5;=6>D
M&6FUVIUY=A,#49,XBDUI__W<:R=IG`](]@7(Y?A<WZ^#S>;^/4V<-U[(6&1;
ME\SFKL.S4$1Q=MBZ__W[?'/G.E*Q+&*)R/C6_>#2O=_]\65S%L6K/'*N'&#(
MY-8]*I6O/4^&1YXR.1,YS^";O2A2IN"Q.'@R+SB+]*(T\>A\OO12%F>N85@7
M8SC$?A^'_$F$IY1GRI`4/&$*]B^/<2XKMC0<0Y>RXO64WX0BS8'B)4YB]:%)
M72<-U]\.F2C82P)QOY,%"RMN_="A3^.P$%+LU0SH/+/1;LPK;^4!TVX3Q1`!
MIMTI^'[K/I#UH[]PO=U&)^AGS,^R\=F11W'^JXBC[W'&(=M0)ZS`BQ"O"/T6
MH0D6>YW5S[H"?Q=.Q/?LE*A_Q/DKCP]'!>4.("(,;!U]/'$90D:!9D8#9`I%
M`AN`5R>-L34@(^Q=OY_C2!VWKK^8T;N`!$O`.R]<JN<8.5TG/$DETE\&14HN
MPT)+%GBO6):SX';ND^LDGMF1#O")*;;;%.+L0->`2YDS[$&R!N+^B"`4Q#X@
M>.M"5\->)93A;1>0NXWW!JD+2\RCP<!KC2$UP@.GM6?P-MXS@M$SYA:W\F@,
M33>TWXT_Q0V"H3B-S0=D5?,:SP:S:&"6-<(*$"#C`T0PU.!R;@UHA&MHJO&N
M$:Q=U\DUEJ65!SKOCW(YQ16";5?&LM3#:V7O=@HO@FW>TF*',-")*-.C9P#!
MMJO20K6$-#M\9?-JU2#!#+)[><QPG>VBM$#3UU,5T(&&)R!OX\/1:-M99>H&
M1'"X1V=*HUO4I3K89?'[.XM,4@B-;GDK1:(G$!SB1B!&T/W9[=7:$%S9<E.:
M[.HL!H*:I`JDEH5Z-BM33U`XMO\O*#/PH#Z?;DJ3'50P$-0D$2!=%:A,/4%-
MT@'2%8+*9+?<@&2C_C93>'E.-;K5"X-B0'K4@`;!F);KZH$F`\]V=6[[JT,G
M"8)&VT%5IFYUZ"1!T.@6M1$$:E?G\TQA_210G.=&@U^NCD:WO"'!UJ7=7QO<
M0),:!6$%>;OBHIS\QMQHHDYE/L\0=D"3Q`"VW9:>RM13F9887`FD*P!XIL1<
M697Q!PX!=)(`:'2K,D83^BK3$@"L#/7U0?M:=;IB0$N3-3?^P+&`3A(#C6X%
M-2@&M$<,1K1;5P@T4;O=_(&3@3])"#3:#J@R==O-GR0$&MVB[CL9^`,G`W^2
M$&ATRYL1`M!/^,&S1M+O$8*`C%!IO;#EI90'N]L&#@9P?[44Z/+`:G3+6RD/
MC9C,A=;<]U)>'/B?/$FD$XH37E8IW.!J:WV1?M#KV_;%^L%<L+WZ&[C@YNS`
M?[#B$&?22?@>..<Z4X6Y(IL')7+8*-QRA8*;K?YXA+\R.-SBYG@6W@NAJ@>L
M1OWGR.XW````__\#`%!+`P04``8`"````"$`^MHTI;(%``!G%@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6RLF-N.HS@0AN]7VG=`W$\XA1Q0DE$G
MG+4KK5:SN]<T<1+4(41`'^;MIXQMP*YL'V;ZINE\*?]0O\NFXM77E_*L/9&Z
M*:K+6K<FIJZ12U[MB\MQK?_S+?RRT+6FS2[[[%Q=R%K_3AK]Z^;WWU;/5?W0
MG`AI-5"X-&O]U+97SS":_$3*K)E45W*!;PY5768M?*R/1G.M2;;O!I5GPS;-
MF5%FQ45G"E[]'HWJ<"ARXE?Y8TDN+1.IR3EKX?F;4W%MA%J9OT>NS.J'Q^N7
MO"JO('%?G(OV>R>J:V7N)<=+56?W9\C[Q9IFN=#N/B#YLLCKJJD.[03D#/:@
M..>EL31`:;/:%Y`!M5VKR6&MWUE>:KFZL5EU!OU;D.=F]+_6G*KGJ"[V?Q07
M`F[#/-$9N*^J!QJ:["F"P08:'78S\%>M[<DA>SRW?U?/,2F.IQ:FVX6,:&+>
M_KM/FAP<!9F)W3U&7IWA`>"O5A:T-,"1[*6[/A?[]K36'6=B+US+G4&\=D^:
M-BRHIJ[ECTU;E?^Q*(L^5:]B<Q6X<A5[_G&5*5>!*U>Q)@O7G<X6\_<_"D1V
M"<&5B\P_+@*KHQ.!Z\\_R9*+P)6+S";NW'2LMXTUV"QUD^YG;;99U=6S!BL)
MIJ&Y9G1=6IX%Q2*FF\U-7P#_-_\P953ECLJL=<@.9K:!HGW:..9T93Q!H>4\
M9HMC+#EB)R)H)5!97P6!"D(51"J(59"H(!T!`VSIO8'B^PQOJ`SU1F2U%6`P
MRU:,$!%BB*^"0`6A"B(5Q"I(5)".@&2$\SE&4!G8#J0B<>7,MRS&FH^"9G+(
MK@_IW4$D0"1$)$(D1B1!)!T3R2389#ZC6J@,+,;7EQ(/>LVE/J1W"9$`D1"1
M")$8D021=$PDEV`7E5RZ_5H1VPJ-[LP026PY@2UPM-.H%=('B6$^(@$B(2(1
M(C$B"2+IF$BYSSZ4.XV6<V?$[M[?W?ZX0\1')$`D1"1")$8D020=$RE1J,L/
M3#*-EA-EQ(9]>33)<V4;Z(/Z248D0"1$)$(D1B1!)!T3*7=8N!_(G4;+N3,"
MN8NT=HCXB`2(A(A$B,2()(BD8R(E"DM02I1U#A/:6;6G(G_85JS+N['"'>@0
M6-]`1>3\.;&'_!FQISWQ&7'A==77ASU7VHV@#Q)&AHA$B,2()(BDC+`'DBRA
M#=2O>]*IR*8(-'*%H[$M'+G4WJ>-;5J.O&2"(:#W!,M$&,7#0*ZL-"S)$""4
M4TE&MHDV7..F\T:)0$LK:L1B_1F\$H7VEB,'7C-]!3CF0DYW)Z)F_4!?(%B^
M_4![KKP_`A&UZ(Q<V%/;5EK54(3,>^U(H.%VL4"OWBX14>QV2]>9N4I;E(J0
M[G:RF;1I^X"9K,>3S&1H"L7;>^*82]5,'C64H&]Q-*S,0"`Z>T^;Q7)IFJ8L
M%(J0850DT*`="S1$)1RY=(,1OS+LA?):2*6!LE.T=1L[]5,[EL4;P'$U,B17
MHZ7DO>,#G:$\?(ZF0Q$%`K%:L.>VH^QKH=`9!D4"#=*QT!FB$HYF;_C'D[E1
M:;2I^W7_>&LX]H^A*>RK_<0ZEK+B=A:/&HK$Y\@=5^Z-U<P&NE97D];<-:?J
M^@J%^%!ND4##_>)WW2\14>Q^MY<SSZ6[G5RDM'M\S>1OU17>#6_^'J<RRCN$
M(6@?!Y?M!:K2/DILMCX]_0&M4=\98!1B%&$48Y1@1,^WACLR>]AY%3NZ*$E]
M)#MR/C=:7CW2LRBP?+/J,3LHV\X\Z%`A"Y7//>C>;O"%!\W.#6ZYXL1-4?*7
M'G0'>(1OF1Y]U^)OX$7JT7<E_@:.]>ZZ2E/NL:7'?3?BM[8'/]>QSM;QX"<J
MYG=3[PYLQ5]LIQ[\6KO!(>LNWNB?"([YKMF1_)G5Q^+2:&=R`.O-KN.KV4$A
M^]#R$KVO6CC?ZZKU!`>Z!$YTS`E,[:&J6O$!;FST1\2;'P```/__`P!02P,$
M%``&``@````A`.D`]B^1!@``L!H``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3$N>&ULK)E;CZLV$,??*_4[(-Y/PB60!"4YVH2[6JFJ3MMGEI`-VA`B8"_G
MVW>,;8P]V71S3E^6S8^9,3/^VPRP^OI>G;37HFG+^KS6S8FA:\4YK_?E^6FM
M__4M_++0M;;+SOOL5)^+M?Z]:/6OFU]_6;W5S7-[+(I.@PCG=JT?N^[B3:=M
M?BRJK)W4E^(,9PYU4V4=_&R>INVE*;)][U2=II9AN-,J*\\ZC>`UGXE1'PYE
M7OAU_E(5YXX&:8I3UL'UM\?RTO)H5?Z9<%76/+]<ON1U=8$0C^6I[+[W076M
MRKWDZ5PWV>,)\GXW9UG.8_<_4/BJS)NZK0_=!,)-Z87BG)?3Y10B;5;[$C(@
M9=>:XK#6'TPO-1?Z=+/J"_1W6;RUH_^U]EB_14VY_ZT\%U!MF"<R`X]U_4Q,
MDSU!X#Q%WF$_`W\TVKXX9"^G[L_Z+2[*IV,'T^U`1B0Q;__=+]H<*@IA)I9#
M(N7U"2X`_FI52:0!%<G>^^-;N>^.:]UV)\[<L$TPUQZ+M@M+$E+7\I>VJZM_
MJ)')0M$@%@L"QRM!;CC:S!&.W-&<S$UC:<]A]!N.,^8(1^;H3F:6,U_TEWW#
M$<+V^<*1.5K6IT9TF2,<F:/SN1'GS!&.]^4(2[2_5#C>E^.2.<+QOAQ-D!]5
M`]$AG>G;64ZIG'IU^EF7;59-_:;!D@?!M)>,;""F1\)R7=*I&93ZD5!!H23*
M`PFSUJ$"H,$65M?KQEI:J^DKK(B<V6RQC2E;[+@%D3\)ZZL@4$&H@D@%L0H2
M%:0C,(6R#+6!9?)_U(:$(;7A66TY&!5+*02WX"Z^"@(5A"J(5!"K(%%!.@)2
M(6#9HT+8();KFQ?7!/&";4K2A"TGNJ4V)JRY03BN;+(;3(9B(!(@$B(2(1(C
MDB"2CHE4$]C14$W(AG[GPB%A8.W=7CG,Z%:5!I.A2H@$B(2(1(C$B"2(I&,B
M50D*(E7IMF*(=5\,GL26$A<V\T$?UG*F*&0PXFX^(@$B(2(1(C$B"2+IF$BY
MPT7?D3NQEG.GQ)T/&\<.$1^1`)$0D0B1&)$$D71,I$1!EW<D2JSE1"FQ8!L>
M3;*C3/)@-$PR(@$B(2(1(C$B"2+IF$BYP\*](W=B+>=.">3.T]HAXB,2(!(B
M$B$2(Y(@DHZ)E"@T*5*BM%&8D/ZO.Y;Y\[:&R8,IO++";6@(:)M`@LCY,V*)
M_"FQ9@/Q*7'@[B3T,5<V@6`PXH4,$8D0B1%)$$DIH1<DE83T2S]?DSZ*7!2.
M1E5A:%P6AAQ27NBW#%.YN0;"8*@)#A-A%`M'%EEIY1)AP".G4ABY3*2_&O>8
M5R0"#S%<(R9MQ^C#6"^;+4,VW&:$`@QUA^!6KE`.1[!\A>-<Z3`";K7H"VD:
MBYFSD'>?D)N(S3CB2`P7<W1SN(1;T>'<N>LJHZ7<HA]-KB5IT>ZH)>WHI%I2
M-`/MBI(LE9+L3&8E%.AS)!9FP!&9O-?-S'4M94Y";B&<(HY$Z)@C895P]&'H
ME%OT3G*12-,V+M(/[54F:_U&C3M#L@Z7<UDK.VXEA.$S-!/R"1ARR?XY/#,M
ME%@ACR4<(XY$^!B'3SABFC:7"T.^S)3'N2(RTLZ-Z_<?"Y9U?^-"400BX_O#
MSF1(3+O/D9CV@",Z[:;C&`ME5PNYB?"*.!*Q8XZ$5<(1BVVYUER)G7*3*YHB
M;=ZX)C^F*=HL2NN1(D53RHZP(T\6<.>TQ:3[#$F:HE:RII9+>>)#'FN\2]F&
M(H^(6XD18SQBPI`THFTHS_4IC_71B/+J)7WFSU>:=JM2I2F:P?U\6'&VH=S:
M=B:S$EKR&7*D+1/?1:BC8_:;H6O:IC*)(0\M-!EQ)$:+/S5:PJW8:(Z+M<P2
MN:)EF(>;%?Y67S[JY<8W:A)&:5PHDEMY=>?9D<=]<!PUO3Y&`48A1A%&,48)
M1JF$9`&2'E@5H.5,8''=^7`/ZD,5&AKLL0B5?6C''*4*#8Y\2PVP58A1A%&,
M48(1>1TNIHE6B+[>IB\0JZ)Y*G;%Z=1J>?U"7EW#,M^L!DS?JV]=#QX<X9)5
M/O?@H>H*7WCP#'*%F^``<W;M#+C`M>(S_M*#=OX*-PV/-,?X#'2^'FEN\1GX
M/O#0+U(U#_+=X(K]UO+@=1J.L[4]>*>$^</,>[B:Q';FP>L5[+!U/'CU`'PZ
M7!%\+[AD3\7O6?-4GEOM5!Q@4HS^$:VA7QSHCXXM[\>Z@R\%_4H_PI>A`MZX
M&D3EA[KN^`\RP/"M:?,O````__\#`%!+`P04``8`"````"$`RWVC!SX&``"D
M&```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLF5N/HD@4Q]\WV>]@
M>!\5!!'2NFGEGMUDL]G+,XW8DE8Q0'?/?/L]1=6AJ#K.I)V9EZ;]>>H/YU)5
MA_+AM\_GT^2M;-JJOJP-<SHW)N6EJ/?5Y7EM_/-W]&EE3-HNO^SS4WTIU\:7
MLC5^V_SZR\-[W;RTQ[+L)J!P:=?&L>NN_FS6%L?RG+?3^EI>X)M#W9SS#CXV
MS[/VVI3YOA]T/LVL^7PY.^?5Q>`*?O,1C?IPJ(HRJ(O7<WGIN$A3GO(.GK\]
M5M<6U<[%1^3.>?/R>OU4U.<K2#Q5IZK[THL:DW/AI\^7NLF?3N#W9]/."]3N
M/Q#Y<U4T=5L?NBG(S?B#4I^]F3<#I<W#O@(/6-@G37E8&X^FGYFN,=L\]`'Z
MMRK?V]'_D_98O\=-M?^]NI00;<@3R\!37;\PTW3/$`R>D=%1GX$_F\F^/.2O
MI^ZO^CTIJ^=C!^EVP"/FF+__$I1M`1$%F:GE,*6B/L$#P-_)N6*E`1')/_?7
M]VK?'=>&94U=<^XM7%!Y*MLNJIBD,2E>VZX^_\>-3"'%12PA`E<ALEA,;<MQ
M5R;<]*,JME"!JU`QIRO'L9>K.QX%;M?[`U<AXMXO`I.C%X'K]S^))T3@*D26
M4\>=+SX0DAE/4I_S(._RS4-3OT]@(D$:VFO.IJ7IFU`KF&V>FR'_7TL_Y)VI
M/#*9M0'>069;J-FWC;4R'V9O4&>%L-E2&\UBAQ:LJ)ALH(-0!Y$.8ATD.DAU
MD(W`#,(RQ`:*[V?$ALFPV*!76P2C8*FAVJ$%#@ET$.H@TD&L@T0'J0ZR$5`"
ML?@Y@6`R:P/^#D5BSU7'M]P$EC=ILU1-=H/)$!Q"0D(B0F)"$D)20K(Q46($
M:\S/*!8F`W/QVS-)&'TK2H/)$"5"0D(B0F)"$D)20K(Q4:($BZ@2I=N;"JXJ
MS+H/!CJQ%016P*&&K)6E5<A@A,,"0D)"(D)B0A)"4D*R,5%\7][E.[-6?>?$
MZG?O?GG<$1(0$A(2$1(3DA"2$I*-B>(HU.4=26;6JJ.<6+`LCY*\T)(\&`U)
M)B0D)"(D)B0A)"4D&Q/%=YBX=_C.K%7?.0'?T:T=(0$A(2$1(3$A"2$I(=F8
M*(["%%0<Y8W#E#56W;$J7K8U)`]2>&.&+Z!!X&T#$U']%\22_G-BV0,).'%@
MMY+UX=IJ?82#$08R(B0F)"$D)23CA#^0$A+6/_UX3'H5-2B(1E$1:!P6@1P6
M7NB_YJ8V94)I,,2$RL04)7*@4-96W%0:H'*FR*AA8OW6N.>\42+0Y&.-F+P]
M@RT1M;<"+6";D16PTBI@AU;+86"`"*:O'.AJ'4:(5JL^D*:U=)W52BVO"&WZ
M%[&^F&-$\GX)HF_>+T4K<;\5>U-2;Y>A27\[-9JL:;LCFKS'4Z+)D0W5*X.R
MTIY@9PHK68,!(CDU0T0L?6\;9S%W/"VZ$9K(43$BJ9T@DE8I(JYM+RS+U+0S
M-.E'J6%BC=L=81)]WKCH.-**3GN"G2FL9!$$B&2IA(AXQJWE?&YI4RI"$SDJ
M1B2U$T32*A7(42>'JQ>4>,X;!<6:MSLB)7J]<:0XT@I*FT$[4UC)I`>(9-)#
M1#SIENUY^GMEA"9R5(Q(:B>(I%4JD,.V+/G:2B(EGO-&3;%6[XY(B<YP'"F.
MM)KRU%SMV.D+;),+F?<`D<Q[B$BL(DO/L;201V@B1\6(I':"2%JEB'!%=.VY
MMKED:'*CH%BC.`[3=[4*)F\WE86+([7./.V5<B<&VK(6`H$<Z6&("/J=K]="
MA%JRB&)$4CY!+2F?(O+XWNS9VF:5H<R-*F.]YH^'CW>L2O@X6BKKOD?.9+B5
M4GQBH-*@TUU46%G<9=MU75/;5"+VHL\J6T8J1C0NR(_<+Q4#E_Q^KF-Z"ZW^
MV;&IO!W?'O@Q*#\2.Y?-<[DK3Z=V4M2O[(@3UM+-PX#Y^>MVZ<.K#_0B.G=]
M>"VXP5<^=-&4!YX/S>4-;LY]UJK1;Z`/\UFK1;^!,^''O@#U9V)GQ3?LMY8/
MASU49[OPX82#\D?;?X3@T2^VM@\O^S>XX\.+,/#9\$1P1GS-G\L_\N:YNK23
M4WF``,_[%X:&GS+S#UU][5\<GNH.3H?[?X_P:T`)YX'S*:R$A[KN\`.[P?#[
MPN9_````__\#`%!+`P04``8`"````"$`HYA5'S0)```],```&````'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;)R:6V_C.!*%WP?8_V#XW;9(ZAHD&8PD]NX`
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M:;:MGM??]N=_U^__JG8OKV<H=P2.C+&[[<^R:C;0HR"SE)%1VM1[.`'X.SOL
MS-"`'EG_:#_?=]OSZ\-<Q<LH"90`?/94-><O.R,YGVV^->?Z\'^$!$FAB"01
M^"01$2YE&HDHOD%%D0I\DHI4RT0$F4JFGTI((O#Y<2K94H3!+2<"O];V"7Q^
M:(BI?;+"_FW+5:[/Z\?[4_T^@SD`/=B\K<V,$G<@;.H4PN=XG:!`ILUOIE';
M%.@&!M?W1Q'(^]5W&!`;8O(Q1ME,,<:$-E..,9'-Z#$F[I@56.W\PECH^W7[
M-/##'/[V?":=;ML7.3)QVPM1%*;L>-$_'F9I&BM&E'UB$09)E@C64;J/9'$8
M"M&=A>4.QFC?G:FF@KGK=FD:<9=IIX\ND4DN+I6\G$*+%(C``.\ZZU*"EBB]
MA'81EE'X&6[4/VQ-(VXT8T:1"7%0Q\Q!@4>Q&Q8RBC+!VI<?[:_V@N8:272I
MMN41IN'M'DTCYE$$S",RZ$+$49HP$P4"<*)72^DEM(NP;,9#F_XQ:QIQFVQ`
MYLA\C-F(+5!%_[!(`A&&;-"72#BZ03.-)`@N?6V93#YCTC3B)IF+')G.I(A2
M7DPD'"Y*+Z%=A.73Y+?>Y<2]\!B8^[O,!5QXD$%_4L0I\U_TCZ=2)&'$+@XE
M$@[_VM90F>@MT9:[S'8W;7DUC;A+=I'+D;FX%%G$!F.!B,-&Z26TB[","KAH
M3*]C2W.+K`PY0;BR9KR,=!1[0"0PC.TUJ^R:7UV3--.0T96Y*$Q<Z`W2:65L
M6W&3[/J0$X0V,AE$[%I?$.`JHQ_13L0NI$D./:_N"2DP9\#?;N$7@EG("7)8
M*`BA:J9*#2:E7T2[1&R/)C5,]X@9P_;(1ELN7$$$XPXAY#$+9'H9;AAW_"+:
M)6)[A.[N>YPX9DTK/F;9]2$7"#GKB0@-:Y7%3*/T:VA"QC1LIR8X3*\FQ@RK
MFI(5(C<WGM`-3H>(X-F%D8K9`E7Z-30A8QJV0Y,:>@XGUA*SANV41Q[AC2P%
M(1]U4&SHEWX)?5W"]FE2P^T^,6O8/EDU<N$*)#0_$4&?8Q<4KX2F7QF1L'V:
M_-#SZ5EC,6WT_65L.N7"FUD*/U(2@J>_$!)RC8K995E[(-NHR0_3C6+:Z!L5
MDL<[@1">8RJSP:V(!8A(9*D,V:@O+68AXBQ30<+&M690(D3:"QF63WE3^FEI
MMLA*'O`(NOA,TX`Q!3&.9:KT(]J)V#8_E8,D;K989>UM1V!J)PCMJBP:6$41
M/)ZDF8@4+RI).'I#6[\"*K#[<AG>ME4XW?[(G;;D2M.*55;PI8B@SJH*!W=@
MA#BLE'Y$.Q';[4V!2(X%(CY/"4*7,DDN_8RKK75<!)%(^9U:28BC%S17">->
M@+8M@LPG"FI:\8*RL9E+A"Y60S%PBPC\[7(RNQ,H2<6!:"=BN[TI$YF][8%+
M9B$G"%V*3+%A7=C'TRR(V8):$N%TV$]5(A-7MT?DIR)1VXJ7DQ4B)Z@S*I*4
M.2D(<3@I_8AV(G8Y3?28?!V5&%2L!5<.RME/.ZD(V?&"1+`7%#R[2`>W9(0X
M>D';*K#G?[V@+!--7'"'V4C(04$10BO&:I@RI)#>_%3Z$>U$[(+>%(SD2#`:
MW&43Y*A&00B-[%3)(!Y<1/&G'"K:J6*Y-+NRTX=M2_/)R69>3I#C_`I"R&44
MPZT9N[\K_2K:J6*[9*G(G>;52!KBYY<3Y'39#T1"P6YTDK(+4^F7T8109W$9
MV^>G(I$:B42273MR@IQ^40=/%$HZ-(N`0T/3SXQIV$YOBD-J)`Y)O@=&D./L
MB@XQCT?#WG,!W!SJ#E^-$+I#N(+M#DZB/RNGK;3*M&*S4PYF)T).EXA@#19)
MJ@9STZNAZ5S&-&RG-Z4@-4Q!&;M.Y,0X#?8C3)S`XS)^WU;Z530A:)&KV"99
M$O(L/\--H<%F@O+O"?F1DA`JDHJ$#*1B*4-[(-OH32%(C84@OFU"$)YCEB6]
MNT&\2[&`*(C@'GPX,?M):A%)`;LF@^?QEM!"A(#T9H_MDR4A3T%'$A"?4[GJ
M)R#C$]XK8&MP08QC:)=^1+M_R?;),M#$=6@L"[$4DRN$L*YA-'@D45A`DL9!
M)!6;ZR4QC@[17"8*U+5G\R'+0M/<MJW8JCO84"#HXC96@V?7Q#C,E'Y$.Q&K
MN.%-H:BEN4VV5N0$X?/`P7X"'<5.4$'*EYJR:W[]^LDTX/:S>Z9HF_M4$@I'
MDI!@@RXG"&TD4<CW/PL"G(7T)R&GBNWUIBP4CF0AP5,"00X+!2'8#6F<R,'C
M%;^(=HG8'N%4^HG(O>*&AF:#E6]&Y@0Y/:(.C5@9A3!HN_&&F<^OH@D95[%=
MWI2&S,M1W.7@/H4@I\M^'(+G]/"B`AOSI5]%$X(NN8KMDL6AB>OL,!:)P5U*
MZ,]%A%`U1NY2_!K:H6$[O2D/A<,\-`A^Q#C+B3(.I"05[(,%W*C!9N$@#WD@
MV^A-@2@<"T0L[.0$X4N8\")7EK`;ML(F5!28D#`8N?A;*+-(@TC!0L4@;2E%
M89RE\,IF-]%MIRP2>1:BD2BDV!*2PSO;9A[3S#%.XZ2W1XXQER!G55''@9C7
MPUT_A4[Q!7!\H_AM_5+]N3Z][([-;%\]P]9XL#2O2)_P]6_\<J[?VC>'G^HS
MO+;=_O,57M.OX+7B8`GP<UV?/[Z8%\R[%_\?_P8``/__`P!02P,$%``&``@`
M```A`#O1512["0``O2P``!@```!X;"]W;W)K<VAE971S+W-H965T-BYX;6R<
M6EUOXL@2?5_I_@?$.\']:3M*LAK;FGM7VI56JWMWGPDX"1K`")/)S+^_U:[&
M[BJ#,9F'F4E\J*Y37Z?=],.O/[:;R??R4*^KW>-4W$732;E;5JOU[O5Q^K__
M?ITETTE]7.Q6BTVU*Q^G/\MZ^NO3OWYY^*@.W^JWLCQ.P,*N?IR^'8_[^_F\
M7KZ5VT5]5^W+'3QYJ0[;Q1%^/+S.Z_VA7*R:#VTW<QE%=KY=K'=3M'!_&&.C
M>GE9+\NB6KYOR]T1C1S*S>((_M=OZWU]LK9=CC&W71R^O>]GRVJ[!Q//Z\WZ
M^+,Q.IULE_>_O>ZJP^)Y`[Q_"+U8GFPW/_3,;]?+0U57+\<[,#='1_N<TWDZ
M!TM/#ZLU,'!AGQS*E\?I%W%?&#V=/STT`?I[77[4P?\G]5OU\>_#>O7[>E="
MM"%/+@//5?7-07];N5_!A^>]3W]M,O#G8;(J7Q;OF^-?U<=_RO7KVQ'2;8"1
M(W:_^EF4]1(B"F;NI'&6EM4&'("_)]NU*PV(R.)'\^_'>G5\>YPJ>V?B2`F`
M3Y[+^OAU[4Q.)\OW^EAM_T&0\*;0B/1&-'COG\NQ1N;H4,.O6!P73P^'ZF,"
M10-+UON%*T%Q#X9/Q-"-ENHEID#1&?GBK#Q.H=J!1`WI^?XDE'Z8?X>0+CTF
M.X.AB/R$</%S9HO@%W/PMW4:(A$Z?3X+)]\<V/EVLIKA+\!VZZQDCO01BD&*
M/B1.6BO$676+LPX,Q1'X)I1I[391R1`#R6K]MQ217T440PCB/2PS/M0._#B%
MT+2>I2EU+4.(;6ID)A,M4B44Q>0$HXR0D>1!*`A&R%0H9;M`$0K082$%5^+Z
M8N^>JL9]B">"A3E##'C2TF6(_"JB&$(0%O8S+-R':$)$Q#."F)"%X0FY#BD0
M$ON\&A,'1@B/F/(8[ET'9OZKF%9+AAA<6<=)PIT/G\M8)VPN%>2YL4F70^*W
MD_)@4`[[[<#<[VX\8!LC!OT6D;1LPN3A<YG$<><7#D?R/!6FRROQ.[W%;P?F
M?G=VT6_$^$P+HU,>\!"@(Z,9\2)\+DP4M?DD?@L0Z?$!;]#,<]U91L\]:+#4
M/>:4%A7%B>450S"Q2B/X<X&$4[#152-0[\C\9%G//&:8`]I!#C86UD0]"@BY
M8(8FPDG=>`XHC"$'H44;'9\(!/D@N^)/N@`VD%P0B(VTY.DL"`0Z1'252@DX
ML1M/`*61$F"]F0D$(0$EHU@J5N4Y@8C$)DIW^M1P+"@DC4R@A)0!Y"EDX"1,
M07\,#R'A/L5[@C5KYD$^%=J`'K-:R3WD0JUX*K@6FI$F#?))F3B]&Y\+5$>:
M"^9>YO;A0!.7MLJF@BE$3A!*)=HP1$$04EK5E2-UW\G<>/=1%$/WTY[WH7#*
M5+/GN0B?:Q,I-A`*`E#)11T03N<"UT?6$*HCE'N[QQ&\CK/&-&RJ`A#S,K\.
M*08A-`M.^@(J5]H`A3+,@M#,OTR$:CH3$6P#@G'B1Q+!Q#*1P1['MP&!"*N#
MW1:EX$1P/`64S)`"KX-,A+)J8J@#-K1R@@".,A9\,U40C$S3M`L4\5_>I,X-
MFDXBOG+F,=C&,Z$2JWH9(!@M9<*$I2"`F=(VD5T4*(&;E%GVE5EH-D0R#_(,
MC(7W^RYZ6$(>$G9*KX:&,90$5,3X*I(.3;/0YX`8Y*"AQ@T+<>ZM(`+>NG1B
MN*Y12)(DP=Z5^G^3,LN^,O.]9>8QWG\3)Y+K,D$(H75LNA+!+O:0"UFB#)SN
M!7T\;JI*]RF:"=&G@B"D`ML;`_L,NH_*O1V$6`4O`:PF"X(PJ3;!BS0E<I,P
MNU.K'H%N^]6$,?,@]&[F=OJVEPRT<R'2/AN#&$J"R?/(;/1E&IREH<YDJ,,S
MV/'!EM4RQCD%"1FK6$DV`PH*TJFUYN*4_91FRS.:S=LX\Z`P\LS1_#JD&(30
MU#AE#!IE6+,EZF@H>(*W:>9!OKXTO(?UMJX4(B,K(C;/"@J!6=5EGA*X2;%E
M7[$%G_29!YT:)()J8?V;>TB8)FZF&,80$NZE87P6&C0;4X9M4#,/.F4ABM,N
M@"AZ%&%A4\0%@R)@UMFN%JG_3+7'-;@ZH]Y<M#(/\CQ,HHQEI9)3B(REX0)?
M4(B*X7VD'224"9/ND4Q0GLEVW'0KX-Q5"`IKAD'RZY!B$$*I,!4?2:6OYCWY
MRA2","EP$@/O/[S\<X9)X<"I5U^A&>&.:RX=V"B(V@T-XM"\09C&98W)T_LI
MB&"XMF\0-!,FC+,LB!5%K=!LW"3DZHR0!R>)OJ`0A%E042IZ'1X"!#P/PMN8
M*/PZ:$*XSKG0%DS!AV5"G5%NVUGVWB,HC&ZO'4)Q!P5P?UK_/($0`N=56@0+
MT00PT;Y"`<6:*!T?/)E"T""%$\1]^:;[[I\>=^_Q71"H^TRH1W;S&<'F)]J9
M0M`@C:N0PELY52/)%67"%'LDDS/*;?FIF4+0().KD,);\=,M<G775AUAHF^2
M[0;-IA(_P\X\"->>G1U+%,)F#G:%AX1Q""87Y?`IZ=9GI#OXG@\[W(,N>-%@
M<H_Q?.'Z1!AL3P;7\A`88O;2OEPS\1YN\0;-\]%UG^>`HNT7UW"*F?"7\]P;
M.CF8-%EK*\:3('883YJ03\FV/B/;ENU:,P]"1^$+DB2%<4D=S0D&7L.537JZ
M33`ZCN)8=-M/2@:2/UZWM4/SC'#=]B`D8>!,.(8-"">!AA`CM(RCH/Q]0D+(
M3*;6B&XERN$FY79?8?<XL!?2S(.\?\8H'7<!;/S+*41:+=FVMR`(.'5+5;<,
M)>`T<O0[GD9%)<H7O'SYM@AEU\!M`2$#W?4,0HPX1[+P:_DX4)*4@M/)@,(X
MS="HKM`:W2EYS,*8>1"40POJE=.02OMR&H)0*DS(KPRI,P(>LX.Q3",(PR@%
MG`XR8<P)PNWS&*#P`-U<%+@\8#\EW1HEEZ:!.9!YT&`:KDOWH!62!G.3=C=H
M-IEXRV8>Y*LY%B+E[X`Y@<!N.S7\:*$@$#A^M,'I'&7`E'NXD,P9Q0XF'K:U
M!R$#;:4(E!:;FB#@Z$3":3\=O@6%I)&\]*6C87(]KJF;3_%4L#?+S(.&JLE#
MD*N"KUWZ.X]!*S07GQ)M<T:T@S-YGQ,$#5)!B"\\N-IA32\I(231<"^KVQQ0
M)K#0[9,6+GGV5"_N5O!,$#3(!"%X#TW`%3,V)MQM4K?0>1M(!&^+XFW*;7EX
M+?-RLZDGR^K=W025,.':W[:W5+](=P^1_3Z#VZO-5<]Y^P`NC^X7K^4?B\/K
M>E=/-N4+F(SN8A#]`UX_Q1^.U;ZYP_E<'>':://?-[@F7,+MR>@.P"]5=3S]
M``O/VXO'3_\'``#__P,`4$L#!!0`!@`(````(0!LISDTU`4``-X7```8````
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK%C;CN(X$'U?:?\ARON0"]<@8-00
M]>Y(N])JM9?G=#`0-2$H25_F[[?*EZ3*R1"0]J5ICLOEX^/RL?'JZV=^=MY%
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MC'!BR_WW6%0I*`II1N$4,Z7%&0C`7R?/L#1`D>13?GYD^_JT=L>ST73NCP,(
M=UY$53]GF-)UTK>J+O)_55"@4ZDDH4X"GSI),!V%BVDPG6&6&SW'NB=\ZI[A
M:![XT7A^N]]$]X//AVE[2@*I:)S4R695%A\.E"E,LKHF6/3!$A(;*17]1MP?
M:0NB8I(GS+)V87^!;!44Q/LFF"]6WCLL8JICMCTQ/&)G(G#%,&U,``_X-J1!
M\_^!-&9!TF:XK0':68060Q-ANL0$8`QA;6V&DQ]6J%$1.T$M,A4CSF"K8H(Y
M"9KQD%T3TK"D"*,)*V[3Q(WTX.IC%JB?V\NO@VX1;T(:XA1AQ($D)=Z_\XVN
M&"SYF;Q;C41$Q6#A6SHV0:9;3!%&9_8('0SF=!022M>3E;_K(#%%V-B@*)4"
M=_`B0N-[=!DQ$>>ED!"V8;NO%X$E4Q/4R$011A4/8&(VMU<-@SD=A0`=,]*N
M@\0486/#6M\_-@;SL142PGXG4MCVT`09@C%%&)T`3KW[^<AH3DA#5(TN%#.(
M$T!S)8N!=1.&T>CQN@F43</^-]/>:LBJG+%5.6V4Z1@SB/-%JR5\;Q=/H(R9
M<5(0$ZP#Q;JCBN($T$7O)Z`]EXJB(*N&)K8H350K"H4X)S3(^SEI.Z6<%,1$
MZ4!Q0"%.`"V1$)#W!Q]D??`(P5/'VG$:LFIH:LNE.I()Q&U'4)"S11,E;`=J
M2%DNJR'MPL2"@@X4,X@30&LD!.2F\T'=`2;*41D3#4V:3;?#2P%J"(H0C[)N
M![&)`MHD:M[(ROFBG1*^`S25^3*:&J(T.U`,/23S&4Z&$T`#)010L/%"GFX#
M7)3S,BX:HEPT-""9CN*2M?=;QAA.<<;X-DT9S8W=0(1F%XH-U)4,-XPM63A%
M7Q^@TK5QF0K842HZZK9BIB-7K+W+<L70A<D:#]!4GDT7%AT5"Y_2[$"QB>I1
M#/V5$,`BFXU'^'-L@(LR9L9%0Y2+A@8DTU%,LJB]DW+)T)`)XP&:RKX93>KH
MZLH9=J"809P`3(82D$8FB^Q!X\=[JF7\&L(::ATJLJ^=;51S3C*(TP55*=T!
MO3#:VI0*`DYFM%W8@6(&<0*6\0\0Z/I]J"!^>8CL"V@;96C&#.*<T'7O+R+M
MT>3R$"J(B=*!8A;%":"O$@*JB*`@'JTA[<^4FH*L&K(OH&$3U<I%(<867K08
MV]M+**-Y#6F(RM6%\.$,BT]%*0+J(4P]V^2B/(J=.)\K)RW>\)$+JGZS:F#U
M`K<-%TL4'J;5:8F@)>IK&?OFV<[N$TR7>*OJR1;,H$4ZJMTGG,`XT@4[+9`-
M2/=D"R$;[*&^ECFTS/M:8#J]LPE@-O#KIR=7`,^3\#NCKR6$EK"W90PMX]X6
MF*<Z>:QYPBOH4W\NZ-"7"0;OC8>A^T9^FBR?H%AZI@&,>H4'W7ME!]5[10?-
M>R6'VI*EY34SAM?5:W(4OR?E,;M4SED<H#!]>8*6ZGU6?:F+*^P)>&,M:GA7
ME?^>X!U=P&.?CS>40U'4Y@M,S&M>YC?_`0``__\#`%!+`P04``8`"````"$`
M"<Y)-%X2``#;9```&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*Q=76\;
M.1)\/^#^@^'WM<49?09)%K$&>W?`'7`XW,>S8BNQL+9E2,IF]]]?-=DS[&ZV
M+%&[+^M-L4F5BLUBSV@HO?_QU^>GJU_6N_UF^_+A.MR,KJ_6+_?;A\W+UP_7
M__GW3S_,KZ_VA]7+P^II^[+^</W;>G_]X\<__^G]]^WNY_WC>GVXP@@O^P_7
MCX?#Z[O;V_W]X_IYM;_9OJY?T/)ENWM>'?#/W=?;_>MNO7J(G9Z?;IO1:'K[
MO-J\7*<1WNW.&6/[Y<OF?MUM[[\]KU\.:9#=^FEU`/_]X^9UWX_V?'_.<,^K
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MI:#`0Z5!&AX$?WF0,,J#O-&QY8[XRQUG-^-F,IO'5W^CXY@[XF\U[=LD052T
M6QU6']_OMM^OD*=XD_O7%65]>(>!>RD3C4'<8]I"5!KD$XWRX1H+#++MD1&_
M?`R+\?O;7S")]QQSY\3HB&4?03-&PW8"N`7?@30T_P-(TRA$NG^YNQ[([Z(Q
M#/N(ODLG`,40D_L',*11D)Q*UHFF=)=BPDP$377(<@@9:$M$\48*_`&\:10D
MU-OYP$%O$1]"!N(24<2Q<"5QWPKZ=*7@R*\?]XZ1A5`Q+*R.0U#?K9.(HC.M
MH4/!FDY"FFB#<2DL"Z23B'IM*'J^%!2L7SLAC9R7L)B9E!J"!BDDHNC0MBL<
MYNV9H6!-)R%-7J;+`NDDHEX;\RE?F]QM`E.I=#<:19-*2(.AA.'-C49#T*"1
M1!3/@#U0$GU;I!BM"3$$1OV++4NH4Y`F0%9[]BR%9,Q8X/VKW3'4P!`'25JS
M!2QS4-^O4Y"F1-YZ/J7DQ(I2@I0F!=0%"6D"Y)*"0-P;F]D-%GUE`@7V6ZE7
M@DP*+4P*<4?Q%CH%:;YDCH+OB21B*Y6<$B1>;1D*"*4=7N;#=8K2!,@.SR?`
MYBD))$@E$8IK*\H0E;-(0IH3V>3YG)*IJBQBGY4KJX"Z("%-@(Q1$(A9-)M?
MDD7)8A4Y=EUI1,TH6,&&J"R8A#1?,E/!]T06)>M5G-B-I6`%U*''L2PBESR?
M0/)418!M%F]QL*)F9$NY,$1E422D1,%.7,$I1FM_9DAN8R74*4@3,/Y,631?
MT.5-K1>1XYC=C"'Z(P1K31;EJ$$P!6F^Y*IG3R(M>,M)VG(J@3@*+YH)R"A-
MP)CWVVG<E`;-D*J#FI'=T7)4YL3./B.:FA,YY_FB))^5F=VP]6;+7)90IR!-
M@&SR?`+)5!4!]EDL%)$IYI)D25E).\1"3)2$-"=RSO,Y)9]5G*3U<J844-=(
M2!,@*Q0$:&G-<#^@?F4E3U7<!IN5>MGK"LJQ84=-5[X*TG3).`7=$XF=;%9Q
MDL[+>A50!Z?*G#0!<LGS"21/50389G42V2L,9$^11!)2G-HJ?X[1VI\9$MZR
M+*%.09J`X\_M_!)_;DM_9HC<5JPZ>[F1HP8K4I#F6^7/;>G/#"G!I!FG-%91
MFD"5/[>E/S-D_-D6T#DJBW+4G]LJ?X[1)HM*?^8HL?%W"M*BD$N>O;3:Y*ER
M:3%$:R=G2K`%=([*HASUYY:,\WQ.R685)^F\R6_BF/TE!&>*C-*B./X<QO'6
M;FWMTY8.S9!>6\%6T#DJ*R9-6Q,FZSQ?L62T2C'IO:Q8`76MA#0!\LGS"217
M5038:+&@11K9"KH=HK(H$E*<QE4.':/UVF)(&DX)=0K2!!R'ON!>T+BT9X9,
M"MGR.4<-:BE(DZVR9WS60ENEG$&&E%JE/:LH3<#8,Q5%S82*HK?KC7%IU#TT
M'JK!90]AN"&_PMR415T?!6<8HIJ0*W!-V'CWV82392OM&)*$&3I!F*,TX5P=
M:\+DN&*1GDV8^IG)9D@29@A_!NT<A3E*$\[SH`F30QO"M(!.)`3U,G09DG09
M.D&7H_!G>%--R(6CINML&UR1G6!<;A)CAB1CADXPYBC-.%=NFC$9>KW`:1M0
M"<R0I,O0";H<I>GFFDK3):^OIYMV"$67(4F7H1-T.4K1;7*UH^A.JC:@&*W3
MEB%IJ274*4@3<#:@=KJXF>%-5MY/IF5G%A5#>A-J;!V3HX9-2$&:<-4F-"DW
M(8:48N4FI*(T`;,)O;UN)^76PY"^G]S8.B9'95'26.@(2',BCQ=9?X(3[PCY
MALW=)$%*E`+J5)0F@'21!&C?"!=]*C&AD4R.)\ADD2UEN*-X"YV"-%^L3LGW
MA&`4;3@E2+S:<E)`G8(T`?)@,6,DV$7W=R9LYG(R$V3TRB5**MZYHW@'G8(T
M7?)@0?>$7NS8DE."Q*LM)P74*4@3(%<5!')A4NM2;,^26X*,7KE"8KV&J+P@
M):3H3JM\/4;K_&)(ZE5"G8(T`<?7SRF5IZ6)]]`TE\H,T2W57/,TN41+5\^Y
MHXPZ4AE-JWP]1AO%V.HE3?;U#'5]QPAIQ8ROYQ7Y=K)/2X?OH?RZ2X:,8KGF
M8L5X+#B)T/5(J3.M,OT8;13C?4#29-//4-=W=!0SIG]"I]+8IPSE5ULRI'5J
M<_7$.@T=A4YMKBOTQ)(O"^LX03.YN"P%IVSLV3*6)=0I2!-PO#ZMQ4KOFI9>
MSY#VKM86$SEJ\"X%:;I57C\MO9XAY5VEUZLH38!L]?P)2R:L)HQ]&<L_+Z/6
M%@S3(2J+(B'%:59EZ#%:+S:&I"@EU"E($W`,?=I>4J?/2HMGR&21K1ARU""8
M@C3?*C^?L7GG)7;'D!*,_5Q\UJJB-`''SR^\0SLK+9XAHYBM&7)45BR-E=Z6
M)ESEYS,V;ZD8FW>69\E10L1.09J`\?-8Q(^@>:5-T;6C*9<9,G*9@F&9H[)<
M:2Q/KBI;GY6VSI#09EE"G8*T7(ZMTW5KK5JEJ<\29-3*A5,J2'-45FOH"$B3
MK3+U66GJ#"FU2E-749H`6:LP=4JNRSZ+G"63EH;/D!',5%?+')4%8\./2T;Q
MG5<9?HS6AL^0%*R$.@5I`L;PWRY;YJ6I,Z3O,[2YF$Q9E*,&412D.569^KPT
M=8:4**6IJRA-P#'U)DPOV0;GI:DSI--H;(K/98[*BATU]7F5J<=HDT:EJ7.4
M$+%3D%;,,_7+/JB<E[[.D%$L%^*<8]+$4P6?.UJGFE?Y>HPVBG&Y+K9!CE**
MR2BMF./KEU5:\]+:&3*"V7H]1^44.VKM\RIKC]%&L,+'EQRE!)-16C!C[2><
MJK3O.;LPG"#7ZV-;K^>H+,K0T6;1HLJ^8[06A2&AP+*$.@4I41;&OO/MA,KZ
M(`YDN"6S-TEDRW7N*-Y!IR!-M\K9%Z6S,R1>;5E"G8(T`>/L;R?1HC1OAO2C
M-V-;D>>H(8D4I#E5F?<B.;6L2Q@2S]DL2ZA3D";@F/<%)>:B-&Z&3`K9@CQ'
M9;6DEVNR5<:]2/ZKU)*6G'8.CA)9U2E($S#&?2*%2G->L,?"580/V;H[1V51
MAHZ%#U69\R)YK!(E07C(KW^U)4<)J%.0%H4LTM3=@3Y<JK6A9+6*&KLOW$C(
M9:ONQ1#5OX%.08IM&%7Y=@K7YMAC(F=PZHB&U<]V:<RP,.;]=B:%4?)CJ4V/
MZ8?>QK;Z%F&#.AHSQ*IL.M#%N[D2[S$M3XH3&$YE2<RP,%Y->]L%MA1&I8OW
M&#TDFI-J8FMP$29T2\.A*S##N,K)PZBT\AX3&B&M4IS`H)O$#`O'SB_[E#2,
M2DOO,;"1TMEB7(0)Z8ZZ>AA5V7H*MRNR-/8^3DLGXXQTQMLIY2X[:A)&I?'W
MF)'.EN4B3$C'WN]E797YAU'I_CTF9$+6I3B!(>LD9J0S.\`I,RN-/HS8PV$)
M8E':`EV$"7F&KL6BC`<_Q=9T@AB?$U4NJ\Z.II(AE!C.<TK_U_+$LYZ"Q>4W
MI@(?&]4,T]Y@,LO6ZGU7-:?]*50GL^+Y4$'ZE'3./J".F/;22<]/%^I!Q1GI
MS#YPBH5C]_W!42PBD5FV:@\Y+&>6P@RQ.KOGPZ-ZWMC&\_UU'!0N,&26Q`P+
MQ^XON^49Z(M$[$;.F,DL6\+W775F';?[>&:T(K.296OII(WWF55@D$YB1CIC
M]Z<RR[%T^O()*OET9MEB/N0PD5E#U]*SZBP=NI3SQE:M,JO`((_$C#S&TLFS
MFCF^Z:6ZK`]\XE1/('NV+B1L8=]WU9DU="VDB^=(S\\L/G:JB/5'4<6MO5!B
M.#U_W.YIN<CKH1.9%<--.<.8OK$^*4K[')8S2V%Z3FFX&F*.I<<AU%7.,I08
MY)$V;U@82Z?,"I<=#'>.KX;^9*K*K&E1W><P(5W:/:!@F5EU=L]'475FL8VK
MS"HP2"<Q(YVQ^U.9Y5AZ?T85\Y-WPVE1P><P(0];>OEP:(BG3"L6GF/IZJ`J
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MX$.Q>CU(D^_3KL"@G<3,#)+E&NTNN8/HG)T-^5BLW`F*PC^'"=V.[P3Q8*M@
M?,*#^1RLUDTZ?*];@4$WB1G=ZG8"/@RK6?!.H&N,HKAWSM$&A6EB\8CK^?+P
MB5A%3)V297E*#-_T=+RXCV=7!8NX$\0#HI6?=@0^!:L)\CZ`Z1'565'W]P=H
M\_4=.`]=D6Q&N;I]P#E62U]K&C>H_(KXBJP"BU]_FN,2B_1UING+-Y_7NZ_K
MY?KI:7]UO_U&7U5*.\?']P.>ODGU#N^&ODLUFDO9U@S?LUJTM1.TP:^@0=DV
MI;;X)'C9-J.V6).4;7-JB^^\;%M06_S"EZ)M/$(;4LGCTE`_E#U>6TO]4(RX
M;:1+^OBA>+V6=(&<;K^6VEJ_;4QM\11B,69#_7"MY(W94#]<K;AM-`^XB'#;
M:!Y0QKMM-`^HH-TVFH=4Q14\`_7#C1:O7Z!^:9F5_6@><(/"Z]?0/.`ZWVVC
M>4@7BL68#<T#+H"]?H'ZX:ZKVT;]<"_4;:-YP.U(MXWF`3<)W3::!]S&<]MH
M'G"'S&L;43]\`N2V43]\9N.VT3S@XP^WC>8!GR*X;30/^`S`:PLT#[B][K0M
MT`T?]3HM^.R51G1[X>-/:O-G842S@$\FW3%I%O"1HMM&LX!/YIRV!;KA$1"O
M!9WP;(;7@@G`LQ%>"^3'$PI>"\3'HP->"Z3'!_A.RQQ]\"R8UX(^>$C+:X'J
M>%3*:5E`=#RPY+5`<CP;Y+5`<#RTX[3,T0=/BGHMZ(-'.+T6:(W')[T6:(V'
M&+T6:(VG!;T6:(TG^YR6&?K@87*O!7WP2+?7`JWQ2+77`JWQ8+/7`JWQ5+'3
M,H?6>+;7:9FB#XZ>."TS],$!$*\%6N.HA=<"K7$&PFN!UCA_X+5`:YP"<%HF
M>*<X@^FU@/7$93T%:YQ#=/I,H35.17DMT!H'D+P6,,#)(*=E@G>*4]E>"]XI
MGFCQ6O!.<6C9:T&&X'BPUP+6.+?KM8`UCL@Z+2W4\>L,*C/\*H.**+^&&N.=
MHGQS7F>"T7"6WVO!:+B`<EI:J./7%BW4\2L+*M3\.JV%.GZ5UD(=OT9K,:=^
MA=:@CU]/-.CC5Q-4G/FU&95F?F760AV_+J.RS*_*&O3Q:P@J(?P*@@HROQZC
M<LROQAIH[==B#;0^4HFASY&Z`7V.5`W0^D@-!JV/5&#0VJ^_J/SRJR]T<7TB
M%@IN[J:RR\O=`*6/U%Q0^DC%!:7=>@N_`/')7568:'?ET#1[K&A!.?BG\;M/
M_`L3MNH$)=^%L&B=D>XPB:X#80I=_\$$1L^\'5X8ORSQNOJZ_L=J]W7SLK]Z
M6G_!Y=PHGI/8I=^F2/\X;%]QF8??E]@>\)L2\7\?\2,B:_S00?PX\<MV>^C_
M`7.Y'7Z6Y./_!0```/__`P!02P,$%``&``@````A``L)&H"N!0``6Q8``!@`
M``!X;"]W;W)K<VAE971S+W-H965T.2YX;6RLF-N.HS@0AN]7VG=`W$\XA(0$
M)1EUPEF[TFHUNWM-$R=!'4($]&'>?LO8!NS*M#HS/1=#YTOYQ_6[#!6OOKZ5
M9^V%U$U17=:Z-3%UC5SR:E]<CFO]GV_AEX6N-6UVV6?GZD+6^G?2Z%\WO_^V
M>JWJI^9$2*N!PJ59ZZ>VO7J&T>0G4F;-I+J2"WQSJ.HR:^%C?32::TVR?3>H
M/!NV:<Z-,BLN.E/PZH]H5(=#D1._RI]+<FF92$W.60OS;T[%M1%J9?X1N3*K
MGYZO7_*JO(+$8W$NVN^=J*Z5N9<<+U6=/9XA[S?+R7*AW7U`\F61UU53'=H)
MR!ELHCCGI;$T0&FSVA>0`;5=J\EAK3]87FK-=&.SZ@SZMR"OS>AOK3E5KU%=
M[/\H+@3<AG6B*_!854\T--E3!(,--#KL5N"O6MN30_9\;O^N7F-2'$\M+/<,
M,J*)>?OO/FER<!1D)G8WC;PZPP3@?ZTL:&F`(]E;=WTM]NT)_G)U[9$T;5A0
M*5W+GYNV*O_C7]+)](-M/ABN?+!M35S+7$Y=F,('11PN`E<Q@\EB-G/FBSM$
MX'9=&G#E(N[](K`G.A&X_OQ,EEP$KG?/Q&"+TZVUG[799E57KQIL(%B&YIK1
M[6AY%M2(6&6V-OVZ_VC98<FHR@.56>N0'JQL`[7ZLK%=<V6\0'WE/&:+8RPY
M8B<B:"5065\%@0I"%40JB%60J"`=`0-LZ;V!XOL,;Z@,]49DM15@9)9BA(@0
M0WP5!"H(51"I(%9!HH)T!"0CII]C!)59Z_#_J$B4$MBR&/JDZ(/FBCE]2.\.
M(@$B(2(1(C$B"2+IF$@FP5/F,ZJ%RL!F?'\K\:#W7.I#>I<0"1`)$8D0B1%)
M$$G'1'()'J.22[??)N*Q0J,[,T026T[@&=C7A^W:2H7T06*8CTB`2(A(A$B,
M2()(.B92[O.[<J?1<NZ,V-UKNWL^[A#Q$0D0"1&)$(D121!)QT1*%.KRCD6F
MT7*BC-CP7!XM\E19Y#ZH7V1$`D1"1")$8D021-(QD7*'C7M'[C1:SIT1R%VD
MM4/$1R1`)$0D0B1&)$$D'1,I4=B"4J*L<YC0UJH]%?G3MH+%@R6\L<.GT"&P
MOH&*R/ES8@_Y,V([/?$9F<'K:E0?CEP?01\DC`P1B1")$4D021EA$Y(LH0W4
MKWO2J<BF"#1RA:.Q+1S-J+W0@)F6LF6"(:#W!,M$&,7#0*ZL/'&3(4`HIY*,
M;!-MN,9-YXT2@9\4HD8LUI_!*U%H;SF:PFMF5`$SN0)V(FK>#_0%@NT[&JAT
M&(&(6G1&SFUK[BYE[5"$N+UV)-!PNUB@=V^7B"AV.\NR'7>JW"\5,=W]9#=I
MUW:'FZS)D]QDR('J'9GBRAGO+!XUU*`OT+`U`X'H\D$-SLREHU1A*$*&49%`
M@W8LT!"5",2TIPL3_LF33$5(-TJVB39N8YM^ZGEE\?9O7(L,*;6XD">VXP.G
M0W'X'#E#"04"\4IPS>52J<U0"`VC(H$&[5@(#5&)0*+*3,=5FN]4"-TH,MK0
M_;I[O"T<N\>0`\_44>TIU;^S>-10'SY',[EH%;<"$65UY6B9SG1N*4L3"O&A
MTB*!AOO%0NG=^R4BBM]O;LUL"]4H3^9&C=+6\3V7OU77'[U3QP],WH&.;6;(
MAK?Y8/-"F=F.'N_`ZQBBQ)/6QRC`*,0HPBC&*,&(GFD-DV!;F)U1L7.+DM1'
MLB/G<Z/EU3,]?P+/-ZL>L\.Q[=R#]A2R4+GK0>MV@R\\Z'1N<&LF3MD4)7_I
M06N`1_B6Z=$7+?X&WJ(>?5'B;^`H[Z$K->4>6WK$=R-^:WOP6QWK;*<>_#[%
M_,'Q'L!6_,76\>"GV@T.67?Q1C\C.-J[9D?R9U8?BTNCG<D!K#>[=J]FAX/L
M0\M+]+%JX7"OJ]83'.(2.,XQ)["TAZIJQ0>XL=$?"V_^!P``__\#`%!+`P04
M``8`"````"$`[S(>1Y0"``#"!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6R4E5UOVC`4AN\G[3]8OF\2YQ,0H6JINE5:I6G:Q[5)'&*1Q)%M2OOO
M=VQ#2L*T,2X@QH_?\YYS;&=Y^]HVZ(5)Q4678^(%&+&N$"7OMCG^\?WQ9H:1
MTK0K:2,ZEN,WIO#MZN.'Y4'(G:H9TP@4.I7C6NM^X?NJJ%E+E2=ZUL%,)61+
M-0SEUE>]9+2TB]K&#X,@]5O*.^P4%O(:#5%5O&`/HMBWK--.1+*&:O"O:MZK
MDUI;7"/74KG;]S>%:'N0V/"&ZS<KBE%;+)ZVG9!TTT#>KR2FQ4G;#B[D6UY(
MH42E/9#SG='+G.?^W`>EU;+DD($I.Y*LRO$=6:Q3[*^6MCX_.3NHLV>D:G'X
M)'GYA7<,B@UM,@W8"+$SZ%-I_H+%_L7J1]N`KQ*5K*+[1G\3A\^,;VL-W4X@
M(9/7HGQ[8*J`@H*,%R9&J1`-&(!OU'*S,Z`@]-7^'GBIZQR'&48;IO0C-U(8
M%7NE1?O+39*CA%L<'A='X/HX'WKA+"%)"L'^H>([)S:Q!ZKI:BG%`<%F@9BJ
MIV;KD04H_SD32,&P=P:V2\"L@NJ_K-(X7/HO4++BR-Q?,A-B?4E$[X@/O@9S
MD/+UY@R<8\AA,!>E$V\.B<^0";'^&S&R!G&NMV9@Z/5YW#B:>'-,ZJH:DC2;
MCX'U.4!(&&?1.S&R!OE=;\W`4VOQ./*]8S)K+4R"^=3[^AR(9@%\!H61,]BF
MUSLS\-19,NC:#7GO&.>,9,%\/NWG""!!G)%!8>0L_1]G!AX[N]AI#G'=A+!1
M2F9#8&L=KBDC<B12DH1D6C1W#;G3VM,M>Z9RRSN%&E;9*R:#Y*2[A`+/#+3H
M[>G<"`V7B'VLX5W!X.@&'LQ70NC3P%QSP]MG]1L``/__`P!02P,$%``&``@`
M```A``&,5CC1`@``+P@``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
ME%7+;MLP$+P7Z#\0O$?4P[)CPW+@-$@;H`6*HH\S35$2$4D42#I._KY+4E:M
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MH=K0)]N!G92/%OJ0VQ`<)F>G[UT'OBN4\X+N:_-#'KYP458&VIV"(VMLE;_<
M<<V@HD`3Q*EE8K*&!.`3-<*.!E2$/KOO@\A-E>$D"F9QNKB.`(]V7)M[83DQ
M8GMM9//'HYRE@27N6>#[R#(/TD683"`A/B-G\(X:NEDK>4`P-2"I.VIG,%H!
M\65'8,5BMQ:<89AJR%5#&YXV:9*NR1.4CO686X^!SP$3#0@"HH,RJ$U7MF"K
M;&MK4[GU@5.9^+),\AX9"X;FG"2?)O.!URM[S.P$\P\Q,@B0Z08M&'KP=FT]
M:((T#-5T:0MVTD-Q^PB\)T,3TV0QU&'D<OX>*0L>2_41-^DCWL68U[YR\UD`
MF;T]HO;86*&/P,"<F+F^;,8N[,EO@P6/I?I([);)Z:POQ[Q^?R3!XK]V[,&Q
M1A\9VUE>MA-!!Z?[<>BQV#%T[@C6[8C:60KC"9;<R5<R_=(8F9J%KTSY]>RW
M5\-5R3_QNM:(R;U=O3'LHR$Z7`M;E_GK^&RU]=<%&?Z!==W1DG^CJA2M1C4O
M@#-T=I1?^/[!R`YRAYTM#>QI][."BYG#3@KM=!92FN.#O5*&JW[S%P``__\#
M`%!+`P04``8`"````"$`["8=.%X*```,,P``&0```'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6RLFUMSXK@2Q]]/U?D.%.\;L,%`J"1;0[CX?JMSSCXSQ$FH
M`9P",IGY]MNRU):EUGKB/?LRD-^T_MUV2RVK@;O??QP/O>_%^;(O3_=]ZV;8
M[Q6G7?FT/[W<]__[G_5OLW[O<MV>GK:'\E3<]W\6E_[O#__^U]U'>?YV>2V*
M:P\43I?[_NOU^C8?#"Z[U^*XO=R4;\4)_N>Y/!^W5_CS_#*XO)V+[5,UZ'@8
MV,/A9'#<[D]]KC`_?T:C?'[>[XIEN7L_%J<K%SD7A^T5XK^\[M\NJ';<?4;N
MN#U_>W_[;5<>WT#BZ_ZPO_ZL1/N]XV[NO9S*\_;K`:[[AS7>[E"[^H/('_>[
M<WDIGZ\W(#?@@=)KOAW<#D#IX>YI#U?`;GOO7#S?][]8\]P>]0</=]4-^M^^
M^+@TWO<NK^7'YKQ_"O>G`NXVY(EEX&M9?F.FWA-#,'A`1J^K#*3GWE/QO'T_
M7//RPRWV+Z]72+<#5\0N;/[T<UE<=G!'0>;&=IC2KCQ``/!O[[AG4P/NR/9'
M]?JQ?[J^WO='DQMG.AQ98-[[6ERNZSV3[/=V[Y=K>?R#&UE"BHO80@1>4>3S
M@\=B,+R*P=;-S''&D]GT\R)@65T&O`J1R8T]<RQGTN$R)D($7NM(NMX*6%=5
M(/!::W2^FELA`J]__VHLF$L\M6Q2B;1U3JV%N65O:I7.5V2-,!AX(V2<F['M
M3&==)IJ%DX6]J:/IFB,+$\W>U"K=KVF*UP1O_H]KPBEC->?,)Z]IP)=S51V6
MV^OVX>Y<?O2@Y,*"O;QM60&WYDP8ZP)?Q76E^*M"`16"J7QA,O=]&`\UX`+5
M[?N#XXSN!M^A(NV$S8+:6*K%(UJP\L-DESI8Z6"M@XT.7!UX.O!U$.@@U$&D
M@U@'B0Y2'60ZR!M@`.FI<P0KZI_($9-A.<*[NT`@DV9K"4$+'++4P4H':QUL
M=.#JP-.!KX-`!Z$.(AW$.DATD.H@TT'>`$I"H#:1A(R@>IHW4UPC;!1LF\H:
M&:LW?,%M+"@4]4*:J":/M4F=%$)6A*P)V1#B$N(1XA,2$!(2$A$2$Y(0DA*2
M$9(WB9(C*/PD1^R!IV-A8S)0&]LKFS!JRUIM4F>-D!4A:T(VA+B$>(3XA`2$
MA(1$A,2$)(2DA&2$Y$VB9`T2I&2M?44QZRHY>%,7@L`#4;U^',?15E!MA,.6
MA*P(61.R(<0EQ"/$)R0@)"0D(B0F)"$D)20C)&\2)1?PT-,A%\Q:S04G-C\"
ML.W\D9`E(2M"UH1L"'$)\0CQ"0D("0F)"(D)20A)"<D(R9M$N?%01SK<>&:M
MWGA.;+5FZ=M(;50O`D)6A*P)V1#B$N(1XA,2$!(2$A$2$Y(0DA*2$9(WB9(+
MN(D=<L&LU5QPHN3"G@VU@E0;U;D@9$7(FI`-(2XA'B$^(0$A(2$1(3$A"2$I
M(1DA>9,HN8"JKN2"GU5NV/'_^KK??5N4O`-AV#1&<";A)Q4FHJ:(DUG5/ZEL
M'CFQQ_6C\I(3!QX(&_O*5$WCJC;"-*X)V1#B$N(1XA,2$!(2$A$2$Y(0DA*2
M$9)SPF^0DB+63*`YFK*>4H<<52IJDA`-P4$C!3,U!8_"K)FZ>J3<B%:"C>#I
ML2%VJXJMA=5L6L^##=5W#?J>47^B+7N?Z@=4/S3H1V9][3@=4_V$ZJ<&_<RL
MKYT.<T5?G0;L*-ML*QB6)$P)7),6/_G"4S:NG(5`4R7=$ZVE\"BL1I-ZX!(1
M5/0ZM?94V_U6:#6K>A66,]+6\AH-FKGG43:<N=*JQ9F'5MR9/9QIB?+10#H+
M$,DK"Q&U7EF$5L*9?:L]_<9H()TEB*2S%%&KLPRMA+.9GJ`<#2IGZA1AA^L.
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M:IU_*R&OE0.MVJR%U:BIU9Q_U0%D@U9R$;B(F@/)KN49@YAJU<8W:9$@`K22
M082(6H.(C$%,M#L1F[1($`E:R2!21*U!9)\*(C=I-8-0IR#KV'28@KS!HSRR
M-'L^_*S)/EN$6=EHDRTI6E&TIFA#D4N11Y%/44!12%%$44Q10E%*4491KB`U
M%Y!])1=_JQG`/FC1*S9'S7:`L%(.E=Q*;0A,M>?ZE1@(5EC]UQ1M*'(I\BCR
M*0HH"BF**(HI2BA**<HHR@4RM0=8;Z>Y@JJL=6X/\`Z1LK`$^E5[@)LIF<21
MS?8`9[]J#W`KI3U`]%V(LIIB0ZGO":;JT_8`T0_$P$;\H4$_,NMKLS,65HWX
M$ZJ?&O0SL[YV],H5?77QLOY1<QK\HCW`VTV@A\MH87&D[>6D/<"ME+U<(%B_
M;8<_;@5[.3O\36WMTM;"/>SB&-$&D=RH7$2MOCQA)7S-+&V?]*4*^@H025\A
MHE9?$5J)ML=P1)[1Z]N#SA(<(YVEB%J=96@EG-EC;0+F:$";`[;>1FR?()6Y
M^N`M4'MS0!@UFP.(X(F\97X(*W@Z9_-C---NXUJJX&W<())[@8NHU9>G^AJ/
MM1.-+U705X!(^@H1M?J*5%]36YN+L51!7PDBZ2M%U.HK4WW=#K4'\5RJ@"^E
M?,"S4I?R49EKLX.W\I3R01H#8ERS>B!JG?@K8:6>!*9Z#3%I-1\]^4D`K>3J
M<Q&U!N&9@]`JI&_2(D$$:"6#"!&U!A&9@]!:)+%)BP21H)4,(D74&D1F#D)K
MD>0FK680Z@QDO;_/;V`V;Q4V-S"!FHT!@91J1'J,*V'5;`S@0'FTWB"2J])%
M)*T\JN53JP"1U`H12:V(:L74*D$DM5)$4BNC6KEBI>:B6YL0OF2M/_(+I%0#
MVA@05DHY$*W#UOFW$@.U<D"V#(-6<_Z)<B"LY")P,:[6(#QS$&0O^4P0`7J4
M082(6H.(S$%HA3\V:9$[D:"5#")%U!I$9@Q"[TZP[^*S:?*7?1H^!?G7[?D7
M:H_%^:5X+`Z'2V]7OK.OTD.O\>&NQOQ[_HOI'+YL`#N:SF=S^.#;P*W)G!V#
MZ?\L;^?9K8E;TSD[E=$1\!N#+]7"TWW#;P^JTXG.;?A-@D%G,9KGU4\5-/LO
M8]`W_<=B/,^KY:T-6#AS^/H1#70!UUQ=\J`>`+]%>-N^%-'V_+(_77J'XAEN
M\+#Z[/_,?\W`_[B6;W#CX1<)Y15^A5"]?85?G1300!W>0!_ON2RO^`<X'M2_
M8WGX$P``__\#`%!+`P04``8`"````"$`D3JYV*49```,A0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6RLG<ER&TF2AN]C-N]`X[U!+(F%-$EM(I#(
M?;6>F3.+@B1:B8*,9"W]]A.!"(>'^Y\%$NJJ0Y'ZX/Y'1GIX+`X@^>Z??SY^
MN_A]]_3\L/_^_G(R&E]>[+[?[S\]?/_R_O)__K7]Q^KRXOGE[ONGNV_[[[OW
ME__>/5_^\\-__]>[/_9/OSY_W>U>+HS"]^?WEU]?7G[<7%T]WW_=/=X]C_8_
M=M_-*Y_W3X]W+^:?3U^NGG\\[>X^'9P>OUU-Q^/%U>/=P_=+IW#S]!:-_>?/
M#_>[S?[^M\?=]Q<G\K3[=O=BKO_YZ\./9U)[O'^+W./=TZ^__?C'_?[QAY'X
MY>';P\N_#Z*7%X_W-]F7[_NGNU^^F7[_.8GN[DG[\`^0?WRX?]H_[S^_C(S<
ME;M0[//UU?654?KP[M.#Z8&][1=/N\_O+S].;OK%]>75AW>'&_2_#[L_GH/?
M+YZ_[O](GAX^E0_?=^9NFSC9"/RRW_]J3;-/%AGG*_#>'B+0/EU\VGV^^^W;
M2[__(]T]?/GZ8L(]-SVR';OY]._-[OG>W%$C,YK.K=+]_INY`//_B\<'.S3,
M';G[\_WEU#3\\.GEZ_O+V6(T7XYG$V-^\<ON^67[8"4O+^Y_>W[9/_Z?,YIX
M*2<R\R+F)XE,6>2$8^0=S4_ON!BMYO-HL5J:UD\XFE</EVU^4HOST70UG\P7
M]KI/>"Z\I_GI/:]'DVC\FMO2NYF?U.#;NF@2[7"EYN=Y7;SVCN8GM3A[TTV=
MF$%T:-+^<DX?)S08["_4YMMZ.3'CQ[7)`^F-H9S0Z+&_4*MO["F-GPD/H#=%
MTV:(N]Q@`+VQIS2`)CR"WMI3&D238!2]<=A.:!S97^@NG;SB*Y?IAXEC<_=R
M]^'=T_Z/"S,;F^`^_[BS<_ODQJK1E.&2YCB)_-4<8B8/J_+1RKR_-/YF>G@V
M$]_O'Q;CV;NKW\UD=>]M;M%F(BW69&%G)BN[T2#68*M!HD&J0:9!KD&A0:E!
MI4&M0:-!JT&G01^`*Q.>8XQ,%OT=,;(R-D9T=V\)<-"F*B!D02X;#6(-MAHD
M&J0:9!KD&A0:E!I4&M0:-!JT&G0:]`$0`3%ST]\1$"MCEM@@:6:KN8S`K;.Q
M<P1GEC19'TV.40(2`]D"28"D0#(@.9`"2`FD`E(#:8"T0#H@?4A$T,RJ\'<$
MS<J8R5).=9$,R:TW.A6UH\DQ:D!B(%L@"9`42`8D!U(`*8%40&H@#9`62`>D
M#XF(FEF21=2&M[*T#%GK0W#HIMXZ<FWTC_D339<R7.NC$;EM@,1`MD`2("F0
M#$@.I`!2`JF`U$`:("V0#D@?$A$+L\<Y(Q;66L;"D6F8.M/56,7B:'2,!9`8
MR!9(`B0%D@')@11`2B`5D!I(`Z0%T@'I0R)B8:86$0N[;YO.1R9VL'-[^?IP
M_^OMWAB8#<9`_LS,?LWMXJRH#)DCR\.9]6"S=F0V/6XC-M[+;H&#'%O)N,9L
M18'=@E0")&6W4/Q:BF=L1>(Y2!5`2G8+Q&=J1%9L1>(U2#5`6G8+Q=66MV,K
M$N]#*1%SDS@BY@.Q-.=="J:UEL%TQ!0@P@O26SYG-'/E@<,FW!,>`[$C2S.<
MC@&?KM2DN@6W!*13L,F.TG0[<K`I0*<$FPIT:K!I0*<%FPYT^M!&A,?<US/"
M8ZUE>#P9BSR:J5/4VEE%KN9RB(\GLV-&QJ2T/)S$9N/Y<J'7O"UX):"<'FV"
M."\7*O><T=+.(K]_&(]FZO7\*$(1+:"A$FPJH;H<J82OP:$!T?9H<^+J.V<T
M&?M;%:UFBVN5H_U1R/1`1-S65,X(^<%<QIS0V(RJ8RY%,[6?7'NS,"L)!6GI
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M*MDW`LQ8$8GK$0_@V%M-S)IA=S"3Y6PVG8_5(6!+6NR8$.+\2`F).0!'@;L(
MD\J'!D=3->/D+,.C`/I2HE7ED5>.1NJ.U.C2$.)>M(1.]J+S5G3?9I/5]60R
M5_>M9RT8!K;.<,8P<&4)4WBC>W)KW[@YS`5RQPR;)V<FY@*/.(%B+R96XFBF
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M6]$V<SH9V_]D]6E+4NR7$.*42`F%D\!`+KMK\+D\'2U5;31G&8I?08@;*PGQ
M)54>>>5HI);U&ET:0BS<$CK9B\Y;T6V;3P>VLSU+Z4$P/:^F=3"7@X"06J_5
M.%Q[LS#]"7$6QQZ]LEZC8T*(LR@EQ/(9RU-$<[0J"+%628BU*M2JT:HAQ%HM
M(=;J4*L75B)OI^?5M`[F*F2^S*7R5F^QO&>8MX1XL,<>F<'.ZS(60M`Q(<1#
M/B7$\AG+<\BPID6.K%428JT*M6JT:@BQ5DN(M3K4ZH65#)DMW81K[$]ML::N
M`&1F=+H5MX14\NDMEC<3R>?$PIK64<Q,C,<MUD`HH0Z5H'Y*B$=YYI%);KK^
M'*T*0IPQ)2'6JE"K1JN&$&NUA%BK0ZU>6,E0FG'^-X32JJBD]$B6NB+U[L1Z
MZLQ$4GI/4XBC&QM[LXFIRQRJ#M%T:!]%8CRN$T(<I)20:8:'!90YO)5?]":C
MI=JTY2Q#5UD0XL9*0GQ)E52>P;M#Z-(08N&6T,E>=-Z*EM-H=3V;+I>JWMBS
MENF*'!ZV<*,S?;KDZO6_]C],W,V=?//;]%-7"Q)I[Y#:<:O]R]H[BJSW6J9.
M0T&(2=\<Z@]#9;9<1,N)WGF1&.=-0HBS*R4D9A`<*NXJCEONE1KD.<O051:$
MN+&2$%]2Y9%7'A@JKN6@'M^0"@NWA$[VHO-6M/\V'UR/QO.Y&O4]:\%0L=4?
M/50F<QPJIP]D]C/O;BKA[%R,U5I^2U;F2'G,85@EO-+R.#8V[$:!B!%M$26(
M4D09HAQ1@:A$5"&J$36(6D0=HEX@F?*V>A3&\95XN6*32&>'[/[A&)PH@AWT
MT8IBL9D"BA%M$26(4D09HAQ1@:A$5"&J$36(6D0=HEX@&1Y;13DC/*[H(L+C
MD`D/W?CU%-`&48QHBRA!E"+*$.6("D0EH@I1C:A!U"+J$/4"R5C8NDD8BY_;
M![OJBPB10^$GU^P'#VV]B3=%&X\FIA9J5[KI>*)*%7%@0;'>HE""*`T\O;9:
MCK/`@K1S%"H0E8&GUU8+9A58D'8MA&08;.4C#,,K,Y8U5YM5A]0&1"TZZZFS
M$AL0C\R/XU0'I9G8._IE?#I:J3AM29F7_H00K^,IH9.-9;JQL:DW!O^IXDW.
MHG2G"T+<=$GH9-.5;'H\FJ@EN689TYB(X>R\PLW!7,:0D#IPJ$M8>[/PP$&(
M]^BQ1W.SA3C&-8K4OGG+CJ&5NL,)6?%\FQ+B%K/A%M7V*V?'$RT69,4MEH2X
MQ6JP1?T6:,V.PRW**-I2QMLS<>8J'^',YY',Q+F:'];>*LQ$0IQ"L4=SLTGF
M(,[5/+9EQ\`J@B"Z2PU:3-F1,B<;;E%E>\Z.)UHLR"K(0D+<QVJX1;77JMEQ
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M'6L4=)=O32+965"<>1=CM6%8LQ4Y;A#%B+:($D0IH@Q1CJA`5"*J$-6(&D0M
MH@Y1+Y`,CZT+A'GV2GA<&4%L*Z"RL)X!VB"*$6T1)8A21!FB'%&!J$14(:H1
M-8A:1!VB7B`9"ULJ"&/Q4V?>F2LXB!`YM#H\),1]6\M;F9HCIXNSFD__ZLCK
M?8P!^6Q1)D&4LN-?''C9@)1SE"D0E>SX%\==-B#E6LC(`-A"0!B`5Y+!U0W$
MG79H:8Y<QX4DBF`I<59F)-!%;68><44U]DCNL?5G3K;L&+8(>VQH,65'NHAL
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M2R4A;JDZV5+-#L,MR6"=5V$P-QN"Y5#X'H:W"M`&48QHBRA!E"+*$.6("D0E
MH@I1C:A!U"+J$/4"R5CH@L-/GF'MEPK<$L4#8#%6\^LM69E=W''5@A3S2CP[
M;-B-5I`8T191@BA%E"'*$16(2D05HAI1@ZA%U"'J!9*!U,6(T_M"L_Y#4CFT
MXOK)VEL%:(,H1K1%E"!*$66(<D0%HA)1A:A&U"!J$76(>H%D+,ZK)T183_#(
MONEU3)1(?Z1WS5:4%QM$,:(MH@11BBA#E",J$)6(*D0UH@91BZA#U`LDPW->
M/<%\J!!2!8H':V\EUA^PBM%JBRA!E"+*$.6("D0EH@I1C:A!U"+J$/4"R5C8
M`WUX$K+KSW_\+)C(E0G"4Z]'X7OJ'IEJ/*>/=[3?+PH23[V%$Y.^,2/7+:HE
MB-+`,VA@JO;I66!&#>2H5B`J`\^@`7@N3&!&#=2HUB!J`\^P`?4>71>840.]
M4)/#P)[]PV'PRNKE2@4BO@Z)^#HDXNL=QQSS./+,?*F(KG1+++!+/`ODT@&S
MC%@@EQ,+Y`J4*P?,*F*!7$TLD&M0KATPZX@%<CTQ)R?C8@_J9\3%G>M%7!R2
M[T?-U+NPZ\A9F1HPA6!#B-^[B3TR[T?QR,-/=*-C0HCE4T(LG[$\742.5@4A
MUBH)L5:%6C5:-818JR7$6AUJ]<)*1&RNJQ)!@?9T4AT\98&"D/AJQ6*L9JNU
M-S.'0+IQ&T+\OFA\%',/+)B,%ZOI=**."%MT3`BQ?$K(G!6.TS1\\";S5OX-
M7OQ`2LXR=.$%(6ZL),1]J:3R<J0.,36Z-(18N"5TLA>=MZ(/<4^BR6H5K53%
MLV<MTQ4Y(LZKC<RQ-D)(?2]#7<+:FX5)3(A'<^R12.)HJ<JI6W;D`.,W7\F*
M\R<E9":44R/#=9+>V1Y-U)#.689'AO,)NE>B5>6142;'&JT:0GSA+2&^51UJ
M]<)*AOF\JHIYAT3O:@F);(]F*C1K;R:RW8F9TREU.O96KWR1BK38,2'$-S`E
MQ%89RU.+.5H5A%BK),1:%6K5:-408JV6$&MUJ-4+*QDR6^H(5]=@KG[[-RKF
MOF`2?`B$D$I8-4NMO5DPHC<>F0T[W=?X*"92"AZ91V(\?A-"/,I30FR5>11D
M3(Y6!2'6*@FQ5H5:-5HUA%BK)<1:'6KUPDJ&\KSRBRW3JW=T",E/3<'#@;R9
MR#XG)K+/Z_M'PTW&\^OQ9*'VZ%O2XO&;$.)1GA(ZN4IEWNK$6@M769`R-U82
MXDNJI/+`6@O"#:FP<$OH9"\Z;\5K[7AAOC^D%H>>M4R2R&%P7N7'OAVEAX%'
M,G7UEX[6WE.DKO,T[V%QZGHQ_WB@N7D`@7D\D/H6.DFQ7T*($R0E)"8!?5F9
MM_+KJOFHLVPK9Q6ZQH(0MU42XBNJI/#U:!%\IMG\J@[H-2HTA+B=EM#)/G7>
MBKX999ZQM)SK\W3/4C`D;!4HG.1?V86[HE%XA#(/#CF,$K4NP_;+F8F9P2/.
MIMB+B74YTE\)W'HK6VX^[J(&ME_08CKD.+`Q=XX\6:CXY2S#XP0:*]&J\L@H
MDV.-5@VA<'Z`6]6A5D^.!WF9^;J0]4J8L4(U]TAF/FZ_G)G(?(\X7V(O9A*1
M`XA'96\53!D)(4Z3E!#+9RQ/MSE'JX(0:Y6$6*M"K1JM&D*LU1)BK0ZU>F$E
M0V8+/V%F_MSVRY>/PNT759G,F#JF3Z0?+KN>.S.1L`Z984;W-?96$_FHH*6:
M6;<D]DK&0I,I.U*3F4=!$N5H51#B)"H)<?95J%6C54.(M5I"K-6A5B^L9'3-
MK"ZB^TI"6G-5_7!(EJ[@24!S9R7RT2,>F+&W.BXB,_.DOF@%003'!.530L;X
M.+H&YEBGY9?BR6@RETNF7IFAZ8+:X90K"7'/*H]\.^:[X5*X1I>&$`NWA$[V
MJ?-6=!>GB]4XFDQ4BSUKF1$MQL1"%\=.CXF#N1P3A.1:K/=!:V\6IC8A'L_Q
M4<Q5Q*9S\P!G6(K1+R'$V9(2"M,?QX2W\NON;#13)X*<96@R*`AQ8R4A[DHE
ME:]'J\/SCH[_4R&J4:$AQ.VTA$YVJO-6M&>/KJ?C:_T=_)ZE8$S8LDZX"KPR
M)EP5*-R?+3Q2"[?>GWFS<*(@Q.D4>R06[D@_?6++CCP%X/Z,K#C/4D+<8L8M
M4LQSM"H(L59)B+4JU*K1JB'$6BTAUNI0JQ=6,K//JWXML/I%2&8V;+^\F<AL
MK'YY*Y-H')](_[F0+6F%5@-1]/*<&"D[4L@R;I%0CE8%(=8J"87)[%H,UO\:
MK1I"K-428JW.HT"K%U8RBN9.B%S\J1W9PJJH:=LCE:*Z(.8]18HZS[`@1OKB
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MO]L>0X&-57BD.)>@+R5:51YY8?.7<]4V'ET:0MR)EM#)3G3>BK;QYN^6V`>C
MJKIDSUHP4FRM1H^4\Y\UM'`E'[&5<RCX%-?:6P5H@RA&M$64($H198AR1`6B
M$E&%J$;4(&H1=8AZ@60VVYI4&*-7MM6^^!5FJD/!C5\O`&T0Q8BVB!)$*:(,
M48ZH0%0BJA#5B!I$+:(.42^0C(6M^H2QL`OO=#7X!]=>"9.K'XF4<6@E:ETK
MF%"/5C0O;>Q7+<PVS3@2BA%M$26(4D09HAQ1@:A$5"&J$36(6D0=HEX@&3DS
MD8K(O1(>:ZYVO@Z)+`*TL<NA<0RL8D1;1`FB%%&&*$=4("H158AJ1`VB%E&'
MR/Z)>[X3+A;N3]:[OSS]N'OZLEOOOGU[OKC?_V;_'+WY4M*'=T=\\;3[_/[R
M=K&XL7.C&=CPRM*\<OBD(;RR,J\<YC]XY=J\<M@]J%<^SJ*;C^;+'0/MF%?L
M-]Z'7IF;5PYKME*[G9FK=E\STZ]$TQO[)1)4^QC-;CX.7IOYLH?Q.>Q%0<U<
MF_GT/*K=1N;:S`>WAUXQU^8.84K-?"#UQG[:%'T^3FX^#EWS[>2F/^QNE=*M
MZ>2@O>G(4#\^FIOOOIRLA6S_!B[HUO1NL'-VM`S8?YS.;SZ:1U)@US:SY4UL
MOB2,KY@O,M]D@Z^8+R+?5(.O;,PMM)]I'E`SK]@/(^,KYH/&-]7@*QLC-N21
M&JDA7AJA(=Z:N`YQ\^"S&_MH,[PF\]BR&_M@,GS%/'3LQCY6#%\QSY(T41^,
MRM2$Q3R);\C')+%Y+IQYY>H8^N</[W[<?=E5=T]?'KX_7WS;?3:3P_CP_,NG
MAR]VQ77_>/&/3/UE__*R?S23M?F[];N[3SOS)^/'=D7^O-^_T#]L`W_LGWY]
M_KK;O7SX?P$```#__P,`4$L#!!0`!@`(````(0`X$(:3F`D``$8L```9````
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*R:6W/B.A+'W[=JOP/%^P%L;&Z5
MY%0`WR^UM75V]YF`$Z@!G,+.9.;;;\M26Y<F#IDS+R'\W/JWW5)+:N&[/W^<
MCKWOQ:4ZE.?[OC48]7O%>5ON#N>7^_Y__O+_F/5[5;TY[S;'\ES<]W\65?_/
MAW_^X^Z]O'RK]D51]T#A7-WW]W7]NA@.J^V^.&VJ0?E:G.'*<WDY;6KX>GD9
M5J^78K-K&IV.0WLTF@Q/F\.YSQ46EULTRN?GP[98E]NW4W&NN<BE.&YJN/]J
M?WBM4.VTO47NM+E\>WO]8UN>7D'BZ7`\U#\;T7[OM%U$+^?RLGDZPG/_L)S-
M%K6;+T3^=-A>RJI\K@<@-^0W2I]Y/IP/0>GA;G>`)V!A[UV*Y_O^H[7(;:<_
M?+AK`O3?0_%>*?_WJGWY'EP.N_1P+B#:T$^L!Y[*\ALSC78,0>,A:>TW/?"O
M2V]7/&_>CO6_R_>P.+SL:^AN%YZ(/=AB]W-=5%N(*,@,;)<I;<LCW`#\[9T.
M;&A`1#8_FL_WPZ[>W_?'DX$['8TM,.\]%57M'YADO[=]J^KR]#]N9`DI+F(+
M$?A$$7O@V.YTUJATM!R+EO`I6LX']LRUW`ESW]'0$0WA4S2T!C/7=2:S:7=#
MN-H\,'RV'F^ZU8EH")_XD`/+&7UVHU/1##Y;?S<](61H<Z/P^;4GG(N&\"D:
MSF2/=H34@L''QP(;A6(PW/*(5CN(X)^O/:2%0X?]\[7'M'#LL']$T^E-MXMC
MQY*#9]S1<,A3ILG`]:;>/-Q=RO<>3&OPM-7KADV2UH)I8>[Q&+?9^%$R0A8R
ME4<F<]^';H8\JV`&^?XPL49WP^^0]5MALZ0VEFZQ0@N6XDQV;0+/!+X)`A.$
M)HA,$)L@,4%J@LP$N0*&$-HVOC`D?D=\F0R++T9FB4`&W#:"B1;89&T"SP2^
M"0(3A":(3!";(#%!:H+,!+D"M&!"DOR.8#(96".4P>K,9GKTEMS&@AE/CFC=
M9-6:M!$FQ"/$)R0@)"0D(B0F)"$D)20C)%>)%FR8#'Y'L)D,3"[ZU&`D_E(8
M=46[-6FC38A'B$](0$A(2$1(3$A"2$I(1DBN$BW:L)1KT;Z^]\'IEEDW0<5@
M+#FQ81IJQZLS'QLCMC7"9FM"/$)\0@)"0D(B0F)"$D)20C)"<I5H,81=S1=B
MR*SU&'(",<3PK`A9$^(1XA,2$!(2$A$2$Y(0DA*2$9*K1`L8Y)L6,+[X#]CN
ML]X?MM^6)=\V7QF,8UCD^=+/1/0X<C)K-OV-S8H37D/PE9T3UV[V"O;(,H:J
MUU['OO")1D!(V+9B.Q!0-=;$J+V.JC'12`A)VU9"U9B]LO8ZJN:JAA9QF`:U
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M[12%I':&2)8&.39LM/2>8%6*6NUU3S^L)C9R1R`C>8P1OA)6:O8@DK?N(1+)
MXHYM:^08^W`?C62[`)',S1"1M(H0<76H1J?VR+C/&&UDLP21%$\12:L,$1>_
MF@YHTK32>X&5-VHO_%H^\"()-M:8VDMV_@#]9>2#$=$56LEQM19(RP>NY<(L
MK.36W)C*4`NVM:W5>&04_@%:28\A]1@A4CVZIE:,6IT>$[22'E.45WOQRC.Z
M(R/M<]3ZR*/>MZR<^OM]*XHRM6\YFJJKECLR]C<K=HP$(T!+/(XF:F5`URW1
M<,YV?GB"XXZ,39F/\C*&`2*9+Z%`W1ZCFSS&*"\])HBDQ_0FC]E-'G.4OY*W
MK'CKZMN_RE=8H#X]*F,RQD+&D5IYL+,XL%+0FB*/(I^B@**0HHBBF**$HI2B
MC*)<0WK.L(*.QA6/SF\_@^2%H7'48*3(DOVPP,*O[N.,U7@E;7!N75/D4>13
M%%`44A11%%.44)12E%&4:T@//BL.U>!_LB7@M:2VZK3EI3IUF/MIJ[62(27(
MHU8^10%%(44113%%"44I11E%N8;TD++J[PLAY<6B%E*.E.1?L?%JS@<$>=3*
MIRB@**0HHBBF**$HI2BC*->0'C]6^:GQ^[7]$:\?M;!RI!Y,L,F"A57NN]<"
M?7PT(0UP*/M4)J`HE`T_.)Z0!J@<4YF$HE0V_."(0AJ@<J[)Z!W`2CFU`SZ9
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M\KD]8:65\ZYE'.'YJ*6-`-JW7%[Q&**\]!@ATJ84BR2HT.KTF.!]J0E*GC&[
M[M%8='+4^LBCWK>L>/[[?<M+<*UO.=+SUC+.IU8VM]+REB,HKG&Q]835)[4[
M:G6ODV@ELR@42/$8W>0Q1JU.CPE:28\I]9C=Y#%'K8\\ZGT+(Z"S;V\KYV'K
M2"9ECM@LTJZF]LPX%5N)AF"%/;FFR*/(IRB@**0HHBBF**$HI2BCB+TB*$L4
M'FK^RA]_X>A47%Z*57$\5KUM^<9>YX.U\N&NQ?BNH;MX!"6(B7$%*O<%*V2O
M79G`E68`D393N-+,2N85V\&7&HTK\+;C8S/1&'P);T$V?65R&X2NW=5X`2]7
MT+M]=!:/<!A"+RSACJYR>.ZKCPU/??VA0>BJA_5T`3^L4L_A=`$_C5*>3A?P
MXR;E4",M/#Z=&<&`&F<17;T"-<HBXU>&;2-XB_-U\U)DF\O+X5SUCL4S#(M1
M\P/TA;\'RK_4XF3MJ:SA_<WFD&T/[^L6\([8:``'.L]E6>,7N-UA^P;PP_\!
M``#__P,`4$L#!!0`!@`(````(0#P9PY2.@4```H3```9````>&PO=V]R:W-H
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M*V!`TVZU^+"R'U"2H\AVULLA07]5^-I)_UO=B5SSMMK_6C48L@TZ404>"7FB
MIM_V%`)GQ_#.!@5^;ZT]/A3/Y_X/<OT%5\=3#W*'P(@22_9O6]R5D%$(,_-"
M&JDD9U@`_+7JBI8&9*1X':[7:M^?5K8?S<+8]1&86X^XZ[.*AK2M\KGK2?TW
M,T(\%`OB\2!PY4&\>!8C=^''$.0=1[@[/!VNW!'-YF$81/,/'"/N"%?N&-_G
M&'-'N(Y/'.F:*W58NH;L;XN^6"];<K6@I"$AW:6@&P0E$$NDG448A?@W'4``
M&N2!1EG9L!<AQ1T4S\LZ0O[2>0'!2VZ3FC9(M=@("ZHN#;O5@9T.9#J02X`#
M%$>>(.G_P)-&H3S%"E,!3,0]C92P$"Y;'=CI0*8#N00HI'R3E`\[[_:>$5I1
M)]@=BE:!NNB4V2`HB$E0U60SFHS$#&1G()F!Y#*BD`M,<K0A_&!ETBA0VVII
MABJ7E!N]1W<T&>D:R,Y`,@/)942A"]3D`GU?0VH\L!*K21GBR3S#(%9Y;D8C
MX;8UD)V!9`:2RXA"`MK8_22HL4J"(0H);^YJ)$:CD82![`PD,Y!<1A024`8R
M"=829[21]Z>J?$H).T=N*.1#ZV,-D<90N3'$AW(?MU08S#5NS,@+Q@:S-9`=
M1Z8FE!E(+GLIW.BX)+7[&QS@N!0DJ+%*@B&+:&CQGHNTOK%A]_UX6C]'ALEA
M2,UNM)D2X<61FHB,&\V'!_DH<OV%:I&/8:`,%(J+'Z%(C56*#%G$@J+6*S;L
M?B!)Q!%O)+TS;#*.T-R^K/T8>8%6UKGLH_!!T-'OUVRP5AEQ:%)-2_:&&\BR
M"4C234"3N)F`N$QSSX^UEI,+D\%+Y46/ZKMK$;&#'1JYV/8IAR:IM&=ON(&L
ME8`DL00T*9H)B,NU\.?Z3LV%R>"E\J*GM<3K/_4/Q(Y\A2Z#)AGUYL%]%!F9
MCR_+R*!`EI%#7$;7BTVZ/-`-&>D!_FFZ?`J0U650!/M<:IA:%]@@9J5(S"%9
M8@:%,F<.+88=B>(H\D)M=,N5X*K&]!C_-&D^"\BD&13#EI](AUJKV"!FI0C-
M(5EH!BE",RBB1YD8U,-0&\/S*?QDY;O3(M1,T%G@TYE@`X52[0Q2Y=<5VM"!
M$/JW(C^'9/D9%,I9-8\<'BM$O"*\V%MHG3)7GJ?F@8X3[^3A.[E`5_YH-H<W
M;/T\XM`'0]%D)=KCUH1V)I29$'W-IXN`)XY'*WMM9R^.-6Z/>(//Y\XJR3-]
M)8<>OUZ.,/M>L(L3F$L@@(;#=X2'01H-3^GWA1OVJ9?`ZX\9)_43>'4P\8<@
M>0`"YHTT2&#XOH&'"<RS-_`H@1'Q!H[@!GN",W*`+Q&7XHA_*]ICU736&1\@
M+>XP,[;L6P;[T?,J>"0]?(,8"N($WYPPO.RZ,ZC2`R&]^`&/=L:O6.M_````
M__\#`%!+`P04``8`"````"$`#Z/:"AL*``!7,0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6RLFUMSXDH.Q]^W:K\#Q?L!;#`0*LFIX6IC&U]J+\\,
M<1)J`*>`3&:^_:K=+;=;\CKA[+X,Y!?U7[*EEKL[GOL_?QT/K9_9^;+/3P]M
MJ]-KM[+3+G_:GUX>VO_\Q_*/<;MUN6Y/3]M#?LH>VK^S2_O/Q[__[?XC/_^X
MO&;9M04*I\M#^_5Z?9MTNY?=:W;<7CKY6W:"WSSGY^/V"C^>7[J7MW.V?2H&
M'0]=N]<;=H_;_:DM%2;GKVCDS\_[73;/=^_'['25(N?LL+U"_)?7_=L%U8Z[
MK\@=M^<?[V]_[/+C&TA\WQ_VU]^%:+MUW$V\EU-^WGX_P'7_L@;;'6H7/S#Y
MXWYWSB_Y\[4#<ET9*+_FN^Y=%Y0>[Y_V<`7BMK?.V?-#^YLU26V[W7V\+V[0
MO_;9QZ7RO75YS3]6Y_U3L#]E<+<A3R(#W_/\AS#UG@2"P5TV>EED(#ZWGK+G
M[?OAFN8?;K9_>;U"NAVX(G%ADZ??\^RR@SL*,AW;$4J[_``!P+^MXUZ4!MR1
M[:_B\V/_='U]:/>''6?4ZUM@WOJ>7:[+O9!LMW;OEVM^_+<TLI24%+&5"'RB
MR-<'#]1@^%2#K<[8<0;#\>CK(F!97`9\*I%AQQX[EC.\X3*&2@0^RTANO14P
MKXI`X+/4N/EJ[I0(?/[UJ[&@EF1J15&IM-V<6@MS*[Z4*C=?D=7'8."+DG$Z
M`]L9C6\I-`N+17PIH[DU1Q8F6GPI56Z_IA%>$WSY'ZX)2\:JULP7KZDKIW/1
M'>;;Z_;Q_IQ_M*#EPH2]O&U%`[<F0AC[@IS%9:?X;XT".H10^29D'MHP'GK`
M!;K;S\>A-;SO_H2.M%,V4VYCF18SM!#M1\C.*5A0L*1@18%+@4?!F@*?@H""
MD((-!1$%,04)!6D%="$]98Y@1OT_<B1D1([P[DX1Z*39)"%H@4/F%"PH6%*P
MHL"EP*-@38%/04!!2,&&@HB"F(*$@K0"C(1`;V()Z4/WK'^8XAP1H^"Q69DC
M\/0R;_A4VEC0*/1$,DUFI4F9%$86C"P963'B,N(QLF;$9R1@)&1DPTC$2,Q(
MPDA:)4:.H/&S'(D%SXV-3<A`;S0[V\A,R509-66M-"FSQLB"D24C*T9<1CQ&
MUHSXC`2,A(QL&(D8B1E)&$FKQ,@:),C(6O.,$M9%<O"F3B6QJ^ER'/(@FI5&
M.&S.R(*1)2,K1EQ&/$;6C/B,!(R$C&P8B1B)&4D82:O$R`4L>F[(A;`V<R&)
MD0M[W#.GSJPT*G/!R(*1)2,K1EQ&/$;6C/B,!(R$C&P8B1B)&4D82:O$R`6T
M%B,7<IG6$3N?Z^M^]V.:R\U7S7SIPW),+M*$B)DB2<;%UK&PF4EB#\I5PEP2
M!YZ%Y2/)<4@'7)1&F,8E(RM&7$8\1M:,^(P$C(2,;!B)&(D921A))9$WR$@1
M]!R>HI'83=^0(B%BIDB1'BPO*O=_3*:1M*JF#<?)';A832\DZL,CLZ)T9RHM
MI=%X5!;`BFF[7-NKTQZ2R;YFVC[3#KAV6*M-]@X;IATQ[9AK)[7:9!F<5K6-
MG,/&V\AYS?2#_./\$]9F<B49&;D=]LV,S*11?UAF9*X(E&*92'M$GG(+930N
M=F.6TR=3=EF*X)1=,4=N:=/@R#,<V;TQR<RZ%$%'/G,4E#8-CD+3D7WGF#=J
M4XJ@HX@YBDN;!D>)Z6A,,Y*6(N#(J`=QEG)#013F9D4H-(22*W,[)O4X4T:#
MXKQ0[92%YX?V`%96Y3A>$SA0U.3/1\NB?7R)!KK_KQ!I9RZB1F<>6BEG0XM4
MX!H-M#,?D786(&IT%J(5.AN0Z;!!`^TL0J2=Q8@:G25H)9W9_3OB+$6#PIE9
M(6*37SUP:6X9ECP3@/T'UO14(:-IW)$N/E-&U::!J+EK*"NG>@.<(=FF+NNT
M^CW2[E=HI3N7BZ@Q"*\^"#+=UW5:+`@?K700`:+&(,+Z($BF-W5:+(@(K700
M,:+&()+Z(,A$2NNTJD&8%2A.-6ZH0'D(8E2@1-"CL"AGXM17M!\]E>:(](1;
M*.3(/S"(-<F26ZT0:2T7D=;RN-::6_F(M%:`2&N%7&O#K2)$6BM&I+42KI4:
M5F8NQ/'%#;E0IQWZQD_%@3G<>*,;.$.Z/%161CN0`_N-];=0`TD[(-UFB?)5
MK6K]%8^H%5KI2>`BJ@YD3RVO-H@1Z3;K.BT6A(]6.H@`46,086T00W(G-G5:
M+(@(K700,:+&()(O!9'6:56#,$L0.OTM)2C,R9)%(EOO-&;BSRY@54%SCA8<
M+3E:<>1RY'&TYLCG*.`HY&C#4<11S%'"46H@,Q?B+*;:#O[2-E^<<M(4253=
MZ"NKZI91(7.K/R++^86VPNZ_Y&C%D<N1Q]&:(Y^C@*.0HPU'$4<Q1PE'J4(U
M&W_QUT&>M5MW_H4*F5CR.,CZ9.^O1AJ9Q)%Z3BZ4V2?;?V55W?]S?5<AJZ?U
MO5I]=@3`]7VN']3HA_7ZI#HW7#_B^G&-?E*O3[9>J:%O3EYHW489?+*R%^8D
MWQ*19SD]#A!_'(*!QK-<(?AHVOQ)*WB6B\W?R":7MD3ARM$/(OV@<A$U^O*4
ME?(UMLAS<JU5L(GXB+2O`%&CKQ"MU$E'K\_6Z/+"8:F#SB(<HYW%B!J=)6BE
MG-D#4H`I&A3.S`(1QTC5[OY)@<A3)V/A+=$GAP/2R%B**P1/Y:;ZD%:P.A?U
MT1^3V[B$2$3AP1$#WL85(KTD=A$U^O*4E?(U&)`=S5JKH"\?D?85(&KT%9J^
M1C:IQ8U605\1(NTK1M3H*S%]W?7(0CS5*N#+K`YQJ'1#=<@S*-##H*>61$;[
MX`<#ZNQ*%_Y<C?ML)R`'FCN!$>LA2KXZB:I+3[438$&X7PK"4U8D"-(AUW5:
M+`@?K?2="!!5HV?;D;`^"')$LJG38D%$:*6#B!$U!I'4!T&.2-(ZK6H01@7:
MMQU>%N;F`TRAZL&`0M5NA$CWD85"U8,!;K5"I&>EBTAK>5QKS:U\1%HK0*2U
M0JZUX581(JT5(]):"==*#2LS%[<=$\)&BRXF%#*Z`3\84%;5Q02BQOI;*"LR
M$^DCHTZK6G^R':"5G@0NHL8@O/H@Z+.D3HL%X:.5#B)`U!A$6!\$:?R;.BT6
M1(16.H@846,026T0]'0BK=.J!F&6X&WGA/#R,BM!B>[ZY3-JIJPJ:,[1@J,E
M1RN.7(X\CM8<^1P%'(4<;3B*.(HY2C@2[W^+6RAOCLR%?)];OK%YS,XOV2P[
M'"ZM7?XNWM6&@\7'^Q++%\FGUF`BCAA@64!_8]OXCCGYS7PT28KU*N66,Q%[
M8:X%KZM_*]H=&3&%U]B+/2'EPG6-SK0_@5>X:O0'H%\[`*ZN]N*<";S)PH6F
MPPF\50&\6T8$K[6_;5^R<'M^V9\NK4/V#+>R5[Q+<98OQLL?KOD;W&)XN3V_
MP@OMQ==7^`\,&1Q;]SIPH/*<YU?\03@H_TO$XW\```#__P,`4$L#!!0`!@`(
M````(0!*4:.D)04``/X7```9````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;)2878^R.!3'[S?9[T"X?X2BB!#UR2#OV4TVFWVY9K`J&:$&F''FVS^G5)16
MANI<J)SY\6][_FVA9_GSLS@J'[BJ<U*N5#315067&=GFY7ZE_OM/\&.A*G63
MEMOT2$J\4K]PK?Y<__[;\DRJM_J`<:.`0EFOU$/3G!Q-J[,#+M)Z0DZXA/_L
M2%6D#5Q6>ZT^53C=MC<51\W0];E6I'FI,@6G>D2#['9YACV2O1>X;)A(A8]I
M`_VO#_FI[M2*[!&Y(JW>WD\_,E*<0.(U/^;-5RNJ*D7FQ/N25.GK$<;]B69I
MUFFW%W?R19Y5I":[9@)R&NOH_9AMS=9`:;W<YC`"FG:EPKN5^H*<!$U5;;UL
M$_1?CL]U[[=2'\@YK/+M'WF)(=O@$W7@E9`WBL9;&H*;M;N[@]:!ORIEBW?I
M^['YFYPCG.\/#=AMPHCHP)SMEX?K##(*,A/#I$H9.4('X%,I<CHU("/I9_M]
MSK?-8:5.YQ/3TJ<(<.45UTV04TE5R=[KAA3_,PA=I)B(<1&![XL(,B<SP[06
MSZA,+RJSFXHQ,18F,N=/]`5ZW0X(OKN^H.?[,N_20@UY-B\:RW%KF9<VZ7I9
MD;,"ZP"R6)]2NJJ0@T"Y,XNE]FK?=^Z!;53EA<JL5%C!8$P-4^YC/4>+I?8!
MTR2[,"YCX+/'V#RSZ1@Z*ZBP)P9\,1"P`-^T(!MV3"<;B2JQ2"2]@`:YNB8,
M)A27L.%9W>6%TC0O7<-N%^@EP="%)-PS!D]X]\140/Q[9&X@7B9@#(STYH@A
MZ(1#C*`3#3'"H.(A1F@K&6<X&V!E<C;0>3N%^3MN![V+LT,,;,2`)P9\,1"P
M0#^+:#'C,QT^P$0/,/$#3#+.<%F$?8W+XGCV*,UE3PQLQ(`G!GPQ$+``V[SI
MB@_%0"0&XB[0G[93/N')$',SA4L";,M/)('2*Q5FZG7-6";?MLL0J]T&T=RT
M3$,7-J0-A\QFMC6W3(N7\?J,;5N+F;T0%HS?1Z"EA3GG-0(&0#*NO16(4"81
M"<#`:&)I*\D8P9D!3[DGS*"T8(8P/I<AHV9PR#=F])EOS.@C@V8P8,P,F40D
M`$-F2%M)Q@C.#.LI,RC-FP$O2?Q\=!G#I<`0'-L,,+R*)R5\*1%(B7"`$/L:
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M-KHAO"_T$-?WA9YO#5ISDAC$#G^\0<(\=*'X)]W1I(@G5_'E2#"$B+6,<`CB
M'WF1'(GE""V+?I\99A`K>[(:6H&K/=[@X[%6,O).2YITHEVCUW+KRXP6@(1X
M@!RH2]W'8UJ>'8B[AN,.Z6P,!\[=]SJ>X<#Q^S[N&PZ<PB&N73L$U==3NL=_
MIM4^+VOEB'<P%'UBP72K6/V6733DU%8,7TD#==?VYP'J[!B.[?H$X!TA37=!
M&[A6[M>_````__\#`%!+`P04``8`"````"$`8*#+QDX&``!C&0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6RLF=N.HS@0AN]7VG=`W$\X0T!)1IT$
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M9[&.8LVQ%5N0:;,ZU*"`#+O15<>U^>0DN>N9UF9%!^B?NGKOI?\;_;E]S[OZ
M\+6^5C#:X!-QX+EM7TCHEP-!T-A"K3/JP!^=<:B.Q>ME^+-]_ZVJ3^<![`Y`
M$1&6'+[OJ[Z$$84T"S<@F<KV`AV`?XVF)E,#1J3X1C_?Z\-P7IM>N`@BVW,@
MW'BN^B&K24K3*%_[H6W^94$.3\62N#P)?,XDN=/0XPW]L:$;+)9!X(?+"!Y_
MIR7\2OL-G_R1P<+Q[9#T^DZSD#>#3][,=1]I%_%V\,G;^0O?#:(E'2;\0(L-
M,W5M7PS%9M6U[P8L!1C(_E:0A>4DD$S8Q3*,!OZ??V`<2?)$LJQ-6,-@30^3
M[FT3^,[*>H.)4O*8+8[1(G8B@LP*DG:O@U0'F0YR"5@@<=0)4^$GZ"19B$[1
MPZT`DW!7E;T3$:+)7@>I#C(=Y!)01,%TU45YL&+GUYKPBC2"5:5XI75ZRV(<
MF!"CH:&F:PP9A2&2(I(ADLM$$0=K4!='-I(?G)DD"\SM^U.3!]V3.X:,<A%)
M$<D0R66BR`5ILMS['I)@JDKT9LM(K.KT-,_&(-%LCTB*2(9(+A-%!&QCCXL@
MP:H(1N)X7%\[1/:(I(ADB.0R47H,GC_>8Q*L]I@1%Q;HN%`"W]>&?0P:AQV1
M%)$,D5PFB@AR>)(V\?MSAP2K(AAQ60TE&^\.D3TB*2(9(KE,E![':H])V?&6
MY$3PH^N;)%+5,`)J9$L"S9(Q:+0$D121#)%<)HI`!_;AQSVAT:H,CI;LD$1=
MP6B/48I1AE&N(+7GI(1*L^GCWCBL&,/F*T9YRY'FCEY;IBC1<(]1BE&&4:X@
M52@IJY+0^\O&8458$<.0O'!XE(3V&*4891CE"E)[3HKFXSWG)5:V@2$7UJ>T
M;T7:(G'&J,D&A%(<E6&4*T@50TKBXV)X`97%,*2(<9>V+F:,FL0@E#H(91CE
M"E+%D-(HB6'GZ05Y>1C.=?FR;6&\85G,S#4/SLW\-,WJJS+5&/)@^"7#EKI&
M%N7ZXX+;DR,3;)`22@6:AC##*!>(YE(UDF(J:9S1`AOY*(:57D4,K\8A?5-P
M;4<OF`X+\"))!T?AB-(I:AH3-]+VDDQ$+>G#/">TO5@=MER$T,>I4DG)?5PJ
M*]"*5(;B2$C5"Q$Y8X,_OFP91ZXD%45EHB$9Z;>-%SFNKTWY7(3,6$@*\^.Z
M6!E7=#$4CQ9JP[Z#8*)+L9`CV4(4E8F&W*^EZT7:OI2+D!F_2#U^7!>KWHHN
MAB:_M&?O'!:@^,61[!>*RD1#[E?L+7UM^>8B!/OE:J>)#VTK-(EZR.!HLE'K
MTHX'R#8*)-G(D3^MUTP@;J/M1DBN2(1M),<#V<:/R<6G#YIW;88PZZ1=5-L.
M=CQ*ME@@R6*.`EDS>V(0TR7I1"'<_FAOUKG(-..Q=ASYF&A\2B$O)[`2(YA"
MD^A`VRMV/$HQFC7T9*,94HQF*(0Z(Z77KG;R*?T4Y=E3)Y1=%^XG?X+][*0B
M+VZ:5[=?=VC'HQ3[62Y?MI^A0!Y57'QXKL#A,\*-W%C;*<EM[%0!V#BPVU5V
M3]=4W:G:59=+;Y3M*[DYA6U]LQHQN];=.GY"CB5PMM%_62;P&C;#XP3>7F:X
M8T,F>LFK9W+@[AB.TW-M7/B%C@YJX\$O]+Y9^P6.(0DY=^!L<$7]-)\+4LW$
M;^'AL_'PZ+DG/_F0?^Z'+8SA[!`&"5QYX(YNPP0N%F9XE,"[.G!KU`Q7W+?B
M5/U>=*?ZVAN7Z@A&VO1<V+%+<O9E:&_T?/C<#G"Y3?][AC]F5/!2;B]@B1W;
M=A!?R`/&/X]L_@,``/__`P!02P,$%``&``@````A`)4H@V.'!P``ZQX``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULK)G;CN)&$(;O(^4=$/<+/H)!
M,ZP6GZU$BJ)-<NT!,U@#&-F>F=VW3[6[R^WN<MA!V5R$G8_JW]U_E\N%^^'S
MM_-I\E;435E='J?FS)A.BLNNVI>7Y\?I7U^C3]YTTK3Y99^?JDOQ./U>--//
MFU]_>7BOZI?F6!3M!!0NS>/TV+;7]7S>[([%.6]FU;6XP#>'JC[G+?Q9/\^;
M:UWD^V[0^32W#&,Q/^?E9<H5UO5'-*K#H=P50;5[/1>7EHO4Q2EO8?[-L;PV
MJ';>?43NG-<OK]=/N^I\!8FG\E2VWSO1Z>2\6Z?/EZK.GTZP[F^FD^]0N_N#
MR)_+75TUU:&=@=R<3Y2N>35?S4%I\[`O807,]DE='!ZG7\QU9EG3^>:A,^CO
MLGAO!O^>-,?J/:[+_6_EI0"W89_8#CQ5U0L+3?<,P>`Y&1UU._!'/=D7A_SU
MU/Y9O2=%^7QL8;M=6!%;V'K_/2B:'3@*,C/+94J[Z@03@/]/SB5+#7`D_]9]
MOI?[]O@XM>V9Y[K.PEN"S%/1M%')-*>3W6O35N=_>)0IM+B*)53@$U46,W=I
MV"9<]*,BMA"!3R%B>K.E::QL-I,;5W?$0/C$JW]H'*AV:X=/O.#BYH7@VV[`
M4@[XV`SA;NL&PN==,UR)<?"),[1GCN4NO<[8&YZ8D$E\8UE*B3V[.=DYSXPN
MT8*\S3</=?4^@;L7MKZYYJP6F&LFBRG&K]XGW7_E'"0;4_G"9!ZGX`!D4P,W
MRMMF81@/\S=([IV(V=(84XWP,8)E,I,-=!#J(-)!K(-$!ZD.L@&8@RV]-Y#P
M/\,;)L.\P55M$4BS+,T(C,`A@0Y"'40ZB'60Z"#5038`BA%PT_X,(Y@,E"`E
M2;04V/(8$VY"F4F:.7U([PXA(2$1(3$A"2$I(=F0*"9!@?H9)C$9N!G56TG+
MCZT(NN52']*[1$A(2$1(3$A"2$I(-B2*2U".%9?&'V585EAT9P8N8LN)!;=L
MGQ^VL]0RI`_"80$A(2$1(3$A"2$I(=F0*&N')\P=:V?1ZMHY@;7CLGQ"`D)"
M0B)"8D(20E)"LB%1%@IYJ2R4/U1F[$G?'LO=R[;B3<?(YMOP\."/%":BKE^0
MKN'J8GQ.+*=W).#$A4K6YX>U=-3\"/L@-#(B)"8D(20E)..$3TBQ!.[G_V\)
M$U$M$61@"2=#2SAQF;-O&\LP;<V-_OO>#:(1$Y+THX2J5J+2_GM4S88:BC?0
M`"G>C*0%=)J8%RQ:-8$3&VI.O^>VXZFK]$700J:*(+!E_3!KN5"'A2+(Z\Q;
M.::MVQ?U,KC0F%PJZ6-N7"I5+F6OEI:I=5!9+P.74AQDG=L=%G;AJH<".2#4
MNV$[*]4-'Z-DO@6(Y#T8(F)[]K;Q7`/^4X4B#)&C8D12.T$DHU*!7%9*L-6T
M/.T!D"D#5:=8LS=L>&\GF\E[0W@<X^YN!5+3S=46Z&/4(-\0+7NM$!%/+\M=
MK"Q-*,(0.2I&)+431#(J1<2U3=/Q5MIV9AC2C5)M8JW@'3;QSE&QB2,UH5RM
MW?--$24W/4`D-SU$Q!/*-A:VH16Q"$/DJ!B1U$X0R:@4$=<VC>72TQX7&89T
MHU2;6#=XATVB>1QF$T=:-FG%U#=%E-SQ`)'<\1"1R";+<?6TC#!$CHH12>T$
MD8Q*$8E"2&_I#"-&DHEU@W>X))K'H4L<:<FDY8!OBBBYX0$BN>$A(K[AKKUP
M]?X@PA`Y*D8DM1-$,BH5Z$?52<QS))]8[WB'4[S55&X[CK1\TC+:9R^1X"%J
MRST/$,D]#Q&)"F)!<=*>JA&&R%$Q(JF=())1J4`N6'&KCHMYCN04:S[O<(KW
MJHI3'&DYY:H/*M\447+?`T1RWT-$HHA8"\O6DC/"$#DJ1B2U$T0R*D6$^6H8
M6G7(,&(DGU@_.G2IZ\27[&WA'9TX^S6NM5P":6FF-4\^1LE4"`1R9"J$B$39
ML@W#(VG&9V#+43'53E!(1J6(N/;26+KD&3B45HL[:UAU\RP(__AO&,@WXAQ'
M#O1R?>+;KM;`^&*@(U,C$,@==FBT7\4HL^N][(5AFIZVY`C%99+%B.3U$E2Z
M>;T4H_CU/!O*J59L,M0>24_6T.H.FZ[\H?BUND*;^L.7C[POANO()HVCX6]E
MDZ"`HI"BB**8HH2BE*),04JV6?>U\%VXVL(C,N2^^B,L&&'A"(M&6#S"DA&6
MCK!,9>KB]:Z<U2G+FT&9NO-%-'LSI-4J@3RHY(,[3BLQOHS")`HH"BF**(HI
M2BA**<H4I#IT7T,.IU+$!H$,?E+$WJ_[&#9@P0@+1U@TPN(1EHRP=(2Q@[1N
MRGPN?/'\9(P?6)R+^KGPB].IF>RJ5W;J!3W$YJ''_$ANNUC#>RG80IV;JS6[
M^T:^L0PXQ>L.XO0Q%CO?ZUZWD6\L//G3O@F6:W@M1*\2>.NPJT]:?.*MX54)
MC8>CQ2]=,=;BMS"E\1G!A$9TMO8:7EF/Z#N@/SK`6</;6SI@ZZ[AS2;P>3\C
M.&J\YL_%[WG]7%Z:R:DXP*887?6N^6$E_Z,55?RI:N&,L2OH1SA4+B`##7:+
M'ZJJQ3_8!?ICZLV_````__\#`%!+`P04``8`"````"$`S%I<`U@%```X%```
M&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RLF%F/ZC84Q]\K]3M$>;]D
MAQ`!5P,A"VJEJKIMGS/!0#0$HR2S??L>QTMBF\[2.R^3X<?QWSE_'R]X\?VE
M/AM/J&DK?%F:SL0V#70I\;ZZ')?F7S^2;Z%IM%UQV1=G?$%+\Q6UYO?5K[\L
MGG'ST)X0Z@Q0N+1+\]1UU\BRVO*$ZJ*=X"NZP#<'W-1%!Q^;H]5>&U3L^T;U
MV7)M>VK5174QJ4+4?$0#'PY5B6)</M;HTE&1!IV+#MZ_/577EJO5Y4?DZJ)Y
M>+Q^*W%]!8G[ZEQUK[VH:=1EE!\ON"GNSY#WB^,7)=?N/VCR=54VN,6';@)R
M%GU1/>>Y-;=`:;785Y`!L=UHT&%IWCG1SO%,:[7H#?J[0L_MZ'^C/>'GM*GV
MOU47!&[#.)$1N,?X@83F>X*@L:6U3OH1^*,Q]NA0/)Z[/_%SAJKCJ8/A#B`C
MDEBT?XU16X*C(#-Q`Z)4XC.\`/PUZHJ4!CA2O/3/YVK?G9:FYTW<,'""*<0;
M]ZCMDHIHFD;YV':X_H=&.4R+JKA,!9Y,Q9U]7L5G*O!D*LXD#`)_&LX^_BH0
MV2<$3R8R^[P(S(Y>!)[__TWF3`2>3&0Z"6:VY[QOK$5'J1_TN.B*U:+!SP;,
M)!B&]EJ0>>E$#A0+'VXZ-J(`_FO\8>")RAV169J0'8QL"T7[M`KF_L)Z@D(K
M6<Q:CW'DB`V/(%5%9&,5;%60J"!50::"7`6[$;#`%N$-%-]7>$-DB#<\JS4'
M@UFN8@2/X$UB%6Q5D*@@54&F@EP%NQ&0C/"^Q@@B`\O!J$@\.Y`S7],89S8*
MFLHA&Q$BW-'(5B.)1E*-9!K)-;(;$\DD6&2^HEJ(#$Q&>2JI+K&@MUP2(<(E
MC6PUDF@DU4BFD5PCNS&17()55'+I]K;"EQ42W9O!DUA3XL*4%2N-9\^4"A%!
MO%FLD:U&$HVD&LDTDFMD-R92[M-/Y4ZBY=PI@=QY6AN-Q!K9:B312*J13".Y
M1G9C(B4*=2D-,MU4)F33[4Y5^;#&]`!P8_`]V#SHED)$Y/P9<8?\*7%]06)*
M`EC)1'VX,V4GVHH@;F2BD50CF49RC>PHH2\D60+S^><M(2*R)8R,+*%D;`DE
M`7'V:>7:CB?/EJWX7KBA::0:R40KIJIL8;GXGJONQAJ2-W">D;RY419PPN%U
M0:)E$RCQ8,T18^[9H9SEA@5-AU)A!(9,-'-GRF:S94%A;U[H^JZK'%H2(<,3
M3;6N,A'S1E>YU-4\\*:!LNSOA`QT)3E(3FZ?L+`/ESUDR`<AX89GSQ43>=10
M;S%'PQS<<D3&[&D5SN>V;<M""0\96J4<#=H91T-4SE!`EA)^U'1#90/820UE
MI\AA3S_P?G)M<NB1$79I/NAKAN0J=)2\-SQJ5(8,^3.AM>6(5IT[<SUE!4NX
MSM`HY6B0SKC.$)4S-'W'/YJ?US>4_2-GQ)_WCYXT)?\H\J'&Q<!ZCC+9-@Z+
M&HHD9B@85ZX^CWF4T]>D,PML7YU>"1<?RBWE:.@OXTIO]I?S*-K?S=G,M?ON
M9)/)(?,MDW_@*TS?=W^4L;/JN$HI<J67#[4J%5&\O&.X<B#++C3D:*NC1$>I
MCC(=Y3HBEQQ#C]0>>FE!?[_6J#FB#3J?6Z/$C^1"`OQ<+02FMR7K:03'%'AE
ME3L>OT91OHEG$>SK>HLXC&"GU'D61K#7Z1SN:>[ZJE'TU^3^YD;\VHW@]Y>N
MLX87[:][%)T[/[H#BVXT\",X?M_@001'4^"64()[FVMQ1+\7S;&ZM,89'<!&
MNU\+&WKS0S]TK-SN<0<7-GWEG>"&#L%/='L"*\D!XXY_(!V(.[_5OP```/__
M`P!02P,$%``&``@````A`(0BIR:2`@``X@8``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C(N>&ULE%7;;IPP$'VOU'^P_!X,;/82M&RT:90V4B-552_/7F/`
M6HR1[<TF?]^Q31#;32+R@O%P?,[,>&987S_)!CUR;81J<YQ$,4:\9:H0;97C
MW[_N+E88&4O;@C:JY3E^Y@9?;SY_6A^5WIN:<XN`H34YKJWM,D(,J[FD)E(=
M;^%+J;2D%K:Z(J;3G!;^D&Q(&L<+(JEH<6#(]!0.59:"\5O%#I*W-I!HWE`+
M_IM:=.:%3;(I=)+J_:&[8$IV0+$3C;#/GA0CR;+[JE6:[AJ(^RFYI.R%VV_.
MZ*5@6AE5V@CH2'#T/.8K<D6`:;,N!$3@THXT+W.\3;*;%2:;M<_/'\&/9O2.
M3*V.7[4HOHN60[+AFMP%[)3:.^A]X4QPF)R=OO,7\$.C@I?TT-B?ZOB-BZJV
M<-MS",C%E17/M]PP2"C01.G<,3'5@`/P1%*XRH"$T">_'D5AZQRGRVB^C&<)
MP-&.&WLG'"5&[&"LDG\#*.FI`DG:D\#:D\P64TE(<,C'=TLMW:RU.B*H&9`T
M'745F&1`_'I`$(G#;ATXQU#3X*N!2WC<S)=7:_((F6,]YB9@X#E@D@%!0'10
M!K7IR@[LE%UJG2LWP3"625^7F7U$QH%S#,_!^?DJ'GB#<L!<CC"+`7$2($"F
M!^C`<`?OYS:`)DA#44V7=F`O/22WMT";C/+PQC4N/B+EP*=2O27U[3<NC^4I
MK^^X.(V6X-O[1>H.GFH$RPJ643AOE(L;V)/[P8%/I7K+*)PP4T+/2:XK_H4W
MC4%,'=R\2*&+!NLPRK;^_/_VRVSK&X`,'V#$=+3B#U17HC6HX250QCY'.@RI
ML+&J`S=AT"@+P\6_UO`OX=!(<00)+96R+QLW!H>_T^8?````__\#`%!+`P04
M``8`"````"$`QNLS`7H4``#7;```&0```'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6RL75V/V[B2?5]@_T.CWV_:DK\;22YL";-[@;W`8K%[[[.GVTF,Z6XW
MVLYDYM_O*;)$5A7+5DLW+Y/)89$Z*A9/%651^?C7/YZ?;G[?OYT.QY=/M]6'
MR>W-_N7A^'AX^?KI]O_^]Y>_K&YO3N?=R^/NZ?BR_W3[Y_YT^]?/__YO'W\<
MWWX[?=OOSS<8X>7TZ?;;^?QZ?W=W>OBV?]Z=/AQ?]R]H^7)\>]Z=\=>WKW>G
MU[?][C%T>GZZJR>3Q=WS[O!R&T>X?WO/&,<O7PX/^_;X\/UY_W*.@[SMGW9G
M\#]].[R>NM&>']XSW//N[;?OKW]Y.#Z_8HA?#T^'\Y]AT-N;YX?[OWU].;[M
M?GW"??]1S78/W=CA+\7PSX>'M^/I^.7\`</=1:+E/:_OUG<8Z?/'QP/N@-Q^
M\[;_\NEV4]VWU6Q^>_?Y8_#0/P[['R?Q_S>G;\<?__%V>/ROP\L>[L9$T13\
M>CS^1J9_>R0(G>^*WK^$*?COMYO'_9?=]Z?S_QQ__.?^\/7;&?,]QRW1G=T_
M_MGN3P]P*8;Y4`<:#\<G$,!_;YX/%!MPR>Z/\.>/P^/YVZ?;Z>+#?#F95C"_
M^75_.O]RH"%O;QZ^G\['YW]&HXI(I4%J'@1_\B#5)`]RI>.4.^)/[KC\,*OG
MRU6X^I6.,^Z(/P?3OHLN"!YM=^?=YX]OQQ\WB%/<Y.EU1U%?W6/@SI611G+N
M)=_"'S3(AD;Y=(L%!K>=$!&_?YZOIA_O?L<D/K#-MK2IM$7369";:=A6`'?@
MFTC#YS^!-(U"I+O+;3L@WT5M&'8679=6`(HA)O<G,*11$)S"K=5ZKBEMHTVU
M%$8+;=(DDT1;(HHW0N`G\*91$%`R'JKU4K/:LM$UXLDD$9>((HZ%*XG[4M"%
M*QD'?MVXVXC4DDS!N$E&7;=6(HK.8@@=,M9T(E+GV&P*I)6(NC9N0KJ"EO0<
M*VG@DJ91-*F(U!@JK?)JO=*SVB2CY".)*)Z4C_]UZ:%13*Q-9YK4EFW`)#&W
M:R29)-X24;S7FO?U4"-C[<:(U%".1,82;I)-8B,1Q:9"^I1NO$XG6&L^#&%>
MNXLU)=0J2!,@E;;S6"\_8&T,#+DJZCUTHV.R9<@$W5K/;Y.MNHZM@C1?TFS+
M=P39*/U*Y%`(:F;;BJVNA5ZVR>Q3-T":/4FW8-\SW2STTJ,14O%7\&ZJ9)4Y
M24AS(E5^/R?6<,DI0BH$"P@U)2[SZ39::0*DPX)`J&*6JS$A&!5=A6"$5`C6
MDZ)V25;981+2?$F[+5]8#UTO,068$#0UR[9BJZLAF&PR>PEI]J3H@GU/")*U
M49P(J6Q;3PSOADH:FNYE4H-609H3J?7[.;&VRQ",D$RYY%<BD*U:!6D")-""
M`(7@:DW[C\&S&J5>A2"KOTR]]<04V$V5K/(D2DCQK4W:&%GXAV%,^JTG-O]V
M5IC1E/-L`LXVB;V"-'N3<ZZ'("U=$X(,F1`TO)MLE3G%L6)4:DXFK_1P2NFC
M&WI+DJSCK2FA5D&:``FT",$>`E'.99C5K/`(FC1-]<1L.)ILU3%O%:0YD6:_
MGU-4>,5)BG[8%39U`;4*T@1(A`4!BO,E=ON#ER6M9!M$$3*9H0CL9)7])2%-
MEU17T.V90];HK%#;.D+@U%VM*:%609H`J>[["42-5A/&LJV#R&S^&EIX%.OK
M1+-5D.8T2-RAU\5$L9)+IQ10RQVCZS0!DE'A%`JBZ6J,N..&"W(1,E%D]U7<
M4<QKJR#%=_ISQ#T,8\1]OC(BN>VL,*-)->P:R#9=5+8*TNP'B?NT%'>&C+C;
M34.VRIPNBOMTD+@':UWS,"2*B::$6@5IIPP2]VDI[@Q1T*1IJBNS7VFR579*
MR@J`-*=!XCXMQ9TA$=1-";4*T@1(1\VZK&;AJ>_0JFL:)5DJ&4-Z85:V\,]6
MV6,7Y7UJY'UDU16&,0NSKDP!O>VLKBY,SB"BR,[=BODFT1;NOIZ<IE'BE4<C
MI/>>EG?#'6&5/9HZ%IP&Y89IF1L84C%8Y@9EI6/0R0TC'K=-R\3`D(D_6_5G
MJ^RME%&LMV8F,5R?P6"M98PAZ:T2:A6DO#4SVDX+H)Y3.=9#I53Y,!38S5*8
M-!V$X9+&52N3C-K."J&?K.HJIS5-V`C_NPF7]?V,(4F8H1[";*4)Y[I<$S:)
MXMV$RY0Q8T@29JB',%MIPGD>-&&318@P+:">@"BSR8PA29>A'KILI>GFDE73
MQ5A2!(DNUX(]C*FC64T,2<8,X8\4G$X(LY5FG&M&S1A6EO$['$R]#%V&)%V&
M>NBR%?Y(-U57N2#3=$V6>6<\E-EFQI"DRU`/7;92=.M<*FFZ@Q+0K$Q`#"E)
M+1.0LM($G`0T7:P_+'&3`Q\HSLHDQ)!.0K4M@K)52D(*4H3G@Y)0L-9QR)#T
M6`FU"M($G"1$[P\,]!:MH;A"1%37M@KKK!!3*?:S$L8G&MDFN4]!FCUE@W=7
M87/.'>(1`4.Z"K.\FVR5.<6Q8F&F.9'@OY\3IP?)*4)J2@NHG4M($R`)%P1(
M-*I1/T+-.1E(<A$R:\`68MQ1W$*K(,T7X2;Y7D\=<[(V:R!"XFH-6PFH59`F
M0))L'#;JN=B<M5WZ*T+&7[G`XJ!/5CG`)*3IDB0+NCW^8@&7G"(DG-/,"ZA5
MD"9@9)X"+!:N0U6CS`#S)/=9(NHZUW?LKV25_24A3=<DA1Y_E;H_CY#R5P&U
MRDH16!B1S_ZZ3B7TTZ'>08M<Z#-$CS&3J-:UD=4V=Y16%^JZA4D*/323]G>3
ML0T#@+FD&:U`L[-JE97VF-%U\EA<D3U42H5?,)2OVS!D/)8KQA!C;>XH/7:A
M4%N0&K][309K,[%1SI7'6.$S\[;K&"#M,2/Z/7XJA7W!4+Y:PY#VTS37?NRG
MU%'X:9JK(DUSD-8O2JUG:!7?9:0WXYH2:A6D"9"LBHG*:W&@=BVB/LM'.@QI
MK9^:(JC)5GDA7-3ZQ2"M#]8FK@IA;]A*R%FK(.TODE7CKQ'UX2*J,[PE@\24
M#=O."IR3E!DA:[)-=A\/'A[<:?:#I']12C]#NCZ<&MY-MLJ<.$&$!W>*T])D
M@^LK-5CK*65(S%]30JV"-`&C[K0$%M,Q>Z1EJ?P,F35@ZYULE1RF(,W7)(,>
MAY4I8!DAY;`":I65)F#$G1PV\M'ZDF5>5&,,&8_9BB=;98]Q?@B_Y&G"@Y+!
MLDP&#"F/12L!M<I*$S`R'SPV@<\'BBSMVTVQSY!QEU6);)7=%<>*-Z#9FIS0
M$V"E\"^E?L<*M81:!6D"1N7)7;3I'>JMJ/4R)2V3_&=%K:>Y[&.RR2I[2T*:
MK,D(/=Y*PM\-O5U&2$124T*M@C0!(^KDK7&_0"]+P6?(A)>I#9MLU=U5JR#%
M=V4$/RP&!./`V0W#A$P@IS+7HV$JMYT5I@]NB></[.+(-HF]@C1[DRVN3_>J
MS`@,F11J>#?9*G.*8SF/6%:DWJ(HZ>$4M5XNBS``-JWB)8@2:A6DG>)DA+I:
MC,FAJS(C,*1C<&;J[B9;98]=S`BK01DA6.NB@R%9=Y=0JR#M,2\CC/MY&AQL
M4F#(>"SO0:+,9:OLL8M)834H*01KX[$R*;"5"+M60=ICI,`BR$DVQI5IJZCE
M:@$D><\R4<_L5H4[*KZI(WRH^9J\,%;F4L*0S$S%O5VQ%=A<EKEDDZ=;0IJ]
M22H]DE(FCE6$M,S-#.\F6V5.J:/UZ-HDCNN<@K4.08;$_#4EU"I(.65MM)^F
M=-2#T3"0X<;JCC_2#-8SNU'@CN(.6@5INB8MC(S`=<H7DIDIR+>=U;4(S#9I
MMA6DV9N<TC/;9=I8L_I+1O7,\&ZR5>:4.A81."AMK,N-!$/R5:\2:A6DG>*D
MC1&5\;I,&0PALN0LVU(I6V5O74P9ZT$I(UB;-5&F#+92"T!::6^1.(N4T1-"
M9&T(1$B_&#>SVX5ULLI.D9#F1)+[?DXLT&)_O(X0WI'LKM:44*L@3<`H>U0%
MA/S`^GM=:CY#)H;L9B%;=3?0*DBQK2:#1#^:ZTGL,!$S.,5&PZJ*%\?8)&98
M&.6_'DG5)(JYK#`ZS,22K?N%6?*.Q@PQH_%]Q)*6=Z-O*WH.H5T!]Q08W",Q
MPX(44P0UQ=0(6:HF47FUWR)&K^3FQ#BWU7_7%6;=G8%QZ@K,,!ZDY-6DE/(.
MTV$5[00&%A(S+!PY'_?3=#4I);W#]'J<VVV`,!.NNZCJU620K$=SNR*E9,?-
M2&>G72?MC.M(84W(C3Q4-8EBK:..!5Q'G=T05-Q5DTY=RZ@SXC^R(JLF*2W(
M-6&*:ZQL-@.AM'1L1A=&8O93Q_(63/KH$YPR2U23B.FMP=RPAP8E,T%,8CH@
MPBED$1`]Q/C0LIIT=9"9P[+$<'[X<J((9XL%"YKA<0_C*CZFK!G&Q&)6M-TE
M=%U56%XY]1Q.&1O2(W[4JKK3RHB>%&_UW%3<.+?-2>AJ6&:C//L*,[-O,E#?
M[#N)ICO7+&D5['&>/':-I_Q"D"`@)&:(#4LT?)!93SHGD%P$@D6!@87$#`LG
MT8P-2R?14+#$$D).?"$UV4S,:>I:2$TXG?PSPC)F$?@TLYNORK!D,SG_Y2TD
M(W$+$C-^QV`R2_6%)9F;7)D/-F?V^"20_I@``B)VU6$I,4.,%%[XMH\8)X0<
M@EC&$9-[60=#6$H[PX+D7+`@M:Q7^%;2X-U(Q2><]<+A;*&3N-V/=%VU6J:N
M15B&H\>"=(_KNI/*TG6,B2LV58FU&M.NHQ1@73=&L\,X(>1D>)EM";Y5$1,/
M15F2]F)Q9*.\.!1F;H'RP`!'<MI0CN0]"?Y(M.JY80_?)C-!3&*&V+!DPD><
M5>AUQY[S=@0L.$MD##,L,</"9(Y0+([[<@6?@=8,.5NHQ;$H]E7J^#2G.X49
MTB3G`^8TJK\F)C,"5V%\PAK!)"90VAD6I,B"Q=@ZFU[UBGHLPFMA-E!8'"D!
M9+-R<20C<0L2,[=`VBUNH4]EHM1K1[+\J\5AV2,LDYD@)C%#;%CFX)/3FAAG
MA#R;8%%@6!P2,RR<S%&-7!Q1ZC7#)/]Y1NM%L?U3QZR[Q9&ZPIV:=#C7+.9T
M;%AVYZ/AGJ1Z<WN6;5MU9IC+9%:$93;*LZ\P<PLF[?2$)1^D5K[-AZLSK7I1
M;/^RF2`6LU`L<@PQDG/AVSYB4?TU,<X(.<'@6T<%UFK,L#"9(Q0TLWK,YP`J
MYZ!VAU%235-:+XK]7W=4.R\PL+Z<:<(IZ@&^BYE#^RYEDVZVX+L"`PN)&=^9
MU/$OY#OGQ':5#V-+UYE=`$C+K,)+6F&&-"GX`->QX.<0PS*-F,AM8%%@<)W$
M#`N2:\$BN&Y=C0N[*/UZ=CD=Z+`KM229=4$`UA(SK$G>!>N^)1NS@28F,P37
M"NH\=C>#TLZP<#+)F&?7SBGM*A_`EC%7[-VRF?#;Y302CE"_WV]\XEKY39W"
M9K^5&#ZK=OE)EW=<>\P&I#MRC1D2DF8V:=NJ,T,X);,B`+-1=J3"]-2'4]<#
M'.GD##ZXK9]E+@S[ILIF@ABGEO*5Z"J<KAY`+$J[GF$I]]T,%QAF6&+&/:35
M@D5(9N%`_L"?"JON^+64/<:HQDL36B^*K5LV$Y[C)!*&,YQ-$NG1%'R*NGC@
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M\"*!-^:$KH>?[-TVNAY^2'?;Z'KX^=MMHYC`#]9N&\4$?L!UVM;HAC>-O!9T
MPOL^7@NF%6_=>"V85+SAXK3@E1/BX,_IA.84;Y*4_38KA!?>^RM;\"+H?8N7
M0;T6L,#KED[+&B3PTJ/7`@KN=39K"JH+SL,<X[4^;SC,,-ZW\UHPOWCKS6O!
M[.*ML[)ELX)^XHW<L@4O_>-6W1M:X8;P:KW7!ZSQ@KO7`M9XN=QK`6N\XNVU
M@'5\-]PNCQ5""R\Y>WT06O[]+'$='"YR^BQQ'9SM\5IP'9RP\5IP'9R#\5H0
M/#AGXK4@>'"BPVE9@`&.EWHM8(##G5X+&."(9=FR62"P+UP'W'#6L>RS78`;
M3APZ+4O$`<[]>2V(`YRP\UH0!SCZYK4@#G#LK&S9S)$]W?O9HJ7%9K+LLYWC
M.OB.AM>"ZZ!2]%H0!_ANA->"6<`'';P6S`*^P^"U8!;P40.O!;[&AP>\%O@:
M!_O+ELT4F1F?52E;\*VY^]8O\:C"\PN\*1CXY=T4#-SB;DMUM%].S3`:/I+C
M<)MA-'R-QFF98S3W?C94M_GE+%5M?M%&-9M?LE'%YA=L4\2!6ZYMJ=KVBVVJ
MM7UN-?KX!5>-/FZYA0_&HL6-':J'_7*8JF&_&*[AZPNE,%5U[BR$FLYE$"HZ
M-WI#/>?.=JCFO.ML4,MM7&Y;JO+<(F]+=;%?%E-5[!?%->;4+8DWH6#T`A'^
M=&\&WO1N!?4EE0W>2!4(7Z@1*9N[\A$*1%>F0GGHRE2%4+M0&R+4W.O@WX7:
M^%=!!^]>R,,>3FO&P3<SY!4'WX*J+ZA8_9X]Y30/QWH(X]^E?(]_5>IU]W7_
M]]W;U\/+Z>9I_P6/`";A2-Q;_'>IXE_.QU<\&L"_+74\X]^3"O_[#?^`V!Z?
M<@@O0GPY'L_=7Z!3=^F?)/O\_P(```#__P,`4$L#!!0`!@`(````(0!>9U5X
MT1$``%)8```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;*R<6W/;.!*%
MW[=J_X/+[VM;-TMB)=F*)=[OK-G=9\=6$M78ELM2)C/_?AL"F@W@,+:UM2^Y
M?#Q]"+`!$``I?OCGGX\/9W]L7O;;W=/'\]'%U?G9YNEN=[]]^O;Q_%^_1?]8
MG)_M#[=/][</NZ?-Q_._-OOS?W[Z^]\^_-R]_+[_OMD<SLCA:?_Q_/OA\!Q<
M7N[OOF\>;_<7N^?-$QWYNGMYO#W0?U^^7>Z?7S:W]\>@QX?+\=75]>7C[?;I
M7#L$+^_QV'W]NKW;K'=W/QXW3P=M\K)YN#U0^???M\][=GN\>X_=X^W+[S^>
M_W&W>WPFBR_;A^WAKZ/I^=GC79!^>]J]W'YYH'K_.9K>WK'W\3]@_[B]>]GM
M=U\/%V1WJ0N*=5Y>+B_)Z=.'^RW50%WVLY?-UX_GGT=!-YV?7W[Z<+Q`_]YN
M?NZM?Y_MO^]^QB_;^V+[M*&K37E2&?BRV_VNI.F]0A1\"='1,0/-R]G]YNOM
MCX=#M_N9;+;?OA\HW3.JD:I8</_7>K._HRM*-A?CF7*ZVSU0`>C/L\>M:AIT
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M9N0J5JQ0K5[9KGT0^B#R0>R#Q`>I#S(?Y#XH?%#ZH/)![8/&!ZT/.@M<4GKZ
M'%'K^W_D2-FH'/'5O6$@21M["6$%AZQ]$/H@\D'L@\0'J0\R'^0^*'Q0^J#R
M0>V#Q@>M#SH+.`FA?@P)F=!(,SR&<Q]1431:6WUD,IJX%_Q&:U1?[SN2UXU6
MO:1/"I`02`0D!I(`28%D0'(@!9`22`6D!M(`:8%T-G%R1+<VR)&ZSYXXL"D;
M&AO=D6WN9<V(7LM:+^FS!B0$$@&)@21`4B`9D!Q(`:0$4@&I@31`6B"=39RL
M48*<K+W>HY3ZF!R^J#>:C.UT348S-UVK7L1A:R`AD`A(#"0!D@+)@.1`"B`E
MD`I(#:0!T@+I;.+DXOJD7"BUFPM-*!=\F5=`UD!"(!&0&$@")`62`<F!%$!*
M(!60&D@#I`72V<2Y\#2..)U`S\DNU)3S\'U[]_O-3D_P!SK'A.9>>D:F3-Q\
M:#*>2CXTN1:RUN1X)I[(34;>'2CL19S8"$@,)`&2`LF`Y$`*("60"D@-I`'2
M`NDTT1?(21$-,$Z*!E)!:RG.A5*[N=#$[AN:7!]7GGKRJ\F<RM#/!28C[]83
M]J(^%X9(MXN!)'V493V^<H?)M!>Q=09&.9"BC[*MO7EEV8O8N@*C&DC31]G6
MW@RJ[45LW6FBKZR31%I5GI!$I7:3J(F=1$WL)&HRI[YN)7'A7NFP%W&9(S"*
M@21]E&4]]I94:2]BZPR,<B!%'V59CY9NJ<M>Q-85&-5`FC[*LAY/7>NV%[%U
M9QLY250K_!.R>)2[:33(SJ-!=B(-\C+I79-05%SR"+UB1`D&IH@R#,P1%1A8
M(JHPL$;42*"=+Z^5M:+B:G>.EYLQM<[%/8<3[V\CO5JFF3F?\L8@)Y%:Y212
M([K'<6!H`BT4&60%QH@2#$P191B8(RHPL$1486"-J)%`.VO>/+@5%5^)SO%R
MLZ86PW;67K_EJ;TS;[@TB.ZF=J&\R<5*5%RHM4%T)V04(HHP,$:48&"**,/`
M'%&!@26B"@-K1`T&MH@Z)]!-CUH(GY`>LVZV>X]&]OQ0[5Q2$NT)HD$T#$HN
MM,I"$0;&B!+T2A%E&)@C*C"P1%1A8(VHP<`64><$NKE0R]L3<F%6PW8N-)HX
M<[^Q-_=;C8Q*<K%F9`>.YUX?"UFU..[43D;+F3>@1ZR0+A<SDK,EC%X]6VI4
M,RJMS('&WAPH&_*:7'ESTIQ54HB"T:N%*%G%59[.O#EIQ0JI<LU(SM8P$E5K
M$-5/[7O3$Q&O:IT3X[84M?@^H:7HM;ISS]/HFB:YUL7UIB4KM?%%'7DZ[GOM
MFI$L_D)&:N'RQZ?E:#[U)M<1*R0H9B36"2-1I0;-J!Q2S(F7W4P"+16V`:A,
M(8$\*I6,=&7&5PO(M[&14M8<(W5I&(FJ-8CJHB[3U85WD3HGQ$VW6O*?D&Z]
M0^"D6Z/Y\1GC<9FX&FDTD4:Z9B2--#2(&BE?H0A5,2/Q2AB)5XI>&:IR1N)5
M,!*O$KTJ5-6,Q*MA)%XM>G6.RLT%C1>GY$+)O76#1G.:Z5AMVAM)5VHOW^]Z
M!DDN0J.B-B7I`56,7@DC\4K1*T-5SDC:>L%(O$KTJE!5,Q*OAI%XM>C5.2HW
M/6K5?D)7T8M\IZMHY'05C9RN8I`THY!,5,:<K@*JV*@LKX21>*7HE:$J9R3-
MNV`D7B5Z5:BJ&8E7PTB\6O3J')6;"[7X/B$7>JU.?MR6;T9F^4Z7T>HJWHB\
M,BKG+J4#I]*,0E;IX7<V'\_'WOPF8HE$Q8RDB2:,1)4:Y-VFO`$^P\"<D=@7
MC,2^9/3KHE<LD:B:D7@WC$35&N05W=M8Z9Q`)\EC?Q]%[3J/:0QZ_Y;ST<(=
M(PVB3F@GWEN(KHS*ZDMK@_2;.,<;7<A(3^%FRXD_AXS81QIZS$BZ0\(^HDH-
MNG:G)W[>V4L"<T9B7Z!]R>B7):_81ZQK1F+=,!)5:Y`[N9[X:7<"W;3_7S9C
MQK@98]"4.G#?Y4=77D]=L4K:]MJ@F=UD<`G#JM%Q$C:?S>93;]H=L;=TDIB1
MG"YAHU=/EQK5W%G#3+S:9&SOJ&#^RBHI1/&N0I2LTG6^OI[-%EZ=*_:6.M>,
MY'0-(U&U["T3D,Y1N8W&WPORGU#]MGNF<>"M%R+&N$=DD+V%AVB-*$04(8H1
M)8A21!FB'%&!J$14(:H1-8A:1)V#W!RI71G[INWGZ%U/$<=Z;\>^EQNTL)8@
M!MG[1`:Y3Q(GW@Y&*"J>*D2(8D0)HA11ABA'5"`J$56(:D0-HA919]#`<T7:
M?7.S]OHNZU'NW7&5`[WF)7U[95367O;:H#<>+HI*TJ/MYS*YBUDE*&&DI@_]
M<V1XP"@JML\8B5>.J&#DVGO3R5)4;%\Q$OL:4</(M?=F`ZVHV+XS2%]HMS>J
MS0:[-[Z15[TWX70[C9R\:N3D52/O*95WEPC5:[[41NP=6X,LKQA1(H%V7KTE
M;RHJOC(9>N6("@FT[.&YHZC8OD*O&E$C@98]/'L4%=MWCI>;U]-V=,:XHV.0
MDU>MLG*Q-BHOK]XV7R@J+GIDD.45(THP,$6486".J,#`$E&%@36B1@+MC'GM
MK1455[MSO-R,4:]V>N+_=E]4+M[`JY&32(VLB[]6*RK5]62>%2**#+("8T0)
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M`6Y;\'=W7I]V3G`;QZ`WGB\:E;USRTC6(2$CO?TY]'R1%1(4,Y).DS`256J0
MM_OIS8\R"93VB<^8625G+!C)&4M&NC*CZ6SA;;I5K)"@FI%8-XQ$U1I$E3D^
M4(8'C$Z(FV]_8^:-?.,&S$0C^ZF)04Y'URIZ/X&[36A4]E,3#A15S$B:>\)(
M5"EZ9:C*&8E7P4B\2O2J4%4S$J^&D7BUZ-4Y*C<7_@;,&[G`G9:)1F\\8#0J
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M5T9E]:6U0?8#1D9F`C>ZFGD^$?M(0X\927=(V$=4J4%O/&!D+PG,&8E]@?8E
MHU^6O&(?L:X9B77#2%2M031867,F>,#H!+II5VMZNV__3_LMZDU(;[_%H#<>
M,+)*VO;:H#<>,+)*/VRC'T'-1UY;C]A;.DG,2$Z7L-'K#QB-RGO`"!-8?1EH
MM+*2`0\8L1#%NPI1LDK7>3Q9SOP>4+&WU+EF)'5N&(FJ96^9@'2.RFTT:L_E
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M:OH8;CTAJW0>1@-UL&/<.J@EV@EUT"LZIP[]NL_DP;N`JZD1V'GH8Z0.!OTZ
M#W:,6P=_/?3ZO7&*:Q^#)`_>S&;%`CL/VH9BI`X&_3H/=HQ;!S4?/2$/>OKJ
MY$$CY_X^]GODBE9IJL59MYDUHA!1A"A&E"!*$66(<D0%HA)1A:A&U"!J$:FO
MU<G%T>G17Y_3'_IZW+Q\VZPV#P_[L[O=#_5E.7KX_.E#C_5G[V[&XT"]34:M
MPCOR>;((/M,Y\`C-G`,U^1LZLJ0CRZ$CTROZOM[QW3'O/#?3.7]YSSM"[]50
MV89*0+>N0-V8L`3T&;_/0[6YH<_[#>EO5/4'?&XF5)$!_GD:?-:=R"OL#97U
M..CZ?!9TQ[6/SZ^#[M@_/4[O*@7J>3M6C5Y9"M1C=SQ";RX%ZKVDH2,S.C)T
M?GK'@HX,E8">X].1H?/0>T"!>LL'ST-ODM"1(3=Z6X&.#+G12U^!>DL!W>C=
MKT"]K(!'Z!6P0+W@-71D1D>&RD9OIM"1H;+1VP]T9.@\Z_&$KL%0`[BA$MP,
MQM#[=L%J\`B]=A>$@Z5>TQ55KV5A?>C5'SHR5&IZEX2.#)4ZHO.H=TC0C5[6
M"]2K)'B$WMFC_`Q=T8YZ.?TN'$/HA]F!^B4V'J&?60?IX!'ZT72@?B6-,?03
MZ$#]YAF/K$<3.L]0$N@GQ'2>H2/T@V`ZS]`1^GDOG6?H2+4(U._KL0#U(E"_
MLL<#S2)HA\:_9AFT0Z,??4Z!SCTT^M%/]NG(T#F294!?\<!STR<CJ.Y#7O19
M`CHRY)4M`O4U`C3+%X'Z)@$>*!8!?:UE@"\#^@#(`*=2J:]-#!T9T9&A<ZQI
MG!EJDC>+0'W3`:U6BV`U>&"]".B+.!BP7@;TD94!3J55W^P8.D)WEL%S1(M`
M?1T"0^)%H+X1@0>214`?TR%^V8_Q]$77Y]MOF_+VY=OV:7_VL/E*]^6KXR<P
M7O0W8?5_#N9%^B^[`WW+E=;>](5.^G;OACZ.>75!4\NON]V!_Z-.T'\-^--_
M!0```/__`P!02P,$%``&``@````A`/IG#Y82!@``KA<``!D```!X;"]W;W)K
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M'[X&95>`HR`S,VVB5#07N`'XJ]45*0UP)/\R?+Y6A_Z\T9>+F>TLE@:$:X]E
MUT<5D=2UXKGKF_I?&F0P*2IB,A'X1)'ES#)MQ_V(BL54X).I&#/7MJV5Z[S_
M5B!RF`]\,A'GXR*P.`81^/S^._&8"'PRD=5[C9W3)`TY#_(^WZ[;YE6#A01I
MZ&XY69:&;T"M8+9I;L;\?RO]D'>B\D!D-CK,#C+;0<V^;&UOL9Z_0)T5+&:G
MQAABQ!XC2%$1V4`&H0PB&<0R2&20RB";@#G8,GH#Q?<SO"$RQ!N<U0X!-\N4
MC,`('!+(()1!)(-8!HD,4AED$R`8L?PY1A`9>!I,BL22:X2&&,XD9B5Y,X:,
MYB@D5$BDD%@AB4)2A613(G@$SYB?42Q$!M:BN)*D=;)C06^Y-(:,+BDD5$BD
MD%@AB4)2A613(K@$#U'!I?N;"CY52/1@!DYB1XD)*W9\T)CN4JJ0,0B'!0H)
M%1(I)%9(HI!4(=F4"'-??6CN)%J<.R4P=YS67B&!0D*%1`J)%9(H)%5(-B7"
M1*$NA233/65&]MS^7!5/NX;N_W>2OX2]@^XH1$2</R,FGS\EIC62@!(;'F2\
M/AQ+K(]P#$(C(X7$"DD4DBHDHX3>D&`)K.<?MX2(B)8P,K&$DJDEE-C$V9>M
MN3"DU1*.OX]N*!JQ0I)Q%%.5=K!T_!U5LZF&X`VT,X(W=\H".D>L"Q(MFD#)
M$IXY/.>NE/,]"QKZ9MI;,`(IX\,<:;,)69`[F&>8*\=V7;&:HE$'9QHKUTK&
MF#>NE8K7<KVE8XN7RD89N)1@(>G</N#A$"Z:R)`%0MP.5[J!/4;Q@@L0\448
M(B))@T9PN;`]R=<(0_BH&!'73A#QJ!01U;:6IFE(VAF&#*-$FTBG-^UVWRXU
M@S:&L!EC:G<,2<4FW<$>HR;5AL@9M4)$M+C,U6)A2JLHPA`^*D;$M1-$/"IE
MR!87A2/5DS!0=(JT@A]PBG:.@E,4204E+9Z]P:)XT@-$/.DA(IITT_(\5VJ)
M(@SAHV)$7#M!Q*-2AFRR.>&[B^DJ3K'[O%-3I"/\@%.L@9S6%$5237EBKO8&
MB^)Y#Q#QO(>(V`-KY=FF9'F$(7Q4C(AK)XAX5(H('X:.M9#VD@Q#AE%B09&6
M<&K3=S4%!FLLI^Y1)-:9_.ZY9P,M7@L!0S:?88@(MJIOUT*$6KR(8D1</D$M
M+I\B\NA6[%G2)I6AS)TJ(UWEC]M'>U-AF5*T$I[[GK2Z]N3\!W;=)2^0@*&5
MT(HK^R=&F73*EN,XAK2I1"C.G8H1\>LEJ/3F]5*,HM=S;,-;2O6?H?:=&B4=
M[5LF?VYNL&O^[UD(;8P%EUFO+!:6]/*[AU,]XK+)JSM04:BB2$6QBA(5I2HB
M1XO\)N@2ID>%]-BH+MM3N2\OETXKFF=R#`@/T.UZQ/2,<K?RX?4`=DV9&_`#
M7$'])7!\Z*?O<->'#E7EB>M#CZER.!U]&%:A<F6X\)WXG>G#L8>JLUOZ\*ZO
M\@?+?[@[@9WEPVNO.F!G^_!*"'P^WA&<EM[R4_E'WIZJ:Z==RB/8N!C>CUIZ
MWDJ_]*S<'IL>SDF'RCO#N7@))V-PHJIKQZ;I\0NYP'C2OOT/``#__P,`4$L#
M!!0`!@`(````(0#MUU$`YP4``"07```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;*R876^C.!2&[U?:_X"XG_!-$I1DU(1O[4JKU>SN-24D00TA`MK.
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MSW`#\%>I2A(-<"3[VE]?RWUW6JN6.W/FNF5`N?)8M%U8$DE5R9_;KJ[^HT4&
MN:E!Q&0B<&4BIC5;.([M+N8?5[&9"ER9BG&_"'37CP>N3.3^X;A,`Z[#C=QK
M"3Q?_7W`=="XVY$E$X'K#P_&@$C1&2;98K/WT1G6:%KZ\/E9EVU63?VJP!,-
M>6BO&5D?#(_TP&-'0S($\:T<0G:(R@.16:O@$42LA8?G9>,LS97V`H'/6<T6
MUQABQ8Y7D$@265\&@0Q"&40RB&60R""=``UL&;R!I^!7>$-DB#=\5%L.1K,D
MJW:\@C?Q91#(()1!)(-8!HD,T@D0C+!N&&%!6&ZO33P3I!6L0I-,F$M+G/$M
MK3'FDR)7+-D-)8,9B`2(A(A$B,2()(BD4R)X`HO;KP@'D8%G3WQR9)=8T7LN
M#26#2X@$B(2(1(C$B"2(I%,BN`2KM^#2^XDAU;T9?!!;2DQX0H>%Q5PZ4D*&
M(M[,1R1`)$0D0B1&)$$DG1)A[/#6N6/LI%H<.R4P=CZL'2(^(@$B(2(1(C$B
M"2+IE`@#A5P*`Z7OD!G9,72G,G_:UG3C<6/R+7A7T#<($1''SX@YCI\2TQZ(
M3XD#"]>8C[DMYB,8BKB1(2(1(C$B"2(I)?2&!$O@>?YY2XB(:`DC$TLHF5I"
MB4.<?=F8NB$M)L'P_>`&TH@0B8=63%5Z8R7#]UPUG6H(WL`F2/#F1BQ@R\IS
M0:I%$RBQ8,T9YUR7UP16Y(Y1802F;&PVEUXV`2M:].89^L)V%F*8PD&&#S1"
M7<5#S3M=)4)7[MQUI9[2005Z$@PD^[0['.S+10L9LD%H-&,IF;'C56/<?([&
M1S#@B$S9R\9V75.:BY!7C(TBCD;IF*.Q*N'H3>F45_2-1)/(K@[O;.]<E0RZ
M-X3W,Y_N+4-B_I9S,28[7C4)($/V?-`*&'+)2LDWSN9"T@JYUM@PXFB4C[%\
MPA&+L[%<Z.)MIERGEQ;](YO!J7_O/Z8&W3L*1E$$(>/>[5B5/4Z[S]$X[0%'
M=-H-Q]$7TB(6\I*Q5<31J!US-%8E'#%MTS7GDG;*2VYDBNP&IY[\T)O.8'O*
M::8HDC(E+0@[UM`:)]UG2,@4U1(SM5R*$Q]RK>ER:.E2/")>-?88XQX3AH0>
M+5WZ<9=RK;=Z%--'=I0_[S3;ETZ=ILB&Q75XXBQ=>IOM#%8U9LEGR!&63/3^
MX%5&OQBZAF5(DQARZ3&3$4=C;S'7>;>WA%>QWAP79YD-Y$:6R;[U/8>_U%=X
M:?S?CSQR1"6]GQD2-^WRRK,;J_CJX&,48!1B%&$48Y1@1`[TR-W3/38-(#V@
MHV<D5=$<BUUQ/K=*7C^3PS=8&S:K`=.3P:WKP=X81B%SP^%'AM(W_MR#S21N
MX2\\V)YA'B\\V&!A#F>2#WUH)/TM.:N\4;\U/?B-CW6VE@<_=#%_L+T'L`A_
ML;4]^,UW@\.(^WIMN",XH[QFQ^+/K#F6EU8Y%P>P4>]?PPT]Y:0?.A:WQ[J#
MT\D^>2<XC2[@&$B?P30=ZKKC'Z!C;3C?WGP'``#__P,`4$L#!!0`!@`(````
M(0#;+Y2,&P4``/P2```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*R8
M76^C.!2&[U?:_X"XGX`)A`0E&96$3^U*J]5^7%/B)*@!1T";SK^?8XP!V]EJ
MLM->E.3)\0OG/<?8L/[Z7EZT-UPW!:DV.IJ9NH:KG!R*ZK31__XK_++4M:;-
MJD-V(17>Z-]PHW_=_OK+^D;JE^:,<:N!0M5L]'/;7CW#:/(S+K-F1JZX@E^.
MI"ZS%K[6)Z.YUC@[=(/*BV&9YL(HLZ+2F8)7_X@&.1Z+'.])_EKBJF4B-;YD
M+5Q_<RZN#5<K\Q^1*[/ZY?7Z)2?E%22>BTO1?NM$=:W,O>14D3I[OD#>[\C.
M<J[=?5'DRR*O24..[0SD#':A:LXK8V6`TG9]*"`#:KM6X^-&?T)>BBS=V*X[
M@_XI\*V9?-::,[E%=7'XK:@PN`UUHA5X)N2%AB8'BF"PH8P.NPK\46L'?,Q>
M+^V?Y!;CXG1NH=P.9$03\P[?]KC)P5&0F5D.5<K)!2X`_FME05L#',G>N^.M
M.+3GC6XM9TO'L1=+%V2><=.&!=74M?RU:4GY+XM"O193L7H5.'(5-'.1N9H_
M(&+W(G#L1=#C5P+7W.4#QU[$?5P$)D<G`L?_?R6K7@2.#U^)P:K4%7V?M=EV
M79.;!C,)RM!<,SHOD8>@67BY66V&!OBO^D/AJ<H3E=GHD!Y4MH&F?=LZ2W=M
MO$&CY7V,K\8@,6+'(VA74=F]#`(9A#*(9!#+()%!.@$&V#)X`\WW&=Y0&>H-
MS\KG8#3+DHS@$7S(7@:!#$(91#*(99#(()T`P8CYYQA!938Z_)\TR5+,W&<Q
MR)T$+<20W1`RN*.00"&A0B*%Q`I)%)).B6`2W&4^HUNH#$Q&<2JM1`O\/N@C
MEX:0P26%!`H)%1(I)%9(HI!T2@27X#8JN'1_6>&W%1K=F<&3\!FQ8,H.362Y
M<]&>W1#$A^T5$B@D5$BDD%@AB4+2*1%R7SR4.XT6<V<$<N=I[12R5TB@D%`A
MD4)BA20*2:=$2!3Z4B@R6U1F=.ENST7^XA.V`;A3_#DL'FQ)H2)B_CWI-C]=
MS(X1RQX<V3/BP)ULTA^VV!_!$,2-#!42*2162**0E!%V08(E,)]_WA(J(EK2
MDXDEC$PM8<2ASKYM+1-)LR48?A_<4#0BA<3#J%Y56L*2X7>NFDXU!&]@0R-X
M<Z<M8*O)^X)&BR8P,H=[SJ3FCECS71^T&%NE)U"RR3!IL0GZH&5GWL)""U>Z
M%X>##$\T4DX5#S$?G"H13H609;MSZ5SIH`/G$BRD6[<'/.S"11-[9(/0Q`YI
M#[?C46/#[3D:)V'`$2T:M)QCKFRIZ4(>,HZ*.!JU8X[&J(0CICU?FO`GECKE
M(=THT2:ZU5.WNP_>F1#;,,(:S4ON]TCJ06ESL^-1DR;LD>T.6@%'K.>0:ZY6
M4E>&7&@<%7$T:L=<:(Q*..JUD6F[TB8\Y4+=*-$]NC_\>??8+E-PCR$;VGO2
M>U+S[^"IE\Y\>^R/?8\<L6DEMP(>A;IVA)SG"R25)N3B8Z=%'(WGB[G2A^=+
M>%1_O@5R+*3T:)_,I$?9(SE[.BMQ?<([?+DT6DY>Z>,VE&6['C![%^`O/%B$
MH0DEOG<]6)ON\*4'=WN5QTL/[M<JAW<-3UWVDKY/WT'<B?<M#YXA5!U_[L&^
M6>5/MO<$9JD_^+8'6\@[W/%@>P7<&*X(WCU<LQ/^/:M/1=5H%WP$L\QN1M?L
M[07[TI(KF`@O($@++QVZCV=XRX3A,=.<P<;D2$C+O]`3#.^MMM\!``#__P,`
M4$L#!!0`!@`(````(0"U<Y%$,0$``$`"```1``@!9&]C4')O<',O8V]R92YX
M;6P@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"<D4%/
MPR`8AN\F_H>&>PMMU1C2LD3-3BXQ<4;C#>';2BR4`-KNW\NZKL[HR2-Y7QZ>
M[Z-:#+I-/L%YU9D:Y1E!"1C1266V-7I:+]-KE/C`C>1M9Z!&._!HP<[/*F&I
MZ!P\N,Z""PI\$DG&4V%KU(1@*<9>-*"YSV+#Q'#3.<U#/+HMMER\\RW@@I`K
MK"%PR0/'>V!J9R*:D%+,2/OAVA$@!886-)C@<9[E^+L;P&G_YX4Q.6EJ%78V
MSC3IGK*E.(1S>_!J+O9]G_7EJ!']<_RRNG\<1TV5V>]*`&+[_;3<AU5<Y4:!
MO-FQX<VUB?=-A7]GE12C'14.>`"9Q/?HP>Z8/)>W=^LE8@7)+U)2IN1R710T
M+VE!7BM\;$WWV0S4D\"_B4<`&[U__CG[`@``__\#`%!+`P04``8`"````"$`
MZG6=N)`#``!(#@``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````"<5V%OFSP0_OY*^P\1WU?2=JI>
M583)(4YCC1B&G:[]9'G$:=`H1.!%[7[]3&@;2"_>LF]@WW/WW-W#&7N?GQ[S
MP595=586(^?\;.@,5)&6RZQX&#D+/OWXOS.HM2R6,B\+-7*>5>U\]C_\Y\55
MN5&5SE0],"Z*>N2LM=Y<NVZ=KM6CK,_,=F%V5F7U*+5YK1[<<K7*4C4ITY^/
MJM#NQ7!XY:HGK8JE6G[<O#ET6H_76_VO3I=EVO"K;_GSQA#V/;39Y%DJM<G2
MGV=I5=;E2@_P4ZIRS^UN>H8=4^G/*M//_M!SNZ\>2V6N`N/87\F\5IZ[7_!F
M2C9%BV56U;ZWU==;E>JR&M39+U.V"V?P7=:JH3-RMK+*9*$-K<:L?=D]YYM:
M5_ZWLOI1KY72M><:@W9Q]]BU[3YGG_RKRYV%>>I;-AY:)F:CSY%G.E=UM(IE
MI0'*5Y==SCL6+>.6T&L7A=&&P(4V]1*D:+N=E5WF;SD$$6512":(XXD8HQ#1
M``LVPYBS4^U%+/\,8=Q$FF/*F8BF(HKQJ1#&HU,A`8)SX3,L@F@>(WH/NF2+
M^1PE]PU11FXHF9(`42Y0$$0+RD$(H;<FMRB!'48F8B*"19(8(X$8.U;E*;DS
M[;`8Q`F.$9D(?!=CRN`B$LH1O2'C$-L\]3F%!(U)2#C!<,EHQ#$3,;I'QBU8
M`=.?X,LL"B<X80)_71`.UX)04WHL.+H[$BK!X4Z4,4J.TADO&*&8,=-&HUO*
M$\2)$31(S(2;$]Y*#]%)`^&$WF`:'$N6X1`'S7?Q=6$XX"2\%U-"S1="4"@F
M8!"V&#.3=-->W"@!IF(7UCGH^4U9@LOO9D:`1OUFMOJQV7=U9K,[D)O-])WJ
M;,9]OAWQ[4!@BH"^;!&Z,K/96=4A8"96><!=[(P<,5%:9GDMJ*PJ<PIN%1S%
M.H0N0,Q>*R\Q0*M^\5_$8@/TU/)W["$(2.90838>[R76)0.Z/PHYS5K`7>U7
MLBOCAA@8P@Z!P_2&[SOY@&'L$#@,](7M"PR&L4/^)0PL;$N<DWF=SNID3N(2
M9-6;2?O*VJ8`!/E[WW"J!P?L@:!`[T?.VQ<H"+$/5IB9'7.D#=9I?`1S>%KW
M:M!-I_?+?O"3'F;%CWJQX>5$:O5Z"^DO>FPM*[4T_^>O^_L%;V8N(%7>.`G6
MLGA0RU>;]QO-G>FVO1CZYY_.AI=#<QWJK'GN_@KH_P8``/__`P!02P$"+0`4
M``8`"````"$`*GF._CH"``"V)0``$P``````````````````````6T-O;G1E
M;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+````
M`````````````',$``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0`N#3RG
MAP(``$\E```:`````````````````)D'``!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+`0(M`!0`!@`(````(0`T0G$JQ`0``&(2```/````````````
M`````&`+``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$`'J#M=;P%
M``!`%@``&`````````````````!1$```>&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL4$L!`BT`%``&``@````A`%<4</)2%@``Y+T``!D`````````````````
M0Q8``'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"+0`4``8`"````"$`
MX]')864+``!P30``&0````````````````#,+```>&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+`0(M`!0`!@`(````(0#^<039)0P``%%;```9````````
M`````````&@X``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&
M``@````A`,Y;\V"C(P``WCX!`!D`````````````````Q$0``'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"+0`4``8`"````"$`6@_:5/$$```)%0``
M&0````````````````">:```>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M`0(M`!0`!@`(````(0#._$K/D04``)`8```9`````````````````,9M``!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!`BT`%``&``@````A`*=0T2]H
M!```]PX``!D`````````````````CG,``'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"+0`4``8`"````"$`J0L1.%4"``"9!0``&0``````````````
M```M>```>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+`0(M`!0`!@`(````
M(0`,Q)--=@(``%X&```9`````````````````+EZ``!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L!`BT`%``&``@````A`*,%]O"Y`@``#P<``!D`````
M````````````9GT``'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"+0`4
M``8`"````"$`;*=Z+N@"```W"0``&0````````````````!6@```>&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0`[*J7RE0(``,X&
M```9`````````````````'6#``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL
M4$L!`BT`%``&``@````A`*<YLE>;`@``6P8``!D`````````````````088`
M`'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4``8`"````"$`%,28
M1P@%``"A%0``&0`````````````````3B0``>&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+`0(M`!0`!@`(````(0"C[B1K.@0``/,/```9````````````
M`````%*.``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!`BT`%``&``@`
M```A`.$:JUKV`P``G0X``!D`````````````````PY(``'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"+0`4``8`"````"$`OS7DJ:H&```<'@``&0``
M``````````````#PE@``>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+`0(M
M`!0`!@`(````(0!X&>[]K`,``'<+```9`````````````````-&=``!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L!`BT`%``&``@````A`/MBI6V4!@``
MIQL``!,`````````````````M*$``'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M+0`4``8`"````"$`FJ$>#2`.``"@D0``#0````````````````!YJ```>&PO
M<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0"BRV9[`8L``-/8`0`4````````
M`````````,2V``!X;"]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(````
M(0">DPW7*0,``&@*```8`````````````````/=!`0!X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`:3BYLZ4%```9%P``&```````
M``````````!610$`>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!`BT`%``&
M``@````A`$`O5!65!```V1```!D`````````````````,4L!`'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"+0`4``8`"````"$`9E"$5\@"``#9!P``
M&0````````````````#]3P$`>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M`0(M`!0`!@`(````(0"C@IDDA0,````,```9`````````````````/Q2`0!X
M;"]W;W)K<VAE971S+W-H965T-C`N>&UL4$L!`BT`%``&``@````A`*^$K5-U
M`@``[`8``!D`````````````````N%8!`'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"+0`4``8`"````"$`\4[L;=("``!,"```&0``````````````
M``!D60$`>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+`0(M`!0`!@`(````
M(0`[UWM1*0,``)D)```9`````````````````&U<`0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L!`BT`%``&``@````A``*FAU'/"0``QD,``!D`````
M````````````S5\!`'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"+0`4
M``8`"````"$`&IE7U9\#``#C#0``&0````````````````#3:0$`>&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;%!+`0(M`!0`!@`(````(0#@/.*P.P0``)`0
M```8`````````````````*EM`0!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"+0`4``8`"````"$`W2&IT?T"``"D"```&0`````````````````:<@$`
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(M`!0`!@`(````(0#@+%$N
MG`,``($,```9`````````````````$YU`0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L!`BT`%``&``@````A`/XT7C[K$@``"&```!D`````````````
M````(7D!`'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"```
M`"$`Q9[$"Z<'``#Y'P``&0````````````````!#C`$`>&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````(0`2+L_B"@4``!H8```9````
M`````````````"&4`0!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`BT`
M%``&``@````A`#B^_;O2,0``UC`!`!D`````````````````8ID!`'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"+0`4``8`"````"$`?+2R-%,+``"-
M.```&0````````````````!KRP$`>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+`0(M`!0`!@`(````(0"`"/3[,00``&$1```9`````````````````/76
M`0!X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`/K:
M-*6R!0``9Q8``!D`````````````````7=L!`'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"+0`4``8`"````"$`Z0#V+Y$&``"P&@``&0``````````
M``````!&X0$`>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(
M````(0#+?:,'/@8``*08```9``````````````````[H`0!X;"]W;W)K<VAE
M971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`*.851\T"0``/3```!@`
M````````````````@^X!`'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M
M`!0`!@`(````(0`[T544NPD``+TL```8`````````````````.WW`0!X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`;*<Y--0%``#>
M%P``&`````````````````#>`0(`>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L!`BT`%``&``@````A``G.231>$@``VV0``!@`````````````````Z`<"
M`'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0`+"1J`
MK@4``%L6```8`````````````````'P:`@!X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"+0`4``8`"````"$`[S(>1Y0"``#"!@``&0``````````````
M``!@(`(`>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+`0(M`!0`!@`(````
M(0`!C%8XT0(``"\(```9`````````````````"LC`@!X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`.PF'3A>"@``##,``!D`````
M````````````,R8"`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4
M``8`"````"$`D3JYV*49```,A0``&0````````````````#(,`(`>&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M`!0`!@`(````(0`X$(:3F`D``$8L
M```9`````````````````*1*`@!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L!`BT`%``&``@````A`/!G#E(Z!0``"A,``!D`````````````````<U0"
M`'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`#Z/:
M"AL*``!7,0``&0````````````````#D60(`>&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+`0(M`!0`!@`(````(0!*4:.D)04``/X7```9````````````
M`````#9D`@!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@`
M```A`&"@R\9.!@``8QD``!D`````````````````DFD"`'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`E2B#8X<'``#K'@``&0``
M```````````````7<`(`>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M
M`!0`!@`(````(0#,6EP#6`4``#@4```9`````````````````-5W`@!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A`(0BIR:2`@``
MX@8``!D`````````````````9'T"`'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"+0`4``8`"````"$`QNLS`7H4``#7;```&0`````````````````M
M@`(`>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`!@`(````(0!>
M9U5XT1$``%)8```9`````````````````-Z4`@!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L!`BT`%``&``@````A`/IG#Y82!@``KA<``!D`````````
M````````YJ8"`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`
M"````"$`[==1`.<%```D%P``&0`````````````````OK0(`>&PO=V]R:W-H
M965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0#;+Y2,&P4``/P2```9
M`````````````````$VS`@!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!
M`BT`%``&``@````A`+5SD40Q`0``0`(``!$`````````````````G[@"`&1O
M8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A`.IUG;B0`P``2`X``!``
M````````````````![L"`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````$@`2`"J
)$P``S;\"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Federal</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">$ 37,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">State</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
        <td class="nump">$ 35,000,000<span></span></td>
        <td class="nump">$ 35,000,000<span></span></td>
        <td class="nump">$ 35,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGBGM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="4">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="4">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Mar. 13, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Feb. 25, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Apr. 25, 2013

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 19, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Issuance of 6% Promissory Notes (January and February 2012)</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012

</div>
          <div>February 2012 Notes Issued To Individual And Entity</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>February 2012 Notes Issued To Individual And Entity</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>February 2012 Notes Issued To Individual And Entity</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012

</div>
          <div>February 2012 Notes Issued To Parties</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>February 2012 Notes Issued To Parties</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes Issued To Individual And Entity</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes Issued To Parties</div>
        </th>
        <th class="th">
          <div>Apr. 25, 2013

</div>
          <div>June 2012 Notes (secured promissory notes)</div>
        </th>
        <th class="th">
          <div>Mar. 21, 2013

</div>
          <div>June 2012 Notes (secured promissory notes)</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes (secured promissory notes)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Stated interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.35%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.02%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Description of interest payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Interest payments were due and payable on the tenth day following the end of each calendar quarter<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Under the extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from revolving credit note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of revolving credit note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">401,085<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAmountOutstanding', window );">Revolving credit outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">613,718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,685,300<span></span></td>
        <td class="nump">3,314,700<span></span></td>
        <td class="nump">5,685,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants (in dollars per unit)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.41<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,220<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,735<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,220<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1', window );">Line of credit facility decrease forgiveness</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump">1,165,981<span></span></td>
        <td class="nump">1,905,409<span></span></td>
        <td class="nump">64,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">735<span></span></td>
        <td class="nump">7,366<span></span></td>
        <td class="nump">5,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">1,358,014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,357,110<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,347,128<span></span></td>
        <td class="nump">2,344,719<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="nump">4,691,847<span></span></td>
        <td class="nump">1,850,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,882,019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Acrued interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">150,068<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,124<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,595<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,517,741<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">859,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">197,383<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Recognized loss on extinguishment of debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(10,307,864)<span></span></td>
        <td class="num">(7,390,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,307,864<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,102,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Amount of shares issued in exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,145,486<span></span></td>
        <td class="nump">8,145,486<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingSurrenderValueOfNotes', window );">Remaining balance of notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,347,128<span></span></td>
        <td class="nump">2,691,847<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,344,719<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of interest rate terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier
of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory
note(s) issued in an amount of not less than $1,000,000, or the Funding.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Accrued interest at the annual rate of 6%, was due in one lump sum payment on February 24, 2014.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="nump">$ 212,853<span></span></td>
        <td class="nump">$ 17,253<span></span></td>
        <td class="nump">$ 696<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 21,595<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RemainingSurrenderValueOfNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amount of remaining surrender value of notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_RemainingSurrenderValueOfNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13476-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28567-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest payable on debt, including, but not limited to, trade payables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAmountOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount borrowed under the credit facility as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityAmountOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of decrease in line of credit facility from forgiveness by the holder of the line of credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityDecreaseForgiveness1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityInterestRateDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effective interest rate during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly unaudited summary information</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years&#160;2013&#160;and&#160;2012&#160;is
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">2013 Quarters</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">(In thousands, except per share)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">1<sup>st</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">2<sup>nd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">3<sup>rd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">4th</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,081</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,295</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,863</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,157</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,646</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,396</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,376</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,009</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,673</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,361</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.05</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid">2012 Quarters</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 36%; font-style: italic; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">(In thousands, except per share)</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">1<sup>st</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">2<sup>nd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">3<sup>rd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 11%; border-bottom: Black 1pt solid; text-align: center">4th</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Revenues</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,241</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">908</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13,290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,850</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(4,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,727</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Loss per common share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.14</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.04</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
        <td class="nump">35.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
        <td class="nump">5.80%<span></span></td>
        <td class="nump">5.50%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
        <td class="num">(32.40%)<span></span></td>
        <td class="num">(18.20%)<span></span></td>
        <td class="num">(5.80%)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
        <td class="num">(8.40%)<span></span></td>
        <td class="num">(22.30%)<span></span></td>
        <td class="num">(29.20%)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (Benefit) for Income Taxes</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid R&#38;D costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">1,267,588</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">189,375</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid consulting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,596</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">432,216</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Deferred financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Other receivable &#150; related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,981</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,528</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,403</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Prepaid guaranty costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,944</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,477,715</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">751,938</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amounts of other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Numbers of options oustanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
        <td class="nump">$ 3,207,238<span></span></td>
        <td class="nump">$ 1,868,345<span></span></td>
        <td class="nump">$ 190,513<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
        <td class="nump">3,921,000<span></span></td>
        <td class="nump">4,391,000<span></span></td>
        <td class="nump">244,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
        <td class="text">1 year 3 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
        <td class="nump">$ 0.10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
        <td class="nump">$ 4.67<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2009 Long Term Incentive Compensation Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
        <td class="text">To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards. <span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
        <td class="nump">13,632,742<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non Qualified 2012 Stock Incentive Plan</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of plan</a></td>
        <td class="text">Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
        <td class="nump">2,650,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non Qualified 2012 Stock Incentive Plan | Restricted stock unit</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
        <td class="nump">53,428<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Number of shares purchased</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate', window );">Vesting date</a></td>
        <td class="text">2014-04-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue', window );">Fair value</a></td>
        <td class="nump">$ 233,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of awards on equity-based plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateTimeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share instruments newly issued under a share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details ) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">$ (90,160)<span></span></td>
        <td class="num">$ (77,159)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump">755,748<span></span></td>
        <td class="nump">316,714<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
        <td class="nump">665,588<span></span></td>
        <td class="nump">239,555<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump">755,748<span></span></td>
        <td class="nump">316,714<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
        <td class="nump">665,588<span></span></td>
        <td class="nump">239,555<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Hormone therapy drug candidate patents</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump">572,726<span></span></td>
        <td class="nump">180,194<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
        <td class="nump">572,726<span></span></td>
        <td class="nump">180,194<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Multiple trademarks for vitamins/supplements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
        <td class="nump">59,328<span></span></td>
        <td class="nump">21,055<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
        <td class="nump">59,328<span></span></td>
        <td class="nump">21,055<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">OPERA&#xAE; software patent</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump">31,951<span></span></td>
        <td class="nump">23,722<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">(499)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
        <td class="nump">31,452<span></span></td>
        <td class="nump">23,722<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period</a></td>
        <td class="text">15 years 9 months 18 days<span></span></td>
        <td class="text">0 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Development costs for corporate website</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
        <td class="nump">91,743<span></span></td>
        <td class="nump">91,743<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
        <td class="num">(89,661)<span></span></td>
        <td class="num">(77,159)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
        <td class="nump">$ 2,082<span></span></td>
        <td class="nump">$ 14,584<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Amortization Period</a></td>
        <td class="text">0 years 3 months 18 days<span></span></td>
        <td class="text">1 year 3 months 18 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsGrossExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid R&amp;D costs</a></td>
        <td class="nump">$ 1,267,588<span></span></td>
        <td class="nump">$ 189,375<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
        <td class="nump">530,596<span></span></td>
        <td class="nump">432,216<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
        <td class="nump">260,022<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Other receivables-related party</a></td>
        <td class="nump">249,981<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
        <td class="nump">169,528<span></span></td>
        <td class="nump">127,403<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidGuarantyCostsCurrent', window );">Prepaid guaranty costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,944<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
        <td class="nump">$ 2,477,715<span></span></td>
        <td class="nump">$ 751,938<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_OtherCurrentAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidConsultingCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidGuarantyCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of the unamortized carrying amount of the contractual right to remit fees, as compensation in exchange for having a guarantee provided, which will be charged against earnings over the life of the guarantee. Current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidGuarantyCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidResearchAndDevelopmentCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueFromRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherPrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EI2AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) (Warrants, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Weighted average fair value</a></td>
        <td class="nump">$ 2.83<span></span></td>
        <td class="nump">$ 2.05<span></span></td>
        <td class="nump">$ 0.16<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">0.88%<span></span></td>
        <td class="nump">0.72%<span></span></td>
        <td class="nump">0.91%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">44.29%<span></span></td>
        <td class="nump">44.64%<span></span></td>
        <td class="nump">39.13%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.12%<span></span></td>
        <td class="nump">1.04%<span></span></td>
        <td class="nump">3.48%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump">45.89%<span></span></td>
        <td class="nump">44.81%<span></span></td>
        <td class="nump">51.83%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 316,039<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">371,240<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">382,377<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">393,848<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">302,748<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
        <td class="nump">1,766,252<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLeasesFutureMinimumSubleaseRentals', window );">Noncancelable sub-lease income</a></td>
        <td class="num">(38,956)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OperatingLeasesNetFutureMinimumPaymentsDue', window );">Net minimum lease payments</a></td>
        <td class="nump">$ 1,727,296<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLeasesFutureMinimumSubleaseRentals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for sub leases having an initial or remaining non-cancelable letter-terms</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_OperatingLeasesFutureMinimumSubleaseRentals</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OperatingLeasesNetFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_OperatingLeasesNetFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHYAK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>6% Notes issued in August and September 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>6% Notes issued in August and September 2012</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>6% Notes issued in September 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>6% Notes issued in September 2012</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>VitaMed July 2011 Secured Notes

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>VitaMed July 2011 Secured Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>VitaMed July 2011 Secured Notes</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011

</div>
          <div>VitaMed July 2011 Secured Notes</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011

</div>
          <div>VitaMed July 2011 First Secured Notes</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2011

</div>
          <div>VitaMed July 2011 Second Secured Notes</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011

</div>
          <div>VitaMed Convertible Notes

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Notes Issued to Mr. Finizio And Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Notes Issued to Mr. Finizio And Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Notes Issued to Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012

</div>
          <div>Notes Issued to Mr. Milligan</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 534,160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="nump">4,691,847<span></span></td>
        <td class="nump">1,850,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">1,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,054,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Numbers of shares converted for debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,775,415<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,415,136<span></span></td>
        <td class="nump">266,822<span></span></td>
        <td class="nump">20,266,822<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,415,136<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Value of debt converted to shares</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(6,716,504)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,716,504<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">849,137<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="nump">1,165,981<span></span></td>
        <td class="nump">1,905,409<span></span></td>
        <td class="nump">64,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,204<span></span></td>
        <td class="nump">21,453<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">735<span></span></td>
        <td class="nump">7,366<span></span></td>
        <td class="nump">5,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,344<span></span></td>
        <td class="nump">2,390<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Numbers of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">613,718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of interest rate terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The VitaMed Notes were assumed by us upon the merger and bore interest at a rate of 4% per annum and were due at the earlier
of (i) the six month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory
note(s) issued in an amount of not less than $1,000,000, or the Funding.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="nump">212,853<span></span></td>
        <td class="nump">17,253<span></span></td>
        <td class="nump">696<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">888<span></span></td>
        <td class="nump">1,519<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtInstrumentRemainingFaceAmount', window );">Aggregate remaining principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtInstrumentRemainingFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to balance amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DebtInstrumentRemainingFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_InventoryAbstract', window );"><strong>InventoryAbstract</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 3 &#150; INVENTORY</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">Inventory
consists of the following:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">December
    31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2013</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2012</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"><font style="font: normal 10pt Times New Roman, Times, Serif">Finished
    product</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">621,679</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">1,124,739</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Raw
    material</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">250,943</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">380,000</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Deferred
    costs</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">170,996</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">110,471</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font: normal 10pt Times New Roman, Times, Serif">TOTAL
    INVENTORY</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">1,043,618</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">1,615,210</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_InventoryAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_InventoryAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>32
<FILENAME>0001387131-14-000771-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-14-000771-xbrl.zip
M4$L#!!0````(`%V)942XY'U34RH!`#O##@`1`!P`='AM9"TR,#$S,3(S,2YX
M;6Q55`D``_*@%U/RH!=3=7@+``$$)0X```0Y`0``[)WK<Z-(DL"_7\3^#SI'
MW+=3FX>>WN[>T,CVK'MLM]9V=^]$=$1'&4IR72/0%."V]J^_*O0"A!!@`P7D
M1,R$1T`],G]D9F455>__\3(W6L^8VL0R/YS([Z23%C8U2R?F[,/)E_OVZ'Y\
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M4W5F>^S>X6G+`_+LR5,3+ZN]>>#=BZV?K"_SRC^<V(1;F)/6Z::HU1NC6::#
M7YP68>T8V9^G7AMEI;VK<WLK>_&)L]S^NOV=Z/S*E#`SYK4,!P2W`6Q\]<?)
M1_["2DJWWU'?GX8?WE5W&EG?NK8%$[JE1[3">W^<C[L.;*M87PF7'RAI\^-:
M'D>%I%1=2$J>0KJDUGQ#NR0[5F6I8D*A#G=?'W?=V92TN[;W&'/(NX<"<MY<
M>5,8UW7\N&"ON+7$^-ZQM)^?%PZ+(V[P_!'3TJ2^$R2>S;&/K^TEG37F96$0
MC3BKMK9TPNY<15MK9W`V^H6H_L#LV.B%V"<?-S\?[._[T\BB_<TZC6Y7)8S/
M1M_?$*6L\'KH>&P@FW5OW:?/]([,GIR@O@/]K;F.E<T[_9=+%KSY]=#RA%I,
M+,YR8C")C4Q]V[W?EA'O=[#O)6H\5V\9MN*@<0$T7N0[?NE2DS@NQ4P\E^2%
M_V4W4/F'Q="0-Q\X$)>#(NW!-48V?K(,_6J^H-8SYCUI(@@Q<FB(10`21"8A
M5YMP.(<"X[XB]5V-%)`":-37*:Q-@>(S!0JD_,I-^07,@I+%+"AYFH48[P'(
MB(",\)X$,"E_,D$XK_+CAIAD[LZ!A&@2TM1^A\Q9J.:`=,&C)?5H:_'%8+NY
M`_!M!K[B>==LUA:]`*[YX>J7+EC;5X\?`->&X%HEZUKE!6?BF87U&%&NI&Q]
M`RNYF,Q]9V<[I5Y;E2HFL/!+W\GPTGO]SONE[^Q>^LK+6<DB9Z4`.3-=]GT\
M#RLNYW5W4O,\+$#.<KWL1I9@H1"[T??9C:KSK&3A62F`9]G'<S4#AX"<Y2P\
MRP4$OQ%R_C&VYG/+],8J]1B5\>\`O=4??+F(L^3?35HF7PP2'"OM];O4\9)X
MR*SC>`DP*1<3WY!$*F!9&9@%<?1=Q!`TRB6,=)WPK!4R)HCH5^88+8B#C$9Q
M$"L#<!5QK@+P$0R?DEP(<"`N!V6YECOL(&)B_0)1DYBSFBQ43PA#=.?!F<0Y
M$P"F=&!*<A^@>9$TGZO#"+[S%4O]%?5ZQ"P/@L&Z"#D\8>?B`1-Q<CIEK=>&
MP9A@@[%JF0[`1S!\!#`I$*"7'J!7RX@`,*4#4_[VCML/;2`:%6'0(MY"[=#^
M)H"+.(.7LG8SV3``4:A@46@U30E@)!A&`ID8B%%+CU&K:50`G-+!*7R/;:G7
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MB@4;4;Z-"(]B\M+Z]@-#;\U;X`/#]8O_E3CH!NL3=B.Q;8LNF_'VQW6[5(>Q
M5E4ZAU',ECBRY&-(]CD/8$@XAJ0L#,GY;U\58$@".U0[AJ0"[)`,=J@J#&7Z
M9KX@.Z3N[)#D2]=9VL^)2[4G9./1C&(O2OQ&G*<)IB9Y>7C"%"VPZQ"M^HG?
M`_MSK_-X&011-FY<JQE,EI13>F_WH3X@5E7$@I_V^UG):5,'J5_IM5+K#N0\
MGN5U]-?VNXH""^\MP[N3UG`%Y)R3X>)U#"LFVST8A[F^L>'UK;4Z%TFTDXD*
M7[D:TFV=3F41[5R4DG7[#?,C<;$^>F91QPS75L>1_:R]KB79EVRZ<0V'+`P\
MTI^1J>$[_&P9S\2<C2G6B<.'S_70?DS2(*D(RIT9D8O]P@D@J08D;W(HAESP
M$G+@25B>!/BL$B`1'9*J?+<B=7T\W3,1$H-8NW68WQ"EC.B:3(N,#62SCJ\[
M]9G>\=C6GV(\TO]RPYMN`9:FZPMO@`QQR0B;EVZ6F*9;B'F1$T`D-YTB60P#
M(Q=A8`8[`P-LB,M&A(D99#`Q<NXFQK\R&3`2#:.BEBS[/XY1AE$?QP`;HK&Q
M_]6,DOYSO?R^FDEK8I2F8Z2`B0$VQ&*C*B8FD-<#C$3#2)R<+[`A&AM52?4F
MQ$AM.D9JO4W,=O=X26&^$#[I%>>3WK5*<O4L7AW;$R<``1$0"!\WD?Z3SA`Y
M.1TW$:#EQM*9NC3$=SMNUES0X9XWUW8`#>734!DSHOKBT(W(KFS;Q?J#]<5$
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MA,O',C$4&T%Y7EIT;)DVWP_!G-UC^DRTNBSA2@]<&NF4:+;D`O)[,<<Y`%7U
MH:HJYT)(,L#8-!@SA/ZYPNC?:?LP@)]9T*)AVE#`@KTOUT=*!?C(0T>-`!7B
M4"'XF2/)0G<`2!2S4D#HG3C:`2J$,2N"1BM'UF8`0$*8%:4`LY)BQ0Y0(8A9
M$7;^X\CB0`!("+-2\J830(4X5%1CS7'2Y-YJ^20D]C)(IO:#I_3S%D!396BJ
M[WP%0%A5"`4=^8?`^XIM)LM;RV2"G&+BH$<#KT_U;=9:M\2":*ZG!%9$9Z4:
M?C!F;`B(50HQ\4:,Q[.:@%BE$!,OUWD\F@?$*H68P+%Z8&'X6G(3QA^Q;8LN
MF[&Q8ERW2PW&\_]*0/9])0`PB`9#V(BD7_PO%[+X/[#?&?@FT7U3T,;DOC>>
M[-L;#UBI&"MA$Y1^3SRY@#WQPEC%V/#M'K#TDICD/\2J!V"Y>;0DC=`Q.;O&
M,V2L4N;^_6:#4JZKI7L-AC?$,,@,F<!AKAP&Q0P@AD&\PT1[ND1S8BROR9PP
M;W0]`21S1/*PP&L.I]+FN0T58L"JQ(#!!<-<=T7R49-`K0HQ4BG:K4?\4XG0
MHP3]UB^LJ)A'+T+G,,=>78]>\EI]'IP_L.#\RM1X%YXQ/]Z.R=D[H69B(%.1
MI&$]:.&]N45S__@C1>]A&48"RP,T"4J3.`:'6>-_N<C@.M&Y>[QW+.WG5F)<
M2K7E(VG7P=0D,#7`D7`<5<_(_%A+F0V3;(<2C46+WJU?3.+8=_=?`*$W2<)N
M&C+ZA:B^2P%O?HX5/AC#@^RKTII]_O>6_1O^J<S"P"/]&3&%WN%GRW@FYFQ,
ML4X<GF"O!]4QTPI)15`^6[NE04G9\G2=-UM*6^ELV&)_=X&MRK'%59B:+:[K
MO-GBYG'#ENK/1`-;56&+JS`U6ZHO"YHC6\,=6PKXQ$JR-<S`EB+,`K<:,R32
MVFR!%M$"#&7#(/@J6?\AY;MCS53?J43`D%@,K565CB$EZ+WRVM<QL'@+N"F;
MFZ+F^K=&Q/LR<?/A<U(8ZKL>!):99C-P'D9I#5R`[YR<Y$&^8:T:(+)-4&XG
M?GC2:@#^4!A_N)^(3#^!XNDT;X8ZOB1WQY?D!H:$8ZB3)9G=R2V9O3L,DG&Z
M'</Q#>QX:NWSM&GH'.EYJ1&YIZ)\(O(`!IT-!I?XD;J(+I7-N:JU5_^!'I>N
M]D[>:O>?*PUJ%T+M11PDW?,E\0`!`1#8/Z0U0^JNEW_J+MY/U.2\WS2X"'$4
M='Z>8F<R6!WJQF0`!$)`$#8:7$6IC8:?G?SFC';'B'=]\X[`CC#LI)]O7.LR
M;X<3&YX`+W6+41-&&DKS%*^(H'BA(@V``"*---X">*FOM_`K_I-KX@:%"%'=
MK:O"CZ>P`M*H_QL?U=VRO8.PR2O@I!%>(:61:);NP41D,Q%`27T,Q'8_AL`G
M5J#N\M0=^@(JK]T6#BV8`M67Z0]$7AXU])UGXLEK=<CGE3ER9^S7D:G?XX7C
M"8L_4'MV$LN@7-\QS/O8&Z4M2[[3VZ3`UBV`B;"8A->'2UD.;I,*F/<Z:'@:
M#)(`_`AJ9@`*,"JI1[<&GR>0[['F4K[';#-"WT.=KNM8-TDR#$`092@D7FKL
M^&G%P(]0_%3N*&+@1QQ^1#YGN'^$F2;,]!_L=8GARUHUN:;J$ZB__L.>F%[7
M7/U*\H.EMQLBGQ.*-<>BM<<B_[U!=ML<&\RPZQ/F%)8/%)DVTOC!`/9O2_^5
MX-;(0364/<K*_3#T7;K&^QL.0Q?UFWPY2YIFK=.\1UH]W_<R2>T>,%32:#W#
M=S.]_!GB<*N[M+'4`=\)OO/56>W4B_X]]'(>&(*;%<M$!L8&`7^9T]!P-2VV
ML5UCRWS&U"&/!O:$,$%+?FI>G1'8GB88U_72,<A]>^/AYCP10$),),*IQF'J
MTT/D`N9)Y?!)3-O)Y@?K*V(%NS;WU:0!;N5HW\LU*KD?T!4S%@N(QHO=ZI]_
M/MAG&(6E'(7M2[+^Z>N#?8:!3<H9=W!)`KFDRL^_`TVBTB3V;/QNS^K1C&+,
M.S\R]=7)FW2&Z3HG40^&O!,^7<UQ*3%GO(\^B!)TO^SYV=U>U/E-S^_V$08>
MA.<AW]6FJSKZF[.F@`V1V0B['*ZYM"XG@%1^>?[=``HP$@VC<+Y7RG>C,-DW
MN`8V!&<C8N5%RA&W7-148BJ,MC,,GQ=\,A?8>O-I\TMB(E,CR+@R>:N\J@,3
M''[)U]7DO9[/;XA2UAX`M'A``Z*O*Z&[+3;DW;E6JRS3!L&+OURRX%T*H7F#
M7LC<G=<#S0FUF`"=)4>/([CM]&_+_;G9D$3>>+T1,F>A^@*2+C4$4+,DMM0"
MTJ29`"8F`%P,P'Y)`\!I`;YW%TQ2F(XM4V-]IXA'3G?$_ED/=/>Z%87L$1D`
M5$FG(@&J:D!5J1E)@*H:4(DW,9G`_;'01F>CQB8S%2\"<'YIG1\@)3)2E71]
M@)3(2%72\8V]?'&SHZDC,@#7E];U`51B0R6L\XNR5.L9K7,\Q91B_0X_8]/%
M343+F\1*)@>P62F7S0->E<%+/.N5X./`1BZ:;]+G@'%!=KVVS*CX;A65\DY`
MD(`$B>>`$N2.@""!"!(O5;0]]@JH$8F:P#%8.08QV[TT0?V"JE\I0/W@,X15
M?UE#F/58]MZQM)\3EVI/R,;;==3?B/,TP=0D+P]/F*(%=AVBV=?7X^8!XPU^
M,TD)!D,I4W7`8CU9K-2P"EBL-8O"#]"`O[KQ5])0#T"J,4A%#AH!I!J#E.OP
M,_H@EUO+'$VGQ"!<?@]/A*Z$V%!@8J51JH7)\>24`TGIL35?N`ZF]];4^84H
MOC)9G3.^C?'(MG%-/F2_)"9Q\#5YYN?8!OK'(+E!_V?1L8%L.[RC<P+)U#RP
MR43+]FYVE1E@[)Q;<T3,6S2ORYJ-3#P=E$;-&=I;T`H6IZ(6IX@(.!,M8'$J
M8W&*8"B4U_FG1>>6B5?#@.4Y=6=C9.I$9]'?A/UK.C5AY,K4\30-)UXPG%0Z
M-?=2&9G9W'_C&@Y9&)B-/W0\1_2G?6EYNR'-66N]+XR]06FC24LGHYKSIH"-
MJI6-*C(V`AL%-BI7WI)\ZPJCN"J-XJJ[4`6`JSYPPJY&B;-PD$L0,I=0?4L&
M8(D/5D4LEJ2R^DK#IKP7V.MWSG+FNS@'/$.UY>QU1W1#67F>,]J-_'E6?#PK
MU>=9R<)S$?8YSO'7ZG``SY5_GJ[[])G>D=F32#OR5\.=QWUE#+C`BO4C'Q4"
M(O5=PBF!KH70M51`ICW.#5S,%X:UQ-A;YERG\Z]&OQ#5(PZ[.-1?<`EOADX]
MSU1Y>Z#2U"[T.2IUQ;=.9UJ)AZ\PYUB)A^^!@!R<M1!'1!8>G(/>R]=[$8%Z
MW(1Q8,!2SPCK[8=MM8FPA)V*SH!LG:(J\9`5)JH2%MG$DRA@91MF986=R,F`
M+%C91EA989%-//<(5K9A5E:\=$MV9,'*-L+*"HMLS$:P_+NB&ZQ/V(W$MBVZ
M]`[\J`>J,<>:Q'4;QD,I-W`%AL1BJ%+1'C`D)$,B^S)F[@:[CP^4+4.?7!-S
MDIN!3D1OR_9<7#%I/9>GP9SG1Z6^S])\<HTE__4>:R[%>E-@.=3I4B=)/<7D
M.DG:X8!):L6^,_`):=V!7(44GI*Y=]A+.#+U:TM#QB>7$ELG6GWFDZ],S9KC
M!_0R<ITGBY+P(2%'NE_B&U/&7GD`@Z`PE'&"$,`@*`Q%+#B*WIT`&>NSA>\Q
M?28:OKJ[;P8,1[I?5S>Q'H=U?&/YU=^]G95P'VW\E\O:?\%$$TZ'UW:=6JC;
M^RO6(N7RM@ERT=?*!8:,G2Q)AC5L;S=D=$VR(OO+_?D>@G.,;#9B^DALJZ/(
M_3-VSZ:PS:5@%;RT`^7?/R&*[8-5K(7@W92Y#M:^R8%Z=/+,V-^7+7_VUIUC
MBAPK`KL4,@BW,:I47Z7GV+3FQ#Q6[7&YA.N-*GAS/2"%!`*=L&J.J&S!_GR5
MPKZP_ZF-NKQ\`^]1\;JZ/:BHU9D+[L[B)=&4CLG9A6?=[O",V`Z?U.2;P[36
M9N0.3^.FV$X^^D_]N#G_WQ:+*-Z]/SU4['ZU8V9;*3+X-H(O?^!EXGK]3N]@
M:?[JSBW-G:]=5N):9*G]QZI\_^-1Q4X\6WRQLM2)R_<',@=+\U<W8E=U?L>E
M@6:)JYDBP\:K&@(%^$L>NY3RGXG-XOX_,:)I^]+V=^10:?L`?,.&\8=I_3+O
M&:R6B?4KVW:9XT]:[:WE!^!`:?O5?K4,UV3.>'E)#$SMC-6%2HG`>R6'.[RP
MJ$/,&1]=N<EK^Y.[@V.E[=?JM6;,Q#VS:/)7:J1IV.#6$>LMKP1_U8$BHUZ`
ME:I7X%ZRWY)W\O+/(/Q[)1VNCI.5KC+^=U1UVY+VI3EQ'UG8>&E8R`E4LQTR
M2KVV,CAI<;OJ7>!!5DO'&IFS]^[#B<1J[0\Z/47I*WZ1^LK=5+I-<Q/T2`SB
M$&RSH;@7T3Y9ALX0N_C+98]&MV/5Q;AV]-A]/77())"TIK=HF9*@9=VATAWT
MA]D;]G9"ZG9ZPT%'ZN_:\E:U)Q%$6^ZHJJP,TM1^AQU$F+&[0-1D9L%F;[([
M=[U#F<[QE`]YLLJB/9"ZJM)3>KOF'*_L;9J72%A=19:9N-37-&^DZX2/%IG-
M042_,L=H01QDC*WYW#(]X6>5GJQVI4%/ZOJD=[RRMVE>HG=.Z@ZDCB2]IG6^
M2U^1X>+,HNITAGW?*Q<N-TN]260P'/8'W>353BB>8N:$]4P]?K')F4F,#R<.
M=?%)ZS1CZ0?Z=:QTGT7-JJ6^*O>'@UZDE4Y971+E]-7N4/(;XF35W5JFMHJ4
MWE`WB<M/TC&UKPX5M1O9L5WIX29XV5AL.Q.T1(\&7D>#S#OFTN&,M27IOMR5
MI)[/PR6HZLU:)REMI;-9*'&)'ZG+PO?M(A-EG::-;[VL=,IH?(*U0+%!J-P=
M=E_5;K[ZX@'3N5?C^KFW?,42%I_H#>L.AG+/;SHB"H]YQ\>IWZ?$AG)\0+B)
M*D_4]Y[,?*F2IO+/SA.F;]=]M2?)\L`7S1\H_Q7-2"*(@:KVNIW4K3A?>^'U
MK%?FD*8GL3&-+[H*E9NAVD3&E852_:Z2N%H6(%NNZ=A!.Y"UTRP>YQE97T@9
M67SV1B020:\CJ[U>ZD9X>VB_W=AZ55[R6C*-D^,JR107!-79[<I]9:^ZPRXB
M2<6)5*@H7>:ODE=\CA>631S[K7K.QFX]OP$_5/YKVI'(F,O#SC!],V(VB?^=
M6G8<Y2G/`CG2^*Z\:_RQ1I76B02'!L0.(F5O'J+(;F8[MR7V55?[BE*!3I2K
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M9[R?_@#J!<H419!-BIIH4YMX/+;ZUP^@NX'NADOK$4"5`G=.,:KW^4Z5C0AC
MCWCEGW\QFT5?_'`L/T3Q9;1X2*>+V5L5-MV9E(LT3<2&)CC@2ELX=J@``JS[
MKSZ&21IG5^B_AOZSKDCXMYQ<!DGV$76EFCLN.4`#!%2U(Q4'<]$$6OYFY\:/
MK^.LT'Z27?+<J)!7U_Y5%MJZ_M&`^?'S!R6]'QT'Y>*V"E3AL!;*LD.L2TJK
M6G:EC6KRW(,/.<O_[8.X2ZPYM+?BZQ!:5BC53&('\"PI-,-2641@6*X7J6XM
MF`3A8YO",<@`H((24PDJXZ:\J^VL`DD@E$TVLF8H0;<PS-YL%"6D&J*J;'.=
MHD+9"V:;"]^+QUAF3XNK/%WGZ_\EXT<9KT94O#D]ZH8!@)TWJY[A+BLNH"G;
M\BS05%:PKJFAGL!M@LD:ZW-5E_M$PYG+L..U#\:K!$:8U6"MR074WCL4(31N
M$&E#A0!55FDUCPL;!%18KX"PUC/]C=^KJE#&J'`)+G:VX$!1?:`"*Y$*AW:J
MZ#I`NU5]P=V<+>".UQ"DFP&'!>%PX&75M>N!%VNW3J@$OSZ'3U*-8-FHOR[9
MJ]KM4MZ2@DFNBK&85!-(!?,4[8M0JY,K&+UG2RZ[X/D<A?I"S]<=5DNJ$/(F
ME-'=4K2WE!H`JB#M/*!<U@J/IX(Z\K>JQ,/V>/)__6FWT*"FLD:Z<$_@G,+>
M4JH)QE91(\01%123-L#8:FG$J-HYS-M)&RRK"@(0'>FV)(HI*T"R)E,+AZUZ
MD.!(D$+M-,)AO7X8%UC8P+B4\UA]@J\[?I2+NUA>8F1_A%`0$\C43@FUAL!L
M-<9X[HJU/6"V*E3I34V)W<I$^O'X2?W8I7R1LR@K0%DI'D*9B#"&,,\UVI60
M;(S/5J<J+<"$XZ[@V6H6.2ZFJ"MT9</05?"DAV.&'Z)X*E4H^S"3JXAV-=.^
M2A&=<T0S@.6$>X0?T6A@F6$<U5T!=W(V4Z[B%QDJIS'3N\WD.0BST1UI\"(A
M=Q+/4>$,,=NK*]&&0VSMX:G#/=>,EKM&;!T+*,3(:RSBK`+V)HZF`4C*R07B
MN:3#^'Q+TK8JQ)1[GGEA4Y^TXIINN7;XB#B'JNM<!X8T-DCC"J0IA:),],G(
MEFGO,-.4PS'M&DP?).UB#XBRM9-'%#F<`<G;6%H..4R:P:E:WYA:'"01#U#5
MQJH^S#41<)2W3%>JD'=$5<KOHR2]GOX219/D+II-8%PH4__DCL!S-&I`L/:)
MA`IDSMUH#L%VN7G410A71G#GSV2RZH'<+9:NJ0?ANHQYYJB6/(T:$*Q/\002
MCJF'YA!L'1QV!,HM!A`I6#DZ@3Q@!+8.#V./P0O!RO$AAW!@"+9+4IF"0.88
M%Q!%V'E"1EQP6[#TB((3>%NP\HPNQN`([#PDPM1J5_B7U*_LR<G%B\I0'N5R
MD.7U-+LC,Z[(?O:38*PSVF"V2&4-;[KOF@Z[3"5YQ,A.ZB%JCZ]RU[#O@A\I
M6^1F5WK?V"K?8_:PQ3'3*0:XMM93P]:5FHW-K:1N=.3\:#;<'B`-@/1@;%&"
MU&R#:Q_IP1"D!*G#.I9I>:12@A31CF5:'M&4R91W+-/RP*<,::<R/1@?E:U]
MU+'VR\.HWFC_8+35&Z0'@[*RM=\QT@/!6SLR56$>=%V&H,C+S?O,T;`&8%V+
M01C"3FYT7S,`MLGV2*5X^5RWL0"L,NT10H(Y@`!L$^V1RUT"*P"K+'M$,8.D
M;UV`@["']%RS%@'\MCM$M\+=(SBNHJO?.KA:6+%O+M=7OUP+'_269GM@,N+$
MY:`+VNZT9"0(1[`+VNJH9(1(=F,$",#NI&3$7.Q6I[_]&TWOO:(?A`ME;*MR
MKRA,?I;32`]/6KWM)9.KKVGL1['*?_WX]6,JG[/!8>HWXRB[%H:L*RZPYQ81
M'UDX`.'#MRL<`,_6H7#>UAH#UKR,,$?(X48;PUYRC7#9EQ8+ST7"O$5K!YBU
M+;A4<&3.FZJ,*S^;0]G,BXQ3/=7M9QEF#P#H>?;ZF_I5N0_23Q=Q71T?:B>`
M@F*M5NXBSLRCD#I(VN(&H$\#4,=\)_OZ;=]H\"J3P1U&N6FT_1+[-BQ17R.#
MUU6EX8WZP2!)]-ROB@P+JG;LGO*;9;-(;#-;M&GLVO]4?'G]6K]754Z]#H1Z
MT<Z4`PA^?U$)4J(]NDRN0^6LU7:^")(G_8'74TV@I;VX%EU[?^H0QQ7<L)&#
M=$&`VOM7LI/S=(-S^?X"62_*YF\QU)=W]E[BI\@/?U%4_3!]U?5#(*>4V-.-
M8\6?;T_=NA.".;JD'8J\K641D8WMAB+?>BM#Z\J"A=N^=F'Q5C*';;JWS,T@
MNPV4R_8$,E/*'(T:$*Q+)3T5%IHM[,TAV/<#$'-\82LR:!A<$8*=@E=U0&74
M$")&E)&.I)AA6LZGN8_^Z<=!M$AN_%B_6E(E4B6T*UDV`XI5&`()M,Q=U(V"
M75+P:E(K2F\`T7SMI%5]U\;(5.Y4&6.6:2BCTO-IP>(RI'RGA_%./F-2J04#
M8,Q%)3H`YR;9V)'E8KU<Q"HT7KZRN[S\S_[R>IX=JUY]E?$X2"K7D?UV]3R?
M1:]2&A]2=4+*2%\7N&+WQ5,KF.TP6K2;-&'49;DI#GUALVBUUYDEA1VV^VAN
M#[@KLM8Z@Z=.R4C7]]$U^#PA&UUSV61)=F6TV?S7)CH],,O',]]OL,;0"A/V
M>=).PT`ON+!N`G4Q.P4F2O>&@F8[?`H\[7F_NLI!HHO8X<W]^"O(4FW*:_5.
M<45<-5"<\')O"?>#Q[I.N2"U8Z?$6WT]$D>0WK&:[2O`>3"T@]"YX_;6;74I
MIU^S6]_3F;..48OQ/T9<(,_<1>V@P3,&%/IC5P7%B'7&U\6S?D*F*D>'*Q*8
M:P%]11P2M&T()3!Y6U;0`]"6.[=>#[A_3-3?H@5&;NZ=RF.PU#PFTLNY?SPT
MB(`<A@2$I94FOY_EE^RO*E\CUIKOSE04[E5,QS>(X/@`<AC$8X0>DP_@,R'*
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M:P'BOM:,NIK+RG&OU`H8I]?3Y;-&RG!NY7BYM%>/#"C`NB0IO8^NOLKQ0G_K
M>IK53`;IZ]57Q4SXN.5F&86V>#J@7U)RU[7$K8!O4SP@XQ49<W5XW0:^'O!N
MZ3!'B/-O5Q;UO:ZR$@^UM$X*-\NG:#:1<7+U^T+]RL=P/%OH27LW^K62*+Q(
MTSAX6&3M`_=1A>[QLH>B=Q,*RCU!G=VHJ3&>[KBLUE1&"4%X-]LX(2ZK=?^[
M>K30"7-9Y6'3HJ28BA,VX'I;MWX?=?=<ZX28=AKOT=03@I-O0.\-SE`8\D3N
M4:13D\':#.I,?5)>RW/1[E'I"3'?:%08]SS=MWNZW#M5WB?@E*(3-N]Z)XOZ
M1>G=%/P$F:Z_KS&'"8>^2<U/4`9UEC;#"!%RRAM;LU/<['WR$_;K<(>_B#!'
MG__NGOZ>L##J+`CA,/U2;6M2R++\=4/^\OSO(M%'P#),L@3_5L[\5$YT3^XK
M2*\)QV(],:$J73"PUL_C'!.L[?'>L@6A-UB;7/P<D1/8Z\6C&E!+E?;0+'T(
M0C\<J[U)MRX;OQ7`U#UXA.PSIA+*+2-N(']P?CY$<>X789KE780\Q@N!OB'8
M%)S]ZW,.HNX>*P9'9VNPE&4O41\)6I-3J>Z``Y=`=VH/[6S+@`ONS:"E-C9E
MCWO[L!Z@WP7X1OLS$&L7D_];)*F^-DONHSUX5@26GW\GXY=@#%.,*;B+-XNY
M-I+V^+'>\AE7FY/37X:LRSD]!XO3XJ?)[M9S;H']4=^-M1T7!KOGK,]+JGS0
M^C4B.3$S&+-_]E;^O@B2()4K,LORJ%LYCA[#[!-!-BE!L&.^2M@1]AZ)S'H;
M%(28/85GB36=A_!'ER?T?(E^+.G2WI_K]$G&+38T"D09%8?KN`TT,/@;#>CO
M&S,E$^E[R$Q6.6QC6.6'CLC!E>N56X5I6ZJD!-P'U$TFJWA$L,Z9`'Y;H[D!
M60>D(-/83<C6"+IBH<F98><,@NU)(U<02_"U#:NCM=XE2^^W[W_HB1.ZFV4[
M=0+P-:,WSZY`@3LRTPW4W"N1%`>[N:&<Z]:GFSAZC/WG6F&]=9T"9M01!")P
M;\3+:8D4XGZYIX+7'D</V+Z>9A]W$6[>L?@0Q>O#I^OX_<P/GD&.X#GAGMG2
M:P4`'+UUQ$X$9;U!;]TJA[GI"!N!OWC695G+=JGK:0M7[90ACYB[>0G!IN``
MIM7;DK1O<_3,UTILI%&\C<"X$\?%Q"Q9+R15'Y#]63,7))>;`@.J<:'%<H6_
MP'A*NOD_1^%_+_Q9,`WD1(MOF1NJ]1ZFP8ON(5\-!#<J.9,T#L:IG&0_^JOB
M*KF]^[5*>3>AV-H*\B:LHZ_+(!GK(6PWL7P.%L\P3QTYF.]?.`5406!:VRUW
M**:=P[3>A(2+O`8@593R$F21=11?1HN'=+J878RSWP!Q&B/$J&>LMC)Z3;'9
M'WHP<SA.F]"L-REFGE?8(,M;P,<P]<-'G4M=)(D$B@.<[/:T&L'F\&RUJE:$
MR[N#9[U@O>REN7KP+N4\5A\&%BU05Y@9D/GQMJ2MU>1206%(VP=NW+R**"+=
MQE""Y3C3FFK;%^QV"[1!5-XM4%N3&+4YLV0)\TVN&8YCJ2*R2[G\[\<P.^+4
M;32+.%:_]BGP'X)9L*^:L(8G=G)/$-@`@`8/D-XUA5#!1.PA**^L?G1BD%;6
MD^&ZGLO8U\_\`JM5N3M&L%.F5CM073!I?;9.E-=T3XM'VRV(>93EGW"$Y?%2
M3J5:%VHO>Y'A0JX/.&'V%LI<@7-/*A03:P+*_I5S1*G+<+NHVMI&LN#^QG_5
MS94PH1X6#!TP+Y,H"$K[CAE"<T4`W<"TKP84PN6@*//K&"Y;8YRY3BG4(LIP
M>-OS]!6(M[(X,^+OES$&8%9-!"?(.ZBH'&$HL-9;*\58E&XF[6&U7:N$<F&^
MI@N#]6.H7$,:Q5#!.7,1\TI1&A0;P[-_GP>[N:=NVH5GG[UYGE>ZQUFA6^_=
M*NN3P0N4`T8J^>+E"_PM82BPUC/GL<#Y1^2[PVKMC#EU&HI5>>GUO?_X]T40
MZ\M[Y5W25WTGDZHH6P_`F.^;BVD=BCFN^9Q\=>*PL*V3,"5G=GS8-6Y(S%?G
MF\/6A_!R'B4!U'$Z<<VMM8!,320`H5=%2@!QUAN]M'%U08GGF!4,!XF"H+0^
M&G<X<E#7*&W7E<J`RC:Q0Q@_R_2]GSQE5UL3.?GY]==$O_VU#>K':?`"=_B)
M'9<+AQM^HCH`6.CVQQA8[0_$',UT+.C6<1GU.&=>F\AU8)>T8"],$&:V4U4G
M#PO<VEJP?K?UL,1;!VYM*\3E!`3W>O28+MP$.6%'6.1CX>WGV]*V3KQ<#$7:
M5B$\GU'5)ZSD38U'0:CQ*,A_+D*)+;IKL$J2&9@F^%83N;Z?VF\F8\0=*'3;
M1SJ67],JZ#:%8Y?*`X]5OENM4@RU+M(,X[*7YC[*1G6A*DUM0K0NSK?(<,6I
MT-6@99M85O.]FYB"G.YB3ES7K&;83Z\9,NN=BV+7,?>NMH#5."SB#(DZP/;X
MI$VM+VP,XA)/>!0=]HD%]&&1V^N>$B[,^<K'0FYK'-1U7!=1"."W<K[*B:ZG
MV28#>9G'/22H<6BPCU@34/:5WCOON;8!ROKTQ^D$$]]B`@HE.L"M%(Q'>.T5
M]=<;K_BF];F24W0[`:W=-]JZ<K.\?N/*/X87BT?UW8MP<B?G:89=_T(5+GB/
MN+`%WXVY;[%G7P.8>P<[1X<A->I`"\IED/64CNQKC.IF550(]>->,[SF&%[=
M=P!<YUJ7I/W9ZW[5[=)KBLWZHLMQ<DEY76R?@E"J_[R/Y20`N=!B)4++$6N$
MRKHSM!-4`%<?EE+(R*REH+XFE;:QU<_<RF#\],%_#F:OGX+G0)G,IYLJ?L7S
M,&Y=EB4G1;4]BUHTKEE661FY(C66<I)H;)N^W/C.G\GKZ?(]!(@UO?M8^F&J
M93C;V'5VEU$9O4HRG*Y[FL$'UY23*P-W]Q3%Z;V,GZ'\B-B-A?=2:P3+.AWB
M@N8.*>O!,B;$77V5\3A(BF?X6'<O.Q[:!ZZ()@A(ZSS70_LUVQI*ZV!!WP,!
M@6P]8-A+K!$JB/H'&WJ0.RND%(X1,.RF0.WP1O2IQ79X&QYA`1$P-$>^]3[&
M&#^00V'!F4,8.>3T#+(@.*T+"'<?N>\&9HV4:K^V2V'FYNYO=M&/X;K[+ZN8
M>M`'4*NVG<(7O.JF-NLI@[51%+*Q>3X`<L(_Y1AY>]^+*)PA;H7'?D(_P1@7
M/VT#`LC:!LV9\S7Q;.XC0"H2*S[QT0"2];$,<SRFJR3;@V2M-BHXWVM&;Q!M
M+I2VQ[L(QIP1-KR!^?%O;\F71?"O>B;(+$H6L;Q7U'^>6?BF__AAEKZ;#Y+T
M=2;__MU4_=)/`^3,T\%]\*R6PV?Y97`;/?OA</F-X4#9;S!]-WCVX\<@_&G@
M?/?#8_I.?\C?YME7?T)D]:^&'_QNH/&/_%GPJ/ZH1[D%T]<-M8?U%PO]Q>?K
M^ZL!&?S@/\_?_0DQ];L?/__SZO/]]>W_9M`6&Y`/QX2[A,>=HT+1'YC_\#"*
ME?E5H)%]QL;J,JS*S))`#^"*IH/T20ZFT6P6?5'KY*>,,TW@--G<4=8A1M+E
MN;Z<S9*YK_<)O9BS/\_]R63]YQ6>+\$D??IIX#E_?C=XB.*)C$=C)3=_GLB?
M!NNOW@TTS5$2_%LN!;-F?3234\4.X?/TNRT0C2%>$\@&;H[]V5HX#U&J8NCM
M3^MM)/N-R?HW"D2YDF\03J06WVB)8<7."H3^7B<B3R<EX->8EFPJ5$<%I12H
M;"#\^W=\H_"5DM?X'F:^VJ$5RD$2S8))WI#U]#"5TD#AOY3C+$?:H"1H>%KB
MS;Z,SY;>`U7LLW3<!TO74<U)B[.7H'JG8WQ:XBS=O1Z4Y![C:!%.=``0Q3\-
MXL>'OV"'#C$10\S87]\-.MWAW@U6L0G'?P:3DLJ=@N1)3C9PYW$T68Q32T6N
MD`$"J[U$30EKX6W$AN#`?=\`4QP\/AF@&!PJCM&0NUX/Y55;F6>[ZH%=H2'"
M=.B2$[4LRUW^RU.0RHZW=C!QW/I?-NB>?>7=`W]646N]6V#]6O+9\H*+E9@S
M]*AM2-P?"?5*-=^ZL1#A#!W'.2$)]26P+L@O.M^2UP/N-KC'^I6"TTJ4BD'9
MY)K]6*,VB&'7,'+5AN_QQA%4+PVAEZ#.UFEAG<@94A>=NG4>(](O9AS_R*JY
M&HP!171_?7_Q:8,Y?\U:?S5GO/1T=638!I-H\3"3+2YIV[S<$BOP8AXZE`PY
M$N#+N2>6T%-89P.M;*`<L2%&33.:'AAH@<?Y6U9ND/L62`T/(#>'RB?,:1O[
MRYAV2Y[>CG;MON+)NC")FH5)U_?_N+H=O/_U]E8YSL'%W=W5_5TFE7.-TA+*
MZLGBI8X'_F:^G2XSVE-E="XL.A<6_0&2SG-AT;FPZ`]FZ7TI.CD7%GW[.CX7
M%IU:8=%-+.=^L+WUN%V*C8AWE[5N0,Z5(+VH!,'<'3+1_&CI7&-TMJR<90EO
M2%S60WGU]-[A6%'L[KZNL__%3$^)KJB[WBVR?BU[V*-61IPA:WSM?*XSZH$H
MVC<62O`0HU,REM.*L]LK*9H:S=;50^M>F?*WOK@P=X8.MLUC^R.A7JFFI\;R
MYO0>&*-'77Q*8OLCQ<79U=@&7[Q]=<^X7XR7(_P4C#A]/:^['F[2U!MZHFD=
MW'F3[H$HSIOT.8:V.<>(LOW[O,QZMR<C[@T9;GKB?-Z3>R"*#HP%NT/JG%)?
MW5%CY#[T1^UNQ(\+7X]W>SWW29T&XI,)JH[>GG(VV9X@!DX:AQZEIVZ;1\X"
M^MM%M;<FO/X*/_>KG%:_"AY2UQVZJ'EU0D\MH:>PS@9:$:S+T-`CWT"_7X$7
MVK93;;N22CJ-"B;;SY5G>KV9J9SB(ISH=WWF^DFB7LQE?EA_L6U(8N:%P8>/
M_W-UV7$CT@ZXH_<<?0B^RLFYU^C<:]0C!]F3ZOQSKU'[N<_9TOM@Z7WI0SGW
M&GW[.C[W&IU:K]$FJ+?4W+GSHP^='XX84G;N*#K;%?`T;'?(^8F:E>6>?M*%
MDQ\6<1BDBUAN,/KA9#`-ONKOG4O9>UAD0?F0XZ:'X>>"G!Z(XFPKO0VG^U":
M\TGZB7R*9MOBG.!Y'D<O4L?:Y]*<WB,^E^9\2P<E?QR3A<LMT=`3\&,F^WW"
M<]+9P#F:ZW,TAQ@;.N*4RJO/QG+$6GP^Q.XI&<LY]M^*ZV(\7CPOLG[5#?2)
MG,=R'/AI$(7G4*KOB&%7\U\\,G0Y?`DDI"'\]6R4?4<,;)3<&?+&+V,=RRB/
M$=?WM]#^3:UC_75\KE\^K?IECH;D_%S)V3I[:IULR!NG,3VPS@)W`_Q626<%
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MQNLHB]9"!(MHC6U",)Z&;UP$,0_N)(`TC?,P-6ICL!RU<7%Y<WKYZ>+]Y_.Z
M0C>65<T7<0RV,XL:`+_.;K4+RU.'2JVD\@5W-_43ER,]6!H(H:-!0-OBB:8)
M=0Y^'D7,Y4K-\3T^A=9BK4++F@&/P7_^3ZH9&:YE@;(\SH0CYA<\*52X>)+K
M\>()=/3*#S2EJ/;OZN:V/A$<\ZGTY^]>:VF=9(XDAF4W%I9^!ID-^D&@FX-T
M^]Z.4OY!$HNKV^WN#G>W*QK.RRJ((RCG+G]]DEB[=T#(-B(HH:+1?,)Y3OLA
MBOV"#\ZR*6_YV:F>_0Y((@T@T630+!_G/(9)X0T=D"0:0*+)8+D4,=D2@L=+
MH_E=MR>\DT<@`:>#WXEUQB5__A5:"I<62V_G*FJ5<'9'WMC2_D3&?%P)/UO>
MOGNR#;$YU\W5CKVA_X?-#5%#DCQ@:DB2AT(-2;*94W_36$>P.U!J2)*'0@U)
M\E"H(4DV)Q#@4>:)KOURZHDM1GWU]?SZ-!OZH/MG%H7C^($KP68\KB)SSC[@
M\2/9.K:@J\2\)N40U&E;H]ZNU:E*9M(/"X\@5`>$WG9'([-8M.W&+^&F)M/3
M[>U:O91,3Q.X4SF6VKW6/O)RU>H2EABL\R0JQUD1^+DN*F>K*U/WP@_33(HY
M=;H*D[[7[(9J%BKP%MF#N(U@>!O*T!0LKXU@J$6QRJ!FU+8&W<J"K*MDBRFB
M.$Q<O!V.K'Z_LE*V%3AXIHC@,/'@6/:PLNKS9"::"@N[U9"Y8TO_JYHMN?VY
M8J0F1JE)LUES]`P@;!`V"!N$#<(&[8!M=GWZ,@Q.>'&%NJ"TA*O41X@<4BK"
M!F&#L$'8(&P0-DQSU&BK[/`A0=I"V"!L$#8(&X0-PH9I'E@%F9T7+M8J5ZP,
M-OP:JFD8+*HVQA.A^&S./)7<,9<'GO3PKE@:7K!K'<<#QLH>U:@W<*R!TV\B
M7TR1Q6$"(Z.FUVXD:TP1QV%B@XP&`6,E-<$OO!D\V=(;JV8_;).:3A5NDGU)
M_%C._"5W37%/3+GZ([W<?R]C:"N(?HF2&;Q6=8'7?8"^M$(ZIA%;GFD?61VG
M_+H;=0O>-'H(B'OS/PF,!$:RBHT`HE%`,]1!KA-%6WK-/[R'N5DMNA6NL=,M
MAQ<W8<S]'95I?3&GVDSE#Y;SJC!10:F5O+:@<]#K68/NOFO,U6'7ZZ>(H+@^
M,G=D6\!5<Z&X:RIN0J#A".SW>U9O2,:0W%QCJ*D?4"O\W6K*8^9.K=WJR>"5
M^FK5C?J`RK,]PM/:\M7XS"C[9&3)D496<]LVMX51DEB[UB9%J$L1#*R]0\7?
M#"719-!0\3?#2#09+%3\K782388'%7_;A_.V+I3N!7>NJKECXR0(FXO/$#5[
MD>'FTI?EXS670!,9:!8UIG.+X$9P([@UAX%F46,ZMPANM"E)JD2J9`)]9E%C
M.K<(;@0W@EMS&&@6-:9SB^#6K'#.3?=DJRCB6="8\HJJ>59R.7.%1I9;!LWI
M6`.'2NH1A'Z<H-TOD1-ZCA<]9(":!J$RW<MCMT1;NI'5E3.H<">4"GHV+YR"
M"GH2+E:&#0X&5KNW:_'V,BBA@IXFX*'=M7K#;A/98HHH#A075-'32%^,U,0H
M-6DV:XZ>`80-P@9A@[!!V#C@+;"J(MRVJNU)2D5*10:7L$'8(&P0-@@;#7#4
M:*OL\"%!VD+8(&P0-@@;A`W"AFD>6"-OBU%%S\:I47MH6^T1W0)I(@/V85^I
MHB=A@XS&,0#C6:KM%\G;)&NY_C$5^-S&3]NDP&>%SAL5^*12=L^H==J6W>OM
MJ,14RHZ`:(P[2F`D,))5;`00C0):,_QEJO>YQE-V'*KW^8KEI!)W.9V==M\:
MM'?=XZ`2=P3%G>DL)W"7ZGT2`G\\T<O(ZE7@\=8O>/,H,MOK-8::^@&UPM\M
MN=YG,9!5Q39+*"2:L3(M][-JV"5WNU(PZ\J7WDS$LZ@:ID1:B`PIBD/F+5+4
MK$M-PV3$LI@=X;$0EAVLTV=3(&0"E$*7[@1?B:''F1*1J^0MO.?+L=#M%?D1
M>>`537I/LN/H[EML'=4,*$Z3,"YR+SZB+(D`SYJ,*%8<5>[$EX%@4Q%/PHQP
M_%9$L9SJ%I68<AG@KY)(C!-?DZ()#\>LW6=SP=73(>9?QRFIPO>%&R?<A[&'
M,UB1S?-+&JTE1!1_?4A43B0VS@2LNCR65]ADG;:%!34[EKX`DAXH//"(!2&3
MTQF72LM*"3>\"W#,+?9<Q^I&WJIAFT?E<HTL)K[/1!`!X('5;X#[MIT5.'WC
M#*W!H&^Q-\X('4D-Z%QXT<O2PZ*HE@8\_`5/02UF`!,)H)^WV'D!0+Z*BKR/
M``R-IF(,O\MZ1,"CFOI^^+`J2*X2ME9JV9I>A7EH6A7FZA,%_Q,MUWF`#"G`
M7U"$M8&W\TTJH7%[3VE%Y;_G4WU%'"TL0D'4#@5"Z^+GEKN8U5P%R+6RI#2=
M]M;[6$>1#+/$?*J]4@CJ6O:0\F#N<V$,JK'IKH9)BF",5I9WI=`:C0;-X(H!
M,T1)T.\3]`GZ1V3J-^6R*1`CO#<+[P:;^B%!GZ!?VNG&7WY)HI,[SF?O+HI]
M[E.=\NJ#C%P_C!(E;H#N]W[H_O&W__XO'-5?\I]<X:[P9\EOI2]C*5;]A+E`
M$7RX%N.__O11A5/<D#RQV_"_.-1_MYV33ONGOR%9I>RXWN9_)/C'Y=7-.1OF
M]9%Z]I_9U<VOY]?L[+?KZ_/+&_;YXO3]Q>>+FXOS;YHQ2<&RHIW*]H9O5PBP
MLEX?'Q3]*XEB.9YK4K04F9LHA9OY_D*<*+M(1G%^O)!N\\K@[MU^":Q014K:
M=!T9NNF:<='HA"W&W5DM-E[[A9BWN9N\?`:[&^DE[&4;>H>44%T?JIV:48V3
M?E.9:!H])@EUV^IAAIJFZM>"6YJOXAB@7\X9SJGKJF3I9&_&YPH<%7T[P`VG
M4QE%>/JO;\!L*5(Z:ZKCK&G4;5N=K6UJ_:=-A"%S,-09#2RG32>6AKJ?3VWV
M6`8\P+7I5F;:)(4R1KM+VQ$<]FS+MG=5H5KX8HHLS`-&!:&A*7&C[L!I"*N:
MY2Y786[ON;O-Q3=3$&R>.I6RU.SUK9%#=K:)#*CV2*[=M88C$ZJBDN-:6%(\
M,0)7=9&+"J,)'B:A+R+N"^;)*%;R-HGAZ5@(\F1-4*2.W;<Z=D-*AQ(P]FAA
M[8$U:$JA87);?7''TWU=[KHPUA@W#+*H+M(G`_3)<;I6KT>N;!,94"DP1@W:
M2CH63_:I<>6W&$8KN'(GI#,&Z$ROT[=Z@X8X)P0,VG\E1W936^OZ,L`!L%A)
M^"^=>9EB<]O.R'+L32,2C.*+*;(P#QAD<X_'J5VY/>N&R2P,(KUSH$2<J("L
MK1G6M@^S.NW+-I$!%2]]+-O>]OYM,RQK9=[L#C5:*I@@=0Q603Y/_=]\KU9;
MWRC1L4IOVVF*UNSCEC(WYN)Z+F\J4/#:%G''MNSAKAXV52@@).Y*[<"V!A6D
MKC8V[*/$NJVUUSE8<.?FZN;T<T'X^ECH']?F^G,O4QKP]5<\K+[=MMI#@U/1
MES:UU$\1@7']S?D.P+'7[`(=*R:7DE.(I_]:3D\&IJ1*J'XXE:;ZU?\P^<)Z
M?BY67FQYZ741L+\G@6".;0\M]H`YQ%V?J^S8`O?.9EQZC#-,M8S'%IZ\ES#7
M>YA.XXW=ZMIL)L#_F&`N<G@4)HJ=A=-I&+!O,69.B4/&?3]]81+ZH)H1OH?9
MMI6':9?A@Z:@;5L9%?!$)P?7)+S!N,#>*,LJC@G)`R`06.&QVSESP:^!QX^;
MY_'S[-%YVFBGM9#!(FO,!BE@GF:-.0L###Q6'*_47\OHCSK3QJP7_6W^QR*7
M###DA+W_[=O%Y?FW;^SLZO(,7*?KTYN+J\N]99#9A.C:T\K\+M@L4>Z$1T)C
M>Z9"+W$QJ3^(DT4"'&M0"EV"5@+V-#4/,IXP/H-7O^O\P_Z<C88_6VS0_SE-
M7S[J_9SK2MYXE+?AI2V'H!'WH&9XHWB3[.B+Y.B:A!4)TO<LPHK3FZ^15R3`
MWJ2RTG439CH/O"=%S-6<+:H%:TH*>8*=6GFA&WK/3!\6(0`S,^6N%(^>/GY;
M1Z!/T"AY*KF#089`!@@0K-*="!`N@`=-8]ZW)@3Z5T"A]!]U,@FCF8RYG[4;
MZB1',H#QQ@D."\^18?3A%+#78M<`QR`163]QCB4<DAY@/%%"+'Y@L3.NP->`
M1GX5,)))FI[_(G!;%CN%-V0$;'0%>R\4-)F2\,7]7Q%%P-"SK*(%,C>[F8D=
M`E@'(\!YO_.S?K_K%%A?5%B`/U-*\?55N-:$;)CY_SB`_7$C*["D_\"P?C>5
M@3-<)P-MD0;IFZ/%FYX8"Z66WL,Z#B\A*PP`U!I>NOL"8N^6<93":!DXSQ'(
M4O2]A+06^QVUTV-!&*=*I&$MHB58:PI`_69*YNA:.>EO,H,_G_6G4QGK6N.G
M@0<MX&UD$;@UIXU;L_):-?EWES/)G5U]^7)Q\P7F_V_L]/(#.@,W%Y>?SB_/
M]IA-[M4!U.X(%"R\FJ$&X"7TSX)G5]"3&NBI;X+U<=R,>U,9X,S'T0Z#U1A+
MF"HPVQR6\&'O0Y=K4JYYC(K^T0^5]#@Z/%'"86V'"P.8)=*21Z#/P8F+9_B^
M3EP7%DQ..\.4+B+-%1#BB@6LS;)C+[[/I,J^_"9F<685]8JB/6QI.K`*4MH8
M#&:68/4CG%6A^[ML7HTGT`0^0Z?N3K!;?%F3!]UA6D&]6'D#S;:[(_96PD(D
MB=*Q+Y4_6I">'WS]J3#+F;WDWRT]\W%@`DSN;)S$8#88\G.:3#&7S33M+2^N
MM%P>*1T#$M+&0$&KV^[N>PJLO+>]50![>9`W2Q6OF*YXA0@`8>4%A18%M#0E
M.&46V2>UB+1LX84W[:$-DNH6CGPDOV>%OEZ<QT&;L$C7;8H[T"=0@%3H'<<:
M]3MI4:_'%&DRELIZI2XPSH$I/6G!+:TJ\()><V<:TEG0V@=P]X<OD_KH9^D\
M_::-D7;M7H'R-VW'L08]9Z.5BW,,;EUZ34F;CQ5UK9ZH?R;5P@KH*F]/RE-5
M7)'J569LEEY4\_FO/V7:G-.7)P+;+MOHXJSJ\9'7]B=;V^>6J^KB&I9\B@HJ
MG]1^:E2>3,/I69%AT!C::J=GRQ/ELN\RY2J6F87!H*X:4_7G`5M-%^62VRZ7
MW+"<7'+MOF5W=C]9/H9<<J5F8-VUJC?=##:%F/+N>0S:EM,]S$CB:J;3DG1Q
MTX)<1D'1%/@?J"X.':LS:&[1F&9-A@WA,RG@'A5PU+&&W89$JQ[29$CA"R9%
M!-2NW+6$+W1LQQKLK/S'&;^POX#D&SQ-*>C*]_734YA\6[_!(B1C<AC&I&T-
M^GV89W>-N6V0.:FB(NH^+<ME&"QN213T1<GM26I=TH/B!LN3;,MAV):WH&"C
MWJ[[1Y4A\4]'[9]<BGC?WDG]X6OF440!=:^Y)\[`<D;E&Q%C0NJ6+R-O<['X
MZ;7D?R1<Q4+Y\X]I227N7P3C4$TY7FVN^SKR)N%(O>4;R=_./Y^?W9Q_8/_X
M[?3ZYOSZ\S_9QXO+T\NSBRSH^\/IS2E[^]OEZ6\?+N"]U)C7&[%4_?6Q;\D4
M'NB;^__.Q9V7T,*X/!YS?>%N#'"!S_K.W8(L7:^T^(0W]9:_<A:?9'HA:2\7
MSE8HWY;)V%;<5GNDA"55QF[;=5U6V]$I^!%V5N>:5TA-<<.KW:VBB.S&E&L]
MRVG+S/*VWE1=+%WK^FX/W96YJ5)%P1?>,0QLD^[6%62[]LMW:39FQ]N+H"`[
MGH1)!"817A#?70&_+T*:7UXG;#'FUR]P5:^FVZY8-[FX9!;53^X1MLL@O(V_
MSB+EHUC3^V,IRS9:V)K!<X+P04'868(P>'T$X::`@2!<''HN05@1A`G"S8-P
M-]ZTO(K16%V[0JCPM&T/"^`L=\:N.<*KA_+&6\(;D[)S[$4)CK;5ZU1VU[$Z
MF1`*2D6!8]G#=NV,(!34C0)G5%D0$*&@,2@8]BLK$E&C3V3.A8&-F?!)A=$B
M3'VFPK&,22GJ<9/:/7*3"`7]Z@*#"`7-04&WLOA,0D%#4.!8G9TO2)GH)AEY
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MH3-_SAXF(F#Q1+"9DJY@,F)C^5UX+%3,$X"M*2`+<&>A"QLEX+3>"R;N);C/
M&4'A&+S89:J9^"ZC&'B!K49"W6?M0@.(3>%9VNW%^'OA`JBE+^,YOJ`$CT+L
M;<YX%"5*>*W]BJ0N*!12+%3A"E8Z)\"_DS-8$($4V%<5>HD;1T\40E:E&IL0
M^YA;-9`"J+X3@5`\%NSJYJP`]AA,%EYW1(ZQB/LB78@!PJ%1"?"*0W@WYM)'
M2Q<E4X#V"SKRO"F6S/0J3LX0[-9"@?34%#'0A_`!B,(W--"5C/Z`IYH$O%O`
M)AQT:`80!S4#2O"W.1F:"AFX?N*!?B;Q+:Z'=6<S6)_JYB;P'Q\_C(70!B*E
M"K\"5?*QN>EC&I<;U504[8GO,Q%$:3-N&,5(O&ZNQ4Y!`/\*%:HFCBB!]2MP
M/D16`>US!JJLGV:\B9@V3"XHK8R9RQ4&Y"--#X(E8#=\X#IP5X#YT"3H0?-H
M`@8BCOW4;@`1\4.8LD0)`4ODX`^DTN-S(.ALT70V9#!-<HK"0A.9H+E,>]`Y
M0FZYCS83G_DP'0+'H=UL;$\G[6R_X7^<'O[+H)5!)D1;AQ8N"4!(GK:LW&<=
M^P3(8K"@%_,3W+I`0"4J8#,]E<+;'FCMPT2Z$V0!4*A3$V1`2M^-4G0A%S,T
M(L/$63@%+H/-+!C>6C@!N;/P"*QI"TN`16708[58(+14LQZMC'6>C%*664_Z
M1%`=K=7]JD3D*CE#&9MD<6MDT*MJ`@H,1@<1&/!IJC2W"C&%_]?66;J`^R7&
M%A;C$:"7C/-$A<G=A'DJN0,-"@&O@%F5FKA,4683#EZN*\4ZNYUI\/.NG^C&
M,Y5PH?4[@5J=Z8>"#_'1*,;OA;W*[10P*0F`3=JRYDPL6+R8&'`.0)>U,(;0
M9^AI'LOO:"SC282.)LP=8(V1LV/P`L,'M/)YLS`G2:47,"UVI2>85=AQ$Z5@
MS@"XX&RJR>`PX0E_S'PY%MBET\U[U#819QP//07X"OB2C+D+-(H6^P230SJ#
M^S"=Q#`I3\!_#54Q\:VDP$*SOJ#"Y4$0IG<(8<*1VHD5P-(I]HC3K(L-+_$S
M=;E7#8W'^DOXK:9U,8N?ZI4`\,J?Z]X],18JQ[YN0QMZK0"I:QZ\T`7`7/H+
MIV4Q0;`@9'X(CKPJO/AT#@M=&&M!F^#*E_!.-@Y-ZHL#2H6C!&J8=C>\0L5G
M(&><^9=_%^'28P&"O(\GA!Z/*DZY#,#F!>P>S&.81)DQ0O;>*3Y-UXAI/B0Q
M!J\L1M7*?U3,<6PQ>7$\B9B)6&JO:!9&*79DJ@-`U!\BGOG<%5I!H3'H:1I"
MCPM',]=XP,J<^_&\Q6Z6G-B,PMR!0BIQ>>>)",:7^KQ"+RI3+$%["2P3,Z<<
M08@4:@\6'B5@X2_&F9.L'_X;O$DYEB)5P0A_SW.FN!,!KECF5,,WF@9L74\3
MA4+BMQP-#[J(VI5]0GN$YS.X"@ZT!4`%5A*7O'KX,O"``6`@P/0H?B<*+=&+
MV'LI'O)%+O=0FB*E0XYAQ@&7-.(*%!B7^CB6=`-'GP<M3S"+39Y7MVN>[N]\
MR]S[T\#[-5LLG(%S7]<FSWH'0WM6WY87.#G-#(E^ZGX=@\9GJS)$Z`M+/U=S
M1MM5U'\]#7F/UHZ`\$BD[SU;W"'TM`:X:`AX,$^;#'0Z#8[SU#C?3H0AP@.]
M%[42FYM![2E`SXJ^C-E[_*J`<W*FN3-FCP@\X#W(FZU1D!JR!<@6:^]\ER!M
M3.,5/Z,##^8-MT1@W9[<1M*3,)$AG?\G8_Y%I"N%]Z'+/\&B'YR^4X`]6FF%
M/4O<_<K;S-?T*?)Q<H*51@1^G'8;]+;*+33!!#IR@1Z#QOZ2,%>B>!T>GV^>
MYUL,T8WBG@#D7P$?U&G&A\7WI_D$\S%4'\+D-AXG?OY6VLD>3;`O8F#D298U
M]1T[L5OMWBS>+JOKR8-`+^P=>(G_W]Z?-K>-)(O"\/<;<?\#PL=]7SL"8A,`
MU_:9CI"W.9['BZXE=]_Y=`(DBQ).@P`'BV3-KW\SLQ840(#[`DJ8I5NB"%16
M5E;N"UA?_N);]<0)NC&$(CHNN7,C0Q`=_&5.#$L\&?+KA<N7BY7L_9H<&4F;
MM;X]$`?``RIUH*'&KO2\<`2/TO7@EV\")C9W<?%=XDU$AL"BF;3(40TJ?3&>
M,SK3R/WOT5+R6Z1;:GX^;HB3?XW_4?CC!`,HZ'`323SR?9I:QM4YTA]="1QQ
MK`1X6X!&E08B/,A-0,PUDH$*KB.KZ)JIF!`92N1-A>L<SKRQH1R%'!?(@#S$
M55*)[+D+\AF1BON8A1'R5MC?L$W.3U1H1VCO@7S]5RH]N@^1E\@0S%3[H[X1
MP[T%*P!E/[#B%=C*5%[0;SU`<XJ;YZ?![ET_Y>?/XSI@L*4^Y_H9?C0C1#A.
MP.`;@ZX.*/&B<3I#7(^YB,V<F]*!$TWH7_>H:=-7%&!S/#`P?3!<!9M.&%J%
M\'?2?3!JQ,@(DMLC,,JW2,YZX8>>K.4(OA&VQ,\$40LBPN4N;?(G`WF,4U]8
M%'%F8("Q$\(_I$?`1>,9/B8?^!21!;B>P)&-DOB-L!%XO(];+C'AET7WZ.1V
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M5*HN?I%!7$7AG$7)XQ4HZ@EPG@_`M<A[>7*&09C^2*D-EW!$AW8LG#QPDX]L
MJ7-XOM$L#%4EY(V7N$!^@A=,!8)03L](GO/+,D%>AC>?@A&HR9$^RKVK+"!5
MBFZHY%63$&6^@7Y.U'I<"@V0ZC"A*PEJ`ZHCOG?/5!``6`Y&!]`7ZQ)ARI#3
MW/4B'E\A)@"J`=XM-]$"]T;._;,)VR:U=#9/$V1EV2XY#^69.Z"MHB%S`7HE
M$PR4:YOWJ,K>9=K.I&)?G/W(37$,49:0#,A@D!^C\LB3C$?F1G$5)WK*A+FI
M.I._V9]1_;T+?7XVGV9H(0E73=55K[]2<79:D&0N7/!KA[",QQB+_&7S*VFH
MZQ@QY$M*!0)37%Y%'VEDM9!?5W@7A?Y'8%1_H(;V;:KEH0*P*:'@Z+ZNE>$&
M!-@@B!%#"F9#`_JYA1TPTI[Y>[T,$=Q[$6.,5B1HJ*S/13^&J=GL[J/Z)$+E
M7>::"<?`71@E%T2D:`8+S=R-(G)#NS-\B;%J$1YA5`NAEEQ8S'#G<!=_"J,<
M[@(<_!1/GRP*,*S'+IKRXIYH0,$#J4Q^(\U:1XG4QZ5C1Z@+GT&.^88E))[P
MC^%[M17O/!#AT?CND>Y[2IX+6!!$J1$)&(%C<-^;S"UP[UV/IUY0/)2\-UX<
MIZ1_4(8`@JW\41B_SS#+39;8F\$K(NZ@$_J%X!9RJ^ATP<BL'B/5`!?N?;Z6
ML;B.$/`\1SE,_0EZ+3($&1PY#FP7.-Q*Y#R/2X<<'U!]"]:SR.(3I$/H]7AJ
MM">(0J519,:P?CS<KXE$@V=*T60DK1`^)D7KPJ<#*,.VL#@]C-",'BFY?&"W
MM>1RC5]^`5&21EHL"$%]#W:O'^+G(KF2*QLW%:=KW)*>B(=_!^*,<>;"<TT!
MX'^E(0I'RD<7&?"D'7,K7Y`_EF^2=Y9C+"-^#6NOQ(5\+<CUH;A2&H0C=+/1
MW1*$*1YR7C\3&KPLISCEC1!I(7I@D"?Y\5@<YERQI$",Q+X484\RQ[*K$0$P
M%(YR$^F/YX'%OYU6Q>,O%R&-/116[3K!D&_A(@GG&#;ZF4V,H)&&%&W*YA;*
M':L9$_!$5AI-:ZMBZQ*$+%97P[++2JL%+$YO:;7T_I"YX<0-`5ZWLT?P!$/9
M`;9]4U\:R!2C!;ZIH%F#?Z(75;O^U=CWEY7P[T)5M:.@>M'T,;E6<]2[\8==
MIJ'L^YSS3`&OOC0%-,4)0<HS@!*U"[D&5Y&4B:)I3_AFBKK@6_67/9H&\S#^
M:$P\4"K0GJ$WJ=]$+K`"1`1S0/V(PE'(DX!-#GDZP@!RXE$U$=D.*18\:9Z.
M,A/V#2HW#94W#*TYZBT9VBY-.?>O\"S:;(+Y9`K/`A,J<7ZN4VF_3_-#MAQJ
MM[I>H-!Q6%M''XQ]*OLR,=ZS,9N-0`(XEFF@JY?^:7./'?QD42+_G<L-RR`L
MUTFYV'E@FWA`:F##9^[UM=SDBQDWXW#&;MR?I\O>WSDK<F66*-\D'0[L]*@)
M.H?<7AV"6'_*A!5W@AD<4D_ZPJ);%HDJ,M[E0?AUZ);)S&SIR,7CX1[RD'2]
M<5J:[RWS](P1QJQ8K/5\0,>BJ*6;4`T,7.X'D3(#^_6"%"/8;[D_7D881%(=
M`@Z;5DDQ7L#A05(A/33;`BXCD_)DU(QJ[GFE-8^?A\$"]*!71O3`MW$2(JOJ
M\/Q.Y$XU8")'<D:+N`KW$.A(SKSUQ)H7O*V/*L$J5XRK3@S>4N7:EH9#EDPP
M3;$NDYY!KR/#I%8T7MPDB;Q1FHA(",_0\*:P!/_[B"4/3%1REI0N%*-+1`,J
M=[<".I<G;GB1GJ:!D`GQ@C!@C1[WBJ^U81[.98%+%:'X11[X446BZ+.?SWF7
M"OBS4'3H-(0SEE(E\)<LY*)G7,!^YV`X18^&CAZ\*/H:(R;3;7FW%]Z(H7B$
M=#3PDG&"`G:-_:GH(";+8*X'PJPVF37+X-5Z_!NQ1$>+H@P\[*W2>>-\>AR5
M"4[2<3FV>0(M)U`>1.1J`W;&H+QJW_N+D?7H!I2K0VB`Z_#O9]-MYI/>4\A0
M_83Z'3WDPT6RD8EC^I0SQ8<J`L$J\3&83"[E)TK^H4I,8]YQR!/%S^I3/-[2
MLX$7CAC>EAC`=XF_"[<FYOZG$R\QL]@"%2*S\5U`;LT9H"/)"JW%6D3<\K)F
M^8^KP,XR,'S,_XJ3!?JZ`U'F<OB]NY"7O'/0)7'Q[P&IW\(G"7%3V$2W_4O+
M>$?7@"YTKI@[DJ#R9#4"F;+',SS0YGB1O60'\.(PEG>+7OH_Z>267D%%W"UC
M'95<:.18#[X<.<_DTN28XBA,[K*X/6D^P,!\$3C+\@<3'7EYDG(Q0R)2^IB.
M62QQB8E8RPY*GI!M:D>4?S?O>"/S@"AM4/!@T7X@LZ2T`#T7"0K>9W*NF/>B
MHP9O69R._@?Y&4D:JA0:/2JI\@F/'3/994KWM>APQM,9N6AVI_R&LT=ZX=0C
MP?I.9G28XFOTN?@R'&F[?/72DL4JNW"Q%AS>^19YY#LL^@]B$J[?*,/],IC`
M:S`0=,\PYZN&F5H$_@7!;^@;*%B(3YY,068K3F"WVQU>A/7Q\OHM90)A4CN*
M<&M@*D!(8.LX,P3P75CG.D$?P@)&A9#W%YM&A%'9IV+1EO&##`0)@S"K/*6Z
M\=HE:DPAA*^\3F,=0%6903VR+[AHSWTCUQPQ)_IOX0_)!35XT3,1@DE!5U$E
M\3DS@6#)JIRSI$HA7">\1H0+6%"O_?"1E>Q.M@L370_CEG&]UD[TYFSA7)39
MH7")/)+V,1[7XB?`K3VTC(65C?J<6,I]X!W8")&4!*?227F;.M'W2^Q$?&^>
M1J`V"/M[CAP!9%!,^6^FL7!2J,R(XU2G(!OLT&GD'72D>X'.!';VOQG/J<LC
M9"9J-CUL*/EHYG/--?/KGG&3C1^-TO%HRRJK#C]YZ[OCORZNQ]1"ZN(+R#74
MJF1QCS>FY+=PPGS3$$9H[@GC"_U-Z9O4$HFL,7HHWYM3TZ/Q`I"$%901"PD_
M3TG<8\H3-@R"O?OLIZB#(I9/FW,C3Y2@<J(0FB=!H<PWV>)([5N5VZNO<`+A
M33WO0U0(R$XGA+J2K!GV4J'*@BBOE_*2Q_QJ2N'DF#Y^ILZ3]Y5CPC6V0M52
M35\)6#K]-]K'\L/!F]<\XYS+`.JI]1@&<%H4<:6C+'(K84:+"\L3!67T-)?N
MR:E6K4EI6HK9B3Q!8O[P`T'1S76D%9OALOO*?50%KE_#X.*#!&JEV*%EX,WJ
MKZ;V9YZUR"^8;BL1&])X/[_R1/,$*8\FY[-Z6P8(6=Y.U#?+W^@)!X8(:+]R
M7_.K))DOC7CP$MX7-$NJ-$5SV_$=][2\&KU6=TGKI/7*>TW+!H`?Q9CUMWNQ
MX!K(8^$UGG@@EYH<<0;)1+&C8M#\6)6+*'.3Z$_GJ@(+O"(G;;%L4I3K%PN[
M<9]DVWCHA8VD*,A23(%OBC-])C;&@D,M)_=D*1?2I.L+3:1*:R!DLDF)ZF,4
M59_,H5HMJ$A<"IKG#5HYE(H\2R&E2%N^%D6P$549)LA7\JG>&\$ZP$3->D)S
MPJKH*[2QV5*T?-ZS49U;7B%XE#A=UN;DR5^)=T(+YZ6+HLLR\@R]`H)KT]*1
MD94;"*T]N%7]/40_H@=2JHF/D3SDS7\"T;Q#U6Y3-,.G4`"O7,B[ULB51Z43
MLB4HOVY<(0VRXD;4UQ9%)CU)G8\E-*(=71(FO`!^S-@D+EP]I1BK-J39;=*T
M/8(A*^P>)9IODGMA$:A<28D,S91=LY([4KQ&EQ-*@HE%9Z_XY(7<&W=^T'90
MVE*NZ?^PK`>=ACQN.I,&I(J."9++Q2^A<_&E99E]9V@:+WM=<]CIT*UX:0W-
MSJ`M+>HLG,4"5$M+'-/%CRQZC_ZI#-7:IF8G^H^E)+^"GHOD_R-FWZ8?5%N7
M,\JZ*.E%E;\7/[)`N]K@>65>5&ZQ#I?H6QJM;J>7=2^FQG5SK/J/RE4V$9SG
MK9)5LT)-@I!_(JO8^1%0+^/KA`@7#OD28V)CEYP=?[^\O.(&`E_25>V;5-I%
M*;C*I9'&O,WL7TSO=J`U0,([*@-/4J;S,"&7GW.0=RALLU@\C^#RRZP%E$W9
M8L4LE)`J,:BJSWA/&,(11<Q*`]2\$RSO9\6+[A30FL]%:,!AG+.9U,O'!!@J
MP@'\\S;,,L[P[:@NY-^,7]5:BA7ZR899<U]NN`/DZ6R>M5L3`1MCQ,!8Y*,,
M>-R:STMA6H)&SAY;Z-7%]26T*#7KGWJ.N31J(3LQ=Q2F_*QDW@1!0JJ.=ERE
MI8JD4&$`%R"<8$MW=XYD'20B#8?V&`."R$5Z.4[0"R6AQ(97/&_!I(8_=!&!
MIF5C("WV"ON3K;USS;<X-F3R0Z*CT^"]?B<+P<M,0N19_D)`!:WXU(>OJ)XX
M(JYS@R=1)UM#`2AKN#-'C^RZWM3;Y>KM1,W8$*OK1N@GBW`6J>_.8_:;(7^J
M+KSCXT.S@KC%+//=!IBJO/2=9Y@>*2]=PB0K$JV3`@4'"#00_.U%3QVX.&0)
MWPC]_PBE06*[VD&\!_BE`JN@1$7VK-!;DCK?4'J]*-VN`Z6CM#MK=-82J-J=
M\:9ECW7F7H<?1KXAAU/U[#W[E[UAZ:,7>/&=\&S2F'+>\G+#@Q20[1&P_;<!
ML/8'W,[C:S.@NON#JF=;9J\_K"&^MC[,AJYJ0%>6:=D==./6$&/[Y_(/=U["
MCLS:]X:.[^Z#@DYY2]8[M=I=L'I=^553QS?4E;IM<]C9I:CZM!BJU=$\=6)Q
M!FVSW6Z?$8;JHEB7V!='9\GO]=[K"/=8!:#/QE`J!VH36[,>=W03B/=[AZT^
M,/QA;V<-JI:$4$N@&NK<@#JMMMGI[]+4KA;4>0I-OWSC=JN[GJBQ[3VBZ.;;
MS>5G!?.GKW]\^'KS[?L_=[S-M)>:W@Z"C88\^>R`5WI3NWQ#6/=\F<UVQS%[
MUF#OU[DFE%!3L!H"79M`>U;7M*U=+9H:$&B)Q,E:AVFY[&MFC"RV?DK<X!8'
M)%Y2J@UZZQ/V&2?7';E0=_O<VVP/A!WZS%A`*$_3?0Y3F39!8'[.RY6+`PA%
M,>+$H-%^V"JS&?-R1(#_9%G"ICL)*=V2SXT3/1LHPRJWF6RZR&66P'F-,T>Q
M0M=X&\*_*"43B[G-\B^]"R>48,E;H?*:.'.C<4].MUVH#,]NYL7?PW!"#7*0
ML&A69$9)555YN3UB-1&LL`E`+>.=._<2T1ME3L0M9FD1G"73<D2)A,""K/GP
MV2W-:,W7DP"$XIW82DF@3@XGD&!7-,)!7&V$W%#.''7EHM3FA2JUJ$N'*N[@
MZ93E^RX9Y).K\Q7?73X-B.?C?\H]X=$@TAQ`-#KV@F:H!H_5$+FBNPWF8.I3
M?3U%.S(+E#J&S7!BV2SC4D%*B<G8Z8VJ)N]Y:7U4J!G$7L!C/G&$#WCTHH5)
M,)@4JKHU4=,J%)TM@X^MB7"N`P<<>\J)G8KJ1E5B4%5AL,[TPQ62>+'VC+O]
MJ,)`"/N<M+Z,OTTU"4V%_/2'']?O7Q@3-O9`58DQ-?%WJ]\>#GMZS<[BN[==
MWUYG?:O=Z5N;K:\4G>_NPQ<YT'-;!-C=]K#CE,RBU%^^-03KH,`9M.$_VT(@
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MXEYDOMWK=P>#/$RKE]L?D&MQOL'0Z7?W`>/?4Q=5ML=]0&4/.YT\3&5O7WMN
M]=\C[!Z\[3%VN^V!L\:`35IE=YC6DU<]NW]\F/Y;?7,-_M3K]WJ#XX'H;`&B
MU1YTND>$4:+Q8QH!4&G$X*F/WD_\*5X#W$ZO9W>/C]'S@%;B5HU2UJ<HKT,+
MUG#0/CYR-P!WE5IRF;E9WFNCA^%GGXF6*Y>:]Z42YFT9)0B2GG;@^P+GF-M<
MA_?VVCW=C-SW-G6A!^\FC5#8Z5_#8+RC9=&WG8)@K5QC9X`VU*[U=;ZX08K=
MJ:B]Q)[V/A@.R?Y?=YU]P+6M@>%A`\I@$E_QL<B7Y#^[8A%U5%H;`5?T]5C'
MPZ>O'U_\WFYU-`)>OE@."S^"L>]Z,Z!T^<RVA]&QG.Y0G,7B6[=8="T;8:U%
MM8M-Y>D2+0%1?\HFG[-"^<TM!&_RMQ<?PS"Y:+<OVL7;Z;3;@T&.M:P+P9Z!
MK\"F#KQ5`+[?[G>'.\%.YW+M^BQ6';6^\X;.^+0:)$#N*6L'H\QV'$$$ZRZV
M-PC7H5*PI=OV+@`*1+_S/>JB?X..S?W8LT.[+<W958OL#-$VTD.2F#N2)NS.
M?HU>M]_);WGQ[=O#L*5\$&N`+C%E,48L7?\CV]WM:'?`U,U=X26K[`[3.I=A
MF/?9KP<2/P=Y13Z&T9_4"ACN$EPE/GXFC/:`,*?=<]J2EVRPWC[A7,M;T.[W
M!YWMX2Q@_P^71V)W);=N#_C)PMD6WKX]#.L%0SJ@%JX+@WZ_/\KVA?O@K(-N
M.U--ERVP$R2[,1L016ZT>VQC"$J8Y2Q@O/#V[6%8*Q(X[-O6(N6M@$&ZUV_<
MGSR`O$.@H[WHM==?N^W2ZVS^0$M;1UA:C952/&Q[GZX#%-`9+`%H<;$]P;>6
MCP%8MMWNGP*\=0ZRWQETVB61IUV@^X2N$9PI6!Y]V%J#Z_2[5DGBP[KK'@+N
M]>(R/:=3DC"R-[@IQ/TYC.-WF*4S#2,:-K'UA>KT^T[764:QY0ON$<ZUC"LT
M87K+Z.'@8.[E@JT'Y0?93%@-&OKN)NQ=2*,Z06/XEHW27#,+.0/Z*HU8B6=)
MU];77WZ_@-L:X(M$46/`+0WP13(Y`>#?&4`Y]GSNTZ8NI,!F/H=C''HLOK=^
M0]W56]&#<;M`=.C=;4=AW>YY[.Y`9'BXS5TF']D$.^CB2]&(?<Q]>6_TZ6QX
M@"O@.M)6MR+6\]SJ5I1[H*V2C?X%8+SS'W$(QG?0RKY-*=Z[!<<L\SY9'1G-
MJ%BFB'7Z%.X<?L?U16+CYB13YF'J.9:&QM*%MH8FCYEV[\)IKXC06GKFR7Z!
M64YB95YSN]^U#XB:_B9$8PW:@V%G0VCX'SF1?PT#,8"=Q@3L#)!C#WN:.ZAJ
MJ;SC:\([/[O^%0V?^1A&5V+HW6*`M/IVR6S,?^#,#73\?/[\3F1>_'[EM-]+
M?]R*U?+!(1S8]D',7+L)/]$(D_<4+N9/\Y!L!80`V%!2N7-AMY=`F.&T(LC;
MZ5@6Y6-L`M?B7JJ^^94]T)\*<:YL+QUM+YT=]V(-NYWNH*_O935<Z^P%_13L
M,%LI(76KK;EYUX-H_0.A/_+92O&'GRP:>S&;E.YH.7.O.`*[TW:&W75.H!R0
MLL%.G]30,K!0J(?#R&=?4T3DMRF?//=)FVM6?CB]@F20A_.1C:+4C1YQDYA1
MO9A45;73?K_;T879YJ`>9K,@;=J:Y&EK+.P/+W&_4%QLYL4Q:"2;[;AM]WJ#
M?.)];;:L"UM+.]_=MFS!"5M.KWX[MI&*K8&XG/CS4+&;U$=JMJ[9&!392?E^
MOYXS/6]ZN"6;K2TAMX>PO]S=%2O\M_Y.W*9(F5ECM\>D8OYC3"F,WIA5).!L
MR(*7)JDY@S4V5@1KK_O9Y@+6?$O;7;2SV-3F-^KPVUJFY?&/P9QXY\9W%=K-
M4--ND(&H+<)R]VZ"HS/';,UJ!YYEH,4^U@9NT3R]Y8DW1X"Z"Z_IZ0:K6+J0
MGIM_[[%@Z]I=+:5X$892<L!L?Z`9SHJ_,Z0?1G^XGOM>4B$]^A=V7T@/_'D`
MS)_J]2W=[[K&ZP\&D>*2E[<1(P1<!A/,<O_"HEL6"48C[>O]`/^G&,Z)#@QL
MHA!_2Q-L2#`I.B<VBF3:0Z>C)P4M6R5'A0M?_).FVK'));8ZN*4X3.32H*SO
MLCO$9VP.L:8W\/<KYY]6^XO=D:Z);1<LY%?+SA8\J?_;5+YV'UY*JZNGW5>O
M53S:=[X;9W_^%M'^I#E)O#9[5OQU:9V-^&ZI",`A>XNZ54NOU-\&G$-MR=Y^
M2[JKK4Y;DJ<D>?$7(-59.EM_:^V6W3F3K;D_-]N:T]*S).N\M0+W>0IWC=C=
MKH7[YW>N[:ZVZ6N78E\A2!F<X^X&C_(EZV_6;NF*9YTV"S:>K6DOZ]FL%3Q(
M-QEJO,<O6B>RS8^RUMO4Z58^PDV9FQ"4C^F4@KAL\B%(0,'<A'Z[_=IN.N^C
M")BB7?F\M=%%K2E76F>C]B;LMZX;+?CVBV3\#8AX#';14[BQ5CX2NWACQ=AF
M?EW1&Z%:NERSZ![6>8IH^(/%";H7`]CPE'G4C5;8S]NPZTY-):^5]Q9OX(H\
MOXTZASO>NAH^DJB5=;"IN0KWM7>$K<G0"'GU>5VRZ_ML\O9QG5WN;B!412CM
M;K[V<4?@CX.++>V&"AP,SA,%UAHH6%3)JH+S`\=Q5KEMZH8#G:]7XV!16WM"
M.,A)]&H<.!OA8!6KKQ4.-K:L*W;>[0VP)\(9;WTM@[MB]XYC=?IGMWMG33O\
M4S#!_BLI['=MA%AG)A-V=TM4J0A.^]SDXSI&_+K;[[>?Y/;7U@QZ3W/_:VL%
MUIGN/U.-UN2,:U.$U3TO=*SK_LEPL9X+J$J1.#OL;.4'7,HNS@P!R\AC4P0X
M/7MP9@KT\]Z_L]_]]ZWN*O]OK;9_".=XE>`8=&QKE?>TSLC9QJ=:60UQ?GQR
M&T=ZE9BPG+YU5O?$.1@I#)UA;U5B2JU0P?T.G9U=+N?I=%BZ];7-BO-T-U6:
M56O3^ME;4W#E+Y7Y='/G133^9GUORF'V3WFOI>]"1@6R^CV`NR*B5EX'OU7<
MZ7?.,-&P$#FYF\-VF*UU+]H#N;7-8BB_9T&'`^[IP\^Y)YKG'/_(AOS99=M;
M"=]"ZC_>`VP907AE0<R[6^!#MY3`__8Q^\J5^T@Y_0]N-/GH>A$5B5R"*CJ3
ME;Z\MERVT]Z@&<E_?YC-_?"1,:UR>.'2KM%UYN#[J04"RQH9-`C<&H&[1N\;
MM.JE^/:PK!1_DRAX@\]=\+FHY#;XS`2/G0F>#2/3#1978W&M('>#R`R1CH;(
M?<3+&]QFN.UJN-TQ^-Z@=9W6).O$\1M,ZIC,"'0O(>$&N5E;&?LBWZ!O[P'F
M!MFK>U*M':YKD+D#Y6X2_*M`=(/FG6)'#?FN;K&Y1[P^-ZQ:FJZP7:"W(=#J
MUKVJ.JEQH<*"W[WXKX\18Y\`=1%<V;TX\2N;>52B4Y_/<?#]U0*A9:QS)66N
M[)92C>#N<T/PAA1;T:.E"J&V[3PWA&X4AMH8H5;_F;.`@X6E]/G"SP:Q!PQ,
M=;J#88/1O8:FK,ZSN_R'"$X]/[H\4'#J62+R6,$I2Q]S]VRP>XSP5/\Y(O9`
M`:K^<S28CA>BZMO/#;TG#5(-GYU^=<@PU3,T_D\4J`)EX=E9KT<*5EG=WG/#
M[''"56VG\PQI=HLXR_;>[.<HSG9"\*;>[>Z3L21D1.V/$&02J*S)XTE"7)UV
MOW_@F&%^AS5!ZE'#7([C',IJJS62#QKJZO3:A^*VM4;J0<-=G6[_4-K7&2'U
M0"&O3L<^E/^V[L@]S[#7T\/JVJ$OP.JA5*U:8_40X:].IWOHO*QSP^4N0;!G
MC,XCA<(ZG<&S5*V.$@[K=`Z6451WY!XD)-;I])ZKI#I66`Q(]E">PUJC^(2A
ML:XU.%0LI^XH/U1XK-,=/DM&<:(06>=P^33GBNX]!G.<8>=98O<XH3*0=\_2
MIW#4<)G3'QXJV>8I(WE#AV[[8$'?#9`\6KWD:),E;U@TL_8=*_O]JOO/`JH.
M`O=I,;3/P-?SP-@N4:S?KWK_=+X\?1SM$I1ZGCC:L@$GX.I98&K[@-'S8$H[
M17^>!XJV".4\>\0LB<L\&]SL)\CR;-"U<\3DV6!JF_#',T+.7F(9SP-?APM,
M_'YEM9\'`K<,,SP?!!T@:/#L;^?Z/NKG@:J]N/.?S97<KOW:\Z"D?88N$&.]
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M97*PYGNM3)@LHTH:T%UKHCR'[6S`/3;8#A\?OL5NI,R_BMC<]2;B>V!C@\B+
M0`%?8Z;Q;FS<:0\L756L`F07@'>OW"C1!8>.9?</"_<AI,M^X'YW).JPNIUV
MKY(ZWNT(ZB'H0DKOPT!\2'UC+8BK68RRTE<,GU4[V;6FNH1:^I8U["Y5<Y=`
M>8@M'E.#K^76UKGDG9YM#6NSM8UK?$OH$,ZJ:W?Z-=W26J6VB[OJ679GT'=J
MM*F],V_EN*K-%C<OBES<U;!C=X8#NRZ[.I[]Y3BU.<IM*]=*:-1Q5AC1=3S,
M3<K'2AP'W>%@J:ONA%O>ILBHY%3M;J=&Q+H?O[+3'@YWE1=2*WW/1LFG($ZB
M%.-"P-VYDYHI=S2HK3,OG7UE5:K^KE)]T!WV.IKEM`%$!]E,IW(S:UE6P[ZC
M%Q1OL1LZ5^XD![@JTK`JX-]'KXJO"SY]R197`;6/'>REO'YQ"\Z&6\BLMG#*
MXAA4.I"7C%6%Q/;=+Z2$5P-A]71K,@_7EG#OO;%!R8WH==>`FP[G.YNY7@`R
MK&8!2LMJVSTE*3>&,K?'R]N(45C^77C/HBL6>6&%N_EPF8>8/E`)S%I.%-C>
M<A_;$;51O1?W:F!SA_&>Q>/(H]2'4D&*2@A`PQ&S0LCOGO!X<\<,^1WC'I8V
M\%0,U^AT+F:PTITQY^0R8K=>@!1HA('Q%;Z$SQNV91JXJ/$JC`S+,7M.SX@I
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MD&,#N0XF`<A.+DGV0$`.M6M/P'$M^%-PF=["IZ#=7;-Y0O#B`VNY-8YSJRHA
MWQ1@^PCP`H/MY_PM/EXLBS)]44=?DW2/P5_7`'4=K!X'5.Y&D/4@8*?=,[!0
MP-`A.$&>HM&S#K1.!^CVX-#JYIE&LS?A'R[8N2D`'&':]UHA_Z.@MQ+@PT/Z
MV0M`J/-\G`HZW<ZQL3R"E`=6!V)7`)<H52I3(OH(RMR_O7`+O!X=U"^>[WNW
M;E!_6+\S;WSWT9UY_N-G;^8!G7R^.C+4]@5>)V?/OIG#`;@1)?:'AP-C$RH[
M'!S;4M`>(=J`[H_&XHI4O75!V'!HVRM@(@]DWE?[/HV4CYA771W,&[ZRO*MG
M.7U+!E-7@;DW5PA_G=1\JX-F2ZH`/H?!+5:U?@(C.DB\>Z:#<.6[`>C'PW6Q
M8#D]Q^YW]M%5M6QK=<(;4,W_35W?FWIL@E>!RI05$A%QZR+-[G7S5[*>.--"
M-@<DL=]O0F,>A??>A!E3'C9Q?<.33\9&$AI,5(;'IC'Q(C9.P@A^="?W7LSH
MIX`.$V,V%,`*IT:81O`1I0H;#W>A`1LT\+;CZW`SD3=*$_P-=QI3H&L<,0*0
M'H_HJ3OW7GS.)CS2=1?Z$Q89]^BI,T:/`G2,0,(K9D:,1&&$W'U'<(7P>20^
M)SC=^$[;GHE+X>J$\KAE[($JM(.K`3&L?6]^QY^-!S>&^Q)[MP&@'`X+3AC.
MP$5D9FBC*&W$$IY^@/%&_GY!";"S!,/Q?[%'G79"$6;.4Q$^`48DO"I'0_@Y
M41A\JT!0K9J>D:HG)JYPF29W8;10)E9>Z+%7H6!S7\`^&%S5ENJ`L_T)!*[7
MGP?">&..^%N:Q'!1D//]R3!$SR:7]RQR;]F'GRP:`V.^BN"R+4-C9;^/O.IX
M586TUE[F$6RVGQJA<65CZ'71:.UC_N;9HK'8D;QJI,`2%+9;UCZN[M-!8<7`
M@"4H[+1Z^Q@*?;8H7+L7TMH4^:0N-9=J2VBO1,;^C+W?`L__VXLD2MD+X]=3
M@K?6>58QZ.[>3.PJR$^"FDWD5Z7WH>\XG<$^4H=JA9IMN$&E:MD=MJW>/N8_
MU@I%[1U0M(HSJ'?QY,_R_7S%V"-Z$[GA?A,FKJ__'9/?OX;)/UF2-<70@*NH
M>BXRLQ)W[M"V<J;"4:"M#8KL-5#4<8;/&476&BBR.YW388A<YEMSB7RVW(&<
M48JO?(<-@W*3B)W\`)3&WZ]_K)71XW15_[<][7:/&!0)]^\WGWJW9QS^#N_H
M7+3A?]9>D*5M;,_A@ZLT&M_AGSZ&$7U<%^*KD/W[C3(L[/YH#(_'-6!9\1%^
M;]W>SMBJ^9_.%VOP_@C,KA30?.G*8D'RV\?O6'X"%*#^^,[UQZGO<B4FN0M+
MO9%[:MY@]3K#P5`5KFP'7TG1Y9BQ28SG@OD_7UGR;2HS=ZDLL.+X,"-5=J>$
MG[M[;=]33/Q;#>7>]H74*/?EZ/D.]=C7=S;G]QU("Y^HWL4PVX6]W^9*'5#J
M!UJA0A&F9;D*']TQI<?K11YZ%+Z263CMG8:CK2YLZ94G.:P">-^;7983L5OE
MCM.VZ[%%*CC/QMTX&F_<<8NVTSW2%M<(LNY(L;_+]0QYNXP'^-V8@"J-(<\Y
M3Z'%>EJ,2F,8]<Z8N(_&-/3]\$$$NK&R$X.BS!W?+91];H"KZB#HCJC:EMZI
M]'CD!G\9/@"`6QSS9"AW/(Y2-C$\B;Y"=:P#9/(+5<&Z09#.#&HRCUATC4<&
MN,&O]-J(21Y:IC!W2GC^@F65!J]9WN0N'0QYV]ZDWW\$F!M!]/$3*`>;&YC&
M*(PB(IS8&"$F=`RZ"G]VR^G^PH/N@AH+F'%:!T/->X8I'C$#Q>T6U)R`Q7'%
MS"BRK65#A>WS%I=DY"V#:9DVHN>_5T[@LQUM`M^.)4K%B'45,#L"K?<3T=NQ
M;06T<R2@U\;T6O4U_>,`O=:LN/7K:[8`N%@I4.;BV6?Q6M?J]SN:9[QB_046
M(G)E%A3E<L-LFU90CM6V\RQ"6W-'>,H*?-;K.=G)M:<J`RG?%N::&HV`2!`6
M)2UU((S9O:$U4!TQEX-P8&C7J_`4-8FG!W>].D]1G;@!N.6W2A?3UPGF58*J
MC!XP][8B,+[/-@.5);7+P-KOAI9QUVVLRE/M8]M:O!H?S1J5D'4Y(62\>QW?
M0X:/^(;!>0G9A2YV(X"/1H]&&AOI7-B%,Q;=DJTS0?V>52CU'=TB(JM'F9K<
M>@)[P/=8]'_^PW+>P/=?>:_IX]C[*7HPP:.@_48Q,"Q\(?YQ(E[N"8<6O?B5
M!X_&*5@+B3>C=&&YEXB-&;QB0L_.A29"_8SP-X$)`B"`7;^*7].+R=*CED>\
M6A*^#W\V?%##X47P^4O+!`%-_Y<9W!]3BEFWUCEY.K\]'/>Z>IL\Y<L*,Q:/
MR/75P?5^,96%"G@(P13VT]D<,#R3?@.TSZ0L,>P.V6B=S?<NFD/IWU7B98V*
M^_6H6S&I]R+O>P,C;3T`2QH^9AYT7G6T8;!HFU*EDH:5/;O;MW(M'XMPY4#/
M>)$T0#\%_Q7Z2-?O4W83?N'WOISQ]"_LOF0\?:UEAVJN=QE,>)0+7R(VLRY'
M'4KM8ST0BW?K;1I[:$1?CO^5>C%%9K(7?9O^$6+,4%(I_U94G@7.^]IU]K@Y
MJZ6K^MM!NL9^/\!/F9]$5`U]BR@P@%([ESG._UK=U\_)^OIMBXNJJ.6@T^X[
MCK44(UOLI8BA=^$,9`P%5M^Y<X#1Y]_&1F?1/84Y/Z8)G)>,G.R=&"H0T%^H
M!M@8U)KL5?'=37/6+&O8'_:>$`($RUT;`YV^/;3VB8#+"6GG\?*NB64!].7]
M8/N./MAQ89'MP"CI7+NBUW1GT-X_&"4]))</L.@.]9*4-<`($F_B^2D&U[,A
MD!]^COUT`F<*4&#&09J(QKH?W`BUCAC$`9U^B6ZTUCE6E6T-AW;/UAUB>X'O
M:)M>3C65M6JPZ>&@?ZZ;7DZCU57;G7Y?SYL^R*9!%P?S+WE$YHA,$H4V=0W]
M$;-IZG_VIFNGGJDT7_F*`G\M3H;N_S/G?EX%QBDA+\P!=W:#_%U(^601[]GJ
MQ7]ENN.Z*5,*M.MT/D?S?.&=:^OL`UV"50.VZR;*.IWO;1/]WG$VL6PT^NXG
MT3W.)I:1$U#S)!TGVQ_$\/34M.L>>L[IB6G7/>BE2*>BI7>D@N]P(7J=TQ/3
MSINPC\1?E[BIWK,IBR(V^<[N69"R[1E4_W3GL>^M;'DJWT#6N^C<^8Q.K9C;
M<T(]$.G8\?N4?0H^@I+V3^9&V]<0M>U^1X-R\Y6WASU,H]U@'SJ#[6"7*V\-
M^\T=&/R[`3^PG7Y_"^"SI;>'_B'<#?:^97?:V\`N%MX2\M73:E>D4O3:NH]B
MLU5SSO'"HU]94O7TML!:?;MOJU&EZZ^W#,S<,]?IR,=/OR,/*A\]M1X=9V-P
M-UAN2PK8'IN]GMVU-S[[JG$MWZ:?J6!GZ:RB77SCOW_`?%KJ%27Z3+GX%,8N
MW<284&:QX1H^_/TBG<LA.%-8.Q<9Q9_E=URY;`R82CS?L`84[!1#<+`Y%7.G
M"4_;?#0>PM2?4*ASYO[%,+(Y=M,8XX./1NSZ3.N$!&_@H+:,2_D"ZI#DLX02
M/UEA,[2NV!"N0,V=?!\7F7CQ/(SI[3,,)U.(U6YU?Y';T5[S_XNU.33<+VI<
M\[9;D9A&0RM%PC5*O:)4L#BE%-7%-ET/<O@-!JSE_!J:.H3+9\G/0'7Z!"(5
M_'T?>2.@=5KY6YH8G$9:Q@\9,<\P(_<D'C&RKYN\$UAV9`\>X`<@F7D![+9D
MEDZ>)!<"RBE#PI3CE;Y%UQD:E]W];>*E>L??9<ON#&-1B]XDI@O<]5A@%JVN
M.J*RH,O3UV69GZ+"/[WD#L@K\'[>`+-PYRQ-O''\^?.[=6IZ>OE6T$<AC(/M
MQFD/CK@=Z]#;L8;;[^8[GYB%7<$?;X!QQNZ8BDG)#PSP:Y]M:MIO=U$V`&C/
M>UEFX6^P%[OGV'78SC+/T2;;:?=ZPSKL9XGO8O]7JK8$>3@.W\XWDJ@7X1Z+
M=VZQ:]+D/H,6B]-?OS-O-DJCF.`Z.17;G>%P()/&2D'<;A-')<SV.O#+\\/>
M]PG[C'FBG\!2#6XQC?DRCED2ZS,011@?O1GH"=O:+AWJWL[MUM[##K@==YH=
MP-J[[X"<8J?:`BV^AST\A"?;P4.X&_Q?`>B;!^;?LR_<F[#E1CIM/7MG-Q@V
MV=%XG,Y28MSZB[?=Q07V65MS'^4K'P;V=1*H+OI]JSNL'^P+83]*0F'1=3A-
M'MR(%5Z]AEBXZ`R?RC[5MRD--F#)^Q#STK^ZL[4JYBX&PY[>%[`NN%B(DNY\
MYO6]E,<]\&->\J]L6<1FCX?K6!W=Q;\<I!-M8,>#L]N#(^YP__?/=OIVW3>P
MXQ$!$0XZVV[Q4S!AT^HG>!:F%]S^/0PG%!'84D/I=[NYL/^FZQX"[G6T$\?J
M]?5IN'6`NV"$_U<8S<*`<3/U\7V4WK[##K88D;MRL8G.6M.4,?K;>Q+[+/8E
MNHG<"9NYT5_QQY""GC,OB"FKD4>ZUL'.T+'K2;Q[)0)KT+:&-2/V+?=Y`"*P
MK7:WNSMRR#.TZ</+-8+EE2&];G<@NSULL>XAX%Z'\]K.L(OXKA/<A^2\3V"?
MA^.\=4+.(3GO$]CGX3COKLA9K2%O7V*SGJ7R^Y75_><PWQ%X'6CVM8.E&>%K
M[J#]S]/`O@S[U883PNO4$^'+@%[H&[T-T.]\-XY5RX5OT7><GZ--N%C&^3<N
M&K:'3LZ]N6KQ?0!K;PFL;9T`V&)"PX9`.^UNOV?WCPMS<=+)*I@/-O?H:QCP
M.G[9?$'V0XE%BY*T8B!S&=<XOUTL8R,;TM%%U[+V,M!IK<V<'G7+<HIJ2`@?
M?LX]7K%SSN2\8A>[D'/]=G-V%,;GYJW=%.K<]K!/9CFP.MW.8!_S#-?8S*D1
M=V:$_'<$:']D7&S.4>R4?;@=G!97>[PN5M]Q[.YS0-HN5V658G]XG.TVZ4HM
MHT]+!*,T\H+8&U>VS5YU#TMRLP9#Q^[W^[N.YEH#X)-B9I496U9=..Q;0^4P
M?+*86?=JE<1M.P.G-]QYJMNF""HULG.3BK,6F.*O_'+NK.WC1&8<TK8HR%I8
M>+8C=`?<Y#;RIW*S5DN%4FJYV6WD1N5FVRVG!IN5?S[\X<)^!SOL5P&Z\Y8/
MX*U9LFF[L\.F2WPQ^^*(0JE8PL6W8V/%"*`M=,J#PGTRY&Q)+`MI2H.A976?
M+):VY)N'5@J.@:0J&S[K-;S/.([3[W7ZUO[H:#7T.W-CWDH<6Q1FK][2`*E2
M*E1%VK[@V_=%TEY]$$NL-^BTN]WA_FY.)<![L^O%0IH`7-8]I8P-JUF]V1SQ
MM1V'G9ZE3VX\P"Y.A*@R8;X+HGKM0;^[#X]1[3"U3&9M@K&#N5;5553AC4/>
MD)IL8]_T:^^3>$OV<"(TG0OQ<B-6[N3O41BO;9+M<.I=R[;V>O`EVS@1IO9\
M/^PNJ-S]?7BW:X>I?5T1;P*O#,.$7E<RD*(WL&UK\!0QV-$PR'_N:6VG1S'[
M5PHO_G#/%CJ7[T"1SG!/<;WCH5.S(.9L##_>A/B1YI+^DZ&I`=^Y9Y%[RW(6
MR3(38!T\HEU4@<MV:X]TN=LN-\9YO%)0"G>A/-JU<;RCS%F*;\O9`.%[W6+]
M$+PK`UZ.Z.&3072>0]6`C.V-V,;^ME<SS&ZK:BW!K-/2AY<]7]3NDS7H^IE5
MQBDV20_;/\9W\\@M1K<+:ZJ!D^]"["4_3E+7IRF:UG9Z!<['L;]8]OM=?8D[
M0%Y+U*WFK8BZ08.ZU6DBRU'8_]*K`P8/97_`;^_=9%D8X'""W>H[_:YS0..J
M='.UP>@!!'IG:+>I(>+SQ.BAY+A=4L%F#08=O9'*66)ZJY3,-3%93,P8#/H#
MR]E'+=&Z.78GP=*&O'&AM_*@W;&L/7I`ZXFE+6_G0B^C=J_?ZVQB>^^*K;TH
M`ORN;Z?$;"6.?[\:[E47W'`#=4/>9I(7D2>J\!OD;2UD=7GJ[%NSWA*E^XN2
M;I!CM4,PPK+L@;V?ZH\JR$M1,UJ]P&CU`FL>SUYN;.^?O2\%+!UW$P?$8UXP
M;>E865Y)XV#/@Z)A=A#H5^;SQ8F&6NQ;L4L!Q.]7G1PKWV#!?0*Z?A8O`NR<
M'N#U$VJ1L5OM+W;G*!"OGZ^(XZHWAVL_$!T"8YM#MEOBZW;X6YG,6IHABYS!
MY;PJN0LGBSFR%9>_=V$/Q>6'GYVV&MG@!F//]T*``]F7&SS*%UIR=V]]=_S7
MQ?7X+O19;'P))\Q?EL.[$L*%CD"N%Q'#NXSC=*9RJRAP_=Z[]R8LF'S',7$[
M%D24#WK5&@.M"<<^X=^F9J&.^]BFJN`4^T#]8U>IT_WG>C#B6ON`;5F[KAQL
MZE,Q#/.<('9_YB#N'1GBM>FW-CC>`N("CJWV@4#^(_1!`/A>\K@)V]X$W:NG
MVW?LX7J;RP-[\FWFSFCU-KN#&FQS;>:Y_6GV.F>YS0U/LZ.'ITZUS5U9X<IM
M.D,]]>Z,MKG9:7:MP<&V^=V+__H8,4:-+\&..!F?;;<'@^6;+`/UQ%O<[!R!
M/.S3;O'@_+7=[I_?%C<]Q?8*$7+H+1Z<K[;;PQ7BHX9;W/`4G<Z!V,W:>?[+
M:IZKDW172H(E":!;@;M&)Z1J<-O=8X.[20>7ZD3SW@Y@?_8"]FWZ+F(3+_GH
MCDD<"^I\&T91^("!#'<.?TD>R^D#@W=6L6?[Y>3>#<;L.[L/_7M\!2WP-4S8
M.C'\=KO0.F\3*-?9(9]MNV8GZWUN;<6>%N!:C/32*2Z-\`AX_\&F4Q9YK&KD
M;&4*7JL[T&.P?,'-`&D/+^QN-A[7FS+_JS<&?2^-,X_K9I?3=G8#"JY:^Z*M
M`;7SS-[J&^DL06`N?K:2[>Y\EOUBR*XZV7X),`<XS\Z^`'/:BGW"%^]QFH3O
MCNDX-X/(*K9;6,R2?\_&$4."R48,OF?S"-Y$KG_XV6<4!@URHP>OHG#.HN01
M``L2#'W\*_7F"."RH_^,"]V%_N33;!Z%]VO/NK"LX4"V7]DWO(OSF1;FP^UM
MX)L<.[3)6ON";Y/Q0ON$CXH_#S@R;YW5]@?C=N/Q-H&1A^/<N9>X/MV7;R/?
MN^7-"3;PTJ/GW?DBHWO5KRNBY@-PY7'BW8/:/0YG[,;]B7KW=P:KHCRG![\E
M($DN)_\#O)-N\+H@K3`*+L`JT'.-MP'E4-LIL6K7V(YM._7<3HEYM\YVAO;Q
MM_/N#K-O/@%C!W4!-$OX$K]&*CI]Z?OA`^JO^Z-#Q]Z0#C>`\@1(V(YZK<&&
MQUUO)&Q'\^WNX&A(`*5SYO&;0BIHD(!\8/#J0DO-Y?)R57>9#5>ID'A5JP@=
M;80Y,O<LBA$C]!.U!)0=[[["IVY\MSFMEEG6W4Y/F7?KKKPW<)=3U2*X@\[0
M<OI;0JN.$#[#LX-_H1Y[[_IXFE>A[XT?;P#`MSY8@FLK"O_'3][,C3AY]-G?
M7DSAH=\,JSU/C!MO!B3QE3T8W\.9&YC\`].X!K-M^L:8N=&M%_QFM-\8H'$G
M++J(T5L1W/YF(//HSI,W!JY_X8+"`=]#*>!-'U_\G]OD#2Z)*^FK7CQ0TNEO
M1A!&@"[UO11_P*WB+[^F\N-?\1GURYQ^^@_+$?^H\9;<V?S-?UB]]EGOXD]&
M$&):<`+_-\9X/=S$F'H!IJ&YON$!$7M)2HJFD=S!W^!_"4$^<Q\-]G/,V,28
ML@F+7-]_Q.\#"YX8O@?<*6X9?S+CSKUG1L#@4L#7Y^@L`*8Y,<`N-WQ0H5E,
M,$2,C$`C"6$9%C-CF@83>`&P62.<&F$:`>#!A2?<R,:(N1&YQQ#DD>LC)XZ-
M!_@C/*E#`O""L4G6J>%8IH$,"1:?X`_P*[P,W6?!+4$QA0N&ZP-F9_,P<J-'
MN3<#3-W;R)W!>PU&`L2@+Q??W8;'HS"]O5M<M67\".!=\`4OEJ\S<36`^<&-
M87\$`Z%.X,%PR>^&&*#]D%2<AH!).'2T10QW/,9O`*;>,J`73.\V_N$&*8+.
MUW5,[=EQR'/!8=^<2^%"+^UNVVRWVP:<#H$P8?,P]A)8![#'W/%=.468^.>'
M.P_^CB2Q[B&YMTAKG'3*B"?#0MRJN%W:K+AUF&B1\\*EN^1X`^BNHC"`'[EC
M1CQY*B:<9Y>@D@!(@)A/<9P"IC*8C3S0!9ZZ9P94QO#VSN.J6-FGP/A'ZC]*
M2L8[\?'R^JWA$4IH<0TMU^B==J-);/R8X_A6TP`:OKS^81I?PY;!3PIN!8+K
M\;>C!FB`=@=@OKH)Y][8Z'?:KW\#!`,3`JZ(=([7SPW@]D:@(]X&WK_A+.`1
MN'$!FWIX!5A`D+@&#IS]!M?()7`^8W>P=VX4/<*=Q1(#N#'&-5"V[T;T!OP"
MP>C2K]SGGGO"^/#3B\'\>^4B$0)(<1HC/`H1'V8,D7C+B80STQLW_LOX&$9C
M]II.B_9JJET;V8<</1(S+>.&>`X+)MSHA'NJ_1F9%J9Y&K>I-R%V`KA!0#+N
M$`/&B";ANQD""2B.Q%1'8@)['FE(!#0$@,!0(="G]FH%!,8"@?BTGR$0?QUS
M!.I/`*-!!+8XJ2P!(+X+4W\"OTK0X>]>Y?Z`C<'_@(U.TC'1"/!1%Y1$;B[0
MBUTT&(A;%[;%&=P>MO;@):#.`A^7#)7'U9#A"[X,G)<9<0H_%7!/,.R\?;"6
M1A0?JJ(<[=H9DQ"D0P(H`SX=H4KP("3_.(U(3$R\>`R[!AD0KZ)$%U[`I!U'
M.)["PP#A(X@<0``*>!)#W@REFA<"2T!LT8Y"P(GXWD@*37Y_I_!$)KBM+F<[
MZVP.`<+=,9%#A/1`FH\+7`[A0-$Y`PTNP4N#DA*O,XB9":D]"L4$1X;FUG&Y
M[8FY/*E)"TQ>QS78E;:I@"$6=@.:!O$_-3[[@H8)&YG'UN"V.]'))S@$+T+D
MKLT:<=&6_HMQ"PO$!KS#2]#@AKL5S@47X'JD%X'Z@PP`+OF_4M@Q,D*D5""`
M,(J1.B8,R&+F!0Q9'VJ!M&_B5HQXZ]1@]_RJ`3&/O6B<SC#ZBBJ4%TR\,="(
MT,GA^H)*.0N!!GWO+^8_\MM]!W`A3=)W\.5^&-Q>^(0<+T,.YU-(P![AADU:
MQJ<IW`TLD$-J!44LMPF^+T0A7C2.!HK!HS,\@XF`R,-E+,(TA16->ZJ]YQ+"
M4^=H5(`*[_01L?0R!(Z8(M(`5Y=-A!:!(G`Y&.K4@08YO<!;!"N"_?Y7^(`*
M,7#.:>F60CR@!R]F^7<;Y>_5V-R$"(=@D,0#7\BS+C<`?=W/\:S">V-D8O#5
M&;**`K/+>)C!^=<UB($<`X,KA;R/@(`GX!C<B:#7.9(@6)>3/'V+/:S/S#(1
M098#*4V1,*Y(7Q'"#WC>\V%I2I!P4W,)6[-0+<VSM;?<7#*N[QB0O-!-;0MU
MT_>9G#3<49B"RCF=PL4@\A.L#HGILY#.P*(T7F=DC`V750NVLN_H?X>[<$=,
MA\!#48U$.5D`(6\ABI$8!`:8=QC]INNB_8E[$U".>\3]0MJ#5"DS11*()R\=
M=0J+T]'_H"V.VA=>VRDJO50M.'-CO`R!0(N;U?_2<T+1<F6"!=Q\V%D\%]<2
M%M6X\B/!R0'DNNPR(-45:!D?E(2(F.(("*S4I$?`6$@Y1$3=4C=A#S<QXX8'
MWG7N#G&S8_6U8R7>AI@@QT*(\L4C/HVF/MS02.AGP"22!P8:=JDN!QH??)4K
M?,#S<'U\AM3+OU]>7M&R2Y_4L0)RPZ,[3SE_`>T$GOJHGO_.YAC2U^VU5H[D
MJCADI!Z4.EW&^Z25$0DNN.`$64\E7`!D(SXHA'_#"_/K_LFD\C]BO@>"5GJ]
MR.0@C(X8F7\2K5Q6<3^;("OT=%$ZC\B**U&>=<J\<[F/D20W8%^X4CCO!>4&
M6!8"]`AW3]&:*=UIN$0L:9-@X?"AV,SL(LD,.375X"PSM]BF'JZ%]";,0L,<
M'Q;%?-`1YA%F@F<OKK$1O']OZ)!.LZ_?;C[`2PV!GRX\<WWS[=W_]U_?/K__
M\/U:?-SI\?/Y\']_?+KYY\;^L[U"OLVE_)5[\;=<WF?3)(^UJTAZ+NCDMW(H
M[@NF$S&I8M"D(NI"W[W,@@H$E:.DS`,CSF.10YV<ZC&E]2'?GRLDQXADTP#1
M*4R?EU@N`"]Q4Y!%$?FF4.XAMT+ER^0*"7IT@K#LC<)M@!>28B!AEJE;Y4.O
M&TZ/&%(K1"7#V0QDS/:$?QZ>]+W2=^Z(1/BH0.U%M*Z[]NH[H!"E(+`Z'7/8
M[YG];G^CI3)HT8C5(>;72%AJJ#K6Y4:=D'J\W+7Y),XE-MZGY+Y%`BG<'^\T
M+,<KP=0)0+E*(T01MTZ!UI@_!47TU@,;F)MW2EWE=FW$[KTPC4%+G7H^$^Y]
M5#2OT44N78T8$AI3>A(1+)`HA6*YI6A<?WAGHL;\Q8U`6%@=[=XR"LN2$13R
M<`!H=P_X7K2/I2%,H-#**K??^/SY'2V@/C'1_8_+12R+\W"S&3]5;P;MT0A<
M]%J1PN]E<&8O_Z%]&>/Q?A8C$4%PR0%H\['KTSKVT.Q8EMGO=9?<8NZYGU.:
MOGC9/!V!YBM5^)"@@/UC`/XE5B6@-L_?R!TRN&8UP!QOW*07-1O<,U#-6"AM
M((WQ^XHZ<DA;/`YTE(A=P!M?8B%,!B;?(_H0YE&(,77R+L,"(IF!;'%ME^X<
MOO?30TL+*.UEI]OJ&#//]WE`GVSG"8]JP0,Z4#PU`$P`2CC@7FE%@/SW4'IR
M^')H-P<X/WON/I)39O0(@+6,3VA*33R>0Y"*I`A,NHAF\0(-Y=#!SP2(^3:B
M^;1+C\9PVA<3]S'SS6=GE,Z%RTC"`7IK9UV"$N%,L4FTB+B?G-\YNRVC1M\"
MXQ).S3?0`YO%KRO`9:(:CO;D1650Y^`E*"QSV.V8W4%_&<7!*RCOP\!_`*/R
M0YXX2.DY0L1Q+Y-XB:#("D!#M:V!*1W;#AT_6MGDLE>4B"[]/+TY+2LC-PJ+
M3A6=U,"$/L:Z0!>9C][NKLFB.2>0%X$+!U[Q9!JRYDE8O<[@C2%JGTP#<QPB
M3&9*T.^Q*]_F*Q(LY8S;6,:T89O];E%1W)II<UZ`C!NKMC3&;4BFS:$]!L<N
MG$Z!8V.5X)8<&]70XA5JM^Q*EDV`Y)CG7ECVC2XL,Y:7T;$CV=[SN,.:SJLR
M,#`J>^]-4M=?X.8\TP$3,'.$M^P2B':D"P+@%HCL%AW\\%2_:W:`LE:9,0H8
M[I]&'WF!HBR\DW3*2Z'*646PX[D;)?AON/P>7?9T#E_%2,Q/QHN\#952J6N^
M0M\-[SU.B(+_:'KNY9@D@S5T',5[X#-31DXF2)C7C.?>=%ZYKU_9KXF>OZ=`
MM-UV#Y_^SFZQMA"_\AX?G*7^K9M(KD:7Y)F0ZWKFF]V8;Z57'-2WI7=<I%N@
MUK;9'<_=M\+=VM.=PHOTU.],POO#,M^?HWX<W&*1!OTNW#[TNX#MP9LD=PA<
M^Y<WQJ:`7B3AG(`5OX[")`EGTK5G-/^ITW^(-")Y[ICO[HU=7Y(8G.2+C)3P
MJY,2:A,?9G\N*:T0!'3].!N%N?*00<%-N?!&^99*2V&%#D"PKXT/E*=F;VB9
MSG`#G8&<L"^M(5<1"EOX-8GR.-PWNJO_O`IWE8_N!'.!BX`FWO6"%TL/M_RK
MQR.B'[$T"]:F%(INN_$=I=E)2C"FS$U2-*_"-513N],&.M-\*1O2ZG*BK*)#
M^A&E04V$TY$TIO)U#ZT9_2,-F,PO!"V&)0EZK5\ZIM6VR<;WI%+B!6-O+E(<
MW?$XXBJ.J!*2U0QL%%'&#E5H8;H!)5HSZ>P6N5#&%=@<F/JD`OD9@:*WR:`4
M(5ZTP54D7ECV(+J>9R90@6`'IM4!<VK06^F:.#M]S2@],'B35%PE4@U0:T/-
M0S+FQ:R+6"TY+.YU67'6LCB.(+&&(CU5./L3(#6`\B5(FF['['7Z)G>$V68?
M#5UKF6,6/2XOL<%1T<VRZ6%Q^B@[,.-Y*M<'2X_5?*"2)//^3\T?0-#(KEC&
M9=X+.A,-T."Q>R"R<&UWY`(1>0%WVV&S)F,NNS4IA^2]5+G4GS17V+=Q$M)F
M3%7&P&F=YVT@A\2LH2+;<<QAUP&V,UQ%W-@'JAB<6N!C2AQGOL>!V:78O$5Q
M%[C1@2!2%5Y<V+"IN?YC%J%'WXT)*H8-;V)T&:LO"\\GX4D]IG'GL3:%1S%Q
MN%+PD8"#2HFH1G3*.,S=KHU04X""6-+<]2:&#WOT\3O<<ZE<E?PRBEQ800'2
M5YS#]4MX;=OJ:56_^+5J1VP):N@U?7,P1%'176`QHN:AG,WP^@[!9\0B.0:3
MA<)V82Q2L)1*@@J6./$B6,%_Y.Y>GK8-&,<,24!IZ%/.J_#"2S<P?UF&<7J?
M//C^&^3]6+(FW"/J>_(;@S<\&(%U(-@1R8L-*OS@F!.;LQ:X)A<K(I-ZT56/
M"2.T$C^L`(L=`KX150/ARA(WX]X#%I:$O/P.ZRIXHJY+O*1X5TP]%,%92(3.
M]23R1BF/U2&BPVG+N"I$"O3()H&@>3H7N1J7SDH(8S(`E1J690[PR!XQ.A)7
MDK7I\3PS8T$\L4!(N:_8O(U85E]4J#\/V;.>,]1JG*%;9H]II2\R/BR*KI41
MZQI4S10)QA-B!,KXPTO<+QBDW&2QS$]19I4.@>%W^P4CM)1KY,2HLBBTI(N^
M:7?;33+E9CJ>5(J0!V?LANCA@4GS0DB(%:9#J4`?=(:FY?2YPK@T!4(8%W;;
MM'L]<V#S)B`6FA7PAA[7I[(*()`;KUQ1N\@;BDQ8/`9.S\4399D/7S\3AODM
M.TB>K6"5:NN4Z;E,4><=;`V]A:W)D\M<XW.8@FWE!B[O'<.R.J='8RQS&>">
M\G>L(V+IX,NDJP"C)!'`-GN.97;[JY1QMTS1SEN?F7[.B:_L"4NFS;8D3!YO
M*L!=%AA=?6QA(P<@P8CB]!.6N)X/6(M!4^:E#O:SHT%'IT&JW4$#A;>T0:5G
M[HOB8W%ZH/%W^UW3;@\K$GHKLI;1JH/7HL9%OO,+$A07%IQ9WH*P>EUST%6.
MHVP1(6ZRA4A#I(R-9\(ZE(HEIPX:ATVQKQ\&+HFNBMV@LE1ZZ9C4"5)FOU9Z
MUZV.:0\=LS-<RJF(Z;K&@Y@#?.&*YD]8LR4F7P(ABZG`P&^GW"/1&HKV&"H!
M-J\/Q0;6TN(C9,("X[,[U$?*:=FY-*S<)<G@,"0<96I6"YAOYL)['B1R`A<^
MFN[WLI>E,:/1H*$?WJ+YSX6BZD^AG,3Y5@U(;8IV/9Y66#*:E'L)2OX@ZZ'Y
MDZETWP=\*#G^G$V*,(4+071;-N[5A";IB>6U3T1'W$Z/O/BOBRE(^$R#Q!1(
ME1I(/@?QL-C&,Z(VKXPWH]?)NT>D-A4=U7UJ1%VYXN$R$UW=!8UOBQQM>V7.
M:XF[*>^V%I2JAGO(7F$8>E$)<E=P*T)#G*9IO))*(H$!U@I=Q=R70`+%(OQ1
MY,1Y9E[V[#U-3-9]WU*XT2W#!I&C8O(AO#^D3@78MX7]G'O"H15FF!4O&98L
M:4J15N@:D\]FM,R^A8GQ/9-\R_2UB2@C)R`F0HKF,)S&5&F@&$,,ZCB)P3?P
M89[A=#HM>_C+&^(Q!O&82+RQW1H,X`]DP!H3,137>/28/Z$__](R+KEN6J(0
MO+1[0"=@F2+4O-<!][RKMF*BTIT*X&-J1$7]:<@DY8F\LB;=Y?TBO!6U\P2*
MZ,R(%4JB$X6'G15$0QT<OH#HNQ>N::DF9`2'-`C[JM)SX#PZ73@/IR,V-L9V
M%;0QM1^"@^]IJW+_9\*Z/V&1R6-5O0"A22A<)?5<<K1X19%`B]C(];M/)I?^
M]\P/Y\8D2F\Q^I&@OXYXVXAQ%0%(ZPX^"P.J)E#Q$?Y`%&(Z>JPXTWOXE+L&
MQ%]4[B.+[CW>THI(V8C3.1*^9))@W\%OM'"<CN&+,??&A"-*Q_S1N@8#6;1H
MQ46,RPGH+,I13@!\?']I<AYQ+\IFIAI8QI4"-E,PX,:[<!CPTK$[CS$6D46N
MF)O(2-!]ZM^[W+LEO^\F43B_>ZP,MA5*F0#?NJL_C*8,NWG!CB,^/AX^%64U
MI1+&&#C.*ME",1:*SO#CDQ)+UC-(:R/G1J$X:!B5TI3!+R*2HB5#!WC_\;O>
MA"U$L]R*R`8!@C\`%D1D1NPQO\75XI,'2-M6)K#XKE&\23$%ZBK.`\%?J0X&
M*,+WQI@L1+].0^SH'O]6-TZR<W*KO9_DUMU3Y?:4*7<1@T#B!T#?L4J<\ALE
M"JZQACUP3,=Q<J%3T`T"6?@'%T&J/A3JS7@5AMRD@!-2\]/7]Y+X\KP!&)51
MQIID@((A6YMXH7_!>_,)-LNMZSB<)K=@5JUD7!*4:N;U!CB[Z(=7K'G*U6AJ
M]UHKH9*!8[QH!G:@\7FZCZH04C64>2WN9:?=-=N]GH)8O"]3,W.O(65"&:D3
M'KF6@=`R>U,H%IKR1T#<B[Y]1?UOBBRW2@'LM@;E"J#5LNP5"N"?+-.!)!#8
M<!!(2J&`VH$'%V,^KT!+H%BET)5J1TL32-=(G6Q8T`KVL"S<MBDK:HYFKT=C
M'U\Z5#`L;L\6>5[/-JUA3]=*M8J@G3F<L2EWD\(!.5RG@L-UK)4F[J(=*-W=
M+ZUN!UC<(&<'4AM!3Z5T7<1@60BU%.'%M5XZ[8%IV<N?PP:W(IMH*RM2.K[P
M442.X,VX6KD#7P'SLM\WVV#A[IEQ4Q"I8=X-\WZ>1^,<C7EW%,^5-F*6LTGV
M-V":YT92E^I'NJX^:NS<<!7>!6XYYW1WLD/1S+]C_ASN>8H\/0906\8GZF6-
M[:0Q[X6G:E);;&R`>L_3)@`:5*;#\1ALWA&;8D**WEBXNQ1%=:V+.4$H[03K
MUB.$TU1U%URHN>(5$N,J8R,792=(NF9OT#6==MM0&0P5L9I9./&FTJ8'/I`-
MYO"X#H8YV;!2""L'O&)&&+I?]"?E,J9*(%%^/VD8*\\8[YA?J"=PK([9WTNT
M22)*9G&J2A\!1[X*2.%'Q9TP0\YX&XJWE^Y2Q6,KWN5F57_$OHC95I3ZE"\@
M&C87]&ZK;7;!UK:QR&@%"`LOD#KRRQXHI!UST`?5_F/V^H+67J*45\:<EOH<
M.JVNKI#SA,4L[C3<S.U00,B2`XIYFP_Q)9I;$R)5(TVG7GRG^Y0F;)1LJWO?
MR&H]/BBC"%W%Z5`6:'>(Y6+BLN1#3`21;(%#7FI7Y*6HU`$*F4UXTD%5):(T
MYE3-&H5?N-DQ$5J"2*0A,-(@"YWE0:B;?_F`D2K>#FTICS5XZQF"YD\MOD$W
M`9`XG=)(5HHW99TWD!&JR!$_/!QAP4-*ZC7DI<U%?Y?>PLS>7'T3!U:%;=SN
M++V&;_)&HSTT^PYY^[(P"[<Y.65M>96>$8FM%.*&A<*[E,:HP9I&86+J2XZX
M>,1,DAB/@N?3#3)*T:81>!EL+=P2?YFLZ.)2C,?C9-SSE?M:#X86XZ`45A5!
M60K!B<"H'K0L?1R>#8/;D"@<ISBD6,)/K^.I$-HK97LPE+:`[W]S0:`6BG@9
M%JHORMQ1?P2;)9I<4,:R7H"E#8[`YF+RVW"Z?[&,V.7'XSLVP]#M(WXC2'%8
M$M=B.61!$H5^G+V%<.*[:4#CS28X;@$(18+F<DW8DY7)/#\"D\%\G_'<1_@F
MJ!#"Z87?^2L('R[NP@=>GSC%LP9];>QE972H*[TQ7HV6'M:*H#42/8]5"UC?
M*%7OU?BU3.3(XJYJ)2Q(2!%RK&KC450R4GFY(MP?BM+@OWGMH2L[2`:PX@(%
MA00S3CGVQ,"U_`W1V2>J7);9=6S3M@?K,-/2E"*[U>V_V<0)V6GURQEMN]5?
MSFC+G9`JZ?:ETP,%D+R)69K-.E[([M`!I:^_GA=RP9]H5/@2E0I:\26E@!><
MCG(7!)IM#<QVITMIMUD5RWX=DGR,(FIJ,H>8NR@HDTLK<\W8B':318:GGB$"
MYH&<,L9U**S(%*<$M*&IT6I@&)7JQK'(:X&U$_>O8HO$C+!R&A]//XB83&N2
M1Z.3-C)X[?%G(TKSO2%DBDB^VZ`L5\GSB36-2;5`P8C,/L\LW[P%^:WX@C_U
M7AYRHDM/]:`OV(PR.43+9A2U7\L><'(/E,5N)$R9=9PS2H9F!XS#X<`^H$'8
MDR$:'C\J<,CN"@ZYPN!:Q+<H6NIUAN9@V"[LBZ<2ZB&JLG>/77\LB[EYUODR
M?*BSSU8U@0>#T6Y;?/W,RB)=BF=Z%U5H-?/;7;3^D'<_RGPN8HB9Q"?#+6OL
MK`L1;5W=]C,TNT_H5YKM)_"'[7%Z@[8.L90=SY7?5.KNW1*]/;E#0M_".#R*
M:=@?5&DLJQ)#+D6EH+AEW5XN7Y8KJ;JE:#PA*[%&_O*F\'_Y',OLNG9UK[C6
M7J/@:W6<@3*W96UK=F'IOI99.]39`DT<\LVY_-I?S&!S=UGF6<F]YEE=:]]M
M)6M!HHA;G;_37:LU<"KN]+`J%4*:,%+.*@A%<H@'^O'$(VVU*G7>,B7(A,$,
MJ9A2WUW(I2_5\I5E^]*QG85'"H9+DWJ_7C.#XC7H"34RIY:6%JJ\M#!;N],5
MUR$$`3;F?F<^$9RPGA=@:O#O1A),:<8K;7(,I+Q9XQ9TNJUA>4(0-K??YA8(
M9QK(3'&I^1S%W$Q/K6F$N!3&*\`.*&$]1]5;([[H#;%A772X,8W?Z-KB&RJ[
MBJ_3Z;SF5?72XHZK['(S4QW5H>,%N@U(]0/[V[0''5/^P.WPOFEU!^;R*_D$
M)/9))(X%V+:!"-:X:G87C*_V@N#1G+QK"9V'T-B[R%GK(NIJ9N$JBC!#_BK*
MNP9_7%6"IM-^!>F+>=42B]-\>+.TANOYV##B0YQ4CR]L5Y"MZ&<D$[SU2BT@
MJPO"?FEY#2=H-8:>APWP*YA"A!3->.DVS9^/D$,R81KIN094U,2[G[$'`B+[
M$,G6]_'?DO+U0`)V1T.3UQ292B8Q,-[*SC3BL8>`@>@20W^RL,`4Z43XVQ<B
M"9)`YZH$C$J&,LYH"M<A8025<S5/:"`D+'>C"Q6*]W4+9-$4>F[DI:R6E1R(
M/5W13%:6%`@LE99*+UOFFRG4V>94QG)WE,H4X>/,^GW3&78,X3B5V^555UER
M2<&)(@]?S&[7(DY22RRK!-6(EWK->3$.4)=>W8HW9B$:#@H>DZ;O%)SG6TOI
M/AC3`Y#(+X==LSO@7\0$$$S>R#G+99N!E3B(58\><D=XL28=GCSWRSPX_F.>
MT_%>G056%P;L0N525[,[RL1P9_K]Q[Z%\*;1H_$NXPE\9K@;QU[6$TQR*>VD
M3-'#4NO.**)RD@U)[JPZE:(G&XB1QP4I=3/K=%G*J=Z5<"J[C%,5N)1"5TZ+
M>46]HN2=1_W$IG[4JNMQL13K'75/PW[$QG>$2M3W%UZ^6`*?XWN"&7"7Z4O+
M-KN=P0H>V+'6B>%1;L>PU:DJ(NCV%I04@F'_7)#OJ8H)YKW(W-%W(B9H%!@@
M`;,O)HB.\YXYQ&P3BF.:/?AVCOD92QB?[E%?QOP,S;.K\06AO5<F0,KOB<A0
M>>]>+?9$'*,KHS>Z$56\6F0NJE_*^K[W<"B=-5A:0.W^Q9,ZD*&-R97/"06S
M/EETRZ+RN[>QGWG3&R?\;1$UR,>2SNSZ44X`7$#+^07/"7_J+E[%7",G"]2;
M"ZO56R=N5/!G<<&9\VGYR1VUOR[D&M*==-KF<`@DF\6**'X+>Z86/1S%]"=9
MM(K=,09P3L,%^R,785%Z%>>_6@Y>YM[5:O'5G^&GE+-Q]=YB:&8#[QA!\>SL
M]EJEWA\ONU%C<P7-9X3D+5,5_)`83T[G^0C&4F+\"*C=)>\5^5(DJX%<">A*
M\R;:]%<N5$`^Q#2O]C9U*4HOVJ$+1Y./K!F[81#K$3VVA"RY6O-1V8$3>[I9
M`A[F4@?IB.7ZDG^)6K`+$#%>:-(O7W`LY2TBE5J4,X3XHSOSX#)^YF\E2#Y?
M&:^N58Q?>/`B)OM;OI;M,[1V$BKY?;U-+`B?A;E):*8-A\"(!EM+C:5CE$JD
MAJ%+#)5*D["`.P.*00*ALTBE:6'Z8P]`4(5+F*LP=GW@UO"F?P%N<"PH\FY$
M#L]A+Q$O7.^C#GY:LL,WS?$J50NN\^K-+&7?(-&N"",)(+F1\]*:DOR-(NF3
MPL75&%*UIIB/)T29HK>1&_Q5N`2DANNYZ/(M^:^9FY")O"8SV&XV'E,C:WI(
MIVP^OGJ,@H+O7DJ37&N$+)=%':HVWUT.70[+5B(HY&IB`.P"NJ3\2C/-6+76
M*FH9Y6@R7EG]H;K:KW,)<P1"IED6":_;`YVZ;Q75'`(CKQY4-.QZ"<)_V!L:
MKUX.>J;E#,406W="3!;UD3!2&A9O\;IB,Z_-376M=;PX?2JKX)46"S:,T^IL
MXFA=7W-_:9O##D85P/YK<X6=7U-G8%K=82'!KZ@/T6T31/^H^H2I]%=07I@^
M/J-1:VC=BC2!ZW0VPTH0P=^E+>K*K`'N`)4A;;3;E+"2:6'6Q3';*!91M=_V
M0B.DLNB"V.<\9K\9\J<WQE9C-0MUQ94ER+Q<N:H*60!^X;.I6+7@H+_@G\GO
MR>)GJ[P`7%3/5J^S\?.`)4!F\+<7=A&3\E74S0%?:-"]R]^",>F5M-375+%G
M(,EK+OEIO'GF3#K,'NJ#@S]%&V%Z^Z5H)?Q!*C97J-B<#PX6]_C&6(Z7'`X,
MN?_O*@/Q7=;<F:O:Z*`"`?!/E$'G@Y@MB>,RI^)_`E1X8$2,C3^H<'./T&O%
M]>OR+SA9V,1M!$K;!'EH&/UF1+>C5W:[8]H@V^UN]_5N/(Z>?BO4<G>Q`*)=
MCH%-SEC'.P*S$8'H#U-_0^WI8:=O'V+M6FSN0$LW>SNGO>V)9?QYYR5L14<6
M!Z,K>9YAVTMXQB<R2)?O5+[ZEXWP(_7"7_(L>^-3DN\IOB@[,0='/9D]NW]4
M@/:,CI>[8J'=<GKGC(#]T4._-3QG1.Q,"3A5U,%Y[X?`PDG5GZ6L[(/J-U]?
ML=+H.LW>GO;>CJ'K;,04L#ZY80E/@;2:O9WGWDZD,FCNG(U,HG?H1/']55;1
MKCZS3?Q<&Y_M)B_?@B&5HG@G@'?%Y@EO0H.,!AF'0<;Q=:EM_<L5IN:)SVE-
MQ]!IQ/0*,W];)\\YZAPK'39G=$)K.E_JKS[MZ#P^,4E9?=-Q;.HB\E0HRVK9
M3_#N=UI.'3>UW=VWS,'0,JWN_HCN^"K`&?M87PU,BTJGMKDGK^M$25AP6L=K
M43O?PE/>6WT%?^-5?3I4UNSM//=V3,V@<:5NZDI]U04]L&-OO.\*8"N4DX/Z
MR+947.S.OC;=>`@;9)Q-:LJVGM,*%G'B([-P.*5C=H9/QS%GM7JU]#343K$X
M^4'US6'?,H?#%8*DIKK2>?M-X=Z+=AM/A9SL5G^%&G:.][[3JJ5_:*L3ZH*H
MW:^K_J2:P!D[4!O?2;.WY["WFND#C3OUZ9!6L[?SW-N)5(;&L]HDJ9Z#;ZU!
M1H.,T^M2$D:[U5WDE^MX8.G=)5[8%9[!TO5WYW7T&F,2IB.?'8*75K]?\[:!
MK%K'TUMQ!'N]-9NC=9_NX?[3P<!NG,-9E8Y[1IC8BA8Z`W/HV&:_OR)Q?'<\
M'%GK+$*VV!IK<\[Z1]8'&)NB?<B/TVP8K6(PCMGO=<Q^52^>YW*YK-9@16[\
M&6&@8;2[,=J>.>BTS6[WX'@H8;2_4@?$[*/L'_Y^6S'B6D?KEED^4C`;@*YF
M)&@-?0DDZM>:;Q,<Y]O$\V[!V!O::=FY&<F5BVI3<45'4C>;LDLK/NBC,&@,
M*G8SS0WUQBG=0^I8^Z0ZCU:OBXUT'V2C/U<T^M,:Z6;CK$4?9W6HJN7U1(XT
M3F=S;$P:&VE,K4KI<Y):%]?CN]`'4+^$$^;+1OF;=JW%&=H$0\P2['X*1RH6
MX0U&1\P/'VIW;NLU/Z57_^V%Z#)8T`"6]$(='J,5J@'_*>>2:RAME4QR%Y>&
M!M'^&EX6=<8=8*SI]NRGO3UK?]L[K*FT>*'$=>XL]M1;>KG^K&;=E;A8MY58
M)9#KM1,K?=*I["1FMP;5EV_K_F'UWW6[^_QVW6Y9O?WO^@"NX46T5+LUUKBM
MW[WXKPOJ[Z\&_]!4U2(J-CVK;:FCPIL/WT&-8E-]21SM`.<["4F#CV;'LP("
M!?DO3PLA??L"A^DV")$(&5H7.-=BCP@YMK3>Q&>IIGT\I4/L=%KV\*+3;0V&
M#5TKE/0Z%_!/X7-L4/*&1@->="VIVM7GLA]6SM_@U)]77L"]&Z^?TI%V+WH[
M'.42F$^+DVHE_+SVL>/9BH#1G@_WV-)YI[O[/C=DJV;'VV[E*Q?.3YXT.U@S
M.N0_Q4A#5&X`:\$#G&<]<F,1Y4_G\$DXBEETST>>9L_$.%3NWRP*C7%(7_O1
MNFX9-Q%SXS1Z!$X23'`R=A@S`"Y)(YRD-@=@0QS6F1L%+(=^XJR^VD4/#K/N
M!_AQ1H$Q;1@AHL68$?[D0$.>:L$G0(X>Q7!8'%(7T_11/N`3GL,Y?V,QS77J
MIS@8"A!+XUQIZ*@6\)$3$2EF].!&DY;Q#5[(RB$2N1[*O2D>O/,`@`@E1V&:
M(OY1@XUBA7-&0TH3,?^<2"+W'3YQ-AWYWACG.=^[GH\7D@`C`&"=<>KSJ7OP
MP@I8.=TB66K@Y8'!@>ZN)$/VKQ2^(&9I+J`E;AE_<OQ3-&WIKO,[G*1,OI7<
MY/"%.)U.O;&'DU&UETS<Q)53!_4#Y:=%:ZO9@L_D8I2N=M)U#[HD#8O\)J*V
M0#-7:32^`RK.#QG6>,$[/K^3P$TK`7]R9/$I,.QV>TB9#>XDG"?B1N*'QN<0
M6!N9?)\"C%=Y]QFN6!!SMG'EX\)"TM!C_!-`NIAUG<U`Q0FJ_#UT*&PV]\-'
MAA!/O`CX;!C!C^[DW@.Y&/,AV#A,-?43GFU!-YHS+GY<R/0P>&Y0*#I!D8E#
MZT9I@K\1MR&XQB`])9.C6>`A'^I,G\.6*1'@+O1Q%"1/#P"AP,$7['TF&$G(
M:4JEZO')L/QO:D)RMDV%F4O!^F[4SQD_-E*:09E#()_?'=/DWMS*IEP,!#W#
M)!#XD*`A12ZF^;:``A):],W%3V`]#[\)[)J&KF)7#?%5_2/QK>(NPXAOTA6[
M`+[,XC$@7:@V(G-![83VC$<$_[>[F(%"<Y/%X&TW3>Z`:_];S'!7<X9Q049X
M:>%4RFPV,Q\`;AI!*"'`C)P18X%(W."B91&CE1DV?"TN+"W'[&'6:L=>-IQ<
M9(B4+?(\V,:WP/C(1E&*TWUM->)\@8=8-D<80:-X2)%EP+?X)RX<:G"!RH,W
M]7`F-]Z#Y,[-3ST'^KI,;P$8.CQ^H]1+Z)M`CP`Q5]I(PP8BE?J6NII$;A%+
MQ.#/;%7.=8##):A5_,4>=3X5HKI!S$GG6/@$&/SPJAR_HN'6R,W@6S++"&E)
M,"_]8ECMXL4HH[MU+DME&AE]B6<ZX:JVV>OF%BPA:H'49T+42$C(_+FDF#'`
M]23TP]M'GO8%Q#1AJ,UZ`4<CXB@_F3W'J%%QKL@3XT1;ED`6@>[LX6G@DVE,
M;X5K08.+Z><L&4TPV[&?DHQ::B[0Z5<9J:9*=5/6CH]C;W.O$9OBD!>AV%=:
M'%V%)@>NR8%K<N":'+@GE`/7Y-:LRISH=2^L5K^)+V<(L2[LEKW/Z/*9(V2(
M".GN,]GH*.'V9Y]0XS@MIXL)-?U=XNM/BI@[[5:_?]'IM=H-PY-4TF\-[0M`
MS%EGSS6Y-96Y-2V[N\/!/M6TE`8M96AI'0XQ1Y'Y>LG+(5-V"NL=H!9B_4*,
MI4412_)*5D&P*.6:73^773?I1+5,)\IYB5N&2KDA2):GW1B'3KDA&):DW1@[
MIMP@O*O2;K(82T7JC7'XM!L>H"A-O3%6I]TL[G+#U)M`!>HU>$7L0&`_'VO0
M=TL!>XSCNWCV?NZ4>1@"MB!)(/9F<Q&XXQ&;>H4(]IOS<MB,&GK[)9SK;(9Q
M78PVC1/00(`F"I%NT;>`1P=YG#-BON(!7D`Y!'12R#14KA7\YOOA0_Q;K<[(
M7S>,LW;<QFK7.7"SV+#JA/&`3?J7BO@9OODK1435^X%6KWD4^P=1JLC\VM,N
MZH@`61^O5K@4?%4VQ\>LF7%UK?P3QL!W-A-)'>\T*?*9Q$Q@_!.]*T\8+9>W
MMQ&[Q0"17.(3IL0%L3<V_EC:/N'@8;3#QYQ/[/78[,$S<.,T&WIN&ZIQP?F2
M`7"+/H<Z',M"?_6&T)H-G<^&CNDK=Q;;0RT=W?!W;-7'!S?$*1ETKRP>,A._
MUMN!6GR'UMFU;?8&MFE;@Y4O.=/N2=5[/TSWI+,Y^G[K3'>_RYE;'=,:#,S.
MH+/_O9]6E]E\A%T-A,BKH6VVN_VUGE*K'2A7H9JL*MG'<#/`GX\L?W(;.D'R
MWJ;CYVJ#]L8.:39TQALZE1C?ZUBY52MLK)3M<:K<UN_=C-'L84C6?E%X=+IO
M,-!@H)ZCX@[EF%TLVCKM`5EMLSMLFU:ONIKL)-)V"UNGVEEP7OK",K?'69R%
MU3';O;[9Z^S+^JRQWT+SN]:(A+JF95NPS0W;U]6-D.S6H&8[V/I$AJT-?4AU
M.PO+[#M]L^OLZT#JYZ^HJ0/2,H>@._0'U?&/FOL@J[L,G-<5;AP39RRG&W?D
MF=)4LZ&Z;^BHDKSQ0:[O@WS5Z9F64]WP?GW/RZ(R\=Q=3@T&&@R<9VKH8E>L
MTYX5CC!W'+.SJ8%3.P/Y*7D@S]Q98??,`5PJR]K7/NKFK:BGV]$VNP/'[/7/
MG'J<EE.S:,@.;L<SYZH=<VBWS>%@7P=2:Q=%33V0_:[9L3?TXM6N75-CQC^W
M#=5-9M?3!?EJXRAA<[6;#3V!J]UD0![8^]AK#\S^$N;2N!\;YUN#@3/)>I1P
MVJWN(N];QQ6IWE_BDEQ_#@$MOQ_&2*\R)F$Z\MF>>6/UJS5W85<.5MIL\_N[
M)]OA<D^^TDYU>>/Y;'L'!^MS//7NP!ST!Z;E''CS]>ERO3W7_(/%>BLG["@G
M_$/4F:UAHIR/6*8]L,V>7>UQ?KK7:5ER[/GL>FL>VFNMG]E0W^UO[`\?F(Z-
M*:$'/OM:MQJ6BT^\^VH>S)>Y2,+Y;X8SSSZ0:''D$>9?A/NXB+U_,Z&3"]Y$
MKUFP?$4G!KO[BWK5K_"NA9^/@;(R1!UTM?(^,S=W7FSP*7RPQBOOM?&'E[A?
MV$3UH$3(;GG\TABQY`$GE7X;)R'*,KO='I"P6VAH18U3L5FQ;.>'/2[[H$,/
MS;YM&S_X;%;XC/=1MGHTRI&Z#H_)^X+S,\7<5`)A'`:@#L38D_55J#IDTC)#
MT^GVS6[/DJ,@YZ+9Z[OLF>_8SO6U"3M<W*)1W-X_W(!&@XH:,-PAP2"W[8C/
MR_;8@^N.6Z$=+H#:[]F@HW17`DI(!5@!V`*0!$CQ'#H9H(LE;*5@=@&0CBVG
MQ/+6QMBH.)93BR<>7U8T+BZC"CJMB$U]W@A9C#N,V!SN'9MA8V4)>S;F$;^1
MC8,4:+@G[:E>G8\/MNYEB2YH4LOJ,$WB!-"/>-+G-..`8";;HHK6V4`,M_B]
M:13.C)?M%MRX)#1>=EJ]/E$58?:98)1:YU[P_MMC?;8W]N@.8M[Y74=HQ,;A
M;4!S:#UJ]8TCIE,_B56/^+(QG]GVLF/C@X-%/VG+>/72,8$GFKUNUS1>6N;`
ML<UVS^+?>&D-'.!471IHC<W#O7OF/[XFB/3^X6(L-+\4].0#TWJL!R%".65>
MDM+-O;Q^9_2M`=@BV?15[0M(%B/]>;!%J/<\8!FO(+$5@H&WP<;AY826.!W%
M\#Z\QKQ!.UQC:JF-W6CU!2;>=`H41Y1(_?7%4O$S(;_R"YV$">`I#31:8[E)
M`Z64*MJ0XZ&E@:"`L""EYMDX<3C+"3)TFB^-HPY^T@+^HP&$..22R!0B-C^:
M0(@10P-/=.-_$'V)+V2G>]&>'VC%:CG\9K2,K["\^Q,H*V!3CP^XCA@@!U\D
MFNV[U`7?"W`J\]Q-0+KP^?7P/MAT<$L@^&$<$Q679#ZJ>[4<F^5W?FU,$ABK
ML-DQG2&7ZW23[4Z'HU:_R<^$W*M5_//3F$^@BG\*,D+GG.*!R=GE+M)3`@(>
MB3-6D^=34"75O/GOUS],,<\`!5<V.1YO7"`'O"M!-D^C\9W+!W%W5PUHYVH@
MK`"6DN^3!`*!1#!<PEWQA4+<H4MPA[>D,$#\I>TX9K?=7C+&_8'SG`@EZ\NN
M`TKH`+\9A,'%V(WO<I?Y"#>JRK1>,0BCUL17>/%__IK&%[>N._^-#ODN](%X
MX@^@*B2/7\.$O??B,;!AD.4W@)BW/GSG]__]O]`A\I_RP4^S.9PSJO3?(OCZ
M/(Q=_]OT<QC<?@;6-[D$'I[$5V!DCQ_5.XC[PR_?V?1O+SZ"<H#G?]&VX'])
M2#];]H5CO?C]L"PCI4NGX$=:0[@O"'"#0TZX2D]@EI^(A?_)2-&#-]"L&C>*
M'M&6H&M,]Q:')K$H>526+RJ6<\(?7GT?$>A[8E836B+DY"9<$N?Q,GP_W(&*
M@)H%_".`/\-?@2$%MPRM0F/L1>-TAE;/F#Z8>&.4P"2+`38O4M`1&`+"F?L(
M#",QA/Z">@K-)KI.0<_1UBF\G)P<M&4^QP7>>MZ37+8:UY)WM;47'&T9^Z@.
MQ,"C680E[\X4,+5;=M<+,DY4YODL_VK%W,7KQ]DH]'4L#H2K<Z,1B_IIQ/")
M!^)2&D#&NO^9L+'O!9R"T;&"A"^`ZO3>('U&?[&$F^K;1[N>/9(3-#PBKM97
M8'I^]QC3W"[EL6KPO26^-:Y,3CH<IL>0C<)"0G"6G4`:TY>$5=?@?VO\NQ-T
M`;/B.8QP5AR+8P-8SDS)QG&8^A,2L^.D]%A(4IJ9XW4[6'"`&CF!(UHACF<D
M6T>/('=O<0)@&,5OC&=^XNX8M`PQ#G$S-,.5&H<Q(%0C&O\13Y[]'..9HXT6
M>2"=@<-QYXW+#T3S;M!TQ#'H9[&W!001<DZP.=.QG.8HJ>FY7^1Q&D5`[1?<
M_;4A6J6/BQ",9NT4]$V#.[O0Q!W!G9Z`E9W<@0W-QT\^\J&4H,&*K^&E0VV:
MP0L2NO:;"M`9'2T-416N.`1)O!X..1Q[1$4<CG+F_H9L@.=-"OK5V^P,B%E[
M"3I?9W"2AN_]A?Y$^#@@"X;^+C'/O2Y@U,1@HI-0A;L=/6#49T)&-R,O;(Y9
M;`;.B"$]<2]]0"_#(.4<C<$PC0&PS*D*1S]-?3XCM^+XJ_(,:F%(/0/GYX$=
ME5/=C!>F.<A[P\7)P!&+X6-RYY&B/@.&QH/"=PRI%HE:>QQYCA'?D=:2CSJ`
M+I$@U8G8L#N?^["0\B=(U2,Q,.%OKC.GO-^"_`[*&T"C@/DT9<IP2&B<M`R/
M:?X+X;3@03):(@N1`<O&QWQVSRCB)0,IF/P'%Y!;ZI*Y<[SX@%=&(GS"YHS2
M!`D($477OHVBG2.*0T!^%8]#[N%)X?<E:M6H90Z!VLC_I)-;Q"_-199WEYY,
MX;SB,0ZKAOU,4]3E>=0I@T`?5(V;9P$*+?RZC.2A;H]PD4L%PWX3X?M34YDS
MV-%OZT9"/<U`"45.@`R3""#R'B<,PD8TH3?,J`FCC20.B]]VHX+;ATXXTT\S
M]/!IWR)P#B!+=/&0:R">D:3'L<0-FBGM:1Z%_\-1Q$F,(PH`)=+)`IXKT,,?
MNV,^C^;B_&I.FI]X\%E3K>E"N7X<DEKF(4XT>X!?A!0'7?^;2,(L9%8D;#8'
MBQET"6_BD_H!&J:+CB/NR\O-/^>!+V]&:01`W9BVP5_DQ=E3F&N+7KX0L3'A
M:F++^#0M<1T6M@UO01&G'141=9"%``Q7Q0!5P()'DQEV0Y%9+MD[L^NO!QYX
MX%I26`$HNAH94=%!YV(6<MJX@)J/Y@;N)=?J`Z4`<3,>$G3'=_(/@S<B9D]C
MZ355#:D'!'ENUOS";30".$J=>RAUC+-15,EH0'@Z0AH4"&@9U^%,(9I4"DT=
MR$+OA!-X))WE,G"8=$UAQAQ]!UC>0W)GJL\Q-F1FA$^PQ,PG8N*I)_C=()UB
M(@`-LD<+AB<XR#T:R$8([X@?#2A"E#9L';$3>7C6/`$&T#S#VPI_(@,'(;_S
MYK%)8`@0L]PDOJJ:34^.B@A-)7V`MSL*TT3B/`'"$E/D1\SWX.+R=;FJGT,8
M\;T,G8)]1LR-PX"+)UP;20+00OO]$<`1>&-O3DQ4N*&)-68WN&0/=R!EX'Z8
MPJ9W@?SAN(GSJ?5-D:`B#7GIHV%(3F%1V,)Z((5P.;%MD;]1@P!U%HO:)J14
M#$M=C^_8)/79M^DW%*7O^#'R1V_PD.H4C"(0=5)#;D-<GK.,)Q27$!$%7C?A
M]+2\W"5#YX>GF3E?@I*-*C\.7?&H)FOW7I2!S"=G*_Q6%/W2<GHP?D^P;N0+
M>$)G8>]Z%AL5`)UPB/OVVUN_:&SO)+9K@9A@2+WV+Z4<<R.2O(H8R+F)\9WO
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M[KBM;:J=`%MWM+'-3K]O]JTSZVU2(PSVN]@>I5J<GTU[E"($2Z-?ZT>NBC&O
M*U&:@S5_R64P^2`K<^H4Z_KH_<QR:YH85Q/C:F)<9W<638RKB7&M1Y)*!%6B
MHZ:!G?;`['2?840+I[WW#K#OT[L?UJ#6CVD44.<:RLV:>C^IBTW-W$*=GMFS
MJXV*\_)Q[74SM7*E;NOM^LS<F&$C!DS;B\)[ZI;6>+L:;]=)#L,""WR#YK1U
M[7U_0,WZM/S3ZG;-]F!?,8*3[\;NF7:_3A&/DXN#2UE!C(4";!XQ+`3`6M[G
MPX->#1VSWZO_\.N:8:W7-GOM0\SL.3K'WF]4XN.G__?A_;.+1O0LT[$.[$I_
MRNCKFKTE@NEL(A%K^<"7AB=6!QFJ2G'"Z4</S&M&13R?5',P'MGX2.5(E[,0
M.`@O8/S`NW6>J%BGU!19Y&,/BH]]R+KH:IO(]1GF=5D_>8WI%.L1>2]A*E$5
MP8_XMT6[Y2`]``]<);\,554K'C[(,CA-D(4F$?#FN?AUOTH9^">0@_&!=_E>
M*URQ\.*=O-TKP.0.\`*QZS=V+V">0''7B:/T7+"Q:>7FZNG'[8!96*W\G8\;
M5S^#11/@Q.:J.1Q6CRLZ'V-5Q_%B>4&#X[T0[^(F&L3NFW@7[9NGB^/:Y"GM
M0ZVOKM[_0#T/X-6?J-/&C?OS.^@=WQG8`6//Y[ZPVM7S7U(3DPS`K%V)^Y,W
M>9NG?-X&;[2"J4\,5%?7!W#<)*66;]@I0S5FP40I]/;P_A$2)S1G@;Y78D*<
M7?84O?IO+X2:63#9ZY<YU23F//?$G#INK[IDZUSRCCIE9MAF:1P+O%3RR1,8
M<>MG`BVQYIQN:WMC[I=FU\]VUR>.U:QQ6:\3:@8H+JA)O<_"J=*'M$E2-5/N
MNZT-"PT7*?+4&]@P\:IN&[AH7^RV@5/;K9ME`DQ0Z18=5ZE'H>ABASH_S3&I
MV?&\<NQ6M=NT/-1<-Q)[90U:&S9SJ-\>-N94"UNH2<A_X\IA%H$!*$<3\9ZZ
M61/1YY14^6JPY"IND`I2K54]09S9=FLC8[A!&B)MN(1A[H"T^LCJI0E(*SH9
MA/<>GU/^ENNTKRDQ@/LVC1OT#JZ-N^/FU&Q+,.LDURS3XS;)K%G_GC6X:W!W
M.-R=1R+7+C&6ZG@-#_A\\0)OELZ^`_]S_2OWD6I8/H;1-SG\AJI<3M6(F9M3
M55-H16/L&=^"$=$>@,OS3="(@0.'6M8XQF/&5WJGKTQ?SP=>)HM57E6\46)5
MC6(!1P/E!$J6H+!^K^#/E.>=/T]YG.ND8YUK9>Z@VB]L]<RV,]S_QH]NW*\\
MW:=2W>KT+=/N5'OSSR?+9N61/94FN\[`-IU^G1*C]GNU]K6SDY_3T#$'G7VU
M>JSUU5J_:J<I7L[32-LV^TMHY!RKES<.&]V$:+Y(:\9'NTL9,PUA;5D5;_9[
M/;CD^W!TUI(G;4QE7\-@C#%(/FTK3D<7G-+X?+2&SK9TIL.Q#;O5JM79UO"N
M0U$LV95K-46L"VS+[IOVDH$89U/'^D(NMFYY9J4[;;'2LLQ%NH-;L]I7^G]3
M-P+5SW_\R$=:N/ZG;#KA*7VCU^D,/J`9O/^2,,JY&SC+U$UHI"5\%..L1JIB
MS=!*.<3J-QP1KO_)SG[S^,3L\_2FKNT^M=I-?KKT:EJ=?22H&^+B["N!8PMY
MN(93T^F)8[^@SW\S/&`:WGCWK)97GW#$9YC&<+6`;-C/,0,4`0OB(UJKFYPH
MOV8I#+LX.P^E-LDE-EU#*U6FA/@XI7L>\QQ2\=O*5<OQ5+6;!NL:UFT-ZR``
M&JP?!>N.AO6HP?J1L-Y)[@Z*WF,[`C801=]QE'5ZJ,SC:A.HRK[I.C7S;V^Z
M!=MLUVWJUN9;L(<U"^!MOH5!KTY="`_K:?E[%,:Q,8_"@]78;'Z1K>Z97V3+
M[-4MUK;%%CHU"^MN?I&=O8U_/2]_/$L,'ZYU/8[A5<]T^AN>PZ(9>RK0V^WJ
MI)M:@]Y?VK.PUJ`/3*>WH1YTDA#'4^@AO>&#]<\-:3;T[#9T5L+Y,^G;+,)&
M0+,PX&Y;$R"*O3%5*DX\'_L#U807MUOM,Y7=`/F&EFB-(#]?G.\(>6W*9_PF
M/GB.\4&[B0\V\<$F/EAKK#?QP28^^%RPWL0':^*&[-L;MO*IFSM[8&WHB:S;
M!BRS[9QY2`$K^O85H6UB@YOCWQF<.0%U.F<>%^S;9\Z%ANVG4#=X[C%!RS'M
MX8:UT75Q<EF6.>B>*>Q`:=TSC0IVL8!E-]";J.":R&YB3LV&SGU#9R6>SRXJ
MN&G/C[I($8!\T[;$M8&\?;Z0GUU4L(J_5!:);E#/65T4>CD>`_M)XBOW$9^X
M#";P292RR6?/'7F^EW@GZYM7'33]1JV5QVF$W?(,/X.4!A=Y,;7TIS%'5.@)
M'/%,9Q0)V+8:/GJB.44E*-E(+ATM^-O;-?9[F,Y^^PS]GLU9-(.DCCE(ZD1M
M%WO%24O;D*203MB=(P*.1YHJ:K!>3(VNQV&\I&-'/6?G#CN6Z2PAWS-O,;ED
M]-"P;]K64Q@;O`LEBT87P6T%\9[62!YTVV:[O:^>DJ?>#7Y';^&RF7I$JPX[
M?9LOFVOE<M[>@UWH]]X=EX]C/^U1V]V>.;2?"N%:5L<<#/<5"#L/_B@'35'O
MGX>[T&>Q"S;3!.R[R!OAI$5CRFHWALII]TRGO:]RWE/OQFKWS?Y@0R_0DV-Q
M/KMUN:KI<G<)2FO&)TO7[,!LNV-V-XT5UI;\AOM4/LZ#ZTF2<T=&Q&+F1N/%
M=+[3'DK7Z9G=_KYXPJEWTZB$^R?>L>\%")T!@AK^64>[QK*'IKVWQ)Q3[^:I
M$_&1E4V0\?,PB$GB1RQ)HZ!^Y-N#&_U4M,RN`V)^7\G2M6*:VQ95[72A>7C,
M%<Q8Z*E$P:+\XI7%PYUZ-<;*6__T^EW;#JB7@V;>P9;HZ[?-?K?:)5&3GO1[
MF`-<.GG3MM<*G-U\N[G\;'R[^:\/WXUW/[Y___#UQOC\Z?+MI\^?;CY]N%X;
M>V??#=PQ>VW+M`;K$TS33[W@BG<`A]WUYRK7MILZ_V_+[GK!DA0*?_\)&^LM
MO#)W8^+=5S./DEP-\5$2SN$3[0-Y4(XF]+5W\V)M[]],\$Y!./2:!18M8F5V
MMS3$!V]5.)4_9UO:&VKY=I>=:*:`&+H&\BDP_I$&S+#;[8%I/#!CPL:^&X'V
M@BKXW/7@!R.>,TQR(G!A$QXPW0DF^KQLMSKMK.`</PK3R'C'\QJO$\Q92D+#
M]7W^A;O0!SS2/,Z(C0&I.&`3?B$(K+8IH(!/'NZ\\9WQ$N.SW2%\>>9Z`<"4
M!@`<H&%"H(P>C3%((_A3_O5NLCCND[:#P?S6@<E[HT2RS7/`9#[9A'F_?0@2
M+WGDV"9D7R,6XF]I$B<NGX&I9XQ=QM^F.%'QHNW`_UX`,CW^!_[8"SQZ;^;Z
M\=]>?/KZ\<7O5J?;MOKM7OL_?UUOM6*NV[?HU@V\?U.,ZAU8=7A?Z!?8YQ6Z
MV(*$?OTV57ETU_`)HVD+[[UX[(=Q&NTG_VT$M+&W'+."B>"S)`'V(-+'0!MI
MMZRNQEE2_.'KMYL/1&N6(:BC"TN`=F*\^_;EZO+K/XE2TG*K8#6YGFQ_>4K?
M$.H]`7P#5I<[9RDHIO&7]R:.66^9P+>^LGMWX@+91/,P(E(S"9(P,O*/&/`)
M9BT"=<_=X-$T[H`Q)0\A!;_\1R-\0.X3IZ/8FWANY"%X]U[B?F$37._SYW>X
MW'OFNP_(!WUO!JKO1.5'/F*B#+X8UJ$K(1@8,,DO[J.!PX@%YXN,/_AK36)8
M;\.Q^_>(L6#YKFCZ$O\-5H7?_^$&J1L]"IYJV?1F];*6\2/P6<R'<N"VQ;TR
M0C1?'[R8`<?]5^I%N,TB;LOAHR1(/EL:T(4XB,,92^AD(S9E$4H4%`6QI/Y.
M_PW*"H$84WXZ$+2BOO3`M+_E'];_`/O+_I;&+>U]1R7%U3K,@=95?,:EJ=8@
M0]^F,0A-40:8'O]6G@H5?S(^N]MX`!(,)"'TWL3&'7/]Y&Z,?YU'X20=)P2*
MO)S3<)S&_`*-(T9S?E26&XM0/'G_QL_$L\`A`!B6D*=G[`.VB?@I9HXKMXQW
M/$_:?R3-"I?-EA`K!_@F?"G=PYSW/C8"T&+B&"\ROC1BMZGO)B'\ZLX!AGO7
M7P"/LP,X?'=RCT[5B7$71B"P&;X?[O$C+3L'R3USQW2I<>2YV$\++[M*[IY$
M*>@/*-E!:,.1$-R@:M&M+0"*6YNP&(Y"7'-@!O<>/$;;BA]G<U"W4=6CY;ES
M%Y;D?^:G`N96_!<RBSCU"2%3$/`&H#&<N[#T103,-='V,V%3;^PQT!J0.H`!
M^BEI/'=A8DQ]-[[#C\,X82'PQ3#V8N)8M/Z]"R2$XXVB1[P?+4-0S(3!`89S
M<1K`!0NX*Z+$%&HJLD]40EF<1.[$"_FQ`%9OX1,6X1M<'_\91K2^A^QR-@(8
M2"2!!0';1TR`:HMGAV?KT6:0"\,QXW&P*>S7'3^B=NN'#Z#:3L(884#@&*C"
M+`!%D9,L_'S'3Q_D%<-'F2!U*O#']'<D>>3)M#;^QA*=M%O&-SCF(@D@DNAF
M8/(<'H]KS.%4L/0!X5;H8N.[(/3#VT<`#L`ER%@F;MP)SGM#9$EJ%4_&')P[
M,+R-D1>Z]Z[G2PDJ,6CDL=<"L6B@^2U0R8!#!.G4'1,7?)7<16%ZB]CU(G[X
ML&W4JE^+2BN1T<*,400?"+/GE@7`;<:`#1:/(V].8,(OL"20#0I^V$",PNR!
M828L4/8]VH=W[(+T>1:1P/UV\\[4OBVH;QS&*!G'\4$LD?JQ8R69+F]!4T#=
MGG!\Y;MT]%\8\-"('[S0+9Z;P/J&-CA(#FM`VII%9$PIZL1QD9\&AL*>8J%+
M,$@81D8=L`<NDF9XUTN5V4>Z0L##`M3?@-`S=C0&]A.+FX5ORYXA(&:XL&`A
MN""!*B'(@0-FW+UW+\4</1=Q:<-_-D9L[,XDIP(Y:F`8D!<2><341%G1._0^
M(R-,&->@\]O'KUPS8%$)"DWX(]F3\F'UBU+488UOXR1$1T&'XYZ0`5<=V`3G
M3BAY.3OWT$@(A:`&B1+<2A#P(PX&'1VR4Y_T@EPEE%2J)TIU1Q3C(H>9AW>T
M(JFM^EOFG7/M!==<-OFQ.O8`CQ;*IXH9[+I/ILI[6_[5BAC@]>,,3&T=BP-G
MB^"]?AJN<H"O]9\(M)0(E)-X#G)1NMPL3`SJFG9[:'AQG"H.D'F"R$,6R^_+
MTF/TXY@&$/MF,(!.DC)T_[7;5N;_,S4S6CD`3;QDKD&W"5>W+N!&70"MM(S+
M&/]`"I]4#=>&`)?)8<(TF`NZF')$YIR0.B($7T&.F]T#6[!>X9?<#!94CK@6
M!^L8:$GP:RV70I5#\B#NH^1*6S@U)>,CW29@%W=I,`$.D=QM!@$J_.5;YUPV
M3S,3Y)!N+/A3D)*CE`BC2"X;0['@_AT)8^6G-P,L@?09#G\Q-2T?M#FKUS4'
MW9ZB4`T*=PI"<$?"X!C@DB55&N?"UT`7G!@!&`^"(#VDVC&HT;<XW'H;&$`S
M1DF&3!_TUWG()2G>D?N0*]NDQ@NLZ1[L[:.Q)1QQZ_R3M9C7'B+(3X2+;T@C
M8+%&8G)ZX1KF.77N-KDI\!@^KQ?U$F3UE#H%:HG-RX7P_PWYG"'Y;$8]BC%Q
MVB$1HB0[.;.`),K<XF_(#FWHX^SH8T/V`A013,C8!D)`NK#;H!M^#D'LW+!H
MAK0`?T3YA#$/%L1<,I)-"4\H[I1C39N!L(2/8?`ONE_@8J@4@0+$(L[0)#]K
M59S]@9(D:ND@2.YTZWBB6;6SS/`D@ST2P24TQ_`[T@9'!^5/P3<0[=7'4R_'
MU)%<5,=UB)7O\O`^N`^2`M`WPL9I1"D&S]#AMOH^8=:*9HL(CQ=RPOC.FU/V
M1*S?+]#EF;IADU57+.^V+JQEA.1RYFGP#VX4N0%&FT+NP$XC6`-8LUQX`:@2
M2'B<*$#9*'V*%6L8ZOW+&`0"<I5&R+@3Y12C]U,S"&[M"^U$8U#"-]$=F)UV
MWW0<:YF0*#(L?%?Q0*IP8&8B!@2:>WL;L5MQQE;;M*RAV1_VEBV>$TS*&<E^
M8J`MEK22`T'@TQ2U"U6KFYV^;0ZMW1=7A\9/XQ)-9>.6>UDY9<N#*?A)$+[$
M_8M;W_`5ZMP$0I=K`/C`XOF(@RL[D@SU!(=`_]HF386[BB>&K;JE@(,8H>WV
M'=,:]$VIH_"X'/>^1O!5":1^7[D;?,$YT3(N9;K:4H#+4"'C%Z6L@CSD>*CH
M6:5#+1YHZ8VDRQRGH_\1!^H:F`IUD<Z!KF0\A6XX^N&\D/+RK`$'`7CF7<PC
M=6OPNV#"774R>P4;$L;T;LLVQ+M(12.O3`V4A"RC;M^99@M=VP`>"CL$R:6J
M0[Z"53#Z_,3RTVP]/^WZQY<OE]__:7S[:%Q_^OO73Q\_O;O\>F-<OGOW[<?7
MFT]?_VY<??O\Z9W,IV_2UZH!SJ/[*@(3RYO[G,GD:/:PVMA)%:\;BBH*%X7(
M3Q4;S_KQN,!^U>44"1.8W<%$4)*GS!;]'3+BN21C3P^.:LEPR.^1_U/%K(=A
M5_G.D>NC"(Y5R#4!GAR+F)UQYP(G'6'R&T.6&;A<M=+VA/D)IV>3^URWXBZM
M?QDIM?Z!86G%;T:`/3/]_,5XY\9WN_&2VFSIF*FQ!]O%GUS+Q01\2G(:P_E@
M#E)V6;T`WIJD_%)0P@_\CZ=^SMQ'&DN'EYNABHE7$[Z?1I0="WH&S[ZBJQ2@
MFDI%DQ'F==%%?:1!!N(&RA0PKM:"WC1-@TG,+[#@!D$87-`59G$"=Q,N/C(9
M!%G>9:Y035,=DI*"`5L6#%A:M(J@4.H4<"B,XF-V'M\;I7Q%[HQT0ZZ!TY>+
M[VX;,BUI855,S>7Q02^6KQ,I7J3K!MP&)-1)]=Z=(4-$#-!^5"TU<*5;#Y5-
MR3);QEL&]!(@3E2&,"^/,+5GQYC,Y-X*NT$@_*6(+Z"6R>M`&$6T4/-,>.BU
ME"),_+-0QSWT4J]W2.ZMRQ5L()TRXLFP(-*HSN]V+;ZUHOGGD]J:9/,WD3OA
MG$76P!C?X3)X]V0>X=W+-P9X'Z:C!&ZM(;]^]C*B)N=?J:KA`67:5J0=#F:!
MPC=#-*S#$3Q*F@[GT9,4C%MB87R7J#*AYL:B&6?UP%0\`*OLQ7C.:2`K"73.
MQ?U7<.^!ZXW=:(+Q+[!:+[#H.);9MEB7)C0U=*AIQ#.1Q"/?)S-W@<F.*!&"
M['%7`E?(A<A`A`>!,0/3H^1G"2D58*C^WZ;2%ME/^"ZY8T`E#&?>&%5#[O+C
MN)">%X&D,IS,7>"1B%3<QRR,4`F&_0W;8,,_DK]NA(G+OA?\*P5]F5[[$'DJ
M/6ZJ_5'?".>PV*\;&/(*;`D<T3:I_"_%S?/38)@*Y`K/%W<VH;`D]3S##P$#
M(C&,$N$@HY+"*:+$B\;I#'$]YK:0)"U)+E0GB/^Z1[V`OJ(`F^.!A6D,@@$W
MG3#,[9BB\T@/KZOM<?E=NL6'.WB6XX=-6D;Q_HJ2]O^PN_A??D%"X95+*%O>
M35ST<*8Q1>.!/,:8K,^$I@*2CGQ,,2S-4(R+-,[Q.(VXZREB4T06X'H"1S9*
MXC>&.\$+2690IO,(SR+7K4:J4F=R##'XO"(XAPW6;.^I^13<`TF$T6+@YBCN
MBQJZ5O;C"]+QRLV-.7<=`A,>_^5B*"5(DXCXMU8UP]E9.I_[W&/!_?_N@_(I
M*&F#@I,R)\GB0.;ARPPP;-2%F6&PI;]88J0JNY@4?*Z/7]"79BRY"R>B5`?;
M>^'C6<V#S+$NE"Y(4.,X''MD1*E\Z8DLSXOX#%?C%;#/B1<#'XZ%H@T\5%&?
MF/2*VEIX&WAYA]5KVB/GV8RJN]7;.:S4R3%BHEZ'^TL\@?='TT#'J@_(E-:"
M&V>Y=&RB7B:.AP/BD;Q$6/Y]8BY8S\N19QX?O9^`R$LXV@45^BDY&O'-7C[R
M#6)R3O43^5U[)R"4TQ5&DF.54E+GO!(GH8MI&@%+A&:5SDAQF4@K/\+>#[S4
M"E564KP-<@>Q0/@+XDRCGH241!MG`1/_D>M(/-L8]"/4NWSOGJD('["JN0A,
MN428,H8Z=SWN;.#,@X+6%*?,FL`*70]K%DO4MF57\$]>J(&U7_HN.>_E=8N@
MEJ/%=@$*-!.,EZO5]SR%6ZEUDXI]<;8E-\4Q%/&0(?<B18S4Q1AYF?'(W.@H
M[HRZ$>:F:E#^9G]&/1\SIPG*3S,T!47PH.JJ-P)B[P!+YL(5!NT0EO$88Y&_
M;'XE#74=>9\8I3HQ7I9*BA;22*,<[-4*`9.=_,O9+3,6X.6%G\]!V]B>?UVY
MB5[628XWM`,:]G5<]H5!*'X*DW`NJS?)KQA3:`M826XS*I7$R')"L,8TF+C1
M)#;>AO`O*HG[>'G]UBS_TKMPPLM9>8UM9%Q>OS,W4F.<;MM4>/3R-_/B[V$X
M>?#$L"9J3II1DJD>,+(/L8V*OD<`QW!X4_MU`6H9[]RYEV`W"IH61>XQKB,2
MG"52P)V%42+2=V0O!R9Z_W/53ZIXY*`4[W3!Y!:HBUMYL#&Y<HQ&*"FH9.J*
MG6R&W%`Z#5VY*%B;MYB8A1UP'IB$G*<FC"OV72*@0%&<J@PL\=WE4HYG^7W*
M/>&1)S$'$/E^+\@)&CQ60T3^!Q&FU=WRGJ(=H;7R7,09:N):\7F04C".IH-@
M_L,]"7KLWYSSYJ*[>,R=H-SAX47HOH\H]4.$+=&-B9L8,>GD1?\T[S\Q]:(X
MD8!C^%/L5#HE$!6H-!N,6C<L-'UK!/XV.>*?U&DC@6+)R,5G](H?Q6M0/^,D
MNQS\C@OR)4=>+-JU@%6:/*H.'YIY#6S71P3ZA,!5MXMN$\^"R&X4I9C&E%BT
M]N4B,`2$51?L&KULU3<WR[AZ(J-<FRX%"[QEDP(TS:-#&UF[#`P;BF(?,HK$
M!9SP]:9<PN4]C[PQ*X+UW*K\=D`RQAJR=H"EF)[?/<8B<"W"T`V^M\2WQI5Y
M`2YONA?)<#`JN"4G@-%A^)+P8C;XWQK_[H27M!3.821:'F*#NIF2C6!W^1,2
ML^.D]%A(4FI-Y+:#1>8%8TH<YBS&W/TU>LPZ]\7"UGJ^)Z[,/ID5LC::190T
M+L061)I@S!/"(X^W]L/HP)C7?,1&/F]4;VNU(0019>PD43I6;18%-3WWBRR:
M1E[P&J0-T:IB.HA@3`.=@KXI$G]%KS_59DSD7U%S+XH3BZ]1!11HTVR,"5-X
M[3<5H#,Z6LK1P3H>+TC)3N>O+P;.*YC[WKLKG"$IZ%=OLS,@9NV16X,RW7SO
M+\R,HH0WM&!X;KG`O$%^K1$V&@;FCD)5-2^>>/$\I(RU:9Y9;`;.B$UYOATV
MXZ.7>?F4LY+HWY1MVJR@%H;4L0O=3[7NP9;\--7->&&:AQ%OF2K2B,1X!0Q+
M`4,C@,#>YQ.C`OUQY#E&?$=:B[#:>78+ZA()BU6_8.$!5?X$J7J@2S!,YSIS
MROLM1#]AX0V@!JO<OWB#=0>XA.H`KOLOA-.")YW2$OE4)GC,QQZZ8FXP9=CB
M@!ZX@-Q2E\R=X\7'5`(2X1,V9S3*1V2M"E>+^C:*=HXH#@'Y5;(1":9(9.*H
M=:5P%O%VN9'_22>W,YDC*^\N3TH(,-^).K=.C&F*NCQ/.\@@X%R-*Q&X>>P0
MF_7!%9D-!!>Y5#!#EK,AUY=N7@UVT7Y7M,=5H,AR;9D.(8#(>YRP!7,D>J0H
M:C(\(0Z+WY;Y6,KM0R><Z:<9>HHEYA)=TMG*GY&DQ['$#9JIS,#^'XXB3F(R
M-3DBTLF*D%>@AS]VQWQ>IX==IX7KF[>>UE1K[H'WXZR$7;<'^$5($\\O1!;D
M%K+Z'6\B>XR.770<<5^>P`@_=QY1QC*_6QZ#\,G!Q`MUU%.8C\Z+ZD7*'>]0
M/"UQ'1:V+5SYVE$140>X13DKA6`@YB`+SB?>=,HB+)8"I"4/6(N8O3.[_L84
M6(M85G0GD`DW>:#H:F1$10>=/:HU/1!0\Y`%<*^L]SZ.(I@Q7E?OCN^T%OVY
M3'NEJB'U@"#7<6TLW$9*'="YAU+'.!N5N8RR3IZ#US*NPUE6YX["7%,'M)QL
MRDJ,XW0F"O"E]U.XIG`2$.\+'84/R9VI/N=-+Q7A$RPQ\WW>2=L;(V?*IV;R
M1`C1>IKVB+TR.-X1/QI0A"BMVB`KC#-5"T_>]EWT&@3([[RYB+()$+."`[ZJ
M:*GM\[SU**!B+56Z8+@C[&`I<)X`84UX%OZ(^1Y<7+ZNZ`^O(XSX7H9.P3XQ
M`3\,5$$/D02@A?;[(X`C\,;>G)BH<$,3:\QN<,D>[D#*W&.W`F[3N[S*CCB?
M6K]8L"=]-$SU0M&%K4AH@R^);7,3YMEUY_Z(]_P/><^SV/8G,GC+TJF>/&YX
M"%(O:A2(X/(F)J<UO,<3EH5>F9*5VIA:N0H?\V0N3`@5-3%W891<4-H25H"(
M'.]"O'35(@1)MA#>N\)B>L^36`2.-"Z/'6G3K"F)!M0,O9PHYJ3MK:-$9G9+
M42S8X6?2!RTIYD1WM[Q<N?-`XD7CNT?B-2D5[8CJT$C`B(9?I&93X(@9Q<A`
MV*9QOF4.=9Q!L%52#2FQ"K/<AH]!FH,*RFO3A%R4X7FQ5:PW@O?GE,6\0.2M
M6W$M8W$=D?+)9914YS,$&1PY#FQWGJY&SO.X=)@#"*B^I3:G2N-;U/DS'T^^
MK$(_'E[2AT2#9\K[V?!^^CSU]D)8*R78%K4+Y'D"JPNS1P:VR![Q"OSR"\@Y
MD!Q9OPH$->LJ(Y-3>*[-3<7Q8NLFH87C_`O&N4M(]PT@_E<:HJ#D6@6IMUQ_
MXS)2T#_96J@K"`504;^&ME?B1KX6]/I07"D-PA&6F-'E$I0I'G)>/Q,BO"PG
M.578(E0*O7L)023JUX$C,)84J)'XEZ+L2594Z6I$0$7\B'(3"9!'WL]\.L#>
M0NUJU":&\->+NR_99*6/%4=IKN5A[7:JA[S"]T?X@[AL]*K15N[4-.!EH$`K
M&_$`W4R#SS4RSL$@T;"1EWHMM):0TNXCYH_5,7C]'6ZVKSQ=V#O019X8J-ND
MT&=*#STC%\T\C/D\)6+Q2L?2N+]T,RCGHAIH:!K,(X?<Q`.FF/!<0'1[BM]D
M@Q-EPD51.,K-8"2(TQ$F'"4>91-RMQ+Z`K3$_3+]>R'*TA#Q"8G8V8FY+>H:
MU4376G;F5?&5_8A).6B^W5HVXO<088Y3130N2X8HRV&B66ND!TR;Y[I/$%9P
M'N(LU'5I;2W]B:F9.[>/6=E.YQ-Y77D(Q_UYU,8`A]Q>'?*B_U3CT";W(K6K
M,.]+.<Q%E`#I776%%F8_.<7)GQ+Z8@QH60=#&5W.,IGF+!+CV\`,Q:_#5R8T
M%S3D[6_)D4SY"E@!^Y9[;[0X6BQB+K!I58POG/0)DHH8?2FW@,O([B4R4L)C
M#AC!49EK"]"#((_H@6R@&@%!0]6>UG5>-GB6>^&X*JXC.?/M$)-<,,T?56.'
M/[6(;W9B\)8J1X@4F%DZ@G3@PS-HHC+L_D-=U1(^[5+XS0B(+(04YV)()<TX
MB[Y(H@'5Y*@".A%(\R(]ZH20"4:/,/R)12[D0UEKPSSJQ`*7!V3AB]Q-J,=H
M,31.[@SXL]`NZ#2TJA'2B3,'G5ZQG84&=?2X$2O&@46\CE$&"@";^*QXA%GG
M911U:^Q/^9+U*2]JDU1P0["B0U)^(Y;H:)%/2D1S9-^C.-^6`T`7XW?+H.%1
M:$Z@W.7,!3BFVY2FY1`:>)'1,[GH%>5E_8[N(.0BV<C$L:BZ(V=P%8%,L0$:
M:/*N%VC\0PT/@QL78,*$J`)3G^+QEIX-O'#$:)X;@.\2?Q?#S#"/*IU@/WCE
MB.)!\?$='^T\`W0DJI>!7(N(6UY6+3-E!=A9;1LE?<3)`GW=N3'U'@?XO;N0
M]S'GH$OB$OEA6`6&(X@COLMN^Y>6\2X+&D997QIJJ)/Y9L4EH#9;&1YH<[QS
MNF0'\.(PGULL<R&,$!MVM8QUE&.A&\,QK$#.,[DT.:8X"I.[+,I#F@\P,%]X
M6;/^(XF.O#Q)N7%NL**.65FS6WY0\H1L4SNB_+MY0%WV$:"V(X(',Y"L@6[3
M:.$<+A(4O,_D7#%*JJ/&S<\K$+5SHT<E53X%(O-`MI*"M>X]FO^$[5"X:*89
M`_C(([T0AY:#;'LGXW^F^!I]+KY,G75+5W\F)Z&LP6M,3+EX2WQ='^_UW`+X
M(*?5[;?;[0[/$\1R?#G%@\2V-2A4T.=&HNG3$&@`R`)&EY73EWTJ%I6]GB4,
MPI3RE+HFID4#&4N!*Z_06`=0=8&C?*0++LYSWZ!9(K>B'4M.W%-!]06-`UG(
M$=/U$UF%GS<->,*3ZM6?U;D+@3KA24]<J()*[8>/K&1WHG>K$7,^@'E;:^U$
MI&EQ?5E.WT&!$GDDX<5TX^(G<D*0L*Q1AQ-+X5#P"?R%3]+%-`G5@B;">GR1
MIR%W(KXG!R;QS`O?Q6X$ES%E2)C&PDE1=CL_3G4*<AP+G4;>/4;ZENHRP%,\
M<PB9B8:V'E7\<T+6^@THD^M>Y`V+]":5?HA;5GD7^,E;WQW_=7$]O@M]%E]\
M`5F&FI1L).A1UN,LG#!?C7O./6%\H;\I'7,\9G-N<-)#/`Y1HCOC!2"IFDM(
M)9\PPHHQ<5!L^6CUGZ+G(K%YVIP;>:(_;R['DZ!0)IO><X'VK89&J*]P`J&@
MBG$?HA)`MCDA5$W8`0"QL7&(^\_IHKDD1K&:4C(YII\'XSVL2[Q6F?\?^'AG
M/17JE9X-FV7/J4S8USPMD4L@]%4$CS3_FP)J1$A%7BD,=\$N>"*+#)`5\W-U
M4"B+0+%:D<="H@=^("BZ[:YFLXK-<,WARGU4O8>_AL'%!PG42J%'R\";U5]-
M[<\\JX9?;]TZ(R:H21[.<+)Z,AXPS&>=T1@]GHOOF^5O](3+1,0K7[FO^466
MK)_R:#WJLFQJ23\F[ROJCN^X;^?5Z+6ZR:!Y^A[OV_K*>\V32P$_2BSH;_=B
MP;,2JOQ]Y8D'<JES$6?/3+1U5>*!'VN^?%&DM&9/Y_J?%CA53M9C%K+(L2WV
MW*;Y#6A->>CWC:0@RE*@@&N+,WTF'&S!A9>3NK+Y)*43^T(/JM)91-.:$L7+
M*"I>F0NW6DR2L!8T3WW#!92*/$LAI2A;OJ^08".JEZ4@7[UJB%@'&,5*-Q.$
M]4R(0!E4[S%I]+W(V']V>=#O"BVX,!!$S$)/S>5*O/299'FPPE@(;M7,!5%<
MH28<9@,5QV$0B($*JJ2#`B<^11UX2FW>BT=>0\KI5045=,^X'BP\Y>3-N2^3
ME?1D<0(J^4'#A/?XQ@DT<>'.*7U<KJE=(TW))!BRWM4CO<57-HLQE^NLFGT]
M(<+*7Z6E_<,/MWP=Q(CL6+YHQVJ\GL<')+_OY=2S*MS1'PMAIVPQ'(XA@T;<
MLL&QGM0''$=AR*I)JA<`]AZG(!?N,6B,N81C%4IV<U#SN)^HO)3"P=/"U:8H
M=*01(#+&R74J7A3T2!5$T;,)&JE35%?A&_","\#?Q3LJ=HN,*]&GOW`A3M&B
M7`&;Q]8)0/DSJ[8UOMV\4X3-Q1#'F!&[O@B<JI(<[OY-7(_Z'<5I;J1,_HXL
MOHI7WV$]'3<,LJ@K^8$H^>$A$/-]R6CQXK^DM4_I$C32;HXQ5=5X1()!4$@Q
M&*;)"(Y_0HO->3GE!)X.>$WJE/$(%(<*_S3R>+GD+`^C_E*ACXKWJ;H?3WB@
MT%6(KP,K$`[@?T)9T\.K^\3T'2Q6(OV6YYR(`1+$F+1!3,(C1H-O4JF/,IEE
MJJJX>61<U,8;R4/(48+N_I$;T"AJ'&?4,MYI,Y[XEH$U>3,JP"R9CJ3FQ2D1
MC\W4^=Z*248E(WS$;$/I?P0.A^.G1+4AB'^G?0%@X>QC]DBSID20PYCCZ-]'
MD=3!U9H')GQ=BI!D0(0GSJ21I$9R(;[CU9M,&W>4I33*1*<<L?(W:`2+EX'V
MJCIKBQ5-@3JEG9B%-9&HGBW7O=(GH]2(X]:D=W7I-3&PJIG/;G1%FN$HHHH_
MK(I&[NR-*T;.Y`A:8\XB07P2I;<TLY<AS4:R#H\NRAPLZIF+([:7\&UQ@Q>7
M+MR-A2O!"W]I@IR<-S'"#)MG<C'^5/Q*\BE*/@$T\;ES`HD*Q9E@0!G@\:1=
MS@S5W/G8^RD'Q5-%&7=N3K(.HNJU(),\GDC(._V6TTY6[IGUYL;:*G^JS"R[
M8Q3'W,MH2E9YSUK&W[U[(<'E>'NMD518!0%E"&10C-U`3FX#@>.1$JMJ0Y7C
M7\-G4CV)B7=-@6=%N:J4XI=D"0"N,,C](%*T\EDM4WD!I)%;O@0?IJ24EDQ`
M8+X#&N@T;=?3AK=0=HN"37-S*E`K-\0/)^+-EU#=F*@K/H=SIBE:VG,Q[Y4H
MB4!-3,D#^GRNHAJOC)$LS/_ES$B.`);-4_D(19F5(A\J<\*[W`V8>*05R<P6
M&<'E93G8PX2[W'D0=A:BHT\IFFK&IQ\^NG[R*&>.<26V`*$(:0"Y8HL-KO,R
MWOM!-M!*8]ZT1A`A0D@:+!5P9UU2^(<88O.FU-OG`<4/RAJYY/B.@2HFE&KY
M9A01/-RG%VOG)UL68-=BX3((R!MLT/:]8`((B![E^#5]:"A/*Y%&KBK0\Z8@
M;3`UVXUD)!;W"7N)$G1B/<GBAB8&J"?>:#;<?TD;CORGS\UI_"?+1G2![EAN
MW5):"1<=^A@OS3SF!0PJ_21GO\I8"EJ&5(3`7YG59)<EL3^MZ[=6.4WI_)[+
M"54,QE4$6J^I0[4H!-(H6D,>ITUR$"D*)D@N%[^$":,O+<OL.T/3>-GKFL-.
MAV[$2VMH=@9MF3&5E2A43+8P%SZRZ#WZIP0$SW/-\H#\I]5'I!A;B!GV41"H
M@-V&?`[#!^$">\*1AMS>)]G>*4OK.X?*&;QY;RI_H,@DX'S64TFYV5=YP;CH
ML"B3\WC-C_@R%IY%+OFZQ.IA=.L&HN%>3&N_^_X-K6V9I,AK@7`D`%49R`>Y
MR])+9"\DT>Y1`8"9'M40/NI.3C$]R*5Z<[3P:#@OWP18MQ']-&(!FWK2-8;I
M&]Q1F07Q%Q,MY1HMW-.2I3%M4.Y/`X/KEUFW)/6=).(2*IW01K_I6W]4*6RY
M)51'\4>NU/J)E*UR:A*8\LS71W:N..%%K&L[$[5B6O5?45[/W+_0W9UE#.&Q
M:SU.;B/&)A=<W\=^2U*9QNDD"F_R<31V)O>RE9-+J,DJ#`F4B>R:)UDR'&'$
MIFDPX?WFQ./JE:C^WX:8^$BI@Y*8L]*F$65`3K1&<!5XDJ$`KK9(5&'YR@AK
MY[)Z33D=B=(]:&F*"="WY*1Y#/JJK*\L2L>AIE11=P+[O"QNAY<:B+VK>4@K
M`"?I8YOMH64.VD,A=P9#T^EW"3]+)<Z">#'*1`L"D@W,R;J/T8W)&I"54[]&
M<(IPU$EE>.6^.FPY$6A-!XFUA+',CZ8A5UE[7!6!H50LO,Q`3;<Y\L)Z$AX(
MH$PYI%_RQE#O-`1?O'2QP""6-X+2T\0]EI$%(/R8SBM;6[^5V?.2D(6)OEB3
M)#.XB&:Q6Q0&G;2NL?Q%LM;XKR!\>"X.%*4`?'`C;-\6&U=`HY1$_@S-+EF]
M31X\C@X@)MFM%.[YAZMK4Y4!EB29V3V]CK$"IR*OL]!C65ZR-!'IZ:+3*>^$
M1I?T(40`9.+Z;^03&:O961//3Q,A4^0L6/X-?"B70O?`T%L(4D4X:(P@)=XD
M*R&()V#,"[[/*S?"-,&D1\H.US1MD=,F'4AJ!"T'9<N%T:-4N?C<3V,RB^<A
MCHOA_6]H/1DZ7?-%);N@N5YE[UT&G&QHB7^;9ZW[]<RHEG&UX4LC)CJ?(XCV
MT!S:/=/NH.3HTL_#09^K7V#/]#I]LS\8Y%]',.1>B6*JO!.)+H=,+NO83](K
MM.;3JK$!=SG+$UZ\)[*H7E9UB*()V1N3*[&B:)>W>,AD.S8TNE#XF:2*16,D
MBG(#`#%AE'`YDSXMA\0>NH'@SQ?\COT&:ETT<_T\E_^1];?X(.7_$;T7A]QB
M'?P<W])HM1<MB\AQK1=(VHW*\Y;=;/#M'+C5V)NC[T[+IJ0P9-95\4=`\;GK
M1.IUEUB*/G9)=OW]\O**!R+XDJX:XZ.ZG92"JR142LH8F2O5S<!EO;?,;^47
MG:M9XNIJ+3!<:IS`_2VYJ00B3&<6^ORJE-"<8.1-7&Y%:^V2OA#<W+FG]@X\
M'41K>9V?7<4+V+7"`?7R,0%&DAG^>1MF+9=4"_+<FXVJ)N3<7LP"5FH^@VP*
M+@"A.FG50%QVS5"-P;.^*+FB!%.6KX%E&V>S'-`"T$I@D$G#2>(>LA/C/<P3
MK74R09+-ZRS';I;)S/OPNQ-,4P`3PJ5NYSR)A_88`X*H2O%R3(,,))1HRO)V
M(:8A1NN*-N8XFT]V9)3U>E(FY7N^$S9DSY%\CW4>OYH\JYX!3RZ&5/17CGEB
MP2=1C9QQRJLH#$)L)7"$SNNGKM'^1XHJ&U?K"@7:W)%>-CG]QQR%DYB9_L,T
MOH8M>L4%*H/*>-&;L!BO;L(Y&!+]3OOU;\855TV5+@C\\$>@%5+!(\9;[B0D
MQXS(/OD*.MPW-;#L,VIS[Y#-`"MZH'GOKG$M^G#B&_`+)A].AK^*]$;]">,#
MI6`8KUS>JRF(4Y4Z0HCX`-+O%A<C(N%L]<:-_S(^AL"&7FO&6%D>`$>/Q`R7
MG"[0U$1YVK0_JTKLV]3C`CRL;@8UUQ`H!3!E4&I(I#Y/&A(!#92.I1!(ZO"X
M@$#5F!V>]C,$4CLKE1^:(9#GL(B8RQ(`LHE*`O1,Y2A5&:BTA!HE$8U0V_#%
MADF\!BR_K2P+>,>M\71;T?X$QQS**G?E%AJCQ":_4P'W7/SNNOVL]V8%Y6C7
MSIB$0G:2J@4H>1"I4K*WXT3OB;Z<$JG7EJJ101Q/X6&`D)R4ILC00,$Z4R7M
M(C&-*S_B>R,&=R>09\(;A2@OIM45<^+7V)S4#/0&8&3SN4K`RQ&C(I^D7(?F
MUOW3C$:OY/+":E_LPJ%P;5^T[4(WCAO1N>!30-6H8!R(>?2?LG'JE]DX]6Q\
M_=JL$1=MZ;^(9OSHNA"Q$=D!041"IEX4)V(6%<]52F2)V9CFON6&<\DQ;[P_
M`'`K)D(;^MR;TN'N0BU=&(HHE6MM,")OU%@Y:YX(F,^]0??:IZG6^`O[?.F;
M<-6,+9.RSA`-%&@B?XJ"2>9\50]K7"Q0Q^$[ZAR-"E#AG3YYS?%E"%RA\:")
MT")0KO*7:1-]Y(0\+RM];QG_)0<'49^,Q2VIZ9'Y=QOE[]78W(0(1\7:D7BP
M&U^.=;E!@(:"SK,*[]7C&T5FE_$PT>CH&LUEG8%A)RO@?3Q4Z&*BF3N1'3N0
M!)-$@&EH(&[&S#(1H7():82@,M"RV.#S86E:<R'4.I>P-0O5TCQ;>RMF15S3
MK`BAF]H6ZJ;:[!!ASGZ;3K&&!FG@,C-?/VM-(S6??,;8<%FU8"O[COYWN`MW
MQ'2X\UM,]YHL@%`^"8EG&T3>O;@NVI^402U:+X2T!ZE29HHD$$]>.NH4IH7:
MZ-I.4>GE[63<&"]#(-"BUR;JS?`Q\,PYF1=I[7#(I:"X,F\RQ@&4>9O50&K-
M$#\H"5'1TX@:W:%R*.;'Q7%NX)IR,R_K!:I/?`3YXA&?9F*(I"RME+U;2W4Y
MW3T'/`_7QV=(O42/&L_27_:DCA75?T2D9(AJJ6QFV'=RDN7LM5:.Y*HX9*0>
MS#SNDO=)*R,27/`?+CP2/1HJ(VH]E7`!D(WXH!#^#2]<B#H*Y5\Y^NXP`K,0
M&LD[P[*VN)NG<5+C1FP\S9URD72E<-X+R@VP+`3H$>Z>HC53=T;'DC8S-S:)
M36V^CV"&S[/IQ7<V]H$KD8><>W2?9"R=M[@0-C;J1\JUGTO7$:A0[G3DH5P+
M#Q6=((/)^44.0C*5./G/7]/XXM9UY[]=9Y&-S'EVA46K(%-N`,UO_7#\U^__
M^W_AG//_E$_)%,++8*(E3XK<R2M>\HJ!!'C^.YO^[<7'*)R1>=RVX'])R$UE
M^\*Q7OS>)'8VB9U-8F>3V-DD=C:)G4UBYU-,[,RTC37TAJ*J(9,*KUA$*87\
M6THS.9J:T>24-CFE34YIDU/:Y)0>4#ZL8/9%V7"%K4.N"#M%%\0E5=JC='FO
M]:"HD;!H?"9GZS/9E.PDV28_9Q-XF,U=;R+=$5D`IVXJS2A'KE^_W7PP>MJ(
MBZOO'ZXN/[TW/OR_JP]?KS\4J'=T`CI6,.</[P2@B#-6^KR0;UDG=MGEZ+SG
MM8NQZSCNEP]#?V.,*/QT@<T\W7G,?C/D3VHD^[#]RQMCW5T51A!7CC#FD]^S
M;^-UHR>6S15^8X@]BAT@.(4AOA=6Q8#1LM'%\FUR#+VU]-$"F(`GP'#PMQ>]
M%V4@8\B"10J_<@F:IX$+&10"H>5RA?W[@95^7'><]!,Z"WO7LT!NO;\SJ./V
M[-.1&(`((-U&V!/U0C0CC&Y'K^QVQ[2=@6EWNZ^7D:%@2#UD2+N2I.3XWPWE
M>#/>BZ8U50@2ZSN_K']T^2>M`N!J[OK+56M:W<*CU$Z-GAW8@#W;6OF&JK77
MH-YZ;GS8!3NPV]W_QO=!UW_>>0D[)$^5!)RU0LRZ+A4QLNFI;4LG%00Z')KM
M=GNMI]99[;2[P>\4Z_W6UXQHU6&G;Y=4`>Z.FV,SY*4TK(F1C0@;W?<,O1US
M0>'+F?).DE6\8[GDW)YO;O+>C,+L/B"_L\F&MX?PZ6'ON/=S#X=Q=&F#("U>
M4[O57;RHMKWDHMY\N[G\;)2Y%=;!%*VW'UJC5QF3,`53>&,]8\,W9H1FF?UN
MV^PL44`J4+RONWKV&%REP.T%?\7K]2MY3$[IXUKJ[?K/7]=T.A9=Z]<XSB[U
MV;<IY:+P5/*O82"<L75R5C;>ML;;UGC;SO\L&F];XVUKO&V-MZWQMM7(/]5X
MVQIO6^-M:[QMC;>M'M*F\;8UWK9:8+#QMI5YVS9UGY6E!LHB":U"@L:N9(_G
MG&Z7\;>IYF@STL#C?_AQ_?Z%,6%C;^;Z,7J2?@=K`XR-O$]P]6K[@]%>`T:@
M*R"K;6%<Q'_6^H<?PF4P^7L83K#@ZP:)Z?B>S%))MR@6'I18N-&=F`9W&LHF
M1J*7"Q681:J/6-8`1Q9@I;.4M_@4$^E5%CKFS1?;ZE`E4SC-B%UZN;)/9$U8
M]@G64"Q_@"!%,OCMB-UK*_6*BZD[\_S'WU:]:=G);+B/S-^K^W>+_M^\!4P>
MW"6.7MI*[/V;2<U\P4^\NUMW-Q2NQ-12D5>JI.6Z(H]"?[+C*6\)HO+M69T7
M%0)UM$SQE<Z_@VRG^@KB#I2O]$Q/8@O=NZ'L+2C;KA]A_QWE'.EFD?$K?O!.
M=F_6/KLDZ?>$3N0,0*PST5QF*E"!3)0V](1.X@Q`K#.Q?&5)PTL:\JC:S9^R
M`CM')+P:>QESD9_STL$,)Z\>H[CU^IP/KT;:F/39".13&]:B>?M;P7FS/M;K
M>SN.1OU;LYL&FN8DGS`TS4D^%6B:DSQ/T7]NJ&O([HE"TYSD4X&F.<FG`DUS
MDOL2ZJO3#M\8NY4I\"0G$0#MM'_9QZZ_77WX?BFVWN^\,>)PFCQ@K[6YF["-
MO7L"-GLOH&U-'I4XL_8"U\L=P*%$H0R>_0#D6.:P:]4+25L?7D-"IR"A5YWA
ML%XHVM3QV]#-B5A/IVO7"TD-ZSDX7`>A):O;&IP=KC94"2E';C]Z8"&#W2XI
M2;'GU?4#&Z5,J?Q2!1UO^3ZEF=K1'`<Y8`OF$<ZI6/,,ZT++6;IU#8!97O.Q
M`31#R^QW-DUEJP5:ZG(43Y,N7@V&9J^WJ[%P3`6O+D?P-.G!-MN#7?6WADW4
M!9B]D46[=2:R8T/]ZS`NN>.I8LTUJ=4U.6_4/'L$-+31T$9#&PUM-+31>,#6
M2Y_^&@87KDJA5I#N(97Z&5).<ZD:VFAHHZ&-AC8:VFAHHVZ*6N,J>_HDT=R6
MAC8:VFAHHZ&-AC8:VJB;!K9'5]FBBE6FBNT##?\51K,P8`HR[//HSA^-293>
M&F,WF'@3S!7CY05Q<XUJ<(VZ?=OLV[USQ$M=SN)I$H:`IFN=)6KJ<AQ/DS8:
MIM$01BDTP:_N>>!D0VWL,/ZPZF;[1W&2?4G]Q)O[FKH6N1,V<Z._>'+_O9?`
MNX+XUSB=P]=F&^AL$J+*<0PG(OI-^J6=_(9N`NS^6/O0=.S=2W'J=O!U@Z<A
MQ*/IGPTQ-L38<,6S(,1:$5I-%>134M&&6O/6/LQE@W*6JL9V9S^XN`D3U]_Q
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MYBK5`;YZ05-W;#7DUI!;0V[G@\!Z05-W;#7D=E[EG.OZ9`\QQ%/!R''53/,\
M2')FR8W<[Q@TVS'[=C-2KR&A[0':/8F\H9[G2ST-`SHW$MJG>OG<.=&&:N3A
MQAD<T!/:#/0\OW**9J!G0Q>E98/]OFEU=QW>O@](FH&>=:`'JV-V!YUS1$M=
MCN*)TD4ST;.6NEAS36IU3<X;-<\>`0UM-+31T$9#&PUM/&$7V*$JW#::[=E<
MJN92-0RWH8V&-AK::&BCH8TS4-0:5]G3)XGFMC2TT=!&0QL-;32TT=!&W32P
ML\P6:R9ZGMTUL@9MTQHV62#GB(!C\-=FHF=#&PW3>`Z$L=!JNQ*\=;J6T\/-
M@,]-]+1U!GP>4'EK!GPVH^P6H+4ML]WM[GB)FU%V#2'61AUMB+$AQH8KG@4A
MUHK0SD-?;N9]+M&4;;N9][F"<S8C[B2<CM4S^]:N/HYFQ%U#BCO#N9_"W6;>
M9T.!VS=Z&9K=`VB\IS_X^D%4;ZVW-M"<GJ`T?9=^E*,^__/7-+ZX==WY;]?C
M.S9)??9M^DF5AEQ29<AE,/E[&$X>/-^_P>=N8&=O_7#\U^__^W_AOO]3ON(]
M&R7OO7CLAW$:95\SQ@`0_/*=3?_VXF,4SNRVY5RT+?A?$M+/EGWA6"]^1]!V
M&3FJ<#F2/Z3XP]=O-Q^,H6P@V&V_,?"3:^/J\I^7;S]_((2D"C7JV;*AH7N$
M+G]F!ULUSV3_)XT3;_KX(H>?3W&<NL&8&6XP,:[<1_26&^'4D$YVXW)RCW\G
M>+ZS^]"_!S(VWD5LXB7&UU"TTDE/L(4\$H^V[K?`^(<;I&[T:#B6B0,Y'=-X
M8`:-HF(3+*X*#9>`&*6Q%[`X-OS0#0SW-F(4C3`>O.3.N/)=_"*@'6Y:./;<
M!.'X_/F=:801_ZM)\0QWX3",TH.@YY*[)4?5,F[N*AXV7-\/'P#\-#8`K$GD
M/H"D?@B,*5C"^-UTCI^[QDNK;;;;]'_`UD]OELZ,>>0%8V\.MB8N[=(<-=-P
M$_AZG.`L/D0*("=.#&K"!/35^\68,]A;$*2SEL#%@QL;-)@7?IZY?P%,?+L$
M$<`U!?9A)'!>^#O]&V!C*_:,8(1I9$3L7RD`8*(Y/[[+7OT`<"%`+GQ#/AZX
M"?`P.AOZLP1JQ,R9.P%$1VSN>A.3OH&?T/(+X+6,3W+;<WZSQ'*3E+\</J57
MAP'NP<!DHSMCXC["L>-I("CX.8.O`H3,!;C'K@^_NI'Q+Z!`>#E@EA87NPH>
M,U03.L?C*`7\XVIIP($>AS.`!:<>X\*7<'@^W`U)R?A-7%2=J3%R?2*Z,$W@
M-`4UK$:\"6BX99A9Q>D="$R!HV#$U4+Z#J>:6.%$K5!%[-X4M\LGX^)62Y#Z
MD8TBNJAVA[;7678!\!TQ&Z=XAT>/1IR.<+>)!W`_$O!P!$A(O&*R90`?P!.A
M]>%/V5I=`N.+&\&!($8Y7E_:XM(0K'"]D"&X7@!(J-PD+<)?9.NLAI,?K?RR
MT[;,]J`+^`C&?DJ'4\2R.M2([S((EY]I%8>($05R/+$AIQ(C5+3``K;AJK'`
M@,?9S[D'+VH!IS-0#\))>4!8H!K$'JSIXN_$ZI8<-VS[-H+S@'W!]1+,4QQ^
MA'_`C^<IX,J-F6&9=I>C.[YS`0?R\-X![<-:UPFJ)LB@X!!_LFCLQ43Q@)&7
M3LMN$V^B)XU7,6.D,\`=(1AG8<2I?L(2U_/CUZWG(?=*5SOINH?7CMZ&4<3Y
M,+\<;Z5`_XP"_5(*="[V4($"$>"!-(=+P*D663!\8\+'T3XG->F3XEQM"WC7
M'U[B?H&[F]>2#*DA$3!E6M)'+P(.^2/P\.*_=8._A$KTTA'L=(2?^?`2O.)C
MSC'P*UP@PCV.B=?<`F="[@&[PH,:N_$=#A_%2<$1_!G%,L&`:@+G55=K/NI[
M,T]P)="-.%`DJDG4SZ/P'G@<B93O(?#-!+84>/_VN.KWC_`.\`3&E7>+6`ZG
M4^!!42R%BF!9<Q1T]'U\"\.-?20#T?@L%K\"92"`!^^\N4E,#017\DC&5P2@
M\O6_>`G8>2#)_K\(A!BNY_HQPB'7-?)+M@@,E)AE2%Z4Y5R220W/:;5M3<F#
M=\3P;6"^KO'(7%K+Z;51W>%XE3(\E(3#)9[-H?B3&0&[#1./U$D7OL4NZ#5`
M?@S$"#RU2"^HAY5#+]5`7!0$P#A-.&QBY:%8&EZDZSEJ+=,82<X0@U;H1CDL
MN`H'=LOI_D*[<X7:5]B=0R+^:WC/9:I0%VR3X-:%LQ#8DC!>VL.A:=M<F^#J
M`(``RKKOFT)OE8R'7E4X.T!,Q*8^&R=<HZ^\2JC"XDF'T83T!<0QP8`OE0L4
M44OJX\+M6?ORZ%>&*P2+!$\P:$0/VYF!,D7D:,Q]=\SHA%%M+P6FF@O@F^`X
M)L1$OD2MW'7%W^5MY73Y2=<RI7[&B0/>H?9$ML$B+\M4+HG+TC.X6?Z%'.."
M`]T>]_JUR'&N%3R'X^*;M";L;DY9O2#RI#7Z3E>N`50+%X9QC2YG<""PZCXE
M=VZB>,-R?!$0$F>D.3\:2FU>@62IHRI6%(1@K+*`/9#>2C<`[J'_6$G>^-`8
M+PEP6U-I!/CE!3*C.XN&=<:C5F+8>)]&TB!$QA<;?"^Z/BZVRCD(K"[U<XL.
M@I\"G<#+ONGT>IQ3O.R:/="5`:)X#@S!NV>X24",.@)`#;`]IDQGN"3<V.#7
MK?@]:<XBVR`Y(EO/H+Z/R2[$PJ=>`,@"ZXJ[",@Z?D::=-[Y!M@NJ([Q,]07
MI5LM;TP2,0/Y`G)0W>C]0H#,,W0%B"XD1"*Z6]`?;ZEX*^,GY%I`)+\<2CZ'
MW"2O9J!Q.O'B<1JCGC)B?OB`+RWWE%ZS)/$SW3]G_\/+BD=(3(-,S`+4)'%F
MX<2;>EP!*1K1-CP9A>GM'>W.TPA&^BJR=Q(H]-YG>Y'R9V,4SX7@>9;7ZUL)
M:>G7JHR*N*@K(6R37,'(^2<>Z`BID-G*[I">:!)@'GY_%()N#J>129`873!W
MH0\"77EGA+S@TE-<Z-)K;)E.=V"BBXDD&/[:-RUK08KA7Z772+B)XIR?B`Q.
MR3'@S4/IVR80EOB.X`U(<HF4WR`"9S'W(Y.S[$JNH)P$P'-(\"T<0\OX$[6D
M,?/N2?_((%+:OJ5<[O`;Z"3**\]]SAFFC70.(.ILHN(("341\]T<:O##.(TB
M1GH6U[^5JNUQ5("=F+BH91=XF=(=\<S8O1>F,:@R@KP6N'/N,/M2\_<Q^I#_
M'K<R!44(18.>ZIJ6W3%>H5XE#]SX*\"0A<M?(JY:I__F*O*`(/F]%Q\.WKS6
MK+MR(M<U>3P6Y;GDGE=''<K"*4RXKD8"QN1*L2F\PH_"J'T67.<9^0S_S/S3
MH%`/NJ9#OGYQL424)N_Q%K>3B_]Q[C.-8HEN'-.Q.GA/LE>2NR-'NQ\Y4R!^
M,F'(D<@B)@M*7F2X/QA,!.)<M2S%0[(@"%[A@B/`N+Q^9W3Z[0LT'\K2&-;.
M)\:'/?SABP94K(RH#S\1XM2+[X29D"=G3QVYS'ZX1-#'=XOH%3$QY#W"Q,</
M,`B@KR"88YQ$Z3CA5UE8E_C""1ME(972PU8\;_5YDP(H#*<)#S8HK>9/$=BX
M1/8&8I4@$&8@\:E,B8&UBC$*0\4GR'\P=;W(N'?]E%4=-NS7FY$\`,8_=OUQ
M"M)!FIS"5B<0<F^9IA0K)1MW"CHS5Z(%@LD9AI5Y+(O\1@P>",18'I#W$47K
M$*D&1L.BE`=**=R*PJ%K]<U^1P2;,O)%<N1/R?6X6!B":3MPQ`F.P]O`^S<Y
M1?PPCE'!+IPT/$,OH6?;<(Y]<]#KE/@HU/$O(K*$!`*6R+_"84_AD/'2C%CR
MP%@@G`)1]$C1.B4)RRX^?`;+X9H:ZGDDCEXND+K(1Q9M<*.QO[,,CC1@RLU+
MDCXFJR&O?XFS46J88UIM6ZIA>7_5@C=\B>KE(16"=AC<,A7U5%%(5))+-%6"
M86!:G:[9&?261#4WLV.UC!]"2:7Q*ARLI:YHLS>TS$&GOVS/R&!T.S=W`!O8
MN%+7U%)="H"71VR-9QBMW>ZXGP=^2GF`$-S+/"O*M"W@SY2&H#0!*LQ7NK-P
M99P.&*SV@-NO^"MH=PA+WG[5K$PE?U9;FA2T`68?X(MD8*P<9@U@9?<)?_S"
MA==UH`JVML3&RVW8JMHP%[MQ.HLS%W,IH\T;A))_%(Y4!,)*;6MQ#FO:U?EC
MEXJVBH^6.2DH!BPXX@+BR=+%;"TM'4:DI%%"F<AXHYP==PJ[7,BF*L@;KBOS
M""S&6^%]6:J=J0(H'FH&S/#3V1RQ+//2*I*E+D5&%(:2D9&BK`E'&/TB_5P+
MQ^`&9;1!MY\+X?YK^39%JSQE"P3O+9Y/,<L*=JT:U?.@D/B5,BNF:40(F;!X
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M4I]4*XM+3$`\5[&>(0=1J,AR"`4M)@\AJ"<!^DN$QE[*1I3JED.ER?6S11;3
M%31,NB:J#P451BE$6:(B5X,XYQ$P<DCR:HV'`192:U`#X2#S/"^E4G%77?[,
M>04";'G&/7.I"/*0RX=%MY1@-\%(!2OFXG&764G%A9G5(8@WH59(^73P=P\I
M$35!4J?"J52DT<U'9)J01D8(69Y>#9]Q-\&<[^Y/)K(BT3>=B.2C&+8>3Q\+
MJ.!8]1^E`S*/%,##A/D(*/Z=?+VPK1%/82R#B<#@<$G7)D<G13#E(O#_X$)/
MNUNL@A!):=>4''Z%*>,MXR-0&&B4\S!FRC-7H#9Y&EE02GM#%I2"$R5S#U/V
MP@>^'>[;P]H9L&/@CSQ/';.B9+PM)`\CSUV*0W^R[%1>86*34C>%B_UQJ;;+
MKYLB.MU5Q0^67)6_8M*M5+'A9_7]<8ZUX6(Z%8G[!#;6:TXJ_+).X6POL!3&
MA6^ZM_`6/XS)&/4F`@/>#&X$YH,"@Y@C;M0Q2J]HMC+IN(L&?X1,0!J&>C(W
MD*4`<B$3,^^O+1RS<ACGB:?40UAAM(IX;[=C]CI]:>:&"X:*;?;[7;-C=5=<
MP9?MEC/(ZAF$#.9^=!ZD`+N"!6SJD3-8.ZPIHS(HY>?#-A,]L]ON&)2_AJ$@
M_@)>P`-[#6=<'UZ2"+:&$YJN4R'-C8<^"JEN-BVF\ML42`MFON.8=EOD"H#=
MU.DZ"XD"<9/&U@1W-\O8D^I(D[FG/`J+2MJ"-J8S>?E=P3S72^$3"EJED[/P
M4JUN3$HGR>$KG4`]RP%>-U@:9;DI+K65HB;==EG)0$>OF5!Z%Q4W<ED$3-'W
MN&;PRGM-'\7>3]`0L'A4U]X*(4)/]UB\\N!1'B*'X^90Q&H_RF'*/=CAF+&)
M<#D7SO-5_%H+=R,>U4&AGN%CK51R!Y]G*4Q*'U?I"C_F0C\C;4'(>1E+$@Y9
M+V<)4#`I8F0Y/FK^/W<4WK-<M&LMNRH7ZP*K0G-TYX]X@4+)$R<+.TFSU7UB
MQMM'8Y8FE!^7I8'EG>O+%\A"C_HBF1/C4\YJ!LR$@8H'Y]],!GHW*T%=*!DQ
MD687H17I7A*0-7"B^VMTJ(5")4TIN]<S![:]F?HBRGU+"P@6`_-+7BWN99FF
MJ/$SC"'DMFO<,9\K(R/,4P8CQ9U./=\31>XJ'7(1PYF']Z5M`I,N\]QRKE)!
M&R:M375<$?<NRTH461GV]B/`?@_O(:OT`[X4.&A,;06224LZQT#]"Q\"SJ/>
M1AX\_Y9%@3?^"S<[\>#R)Z$J!9,IF57'G*4HJ@H2G4+1OEMT`WW+J+:3T\9Y
MI4A1XUZ@MP)&>3I>UW0Z5BE6GXT8SOQV2!%YQI"7RU*15698WE4BO_Q.^T:5
MD-9%L]-!TLX+QX5WE$O`1"L=K):!R@3@%H!5*)\;F)DYD//;8'<:0Y,%*OX4
MYTO:M(3D)3C0DW^5$9ZQMT+<=TEV2,D:!(JD='B_A3:>:3G+<C[*&&5%E=5Z
M3%+SEE0SRF=SK131*=H2*D_GEP7]5NJ6RRH'>=YAT4BU-.=YH3+E9DGQ2&ET
M0TJHHCA'@N7N!OGJO+"356)"[].7RTD?=19RBV5B;C`8R.C7HJ#3\2'=7[TW
M\<*JO$!W"V%"^ZA8I<Q/7+H%S#X</F.94N*)62@XU+PP7#E;YHGI8>*'2GH9
M+A9LK.>'.8M4QJR]6D5OM&(+M:P+V[56'//A7ZF7/*)$$/G`\;?H.W:XBT_8
M9,W+>46NT]E,6)PH0V3>LBOREG.U)EX`W&^F6K[(I!'K`N$LN$Z\0SE1BF>V
M\GI1SSRPA7P_GKO8.NEO+]HOZ'?1V(]^%P`]>)/D#B%J__+&$)TPJ?QW'K/?
M#/E315MNM:+J2+U[X^F-![3D\;%=+_9UW@&X`'P&?WMA*^1MTB=_3#H>+?=5
M17^NN3[#:WODE3GP/NJ%BS\9L@>X:Y<B=O)!1FQXM.E9X^*[LJ[?87,4X%&H
M(7WVIJ0!_!,%W;-"T*62SY\`'5X0>V/C#[0/]KT#?[.N^WL;7;4>RWLKPKM@
M2145G'8U)C8]\_*6N5N^0&MS2V\8=OKV(6&HU68/#$*SUZ>RUPW9SF[CC%=.
M]7AC".6PT_[EA0PHBN9P2W<L'K-_V1E7"@1KMW>)V3+R9>)MCMGN]LV>W3\N
M8(=#S\M]8*7=<GI/!2'[I9=^:_A4$+,72G',SL#!@KI#8:66:I@:>"0ME24<
ML5;BJM&YFKTV>ZVWSB48"[7W.Y,3:=A*L]=FKS507;;TI"NV\XX:@OKK6'C[
M\"EN-Q'W0`OLB:DMF11Z+&]K?6]+@YP&.<=!3GUTNG5\]DO,YYJ<W0Z.LN.J
M`]NX-79P>IV;KK.5`^M,3G`'9U2]U+@--+95#OF:D)W5-QW'-KOM)='),Z<^
MJV4_`_[1:3EUW^3V_,,R!T/+M+K[)=+ZJ")GZ+=^I9H(;@G"Z[I2&R;`U_TJ
MU=:W\ISV6F\%I/%4UW:SS:UK]EHK#:5Q3V^_@*82=4%'[=B;4T"U#VV)DG1P
MO^(."I3=V2<2&B]K@YP3NJ#KDT&^A+74Y!@MV[2&CMD9/EUGIM7JU=[34EN%
MIE8'V3>'?<L<#K<05C70V9Z>+QIXAQB:]E1)SF[UMU`/SXUW=%JU]Y]M?8)=
M4`/V'RZII49RAD[IQI?4[+79Z]GH)8V+NK:;;:Y:L]>ZJBZ-MWK[!9IDZOKY
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M;*XIA[1IW>55)WHY347-AI.C1`/>9]S-MFND,1\D@Y^_1<Y^`2@,?0#U2SAA
MOC%)(SGC;5E+:J?0F-IPQ1BSF"78=#A1@Q]Y7]\1\\.'&G2,SJ^[7L]A>O7?
M7HB.GA)4T0EJ>*H.Q!OH,4=S'^RO9^IV.M49-XE=GL/V-#>\AE+T1-(7LZ:4
M0]XY[L]JOKX:*75ML.?\(E)Y!END`3[%CH,*(>UN@Q`-(>V6=;!FG1OR@-V"
M^3GH-I#(W[WXKXMIQ+1YTCB9J1HGIS?7*E09>`@_WU2!$V0P&%Q8+2'X\-'L
M!#?>W"_/#GE]&Y#7[C3(VP9Y0^O":74&>T=>;540[M$,?3"`?3"QG]F!=SHM
M>WC1Z;8&P^:^;(6^7N<"_BD<F0WZ-D*?,VQ9SD77DHKQ"1G.:?2=&Q;-C%=>
MP'U*A^YO4;?C[U[T]G'L9Y11MX6Y<T9;/`B)B*#906CD5$K)MNSB/0YY9L'$
M>/1P&'2-24%HDUL7O=1:$C:;VT$(9W&T__SUL*&J)4,N\6UOW9A-WH4S'/5)
MKZ1XVS?^SDLQ0'(?P2\5DM$8XF&C/9H[>76P9^<HYJ419U,XU>3-E*8@8J3+
M;K>',B!F&U>^&\3Z7$X"I#";TU!S.>$WWP\?XM\.C[5#Q,CR?L=F+N<1`RD5
M<SG%!3_P-NJ%BF8L9S.6\\S&<IX\\%\33:RI-VOVVNRU5M9[,]:W(<]FK\]V
MKQNRG6./]?T[>D)XH7*<DMWZRN*!!?'K:F2<RP17JVWV!K9I6ULT#WJ*6436
MX;.(SIM@^JTG@YB]4(K5,:W!P.P,MFJ^VLS\/9XL>S6T<6K3ENO7>'""5?NV
MG[551)[37NNE=`GFT;2BJNEFFZO6[+6N+J2F%=7V"S2MJ`Y_6QKD-,@Y#G+J
MH],]C;F^5MOL#MNFU=OOT-2:V8O/8##G5FZJ,SE!JV.V>WVSU]FOW7\"16X#
MG4WSR=>:\+JF95N`D*<\3F%0^\WM?H[#UM.=[6Z9?:=O=IUFL&]MR.V590Y!
M2^H/MAWB46?_=#.YJ=GKN>L?C:NZMIMM;EVSUUII*(U_>OL%-)6HTS,M9ZON
M1G4<['M>CL4&.0URCN*2KD]*^1G,^77`<'?,SM9&XAFX)IZ)=_KI.I?LGCF`
M^VQ9^]WBL72W)^B2MLWNP#%[V\QG.!.:<UI.[0-V^W!)/UV^WS&'=ML<;C/,
MX-QTD7/T3O>[9L?>UHU;ZYY<C6^EV>L3T$7.Q3W]:OO(>,-&FKT^J;V>0#MI
M/-/;+Z`QL5Y[8/:W862-:[KQOC;(.1/7=#.XM\;S(+MF#X>.=M:8;+2:;)[.
MC#^KU=FJ$+WV&-F'T[VAE7RJ\L`<]`>FY1P%+R?0=M<$NAG<>TA&;9GVP#9[
M]E&F0Y_/Y=LJB?X,$+([G^ZU]I+S4SO,[#)@W;$Q/_PH%%/"I_<\MW>7EM%/
M;%V_JL/8S9T7&UXP]M,)K/'*>VW\X27N%Y`\LODR0G;+(]#&B"4/C`7&MW$2
MH@2RV^T!B:B%MHG4&=P-#%=UJ`VG1A]TZ:'9MVWC1^`EL`/X#(R?\9UA]<QV
MNVT\L(@98_+]P&KSR(.7)"&!,`X#$,PQ-AU_%:K6T+3,T'2Z?;/;L_@HX9BF
M"F,W\W?9,]^Q7_EK$W:XN$6CN+U_N$&*/=)%-2GND&"0VW;$YV5[[,$-PJW0
M#A=`[?=LT#2Z*P$EI`*L`&P!2`*D>`Z=#-#%8MA2,+L`2`<.@@/2,G!0<\*B
M&6_W#LB>>'Q9^"Y"6$85=%H1F_ILG&03F2,V!Z'-9J#C*-@Y@<FAS('J]BW0
M<$^Z3KU&*Y=#4#T?H'0J^):S"]:9AG#E/B**+Q_<:**_L6SJ0BW'@KL9?(3G
M?4WUQC'>QIF.\-;'$13'%="K%T9X+QE0H$_WWFB03XG=M+UO*C-KRLR?Y?K!
MGAR+)?W6]</B&%6S'N02;_,^>I[A5+"V=H"QIMNSG_;VK/UM;]-^^`#B2N?#
M=DZ&-:[8&L-Z_0,'0M?QT?L[S4/M=2^L5K]ZNN-JR(L#D<X=(=:%W;*KYS4^
M.X0,$2'=ZG'#FR-D'US@3XS_[$F6ED_'/?>3<YR6T\71M_WJ*93/C)@[[5:_
M?]'IM=H-PY-4TF\-[0M`S)*9V*>YX4>3\TN&U)[[Z78O>BV[N\/!+@&[0<N3
M0TOK<(@YBLR7HR)ZORQ&U39B"=6#:,O6<[9NG&^5`+HN`<A7.+]4A?>*4TXW
M@F!1RC6[?BZ[7A5C.K[S;[FG>'N_;M%K_&W.P,8'+O$YC.-W;A0]3L,(7QOG
M/,"7\;=IYO7];_'T?U\G;H)3?#^'P,_^D49>//'&N.H7<K>^,-+`XR_X<?W^
MA3%A8V_F^C&Z*G]WNFWZ3[;3:EAV@]H^2ZBMLX2Z2"&?T),4N/YW=L^"E,&E
MN/?&[-/WZW6@[F\.-4V@OIS<8WA0W)+X8QA]3),T8M]9#!KO^`ZP^![@\<,Y
MW2(>7O'8L@TM!=1N#ZU!>RCF7V^[^L&V8*^Q!6LP=/K=/>U`'M=[-F51Q"8W
M[D]@2"R)_Q[!N6V+9:OKV%:[,\C(H?S]VT.Q#J)Z5KMOM_N'`\):`XA^9]!I
M=S:%X3N?SWWE1LGC3>0&L4O\(W[OQ6,_C.&`CQ_^4TK\2/Z0X@]?O]U\,"S;
M$**Q"]+S^X?/ES<?WAM7E]]O/GVX)E&9*@&N'C_(1/0,P+RH/MBJR[,T:-N?
M0S<P_IZZ&/%_+&"C1G'+PZS[*3"^(">BW`53)1Y0F(<BQ$EHN,8HC;V`Q3QT
M[(>4WA`QGG7PX"5WQD<OBA/*PH"'*`/">.FTVY2;X<.CF'XPAA=Z%"@6:2@@
M@^(01)IQRY'/F,B'<.,['ED%(.#/(O/A7RG60K8(AJLU'_6]&8$$NWAI"7B8
M"VO3.^=1B-;:Q!@]&E^B%NPB\/[MA2;]\L7S`5V(5'SQ=X80?W1GGO]H?.9O
M)4C$SP8R@P"@NO/F+<`_,_#F71M#>EIDZ,Q"6'3"$M?SX]K%Q8]PRV)C"AS0
MN)Q./=^#$XJ?X6W[1PJW(7_9/+`Q*`$KG,&/8?1H!"$@QR1@PBB7$?25_B+S
M++(DHWGD!6-O#B3OSL(4KB5<N)==3O%:YI>Z!`]NC+%:NAFN.H^6H4%HF[@&
M`:&^P2'CMP?VR)-"X!4R-<KJ\J9+QJL07G+'?'6WY'6BBP"0$11X-_"+^F?R
MH;<?`1C,52+5B2/C\^=WIMB)%QOA0\#O[MO(@Q>_!?W8&_\%]]68,9GSA%@:
MA:#8XB\38"``:$1Y5F$:`:>8S=W@L65\*V9WV?ADG.']2AT.`?(U0\/<]2B3
M9IKZOI9Z];)K.AT+_^".QU'*>2G%@I_)S0=*4ME"G-X?F"3USB\+U$[0`"5I
M?)C((T<[^$%9?ITBZU>2BI#)O^:R*8P\@-7%G";@ODCF^`B7>J)'&&7DQ9S6
MBX`5B!W(;08Z/%XT)0(!;+HTZFT+MZB$CN@JYZZ(V#;/]H/[J5.6J9/68#`H
M):P<LL2Y=WIOXLK5<96*:TQ0\-V47@XOSO,DHPBQ#K!E=JWA,[X+FA0$D^#'
MW+B4M//L1.!EK%0YI/M$9<(*9CUCT2T0FKI<_#;@/9;DAE=X`O<+%#%K8&:\
M):>S(J(O<HCFS"!&)]\="#Y0U8#]WS.5YIC/G>:"$SD)SYKELIA+C7?A;!8&
M!OD+E?!.HSAU.2_0M@&\"AYFT;U0B_';5`*J?Y]@,D*1O8L\[L&-4*L%>?P!
ME54-:"Z.<5-P8>_<1"9JN@9:FQ?I'+5J+YQP30LAF8@MX<_R.VZ&%=`5/!\0
M"<IID-S%^+6(N=.$YTH_&@]A"AP*."$<[E\,-S1V4\$J070:L>LS39PB8@C<
M%JAYXB4D9GV&VS.Y]JUMR!";P140%PPX!RPR\>)Y&-.;26N&O098Y/"+W(J.
MDXS3"?3(D\R=%+Q59$"7'TD:(#C5AT'YX_\">P.WA91#<$S!V`@?\`C`D"<<
M<BE"IV`:0GU['WDC3#O]EB;&%?VI!6P@#`KHD9M;_#J7(CEJ!D3AS0'1EK!G
MQ$?7S!T_TKK[<HJ0!+A*02=Q8W@2.*-P,I%AZ1W:5#KIJ;[G+`R]8:90F?#>
M*<9.=@KR%U#-)NDX4;KB>U!W%G1_J>07=/S,9B+[B.3-2S"-7MI8<DX+OK3;
M9J\W-)$_S!DZ8YG_2/8&7$7ZKF7:??'=MI0(L!KS[C$VA(R%GQDQ40`P8C/7
M0R,E3),X@>>(59<4E0JU*MNV#L*3NMR5R087#PQCDK^!)(AFKI^_&44Q?H7G
M_1.U]LB=LS3QQIF%6+@IN72$DVXFC]=#PE5]N*#+?V2CB`JN[*&\;N_"$(7;
MNQ;\!-9#`*^\`@K$3(9$2/J)X</;,969A*@0WD#_94=AD*$.=Y#_T>2&AJA<
M(BD/XM=`>0<7=-$\;QE_@E3T0ZQ1<;E$YD)5\,>B]U&`$&9V"G=#6&!3D1H$
M6"+%#/Y-'.7.O2_HBVXY@0F>P4]15,:!YD9ZB72*@J8#HCA.0:_1WN*2S_+>
M8P]<T<54D3FC?!'=#X&>4E2;O"1AJ`D$L1=C7`X7*'V$^S_?KUF>4\I/9^Z$
M%%`A:V`E=PZL]:<W`^8%6C6QNDZ[HUPT+ZTA]R/E&",!0FHF1Q;@H9*SZ1`0
M<^16M>3%:)G+0UR`IM/CB[]TV@,%$H>(\^",MSYAOKG$HIKPZD'71VE5@5U1
MUYD*%ZQ`-NJ_/JC*OC%E2*[>;(3433>+9!D1&48`?%CBEC(B`*0$-6#=@L&_
MCUF`-Q/.)D[G<S@X=1F*HE=*SI=V9XC-885`)6CP:UQW)IK&]4MJSDH*+^UG
M>?8;"](_A3'#N7H<PQLY2];5S6(4[#2BZJSDZKK`YCR#_!"D@8FGH"2<E?,^
M&&6>!Y2I^@F259S9D._N7`^6#>2S)5YP$$LNP1"$P87R\:/ZZL%7YT@)K3/`
MZ4H"R.+[&T3N%\J"\21&Q?+B2SRZ6V)S;Q^SK^AY9=3$E;[,3?FRE(".EA+`
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MN/>NYU,[`1"_X71*?1`HP0_/C3*?<7%YE'<`\"UFVCA.<W@;'UZ)(4N'&2>4
MEU!QD"K%MN0@NVL<I,AXBM%0SAT@NBA`",!#7GP'.M.]S!@W7`P(8$0!>,&_
M,%`L=#,*BF;9&12;$7<9R05U.0;6VHA1@$5\A5MM\+(H<;T@>91/IEAV^F]7
M#QKDM\]B'H@E:A06%0'-?\:Z&;31\(LQCPUY?S'?NPM#$5@"_&*,@0`8P9T1
MV`'=4<4^2L#GKAMT8U!L!W>L<,NH-&;,3*S4N3/F8>RAL49G&F#`!GXQY8T1
MH>,[+P95%:$%0Q4,NY@[1O!"F0;[B?:>FX5J(B_^BY3B<,PU6?+EH*R>R;A_
M_GZ*5SWCZ\B]@FE4<IB$4C`)1E3A;&!\'R-GJB^2M.K'PL6.YX5'CRT@"/M3
M+X![X,'9T27ECC'AXY)4J^)GO]7-8F\:Q1R]U<CRMB+YPQ08QS>?2Z.8[;=W
M%HUBMM_>"1O%'*PX7)82&-P@-,`B-"Y)1OZVL-NUL7Z8TM_-'CR#6N9F0S5K
MIR3KJ]MKU%?C6)+*6_5U0<\7J1''K;Q]N6I-JUM9<&MUS'[?,;M.?^5+=B_\
MK=G>NS00<-"K9OA/=NO]SL#LM#O[W_A1FR+E1@QM<&^_<_"=P9OWQCLJ!#J,
M6K*%*K():6WR7HWJ.WVSNYF2LSV(3P]]UJ!G.IU>@[[MT+?=ID_!A3;1*'9E
M2#=A@B4A4DG/W.W"]W%0`MFO=FAUJ9-\NS,XGRNR7PST3*O=-^UVM4;UQ!&P
M2KFHR05?J694VP;;WO,_%OWRSXCWO]HK;UCL</>$,;=/GO*L$+<_7E1$6WV:
M0Q8F3>W%+6AB$'-MK.UEJ-3;=8=*51N^&[XQHY.+]L5FF]V?O&YPU^#N<+BK
M7P^\8X60JS.8C(DWG6+)+6:?\[17S!&7-0P8'DX3+$O_T;INJ>P<S2C#_ODR
MD4)\/&)3K`S5E^&3=>:1-\/Z%KXFHTR,B,6IG_#D]PG#*C)8FQ=T\-0*2B8(
M,&T"82^)7&-N+I:DQL8H3:A<E;ZX"*K\WC-*07]2-9E+*BTH^P7H`O.DD<SE
M9"A.XY@&D=(825XT1>D-@CXR"B=*QLP*7OJKI4LP(%<J7\@HWL-L%I$C$3<9
M$DV&Q&(,O1FE<SX9$MMO[XQ'Z6P2^UUZW3XN\%+))RN14XO>R]4Q0:?;>K(=
MIYM='W#7)W;&KG%9J<NRNJ`F3]">*GT(_S!B`9N6!((W/;[]NM*[K6I7Z9H4
M>>H-=,][`\LL]*/=CJ,-D;F<H-)-%B98H65E!#4[GE>.W:KV[I8[<NM&8J^L
M0:M:8SR3/6S,J1:V4-^8WM(K<\6PL!EO##40Q2HZW=ES&'6^GL&6P9*KN$&@
MI5JK>H(XL^W61L9P@S1$VG`)P]P!:?61U=O']*Z4W_O56Z[3OB;G<!;BVX`I
M'3?`LBW!'#/2LOX]:W#7X.YPN*M-8&_IF*ME_2<6>IJHD5@+@T]P0)(H_?18
M8?;5T=I8-!6K33RFWO&8IF*UJ5C=<7M-Q>KIZR&;#=5]0W6.6C85JT^W;+.I
M6-W_QIN*U;J[^YJ*U9W0UU2L[H2^IF*UJ5BMW179+P::BM6F8K7BGC<5JTW%
M:E.QVE2LUB6ZW52L-E67#>Z>,NYJ$]CV%\/96X:H%R+=^9D1<9UBV?CFD?Q!
MF]/0^V]]4,/UC[?7'_[OCP]?;XP/?\`_CS:MH1XEIUR:Y414N]7U`IX-$!C_
M<`,::M=3/>,[IAKCBLE8SK`X48>/>J516;<X@(>/T9'UP'R&O!J]\U:.SWFO
MQN?P@;&8$D!C':Y\/MU>UGYZ$<VY\[#\&-X[P@%;^`39[OA(AY<K2R!S@-"4
M<SG+%U:UVF*\A(M)#@;[R:*Q%U.M\YCE^LSSHF8_C#'<P/\,S^B3@&D-WDK_
M'@?ZA<'"-"T`[?2DI#&!JMN;GT6#Y_F)YC'S^7A\7@U-<(FU<3#Q!X&]B5UV
M^VWM]MOB]L-9>_Q+_&TOC`D;>S/7C__VXM/7CR]^MWI#RQDZ<J[,YI#(G?A>
M\-=OTS!,</C\9_C%^$D?)8]SP#D3P]I?B$^C$$_B+DGFO_WZZ\/#0^OG*/);
M873[J]UN.[_BGW_%+[X0KY<+`.YR[X7?7:!I^=J["+?Z'Q\!C(MV^Z(M/_?=
M$?,!4?SS_X:G7AB_[O1J:Y-72[1<1ODEW&@L7P,_KL")^,:O4W><7,@WRL>Q
M/T`!"+%0R#_&+U^T[1<&"?._O;!V0X!5@5MK=]Q:%;C=RZOMP[W:V>35QZ4(
MJYHBK&44(=^9`Q$X`<B5,=OD*A>!TU"DP/@Y\^%SS/5BP<6/ZQ>_W]QY.`L$
M)VH`DW[EO3;^\!+W"P@9P824T)'M#.0455AX4#ILD<]J!#F4C5H'N=(W>\[0
M[-NV\0.X);!_^.SASAO?@2I#HI<DW!@=6CZL!K()!R>%R(/!&N;YT_#)-TUH
M#TVGVS>[/4N*[;F0N.^R9[ZCL^RU"3M;8VM23>#[X*,GY78=\5G9WGKHDH(M
MT,X6P.SW;##/NRN!I.4`3@!T%>X[&H!%])>#V`4@.H!\#@37+7!`/!^-`DCF
M8T)CF<=81!6=#MQ%,:97Y$I&;`Z&"N^`(K^9C6>AX;@IP88*%=\^*A5LTOK/
M7W/$?[([89?<B6P,8WM`HX1`G/LNJF:(J[GKT>#A.:-4T(E'@VLF?&1XJ].F
M`Z;-E@YFQ(&H.!$XFY-,.,?>(:!"NO0+K6ZU30&!NBDO.Q:0_#";')X"KEW0
MIFB(L-1-<Z\NFR<NYR39%:=0^!3U#/C+?_Z*^/5^PW_"K_]_4$L#!!0````(
M`%V)942CR0&ZRA0``"`8`0`5`!P`='AM9"TR,#$S,3(S,5]C86PN>&UL550)
M``/RH!=3\J`74W5X"P`!!"4.```$.0$``.U=;6_;.!+^?L#]!UT.A^M]<!,G
MZ=XVM[V#8RM9XQS;:SG=%BBP8&0Z$5:64DIJDOWU1\HOL<2WD6V)+'#]T*8.
MAYZ99\@9DL/A3_]Y7H3.-TR2((X^'+7?GAPY./+C61#=?SBZ]5H=K]OO'SE)
MBJ(9"N,(?SB*XJ/__/O/?W+HGY_^TFHY5P$.9Q=.+_9;_6@>_\L9H@6^<*YQ
MA`E*8_(OYR,*,_9)?!6$F#C=>/$8XA337RR_^,(Y?WN"G%8+T.U'',UB<COI
M;[I]2-/'B^/CIZ>GMU'\#3W%Y/?DK1_#NO/BC/AXT]?XXHO;N^Y,@C\P^=(-
M`QRER9?I`Q7D$6=IX"<WO2^?+B>#+Z<G[;/VZ5G[2_J\F/W&?FJ?O7V>4V%[
M**4=T=^?_^VT=W+&_GHW;;^_>'=Z<7X.9"I%:99LF#IY_O'DI'U"_RS)?PJ#
MZ/<+]M<=2K!#$8R2B^<D^'"TI8JGL[<QN3\^I93'GVX&GO^`%Z@51`Q)'Q^M
MJ5@O(KKV^_?OC_/?KIMR+9_O2+C^CK/C-3N;GNEO`T7[+4Z2X"+)V1O$/DIS
M0]1^C2-MP?[76C=KL8]:[=/66?OM<S([6BL_UR")0SS!<X?]2PUJ\ZWI%MZ+
M&36EQ3%K<DQARA;4(CK1S(W2('UAF)%%SC(5(^_S@>#YAR-F%*VUB;`O_BN$
M-GUYI,,K"=CH.'*.]^*U&T=)'`8S:HRS2Q0R37L/&*>)CE$M82-<CA&ARGK`
ME`"%.[,L[*4N_MF@Q0SB9#0?/;*ICT);2=WJ'IK@VTMC__>'.)S1>=G]FE$S
M[>%YX`?IKF)H.VQ"JBY*'J["^&EG,+@.#LOUXA%%+WK>"LT.R8&7+1:(O%"T
M@OLHH/`@.D_Y?IS1B2JZ'U.-^`'6*J]:+X?DOQ]]HSC%1*M#KN$AN1BQ7W0S
MPJ:<3I(`IEHYQ2'YN@J>\0S&D*#I(3D9$_R(@IG[_(BC/%!0,B-N?5B[H1'(
M?7`78IAZ9.WKLJ)!@.Z",$@!@T]#=D@.AW&*J6=]07>A%D-1VX/.7)Q[T<Y2
M4HK#6A;]$4_1LQXY0=-#<C+!(?-F-!*"F)&X]2'YN<R2(,))0EVM3VT5&"6I
MJ0[LC1=!FOM]&JK3[V/.BZZ(`<H#D![4]G&(?0K6+QE%"Y/PY2J(:.@;H)"N
M0)%V'("H#QMEW"7X:T;5XS(O#(@GQ.V;CWP.&P$U$@E-V8P+F'N$S>N-BF"L
MZ>AJBI!@S$D)ZHN68(RI:.J,G*#FIJ)J((JJ;GI2XGJC&!BC.KJ:(AHHV!*"
MAKPUC$MP!\UY;B#V%?JH8;>BAU,4A,D0$1:+?=,N!#1DS?OTJ@+LUVLM/G[U
M96`G7VI?KY<',J<EK,G/5X4?0%HOI]49K#\F`;*F)*HS*JD*,I2^`9YW9+5!
M#ML[LMAN,-ZK:@`5NVE.@OT8KWL7L*J:(;1-\:HU8Q!QO:N!RK$*N(=F^=;J
MND(7S7)^NC_GIXUROC._C7*YNT$T:P>[P]\LZF<[\WE63^2PV0*H'HII2>OE
MM#J#S?`%"+ND)/6=*U6%%T9=_[E35;ZK]=+03M<.>S%5NVI6DOT%:'[7#NIW
MJW12Y^E;]?TO&+V*9Q^%?A;F8V9`_U^@P,\ICF9XMNZ',7V0A$SZ,>OI9/FG
M[;2<-=7VCRB:.<LNG$(?-0N@3[8L<']*6=[DI=&?NZ.A-QKT>YVIVW,N.X/.
ML.LZWL^N._76F:YKUL/8+[`;LE3;F!1A7W&;Y]/.47*7)]5F2>L>H<=C9@['
M.$R3]2>Y@;1.VJO<VK^N/OYMN=Q?K4;77Q"B.QSF7_O;JEVIV;$YAEEZGYS/
MY6_+[&V90H?X3DQH2/7AJ'URLNX($;]@`GRB\JK%<<*VEEE'K8`BNZ:?DWBA
MTM=*-[&`UVVUT2\Y<IYP</^04O:,JGFU79Y,L(^#;VP]/<2IWDR45#!83@W#
M`I'<.K@VYP:45SD\Q58P.,X,PR&2S#KUYUMZP*E4U!8&Q;EA*.126@?(DLLA
MC?QAGFV[I4&VBZ<O-%+:4KE<!#65+<Z0!Z-D7A#AK3.T\L$)G:7<9S_,V)V\
MZSB>/05AJ)J0(=2V^$TM@E6481V2/?P8)P%=I8*G#CF%+:Y5BYA.:.M0TLV%
MLEFOT4D\?L0D?1F':+G:_9H%CVP1J(S-U%2V3.+2J5LO,LR43,UMLL7`[M&.
MJ3&OE.0[&.%;1^+:6%K4UH)%\^H$&KQ<+K<W/]KE($A6RV*1K3.N'IYCRN%L
M@NFJ,L,JWUYJ:'ZB`F,B$=(Z,/+XOLIPEQ*8GWO!X&B$M@ZD+58A,;&DN4D!
MXNA^BLE"=+U1P+^PM543LC:H5TELG7W1-2,F.$F+#H3&D!!K`Q%;-7-#UM!0
M?5B'I>`RLW*&L&Q@R8;3GI.U47O3R_0=V)7\'CAO7J*V9G=TE\%8SE=>(TJY
MD<LW-C]$%-?PN1U<F;#6V13+2XDC""I\2_,C'`R)3$SK\.C,9@&3&X5C%,SZ
M41<]!BD*M_A7K*,!M.:7"&#,X*JP#L4)RS2*\,Q%)`JB^Z3C^]DBR_,'2[6D
M>!0AM.8/2L$HPE5A'8I;T0$-/*MX7SVE>7<&E4X>,GU'\5\5"77E=F2"_G1<
MEG-`_V\H&4]<1K"0F7<&S\QSWA3Z^T>C28::$H,%F<Y5,GE3^L^-.Z3RC*Z<
MT=B==*9]VL!@WN$UB9-D3.*YRB,4&IE<?Z`0)ZO=5.4A'M?0_&PG4'1YV(NE
ML\XK=>,D'<U9'D'BT4E*%;"7&IJ?D?4H2*03H-`RO&N_G(FB^U6BCF*K1]#4
MY"C&8<@24?)2UR%UC)W9(HB")%TFQ9=J%PH&-Y#>_)B70E0>^94T8MV$,,$)
MINP\4,9[=/H*XSSE0(NCALS\9`&%#R2_=:CU\"/!?K!4*#6Y14S2X(_"-1!A
MJI6<R/S2'HH80';K\-K(MKRL.*".###C;S>V:$+D92@A)'+4EJ[RX$+)S=.Z
MZ&(81W%1+NU\KB`QG=S`LZ9);A`1F!\^6E!$.0YRV:V;XM@=DR2_H[ID='T&
MJSIXEE&8GQ>JHJ63WD*XE@QJ9P:NH?E(H3HX0EGMF[A[^"[M)TG&=N+86E81
M)`B:FM_7KPJ,5-Y#0L-?[<Y?,!K$*+K.$$%1^B+3-6LH:`=3]#L;%"V1P.H!
M$-&U<WY)O1O3694&]W<AOJ3+:W;>PT[PHM7K75<8I1E1YI_NTAL,W1]L0'<O
M.2UU3-<HB!(6A^-D%+G/3`=9D#PPR49S)JEBJUM/"@/WGQ:!"]:'=4B^+JFN
MJ!*654LRRO[K,<PEGL<$;Q7PH?(11$$((D1>^E2->685I:0:#G.%Z8/*&K_4
M_"JB`9W*UKV"%;*EB_KFE:0?U+8-SB%.(7M1I6;F!X"0;R[>KQ]_V_#<R+(R
MO*7KUTZ4`@+SXQ>.L51>36AK.MNBVHN!A22%=_`D!6\ZZO[WY]&@YTZ\OSON
M+[?]Z6?G3<^]ZG?[4W-I&/SC@@4!?X`+V.UX/SM7@]&O)K,P6&4;*M&8Q-\"
MJJ++E]L$S_K1QF]V_#3XILGGK]+'_YW&+A-*18C*_ETX(QW.!TCV*-SY'/LT
MS+_!Y!Z33C2;8'^9Q[HZ\!IGA.V>I-/8?<9^QCZB$PK]B=!IQ'WV'U!TCSOW
M!.>#J;-@UTPE^QPU?9<5WF1'\&M4BZ51Q/;9*NP@V8K]X'V'MTALZ[#9/N@>
MS65/<PH2^S5T%FP;[XL?3#76(9H+G._)Q:079W?I/`O7M0#D>*JI+-B;WA=-
MB%JLP]*&;<M:]Z3W176??<S_GTK8L'&]OY<]Z#&%8:,H^APF6R](\DEJ3/`B
MR!90CRPDA<']H\UP@Q5DW5SN/2""+Q&5E[WBAZ-$$P_+VL-`?&\SB&I56(=<
MT>96I>:C>TTNA9H*O'UA,8P0O5@'YCHS9+5%2M?>O[+B^S0*I(&AA\FWP*>Q
M!.F&*%@HT*W8#1!NJ[>K=M)<_=M9M:?<M.W=1ZJ2A&/\)(E@Q-ZM7/[;C_AJ
M[LIC)0`U$$ZK-XVJZ,F^\)7G?ETD7GE0H2$#XFKU9A)(,]\#H/Q3PU5P%5$#
MX;5Z=ZF*GKX;E%_%WPUGCAZ(M-4[3M5T]3U@72H4NXL7KEJ.T>H=);"&K`NR
M2N5EU]6*E`G_,@H@DE9O%NGT\9V,3I+A6;%P3''*`15WW+]GH$58O?-T*/U:
M-_0E;NFUA.2.1J+J!9R%\5T9A%YOUH$OT<+R^N!^R6+"/DR>;J.7/.%O&G?\
MKUG`TFVA*0L`4FN3RA10EL^YH0JRS_FM66<G]*O7;_1H%AI;FQ=6'3^!$NQ%
M;&-LTN=F*@Q+11_69H7M,3ZU*K,/=HD2-B=`>_@;81]FLZE\C&?YG8_7`Q!0
M[5L`J;7^1@$EGU<%4Y!U4=,VYP/V'CUEFRX65==;%"36NI[=H!0JQ&H(<V,;
M/>8+?/<9$S](L*(4(8#46F^S&Z1*!=D-[4-,4O9NBCKE44%B;3KRCE"*%&(U
MA*^N89TT4-5QOM)9FXV\K]<LJ\9J1"<XKY@^1H3=+82.2Y[*VBSDW="4J<5J
M+#<F2%C)X=%<5TP>0FMM;O&>HU2H(NO0G>#'U4)S-`<&MPH2:Q.'X5AJ%6+?
M,GN;9?ALJZ:R-GMX-R0KS+86@0E[\%!.86_R\&XH`I]#-(Q@+B\F03PK'QK)
M,531F-_\T4O$WUBO>MQF:36?0XFNVOC=0_0Z-Q4.);IJK%OX*LWB$46O\5JA
M.,@_G9;#KA&%<9(13/\S_=EUNJ.;<6?XN?:")AY#C;R,YEYP'P7SP&?'`,N$
M(ZK;<1P&_K9F"XS_6&;<N[VYZ4P^YW5:^M?#_E6_VQE.G4ZW.[H=3OO#:V<\
M&O2[?=>K7:YU?JM$Y^_+K/>'']WA=#2I7^.*U,QM%MLG919'U"XF3O=V,G&9
M4CW/G=:OQZO@&<]4;+;+;%[U/[F]IM@;$^K(@UFY,EF!P],RA^.).^[T>X[[
M:>P./;<!6Y2<@1?8/.--<MH97O<O!VY3VMPV35'F28'?<[5]#OJ=R_Z@/VUB
ML`LCN`*S[\K,#D=3UW/&G<\=JM_Z9UGY"VH%-G_@9E1!N:L&['530T[,)N>Q
M^D/JKUQGVOG4`-I;JRZI<7*N:>(.\F);X\ZD$9.\S!*VS$^Z<>33T:1ZHZW-
M.:/+6Z\_=#V/U0GKTL&T?I:M_NIFBT605WQG:8C+(H/W.))&`*><CZ)F<-.?
M+HN9=88])@#S^^ZP$:?OX1#[U#1^R:AM8!*^K()$%/90BL0B</[+<P=NEYG*
M+[?45MS)X#-U:<,.E:`S<'J=:<=Y<SOLW/;ZM$W]!>>\["[!7S/V?@\+:"0X
M<"[.N[WTZ&S!)F*7!38-Z!X42"H#RE/.!<(#2N?-NNOZ,=G$EE/F<"2R<.YQ
M$V$Z;Y9T]3/*AYHJCCD?*0HXFV-^*_)4<<VYS.WXLSENBX&HBF'.>9;"T>9X
M+L>E*JXYA\I%IV;,>BM,5;'/N5AIL-J<&'Q0J)#@C'.UXDJHS=G.)D94<<UY
MU^U(L3EN%8&-BGO.K2K#FP8M1QGGJ"3B/:P^VFD0)+9)UF/OHX?)D&4CL-<F
MQ8)P[G5KT\QYL^K#V7321*`&B7]@PG&>N$H<9$#V34"T^FZQ5)RGWHJ(5H3_
M,%CS>".$\B7G8BO#;Y/EC%RQEUD?\"Q_(AC`>*F]^7,@D>(%3Y')A;4N_6'#
M[@0]W2`Z0].9&0)-L;GY8ZHJR(A$M0Z8]97<O%K-*H*4XR)N;?X(#0"+2E#[
MCL?X=:K2D7`K*/%"U0*?D@NVE$AK;:*VAZQ4M5JABA^'U@P(UD$%>O,^1:[X
M[0)6E552?SVQ%4OLG8DL9)$C"!1!<_/>HQ(&4H&M]2'+-1?>-A-EY*BC,^]7
M](`!1;$5N0R7<J3IBDP?!2BIS%_M@*,&$-\ZS'+IBINK,$\JH3%_>P.,EU[T
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M@9L&CO([)DJYZX\"5M]??$!%O<97DYB/RH``Z$6Q=%-LQ?1'Y.?*@`X5KKWY
M.&VGH2*1NX&A$H;Q$]OQOHK)KP]4S`2%F/J)E`1W&>WD"JOFK=S<JO1@R=XR
M<"!5UXVMXVI,XCE.V(M]*%1#6K1+*9TEF\Y5QYE&#XVYI@&Z6V]J@/R2J+TE
M.\^5G))<[L94WZ4M`ZJK*<E?LH1&!@HR\X5YJ@.AU4+]>+"R/\GZL<ED@M.,
M1"R7>3/M)GE*7%N""YS<?+&="OA4U8J-'F?[;0_&.O<B`,3]P#LQ7X*GLB^J
MJB'[-NFV+RC#-E6X9.G"A64C&RDJ(23;7%RFGDZ*)C:[^'LW,$CX<A?"&S@F
M[AYH)9+@PYVC`D6R`Z93H5#O@#>E>*%.#0HE%H6_G*P2Q2#[8OMZQ]]+5D)A
MTJHDQL1?F%)*8-*$SL02<-OS:@G.&KT[")IYWW';\<5;A$8.JLHBB#D7W'D2
M<&[R[&"=RTEE61Y<79,X`;S95FYO04;NAJ5EA$G9ZE*+>)G'Y`D1U=TH<`?F
MSQ;4<$GR=(&*L6YUQ/'?C_*BN$DB3MFO@+"V)_.G&/M!#525_9B#DNJ+K2T<
MIOJK6A*8K<?G(PJSI6K7FRX5X!(16SCR*J`G5X>FIJR9Y*%R&",)Y)45OQH-
MX(O7%V#QHZX:F)$04EPA#"80M&*8$<$4Q39`TOU0K:J8I3**1>,6]##1=EL@
M2(X27E^6955WV=QVE:64FYL@"A;98OU$7"\33>2LARH=F+PZ5&2S@I#KC6IH
M!P;CC:IX")U814W5?]JE8LC+[D+VZ81R)2ZK(-")N@>#$<=^^%66U-I(1%W2
M2#FG\IN,^II&S>V8ENHWPCR@H!!BJ9ZCW.NMT&-_W5'HZ2?_`U!+`P04````
M"`!=B65$I+GZWI4V``!MO`,`%0`<`'1X;60M,C`Q,S$R,S%?9&5F+GAM;%54
M"0`#\J`74_*@%U-U>`L``00E#@``!#D!``#M?6USXS:R[O=;=?Z#[IRZM=D/
MDQG9\WZ2<TJ6Y8EV94F1Y$E2E2H534$RSE"D`Y(>*[_^`J0DDR(;`"F0`#U*
MU68=&P"[^VD`C4:C^Z?_>5P[K0=$?.RY/[]H__CZ10NYMK?`[NKG%S?3EYUI
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MF?YU$>P[)!N_?17_,=D4<X9.$.WC3W[$R<"SK2#262%%+;`%^Z^7NV8OV:]>
MML]>GK=_?/07+W8X1<(FGH,F:-EB_T]U;__5(*$:ZP75NO4KUN05131<4^7I
MN(N>&^!@P^`EZXADRD8TYAU!RY]?,/UYN=,F]N'_E.D;;.[I3/0QFT@O6J^.
MHK7KN;[GX`75V\6%Y3!)3^\0"GP1H<*.M5`YM@@5UAVB'2RG-,FYHU1%/YO?
MB$'LCY:C>[9*4F@+B9L_0AUT3P//_GKG.0NZA/?^"JF:7J(EMG%0E@WA@'5P
MU;7\NRO'^U8:C,P`:JE>WUON1DQ;JIE*"J;A>FV1#44+KUQ,X;'H.F7;7D@7
M*G<UIA*Q,1(*K]@H*NGONP\4)X\(99AIJ)**$?M#-R1LR>GXOL12"_=02=<5
M?D0+.8)RFJJD9$S0O847O<=[Y$8V!9>8_-9J]89:("M\ZR`Y\4#MJ]*B`;9N
ML8,#B<DGZ*:2PJ$7(+JS;JQ;1XAA7ENE*U=F>Q&N4F`/M9I%?T0SZU&,7$Y3
ME91,D,-V,VH)R:A1?FN5]%R$/G:1[].MUJ:Z*FDE\7LIWHW7.(CV?6JJT^^Q
MS8L>GB6$)]%5J>XC!]D4K%]#BA8BSN8*N]3TQ99##ZN6<!Y(]59K9=SZZ*^0
MBJ?'=F$)>R*_??V6CUH+J!9+:,967(FU)[=YM5:1'&FB?A592'+$@1VJLY;D
M"./UJ=)RDE4W7J\:K*CBJ@=VKM:*D2-4U*\BBT86;*!#3;NU')72`]2W<TMB
M7V","KP5ERBPL.,/+<)LL0?A04#0K?X]O2@#QXU:R1Z__9CT)G_0OMI=7I(X
M8<>*]OFB\$MTK9;2X@16;Y-(DL;M5*554A1DV?XUT%R2U!HI;)<DL5VCO5=4
M`0H.4Q\'QQ%>M1>PJ)AE^M9%JU"-I3I7>QHH;*M(CU`OW4)9%QBB7LK/CJ?\
MK%;*2]-;*Y7E%:)>/2@/?[VHGY>F\[P:RV'O`BANB@F[5DMI<0+KH4O"[`*[
M5'>O5!1>N=[5WSL5I;O8*#5YNDKX8HH.52\GQS-0O]=.=M\M,DB5MV_%_5]R
M_7DT6\3>D9W7.$D`$-VY"S)E89UO([KNZ!#$#F_1RP6F&N%'X93;#R7ELA\%
MN\$KVO35MLVKW`&JIWO_L9<+;VWA@D1G>]=`<?2EEVNTOD6D(+GIKM73:CE.
M,0JC#M73Y7I!IRAINSZUZB1:6J$3E%;*7?<TS?37V,5LRQS0_TS1C1X#Y"[0
M8D<Y&U!)/#;]-1OI=?Q/N_6RM>N5_-%R%ZUXB%9JC&KI%X=:IX@_HQ3OHU+I
MS]W1<#H:]"\[L]YEZZ(SZ`R[O=;TEUYO-M5&>7[$=8J-<WDV6C^DQOMGG6P)
M@K%3++WAL32=T?^[[@TI.Z.KUFC<FW1F?=I`%S/BD.P4;V_E>9O.1MU__S(:
M7/8FTW^T>K_>]&=_M'ZX[%WUN_W9/W=O+W;\.IZ=8M)ACS\\DKMV16O.TO)O
MHX4G]%^N+.O^%3-07B$G\'>_B4R6EZ_;V]<>_[G]]7Q//Y4LZM,?]S@ZUBUR
MHF_/MXWSVKXR@/19,H:20_:VW2')3]K5(3OBMPNWY.X8[Q:?;&IN4WWL.='7
MZ(Z#5NR''65+XJV%\MS*SN-RD!0P)>1%RR-497]^T7[]1(OC^6A!S542YK"L
M`Z5X0K';;L^-SB>/6$;7\KLIQ3#7SA5AEH8"P(O'<PY\6H$ZH/5R:SU#``'-
ME0*3M>5%J'`%[LDP`(%S]KKQZ,S;.3RH`FAGUQZ[%AZ+8,0D!.*Y7A"9=\9S
M(ROC>GO@@P#,-)TKQRY]\@1PX<\23TRSF8M=9[&(Y&8Y8PLO^F[7NL>!Y8A0
MX7:K8'HIATC,`(B77L`FS*GFHD7/(BYV5[X(J?SV\[Q5W#"(.)2#>Y->;++'
MIKYK.^$BBOXCD6"#@.#;,&`VT\P;>B[;'JC\*"FK/MTH"/(#GBVH8OSY6SW8
M%[#RE;%IYJ*;V!^F=Q8E=A0&4:(-2K[43ICI93RF0N+!*5T2J>SU1)2PH[=<
M(CL8+:\162'2<1<39,=+/_X[<M^,0^*'%CW6>+U'9(?L5Z/EE/Y$J![V'NT[
MRUVASHH@E#3C$FBQSRC^BKGH5L4L:+<:K0VQ9M>C$_&WOBO-2+`,Z<<;_?M_
MW_=#M+BD+-#M"A'L+:)L/D/T+?H+U]4CT=U<Q`MS`8'XUD008^4KC^)!_Z;"
MF,<&A.,[K3A>HMN@Z[G;%&?Q3P&B1ST_(/&5X)J]S&G#2,J.8#R6A1B!T'QO
M-IJQ8L8*>PRFJ7&:CVR6'0C?#R:NNM&N$?UM=!]=KE([@=C8?[KG++:-Y@YE
M/,KE.(*`_F@BT+&>JD&:,U93H1:QQ+L(-0_L2'&C]TCE9G'4M:E0'G!@J)N9
MJX?EH$OT;2IVARR`X)7U6JFZU/G?T(^#GV<><-,1L7)AT06$>>.1ZT<'\N0*
M,T%_A=C'`9HB\H!M%(N`'N&]50P3[WJH%@*,5Z,ZY0#JHF*?F0Q/O[&0;S>(
M)]"6:L@O5GH\<]$_GBT0S+(.+@#,+07;`\*51P:>Y7X.+?;+3=?S`S\_W=L!
MAD6',1NZ4MR`B.GU9I5?@7KK>\?;H/B`,0Z)?4=;C(FW(M9:R]9P%$'F:IP!
M<@%UMZP'3W:UV;YL<E?1K))=7-*]S$56EGA0_&5=;E+B[_@I4DJL\]P1F@2+
MF!$0HK)>,TF(DO,\0=9&$A^H>[/`X7(!(J/7S578_#MNQTP-92ZZ1W$$1HCH
M]7'),"-PF$@/\2R0%;M/-(?QR3"QO6K!4<:?V^`W'-P]W<-<(2L("><ECJHO
M/`M]D&845!>]WK8A"N*$&@//Y\0%I)H9#UR66E#Z"?_23Z\.&*&?^:KE!6.V
M'$OJQ>([^1>+W<[TE];58/1;#:\QT^5;4A2_9V^1L<^>L]'Y0/]C]DN/DGT]
M[@S_J)JP@F5;4G1_.*1[>G-]W9G\$3T&[7\>]J_ZW<YPUNITNZ.;X:P__-P:
M4R2Z_5[E\LZ6>DE1_O&0\O[P"U6*T:1R>7.*OB0I;+\^I'!$E6+2ZMY,)CTF
MTNFTAG?>>05A4E2V#ZF\ZO].9UD]U`$58E($GAT2.)[TQIW^9:OW^[@WG/:J
MUT.@9DR*RO.L.LXZP\_]BT&O)EF*"LBDR'W#U\U!OW/1'_1G-4SSW`(S*5K?
M'M(Z',UZT]:X\T>'2K?RU14N-Y.B\EUF)<UY2U^]KF9+T:2HS.Q3_2'=I7JM
M6>?WZJ$&:M.D",QL2)/>(-KVQYU)'>HHJ%.3HC6S!5W<3/O#WG3*#)8NG4>U
MY8D0EZU)$GZ6V9FH#ESW9[%1U1E>,OK97M\;UK'12Q:R27&0V;6FO4&OR_3D
MUQNJ*+W)X`^ZD0T[E('.H$4-QT[KAYMAY^:R3]M4GH4$+'R3XB&SL4UO+J9T
MG6`+<(_9,M5+OERYFQ07F8U/WH)L_;`;NG)$H#HY*58RF^+>I&S]$/>KG$YA
MT9P4P9F=,<_"K(UVN*9.BNC,1IDT.&LCEEMG)T5O9LL\L#]K(UE0?"=%=&8;
MS9BC6E0:+L:3HCZSL8+6:6U<""OU)!DXSVRP^8F5:E,<J)!/BNC,GIJT#6LC
M5KZ>3XKXS&;*-6GJ4YLB17Y2#&7W5;&%4Q]$W%)`*3XRFVK",];Z83M&:S_(
M*<G8*<G8LTTR-D'LX8\=Q#'+CN7RDXL!S<U.*L;ET;14#QEB10FKP`YZ$HKQ
MA2T`QO!48JJP,3F=F`+\JDDD!D67[Q[[4].,D1"G#OB"`^L:+<!<1U'`M;BG
MIM1AHGGA%6;"S+5N;WDF'A9SMQ^P@]D;D(!/=3ELU,`R(Y;K+^FIDNI4'`9,
MU7"TS.'"GU%:_/P_B=9&M5_1L]F)@/4JY-C0/;)YRF/R;JQ/P4S.!AH_<Q,E
M,DRVTA4^5<F4]_AL0J"]U;NK;.-S1:BEFLW?/5O8LGQ"N+W3BULF$9\H_!SH
M,/]@>`0CCVX(&V.R(JM*"]DXD`Z)-_.DD[VKF2`6L!R_P9O>.[A0%M=,9^-Q
MD^5!]8D(\!J,Z0&/4FVMT"6R";)\U'=_H=11+;H,T<R+C]&`XT"NL[F0%.0!
M-`+-6OLZ87#G$?QWH:WIJ9.Y<$G2#L&D-\/E+GBM8\?OBED.S[WJC99?O""1
M@3EN17@(EAO/>'"/8`LT]TW#?9>9>\M$;%V-"/M_YCL;ADR4HZ6<D:EF_";J
M15DVP>.%*<MX,F>!/T$^/7?%#^!#]J`KXL^U.1?)A8<R'OUR'$%`*TX.<(E\
MF^#[.`7S@&6_<N-D$8#5!+8W%P8QV9"L$Z_\ZW_B)A=#*Q<KDXGG+!)+:U0H
MS9AX]X@$&W9+%E7WI.OHO61HC4Q?G:=+^PXM0H<:"B"AHB`<Z1&,"<^1Q_/P
M*%I06LT(Y`%YN=@P%R7_7E6JL[X[UJ*`><69,]-M!/-+ORRZ(Y/JK.?>M`@D
MDF!F)6+<U6C5:)I\D5DIXB;?5>[)%5U\'334=6-99()EBTH>,@`Z)S0'649E
M8OB1KD]-FKKQ9;@T+=`H(E!8CS#92%-,:T:0.8).\V'<YE-4UB9O)@7P,'EK
MN+8>\3I<BT!)-=.U+>2IN"<@$US\]:XZUU16,F)/-M,5B"(A]@R9H*-7K]C!
M+>S&1\O0&>`EQS\AT5F7&[&T'T*6)PA/W5D,HQQL/G97![ER\K+7';9M'%@`
M"ZK=!F`*_0?FWA];FRBP;._W9Q<!]+-WE)-+](`<+^*E8P?X`7.R\I8=KCFH
M'<VEF09SQPWP`CLA\Z5OJUY2@GN/K-@Q6EQ1N;&'L&%@Q=<5NT+88T2BBZ.X
M:AMGGJH8OCE*HIQKT,[4>1NTSS.RO8W)O^?)I,!()!K9=M20:81+<B8+1GZJ
MD;JH3^0:D;M:RR3$2&<=,>KR[/0._?0._71]5>$3P=,EU>F2R@@_X>F2ZCN\
MI!JP`'`6G=]?WQ/O(<Z)+7*0<3K-\_@Q^O)*Q`P(G-ZU]Q+=$V1CBU]"*]G*
M^$3R&6)5^[_`>,;X'43'ML-U&*6%39)"?W90)"%W08]\),!_1[\'50X,@U3[
M&7/QK(Q;"3.H_F-V]OB7?^K+)!+,/?6=SGJGL][IK'<ZZYW.>J>S7G/1/)WU
M##SKE0Y(;-J1+H=^,Q?5JY!0(5)KD+)'S4CVD_#P#?>I8-)5#)2`%Q`TO:@I
M]YGD;09&XR9B!MSU#+5A/A-N/3Y^O_E'4\_A\N2K]K0H"GJHSB&SBP!0Y9TP
M70>4,FKF9@K2/$0<#>#U,AY5(?'@0JS3898N=\+SF;W)U*[(U#NI*\CCL.")
M5*3'FYPR%IG2)SGA'GIXR6<A4\R"P\+)>7ER7CY;Y^45DRT:T`FZ.)Q`%YMK
MZW\]TG4LWQ?FL98?Q&QG9@EYF&8R<%AX8F!HK84NL<(#:<M:71@R:=!Y$C/.
M`:H+>9,=H[5KA\G.TCCR&Y&IMPR^600=\"-R]TAUU^18+3N',RFJY#@T<^F/
MTJBY*(AY9-P*77A@%UV.5S5`\MDRU`?;=[?R/=8@*SR0V4992;F8]MQ)P$:Q
M+;K48'H,M++P%5*"1AEJNC7!9(--F[;46N?K%X^L/1?-(F?6YI*$JR[+^KZ@
MJ^&8_H]W]\;ZRW:?O]&SB1\S6;V2;$+0O5'\>OF::C>^=]",6`NTMLA7]A:7
ME2A;8]>?AO?WCN#RE(U2;!!=4;&*8"S!+`2FYDQ+'.-TB(+.K1\0R^9<S,CU
MG[>-C8(NP8>9U[`<#@07YZ*>VM`K`8HTJ@G.S#SZ<FA/7!,GKX-+(0R,]2PQ
MY_)JYA&++XZRZ_*S1'?/%VCR&HJD3((EF=[/$=5#[D";V.3C;YRK!+NKSYZW
M^(8=1VQ7E1W1?$OK.,X@_,L63]"#OSK<M>&M!,;C-(.O$1_4'I*+$I>_.[.A
M2HST+%`^BG<(Y8^ZKZ>RAXI"LUVF_[-`OP3'QEYJ94R<(R#/Z_V<`8?Y!>'6
M&@8+1&&V\\,PSPN$8;9K3=@VP-8M=J+4>7)!L6_XZ=L&_<Y%?]"?086$M+*6
MSU&F5I*8H\KY&'H!\L?6AET6R^&2R00X',THQ>/.'QVF96;EI;M$M\%3Q>W,
MT2`O%0K006L2ER1-@NC?W,;&A``+\,BD>@$9;T8P\,!S5P$B:\:(.'5!?FMM
MD20\Z7L2A)OIUCZD510,`+77$_G!E30?%,,C.-3@8G(<QM'8U1I/L;MBWF;)
MGJ`'SWF@-G.7H`4.F-D@=1TOZJXIN%4P.7*NVF484;WB`="PB_YKM!A3IK#O
M>V03&7%<.'A=YN]-QT!(/>B552SY71W=J."2M/`%O>9GF@*#Y0&0X@#<6$K[
M2P`4KM`M"2VRH7\YBZAH<\4/-9^?:<JH("]W/NF@P$LG4)`5>#%Y[VC6E/3S
M"'$G*0>E73K%IZRTSXJ)^VQ'M28GWA'R3I$."KQTR!H@\'^%+I)<2_*:SL]?
MFRYHF&S8G*Q2R'R-SFLZ/S=^DX3)!H6L>F=,D2`OXQVMQB\8(-6@A)6$M_K(
M_G'E/;Q:(!P?:.D/A^=8^JOY`*TLI^<&.-@`GA[:*M/(9`=/'KW@NERCI&-Z
M0!\!;9)N4;.WAB,V#Z"P4K=,-6(UTME26/3U>E4("S7[&WM\YTFZ5>T)AB#E
M]/@D0D+\6'9E`(5XC1T'KRQ7(,5T,PJTB7+,(Q*^XU`LR@G"]MV5M<;.9H#7
M.$"+P9@K5+C#O%VWA28A7A&YH*#;*G:S([SAV$6C9>QCO+)L=KN\V1;0O?`(
M\;XQ#Z1U3_\2;#@^\@*CS-]H>ME6[$JP.$L0Q)JO.W+XB)[8(S^86`&Z#`GE
M9(P(]A;%`(9&:3#`?)94>]UK`ACY-L'W_'<S!09Y+O`><E3E:>.H+)(V0@N?
M5?]D`ABB8+3<><F[GA_P\\0*^C8$2UE&0.-:*X03=+^M_#M:,NIAP`Y;-@2>
M?+(A,/0^8,E;%N+"N:,P\`/V1MU=%5LG,]T;`EL!7B`LW^K-B<7>KX^6O['X
M/THTF>#573`,F8A&RZ<"REW+<=#B8K-MYV\;<A;.(P=N"/Y*N(0TXYUYFM%[
M1,3&/AH3S"Z8CU0'P6A-U@$IUB#@];Y/2ZYI<JMX0X#*D@PZP8PQ=AC-OA@-
ML$M#H!'0#[O8C#E82`(%=FD(4`+Z81>=,4O:SDS;5;.\HB/B!T19>7JG(V>T
MYHW0$!B+L0.BJCNC8.R*V%8=@,$[:-@0C'*I!J'0>SY/<T8U"L6G(!@3J$=#
MP.&3#Z*D]["77+R3;\GDMJMDCX:@Q"<?1$FO_9VTA>10@GHT!"4^^2!*97,V
MJ-U\MK1N7Y=VW,70<^WX/\0;$J=S0["3Y@2$4>]9ZW`=Q^2+Y8323S;W'1H"
M%Y=Z\/9&[RDK3?.-:\79V-""/6QF>^Z8H#4.U]P49P4&:224$AR!\.H]FWVF
MDO$'GN_3LZ3;>PRPNPJQ?\>8$MWU"+LV!$I)/D``-8>_>.YJMHT(YAR@$ZT:
M`DN69!`!O:>O:>#97]E=+IW\B8B+Z9U%M^8H^06,B[AO0]"2903$L.RE*ABM
MQWBD=$PC,XA^(]IJMR8N&+''ZV0Z$K(<@!#H/1ZGN4P&ND3Y"A=4H6SZ!VLE
M;1[RQC`=S)(,@=CJ/53#;+`57CK'3*9CXU%,<`%"9\I)&W.B*Y.M&@)*EF00
M@<0AN?ZL9KRT4T!JL_=%\TZQ!&>FK`X9W$Z9ITK,F%/FJ5/FJ5/FJ5/F*1-Q
M,?(QI"KL:GTC&=D&\:F[[W;"5>@SY_\4W0>1I<3>?W.?J$GW-S[W5"%.5"]Z
M,NB4!"6/`^-S\4AQH-PA#B9Z<%C6E'84#XP6,OD>H`ZZ*MH5R?K`I1V2N>HR
M=7EDB++%@#WF'YHH]23QD-@_U"!V4?X8L$?M3^F5B#U)/"3VCX8G&:S]\7UA
MR8O)AP^`>D\67<]]0"1@2>*3CA51I7)NMWG;Z+20\BR`H*E.#IDP$&;>%XM@
M+Z3T$/981]8TRN\W;QN_:DGR`&*A>O5*T<,(V?!W:K`]M>H:)?LL[?"INW*9
M2Q\)TNT;D!!50#M\#-"[44Q05'PR(GA&+->W;"90_V*3_`O?5UADC`9X$(N+
MQ+1<!$DZ1;ZKO+9Z_(DEY`X#9[B'\3B$3/8L5H!B-;Y&1?=AF"";CBVRK-/M
MZL^,)9XBGI!>T%;3_$1+X;N@LW=-N-/GDP_!I'O%4_;@I!D@\<DW\T*RYN"T
M9@!9E"$S;<(2`=3-@"=+,F@J&#2WDFZJ;2:7WE]AE/ILUT0Z,DAFK(:`698Q
M\,;'3,CC'YF]':5NX:0$D!ZBZ0#G\P/A:E(,=X*)"^12@=O8<I[8N4)6$!+I
M#5-NM*:C+60-`EYONJK2R2":`5<NU1`2>D/MC4TIUPRDE7`):8;>2/[*'F$T
M`UDI+B#D]#Z3+_$&HQF89$D&C_^*(R?3=.Z?S7%]9*RCL)_IDB_`!.S6U/D>
M)GII>N<YE!0_/O3(%6/_</@H9CH;=?_]RVAPV9M,_]'J_7K3G_UA6$WVR(\B
M^2@FKZW65]%;<@1/80[;&?,*!I9]YNES'J=UOGUYID6W`,&6J+=59V6SWJG>
MEGZQ&GD1;':]K7^AY1(1>K89#+K\F.%,P]I?)$B4,P*H!'59<837-,!+Y`RQ
M[3E6Z'?<1==;WUONABM9?J=YW34G):0L03'HJ33KB6&C7GWR=T:9IVP&7L*=
M'GR:%XYU>O`IQUQ=F[2:\O+F/S#A4@X?L$Q_V&/\^T$Q^:#P5;\A'!/\0'>Y
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M=/T\`X_7;WZFZ2PO?2TM0S^$F6Y3/$GYV"(C$C\HB7)94T6,F)%%#NK?-`3Y
M?("SSR`D8QV,4P$4FW=QGZ8AEJ7=S,N7/*JE:HD+.C83KPP#JMURJA(9K=>>
M6W!/XW0R'RPA\68>H3-DBQ9`H$,#`9)9^O0^6,J0++7N\7HU$";I%4_O&R-N
MB9DA^A;]B1L@*]/??/R*\`$AJ?<E2D1J])I1X,")VC0`D0-:(:F7?44"N4/V
MG\U[)QL=YY]:&"S%7$K!`XUF+V;^Y(M.9.77H'1W@Z$JS@:(H^)P@<YB$0G'
M<F):KCRR\V-![@+63]3-8"SDR8>O]2KPS[(WLG;`DOU!>Q3/(RON;3@BA;@`
M@5$<\B%G,H"[B%SO)@`CRP4(C.(RA5(+:4%<#CHW$Y9<)D!4RAXBRTR7Z(^C
M^RAW7^\1$1O[:'%69NKDC]1,O,0<@>`9>:J,]"^7G7+&7>Y0!D-]'$L@UF5S
M8RB;J*7VN/R1#$;O*(Y`\/0F0>"I8KDJRT]=#8:R&`O@!9.1IV95);*;BEZ&
M!Q`^D[)?ZDGK93K$Y;D"03<I>7#]:1D;"[B`)Q!N0[-P5I*2L;'@YK,"8JK8
M77`8NW^%0&]:7E.#Y<XG&92OWMOC*)L#@,&VS;Z)P;+/)Q64N;GG]?C75Q[I
M6OY=N>-`:@CS,2O("HBIWIR5V91>$\16V=C%,+UW,"<SMT3GAN`HPP2(8.)&
MW\2<;'NS(9V4[6/)I&RM]BDMVRDMF^%IV8ZH"<*>=0AJBSTU,?N=8X87TX+4
M(P)%SWU3C325`<L(,D?0:3Z,<P06E;7)3^X*X&'RP_=K*LMUN!:!DFJFJP1]
MGHI[`C(-]:E>6X]28D\VF^>IBAEBSY`):KM>L?^&6)YVM.A0Z]H2+T6YS>>:
M3A-B&&!R(3A*9^TY9>$[9>$[9>%K$BXFVU+-RL)W35G%]P[J+!XLUT83].`Y
M#]A==0E:X("E3..F'I#M7GO"5[G9X97D!$*G="+82G,DFE_,GDLYO)(9GB/Q
M[7O3Y2XF']3T]WJMK=SB1GR3B]/%;+M+R*MQ#[KS"!;M]-Q.>LPPL>`E@#+<
M(%.-E<FFF4(\ZTT612T2[&#O*2G]KE@;/R^4H-O\HY[]26::>`79@*#XJ+H8
M`DA,NR06[9U?5?W$J1>-%"/@_8CJQY(P/6<E`3G;\:'IS*(,D!0C(""JSRPP
M/><E`3G?\='T]2K%"`B(ZB7KVEO@);:C-'M2^P;<87ZFZ;:D(`0B#D!;3'7M
MG-W'XP"FF7?C6LLE50Z6^JSO+O`#7H26PX>CT!C:XH,*(E2"*1`TU>GZ>;3%
M581*XY7LKJV\ID*HLOR`*+U3C-*_0A?M_452ZQJGQ_R\&=:7D`7XKK(.\?-M
M8%Z7^;FF"V$5`*1X`!$H?5U<!`&^T<OK,C]OQLXAY@%$H,Z-(K&)\6=%L4'F
MY\W?-""N0-Q4;QU9X@ARTI2Q6'//]=FED+N:(O*`;<%5P'&#SL\UI>,^&M?B
M7((XETZO+8GSB*J@C4@Q'-.=YF^:82C(<`'A\$:UK0`J36P^*IQKP@'G;YKA
M1#B60Q!;U=Z%+\BG5`T]EY*T1#A@]UC;:T4IHURZ__QM,WP/!1D"+UB5!'6>
MRJD+RJFK2*A\*J=>R9WFJ9PZ+/IZ8\3(%97.W]CC>XW3K>;OZC:4)&I\Y]((
MB?&=ZIR2U^0:.PY>6:Y`D.EF\W<&UJ3/)Q(49>D$((`H)PC;=U?6&CN;`5YC
MNN$.QERAPAWF[^KV/$F(5T0N*.ASQ8+>F2R=6S\@EIWW>#EIKNZ:S=]KBCF4
M2\^03RXD5+T!.GM:W45D><KE]>?UJA\<H<R]@L2#AD=%VK\CY.!5"CV#1;R$
MEC-!3`*4P`%>0AF:RPYG+F#'<P4:,>9%Q>VR"T;I<O9_]+=_+1IY*AC-7,R/
M9DKU60R8O#>NM?9(P(KJ=#T_>*(5RC,$=S`7#!FZ01>#>5-LEW!LBNR04-$B
MOVLY#EI<;(Z<;?(#FXNU2OX@G5"<U198).XQB6)S_$MJK4FMI&RT<H.9B^>Q
M/$$8EJV(4P1#YN6D^_CQ^'$':B!V$OQ`N"FNJ9-+WI6%29QI]RC4.,,T$#,A
M-Q!BNBOXL*2[MYQ2RMM*RK>'E93W#'=\/USO<F=O"WT@LN9DQJSNF^8J3DVL
M@UJF]ZF=L&`W5*^;Q_87SZ'#."P['%TI!>I6[<>;H7=UR`!40+VY')3R/\'^
MURN"4-\-$*%[=8WJE_?I[TOY8`F`JJ?7#U3)U+MD@5+(76A8^9*?_KY4#Y8`
MJ'IZBRUW8I].Q/-H>85=]JS(744>GHZ[8*E&O9";JEYV!.,5H1@C()YZ_5V7
MV_KL,?DH(KX;TM^XP1!QD@+S^QF/G0SY(&)E\W,7.1%G/6?;P"TIGR-XIBPP
MK+D8JN,.A+@.AR/;"Z+%XQH%=][B2(>5:+`&PBG)$PAB'1Y'MH&[/IH@VUNY
M[*ZCH)<XW;F!(`$\@*#HK7$V)NC>PHLMT=L5'][E<IN;"Y*8:C!"0:_+,$WQ
MT'/M8L@\]6@8.(>$@_CH=;;E:A2U<8LCE=>W89C!+(#H*0X`RKD9N-A,V$L,
M_(#V?^Q:CATZB0T4V)I*CF8N:D<S!>*HN&KX/O#HB%-U')=9<!RSL2O)#HB:
M7H])NM)9(BIF1SY=7=8X7`N.V]*#F(MM65Y`8!57)8^/C]3"!9X%`[-/U,U<
M0.2I!R'06ZML3+PE\MDK%U&9N,.6YH+")1C$0;'#XA+Y-L&1CYH73Q(70Y/V
M7!PYJKF8*6,.Q%>Q+Z.S(@C%E3<?$(EI`D#+:VHV$C#%H'@5!SGM397MD0&R
MO`^:F2W6?&HAD:I^[I>T!2?(1_1;=\P&1`_(\>X9VGQ92_<W&X2";(#H:*X(
M5A#`;;^&XB9//0B7WE"7M,5^9=F(JF'(<_I`/8P'B4\XB,\SC`=)AV)MRWYI
M#8G;TF"\#M4M"E`K]3H^ZA!#7!5-KU;&-)RT\D`4H%;J#7BI/'*PWI620\'W
MI9%"08#ZJ->%5;T0:ETC.12<]%%N?2SKRE-4"@^[:+2,ZXO!.I-L93RN66)!
MV2MVL^V(C//E789D[P",%`GRDXJZF2MQ>>I!"!2[XG8Q@3NJXD1XW*N<P\9F
MBYM',R3DO)S*QPAYX%GNY]!BW]]$M[.`?#/MS!8M0"XHU813[:=7!YS01>CK
M[F\Y?TH-BAX#Y"Z>M#3%>'"'B'6/P@#;_GKQH^VM7T5\3P//_GKG.904O_=7
MR!(YH<#"CC]DW+*PA[,]Z3A@`[Z._GG[NO6RQ:Y>'<\/":+_,9V-NO_^932X
M[$VF_VCU?KWIS_YH_;`=K;4?KG7VSQ<:[28PI5*.A9/35J?)EYLGDD/VMIW2
M:6(YSHNR%<O$Z:SX&3%S7RSO:*%JB!9TI2%A#LMUWBT[ECNTUH**V>E6AJ8>
MS:45Q,((J8MJ_1VVJSDK*4^B^4(WO.!B.;D;F;:T+#:U9B]EU7#9(_N^:U,F
MZ&Z:/'(RNLY>O_[(S1U98(1YS3867_6]TCRH7K*@(X/G_AI:#EYBM&`U/2++
M:D\B(XL+C&SWN:;,X6)8"G$`+FB:KYB9TX:_=R>:F+UQ9WA1EV)2H;#!29'D
M8M=(SWZ=%62.H--\&+=3%Y6UR7MT`3RJV9W50+*]9Q"!DFHVUU37*D_%/0&9
M,@X/'6*/W>E"L2>;S365SY40>X9,2.RE:^,J2@'!KCQF]"O\W?6@F=D[;"Y/
MIJ7_%=Y/^=`%U1-[[D+VI%?-U_3L^_GP%KS].T*ZQAD1S5<ED\T:7>IFLHTT
M07Y`,(L9BDZ3-Q0F?S*]$1JRO&YS354G*UTJ,D'#`OXAO-\U-#U>XAU-!3$K
MB='G;4TFN/SUB3(N(24Q?!>"^-LG^HD""CIA<.<1(/G*L:*$/O6,M8?/LIGW
M1J69C9F,8U7Z+O@2[EB9YGWF&:L0S*Z9#LS2C([B:+]$*:!X]E2@0M"GGK$:
M\5ENZ"E=GMF#DD6I,C:U*!B/@.]*[<2"`'VD!BIC4=UI*M1\9/2^0^FM[QUO
M@]"V3'8^`T//?8C".2.U]&=>8#G)O[.@Q*$7_(&"I_Q[T3EQJ\$PT+5\WGR]
MJ5$,X#G]>:IA;/-=>63[*]:.4\"C7CJ^8\7DR`/24+T/4HX\@XQ#8M^Q/U&6
MHU]7=KC+?,E\+:N&8TB/%#^N*4U\]*]$12P@CDO9^`;K005\0N@K?M=S'-7[
M%WN58+\?_5DC?\`EZ!=,2,"@5S%[@E-O8=J%WL+H?/^2FV,L@[9D'=*!$>]B
M<DD3O)'A]3'FO8P<5C(%51OXCB:7#W[H$*>+MC`B"3@D\#/YZ4TNP:+0#FXG
M/<$^8L%+`&5X_(YJK$R.IE&(I\D!,EMZ10$QJ6::'O;(S!B/3[7J)5"0@*%C
M!_B!&G\==Q$E@6>WDDN/K&.#=_L,'#@+%!I#5UAW,1.C'%NJ@T@$&1MB'\,-
M-?G)EE8!4.*.S4%'DI<&61*)V[2"6U2B9^T`%L="8C,Z9.B9Q40,/3>^^8@/
MW$_I-/W/3`C5A&F)OMDXS:E8%,\L>`)F>G=77Z_6[;]ZTKM#830I4N)(MN\Q
ML007\=5^]Z1]67&8&0]2`>/;XJ=A?J*YZ@2>^.Y)_[+B4!T(HOJ"3+B.,Z<G
M&.5ZU+U2@4\W1[-JE4A-=^^\>$B1.T6B:W/.Z=+<R%R/FG)43W$A5=V))S_!
M:%HF<E'8)`[U,FR"2J#8[5F&P.AP6*CFN-2`38)7`:<@PF5].0H1WOU9)<C[
M,;\'G-/,@E`KKA);CE+>T;,\_WH/EK7#+7=P;)?U7"@$G'_6*RL!W2>YF@&7
M/:FU%1>>+4-KG.:[XRX2YP"%R.<-_SVH`,@WJ`N**Z\>\+NOA=WUW(C7T'(&
M>%GPD"4:I;'G+2G&0.@4AR3G<>,'!Y05F*.9OB9,P"(2%\S%?/[`RU#%8092
M%!4^%`$C/'?D)$Y`I?/!'H-?F2,//,AS1U'N?'-6PU$VA[0R!QK>,,\?3+G3
MRUD-Q]4,<>6.*[QAGCN<LF>3LQH.HQGBCCR,2(WWW`$N?/(X4WQAV%FM"%I9
M`2M91[#K8SNN:<<_:0AZ->=D(<,("(4I3UOWUX7)Y"5IABJ[LX4_J67J%L!3
MZ46M0`R@"IGR/O:)D6VX8%WJD_NY[TMU8!%`:J.Z+HT")A+[5UVJ`W[R^U(?
MOAA`%4J<YPQZH+U/%I-^H7U6K%IA^_1&^_1&^_1&^_1&6QZ_TQOMTQMM$[$Z
MO=$^O=%N]!OM[ZJP7^&]*,.7:>]!)Z<B?\;*VN2]H0`>)J_]I8K\J8>EDB)_
M/+&7CES66.1/4V5=";%GR%1^RZY&[/OD?AW?#]<I]Y(H_[RPZ[R=-Y6-NQ0J
MQ@Z$H]Y%*X_X"?:_7A'$7(2((#^8Y*=`Y;"?-T+S086Y,M,0SE?,>\2*A7WQ
M'"O`#@XVQ='-'Z/Y^/+X,M/BYG$Q0V1=#E?6\_F@^<0-:#<:B^$E?L`+Y"[*
MS]'D",\'TRQ7$+9OC+RZ.LN_NCHO=G5UIO/JJO1M9`9WA2DG!D9<@4WM.[0(
M';1-`U"J#JC@QDSA)XRY8%.G48<I.U3CT8P[NZ:585>.4JD*[H97J32^[/:I
M@KLA'N+FJY+)/NM3!7=.J;"GTF8BKRS81=.E:*4K!%#`*X]U,W>GAMRL5FU)
MG"YB3Q>QIXM8<_>ATT7LZ2+V^[F(+>TV.?[JK_)/4W4WU`XL[8NJ1V1F7C8K
M9;[H368-'S^I:VFAF7G@B7B[%;-_6X1]=B')*71=W3>?J7I6*"LSCW>53$JY
MJ^;*/_U,=;1ZD4D$-QAT`7Z>?P'^IM@%^/GI`OQT`7ZZ`#]=@)\NP$\7X*;<
M6IXNP`WQS#=?E4R^*SA=@)\NP!MT`0ZEM-O6-HXJ-0T"?"]*9@>UUY7&3KW-
M*&93M7.97^8Y/OC*579.MWU>F,`L-M22@Z20S9('UI([5N#0IW36CH,!5N17
MXC+]S#R>R;1Y?M\=(X*]Q6?B^54X7^"/?0_Z!+$MX9C4H5',Z.C[?H@6ER&A
M<R`F.Z[;F+!(I*I#%QZK$?I0CBL([H86;][SN,^5OM/PZA:0G(\U0F$J8AO2
MJ(:68]YRFTC77KU&Y7SL>]`HB&U(H\KF2S=#HV2*+RN;J@856ZYO?3K54V[&
M4;GI-9<5'NUXHJCE0,TCP(2*'04K.]<I&5`[#7?L@"[BW)-B11JJCHCGJ*6*
MI0-JJN%N(Y$8]O7.-"MK(3J^1WTM+B!0937[I=0=>:)*49DCM1Z#X"BRGJ-"
M5RXO4+^;[8A+%$';1FM[[%?:+=[CZ/H.-5R!P$`55USW[KNJN%W+B?RXJMRF
MU-(3'NGRV&2O2_R\YS]'E7@Z@A03UIZ293.UB0M435-J]*6.<;JULB`5W[%"
MEI$4&+%A@`^SS-.\K+==4AY5O*DL3TQ#M5BSP$!E+NM(^AY*&5<4`WI,N>-F
M'S*+E$96?R_0R`*EM8@!5+=FAX(<1L[1_[K,R+Z^>,7<SW]?:B@O$E`E#8@E
M4;-_IYFNQ\@Z^&8#E:\Z.8`:EW"+U/_2O^_2']',>D3^]G7^D&7[#_##TW/4
MU%/_MX=/_?O#[NBZUYIU?N]-GY[X[T?1^M0_H&K`8,H83'G!P-FV6N.<M^2(
MWM,?M#/G43PH^TR\<AZGS7BIOI\]G3"X\P@.-OPGZU![?6_7\X7O25$-(F48
M)J(GP'`//2_"!?(6@6/X\VYU^)C\S%H)AB:_F8YR%[J6,T$/R`W1%)$';*/^
M9"IZ.2WHJ.G]M'`:'2(F9,+,U3%:\#ON8D`_X?PK)-A?8)M)5@2;H*.N/+P%
M<9/A`@1.+W(CNJM3B]I=#3S?[U+S>K/T"#M^<.P-N,_\K2:?IZQ9*"`=`NFU
M68>I_#/4.ZDSU#\3K-1$;CN?WO=R9[YVY11/D$/5AQZ^28!E#ZP?#HF?]`:=
M6>^R->Y,9GWCSJP)%C<S8KF^96_E)SK!BGL:D5H.(-._V*3^(IM&KM!PQIR.
M95$&$\*5D&(SCM0#SUU1VVI]B6X#<0ZX_-8&I((K@X\GP9J95N4AK:(3'=1>
MSWF;*VD^*(:?M=7@8O(Y^VCLJCEC`^$+7W!@7=.Y3[G`ON^1S=`+D`\>O5@?
M7A=-9V7!)/#DB5>]FD$9J=A7XY08,V]K/'*%#G>8OS==Y@+:(9&_KUKFFW8Q
MD>_:SS\T3N(ITB&!?ZA<X&<%!;YM/__8/($G28<$_E&%C>0C^\>5]_!J@7"\
M#=,?#G=?^JOY`*TLI^<&\)40;95IU&S#-8\CT#"J$8N8'M#VH4W2+6JV0CEB
M\P`**S4WJQ&KD49D8='7:BU>DRLJG;^QQUW'#UK5[HB'E-/CDPB:?HHCAJ_)
M-78<O++@&XZ8Q'2SV@O<28DQAT9P*5`LQPG"]MV5M<;.9H#7F&X$@S%7HG"'
M>=Y$T2Q;`;7@E-=<,%9JLQ94_BTP1K/MDQ(,@[@;`[O(I9/75E/5X.)RAX$S
MW/%V'$)&VDK5H6ARF,LE)LBF8XO"(]+M=-VN<V:()R(7`N"M8D,B2D$[#HE]
M9_FHLR(H4KS?<'`W1L3%C[/$W>]@T.7:&*7&FK<U>93$Z!S)$VA3J_<UN9WE
M$CN8\3.[PR1F2N!OXO29GVEZ@R>'B03MX$;T1N_5W`3Y`0GM($X%[5BNR!K,
M;?Y,##^.*$S+?)TA5FQ&`!UT67L\80N`,=ZZ4X.-V7;>T?C5ZBS;[Y3;,D;7
MB*P0V5Y`<C<FB9[:JMN*9H97@@W02GBM.8@$NW29[Q*TP'D/^7>W1(E6\[-W
M^JV&`N%;6=HA+#0?>M!MT'>9YC%]NK)LU%E[H<M!!>K1-(3X?(`S1^U2EB9B
MGWB#BP/K*.S7&#0*<`.:")HMA/OX@;`_6D:WU6-KPX]HA7HT!C,I/LSTIT:O
M>>A..[8PIYA'LE734,G2;N:II^NMUYX;N4"ZUCVU79RX;A&U@Q!Y0(LKCUR%
M++TJB_ZP7%YFT,)#-0W3D@R"?C[5FYAO$QQE1A@M!ZPD%5PM)U[N@?:-@46"
M"TCV>I..`(S&NRQ=QA._*WR-F#=(8Q`MRQH$\WN]5GV(KJA$1LLEMA'Q1R1:
M.NX\A]+&\0ARNS4-2@EF(/`49Z^-XHZN$)H@O+X-B8^2WIB#M3&W;6-$+^``
MDG?9E*R*#!''\NG4_HT]"72#$9FP9(C;PE7+*;)#@EE@===R'+2XV&S;^=N&
MG.ETY,"-05TEN[#'2N=KWXO0I\S[?M>CMA7+B1E=1\@]2OUX^"CUXF;:'_:F
MTU9W-.SVAK-)9]8?#4U[G)IB=8+]KQGX\^QPN(_6D\8!68(7IU![8YZ4BK')
MG!]X$FC&:]$,#Q<;\:-1;B=M-YT".`389?DV[8UHEC^)!XG<3GHN-F5$+YIH
MYK\<58V6R5>=2A$U.9AM&M[?.QB1#/G"Y#_\CIK>H<K,*Z\H'V8NGF/B+4([
M*`P<OU_M@?BE@9/@`YQSFK>]T`^\=8DY)^@XUW0.+(Z=#".@8U3YU>H2$8(6
MV[QM\J#$SEV9SKK>*Q<`IB`SH$?,,(-R3&UM^@MKQ<MVS>LU;VO*8G?\V2W#
M!02:5I<)N[+"070[W'$7K)((=E?(M663>;U[?>@WZ8ZNK_NSZ]YP-FUUAI?,
M?3+K#S_WAETHM5?%*<K$+.9SUB['6>7\3)$3E?G[-;1(@(BSN<*N1=FQG$LK
ML+@LG1VR-.T->EV6>NW7F\YDUIL,_FA=]8<=RE%GT+KLS#HULA7>^NBOD,+4
M>V!8R:G?>8:CFXMI[]<;"E*K]R6"RBR'W2D#^BD#>L5'RM0\$CO?P`YFYT`7
M\&G:>3&'7)'SAM-%CZ--)'(A0(:[V%1B9+)[31&.9CO64D2+W6DYS34YT<3S
MAHN/Z8ZSJ$"/>%<Z:&;V7I3+DVD1T,)27CY4R^N)O?@AR]!:BQ?&2KZF9]_+
MA[=@H;0CI&O>1MEX53)Y>]:E;B;OY[WUO>-M$(JB`^/R;J(]'>RB:U^O<H7P
MY%EOZ.Y4L-"DY_..O.H_5GMZLL(^C8IXEG!KZU*G,J4C>X_W.';B@X\CD@)5
M\8EFJ(XR3E4?2Z"L-F7U_0ORV0T!*U,+7#NJ&-I<T)5R*+'90)=>V]^S?S'%
MHK_Y_U!+`P04````"`!=B65$M?@("9"```#?5P<`%0`<`'1X;60M,C`Q,S$R
M,S%?;&%B+GAM;%54"0`#\J`74_*@%U-U>`L``00E#@``!#D!``#MO7MSY#:2
M+_K_C;C?`==[SHX=(=GNMN=AS^[9J-;#HUF]1E+;ZYC=<%`DJL0QBZSA0RW-
MI[](@&21Q),L%IFE.1NQ8UN5F<P$?@`2B43BW_[C91V19YIF81+_^V?OOOSZ
M,T)C/PG">/7OGWV\/U[<GUQ<?$:RW(L#+TIB^N^?Q<EG__%__M__A[#_^[?_
M[_B8G(<T"KXGIXE_?!$ODS^2:V]-OR<_T)BF7IZD?R0_>E$!?TG.PXBFY"19
M;R*:4_:#^/#WY-LOO_;(\;&#V!]I'"3IQ[N+6NQ3GF^^_^JK3Y\^?1DGS]ZG
M)/TU^])/W,3=)T7JTUK6[??_?7;ZP^(N_`=-__LD"FF<9__]\,0,V=`B#_WL
MZO2__^O#W>5_O__ZW3?OWG_S[K_SEW7P"_S;NV^^?%DR8T^]G`EBOW_[O]^?
M?OT-_,]O']Y]]_UOWW__[;>.2N5>7F2U4E^__.'KK]]]S?Y/L/];%,:_?@__
M\^AEE+`>C+/O7[+PWS]K-,6G;[Y,TM57[QGG5_]U=7GO/]&U=QS&T),^_:SB
M`BDJOG?????=5_S7BE2B?'E,H^H;WWQ5J5-+9K^&!OJ&)EGX?<;5NTQ\+^=`
MM'Z&:"G@OXXKLF/XT_&[]\??O/OR)0L^JQJ?MV":1/2.+@DW\_O\=</`G86`
MS<_*OSVE=*E6)DK3KX#_JYBN6(<'\*'OX$/O?@<?^I?RSY?>(XT^(T#)(*NU
MZ[N6K)+IJZF5O:5IF`1G\3"MN]PSJ<_&3IKO8$"3?W(3'I+<BP8IW^2<7.UK
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M8)3J-4'2(D`##)5673!P&@)$Y*]`]C\X`/&3EZ9>G!MGDP[-E(!0JM<$1(L`
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MK:LP#M?%VHBF#LV4^%&JUT1,BP`-1E1:=5%1TN"`P1W3S.0W-7Z?LOLEM9I=
M7_^(IMN[&G6[G/^.RF.Y\E[LP[]-,^GP5ZG7&OY-`C0X4&DE#7]!@P,&)\EZ
MG<0\XFR$@H)NTGB-3LU6G*9+A`86.LVDN`RG(YP0!SX@@X%[+;#[RE\AXR.)
MP8DQ+!D6GBEQXZ1^$T-&!C1X<M%2%<G)7\F6%M5RM`B"$,Z[O.C6"X.+^,3;
MA+D7&><D"\^D!U`NZK<.I$P,:'#FHJ5T8%7S$&`B84Q*-AQ(NZ.Y%\8T.//8
MOC]>F;?3.N))76&CPBV_6$F)!DU&]208^7ZQ+B)(U""G=!GZX<XA:,CP.Z[R
M_3@F>,[?G^ER2=.09I>7)THP:*FF0(%%1>A^#<GL_6[6J]OA-2%AE.3SCW%`
MTT]IF-,T^V+,F2.C_I>KY/FK@(9BTF#_TITKV)]^N:0K+SJ+<[9H*GP=)<44
M>#"H!EA0_#P[#O0ZR?$R1D4$V4CNB6;0W^?ADD;7H9]$7I$MX@#\(B]^U4\`
M-H[))@,WU>N)P4P^.SC<=933I(#IB%1LY%^]]>:/I&0=>0;1P.B</J:%E[ZR
M7]Y?)[GFT,=,.AEP+,K6B-'0X8"*63GI<*>DAC3^]X33?T5P9=!<)O&*071]
M2A]SRQFVFG324QV#LJWC'`7=[/AQ4$Y:D!CI,=`2($9X\'R;AL_,1[Z-/)]:
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M.8Q7)RD-PASF7/UDY\X[V?S6UYQZ2G-EG!U+0[254BY*=E+RDUH`$1+X8DL^
M9UY:GE3Q@7W%C.Z9!F$4)MLP5Q60,"RS5I[I5E1'];>+IX4!!\(<M926Q)*M
M$WP<*\34&T+OAF#H'2(0O>N-HG>'`:-WN^"(O,MR<@&5-J)HE!SBWL!Z/P18
M[Q$!ZWUO8+T_#&"]WPE8[^-@7F!],P18WR`"UC>]@?7-80#KFYV`]4TZ";"N
MDB!<AJ+<D-V/,E%/Y[-;5=YZZ5I2'."QZB=YX@V&?7M)E?B++"N@L,['V%LN
M&60AI^@B#L+G,"B\R("6G@(F`]`@PVI,]>+&`;,A*NOJ)A`AA+"-7E,,:<B9
M`8\BYV48%-N\*%"H,L<)@$U&_-A3:-L7=D+$OE(;BYC6B1+VU=%(/EVRHUWI
M;=:CGA8'>NP*2GF0C*.9KK+G15*IH"&*8*:?%R2ZV(&)&#%,S!$#'4Y$J``F
MFRD18P@/F.GG18PN*&`B1HP8<RA`BQ@>`]@C8AS=-\.LTU<""B=(;UI?7WR.
MN>J9IH])72!SURXY(*<\I5';AO,D/4GB#,Z0XM4]39]#WY13LZO$&;$[Q'0#
MEON(PS&KCF*#$\A+N0V$DV4")=4KT:22/1'P;]BH\VG:`]A=CMF`JU9="\PV
M.4[@*76T`:MBFGJJ%'O8L:9)!VGS3Y'.)MNG1ZLHG`CMK7^O:;&\`S;ME/@C
MS:"8>1(S8Y8TS+W'B):)F?;@20_FZ?)J^QJT3;)UY<0!SK[J2NFWG)_$20R0
MJR20*BMWSS&8J_0\C,-_A(GAX*I+,MUIE5JY[1%5^W<<>%`K)1U&I5^2DFYO
M/7L51E&X\M1U]S4T$_:M6KU&Y[8)L/2N4BM5]U:$>^K?.QKZ3^?>.HQ>+\-U
M"&^^W.I[VD0]69_;5:Y[7T^*`P=6_:0R;,!`!`<I6<CE[9[``9<''VBZOF`=
MPMR99PHY$C3.^.$WU+6%)TGT:.G%/AE\!AA5XZD'+PZ`]5>XBS@@(""&@!Q2
M"R)-2;S(,8Y[$J`)O%UFJJ3=(IGT[JA"N=:-T<;OLP/(H)1T29#]%W\Q;K^7
M`YE[_)?"B\)E2`,X!N#7>6I$@A+ZR<B==[*9J*\Y]33DRC@[A(9HV\468R<U
MOSC]$=>XME,1GMGGCFW#TM!GJS+7\6,<YMG=_4?C;2T+S[25NAS4;Q?L,C#,
M#K\^6LJ>5L5#,@ZW(MY;`2^('\&MGINE\[UG*\MDLYBC\O7D9:&?'30]E.QB
MIN*"AVE^][^EJ]#D\S][,2_FP@OU-RN[3%;>QW!$K:>=K\"/[MA91X@#/1;M
M'&K\5"'EAZ1YOK:(]YQN)RENR(K1T\X'%UTVC(X0*5S,63!FN-QZ:1[N[8"A
ME;3CFF0W<W*=4U(=JOG#H)DE)6JF>:.EL&LFW<P9=$Z9<ZCF"8-F[K"8<'YP
MQ,&\,'!!`5H0],+`YQGUBY2A8+/U2V/X95_.)_^L0-Y%O"A6109OJ-VSKN%J
M@VJF>(TS\X0!FYX&-2(VCIPX0-97W2[TV.9'8"X4\TX8$R&%[WQJ.1R=4X!O
M".800:TWP@X#6#OA:1(0_;F(P"M_=R]F3NNJIJ>><'&SJ=Q8XW2D.,!BU4]7
M@PX8`1;O2,FZUU)T*C6-6R,#^:PPT6^4M+1X@6+>-LE(.0]3MCS-A1?CGLE`
M/BM>]#LH+2U>O)@7(.7,DG!?9D3`C',&=1JFU&>RC8=.7:(I3YG4"C:/E=H4
MLX/&J%87*A_2T(O)!Z@EB>4-M#N1DPQ;_]>'U(LSSX>LC>S#:_,7TQN:/01,
M>U[9U[#VX:4K-QH$]E99/M84Z>F<#E4A^),D?J9I'CY&E$^FM]XKI#`;9S$+
MS[0//#JHWW[LT<"`!G`N6NH6RP;O7AVJQJ;R(?G12\.DR,HPI]->7\<TQV;?
M;(!JMZ_FF!U`O=24<WX:0>L\(8T\=WZ8,4%B=$MU/EL:]G0&XGE`I%)8#9XF
M)4+0*-3K`9;)L.$65.P2SX@-AS!BFQ(K-LS[-A4V]CQQU$7EV40EDAO3%4W+
M-5$/$R>VR0#3PX@:.@X\.$#DKJCTIF?]8`"<8_"LYV1)!#_Y!&\(E%)PN-0\
MA['P\R(-XQ5H:]SB*6DGSS[5J2MEG78)9\>6BW;*+-.*5@`*TY[L9@.[2^,6
MK$TR)5Q4RC51TOP=#3@42G4Q(4B0!!.9(P5E<KT(*N&FA>9)+BOUE+BPJ-R$
MB(84#5K,^DF)@14UV9*CFD[NB\TF"BG468"K&RF_.W879K\:9Q@KUY3@<C2A
M"3(+"QJPN>DI5=$NN4B+C0`?#M!)YGQX?7@UOE)JY)@XIFA3O1-1U)&C`9E=
MQR[`9%QA?,0T"9@7UV]>LS%-^ZBIBP'MQTU-'&CPYJ2F[)4_T[B@Y)C<,GW\
M-.0>&0E"FGOISCG4(TUK198GZ[YKJ95KTNG-S836%&=F00,[-SVE:!7-28F]
M/06G3NF2IBD-RJ^X@:<7YV0AJGZFU%$J-[;9@=1?URZ8*F:2[A514D36_=0-
MQ7%;CW.V^0[8;*5LK6JB/&"+%W6=W(>G,!6Y"\8*#B:&*<LVV!5OUFK04^.8
M9EQ45%1E.&Z4.<Z!BVR`#8E[E*PW14[3^V29?_)2>A'G3'U(15AD&<TM625.
MO-/N!'N8T]X3.C#.#L,AVDIAT]NSN\6__LN[WW_[1Y*5_`R1.5LQ<4`2YM><
M7H;/</>A95?VX?7*^UN2GD1>EIG#J^X2)@ZY]C6M$X9U94<#U?XZ*\*U3,(Q
M%T&V,H@00AY?"1=#N!Q4X0ZF+$UCFI\F:R_DM:'4+I\#_90HM:K=Q*26&`T"
M;1K*&X)G&B4;?BK@)QF#&!0G]I-TD[`M!26?Z&/&`+DG=^]/2;I.8OKP1%-O
M\WJ:%JL3+P["@'WYED_2AEV#.^]D3F!?<VI_T)5Q=I@-T;8+N9*=N8><GP1,
M`/$K">7JC.2D\R(.Z'+G);JWE&DGP$$FMJ?%7B)F1_%N>DL%GFHIQY%FV=YK
M`<0K*"._B>A#Z@5T[:6_9N<)3UQ:AW'&3^)X=I+I_=B>$J:KY#S(M&V=YU[L
ML\-RN,Y2C>A2",EK*7Q=?R[E?)5M!>&8:.]S-NTOXN"2?2+Z<Y&&61#ZUCPC
M*]>D60!N)K2R`,PLLR.RGYY2%@!PX8#71>PG:_K@O2R*_"E)0^/%-AWQM*NR
M2>'VXJNB1`,=HWKR4@K$A%&3FASA)M>+RL.7\N66B[M[AZVN@6OZ#:_5!'G;
MJV5!A#47/>72>0';B$0X`'9?/&;T[P5;F,^8#>:0M(9VVLPW@[KM?#<%(1K@
MF+23<]LJ6L*)4>+&DLRFI9X1.Z8D-@TI5OQ8DM>Z"!HS=4V7XI'X17FY1=1\
MO(C9?F#-DP86CQG;)OBY,MG`B6^Z](X>9FR3.QR89D=27TVE.&[)VBCK21K<
M8TY2&?6_7"7/7P4T%/,3^Y?NM,3^](O0XHZN0M`\SB$8W;%:3S8%I&Q*`H)T
M-+,#QJ)8%Q\E)+:T_&6.^6!QPG.6(HB=O?PG?=4:)]%-"PR-FFUD=(@004.M
MF08;)3'AU(21SX&.:AZ#)5%A5OOGJ;"@4JJ"0/,W%#VO4$B[6`#-G+U\2],P
M86M=<.KEIN[NT$W=[THUNP!H$:%"@DHS+20$,7,A`G(Z<OC.%1T+ID@`RIQ'
MWDIA5^?WJ="@5*M"0>M'%+VOTDBZNE[1$"":HZ]/BC0%'</,]Z*?J9?J)P,]
MZ50(L"E;@4%'AP(7%N6DFU:"G`AZ`@RS3@["6?F)1M%_QLFG^)YZ61+3@&<M
M=P-E#O33NI,6M=MNI888!8A<-)0?0JHVIAX!SN-?@954O"+Q//V/^4#U8Q(5
M,5SF.@\CFG9C9P:Z:4&D4;,-G@X1(M"H-3.!I>8@G&5&A)23X1W=)&D>QBLX
MX2ST0-&13[R'-2K=V<HJ:1&AQZB@%D2_R4C-000+*27-B":.YA.VCJZ25!\!
MZ5!-BQVEBFW(M$@0(46EER;RP4E)13L?(&Z+QRCTSZ/$ZP;C-333@D&A7AL*
M#0)$0)"UTL!`$!)..>,:DZS72<S?)+U_\EASW!1YED-Z;*S:#+LP3;S>.!C0
M674,'(B`Y*"F+K3*.<43Q4=$,),&]YPQ.+&Q$V&?<_8WE3MCH)TZ%J=5MQN/
MDPA1(,FFG38N5^Z_R_`<9YD?-1`-<,-,@W(>Q$BJJO%2DR%$2U<W&U9XK&9T
MI.R8XPL*WBSKJF2W218:DA#ZL4Z>[>MHC)3R:^&;'7L#E%4F_W(T)DNR+4)7
M<9._5OQ(,CO%30T+#+M$4P).K6`36FT*-"!2JB6=1-S?GSW<8X)"&1]P0H1$
M.STP-.K*^.@0(H.)6CO=H83@^1X';$Z\[$ECF_AITMH0#65:I1_8W]%T>4,9
MJ8?93SBZ=>'[21'GV1WU:?@,[YQ<T[P$H`[*1I9)YP8'Y5M3A($>#6P<E)26
MEY*%I#7/$8DI=TZ\*$H^,?>$\BMR05(\YLLB(E[%PDC^U_O?'?WVM[_E!=[_
MU[?OC[[^]@]'3%2VH7X>/M,(27V;BQC2B9/TE;6'INW:)-/>.Y&5:U\RV?Z.
M!FH*I>0[2R4)#@S<P+7ZUEJJ,4U%.&FE=JVBK7KM$A4:;&A5DXH0`2'Q2Y_%
MXQPXP.*"DQDA8D7'?,#(D]R++EW=60TP'D`(2F#<ILF&IODK/#[!KR/\O0AY
MD1C]RF)FF;ANL57Y3M5B+3V:V<9!2;F6U`L-2EAQ;P<'MAKSIF5SK:2<:8TR
M;:P59&APH]=-O4RAVE+?IG3CA<'9RX;&&10@:%BC'2<FEFFG(;OR[6E(3X\&
M3@Y*=G%5LA`J>'`@JUOKA\VB9R]^5,!I[`])$GP*(\,M<P?6B:_T.QO3N==O
MY4.#O![*RENTNB`3)B?KE&[@-"0K[6'];'3$]>23OM-N4;KU8KN&%@VF+`I*
M9UJ4_0[Y'('@PP$C1_C,"QL7N,P*$\<-G14C8D^7<%\*TV1C=)KF<(_TCM`,
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M`4N'3F>ZDG123!F4;4%)08<'07KEU*\UEHYSG<P8T,><!&'&_6J>NOBUR%I\
M=_3NZ_='O_O#US@3%W/*M,K;FX9%'%BCVDZ<DY?7=C-%*K%M9D,#4G==%?N]
MM!`OI'`).-"GG+;[3/$(%D_G11.M/^9XLL+7RQS62\Q.F=W<V3!C00I:?!A1
M@0X+<.,_S/D#.VQB/$EB*#U#8U^/#2/'Q,_*VE3O/":K(T>S8MEUE$+;6P[N
M/[5X<$"L]ZD>EG.\?B=W!W!6U_MTKLGP&R)8D.SY;M,RY,IU_-&+M`%P)>7$
M"98Z53MYE5TR-,C1ZZ;(HBQ#X1F0DF-X6)T\`P?;XWWY]=?O_DC>?7WT]=?\
M_TDF:LQXXA6E?]#@CR1.JK^&4&DQX/-:LI\B-+LMG&61'1/X9+*IETB5DMUU
ML4F#!G,:Q50K8!(;T/;^MT:XO?OVVZ/O?O^[H]__]O<<:=]]=_3[/[`__>&]
M!G\8`Q.+(.#E*KSHU@N#B_C$VX3,WVPTH>X8U(%QTO-E9T-:9\U6+C2H=E95
MBDG4C(2GJ8<Q\04O#@C>T=P+8QJ<>6G,1DFV\/UB741>3H-3N@S]4.?NN3!.
M"4%W0YH0M'.A@:"SJHJP6$5(`D&)`WNR8^OL`<^]I7#;2N"*=FCU4P<]LM8N
M@G(&'+BQ)2_:HST:-DSIII9`FI('%]X<M;6&W+@GAQ>-BZK`QWF2GI;E/>0:
M(I8<P7XR)G7MAIC7\O+Z"$"SV@[16EIXS:5?<,#WE#[F%W&6I[RXX\?86T,A
M<[;'.BV/>34-Y,`W;<JBHQGM)$8+$QHXNFHJ9SBV#NQC$C?/]7$@L!VENO72
MFY27=PQX_."6IKRBL5.(2\\\7^309I`^F*CC1(/*7NI:0HY'VQ@01EB*JMJ+
M.@+EU"(RTWPPU!F@AU^7`RGL-&I:X28%%?'"CK]=U`=R%</<<&LK;H.:H$8-
MLY:*KA`3`6F\\-(_`>',-3?0-(]`.+*@AIS]&0@=[C"?OO5T\YPX9SJCZ^/@
M.;"A`:.[KJ;#/71^G?3.BM6I,W+,!#H7=\Y`CA%DCHY<&UQ(O3C)+*,+IZ6>
M%5QZYTU#BA=41K=-"2A,/EN/-[O<6&:%E<550_U:5P\EG5"&SD.[B/UD3>O7
M52PIGUKJ::_$&%5N7X-1DJ*!E5D_N>X<4)/M4SC8'KVY]R*:E3?P]95]):I)
M3_;5*K:.]=LD:,"BUJL+DI(`4X7>DR3+;Y905#&[3R*]3]2AFG;14JK87J=:
M)&A@H=9+7HTR?G]S!70D8X0XL/%#FF39;9HLM7EG+8HI,:%0K8F'QL^XTC!D
MQ;I@X!1DPTEPP.!F0U,/;L24E8"MI;SU]).60;&IW2J$HB-&,Y78-)2*H53T
M53%F+)4&[FD401U?&C,%HT4<+()U&(=@#*2#E^;IUEE'YDG=EEX&M;P9)TXT
M$.REKG0/"CRD([(2S$<\C\QK\>.`YQW-*&O?)V;>*7/7HH2_O&!&I85GVLQK
M!_7;2=<&!C30<]%2]K8%#X=:L.7"@;-3NDFI'WK\?54VE$0.$?]/;=J1@6/B
MNN`VU3NEP77D:/!EUU%.YMIRB,FLP8,#8I++X.I:S.RH.3EHN/QZG7J:DN%=
MWPP97D0PZY)M1&SF-BEGP8RLJA(U6S*DN)$4U/OS$2-"`A@HN.BZ*U333EX8
MTVDWJ")$LU:9M%.7Q`Q%<!I6J<_+&><+1`BZ3N*D/0Y,EJNH)T>17F4)1S(I
M+B1I]>MBZ2K,?+8#]&*:%%F)*1PH@G=9,U[!11A0U1S3GNSHR*=^)->D=/?!
M7!4M&B19%%2\TL1_1H4B?JTCRPJX)`0A>9WSHZ";_'*-2DWI,DV3:!JD?">0
M$M,59*>9'!^=@O+#EC$C`;?'!RH<2*G@:XX*251SU*8T1'XZ)-@0HE9/.Y.,
MM)/*7]8![_9W[\M.A[_\<IEX\0^%EWIQ_JJ:&W1$4W2Y64'H<34%E@XW:B?7
M4/9BLBH),<T)/WAAG,'^C68W\=D+>%-%F#W!DGBSA-E.=R)HYYOT8-75C-9Q
MJXT)C9_BJJD,NRR#&YNTQ5)58<:!P/:UU).$N61I#B]A?J`QKS0")7+@CUF8
MQ.?4RPMMAO\P4?-=,>YGK/[6L9L<-&C>0?DNP+<<;%*M6,A2\.#`M[Q1-?M?
M!OHID6I5NPE'+3&NL*5-3=-+F64P"ED@:AM_/6>])TK`%LRZ,NR:Q-D'NDQ2
M*N@>O!>:L>4C]9(T8#N4]/4BIVM>UYIQLC:,>,-8HA![_.+T.;][;3HY;W@O
MG\,UR/9OJ-++>>1"20[R,(U-9F`YR8BURCRN%-33CPFMRC*>)5(LNS,W->5;
ML,ES*%R(I)[R$4'JFN;60\X.S:0^@TJ]EI_0),`U;:E4DQZTH3FB8\RJB&-U
MD?:#EX4^9!J%49%K[PE:N:8$C*,)30A96-!L<MSTU"&,L,527/`Z(H_`*;+!
M!"\.^/U$P]43TV;!=EW>BEX7ZT>:WBRYL8VK;&ZH'"IL2K#N9G`3P\,DH8'V
M3NIW$5\)(YZ01F(N#F)46"\XUK?E'@S/S76)IJTUJU*P76>V28$&64JUY*<I
MZLN*G`S+3<5*K<LPIGP38S.R03@+.B1%E0BIJ?"AI*N:`2E`2C@M&KAT:]DR
M]S,J8):[A8S<)%[D>1H^%CE@_"'I%:092_B\!;)W:1!S4>TADB>%/W/_PB1@
M^$USTZ9E5,ODV/HJC,&'91YH!`D/IH&S1V",6OWA/<9N=-+8VCU518@]Y1*<
M+9?4SV^65S1=T93Y=7>T?(6BO#UP6Z20&),_)&<OU"_@3\PI9/^6,ER>O?A/
M3'NZ6*643\FJT_31/S%9'L.>&J?.@AA9/I8HW1YMZPX7\1785JSY=_B&.NU\
MB6S*3Y$\(;3Z&#!5GR/5]TC]P<,8;V)BF:#]JP\=ZMAK-]2^1J#XRNPN]=Y-
MFVX8CK7\C>C>BY)AITQCYH]Q5X!7/KRFG_@O^@VB$^_DSKFK.9+O;6.<?1@,
MT5;:;+9>+@P9B-/PF2U\9!-Y?HG0F'+H0_X?:I@*6P;B5&)&`%2-00Y([7!B
MAZI:W1VQBFMJA?2Q;7Y8F3Y&@VU&V6(-+U6\,V2?N;%/G1C8QZAN,J`++QKL
M]E38BEY:.0/\C1Q4F:U&,YN%10?#M2,$%6B5!O:";DO"X0!8I79_&..:=TW.
M$?_M9L/3N]@>(?7#3'O6.T`.`@_";J:KVZL4@@;:0S4WHQL034L.\"H2(00U
ML(4%(R#;*`@!M!T,=7:4#Q+<=M4'H?MPIF]^HW[`A%#R(<"P;(;K=,R9L"-4
MTM3!F=CB\9.7PL5#W$`L3[[Z(['%B`"*"D.<I\^#`*.LZB`TXIH>%\'?"E$*
M(GM(%D$0PA3N1;=>R-SZ$Q&>KA(Y:7"2K"&=G$>KF^O&';PJG(4YO:?I<^A3
MT6!WU$]6<6@HDC?9UR=]]G?:)FT]&#S-I]&,U&GME8M\<?9JO'L9\1M?V-/Y
MJ(O)/XFI1DQAI5'*,]`=A$UVSKFSP?59YF!)L^-]%/6E%.1R06JZ\UG)LB?P
M5I\4^ITGJ51(XHY&D#5QZZ7P?KVJ&?K+F`RJ0\VK$=I7``Y@#M3:!8^17$#D
M.!7"X'$\D';H?M39>A,EKU1$F6Y9ISPQBMLT6:7>>GJ_:D=M#L//&J7)Q_&[
M=E)E]N&/PWXIV::42?@G"?\F.=F_:R;-@W4Y-&T1*BO+?&N76GG]4M6FGQV:
M/91T68B6XU:V<T+0(FNIV]<ULK#/A"PGHS0H,_)B1)R+PC;TL6UE!WQC>T".
M8&S.H`U+7EV:0<\[&PQMYF@QJ&/$"4"+M@[H:P8U6M![/1S7N[4OWL&)Z<C!
MYNXJS>SKJ+:$S`[J735W6=Q]+WLZ'"R;SHIZ\&/#KO;DR)GYH+!J.D<Z@7MM
M4>15Z?^?WGIDI%$,$7+,?@KS)]?BE^.)QS8@^C1*W_'B(GO2X<0^_9AD]'+'
M4=7#KM%J:NX1)CTK2TU[R]<T`ZKU&E)8:M^)#)BOWL]Q:_LL-A:6&]DR*73'
M+W^_I9OWW^#K0R=]S3V#*XFE+GARLSQAKOQYE'RR/7!E9IFE+HU!>66%&@4]
MFOG?04E]U1KF\0(3X5SDKQ4?D@HV;-$"[7C-S(`&'UX_9G`%HG[Q;>'GX7,(
M_K<%@D,$35S6<J"A'0^EIQ0T(!ZLNK2?6]S_B9Q?WOQT3\[O;J[(S>W9W>+A
MXOH'LCAYN/CQXN'B[!X'N%L^-IRTQ7X8T98W]Y",`__]?&JV3=S(C:7=T(WT
M'32#;(_&=8=AXU-082&M/L;O_/+RH^RO\.\0#R1+OOH4F<CDW3X"Z]6?^_XP
M2J"(6Z6JLX(]?>A02Z"T&VI?)5#$5V8??WLW[7`J$8UU[7G[Q+AFKFN3S/4(
MO&J):?X^.S0-2IG>=<<!@^9C]#?+BYCMJU<0CEQD&=4^4FECFM2K<3*@Y9\8
M.=#`R4E-R6=H,,$T%-9LQ.-\.%!7O^!PGJ2G2?&8+XMHX?LP'>LP9V:9$G$N
MRC?Q9J)'@S8')<W/<`0E$W,X!==,T=`]O3$X46S;_<D4=Y5USPU"[8K.FX,S
M]=FL[^VAZ]F=K#C`I_?:"QU8?QIF?`ZY3>DZ+-9."Z22;SY'Q&"&WA=1,*%9
M(%PUM7DD?-8)2E8<`%2G^NN."C3$DY[!&!5NG;XH*=&`RJB>?.*2^+_".SLT
M&/7FZCYF,>-5"C>6^>8N_54*%WHTX')0TCY9+6F:0@K;N/<I1GJZ,(/8DT]O
MEGQH+.*@RA9E3GQUF_8F/8F\4/O,24\9DSYS.,2\UN.'?02@@>T0K4U39?D4
MKO-]Z7U%OZ5;ME+D6J)`D"%F44S>6TEIKDCFBMA/*</#*17_;!Q(E;F(EO//
M/@(F?@RUIV&=]U$=N6='XF"5I>-]?AZ1=8X)>720'W)$H?<81N,<&>X+O%5H
MZH[Z-'PV//#FQCHO8/7&F*$J\V$+9?3067+%2D(X<RLIL8+Q(GZF,?N:?,W5
MD6=>^"G4-^.NP8`?<+*R7:15%$CN!RKF=[A[<U*PC4B<&\_EW%AG7IVUQEC6
M98D//_:T.DNEN8"0^((2U4F=QJAM-M,`/$K,"!"I,<@!DQW.`T&E6FLU+G'C
ML7(4;KW707Y@S8?#">R8X>8!EDS8KL"Y*JSU_3:"#`?T3LM@X!UE_D)!JRM]
MNLE/3SYM)I59Z?;QJ9H6VY1FT5-.NBJ#N*F@QX$FY=A("V;Y=ON]B(/V9-WX
MK<^0ZR5V]FEP0"-89\D>,A$'>@89HIA<04@5%Q8QGZ3E@#8B0%@'"[<:;FL*
ME8<,#),(!!ZIT3@'OU3)CQC<5J75SBDZK+I?P](T31\!."_8J5#JSCTI1O,D
M]R*3L]%;;U75`,<;.J@!#&&R;(P;HT9!"`#M8*@#L`U2T$S"@U6WW1B]N/[Q
M[![EC5&V\:Q*LOA_+\*4.EYY<.";-`?=U8Q6(KJ-"=M&SU5A*3.="69N+#]^
MKY](]1Z9HYO$/'D,S;%\92%DW=--DH56`+8HYX"<0E45R!ID6&$EJR@#Z;4J
M\9!5%_H"P8(+/_4(87,Y<RSRUUMF1\YVAU#T9@,DKD/,(&#6"<YJF'&FTW)C
MQ::SYA)DRZ+D@-E-R<NW^+1BQ(%<=]]C9^<%JU>YFS=Y$-LDO=Z.VZ2P$G`H
MVZ0ZSWC7;9)1$`)`.QCJ`&R#%.S;)+OJMFW2^<7UXOH$Y38I37Q*@^R<(6&;
MD-RHQ*9;ONQ\$U_5=3.C<U_7S(0&F*Z:*F[N<CX"K44R+^+>@L_Y2`:,]:X)
MTUZI8>UE&-.,F9K2(-2ZMGKZN3"H5%N'O18Q2LRI--1BC6V_?R5,HL`:9\&'
MJS[OB#OPS84SYU?"K4PH<=?G#?#V7(?V=?N6>4])FC_0=-TL5V!JCC;];*!3
MJ:T%6Y,8)\@4&IK!%2=Y>9P.U>Z192^I?87J:EDO!V/+-+\OUS7`[LA5'"A!
MIU73S87#]81\T[#F6SZ.TYK,,A?<=,KKP-:E1PDUC9*#ICB<3WDH!U9ZS\;*
MS5(4@^\S(CN,LT]]2D.LTU^+"R4NC:JZ38-KNGZD:?84;D@1AXTSP"KG#0<^
M[^BFC/;?+%TVM`;Z*=%H5;L)0BTQMH,7FZ)=Y-7T@"NT>]NF58Y+L)EE+J"Y
M+,$F>LQP<UR)6X@3"W&Y_))C@O"APZ:)UZ"N^8:.GGPNS*F4UN&M28L9:PH]
MW7&&`U?NQS$[G^=@/6C;[8#M($Z.]7I;3HXWI2#R^-HHVX3M])B;S%\_ZF;"
M:YK)Q#`E2.V*M]Z:TE+C`J%53[EH@/@9<A1L[['NN3=T[3[+>VSW.7-`;"VM
M+9\$/QZ11[H*XQA&+>0P<;$8FQ?C4VE-O=2-2^&VETNS3EA_L]AL(OXT@A=5
MSV]=Q,LD7?-"?+:GT5RY)ZW0V<^D5LE.-U8TL9M^^DJ5ZC[>WEZ>79U=/RPN
MR>G%_<GES?W'N[-[<G-.ZG09<G%]?G-WM7BXN+E&4Y)*/`T)S[EJ&J9-,NV-
M0EFY]HW![>]H<*102C6#L;U(*)Z4#DL&+("`]Y\>O!?87ADPT:&:^**I2L7.
M7=(F"2)PJ/2RX0-X2`Y,.#`"MUN9BMNDV#BHMSD7.5U;,T7=^2?=M_8UJ[5M
M=65&@\6^&AN7O/N3/YV=?KP\@_7N^N;Z6*QYBKS0?;W>5ITSP[$+#<Z3M+:E
M8[Z5>K)WU.PJUR5E]:2SP\E-ORYX*@82<@X^T=51CJD@4E4A=K)H2SP?0+H*
MZ_%146(II>2DI0M(7$H_CX"1.AWO(JY>ON/7[![A[E)9>J3[%+W*U'YR)D?6
M$#,ET/41@FNZ&J"Y%J-52B:_[D.KUQ+YDU+P5`CDFGAER9JQ/'X-AD'_[<LZ
MY<,[8$CU%@];^9L1H6;+N/-.AM6^YM3X=&7$@<F>VDK>&#Q!4L^4DT%PK`U%
M3LM5X9W66VV23+LMD)5K>_[;WV>'DD$IZ;RI=?3>6&)Q8N0F77EQ^:8)&QU9
M$H6!B,S%P2U3$P)WK2=2O.B>_85']&P;TI%D3XG*49NC">=1!*,9!V-:(Q7N
M:L@^(BWI?*YMRH>SBOH+9/L)\M?J(__S!H89/*46)5F1T@?ZDG^(]!<LQ__,
MP0P^0R.--@X5WW@;0U)O6'=T/OSIC)S<7-TNKG_&,;+*:L!AO+IE)OOV"_4F
MADE?5;,JWGI334N-!H%6%36%G.$HO^)`-W'?AZLX7(8^E%>1[+--QZ[,DYX]
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MZ>[/]!.!`J&._DX??ORX=?>'SB_^Z^P4V91)(5/P3-P(K]8!VW1IY)D6B`[J
MMY%G8$`$-;N6\O3(>4C)=$1*MA%G1LT6OJVM0Q3?F6NR3;Z["?6NW\XR.YSZ
MZ2D!ZN[L=G%Q2L[^Z_;L^OX,QWSU0Y($G\(H8O-OMPK^UC++_-53QI3SV2#S
MFO-;+P&S`W07K;MPK61POW`KI=H%;^6@<Q7U)MLC7@Z<$U^Y<36E<Q/'QH8&
MJ^ZZRM&PA\7U#Q<?+L]0N8`\`M!X9\S-";1R31Z7L9L@Q6;T+&C@YJ:G.@#8
M8-N'.[@?^/5(`G'AG!.&KJD:=C:T<'2?_=IAP\N+Q8>+2T2EWIL58:SWSU2D
MD^>4:I25<DL[=&B@9%!.G6M:TJ*;P2#UVGW6TE)/^QZV4>7V<]A*4C0P,NLG
M(>GFX>R>W"Y^7C`W#`=\1&5'RYS3)9H2+&H%FQAI4Z"!AE*M+B($$;I)A1=W
M?TJB@*:94!$F0?=II@?_I%E9?<UJ)6:Y,J-!8%^-I?2LAYN3__S3S>7IV=W]
M;\C97SY>/"!)1ZU+$3B'W8P<LQ2`<`NI&<C1X,RNHZ)R%Y2%8"RX0V.27?:8
MF(EE9IQ9HF!Z>LQ(L\>]3FZNSLC#XK^P;/::I68?4B_.H"YB$MLRZNULT]9H
M=3.B7:O5S(,&9HZ*RD5;1?U?SD>:C.BF-IV%[C-=+PD8D.DX#_9@1X]7]UGR
M[NQR\7!VRO:F=WBB8G=A]FNVB(./K,_3W`MCAX<\+3R3`M%%_1;T3`QXP.:@
MI00OX.%GHRTN=-/B"?1JS#2"X0-*N\^';JR35@GN84RKL*H#'QHT]E"V"\H/
M'^\OKL_N[\G)S?7)V?7#':]MB63N@P=$PUS<Y(X#9B7<JZ*QWSKUL,R%/65,
MB\T!YK5!VD,`(K3VUUHJL+B5P6?4EA3,VVDGX^W3;#\AZ$!MF7K[2#@L6-NF
M8[9-O[IX@)*,]V1Q?0JS,EP!/;L>X_[G.`C^2\$\;)I&K_7E_D:19>=IN;>4
M*3$\T,0FB'N*0(/B87IW85Q+:91,:<C!/$$;&\`V,;LRHP&S<2)VXSP,Z%J/
M><XNSTY@\_^7CVSW?W9W^7-5_!;*P2\>%N3SC]>+CZ<7C.8+'$B]+QXS^O>"
M+3AGSPXELO3DT[Y'8%:Z_0"!FA8-XBP*2ABKR8F@1S?Y=0VR'G'KZ><$E?D(
M6T>,%E;V"B(?[L_^\A&2^L[@MC\21[%5&HI70WEUB!\96":.&UF5[\2+M/1H
M@.6@I'RG+61+Z29BN^IDV2Z1AP1E7O8$^RWV#TCO>/8B&#*.<'/CG?I5,V=S
MNB]!61FQ5=3HH[3JC0T<$+RC/F6Z/[)!\I!Z`646B5(AHA94MOU]$47))WA3
M&HI4)\5COBRBBDI8K3W<&O,3TYY$CM\X[:/*\>2CF:CW8)1471'DDHJ4;"7R
M>&HMEM<3K@37Y#C&75T.R6VVUY//4IC*84[7T:+!J45!78$S-(^?:@M*N"'*
MG1U%:1`'Q+GRHD%@3X6E<B#A"PW*"\HX(-F]W'H>QF%.+\-G&A@]!`>^.:\A
M:\TP74*6F-#`SE53>0;LW(I'`KKUQ@M3&#8WZ6F8;9+,BVZ6ETF\XB8)51U7
MV4&B)H7F#L:VT#I`#AX`#U=>PG0M"D($(.*8RT"%\'.FXH]>5-!&4?+MRRSF
MS9<C[Y08[F5.$[1.C&A0VD=;:6EGO(0SMY]N:/#C@&:=S^^ZC=&1SW*SPFD;
MHZ9%`S.+@OJ+.UCV,?SMJ`]>1H.39`U5IL3["YOR488+GA[(YF3PDLUSW2!)
MDY[U##>U=0K47PP:N`[77?GFV#$719JR<*`:[I6[S8E*RJEO\SO,A`HR-*C2
MZ]9%#5#R%!Y$L<`[^DSC@MY1/UFQK9CSB:,#W[31<D<SVB%P"Q,:C+EJ*E\J
MXWRDP8@#=O=/X68CGM[^DQ<'3/[J),D<9RU7YFF7USX&M5=4%TXT4.REKKQN
M"F9^5E*Q$^!',ATN`GA\-,Q*JQQC-U:N21^M<C.A]7*5F04-]MSTE-ZPVG)A
M@MH=S2AK1SC'/V73=)3P\'M9[-9RJ.W`.>WJZVQ*>_VULJ&!GKNN\AHL./F<
MU^#%@<(S+XW9P,AN:<HW-6X3GI5KTB)/;B:TJCZ96="@SDU/J2Y4R448&^%\
M.+#V,:,WR[,L#]=>3C.-R5VB*9&D5K`)G#8%&IPHU>K"@A%!1+<FPP&*:_JI
M\?9?FL3L7WW:"%.[S4C]Q4Q:]7*@D:V*F#UEH`'G0,7E=13"<]$K$8^[\^64
MB69_6`3)!DJG-!\K;7T&!])OTS!)V90<)@&S)?*RC+]]R:./P=^*C-^!/*69
MGX8\)*G-W.@K9MHDFF%&MI-I^LE`@_2!BBN0WN)%@E_%*XK6NGD&CIE?M337
MS=.2H\&:74?M,ZF8KY'>^T\T*"+FSM3JEN7?'R#)UAH:=&:?-#C8TZA6>-"1
M%PTP>RHLA0A+=G!5D3WLN[5,\?1D/W3:!<R#3U?#U`BU<2/$J*/*)I0F_,4*
MOWRDPD.4O*5-\AV<H(TM-7M84C8^0#JK:@+BDB=E8P)@9YR)`7;-^KM<$/K-
MEP;V&6=+JU&&N5++BP:8/14VP7-3/O-(1=`<&T*[J>EL%%8/L_5V/9TES>6%
M]C15YY`ZBD&(YKZZFX`=;B\G8)Q\DV7CEH5T`:/(8>>X3M(\_`>/-I1G6KTP
M/\XGYA@,8S:.:I2,(1_=\!G1*-.XHN5)!?-I&M)PK1^P%"9QSIJ.B5ZQMJ"L
MT6TO$-J8IGV0R\6`]M-<)@XT8'524WZNJ\E$*B[$8;+ZTGKY'%D<L+^D!0T:
M3]WU]%^&B)S'D1ENO-JCZ2\/#=Q',,(]R!%M)6$;#^IWBW[RTI3MK+.;]"Y<
M/3D4Z!HN;YZ1,-!L]3#H*0SA&!AF@6D`?!*\!%Y'>&;R=L4]O'#/T?SN?8EE
M_N;]UH2?*.A(@\4S3;T5K:_T5;E`;%S#?XO3Q2PKUOQ(,6.,I97&67_?'YMB
M%$S38#!$]ONEV<?/).89!U?Y1>*)3Y(E7$)]YI=0-VS=R>"S/./#VWZ/%'#]
M*HP)6YK(A\CS?SUF,A,HN7:5!*RIQ*CUT"2`-*:G^B8:6Z0AS+M@B@9\TA+7
MT3)5`_=TX\;YR$S+V8@-I%GC1OC"[`-WKV:9!FS/89C!]TFR093-HFJRYE7.
M9I,MRC5_\`#L*WCN03>L(6P#K9]4U(-KD"FF`27X1_,NQQXCIW1)V=8O>/!>
MZGCY\`!#3VGSC(9!)JN'0"]1"'$_1'\3V(-2'LF]E_+(A#MWB,,*9\LEA;%)
MZYH7=U[.+^3&/E-9U,KO-PJ&B)QG*`PW7CT>^LM#."@&&V$:&3`@4B:&I"TY
M>PHV&)[>X9KKGD;HRSQ9,*"W0?7FWIES=B0.4M?T#MA">@=,B,`V!8N#Q:LP
M#M?%^HZI[D7E'B<[3]*;#85W_.+5)64.6E^/9"?9\TS*(S2'>G;>0?#L@V,?
MUAA3[KATLA;B2<KEDTWY`6PCR/S23[\1TTO6/"-D@+GJ$=%#$,(1T%][$^+_
M7C]15L1>$800M<V*]=I+7TFXE8L$^M(Q$%3$23/*?[C?L+V&KOE<.">%M;LI
M+1#;V?!`UEE759TC1E?&&3.@)/Q5WSTYSK<TA<NHWHJ>4C^%I>,B_A-3G"TD
MIP5]2*YHNJ*IRG%SY9S,9>YG2NTON['-#JW^NDH/^=3,)"BY(=C])/A)4%"2
M)V3-1>"8]#X461C3+%OX;`QEHEI8;<3-\L<D;^1#":J4!IHQ.538E%/C;@8W
M9\MADF9'^2CJ&X#/EOT*[U[)A!;J8N&HC13%`FY2^">X.M?%^I&F92B__-6]
M-0<)GWDH[-`@EJ$Q0#+FH3+<'&5YV(R$HE!%""G+_A,C$*\")46>Y5[,A].:
M@M#L*=PP=SK$LF.$Z%!YKG7B;4*VI14602FK])D&;.,LMM6\;>)MKW0:>8"<
MJ9]<'V1F]]7U7D+0#(&AFFO0GI9L'.-E7(2-`,&Z)S^\44L#'F'P?[V(1?D-
ME1MH()[,V[8J7#O86LK9\>.DGES[N*8'=P*"#3`Q;C@/CEEO&S'1W\:%A<`:
M<+&QSQ,-<S-*'0`S\\Z.R($*RV^V"J8CPMGXD73-2/[*69'<_]#:=\F\FHN<
MKG7E]5P84=SLEPQQNME?<Z'!I+.J/=$([(3S8X?DQXPNB^@R7.IF3B=.%*"4
M37%"Y98-/RPE7:7JHO6MS(*3DBA\QG)8W"CU7%XZU9BO(IRI2'='44U=[I(*
MVT/46@WW7H1;LR-@WX']1N.(5^QAU/6;RW3-4*I&NZ.LR?83NYI;;S>&"II]
M0AM#>P58^1O.U3E^<TN;-LMY!UNA5>HNFMS%19R'01@5D*)V3_TBY;J=O?A1
M$;#-/<,0)#$7N7@$:=DM-;U8PR52W;`?1_:D,^Z8S=&:I,<0//LPVH<UTK!B
MLH\KX>).5P:A42Z:0'<16I4NW][Z\KW(+R)$205U5<)K:BOTH":=I?*I0EEE
MR=,&'39GPZ"CMM8I,LA`W93LB?):0[HMNHYX%M@H%58"IT6)9CXSJB>_:BYH
MH'QX4/A(GNBH3;CS/EVQC5<:>I$5.VW:6:"C4E>)G"8A/N`HM)/2C[Q/I*+!
M@9GJQ@[?:I7E336&JDFG?012KVS[%4B9#@U>#,K)9R'E]2?K1G@BQ\#F$/SR
M?M)FSI/<BUP=@5JWO;D`FDB#7#G8=%O&1#U9M,"N<AT/T)/./N+<].O"@3.0
MDH,L1JG3J,L.%85.U<$'PXS<EWFZ'-&^!FW31%TY<:"JK[KRF8TH<7OWK]YZ
M\\=3XN\QTEE^ZR2)LR*"Q#X[J!2T4V-(JVX7,A(A*H3HM-,!PJ_I<?F'XDH(
M;4*[X0]H7!P=TQP^H]D`E?>HYI@=7;W4U'J42W'%)UZ-,_6,!+:"0N#PCD9P
M;'CKI1!2M&Q*C"R3`LU!^1;,#/1X0&974NT_I=2GX3._'GR<"FZR8>Q(XFQ<
MR7+.+<\CS3@S,4R),KOB38SIJ=$@S*JB;J7DA4;WZS+]4/"J<*^.KKB:?&K'
MR:1TUW=2T<Z.#$<%=;A8E2SVA6W?PU3L'6W#LT6%+8!BT+#;_@\W#XM+<O/P
MI[,[<O+Q[N[L^H$L[N_/'NYGZH-3NF&KD*B+HO;SMK]/W.X.9UA*[61W;DM$
MSL8I=Z_-H!=W&A>^7ZP+OJ`WO\[^/:*\6&`<-$OZ:]/'5(-^_&],F*^_G^9I
MI/F/^P$<T_R>K)+'27DAU]M^AP2-#^'P2K5F_9`F6>]$[9()13YLRP"G5%C.
M,3M(>ZDIGQ)OGUD[(BN@Q(&S/<WAXXN?-.]K#S/WV+*G&0_?B?$0TQ4H;')2
M]CQM+P;,UG/,;II`HHD>G\/II*UZBEN44UQ,C9DPT^RW3,EK"K)?OIEVQP7E
M9QQW7)**ZE#;E$>4W5.N[0./#J=D)N:YCBCM!NF.*/6<6$;V(*T1G%1>>7&Q
M9+@O4C@V<X:9F6UJ@+D8T866B6=V5[BGHCH<K9NL4Z`)WK2BO/R<.Y0,/%/C
MR*I^%T1:!E0(LFFI<`53R@^1ZH/R^:*[[>,*YBLU%FVU(ZBGQQ;Q==)5'?N]
MO3N[75R<DK/_NCV[OC^;J7.:&P[Y^5[E[LS(@<]3=]17&D)HWT8U/!)KOSKC
MRCQE+*&?04TLNG'./I4/4E=UBR*GQYR;;-E'VM#L'9JFH*R=#0D<M8%9&\\A
M0-`4G.6_D1,O35_!$17W$=%CKA$1:T[G_9M&*P@)+BV&.B)5(^40L&M6W10I
M;9*C![0^B=3&A`2HFMBOF>,0`*A/(F6_',A\::THY,:*`VKFFD(N?`<`.VM5
MH>K-65(^.MN:[L@MHC*!%W%`E_KQ)4HE,-\#+AI_"J/(6B)@J+AI+_7N9G3[
M9N$P66A@OJ,!\D7%2ASN/5-?LT=J/=Q`'P/@V`)1`_6?9"NF.13HJ[+LGPX7
M,]G1P0Y&UJ<)`V1@@>>.^F-W=Y51#O=)U8UYVJFTCT'M"=2%$PLN!VF]\V0Y
M8<>QD3*HVU1\^(Y=>FF-?1(Q19X:&ZKR&/":ON0/GVCT3*^2.'\:$/5V$HIC
MG]VG`5SCD':):#8MHYC1A3]#X;>'"/R?J9<^?$I&::I:%EZ8=\P=CNY2T(&"
MNJV]`LN_/5@LL\_WCX5:I"''<]/D'1$-H@X9TPW]%:C^W:&B^IRUZVB-)(3A
MQG33X-T@#9(.&-$-]16`_OW!`IK1CM=&7!AR0#<,WA'0C/:0`;U57P'H/^``
M]&GX'`8T#K);[Q5*O(B-;57:6],6-J9):_4X&=`J%F#D0`,X)S6EV]$5$RFY
MCHC'^;;%U?<4C?\8^Y$7KFE0JZ`*Y:JH)HNEZU6L0^4RR>QX,.O5!4!-2(**
M$L=$`UG_!0WNO<A+K:7`=,037R(V*-RY$JR@G!TX3NJI+F<4O,#7*Q,<\1=/
M_&2]#K,,DC+V><FG_/1Y5<[.5JK)3#_=<SP.:F^?W#$0SPX85PUUF$%9B+!4
M[D?/Y_Z9T[PC$<\P[V@45LP['<K98>2DG@Y#SR7UON:8*$H^08W-\R3]Z8E9
MD'D1/0VS/`T?"R;DG.J6IO[LT\U`_8W:3DCNO+,#:Z#"$M0J"?R)KT^5#.8P
MU4+(DJ)YTDL,C-LT65*^!GN1'J2N3#/,9Q8#%/.:AF-V&/924S?/173E">_*
M\WW8H,&R.=)-/K-_=>D]5A4$[,Z5BGAJSTJO<->MDBEG!XN3>EJ0>(_UVX/[
M!<4)HPQ]+WJ`YVP<'6\#S]00L:K?18J6`15@;%KJ<..7?"0'QKUNVMBNDF9L
M^>5S6'9'\R*-,Z@552VR&7]\ZYW*2G?>R?#4UYP:5ZZ,./#54UNS!\6$;)(X
MXXM9*D2A<9VX?54`-0ZJB3CT'L,HM)>D[R5A8J>JKVD=#\N5?7;`#M=976/+
M*R?)TMF:M:RT6V]I2+&5&[&IZ5)E^O)B\>'B\N+AXLQ8:GK*1U,>\XN8;0P+
MJ+/U`,C3G=>H**=]'D6K:KM6MD2&9HSK=>N"Y]Y_HD'!=NW)DEPF\>HXI^F:
M`#_9"LC(7[F,_\&(I<LPIA<Y7>LR<+74\V%*4EF/JYH4*;:Z^LEEIEM((G\%
M!L(YD*`)%+I9GO#26^>>#Y/NZY7W$JZ+]8<D39-/$+SW-NR7_%73)/U$3(F[
M(<8UP=B''PU"!RC=A6U)3C9I&/OA!D),B&XJJ`R\B-G,3;/\SLOI*:\D*"Y^
M]V@CO8BY(6LSS@99'3]JR%J4EE;RG)<Z"4LNDK+_/!"XTLQ/PXVA:D\O":C`
M*IO6"ZM;]L.!JJ2S[!/4%.!VUHC=>*_@(^``[6V:^)0&&;SU!D[,-<UOEA=9
M5M0O"VK:QX5QX@<H'`WI%&JW<*$!I+.J<OU=P4B@P4A*GY/HF6==<&R3.,$R
M@=[1<FAD-TNP4-,0,MF4.-,IV415EP8-AC2*=1%3D\&\A1@PJCE:Y+W>%'F6
M>S%<T.TQORMXYUYEM>;8UE>)$0T(^V@K([,#QF3+@@.3)Y&7L='UDY?"6X0W
MZ1T4K;HNUH\TO5G>4Y]YN#S:Z441#3Z\EG192:A;;7>6.B6.1VJ")L)W%(D&
M^^/8(948X`)@LN8I^QG9,)V?O(PBJ8>FM/KLA:9^F-';-/1I_>.@@6`5-3OZ
M'8VU0MXB!S?.W93O@KOB@B"5SP/XGTI&\GD8DR")(B_-^(65(@[S+W!`OKG(
M.:R#\SD:-G\"#:042G6A`B0`$.$;S'12V_2Q0:',U-):XHE/:UTW#6H=M?N'
M#'HC`I[9NZ6Y?;9VBY887VTBNZKF>$"/WIEW8U>]Y'K.)(;/E&DMI8GU9Y][
M>V<RRK;#4_&BF31Z*FR>R<FRE$""ZCG?Y5;&?"70>#RWO,*MZK4.":(Y7:>9
M7'BV#%JC>C6F?3;/X%7>=G8ZRF^2SY<;(2NM3X[8TJ+!CT5!*0-TM4KYF[)(
M3YJ;B^AUDM,J:]!AS6V3SW7BH5):Y]`T:=$`RJ*@V8>!B'0&YVK`@<#MM_6&
MCA;1`F%5T>SS8^B1:NTJ-2_S2Q=QH'Y)L0<;OEU`'Z7E:R`\P;DZG\8Q(W<7
MF##]T8L*MV3:!O6<"WQ'9=/Z7I*B&?UF_:37W-COY!D(ZJ&/$40?8T]47H*R
M*.(NRVU*UV&QUC]%U$O"?&!S,DT/0",[4E"ZZ*S,T@U*ZIE6I1^\,,XNDRRC
MV4U\]@(7>8LP>P*3]`D%5J:)W[)W6)'<598]"3]9Q="Q)(**Y_S-TB8_S#(!
MDX!CDH'K!`\T71LR5MHDD\:<%,JUXDJ-W]$,=(523AM*<3O>V9G98[/?YXG_
M*^1FL<FID=+*2[%E_.*3JC/L7/@<SQXZ*UXE+L1@+D^M0RZ&]1T;[^697^.T
M;T\WDN_HFLU43/%[[B8'5+@ZY:ZG8[43QV2WC]U4K^\<F\EG'_WN.LH+1LE$
M'KV(WS/&[(8VDXA%,CL;,C[[P5NY;6_,`N9S0ET,T_N@)N[9L3E896T\'<^U
M!;U-L`:[73=4<.'`8<L$-_!QE@-`7%-/UZL'@#H"5U_G/C2[]4+EK:;F[_B<
M':5VEG`:V3!BC"/])(F9R3G4I:X2$,_^7O!;+O6%:"=0N@F:;S[H8ZA^BG"1
M@G36Z*&Z.K,T:SCIOA`&]3N3%-$V7&NR^%<HN,;S#G4Y(SWX44!99Y83@KO,
M^(&KT;B+URU9F2[:31'E*#;FB,[1F1]H3)>AS\MV50:<4R\O-"7I!\C!%R'<
MR8INQ_]8'3_`C-28I/*DG+AFZG*$=R'0N55C&61?O$:[%Z$))K4A7<<EM!E*
MKDR3A92<#:BC2E:.V=>67FKJ`\UI'67JD\.TKXYBJ^`ST^HV8@:`18N74([X
MJ8CP#'^[BG+6CTQ,_@K_:RRRL]<<++JD:4H#'@>_]=*;5$2"^'ID>E;&C1-/
M;PW46^["DIUDP'_$ML=5[@`J5\UXKG%-/_&?E,NS&R>^CNVIM_4.8GF:$W!9
M)'^BT*E,(([M(C>+;R5TS=$@F'+#)RO6`E?]Z^S+JE8EJ6(/$`S>CNU2;+C6
M3%U/N/GS="6#9:6V58&WO\W>O1J%3)W+]EH%'-E]8OYZ#H[W(<SH?-D:,J&W
M&0]F/M>H/7@Z/^*+][[*S0=!F/.G$H3RYTEZ6V[A5`\..O),5V[>4?UMN7D+
M`XY9P5%+:2M5LY70X1'D:DN^U]<&^5B`NTX^<U0?$IV7HYP"75FG6T'Z&;-=
M7=SX<&"LG[)2K6@H/DT:@(,WZ9)8[#FJJ8RO50QV-((B1RMXSH>_)<6HV'YF
MC!)M)C1:/6VUS^+*.BT:W8UIH]'.APB-SLH:)KY#P&';0^@#0XES;A1J3+&!
ML,.&&H-J74>'X%[=/./PXC_>\%R6K*H%$[SO/4IU8N:&J(N1;I.F6@9J\#HH
M;CC4200+[#O;7J2H9]'$>950+'Q.W\N,#V3-M`M5MD/?':E2R&'M3LTF2,^T
M.*/@B.":Q/I[>#HQB">QGIZ?6L:A3F*ZY7C0)';$YZV(9ED]G2&<Q/K>;MDR
M'=8D9;[;H@N?37NWI7M>"N^-NAS""KK))A63FMJS;"#",2T8-)/B$JRW,\_G
MKC4,9D0/!U_""[,*@"A^G_0"8U>MUNW%ZL?9@:#32*IKQ=_QA5[GUQ6K1^40
M)8F;YCSQY_,D/6'8'3!G=O@G/5;M:Y;KTM5B1H/#OAH;[M=63DE=?K6UL<J2
M:%_)=%6>W^(1PA&^,G=.IIELU=*I5Z]878+9P6'2J@N`BNQ['+-2K74<B*1/
M>X%_,\N4<X^+\LWIQD0_.XAZ**G#U)A%^VUS1Z7=3Q3^08,%<_N]%5PGX.@O
MO*C.!;T,E\H#Y>&RII^+!IHKSUD]!<T.RS&TE_!:<A][@AVN%53\C73@B$G`
M=+M@JEKSZ+;K.UFQ0]GYO2:Q->H<\4>>MB:H1H")>K+9R*YR/=_H27',*%;]
MNK!I,+#I(A/5$/<<YM'@?A.*0[SLE/GQU@<V=I(T&;1V,[6&W3`Q.""YD^[R
M+%?QD0!V>S.!]4>:08&O'8%JD3(O2)U,-`/4*`(Q.%WTENYS"IY945G7O=P!
MDT89\R+2P3PS'@T"$*/1KK6YONE82!SQ'LLC7&D]2=803.:3^0)47/'3B`^O
M6Y);4:%YP4P(ZF989%FQKLXMRWQ+FJYU=1+V^<')[]GLM>&D>SM[^=KL(VTR
M$Q6^"Z?A!8T0C<8/]C;XT*<-?DPB)@:>/X&R3Z;6W_>7)Q^?TS2E-%#W^UE<
M(W826R7OKB9"5`AOU.:X"[-?SU-*FQ7;IN@&]7</=N":FG%OPU;UT;<Y:`V6
M2D56&2E9,MJW.F*K">PT?`X#&@=3+[;M[Q[LB#4UX]X7VN9'W^:(-5@J%0$M
M2<AK2'=/TAAGQ"Y$<)RWP,WR/(R]V`_C%8^M+^+Z)0==$IH[^Y3CIZ]1S6'@
MRHL&S3T55A1]K]E)4-6"659BQ)G)E$$^N<[8>9(N:9CKB[%90TR]9,X;!!Q@
MOCDHV$/@[)@>TPIK!GA=>PZN((&H20]8V#+"Q]P5S9^28)=#%KNDF0]:7$VU
M'+;8Q"!&KZONJB*:8F9><\89SZXA+7K[$%"?<]`NY^QGTVI3K&?1;3;$:-/I
M*LV(27S,+SWX#3>8I(PM7H4CU.0<ZRE8"LGXI5$G[7<B.[Z0AG;:1V`-ZG;J
M#<J$LZ/*13M%"4&@K2Y/'&=/S*5$=`C0MD5^;-1H>I-\/AR97TC5T2)%DZ2@
M#5!1`A6ND.+)](RMRZ#J,,X^5UG?X[5S8<M#==;8`L0]N5R*!(@/KW<43F2>
M:?WCB1?Y1=3P(E7^P&!1DSEE.QI;>VD#Y<P^)8Z@O%LZ#'E\9;Z<$$F66Q)_
M*[7<5>S[(;^!,<:A0J9_[F](O'&8!!SP':JV_IU`;\8H9%G[X6;Y,?:6RS`*
MH7CV11Q`M+[P(B4L[3R3H=!5_1IT-@8<&'/44A_E*QI\)-PR8O$ADR7-,EX!
MS'#)7R:;UC]4*]GV!MLTLZ/'HICLXFW)1JG^H)EE&B\`FG*RQ;5PMW#PSB(G
M?,5D%.,;;YSL)&]VC(YHA.6ER><R;;\L\+O_^/%BE5(JWH]B.S.AO,IZ-=UT
ME:`-:FZK/RN(<&#'H)E<.:(D94X4H]V"85^[V<II*[?;ROV/1#/=_E.CWG9C
MV2'`T>$:K:2M8.TQ[S=DT73\[VA&69,\@<-/GVF4;`!MAM[OP3S=?-#7H.TD
MX<J)`TA]U37FBZ2E`%X[*=B*<$'?'OU6YPYT8L!WK]Y-77FWC;*SV@_!J1^V
ML]'BZR*KIO)A+-1V\EZ]Q^@M)_.V;R-<A7&X+M::-IQ2@8-/[S4V[,07:LJO
MS[[@S69R=W"7OY+G-W_-1M,ZWLO,X[Q2X*V-\W;#3CW.Q=?_J<9YRV1IG(M?
M_PG&N>JBTH2KN?'S!SO&'1IUTCMV;WH=MQNL6\73MW[S3MDTTRWAQL^_K<$]
MT?)M^/8_T>!V6KK''=R6:JA]WCVT\TQ>W=3YI4,;P^P@[*.EMHJN>%)BKUDJ
MVV-`.!U4W\/044Z<D:)3M9.'TB7#`06C;OJ<DSKW[IG3'[AKT#A*'GO.;HD^
MB"5=T1BC+-<-N;-#?P_&6-(3-NS'`Q\E]<U4OD8LBOPI2157Y/;XG8,8/[9F
M&F4PZ3YR^"/+8IGULK-7<_`'%\%5\5AG'_C8$ZTA_+6+6)ELM*=O',28,S7/
M*.--]8'#'VL&JQR?E3OP856^FMAX0$38.79#Z[]S$,/+UDRC##'=1PY_F%DL
M<WBB,RG&>K4&W8#K/)32>C1C_QUA_OJ!#DZ7)MW3D#5]^BT.9`=[U:]&;Q]C
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M1I,\^U*U%W-,S\ZA!'^=?39^ZS1$'PCPI<88"?:UW+<`^JXQ^G)>.+PK97&*
M![BGJ%DE30Q3>CQVQ:U/;G/JV4'GK&(72IP!_(B2A20IX4SDKYSM?Q`C[#*,
MZ45.U[I`FXUI=J1)!EC15G/@1EQ7S1ZH`U;">7>&GB6U>N'GX7.8OR[B@!=6
MA*/\99*NQ53]F.6IYW?KM`X1,'G2=2_#I`QL)^[9X3=894UN-O%*&;SV02JD
MD'`K9L])VV+[]S$.:%IJ9$*@"]?DR=QV$Z3$;CT+#H`YZVG=GQ?`6V5_(UY3
M&T>T?2;\%MOLZZK"".O*VN"9%'LB2GJ?>VENBBLYZJR]>9)L28_((UV%<7SX
M23'722P.K<[^7K"I>UM-)?L!K-Y#AK7]@P<1L'5NN'%RKFU?>S-!7%=+]WQ!
M#.VPK-)\)AR8C4\>^-"4&F_/@[/^WNR^V(1&:D=FE7;VE@?G)DP]4^;2OC]Z
M\`-4:L"]#]'ZBV][D';--`Q31OJ&!VGYIF4AEP"8ZJ,'/D@5#;CG0=KXXEL>
MI+*9VD'JP\7"*#(/TT,+&DR;N"W"!F=QL%/00)?$K0X;T%$NTHQ]QF[U[>`8
M2WD[;<+OXC^=']",NQ_=]_@HGM$UM<FJA!<:\'.*!LN^#LL,]W2,9V1.?-,=
MC?4P8WLBYL`T^XK>5U-IJB]92<E;88H2SHUIA6Z997X#9A<YOWQS,`<`KI9,
M?"S0[^%PHPD\;NK^U+VCM+D?&.]ALNW1<0=16,+KXY@Q3W&U(6I7/X\&WX9`
MU`B6#-\)Q+6T@\=QUY+]!YM'1;,N/#R.2.2(5H9VQY#W!E`]=71V1%3KXZGC
MB$2-:DTL=`QY!X_J0P]G3K59^A9/8&84.Q"$0H?H+X)"BSAHA(3&&@IJV:AG
M-E-S[#3%J03C&0'[,`M3^+%^#OXDB7E0J_"BRW#9)Q)I%S%74-+5.%U\TL:/
M,E3IJ+0U:EG+(0U!!"1-.$EG><<*U^&I8)QU>M4:8IP[)2Y,<=3>6N.-F4H:
M]PN2:MEQ0:Y'&%3#BWX/8M8;3Z!3TK-W9-,D`1?L^L4N]>R'!S[4T4F%MKW#
MD689V&#8+^!H$G"(4$0<4I2T'1!#-,O`!<6^44*3@,.#X@'$`??NQB-*;1R@
M-=*(GJ3P+B$\1V&X)I;!03HG28>(6:QAN,5JE=*5E\-KB6D89Z$OGE,TA-VL
M+)-AT5'Y&G$6>AQA-#<ENZ"IN4C-1GX<HX[4WI*ZFS7CVZ:J6F6_WSN@)&Y[
MLXV8O*W_&+H`X`3&XH@;CF!H>65]DE&G^=8AC3AC<XTYVI0?0K6QVK.1.P1&
M$>,'R8R-;:\WB;$(MH@CV-G8!TPR:1N^=T@3M[79QAQXVH^]O6%G,W6:'>TX
M-_GKBKP+ML2L6_897UQSX)OR/KVS&<VT0"O3[#OBOIIJLTFJIRN6R`HLJPR[
M"[-?SU,*8XNRALSOY.+Z_=GG!J/)*!LF5;RHH6E06'IGA9$>+QDM"4MBDHY0
M[WZ?D^.&^FQ(_9A$;.6(PORU)SYU`N9&J-DP^[RIXD:-4J/*TAI>$^&'Y@--
MUP/:0;!A@6'3"%?P`<]!0*ZAJ/0<'?N)/_WY2KW4_-HG#K2=AL]AP':0`Z?!
M-CL6]*F,<D5ADQ=+]&J@WEUP5B3D-:01EEID_A,-BHB6Q:Q-6[M,M[<S/>DQ
MHOQ)*XR-W2RM8F)C"4<S6X]MD?1Z<"D?*J=S[O(EX>8W2/,CY/&U15A^B/`O
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MJ=XV_7!["V\YE=8T[I'O>;`IOW1(@\W05&,.-L5GWLQ@T]NF&VPG,Q<Q/=`-
MYQQO15C*G^[/2*?MYCBW9'!,VK87I/;XG4.:L(TO1.WM(V]OY`UX`8JZW91!
M#)[&=&-ZQFC/T[GITV\^JNAD_)N,-6J3U)3A'Q=\]NVE,35`M6:,W[2]AOYX
MGS^<3<'H-G?'O$-L\X`&=UWP<L[QW5.)@QKB@QIXU%'>2X.W,]"'F"VGJ+RI
M8'<C(L+KJTG!R'T,_OWJA&HNF*+Y]Q3]ZZ_0X<P4$[1"=^)X0Y%$K!O2MQUU
M=#+]GRX6V:@-6MZ.3>!//=$Z<J_MJM0A+6'C=,"8T\5N&KV].624]M@]V#I'
M%3#K+*IZ:`DNT6?O5/FJ\^B!OVK8",V\>S6Q'93`%,B>NQ&F#6CO:<"+D-ZL
M8[VW"@<SS`<V[F@CO.?WL61@SFC[@(`U5O`=[AKS9DK(CM$(A[E/?;2WUJ,]
MB<&QM;JKTJR:3+XCG:>II6WHM&K@"J#.8OLT^TP<L2O71SPF^-XA19R<2L+O
M_6.8]HQ3&?LFDYUZ7G5C_W4J/3`TT34[S;</:?#V:LY]7L=4?AC+7G$.HW%L
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MD$:":I4.Q2J=LU7:`UZD@(*-D-A/15'R"1+S7=M"Q3DKU/2F&'$GLTT#PN\$
M"&.Z\MANLQ<,M2I+.]F*D'@5)5(<,@?"U7I..BO2&LH:H<7HD$]H6PW=MQM'
M),8RG9TMEQ0*(M-Z*P5%M>\H=&H8A6*,Y.<T8)YI=)][><$4>6T1:UIJ%,E3
M@G3$IFAB>@2Q:!S%\6SI#I:2AV05$U_W\3S`Z6(Y&$R9IWS)U(AJ.JKS-G<3
MB6UDV(SO.R1T\@YJ+%B,D-X.`O(:^'R5@%>ZEN78@!\>:4R76#97+DUP\@2'
M#!?Q<+]Y]*]@&SH#FJCO:.KQB8,:8/WMDIZ#"/Y69#E$-=B&DS](WG'WD43A
M7%J#!QRW!NVR\,BBL(T:G;%]AT97SD'A7Z-\%^2W-%U[,6`<CF038")!R.2G
M%#O"(;4WC(LP7I7'A4G<#]=J`?.CV628'<,J;N3(-:@LX35-GL,,IN'//PB'
MYPNR3-+&3AH+:+>OM=[1",)0MUZ:OSZD7IQY/C?QPVOK%Z?W?7O)FN<MWP'F
MJM_M[2$(#<!WT=[T'F_)0S@3:<H[@C=#VS^C>GE7TPZ7EG=U[6Q3HMO5B":0
M;3QH,.NHJ'2HIX.D\SNULX-PL4X*YAO=+!M_Z]=(:@D(H&DRS0&E*G;L@#7H
M+!TH-M#J"38<0#TMZ#GKWIOE,O1IFMVD_+&<IR0*V'_I3A[,/),>Y[BHWSK7
M,3&@`9R+EO+TZ-/P&1;B5DKZGC(1+^G*B\XIVP2&Z\<BS:@BW\9$.%G6H5'1
M.M=0234['*RJ=3'`:<F24I(VJ7%,-2?04W`[%F9!>/7;M`/1$4\YN9@5;LXJ
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MLA;TY62U*=EPP)/;M8@#&&I>!(5YXTP'1@WME-`SJML$FI(0#:Q,VLE1(J`A
M)1$.U`B=Q(DJ6YOK]5@;C=613QL&-RO=CGFK:=$@R**@!D2"'@>&&G77MD[@
M>9CY7O0S]=(KC\V=8?Y:'7%J;DSO+&WBO=XN)G>V@4-$H<'O;OI;%MI4H!W7
M2NOH2IP4::J_"-M7"$*WL&/@`.^PE("M1M8@[;M(9N#Y]J#P>A$_?$I@R-I+
MH#C+08A:V<P!P-T*.5#L2@8HX/O;0X,O^RH=!\`-23@A+)DZ#,2UF,.%<=<$
M!9!_=V!`/F<M.@J.&X)0PE@R=!"*:RD'"^*N!0H,__[0,!P^CS,7-P3AQ'#7
MT&$8KJ0<+H8[%B@P_(>9*K].$.:>MBKK>/VFK;`JRK#L)^"M.:$SJ7Q?/'(=
M1/A+>6K7BWVRD[P!1M6G>SUXL=1:&:BWXIBX<4J<%8_'`H'A*&%/-_Q=T]SQ
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M']L2J>H@E)#R>*5I\LRHYWB7]23RLNQF^9,'!N4WZ5VX>LKR1KK`9;B4N]>)
MZY<@\2?K/_:M`IK>4]P8[JVR%&9YHN13^9XA\<2#AB2M7C1D'D$MA$1,"N3$
M?A+?:=TT_!)M!U<3KAS=Z,=^@%W>U7W,OB\?5.$%DDG^5*UGF'%0K<^#D5`+
M.$@L=+4?%PU,^N%@X3Q)ES2$N,Q`+#0$'"`69.W'Q(*(FT:,,4FA7!)\ZG"@
M(9X7'(8*P7N`@&@I/B865N+!Q4/I?/%@V"(.&D^-#8."2M(!`L-@QI@P>58^
MU(8&)WGE2-VFH4_K'[/RUZR?B^DL#3]>^IJBP@RM`R(@`V!!/?^)^/"Y@_(X
M[8W1SP'M(>\M(,7%/>V!%<S^J*TQ^KJG/>0=/E+<G%=GI!R4MVIKFQ[.JYNH
MPX>+U;5U1@IN7];6#H-=VR&"#Q\V/1U?9Q`A\G0O$R_^H?!`K]>3)%/,&Q(%
MKG[5J:?N('[G&?*W"OX:$M1QCI@`LBHEL!T*$S%+3^Q:;`-5KYB5[/8-+[:Q
M+BMO5$4W.D59LB/B923+PTTABL"R&1A^``)OE5)^5#5/S]VF=..%`=LU9T4$
M&BNN)!H)<?6=14NIT!(\*,M[@5<UA5YBO0>+XZ,7@5]%LB=*<Q+`82#[I8@9
M89J'_V!]R$<;_-&O/U;'"%B'?WH*V?SY*8PB\DB)_^2E*Y@V5UX89SF;7$6B
M"SQ0P^;/5Y(\T[2Q*@-"A(1&V(&1<;0$I-A`D@M-G]E<G=4?V4"U]X`&?R19
MP3B%I&HKP:CR)R8UB2EY99\';Q&^%R?IVHL:B/5?_8@>D7#)9I=X1=,O2=F&
M9`.F)_&<.&W-EA:HJFA1HM6@Z*Z`A5]:H.WPER3-V%8*[@/)$PA]A3F4XQ33
ME]\X80=XTA>?/QK#%Z(G[YE+K18CND6C\U"HAT`578-_K^7A@"'/PSP-,Y\7
M0;ZC;!<79\S)JE_'R7Y(V)A[)V'2E1$70'MJ+;T)M&+3U8HG4E0,?+8,>?(%
MZ^+OR>?A%R2#KY"@^@Q9A<\TACK]``"F7IB_'H'?$Q5P4']$'HN<35LYP\F:
M;W7SY`A0Q*;'*M,8T./YI;B@8-/9YR'[$,C+R\=Q@T+4LX;.K30H4E"K,0M[
M:<@7:4ZT`E/9J(!&8%]E^OE%EB=KFF;D<_$63,Y&!!MO`?O7TF%^%>,`WN#(
MOCCB;C-3A>DB_.RTTH.)J-OHJ/R1<>:TK+I=>PE?J)KG2U)WTE&I8<:_M7U]
MB=G"NJ%K^(KGM:8B:QA&-=,Z%$,YY\^FE3_-,]B&9O=<)_'-!FC/_EZPUKE@
MTTS*@9XU-D/7Q?J1IO)`G>"CR`;Y=!:K-C8Q)X`1*Y)Q&0K9XB/6C&4!3@];
M7S8>F_.Y!U3N/V.&X(1_G%#^=1)N/]_,ZS$OD3X;K[`FB:4E@CU4S)8A]H4#
M17RSZ2_8HLY:)?3A$;<1TP`=/O;6$&ZU5%KZ:O]J^SX80UK^B;*Y>^F%*7\B
MK^&CL34CXIY9.0K8_S/_OMSGAUE6<.@VPBZ-4`W&X,P(;7ZS'<7[A[+V8V\.
MRC9+<4!Y[M3,P0U=MK((V_]4YA,L1#K!795-T,A2@%*_J@W#M-]_(RC?R?@N
M\']R2P:!BLL<VJ4_4B:-*T];8!]#?G,;_QQ?Q:</\9_8/^Y_`\QK+S_B0NB+
MM]Y``.8WM^]^_NW5NV].?\.^NX$Q!,,"1+'_3,!%88//%^'&,J;#)+"]@8A&
M9F*SD3^%C)0-U,![G2?"N&M?-J:K^4;3$"7>UI#:H07&'5>-A>&?<#15QWP7
M;!FEP7F2GH<Q6TX[I5LMI+B0:=53PD_E(X2<HSW#\FY?5A)X2`,VB[Z7/9%\
M^XX9CLZ[+T/X]KZK*)%W74?-_CU7'VJ@ZK@R4'_'I@W&\@0WDNDSC9(-M([+
M682=$U?']E5[+P=K:?EU<8-[^_W_>\RV;Z!?>7$!RR$/B//NAG(R9HB;>%""
MVT'AO<!ZW?SN&\7RMB7G/:[;/5KR@]C&[3\`I?P0KH&S9RMQ!)ZJ?;MT&CCG
MA+SP_90&<-KI.!MK&7`ARE';O<S#7OW1_SL)[Q/"9VSL^OG-\HJRIDSY2R^^
M>/4L_(<H-U*D,#3SA^3LA?H%_.EF><_^#5X]."O33!;5";B$^)'EXQH@^S%.
M=0[;FDLI_RSW5OB'^:29=CY--N6W(5LH%TG$0@,^O!C0A1;;5*$ZC>$M`)$O
M=?+6?2]?>=.@;)DHE1.4T@-$Z$"1K),QS#&*(JKSVES!"T@-TQ*IL3<[4J6X
MBI0I?D=Y)O$MY$6XQ(\L`G#A:Z#V7>A<Q&R!%S5/B1>PE9Y]CC^%$_)UNL0#
MY(<!!CYU8E,X_#]]<%1]X\%"C[R?E<J^_6Y=9"W#>XUM(R_F[G91_)^AZYM;
MZ48CO%K[7<>(N],M6K_%'E\$?RNRG&<F/B2+VHA;9L-%7#X`73:3:"7ML=!@
M2;@PL:L9^D!16,'E\X"*?_L"<&%`SN>+VXN3+TJ_L<[U%AXJ/X5J!YK*`K/@
M46Y2NJ3\*EZ6)_ZO%>;8Y^AZ$R6O%()5,5V&S,5,F;T\;[V((80P4WII-1:K
MJZ.LM2MGG"V^I_0QA]Q^WT\+'J&CK%'D[?80(;C@MX,%<KWM):3_`\1J#&YK
M./B->A^MZS(!^X;(SQ=?@9QG_IFWL"\6HW'?^V+Q%5S`VJ>)+LCK'[5I16RP
MQ6O*X'#YVC._AQ0E69'2!_J2?XC8G*N+?AM8<"'&65^I/&U-"3VW$6*J2^(S
M)?J5[]/>+#L)8N=L!>7G/%59=S8RX+_%Z1%;-==EBEE=Q.`!TM;UO;RW+^$"
MQ[[--&,J*[_.E[1NQE[#*:K+Z//9YKE2@WA;/9JKXBS0_!C[D1>N:7`:PDE+
M',BNM4R""PQ:_4RGIH*R/)%Z8IW'/%(:"Q^X=8&POE-9?J3ZE7?L4Q(%-)UE
MYR3<HW982)=J92+&U9<.FFI//,6@<[GWG=1OB6?;JB'Y4YH4JR>XJ5I2\ZV,
M]\J?B6KG3HIZ(N1C)G8U;+L3@7O!+XRWSQ6K3T:A]QA&(41PV`ZL4!Y>EG_2
MGV%NCS"_F&>[7MV999N!GQCV*=P.9G-CGH9LE"3I.:5Z#+KS(H-D;\7G0^BG
M2C^X,UXIR`L5_!."54PEE]YCE:MIF1YE2F1`M*@Y'^R8EG5*ZC\MT$[8WT/?
MBQ[2T(M<EF,M`TK8V;2=#WU^J1G)0;5_UK7YM`RY7O!7+!^\%[;;H7FV>,QX
MLI4$0@L]+@RZ*2OMVJHHM&`CC(\(QN_G.>RHP_G\Q(7Y$[>LI9Z\C/*MJN),
MP\R`JX\<M35$ZT"`.(G8WGK9E"*V:2[S1'#@'`-B43[;ZS\DXNSEE)^A"6LU
M*4^.?+AZLI_2^@X5]4NRNNMX$,X7=8D@NQ/5420W6F?J-?W$?U+=GW7C0]C#
MSDKK$\]B^JE]Q(>Z+WE@L']7=M@.HB?5.DL/%I;U@=:;\H)OWLQV=>A<6%FC
M(F!^4SL%$5(2H!1>"*6)V!S.'#N?B603`Z]NEHH4V"0.O/2U^_,LB/DSY5^G
MV>7ER155EK^227`A0:M?M]=K0L(HB2"=:9B&2QI=AWX2>044SX,,&"]^U72`
MF1Q79SCIVNT8P40J+L+8>&U)QC=O-QD6"_YCNQ(4#7JNDFH9V#ITJ`&CI6U[
MD)J3/44TVSZ80I;4@_<29CJ%#I_9AOPV\GQ^%`Z14,6YLTR$JVL-&NI]6XBI
MEO?E1/5Q*.>9\K)Z&R&/;"J!LW3..7U,"[:\OO_ZW?OK)*>99E;5T.'J(K.2
MW5ZJJ`F0$TX_Y_S9Q=?B);0/$R#"U0<&#:6#5GD,L%D.:JR&J4C#J3S!.K4&
MW!&(`=2E:QO%+Y/-$]3%]<L"\5#*+V&CD%\)]"!4F!5I64$7%LL0RC+#H(00
MW[*(`_:?:_J/?[!?8EK]03BV_#]$_1K(0YPGMO!CF'M7-+AE?V%+09*^FH:K
MB1@77APT[>*F9"%;GOE'+U_;JT!6G8#V4Y@_,0\@#E\>GFCJ;6C!\&G8/`R2
M@JL_=S%!]G1A]%7"2"V-@#@BY)&FP+FW*E6V$&0N\D=D.GE'C0)?==$OY1/D
M0P7APL*.5LB7;-GJP&;]=77A6]0?JW*KCJO<JE8Q_KHR6O?)R9GRJ.I[]/QP
M;)M@ILBGTI'BZF2KGGKO6*XJX+'IW`_Y"@Y':?-VEN;5J/J9PE.FI_QNE-21
MP\3@ZN2=;)`.W,#EXR.WKE6;BE<S1)']QM.-)R<__WQ\=75\>EI6)<0#!'@?
MC,TKNX#`*.(``."B?]_.?Q8RD7=^G4`\M.L-`@Z@X^W:&T(BK>M@,@KP=+((
MP=7W2]B&L7QY],/KL$[O(?``0-#?&B4H5$?`6?4.*Y*30MWR!R&].^HGJQA\
M&.>5O\UV`%VMT]EPJ)^(,'3[U:OJ>LWL?O@5W%7=1'01/$-(Z(X^)Q&\VG/"
M"UI!-$&S0W=EQ-6I/;7N=FO%3DI^4@L@0@*/O\P:?H&,^RA,MD=HU12DB[18
M&'#UGZ.V4ORD9.-'A"4CJ4L(H^RN=[W[Z]UA==B[M]9C[WOWV/O#ZK'W;ZW'
MONG=8]\<5H]]<Y@]5L=`%R(JYHGK[>U;;E!)O'JJ4.K!WA)P]>A0]?5NZ#;\
MZS5$DJ!*^>[<U4.RW1`[*^:%?XR]Y9)AU>,5?_EUU,*+Y'ZW,>#J9D=MG3*&
M^>W;<*9T[ZLD")=PX,P,M?B;>E)<?6/54]H;-!A0S*+M>ED/B09DFG[JQ8VK
MZX:HKGU?1`@A#PEIBB$-.5C[^(S?QQ_0O4W&P^E9A=9].U6(F+,__US$M$[:
MLLRD!EI<O6975$JY9AS-;#0,TZG2"MTNW41\`)UCWIMK>^<=NO[1[<E-Q`?0
M/^:=N+9_WF-=JAJKJ6Y$]6/'U8>#=-_%(YEU()[2S$]#GMUO.BP7%P(<CHUW
ME(<+"N,8H]\1!EOYK5-E7K]OOF/E.F/Q!)XY$=9)':TBPM5[!@T=<_3J.HC$
M!Q'\_L-\\94ZH%2>:TI=TB7`U1T:[0PI%W64:WL-A1>.%D/G$<LQ>S/LIWXY
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MTTT]>''U6W_%NQT)$@B((+4,TA1"0`H!,7-V+EOB_L+V'>$RI`$<AHF*1)7"
MH**F9UT9<75K3ZVE:`OKMII?'!Z*H@/;+N:].F<>+T2!/G@9#9I@6X##LN(A
M]0^O6Y);[Y477?GDI0'_G\853:G'1Y.,"Q)CFZ6\P2I>!&'(J)ZJ^TTF#IK*
M1Z%$V2WVNP="H:Q-G)2%GWE]`O8)",A"*(^IERT]OSJ[8K[I$Q6E#_E&`\A%
MR=PCLO;27VF^_8NHD;BA*;\?&S>)#Q"K]:W2D9%:RWU+..T:Y7KAEN,Q`^!1
M7M;S^!'$0P6F>)XS4L5=X@^O_&%3-OO6/YYXD5]$O(6N:/ZD.$8=*`<7)G8S
MHB<&'E_9Y.%O99$U%S8+"B#^`A/8S=*MP)6%'E>ONBDKO=Q;<I&;):I25_4M
MC7O^3D)`*\1RS10;.Q,YKHYRTM7E(<GMO9.LDM2HF`S"<%1[U*6=Z0AQ=9=%
MR[?44;J,3ATA\HXR9W*J*G/B2;)U2GY&.5X,&MJ2:?$TOU-N,\I18-#0UORS
MIC"W]'9I??2-WZOM9PWF,07$T>1%O"A6108OJ]\S%JX3**F-YCERXNJEOFK+
M\3SHL?(P]R(F0@2_Z5T+$7V+I5=[=^9A]>'PKL/37W\N(O!<WO%"5W`*;9H&
M=:2X^LBJISPI1MP=>T=*EODG1Y4->M],2XN_8VR>FKIG9O;89#/TCIN6%G_?
MV-PX==_,.IV=TL?\(L[RE%M;ASS./9^*I\^E'K)RX.HG5W7U\8'J\=%MG(#?
MD@AKH<3+21ZN>90@+.-T<_L2#\F/7AHF17;KI5`2P^Y,J#EP=::KND9W@G5I
MR4I*7B3^WT,"^KSJEBTM)>(^4JAI[)N'A/?)Z[P+EFR"@S/>IL3>)SW<[[I/
M9EVH;FD*21C>BIY2/Z5>1B_B/R41O)YT6M"'Y(JF*T4'N;'AZJU>.NO7K4TM
MABU80@X4TGX2D@@\6LVHUES8W)>D;Y:7/%5'<RM62XFKXVQJ.E]9COB%KGC6
MZY?5)=U%'(C,*<!)F2.MF0T=>'!UF+O"TG-5]1UF"">5:6'`7*>1S^K4BXIV
M=_29Q@6\K`(3@7B=X2[,?M5TGQL;KA[LI;/VL?>2F[38"?#/V8TW;/A[D!QV
M"7-W=E[`JXU7;/NR+M;WQ6,$?[V#QE$4`>S!BZM#^RLN#<W&>>[?"_YXR%KP
MLS\`(]F(_"EQB38K'@F7FI$GCY>Q;CQ##`\1U(?"<1(?^["YB_A]D8CF.4V/
MV?^O,P3PN*9YJ['*)+'L5)%"Y\Z*&AQVO27'EN:M\WX'?.R,#5C(Z8L/3["R
M;R8Q):_42U'L:QP#`X<2$>@="BBW-C.'`"[IRHO.*9O6PO5CD6;<KY!Z1$F%
MJS-,*IK*\@IJ[DV!\PM2^&.Y<]V96-05I1Z>PC3@NU_]10D]-:[><5%5=25B
MRT0X5QD-F''`7,0!7<(T3"_#9SA8S)G.(9MW%UE&\^SLQ8\*V./^D"3!IS"*
MV*PO==P`&;BZ<[@!YD71X^Q'L&0)`57%(#8HQ6^\DLRJ%'M$(L__E==P>GK-
M0I]1,8\JRT7(G!%6"R?4@/H;]<5[O)7JU;/E[+N/-&9_G.=9KS\EZ9HMS.+U
MT-?3M%B=,-7#`-XN9O^OOT'MRH@+.CVU[N*E9"\?6WTE((#4$D@I8M9KO>4;
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ME&`,=U`C?@.U\/EG'@L&9PB"P-%4FK`_4^Y$"G>RO-\Z2R#MQ-NP=2WB,:6;
M1ZB3P9\QAMO]\E*AI\6%)[NB<K56.!"$^!>$K<CGK">9FY<_95]`]T&GEM/+
M;]AL4^3@XO/M`0^0D:3^QFQY3"=)_,R6+2@KS/^-%W6KDG383O;$RYZ4Z4PN
MC+AZMZ?6JJZN+S9!SVZW>-NTIL]9Q^=/D-O$"!*VT#.:J,Q]RMAV33R45'Z9
M\;%QS2#C02B4/_;Y.4P17II7?V#2F-N0B<OM\^00I'3CA4%57+51694_)L7:
MS.?WON2UQYD3%TSZJMW%R0GS]%[+![-@M?"R"C!54ESV1&E.^+Z/_5+$Y2+!
M`"'>T.)1=DT!6BA]D#(X9$=E!06()S!@$9\Y/"LFPEMY`$?"V"'(GI'4@U)=
MKP3*1C<JU@+NA(1*9.%%C(P7F@Y(L8'*"E6EMNHC94GJX(\B=B_:@6Q`_9G@
M63ZH6IUBL`V7.-U0%P->L''TS)^[DL_A!PK"!=X=K;!A&3R?\@7;^KQGS7:[
MW+59\B_IH>OQKX5PE``9HK0NIGQ8E3;V4A#F[=6"<2P#`Q-2JXZ&*/<"=8#9
M%,?FJ).3GW\^OKHZ/CTEO$;+/,%.415)4XB:_WC#$Y&RL[)R3?!>!D=_&<BP
M,-@`=8WNND0W200?=W_$7XHXS)DO514""IH%]NMU1RQDO*HW\Y60U)C=Y^LT
MW_P2/4:3`:)E<Q,(`[76U8YU$W.XA_](>LU!0^7!OY)EXMXHLN.5YVU^$>=T
M)_*.0TGPR_O96]ZLEY2&59XCEG2S-K)Z9Z>C0=?4"M5TK;TEG;7!]<V,KG$M
M33I3,W;R6E7MV2%!U+`ZS6SYMS.U]67H/;*E&A8$PVPL4R%J<8-R4N7:+>G<
MDW-#%?,,K23$V?P.<W6K!V:?L!O:6)H>9X.[-/-,3<OWD7#?BJ;9&0\,J%I8
MID+4T`;ENNW=)/T-$<1DD>=I^%B(%Q9RGFZ+`NI02,:I=VP\B/K*657#2.&1
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MZA>BY`>OZ\:,/7OQGR"GH"X2(9VPC2P?`;;V:E8782-_9ZZCDN!O19;SS*.'
M9!&(IWJ\Z-8+@XNXS-\M4SOA7A^XSC^%^=,V[_.<>I"FI#QL&4DVHC5J=).D
M`Y_M!V`ZVGZ"P#=X`H_XRA%I?(?P+<TG]B6R_10IOS6?;\*S_+?UHQ:^#UEO
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M\:M[0;`;%+QDRSSO"M>X%G5*-TD6FCNJ08:P:U3::3L#[DA4U%C&C%,5@_[<
M"+NJA](NPZF2<L1KZ.9'=?[)9L;`G&;^AZUF-GC)4W`CZMX!2O=<\FI1\R]Y
M=[2Z\7FSY.\I4U$*#R)YJAXUT2/J0R<UY5(_]>W79$E*MK+$'S#B&H+GHD[!
MP"&HX$;4?0.4[CD$:U'S#T%N*;_SV-W)JOI33XVH_QR4E.^D9T]LY1-W/Q4;
M\_EO@3+/[+ZLG"`=8FHIL1Q'VA4T7^-L<,Q3YE2$ME\7CQFO:B'U@$2!8#A8
M%)/#41W*&2<DYL7"/\#]?/8B6!-ODRCT7Q_H2_X!WN30S4U61@3],DQ?U8S%
M?73^+PT!;!KC(LA?RW^"+,*%_<]LY^O\C#;;IF*K3\J[5(@ZRZ"<?'I=DU8Y
M6;,%W\LAS=P1U=1EHD/4]D;UM-/8$0$G[*\5PVS8WT,5QK%E(^KKT4V21F>C
MR.)IJ\CB::O(8O,K1[BB(Y.54$/B/?976"[EZBAAMHFZ7PEY]23>3P:B03]8
M=7GRKP0=<TGR(0'<JZC27RMQL^SNYGHZ`<F8WD5U?:\[RYIMG+=5^R%-,M?1
M[<*):DSW4ECNT\[`/2)<`H;Q6Y_$B%6E]/&K_*LX,)=0L',AZL4>RFK6W)FW
M0(-+#8H"=+>L,9_@I_,DY7]6]>C8WT#4_WLS3;JJ`O1EM<;FITCC6Q!#;]*5
MWR-<\I'X*2/U-_GY-/]MKDB6ZB6(FVW!;F40R\*#8/WNK:H4N@)&..0J6>'Y
M"LY\1!KLAS9AL"E15*JL+G)5Y;O9TL>,I.-.'=:OO85)Q-W(/4PG[./'XNM5
M"97&]\$;X1H<5)5A?7N6Q54AWU24497V&E-\%,'D-KVM2NCN^>-HGHBJBOKR
MMW;D5Y'X('-\)LI)%!:$C6"!<E4=)/)0T%#]/`X@:FF'C`G9B#%@44L]'&1L
MPK*,Q4C8J.4=-CID,\;!1RWW4!#"-J!+&L)-X'$0TI!WR`A1F3$&0AIR#P4A
M\+8$#>`,<>LMC0(5E>!#QHS1GC'`H_H`%A1E\-I7];+19;AT@XC$]<NW>/M?
MKZQ+YTK<:'NNQ^9"PXMY%-M4'M27N/8+DGK]-@AZ]H/JUV%;`+T8Q+W;S\DW
M"3BP'A[FQIL$H>WEOHZZ2<!!]?)05]PD"&TO#W:VG20=5+_O[$X[23S,<XJL
M<1YXP6P,XRST?X3W<O=P/J'_&!9O?1(;QS^/T'_T0%%9GOWM'Y'*#V&9W?9N
MWQZ0J/S@@:*P,;OO'XG:C[TA--IMW`,BM1^=*?_EW`M3_OU%EA7K2L<-]>%&
M!KR>2>/@KO-,<5]>1+DIO57N0@`$$"Z!-$0<D4H(J:00$'-H24TR2.7TD+U]
M!!%,]F?;'C*7;K88K+]Z1&;)_!BK_1I;&C&L'A+X4\.Q_(G"V0&C>::IMZ*M
M(X9]H'4WC=X0M$=JB'V.`Z&BN+-73<MYPO_<2CD](I6JI-2U&D)0'XEI>U">
MHKSYZG3$'5U[8<S^WH@?/-!TG;T;SX/<08F#WW6/8?MH'N<.RAPBZL5)U7R`
M[_G]@]]%[6CVV##OJ<>!>D5.T=&]?PP!=J>S<9]N2LL3J;]/YHP&C#,.+V)1
M68O_URG;!N\?K4X??D->>#][]XEBH0E4,A>ZE'\AH`XF5#_:&_O1OIMO-_`[
M+93W\C5L^-VOD9-%2G"`M"I`_^"]-&[0JP"FID0$#HN"VM+[\*IAZ_8_EJX`
M7`B`1U'R"5[0=>H7F0US)QFT=>JQFI_4`K#T7Z>8BHD.<P\UU7/J$JB(EBP1
M]4S]_,(EE%G-S@M(6[IBF[1UL:ZJE)\65>$)59_UDX"H-P<JKG]`7<@Y(D(2
M*4552UY&3N$1DVLH!OGPB4;/C()M@Y]F?^G>;/Y%_/`I^9EZJ7+EZRWD\/I?
MH?M@"!P!!L`S9R()EXF^\Y]22D?H_EK,00)`UGX$"(#0PP#!.6OVW3%02SE$
M",C*[XX`D'D@``B?1Y@$:BD'"0!)^1$`P&3.`@!^U&`R_;Y@&W'VUSNFKQ?)
M%P%Z\"*(3@]66=O%=AD(>I1M-G1XMG6H@15I?[IH;.E.@PA%;S;_=,G^C?VY
M^A/['XAVL;_\_U!+`P04````"`!=B65$/H=+X_!0``!BF04`%0`<`'1X;60M
M,C`Q,S$R,S%?<')E+GAM;%54"0`#\J`74_*@%U-U>`L``00E#@``!#D!``#M
M?>MSX\:Q[_=;=?\'79^Z=7(^K-?2VDGLD]Q3%$FMF5`D35+KN"I5+H@<4HA!
M0,9#*^6OOS,`2('`/'H`#*:I9:IBR]+T8+I_/:^>?OSE?YYWWL43"2,W\/_Z
MU>77WWQU0?Q5L';][5^_NEN\ZRWZH]%7%U'L^&O'"WSRUZ_\X*O_^7__^W]=
MT/_]Y?^\>W=QXQ)O_</%(%B]&_F;X+\O)LZ._'#QD?@D=.(@_.^+3XZ7L-\$
M-ZY'PHM^L'OT2$SH'[(/_W#Q[=??.!?OW@&Z_43\=1#>S4>';A_B^/&']^\_
M?_[\M1\\.9^#\+?HZU4`ZVX1).&*'/J:_?#/X>!C;^[^FX3_['LN\>/HG\L'
MRL@C26)W%=T._OF/Z_GXGU??7'ZXO/IP^<_X>;?^E?UT^>'KYPUE=N#$M"/Z
M]V__[]7@FP_L']\M+[__X;NK'[[]%CBHV(F3Z#"H;Y[__,TWE]_0_V7D?_%<
M_[<?V#_NG8A<4`3]Z(?GR/WK5P51?/[P=1!NWU]1RO?_N!TO5@]DY[QS?8;D
MBGRUIV*]\.@NO__^^_?I7_=-*RV?[T-O_XT/[_?#.?1,_^I*VA=&$KD_1.GP
MQL'*B5-%5'[F0MB"_=>[?;-W[%?O+J_>?;C\^CE:?[47?BK!,/#(G&PNV+^I
M0AV^&A?PWJVI*NW>LR;O*4S)CFI$SU\/_=B-7QAFX2X=,F4C[?,A))N_?L64
MXMU>1=B'_P-"&[\\TND5N6QV?'7QOM%8^X$?!9Z[ILJXOG8\)NG%`R%QI!JH
MDK"34<Z<D`KK@5`"QZL]9&XOIL;/)BUA$$?3S?21+7T46BUQRWOH8MR+.%C]
M]A!X:[HN#W]/J)H.R,9=N7%=-I0==L%5WXD>;KS@<VTP*AVT.^K=H^._J,=V
MU*S-$2R2W<X)7RA:[M9W*3P.7:=6JR"A"Y6_G5&)K%RB%)Y>+VV.?^0_49R"
M4"G#2L,V1S%E?^@G(5MR>E$$6&K%%&V.Z\9])FO8@#A-VQS)+"2/CKL>/C\2
M/STH2`?#;]VNWM`3R-:]]PA,/*+VIK1H[#KWKN?&@,FG(&MSA),@)G1G?7'N
M/26&O+:MKER5[46Y2@DIVM4L^B-9.L]JY#A-VQS)G'AL-Z,G(8@:\5NW.9[K
M)')]$D5TJUU1706>DN14+>_&.S=.]WUZ5*??8YL7O1$#A`<@;57WB4=6%*R?
M$HH6";V7&]>G1U_7\>@-U%'.`Q!UNZ>,^XC\GE#Q#-DN##A/\-MW?_)I]P34
MR4EHR59<P-K#;6[V5`0;FHK.T`D)-C@A@;G3$FQ@,AJ3)R>HNLFH.CA%Z:N>
MD-CL*08V4!6=H1,-%&P!04>[-6R4X`ZZV[F!V&OT8<!:,2"QXWK1Q`G96>Q)
M>1%0D'6_I^LRT*Q7(WM\_C'P)E]J;W:7!PY.26AHG]>%'T!J=J3Z`S1_)@$.
M34ID\E2B"S*4OH,QUQQJAR.\K#G$RP[/>[H*H-E-=QPT&[AI*Z"NF"&T78U5
MJ<8@8K.W`>VS"KB';L>ME+5&%]V._*KYR*\Z'7GM\78ZROH*T:T>U(>_6]0_
MU![G!S,GAX,)0/\HIB0U.U+]`78S+L"Q2TAB[EU)%UX8M?EW)]UQZ_72D:6K
MABU&MZMN.6G.0/=6.^B^J].)R=<W??L7C%XVYL>01)0VG31C^HLC$O(<$W]-
MUON.V*A;\<BDOV8]?9/][_+BW<6>JOBCXZ\OLBXNBGWDX]]SX`6KHT%[S&$U
M"%7"2WV$96/MW4=T,5D=O.(\YYYX:?>_,EH8Z?LZ@\T%G+K01F3U]39X>K\F
M[GLV?O9#RLB[;RYS!]K_H+_Z-1O#G&Q=]FD_9D[+G)'3IOR6Y8$6]:(7KBZ"
MD)Y/*&+[/IUP=:0-59_?O,7[Q]3A\]WJP?4.BK0)@YVN*'.Q!0I&BM*E0^@<
M@GZZ!WDC.F^>_TY>9!A4F@)!N,2'@H!K&S#L^5C2;OG2/VX!%/H5)J'S>+0I
MZQD)W8!RL&:!%G*AEYH"I?\!H_2Y7-N`H4='LV8CNO&<+5_\I29`L7^+2>Q<
M+FV(.S?JWKC1RO%^(4XH57QQ:R`(WV$"0<6[O8WW9^)Y?_>#S_Z".%'@D_4H
MBA(2RC9@(0D0F3]B0@8D!7OP?`J\A$HP?$GC#2,9+)6F0#C^A`\.`=<6CZ?9
M_)V3QR!D5_0LK%%Z2A50`$'Y,SY0Y#*PATVJ(WVZF&X+X3`\2$H-@4A\CP\)
M+L?V`)@E]YZ[NO$"AW?K/XSZJ!GXSH9/^AQV+2Y,P6X7^.ECR.*!\AU-DSB-
M<*<35+H\2>F@Z&"\4@,$8O/.EQT!LSO0#?V=8!.1-(>"@_+J+63?/B;L6`Y&
MI-`8B@?*R[B`=0X:?WE?X6Y,?V'8+*Z.X3^RB5]=O+LXA#O3G_O3R6(Z'@UZ
MR^'@XKHW[DWZPXO%C\/A<E'+(%[4LHT3W:>()=&[K>,\9JI&O#C:_Z:L<_FO
M?SV,<+HY/)K,@LA5V,]S<AAUXTE4G[W,24[-2+F=+6.ZEER/9Y*`D_:7M*9H
M[!V3@:!4FENSL;<%CD``.#!B61G$D&1_M69P!XDQX(P8DX3S`(=H3E;$?6(>
MD!,2Y\Q()H.4RIH1O@8B$/YQ('4(\J`#%"-SW,J:7;X&$CS^<$@^=;T^8D4L
M?UY;:X;Y&BB(><6!!1"&>@BT;X!O>9?F8$%9V1#ZQ_4X$X)PP.EHXR!VO+2E
M511G8?!(POAEYCG9#>WWQ'UD\I&N;7(J:P;DYAA#Q(%C^A66!_61F=O8GH&S
M.4X2[G'`<QR'1S6I,&+9O))1V;-Y`J1>GD=J]G$`58Z<HQ-]^+SR$F:-_1@$
MZ\^NYXD!@U';LX=J`Z<C#AP`#L@C6S.B?+R!OU(=2<04]@REVD"IV,8!#AR4
M^F`8NS/!P0"`<)*G0]5^I;LS&;M8-3[6OQ7$"@')=->MAJ"ISXKP'J"HM^^^
MTQQU73GA6$X+HP:;RV4T4`2-7=6T81"BB-IZOK=MYJ'M8*MNN3T4K_8]@N`"
MYUMU^9SC0&>0K_-S\D3\A.?M>SASE1J"7SS0X"'@M?:V]T3"^R`B]C>^]+!6
M%8?")L(C@()J[)JM#:J"=QRS3`>;)K`8NT2WOE>]P3/GZQ5(ZV#"(X/B;>PN
MWA[>8JD@F9J!OUV2<,?+(,[!C=L:"I>QVSI,W@&`%4S0C/R84$G&Q^<GJH\0
MFPJ(&`J<L;M['>`TQ((#1RZ3FFLC'"MCSZ>U)IF,]3>T]X'0A&-HS&K2$,.W
M@AR@@@#'T4U&!$6VB]MYG1,+N*:"[<6TCEFS!4/FARYN?'6`.Q7SY6R_3J0#
M3@LN2M_"JXVA2!F[!&IC(^$9!RB%<"0%(M664#B,W=%JK7$\;G%@T5NOT\<+
MQYLY[GKD]YU'EVZ6A4%+;,8`6BA>QBYIVGC!)8(#P3E+U>63]=`)?;I[1KW5
M*MDE:0*^4C'&*H(06BB"!E]:-1&$2P0'@N*B99!#!1PA@RZNC8\/;^6,KSI7
MU7\%A^/<Q3VNH7U2*IM6=0!9B":_9O%1O.8'>+SFQ1^.^ONO<_RFL7.2YP6?
M&8PW03@(DOMXDWC5^"'U,[M>-R<<_5E'7CBVXP&YCT<^Y2X-!K_SG1W+[?)O
M>GAPHY0!V7.]DO2$@T;!@L&!X_$]F"Z4TS!E?IU>PV8D3'-A0,T!8GK;0:B-
M@D]T1(01UBR?22^)'X*0J2(4SBJ=[<C5UF`4B00O?&EB.4WH]C2VPUQ;ANU8
M%'@ADZ=4DC!8)Z<21B=NH%!P(%@P7NGO@R#B$XZRU1`..C3AVY^4R%I6S%;1
MP[WQ50:JVO6$!"<<[:P0`E*D0)M=*]D#C3W4MXD9;)NS;W@[\!Q--]-'DI?S
MX1O=OI49W19+^J_;X62YN)C>7$QGPWEO.:(-+)K;LCI0AQ&K+6Q"`IL/'XY'
MHCPN0)K]H=+0MA5%(?[R<P>?3RRK7407!19I'2T"3[H?E1K:OC'K@2#@$P<(
M'\,@BF9AL)&]UAXULGUUTA,^A[]3?^G+=Q1_FZ><@"1%$9/8/H'KP:GD'<>L
M6A#/8UDDB$^'Z_7\=6^]<_VTQA,K:I8/7K+M`.EM'\C5<`2U^,*$Y9R*E([A
M@8YV0'=2+TB3)"DA5)#9/I;K(@>2`@[`!H0*DUXS4E%2%<L>BXYJ]W$3I8B)
MK*>/TD4+(`(<6%48T]C#,&2)TL1%R.Z;.9-DV_F8'KH`2!8;V\]'5!?+*LLG
MCR8S<FB<+OG-K6?*T3Q:RIA&LEJR(4X"/SA6/04R/`(H-L:>3>32YB`C9AL'
M-BR3<)1&%&6CVX=MR@QC(@KKV89TT%$QC@.>U(4HBA+F&<8,,I+MB=/4>O(@
M'4"$K.IO2]]GVY)/MLRL;7]CVNN6\O95:6@]G9#>E.*R:1,_0?'Q<>#X'Q.'
ME:Y^$4TKUI#3SGI"(1`B@L';!Z0E\Z_C^A$[NI)HZ@^?V>::N-%#]E['%A*)
M45A-:CV]D,ZD`XL"T89V\(GM!W07IG?\>X]<$S^--6*18^R7$17V#7'B1.9J
M4Z\WZWF*M+?%F@+#`7GU"*S<!R4DUI,.Z8"G9/W4K]RO1H0;*J<L(4%"F7UU
M'[@FFR`D6;NE\TPBND:%#D7)]9WP943ON&F."TI)^?)2.:EO(`8_:CU+DMZ)
MR[CXWX:&4M9SD6;+IE*[.`36TS#I:X:0[=,_`DY(##':EII93^VCM7OP6#SU
M^;@/,M^["E\[D;MBSW.NE\0R]TXEH?7D/GJ&6Z`@<)SA?B;N]H&.JD</FLZ6
M3)+=/0FGFW3@!?=&,)AU^[.>!T@/XV9B0^\D6@U)+^>+./(9_0[N,[I83OM_
M_W$Z'@SGB_^\&/YT-UK^<O&'P?!FU!\MZX5M"TQ!VKQ)'I98APWZLYI2(Q_I
M4IY9M-Q.-1\KBMSNI&PH<.Z<+;-8])+`@!"=TB0]MP-0*K2UC)1`N'($"L,O
MFE4QH)!I5#_8/08^T[?>LPL!A$]VBMCP.2GXD=L\8QZ/;1#L'%?B1"5HC@P5
MF<:5CY9\A@JAO3BBA6X).P^)@>$TM1W(4`<.(<<XSO:"!&XJ<!1D:+(\:``%
MD@0.T,HYVU1HB=K;CDFI`Y.<=QSX5$^?].:8%6F<,:]6*MTX#MW[)&:;[3+0
MM8&WU3^:];1RK%6FP&LBT-I6M$<2N@&[9X2Q?5N:Q<!;\^NV2B$TPVRMP"RP
M.0PW&[**IYM;$FY)V//7<[+*MIK<VWV6A,P1*EX&PV>R2MBOZ(66_A12O1\^
MKQX<?TMZVY"DDA)8(EK_"IJ]0J@:1MBV_V+2C1IELZ@;9=I_"TTVHBY5ZEC0
MB,XK67*)`1TUW533%3#-ZC(AG]._2`T<('+;0;AZIPVH.%`CF"E;?0@K]&@R
M%]7$4"`0'"`R;Z]7=Z[<VXNL7QW`>CN6./)2[A('Z\%V"#482%VAG`B4Q80^
M30`M]6,[N+H]6+D"P@&N;'](_S9]3-VOZ'$@7+F1["F\1E>VH[!;V4:E8D*-
M<J:7[<`L[<MZ`'<[>^WI(ITJ:NJR56_^YJ36`[Y;F;!'<D`-6VX/JH7;$2T4
M./O6,+@D<"#76_\KR<(OHV4@>'?9N\61-7L6('Z4RKVXFLS)[XD;N3%9D/#)
M79&,:7H[#[:^*\^<T=D`K&<(`.M0QY@T542!50S"Q<].R,+BLOF2CU-D^6K0
M'Q1ZR^:MQA(SA&3^S?P&<!.$E8C&.4FK5,V<4%#>E?6CWXWU%!`PW.K*Y]1W
M@.'NT0M>2':#F"7AZH&VF(7!-G1V5G:$A@.RGM6B@QVB%<RZ6F?RC+_^5A8;
MKJ2RG@ZCYBK"Y[X3V?>BHX_76-X5/5C/B%$'$Y!4.L*G.*<+`^'5Z>,Q(B:W
MGNFB'C(J>9S.7GMTPFNV2Y:ZLIXRH]7]C2NGTX%98171Z,)ZFHQ683U1&TDA
M(01[3_G9C1\T\F>T]P7K.35:508=J=;V,:/=W0<1L>]&:#:4VKY=2Q5';=N`
MC=Y-^-<K!'DQ.O849CPWG."9$^G01Y`MH7U/81V=L._/I>+$$-*XPK7[3O1P
MXP6?!25]_@@/S^[W%C]>W(RG/]LLZ5,HT73@3*MR-H?*[B[,!C0+@R>7(G[]
M<A<Q9YA#ON;>*G:?LF+P2B;K]`6<S!T4W!*B6=W7:TH,Q^9O]-S514%L#:"P
M'L".;@/,Y.RO7(\<#7@9M#8OS7P-3<@.7"-,BMV0);3E((#,9U5@-C7T+=L!
M/$91-Q>O<0P5CG6K6"I%O-X<M[(=;-,%_%S&,0%7+&HSW=#;)E4U9F?J11&1
MI7=7T=D.K>D07)@(<<"=<IM:#8-P$"3W\2;Q>JL56U`D8,NI;$?@=`@U1'PX
M@$:1DMR8*T&'D-=):'ZB.4Q/*!FZ,8>(3@\%K:12/U%E.]XUF2P&;I2NI+.0
M[-QD!SU[<$EMAR19.WY(!(EC8^+[XTD,I(+VUH.1.H18+C,<N!ZKH=)ED:N\
M=5T6C1D7K4UC,TZ/+:6PSZMBY3E->_[!"XV>BO>^^-.P[SFN+"NH9C?68Y\Z
MU(5:$C9D9S1?F\I<J%%7!CY(:2N[-2="0G>/`<G^7>`O=S!2/Q7H]&$]SJC+
MJ:HM6ZPZL;=C4'D1]TF>=QM&;3UNJ08X*G3%4CK]*UF56U:5U*=?XX<["(5T
M1&8]G,B`%G#D\A;A3YV0^TG(A*QZ$(!16P]",J`,8BF]69UXW2?K:46%WGH@
ME"F]$$CJ+6K&?FN<.2]U3P\'4NOA5P:/#B7YG+[#_B`?]9S073$A^R`&:7%P
M$87UX*S&P*ND\4:G?IC0H;G.O>MEUR9_?;S^%?ZFN3)H]6P]"LS,PE%#NECO
MF>G`69!#=F*JJ1>R7JP'?YDZ3$BEA@-ON!.T&&V=/O#$`9EP%&]\1D!295/`
M,;M&1RT%$TC[@FJ)^90FC;4$(#,<*P$]YNZC6E>_)RZK^@QU+@206J^<VP">
M0)?9MW)PW+/*O.?(8Q"Y$"4X:@R%W9B=H'78.;)X.T`?=)K*B^YN\<O,<_R8
MGEY9(.RCH%B(:%Y(^K!>:]G<:J"4W.EK"UQX;9P*$%1M-GH:>.-GQH-G3`MG
M1FE?4"TQGU"BL98`9(;DS!@&*T+6T0V5Q:L33"%:7K)=J$FAB!J[*S:`IQ*'
M`),3/EC'KD]8\#]=C5S9[B\F@<)HS*W`"(Q<N>"#3[/,`(`4"J>QN[D1.$^@
MR,#1<!^",%Z2<"</#9*00&'L^D+>$$:>7/#!][H'[!U%=3?*5SHHD%U?L=O:
M)<L2PH=F,7$G?#Y6J:!(=GTK;H:D2#KX<#SH7+AP/*IY6?8OS9E9H@4'S9\4
MIG))X4!V3AYSV\QT`SS$2DB@.!JS0;2&HU(NIV^@*K((7YSE5%`%,/9(;40!
M`(OS&]"!21`3M9N;F`**O3'3DA'L>5(Y?=SAHFK#_`C7#?S6#7W)G;K).F4W
MS;U9=N`1ZX:,!JH+YDMVP$W0:AF\!93E>,*1,U_80P^YQAAEJ6?IU\/X%)#2
M2!O\K?E2'WI8O:V4T(OD\=%+I>!X>RF,_$T0[C(@U)ETH1U`4Y-A>O[5E`Z.
M&_,^=SFK92#&[;@5%!QSV4,U)5UVW*VRC`4,%OJ\=)[9&5V.1ZDA%!)S#^$-
M(>$RC@,5YM%-.7IUX_#7A_-QFD`>X-L`[P**I/D$^1HN#;H2ZKPJ'P<:>2$[
M.!#FWCRUI0HJT=<U!HI:N9+V4`3,/5>VBH"D!&[G084*\`ZOX2-_G]HX]8&]
M9]Z->:B3I)),D7V]KJ"0FWO8;`/R.N(S-!W91U\S%.8)#-G7]SD-*<."*QBC
MAY-#D3/WD-D$.5TQ83F9Q"1?7RYEAX]B*W`F8'0X<=D1PF&KCL[NT?%?7T6/
MJN7\Z>+=!<O[Z`51$A+Z'\L?AQ?]Z>VL-_G%8E&<:;AU_#RKW6L=(*8._GI6
MD-`AXYWCO98(4I]]6^K>XC1KQ,$KX$NJ4=>>U$&V_2]9+M'3JFZ5%@)3L*!9
M3!;);N>$+]/-PMWZ[L9=L>B2+$%%6IC.<U?%AYFCM>;/Y;5F<7=[VYO_PDIQ
M+48?)Z.;4;\W65[T^OWIW60YFGR\F$W'H_YH:+,^5Y4[0($<"8U-6ZD,,\!2
M`*6W/,'5B)6MI%IR03,7]]G$!%O[]^7I-II\&DZ6TWF]C5UPF#\,0C(K6$-.
M.ZM6S7PT6ENAG,J6U@ND*S!JJOE&H]^2!&E%1;_\IJSH4WJ(G5_T[^;S(=M.
M%HOATN8.DO*1,0`XFO(:VSQH5D"`G!EE1+:/?V(TRH<Y->MHYLJ-^TS6LDER
M69XD-Z-_#`?V)X<P3ED]50"D=CVZ^:/3VG+T>K$\M<!85EVZM46%9N;1:]VC
MXZZ'SZS``N%/OJORY)O-A[/>:'`Q_,=L.%D,K<Z_XO#WJQU@[DG)VC07'W\*
M:+Q@E!!"ZS,&(/VB41@N##031)B7YFB*?*C>5I:]R<?1]7AH?Y/Z&`3KSZ[G
MT;6IS,WKF-631K,;NRXX@N&!KDD`8LL3KQ:B5:<=J)#03,;BF9:7#/!H3GXK
MOUB-1[WKT7BTM&N?2SDJL`+>PI2$MF]=A;'I6>PAQ!AN86K4>#<RF%C0S#AN
M>,O1-/NN/,TFT^5P<3'K_=*CNY_%J54<.L2AC-?:<EU*K8DC)+`\660X<(I#
MGL*L2/-</`0>E5M4BMH]FAM_K+P9+:?]O_\X'0^&\\5_7@Q_NALM;3Y49V-7
M3XYR.YNO0!71,_W2FB@:75B>.GQ\RN\_NA)!,XT*3LK\^5/Q[QA-^M/;X<6R
M]P^KI[;#P'7N3U(B##[RFM<D&97E>0/`1^0O?PKSIA!O+KS]5-P5YL-Q;SD<
MT(/9W/*=IQ@NOPP=/Z*PL(Q1ZBFDIK0:*\\?G-:TTNK$\BR#XEB)GM>6$YJ9
M=YU$+-E'U`_\%>TY=(Z+G!S-P(H'P_7=8C09+A87_>FD/YPLY[WE:#JQ.A/=
MZ#=65N..<A/&CNO#$HLJR&S&OA9Q8</4FGPP:MNS#H)9.7!60RQHYAI+[.EF
M]4PINY0%YM=$?*&'WE7%DX*>%6]'RULZU187O<F`S3OFES><6';*DW"F<Z#4
M[,;JM`2,%#1!]?JQ/%5KX5R9NG5$AV82+XA'5G2W_RFAVST)O9>#Y_#`B1W^
M/*XX>RR&XV&?G5U_NJ.'U^%\_,O%S6C2H].X-[X8]):]BS_<37IW@Q%M\U\6
MYW65R4+`KL[,UN[(XMR6CA4PIZ'TEN=R36Q+LUE/6'AF<7(?D=\3VNF0>6`*
M]M^*G\CB[GHQ_.F.O;8-F?.NS3VWS`(DM8:(PFK"D.-!0<R=8A++<TJ%224=
MB()W1/,%$F<BC3>YJKB4P.--+OZP[]KF;OB&0D^.@J'2D;W`KI,2JE,+,X'(
M`$<0+PLK9F=E^B_V'O+D>&RU@,,&(X<6:\8#H(Y8;*92:,L<NR*4R7N/1,O0
M69-]]=A]0>K7O_<\+_C,$C&SE`)!<A]O$N]0MCH5C\Q>V^97P'6@L>B4"2'C
M6$0.L4;@=4-,`4U)CP96%?,X(!(ZWH,A@_<`SD"/!4)=X>"`M.R42J_);DS&
M[A-9JU9B`"DTHPH:$,'B0(+>[M%QPS3364BO+H]!Y'C3S3A@E=J?]@%>\/6T
M5F_@;"QH,&X@-!RPW]#Q?W*\A!3R0KSF^5$>H8#D0&"-I2[3!E9++#B0/'C!
M:!QZ1!1`O(SE':NQV,J9QP'1XH$R?^U$9,TR(Q$_RC*R/.9I6D;I0R]=.-B^
MKYQZM3H#`FLL+9E^@HSZ(L.!.7.+!L](;F.PL0(-:!*><8`R)_2.E!!ZPPVV
M]%2F8Q@$D$(!PV->`LL#!WR+!_?Q,4N6]Z/CKVG_VWX0P:<9E!X*)!Z;CIYD
M<*#96[/TDFZ4CQ5^R5`20O'#8[P!R@('<',J33H&9I@>T`7$"U(;11X@KC:^
M`HBA`.(QW6C(!`>(0R?T*7O1C(3I60L\^Y2$4/#PF&R`LL`!W%W$RDY&L;MS
M8EDIKW([*"QXK"Q\3G&@,"&?"_R$@4]_7)&"D0`\G_1[@B*)QZQ25UHXL)Z%
M;A!FE<+H2=ESHBAU#TG%O?Y7$J6>G@,2K4(WO9_*WBYT>X)BC<<D4U=::!R!
M#@]IR_2-E._I4TE4<4AU>?&'C,ZF&P\GZ2(DUE%"9//6MWH@ZX056SZ,,,_=
MD`H:<N\#]V`]!E*)6_GBIRD<-+.,D^I0,MTJ"2MX"3<QS+R3SKSYJDP"=+3F
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MH"S<$>K+$<U$KJ9,E,SA#Y6\,KPLGABF[RFF\SRH%3^-Y;X`\#2<N]L'6+Q[
M_2Y/(MUG4XDU/:`)"EV\CNMGPCY,UKTG.ONVY.`'OW>)H"L&^^],JE&4[-*W
MNX@2YD-7KL+L@P:_9_L@)M<#P\QC/,5373_X<--M)S7Y?7;"=3H#,D?NB,>E
M_G;>SG=LQ_'J+B0M"A>OXA2=_XN\]5:Q^[0_`M14%MV^;4<$UU:0>D)$<_`K
M9)R6G?@J&<B*>:<QG/3>5`+J5ST;Y)DFZ!@/UJ9&MS/-#JV[;.BFK6XH.FR+
M]7"S(6PA(0=)S)TX#2GQ5Y21+$N:MA+4Z=7V$;")*M27(IIU6I+U4K9N5S+0
M23/`-EO(!=<@Y<@5E:8UZ%%,V<R6>^OZ[B[9S9D6>/DA,KH)PNDC84F'_>V8
MT--#C06\4?<V:UIKZX%P.K<@833S6IX.5C:UJ^GPU$EA[9_3OLB,L*^J*T]W
MJKT8:'7W)O+%-A(EFEG/+HV._S(@L>-ZT809GMCQA#_1*][PRQ^';!^?]2:_
M7/PA[^/BT(E5!]UPZ_CY"^91>D2ZXL\*4BPD`%G0WV3!*@"7WG:ZMUJL*Q_.
MLE@_D%>1Z[B=:NY6]-O(%&X5WDK1KF..BPD8,`!&)SX9T1\E08&\MCB`XZN=
M"('"\`]V6;LHS`G+$K2BQSX6*N4Y?N_9E0`A:'Y"6`@X*%RR,:$Q"':.*XG,
M$Q+@0$2J72I@]JR\GI[:?$/L;4.2*@M;8>G7;DFX)>$G-W9NR?J6[.Y)R!$[
M(P51VC;J*#2I^,"G(0D<1CQ.BC/YJB4DP#%+0.N6D(?"`Y]%3-+J:AL2,@O$
M@H1/[HKJ'3\;W9*.)>+_2;7<M?L5'.@KM+FD!NU*H.'2VM+5)GW6$RZY^Q/R
M42O;J3=-J'NYA#M'+#C6W]R=0X58J9GMI)H=0,85#`[,F(TX?T9/7]BC410E
MK[85?OTS+H'M0B[":R.GFIF$8Z2P3),XBAU_3753`YLC*MM'S_H(<9C'`5/5
M_9&E(`PCD@W^T7-EQ9T@Q+;=N,"@:8C"D/?GC(0LBZJS)0.R"ME3U,C_D0Z(
M:LT@(<L@N[\(+F]08MM>4VH\=+C!-)<JL[Z7Q`]!Z/Y;:S<J$MDNF%!_P:NR
MC@.C?>WIWHK.\"C+L'I0M>GF4Q`7HCFR5J$,OKK]V:ZB`$:VF<#0@IXM\(=Q
M9R>H:<C^S4P5DX0=='.?3>6)LJW^;=_]FBA%`X'B4)+"$M9W'MW8\;*QLD2B
MX1-9WP1AYD22LN2O)"]Q-;JR?8>LL]+KB<G0F:F0N(X5_%C]-O*S7'>"8Y*D
MO>UB"["3D9)A-!X+L`*>,(>&2KXQG4*>J/P=WE!%SU?'&G%R((7/`K@''"9M
M_3SP8`:1."\(AUE9E#2R7XW1.3=H:BXT%]88G1N$<*C7+\P8+']>!!&_;42+
MG.)PI1#S1[^L>F<$$>-`5$-SP:GJ"DRB>"$\C$SUY%1I:/NNJ*&%Y>3^?)YQ
MW`+GCK]5+(J%)C@F2L.EK\`/#H^+=$"J"7'4"`<.%=WA"7H_9!3+SZWSS.)A
M5+(N-;.]]'#THR1I+E\X%I@\!$DI\N-FMLU#`)'S^,(A<N&J>!>13>*-W8WD
MA@HBMIY=%'IG@QZ4JI+!`66A+%>>[4YB-.&TM>U!4!LI,>,%8"@W6?SZ.!.&
M<,SI@&F']T%$TK8M>R"OGYCEMQ!@F9F$^36Y\JP7+K=V4NK&6[L[V[X'^G`W
MXQ?55/5C=^UZ";.W+L@J"=,Q#I]77K(FZQLJ*A;1ENRC?\HEOWH[9FB3S.YV
MNK?M#5%_06A3O&B>#%[KK60F>_YC0*4V0J'63TYX+O;3-C,3`LAARF]M/2.,
M;A$?&=,V]]N6(679A:,'DN:BEA@\1.UM'Z:D*`D`Y;*,8\,\C''N?+YU8A*Z
MC@=!Y;BY[2-/'5!X#./`9)\0*JT!G">M%D/";VW[B*&!B(Q='(`4F8%M0_:]
M*.M,B0)[M3><.(@=K[3=V,_YGN?"EYWO*M5X^,7E$!SU+%67$]R[JV)6Y,F2
M$>"O!:?BH)UU2^2KGU7TX=_)%=M%ZN`.I[=VS@(*.*C%51?HL(0CB<?<=4!@
M<)I;.T[5EKV09QP;^/Z(D84@DJ).2+=T%9VU4Y8>4$!N4"&6$&9.FA./GM'7
M,R=DAB;U65A*9>U(5@\M@`1P8)6RQBTVISB6"&BLA:G4PDG-O=GMYF/BL"CI
M%_CVSZ>P]L!>>].1<8YH9F3\P&9$J:VU%_CZ,X'+[1NX318J*,."!RI%)H]K
M*:,*#WBS995/.XUAW:K)YQ2%MM-+(4Y1^,7XYD-P.GO@GSWP+6"99GQG63]&
MN\<P>,KRSJJ\,Z5$MI\;ZGOF`V2!XS`_(%2HJZP(A\QD5&QU*MF=>+PA]/';
MIV7IK5;)+DD-(\61TY\]DJ=Y+M8H%BJGX)[<_F=L>RU`H[S-B!>-IU?U$L>_
MNU5J/W/O;N<;V_G&=KZQG6]LYQO;^<9VOK&][1N;\9CI[J-_3CMF^B8)?9<%
MJ%"6Z+&._:2\0<MH;+NPUH=)+0D<B%DS>G0?1_-VC!Y"%C^&053GV)'3G8IA
M!,8_#JP,6D7R3WQ)!I'66:YK5?L^LUWX9,L&83^21\BBU)5.3F5[]VV^'K3A
M.\\WG-HQE1U[-,FL9=]^4[:6S>;#66\TN!C^8S:<+(9(#&8<#RV(L4Q*AL.W
MJ*4H@,X32``0$;L8M18B&;-T^P8>*TINZ66?]$G@KW2<]67TMG=38-R$MD00
M/D'E/-PZ?K)Q\H)P6GC**6UOA'I(0J1@UON5'L^H3KAQ'CX(!4%"9OM2J8>`
MDG\<5Y/CM9Z>FPI<0C??,I5MEP<`4"`^FFY?:%QD1[0W?^O>>T3#3_;;RVI>
MC65O\G%T/1[B=)9E4?R?7<^C.%8XULB]H=F-3;M"X7X[W90'*[$6*.@LGS]K
MX5BV#H!$\R8NA(+9S9_45QJ3^CR7S^X5'4[9LZN%[2=\Q*X6+%-/3,;TA%%1
ML.N76^=?0=CWG"A2UL>&=W)"N&GQA<,%0S+DUP%/G)W2'4.[(QRXUM!G..A\
MQE&X:V1I"$FX"#;Q9RJHTM!5K\Y`<MMFMYK:72VN!9<5#G-"6O'-)W'&%^-0
MZ4@@(;%M<VL'1J5,L$"W)ILV=EGMCG"LR*"=5ILW'#44%,/6VW%K=88#XYHZ
MKJ<$1G9?@;']QR#<!3Y9IJ:!ET&8;/NLKOB:JO*,_E_FQ\7HX>364G\TD7G5
M.*\K+T-O)+<L)=.C1Y:ALR8[)_R-I?7^Y,;.SO6C1?)(_R1WPF.]Z'9BNU!'
M2Q#6DQV./59RH``E5(;2GXH3GYX\T&.H<+U44R*^MZBSE4(%@Q[&@F=A\1FA
M%K#"OA#?;1I!K1`>>O"EOI(J.MLN"J9`19>%4#Q62!4G&+5M-P9#8&(MYJ0X
M'F:U3%Q_>WAJ`I2?J-NC[0)KX`-44Z&=)O3M00Z&^L^6;D5J!)LI!&*'3EU6
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ML`O.ZZ`DM)EHVGURUU0#HIGSPIP$L[+I^R+J8IY4=!B**ZJQ*F>F!@G#D`/5
MG;_R''='UH=1"$R_O(:VC].:\A:Q<5+K'']Y^TY_>3LO:BTSQ1(5)&2]<#PG
MA)3R$[6W?2>IMXK)N3>T>N4?S<H][A-TR"O$R4EL'_]KK&@0&>`XT^<C_>2L
M4GE")TBEO>TS>:,)(N#>U`3QO.`S*X5Z$X0_/U`.(\<C=*.(0_<^H9W<$-E"
ME:J73@^VG=OK3!]]":&:3;,PV)`HH@)V/#F:QWHHI+/MW=YH=BFD878;&COW
M^\1?H#V(U]ZVPU3]#4C,O5FI]VE+=^5XR]!U//@!0$)FVY.I/@9*61B"@I[Z
M2&J/8C?7:$[B)/0CEC=VO[A&S([U^KA;@@1.;MN7J`8TNK)!L[NDX]W;)/S#
M-*\P+]UJX)V`C0E(L*W#(R:$!>QJW[T1^&O50TXA@#>0KFX2Q&2OF#`S^1_+
M=J3)=#E<7,QZO_28JPTNTWB1/;7IB-_::K7%^WCDTX$D@&Q5W,8X8L%E,%2*
M,'*X0)*>ZGAL8W6.*B$!#E@DZB5%98PN9=4X\+<Q"7=LG.5R2YQZ*MS6IX8)
MGPL<*:?*8U/EN1"UQX&)3+L4H)A-2;&/S^^MG]@U84Z>`N^)&7C3=,ALU05E
M-5"3VW[&D^L3+V4!5"2&KKLL2<)M:FS:N5$4A"_I%BA%0TYBV^(`1P#"NB&I
MCZ(H8:A/-SJ"5U)!G]N,O;?!A0^4@"'YWY#[,''"%_J7J_2KEU+!BYM#)6[L
ME0TN<17/78E:3]*Z@C;V4M9`T';D?*4GZ"M=21M[-6D@Z:M.1/VWQ"?`E8/?
M%/HTC^"8(N.U"_'*M9C?%"I>!-N@C-<NQ`N7KJYP$2P/$D[;M%M'9/7U-GAZ
MOR9N=O&D/Y3OF_17OX[)UO&&?NS&+X)K/VU5:83C9@FX[?,&WV:F2ZB8L^\+
M+_*TR7$+RP+FB:TBV.,1&[JCA\RY_M]N(+^*EUO9>^NJR(5SR>;S9"J#8WCK
M>IZ[=7R%",O-[+TZ@63(Y\J0$.?$73W<.#O7>QF[.U8K:SR3BE-&8"^T'B!8
M-:<X7E?'KD^OZ9E=ZL99L2?&EUOGV=TEN^L@#(//S&KE/-*_Q"\2RZE6+Y:C
M'Q0/*&5;:@T!X84V34U.HGCNQ&20U@J<D=`-UGK0BGNQ;:)MCJU*0B>"+8E6
MH?LHSV*IU8EM;_^6D:W*!P>PLS!8$;*.;BC_C.4)B:>;O3TU]903XPFAM1TX
MH`<C7!HXT)N31^<E348]W;#QBK&JMK0=+:"'C(A3'#CPIG\6KCA-XBAF&>#]
MK=["R"&W'470?$D4R@0'C&ER^.GF9^;$18<9SMWM0SQ)V"EZNEF0%=V>4X<X
MQ_/(^OHE;Q?E#24K9>..;0<?Z$'?DAP1*\7PF80K-R*ST&7/C@TU0=F;[>B'
M%N`'2@P'YL6U"[9LVW?!K[\ZXY)]<:=GHXS40$A(K'O/US_F<)G'@5'QG`S$
M2$)BW4^^_B5!A=&)9BKEG=T&9!42)V+QH%OWB5"^N7%+DM,?OP?K&4N;'VME
MHL$Q8?>VB#R7D1BW2D,H/$AN\`)&<:!PS`K5GCRGC1@.,044%R2W017K.``J
M+NW%\`W8MG9,`04(R:%=Q3H.@(KG(QA`8@HH0,:\B^L?#?$"M%]_\\'M(P[]
M]23P5ZI(2A`Q%#8D%RT-@9S^N;&\RKOA)\=+P.%[!0+P\P\.E!6,XYB;QX.\
M\YTLR27+^99%X<]"LG.3G;1"F58G4!21W.QJ"`@'LA\=UX_&0131RZ@_?(Y=
M?YNXT0/C0O4P!""U'@FBAR)8&*>_WC+WU67NOBJYBQ^ULAYEHGG?YK"(8](M
MXF#U&WL<INM#P7$CS4X:I4D4Q)!`:*U'J>@!!1>'S7DG=!1DCG5TT(OT2$8%
MF^[?^4F;@V/F<R<G@@)H^XH.X073Q#MFJ^AFDY8U7%/%6S$Y;\$'3WD?4!R1
MW.3UQ8,=5K;^@Q-.<`BA`"*YZ0,%@0.UU_NM*_'J/&X%Q0/=%=[EN66>;JTQ
M61XD0<&Q/^DF0K);=NR<"@E%Q-<Y%=(Y%9+QB_`Y%=(Y%9(93-"F0DK7U>S.
M/?)[R3:)V,O"@CS&:>@7BU>6AKMIT-N.M(%':FL+Q5#PX=$X:F+2!`H$:6*@
M(C"6G<!CZ3PN4Y=CLH8D*1`3V/:^UTE5H&*[0WFK4II(*&Q[U#:3>%?Y3:I?
M5J4YD5!8=Y=M)O-NEA5;:>[,.<#BRG/74MQ&X#^1,&8U'8O73R%,.9V"S+K3
M$`PJ&#-='7^6P2<G=(.$?C]D@3_0\X^(SKIS2*T3D%P*7:#`/OPBWY`E[:T[
M<]24.H_KSJ0-/NN7VUMWNF@B[9;WX;9\1[WT^8L-<!DZ?N2LF#"CZY?B7^26
M(YT^<-@NX/8D'=[:S,75#J(J"Q.O+0Z$]/52`EQ+]J:VRAF'9$7[5IVYRNVL
MAP2)%:M2HYC'(8[USD*T"8[WVM.(-;$1RH`#G].(9,#J980#PU-U,C+H,7MV
MF-6:447;1)X:9/A[DN;-VC<!OZS#^CJMC$?UI84<[>Q'5HLVS04B"2+7Z,+V
MZTQ+V(ID@QS2:^*3C;M*BZON&;@A3IR$X,T1VMMI94)J(K'3#T\QGG4`B<<U
MZJ0#)Y_4#(E7=OM)S4YT5EOWTT?B%GYVT\>5.ZL#-_TVWHB.F3K$74GM<XP0
M0&?=CT`CX`PL!L[\L1,MD08X/@0>E6&4W;U@M:/_7`Z96"RG_;__.!T/AO/%
M?UX,?[H;+7]!5D(ZXT\=,5%N9S4<EZZ\@#")<CL<CT!\@5=";(^'CB0LXC"L
MRH272'^,+1B"KS\B!,:&0B"^A/I/<DE+2C^U$M1P+OUD-B;A;V1#SUGT)C0>
M]^6.J)R&UDSM@!([8L8,>1,M8G=#O(F["CPGB7K^NA_L'AW_12I5%9$U^QE`
MPC"&<5RHWD[$&6CCDP:;678#.@>;=1)LUFWQ90S.[G:*+UL++T`0NM1%>(%`
M[+/0?:(+X<QS5NEJ*%C065M^4QS+AWPU%X^^<+(R*57AVLP;&9*%62PTM7!1
M^6.6!Z?RRQ2UMY<37"9B[A8I9QG'4;+WV0G7ZC-DJ=DI+#?\D1?\;&Q:K5AB
MNFLG(NDM@_A1+KG0\;<I1]'URVN;6>:QF'+RRHZ_IHKE3YR=\LQIYFLX=("K
MOV7#F1'^S1QT4T/_+`E7#W0LO6U(T@'^[,8/,Q+Z[O.R\$"@,G+4[,MZDFN3
ML^/XRM]`UCB6[]G^83'E)<MWV4OBAR!DJ8-ENZN<SK+/O=BJ7]EB(?QCQ&KF
MA-,P\U=.LUU2E4N'#\5,3&_;(;\F>"J!G+[S"D]9L]!%O8FZI['MM=]HEAXS
MCG&&YMF#(454E82VW?@;086W9FJPVP6^YM8G);+MI@_&"<`Z4HQ4*YZ0P+:;
M?7UL,*YUE4&"%CHYE6W_^/H(H5WBI)GM)^1S^B>ISPN,WK8_-!@Z/8&<_J$Q
M92P-R%$8>/(VMOV8X4!6&#/ERG#X$"_<*S4$%%M8]SQ62[`RYA-8L=([7?T%
MJTQN_26WZ8+%EP="G_'>>NTRJ3I>-O";(-S;S$0&"T:G)K.>:0,VT:#\&W/$
MHNK#@KM6,4MQ)-KY9"9@"+6]9S6]54]/&B8Q49Y!A+L-E!J*B<7;J!8_-C`Y
M7F8U(:D06_=F:82(0!8V)DGZQ^ECFFMJ^$S"E1N1]56="2/J"0J5Q<MH;=Y.
MY;C''7^]HY^@*RC*QH*U6SD&2N6$\$BHK[2U]D)13_8?J`U-[1.ZR=6K,5DD
MM9Y(MY6IBZ:XY-NJ*XKVVHZLI.@7EUO'7,YAL&9\V7EU3B21FKD2TLWUY)Q$
MK7X2-7,5IYOC:BJ!&C"\X88(S8#\IE"16[9FR/C$,5/2X&>!^/=A2*]-H&*W
M_TQ>X0N'N&7G\>S7-T'8=Z*'>O>34A=0N'";&+AR003G46Z;.6'K:&8663QZ
MKB0)#(@8"B$2[P:8+$XH-Y&@GO/W-9,3V2WK?$Y/=$Y/=$Y/)$%@;"@]48-R
M!RQP2%%<Y[7)"<F\,&H<M9?3`:E">X\:X9!V14-X@MX/&44\]:WKN[MDIY)U
MJ9GM.`2.?I0DS>4+QT'UUGD&B?RXF>V0`H#(>7SA$/G/A"4P)NL>/00[ZI5%
MT-QVY(`:`BF?.*`X)YTZ)YTR`@?:I%.WB1>[CQ[IK9\<?T7H33SPGEQ_VP_)
MVHU9=B!I^#V<W';<##Q'DJY(#)F^NTT'AJ&J[)>5#NP[RR6L3ZS:.*\ZA'Q[
MEI#@V!1`>[2$BZ8IQ0PBH]JMI40XT%%J'`0HPXETZ/[D>F[PFLEU7Q5%GC-'
M268]/@R@5$=NB$!!F'(#%WY>7@P>0&<]@*@U)+JI$"_^OKQ2/(#.NK=]:U"T
M7#Y>&XH/-:'XH'NHQ;\^?>@$BMM@[6[<52H?T!8A([#NG:8I?#7SAJ2^_UCF
ME[`,[GQGLZ%JP-(_C?RU^^2N$\>3`Z'9AW5W)TUL:HG(`ES#-+-^;:2.R:U[
MV[0($D\PAO#Y6^*3@VD`M(I)*:#/1%A.5@#VNQ2\_&0K)X&*WMA[41NB[^8\
MR_VT_"@K)X'*'LL.`1&`W?U;/A-T.X'B<PJ;@UA("`,^JXR$Q#OF@KF6!G[$
MW@?\[8*$3^Y*82ENVBE4&XR%@3;6ACI"[&@^3ZFBKDBHAV"9".KZ@.48`1-"
M9RMJKA[9,;+%^07H$.PQ@10Y?>&9>D$C$1W%)/#I$#;$C=EK1OZR!#JF:]!#
M,<-B>]`639NO;>=:EY):EZU4QSC7NC3LG1+>N+[[;S>0&RO+K:"^)NWOR8`B
MC`*>3%E^PUO7\]RMXRM$6&X&E:&54J$BK@P)<4[<U<.-LW.]E[&[<^F*/IY)
MQ2DC@`JV?>,'0+!J3@V?#"4Q1\4SD#CD"%T5#_ZPV]_M&S@@[T?GK]/C#"Q-
MMIS*6MT&J;@##0ZZ4??]ITO.T?0DGXZ<WI?GA$U6.J2QNQ$E(JW?G;5@"0A.
MS5C#-,6XUX9]3JPTD\+ACU'^5UW/-F5OUH(T-*9D$SDAM"G>^<XN"&-6L:(?
M1/$K9Z(D%C(":Q$>T*FJYA;Q9-PGK%F051*ZL4NBON-Y9'W]TG!>ZG0,A+A]
MVW_3*:HO/4,;JV`!>73#5(C1@![70$LMZZUN9]8*34!G:C,I=0D=,Z#1';TY
M;(J.K)64:`092#I=PG7CN&&6,[(16-)N[#DG-\(*(!H<VV.:_O%>4IHTKTQZ
M7ZY,>N"P%T7);I_W-<]C3\*=)(F:R6_:*Z.AL:N:%SHBY9+5O165O97Q^2GP
M:#<>RR1$5T*%EIG^N#V/?5UUZP:&-ZAW<S?Z[28D9.3'A*(;=ZAU_$_;JVQB
M2^=D$+Q!C=M/L0%SHB'^VL(Z=_QI>W5;;*]R/`AP:%POL[ZD3$XW-Z[/HD[\
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M&IW82\&@=<W6%HNAR9?=$>G!5A`X*IAK:C)[)6B@4PO*.HZ9-`N##8E8Y2=5
M':!J2WL9+[2.('P&#2G^@$2KT$UMRS+?CJR^#=@VT;A7>W5DH-.F)<$9@K6W
M#0G)BJ;1`V<V"`%6_*90`.Q9(F0LFDJ&NS]NY!<$T=&YT@SLWV[O3"Q@S91^
M%HYQ<RH+^H$'=GPC3\0+'AFJ<A%KT$-E;\=&H,D,IJU8%[=]BOYVX+)J)]!%
MZ4U4H+UQ5H2J:B*S!(DIH+A:=0Y1,7SZD';@<I77E>G8,40P!GM)OFQ[B$A!
MP;&#=,%W5G''KC+NQV`OZQDR93P&Y0TJ(\\QL-MU43H"J"):=<+I&I`O10T[
M71&E(["791"5&F)<#<>N3Z:;K-B06%6.6T'AM&.TXP[9J)%C/Z)JH?!4843&
M4S69O7R,NOD25*P;?<YYM;IF"="DCSC5QN!,!9:?;D1L&I+M.'#\CXG#/OB2
M/KL*Q,II!Y6H/5.<D#F.,+'6@+\ZC+E8`_Z[;^K6@+\ZUX#7.\&=:\#;EOSX
M7`/>XA.]Y_@39Z<H6WO<ZH0D?SQP',7@]V-2%;PKM\,A=I[""(1N-M$G*UG)
MHM5'_HJ.FNY]Q1L?&P+E[7MIRD6M'L`I)`S+79R(L89`3)WH`_^GQ/'<C4O6
MK!!#>@PZ#(L-18H+G-Q:*CHP*+JBP&%0F#-SB7Q+*#3!L3"!]H/"J''4+$\'
M))P-Q5%#=;X;:5<TA"?H_9`;;@#M2#HW(*MD76IF+8,>3XY<27/YPK&,Y,92
MI<B/FT&S'5L4.8\O'")/C=E+^A7YZEUJAF--`:W@I9'C*&BM?':(1.\.K^SX
M:^C%P,S7<.@`5W]U'WEJ\8]BDYJ3*`Y=]@B?'A3O?#>.YHL[Y0%!3F8M1ZA1
MP/CG#H@`<2S5M=\J"][L!AZ&CWI'GRJ_56[?A'8<,FBD;W>])'X(0D&V@Z;"
M$W_*MK7$O.*HQ'SB6I2QE;T(CWQA3$I3*?(_8ZT21&?:(Q/OB6O.-'.>*13&
MR*:*`>T1?\JV8="\!JG$_.:TJ%3$XZC"0R>Z)1^`M5(9%C4.`@EF/=15&_OF
MP(8H<T`YT="8X>[1"UX(R:N6\MF=!/Y3ZF65ZF^T#&+'*_Z=.0U-@O@7$K]F
MPTJOC;FJ2SQ8NOF\;5,H6-TZA0/'DF*,Y>PT>!.$^:]8.TD>_*['8=V89%TG
MI0#A4,Z&%Y-9$JX>V)\HD^FOC5W].%^R5@JGX]N?4,@(TY759C7]1Z'FC,#E
MH\7^K97E`:M/RPP;=>5I-LY#5(T1V`N]VROPTR'J%6GB]W,_C/3(N_U2R[O]
M[-&N-61N@B.%=[N,!L>[,,C37<8&$J]W[A`K:P80H3$V;WBU[D$0&Z/SDN<.
M4^YA(R%Y2UAA<JSG#E#E3",E0HR4Q#]&RA(*-Y=\:"JWEE(SVX_*`/WBEXOO
MQ.G^$#&YBMTGME?ZZS1-,GM@W`3A+A.3^"1S%'4)Z\.R=PAL+^56AM>1D>&P
MY\P8<$?/W&$^/`5($$*44T4*#5P<."QL7`X+;V.:.\X1I37_!TT@`-L.1R*U
MS5N/64Z"V`EC^P]0]1V'`C][S\BN-*\9[**/3&YF'+74W[3F,=%(Y\RC</I/
MI09DM'_I[U97"U^UYFV!35LK2.#8'8UP^NB&CN)=WO1WK?E_X-.["AIO5O/R
M"H0)/PN4.1D??=>:*P@VS>.@@4/SS-T(?KVRZ'9A]$[PZU5+MX*AO\;T[*W<
ML)F=5>@7W>BI4.O3UGPMZFE5=X)!K)0RKUN5?0]$:OTQO89A3T,FB'>+HW&#
M"OC()*;L#0JTH11_.I@!MA6@\&R;G_1*%DM92DT56B6G@1U"%<-078\:BM&4
M8_O&GA;U8O_G-E6CT"=4.PQ5!^E0.RJ"?#,*(K.EU)>6OJ7DTE`MCTZ51&8*
M.64UD1L^ZLJKCEGCTE"5C0[51&ZW.-&W!?NG6`W;R*6A"AG=GF.1FTSJL)2E
M0N_YZ\)%O,4%A]\]5&D,U;/H<.61B1>E#I6$<Z@GW@_\5#")XXW=C::Q0]T+
M5".,A8XTMGM`)67(I8DW_B@NC45C8G-HP:XQ7<Q:L+@5$U@HHQ.R551XT#9.
M"'N`8MZ)F<H8YB=IB:AP4<?T(.L$BGTGEBACV)^JG8'#2!W#@KP;J`IT8FXR
MJ`*G:D6HL%+/;"#O!JH$G9B3C"D!,AN!K6.>QIW^JA/#D#'`3_`R7^&AX>T=
MV!]4'SJQ\1C3AY.[JO>VVY!LG9@5R0Q=/W)7615-^=5<205%VU@2$/VK.%`2
MV/(T'+QBBHG=CEDPYJ$D^R14`\R4S82"V:I?DAH!I/:`%EC/HRZZ4CS!Y\!!
M,&](Z:221WCZ?&,KG<99]X,9`Q>RM0[YD;@%U@MGNZ[43_))J/*9L;#943XE
M`JVK'K*\3*_I"H\2,UWIE1V^/*=F.J=F.J=F.J=FPH;:.373.363/:3.J9EP
MY)OI/C73EUM]5WO)*G!PKL1[KL3;6B5>8T6A./IQKL1KMHH20.1X*_$>LC7W
MHBC9'=D=5$6+`*0GE7H/SA9V`.=N]-M-2)C5B%")QW-^2GL)P_P>4)Z?ZN`I
M$Q!>6(?/CX35C/T4>%3DGAN_Z`,KZL/VOM7B5)4)"3^X2Q+NZD&:4=K>#5L'
MLB@0_/`-W"=W3?QU_9EYW(/M@GVMP\D34,OOM\A>,5Y?"H]>,3[HO6)<G5\Q
M]#*LK1[(.O%(GKBG5EUWQ:-'BY_`<4D'O9&TR#62)Y7:3[65=;#%A'MC;$\S
MK4^HMI+PC=&]]F2\TJ_(S:.E9E\&S"6F<3S\U&?UE1U_/?,<?^+LB.K%R,S7
M<*@/5_5U9WHM_E$8C0_5/%\+PJJLF1(2V_86D]-"5`95)#@<5[]3?/0RO:*?
MW\C.;V3G-[+S&]F;?2.K?3-I_C;3P:<MO]&U=_ENZS[9X,'H1/.CM2HJW5>J
M3CZ._B2-0LO!;V>GK.?W:F'=ZPB+O4]=*M3;T#=M'Z3,:K51H-[@R4+O";*#
M3]L^=)[6HOOE/8Q^X#^,?JOW,/KA_#!Z?A@]/XRBVIXJ"^CY8?3\,'I^&#T_
MC)X?1L\/H^>'450/HZ*4::N87DCBE[3@W3AV'U7)TL3MWYR%6<&O45SR<H39
MW5&!B:`M^ME3"Q"I8$[<W%/-1B2LRME4QN)/6;,VJM%MZ<"L$K/MQ'8XM#!+
M`3_R9RE3'\,@,G'-DWW,FF&Q:TV4B!K)BL9.):,H2LAZD(1TPF0CS6KE%HXL
MAPC*M415:O1E+3Q&6Q-J"^J-/+LUF`6%I//[J6!NP>%^#*AF9K)\=[G@2$2-
M9,%IR&`A=[UY7>)^#*A+9C*$=ZE+$E&_#5VR>1S72,AJIC2<U0,YENRK./2P
MD"?4M!YR/@74PO9SX'>_-PK$C#(#L$[I1GE)0@$IV(IT6F8DK9*7;VT;DS'?
MR>8F'P!4Y3HIL:=30;=CB+X0.Y7PD85K/3&DVVT.`JK?G901;%6_VX?J1-9>
M%>.'FHJ6U51S'%!-[:3:8:>:6@NP$U%6^(4^K?U5,179.3XT'!94E3NIV=CE
MH:(5.-^&9I_*$5C#ZG/92<E)A(?@LVVH*+1"J<8\"B9@O[*N\$W'!9T%G13:
M['(6M`/H*9BLH.5+Y=8K=2]053)6Q;,30Q:X&"RRRI_*Q9_'&`OUBWA!F8TJ
M<S4:"E3+S%0*;:$RL$T$;1NT#"EU9O6PK<_:HP`[`KY55:Z)VULJ4_HVEF6-
M^]15)X\*I[(PO\%+UKU:@O?JEV&@!$TDC&@R&.@DZ.3E07<2V!2<T4,SL.QL
M.1)'104%VUA2>4,1.<`BO6_-8JFLSMR^_:UF=>8K,S9)S>K,YL6!X]*"0U'+
M(0STOP85J+J+'Q%\'JK`9LR)=A18"YES%`*F%5?GWF+&_1?9FGN^CPA.LL=B
MZN;:4?DF5%7-^`@W4%6C&+2NJ7;2>XU\^B-9.L\DRE-R35BQJ-A]>MT\CO)[
M?5?.[S6:]*>WPXME[Q_#Q6M>KT,O-O-['9A[';`ZV9>4R&JP)IT$3$]5Z;M*
M[7`D4`%`48FY/.8#2U:M_;`JMUD)%&-T6:^XRB1"8(PN%=5!G7I)_!"$++V;
M-">5J/T)H2%B`4>JJ>KH5.FBQ!0X0)&KF!(<5/F;TL3GON/-R1/Q$[(@X9.[
M(J/Y0I7%24EH.QN-2N\J.($$@<3*R):%'CTHTD]X?TM"-UJ[*R98%6I*0MNI
MIS51`PH"!VI3>L"G@O2WXR"*^O08_+()0G:UD&Q/,AK;^;>$YYT22&J^.?A@
MN?3P[SI_!-UUSC<<T0O8(+\7OT[W*"*Q*N^9DLKRC-"XRH#8P;1X[0=[&.:4
MS2&-E0S<@;6#@PXF03W>4",Z\F=AL")1-*<"IZ-[H!OK@!Z'O."1+?,:T"I[
MLIISKB6,@>)""K8BOYNHO=44;2T!)\JWIF>MC8/8\>R_*52X8\;H#`[/"SX[
MOBS:`T1L-1=;2Y"+A:*/__<9_G[Z]H#@5:G"[(3HK-5I:ZN)T%K"N,!VJY,:
MRTWD]8'IZ"KR)]BSR^7Y,M)6RO/-AK`DT>0P0%;:9TY6@;]R/3>;,_$-H3/&
M\=@E.:$#>3EJ+&:ZE<Y/YQK4)M>8CEL0AHYL5X7IWDPYQ+VB,<BVJA8J*9Z.
M/O0?F`O"R&]THFO]0V@,PJUJ30U9GXXBI<:'WOI?212GF4^::4NU-]OU_\RH
MA$AJF'%G<0NNG[C^-K>Q![XVVOP^K%WZ6L98)B$TKPYSXK&KY,P)8Q?J;?7G
M\K%_/ASWEL/!Q:PW7X[0.5P56'Q9AHX?.>DSG<SBGY.J*5$4710-\_KEZ"_0
M`HM:W>%PBX!"+"ROJ,4S$J<OP9C':A<P-24.6!NI>`EK-<](O,C&@;^-2;@;
MD/M87=>0W_KMP<?G$X>;67EL*B<S47L<J,GT3P%*2^YE@H?[3V[LW%)5H0-V
MHR@(7R9!3"*AVQ&CD9/8MDK(]:;X7`]AW51Q./:EK,K,,LB/B5*9RPBL)7;7
MEKB:;82I-RJ#?KG4@^JU/1"I]E,+-4>JS'17$^/E2E/85]H+$49I7YGS=XS(
MZNMM\/1^3=QL-Z8_E#=A^JM?QV3K>$-ZVQ9ZW--6E48XMMM6#DD\]@K6T<Z`
MR+XO//_0)L<M+$/`$UM%L,<C-G.TN0UO7-_]MQM(5Y!**VL&\HI8J@N%@"5#
MB_%M>.MZGKMUQ&[HV:#*S:P9E$$BY#-E2(9SXJX>;IR=Z[V,W9W+'$QF4FG*
M"*P9<0%R53.*P_`.VQ#D]@&=/M[0AEB#^\),1X*YRH[`:XL#0WW-E0"'*FAM
MX(9D1?M613N5VUDKT2@1*%?R?`9-I?!E56IG2;AZ<"+2VX8D#>KYV8T?9B3T
MW>=EX=5J/.Y+=Z.:?=E+H@M&I@%WAF_`?F^S21^QZ6WPP0TS)A2W8"F-O:Q?
M6FB`.,=RB(CB,%G%685HS_%5YP5N<QS;2KM'`RZCA7,I)M#41P$!`0[@I$JH
M`L;LU?NPEO;\-?O:+0FW),P-[M*E#$1IK[Z@2IS554U#%#C6MK'KT[6@'Y*U
M*_'B.&YEV4$9^FA??FGC<(H#`V8R'OE,QYCFW#@KTML%B3QD3T1A^T&N)C@J
M$1@Z?AU_]I!06`I!%O.BI+/M>:L+!)`M3/-F3AZS#&_1=),^JLR<%[F'EIC"
MME=LS7FC$@$.H-+L+'03G3GN6@S.<2O;+JPU`>&Q>OI96OO!;L>"->@%NN\\
MTM.,EV993&.GPR>RO@G"FX35+&3/FO(0AQI=60MO;*8*M85F;+.+5J&;YL&<
M;L9T5/LDP\)-3M@>DRD.OKDIV,>Q5@I8R_9?NLH7?J?]9,'O!`AF^QF+FVY]
MVH+"@?`@(3=4!M/-QEV1,)J&Z1+Q$'A4S+*<#G(RVWYA=0_^$&$86A!3QX4;
M0N;$W=TG840$>5)88T%;VSY>=19"*=LXIDC?<R(ZA7]FL2]^/`WGK/#+)&'F
MD^EF059)Z#)OPK[C>61]_9*WB_*&DDG4N&/K?F9U#R/M2!1-T-5U$E&.HZ@?
MT(,3*_^3VJYAP5??EX.OKN\6H\EPL;CH3R?]X60Y[RU'TPFZ("PW^HW5!+^C
M'(=T7#X##!"!)2>S>JLH8,>&J8BO$K5'8J"'P%.Y(O`Y0A(>51E>994!@#3&
M%A(E5SL50F-TT4Z5(5Z_J(.>I$1O`:<B/SABG*K\``*=I$1(<:KJGW+9:R_R
MJ:7(X.3QT7-)6!FI,D6SBM#V`PU`"\LAOC!9X+@YS,)@G:QB;=Q4=+;-T?JP
MP22!`[5^$L7!KL9T4Q+:-F[IXP:4A3$C<?8^D2?2AP-23`6H(K9M-=$`18<M
M5#.J/,@9"=DOG*VLW)B<RK+?A_HVHCIF<&2`QJ#!7HO<+'<1O41FB6^VQ%]!
M4\K\\9NR5:,_O;T=+6^'D^7BHC<9,./&<C3Y.)ST\268D7&OD712LYLV%\[\
MB6],G(A,[UG(46J18@6I!:NEE,+Z7*N!1W'-!(C#5!P;'>R#]\**5<[I^*>;
M=`R\JW`:("9J;?^<WA`!A1QP;%.OQ472P67OX;>N[^Z275Z^,1K(BKF".[#M
MC]4(3UUF,4&<CI6RS)30\8;/K&JG!%!!<]O^66W`)Y4$#K"RH64Y^":!'^P5
M3N9J(**P?V5N#IE*'B=T?.2?&B_KG1K/9\5N[W+I(!+'>SU*W=`Q.MXOQ`EO
M'1:9$+_L0WL@K-?L\)1/I4UYQ[1,`P\"_20,^2XM>@>*0S_V#\7-P*MUG"I)
M\?2]>8%\C_SEYX")%53@$-R5_8.X!1VJRO)+4B/Z5=*:(A4ZLW\IL*-*%7E^
M0<IT$R1A6[I4Z,O^9<6**E6D^25IDOO4VJI4Z,MVM(HM32I+\XO1I.Z,D\;B
M::SH#`9%$;PAR#A8)/<>R8WJCB=Z5]#J`8&30AOP:_-=%__V:CC"\)^06&/R
M<\0@[<!VY(XY]`%RJSWY\=1Z7!"/K*@>_I0X84Q"[^7&]1U_Y3K>P(D=J?7U
MJFQ]70S'PSZK`_/376^^',['OUS<C":]27_4&U\,>LL>"@MLE=.1OPG"72I4
M'1NL=D<V74(=C\7NIBY`TAJME8:6K:8UT2I[@?+9/_U37EI/>A8&&UD"G*-&
MMJV@[0#*X1N'<9MJ5_;@-I;6."\ULVU6;`<4+N\X8!DZ(4L&$\U(F.8QN'8B
M=]7SUP/72^+7+9-3N$Y%:-N,UPYT0/FTO&!:.O(D]Q'Y/:&=#I_2`QW(0_%#
MY;1S=[T8_G0WG"POAI_2%V=<7HEE-M4'&C&%S9,+*[++#MZJ^G6E=CC"BU0@
ME,\I)2:0A%(>AC56AU#RVB+!@JM)(@3&Z$(E2[JD#I,4$IP2'B(><(1%<H:G
M"HJ4D"#!1:YG:H"0!4,>C4\=`LEM;OO6I-0S.2H8@WQZGYUPK5[$2LV03!'(
MTE4:>9OUF!I,A_QT3];]8,=\>'/)A:PH?6K?O'YY;9/;/%-.7MG)L@-/G)UZ
MK3/R-1PZP-7?\C0TPC^*=76X>_2"%T+2E%?3-#.=:FV5D%A?7PU.B_)56R4X
M',NS4B(B@60L11_3%$S[-(6IO:[!.E'G8Y8MU^)+D^XB45_2B%3I7LW@?9G!
MX?.CFP7`"G-]%F78SB>L+T5:>M.F6`W%--;6[T\D8L^Q`RH/P4MU.UW;MKZK
M$6^/5R'28EML_A?V#Z9*]#?_'U!+`P04````"`!=B65$\'7H`Q`5``!!\```
M$0`<`'1X;60M,C`Q,S$R,S$N>'-D550)``/RH!=3\J`74W5X"P`!!"4.```$
M.0$``.U=>V_C.)+_^PZX[Z`+L-@^+-*)G>[>Z6SW+A3;27O6K[&=?@P:6#`2
M;7-;HCQZ./%\^BM2#TNB1$FV,U;6'F![';&*JE\566052?'#/YY,0UEAVR$6
M_7C6>'UYIF"J63JA\X]G]Y-S==+J=L^4?_S]?_Y;@?\^_._YN7)+L*%?*VU+
M.^_2F?4W98!,?*W<88IMY%KVWY3/R/#8$^N6&-A66I:Y-+"+H<!_T[7RYO4E
M4L[/2U3[&5/=LN_'W:C:A>LNKR\N'A\?7U-KA1XM^X?S6K/*53>Q/%O#45VC
MZ^^=]ITZ)K]C^WO+()BZSO?I`H`LL><2S>FWOW^]&?>^-R\;5XWF5>.[^V3J
M_V*_&E>OGV8`MHU<J`C*W_RIV;Z\8O^\G3;>7[]M7K]Y4U(H%[F>$PEU^?33
MY67C$OXKQ]XGCA8Q_P5UE\Y?G\;DZQS3G[Q/WZX:_2'Z2^_N8:@__OKV7>M7
MXV9U][GY\*OY3[KNVS<_]3O_;CD7G3>]+Y>?M8[_R@^.ML`F4J!Y4.?C64SE
MCU>O+7M^T00)+[[V>Q-.=^837C\9A/[((F^\?__^@I>&I`+ETX-MA%5?7;#B
M!^3@J&8H)1)Z0AT742U!K[L10YSX[85?F"`EF:3O?%(2DGK.^1RA940[0\X#
MIPT*+E@S.;]LG%\U8BRV96`GDX>79#!1BU+/S(:KN_:%NU[B"R`Z!RIL$RWB
M*V9*,H`,['&V=+PD0SK6!2(&-]993!WZH7D1]A7P)08VH4O=6K;9QC/D&6"1
MWSQDD!G!^IGB(GN.7=:(G272<*DZP_Z`*+6@VX`W"9ZP9\LE@7X!#_[K`VM`
MUTR_4T"AL!_@0V1O8"07T+4\)K%*]0YUB;MF_<PV^7O.%`*PI13LS2`'?[>.
M9X02+N"E_U]#.5="]OA/1'7%KTN)5?;A(EU-K'+/P?J0_IW_7MK8@6HX4P\>
M!(P!20Z3A@S-,ZKQ;$3)9`D>A#K?P0HMBSJ6073PK/H-,EB_GBPP=AW?!/G%
M<OTW0>G,U>+``*WA8#+L==OJM--6;M2>.FAUE,FG3F<Z.2E?U.X(V8!T@8$!
M&0662-+*S7)5WBS*JT3%_W<R$U=]I#UG.!LNV2P,WI_167+HY.9Y(S//9`K_
MU^\,P#3#6V4XZHS5:1<(3H81%#YQ+>W'PC)TF`-W?O/`V\.02#3BRNV4SR8W
MV]OR9IM,AZU_?AKVVIWQY,]*YY?[[O2;\JK=N>VVNM-3'Q-MTD+.XM:P'@NZ
MV(9,;JIWY4W54B>?E-O>\,MQ]S!SB>@Z5+[_AUS%?V7S+0B3#,OQ;`Q_3#]U
M0,_]D3KX=L2:G'BFB>PU>!DRIS`IUQ!,;#7-\F`V2N<C:-0:P4$K+TDKM\-/
M:3M,[OM]=?R-NZ'NW:`+/D<=3!6UU1K>#Z;=P9TR@J[0ZG:.N<%WZ0H`67;0
MY#=_RI7]/JWL[N`S.)+A^)B;_)`5M#R;32-5QXF"BHSG4NTV+M/:'8)/&2NM
M^_&XPUKP9'+<<<0M><)Z7,/Q!W+5-M*JO>U^A:'PZ%4ZLO$2$;WSM,24I<:8
M5E//Y(IMIA4[&G=&:K>M=+Z..H-)YXAUVP4T=$X>#!QOL\)3N7ZO1(\[50=W
MW9M>Y]1ZXQZV1]`#,>"M.,/]Q@OE^GXC]\&]KGK3[76GQSU[&%@N=D9HC:`5
M^\I./)%K^&U:PX/AM#-11NHW%1KU$6M5C,N#:;+X7*[A=\*4.",</V)%=RG\
MQ%/TA".?O'D@5ZT0]74'$/-UE*GZ]:@]PA@;+%<Q0O;&`:>>R14KA''C3H]G
M*T;J^,B][8WG$(H=IV51#9`E<K$Y97)="U'<S?VD.^A,)BQ/U()A[I1R;5FF
M25R>=5.I#MIE&0E,-[D+&8%4^TTAR@,'TN]._82<.F@S([`T16=PY#F*"3:P
M!@[D%P\\"+:-]2VA"#2,C#9R43`VRFGDEA""PDFGUVDQI_/+/7B=SKCW#>+$
M@0J&4'M*6YVJRJO[@7K?[@+-,6>Q)]Z#@W_S`%2'Y8VB=%[JJ5S[0N0XN;^9
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MU&V$`+RD>4Z]1Z[W9ED#->4&>EMR\5LT4/-DH`R]%YBEP!CBOF^9,4X&R-!P
MD><J<%AOQ<W?TOYP<E-92B[R3D5.25SZEAKAY(JRE'Q58(2K`B,(,;K<"%?'
M;(38%JB\9&X^@=P,0D">W"UUFMA*S9"G_0*E9ZQ39RC]I.JX2AMYNBX:<J5'
MET]#+5=W\LARMH\IH)$;H>B8\\G3E#CZG&V7DK1R^Y0]&GVR4]FMM+E;!$LS
M2"WVKMIQZI/=*MJMK+D*K"2$W.6L=,RVD>]M3B9"2I'*+21&Y,7[H$]6$H["
MYVVZ+:"2VR;C,';JJ/Q_ME]C_["K&\9XIO`K'Z[910(?SQS"K@$Y"YXM;#S[
M>,:N$C@/O^W_+X#V^LDT0A)6M>3*!V[1M#:"%X=5(%L3:A&NI(!*K"7F$\2+
M4/BP`I>XC'T4>XW"W@-]^6(?D`WT4!4RL&#C&;'V6/U[!0FMKRK(5(-])JBM
MS5OV"ABZ3E7`R=[V3'C;T4OB<(/;,RXVUV<$?Z>OV/@`P"W;5:AP8X?L0A;_
M*IF>I?&J)"SLK_.0[YP].F\TSZ\:KY\<?2-I%2$V:J@F1,BWA1#9-\V4?'W(
MP-[[MM(;':R]GELK:$8D<6-+SHLS>=B/\PUSV?=++\&1O3^3\0(;KA,^V5$:
MUEV=/8G#Z]I"GA)W]Y1I'''.@<_(&LE[UC@;[W849CM!BJ0(+O_A4RI^:];/
M>#8#%NST>JT^-A^P?<9E_'B664(,@VU*`6;;8XZ,W0!U#0Z.6/J4^V'=\],&
M9XKOE_U;DZYURT2$=EUL,C)`!=,Y\'\>([VS+6_Y\<ROBP")3-Z)2V;8&!#-
M,I#GAU+\J%Q2]D*J@^.XQ0\VQ!IK:+Q-OMTG"2"_^."2?R8NZF-]9%LF<1S+
M7F>(7T!S<`Q\K6GDV=H"!A1U;F->_H6XBQ&V*7F*WS8G=(QMF0^.NN\9+H%9
MDJJOV&@^QBO+6!$Z;]E8)RXS41)H!?J#8YNP:-T@UJ:O?V%A'$2**>,5T]48
M2Z,LF,9+0-,LBZ;Y$M!<E45S51\T?4OG!Y@98W9_D5(<7/Y0HJ[C>%B?6O<4
MS6:@=;:\U*4Z61'=0T8*4E6F6J/L\#L*RP-,T1\<V\\>Q=$D)[L)RDGJB:!1
M`D*-?'2F?,T2&&KDF4MVZ\96SJ!&MA(EMOWU](VXMY;-[C]CTS<ZGV![1;3T
M#'WG6FJGAR'83<-V`4Z!JG8X(DOXKGH76Y:IX>#X/V,'1!U8%.2<80@<09H@
M?LP>#ZHP'!Q=W[XEE/Q.K-2T2GA<`TG[(`.9(YH657A^<%G'F&B+6V028]TC
M)E#KO5%2:BG%P>7O670^Q;;9Y1MMR`JS$`%3A[]T9"#*$GA)0-58#HX0NN<O
MX:7B;-;`DR:1[$S>)+P*]`?'QOPL2X@,9](D6#'9P9$(:<;4[$A27C_9FP6R
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M!`44X`?B)B&PUNY"^+P'$"S[;!F\K^@3%_[E[6@XRSKQ/2,:<=/&VZ&"VEFT
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MFLWSZBZ&J86;!ER1M[:Z8!)#W+""T`!8_5]\>Q/,Y'DD.("GR%EL$DBEZ6N+
M.;KD)AU`9134+C!*WN+@;$YK3_&3>V-`I!>B*46Y;7;"#>O8QV9Q;8%US\##
MV1=,Y@MH3BJT*@0]"A'[,S(\/,(V#Q&@;[&__70$N!QSR7Y!B!MV2WYAFJ")
MYWQ!'118>'.@F"DHS5"_#@".EYUGG^,V!D>!'-REGRQ#A]K;'IY:_IPCZ@1E
MJ:O;$8RX]&O?BQ]V-)LL_8E0CV_J&?&7;QQO/L&A31*<?!JA-6]2;';CN>!H
MQMC!R-86T,;:>(4-:\EG<YI+5B0>1NS`7PC=/Y3M_L$30O%JKW07E%'4K\_Y
M0TFV/7A@&R!)C3VE&&IJP@#"9D]P-L2L\GHC2B1@LD'ED-045^C98=KMF1X/
MO]MX:6.-\#X!OPW,!W28F9N6[88QJ/_-B35;W.4+'K]Y9!E/%C]#O5MK\)FG
MQ*G^FNZL,*G7I!U<RE#39A-`Z"/JS<#9>G:8I,M%6T!:;YPL*&5M".MRD#*Z
MFB+LTN`3-+A'5CSN3EPP!0&ZX;$9WYUEZ8^`88!C(=\VK#75PSW5#$1,<%/L
M;!*F>C3#RBRIJS,*TB?)S'EJH"J@J2TTP[`>V9M@COME84&DA0P,D3E,U!X\
M%^:]&`M(*['4%KAOKQYZ"(>,;(-F$M0<5,L`!Z(A8VH39$@:JXRNKA`GT-AX
MZHAEX)TQAK&/LIQ!U"H=YAG9QZ+#\_REZ>L*>8S9QAMV")!;1\=^BF@XXQO.
M-B>G"JCJ"H]E<#?IV@C&+=)P<A&G#&%=08YLLF)[S@P0EN<,GHBSF>=DE?W!
M,;?N7NLP'E.61>]6!-/F.\/RX(2ENP/:^T=!6(85Q-7PQETD'I5O38D4'*]D
M+VFL:+L&?R<,N.'WB_@K-NFJ0KHM&T_X=!_*9IN^6.Z??:]W:OD+=&T>N?A2
M)S?TE"<_]!8=_\ACCGP#_,B+8@-2:?*:`N/#2FE<(G5ME^&DEN&%0W_U)5IK
M;98R:BYK30TLD;I<*\YE/33@]-#$0I6\82LHJ_L.CW0:7WQ>N^1])"+5QVSU
MTTDM@K+E/R:PAXQHDM<C,RQ`K,Y_^&'P'C#PU&R0SMJLY&Y2(Q**NC;'EH&<
MC:1#FQL&AF\2WD8"76L#)"B/(&_-O:T]H;[G`LT^<\(6<ZL#+N*L(=AHOT)%
MJ'*^FF8S,Y$,/':L)MHK2+`3?-[F9EU)(]7J.?1`FMU^PXTJ?>PN++UJZR_!
M?>B1*\]/L?U,8ZQ9<\J\=I%7$ZCKZM0S>NG-FN\G)JO-5J78A_]]TX7XMV>O
MJ0.(9A/QU=7A+)GS9UL+PG2CD)NKP%C71N$[*FC7.9_<BXZ2%M-53:\$`E(7
MS[&]WSU.L@'9#VWRW=GNU1S:KT4;VUL63*&3^[QRR@X_DXYZ3^!2([<C/J]K
M7XJ[@^RM22EL51CJ"CJY13\_`UB"[M#3H'#2%HKJ?^(PZ0$S2K<4>W^.CROP
M!CE8CY\44IF8<TYZL]Z0!+L@U4=DZ_R?6)R22)OOJ<(=PIPI,?<1ZNR&)IK9
M[$<Y\>KJWJ6#G;!K?L`J^"QM[M'^BDRU2V-%$1OW)O=LQ36`E$9:AK)V\+9N
MM0.8VO+)D'^T?[-B&^:"&2Q?)3OWD&KOVFZ^N;?1(I6F##/C?+51Z!RE:&O7
M:')"WICPXOSW+I']W*F&RO##RZ@8T3TE^S@XL0V`L'@G+<0K>;F*B'*^NZDB
M7LU+54:0`/3LW=I%LIJ7J@Q_\LQVKV\<^RY:R:FOZA#Q#-I)N?XH=Q1;UF*K
M604C1C';BQ@\'#<EO\SF6<3;C?E[3%.4$K1X#,QG.7PFII2\I<8X*=>+`5IJ
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M'@,4````"`!=B65$N.1]4U,J`0`[PPX`$0`8```````!````I($`````='AM
M9"TR,#$S,3(S,2YX;6Q55`4``_*@%U-U>`L``00E#@``!#D!``!02P$"'@,4
M````"`!=B65$H\D!NLH4```@&`$`%0`8```````!````I(&>*@$`='AM9"TR
M,#$S,3(S,5]C86PN>&UL550%``/RH!=3=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`78EE1*2Y^MZ5-@``;;P#`!4`&````````0```*2!MS\!`'1X;60M
M,C`Q,S$R,S%?9&5F+GAM;%54!0`#\J`74W5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`%V)942U^`@)D(```-]7!P`5`!@```````$```"D@9MV`0!T>&UD
M+3(P,3,Q,C,Q7VQA8BYX;6Q55`4``_*@%U-U>`L``00E#@``!#D!``!02P$"
M'@,4````"`!=B65$/H=+X_!0``!BF04`%0`8```````!````I(%Z]P$`='AM
M9"TR,#$S,3(S,5]P<F4N>&UL550%``/RH!=3=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`78EE1/!UZ`,0%0``0?```!$`&````````0```*2!N4@"`'1X
M;60M,C`Q,S$R,S$N>'-D550%``/RH!=3=7@+``$$)0X```0Y`0``4$L%!@``
0```&``8`&@(``!1>`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="8">3 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
        <td class="nump">$ 2,863,000<span></span></td>
        <td class="nump">$ 2,295,000<span></span></td>
        <td class="nump">$ 2,081,000<span></span></td>
        <td class="nump">$ 1,537,000<span></span></td>
        <td class="nump">$ 1,241,000<span></span></td>
        <td class="nump">$ 1,036,000<span></span></td>
        <td class="nump">$ 819,000<span></span></td>
        <td class="nump">$ 722,000<span></span></td>
        <td class="nump">$ 8,775,598<span></span></td>
        <td class="nump">$ 3,818,013<span></span></td>
        <td class="nump">$ 2,088,177<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">2,396,000<span></span></td>
        <td class="nump">1,646,000<span></span></td>
        <td class="nump">1,617,000<span></span></td>
        <td class="nump">1,157,000<span></span></td>
        <td class="nump">908,000<span></span></td>
        <td class="nump">729,000<span></span></td>
        <td class="nump">447,000<span></span></td>
        <td class="nump">386,000<span></span></td>
        <td class="nump">6,816,001<span></span></td>
        <td class="nump">2,469,900<span></span></td>
        <td class="nump">1,141,065<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (8,361,000)<span></span></td>
        <td class="num">$ (7,673,000)<span></span></td>
        <td class="num">$ (6,009,000)<span></span></td>
        <td class="num">$ (6,376,000)<span></span></td>
        <td class="num">$ (5,727,000)<span></span></td>
        <td class="num">$ (4,253,000)<span></span></td>
        <td class="num">$ (11,850,000)<span></span></td>
        <td class="num">$ (13,290,000)<span></span></td>
        <td class="num">$ (28,419,313)<span></span></td>
        <td class="num">$ (35,120,235)<span></span></td>
        <td class="num">$ (12,913,365)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted (in dollars per shares)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.05)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.14)<span></span></td>
        <td class="num">$ (0.16)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (0.38)<span></span></td>
        <td class="num">$ (0.21)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>34
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W
M834Y-S1E9#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^5$A%7T-/35!!3ED\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y354U-05)97T]&7U-)1TY)1DE#04Y47T%#
M0T]53E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)
M3E9%3E1/4ED\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y/5$A%4E]#55)214Y47T%34T544SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D9)6$5$7T%34T544SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E!215!!241?15A014Y313PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5$%.1TE"3$5?05-3
M1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3U1(
M15)?0U524D5.5%],24%"24Q)5$E%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DY/5$537U!!64%"3$4\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%52519/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y#3TU%7U1!
M6$53/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4D5,
M051%1%]005)42453/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0E5324Y%4U-?0T].0T5.5%)!5$E/3E,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-14Y44U]!3D1?0T].5$E.
M1T5.0TE%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-%3$5#5$5$7U%505)415),65]&24Y!3D-)04Q?1#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-50E-%455%3E1?159%3E13/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5-34%265]/
M1E]324=.249)0T%.5%]!0T-/54Y4,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DE.5D5.5$]265]486)L97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/5$A%4E]#55)214Y47T%34T54
M4U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y&25A%1%]!4U-%5%-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4%)%4$%)1%]%6%!%3E-%7U1A8FQE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5$%.1TE"3$5?05-3
M15137U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D]42$527T-54E)%3E1?3$E!0DE,251)15-?5&%B;#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+2$],1$524U]%455)
M5%E?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^24Y#3TU%7U1!6$537U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/34U)5$U%3E137T%.1%]#3TY424Y'14Y#2453
M7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-%3$5#
M5$5$7U%505)415),65]&24Y!3D-)04Q?1#$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S,N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y42$5?0T]-4$%.65]$971A:6QS7TYA<G)A
M=&EV93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-5
M34U!4EE?3T9?4TE'3DE&24-!3E1?04-#3U5.5#(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S4N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3E9%3E1/4EE?1&5T86EL<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]42$527T-54E)%
M3E1?05-315137T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S<N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y&25A%1%]!4U-%5%-?1&5T86EL<U].87)R871I=F4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&25A%1%]!4U-%
M5%-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!215!!241?15A014Y315]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^24Y404Y'24),15]!4U-%5%-?1&5T86EL
M<U].87)R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M24Y404Y'24),15]!4U-%5%-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DE.5$%.1TE"3$5?05-315137T1E=&%I;'-?
M,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]42$52
M7T-54E)%3E1?3$E!0DE,251)15-?1&5T83PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D]42$527T-54E)%3E1?3$E!0DE,251)15-?
M1&5T83$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.
M3U1%4U]005E!0DQ%7T1E=&%I;'-?3F%R<F%T:78\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#8N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.3U1%4U]005E!0DQ%7T1E=&%I;'-?
M3F%R<F%T:78Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#0W+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4U1/0TM(3TQ$15)37T5154E465]$971A:6QS7TYA/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM(3TQ$15)37T5154E4
M65]$971A:6QS7TYA,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T.2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-43T-+2$],1$524U]%455)5%E?1&5T86EL<U].83(\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2TA/3$1%4E-?
M15%525197T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y35$]#2TA/3$1%4E-?15%525197T1E=&%I;'-?,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970U,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+2$],1$524U]%
M455)5%E?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4S+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4U1/0TM(3TQ$15)37T5154E465]$971A:6QS7S,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3D-/345?5$%815-?
M1&5T86EL<U].87)R871I=F4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y)3D-/345?5$%815-?1&5T86EL<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%4U]$971A:6QS
M7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214Q!
M5$5$7U!!4E1)15-?1&5T86EL<U].87)R870\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y"55-)3D534U]#3TY#14Y44D%424].4U]$
M971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T-3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#
M3TU-251-14Y44U]!3D1?0T].5$E.1T5.0TE%4U\Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#8P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T]-34E4345.5%-?04Y$7T-/3E1)
M3D=%3D-)15-?,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970V,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-%3$5#5$5$7U%505)415),65]&24Y!3D-)04Q?1#(\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y354)315%514Y47T5614Y4
M4U]$971A:6QS7TYA<G(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C,N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\
M>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^
M#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R
M;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@
M/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@
M/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE
M9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T
M,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T
M960Y+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1592044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O
M<FUA=&EO;B`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,#,L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`R."P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!!;F0@16YT:71Y($EN9F]R;6%T
M:6]N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=4:&5R87!E=71I8W--1"P@26YC+CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<P,#`P,#(U-S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<Q,"U+/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%
M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q
M+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%
M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^27,@16YT:71Y(&$@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U97(_
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3F\\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27,@16YT
M:71Y(&$@5F]L=6YT87)Y($9I;&5R/SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DES($5N=&ET>2=S(%)E<&]R=&EN9R!3=&%T=7,@
M0W5R<F5N=#\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=997,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG06-C96QE<F%T960@1FEL97(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U8FQI
M8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W
M."PT-C(L,C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4L,#$W
M+#`V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=&63QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P
M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V
M7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-2T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/3$E$051%1"!"
M04Q!3D-%(%-(14544R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($%S
M<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4T
M+#$Y,2PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$L-34S+#0W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92P@;F5T
M(&]F(&%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N=',@;V8@)#(V+#4U
M-2!A;F0@)#0R+#`T."P@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8Y,"PW-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,30L-#(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#0S+#8Q.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C$U+#(Q
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#<W+#<Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U,2PY,S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DL-#`S+#,T
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0L-C,U+#`T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1FEX960@87-S971S+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8Q+#,Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8U+#8W,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!!
M<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E<&%I9"!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#<U,"PT-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY-3,L-C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8U+#4X.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S.2PU-34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E8W5R:71Y(&1E<&]S:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$S-2PV.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,2PY-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-34Q+#<R.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C(U+#$U.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C(L,#$V+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L.3(U+#@W.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT($QI86)I;&ET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,3$T+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C0Q+#,V-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,#(L-3@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-#0L
M-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#8P,2PQ.#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S,L-C4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R
M<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPS,3<L.3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPV,3DL-S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M5&5R;2!,:6%B
M:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.;W1E<R!P87EA8FQE+"!N970@;V8@9&5B="!D:7-C;W5N="!O
M9B`D,"!A;F0@)#$L,3`R+#8X,"P@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU.#DL,38W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-R=65D($EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34P+#`V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QO;F<M=&5R;2!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L-S,Y+#(S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,Q-RPY.#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,U.2PP,#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@+2!P
M87(@=F%L=64@)#`N,#`Q.R`Q,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D
M.R!N;R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:R`M('!A<B!V86QU92`D,"XP,#$[(#(U,"PP,#`L
M,#`P('-H87)E<R!A=71H;W)I>F5D.R`Q-#0L.3<V+#<U-R!A;F0@.3DL-S@T
M+#DX,B!I<W-U960@86YD(&]U='-T86YD:6YG+"!R97-P96-T:79E;'D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PY-S<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.2PW.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M9&ET:6]N86P@<&%I9"!I;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S4L,#@V+#`U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#4X,"PT,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D
M(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@P+#4S
M,BPV,C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-3(L,3$S+#,Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&5Q=6ET
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L-CDX+#0P-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M-#,S+#$R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)S
M)R!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C(L
M,#$V+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2PY,C4L.#<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?
M-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970P
M,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P139'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0T].4T],241!5$5$($)!3$%.0T4@4TA%1513("A087)E;G1H971I8V%L*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=&%T96UE;G0@;V8@1FEN86YC:6%L(%!O
M<VET:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V+#4U-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-#(L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$96)T(&1I<V-O=6YT(&]N(&YO=&5S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ,#(L-C@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA
M<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X-"PY.#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X-"PY.#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?
M-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO
M5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%65!!1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/
M4$52051)3TY3("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!3=&%T96UE;G0@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2979E;G5E<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#@L-S<U+#4Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPX,3@L,#$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#`X."PQ-S<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M<W0@;V8@9V]O9',@<V]L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PY-3DL-3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PS-#@L,3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.30W+#$Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V9I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX,38L,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-CDL
M.3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PQ-#$L,#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!E>'!E;G-E<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L
M97,L(&=E;F5R86PL(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3DL,#$T+#@S-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`V.2PW,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0P-BPQ
M.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,L-34Q+#(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#DR+#,V,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-RPR-#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU."PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-BPR-C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PX-#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O<&5R
M871I;F<@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S(L-C(T+#(T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X+#8Q."PS,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#4V."PR.#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&]S
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4L.#`X+#(T-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-BPQ-#@L-#(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4L-#(W+#(Q."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC;VUE(&%N
M9"`H97AP96YS92D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36ES8V5L;&%N96]U<R!I;F-O;64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T+#4T-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS.3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T
M(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,C,T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEN9R!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,#,L.3(R*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$V-2PY.#$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PY,#4L-#`Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8T+#,X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQO86X@9W5A<F%N='D@8V]S=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L.30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#0U+#`S-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S."PQ-3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N
M(&5X=&EN9W5I<VAM96YT(&]F(&1E8G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PS,#<L.#8T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L,SDP+#`P,"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)E;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPW,38L-3`T*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#8Q,2PP-CDI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@L.3<Q+#@Q
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W+#0X-BPQ-#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!B969O<F4@=&%X97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(X+#0Q.2PS,3,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4L,3(P+#(S-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPY
M,3,L,S8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#(X+#0Q.2PS,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@S-2PQ,C`L,C,U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(L.3$S+#,V-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S('!E<B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA<F5S(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C<L-38Y+#<S
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDQ+#8S,"PV.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,BPU,38L-#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W
M834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P
M-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE
M970P-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14A21$D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0T].4T],241!5$5$(%-4051%345.5%,@3T8@4U1/0TM(3TQ$15)3)R!%
M455)5%D@*$1%1DE#250I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"!I;B!#87!I
M=&%L/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA
M=&5D($1E9FEC:70\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M5&]T86P\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E
M9VEN;FEN9R!B86QA;F-E(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-34L-#@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#DX."PV,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L,#<Y
M+#<Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#DV-"PT,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E+"!S:&%R97,@870@
M1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-34L-#@W+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^169F96-T(&]F(&UE<F=E<B!A;F0@<F5C87!I=&%L
M:7IA=&EO;B!P=7)S=6%N="!T;R!E>&5C=71I;VX@;V8@4V5C=7)I='D@17AC
M:&%N9V4@06=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R-34L.3$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@R-34L-S4S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T(&]F(&UE<F=E<B!A;F0@
M<F5C87!I=&%L:7IA=&EO;B!P=7)S=6%N="!T;R!E>&5C=71I;VX@;V8@4V5C
M=7)I='D@17AC:&%N9V4@06=R965M96YT+"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V-2PX-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@
M:6X@<')I=F%T92!P;&%C96UE;G0L(&YE="!O9B!C;W-T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+#4U,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S`Q+#0T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<P-RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C96UE;G0L(&YE="!O9B!C
M;W-T+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-34Q+#4X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!E>&-H86YG92!F;W(@9&5B
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L-C@R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PR,3<L
M-#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,C,Y+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!E>&-H86YG92!F;W(@
M9&5B="P@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,2PV.#$L.34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&9O<B!E>&5R8VES92!O9B!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#$U
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RPR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R(&5X97)C:7-E(&]F(&]P=&EO
M;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L
M,#4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y/<'1I;VYS(&ES<W5E9"!A<R!C;VUP96YS871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#,L,S4U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,RPS-34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.3`L,C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,"PR.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E
M9"!F;W(@;&]A;B!G=6%R86YT>2!C;W-T<RUR96QA=&5D('!A<G1I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,RPY-CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L.38Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!I<W-U960@9F]R(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#,V,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PS-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M(&ES<W5E9"!A<R!F:6YA;F-I;F<@8V]S=',M<F5L871E9"!P87)T:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PS,S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PS,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&ES<W5E9"!A<R!C;VUP96YS871I;VXM<F5L871E9"!P87)T>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,34X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,34X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPY
M,3,L,S8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$R+#DQ,RPS-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$96,N(#,Q
M+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,BPY-SD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PQ.3@L,C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,38L.3DS+#`W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<Q,2PX-3@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC
M92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@R+#DW."PX,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@
M<')I=F%T92!P;&%C96UE;G0L(&YE="!O9B!C;W-T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.#DQ+#4S,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@Y-2PT.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C96UE;G0L(&YE="!O9B!C;W-T
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.34S
M+#0X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!E>&-H86YG92!F;W(@9&5B=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW-S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`U,2PX.#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP-30L-C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X8VAA;F=E(&9O<B!D96)T
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S<U
M+#0Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE<F-I<V4@;V8@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY,S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#DL,#8X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R(&5X97)C:7-E(&]F(&]P=&EO
M;G,L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY
M,S$L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X97)C:7-E(&]F('=A<G)A
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#$T-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#DS
M+#@U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#$P,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@97AE<F-I<V4@;V8@
M=V%R<F%N=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PQ-#4L-#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&ES<W5E9"!A<R!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S,BPP-C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PX,S(L,#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960@9F]R('-E<G9I8V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU-C,L-C(P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-38S+#8R
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N=',@:7-S=65D(&9O<B!F:6YA;F-I;F<@8V]S=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPP,30L-S@T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#`Q-"PW
M.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S(&ES<W5E9"!A<R!C;VUP96YS871I;VXM<F5L871E9"!P
M87)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#(X-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M-BPR.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!F;W(@8V%S:#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&QA=&EO;B!O9B!W
M87)R86YT<R!I<W-U960@9F]R(&QO86X@9W5A<F%N='D@8V]S=',M<F5L871E
M9"!P87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPX
M,S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#<L.#,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<Q-BPU,#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,38L
M-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S-2PQ,C`L,C,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,U+#$R,"PR,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@8F%L86YC92!A="!$
M96,N(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M.2PW.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"PU.#`L-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3(L,3$S+#,Q,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#0S,RPQ,C@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@
M8F%L86YC92P@<VAA<F5S(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X-"PY.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X-"PY.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C96UE;G0L(&YE="!O9B!C;W-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PQ,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."PV,#4L
M,C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<X+#8U,"PS-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@:6X@<')I=F%T92!P;&%C
M96UE;G0L(&YE="!O9B!C;W-T+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0U+#$Q-BPS-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@9F]R
M(&5X97)C:7-E(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S`L.#,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P+#DQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!F;W(@97AE
M<F-I<V4@;V8@;W!T:6]N<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW-2PT,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!F;W(@<V5R
M=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C<L,C8R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@V-RPR-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E(%-H87)E($)A<V5D($-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4T+#`X,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(U
M-"PP.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"!F;W(@9FEN86YC:6YG(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW,3$L.34V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S$Q
M+#DU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@:7-S=65D(&%S(&-O;7!E;G-A=&EO;BUR96QA=&5D
M('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,C@T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,V+#(X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C@L-#$Y+#,Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R."PT,3DL,S$S*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG(&)A;&%N8V4@
M870@1&5C+B`S,2P@,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q-#0L.3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q,S4L,#@V+#`U-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H.#`L-3,R+#8R-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4T+#8Y
M."PT,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N9&EN9R!B86QA;F-E+"!S:&%R97,@870@1&5C+B`S,2P@,C`Q
M,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T+#DW-BPW-3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T-"PY-S8L-S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T
M,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970P-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14-004D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].4T],
M241!5$5$(%-4051%345.5%,@3T8@0T%32"!&3$]74R`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY3=&%T96UE;G0@;V8@0V%S:"!&;&]W<R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(X+#0Q.2PS,3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@S-2PQ,C`L,C,U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,3(L.3$S+#,V-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N
M=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H(&9L;W=S('5S
M960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C="!O9B!M97)G97(@
M86YD(')E8V%P:71A;&EZ871I;VX@<'5R<W5A;G0@=&\@97AE8W5T:6]N(&]F
M(%-E8W5R:71Y($5X8VAA;F=E($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-34L
M-S4S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT-RPX.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-RPT.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-2PV.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!I;G1A
M;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C@L-S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CDL,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]V:7-I;VX@9F]R(&1O=6)T9G5L(&%C
M8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PT.3,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#`L-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@;VX@9&5B="!E>'1I;F=U:7-H;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,P
M-RPX-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#,Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)E;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BPW,38L-3`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@
M9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3`R
M+#8X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-C`T+#(T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X+#<Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(P-RPR,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@V
M."PS-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.3`L-3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN86YC
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0U
M,2PY,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4L.3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!E>'!E;G-E
M(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C,V+#DQ-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S."PT-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,BPV,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO86X@9W5A<F%N='D@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.30T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4L,#,V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,34Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L,#8X+#8Q.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W,C@L,C4S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#0P.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<Q+#4Y
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$L,#(W+#$S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.2PY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#,X-BPS,3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L,C@Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S0V
M+#@R,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-38U+#<P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<R+#@U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S,T+#@U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X."PX-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U-RPX,C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$T-"PW-3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#@W-2PS,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,SDL,34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3DT+#4S-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$U,"PP-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!F;&]W<R!U<V5D(&EN
M(&]P97)A=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R,"PW-C@L,#8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$R+#<S-RPS,C8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PY-C8L-3DV*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#05-(($9,3U=3($923TT@24Y615-424Y'($%#5$E6251)15,\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%T
M96YT(&-O<W1S+"!N970@;V8@86)A;F1O;F5D(&-O<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T,SDL,#,T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(P-BPQ,#$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PX-S`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT(&]F('-E8W5R:71Y(&1E<&]S:70\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$P,RPW,S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P+#<Y,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-BPT,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@L-S8V
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!C87-H(&9L;W=S('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X,RPU-C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<R
M+#4P-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S-RPV,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/5U,@1E)/32!&24Y!3D-)
M3D<@04-4259)5$E%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@8V]M;6]N('-T
M;V-K+"!N970@;V8@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<X+#8U,"PS-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW+#@Y-2PT.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&)A
M;FL@;&EN92!O9B!C<F5D:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!E>&5R8VES92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,"PY,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,C4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&YO
M=&5S(&%N9"!L;V%N<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^."PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPV.#0L,38P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A
M;&4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M(&YO=&5S(&%N9"!L;V%N<R!P87EA8FQE
M+7)E;&%T960@<&%R=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@;65M8F5R<VAI
M<"!U;FET<RP@;F5T(&]F(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<P-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N="!O9B!B86YK(&QI;F4@
M;V8@8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,#`L
M,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT(&]F(&YO=&5S
M('!A>6%B;&4@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`P+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#`L-CDV*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P
M87EM96YT(&]F(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0L-CDQ+#@T-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@U,"PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`P+#`P,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!F;&]W<R!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,L.3@Y+#0Q-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0S
M-BPX.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#<P-RPW,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!C87-H/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,BPV,S<L-S@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C<L,#4S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDV+#4Q
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@L(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-34S+#0W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-BPT,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C(L.3,Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M+"!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-"PQ.3$L,C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU-3,L-#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(V+#0R,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY355!03$5-
M14Y404P@1$E30TQ/4U5215,@3T8@0T%32"!&3$]7($E.1D]234%424]..CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H('!A:60@9F]R(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,3(L.#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<L,C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-54%!,14U%3E1!
M3"!30TA%1%5,12!/1B!.3TXM0T%32"!&24Y!3D-)3D<@04-4259)5$E%4SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@:7-S=65D(&9O<B!F:6YA;F-I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-S$Q+#DU-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`Y+#4S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T."PV-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0V,BPQ.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4S,BPR,C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`L,C@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!E>&5R8VES960@:6X@97AC:&%N9V4@9F]R(&1E8G0@86YD(&%C8W)U960@
M:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$P
M,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X8VAA;F=E(&9O<B!D96)T(&%N
M9"!A8V-R=65D(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PP-30L-C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#0Y+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@<&%Y86)L92!I<W-U960@
M9F]R(&%C8W)U960@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$U+#$R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW
M-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T
M,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#`W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^5$A%
M($-/35!!3ED\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!0
M<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5$A%($-/35!!3ED\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQU/DY/
M5$4-"C$@)B,Q-3`[(%1(12!#3TU004Y9/"]U/CPO9F]N=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY4:&5R87!E=71I8W--1"P@26YC+BP@82!.979A9&$@8V]R
M<&]R871I;VXL#0IO<B!4:&5R87!E=71I8W--1"!O<B!T:&4@0V]M<&%N>2P@
M:&%S('1W;R!W:&]L;'D@;W=N960@<W5B<VED:6%R:65S+"!V:71A365D340L
M($Q,0RP@82!$96QA=V%R92!L:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY(&]R
M9V%N:7IE9`T*;VX@36%Y(#$S+"`R,#`X+"!O<B!6:71A365D+"!A;F0@0F]C
M84=R965N340L($EN8RXL(&$@3F5V861A(&-O<G!O<F%T:6]N(&EN8V]R<&]R
M871E9"!O;B!*86YU87)Y(#$P+"`R,#$R+"!O<B!";V-A1W)E96XN(%5N;&5S
M<PT*=&AE(&-O;G1E>'0@;W1H97)W:7-E(')E<75I<F5S+"!4:&5R87!E=71I
M8W--1"P@5FET84UE9"P@86YD($)O8V%'<F5E;B!C;VQL96-T:79E;'D@87)E
M('-O;65T:6UE<R!R969E<G)E9"!T;R!A<R`F(S$T-SMO=7(@8V]M<&%N>2PF
M(S$T.#L-"B8C,30W.W=E+"8C,30X.R`F(S$T-SMO=7(L)B,Q-#@[(&]R("8C
M,30W.W5S+B8C,30X.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^3F%T=7)E(&]F($)U<VEN
M97-S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@87)E(&$@=V]M96XF(S$T-CMS(&AE
M86QT:&-A<F4@<')O9'5C=`T*8V]M<&%N>2!F;V-U<V5D(&]N(&-R96%T:6YG
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M9R!A;B!E;FAA;F-E9"!S:61E(&5F9F5C=`T*<')O9FEL92!C;VUP87)E9"!W
M:71H(&-O;7!E=&EN9R!P<F]D=6-T<RX@3W5R(&1R=6<@8V%N9&ED871E<R!A
M<F4@8W)E871E9"!F<F]M(&$@<&QA=&9O<FT@;V8@:&]R;6]N92!T96-H;F]L
M;V=Y('1H870@96YA8FQE<PT*=&AE(&%D;6EN:7-T<F%T:6]N(&]F(&AO<FUO
M;F5S('=I=&@@:&EG:"!B:6]A=F%I;&%B:6QI='D@86QO;F4@;W(@:6X@8V]M
M8FEN871I;VXN($EN(&%D9&ET:6]N+"!W92!M86YU9F%C='5R92`H=&AR;W5G
M:"!T:&ER9`T*<&%R=&EE<RD@86YD(&1I<W1R:6)U=&4@8G)A;F1E9"!A;F0@
M9V5N97)I8R!P<F5S8W)I<'1I;VX@<')E;F%T86P@=FET86UI;G,@87,@=V5L
M;"!A<R!O=F5R+71H92UC;W5N=&5R+"!O<B!/5$,L('9I=&%M:6YS(&%N9`T*
M8V]S;65T:6-S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^06=R965M96YT(&%N9"!0;&%N
M(&]F($UE<F=E<B!W:71H(%9I=&%-960\+W4^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*
M=6QY(#$X+"`R,#$Q+"!W92!E;G1E<F5D(&EN=&\@86X@06=R965M96YT#0IA
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M;VYS.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P
M.B`P.R!M87)G:6XM8F]T=&]M.B`P)SX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!3>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SYA#0H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(')E=F5R<V4@<W!L:70@;V8@;W5R
M(#$V+#4W-2PR,#D@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!S:&%R97,@;V8@
M;W5R(&-O;6UO;B!S=&]C:RP@<&%R#0H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@('9A;'5E("0P+C`P,2!P97(@<VAA<F4L(&]R
M('1H92!#;VUM;VX@4W1O8VLL(&]N(&$@<F%T:6\@;V8@,2UF;W(M,3`P+B!!
M<R!A(')E<W5L="!O9@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("!T:&4@<F5V97)S92!S<&QI="P@96%C:"!S:&%R92!O9B!#
M;VUM;VX@4W1O8VL@;W5T<W1A;F1I;F<@;VX@=&AE($IU;'DF(S$V,#LR."P@
M,C`Q,2!R96-O<F0-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@9&%T92P@=VET:&]U="!A;GD@86-T:6]N(&]N('1H92!P87)T
M(&]F('1H92!H;VQD97(@=&AE<F5O9BP@8F5C86UE(&]N92!O;F4M:'5N9')E
M9'1H#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(&]F(&$@<VAA<F4@;V8@0V]M;6]N(%-T;V-K+B!4:&4@<F5V97)S92!S<&QI
M="!D96-R96%S960@=&AE(&YU;6)E<B!O9B!O=71S=&%N9&EN9R!S:&%R97,-
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@;V8@
M;W5R($-O;6UO;B!3=&]C:R!B>2!A<'!R;WAI;6%T96QY(#DY)2P@<F5S=6QT
M:6YG(&EN(#$V-2PX-38@<VAA<F5S(&]U='-T86YD:6YG(&%F=&5R#0H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@('1H92!R979E
M<G-E('-P;&ET+B!4:&4@969F96-T=6%T:6]N(&]F('1H92!R979E<G-E('-P
M;&ET(&1I9"!N;W0@<F5S=6QT(&EN(&$@8VAA;F=E(&EN#0H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@('1H92!R96QA=&EV92!E
M<75I='D@<&]S:71I;VX@;W(@=F]T:6YG('!O=V5R(&]F(&]U<B!S:&%R96AO
M;&1E<G,[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`G/@T*/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT9"!S='EL
M93TS1"=W:61T:#H@,"XR-6EN)SX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,"XR-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%-Y;6)O;"<^)B,Q
M.#,[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GDG/F%N#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(&EN8W)E87-E(&EN('1H92!N=6UB97(@;V8@<VAA<F5S(&]F(&]U<B!#
M;VUM;VX@4W1O8VL@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4@=&\@,C4P+#`P
M,"PP,#`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`G/@T*/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT9"!S='EL
M93TS1"=W:61T:#H@,"XR-6EN)SX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,"XR-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%-Y;6)O;"<^)B,Q
M.#,[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GDG/F$-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@8VAA;F=E(&EN('1H92!N86UE(&]F(&]U<B!C;VUP86YY('1O(%1H97)A
M<&5U=&EC<TU$+"!);F,N.R!A;F0\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@4WEM8F]L)SXF(S$X,SL\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>2<^86X-"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@86UE;F1M96YT('1O(&]U<B`R,#`Y($QO;F<@
M5&5R;2!);F-E;G1I=F4@0V]M<&5N<V%T:6]N(%!L86X@=&\@:6YC<F5A<V4@
M=&AE(&YU;6)E<B!O9@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!R97-E<G9E
M9"!F;W(@:7-S=6%N8V4@=&AE<F5U;F1E<B!T;R`R-2PP,#`L,#`P+CPO=&0^
M/"]T<CX\+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!T:&4@969F96-T:79E(&1A=&4@
M;V8@=&AE(&UE<F=E<BP@=V4@86-Q=6ER960-"C$P,"4@;V8@5FET84UE9"!I
M;B!E>&-H86YG92!F;W(@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VLN/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/D5X8VAA;F=E(&]F(%-E8W5R
M:71I97,\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
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M;6)E<G-H:7`@=6YI=',@=V5R92!E>&-H86YG960@9F]R(&%N9"!C;VYV97)T
M960@:6YT;R!O<'1I;VYS(&%N9"!W87)R86YT<R!T;R!P=7)C:&%S92!S:&%R
M97,@;V8@;W5R($-O;6UO;B!3=&]C:RX-"E!U<G-U86YT('1O('1H92!C;VYV
M97)S:6]N(')A=&EO(&EN('1H92!M97)G97(L('=E(&ES<W5E9"`U."PT,#<L
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M<G-H:7`-"G5N:71S+"!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!O=7(@0V]M
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M<G-H:7`@=6YI=',@86YD(&ES<W5A8FQE('5P;VX@97AE<F-I<V4@;V8@=&AE
M(&]P=&EO;G,@86YD('=A<G)A;G1S('=E<F4@<W5B:F5C="!T;R!A(&QO8VLM
M=7`@86=R965M96YT(&9O<B!A('!E<FEO9"!O9B`Q.`T*;6]N=&AS(&9R;VT@
M=&AE(&5F9F5C=&EV92!D871E(&]F('1H92!M97)G97(L(&%N9"!O;B!A(&QI
M;6ET960@8F%S:7,@9F]R(#$R(&UO;G1H<R!T:&5R96%F=&5R+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W
M-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-534U!4ED@3T8@4TE'
M3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O
M;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.
M5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^/'4^
M3D]410T*,B`F(S$U,#L@4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y4
M24Y'(%!/3$E#2453/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS
M1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\=3Y0<FEN8VEP;&5S(&]F($-O;G-O
M;&ED871I;VX\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
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M:6X@8V]N<V]L:61A=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[(&QE='1E<BUS<&%C:6YG.B`M,"XQ-7!T.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L
M)SX\=3Y#87-H/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86PG/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
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M86YC97,@=V5R92!F=6QL>2!I;G-U<F5D(&%T($1E8V5M8F5R(#,Q+"`R,#$R
M(&%N9"`R,#$Q+"!R97-U;'1I;F<-"F9R;VT@=&AE('1E;7!O<F%R>2!F961E
M<F%L('!R;V=R86T@:6X@969F96-T(&9R;VT@1&5C96UB97(@,S$L(#(P,3`@
M=&AR;W5G:"!$96-E;6)E<B`S,2P@,C`Q,BX@56YD97(@=&AI<R!P<F]G<F%M
M+"!T:&5R92!W87,@;F\-"FQI;6ET('1O('1H92!A;6]U;G0@;V8@:6YS=7)A
M;F-E(&9O<B!E;&EG:6)L92!A8V-O=6YT<RX@0F5G:6YN:6YG($IA;G5A<GD@
M,2P@,C`Q,RP@:6YS=7)A;F-E(&-O=F5R86=E(')E=F5R=&5D('1O("0R-3`L
M,#`P('!E<@T*9&5P;W-I=&]R(&%T(&5A8V@@9FEN86YC:6%L(&EN<W1I='5T
M:6]N+"!A="!W:&EC:"!T:6UE(&]U<B!N;VXM:6YT97)E<W0@8F5A<FEN9R!C
M87-H(&)A;&%N8V5S(&%G86EN(&5X8V5E9&5D(&9E9&5R86QL>2!I;G-U<F5D
M#0IL:6UI=',N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L
M971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(#!P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!L971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(#!P="<^/'4^5')A9&4-"D%C8V]U;G1S(%)E8V5I
M=F%B;&4@86YD($%L;&]W86YC92!F;W(@1&]U8G1F=6P@06-C;W5N=',\+W4^
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T97(M<W!A
M8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(#!P
M="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY4<F%D92!A8V-O=6YT<R!R96-E:79A8FQE
M(&%R92!C=7-T;VUE<B!O8FQI9V%T:6]N<PT*9'5E('5N9&5R(&YO<FUA;"!T
M<F%D92!T97)M<RX@5V4@<F5V:65W(&%C8V]U;G1S(')E8V5I=F%B;&4@9F]R
M('5N8V]L;&5C=&EB;&4@86-C;W5N=',@86YD(&-R961I="!C87)D(&-H87)G
M92UB86-K<R!A;F0@<')O=FED90T*86X@86QL;W=A;F-E(&9O<B!D;W5B=&9U
M;"!A8V-O=6YT<RP@=VAI8V@@:7,@8F%S960@=7!O;B!A(')E=FEE=R!O9B!O
M=71S=&%N9&EN9R!R96-E:79A8FQE<RP@:&ES=&]R:6-A;"!C;VQL96-T:6]N
M(&EN9F]R;6%T:6]N+`T*86YD(&5X:7-T:6YG(&5C;VYO;6EC(&-O;F1I=&EO
M;G,N(%=E(&-O;G-I9&5R('1R861E(&%C8V]U;G1S(')E8V5I=F%B;&4@<&%S
M="!D=64@9F]R(&UO<F4@=&AA;B`Y,"!D87ES('1O(&)E(&1E;&EN<75E;G0N
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M;V5S(&YO=`T*86-C=7)A=&5L>2!R969L96-T(&)A9"!D96)T<SL@861J=7-T
M;65N=',@=&\@=&AE<V4@<F5S97)V97,@;6%Y(&)E(')E<75I<F5D+CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/"]P/@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQU/DEN=F5N=&]R:65S/"]U
M/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M<GDL('5N=&EL('-U8V@@=&EM92!A<R!T:&4@<F5L871E9"!D969E<G)E9`T*
M<F5V96YU92!I<R!R96-O9VYI>F5D+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/'4^1FEX960@07-S971S/"]U/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^17%U
M:7!M96YT/"]U/CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E('-T871E(&5Q=6EP;65N
M="!A="!C;W-T+"!N970@;V8@86-C=6UU;&%T960-"F1E<')E8VEA=&EO;BX@
M5V4@8VAA<F=E(&UA:6YT96YA;F-E(&-O<W1S+"!W:&EC:"!D;R!N;W0@<VEG
M;FEF:6-A;G1L>2!E>'1E;F0@=&AE('5S969U;"!L:79E<R!O9B!T:&4@<F5S
M<&5C=&EV92!A<W-E=',L(&%N9"!R97!A:7(-"F-O<W1S('1O(&]P97)A=&EN
M9R!E>'!E;G-E(&%S(&EN8W5R<F5D+B`\9F]N="!S='EL93TS1"=L971T97(M
M<W!A8VEN9SH@+3`N,35P="<^5V4@8V]M<'5T92!D97!R96-I871I;VX@=7-I
M;F<@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D#0IO=F5R('1H92!E<W1I;6%T
M960@=7-E9G5L(&QI=F5S(&]F('1H92!R96QA=&5D(&%S<V5T<RP@=VAI8V@@
M<F%N9V4@9G)O;2!T:')E92!T;R!S979E;B!Y96%R<RX\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P
M="<^/&D^/'4^3&5A<V5H;VQD#0I);7!R;W9E;65N=',\+W4^/"]I/CPO9F]N
M=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G
M/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^/'4^26YT86YG:6)L
M93PO=3X@/"]F;VYT/CQU/D%S<V5T<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C
M:6YG.B`M,"XQ-7!T)SX\:3X\=3Y0871E;G0-"F%N9"!4<F%D96UA<FMS/"]U
M/CPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG
M.B`M,"XQ-7!T)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)VQE
M='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SY792!H879E#0IA9&]P=&5D('1H92!P
M<F]V:7-I;VYS(&]F(#PO9F]N=#Y&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N
M9&%R9',@0F]A<F0L(&]R($9!4T(L($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O
M9&EF:6-A=&EO;BP@;W(@05-#+"`\9F]N="!S='EL93TS1"=L971T97(M<W!A
M8VEN9SH@+3`N,35P="<^,S4P+`T*/&D^26YT86YG:6)L92U';V]D=VEL;"!A
M;F0@3W1H97(\+VD^+#QI/B`\+VD^;W(@/"]F;VYT/D%30R`S-3`\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^+B!#87!I=&%L:7IE
M9"!P871E;G0@8V]S=',L#0IN970@;V8@86-C=6UU;&%T960@86UO<G1I>F%T
M:6]N+"!I;F-L=61E(&QE9V%L(&-O<W1S(&EN8W5R<F5D(&9O<B!P871E;G0@
M87!P;&EC871I;VYS+B`\+V9O;G0^26X@86-C;W)D86YC92!W:71H($%30R`S
M-3`L(#QF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SYO
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M=F5R86)L92X@3W5R(&9I<G-T('!A=&5N="!W87,@9W)A;G1E9`T*:6X@=&AE
M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,N/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\=3Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@07-S971S/"]U
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
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M;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT
M;W`Z(#`[(&UA<F=I;BUB;W1T;VTZ(#`G/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%-Y;6)O;"<^)B,Q.#,[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/G-I9VYI9FEC86YT#0H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&1E8VQI;F5S
M(&EN(&%N(&%S<V5T)B,Q-#8[<R!M87)K970@<')I8V4[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`P+C(U:6XG/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`P
M+C(U:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@4WEM8F]L)SXF(S$X
M,SL\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>2<^<VEG;FEF:6-A;G0-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@9&5T97)I;W)A=&EO;B!I;B!A;B!A<W-E="8C,30V.W,@
M<&AY<VEC86P@8V]N9&ET:6]N.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR
M-6EN)SX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%-Y;6)O;"<^)B,Q.#,[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/G-I9VYI9FEC86YT
M#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&-H
M86YG97,@:6X@=&AE(&YA='5R92!O<B!E>'1E;G0@;V8@86X@87-S970F(S$T
M-CMS('5S92!O<B!O<&5R871I;VX[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P
M+C(U:6XG/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@4WEM8F]L)SXF(S$X,SL\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^<VEG;FEF:6-A
M;G0-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M861V97)S92!C:&%N9V5S(&EN('1H92!B=7-I;F5S<R!C;&EM871E('1H870@
M8V]U;&0@:6UP86-T(&%N(&%S<V5T)B,Q-#8[<R!V86QU92P@:6YC;'5D:6YG
M#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&%D
M=F5R<V4@86-T:6]N<R!O<B!A<W-E<W-M96YT<R!B>2!R96=U;&%T;W)S.R`\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3
M>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y)SYA8V-U;75L871I;VX-"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@;V8@8V]S=',@<VEG;FEF:6-A;G1L
M>2!I;B!E>&-E<W,@;V8@;W)I9VEN86P@97AP96-T871I;VYS(')E;&%T960@
M=&\@=&AE(&%C<75I<VET:6]N#0H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(&]R(&-O;G-T<G5C=&EO;B!O9B!A;B!A<W-E=#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3
M>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y)SYC=7)R96YT+7!E<FEO9`T*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("!O<&5R871I;F<@;W(@8V%S:"!F
M;&]W(&QO<W-E<R!C;VUB:6YE9"!W:71H(&$@:&ES=&]R>2!O9B!S=6-H(&QO
M<W-E<R!O<B!A(&9O<F5C87-T('1H870-"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@9&5M;VYS=')A=&5S(&-O;G1I;G5I;F<@
M;&]S<V5S(&%S<V]C:6%T960@=VET:"!A;B!A<W-E="8C,30V.W,@=7-E.R!A
M;F0\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<"<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!3>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y)SYE>'!E8W1A=&EO;G,-"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@=&AA="!I="!I<R!M;W)E(&QI
M:V5L>2!T:&%N(&YO="!T:&%T(&%N(&%S<V5T('=I;&P@8F4@<V]L9"!O<B!O
M=&AE<G=I<V4@9&ES<&]S960@;V8@<VEG;FEF:6-A;G1L>0T*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!B969O<F4@=&AE(&5N
M9"!O9B!I=',@<')E=FEO=7-L>2!E<W1I;6%T960@=7-E9G5L(&QI9F4N/"]T
M9#X\+W1R/CPO=&%B;&4^#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEF
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M=`T*;V8@=&AE(&-A<V@@9FQO=W,@;V8@;W1H97(@87-S971S(&%N9"!L:6%B
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M:6]D<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQU/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L
M($EN<W1R=6UE;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
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M<W1R=6UE;G1S(&%N9"!A<F4@8V]N<VED97)E9`T*3&5V96P@,2!A<W-E=',@
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M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
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M(&%S<V5T<PT*86YD(&QI86)I;&ET:65S("A,979E;"`Q*2!A;F0@;&]W97-T
M('!R:6]R:71Y('1O('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L(#,I+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^07-S971S(&%N9"!L:6%B:6QI=&EE<R!R96-O<F1E9"!I
M;B!T:&4@8V]N<V]L:61A=&5D#0IB86QA;F-E('-H965T(&%T(&9A:7(@=F%L
M=64@87)E(&-A=&5G;W)I>F5D(&)A<V5D(&]N(&$@:&EE<F%R8VAY(&]F(&EN
M<'5T<RP@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P
M.B`P.R!M87)G:6XM8F]T=&]M.B`P.R!W:61T:#H@,3`P)2<^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S-G!T)SX\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@-31P=#L@=&5X="UA;&EG;CH@;&5F="<^/&(^3&5V96P@,3PO
M8CX\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SYU;F%D
M:G5S=&5D('%U;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED
M96YT:6-A;`T*87-S971S(&]R(&QI86)I;&ET:65S.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ
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M;"`R/"]B/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG
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M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CPO<#X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D%T($1E8V5M8F5R(#,Q+"`R,#$S+"`R,#$R+"!A
M;F0@,C`Q,2P@=V4@:&%D#0IN;R!A<W-E=',@;W(@;&EA8FEL:71I97,@=&AA
M="!W97)E('9A;'5E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A
M<VES+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@;&5T
M=&5R+7-P86-I;F<Z("TP+C$U<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF
M;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`P<'0G/CQU/DEN8V]M90T*
M5&%X97,\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L
M971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z(#!P="<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY7:71H('1H92!A9'9E;G0@;V8@=&AE($UE<F=E<BP@=V4@9&5T
M97)M:6YE9`T*=&AA="!6:71A365D('=O=6QD(&)E8V]M92!T:&4@<V]L92!F
M;V-U<R!O9B!O=7(@8V]M<&%N>2!A;F0@<')E=FEO=7,@8G5S:6YE<W,@<&5R
M9F]R;65D(&)Y(&]U<B!P<F5D96-E<W-O<B!W87,@9&ES8V]N=&EN=65D+B!"
M96-A=7-E#0IO9B!T:&5S92!E=F5N=',L(&1E9F5R<F5D(&EN8V]M92!T87AE
M<R!A<F4@9&5T97)M:6YE9"!B>2!C86QC=6QA=&EN9R!T:&4@;&]S<R!F<F]M
M(&]P97)A=&EO;G,@;V8@;W5R(&-O;7!A;GD@<W1A<G1I;F<@3V-T;V)E<B`T
M+`T*,C`Q,2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
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M:&EC:`T*=&AE(')E;&%T960@=&5M<&]R87)Y(&1I9F9E<F5N8V5S(&%R92!E
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M(')E86QI>F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@86-C;W)D86YC92!W:71H($%3
M0R`W-#`L(#QI/DEN8V]M92!487AE<SPO:3XL#0IW92!R96-O9VYI>F4@=&AE
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M;V8@8F5I;F<@<F5A;&EZ960@=&AA="!I<R!G<F5A=&5R('1H86X@-3`E+B!#
M:&%N9V5S(&EN(')E8V]G;FET:6]N(&]R(&UE87-U<F5M96YT(&%R92!R969L
M96-T960@:6X-"G1H92!P97)I;V0@:6X@=VAI8V@@=&AO<V4@8VAA;F=E<R!I
M;B!J=61G;65N="!O8V-U<BX@070@1&5C96UB97(@,S$L(#(P,3,L(#(P,3(L
M(&%N9"`R,#$Q('=E(&AA9"!N;R!U;F-E<G1A:6X@:6YC;VUE('1A>"!P;W-I
M=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY792!R96-O9VYI>F4@8F]T:"!I;G1E<F5S
M="!A;F0@<&5N86QT:65S(')E;&%T960-"G1O('5N8V5R=&%I;B!T87@@<&]S
M:71I;VYS(&%S('!A<G0@;V8@=&AE(&EN8V]M92!T87@@<')O=FES:6]N+B!!
M="!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@=V4@:&%D(&YO('1A>"!P
M;W-I=&EO;G,@<F5L871I;F<-"G1O(&]P96X@=&%X(')E='5R;G,@=&AA="!W
M97)E(&-O;G-I9&5R960@=&\@8F4@=6YC97)T86EN+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M3W5R('1A>"!R971U<FYS(&%R92!S=6)J96-T('1O(')E=FEE=R!B>2!T:&4-
M"DEN=&5R;F%L(%)E=F5N=64@4V5R=FEC92!T:')E92!Y96%R<R!A9G1E<B!T
M:&5Y(&%R92!F:6QE9"X@0W5R<F5N=&QY+"!Y96%R<R!F:6QE9"!A9G1E<B`R
M,#$P(&%R92!S=6)J96-T('1O(')E=FEE=RX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/E-H
M87)E+4)A<V5D($-O;7!E;G-A=&EO;CPO=3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($1E
M8V5M8F5R(#(P,#0L('1H92!&05-"(&ES<W5E9"!!4T,@-S$X+`T*/&D^0V]M
M<&5N<V%T:6]N("8C,34P.R!3=&]C:R!#;VUP96YS871I;VX\+VD^+#QI/B`\
M+VD^;W(\:3X@/"]I/D%30R`W,3@N(%5N9&5R($%30R`W,3@L(&-O;7!A;FEE
M<R!A<F4@<F5Q=6ER960@=&\@;65A<W5R92!T:&4-"F-O;7!E;G-A=&EO;B!C
M;W-T<R!O9B!S:&%R92UB87-E9"!C;VUP96YS871I;VX@87)R86YG96UE;G1S
M(&)A<V5D(&]N('1H92!G<F%N="UD871E(&9A:7(@=F%L=64@86YD(')E8V]G
M;FEZ92!T:&4@8V]S=',@:6X@=&AE(&9I;F%N8VEA;`T*<W1A=&5M96YT<R!O
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M;&EF92!O9@T*=&AE(&%W87)D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^
M#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M/"]I/BP\:3X@/"]I/F]R($%30R`U,#4\:3XL(#PO:3YD969I;F5S('1H92!M
M96%S=7)E;65N="!D871E(&%N9"!R96-O9VYI=&EO;B!P97)I;V0-"F9O<B!S
M=6-H(&EN<W1R=6UE;G1S+B!);B!G96YE<F%L+"!T:&4@;65A<W5R96UE;G0@
M9&%T92!I<R!W:&5N(&5I=&AE<B`H82D@82!P97)F;W)M86YC92!C;VUM:71M
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M<R!D969I;F5D(&EN($%30R`U,#4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!R96-O9VYI
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\=3Y$96)T($1I<V-O=6YT<SPO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D-O<W1S(&EN8W5R<F5D(&9R;VT@<&%R=&EE<R!T:&%T(&%R92!P<F]V:61I
M;F<-"FQO;F<M=&5R;2!F:6YA;F-I;F<L('=H:6-H(&EN8VQU9&4@=V%R<F%N
M=',@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@=6YD97)L>6EN9R!D
M96)T+"!A<F4@<F5F;&5C=&5D(&%S(&$@9&5B="!D:7-C;W5N="!B87-E9`T*
M;VX@=&AE(')E;&%T:79E(&9A:7(@=F%L=64@;V8@=&AE(&1E8G0@86YD('=A
M<G)A;G1S('1O('1H92!T;W1A;"!P<F]C965D<RX@5V4@9V5N97)A;&QY(&%M
M;W)T:7IE(&1I<V-O=6YT<R!O=F5R('1H92!L:69E(&]F('1H90T*<F5L871E
M9"!D96)T('5S:6YG('1H92!E9F9E8W1I=F4@:6YT97)E<W0@<F%T92!M971H
M;V0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\=3Y2
M979E;G5E(%)E8V]G;FET:6]N/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
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M(')E87-O;F%B;'D@87-S=7)E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/D]V97(M
M=&AE+4-O=6YT97(@4')O9'5C=',\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V,#L\+VD^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M(')E;&%T:79E('1O('-A;&5S+B`\9F]N="!S='EL93TS1"=C;VQO<CH@(S(U
M,C4R-2<^5V4-"G!R;W9I9&4@86X@=6YC;VYD:71I;VYA;"`S,"UD87D@;6]N
M97DM8F%C:R!R971U<FX@<&]L:6-Y('5N9&5R('=H:6-H('=E(&%C8V5P="!P
M<F]D=6-T(')E='5R;G,@9G)O;2!O=7(@<F5T86EL(&%N9"!E0V]M;65R8V4@
M8W5S=&]M97)S+@T*/"]F;VYT/E=E(')E8V]G;FEZ92!O=7(@<F5V96YU92!F
M<F]M($]40R!S86QE<RP@;F5T(&]F(')E='5R;G,L('-A;&5S(&1I<V-O=6YT
M<RP@86YD(&5#;VUM97)C92!F965S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^4')E
M<V-R:7!T:6]N(%!R;V1U8W1S/"]U/CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)V-O;&]R.B`C,C4R-3(U)SY792!S96QL(&]U<B!N86UE#0IB
M<F%N9"!A;F0@9V5N97)I8R!P<F5S8W)I<'1I;VX@<')O9'5C=',@/"]F;VYT
M/G!R:6UA<FEL>2!T:')O=6=H(&1R=6<@=VAO;&5S86QE<G,@86YD(')E=&%I
M;"!P:&%R;6%C:65S+B!792!R96-O9VYI>F4@<F5V96YU92!F<F]M#0IP<F5S
M8W)I<'1I;VX@<')O9'5C="!S86QE<RP@;F5T(&]F('-A;&5S(&1I<V-O=6YT
M<RP@8VAA<F=E8F%C:W,L(&%N9"!R96)A=&5S+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
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M871I;VX@;V8@=&AE(')I9VAT(&]F(')E='5R;BX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E
M(&UA:6YT86EN('9A<FEO=7,@<F5B871E('!R;V=R86US(&EN(&%N(&5F9F]R
M=`T*=&\@;6%I;G1A:6X\:3X@/"]I/F$@8V]M<&5T:71I=F4@<&]S:71I;VX@
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M;B!A('%U87)T97)L>2!B87-I<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H-
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^5V4@97AP96YS92!A;&P@<VAI<'!I;F<@86YD(&AA;F1L:6YG(&-O
M<W1S#0IA<R!I;F-U<G)E9"X@5V4@:6YC;'5D92!T:&5S92!C;W-T<R!I;B!C
M;W-T(&]F('-A;&5S(&]N('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0G/CQU/D%D=F5R=&ES:6YG($-O<W1S/"]U/CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@97AP96YS
M92!A9'9E<G1I<VEN9R!C;W-T<R!W:&5N(&EN8W5R<F5D+@T*061V97)T:7-I
M;F<@8V]S=',@=V5R92`D,3$L-S,Y+"`D-C4L.30T(&%N9"`D,3DL-#@P(&1U
M<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3,L($1E8V5M
M8F5R(#,Q+"`R,#$Q(&%N9"!$96-E;6)E<B`S,2P-"C(P,3(L(')E<W!E8W1I
M=F5L>2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQU
M/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E<SPO=3X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N="P@;W(@4B8C,S@[1"P@97AP96YS97,-"FEN8VQU9&4@:6YT
M97)N86P@4B8C,S@[1"!A8W1I=FET:65S+"!S97)V:6-E<R!O9B!E>'1E<FYA
M;"!C;VYT<F%C="!R97-E87)C:"!O<F=A;FEZ871I;VYS+"!O<B!#4D]S+"!C
M;W-T<R!O9B!T:&5I<B!C;&EN:6-A;"!R97-E87)C:`T*<VET97,L(&%N9"!O
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M:71I97,@=V5R92`D,BPP.3$L.#`Y(&%N9"`D,3@Y+#,W-2!F;W(@>65A<G,@
M96YD960@1&5C96UB97(@,S$L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R
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M;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CQU/D5A<FYI;F=S(%!E<B!3:&%R93PO=3X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/E=E(&-A;&-U;&%T92!E87)N:6YG<R!P97(@<VAA<F4L(&]R
M($504RP@:6X-"F%C8V]R9&%N8V4@=VET:"!!4T,@,C8P+"`\:3Y%87)N:6YG
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M(#$S+#8T-RPW.#@@<VAA<F5S(&]F(&]U<@T*0V]M;6]N(%-T;V-K(&9O<B`R
M,#$S+"`R,#$R+"!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+"!W97)E(&5X8VQU
M9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@96%R;FEN9W,@
M<&5R('-H87)E(&9O<B!T:&5S90T*<&5R:6]D<R!B96-A=7-E('1H96ER(&5F
M9F5C="!W;W5L9"!H879E(&)E96X@86YT:2UD:6QU=&EV92!D=64@=&\@=&AE
M(&YE="!L;W-S(')E<&]R=&5D(&)Y('5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M=V5I9VAT
M.B!N;W)M86PG/CQU/E5S90T*;V8@17-T:6UA=&5S/"]U/CPO9F]N=#X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@;&5T=&5R+7-P86-I;F<Z("TP+C$U
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!N;W)M86PG/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
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M8V$L(&]R($=!05`N(%1H92!P<F5P87)A=&EO;@T*;V8@=&AE<V4@9FEN86YC
M:6%L('-T871E;65N=',@<F5Q=6ER97,@=7,@=&\@;6%K92!S:6=N:69I8V%N
M="!E<W1I;6%T97,@86YD(&IU9&=M96YT<R!T:&%T(&%F9F5C="!T:&4@<F5P
M;W)T960@86UO=6YT<R!O9B!A<W-E=',L#0IL:6%B:6QI=&EE<RP@<F5V96YU
M92P@97AP96YS97,L(&%N9"!R96QA=&5D(&1I<V-L;W-U<F4@;V8@8V]N=&EN
M9V5N="!A<W-E=',@86YD(&QI86)I;&ET:65S+B!792!E=F%L=6%T92!O=7(@
M97-T:6UA=&5S+"!I;F-L=61I;F<-"G1H;W-E(')E;&%T960@=&\@8V]N=&EN
M9V5N8VEE<RP@;VX@86X@;VYG;VEN9R!B87-I<RX@5V4@8F%S92!O=7(@97-T
M:6UA=&5S(&]N(&AI<W1O<FEC86P@97AP97)I96YC92!A;F0@;VX@=F%R:6]U
M<R!O=&AE<B!A<W-U;7!T:6]N<PT*=&AA="!W92!B96QI979E('1O(&)E(')E
M87-O;F%B;&4@=6YD97(@=&AE(&-I<F-U;7-T86YC97,L('1H92!R97-U;'1S
M(&]F('=H:6-H(&9O<FT@=&AE(&)A<VES(&9O<B!M86MI;F<@:G5D9VUE;G1S
M(&%B;W5T('1H92!C87)R>6EN9PT*=F%L=65S(&]F(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@=&AA="!A<F4@;F]T(')E861I;'D@87!P87)E;G0@9G)O;2!O
M=&AE<B!S;W5R8V5S+B!!8W1U86P@<F5S=6QT<R!M87D@9&EF9F5R+"!A="!T
M:6UE<R!I;B!M871E<FEA;`T*86UO=6YT<RP@9G)O;2!T:&5S92!E<W1I;6%T
M97,@=6YD97(@9&EF9F5R96YT(&%S<W5M<'1I;VYS(&]R(&-O;F1I=&EO;G,N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`G/CQU/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%!R;VYO=6YC
M96UE;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^26X@2G5L>2P@,C`Q,RP@=&AE($9!4T(@:7-S=65D#0I!8V-O=6YT:6YG
M(%-T86YD87)D<R!5<&1A=&4L(&]R($%352P@3F\N(#(P,3,M,3$L(#QI/DEN
M8V]M92!487AE<R`H5&]P:6,@-S0P*3H@4')E<V5N=&%T:6]N(&]F(&%N(%5N
M<F5C;V=N:7IE9"!487@@0F5N969I="!W:&5N#0IA($YE="!/<&5R871I;F<@
M3&]S<R!#87)R>69O<G=A<F0L(&$@4VEM:6QA<B!487@@3&]S<RP@;W(@82!4
M87@@0W)E9&ET($-A<G)Y9F]R=V%R9"!%>&ES=',@*&$@8V]N<V5N<W5S(&]F
M('1H92!&05-"($5M97)G:6YG($ES<W5E<PT*5&%S:R!&;W)C92D\+VD^+#QI
M/B`\+VD^;W(@05-5(#(P,3,M,3$N(%1H92!A;65N9&UE;G1S(&EN($%352`R
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M;V=N:7IE9`T*=&%X(&)E;F5F:70@<VAO=6QD(&)E('!R97-E;G1E9"!I;B!T
M:&4@9FEN86YC:6%L('-T871E;65N=',@87,@82!L:6%B:6QI='DN(%1H92!A
M;65N9&UE;G1S(&EN($%352!.;RX@,C`Q,RTQ,2!D;R!N;W0@<F5Q=6ER92!N
M97<-"G)E8W5R<FEN9R!D:7-C;&]S=7)E<RX@5&AE(&%M96YD;65N=',@:6X@
M05-5(#(P,3,M,3$@87)E(&5F9F5C=&EV92!F;W(@9FES8V%L('EE87)S+"!A
M;F0@:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!Y96%R<RP@8F5G:6YN
M:6YG#0IA9G1E<B!$96-E;6)E<B`Q-2P@,C`Q,RX@5&AE(&%M96YD;65N=',@
M:6X@05-5($YO+B`R,#$S+3$Q(&%R92!N;W0@97AP96-T960@=&\@:&%V92!A
M(&UA=&5R:6%L(&EM<&%C="!O;B!O=7(@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;`T*<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;'D@,C`Q,BP@=&AE
M($9!4T(@:7-S=65D($%352!.;RX@,C`Q,BTP,BP-"CQI/E1E<W1I;F<@26YD
M969I;FET92U,:79E9"!);G1A;F=I8FQE($%S<V5T<R!F;W(@26UP86ER;65N
M=#PO:3XL/&D^(#PO:3YO<B!!4U4@,C`Q,BTP,BX@05-5(#(P,3(M,#(@9VEV
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M96%R<R!B96=I;FYI;F<@869T97(@4V5P=&5M8F5R(#$U+"`R,#$R+"!W:71H
M#0IE87)L>2!A9&]P=&EO;B!P97)M:71T960N($%352`R,#$R+3`R(&ES(&YO
M="!E>'!E8W1E9"!T;R!H879E(&$@;6%T97)I86P@:6UP86-T(&]N(&]U<B!F
M:6YA;F-I86P@<&]S:71I;VX@;W(@<F5S=6QT<R!O9B!O<&5R871I;VYS+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^26X@1&5C96UB97(@,C`Q,2P@=&AE($9!4T(@:7-S=65D
M($%352!.;RX@,C`Q,2TQ,2P-"CQI/D)A;&%N8V4@4VAE970@*%1O<&EC(#(Q
M,"DZ($1I<V-L;W-U<F5S(&%B;W5T($]F9G-E='1I;F<@07-S971S(&%N9"!,
M:6%B:6QI=&EE<SPO:3XL(&]R($%352`R,#$Q+3$Q/&D^+CPO:3X@05-5(#(P
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M=`T*;VX@=&AE('-T871E;65N="!O9B!F:6YA;F-I86P@<&]S:71I;VXN($5N
M=&ET:65S(&%R92!R97%U:7)E9"!T;R!P<F]V:61E(&)O=&@@;F5T(&%N9"!G
M<F]S<R!I;F9O<FUA=&EO;B!F;W(@=&AE<V4@87-S971S(&%N9"!L:6%B:6QI
M=&EE<PT*:6X@;W)D97(@=&\@9F%C:6QI=&%T92!C;VUP87)A8FEL:71Y(&)E
M='=E96X@9FEN86YC:6%L('-T871E;65N=',@<')E<&%R960@:6X@8V]N9F]R
M;6ET>2!W:71H($=!05`@86YD(&9I;F%N8VEA;"!S=&%T96UE;G1S('!R97!A
M<F5D#0IO;B!T:&4@8F%S:7,@;V8@26YT97)N871I;VYA;"!&:6YA;F-I86P@
M4F5P;W)T:6YG(%-T86YD87)D<RX@05-5(#(P,3$M,3$@:7,@969F96-T:79E
M(&9O<B!A;FYU86P@<F5P;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&]N#0IO
M<B!A9G1E<B!*86YU87)Y(#$L(#(P,3,L(&%N9"!I;G1E<FEM('!E<FEO9',@
M=VET:&EN('1H;W-E('EE87)S+B!!4U4@,C`Q,2TQ,2!I<R!N;W0@97AP96-T
M960@=&\@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!O=7(-"F9I;F%N8VEA
M;"!P;W-I=&EO;B!O<B!R97-U;'1S(&]F(&]P97)A=&EO;G,N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY792!D;R!N;W0@8F5L:65V92!T:&5R92!W;W5L9"!H879E(&)E96X@
M82!M871E<FEA;`T*969F96-T(&]N('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L
M:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&AA9"!A;GD@;W1H97(@<F5C
M96YT;'D@:7-S=65D+"!B=70@;F]T('EE="!E9F9E8W1I=F4L(&%C8V]U;G1I
M;F<@<W1A;F1A<F1S#0IB965N(&%D;W!T960@:6X@=&AE(&-U<G)E;G0@<&5R
M:6]D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/'4^4F5C;&%S<VEF:6-A=&EO;G,\+W4^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY#97)T86EN(#(P
M,3(@86UO=6YT<R!H879E(&)E96X@<F5C;&%S<VEF:65D('1O(&-O;F9O<FT-
M"G1O(&-U<G)E;G0@>65A<B!P<F5S96YT871I;VXN/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P
M93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C
M-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^24Y614Y43U)9/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DEN=F5N=&]R>4%B<W1R86-T/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)3E9%3E1/4ED\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\8CX\=3Y.3U1%(#,@)B,Q-3`[($E.5D5.5$]263PO=3X\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEN=F5N
M=&]R>0T*8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN9SH\+V9O;G0^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T
M:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4Z
M(#$P<'0[(&UA<F=I;BUL969T.B`S-G!T)SX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE
M9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D1E8V5M8F5R#0H@("`@,S$L/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q
M,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR
M,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=VED=&@Z(#8R)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D9I;FES:&5D#0H@("`@<')O9'5C=#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8R,2PV-SD\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PQ
M,C0L-S,Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E)A=PT*("`@(&UA=&5R:6%L/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(U,"PY-#,\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS.#`L,#`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D1E9F5R<F5D#0H@("`@8V]S=',\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$W,"PY
M.38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,3$P+#0W,3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY43U1!3`T*("`@($E.5D5.5$]263PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,2PP-#,L-C$X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PV,34L,C$P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V
M-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3U1(15(@0U524D5.5"!!
M4U-%5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W1H97(@07-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3U1(15(@0U524D5.5"!!4U-%5%,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/CQU/DY/5$4@-"`F(S$U,#L@
M3U1(15(@0U524D5.5"!!4U-%5%,\+W4^/"]B/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CXF(S$V,#L\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D]T:&5R(&-U<G)E;G0@87-S971S(&-O;G-I<W0@;V8@=&AE(&9O;&QO
M=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)W=I9'1H.B`Y,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ93H@,3!P=#L@;6%R9VEN+6QE9G0Z(#,V<'0G/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[
M('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1&5C96UB97(-"B`@("`S,2P\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D
M9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR,#$S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA
M;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!W:61T:#H@
M-C(E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E<&%I9`T*("`@(%(F(S,X.T0@
M8V]S=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXQ+#(V-RPU.#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,3@Y+#,W-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED#0H@("`@8V]N<W5L=&EN9SPO9F]N
M=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXU,S`L-3DV/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-#,R+#(Q-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY$969E<G)E9`T*("`@(&9I;F%N8VEN9R!C;W-T<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR-C`L,#(R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(SDT-S([/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY/=&AE<@T*("`@(')E8V5I=F%B;&4@)B,Q-3`[(')E;&%T
M960@<&%R='D\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C0Y+#DX,3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="US:7IE.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-#<R.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P
M861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA
M;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED
M#0H@("`@;W1H97(\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,38Y+#4R.#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$R-RPT,#,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I
M;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R97!A:60-"B`@
M("!G=6%R86YT>2!C;W-T<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(SDT-S([/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L.30T/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G
M8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`R
M,G!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^5$]404P-"B`@("!/5$A%4B!#55)2
M14Y4($%34T544SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA
M;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPT-S<L-S$U/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-S4Q+#DS.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R
M,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1DE8140@05-3
M1513/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9)6$5$($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^/'4^3D]412`U("8C,34P.R!&25A%
M1"!!4U-%5%,\+W4^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M8CXF(S$V,#L\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D9I>&5D(&%S<V5T<R!C;VYS:7-T(&]F('1H92!F
M;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUL969T.B`S-G!T)SX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TQ
M,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R#0H@("`@,S$L/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[
M('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXR,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=VED
M=&@Z(#8R)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5Q=6EP;65N=#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P."PT
M-3@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-C<L-C8X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D9U<FYI='5R90T*("`@(&%N9"!F:7AT=7)E<SPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA
M;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT-BPV,C4\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA
M;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT-BPV,C4\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^3&5A<V5H;VQD#0H@("`@:6UP<F]V96UE;G1S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M
M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ
M93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C.30W,CL\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,3$L.3@P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,34U+#`X,SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$R-BPR-S,\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^06-C=6UU;&%T960-"B`@("!D97!R96-I871I;VX\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO
M<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B@Y,RPW-C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@V,"PV,#`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R
M;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E1/5$%,#0H@("`@1DE8140@05-31513/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO
M<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXV,2PS,3@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO
M<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV-2PV
M-S,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1E<')E8VEA=&EO;B!E
M>'!E;G-E(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(-"C,Q+"`R,#$S
M+"`R,#$R+"!A;F0@,C`Q,2!W87,@)#0U+#$T-2P@)#(W+#0X-"!A;F0@)#(U
M+#8X-BP@<F5S<&5C=&EV96QY+B!);B!$96-E;6)E<B`R,#$S+"!A8V-U;75L
M871E9"!D97!R96-I871I;VX@=V%S(')E9'5C960-"F)Y("0Q,2PY.#`@87-S
M;V-I871E9"!W:71H(&QE87-E:&]L9"!I;7!R;W9E;65N=',@;V8@;W5R('!R
M979I;W5S;'D@;&5A<V5D(&]F9FEC92!P<F]P97)T>2X\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F
M7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y
M+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!215!!240@15A014Y313QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F5P86ED($5X
M<&5N<V4L($-U<G)E;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)%4$%)1"!%6%!%3E-%/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CX\=3Y.3U1%(#8@)B,Q-3`[4%)%
M4$%)1"!%6%!%3E-%/"]U/CPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY0<F5P
M86ED(&5X<&5N<V4@8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!S='EL93TS1"=M87)G:6XM;&5F=#H@,S9P=#L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z
M("TQ,'!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$-B!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9"<^1&5C96UB97(@,S$L/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#8P)3L@=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q
M,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E!R97!A:60@4B`F(S,X.R!$(&-O
M<W1S/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R
M:6=H="<^.#(T+#(R,3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,34E.R!T97AT+6%L:6=N.B!R:6=H="<^.34S+#8U-3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0G/E!R97!A:60@;6%N=69A8W1U<FEN9R!C;W-T<SPO=&0^
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXX.3DL,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C.30W,CL\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M="<^06-C<F5T960@<')E<&%I9"!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,C<L,C,T
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(SDT-S([/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`R
M,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E1/5$%,(%!215!!240@15A014Y3
M13PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H="<^,2PW-3`L-#4U/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
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M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^)B,Q-C`[)B,Q-C`[/"]B/CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U
M,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W
M834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y404Y'24),12!!4U-%5%,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1V]O9'=I;&P@86YD($EN=&%N9VEB;&4@07-S971S($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^24Y404Y'24),12!!4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB/CQU/DY/5$4@-R`F
M(S$U,#L@24Y404Y'24),12!!4U-%5%,\+W4^/"]B/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,35P="<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H#0IT:&4@9W)O
M<W,@8V%R<GEI;F<@86UO=6YT(&%N9"!A8V-U;75L871E9"!A;6]R=&EZ871I
M;VX@;V8@;W5R(&EN=&%N9VEB;&4@87-S971S(&%S(&]F)B,Q-C`[1&5C96UB
M97(F(S$V,#LS,2P@,C`Q,R8C,38P.V%N9"8C,38P.T1E8V5M8F5R)B,Q-C`[
M,S$L#0HR,#$R.B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#DP)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM;&5F
M=#H@,S9P="<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R)B,Q-C`[,S$L
M#0H@("`@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D=R;W-S/&)R("\^0V%R<GEI;F<\8G(@+SY!;6]U;G0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^06-C=6UU;&%T960\8G(@+SY!
M;6]R=&EZ871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3F5T/&)R("\^06UO=6YT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D+3QB<B`O/D%V97)A9V4\8G(@+SY!
M;6]R=&EZ871I;VX\8G(@+SY097)I;V0F(S$V,#LH>7)S+BD\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY!;6]R=&EZ:6YG(&EN=&%N
M9VEB;&4@87-S971S.CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@
M8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@-#`E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]015)!)B,Q-S0[
M('-O9G1W87)E('!A=&5N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C,Q+#DU,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#0Y.3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C,Q+#0U,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$Q)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ
M-2XX/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,G!T.R!P861D
M:6YG+6QE9G0Z(#$R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5V96QO<&UE;G0-"B`@
M("!C;W-T<R!F;W(@8V]R<&]R871E('=E8G-I=&4\+V9O;G0^/"]T9#X-"B`@
M("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^.3$L-S0S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B@X.2PV-C$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@
M("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L,#@R/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C`N,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR
M,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3)P=#L@
M<&%D9&EN9RUL969T.B`Q,G!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M("TQ,G!T.R!P861D:6YG+6QE9G0Z(#$R<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^
M3F]N+6%M;W)T:7II;F<-"B`@("!I;G1A;F=I8FQE(&%S<V5T<SH\+V(^/"]F
M;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M,3)P=#L@<&%D9&EN9RUL969T.B`Q,G!T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,G!T.R!T97AT+6EN9&5N=#H@+3$R
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^2&]R;6]N90T*("`@('1H97)A<'D@9')U9R!C
M86YD:61A=&4@<&%T96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXU-S(L-S(V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXU-S(L-S(V/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/FXO
M83PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M:6YD96YT.B`M,3)P=#L@<&%D9&EN9RUL969T.B`Q,G!T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/DUU;'1I<&QE#0H@("`@=')A9&5M87)K<R!F;W(@=FET86UI;G,O<W5P
M<&QE;65N=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C4Y+#,R.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXU.2PS,C@\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^;B]A/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI
M;F1E;G0Z("TQ,G!T.R!P861D:6YG+6QE9G0Z(#(T<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C<U-2PW-#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*#DP+#$V,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C8U+#4X.#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@.3`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4Z(#$P<'0[(&UA<F=I;BUL969T
M.B`S-G!T)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D
M:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R)B,Q-C`[
M,S$L#0H@("`@,C`Q,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY'<F]S<SQB<B`O/D-A<G)Y:6YG/&)R("\^06UO=6YT/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%C8W5M=6QA=&5D
M/&)R("\^06UO<G1I>F%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/DYE=#QB<B`O/D%M;W5N=#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H
M=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"T\8G(@+SY!=F5R86=E
M/&)R("\^06UO<G1I>F%T:6]N/&)R("\^4&5R:6]D)B,Q-C`[*'ER<RXI/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!;6]R=&EZ:6YG#0H@("`@
M:6YT86YG:6)L92!A<W-E=',Z/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UW
M96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN
M9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I
M9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UW96EG
M:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@
M8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M=V5I9VAT.B!B
M;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!W:61T:#H@-#`E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D]015)!#0H@("`@)B,Q-S0[('-O9G1W87)E('!A=&5N
M=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(S+#<R,CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C,L
M-S(R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY$979E;&]P;65N=`T*("`@(&-O<W1S(&9O<B!C;W)P
M;W)A=&4@=V5B<VET93PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXY,2PW-#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#<W+#$U.3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,30L-3@T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$N,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG
M+6QE9G0Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/DYO;BUA;6]R=&EZ:6YG#0H@("`@:6YT86YG:6)L92!A<W-E=',Z/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^2&]R;6]N90T*("`@('1H97)A<'D@9')U9R!C86YD
M:61A=&4@<&%T96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXQ.#`L,3DT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,34Q.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXQ.#`L,3DT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/FXO83PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/DUU;'1I<&QE#0H@("`@=')A9&5M87)K<R!F;W(@
M=FET86UI;G,O<W5P<&QE;65N=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(Q+#`U-3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,2PP-34\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^;B]A/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D
M:6YG+6QE9G0Z(#(R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q-BPW,30\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#<W+#$U.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C,Y+#4U-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/CQF;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SY4
M:&4@:6YT86YG:6)L92!A<W-E="!R96QA=&5D#0IT;R!D979E;&]P;65N="!C
M;W-T<R!F;W(@8V]R<&]R871E('=E8G-I=&4@:7,@86UO<G1I>F5D(&]V97(@
M,S8@;6]N=&AS+"!W:&EC:"!I<R!T:&4@<')E<V-R:6)E9"!L:69E(&9O<B!S
M;V9T=V%R92!A;F0@=V5B<VET92!D979E;&]P;65N=`T*8V]S=',N(%1H92!I
M;G1A;F=I8FQE(&%S<V5T(')E;&%T960@=&\@3U!%4D$F(S$W-#L@:7,@86UO
M<G1I>F5D('5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H
M92!E<W1I;6%T960@<F5M86EN:6YG('5S969U;`T*;&EF92!O9B`Q-B!Y96%R
M<RP@=VAI8V@@:7,@=&AE(&QI9F4@;V8@=&AE(&EN=&5L;&5C='5A;"!P<F]P
M97)T>2!P871E;G1S+B8C,38P.R8C,38P.T1U<FEN9R!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,RP@=&AE<F4-"G=A<R!N;R!I;7!A:7)M96YT
M(')E8V]G;FEZ960N(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/B8C
M,38P.R8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/D%M;W)T
M:7IA=&EO;B!E>'!E;G-E('=A<R`D,3,L,#`Q+`T*)#(X+#<W-BP@)#(Y+#$U
M.2!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"`R,#$R
M+"!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B!%<W1I;6%T960@86UO<G1I>F%T
M:6]N(&5X<&5N<V4@9F]R('1H92!N97AT#0IF:79E('EE87)S(&ES(&%S(&9O
M;&QO=W,Z/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*
M/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4]
M,T0G=VED=&@Z(#@P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N
M="US:7IE.B`Q,'!T.R!M87)G:6XM;&5F=#H@,S9P="<^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/EEE87(@16YD:6YG($1E8V5M8F5R#0H@("`@,S$L/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5S=&EM871E9`T*("`@($%M;W)T:7IA
M=&EO;CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X
M+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@.#$E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+#`X
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-3PO9F]N=#X\
M+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#DY-SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-CPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#DY-SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(P,3<\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,2PY.3<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3@\
M+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PY.3<\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V
M-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3U1(15(@0U524D5.5"!,
M24%"24Q)5$E%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/=&AE<B!,:6%B:6QI=&EE<RP@0W5R<F5N="!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/5$A%4B!#55)214Y4($Q)04))3$E42453/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\=3Y.
M3U1%(#@@)B,Q-3`[($]42$52($-54E)%3E0@3$E!0DE,251)15,\+W4^/"]B
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CXF(S$V,#L\+V(^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D]T:&5R(&-U<G)E;G0@;&EA8FEL:71I97,@8V]N<VES="!O9B!T:&4@9F]L
M;&]W:6YG.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-
M"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)W=I9'1H.B`Y,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0M<VEZ93H@,3!P=#L@;6%R9VEN+6QE9G0Z(#,V<'0G/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A
M9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB
M97(-"B`@("`S,2P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TQ
M,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('=I9'1H.B`V,B4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^06-C<G5E9`T*("`@('!A>7)O;&P@86YD(&-O;6UI<W-I;VX@8V]S
M=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXY-#$L,S$S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXS.3<L,C$P/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^06-C<G5E9`T*("`@(&9I;F%N8VEN9R!C;W-T<SPO9F]N
M=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX-3`L,#`P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C.30W,CL\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F
M=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!8V-R=65D#0H@("`@=F%C871I;VX\
M+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C4V+#DR
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXQ,30L.#DY/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D%L;&]W86YC90T*("`@(&9O<B!W:&]L97-A;&4@9&ES=')I8G5T;W(@9F5E
M<SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,#8L
M,S`S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P-RPW.#0\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY!8V-R=65D#0H@("`@;&5G86P@86YD(&%C8V]U;G1I
M;F<@97AP96YS93PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR,C0L-34P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CDP+#`P,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY!8V-R=65D#0H@("`@;&%B(')E<V5A<F-H/"]F;VYT/CPO
M=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4S-BPU-S0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-#<R.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q
M,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D%C8W)U960-"B`@("!C;&EN:6-A;"!T<FEA
M;"!C;W-T<SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ,CDL,C`X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M.30W,CL\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE
M9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^06QL;W=A;F-E#0H@("`@9F]R(&-O
M=7!O;G,@86YD(')E='5R;G,\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,3(V+#(S,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,RPP,#(\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@9F]N="US:7IE
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY/=&AE<@T*("`@(&%C8W)U960@97AP96YS
M97,\<W5P/B@Q*3PO<W5P/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,C,P+#`X.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-S`L-S4Y/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z
M("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[5$]404P-"B`@("!/5$A%4B!#55)214Y4($Q)04))3$E42453/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+#8P
M,2PQ.#D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^.#,S+#8U-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N,C5I;CL@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#`N,C5I;CL@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`@,"`P(#,V
M<'0[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQS=7`^*#$I(#PO<W5P/DEN($IU
M;F4@,C`P."P@=V4@9&5C;&%R960-"F%N9"!P86ED(&$@<W!E8VEA;"!D:79I
M9&5N9"!O9B`D,"XT,"!P97(@<VAA<F4@;V8@;W5R($-O;6UO;B!3=&]C:R!T
M;R!A;&P@<VAA<F5H;VQD97)S(&]F(')E8V]R9"!A<R!O9B!*=6YE(#$P+"`R
M,#`X+"!O9B!W:&EC:`T*)#0Q+#,U.2!R96UA:6YE9"!U;F-L86EM960@8GD@
M8V5R=&%I;B!S:&%R96AO;&1E<G,@870@1&5C96UB97(@,S$L(#(P,3,@86YD
M(#(P,3(N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R
M8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T,34N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.3U1%4R!005E!
M0DQ%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DYO=&5S(%!A>6%B;&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D]415,@4$%904),13PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,"<^/&(^/'4^3D]412`Y("8C,34P.R!.3U1%4R!005E!0DQ%/"]U/CPO
M8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^)B,Q-C`[/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\=3Y)<W-U86YC92!A;F0@4&%Y;65N="!O9B!-=6QT:7!L92!!9'9A;F-E
M#0I2979O;'9I;F<@0W)E9&ET($YO=&4\+W4^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!*
M86YU87)Y(#,Q+"`R,#$S+"!W92!E;G1E<F5D(&EN=&\@80T*8G5S:6YE<W,@
M;&]A;B!A9W)E96UE;G0@=VET:"!0;&%T;R!A;F0@07-S;V-I871E<RP@3$Q#
M+"!O<B!0;&%T;RP@9F]R(&$@375L=&EP;&4@061V86YC92!2979O;'9I;F<@
M0W)E9&ET($YO=&4L(&]R('1H90T*4F5V;VQV:6YG($-R961I="!.;W1E+B!4
M:&4@4F5V;VQV:6YG($-R961I="!.;W1E(&%L;&]W960@=7,@=&\@9')A=R!D
M;W=N(&9U;F1I;F<@=7`@=&\@82`D,3`L,#`P+#`P,"!M87AI;75M('!R:6YC
M:7!A;`T*86UO=6YT+"!A="!A('-T871E9"!I;G1E<F5S="!R871E(&]F(#8E
M('!E<B!A;FYU;2X@4&QA=&\@=V%S(&%B;&4@=&\@;6%K92!A9'9A;F-E<R!T
M;R!U<R!F<F]M('1I;64@=&\@=&EM92!U;F1E<B!T:&4-"E)E=F]L=FEN9R!#
M<F5D:70@3F]T92!A="!O=7(@<F5Q=65S="P@=VAI8V@@861V86YC97,@=V5R
M92!O9B!A(')E=F]L=FEN9R!N871U<F4@86YD('=E<F4@86)L92!T;R!B92QM
M861E+"!R97!A:60L(&%N9"!M861E#0IF<F]M('1I;64@=&\@=&EM92X@26YT
M97)E<W0@<&%Y;65N=',@=V5R92!D=64@86YD('!A>6%B;&4@;VX@=&AE('1E
M;G1H(&1A>2!F;VQL;W=I;F<@=&AE(&5N9"!O9B!E86-H(&-A;&5N9&%R('%U
M87)T97(@:6X-"G=H:6-H(&%N>2!I;G1E<F5S="!W87,@86-C<G5E9"!A;F0@
M=6YP86ED+"!C;VUM96YC:6YG(&]N($%P<FEL(#$P+"`R,#$S+"!A;F0@=&AE
M('!R:6YC:7!A;"!B86QA;F-E(&]U='-T86YD:6YG('5N9&5R('1H90T*4F5V
M;VQV:6YG($-R961I="!.;W1E+"!T;V=E=&AE<B!W:71H(&%L;"!A8V-R=65D
M(&EN=&5R97-T(&%N9"!O=&AE<B!A;6]U;G1S('!A>6%B;&4@=6YD97(@=&AE
M(%)E=F]L=FEN9R!#<F5D:70@3F]T92P@:68@86YY+`T*=V%S(&1U92!A;F0@
M<&%Y86)L92!O;B!&96)R=6%R>2`R-"P@,C`Q-"X@5&AE(%)E=F]L=FEN9R!#
M<F5D:70@3F]T92!W87,@<V5C=7)E9"!B>2!S=6)S=&%N=&EA;&QY(&%L;"!O
M9B!O=7(@87-S971S+B!/;B!E86-H#0IO9B!&96)R=6%R>2`R-2!A;F0@36%R
M8V@@,3,L(#(P,3,L("0R,#`L,#`P('=A<R!D<F%W;B!A9V%I;G-T('1H92!2
M979O;'9I;F<@0W)E9&ET($YO=&4N($]N($UA<F-H(#(Q+"`R,#$S+"!W92!R
M97!A:60-"B0T,#$L,#@U+"!I;F-L=61I;F<@86-C<G5E9"!I;G1E<F5S="P@
M86YD('1H97)E('=A<R!N;R!B86QA;F-E(&]U='-T86YD:6YG('5N9&5R('1H
M92!2979O;'9I;F<@0W)E9&ET($YO=&4@87,@;V8@1&5C96UB97(@,S$L#0HR
M,#$S(&%N9"!&96)R=6%R>2`R-"P@,C`Q-"!W:&5N(&ET(&5X<&ER960N($%S
M(&%D9&ET:6]N86P@8V]N<VED97)A=&EO;B!F;W(@=&AE(%)E=F]L=FEN9R!#
M<F5D:70@3F]T92P@=V4@9W)A;G1E9"!T;R!0;&%T;R!A#0IW87)R86YT('1O
M('!U<F-H87-E(#$L,C4P+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C
M:R!A="!A;B!E>&5R8VES92!P<FEC92`D,RXR,"!P97(@<VAA<F4@*'-E92!.
M3U1%(#$P(&9O<B!M;W)E#0ID971A:6QS*2X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^26X@36%R8V@@,C`Q,2P@5FET84UE9"!E;G1E<F5D(&EN
M=&\@82!B=7-I;F5S<PT*;&]A;B!A9W)E96UE;G0@=VET:"!&:7)S="!5;FET
M960@0F%N:R!F;W(@82`D,S`P+#`P,"!B86YK(&QI;F4@;V8@8W)E9&ET(&9O
M<B!W:&EC:"!P97)S;VYA;"!G=6%R86YT965S(&%N9"!C87-H(&-O;&QA=&5R
M86P@=V5R90T*<F5Q=6ER960N(%!E<G-O;F%L(&=U87)A;G1E97,@86YD(&-A
M<V@@8V]L;&%T97)A;"!L:6UI=&5D('1O("0Q,#`L,#`P(&5A8V@@=V5R92!P
M<F]V:61E9"!B>2!2;V)E<G0@1FEN:7II;R!A;F0@2F]H;B!-:6QL:6=A;BP@
M;V9F:6-E<G,-"F]F(&]U<B!#;VUP86YY+"!A;F0@8GD@4F5I8V@@1F%M:6QY
M($QI;6ET960@4&%R=&YE<G-H:7`L(&%N(&5N=&ET>2!C;VYT<F]L;&5D(&)Y
M($UI=&-H96QL($MR87-S86XL(&%L<V\@86X@;V9F:6-E<B!O9B!O=7(@0V]M
M<&%N>2X-"E1H92!B86YK(&QI;F4@;V8@8W)E9&ET(&%C8W)U960@:6YT97)E
M<W0@870@=&AE(')A=&4@;V8@,RXP,B4@<&5R(&%N;G5M(&)A<V5D(&]N(&$@
M>65A<B!O9B`S-C`@9&%Y<R!A;F0@=V%S(&1U92!O;B!-87)C:"`Q+"`R,#$R
M+@T*5V4@;F5G;W1I871E9"!A(&]N92UY96%R(&5X=&5N<VEO;B!W:71H($9I
M<G-T(%5N:71E9"!T;R!T:&4@8F%N:R!L:6YE(&]F(&-R961I="P@=VAI8V@@
M=V%S(&5X96-U=&5D(&]N($UA<F-H(#$Y+"`R,#$R+B!5;F1E<B!T:&4-"F5X
M=&5N<VEO;BP@8F]R<F]W:6YG<R!B96%R(&EN=&5R97-T(&%T(&$@<F%T92!O
M9B`R+C,U)2!A;F0@87)E(&1U92!O;B!-87)C:"`Q+"`R,#$S+B!/;B!.;W9E
M;6)E<B`Q,RP@,C`Q,BP@=&AE(&]U='-T86YD:6YG(&)A;&%N8V4-"F]F("0R
M.3DL,C(P('=A<R!R97!A:60@:6X@9G5L;"P@86YD('=E(&%M96YD960@=&AE
M(&QI;F4@;V8@8W)E9&ET('1O(')E9FQE8W0@82`D,3`P+#`P,"!B86YK(&QI
M;F4@;V8@8W)E9&ET+B!);B!A8V-O<F1A;F-E('=I=&@-"G1H92!A;65N9&5D
M(&QI;F4@;V8@8W)E9&ET+"!T:&4@<&5R<V]N86P@9W5A<F%N=&5E(&%N9"!C
M87-H(&-O;&QA=&5R86P@;&EM:71E9"!T;R`D,3`P+#`P,"!P<F]V:61E9"!B
M>2!T:&4@4F5I8V@@1F%M:6QY($QI;6ET960-"E!A<G1N97)S:&EP(')E;6%I
M;F5D(&EN('!L86-E+"!W:&EL92!T:&4@<&5R<V]N86P@9W5A<F%N=&5E<R!A
M;F0@8V%S:"!C;VQL871E<F%L('=E<F4@<F5M;W9E9"!F;W(@37(N($9I;FEZ
M:6\@86YD($UR+B!-:6QL:6=A;BX-"DEN($9E8G)U87)Y(#(P,3,L('=E(&)O
M<G)O=V5D("0Q,#`L,#`P(&9R;VT@1FER<W0@56YI=&5D($)A;FL@=6YD97(@
M=&AE(&%M96YD960@8F%N:R!L:6YE(&]F(&-R961I="X@5&AE(&%M96YD960@
M8F%N:R!L:6YE(&]F(&-R961I=`T*<F5Q=6ER960@82!P97)S;VYA;"!G=6%R
M86YT964@86YD(&-A<V@@8V]L;&%T97)A;"!L:6UI=&5D('1O("0Q,#`L,#`P
M+"!W:&EC:"!W87,@<')O=FED960@8GD@4F5I8V@@1F%M:6QY($QI;6ET960@
M4&%R=&YE<G-H:7`N#0I/;B!!<')I;"`R-2P@,C`Q,RP@=V4@<F4M<&%I9"`D
M,3`P+#<S-2P@=VAI8V@@<F5P<F5S96YT960@=&AE('!R:6YC:7!A;"!A;F0@
M:6YT97)E<W0@=&AA="!W87,@9'5E('5N9&5R('1H92!A;65N9&5D(&)A;FL@
M;&EN92!O9@T*8W)E9&ET+B!/;B!-87D@,2P@,C`Q,RP@=&AE(&%M96YD960@
M8F%N:R!L:6YE(&]F(&-R961I="!E>'!I<F5D(&%N9"!W87,@;F]T(')E;F5W
M960N($%C8V]R9&EN9VQY+"!T:&4@<&5R<V]N86P@9W5A<F%N=&5E('=A<R!C
M86YC96QE9"P-"F%N9"!T:&4@8V%S:"!C;VQL871E<F%L('=A<R!R969U;F1E
M9"!T;R!T:&4@4F5I8V@@1F%M:6QY($QI;6ET960@4&%R=&YE<G-H:7`N($1U
M<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3,L(#(P,3(L
M(&%N9`T*,C`Q,2P@=V4@<&%I9"`D-S,U+"`D-RPS-C8L(&%N9"`D-2PV-3`L
M(')E<W!E8W1I=F5L>2P@;V8@:6YT97)E<W0@97AP96YS92P@=VAI8V@@87)E
M(&EN8VQU9&5D(&EN(&EN=&5R97-T(&5X<&5N<V4@;VX@=&AE(&%C8V]M<&%N
M>6EN9PT*8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/'4^27-S=6%N8V4@;V8@4')O;6ES<V]R>2!.;W1E<SPO=3X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/DEN($IA;G5A<GD@86YD($9E8G)U87)Y(#(P,3(L('=E
M(&ES<W5E9"`V)0T*<')O;6ES<V]R>2!N;W1E<R!I;B!T:&4@86=G<F5G871E
M('!R:6YC:7!A;"!A;6]U;G0@;V8@)#DP,"PP,#`L(&1U92!-87)C:"`Q+"`R
M,#$R+B!!<R!D:7-C=7-S960@8F5L;W<@:6X@/'4^27-S=6%N8V4@86YD(%-E
M='1L96UE;G0-"F]F($9E8G)U87)Y(#(P,3(@3F]T97,\+W4^+"!T:&5S92!P
M<F]M:7-S;W)Y(&YO=&5S('=E<F4@;6]D:69I960@;VX@1F5B<G5A<GD@,C0L
M(#(P,3(@=&AR;W5G:"!T:&4@:7-S=6%N8V4@;V8@<V5C=7)E9"!P<F]M:7-S
M;W)Y#0IN;W1E<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/DES<W5A;F-E(&%N9"!3971T
M;&5M96YT(&]F($9E8G)U87)Y(#(P,3(-"DYO=&5S/"]U/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M,3`L(')E<W!E8W1I=F5L>2P@86YD(&=R86YT960@=V%R<F%N=',@=&\@<'5R
M8VAA<V4@86X@86=G<F5G871E(&]F(#DL,#`P+#`P,`T*<VAA<F5S(&]F(&]U
M<B!#;VUM;VX@4W1O8VL@<'5R<W5A;G0@=&\@=&AE('1E<FUS(&]F(&$@3F]T
M92!0=7)C:&%S92!!9W)E96UE;G0L(&1A=&5D($9E8G)U87)Y(#(T+"`R,#$R
M+B!792!R96-E:79E9"!A;B!A9V=R96=A=&4-"F]F("0Q+#`P,"PP,#`@;V8@
M;F5W(&9U;F1I;F<@9G)O;2!T:&4@4&%R=&EE<R!U<&]N(&ES<W5A;F-E(&]F
M('1H92!&96)R=6%R>2`R,#$R($YO=&5S(&%N9"!R96QA=&5D('=A<G)A;G1S
M(&%N9"!S=7)R96YD97(@8GD@=&AE#0I087)T:65S(&]F(&-E<G1A:6X@<')O
M;6ES<V]R>2!N;W1E<RP@=VAI8V@@=V4@<')E=FEO=7-L>2!I<W-U960@:6X@
M=&AE(&%G9W)E9V%T92!A;6]U;G0@;V8@)#$L-S`P+#`P,"!P;'5S('1H92!A
M9V=R96=A=&4@86-C<G5E9`T*:6YT97)E<W0@;V8@)#$U+#$R-"`H8V]L;&5C
M=&EV96QY(&MN;W=N(&%S('1H92`F(S$T-SM0<FEO<B!.;W1E<R8C,30X.RDN
M(%5N9&5R('1H92!&96)R=6%R>2`R,#$R($YO=&5S+"!W92!B;W)R;W=E9"!A
M;B!A9&1I=&EO;F%L#0HD,RPP,#`L,#`P(&9R;VT@=&AE(%!A<G1I97,@9'5R
M:6YG($UA<F-H+"!!<')I;"P@86YD($UA>2`R,#$R+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\+W`^#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY792!G<F%N=&5D(#4L-C@U+#,P,"!W87)R86YT<R!I
M;@T*8V]N<VED97)A=&EO;B!O9B!T:&4@;6]D:69I8V%T:6]N(&]F('1H92!0
M<FEO<B!.;W1E<R!A;F0@,RPS,30L-S`P('=A<G)A;G1S('=I=&@@=&AE($9E
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M8W1U<FEN9R!O9@T*=&AE(&1E8G0L(&%N9"!T:&4@-2PV.#4L,S`P('=A<G)A
M;G1S(&ES<W5E9"!I;B!C;VYS:61E<F%T:6]N(&]F('1H92!M;V1I9FEC871I
M;VX@=V5R92!E>'!E;G-E9"`H<V5E(#QU/E=A<G)A;G0@06-T:79I='D-"D1U
M<FEN9R`R,#$R(#PO=3YI;B!.3U1%(#$P(&9O<B!M;W)E(&1E=&%I;',I+B!4
M:&4@9F%I<B!V86QU92!O9B!T:&4@4')I;W(@3F]T97,@=V%S(&5S=&EM871E
M9"!B>2!C86QC=6QA=&EN9R!T:&4@<')E<V5N=`T*=F%L=64@;V8@=&AE(&9U
M='5R92!C87-H(&9L;W=S(&1I<V-O=6YT960@870@82!M87)K970@<F%T92!O
M9B!R971U<FX@9F]R(&-O;7!A<F%B;&4@9&5B="!I;G-T<G5M96YT<R!T;R!B
M92`D,2PU,3<L-S0Q+`T*<F5S=6QT:6YG(&EN(&$@9&5B="!D:7-C;W5N="!O
M9B`D,3DW+#,X,R!A;F0@<F5C;V=N:7IE9"!A(&QO<W,@;VX@97AT:6YG=6ES
M:&UE;G0@;V8@9&5B="!O9B`D,3`L,S`W+#@V-"P@=VAI8V@@<F5P<F5S96YT
M960-"G1H92!F86ER('9A;'5E(&]F('1H92`U+#8X-2PS,#`@=V%R<F%N=',@
M;F5T(&]F('1H92!D:69F97)E;F-E(&)E='=E96X@=&AE(&-A<G)Y:6YG(&%M
M;W5N="!O9B!T:&4@4')I;W(@3F]T97,@86YD('1H96ER(&9A:7(-"G9A;'5E
M(&%S(&]F('1H92!D871E(&]F('1H92!M;V1I9FEC871I;VX@;VX@=&AE(&%C
M8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY/;B!*=6YE(#$Y+"`R,#$R+"!W92!S971T;&5D(&%N
M(&%G9W)E9V%T92!A;6]U;G0-"F]F("0S+#$P,BPP,#`@;V8@<')I;F-I<&%L
M(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F('1H92!&96)R=6%R>2`R,#$R($YO
M=&5S(&EN(&5X8VAA;F=E(&9O<B!T:&4@97AE<F-I<V4@;V8@=V%R<F%N=',@
M=&\@<'5R8VAA<V4-"C@L,30U+#0X-B!S:&%R97,@;V8@;W5R($-O;6UO;B!3
M=&]C:RX@07,@9&ES8W5S<V5D(&)E;&]W(&EN(#QU/DES<W5A;F-E(&%N9"!0
M87EM96YT(&]F($IU;F4@,C`Q,B!.;W1E<SPO=3XL('1H92!R96UA:6YI;F<@
M8F%L86YC90T*;V8@)#(L-CDQ+#@T-R!O9B!T:&4@1F5B<G5A<GD@,C`Q,B!.
M;W1E<R!W87,@;6]D:69I960@;VX@2G5N92`Q.2P@,C`Q,B!T:')O=6=H('1H
M92!I<W-U86YC92!O9B!S96-U<F5D('!R;VUI<W-O<GD@;F]T97,L(&]R('1H
M90T*2G5N92`R,#$R($YO=&5S("AS964@3D]412`Q,"!F;W(@;6]R92!D971A
M:6QS*2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQU/DES<W5A;F-E(&%N9"!087EM96YT(&]F
M($IU;F4@,C`Q,B!.;W1E<SPO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($IU;F4@,3DL
M(#(P,3(L('=E(&ES<W5E9"!S96-U<F5D('!R;VUI<W-O<GD-"FYO=&5S+"!O
M<B!T:&4@2G5N92`R,#$R($YO=&5S+"!T;R!T:&4@4&%R=&EE<R!I;B!T:&4@
M<')I;F-I<&%L(&%M;W5N=',@;V8@)#(L,S0W+#$R."!A;F0@)#(L,S0T+#<Q
M.2P@<F5S<&5C=&EV96QY+"!P=7)S=6%N="!T;PT*=&AE('1E<FUS(&]F(&$@
M3F]T92!0=7)C:&%S92!!9W)E96UE;G0N($EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@2G5N92`R,#$R($YO=&5S+"!T:&4@4&%R=&EE<R!S=7)R96YD97)E9"!T
M:&4@<F5M86EN:6YG(&)A;&%N8V4@;V8-"G1H92!&96)R=6%R>2`R,#$R($YO
M=&5S(&EN('1H92!A9V=R96=A=&4@86UO=6YT(&]F("0Q+#,T-RPQ,C@@86YD
M("0Q+#,T-"PW,3DL(')E<W!E8W1I=F5L>2P@=VAI8V@@<W5M<R!I;F-L=61E
M9"!P<FEN8VEP86P@86YD(&%C8W)U960-"FEN=&5R97-T('1H<F]U9V@@2G5N
M92`Q.2P@,C`Q,BP@86YD('=E(')E8V5I=F5D(&%N(&%G9W)E9V%T92!O9B`D
M,BPP,#`L,#`P(&]F(&YE=R!F=6YD:6YG(&9R;VT@=&AE(%!A<G1I97,L(&]R
M('1H92!*=6YE($9U;F1I;F<N#0I4:&4@<')I;F-I<&%L(&%M;W5N="!O9B!E
M86-H(&]F('1H92!*=6YE(#(P,3(@3F]T97,L('!L=7,@86YY(&%D9&ET:6]N
M86P@861V86YC92!M861E('1O('5S('1H97)E869T97(L('1O9V5T:&5R('=I
M=&@@86-C<G5E9"!I;G1E<F5S=`T*870@=&AE(&%N;G5A;"!R871E(&]F(#8E
M+"!W87,@9'5E(&EN(&]N92!L=6UP('-U;2!P87EM96YT(&]N($9E8G)U87)Y
M(#(T+"`R,#$T+B!!<R!S96-U<FET>2!F;W(@;W5R(&]B;&EG871I;VYS('5N
M9&5R('1H92!*=6YE#0HR,#$R($YO=&5S+"!W92!E;G1E<F5D(&EN=&\@82!3
M96-U<FET>2!!9W)E96UE;G0@86YD('!L961G960@86QL(&]F(&]U<B!A<W-E
M=',L('1A;F=I8FQE(&%N9"!I;G1A;F=I8FQE+"!A<R!F=7)T:&5R(&1E<V-R
M:6)E9"!T:&5R96EN+@T*5V4@86QS;R!G<F%N=&5D('=A<G)A;G1S('1O('!U
M<F-H87-E(&%N(&%G9W)E9V%T92!O9B`W+#`P,"PP,#`@<VAA<F5S(&]F(&]U
M<B!#;VUM;VX@4W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H('1H92!*=6YE($9U
M;F1I;F<N#0I/;B!-87)C:"`R,2P@,C`Q,RP@=V4@<F5P86ED("0T+#@X,BPP
M,3DL(&EN8VQU9&EN9R!A8V-R=65D(&EN=&5R97-T+"!L96%V:6YG(&$@8F%L
M86YC92!O9B`D,C$L-3DU(&EN(&%C8W)U960@:6YT97)E<W0@87,@;V8@36%R
M8V@-"C,Q+"`R,#$S(&]N('1H92!*=6YE(#(P,3(@3F]T97,N($]N($%P<FEL
M(#(U+"`R,#$S+"!T:&4@8F%L86YC92!O9B!A8V-R=65D(&EN=&5R97-T('=A
M<R!P86ED(&EN(&9U;&PN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y)<W-U86YC92!A;F0@
M4&%Y;65N="!O9B!!9&1I=&EO;F%L($YO=&5S#0II;B`R,#$R/"]U/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^26X@075G=7-T(&%N9"!397!T96UB97(@,C`Q,BP@=V4@:7-S
M=65D(#8E#0IP<F]M:7-S;W)Y(&YO=&5S(&EN('1H92!A;6]U;G0@;V8@)#$L
M-C`P+#`P,"!D=64@;VX@3V-T;V)E<B`Q+"`R,#$R+"!W:&EC:"!D=64@9&%T
M92!W87,@<W5B<V5Q=65N=&QY(&5X=&5N9&5D+B!4:&5S92!N;W1E<R!W97)E
M#0IP86ED(&EN(&9U;&P@:6X@3V-T;V)E<B`R,#$R+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M26X@4V5P=&5M8F5R(#(P,3(L('=E(&ES<W5E9"!A(#8E('!R;VUI<W-O<GD-
M"FYO=&4@9F]R("0R,#`L,#`P(&1U92!O;B!/8W1O8F5R(#$U+"`R,#$R+B!4
M:&ES(&YO=&4@=V%S('!A:60@:6X@9G5L;"!I;B!/8W1O8F5R(#(P,3(N/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\=3Y#;VYV97)S:6]N(&]F($IU;'D@,C`Q,2!396-U<F5D
M($YO=&5S(#PO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;'D@,C`Q,2P@5FET84UE
M9"!I<W-U960@='=O('-E;FEO<B!S96-U<F5D#0IP<F]M:7-S;W)Y(&YO=&5S
M+"!O<B!T:&4@4V5C=7)E9"!.;W1E<RP@96%C:"!I;B!T:&4@86UO=6YT(&]F
M("0U,#`L,#`P(&%N9"!A;'-O(&5N=&5R960@:6YT;R!A('-E8W5R:71Y(&%G
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M8V]N=F5R<VEO;BX@3VX@2G5N92`Q.2P@,C`Q,BP@=V4@<F5A8VAE9"!A;B!A
M9W)E96UE;G0-"G1O(&-O;G9E<G0@=&AE(&]U='-T86YD:6YG(&%M;W5N="!O
M9B!T:&4@4V5C=7)E9"!.;W1E<RP@<F5P<F5S96YT:6YG('!R:6YC:7!A;"!A
M;F0@86-C<G5E9"!I;G1E<F5S="!T:')O=6=H($IU;F4@,3DL(#(P,3(L(&]F
M("0Q+#`U-"PV-#<-"FEN=&\@86X@86=G<F5G871E(&]F(#(L-S<U+#0Q-2!S
M:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A="`D,"XS."!P97(@<VAA<F4N
M(%1H:7,@<F5S=6QT960@:6X@82!B96YE9FEC:6%L(&-O;G9E<G-I;VX@9F5A
M='5R90T*;V8@)#8L-S$V+#4P-"!A<R!R96-O<F1E9"!I;B!O=&AE<B!I;F-O
M;64@86YD(&5X<&5N<V4@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T
M960@9FEN86YC:6%L('-T871E;65N=',N($9O<B!T:&4@>65A<G,@96YD960-
M"D1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+"!W92!R96-O<F1E9"!A;B!A
M9V=R96=A=&4@;V8@)#,S+#(P-"!A;F0@)#(Q+#0U,RP@<F5S<&5C=&EV96QY
M+"!A<R!I;G1E<F5S="!E>'!E;G-E(&]N('1H92!A8V-O;7!A;GEI;F<-"F-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
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M;W)Y($YO=&5S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@2G5N92`R,#$Q+"!6:71A
M365D(&ES<W5E9"!P<F]M:7-S;W)Y(&YO=&5S+`T*;W(@=&AE(%9I=&%-960@
M3F]T97,L(&EN('1H92!A9V=R96=A=&4@<')I;F-I<&%L(&%M;W5N="!O9B`D
M-3`P+#`P,"X@26X@8V]N;F5C=&EO;B!W:71H('1H92!6:71A365D($YO=&5S
M+"!W92!G<F%N=&5D('=A<G)A;G1S#0IT;R!P=7)C:&%S92!A;B!A9V=R96=A
M=&4@;V8@-C$S+#<Q."!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:RX@5&AE
M(%9I=&%-960@3F]T97,@=V5R92!A<W-U;65D(&)Y('5S('5P;VX@=&AE(&UE
M<F=E<B!A;F0@8F]R92!I;G1E<F5S=`T*870@82!R871E(&]F(#0E('!E<B!A
M;FYU;2!A;F0@=V5R92!D=64@870@=&AE(&5A<FQI97(@;V8@*&DI('1H92!S
M:7@@;6]N=&@@86YN:79E<G-A<GD@;V8@=&AE(&1A=&4@;V8@:7-S=6%N8V4@
M86YD("AI:2D@<W5C:"!T:6UE#0IA<R!6:71A365D(')E8V5I=F5D('1H92!P
M<F]C965D<R!O9B!A('!R;VUI<W-O<GD@;F]T92AS*2!I<W-U960@:6X@86X@
M86UO=6YT(&]F(&YO="!L97-S('1H86X@)#$L,#`P+#`P,"P@;W(@=&AE($9U
M;F1I;F<N(%5P;VX-"G1H92!C;&]S:6YG(&]F('1H92!&=6YD:6YG(&EN($IU
M;'D@,C`Q,2P@87,@;6]R92!F=6QL>2!D97-C<FEB960@86)O=F4@:6X@/'4^
M0V]N=F5R<VEO;B!O9B!*=6QY(#(P,3$@4V5C=7)E9"!.;W1E<SPO=3XL('1W
M;R!O9@T*=&AE(%9I=&%-960@3F]T97,@:6X@=&AE(&%G9W)E9V%T92!O9B`D
M,C`P+#`P,"!W97)E('!A:60@:6X@9G5L;"X@0GD@;75T=6%L(&%G<F5E;65N
M="P@=&AE(')E;6%I;FEN9R!6:71A365D($YO=&5S(&EN('1H92!A9V=R96=A
M=&4-"F]F("0S,#`L,#`P('=E<F4@97AT96YD960N($EN($]C=&]B97(@,C`Q
M,2P@;VYE(&]F('1H92!6:71A365D($YO=&5S(&9O<B`D-3`L,#`P('=A<R!P
M86ED(&EN(&9U;&PL(&%N9"P@8GD@;75T=6%L(&%G<F5E;65N="P@8V5R=&%I
M;@T*;V8@=&AE(%9I=&%-960@3F]T97,@:6X@=&AE(&%G9W)E9V%T92!A;6]U
M;G0@;V8@)#$P,"PP,#`@=V5R92!C;VYV97)T960@:6YT;R`R-C8L.#(R('-H
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M8VQU9&EN9R`D,BPQ-C`@:6X@86-C<G5E9"!I;G1E<F5S="X@5&AE(')E;6%I
M;FEN9R!6:71A365D($YO=&5S+"!H96QD(&)Y($UR+@T*36EL;&EG86X@86YD
M(&)Y($)&($EN=F5S=&UE;G0@16YT97)P<FES97,L($QT9"XL('=H:6-H(&ES
M(&]W;F5D(&)Y($)R:6%N($)E<FYI8VLL(&$@9&ER96-T;W(@;V8@;W5R(&-O
M;7!A;GDL(&EN('1H92!A9V=R96=A=&4@86UO=6YT#0IO9B`D,3`P+#`P,"P@
M=V5R92!E>'1E;F1E9"!T;R!/8W1O8F5R(#$U+"`R,#$R+B!/;B!/8W1O8F5R
M(#0L(#(P,3(L('=E(')E+7!A:60@=&AE(&]U='-T86YD:6YG(%9I=&%-960@
M3F]T97,@:6X@9G5L;"P@:6YC;'5D:6YG#0HD-2PS-#$@:6X@86-C<G5E9"!I
M;G1E<F5S="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(%-E<'1E;6)E<B!A;F0@3V-T;V)E
M<B`R,#$Q+"!6:71A365D(&ES<W5E9`T*8V]N=F5R=&EB;&4@;F]T97,L(&]R
M('1H92!6:71A365D($-O;G9E<G1I8FQE($YO=&5S+"!I;B!T:&4@86=G<F5G
M871E(&%M;W5N="!O9B`D-3,T+#$V,"X@5&AE(%9I=&%-960@0V]N=F5R=&EB
M;&4@3F]T97,@8F]R92!I;G1E<F5S=`T*870@=&AE(')A=&4@;V8@-"4@<&5R
M(&%N;G5M(&%N9"!W97)E(&1U92!$96-E;6)E<B`Q+"`R,#$Q+B!/;B!.;W9E
M;6)E<B`Q."P@,C`Q,2P@=V4@96YT97)E9"!I;G1O($1E8G0@0V]N=F5R<VEO
M;B!!9W)E96UE;G1S('=I=&@-"G1H92!H;VQD97)S(&]F(%9I=&%-960@0V]N
M=F5R=&EB;&4@3F]T97,L('!U<G-U86YT('1O('=H:6-H('=E(&-O;G9E<G1E
M9"!T:&4@<')I;F-I<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F('1H92!6
M:71A365D($-O;G9E<G1I8FQE#0I.;W1E<R!I;G1O(#$L-#$U+#$S-B!S:&%R
M97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A="`D,"XS."!P97(@<VAA<F4L('=H
M:6-H(')E<')E<V5N=&5D('1H92!F86ER('9A;'5E(&]F('1H92!S:&%R97,@
M;V8@;W5R($-O;6UO;@T*4W1O8VL@;VX@=&AE(&1A=&4@;V8@8V]N=F5R<VEO
M;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/DEN($1E8V5M8F5R(#(P,3$L('=E(&ES<W5E9"`T
M)2!P<F]M:7-S;W)Y(&YO=&5S#0IT;R!-<BX@1FEN:7II;R!A;F0@37(N($UI
M;&QI9V%N(&9O<B!A;B!A9V=R96=A=&4@;V8@)#$P,"PP,#`@9'5E($UA<F-H
M(#$L(#(P,3(N(%1H97-E('!R;VUI<W-O<GD@;F]T97,@=V5R92!S=6)S97%U
M96YT;'D@97AT96YD960-"F)Y(&UU='5A;"!A9W)E96UE;G0@=&\@2G5N92`Q
M+"`R,#$R+B!);B!*=6YE(#(P,3(L('=E('!A:60@=&AE('!R;VUI<W-O<GD@
M;F]T92!H96QD(&)Y($UR+B8C,38P.T9I;FEZ:6\@:6X@9G5L;"P@:6YC;'5D
M:6YG("0X.#@-"FEN(&%C8W)U960@:6YT97)E<W0N($UR+B!-:6QL:6=A;B8C
M,30V.W,@<')O;6ES<V]R>2!N;W1E('=A<R!E>'1E;F1E9"!T;R!/8W1O8F5R
M(#$U+"`R,#$R+B!/;B!/8W1O8F5R(#0L(#(P,3(L('=E('!A:60@37(N($UI
M;&QI9V%N)B,Q-#8[<PT*<')O;6ES<V]R>2!N;W1E(&EN(&9U;&PL(&EN8VQU
M9&EN9R`D,2PU,3D@:6X@86-C<G5E9"!I;G1E<F5S="X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P
M,3$L#0IW92!R96-O<F1E9"!A;B!A9V=R96=A=&4@;V8@)#8L,S0T(&%N9"`D
M,BPS.3`L(')E<W!E8W1I=F5L>2P@87,@:6YT97)E<W0@97AP96YS92!O;B!T
M:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U
M.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C
M7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T
M,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M5$]#2TA/3$1%4E,G($5154E463QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TM(
M3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/'4^3D]412`Q,"`F(S$U,#L@4U1/0TM(3TQ$15)3)B,Q-#8[#0I%455)
M5%D\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!L969T)SX\=3Y0<F5F97)R960@4W1O
M8VL\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R
M+7-P86-I;F<Z("TP+C$U<'0G/D%T($1E8V5M8F5R#0HS,2P@,C`Q,RP@=V4@
M:&%D(#$P+#`P,"PP,#`@<VAA<F5S(&]F('!R969E<G)E9"!S=&]C:RP@<&%R
M('9A;'5E("0P+C`P,2P@875T:&]R:7IE9"!F;W(@:7-S=6%N8V4L(&]F('=H
M:6-H(&YO('-H87)E<R!O9B!P<F5F97)R960-"G-T;V-K('=E<F4@;W5T<W1A
M;F1I;F<N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN
M9SH@+3`N,35P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P)SX\=3Y#;VUM;VX@4W1O8VL\+W4^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A
M8VEN9SH@+3`N,35P="<^070@1&5C96UB97(-"C,Q+"`R,#$S+"!W92!H860@
M/"]F;VYT/C(U,"PP,#`L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^(&%U=&AO<FEZ
M960@9F]R(&ES<W5A;F-E+"!O9B!W:&EC:`T*/"]F;VYT/C$T-"PY-S8L-S4W
M/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B!S:&%R
M97,@;V8@;W5R($-O;6UO;B!3=&]C:R!W97)E(&ES<W5E9"!A;F0@;W5T<W1A
M;F1I;F<N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^27-S=6%N8V5S($1U
M<FEN9R`R,#$S/"]U/CPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^)B,Q-C`[/"]I/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY0=7)S=6%N
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M9F5R:6YG('=A<R`D,2XW,"!P97(@<VAA<F4L#0IA;F0@=&AE($IE9F9E<FEE
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M;F1E<G=R:71E<G,@82`S,"UD87D@;W!T:6]N('1O('!U<F-H87-E('5P('1O
M(&%N(&%D9&ET:6]N86P@-"PT,3$L-S8U('-H87)E<R!O9B!O=7(@0V]M;6]N
M(%-T;V-K+B!4:&4-"F]F9F5R:6YG(&-L;W-E9"!O;B!-87)C:"`R,"P@,C`Q
M,RX@3VX@07!R:6P@,3(L(#(P,3,L('1H92!*969F97)I97,@56YD97)W<FET
M97)S(&5X97)C:7-E9"!T:&5I<B!O<'1I;VX@=&\@<'5R8VAA<V4@86X@861D
M:71I;VYA;`T*,2PY-30L-3@W('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K
M('1O(&-O=F5R(&]V97(M86QL;W1M96YT<RX@5V4@:7-S=65D('1H97-E('-H
M87)E<R!T;R!T:&4@2F5F9F5R:65S(%5N9&5R=W)I=&5R<R!O;B!!<')I;"`Q
M."P-"C(P,3,@86YD(')E8V5I=F5D('!R;V-E961S(&]F(&%P<')O>&EM871E
M;'D@)#,N,2!M:6QL:6]N+"!N970@;V8@97AP96YS97,N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M86YC92!A;F0@<V%L92!O9B`Q,RPW-3`L,#`P('-H87)E<R!O9B!O=7(@0V]M
M;6]N(%-T;V-K+B!4:&4@<')I8V4@=&\@=&AE('!U8FQI8R!I;B!T:&4@;V9F
M97)I;F<-"G=A<R`D,BXT,"!P97(@<VAA<F4L(&%N9"!T:&4@4W1I9F5L(%5N
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M5&AE(&]F9F5R:6YG(&-L;W-E9"!O;B!397!T96UB97(@,S`L(#(P,3,N/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY$=7)I;F<@,C`Q,R!C97)T86EN(&EN9&EV:61U86QS(&5X
M97)C:7-E9"!T:&5I<@T*<FEG:'0@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&]U
M<B!#;VUM;VX@4W1O8VLN($]P=&EO;G,@=&\@<'5R8VAA<V4@86X@86=G<F5G
M871E(&]F(#<U+#0R,R!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!W97)E
M(&5X97)C:7-E9`T*9F]R(&%P<')O>&EM871E;'D@)#,Q+#`P,"X@5&AE<V4@
M<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@=V5R92!I<W-U960@:6X@<&%R
M="!I;B!R96QI86YC92!U<&]N(&%N(&5X96UP=&EO;B!F<F]M('1H92!R96=I
M<W1R871I;VX-"G!R;W9I<VEO;G,@;V8@=&AE(%-E8W5R:71I97,@06-T(&]F
M(#$Y,S,L(&]R('1H92!!8W0L('!R;W9I9&5D(&)Y(%-E8W1I;VX@-"AA*2@R
M*2!A;F0@4G5L92`U,#8@;V8@4F5G=6QA=&EO;B!$('!R;VUU;&=A=&5D('1H
M97)E=6YD97(N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3X\=3Y)<W-U86YC97,@1'5R:6YG
M(#(P,3(\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V,#L\+VD^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R`R,#$R
M+"!C97)T86EN(&EN9&EV:61U86QS(&5X97)C:7-E9`T*=&AE:7(@<FEG:'0@
M=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VLN(%1H97-E
M('-H87)E<R!W97)E(&ES<W5E9"!I;B!R96QI86YC92!U<&]N(&%N(&5X96UP
M=&EO;B!F<F]M('1H92!R96=I<W1R871I;VX-"G!R;W9I<VEO;G,@;V8@=&AE
M($%C="!P<F]V:61E9"!B>2!396-T:6]N(#0H82DH,BD@86YD(%)U;&4@-3`V
M(&]F(%)E9W5L871I;VX@1"!P<F]M=6QG871E9"!T:&5R975N9&5R+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XM=&]P.B`P.R!M87)G
M:6XM8F]T=&]M.B`P)SX@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\
M=&0^)B,Q-C`[/"]T9#X\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3
M>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y)SY/<'1I;VYS('1O('!U<F-H87-E(&%N(&%G9W)E9V%T
M90T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("!O
M9B`Q+#8Y,2PS.3,@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@=V5R92!E
M>&5R8VES960@9F]R("0Q.3$L,#`P+CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT9#XF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!3>6UB;VPG/B8C,3@S.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y)SY5<VEN9PT*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("!T:&4@8V%S:&QE<W,@97AE<F-I<V4@
M9F5A='5R92P@;W!T:6]N<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@
M,C0P+#,Y-2!S:&%R97,@;V8-"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@;W5R($-O;6UO;B!3=&]C:R!W97)E(&5X97)C:7-E
M9"X\+W1D/CPO='(^/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN
M9R!*=6YE(#(P,3(L('=E('-E='1L960@)#,L,3`R+#`P,"!I;@T*<')I;F-I
M<&%L(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F('1H92!&96)R=6%R>2`R,#$R
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M*2!A;F0@4G5L92`U,#8@;V8@4F5G=6QA=&EO;B!$('!R;VUU;&=A=&5D('1H
M97)E=6YD97(N($1U<FEN9R!*=6YE(#(P,3(L('=E(&%N9`T*=&AE(%!A<G1I
M97,@86QS;R!A9W)E960@=&\@8V]N=F5R="!A('!O<G1I;VX@;V8@=&AE($9E
M8G)U87)Y(#(P,3(@3F]T97,L(&%N9"!P<FEN8VEP86P@86YD(&%C8W)U960@
M:6YT97)E<W0@=&AR;W5G:"!*=6YE(#$Y+"`R,#$R+`T*=&]T86QI;F<@)#$L
M,#4T+#8T-RP@:6YT;R`R+#<W-2PT,34@<VAA<F5S(&]F(&]U<B!#;VUM;VX@
M4W1O8VL@870@)#`N,S@@<&5R('-H87)E+B!4:&4@<VAA<F5S('=E<F4@:7-S
M=65D(&EN(')E;&EA;F-E('5P;VX@86X@97AE;7!T:6]N#0IF<F]M('1H92!R
M96=I<W1R871I;VX@<')O=FES:6]N<R!O9B!T:&4@06-T('!R;W9I9&5D(&)Y
M(%-E8W1I;VX@-"AA*2@R*2!A;F0@4G5L92`U,#8@;V8@4F5G=6QA=&EO;B!$
M('!R;VUU;&=A=&5D('1H97)E=6YD97(N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!397!T
M96UB97(@,C`Q,BP@=V4@96YT97)E9"!I;G1O(&$@4V5C=7)I=&EE<PT*4'5R
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M;B!A9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@)#@L-3`P+#`P,2X@26X@
M8V]N;F5C=&EO;B!W:71H('1H92!P<FEV871E('!L86-E;65N="P@2F5F9F5R
M:65S('-E<G9E9"!A<R!O=7(@97AC;'5S:79E('!L86-E;65N=`T*86=E;G0N
M($IE9F9E<FEE<R8C,30V.R!C;VUP96YS871I;VX@9F]R('1H92!T<F%N<V%C
M=&EO;B!W87,@82!C87-H(&9E92!O9B`D-34R+#4P,"X@5V4@86QS;R!P86ED
M(&QE9V%L(&9E97,@86YD(&5X<&5N<V5S(&]F('1H90T*:6YV97-T;W)S(&EN
M('1H92!A9V=R96=A=&4@;V8@)#4R+#`Q-BP@<F5S=6QT:6YG(&EN(&YE="!P
M<F]C965D<R!T;R!U<R!F<F]M('1H92!P<FEV871E('!L86-E;65N="!O9B`D
M-RPX.34L-#@U+B!4:&4@<VAA<F5S('=E<F4-"FES<W5E9"!I;B!R96QI86YC
M92!U<&]N('1H92!E>&5M<'1I;VYS(&9R;VT@<F5G:7-T<F%T:6]N('5N9&5R
M('1H92!!8W0@<')O=FED960@8GD@4V5C=&EO;B`T*&$I*#(I(&%N9"!2=6QE
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M9FEL960@;VX-"DYO=F5M8F5R(#(W+"`R,#$R+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^
M/'4^27-S=6%N8V5S($1U<FEN9R`R,#$Q/"]U/CPO:3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^)B,Q-C`[
M/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P
M="<^26X@1&5C96UB97(-"C(P,3$L(#PO9F]N=#YA(&9O<FUE<B!D:7)E8W1O
M<B!O9B!6:71A365D+"`\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@
M+3`N,35P="<^97AE<F-I<V5D(&]P=&EO;G,@=&\@<'5R8VAA<V4@.3(L,#4W
M('-H87)E<R!O9@T*;W5R($-O;6UO;B!3=&]C:R!F;W(@86X@86=G<F5G871E
M(&5X97)C:7-E('!R:6-E(&]F("0Q-RPR-3`N/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);B!/8W1O8F5R(&%N9"!.;W9E;6)E<B`R,#$Q+"!W92!C;VYV97)T
M960-"G!R:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S="!I;B!T:&4@86=G
M<F5G871E(&]F("0X-#DL,3,W(&EN=&\@<VAA<F5S(&]F(&]U<B!#;VUM;VX@
M4W1O8VL@=&]T86QI;F<@,C`L,C8V+#@R,B!A;F0@,2PT,34L,3,V+`T*<F5S
M<&5C=&EV96QY("AA<R!M;W)E(&9U;&QY(&1E<V-R:6)E9"!I;B!.3U1%(#DI
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^3VX@3V-T;V)E<B`U+"`R,#$Q+"!W92!E;G1E<F5D
M(&EN=&\@82!3=&]C:PT*4'5R8VAA<V4@06=R965M96YT('=I=&@@4&5R;FEX
M(%1H97)A<&5U=&EC<RP@3$Q#+"!A($QO=6ES:6%N82!L:6UI=&5D(&QI86)I
M;&ET>2!C;VUP86YY+"!O<B!097)N:7@N(%!U<G-U86YT('1O('1H92!T97)M
M<R!O9B!T:&4-"E-T;V-K(%!U<F-H87-E($%G<F5E;65N="P@4&5R;FEX(&%G
M<F5E9"!T;R!P=7)C:&%S92`R+#8S,2PU-SD@<VAA<F5S(&]F(&]U<B!#;VUM
M;VX@4W1O8VL@870@82!P=7)C:&%S92!P<FEC92!O9B`D,"XS."!P97(@<VAA
M<F4-"F9O<B!A('1O=&%L('!U<F-H87-E('!R:6-E(&]F("0Q+#`P,"PP,#`N
M(%!E<FYI>"!I<R!A(')E;&%T960@<&%R='DN($9O<B!F=7)T:&5R(&1E=&%I
M;',L('-E92!.3U1%(#$R/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!/8W1O8F5R(#,L(#(P
M,3$L('=E(&5F9F5C=&5D(&$@<F5V97)S92!S<&QI=`T*;V8@;W5R(#$V+#4W
M-2PR,#D@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!S:&%R97,@;V8@0V]M;6]N
M(%-T;V-K(&]N(&$@<F%T:6\@;V8@,2T@9F]R("TQ,#`L(')E<W5L=&EN9R!I
M;B`Q-C4L.#4V('-H87)E<R!I<W-U960@86YD#0IO=71S=&%N9&EN9R!T:&5R
M96%F=&5R+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^5V%R<F%N=',@/"]U/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
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M,RXY('EE87)S+`T*86YD(&5X97)C:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@
M)#`N,C0@=&\@)#,N,C`@<&5R('-H87)E+"!R97-U;'1I;F<@:6X@82!W96EG
M:'1E9"!A=F5R86=E(&5X97)C:7-E('!R:6-E(&]F("0Q+C<Y('!E<B!S:&%R
M92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
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M:&4@=&5R;2!O9B!T:&4@=V%R<F%N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/E=A
M<G)A;G0@06-T:79I='D@1'5R:6YG(#(P,3,\+W4^/"]I/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V
M,#L\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/DEN($IA;G5A<GD@,C`Q,RP@=V4@9W)A;G1E9"!W87)R86YT
M<R!T;R!P=7)C:&%S90T*,2PR-3`L,#`P('-H87)E<R!O9B!O=7(@0V]M;6]N
M(%-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AE
M(%)E=F]L=FEN9R!#<F5D:70@3F]T92P@;W(@=&AE(%!L871O(%=A<G)A;G0L
M("AS964@3D]410T*.2DN(%1H92!0;&%T;R!787)R86YT(&AA<R!A;B!E>&5R
M8VES92!P<FEC92!O9B`D,RXR,"!P97(@<VAA<F4N(%1H92!0;&%T;R!787)R
M86YT('9E<W1E9"!O;B!/8W1O8F5R(#,Q+"`R,#$S(&%N9"!M87D@8F4@97AE
M<F-I<V5D#0IP<FEO<B!T;R!I=',@97AP:7)A=&EO;B!O;B!*86YU87)Y(#,Q
M+"`R,#$Y+B!4:&4@4&QA=&\@5V%R<F%N="P@=VET:"!A(&9A:7(@=F%L=64@
M;V8@87!P<F]X:6UA=&5L>2`D,2PW,3$L.34V+"!W87,@=F%L=65D(&]N('1H
M90T*9&%T92!O9B!T:&4@:7-S=6%N8V4@=7-I;F<@82!T97)M(&]F('-I>"!Y
M96%R<SL@82!V;VQA=&EL:71Y(&]F(#0T+C(Y)3L@<FES:R!F<F5E(')A=&4@
M;V8@,"XX."4[(&%N9"!A(&1I=FED96YD('EI96QD(&]F(#`E+B!!=`T*1&5C
M96UB97(@,S$L(#(P,3,L("0R-C`L,#(R('=A<R!R97!O<G1E9"!A<R!D969E
M<G)E9"!F:6YA;F-I;F<@8V]S=',@:6YC;'5D960@:6X@;W1H97(@8W5R<F5N
M="!A<W-E=',@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960-"F)A
M;&%N8V4@<VAE970@86YD(&ES(&)E:6YG(&%M;W)T:7IE9"!O=F5R('1H92!L
M:69E(&]F('1H92!0;&%T;R!.;W1E+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q
M,RP@)#$L-#4Q+#DS-"!W87,@<F5C;W)D960@87,@9FEN86YC:6YG#0IC;W-T
M<R!O;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@
M<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($UA>2`R,#$S+"!W92!E;G1E
M<F5D(&EN=&\@82!C;VYS=6QT:6YG(&%G<F5E;65N=`T*=VET:"!386YC:6QI
M;R`F(S,X.R!#;VUP86YY+"!);F,N+"!O<B!30TDL('1O(&1E=F5L;W`@9')U
M9R!P;&%T9F]R;7,@=&\@8F4@=7-E9"!I;B!H;W)M;VYE(')E<&QA8V5M96YT
M(&1R=6<@<')O9'5C=',L(&]R('1H92!$<G5G#0I0<F]D=6-T<RX@5&AE<V4@
M<V5R=FEC97,@:6YC;'5D92!S=7!P;W)T(&]F(&]U<B!E9F9O<G1S('1O('-U
M8V-E<W-F=6QL>2!O8G1A:6X@52Y3+B!&961E<F%L($1R=6<@061M:6YI<W1R
M871I;VXL(&]R($9$02P@87!P<F]V86P-"F9O<B!T:&4@1')U9R!0<F]D=6-T
M<RP@:6YC;'5D:6YG(&$@=F%G:6YA;"!C87!S=6QE(&9O<B!T:&4@=')E871M
M96YT(&]F('9U;'9A<B!A;F0@=F%G:6YA;"!A=')O<&AY+B!);B!C;VYN96-T
M:6]N('=I=&@@=&AE(&%G<F5E;65N="P-"E-#22!A9W)E960@=&\@9F]R9F5I
M="!I=',@<FEG:'1S('1O(')E8V5I=F4@=V%R<F%N=',@=&\@<'5R8VAA<V4@
M.#,S+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!T:&%T('=E<F4@
M=&\@8F4@9W)A;G1E9"!P=7)S=6%N=`T*=&\@=&AE('1E<FUS(&]F(&$@<')I
M;W(@8V]N<W5L=&EN9R!A9W)E96UE;G0@9&%T960@36%Y(#$W+"`R,#$R+B!!
M<R!C;VYS:61E<F%T:6]N('5N9&5R('1H92!A9W)E96UE;G0L('=E(&%G<F5E
M9"!T;R!G<F%N="!T;R!30TD-"F$@=V%R<F%N="!T;R!P=7)C:&%S92`X-3`L
M,#`P('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K(&%T("0R+C`Q('!E<B!S
M:&%R92!T:&%T(&AA<R!V97-T960@;W(@=VEL;"!V97-T+"!A<R!A<'!L:6-A
M8FQE+"!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q
M,#`E.R!F;VYT.B`Q,G!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XM=&]P.B`P.R!M87)G:6XM8F]T=&]M.B`P)SX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#`N-6EN)SX\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$N/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P="<^,C@S+#,S,R!S:&%R97,@=V5R92!E87)N960@
M;VX@36%Y(#$Q+"`R,#$S('5P;VX@<W5C8V5S<V9U;"!F:6QI;F<-"F]F('1H
M92!)3D0@87!P;&EC871I;VX@=VET:"!T:&4@1D1!(&9O<B!T:&4@1')U9R!0
M<F]D=6-T(&9O<B!A;B!E<W1R861I;VPM8F%S960@<')O9'5C="!I;B!A('-O
M9G1G96P@=F%G:6YA;"!C87!S=6QE(&9O<B!T:&4@=')E871M96YT#0IO9B!V
M=6QV87(@86YD('9A9VEN86P@871R;W!H>3L@:&]W979E<BP@<'5R<W5A;G0@
M=&\@=&AE('1E<FUS(&]F('1H92!A9W)E96UE;G0L('1H92!S:&%R97,@9&ED
M(&YO="!V97-T('5N=&EL($IU;F4@,S`L(#(P,3,N(%1H90T*9F%I<B!V86QU
M92!O9B`D-#`U+#`V-B!F;W(@=&AE('-H87)E<R!V97-T960@;VX@2G5N92`S
M,"P@,C`Q,R!W87,@9&5T97)M:6YE9"!B>2!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<R!-;V1E;"!O;B!T:&4@9&%T92!O9B!T:&4-"G9E<W1I;F<@=7-I;F<@
M82!T97)M(&]F(&9I=F4@>65A<G,[(&$@=F]L871I;&ET>2!O9B`T-2XX.24[
M(')I<VL@9G)E92!R871E(&]F(#$N,3(E.R!A;F0@82!D:79I9&5N9"!Y:65L
M9"!O9B`P)2X@5V4@<F5C;W)D960@=&AE#0IE;G1I<F4@)#0P-2PP-C8@87,@
M;F]N+6-A<V@@8V]M<&5N<V%T:6]N(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S.SPO9F]N=#X\+W1D/CPO
M='(^/"]T86)L93X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$R<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA
M<F=I;BUB;W1T;VTZ(#`G/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XU:6XG/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CPO=&0^/"]T<CX\+W1A8FQE/@T*#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T
M:#H@,3`P)3L@9F]N=#H@,3)P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`P+C5I;B<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXR+CPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(X,RPS,S,@<VAA<F5S('9E<W1E9"!O
M;B!*=6YE(#,P+"`R,#$S+B!4:&4@9F%I<B!V86QU92!O9B`D-#8R+#$Y-@T*
M9F]R('1H97-E('-H87)E<R!W87,@9&5T97)M:6YE9"!B>2!U<VEN9R!T:&4@
M0FQA8VLM4V-H;VQE<R!-;V1E;"!O;B!T:&4@9&%T92!O9B!T:&4@=F5S=&EN
M9R!U<VEN9R!A('1E<FT@;V8@9FEV92!Y96%R<SL@82!V;VQA=&EL:71Y#0IO
M9B`T-2XX-"4[(')I<VL@9G)E92!R871E(&]F(#$N-#$E.R!A;F0@82!D:79I
M9&5N9"!Y:65L9"!O9B`P)2X@070@1&5C96UB97(@,S$L(#(P,3,@=V4@:&%D
M("0Q-30L,#8X(')E8V]R9&5D(&%S('!R97!A:60@97AP96YS92US:&]R=`T*
M=&5R;2!A;F0@)#,P."PQ,C@@<F5C;W)D960@87,@<')E<&%I9"!E>'!E;G-E
M+6QO;F<@=&5R;2!I;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F
M:6YA;F-I86P@<W1A=&5M96YT<RX@1'5R:6YG('1H92!Y96%R#0IE;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,RP@=V4@<F5C;W)D960@)#<W+#`S-"!A<R!N;VXM
M8V%S:"!C;VUP96YS871I;VX@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',[(&%N9#PO9F]N=#X\+W1D/CPO
M='(^/"]T86)L93X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A
M8VEN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$R<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA
M<F=I;BUB;W1T;VTZ(#`G/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XU:6XG/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P="<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CPO=&0^/"]T<CX\+W1A8FQE/@T*#0H\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=W:61T
M:#H@,3`P)3L@9F]N=#H@,3)P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN+71O<#H@,#L@;6%R9VEN+6)O='1O;3H@,"<^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`P+C5I;B<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXS+CPO9F]N=#X\+W1D
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M(&YO="!O8V-U<B!B969O<F4@1&5C96UB97(@,C`Q-2X\+V9O;G0^/"]T9#X\
M+W1R/CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/E=A<G)A
M;G0@06-T:79I='D@1'5R:6YG(#(P,3(\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3XF(S$V,#L\
M+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/DEN($9E8G)U87)Y(#(P,3(L('=E(&ES<W5E9"!A;B!A9V=R96=A
M=&4@;V8-"C4L-C@U+#,P,"!787)R86YT<R!I;B!C;VYN96-T:6]N('=I=&@@
M=&AE(&UO9&EF:6-A=&EO;B!O9B!C97)T86EN(&5X:7-T:6YG('!R;VUI<W-O
M<GD@;F]T97,L(&]R('1H92!-;V1I9FEC871I;VX@5V%R<F%N=',L(&%N9`T*
M=V%R<F%N=',@9F]R('1H92!P=7)C:&%S92!O9B!A;B!A9V=R96=A=&4@;V8@
M,RPS,30L-S`P('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T;V-K(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AE($9E8G)U87)Y#0HR,#$R
M($YO=&5S+"!O<B!T:&4@1F5B<G5A<GD@,C`Q,B!787)R86YT<R`H<V5E($Y/
M5$4@.2DN($)O=&@@=&AE($UO9&EF:6-A=&EO;B!787)R86YT<R!A;F0@=&AE
M($9E8G)U87)Y(#(P,3(@5V%R<F%N=',@87)E(&5X97)C:7-A8FQE#0IA="`D
M,"XS."!P97(@<VAA<F4N(%1H92!-;V1I9FEC871I;VX@5V%R<F%N=',@:&%V
M92!A(&9A:7(@=F%L=64@;V8@)#$P+#4P-2PR-#<L(&%N9"!T:&4@1F5B<G5A
M<GD@,C`Q,B!787)R86YT<R!H879E(&$@9F%I<B!V86QU90T*;V8@)#8L,3(T
M+#@W,RX@1F%I<B!V86QU92!W87,@9&5T97)M:6YE9"!O;B!T:&4@9&%T92!O
M9B!T:&4@:7-S=6%N8V4@=7-I;F<@82!T97)M(&]F(&9I=F4@>65A<G,[(&$@
M=F]L871I;&ET>2!O9B`T-"XU)3L@<FES:R!F<F5E#0IR871E(&]F(#`N.#DE
M.R!A;F0@82!D:79I9&5N9"!Y:65L9"!O9B`P)2X@5V4@<F5C;W)D960@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE($UO9&EF:6-A=&EO;B!787)R86YT<R!A<R!P
M87)T(&]F('1H92!L;W-S(&]N(&5X=&EN9W5I<VAM96YT#0IO9B!D96)T(&EN
M('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S+B!4:&4@<F5L871I=F4@9F%I<B!V86QU92!O9B!T:&4@1F5B<G5A
M<GD@,C`Q,B!787)R86YT<R!O9B`D.#4Y+#8T-PT*=V%S(')E8V]R9&5D(&%S
M(&1E8G0@9&ES8V]U;G0N($%S(&$@<F5S=6QT(&]F('1H92!S=7)R96YD97(@
M;V8@=&AE($9E8G)U87)Y(#(P,3(@3F]T97,@;VX@2G5N92`Q.2P@,C`Q,BP@
M=V4@97AP96YS960@=&AE(')E;6%I;FEN9PT*=6YA;6]R=&EZ960@9&5B="!D
M:7-C;W5N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($UA<F-H(#(P,3(L('=E(&ES<W5E
M9"!A;B!A9V=R96=A=&4@;V8@,S$L,#`P#0I787)R86YT<R!T;R!F:79E('5N
M869F:6QI871E9"!I;F1I=FED=6%L<R!F;W(@<V5R=FEC97,@<F5N9&5R960N
M(%1H97-E(%=A<G)A;G1S('=E<F4@=F%L=65D(&]N('1H92!D871E(&]F('1H
M92!I<W-U86YC92!U<VEN9R!A#0IT97)M(&]F(&9I=F4@>65A<G,[(&$@=F]L
M871I;&ET>2!O9B`T-"XX,24[(')I<VL@9G)E92!R871E(&]F(#$N,#0E.R!A
M;F0@82!D:79I9&5N9"!Y:65L9"!O9B`P)3L@=V4@<F5C;W)D960@)#(Y+#<S
M-B!A<R!C;VYS=6QT:6YG#0IE>'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@
M8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^26X@36%Y(#(P,3(L('=E(&ES<W5E9"!A;B!A9V=R96=A=&4@;V8@,2PS
M,#`L,#`P#0I787)R86YT<R!T;R!A;B!U;F%F9FEL:6%T960@96YT:71Y(&9O
M<B!S97)V:6-E<R!T;R!B92!R96YD97)E9"!O=F5R(&%P<')O>&EM871E;'D@
M9FEV92!Y96%R<R!B96=I;FYI;F<@:6X@36%Y(#(P,3(N(%-E<G9I8V5S('!R
M;W9I9&5D#0IA<F4@=&\@:6YC;'5D92`H82D@<V5R=FEC97,@:6X@<W5P<&]R
M="!O9B!O=7(@9')U9R!D979E;&]P;65N="!E9F9O<G1S+"!I;F-L=61I;F<@
M<V5R=FEC97,@:6X@<W5P<&]R="!O=7(@;VYG;VEN9R!A;F0@9G5T=7)E(&1R
M=6<-"F1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!E9F9O<G1S
M+"!R96=U;&%T;W)Y(&%P<')O=F%L(&5F9F]R=',L('1H:7)D+7!A<G1Y(&EN
M=F5S=&UE;G0@86YD(&9I;F%N8VEN9R!E9F9O<G1S+"!M87)K971I;F<-"F5F
M9F]R=',L(&-H96UI<W1R>2P@;6%N=69A8W1U<FEN9R!A;F0@8V]N=')O;',@
M969F;W)T<RP@9')U9R!L875N8V@@86YD('!O<W0M87!P<F]V86P@86-T:79I
M=&EE<RP@86YD(&]T:&5R(&EN=&5L;&5C='5A;"!P<F]P97)T>0T*86YD(&MN
M;W<M:&]W('1R86YS9F5R(&%S<V]C:6%T960@=&AE<F5W:71H.R`H8BD@<V5R
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M(')A=&4@;V8@,"XW-"4[(&%N9"!A(&1I=FED96YD('EI96QD(&]F(#`E+B!!
M="!$96-E;6)E<B`S,2P@,C`Q,RP@=V4@:&%D("0S-C`L-3(X(')E<&]R=&5D
M(&%S('!R97!A:60@97AP96YS92US:&]R=`T*=&5R;2!A;F0@)#4Y,RPQ,C<@
M<F5C;W)D960@87,@<')E<&%I9"!E>'!E;G-E+6QO;F<@=&5R;2X@1'5R:6YG
M('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!T:&4@>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P-"C(P,3(L('=E(')E8V]R9&5D("0S-C`L
M-3(X(&%N9"`D,C$X+#`T-2P@<F5S<&5C=&EV96QY(&%S(&YO;BUC87-H(&-O
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M92`D,2PU,S(L,C(X(&]V97(@9FEV92!Y96%R<RX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN
M($IU;F4@,C`Q,BP@=V4@9W)A;G1E9"!A9V=R96=A=&4@;V8@-RPP,#`L,#`P
M#0I787)R86YT<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&ES<W5A;F-E(&]F
M('1H92!*=6YE(#(P,3(@3F]T97,L(&]R('1H92!*=6YE(#(P,3(@5V%R<F%N
M=',L("AS964@3D]412`Y*2X@3V8@=&AE($IU;F4@,C`Q,B!787)R86YT<PT*
M:7-S=65D+"`V+#`P,"PP,#`@87)E(&5X97)C:7-A8FQE(&%T("0R+C`P('!E
M<B!S:&%R92!A;F0@,2PP,#`L,#`P(&%R92!E>&5R8VES86)L92!A="`D,RXP
M,"!P97(@<VAA<F4N(%1H92!F86ER('9A;'5E(&]F('1H92!*=6YE#0HR,#$R
M(%=A<G)A;G1S(&]F("0Y+#0R-"PY.#(@=V%S(&1E=&5R;6EN960@;VX@=&AE
M(&1A=&4@;V8@=&AE(&ES<W5A;F-E('5S:6YG(&$@=&5R;2!O9B!F:79E('EE
M87)S.R!A('9O;&%T:6QI='D@;V8@-#0N-C0E.R!R:7-K#0IF<F5E(')A=&4@
M;V8@,"XW-24[(&%N9"!A(&1I=FED96YD('EI96QD(&]F(#`E+B!4:&4@<F5L
M871I=F4@9F%I<B!V86QU92!O9B!T:&4@2G5N92`R,#$R(%=A<G)A;G1S(&]F
M("0Q+#8T.2PX.3`@=V%S(&1E=&5R;6EN960-"F)Y('5S:6YG('1H92!R96QA
M=&EV92!F86ER('9A;'5E(&-A;&-U;&%T:6]N(&UE=&AO9"!O;B!T:&4@9&%T
M92!O9B!T:&4@:7-S=6%N8V4N($]F('1H92`D,2PV-#DL.#DP+"`D-30W+#(Q
M,"!W87,@86UO<G1I>F5D('1O(&EN=&5R97-T#0IE>'!E;G-E(&EN(#(P,3(@
M86YD(&%S(&$@<F5S=6QT(&]F('1H92!R97!A>6UE;G0@;V8@=&AE(&%S<V]C
M:6%T960@9&5B="!O;B!-87)C:"`R,2P@,C`Q,RP@=V4@86UO<G1I>F5D('1H
M92!R96UA:6YI;F<@=6YA;6]R=&EZ960-"F1E8G0@9&ES8V]U;G0@;V8@)#$L
M,3`R+#8X,"!T;R!I;G1E<F5S="!E>'!E;G-E+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@
M2G5N92`R,#$R+"!W92!I<W-U960@86X@86=G<F5G871E(&]F(#$L-3`P#0I7
M87)R86YT<R!T;R!T:')E92!U;F%F9FEL:6%T960@:6YD:79I9'5A;',@9F]R
M('-E<G9I8V5S(')E;F1E<F5D+B!4:&4@5V%R<F%N=',@=V5R92!V86QU960@
M;VX@=&AE(&1A=&4@;V8@=&AE(&ES<W5A;F-E('5S:6YG(&$-"G1E<FT@;V8@
M9FEV92!Y96%R<SL@82!V;VQA=&EL:71Y(&]F(#0T+C<X)3L@<FES:R!F<F5E
M(')A=&4@;V8@,"XW,B4[(&%N9"!A(&1I=FED96YD('EI96QD(&]F(#`E+B!!
M('1O=&%L(&]F("0Q+#8U-B!W87,@<F5C;W)D960-"F%S(&-O;G-U;'1I;F<@
M97AP96YS92!I;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^/'4^5V%R<F%N
M="!!8W1I=FET>2!$=7)I;F<@,C`Q,3PO=3X\+VD^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/B8C,38P.SPO
M:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^26X@1&5C96UB97(@,C`Q,2P@=V4@:7-S=65D(#4P,"!787)R86YT
M<R!W:71H#0IA(&9A:7(@=F%L=64@;V8@)#,S."!T;R!A;B!U;G)E;&%T960@
M:6YD:79I9'5A;"!F;W(@8V]N<W5L=&EN9R!S97)V:6-E<R!C;W9E<F5D('5N
M9&5R(&$@=&AR964M;6]N=&@@86=R965M96YT+B!4:&4@5V%R<F%N=',@=V5R
M90T*=F%L=65D(&]N('1H92!D871E(&]F('1H92!I<W-U86YC92!U<VEN9R!A
M('1E<FT@;V8@,3`@>65A<G,[('9O;&%T:6QI='D@;V8@-3$N.#,E.R!R:7-K
M(&9R964@<F%T92!O9B`P+CDQ)3L@86YD(&$@9&EV:61E;F0@>6EE;&0-"F]F
M(#`E+B!4:&4@5V%R<F%N=',@=F5S=&5D(&EM;65D:6%T96QY+B!!<R!O9B!$
M96-E;6)E<B`S,2P@,C`Q,2P@;V8@=&AE("0S,S@@9F%I<B!V86QU92P@)#$U
M('=A<R!R96-O<F1E9"!A<R!N;VXM8V%S:"!C;VUP96YS871I;VX-"F%N9"`D
M,S(S('=A<R!R96-O<F1E9"!A<R!P<F5P86ED(&5X<&5N<V4@;VX@=&AE(&%C
M8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY);B!/8W1O8F5R(#(P,3$L('=E(&ES<W5E9"`V,#`L
M,#`P(%=A<G)A;G1S#0IW:71H(&$@9F%I<B!V86QU92!O9B`D,3,S+#`T-2!T
M;R!A;B!O9F9I8V5R(&]F(&]U<B!C;VUP86YY(&9O<B!S97)V:6-E<R!P97)F
M;W)M960N(%1H92!787)R86YT<R!W97)E('9A;'5E9"!O;B!T:&4@9&%T92!O
M9B!T:&4-"FES<W5A;F-E('5S:6YG(&%N(&5X97)C:7-E('!R:6-E(&]F("0P
M+C,X.R!A('1E<FT@;V8@,3`@>65A<G,[('9O;&%T:6QI='D@;V8@-#4N.30E
M.R!R:7-K(&9R964@<F%T92!O9B`R+C(S)3L@86YD(&$@9&EV:61E;F0@>6EE
M;&0-"F]F(#`E+B!4:&4@5V%R<F%N=',@=F5S="!O=F5R(&$@-#0M;6]N=&@@
M<&5R:6]D(&)E9VEN;FEN9R!O;B!.;W9E;6)E<B`R,2P@,C`Q,2`H;W(@,3,L
M-C,V('-H87)E<R!F;W(@;6]N=&AS(#$M-#,@86YD(#$S+#8U,B!S:&%R97,-
M"F9O<B!M;VYT:"`T-"DN($9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@
M,S$L(#(P,3,L(#(P,3(@86YD(#(P,3$L('=E(')E8V]G;FEZ960@)#,V+#(X
M-"P@)#,V+#(X-"!A;F0@)#<L,34X+"!A<R!N;VXM8V%S:"!C;VUP96YS871I
M;VX-"FEN('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@1&5C96UB97(@,C`Q,2P@
M=V4@:7-S=65D(#$X-"PR,3$@5V%R<F%N=',-"G=I=&@@82!F86ER('9A;'5E
M(&]F("0R-2PY.#`@=&\@86X@=6YR96QA=&5D(&5N=&ET>2!F;W(@8V]N<W5L
M=&EN9R!S97)V:6-E<R!C;W9E<F5D('5N9&5R(&$@='=O(&UO;G1H(&%G<F5E
M;65N="X@5&AE(%=A<G)A;G1S('=E<F4-"G9A;'5E9"!O;B!T:&4@9&%T92!O
M9B!T:&4@:7-S=6%N8V4@=7-I;F<@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N
M,S@[(&$@=&5R;2!O9B!F:79E('EE87)S.R!V;VQA=&EL:71Y(&]F(#0Q+C`T
M)3L@<FES:R!F<F5E(')A=&4-"F]F(#$N,#@E.R!A;F0@82!D:79I9&5N9"!Y
M:65L9"!O9B`P)2X@1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$Q+"!T:&4@)#(U+#DX,"!F86ER('9A;'5E('=A<R!R96-O<F1E9"!A<R!F
M:6YA;F-I;F<@97AP96YS92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M)SY);B!$96-E;6)E<B`R,#$Q+"!6:71A365D#0IE;G1E<F5D(&EN=&\@82!T
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M+"!T:&4@8V]N<W5L=&%N="!R96-E:79E9"`X,#`L,#`P(&9U;&QY('9E<W1E
M9"!A;F0@;F]N(&9O<F9E:71A8FQE5V%R<F%N=',N(%1H92!787)R86YT<R!W
M97)E('9A;'5E9`T*;VX@=&AE(&1A=&4@;V8@=&AE(&ES<W5A;F-E('5S:6YG
M(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C,X.R!A('1E<FT@;V8@,3`@>65A
M<G,[(&$@=F]L871I;&ET>2!O9B`T-2XY-"4[(')I<VL@9G)E92!R871E(&]F
M(#(N,C,E.PT*86YD(&$@9&EV:61E;F0@>6EE;&0@;V8@,"4N(%1H92!787)R
M86YT('9E<W1E9"!I;6UE9&EA=&5L>2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE
M('=A<G)A;G1S('=A<R`D,3<W+#,Y-"!A="!T:&4@9&%T92!O9B!G<F%N="!A
M;F0-"G=A<R!A;6]R=&EZ960@=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&5X<&5N<V4@;W9E<B!T:&4@;&EF92!O9B!T:&4@86=R965M96YT('=H:6-H
M(&ES('=H96X@=&AE(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W1I=FET
M:65S#0IW97)E('!E<F9O<FUE9"X@1'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@=V4@<F5C;V=N:7IE
M9"`D-S$L-C@X+"`D.34L-3@R(&%N9"`D,3`L,3(T+"!R97-P96-T:79E;'DL
M#0II;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,@<F5L871E
M9"!T;R!T:&ES(&%G<F5E;65N="X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;'D@,C`Q
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M96YS871I;VXL('1H92!#;VYS=6QT86YT(')E8V5I=F5D(#(P,"PP,#`@9G5L
M;'D@=F5S=&5D(&YO;B!F;W)F96ET86)L92!6:71A365D(%=A<G)A;G1S#0HH
M;W(@82!787)R86YT(&9O<B`R-#4L-#@U('-H87)E<R!P=7)S=6%N="!T;R!T
M:&4@0V]N=F5R<VEO;B!2871I;RDN(%1H92!6:71A365D(%=A<G)A;G0@=V%S
M('9A;'5E9"!O;B!T:&4@9&%T92!O9B!T:&4@9W)A;G0@870-"B0Q,BPU-#@@
M=7-I;F<@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N-#$[(&$@=&5R;2!O9B!F
M:79E('EE87)S.R!A('9O;&%T:6QI='D@;V8@,SDN-#0E.R!R:7-K(&9R964@
M<F%T92!O9B`Q+C4V)3L@86YD(&$@9&EV:61E;F0-"GEI96QD(&]F(#`E+B!4
M:&4@5V%R<F%N="!V97-T960@:6UM961I871E;'DN(%1H92!F86ER('9A;'5E
M(&]F('1H92!W87)R86YT<R!W87,@)#$R+#4T."!A="!T:&4@9&%T92!O9B!G
M<F%N="!A;F0@=V%S(&%M;W)T:7IE9`T*=&\@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&5X<&5N<V4@;W9E<B!T:&4@;&EF92!O9B!T:&4@86=R965M96YT
M('=H:6-H(&ES('=H96X@=&AE(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A
M8W1I=FET:65S('=E<F4@<&5R9F]R;65D+@T*1'5R:6YG('1H92!Y96%R<R!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@=V4@<F5C
M;V=N:7IE9"`D,"P@)#8L.3,V(&%N9"`D-2PV,3(@<F5S<&5C=&EV96QY+"!I
M;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0-"F5X<&5N<V5S(')E;&%T960@
M=&\@=&AI<R!A9W)E96UE;G0N($EN($IU;F4@,C`Q,2P@5FET84UE9"!I<W-U
M960@<')O;6ES<V]R>2!N;W1E<RP@;W(@=&AE(%9I=&%-960@3F]T97,L(&EN
M('1H92!A9V=R96=A=&4@;V8@)#4P,"PP,#`-"G=I=&@@-3`P+#`P,"!A8V-O
M;7!A;GEI;F<@5FET84UE9"!787)R86YT<R`H;W(@5V%R<F%N=',@9F]R(&%N
M(&%G9W)E9V%T92!O9B`V,3,L-S$X('-H87)E<R!O9B!O=7(@0V]M;6]N(%-T
M;V-K('1A:VEN9R!I;G1O(&%C8V]U;G0-"G1H92!M97)G97(I+B!4:&4@5FET
M84UE9"!787)R86YT<R!W97)E('9A;'5E9"!O;B!T:&4@9&%T92!O9B!T:&4@
M:7-S=6%N8V4@=7-I;F<@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N-#$[(&$@
M=&5R;2!O9B!F:79E('EE87)S.PT*82!R86YG92!O9B!V;VQA=&EL:71Y(&9R
M;VT@,SDN,3,E('1O(#,Y+C$U)3L@<FES:R!F<F5E(')A=&4@<F%N9VEN9R!F
M<F]M(#$N,S@M,2XV-24[(&%N9"!A(&1I=FED96YD('EI96QD(&]F(#`E+B!4
M:&4@5V%R<F%N=',@=F5S=&5D#0II;6UE9&EA=&5L>2X@06QT:&]U9V@@=&AE
M(&9A:7(@=F%L=64@=V%S("0S,"PY.3,L('5S:6YG('1H92!A<'!R;W!R:6%T
M92!A8V-O=6YT:6YG('1R96%T;65N="P@)#(X+#<Q.2!W87,@<F5C;W)D960@
M87,@9&5B="!D:7-C;W5N=`T*86YD(&9U;&QY(&%M;W)T:7IE9"!D=7)I;F<@
M,C`Q,2!W:71H('1H92!A;6]R=&EZ960@86UO=6YT(')E8V]R9&5D(&%S(&EN
M=&5R97-T(&5X<&5N<V4@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T
M960@9FEN86YC:6%L#0IS=&%T96UE;G1S+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*
M#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\+W`^#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY);B!-87)C:"`R,#$Q+"!6:71A365D(&5N=&5R960@:6YT;R!A
M(&)U<VEN97-S#0IL;V%N(&%G<F5E;65N="!W:71H($9I<G-T(%5N:71E9"!F
M;W(@82`D,S`P+#`P,"!L:6YE(&]F(&-R961I="!F;W(@=VAI8V@@<&5R<V]N
M86P@9W5A<F%N=&5E<R!A;F0@8V%S:"!C;VQL871E<F%L('=E<F4@<F5Q=6ER
M960N#0I097)S;VYA;"!G=6%R86YT965S(&%N9"!C87-H(&-O;&QA=&5R86P@
M;&EM:71E9"!T;R`D,3`P+#`P,"!E86-H('=E<F4@<')O=FED960@8GD@37(N
M($9I;FEZ:6\L($UR+B!-:6QL:6=A;BP@86YD(%)E:6-H($9A;6EL>2!,:6UI
M=&5D#0I,4"`H4V5E($Y/5$4@.2!F;W(@;6]R92!D971A:6QS*2X@26X@8V]N
M<VED97)A=&EO;B!F;W(@=&AE('!E<G-O;F%L(&=U87)A;G1E97,@86YD(&-A
M<V@@8V]L;&%T97)A;"P@5FET84UE9"!I<W-U960@86X@86=G<F5G871E#0IO
M9B`T.3DL.3DX(%9I=&%-960@5V%R<F%N=',@*&]R(%=A<G)A;G1S(&9O<B!A
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M9W)E96UE;G0@=V%S(&%M96YD960@=&\@<F5F;&5C=`T*82`D,3`P+#`P,"!B
M86YK(&QI;F4@;V8@8W)E9&ET+B!!<R!P87)T(&]F('1H92!A;65N9&5D(&QI
M;F4@;V8@8W)E9&ET+"!T:&4@<&5R<V]N86P@9W5A<F%N=&5E<R!A;F0@8V%S
M:"!C;VQL871E<F%L('=E<F4@<F5M;W9E9`T*9F]R($UR+B!&:6YI>FEO(&%N
M9"!-<BX@36EL;&EG86XN($EN(&%C8V]R9&%N8V4@=VET:"!T:&4@=&5R;7,@
M;V8@=&AE(%=A<G)A;G1S+"!787)R86YT<R!P<F5V:6]U<VQY(&ES<W5E9"!T
M;R!-<BX@1FEN:7II;R!A;F0@37(N#0I-:6QL:6=A;B!W97)E(&%M96YD960@
M=&\@<F5F;&5C="!T:&4@86UO=6YT('9E<W1E9"!P<FEO<B!T;R!T:&4@9&%T
M92!O9B!T:&4@86UE;F1E9"!L:6YE(&]F(&-R961I="`H,3<Y+#`P,"!E86-H
M*2X@070@1&5C96UB97(-"C,Q+"`R,#$S+"!A;B!A9V=R96=A=&4@;V8@-38R
M+#4W,2!787)R86YT<R!W97)E('9E<W1E9"X@5&AE(%=A<G)A;G1S+"!W:71H
M(&$@9F%I<B!V86QU92!O9B`D.3,L.38Y("@D.#8L,3,Y(&%F=&5R(&%D:G5S
M=&EN9R!F;W(-"G1H92!E9F9E8W0@;V8@=&AE(&%M96YD960@;&EN92!O9B!C
M<F5D:70@*2P@=V5R92!V86QU960@;VX@=&AE(&1A=&4@;V8@=&AE(&ES<W5A
M;F-E('5S:6YG(&$@=&5R;2!O9B`Q,"!Y96%R<SL@82!V;VQA=&EL:71Y(&]F
M(#0W+C@Y)3L-"G)I<VL@9G)E92!R871E(&]F(#,N-#@E.R!A;F0@82!D:79I
M9&5N9"!Y:65L9"!O9B`P)2X@1F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@)#(L.30T+"`D-#4L,#,V(&%N
M9`T*)#,X+#$U.2P@<F5S<&5C=&EV96QY('=A<R!R96-O<F1E9"!A<R!L;V%N
M(&=U87)A;G1Y(&-O<W1S(&EN(&]T:&5R(&EN8V]M92!A;F0@97AP96YS92!O
M;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"G-T
M871E;65N=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SX\:3X\=3Y3=6UM87)Y(&]F(&]U<B!787)R86YT(&%C=&EV:71Y(&%N9"!R
M96QA=&5D(&EN9F]R;6%T:6]N(&9O<@T*,C`Q,2TR,#$S/"]U/CPO:3X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS
M1"=B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!W:61T:#H@,3`P)3L@9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^3G5M8F5R#0IO9B!3:&%R97,@56YD97(@
M5V%R<F%N=',\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^5V5I9VAT960-"D%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^5V5I9VAT960@
M079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P-"DQI9F4@:6X@665A<G,\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q
M-C`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^06=G
M<F5G871E#0I);G1R:6YS:6,@5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^0F%L86YC92!A="!$96-E
M;6)E<B`S,2P@,C`Q,#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(SDT-S([/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S-B4[('!A9&1I
M;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY)<W-U960\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG
M:'0G/C,L,#4W+#8R-SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT)SXP+C,V/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H
M="<^-RXY/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
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M,T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5X
M97)C:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(SDT-S([/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M5VAI=&4G/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY%>'!I<F5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C.30W,CL\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#(R<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^0V%N8V5L;&5D/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF
M(SDT-S([/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY"86QA;F-E
M(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,L,#4W+#8R-SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP
M+C,V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^-RXY/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C,L-#@S+#8Y,3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY)<W-U960\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,3<L,S,R+#4P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXQ+C(V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-"XS/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,Q+#@Y,2PQ
M-3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5X97)C
M:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*2<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/D5X<&ER960\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M:6YD96YT
M.B`M,3!P="<^0V%N8V5L;&5D/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH-3$L,30R/"]T9#X-
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M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*2<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q
M,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D)A;&%N8V4@870@1&5C96UB97(@
M,S$L(#(P,3(\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,3(L,3DS+#0Y.3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ+C8S/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
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M92<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0G/DES<W5E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR+#$P,"PP,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,BXW
M,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C0N.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXU+#(S,BPU,#`\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#(R<'0[('1E>'0M:6YD96YT.B`M,3!P="<^17AE<F-I<V5D/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C.30W,CL\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/D5X<&ER960\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z
M("TQ,'!T)SY#86YC96QL960\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B8C.30W,CL\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!7:&ET92<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M="<^0F%L86YC90T*870@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^,30L,CDS+#0Y.3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2XW.3PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXS+CD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0X+#DS,BPW-S<\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L
M,C,X+#(U-2DG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/E9E<W1E9`T*86YD($5X97)C:7-A8FQE(&%T($1E
M8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$S+#<V-"PW
M,3`\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/C$N.#$\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,RXY/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXT-BPX-#`L-34Y/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
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M:"!W87)R86YT<PT*=&]T86QE9"!A<'!R;WAI;6%T96QY("0Q+#4Y.2PP,#`N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY4:&4@=V5I9VAT960@879E<F%G92!F86ER('9A;'5E
M('!E<B!S:&%R92!O9@T*=V%R<F%N=',@:7-S=65D(&%N9"!T:&4@87-S=6UP
M=&EO;G,@=7-E9"!I;B!T:&4@0FQA8VLM4V-H;VQE<R!-;V1E;"!D=7)I;F<@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"`R,#$R(&%N9"`R
M,#$Q(&%R90T*<V5T(&9O<G1H(&EN('1H92!T86)L92!B96QO=RX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q
M-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z
M(&-O;&QA<'-E.R!W:61T:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$S/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3(\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#0V)3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/E=E:6=H=&5D(&%V97)A9V4@9F%I<B!V86QU93PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G
M/C(N.#,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C(N,#4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$S)3L@=&5X="UA;&EG;CH@<FEG:'0G/C`N,38\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T)SY2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXP+C@X+3$N,3(\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP
M+C<R+3$N,#0\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+CDQ+3,N-#@\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G
M/E9O;&%T:6QI='D\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#0N,CDM-#4N.#D\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)3PO
M=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXT-"XV-"TT-"XX,3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C,Y+C$S+34Q+C@S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5&5R;2`H:6X@>65A
M<G,I/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4M-CPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXU+3$P/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0G/D1I=FED96YD('EI96QD/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C`N,#`\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C`N,#`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C`N
M,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\
M+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(')I<VLM9G)E92!I;G1E<F5S
M="!R871E(&%S<W5M<'1I;VX@:7,@8F%S960-"G5P;VX@;V)S97)V960@:6YT
M97)E<W0@<F%T97,@;VX@>F5R;R!C;W5P;VX@52Y3+B!4<F5A<W5R>2!B;VYD
M<R!W:&]S92!M871U<FET>2!P97)I;V0@:7,@87!P<F]P<FEA=&4@9F]R('1H
M92!T97)M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M=&]C:R!P<FEC92!D=7)I;F<-"C(P,3$M,C`Q,RX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO
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M8VL@;V8@=&AE#0I#;VUP86YY/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@,C`P.2P@
M=V4@861O<'1E9"!T:&4@,C`P.2!,;VYG(%1E<FT@26YC96YT:79E#0I#;VUP
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M:R!O<B!C87-H(&%W87)D<R!A<R!D97-C<FEB960-"FEN('1H92`R,#`Y(%!L
M86XN(%1H97)E(&%R92`R-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D(&9O
M<B!I<W-U86YC92!T:&5R975N9&5R+B!0<FEO<B!T;R!T:&4@;65R9V5R+"!N
M;R!A=V%R9',@:&%D(&)E96X@:7-S=65D#0IU;F1E<B!T:&4@,C`P.2!0;&%N
M+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,R!T:&5R92!W97)E(#$S+#8S,BPW
M-#(@<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VL@:7-S=65D('5N9&5R('1H
M92`R,#`Y(%!L86XN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!&96)R=6%R>2`R,RP@,C`Q
M,BP@=V4@861O<'1E9"!T:&4@,C`Q,B!3=&]C:PT*26YC96YT:79E(%!L86XL
M(&]R('1H92`R,#$R(%!L86XL(&$@;F]N+7%U86QI9FEE9"!P;&%N('1H870@
M=V%S(&%M96YD960@:6X@075G=7-T(#(P,3,N(%1H92`R,#$R(%!L86X@=V%S
M(&1E<VEG;F5D('1O('-E<G9E(&%S#0IA;B!I;F-E;G1I=F4@9F]R(')E=&%I
M;FEN9R!Q=6%L:69I960@86YD(&-O;7!E=&5N="!K97D@96UP;&]Y965S+"!O
M9F9I8V5R<RP@9&ER96-T;W)S+"!A;F0@8V5R=&%I;B!C;VYS=6QT86YT<R!A
M;F0@861V:7-O<G,@;V8-"F]U<B!C;VUP86YY+B!4:&5R92!A<F4@,3`L,#`P
M+#`P,"!S:&%R97,@;V8@;W5R($-O;6UO;B!3=&]C:R!A=71H;W)I>F5D(&9O
M<B!I<W-U86YC92!T:&5R975N9&5R+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q
M,RP@=&AE<F4-"G=E<F4@,BPV-3`L,#`P('-H87)E<R!I<W-U960@=6YD97(@
M=&AE(#(P,3(@4&QA;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!V86QU871I;VX@;65T
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M;V1E;"!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S
M(&%R92!S970@9F]R=&@@:6X@=&AE('1A8FQE(&)E;&]W+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3,\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$Q/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D
M/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,"XV-2TQ+C<Q/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,"XV,2TR+C(S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
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M8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^5F]L871I
M;&ET>3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,RXS-2TT-2XW-CPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C0P+C<W+30V+C`Q/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,S<N.3(M-#`N-#@\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E1E<FT@*&EN
M('EE87)S*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+38N,C4\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4M-BXR-3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^-2XU+38N,C4\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0V)3L@=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D1I
M=FED96YD('EI96QD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[
M('1E>'0M86QI9VXZ(')I9VAT)SXP+C`P/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXP+C`P/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXE/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT)SXP+C`P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXE/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
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M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/"]P/@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^02!S=6UM87)Y(&]F(&%C
M=&EV:71Y('5N9&5R('1H92`R,#`Y(&%N9"`R,#$R(%!L86YS(&%N9"!R96QA
M=&5D#0II;F9O<FUA=&EO;B!F;W(@,C`Q,2TR,#$S(&9O;&QO=W,Z/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED
M=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M
M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E
M<@T*("`@(&]F(%-H87)E<R!5;F1E<B!/<'1I;VYS/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/E=E:6=H=&5D#0H@("`@079E
M<F%G92!%>&5R8VES92!0<FEC93PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SY796EG:'1E9`T*("`@($%V97)A9V4@4F5M86EN
M:6YG($-O;G1R86-T=6%L($QI9F4@:6X@665A<G,\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^06=G<F5G871E#0H@("`@26YT
M<FEN<VEC(%9A;'5E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0G/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3`\+W1D/CQT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Y-#<R.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`S-B4[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z
M("TQ,'!T)SY'<F%N=&5D/'-U<#XH,2D\+W-U<#X\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0G/C$P+#8X,BPR
M,3@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA
M;&EG;CH@<FEG:'0G/C`N,38\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H="<^-RXV/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ-"PQ.#@L-#@T/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%>&5R8VES960\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^*#DR+#`U-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C`N,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY%>'!I<F5D/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C.30W,CL\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M
M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY#86YC96QL960\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/B8C.30W,CL\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^
M0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,"PU.3`L
M,38Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXP+C$V/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/C<N-CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,30L,#8W+#8T.3PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D=R86YT960\
M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^-2PQ,C$L,C4P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXR+C@P/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDN-SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PW,S<L-3,P
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5X97)C
M:7-E9#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXH,2PY,S$L-S@X/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,"XQ,SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M:6YD
M96YT.B`M,3!P="<^17AP:7)E9#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(SDT-S([/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G
M/D-A;F-E;&QE9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#0V+#$S-3PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T)SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R
M,#$R/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/C$S+#<S,RPT.#@\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$N,38\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-RXW/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR-BPX
M,#0L,3$W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G
M/D=R86YT960\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,BPU.#,L-C<W/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS+C,Q/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CDN.#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M-"PY,C`L.3@Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M
M:6YD96YT.B`M,3!P="<^17AE<F-I<V5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@W-2PT,C,\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R
M,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D5X<&ER960\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#(U
M,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY#86YC96QL960\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@V,#@L
M-S4P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X
M="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/D)A;&%N8V4-"B`@("!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT)SXQ-2PV,S(L-S0R/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2XT-#PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^-RXR/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3@L.#<X+#$S,CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X
M+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY697-T960-"B`@("!A;F0@17AE<F-I<V%B;&4@
M870@1&5C96UB97(@,S$L(#(P,3,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^,3$L
M,C@R+#8R-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/BXX,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-BXU/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^-#@L,S(Q+#DS,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"@T*/&1I=B!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!M87)G:6XM=&]P.B`S<'0[(&UA<F=I;BUB;W1T
M;VTZ(#-P="<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#%P=#L@8F]R9&5R
M+71O<#H@0FQA8VL@,7!T('-O;&ED.R!W:61T:#H@,C4E)SX\+V1I=CX\+V1I
M=CX-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^/'-U<#XH,2D\+W-U<#Y4:&ES(&EN8VQU9&5S("AI*2!6:71A365D
M($]P=&EO;G,-"F=R86YT960@8F5T=V5E;B!/8W1O8F5R(#(P,#@@86YD($1E
M8V5M8F5R(#,Q+"`R,#$P(&9O<B!A;B!A9V=R96=A=&4@;V8@-RPV,SDL-S(R
M(%5N:71S+"!O9B!W:&EC:"`Q-BPP,#`@=V5R92!C86YC96QE9"!P<FEO<B!T
M;PT*8V]N=F5R<VEO;B`H;W(@3W!T:6]N<R!F;W(@.2PS-3<L-38Q('-H87)E
M<R!P97(@=&AE($-O;G9E<G-I;VX@4F%T:6\I+"`H:6DI(%9I=&%-960@3W!T
M:6]N<R!G<F%N=&5D(&)E='=E96X@2F%N=6%R>2`Q+"`R,#$Q(&%N9`T*3V-T
M;V)E<B`S+"`R,#$Q(&9O<B!A;B!A9V=R96=A=&4@;V8@-C(Q+#`P,"!5;FET
M<R`H;W(@3W!T:6]N<R!F;W(@-S8R+#(S-2!S:&%R97,@<&5R('1H92!#;VYV
M97)S:6]N(%)A=&EO*2!A;F0@*&EI:2D@3W!T:6]N<R!G<F%N=&5D#0IB971W
M965N($]C=&]B97(@-"P@,C`Q,2!A;F0@1&5C96UB97(@,S$L(#(P,3$@9F]R
M(&%N(&%G9W)E9V%T92!O9B`U-C(L-#(R('-H87)E<RX@5&AE('1E<FUS(&%N
M9"!C;VYD:71I;VYS(&]F('1H92!6:71A365D($]P=&EO;G,-"G=E<F4@<F5F
M;&5C=&5D(&EN('1H92!R97!L86-E;65N="!/<'1I;VYS(&EN8VQU9&EN9R!T
M:&4@;G5M8F5R(&]F('-H87)E<R!V97-T960N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$
M96-E;6)E<B`S,2P@,C`Q,RP@;W5R(&]U='-T86YD:6YG(&]P=&EO;G,-"FAA
M9"!E>&5R8VES92!P<FEC97,@<F%N9VEN9R!F<F]M("0P+C$P('1O("0T+C8W
M('!E<B!S:&%R92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E(&9O<B!O<'1I;VYS#0IR96-O9VYI>F5D(&EN(&]U<B!R
M97-U;'1S(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(S$V,#LS,2P@
M,C`Q,RP@,C`Q,BP@86YD(#(P,3$@*"0S+#(P,"PV-34L("0Q+#@S,BPP-C$L
M(&%N9"`D,3@S+#,U-2P@<F5S<&5C=&EV96QY*0T*:7,@8F%S960@;VX@87=A
M<F1S('9E<W1E9"!A;F0@=V4@97-T:6UA=&5D(&YO(&9O<F9E:71U<F5S+B!!
M4T,@-S$X+3$P(')E<75I<F5S(&9O<F9E:71U<F5S('1O(&)E(&5S=&EM871E
M9"!A="!T:&4@=&EM92!O9B!G<F%N=`T*86YD(')E=FES960@:6X@<W5B<V5Q
M=65N="!P97)I;V1S(&EF(&%C='5A;"!F;W)F96ET=7)E<R!D:69F97(@9G)O
M;2!T:&4@97-T:6UA=&5S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^070@1&5C96UB97(@,S$L
M(#(P,3,L('1O=&%L('5N<F5C;V=N:7IE9"!E<W1I;6%T960-"F-O;7!E;G-A
M=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=6YV97-T960@;W!T:6]N<R!G<F%N
M=&5D('!R:6]R('1O('1H870@9&%T92!W87,@87!P<F]X:6UA=&5L>2`D,RPY
M,C$L,#`P+"!W:&EC:"!I<R!E>'!E8W1E9"!T;PT*8F4@<F5C;V=N:7IE9"!O
M=F5R(&$@=V5I9VAT960M879E<F%G92!P97)I;V0@;V8@,2XS('EE87)S+B!.
M;R!T87@@8F5N969I="!W87,@<F5A;&EZ960@9'5E('1O(&$@8V]N=&EN=65D
M('!A='1E<FX@;V8@;W!E<F%T:6YG#0IL;W-S97,N($%T($1E8V5M8F5R(#,Q
M+"`R,#$R(&%N9"`R,#$Q+"!T;W1A;"!U;G)E8V]G;FEZ960@97-T:6UA=&5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@=6YV97-T960@;W!T
M:6]N<R!G<F%N=&5D('!R:6]R#0IT;R!T:&%T(&1A=&4@=V%S(&%P<')O>&EM
M871E;'D@)#0L,SDQ+#`P,"!A;F0@)#(T-"PP,#`L(')E<W!E8W1I=F5L>2X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY);B!$96-E;6)E<B`R,#$S+"!W92!I<W-U960@82!R97-T<FEC
M=&5D('-T;V-K#0IU;FET+"!O<B!T:&4@4E-5+"!U;F1E<B!O=7(@,C`Q,B!0
M;&%N('1O(&%N(&]F9FEC97(@9F]R('1H92!P=7)C:&%S92!O9B`U,"PP,#`@
M<VAA<F5S(&]F(&]U<B!#;VUM;VX@4W1O8VLN(%1H92!24U4@=VEL;"!V97-T
M(&]N#0I!<')I;"`Q+"`R,#$T(&%N9"!H87,@82!F86ER('9A;'5E(&]F("0R
M,S,L-3`P+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,RP@=V4@<F5C;W)D960@
M)#4S+#0R."!O9B!N;VXM8V%S:"!C;VUP96YS871I;VXN/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO<#X-
M"@T*#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?
M-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970Q
M-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.
M0T]-12!405A%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M24Y#3TU%(%1!6$53/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SX\8CX\=3Y.3U1%(#$Q("8C,34P.R!)3D-/
M344@5$%815,\+W4^/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\
M9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^1F]R('1H92!Y
M96%R<R!E;F1E9`T*1&5C96UB97(@,S$L(#(P,3,L(#(P,3(@86YD(#(P,3$L
M('1H97)E('=A<R!N;R!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<RP@8W5R
M<F5N="!O<B!D969E<G)E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^070@1&5C96UB
M97(@,S$L#0HR,#$S+"!W92!H879E(&$@9F5D97)A;"!N970@;W!E<F%T:6YG
M(&QO<W,@8V%R<GD@9F]R=V%R9"!O9B!A<'!R;WAI;6%T96QY("0S-RPP,#`L
M,#`P(&%V86EL86)L92!T;R!O9F9S970@9G5T=7)E('1A>&%B;&4-"FEN8V]M
M92!T:')O=6=H(#(P,S,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/D%T($1E8V5M8F5R
M(#,Q+`T*,C`Q,RP@,C`Q,BP@86YD(#(P,3$L('=E(&AA=F4@<W1A=&4@;F5T
M(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@;V8@87!P<F]X:6UA=&5L
M>2`D,S4L,#`P+#`P,"!A=F%I;&%B;&4@=&\@;V9F<V5T(&9U='5R90T*;&]S
M<V5S('1H<F]U9V@@,C`S,RX@5V4@97-T86)L:7-H960@=F%L=6%T:6]N(&%L
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M;&4@979I9&5N8V4L(&)O=&@@<&]S:71I=F4@86YD(&YE9V%T:79E+`T*:6YC
M;'5D:6YG(&AI<W1O<FEC86P@;&5V96QS(&]F(&EN8V]M92P@97AP96-T871I
M;VYS(&%N9"!R:7-K<R!A<W-O8VEA=&5D('=I=&@@97-T:6UA=&5S(&]F(&9U
M='5R92!T87AA8FQE(&EN8V]M92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY/=7(@9&5F97)R960@=&%X(&%S<V5T(&%N9"!L:6%B
M:6QI='D@87,@<')E<V5N=&5D#0II;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!C;VYS:7-T(&]F('1H92!F
M;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z(#DP)3L@9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R)SXR,#$R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97(G/C(P,3$\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T
M)SY$969E<G)E9"!);F-O;64@5&%X($%S<V5T<SH\+W1D/CQT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T
M,"4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY.970@;W!E<F%T:6YG(&QO<W-E<SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0G/C$T+#<W
M,RPU,S<\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C4L.3(P+#@V,3PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H="<^-S0X+#0P-#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`R
M,G!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E(F(S,X.T0@0W)E9&ET/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT)SXU-#<L-3$Q/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M)SXQ.#8L,S0V/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ
M,'!T)SY4;W1A;"!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T(#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ-2PS,C$L,#0X/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/C8L,3`W+#(P-SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXW-#@L-#`T/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`R,G!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@Q-2PS,C$L
M,#0X/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X
M="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#8L,3`W+#(P-SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ
M(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@W-#@L-#`T/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^*3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M="<^1&5F97)R960@26YC;VUE(%1A>"!!<W-E=',L(&YE=#PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H="<^+3`M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G
M/BTP+3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXM,"T\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D$@<F5C;VYC:6QI871I
M;VX@8F5T=V5E;B!T87AE<R!C;VUP=71E9"!A=`T*=&AE(&9E9&5R86P@<W1A
M='5T;W)Y(')A=&4@86YD('1H92!C;VYS;VQI9&%T960@969F96-T:79E('1A
M>"!R871E(&ES(&%S(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED=&@Z
M(#DP)3L@9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9"<^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@
M0FQA8VL@,7!T('-O;&ED)SXR,#$R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3$\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T
M,"4[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY&961E<F%L('-T871U=&]R>2!T87@@<F%T93PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R
M:6=H="<^,S4N,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA
M;&EG;CH@;&5F="<^)3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,34E
M.R!T97AT+6%L:6=N.B!R:6=H="<^,S4N,#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H="<^,S4N,#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)3PO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T)SY3=&%T92!T87@@<F%T92P@;F5T(&]F(&9E9&5R86P@
M=&%X(&)E;F5F:70\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^-2XX/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU+C4\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/BTP+3PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z
M("TQ,'!T)SY!9&IU<W1M96YT(&EN('9A;'5A=&EO;B!A;&QO=V%N8V5S/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B@S,BXT/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^*24\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^*#$X+C(\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXI)3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH-2XX/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^*24\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD
M96YT.B`M,3!P="<^4&5R;6%N96YT(&%N9"!O=&AE<B!D:69F97)E;F-E<SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^*#@N-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/BDE/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH
M,C(N,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M86QI9VXZ(&QE9G0G/BDE/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH,CDN,CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/BDE/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T)SY0<F]V:7-I;VX@*$)E;F5F:70I(&9O<B!);F-O;64@5&%X
M97,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^+3`M/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXE/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0G/BTP+3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT)SXM,"T\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.R8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P
M93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C
M-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3
M:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4D5,051%1"!005)42453/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)%3$%4140@4$%25$E%4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^/'4^3D]4
M12`Q,B`F(S$U,#L@4D5,051%1"!005)42453/"]U/CPO8CX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,"<^/&(^)B,Q-C`[/"]B/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y,;V%N($=U
M87)A;G1Y/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@36%R8V@@,C`Q,2P@5FET84UE
M9"!E;G1E<F5D(&EN=&\@82!B=7-I;F5S<PT*;&]A;B!A9W)E96UE;G0@=VET
M:"!&:7)S="!5;FET960@9F]R(&$@)#,P,"PP,#`@;&EN92!O9B!C<F5D:70@
M9F]R('=H:6-H('!E<G-O;F%L(&=U87)A;G1E97,@86YD(&-A<V@@8V]L;&%T
M97)A;"!W97)E(')E<75I<F5D+@T*4&5R<V]N86P@9W5A<F%N=&5E<R!A;F0@
M8V%S:"!C;VQL871E<F%L(&QI;6ET960@=&\@)#$P,"PP,#`@96%C:"!W97)E
M('!R;W9I9&5D(&)Y($UR+B!&:6YI>FEO+"!-<BX@36EL;&EG86XL(&%N9"!2
M96EC:"!&86UI;'D@3&EM:71E9`T*3&EM:71E9"!087)T;F5R<VAI<"X@4V5E
M($Y/5$53(#D@86YD(#$P(&9O<B!M;W)E(&1E=&%I;',N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\=3Y,;V%N<R!F<F]M($%F9FEL:6%T97,\+W4^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;B!*=6YE(#(P,3$L(%9I=&%-960@:7-S=65D('!R;VUI<W-O<GD@;F]T97,L
M#0IO<B!T:&4@5FET84UE9"!.;W1E<RP@:6X@=&AE(&%G9W)E9V%T92!P<FEN
M8VEP86P@86UO=6YT(&]F("0U,#`L,#`P+"!O9B!W:&EC:"`D,3`P+#`P,"!W
M87,@<V]L9"!T;R!A9F9I;&EA=&5S+B!);B!*=6YE(#(P,3(L('1H90T*869F
M:6QI871E(&YO=&5S('=E<F4@97AT96YD960@=&\@3V-T;V)E<B`Q-2P@,C`Q
M,B`H;VYE(&AE;&0@8GD@37(N($UI;&QI9V%N(&9O<B`D-3`L,#`P(&%N9"!O
M;F4@9F]R("0U,"PP,#`@:&5L9"!B>2!"1B!);G9E<W1M96YT<RP-"DQ,0RP@
M=VAI8V@@:7,@;W=N960@8GD@0G)I86X@0F5R;FEC:RP@82!M96UB97(@;V8@
M=&AE(&)O87)D(&]F(&1I<F5C=&]R<R!O9B!O=7(@8V]M<&%N>2X@3VX@3V-T
M;V)E<B`T+"`R,#$R('1H97-E(%9I=&%-960@4')O;6ES<V]R>0T*3F]T97,@
M=V5R92!P86ED(&EN(&9U;&P@:6YC;'5D:6YG("0U+#,T,2!I;B!A8V-R=65D
M(&EN=&5R97-T+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@1&5C96UB97(@,C`Q,2P@=V4@
M:7-S=65D(#0E('!R;VUI<W-O<GD@;F]T97,-"G1O($UR+B!&:6YI>FEO(&%N
M9"!-<BX@36EL;&EG86X@86YD(&9O<B!A;B!A9V=R96=A=&4@;V8@)#$P,"PP
M,#`@*"0U,"PP,#`@96%C:"D@=VET:"!O<FEG:6YA;"!D=64@9&%T97,@;V8@
M36%R8V@@,2P@,C`Q,BX@5&AE<V4-"G!R;VUI<W-O<GD@;F]T97,@=V5R92!E
M>'1E;F1E9"!B>2!M=71U86P@86=R965M96YT('1O($IU;F4@,2P@,C`Q,BX@
M26X@2G5N92`R,#$R+"!T:&4@5FET84UE9"!0<F]M:7-S;W)Y($YO=&4@:&5L
M9"!B>2!-<BX@1FEN:7II;PT*=V%S('!A:60@:6X@9G5L;"P@:6YC;'5D:6YG
M("0X.#@@:6X@86-C<G5E9"!I;G1E<F5S="X@37(N($UI;&QI9V%N)B,Q-#8[
M<R!6:71A365D(%!R;VUI<W-O<GD@3F]T92!W87,@97AT96YD960@=&\@3V-T
M;V)E<B`Q-2P-"C(P,3(N($]N($]C=&]B97(@-"P@,C`Q,B!T:&ES(%9I=&%-
M960@3F]T97,@=V%S('!A:60@:6X@9G5L;"!I;F-L=61I;F<@)#$L-3$Y(&EN
M(&%C8W)U960@:6YT97)E<W0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y,;V-K(%5P($%G
M<F5E;65N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!R97%U:7)E9"!B>2!T:&4@
M=&5R;7,@;V8@=&AE(&UE<F=E<B!A9W)E96UE;G0-"G=I=&@@5FET84UE9"!D
M871E9"!*=6QY(#$X+"`R,#$Q+"!W92!E;G1E<F5D(&EN=&\@3&]C:RU5<"!!
M9W)E96UE;G1S('=I=&@@<W1O8VMH;VQD97)S(&-O=F5R:6YG('1H92!A9V=R
M96=A=&4@;V8@-S`L,#`P+#`P,"!S:&%R97,-"F]F(&]U<B!#;VUM;VX@4W1O
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M97(@=&AE(&9O;&QO=VEN9R`Q,BUM;VYT:`T*<&5R:6]D+"!O<B!T:&4@1')I
M8F)L92!/=70@4&5R:6]D+B!5<&]N('1H92!C;VUP;&5T:6]N(&]F('1H92!$
M<FEB8FQE($]U="!097)I;V0L('1H92!!9W)E96UE;G1S('=I;&P@=&5R;6EN
M871E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\=3Y0=7)C:&%S97,@8GD@4F5L871E9"!087)T:65S/"]U
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^1'5R:6YG
M(#(P,3,L(#(P,3(L(&%N9"`R,#$Q+"!W92!S;VQD(&]U<B!P<F]D=6-T<PT*
M=&\@1'(N($)R:6%N($)E<FYI8VLL(&$@9&ER96-T;W(@;V8@;W5R(&-O;7!A
M;GDL(&EN('1H92!A;6]U;G1S(&]F("0P+"`D,BPV,S(@86YD("0R,"PV-CDL
M(')E<W!E8W1I=F5L>2P@=VAI;&4@)#`L("0Q+#(W,B!A;F0@)#`-"F]F(')E
M8V5I=F%B;&5S(')E;&%T960@=&AE<F5T;R!R96UA:6YE9"!O=71S=&%N9&EN
M9R!A="!$96-E;6)E<B`S,2P@,C`Q,RP@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C
M=&EV96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;"<^/'4^06=R965M
M96YT<R!W:71H(%!E<FYI>"!4:&5R87!E=71I8W,L#0I,3$,\+W4^/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@;F]R;6%L)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($9E8G)U
M87)Y(#(Y+"`R,#$R+"!#;V]P97(@0RX@0V]L;&EN<RP@4')E<VED96YT#0IA
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M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@,C`Q,BP@86YD(#(P,3$L('=E
M(&UA9&4@<'5R8VAA<V5S(&]F(&%P<')O>&EM871E;'D@)#`L("0T,#0L,#`P
M(&%N9"`D,3DL,#`P+"!R97-P96-T:79E;'DL#0IF<F]M(%!E<FYI>"X@070@
M1&5C96UB97(@,S$L(#(P,3,L(#(P,3(L(&%N9"`R,#$Q+"!T:&5R92!W97)E
M(&%M;W5N=',@9'5E(%!E<FYI>"!O9B!A<'!R;WAI;6%T96QY("0T-BPP,#`L
M("0S,#@L,#`P(&%N9"`Q.2PP,#`-"F]U='-T86YD:6YG+"!R97-P96-T:79E
M;'DN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY!9&1I=&EO;F%L;'DL('1H97)E('=E<F4@86UO
M=6YT<R!D=64@=&\-"G5S(&9R;VT@4&5R;FEX(&9O<B!L96=A;"!F964@<F5I
M;6)U<G-E;65N="!R96QA=&EN9R!T;R!A(&QI=&EG871I;VX@;6%T=&5R('!U
M<G-U86YT('1O(&$@;&EC96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="P@:6X@
M=&AE(&%M;W5N=',-"F]F("0R-#DL.3@Q(&%N9"`D,"!F;W(@=&AE('!E<FEO
M9',@96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q,BP@<F5S<&5C=&EV96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&YO<FUA;"<^/'4^5V%R<F%N=',-"F%S<VEG;F5D
M('1O(%)E;&%T960@4&%R='D\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS
M1"=F;VYT+7=E:6=H=#H@;F]R;6%L)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86PG/DEN($IU;F4@,C`Q,BP-
M"F$@=V%R<F%N="!T;R!P=7)C:&%S92`Q,#`L,#`P('-H87)E<R!O9B!O=7(@
M0V]M;6]N(%-T;V-K('=A<R!A<W-I9VYE9"!T;R!T:&4@<V]N(&]F('1H92!#
M:&%I<FUA;B!O9B!O=7(@8F]A<F0@;V8@9&ER96-T;W)S(&)Y(&$-"FYO;BUA
M9F9I;&EA=&5D('1H:7)D('!A<G1Y+CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&YO<FUA;"<^)B,Q-C`[/"]F;VYT/CPO<#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C
M7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#DO5V]R:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0E5324Y%4U,@0T].0T5.5%)!5$E/3E,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4FES:W,@86YD(%5N8V5R=&%I;G1I97,@6T%B<W1R86-T73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0E5324Y%4U,@
M0T].0T5.5%)!5$E/3E,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB
M/CQU/DY/5$4@,3,@+2!"55-)3D534R!#3TY#14Y44D%424].4SPO=3X\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@<'5R8VAA<V4@;W5R('!R;V1U8W1S
M(&9R;VT@<V5V97)A;"!S=7!P;&EE<G,-"G=I=&@@87!P<F]X:6UA=&5L>2`Y
M."4L(#<V)2P@86YD(#DU)2!O9B!O=7(@<'5R8VAA<V5S('-U<'!L:65D(&9R
M;VT@;VYE('9E;F1O<B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$S(#(P,3(L(&%N9`T*,C`Q,2P@<F5S<&5C=&EV96QY+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^5V4@<V5L;"!O=7(@<')E<V-R:7!T:6]N(&1I971A<GD@<W5P<&QE
M;65N=`T*<')O9'5C=',@=&\@=VAO;&5S86QE(&1I<W1R:6)U=&]R<RP@<W!E
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M;W)P;W)A=&EO;B!A8V-O=6YT960@9F]R(#<Y)2P@-C,E(&%N9"`T,B4@;V8@
M;W5R(')E8V]G;FEZ960@<F5V96YU92!F;W(@>65A<G,@96YD960@1&5C96UB
M97(-"C,Q+"`R,#$S+"`R,#$R+"!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^1F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,R!A;F0-"C(P,3(L(#8T)2!A;F0@,C@E(&]F(&]U<B!R96-O9VYI>F5D
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M>65A<G,N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R
M8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y4
M4R!!3D0@0T].5$E.1T5.0TE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13($%.1"!#
M3TY424Y'14Y#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!L969T)SX\8CX\=3Y.
M3U1%(#$T("8C,34P.R!#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO
M=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&QE9G0G/CQB/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^3W!E<F%T:6YG($QE87-E/"]U
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^5V4@;&5A<V4@861M:6YI<W1R871I=F4@;V9F:6-E
M('-P86-E(&EN($)O8V$-"E)A=&]N+"!&;&]R:61A('!U<G-U86YT('1O(&$@
M-C,@;6]N=&@@;F]N+6-A;F-E;&%B;&4@;W!E<F%T:6YG(&QE87-E(&-O;6UE
M;F-I;F<@;VX@2G5L>2`Q+"`R,#$S(&%N9"!E>'!I<FEN9R!O;B!397!T96UB
M97(@,S`L(#(P,3@N#0I4:&4@;&5A<V4@<W1I<'5L871E<RP@86UO;F<@;W1H
M97(@=&AI;F=S+"!A=F5R86=E(&)A<V4@;6]N=&AL>2!R96YT<R!O9B`D,S`L
M,30Y("AI;F-L=7-I=F4@;V8@97-T:6UA=&5D(&]P97)A=&EN9R!E>'!E;G-E
M<RD@86YD#0IS86QE<R!T87@L(&9O<B!A('1O=&%L(&9U='5R92!M:6YI;75M
M('!A>6UE;G1S(&]V97(@=&AE(&QI9F4@;V8@=&AE(&QE87-E(&]F("0Q+#@Y
M.2PT,30N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!C96YT97(G/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@<W1R86EG:'0@;&EN92!R96YT
M86P@97AP96YS92!R96QA=&5D('1O#0IO=7(@8W5R<F5N="!L96%S92!T;W1A
M;&5D("0Q.#`L.#DT(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,R!O9F9S970@8GD@<F5N="!I;F-O;64@;V8@)#,R+#DV,RX@
M5&AE(')E;G1A;"!E>'!E;G-E#0IR96QA=&5D('1O(&]U<B!P<FEO<B!L96%S
M92!W:&EC:"!E>'!I<F5D($IU;F4@,S`L(#(P,3,@=&]T86QE9"`D-C`L,38X
M(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$S+"!A;F0@
M)#$P-BPS,34@86YD#0HD,3(R+#<U,B!F;W(@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY!<R!O9B!$96-E;6)E
M<B`S,2P@,C`Q,RP@9G5T=7)E(&UI;FEM=6T@<F5N=&%L('!A>6UE;G1S(&%R
M92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V
M,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`V,"4[
M(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ93H@,3!P="<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^665A<G,-"B`@("!%;F1I;F<@1&5C96UB97(@,S$L/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@-S<E)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q-BPP,SD\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXS-S$L,C0P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P
M,38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,S@R+#,W-SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C`Q-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS.3,L.#0X/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3@\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,P,BPW-#@\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG
M+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P-"B`@("!M:6YI;75M
M(&QE87-E('!A>6UE;G1S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXQ+#<V-BPR-3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M
M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.;VYC86YC96QA8FQE#0H@("`@
M<W5B+6QE87-E(&EN8V]M93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#,X+#DU-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^3F5T#0H@("`@;6EN:6UU;2!L96%S92!P87EM96YT<SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ
M+#<R-RPR.38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E
M9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D
M.2]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY314Q%0U1%1"!154%25$523%D@1DE.04Y#24%,
M($1!5$$@*%5.055$251%1"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^475A<G1E<FQY($9I;F%N8VEA;"!);F9O
M<FUA=&EO;B!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-%3$5#5$5$(%%505)415),
M62!&24Y!3D-)04P@1$%402`H54Y!541)5$5$*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&(^/'4^3D]412`Q-2`F(S$U,#L@4T5,14-4140@455!
M4E1%4DQ9($9)3D%.0TE!3`T*1$%402`H54Y!541)5$5$*3PO=3X\+V(^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY3=6UM87)I>F5D
M('%U87)T97)L>2!F:6YA;F-I86P@9&%T82!F;W(@9FES8V%L('EE87)S)B,Q
M-C`[,C`Q,R8C,38P.V%N9"8C,38P.S(P,3(F(S$V,#MI<PT*87,@9F]L;&]W
M<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E
M<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ93H@,3!P="<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0Q-"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C`Q,PT*("`@(%%U87)T97)S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<W1Y;&4Z(&ET86QI8SL@=&5X
M="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('=I9'1H.B`T
M,"4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BA);@T*("`@('1H;W5S86YD<RP@97AC97!T('!E
M<B!S:&%R92D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#(E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@=VED=&@Z(#$Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3QS=7`^<W0\
M+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#(E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$Q)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,CQS
M=7`^;F0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#(E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$Q)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,SQS=7`^<F0\+W-U<#X\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED
M=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#(E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$Q)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-'1H/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E)E=F5N=65S/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#4S
M-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C(L,#@Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,BPR.34\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#@V,SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D=R;W-S#0H@("`@<')O9FET/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ+#$U-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$L-C$W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PV-#8\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#,Y-CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@
M,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3F5T#0H@("`@;&]S<SPO9F]N=#X\+W1D/@T*
M("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#8L,S<V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^
M/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@V+#`P.3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-RPV-S,\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#@L,S8Q/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P
M861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P
M<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/DQO<W,-"B`@("!P97(@8V]M;6]N('-H87)E+"!B
M87-I8R!A;F0@9&EL=71E9#PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#`N,#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*#`N,#4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*#`N,#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D
M/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*#`N,#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N
M=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL
M87!S93L@9F]N="US:7IE.B`Q,'!T)SX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#$T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR,#$R#0H@("`@475A<G1E<G,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US='EL93H@:71A;&EC.R!T97AT+6EN9&5N=#H@+3$P<'0[
M('!A9&1I;F<M;&5F=#H@,3!P=#L@=VED=&@Z(#0P)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*$EN#0H@("`@=&AO=7-A;F1S+"!E>&-E<'0@<&5R('-H87)E*3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!W
M:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T
M:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXQ/'-U<#YS=#PO<W5P/CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR/'-U<#YN9#PO<W5P/CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS/'-U<#YR9#PO<W5P
M/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!W:61T:#H@,24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT=&@\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[
M('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4F5V96YU97,\+V9O
M;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C<R,CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@Q.3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L
M,#,V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,2PR-#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN
M9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY'<F]S<PT*("`@('!R;V9I=#PO
M9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S@V/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#0W/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-S(Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^.3`X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.970-"B`@("!L
M;W-S/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3,L,CDP/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,2PX
M-3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#0L,C4S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\
M=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B@U+#<R-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,;W-S#0H@("`@
M<&5R(&-O;6UO;B!S:&%R92P@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]T
M9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@P+C$V/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O
M;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C$T/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`T/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`V/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C
M7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#DO5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.5%,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U5"4T51545.5"!%5D5.5%,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/CQU/DY/5$4@,39?("8C,34P
M.R!354)315%514Y4($5614Y44SPO=3X\+V(^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/D]N($IA;G5A<GD@-BP-"C(P,30L(&]P=&EO;G,@9F]R
M(#,Y,"PP,#`@<VAA<F5S(&]F('-T;V-K('=E<F4@9W)A;G1E9"!T;R!C97)T
M86EN(&UE;6)E<G,@;V8@;W5R($)O87)D(&]F($1I<F5C=&]R<R!U;F1E<B!T
M:&4@,C`Q,B!0;&%N(&9O<@T*=&AE:7(@<V5R=FEC97,@=&\@8F4@<F5N9&5R
M960@:6X@,C`Q-"X@5&AE(&]P=&EO;G,@=V5R92!G<F%N=&5D(&9O<B!A('!E
M<FEO9"!O9B`Q,"!Y96%R<R!A="!A;B!E>&5R8VES92!P<FEC92!E<75A;"!T
M;R!T:&4-"F-L;W-I;F<@<')I8V4@870@=&AE(&1A=&4@;V8@9W)A;G0L(&%N
M9"!V97-T(&]N($1E8V5M8F5R(#,Q+"`R,#$T+B`\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P
M-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A
M-3DW-&5D.2]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+1T%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-534U!4ED@3T8@4TE'3DE&24-!
M3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`H4&]L:6-I97,I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I
M;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SX\=3Y0<FEN8VEP;&5S(&]F($-O;G-O;&ED871I;VX\+W4^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@86-C
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M=&EO;BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T97(M<W!A8VEN9SH@+3`N,35P
M=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&YO<FUA;"<^/'4^0V%S:#PO=3X\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[(&QE='1E<BUS<&%C:6YG.B`M,"XQ-7!T.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT+7=E:6=H=#H@
M;F]R;6%L)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[(&QE='1E<BUS<&%C:6YG.B`M,"XQ-7!T.R!T97AT+6%L:6=N.B!J=7-T
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M;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@<F5S=6QT:6YG#0IF<F]M('1H92!T
M96UP;W)A<GD@9F5D97)A;"!P<F]G<F%M(&EN(&5F9F5C="!F<F]M($1E8V5M
M8F5R(#,Q+"`R,#$P('1H<F]U9V@@1&5C96UB97(@,S$L(#(P,3(N(%5N9&5R
M('1H:7,@<')O9W)A;2P@=&AE<F4@=V%S(&YO#0IL:6UI="!T;R!T:&4@86UO
M=6YT(&]F(&EN<W5R86YC92!F;W(@96QI9VEB;&4@86-C;W5N=',N($)E9VEN
M;FEN9R!*86YU87)Y(#$L(#(P,3,L(&EN<W5R86YC92!C;W9E<F%G92!R979E
M<G1E9"!T;R`D,C4P+#`P,"!P97(-"F1E<&]S:71O<B!A="!E86-H(&9I;F%N
M8VEA;"!I;G-T:71U=&EO;BP@870@=VAI8V@@=&EM92!O=7(@;F]N+6EN=&5R
M97-T(&)E87)I;F<@8V%S:"!B86QA;F-E<R!A9V%I;B!E>&-E961E9"!F961E
M<F%L;'D@:6YS=7)E9`T*;&EM:71S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D92!!8V-O
M=6YT<R!296-E:79A8FQE(&%N9"!!;&QO=V%N8V4@9F]R($1O=6)T9G5L($%C
M8V]U;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!L971T97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(#!P="<^/'4^5')A9&4-"D%C8V]U;G1S
M(%)E8V5I=F%B;&4@86YD($%L;&]W86YC92!F;W(@1&]U8G1F=6P@06-C;W5N
M=',\+W4^/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T
M97(M<W!A8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I
M;F<Z(#!P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4<F%D92!A8V-O=6YT<R!R96-E
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M96-T:6]N(&EN9F]R;6%T:6]N+`T*86YD(&5X:7-T:6YG(&5C;VYO;6EC(&-O
M;F1I=&EO;G,N(%=E(&-O;G-I9&5R('1R861E(&%C8V]U;G1S(')E8V5I=F%B
M;&4@<&%S="!D=64@9F]R(&UO<F4@=&AA;B`Y,"!D87ES('1O(&)E(&1E;&EN
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M871E<R!D;V5S(&YO=`T*86-C=7)A=&5L>2!R969L96-T(&)A9"!D96)T<SL@
M861J=7-T;65N=',@=&\@=&AE<V4@<F5S97)V97,@;6%Y(&)E(')E<75I<F5D
M+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4]
M,T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQU/DEN=F5N=&]R:65S/"]U
M/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y
M;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/B8C,38P.SPO9F]N=#X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M<GDL('5N=&EL('-U8V@@=&EM92!A<R!T:&4@<F5L871E9"!D969E<G)E9`T*
M<F5V96YU92!I<R!R96-O9VYI>F5D+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!!<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`G/CQU/D9I>&5D($%S<V5T<SPO=3X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,"<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/CQU/D5Q=6EP;65N=#PO=3X\+VD^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
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M="UL:6YE(&UE=&AO9`T*;W9E<B!T:&4@97-T:6UA=&5D('5S969U;"!L:79E
M<R!O9B!T:&4@<F5L871E9"!A<W-E=',L('=H:6-H(')A;F=E(&9R;VT@=&AR
M964@=&\@<V5V96X@>65A<G,N/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@
M<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/CQI/CQU/DQE87-E
M:&]L9`T*26UP<F]V96UE;G1S/"]U/CPO:3X\+V9O;G0^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQF;VYT('-T
M>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`M,"XQ-7!T)SY7
M92!S=&%T90T*:6UP<F]V96UE;G1S(&%T(&-O<W0L(&YE="!O9B!A8V-U;75L
M871E9"!D97!R96-I871I;VXN(%=E(&-O;7!U=&4@9&5P<F5C:6%T:6]N('5S
M:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H92!R96UA:6YI
M;F<-"G1E<FT@;V8@=&AE(&QE87-E+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE
M($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0G/CQU/DEN=&%N9VEB;&4\+W4^(#PO9F]N=#X\=3Y!<W-E=',\
M+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^/&D^/'4^4&%T
M96YT#0IA;F0@5')A9&5M87)K<SPO=3X\+VD^/"]F;VYT/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S
M='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@+3`N,35P="<^
M5V4@:&%V90T*861O<'1E9"!T:&4@<')O=FES:6]N<R!O9B`\+V9O;G0^1FEN
M86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D+"!O<B!&05-"+"!!
M8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VXL(&]R($%30RP@/&9O
M;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0G/C,U,"P-"CQI
M/DEN=&%N9VEB;&4M1V]O9'=I;&P@86YD($]T:&5R/"]I/BP\:3X@/"]I/F]R
M(#PO9F]N=#Y!4T,@,S4P/&9O;G0@<W1Y;&4],T0G;&5T=&5R+7-P86-I;F<Z
M("TP+C$U<'0G/BX@0V%P:71A;&EZ960@<&%T96YT(&-O<W1S+`T*;F5T(&]F
M(&%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;BP@:6YC;'5D92!L96=A;"!C;W-T
M<R!I;F-U<G)E9"!F;W(@<&%T96YT(&%P<&QI8V%T:6]N<RX@/"]F;VYT/DEN
M(&%C8V]R9&%N8V4@=VET:"!!4T,@,S4P+"`\9F]N="!S='EL93TS1"=L971T
M97(M<W!A8VEN9SH@+3`N,35P="<^;VYC90T*82!P871E;G0@:7,@9W)A;G1E
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M+"`R,#$S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F($QO;F<M3&EV960@
M07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\=3Y);7!A:7)M
M96YT(&]F($QO;F<M3&EV960@07-S971S/"]U/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
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M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO
M<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;BUT;W`Z(#`[(&UA<F=I;BUB;W1T
M;VTZ(#`G/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX-"CQT
M9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%-Y;6)O
M;"<^)B,Q.#,[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GDG/G-I9VYI9FEC86YT#0H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(&1E8VQI;F5S(&EN(&%N(&%S<V5T)B,Q-#8[
M<R!M87)K970@<')I8V4[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6XG
M/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@4WEM8F]L)SXF(S$X,SL\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^<VEG;FEF:6-A;G0-"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@9&5T97)I
M;W)A=&EO;B!I;B!A;B!A<W-E="8C,30V.W,@<&AY<VEC86P@8V]N9&ET:6]N
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN)SX\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%-Y;6)O;"<^)B,Q.#,[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GDG/G-I9VYI9FEC86YT#0H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(&-H86YG97,@:6X@=&AE(&YA='5R
M92!O<B!E>'1E;G0@;V8@86X@87-S970F(S$T-CMS('5S92!O<B!O<&5R871I
M;VX[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`G/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@4WEM8F]L)SXF(S$X,SL\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>2<^<VEG;FEF:6-A;G0-"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@861V97)S92!C:&%N9V5S(&EN
M('1H92!B=7-I;F5S<R!C;&EM871E('1H870@8V]U;&0@:6UP86-T(&%N(&%S
M<V5T)B,Q-#8[<R!V86QU92P@:6YC;'5D:6YG#0H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(&%D=F5R<V4@86-T:6]N<R!O<B!A
M<W-E<W-M96YT<R!B>2!R96=U;&%T;W)S.R`\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3>6UB;VPG/B8C,3@S.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SYA8V-U
M;75L871I;VX-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@;V8@8V]S=',@<VEG;FEF:6-A;G1L>2!I;B!E>&-E<W,@;V8@;W)I
M9VEN86P@97AP96-T871I;VYS(')E;&%T960@=&\@=&AE(&%C<75I<VET:6]N
M#0H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(&]R
M(&-O;G-T<G5C=&EO;B!O9B!A;B!A<W-E=#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3>6UB;VPG/B8C,3@S.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SYC=7)R
M96YT+7!E<FEO9`T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("!O<&5R871I;F<@;W(@8V%S:"!F;&]W(&QO<W-E<R!C;VUB:6YE
M9"!W:71H(&$@:&ES=&]R>2!O9B!S=6-H(&QO<W-E<R!O<B!A(&9O<F5C87-T
M('1H870-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@9&5M;VYS=')A=&5S(&-O;G1I;G5I;F<@;&]S<V5S(&%S<V]C:6%T960@
M=VET:"!A;B!A<W-E="8C,30V.W,@=7-E.R!A;F0\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G
M=VED=&@Z(#`N,C5I;B<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I
M;B<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!3>6UB;VPG/B8C,3@S.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SYE
M>'!E8W1A=&EO;G,-"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@=&AA="!I="!I<R!M;W)E(&QI:V5L>2!T:&%N(&YO="!T:&%T
M(&%N(&%S<V5T('=I;&P@8F4@<V]L9"!O<B!O=&AE<G=I<V4@9&ES<&]S960@
M;V8@<VEG;FEF:6-A;G1L>0T*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("!B969O<F4@=&AE(&5N9"!O9B!I=',@<')E=FEO=7-L
M>2!E<W1I;6%T960@=7-E9G5L(&QI9F4N/"]T9#X\+W1R/CPO=&%B;&4^#0H-
M"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEF(&EM<&%I<FUE;G0@:6YD:6-A
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M;&]W<R!A<F4@;&%R9V5L>2!I;F1E<&5N9&5N=`T*;V8@=&AE(&-A<V@@9FQO
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M:7)M96YT(&-H87)G92!I;B!F=71U<F4@<&5R:6]D<RX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/D9A:7(@5F%L=64@;V8@1FEN86YC
M:6%L($EN<W1R=6UE;G1S/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M(&EN<W1R=6UE;G1S(&%N9"!A<F4@8V]N<VED97)E9`T*3&5V96P@,2!A<W-E
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M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
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M<W0@<')I;W)I='D@=&\@=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V96P@,RDN
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY!<W-E=',@86YD(&QI86)I;&ET:65S(')E8V]R9&5D
M(&EN('1H92!C;VYS;VQI9&%T960-"F)A;&%N8V4@<VAE970@870@9F%I<B!V
M86QU92!A<F4@8V%T96=O<FEZ960@8F%S960@;VX@82!H:65R87)C:'D@;V8@
M:6YP=71S+"!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!W:61T:#H@
M,3`P)3L@9F]N="US:7IE.B`Q,'!T.R!M87)G:6XM8F]T=&]M.B`P<'@G/@T*
M/'1R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('9E<G1I8V%L+6%L
M:6=N.B!T;W`G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S9P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@-31P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/DQE=F5L(#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/G5N861J=7-T960@<75O=&5D('!R:6-E<R!I;@T*("`@(&%C=&EV92!M87)K
M971S(&9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I;&ET:65S.SPO9F]N
M=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=F5R=&EC86PM86QI9VXZ('1O<"<^#0H@("`@/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!V97)T:6-A
M;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3&5V96P@,CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^<75O=&5D('!R:6-E<R!F;W(@<VEM:6QA<B!A<W-E
M=',-"B`@("!O<B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R:V5T<R!O<B!I
M;G!U=',@=&AA="!A<F4@;V)S97)V86)L92!F;W(@=&AE(&%S<V5T(&]R(&QI
M86)I;&ET>2P@96ET:&5R(&1I<F5C=&QY(&]R(&EN9&ER96-T;'D@=&AR;W5G
M:`T*("`@(&UA<FME="!C;W)R;V)O<F%T:6]N+"!F;W(@<W5B<W1A;G1I86QL
M>2!T:&4@9G5L;"!T97)M(&]F('1H92!F:6YA;F-I86P@:6YS=')U;65N=#L@
M86YD/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!V97)T:6-A;"UA;&EG;CH@=&]P)SX-"B`@("`\=&0^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('9E<G1I8V%L+6%L:6=N.B!T;W`G/@T*("`@(#QT9#X\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,979E;"`S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYU;F]B<V5R=F%B;&4@:6YP=71S(&9O
M<B!T:&4-"B`@("!A<W-E="!O<B!L:6%B:6QI='DN/"]F;VYT/CPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT
M.B`P+C5I;B<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&-E;G1E<B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%T($1E8V5M8F5R(#,Q+"`R,#$S+"`R
M,#$R+"!A;F0@,C`Q,2P@=V4@:&%D#0IN;R!A<W-E=',@;W(@;&EA8FEL:71I
M97,@=&AA="!W97)E('9A;'5E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R
M:6YG(&)A<VES+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M(&QE='1E<BUS<&%C:6YG.B`M,"XQ-7!T.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A8VEN9SH@,'!T)SX\=3Y);F-O
M;64-"E1A>&5S/"]U/CPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@;&5T=&5R+7-P86-I;F<Z("TP+C$U<'0[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQF;VYT('-T>6QE/3-$)VQE='1E<BUS<&%C:6YG.B`P<'0G/B8C,38P
M.SPO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
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M97(@-"P-"C(P,3$N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!A8V-O=6YT(&9O<B!I;F-O
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M="!B92!R96%L:7IE9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&%C8V]R9&%N8V4@=VET
M:"!!4T,@-S0P+"`\:3Y);F-O;64@5&%X97,\+VD^+`T*=V4@<F5C;V=N:7IE
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M97,@:6X@:G5D9VUE;G0@;V-C=7(N($%T($1E8V5M8F5R(#,Q+"`R,#$S+"`R
M,#$R+"!A;F0@,C`Q,2!W92!H860@;F\@=6YC97)T86EN(&EN8V]M92!T87@@
M<&]S:71I;VYS+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M870@=V5R92!C;VYS:61E<F5D('1O(&)E('5N8V5R=&%I;BX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D]U<B!T87@@<F5T=7)N<R!A<F4@<W5B:F5C="!T;R!R979I97<@8GD@
M=&AE#0I);G1E<FYA;"!2979E;G5E(%-E<G9I8V4@=&AR964@>65A<G,@869T
M97(@=&AE>2!A<F4@9FEL960N($-U<G)E;G1L>2P@>65A<G,@9FEL960@869T
M97(@,C`Q,"!A<F4@<W5B:F5C="!T;R!R979I97<N/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M0F%S
M960@0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M=3Y3:&%R92U"87-E9"!#;VUP96YS871I;VX\+W4^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;B!$96-E;6)E<B`R,#`T+"!T:&4@1D%30B!I<W-U960@05-#(#<Q."P-"CQI
M/D-O;7!E;G-A=&EO;B`F(S$U,#L@4W1O8VL@0V]M<&5N<V%T:6]N/"]I/BP\
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M92!";&%C:RU38VAO;&5S($UO9&5L+`T*86X@86-C97!T86)L92!M;V1E;"!I
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M=&5D(&QI9F4@;V8-"G1H92!A=V%R9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D5Q=6ET
M>2!I;G-T<G5M96YT<R`H)B,Q-#<[:6YS=')U;65N=',F(S$T.#LI#0II<W-U
M960@=&\@86YY;VYE(&]T:&5R('1H86X@96UP;&]Y965S(&%R92!R96-O<F1E
M9"!O;B!T:&4@8F%S:7,@;V8@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&EN<W1R
M=6UE;G1S+"!A<R!R97%U:7)E9"!B>2!!4T,@-S$X+B!!4T,-"C4P-2P@/&D^
M17%U:71Y($)A<V5D(%!A>6UE;G1S('1O($YO;BU%;7!L;WEE97,\+VD^+#QI
M/B`\+VD^;W(@05-#(#4P-3QI/BP@/"]I/F1E9FEN97,@=&AE(&UE87-U<F5M
M96YT(&1A=&4@86YD(')E8V]G;FET:6]N('!E<FEO9`T*9F]R('-U8V@@:6YS
M=')U;65N=',N($EN(&=E;F5R86PL('1H92!M96%S=7)E;65N="!D871E(&ES
M('=H96X@96ET:&5R("AA*2!A('!E<F9O<FUA;F-E(&-O;6UI=&UE;G0L(&%S
M(&1E9FEN960L(&ES(')E86-H960@;W(@*&(I#0IT:&4@96%R;&EE<B!O9B`H
M:2D@=&AE(&YO;BUE;7!L;WEE92!P97)F;W)M86YC92!I<R!C;VUP;&5T92!O
M<B`H:6DI('1H92!I;G-T<G5M96YT<R!A<F4@=F5S=&5D+B!4:&4@;65A<W5R
M960@=F%L=64@<F5L871E9"!T;R!T:&4-"FEN<W1R=6UE;G1S(&ES(')E8V]G
M;FEZ960@;W9E<B!A('!E<FEO9"!B87-E9"!O;B!T:&4@9F%C=',@86YD(&-I
M<F-U;7-T86YC97,@;V8@96%C:"!P87)T:6-U;&%R(&=R86YT(&%S(&1E9FEN
M960@:6X@05-#(#4P-2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(')E8V]G;FEZ92!T:&4@
M8V]M<&5N<V%T:6]N(&5X<&5N<V4@9F]R(&%L;`T*<VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&=R86YT960@8F%S960@;VX@=&AE(&=R86YT(&1A=&4@9F%I
M<B!V86QU92!E<W1I;6%T960@:6X@86-C;W)D86YC92!W:71H($%30R`W,3@N
M(%=E(&=E;F5R86QL>2!R96-O9VYI>F4-"G1H92!C;VUP96YS871I;VX@97AP
M96YS92!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4@96UP;&]Y
M964F(S$T-CMS(')E<75I<VET92!S97)V:6-E('!E<FEO9"X\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T
M($1I<V-O=6YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/'4^1&5B
M="!$:7-C;W5N=',\+W4^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#;W-T<R!I;F-U<G)E9"!F
M<F]M('!A<G1I97,@=&AA="!A<F4@<')O=FED:6YG#0IL;VYG+71E<FT@9FEN
M86YC:6YG+"!W:&EC:"!I;F-L=61E('=A<G)A;G1S(&ES<W5E9"!I;B!C;VYN
M96-T:6]N('=I=&@@=&AE('5N9&5R;'EI;F<@9&5B="P@87)E(')E9FQE8W1E
M9"!A<R!A(&1E8G0@9&ES8V]U;G0@8F%S960-"F]N('1H92!R96QA=&EV92!F
M86ER('9A;'5E(&]F('1H92!D96)T(&%N9"!W87)R86YT<R!T;R!T:&4@=&]T
M86P@<')O8V5E9',N(%=E(&=E;F5R86QL>2!A;6]R=&EZ92!D:7-C;W5N=',@
M;W9E<B!T:&4@;&EF92!O9B!T:&4-"G)E;&%T960@9&5B="!U<VEN9R!T:&4@
M969F96-T:79E(&EN=&5R97-T(')A=&4@;65T:&]D+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@
M4F5C;V=N:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQU/E)E=F5N=64@4F5C;V=N:71I;VX\+W4^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!R96-O
M9VYI>F4@<F5V96YU92!O;B!A<G)A;F=E;65N=',@:6X@86-C;W)D86YC90T*
M=VET:"!!4T,@-C`U+"`\:3Y2979E;G5E(%)E8V]G;FET:6]N/"]I/BX@5V4@
M<F5C;V=N:7IE(')E=F5N=64@;VYL>2!W:&5N('1H92!P<FEC92!I<R!F:7AE
M9"!O<B!D971E<FUI;F%B;&4L('!E<G-U87-I=F4@979I9&5N8V4-"F]F(&%N
M(&%R<F%N9V5M96YT(&5X:7-T<RP@=&AE('-E<G9I8V4@:7,@<&5R9F]R;65D
M+"!A;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&D^/'4^3W9E<BUT:&4M0V]U;G1E<B!0<F]D=6-T<SPO
M=3X\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQI/B8C,38P.SPO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
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M<G-H:7`@86YD(')I<VL@;V8-"FQO<W,@:&%V92!P87-S960@=&\@=&AE(&-O
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M;VYT('-T>6QE/3-$)V-O;&]R.B`C,C4R-3(U)SY790T*<')O=FED92!A;B!U
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M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\:3X\=3Y0<F5S8W)I<'1I;VX@4')O9'5C=',\+W4^
M/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G8V]L;W(Z(",R-3(U
M,C4G/E=E('-E;&P@;W5R(&YA;64-"F)R86YD(&%N9"!G96YE<FEC('!R97-C
M<FEP=&EO;B!P<F]D=6-T<R`\+V9O;G0^<')I;6%R:6QY('1H<F]U9V@@9')U
M9R!W:&]L97-A;&5R<R!A;F0@<F5T86EL('!H87)M86-I97,N(%=E(')E8V]G
M;FEZ92!R979E;G5E(&9R;VT-"G!R97-C<FEP=&EO;B!P<F]D=6-T('-A;&5S
M+"!N970@;V8@<V%L97,@9&ES8V]U;G1S+"!C:&%R9V5B86-K<RP@86YD(')E
M8F%T97,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M<F5N=&QY(&-A;FYO=`T*<F5L:6%B;'D@97-T:6UA=&4@97AP96-T960@<F5T
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M<F5T=7)N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5V4@;6%I;G1A:6X@=F%R:6]U<R!R96)A
M=&4@<')O9W)A;7,@:6X@86X-"F5F9F]R="!T;R!M86EN=&%I;CQI/B`\+VD^
M82!C;VUP971I=&EV92!P;W-I=&EO;B!I;B!T:&4@;6%R:V5T<&QA8V4@86YD
M('1O('!R;VUO=&4@<V%L97,@86YD(&-U<W1O;65R(&QO>6%L='DN(%1H92!C
M;VYS=6UE<B!R96)A=&4-"G!R;V=R86T@:7,@9&5S:6=N960@=&\@96YA8FQE
M('1H92!E;F0@=7-E<B!T;R!R971U<FX@82!C;W5P;VX@=&\@=7,N($EF('1H
M92!C;W5P;VX@<75A;&EF:65S+"!W92!S96YD(&$@<F5B871E(&-H96-K('1O
M('1H92!E;F0-"G5S97(N(%=E(&5S=&EM871E('1H92!A;&QO=V%N8V4@9F]R
M(&-O;G-U;65R(')E8F%T97,@8F%S960@;VX@;W5R(&5X<&5R:65N8V4@86YD
M(&EN9'5S=')Y(&%V97)A9V5S+"!W:&EC:"!I<R!R979I97=E9"P@86YD(&%D
M:G5S=&5D#0II9B!N96-E<W-A<GDL(&]N(&$@<75A<G1E<FQY(&)A<VES+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H:7!P:6YG(&%N9"!(86YD;&EN9R!#;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/'4^4VAI<'!I;F<@86YD($AA;F1L:6YG($-O<W1S
M/"]U/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F5R
M=&ES:6YG($-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=L971T97(M<W!A
M8VEN9SH@+3`N,35P="<^/'4^061V97)T:7-I;F<@0V]S=',\+W4^/"]F;VYT
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=L
M971T97(M<W!A8VEN9SH@+3`N,35P="<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY792!E
M>'!E;G-E(&%D=F5R=&ES:6YG(&-O<W1S('=H96X@:6YC=7)R960N#0I!9'9E
M<G1I<VEN9R!C;W-T<R!W97)E("0Q,2PW,SDL("0V-2PY-#0@86YD("0Q.2PT
M.#`@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@
M1&5C96UB97(@,S$L(#(P,3$@86YD($1E8V5M8F5R(#,Q+`T*,C`Q,BP@<F5S
M<&5C=&EV96QY+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^/'4^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V5S/"]U/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T
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M<FEE<RP@8F5N969I=',L(&%N9"!N;VXM8V%S:"!S:&%R92UB87-E9`T*8V]M
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M92!P87EM96YT<R!T;R!B92!E>'!E;G-E9`T*:6X@9G5T=7)E(%(F(S,X.T0@
M86-T:79I=&EE<R!W97)E("0R+#`Y,2PX,#D@86YD("0Q.#DL,S<U(&9O<B!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@1&5C96UB97(@,S$L
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M(&MN;W=N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%87)N:6YG<R!097(@4VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQU/D5A<FYI;F=S(%!E<B!3:&%R
M93PO=3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&-A;&-U;&%T92!E87)N:6YG<R!P97(@
M<VAA<F4L(&]R($504RP@:6X-"F%C8V]R9&%N8V4@=VET:"!!4T,@,C8P+"`\
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M;V-K(&9O<B`R,#$S+"`R,#$R+"!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+"!W
M97)E(&5X8VQU9&5D(&9R;VT@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@
M96%R;FEN9W,@<&5R('-H87)E(&9O<B!T:&5S90T*<&5R:6]D<R!B96-A=7-E
M('1H96ER(&5F9F5C="!W;W5L9"!H879E(&)E96X@86YT:2UD:6QU=&EV92!D
M=64@=&\@=&AE(&YE="!L;W-S(')E<&]R=&5D(&)Y('5S+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y5<V4@;V8@17-T:6UA=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T97(M<W!A8VEN9SH@
M+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&YO<FUA;"<^/'4^57-E#0IO9B!%<W1I;6%T97,\+W4^
M/"]F;VYT/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!L971T97(M<W!A
M8VEN9SH@+3`N,35P=#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;"<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/
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M8V]N9&ET:6]N<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y296-E;G1L>2!)<W-U960@86YD($YE=VQY($%D
M;W!T960@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/'4^4F5C
M96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W4^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*=6QY+"`R
M,#$S+"!T:&4@1D%30B!I<W-U960-"D%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P
M9&%T92P@;W(@05-5+"!.;RX@,C`Q,RTQ,2P@/&D^26YC;VUE(%1A>&5S("A4
M;W!I8R`W-#`I.B!0<F5S96YT871I;VX@;V8@86X@56YR96-O9VYI>F5D(%1A
M>"!"96YE9FET('=H96X-"F$@3F5T($]P97)A=&EN9R!,;W-S($-A<G)Y9F]R
M=V%R9"P@82!3:6UI;&%R(%1A>"!,;W-S+"!O<B!A(%1A>"!#<F5D:70@0V%R
M<GEF;W)W87)D($5X:7-T<R`H82!C;VYS96YS=7,@;V8@=&AE($9!4T(@16UE
M<F=I;F<@27-S=65S#0I487-K($9O<F-E*3PO:3XL/&D^(#PO:3YO<B!!4U4@
M,C`Q,RTQ,2X@5&AE(&%M96YD;65N=',@:6X@05-5(#(P,3,M,3$@<')O=FED
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M05-5($YO+B`R,#$S+3$Q(&1O(&YO="!R97%U:7)E(&YE=PT*<F5C=7)R:6YG
M(&1I<V-L;W-U<F5S+B!4:&4@86UE;F1M96YT<R!I;B!!4U4@,C`Q,RTQ,2!A
M<F4@969F96-T:79E(&9O<B!F:7-C86P@>65A<G,L(&%N9"!I;G1E<FEM('!E
M<FEO9',@=VET:&EN('1H;W-E('EE87)S+"!B96=I;FYI;F<-"F%F=&5R($1E
M8V5M8F5R(#$U+"`R,#$S+B!4:&4@86UE;F1M96YT<R!I;B!!4U4@3F\N(#(P
M,3,M,3$@87)E(&YO="!E>'!E8W1E9"!T;R!H879E(&$@;6%T97)I86P@:6UP
M86-T(&]N(&]U<B!C;VYS;VQI9&%T960@9FEN86YC:6%L#0IS=&%T96UE;G1S
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^26X@2G5L>2`R,#$R+"!T:&4@1D%30B!I<W-U960@
M05-5($YO+B`R,#$R+3`R+`T*/&D^5&5S=&EN9R!);F1E9FEN:71E+4QI=F5D
M($EN=&%N9VEB;&4@07-S971S(&9O<B!);7!A:7)M96YT/"]I/BP\:3X@/"]I
M/F]R($%352`R,#$R+3`R+B!!4U4@,C`Q,BTP,B!G:79E<R!E;G1I=&EE<R!A
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M=`T*:7,@;6]R92!L:6ME;'D@=&AA;B!N;W0@=&AA="!T:&4@9F%I<B!V86QU
M92!O9B!A;B!I;F1E9FEN:71E(&QI=F5D(&EN=&%N9VEB;&4@87-S970@:7,@
M;&5S<R!T:&%N(&ET<R!C87)R>6EN9R!A;6]U;G0L('%U86YT:71A=&EV90T*
M:6UP86ER;65N="!T97-T:6YG(&ES(')E<75I<F5D+B!(;W=E=F5R+"!I9B!A
M;B!E;G1I='D@8V]N8VQU9&5S(&]T:&5R=VES92P@<75A;G1I=&%T:79E(&EM
M<&%I<FUE;G0@=&5S=&EN9R!I<R!N;W0@<F5Q=6ER960N($%350T*,C`Q,BTP
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M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY)
M;B!$96-E;6)E<B`R,#$Q+"!T:&4@1D%30B!I<W-U960@05-5($YO+B`R,#$Q
M+3$Q+`T*/&D^0F%L86YC92!3:&5E="`H5&]P:6,@,C$P*3H@1&ES8VQO<W5R
M97,@86)O=70@3V9F<V5T=&EN9R!!<W-E=',@86YD($QI86)I;&ET:65S/"]I
M/BP@;W(@05-5(#(P,3$M,3$\:3XN/"]I/B!!4U4@,C`Q,2TQ,2!E;FAA;F-E
M<PT*8W5R<F5N="!D:7-C;&]S=7)E<R!A8F]U="!F:6YA;F-I86P@:6YS=')U
M;65N=',@86YD(&1E<FEV871I=F4@:6YS=')U;65N=',@=&AA="!A<F4@96ET
M:&5R(&]F9G-E="!O;B!T:&4@<W1A=&5M96YT(&]F(&9I;F%N8VEA;`T*<&]S
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M;F1A<F1S+B!!4U4@,C`Q,2TQ,2!I<R!E9F9E8W1I=F4@9F]R(&%N;G5A;"!R
M97!O<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@;VX-"F]R(&%F=&5R($IA;G5A
M<GD@,2P@,C`Q,RP@86YD(&EN=&5R:6T@<&5R:6]D<R!W:71H:6X@=&AO<V4@
M>65A<G,N($%352`R,#$Q+3$Q(&ES(&YO="!E>'!E8W1E9"!T;R!H879E(&$@
M;6%T97)I86P@:6UP86-T(&]N(&]U<@T*9FEN86YC:6%L('!O<VET:6]N(&]R
M(')E<W5L=',@;V8@;W!E<F%T:6]N<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E=E(&1O(&YO
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8VQA<W-I9FEC871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\=3Y296-L87-S:69I8V%T:6]N<SPO=3X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/D-E<G1A:6X@,C`Q,B!A;6]U;G1S
M(&AA=F4@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;0T*=&\@8W5R<F5N
M="!Y96%R('!R97-E;G1A=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?
M-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T,C0N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/
M4ED@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);G9E;G1O<GD@8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN9SH\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W`^#0H-"CQT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I
M9'1H.B`Y,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ
M93H@,3!P=#L@;6%R9VEN+6QE9G0Z(#,V<'0G/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M
M;&5F=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\
M9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1&5C96UB97(-"B`@("`S,2P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR
M,#$S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!W:61T:#H@-C(E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^1FEN:7-H960-"B`@("!P<F]D=6-T/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!W:61T:#H@,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M
M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C(Q+#8W
M.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ
M+#$R-"PW,SD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^4F%W#0H@("`@;6%T97)I86P\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C4P+#DT,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,X,"PP,#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SX\9F]N="!S='EL
M93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^1&5F97)R960-"B`@("!C;W-T<SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL
M93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B!N
M;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3<P
M+#DY-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F
M;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,3`L-#<Q/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E1/5$%,#0H@("`@24Y614Y43U)9/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ+#`T,RPV,3@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S
M='EL93TS1"=F;VYT.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@;F]R;6%L(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(&YO<FUA;"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#8Q-2PR,3`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT
M.B!N;W)M86P@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R
M,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O
M<FMS:&5E=',O4VAE970R-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D]42$52($-54E)%3E0@05-31513("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]T:&5R($%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&]T:&5R(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/=&AE<B!C=7)R96YT(&%S
M<V5T<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-
M"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z(#,V<'0[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60G/D1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N
M=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA
M8VL@,7!T('-O;&ED)SXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60G/C(P,3(\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V,"4[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY0<F5P86ED(%(F(S,X.T0@8V]S=',\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SXQ+#(V
M-RPU.#@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X
M="UA;&EG;CH@<FEG:'0G/C$X.2PS-S4\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ
M,'!T)SY0<F5P86ED(&-O;G-U;'1I;F<\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3,P+#4Y-CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXT,S(L,C$V/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D
M:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^1&5F97)R960@
M9FEN86YC:6YG(&-O<W1S/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(V,"PP,C(\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
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M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D
M:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^3W1H97(@<F5C
M96EV86)L92`F(S$U,#L@<F5L871E9"!P87)T>3PO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR-#DL.3@Q
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C.30W,CL\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M
M:6YD96YT.B`M,3!P="<^4')E<&%I9"!O=&AE<CPO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ-CDL-3(X
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C$R-RPT,#,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O
M='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M
M,3!P="<^4')E<&%I9"!G=6%R86YT>2!C;W-T<SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
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M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/C(L.30T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('!A
M9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY43U1!3"!/
M5$A%4B!#55)214Y4($%34T544SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
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M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
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M4V5R:68[(&UA<F=I;CH@,"<^)B,Q-C`[)B,Q-C`[/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T
M,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7
M;W)K<VAE971S+U-H965T,C8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY&25A%1"!!4U-%5%,@*%1A8FQE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@
M9FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&:7AE
M9"!A<W-E=',@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M('-T>6QE/3-$)VUA<F=I;BUL969T.B`S-G!T.R!B;W)D97(M8V]L;&%P<V4Z
M(&-O;&QA<'-E.R!W:61T:#H@.3`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED)SY$96-E;6)E<B`S,2P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ
M($)L86-K(#%P="!S;VQI9"<^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$R/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-C`E.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^17%U:7!M96YT/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H="<^,3`X+#0U.#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R
M:6=H="<^-C<L-C8X/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P
M861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^1G5R;FET
M=7)E(&%N9"!F:7AT=7)E<SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT-BPV,C4\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-#8L-C(U
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O
M;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P
M="<^3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Y-#<R.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C$Q+#DX,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ
M,'!T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^,34U+#`X,SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,C8L,C<S/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@
M,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^
M06-C=6UU;&%T960@9&5P<F5C:6%T:6]N/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH.3,L-S8U
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA
M;&EG;CH@;&5F="<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#8P+#8P,#PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G
M/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[
M('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY43U1!
M3"!&25A%1"!!4U-%5%,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C8Q+#,Q.#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G
M/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXV-2PV-S,\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[)B,Q-C`[/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V
M8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P
M93=A-3DW-&5D.2]7;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY04D5004E$($584$5.4T4@*%1A
M8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E+"!#=7)R96YT(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F('!R97!A:60@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^4')E<&%I9"!E>'!E;G-E(&-O;G-I<W1S(&]F('1H92!F;VQL
M;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$
M,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#,V<'0[
M(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/D1E8V5M8F5R(#,Q+#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL
M969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$S/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3(\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`V,"4[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A
M9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY0<F5P86ED
M(%(@)B,S.#L@1"!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@
M=&5X="UA;&EG;CH@<FEG:'0G/C@R-"PR,C$\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0G/CDU,RPV-34\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY0<F5P86ED(&UA;G5F86-T=7)I
M;F<@8V]S=',\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^.#DY+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(SDT-S([/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/D%C8W)E=&5D('!R97!A:60@8V]S=',\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0G/C(W+#(S-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
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M;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('!A
M9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY43U1!3"!0
M4D5004E$($584$5.4T4\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-S4P+#0U-3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0G/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXY-3,L-C4U/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/B8C,38P.R8C
M,38P.SPO8CX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T
M,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970R."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.5$%.1TE"
M3$4@05-31513("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D=O;V1W:6QL(&%N9"!);G1A;F=I8FQE
M($%S<V5T<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&EN=&%N
M9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET92<^5&AE(&9O;&QO=VEN9R!T86)L92!S971S(&9O<G1H
M#0IT:&4@9W)O<W,@8V%R<GEI;F<@86UO=6YT(&%N9"!A8V-U;75L871E9"!A
M;6]R=&EZ871I;VX@;V8@;W5R(&EN=&%N9VEB;&4@87-S971S(&%S(&]F)B,Q
M-C`[1&5C96UB97(F(S$V,#LS,2P@,C`Q,R8C,38P.V%N9"8C,38P.T1E8V5M
M8F5R)B,Q-C`[,S$L#0HR,#$R.B8C,38P.SPO9F]N=#X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^)B,Q-C`[/"]F;VYT/CPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G=VED=&@Z(#DP)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE.B`Q,'!T.R!M
M87)G:6XM;&5F=#H@,S9P="<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,30@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R
M)B,Q-C`[,S$L#0H@("`@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D=R;W-S/&)R("\^0V%R<GEI;F<\8G(@+SY!;6]U;G0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^06-C=6UU;&%T
M960\8G(@+SY!;6]R=&EZ871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^3F5T/&)R("\^06UO=6YT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E
M:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D+3QB<B`O/D%V97)A
M9V4\8G(@+SY!;6]R=&EZ871I;VX\8G(@+SY097)I;V0F(S$V,#LH>7)S+BD\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY!;6]R=&EZ
M:6YG(&EN=&%N9VEB;&4@87-S971S.CPO8CX\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O
M;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@
M8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@-#`E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]0
M15)!)B,Q-S0[('-O9G1W87)E('!A=&5N=#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C,Q+#DU,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#0Y
M.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C,Q+#0U,CPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$Q)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXQ-2XX/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ
M,G!T.R!P861D:6YG+6QE9G0Z(#$R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5V96QO
M<&UE;G0-"B`@("!C;W-T<R!F;W(@8V]R<&]R871E('=E8G-I=&4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.3$L-S0S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B@X.2PV-C$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L,#@R/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C`N,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M,3)P=#L@<&%D9&EN9RUL969T.B`Q,G!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z("TQ,G!T.R!P861D:6YG+6QE9G0Z(#$R<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^/&(^3F]N+6%M;W)T:7II;F<-"B`@("!I;G1A;F=I8FQE(&%S<V5T
M<SH\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3)P=#L@<&%D9&EN9RUL969T.B`Q
M,G!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,G!T.R!T97AT+6EN
M9&5N=#H@+3$R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^2&]R;6]N90T*("`@('1H97)A
M<'D@9')U9R!C86YD:61A=&4@<&%T96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT
M9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXU-S(L-S(V/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU-S(L-S(V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/FXO83PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M:6YD96YT.B`M,3)P=#L@<&%D9&EN9RUL969T.B`Q,G!T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/DUU;'1I<&QE#0H@("`@=')A9&5M87)K<R!F;W(@=FET
M86UI;G,O<W5P<&QE;65N=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4Y+#,R.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU.2PS,C@\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^;B]A/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@=&5X="UI;F1E;G0Z("TQ,G!T.R!P861D:6YG+6QE9G0Z(#(T<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C<U-2PW-#@\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#DP+#$V,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C8U+#4X.#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=W:61T:#H@.3`E.R!B
M;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4Z(#$P<'0[(&UA
M<F=I;BUL969T.B`S-G!T)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ
M,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,30@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M
M8F5R)B,Q-C`[,S$L#0H@("`@,C`Q,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L
M9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY'<F]S<SQB<B`O/D-A<G)Y:6YG/&)R("\^06UO
M=6YT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%C
M8W5M=6QA=&5D/&)R("\^06UO<G1I>F%T:6]N/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT
M.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYE=#QB<B`O/D%M;W5N=#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"T\8G(@
M+SY!=F5R86=E/&)R("\^06UO<G1I>F%T:6]N/&)R("\^4&5R:6]D)B,Q-C`[
M*'ER<RXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q
M,'!T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!;6]R=&EZ
M:6YG#0H@("`@:6YT86YG:6)L92!A<W-E=',Z/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B
M;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UW96EG:'0Z(&)O
M;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,3!P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7=E:6=H=#H@8F]L9"<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7=E:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7=E
M:6=H=#H@8F]L9"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UW96EG:'0Z(&)O;&0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!W:61T
M:#H@-#`E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]015)!#0H@("`@)B,Q-S0[('-O9G1W
M87)E('!A=&5N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(S
M+#<R,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,24G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`R)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C,L-S(R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F
M=#H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$979E;&]P;65N=`T*("`@(&-O<W1S
M(&9O<B!C;W)P;W)A=&4@=V5B<VET93PO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXY,2PW-#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#<W
M+#$U.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,30L-3@T/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$N
M,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U
M*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN
M9RUL969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T
M.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/DYO;BUA;6]R=&EZ:6YG#0H@("`@:6YT86YG:6)L92!A<W-E
M=',Z/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE
M9G0Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^2&]R;6]N90T*("`@('1H97)A<'D@
M9')U9R!C86YD:61A=&4@<&%T96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT9#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXQ.#`L,3DT/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,34Q.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.#`L,3DT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/FXO83PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL
M969T.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DUU;'1I<&QE#0H@("`@=')A9&5M
M87)K<R!F;W(@=FET86UI;G,O<W5P<&QE;65N=',\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Q+#`U-3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-3$[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,2PP-34\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^;B]A/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TQ
M,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C,Q-BPW,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*#<W+#$U.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C,Y+#4U-3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M8VAE9'5L92!O9B!E<W1I;6%T960@86UO<G1I>F%T:6]N(&5X<&5N<V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`G/CQF;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SY%
M<W1I;6%T960@86UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R('1H92!N97AT#0IF
M:79E('EE87)S(&ES(&%S(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/CPO<#X-"@T*/'1A8FQE(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G;6%R9VEN
M+6QE9G0Z(#,V<'0[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H
M.B`X,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@=&5X="UA;&EG
M;CH@;&5F="<^665A<B!%;F1I;F<@1&5C96UB97(@,S$L/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT
M+6%L:6=N.B!C96YT97(G/D5S=&EM871E9"!!;6]R=&EZ871I;VX\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9"<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@.#`E.R!T97AT+6%L:6=N.B!L969T)SXR,#$T/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,34E.R!T97AT+6%L:6=N.B!R:6=H="<^-"PP
M.#`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET92<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/C(P,34\+W1D/CQT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M,2PY.3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/C(P,38\+W1D/CQT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^,2PY.3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXR,#$W/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$L.3DW
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXR,#$X/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$L
M.3DW/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF
M(S$V,#LF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E
M9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E
M9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970R.2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]42$52
M($-54E)%3E0@3$E!0DE,251)15,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]N8V]N=')O;&QI
M;F<@26YT97)E<W0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@;W1H97(@8W5R<F5N
M="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3W1H
M97(@8W5R<F5N="!L:6%B:6QI=&EE<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I
M;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C
M96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z(#,V<'0[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#8@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/D1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T
M.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$S/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3(\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`V,"4[('1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I
M;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY!8V-R=65D('!A
M>7)O;&P@86YD(&-O;6UI<W-I;VX@8V]S=',\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SXY-#$L,S$S/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT
M)SXS.3<L,C$P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D
M:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^06-C<G5E9"!F
M:6YA;F-I;F<@8V]S=',\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.#4P+#`P,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(SDT-S([/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G
M/D%C8W)U960@=F%C871I;VX\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,C4V+#DR,#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,30L
M.#DY/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@+3$P<'0G/D%L;&]W86YC92!F;W(@=VAO;&5S86QE(&1I
M<W1R:6)U=&]R(&9E97,\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S`V+#,P,SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ,#<L-S@T
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE9G0Z
M(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^06-C<G5E9"!L96=A;"!A;F0@
M86-C;W5N=&EN9R!E>'!E;G-E/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C(R-"PU-3`\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.3`L
M,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUL969T.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@+3$P<'0G/D%C8W)U960@;&%B(')E<V5A<F-H/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C4S-BPU-S0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
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M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY!8V-R=65D(&-L:6YI8V%L('1R
M:6%L(&-O<W1S/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C$R.2PR,#@\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)B,Y-#<R.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6QE
M9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^06QL;W=A;F-E(&9O<B!C
M;W5P;VYS(&%N9"!R971U<FYS/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$R-BPR,S,\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-3,L
M,#`R/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O
M='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M
M,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3W1H97(@86-C<G5E9"!E>'!E;G-E<SQS=7`^
M*#$I/"]S=7`^/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,C,P+#`X.#PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^-S`L-S4Y/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q
M-C`[5$]404P@3U1(15(@0U524D5.5"!,24%"24Q)5$E%4SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U
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M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O
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M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XR-6EN.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"`P(#`@,"XR-6EN.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^
M#0H-"CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@;6%R9VEN+6QE
M9G0Z(#,V<'0[(&UA<F=I;BUT;W`Z(#-P=#L@;6%R9VEN+6)O='1O;3H@,W!T
M)SX\9&EV('-T>6QE/3-$)V9O;G0M<VEZ93H@,7!T.R!B;W)D97(M=&]P.B!"
M;&%C:R`Q<'0@<V]L:60[('=I9'1H.B`R-24G/B8C,38P.SPO9&EV/CPO9&EV
M/@T*#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,S9P=#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/'-U<#XH,2D@/"]S=7`^26X@2G5N92`R,#`X+"!W92!D
M96-L87)E9"!A;F0@<&%I9"!A('-P96-I86P-"F1I=FED96YD(&]F("0P+C0P
M('!E<B!S:&%R92!O9B!O=7(@0V]M;6]N(%-T;V-K('1O(&%L;"!S:&%R96AO
M;&1E<G,@;V8@<F5C;W)D(&%S(&]F($IU;F4@,3`L(#(P,#@L(&]F('=H:6-H
M("0T,2PS-3D@<F5M86EN960@=6YC;&%I;65D#0IB>2!C97)T86EN('-H87)E
M:&]L9&5R<R!A="!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,"`P(#`@,"XR-6EN)SXF(S$V,#L\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V
M8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U
M.3<T960Y+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15=!04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D@
M*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('=A<G)A
M;G0@86-T:79I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CQI/CQU/E-U;6UA<GD@;V8@;W5R(%=A<G)A
M;G0@86-T:79I='D@86YD(')E;&%T960@:6YF;W)M871I;VX@9F]R#0HR,#$Q
M+3(P,3,\+W4^/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V
M,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P
M<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4Z(#$P<'0G/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I
M;F<M;&5F=#H@,3!P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E<B!O9B!3:&%R97,@56YD
M97(@5V%R<F%N=',\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<B<^5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R)SY796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!,:69E(&EN(%EE87)S/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/D%G9W)E9V%T92!)
M;G1R:6YS:6,@5F%L=64\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY"86QA;F-E(&%T($1E8V5M
M8F5R(#,Q+"`R,#$P/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C.30W,CL\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P=#L@
M=VED=&@Z(#0P)2<^27-S=65D/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#(E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E)SXS+#`U-RPV
M,C<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`R)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24G/C`N,S8\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@=VED=&@Z(#$Q)2<^-RXY/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,3$E)SXS+#0X,RPV.3$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR
M-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/D5X
M97)C:7-E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(SDT-S([/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/D5X<&ER
M960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S
M."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UI;F1E;G0Z("TQ,'!T
M.R!P861D:6YG+6QE9G0Z(#(R<'0G/D-A;F-E;&QE9#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D
M9&EN9RUL969T.B`Q,'!T)SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$Q
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/C,L,#4W+#8R-SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^,"XS-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXW+CD\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/C,L-#@S+#8Y,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/DES<W5E9#PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXQ-RPS,S(L-3`P/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXQ+C(V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0N,SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,S$L.#DQ+#$U,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@
M<&%D9&EN9RUL969T.B`R,G!T)SY%>&5R8VES960\+W1D/@T*("`@(#QT9#XF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^*#@L,30U+#0X-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/BD\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C`N,S@\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P
M861D:6YG+6QE9G0Z(#(R<'0G/D5X<&ER960\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Y-#<R.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`R,G!T)SY#86YC96QL960\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@U,2PQ-#(\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T)SXI/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXP+C(T/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY"86QA;F-E(&%T($1E8V5M
M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$R+#$Y,RPT.3D\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C$N-C,\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ-RPY-S$L.3DT/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/DES<W5E
M9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR+#$P,"PP,#`\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C(N-S(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-"XX/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXU+#(S,BPU,#`\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`R,G!T)SY%>&5R8VES960\
M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`R,G!T)SY%>'!I<F5D/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C.30W,CL\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN
M9RUL969T.B`R,G!T)SY#86YC96QL960\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0G/B8C.30W,CL\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M:6YD
M96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY"86QA;F-E(&%T($1E
M8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0G/C$T+#(Y,RPT.3D\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXQ
M+C<Y/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXS+CD\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXT."PY,S(L-S<W/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TQ,'!T
M.R!P861D:6YG+6QE9G0Z(#$P<'0G/E9E<W1E9"!A;F0@17AE<F-I<V%B;&4@
M870@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^,3,L-S8T+#<Q,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C$N.#$\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C,N
M.3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0V+#@T,"PU-3D\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('=E:6=H=&5D
M(&%V97)A9V4@9F%I<B!V86QU92!P97(@<VAA<F4@86YD(&%S<W5M<'1I;VYS
M('5S960@:6X@=&AE($)L86-K+5-C:&]L97,@36]D96P@;V8@=V%R86YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE('=E:6=H=&5D(&%V97)A
M9V4@9F%I<B!V86QU92!P97(@<VAA<F4@;V8-"G=A<G)A;G1S(&ES<W5E9"!A
M;F0@=&AE(&%S<W5M<'1I;VYS('5S960@:6X@=&AE($)L86-K+5-C:&]L97,@
M36]D96P@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,RP@,C`Q,B!A;F0@,C`Q,2!A<F4-"G-E="!F;W)T:"!I;B!T:&4@=&%B;&4@
M8F5L;W<N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=VED
M=&@Z(#DP)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE
M.B`Q,'!T)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D
M:6YG+6QE9G0Z(#$P<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXR,#$S/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/C(P,3(\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<B<^,C`Q,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('=I9'1H.B`T.24G/E=E:6=H
M=&5D(&%V97)A9V4@9F%I<B!V86QU93PO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`R)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,R4G/C(N.#,\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Q,R4G/C(N,#4\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,R4G/C`N,38\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T
M)SY2:7-K+69R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+7-I>F4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N.#@M,2XQ,CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,"XW,BTQ+C`T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="US:7IE.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+CDQ+3,N-#@\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P
M<'0G/E9O;&%T:6QI='D\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE
M.B`Q,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXT-"XR.2TT-2XX.3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#0N
M-C0M-#0N.#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z
M(#$P<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C,Y+C$S+34Q+C@S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@
M,3!P="<^5&5R;2`H:6X@>65A<G,I/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2TV/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXU/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2TQ,#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P
M-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P
M=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY$:79I9&5N9"!Y:65L9#PO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXP+C`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C`P/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXP+C`P/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/"]T<CX-"CPO=&%B;&4^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!A<W-U;7!T:6]N<R!U<V5D(&EN('1H92!";&%C:RU38VAO;&5S
M($UO9&5L(&]F('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/E1H92!A<W-U;7!T:6]N<PT*=7-E9"!I;B!T:&4@0FQA8VLM4V-H
M;VQE<R!-;V1E;"!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$S(&%R92!S970@9F]R=&@@:6X@=&AE('1A8FQE(&)E;&]W+CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3,\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$Q/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^4FES:RUF<F5E(&EN=&5R97-T(')A
M=&4\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XV-2TQ+C<Q/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,"XV,2TR+C(S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XY,2TR
M+C4T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^
M5F]L871I;&ET>3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,RXS-2TT-2XW-CPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C0P+C<W+30V+C`Q/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,S<N.3(M-#`N-#@\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T
M+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E1E
M<FT@*&EN('EE87)S*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+38N,C4\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4M-BXR-3PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-2XU+38N,C4\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0V)3L@=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P
M<'0G/D1I=FED96YD('EI96QD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXP+C`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT)SXP+C`P
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M)SXE/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI
M9VXZ(')I9VAT)SXP+C`P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T
M97AT+6%L:6=N.B!L969T)SXE/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y38VAE9'5L92!O9B!/<'1I;VX@86-T:79I='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/D$@<W5M;6%R
M>2!O9B!A8W1I=FET>2!U;F1E<B!T:&4@,C`P.2!A;F0@,C`Q,B!0;&%N<R!A
M;F0@<F5L871E9`T*:6YF;W)M871I;VX@9F]R(#(P,3$M,C`Q,R!F;VQL;W=S
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4Z(#$P<'0G/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A
M9&1I;F<M;&5F=#H@,3!P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/DYU;6)E<B!O9B!3:&%R97,@
M56YD97(@3W!T:6]N<SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R)SY796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97(G/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L($QI9F4@:6X@665A<G,\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^06=G<F5G871E
M($EN=')I;G-I8R!686QU93PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY"
M86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$P/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/B8C.30W,CL\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I
M;F<M;&5F=#H@,C)P=#L@=VED=&@Z(#0P)2<^1W)A;G1E9#QS=7`^*#$I/"]S
M=7`^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3$E)SXQ,"PV.#(L,C$X/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)2<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!W:61T:#H@,3$E)SXP+C$V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,B4G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I
M9'1H.B`Q,24G/C<N-CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#(E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24G/B0\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$Q)2<^,30L
M,3@X+#0X-#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N
M=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P="<^17AE<F-I<V5D/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B@Y,BPP-3<\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXP+C$Y/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I
M;F<M;&5F=#H@,C)P="<^17AP:7)E9#PO=&0^#0H@("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF
M(SDT-S([/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P="<^0V%N
M8V5L;&5D/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXF(SDT-S([/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/D)A;&%N8V4@
M870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,3`L
M-3DP+#$V,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,"XQ-CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXW+C8\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$T+#`V-RPV-#D\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M<F=B*#(P-"PR,S@L,C4U*3L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL
M969T.B`R,G!T)SY'<F%N=&5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C4L,3(Q
M+#(U,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,BXX,#PO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXY+C<\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C$L-S,W+#4S,#PO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`R,G!T)SY%>&5R
M8VES960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#$L.3,Q+#<X.#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/@T*("`@
M(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C`N,3,\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#(R<'0G/D5X<&ER
M960\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Y-#<R.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL
M969T.B`R,G!T)SY#86YC96QL960\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G
M/B@T-BPQ,S4\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T)SXI/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3$P<'0[('!A9&1I;F<M
M;&5F=#H@,3!P="<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXQ,RPW,S,L-#@X/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXQ+C$V/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C<N-SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B0\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,C8L.#`T+#$Q-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@
M<&%D9&EN9RUL969T.B`R,G!T)SY'<F%N=&5D/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C(L-3@S+#8W-SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,RXS,3PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT)SXY+C@\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C0L.3(P
M+#DX,3PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!R9V(H,C`T+#(S."PR-34I.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TQ,'!T.R!P861D
M:6YG+6QE9G0Z(#(R<'0G/D5X97)C:7-E9#PO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXH-S4L-#(S/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F="<^*3PO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T
M.B`R,G!T)SY%>'!I<F5D/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@R-3`\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X-
M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z(')G8B@R
M,#0L,C,X+#(U-2D[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6EN9&5N=#H@
M+3$P<'0[('!A9&1I;F<M;&5F=#H@,C)P="<^0V%N8V5L;&5D/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT)SXH-C`X+#<U,#PO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/BD\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M:6YD96YT.B`M,3!P=#L@<&%D9&EN9RUL969T.B`Q,'!T)SY"86QA
M;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0G/C$U+#8S,BPW-#(\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXQ+C0T/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXW+C(\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXU."PX-S@L,3,R
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*3L@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UI;F1E
M;G0Z("TQ,'!T.R!P861D:6YG+6QE9G0Z(#$P<'0G/E9E<W1E9"!A;F0@17AE
M<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,3,\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H="<^,3$L,C@R+#8R-SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0G/BXX,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H="<^-BXU/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-#@L,S(Q
M+#DS,#PO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T
M86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\<W5P/B@Q*3PO<W5P/E1H:7,@:6YC
M;'5D97,@*&DI(%9I=&%-960@3W!T:6]N<PT*9W)A;G1E9"!B971W965N($]C
M=&]B97(@,C`P."!A;F0@1&5C96UB97(@,S$L(#(P,3`@9F]R(&%N(&%G9W)E
M9V%T92!O9B`W+#8S.2PW,C(@56YI=',L(&]F('=H:6-H(#$V+#`P,"!W97)E
M(&-A;F-E;&5D('!R:6]R('1O#0IC;VYV97)S:6]N("AO<B!/<'1I;VYS(&9O
M<B`Y+#,U-RPU-C$@<VAA<F5S('!E<B!T:&4@0V]N=F5R<VEO;B!2871I;RDL
M("AI:2D@5FET84UE9"!/<'1I;VYS(&=R86YT960@8F5T=V5E;B!*86YU87)Y
M(#$L(#(P,3$@86YD#0I/8W1O8F5R(#,L(#(P,3$@9F]R(&%N(&%G9W)E9V%T
M92!O9B`V,C$L,#`P(%5N:71S("AO<B!/<'1I;VYS(&9O<B`W-C(L,C,U('-H
M87)E<R!P97(@=&AE($-O;G9E<G-I;VX@4F%T:6\I(&%N9"`H:6EI*2!/<'1I
M;VYS(&=R86YT960-"F)E='=E96X@3V-T;V)E<B`T+"`R,#$Q(&%N9"!$96-E
M;6)E<B`S,2P@,C`Q,2!F;W(@86X@86=G<F5G871E(&]F(#4V,BPT,C(@<VAA
M<F5S+B!4:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@;V8@=&AE(%9I=&%-960@
M3W!T:6]N<PT*=V5R92!R969L96-T960@:6X@=&AE(')E<&QA8V5M96YT($]P
M=&EO;G,@:6YC;'5D:6YG('1H92!N=6UB97(@;V8@<VAA<F5S('9E<W1E9"X\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^)B,Q-C`[/"]P/@T*#0H-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G
M/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V
M-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%6D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y#3TU%(%1!6$53("A4
M86)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE
M9'5L92!O9B!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3W5R(&1E9F5R<F5D('1A>"!A
M<W-E="!A;F0@;&EA8FEL:71Y(&%S('!R97-E;G1E9`T*:6X@=&AE(&%C8V]M
M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@8V]N
M<VES="!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-"CQT86)L
M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H
M.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD
M96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97(G/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<B<^,C`Q,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R)SXR,#$Q/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M
M:6YD96YT.B`M,3!P="<^1&5F97)R960@26YC;VUE(%1A>"!!<W-E=',Z/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@-#`E.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE
M9G0Z(#(R<'0[('1E>'0M:6YD96YT.B`M,3!P="<^3F5T(&]P97)A=&EN9R!L
M;W-S97,\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-24[('1E>'0M86QI9VXZ
M(')I9VAT)SXQ-"PW-S,L-3,W/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-24[('1E>'0M86QI9VXZ(')I9VAT)SXU+#DR,"PX-C$\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXD
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG
M:'0G/C<T."PT,#0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A
M9&1I;F<M;&5F=#H@,C)P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY2)B,S.#M$
M($-R961I=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H="<^-30W+#4Q,3PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H="<^,3@V+#,T-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#(R<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^5&]T86P@9&5F97)R960@:6YC;VUE('1A>"!A
M<W-E="`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M,34L,S(Q+#`T.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXV+#$P-RPR,#<\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^
M-S0X+#0P-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,C)P=#L@=&5X
M="UI;F1E;G0Z("TQ,'!T)SY686QU871I;VX@86QL;W=A;F-E/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXH,34L,S(Q+#`T.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@V
M+#$P-RPR,#<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SXH-S0X+#0P-#PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L
M,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/D1E9F5R<F5D($EN8V]M92!487@@07-S971S+"!N
M970\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0G/BTP+3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT)SXM,"T\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H="<^+3`M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F('1A>"!R871E(')E8V]N
M8VEL:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!(')E8V]N
M8VEL:6%T:6]N(&)E='=E96X@=&%X97,@8V]M<'5T960@870-"G1H92!F961E
M<F%L('-T871U=&]R>2!R871E(&%N9"!T:&4@8V]N<V]L:61A=&5D(&5F9F5C
M=&EV92!T87@@<F%T92!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M('=I9'1H.B`Y,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M.B!";&%C:R`Q<'0@<V]L:60G/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$Q/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@-#`E.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P
M<'0[('1E>'0M:6YD96YT.B`M,3!P="<^1F5D97)A;"!S=&%T=71O<GD@=&%X
M(')A=&4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA
M;&EG;CH@<FEG:'0G/C,U+C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0G/C,U+C`\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U)3L@=&5X="UA;&EG;CH@<FEG:'0G/C,U
M+C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE
M9G0G/B4\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^4W1A=&4@=&%X(')A=&4L(&YE="!O9B!F
M961E<F%L('1A>"!B96YE9FET/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/C4N.#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B4\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^-2XU/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)3PO=&0^/'1D/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXM,"T\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M
M:6YD96YT.B`M,3!P="<^061J=7-T;65N="!I;B!V86QU871I;VX@86QL;W=A
M;F-E<SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXH,S(N-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0G/BDE/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/B@Q."XR/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^*24\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#4N.#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BDE/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T
M97AT+6EN9&5N=#H@+3$P<'0G/E!E<FUA;F5N="!A;F0@;W1H97(@9&EF9F5R
M96YC97,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!"
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0G/B@X+C0\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXI)3PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H="<^*#(R+C,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!T97AT+6%L:6=N.B!L969T)SXI)3PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^*#(Y+C(\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L
M:6=N.B!L969T)SXI)3PO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S
M."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E
M>'0M:6YD96YT.B`M,3!P="<^4')O=FES:6]N("A"96YE9FET*2!F;W(@26YC
M;VUE(%1A>&5S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!";&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/BTP+3PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M="<^)3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M0FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!";&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SXM,"T\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0G/B4\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H="<^+3`M/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T)SXE/"]T9#X\
M+W1R/@T*/"]T86)L93X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SXF(S$V,#LF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?
M8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS
M:&5E=',O4VAE970S,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S(%1A8FQE<SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H
M961U;&4@;V8@9G5T=7)E(&UI;FEM=6T@<F5N=&%L('!A>6UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,RP@9G5T=7)E(&UI;FEM=6T@<F5N
M=&%L('!A>6UE;G1S(&%R92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P)SXF(S$V,#LF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9'1H.B`V,"4[(&9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTZ($)L
M86-K(#%P="!S;VQI9#L@<&%D9&EN9RUL969T.B`Q,'!T)SY996%R<R!%;F1I
M;F<@1&5C96UB97(@,S$L/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-S8E.R!T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M;&5F
M=#H@,'!T)SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,R4G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M."4[('1E>'0M86QI9VXZ(')I9VAT)SXS,38L,#,Y/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@5VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('!A9&1I;F<M;&5F=#H@,'!T)SXR,#$U/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G
M/C,W,2PR-#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN
M9RUL969T.B`P<'0G/C(P,38\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,S@R+#,W-SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@<&%D9&EN9RUL969T.B`P<'0G/C(P,3<\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,SDS+#@T.#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6QE9G0Z(#!P
M="<^,C`Q.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H="<^,S`R+#<T
M.#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!7:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M;&5F=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY4;W1A;"!M:6YI
M;75M(&QE87-E('!A>6UE;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT)SXQ+#<V-BPR-3(\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,3!P=#L@=&5X="UI
M;F1E;G0Z("TQ,'!T)SY.;VYC86YC96QA8FQE('-U8BUL96%S92!I;F-O;64\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0G/B@S."PY-38\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T)SXI/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T
M.R!T97AT+6EN9&5N=#H@+3$P<'0G/DYE="!M:6YI;75M(&QE87-E('!A>6UE
M;G1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M($)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0G/C$L-S(W
M+#(Y-CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SX\9F]N="!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO<#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C
M7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#DO5V]R:W-H965T<R]3:&5E=#,S+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4T5,14-4140@455!4E1%4DQ9($9)3D%.
M0TE!3"!$051!("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@26YF
M;W)M871I;VX@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!Q=6%R
M=&5R;'D@=6YA=61I=&5D('-U;6UA<GD@:6YF;W)M871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/E-U
M;6UA<FEZ960@<75A<G1E<FQY(&9I;F%N8VEA;"!D871A(&9O<B!F:7-C86P@
M>65A<G,F(S$V,#LR,#$S)B,Q-C`[86YD)B,Q-C`[,C`Q,B8C,38P.VES#0IA
M<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SXF(S$V,#LF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I
M;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I
M9'1H.B`Q,#`E.R!F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT
M+6EN9&5N=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0Q-"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTZ($)L86-K(#%P="!S;VQI9"<^,C`Q,R!1=6%R=&5R<SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#,V)3L@9F]N="US='EL93H@:71A;&EC.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M
M:6YD96YT.B`M,3!P="<^*$EN('1H;W5S86YD<RP@97AC97!T('!E<B!S:&%R
M92D\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<B<^,3QS=7`^<W0\+W-U<#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/CPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUB;W1T;VTZ(#%P
M="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B
M;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[(&)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXR/'-U<#YN9#PO<W5P/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F="<^/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R!P861D:6YG+6)O='1O;3H@,7!T)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E
M<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97(G/C,\
M<W5P/G)D/"]S=7`^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!P861D
M:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SX\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,R4[('!A9&1I;F<M8F]T=&]M.B`Q<'0G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O
M='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!B;W)D97(M8F]T=&]M
M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^-'1H/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!P861D:6YG+6)O='1O;3H@,7!T
M.R!T97AT+6%L:6=N.B!L969T)SX\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B
M*#(P-"PR,S@L,C4U*2<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY2979E;G5E<SPO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^,2PU
M,S<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0G/C(L,#@Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT)SXR+#(Y-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H="<^,BPX-C,\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@5VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M,3!P="<^1W)O<W,@<')O
M9FET/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT)SXQ+#$U-SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^,2PV,3<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0G/C$L-C0V/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXR+#,Y-CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0G/DYE="!L;W-S/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH-BPS-S8\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH-BPP,#D\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH-RPV-S,\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH."PS-C$\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z(%=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@<F=B*#(P-"PR,S@L,C4U*2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SY,;W-S('!E<B!C;VUM;VX@<VAA
M<F4L(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,"XP-CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`U/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#`N,#8\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,"XP-CPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@=VED=&@Z(#$P,"4[(&9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#$T('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R
M+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED)SXR,#$R(%%U87)T97)S/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S8E.R!F;VYT+7-T>6QE.B!I=&%L
M:6,[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,3!P=#L@
M=&5X="UI;F1E;G0Z("TQ,'!T)SXH26X@=&AO=7-A;F1S+"!E>&-E<'0@<&5R
M('-H87)E*3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUB
M;W1T;VTZ(#%P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,24[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R)SXQ/'-U<#YS=#PO<W5P/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@;&5F
M="<^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R!P861D:6YG+6)O='1O
M;3H@,7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&)O<F1E<BUB;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97(G/C(\<W5P/FYD/"]S=7`^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T)SX\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,R4[('!A9&1I;F<M8F]T=&]M.B`Q
M<'0G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M8F]R9&5R+6)O='1O;3H@0FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L
M969T)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3$E.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<B<^,SQS=7`^<F0\+W-U<#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUB;W1T;VTZ(#%P="<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D
M97(M8F]T=&]M.B!";&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[(&)O<F1E<BUB
M;W1T;VTZ($)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R)SXT
M=&@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0G/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!R9V(H,C`T+#(S."PR-34I)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/E)E=F5N=65S/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M)SXW,C(\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0G/C@Q.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G
M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H="<^,2PP,S8\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C$L,C0Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z(%=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0G/D=R;W-S('!R
M;V9I=#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H="<^,S@V/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M="<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT)SXT-#<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/C<R.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H="<^.3`X/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[('1E>'0M:6YD96YT.B`M
M,3!P="<^3F5T(&QO<W,\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0G/B@Q,RPR.3`\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,3$L.#4P/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#0L,C4S/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#4L-S(W/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!7:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@
M,3!P=#L@=&5X="UI;F1E;G0Z("TQ,'!T)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0G/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0G/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z(')G8B@R,#0L,C,X+#(U-2DG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[
M('1E>'0M:6YD96YT.B`M,3!P="<^3&]S<R!P97(@8V]M;6]N('-H87)E+"!B
M87-I8R!A;F0@9&EL=71E9#PO=&0^/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H="<^*#`N,38\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T)SXI/"]T9#X\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F="<^)#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXH,"XQ-#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0G/BD\+W1D/CQT9#XF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0G/B@P+C`T/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F="<^*3PO=&0^/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0G/B0\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H="<^*#`N,#8\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T)SXI/"]T9#X\+W1R/@T*/"]T86)L93X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!L969T)SXF(S$V
M,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W
M-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14A-04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^5$A%($-/35!!3ED@
M*$1E=&%I;',@3F%R<F%T:79E*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,C@L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;"X@,CDL(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`P-"P@,C`Q,3QB<CY!9W)E96UE;G0@86YD(%!L
M86X@;V8@365R9V5R('=I=&@@5FET84UE9#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6PN(#(Y+"`R,#$Q/&)R/D%G<F5E;65N="!A;F0@
M4&QA;B!O9B!-97)G97(@=VET:"!6:71A365D/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;"X@,C@L(#(P,3$\8G(^06=R965M96YT(&%N
M9"!0;&%N(&]F($UE<F=E<B!W:71H(%9I=&%-960\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`P-"P@,C`Q,3QB<CY!9W)E96UE;G0@
M86YD(%!L86X@;V8@365R9V5R('=I=&@@5FET84UE9#QB<CY/<'1I;VYS/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,#0L(#(P,3$\
M8G(^06=R965M96YT(&%N9"!0;&%N(&]F($UE<F=E<B!W:71H(%9I=&%-960\
M8G(^5V%R<F%N=',\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38L-3<U+#(P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PY-S8L-S4W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DL-S@T
M+#DX,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V-2PX-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38U+#@U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V+#4W-2PR,#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V+#4W-2PR,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#0L.3<V+#<U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#<X-"PY.#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C4L.#4V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$V-2PX-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-BPU-S4L,C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5R<V4@<W1O8VL@<W!L:70@<F%T
M:6\\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q(&9O<B`Q,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S$@9F]R(#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!D96-R96%S92!I;B!H;VQD
M:6YG(&1U92!T;R!M97)G97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3DN,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H
M;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@
M;V8@:&]L9&EN9R!A8W%U:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D(&EN(&5X8VAA
M;F=E(&9O<B!O=71S=&%N9&EN9R!M96UB97)S:&EP('5N:71S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@L-#`W+#,S,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E<R!R97-E<G9E9"!F;W(@9G5T=7)E(&ES<W-U86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#$Q.2PW
M.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#0W,BPY,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(&QO8VL@:6X@<&5R:6]D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T5A8V@@<W1O8VMH
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M<G)A;G1S('!E<B!Q=6%R=&5R(&]V97(@=&AE(&9O;&QO=VEN9R`Q,BUM;VYT
M:"!P97)I;V0L(&]R('1H92!$<FEB8FQE#0I/=70@4&5R:6]D+B!5<&]N('1H
M92!C;VUP;&5T:6]N(&]F('1H92!$<FEB8FQE($]U="!097)I;V0L('1H92!!
M9W)E96UE;G1S('=I;&P@=&5R;6EN871E+CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B
M-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H
M965T<R]3:&5E=#,U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2U!!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY354U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@
M4$],24-)15,@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061V
M97)T:7-I;F<@0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,3$L-S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q.2PT.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#8U+#DT-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061V86YC92!P87EM96YT<R!F
M;W(@9G5T=7)E(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#DQ+#@P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3@Y+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<VAA<F5S(&5X8VQU9&5D(&9R;VT@
M96%R;FEN9W,@<&5R('-H87)E(&-A;&-U;&%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR.2PY,C8L,C0Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L.3(V+#DX-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8T-RPW
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5Q=6EP;65N="!\($UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q
M=6EP;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D('5S969U;"!L:79E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17%U
M:7!M96YT('P@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI=F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R
M,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O
M<FMS:&5E=',O4VAE970S-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P131%04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^24Y614Y43U)9("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY);G9E;G1O<GD\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&:6YI<VAE9"!0<F]D=6-T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8R,2PV-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,3(T+#<S.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F%W($UA=&5R:6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-3`L.30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5F97)R960@0V]S=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W,"PY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`L-#<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#0S+#8Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV
M,34L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W
M-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970S-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15I+04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3U1(15(@0U524D5.
M5"!!4U-%5%,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R
M($-U<G)E;G0@07-S971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!2)F%M<#M$(&-O<W1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C8W+#4X.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@Y+#,W-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E<&%I9"!C;VYS=6QT:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,S`L-3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#,R+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@9FEN86YC:6YG(&-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C`L,#(R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@<F5C96EV86)L97,M<F5L871E9"!P87)T>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0Y+#DX,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@;W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V.2PU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,C<L-#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&=U87)A;G1Y(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!/
M5$A%4B!#55)214Y4($%34T544SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+#0W-RPW,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<U,2PY,S@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V
M7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C
M-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T
M<R]3:&5E=#,X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$I!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY&25A%1"!!4U-%5%,@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5P<F5C:6%T:6]N($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-#<L.#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-RPT.#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U+#8X-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD
M($EM<')O=F5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$96-R96%S92!A8V-U;75L871E9"!D97!R96-I871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L.3@P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?
M-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO
M5V]R:W-H965T<R]3:&5E=#,Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$=!13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY&25A%1"!!4U-%5%,@*$1E=&%I;',I("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&:7AE9"!A<W-E=',L(&=R;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$U-2PP.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R-BPR-S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D
M(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.3,L-S8U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8P+#8P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I>&5D($%S<V5T<RP@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,2PS,3@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-2PV-S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6EP;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I>&5D(&%S<V5T
M<RP@9W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PT
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-RPV-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9U<FYI='5R92!A;F0@1FEX='5R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!A<W-E=',L(&=R;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPV,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPV,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M87-E:&]L9"!);7!R;W9E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&:7AE9"!A<W-E=',L(&=R;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PY.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q
M969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E
M9#DO5V]R:W-H965T<R]3:&5E=#0P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-45!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY04D5004E$($584$5.4T4@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($%S<V5T<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@4B9A
M;7`[1"!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X
M,C0L,C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Y-3,L-C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&UA;G5F86-T=7)I;F<@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y.2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R971E9"!P<F5P86ED(&-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-RPR,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@
M4%)%4$%)1"!%6%!%3E-%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L-S4P+#0U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@.34S+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E
M-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T-F,U
M,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S+U-H
M965T-#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$580D%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DE.5$%.1TE"3$4@05-31513("A$971A:6QS($YA<G)A=&EV92D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1V]O9'=I;&P@86YD($EN=&%N9VEB;&4@07-S971S($1I
M<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PR-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X+#<W-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,CDL,34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W
M-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970T,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14Q-04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y404Y'24),12!!
M4U-%5%,@*$1E=&%I;',@*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN:71E+4QI=F5D($EN
M=&%N9VEB;&4@07-S971S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@06UO<G1I>F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#DP+#$V,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<W+#$U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YD969I;FET92U,:79E9"!);G1A;F=I8FQE($%S<V5T<SPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M;W-S($-A<G)Y:6YG($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S4U+#<T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Q-BPW,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!!;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8V-2PU.#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,SDL-34U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!#87)R
M>6EN9R!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U
M-2PW-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,38L-S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-C4L-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,Y+#4U-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^2&]R;6]N92!T:&5R87!Y(&1R
M=6<@8V%N9&ED871E('!A=&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN9&5F:6YI=&4M3&EV960@26YT86YG:6)L
M92!!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'<F]S<R!#87)R>6EN9R!!;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4W,BPW,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L,3DT/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@06UO=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-S(L-S(V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#$Y-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M375L=&EP;&4@=')A9&5M87)K<R!F;W(@=FET86UI;G,O<W5P<&QE;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN
M9&5F:6YI=&4M3&EV960@26YT86YG:6)L92!!<W-E=',\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!#87)R>6EN
M9R!!;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y+#,R
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q+#`U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3DL,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$L,#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/4$520<*N('-O9G1W87)E('!A=&5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN
M:71E+4QI=F5D($EN=&%N9VEB;&4@07-S971S/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)O<W,@0V%R<GEI;F<@06UO
M=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PY-3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPW
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W5M=6QA=&5D($%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#DY*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!!;6]U;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Q+#0U,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#<R,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E
M<F%G92!!;6]R=&EZ871I;VX@4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,34@>65A<G,@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<P('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$979E;&]P;65N="!C;W-T<R!F;W(@8V]R<&]R871E('=E8G-I=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9I;FET
M92U,:79E9"!);G1A;F=I8FQE($%S<V5T<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S($-A<G)Y:6YG($%M;W5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$L-S0S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$L-S0S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-U;75L871E9"!!;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@Y+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@W-RPQ-3DI/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@06UO=6YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#@R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"PU.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E
M:6=H=&5D($%V97)A9V4@06UO<G1I>F%T:6]N(%!E<FEO9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)S`@>65A<G,@,R!M;VYT:',@,3@@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<Q('EE87(@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?
M83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T
M-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S
M+U-H965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5+0T%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\
M<W1R;VYG/DE.5$%.1TE"3$4@05-31513("A$971A:6QS(#$I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY';V]D=VEL;"!A;F0@26YT86YG:6)L92!!<W-E=',@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0L,#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#DY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C
M7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970T-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Y"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3U1(15(@0U52
M4D5.5"!,24%"24Q)5$E%4R`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D]T:&5R($QI86)I;&ET:65S+"!#=7)R96YT(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$:79I9&5N9',@4&%Y86)L92P@86UO=6YT('!E<B!S:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F-L86EM960@
M9&EV:61E;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q
M+#,U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-#$L,S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T
M,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970T-2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13%!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^3U1(15(@
M0U524D5.5"!,24%"24Q)5$E%4R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@3&EA8FEL:71I
M97,L($-U<G)E;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@
M<&%Y<F]L;"!A;F0@8V]M;6ES<VEO;B!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y-#$L,S$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S.3<L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-R=65D(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@=F%C871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U-BPY,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,30L.#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO
M=V%N8V4@9F]R('=H;VQE<V%L92!D:7-T<FEB=71O<B!F965S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#8L,S`S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`W+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C<G5E9"!L96=A;"!A;F0@86-C;W5N=&EN9R!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C0L-34P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QA8B!R97-E87)C:#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,V+#4W-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@8VQI;FEC86P@=')I86P@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.2PR,#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(&-O=7!O;G,@
M86YD(')E='5R;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M-BPR,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPP,#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%C8W)U960@97AP
M96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S,"PP.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P
M+#<U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5$]404P@3U1(15(@0U524D5.5"!,24%"24Q)5$E%4SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#8P,2PQ.#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@S,RPV-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-3X\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^
M#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@("`@
M/'1D(&-O;'-P86X],T0T('9A;&EG;CTS1'1O<#Y);B!*=6YE(#(P,#@L('=E
M(&1E8VQA<F5D(&%N9"!P86ED(&$@<W!E8VEA;"!D:79I9&5N9"!O9B`D,"XT
M,"!P97(@<VAA<F4@;V8@;W5R($-O;6UO;B!3=&]C:R!T;R!A;&P@<VAA<F5H
M;VQD97)S(&]F(')E8V]R9"!A<R!O9B!*=6YE(#$P+"`R,#`X+"!O9B!W:&EC
M:"`D-#$L,S4Y(')E;6%I;F5D('5N8VQA:6UE9"!B>2!C97)T86EN('-H87)E
M:&]L9&5R<R!A="!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?
M83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T
M-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S
M+U-H965T-#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5'0D=-/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DY/5$53(%!!64%"3$4@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,"!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0U/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^3F]V+B`Q,RP@,C`Q,CQB<CY-<BX@1FEN:7II;SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#$S+"`R,#$R/&)R/DUR
M+B!-:6QL:6=A;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.
M;W8N(#$S+"`R,#$R/&)R/E)E:6-H($9A;6EL>2!,:6UI=&5D($Q0/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,C$L(#(P,3,\8G(^
M375L=&EP;&4@061V86YC92!2979O;'9I;F<@0W)E9&ET($YO=&4@*%!L871O
M(%=A<G)A;G0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,3,L(#(P,3,\8G(^375L=&EP;&4@061V86YC92!2979O;'9I;F<@0W)E
M9&ET($YO=&4@*%!L871O(%=A<G)A;G0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D9E8BX@,C4L(#(P,3,\8G(^375L=&EP;&4@061V86YC
M92!2979O;'9I;F<@0W)E9&ET($YO=&4@*%!L871O(%=A<G)A;G0I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,3,\8G(^
M375L=&EP;&4@061V86YC92!2979O;'9I;F<@0W)E9&ET($YO=&4@*%!L871O
M(%=A<G)A;G0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^375L=&EP;&4@061V86YC92!2979O;'9I;F<@0W)E
M9&ET($YO=&4@*%!L871O(%=A<G)A;G0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,C4L(#(P,3,\8G(^5FET84UE9"!0<F]M:7-S
M;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,3DL(#(P,3(\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C@L(#(P,3,\8G(^
M5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^5FET84UE9"!0<F]M:7-S
M;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C
M="X@,S`L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S
M;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S
M;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO
M=BX@,3,L(#(P,3(\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^
M5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/DUR+B!&:6YI>FEO/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^
M5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/DUR+B!-:6QL:6=A;CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#$S+"`R,#$R/&)R
M/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CY296EC:"!&86UI;'D@3&EM
M:71E9"!,4#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$Q/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CY296EC
M:"!&86UI;'D@3&EM:71E9"!,4#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/DES<W5A;F-E(&]F(#8E(%!R;VUI
M<W-O<GD@3F]T97,@*$IA;G5A<GD@86YD($9E8G)U87)Y(#(P,3(I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@,C0L(#(P,3(\8G(^
M1F5B<G5A<GD@,C`Q,B!.;W1E<R!)<W-U960@5&\@26YD:79I9'5A;"!!;F0@
M16YT:71Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S
M,2P@,C`Q,CQB<CY&96)R=6%R>2`R,#$R($YO=&5S($ES<W5E9"!4;R!);F1I
M=FED=6%L($%N9"!%;G1I='D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY&96)R=6%R>2`R,#$R($YO=&5S($ES
M<W5E9"!4;R!);F1I=FED=6%L($%N9"!%;G1I='D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY&96)R=6%R>2`R
M,#$R($YO=&5S+R!787)R86YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/D9E8G)U87)Y(#(P,3(@3F]T97,O
M(%=A<G)A;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E
M8BX@,CDL(#(P,3(\8G(^1F5B<G5A<GD@,C`Q,B!.;W1E<R\@5V%R<F%N=',\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R-"P@,C`Q
M,CQB<CY&96)R=6%R>2`R,#$R($YO=&5S+R!787)R86YT<SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(T+"`R,#$R/&)R/D9E8G)U
M87)Y(#(P,3(@3F]T97,@27-S=65D(%1O(%!A<G1I97,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY&96)R=6%R
M>2`R,#$R($YO=&5S($ES<W5E9"!4;R!087)T:65S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,3DL(#(P,3(\8G(^2G5N92`R,#$R
M($YO=&5S($ES<W5E9"!4;R!);F1I=FED=6%L($%N9"!%;G1I='D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY*
M=6YE(#(P,3(@3F]T97,@27-S=65D(%1O(%!A<G1I97,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`R-2P@,C`Q,SQB<CY*=6YE(#(P
M,3(@3F]T97,@*'-E8W5R960@<')O;6ES<V]R>2!N;W1E<RD\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R,2P@,C`Q,SQB<CY*=6YE
M(#(P,3(@3F]T97,@*'-E8W5R960@<')O;6ES<V]R>2!N;W1E<RD\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY*
M=6YE(#(P,3(@3F]T97,@*'-E8W5R960@<')O;6ES<V]R>2!N;W1E<RD\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B
M="!);G-T<G5M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<')I;F-I<&%L(&%M;W5N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A=&5D
M(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+C,U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`R)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!I;G1E<F5S="!P87EM96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG26YT97)E
M<W0@<&%Y;65N=',@=V5R92!D=64@86YD('!A>6%B;&4@;VX@=&AE('1E;G1H
M(&1A>2!F;VQL;W=I;F<@=&AE(&5N9"!O9B!E86-H(&-A;&5N9&%R('%U87)T
M97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=5;F1E<B!T:&4@97AT96YS:6]N+"!B;W)R;W=I;F=S(&)E87(@:6YT
M97)E<W0@870@82!R871E(&]F(#(N,S4E(&%N9"!A<F4@9'5E(&]N($UA<F-H
M(#$L(#(P,3,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=4:&4@8F%N:R!L:6YE(&]F(&-R961I="!A8V-R=65D
M(&EN=&5R97-T(&%T('1H92!R871E(&]F(#,N,#(E('!E<B!A;FYU;2!B87-E
M9"!O;B!A('EE87(@;V8@,S8P(&1A>7,@86YD('=A<R!D=64@;VX@36%R8V@@
M,2P@,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M
M(')E=F]L=FEN9R!C<F5D:70@;F]T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N="!O9B!R979O;'9I;F<@8W)E
M9&ET(&YO=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0P,2PP.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M979O;'9I;F<@8W)E9&ET(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8Q,RPW,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8X-2PS,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q-"PW,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#8X-2PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@;V8@=V%R
M<F%N=',@*&EN(&1O;&QA<G,@<&5R('5N:70I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C0Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:6YE(&]F(&-R961I=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W.2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-SDL,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CDY+#(R,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<&%Y;65N=',@;V8@;&EN97,@;V8@
M8W)E9&ET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PW,S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.3DL,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!L:6YE
M<R!O9B!C<F5D:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6YE(&]F(&-R961I
M="!F86-I;&ET>2!D96-R96%S92!F;W)G:79E;F5S<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,38U+#DX,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3`U+#0P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8T
M+#,X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S8V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,S4X+#`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4W+#$Q,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,T
M-RPQ,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#,T-"PW,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@;F]T97,@<&%Y86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F5P87EM96YT<R!O9B!N;W1E<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8Y,2PX-#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@U
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#@R+#`Q.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C<G5E9"!I;G1E
M<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$U,"PP-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M+#$R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,2PU.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&YO=&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,3<L-S0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(&1I<V-O=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@U.2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DW+#,X,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;V=N
M:7IE9"!L;W-S(&]N(&5X=&EN9W5I<VAM96YT(&]F(&1E8G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PS,#<L.#8T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#<L,SDP+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L
M,S`W+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A;"!A;F0@86-C<G5E
M9"!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,#(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UO=6YT(&]F('-H87)E<R!I<W-U960@:6X@97AE<F-I<V4@;V8@=V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,30U+#0X-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,30U+#0X-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5M86EN:6YG(&)A;&%N8V4@;V8@;F]T97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS-#<L,3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPV.3$L.#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S0T+#<Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E
M<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97-C<FEP=&EO;B!O9B!I;G1E<F5S="!R871E('1E<FUS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!6
M:71A365D($YO=&5S('=E<F4@87-S=6UE9"!B>2!U<R!U<&]N('1H92!M97)G
M97(@86YD(&)O<F4@:6YT97)E<W0@870@82!R871E(&]F(#0E('!E<B!A;FYU
M;2!A;F0@=V5R92!D=64@870@=&AE(&5A<FQI97(-"F]F("AI*2!T:&4@<VEX
M(&UO;G1H(&%N;FEV97)S87)Y(&]F('1H92!D871E(&]F(&ES<W5A;F-E(&%N
M9"`H:6DI('-U8V@@=&EM92!A<R!6:71A365D(')E8V5I=F5D('1H92!P<F]C
M965D<R!O9B!A('!R;VUI<W-O<GD-"FYO=&4H<RD@:7-S=65D(&EN(&%N(&%M
M;W5N="!O9B!N;W0@;&5S<R!T:&%N("0Q+#`P,"PP,#`L(&]R('1H92!&=6YD
M:6YG+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C8W)U960@:6YT97)E<W0@
M870@=&AE(&%N;G5A;"!R871E(&]F(#8E+"!W87,@9'5E(&EN(&]N92!L=6UP
M('-U;2!P87EM96YT(&]N($9E8G)U87)Y(#(T+"`R,#$T+CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-R=65D(&EN
M=&5R97-T('!A:60\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C$R+#@U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3<L,C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPQ-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C$L-3DU/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V
M7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C
M-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T
M<R]3:&5E=#0W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%2%E!2SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY.3U1%4R!005E!0DQ%("A$971A:6QS($YA<G)A=&EV92`Q*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0U/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R
M,#$R/&)R/C8E($YO=&5S(&ES<W5E9"!I;B!!=6=U<W0@86YD(%-E<'1E;6)E
M<B`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3(\8G(^-B4@3F]T97,@:7-S=65D(&EN($%U9W5S="!A;F0@4V5P
M=&5M8F5R(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M3V-T+B`S,2P@,C`Q,CQB<CXV)2!.;W1E<R!I<W-U960@:6X@4V5P=&5M8F5R
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,CQB<CXV)2!.;W1E<R!I<W-U960@:6X@4V5P=&5M8F5R(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q
M,CQB<CY6:71A365D($IU;'D@,C`Q,2!396-U<F5D($YO=&5S/&)R/DYU;6)E
M<CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/E9I=&%-960@2G5L>2`R,#$Q(%-E8W5R960@3F]T97,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY6
M:71A365D($IU;'D@,C`Q,2!396-U<F5D($YO=&5S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3$\8G(^5FET84UE9"!*
M=6QY(#(P,3$@4V5C=7)E9"!.;W1E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$Q/&)R/E9I=&%-960@2G5L>2`R,#$Q
M($9I<G-T(%-E8W5R960@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5L+B`S,2P@,C`Q,3QB<CY6:71A365D($IU;'D@,C`Q,2!3
M96-O;F0@4V5C=7)E9"!.;W1E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E9I=&%-960@4')O;6ES<V]R>2!.
M;W1E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#,P
M+"`R,#$Q/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,P+"`R,#$Q/&)R/E9I=&%-
M960@4')O;6ES<V]R>2!.;W1E<SQB<CY.=6UB97(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,3QB<CY6:71A365D(%!R
M;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q,3QB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`S,"P@,C`Q
M,3QB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY6:71A365D(%!R
M;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^3V-T+B`P-"P@,C`Q,CQB<CY6:71A365D(%!R
M;VUI<W-O<GD@3F]T97,\8G(^0G)I86X@0F5R;FEC:SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E9I=&%-960@
M4')O;6ES<V]R>2!.;W1E<SQB<CY"<FEA;B!"97)N:6-K/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,3$\8G(^5FET84UE
M9"!#;VYV97)T:6)L92!.;W1E<SQB<CY.=6UB97(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY.;W1E<R!)<W-U
M960@=&\@37(N($9I;FEZ:6\@06YD($UR+B!-:6QL:6=A;CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/DYO=&5S
M($ES<W5E9"!T;R!-<BX@1FEN:7II;R!!;F0@37(N($UI;&QI9V%N/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^
M3F]T97,@27-S=65D('1O($UR+B!&:6YI>FEO/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,#0L(#(P,3(\8G(^3F]T97,@27-S=65D
M('1O($UR+B!-:6QL:6=A;CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC:7!A
M;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-3,T+#$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P87EM
M96YT<R!O9B!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#8Y,2PX-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#@U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E('!R:6YC:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4T+#8T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R<R!O9B!S:&%R97,@8V]N=F5R
M=&5D(&9O<B!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPW-S4L-#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,34L,3,V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8V+#@R,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#(V-BPX
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PT,34L,3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P<FEC92`H:6X@
M9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C,X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F%L=64@;V8@9&5B="!C;VYV97)T960@=&\@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPW,38L
M-3`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW,38L-3`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@T.2PQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$V-2PY.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DP-2PT,#D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PS
M.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S+#(P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Q+#0U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S8V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#,T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<G,@;V8@<VAA<F5S('!U<F-H87-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,3,L-S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<V-R:7!T:6]N(&]F(&EN=&5R97-T(')A
M=&4@=&5R;7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)U1H92!6:71A365D($YO=&5S('=E<F4@87-S=6UE9"!B
M>2!U<R!U<&]N('1H92!M97)G97(@86YD(&)O<F4@:6YT97)E<W0@870@82!R
M871E(&]F(#0E('!E<B!A;FYU;2!A;F0@=V5R92!D=64@870@=&AE(&5A<FQI
M97(-"F]F("AI*2!T:&4@<VEX(&UO;G1H(&%N;FEV97)S87)Y(&]F('1H92!D
M871E(&]F(&ES<W5A;F-E(&%N9"`H:6DI('-U8V@@=&EM92!A<R!6:71A365D
M(')E8V5I=F5D('1H92!P<F]C965D<R!O9B!A('!R;VUI<W-O<GD-"FYO=&4H
M<RD@:7-S=65D(&EN(&%N(&%M;W5N="!O9B!N;W0@;&5S<R!T:&%N("0Q+#`P
M,"PP,#`L(&]R('1H92!&=6YD:6YG+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8W)U960@:6YT
M97)E<W0@<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$R
M+#@U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W+#(U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS-#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!R96UA:6YI;F<@<')I;F-I<&%L(&%M;W5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?
M83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T
M-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S
M+U-H965T-#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5"3$-+/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-43T-+2$],1$524R<@15%52519("A$971A:6QS($YA<G)A=&EV
M92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0U/C$@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;"X@,C@L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5L+B`R.2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#`U+"`R,#$Q/&)R/E-T;V-K(%!U<F-H
M87-E($%G<F5E;65N="!7:71H(%!E<FYI>"!4:&5R87!E=71I8W,@3$Q#/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^4')I=F%T92!P;&%C96UE;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY&96)R=6%R>2`R,#$R($YO=&5S
M+R!787)R86YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$S/&)R/D9E8G)U87)Y(#(P,3(@3F]T97,O(%=A<G)A;G1S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,S`L(#(P,3$\8G(^5FET84UE9"!0
M<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D]C="X@,S`L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S
M/&)R/DYU;6)E<CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/
M8W0N(#,Q+"`R,#$Q/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$Q/&)R
M/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!<'(N(#(P+"`R,#$S/&)R/DIE9F9E<FEE<R!,3$,@
M*%5N9&5R=W)I=&5R<RD\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`R,"P@,C`Q,SQB<CY*969F97)I97,@3$Q#("A5;F1E<G=R:71E
M<G,I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^2F5F9F5R:65S($Q,0R`H56YD97)W<FET97)S*3QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(U+"`R,#$S/&)R/E-T
M:69E;"P@3FEC;VQA=7,@)F%M<#L@0V]M<&%N>2`H56YD97)W<FET97)S*3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D
M('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S
M:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-BPU-S4L,C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30T+#DW-BPW-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY.2PW.#0L.3@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V-2PX-38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-3<U+#(P.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PY-S8L
M-S4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3DL-S@T+#DX,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-C4L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M('-H87)E<R!I<W-U960@9'5R:6YG('1H92!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,S$L-3<Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY-3,L-#@Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDL-#$Q+#<V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E('!R:6-E("AI;B!D
M;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,BXQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E('!R
M:6-E('1O('5N9&5R=W)I='1E<G,@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&ES<W5E9"!D
M=7)I;F<@=&AE('!E<FEO9"QV86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-S@L-C4P+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPX.34L-#@U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<P-RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#<L.#DU+#0X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#4L-#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,S`L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061D:71I;VYA;"!P97)I;V0@9F]R('!U<F-H87-E('-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)S,P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!9&1I=&EO;F%L(&-O;6UO;B!S=&]C
M:R!I<W-U960@=6YD97(@<VAE;&8@<F5G:7-T<F%T:6]N('-T871E;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PT,3$L-S8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@8V]M;6]N('-T;V-K(&ES<W5E9"!U
M;F1E<B!S:&5L9B!R96=I<W1R871I;VX@<W1A=&5M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.34T+#4X-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!C;VUM;VX@<W1O8VL@:7-S=65D('5N9&5R('-H96QF
M(')E9VES=')A=&EO;B!S=&%T96UE;G0L=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97)S(&]F(&]P=&EO;G,@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!E>&5R8VES960@9F]R(&-A<V@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV.3$L,SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I
M;VYS('1O('!U<F-H87-E('-H87)E<R!O9B!C;VUM;VX@<W1O8VLL('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L.3$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DQ+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<G,@;V8@;W!T:6]N
M<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K+"!C87-H;&5S
M<R!E>&5R8VES93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-#`L,SDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&ES<W5E
M9"!I;B!E>&5R8VES92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$P,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3`R+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UO=6YT(&]F('-H87)E<R!I<W-U960@:6X@97AE<F-I<V4@;V8@=V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M+#$T-2PT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#$T-2PT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5E(&]F(&1E8G0@8V]N
M=F5R=&5D('1O('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V+#<Q-BPU,#0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#`U-"PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#0Y+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<G,@;V8@<VAA
M<F5S(&-O;G9E<G1E9"!F;W(@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#<W-2PT,34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,34L,3,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8V+#@R,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M+#(V-BPX,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P<FEC92`H:6X@9&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%N<V%C=&EO;B!C87-H(&9E
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U,BPU
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&5G86P@9F5E<R!A;F0@97AP96YS97,@<&%I9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L,#$V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%G9W)E9V%T92!P=7)C:&%S92!P<FEC92!O9B!C;VUM;VX@
M<W1O8VL@<V]L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`X+#4P,"PP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S92!S=&]C:R!S<&QI
M="!R871I;SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@9F]R
M(#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W
M834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P
M-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE
M970T.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15121D\^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4U1/0TM(3TQ$15)3)R!%455)5%D@*$1E=&%I;',@3F%R<F%T:79E(#$I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXP($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0T/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y.;W8N(#$S+"`R,#$R/&)R/DUR+B!&:6YI>FEO
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,3,L(#(P
M,3(\8G(^37(N($UI;&QI9V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DYO=BX@,3,L(#(P,3(\8G(^4F5I8V@@1F%M:6QY($QI;6ET960@
M3%`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R
M,#$S/&)R/E-A;F-I;&EO("9A;7`[($-O;7!A;GD@5V%R<F%N=',\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CY3
M86YC:6QI;R`F86UP.R!#;VUP86YY(%=A<G)A;G1S(#%S="!);G-T86QL;65N
M=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#$Q+"`R
M,#$S/&)R/E-A;F-I;&EO("9A;7`[($-O;7!A;GD@5V%R<F%N=',@,7-T($EN
M<W1A;&QM96YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$S/&)R/E-A;F-I;&EO("9A;7`[($-O;7!A;GD@5V%R<F%N
M=',@,FYD($EN<W1A;&QM96YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-A;F-I;&EO("9A;7`[($-O;7!A
M;GD@5V%R<F%N=',@,FYD($EN<W1A;&QM96YT<SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-A;F-I;&EO("9A
M;7`[($-O;7!A;GD@5V%R<F%N=',@,W)D($EN<W1A;&QM96YT<SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/DUO
M9&EF:6-A=&EO;B!787)R86YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/E=A<G)A;G1S($ES<W5E9"!T;R!5
M;F%F9FEL:6%T960@26YD:79I9'5A;',\8G(^3G5M8F5R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S,2P@,C`Q,CQB<CY787)R86YT
M<R!)<W-U960@=&\@56YA9F9I;&EA=&5D($5N=&ET>3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E=A<G)A;G1S
M($ES<W5E9"!T;R!5;F%F9FEL:6%T960@16YT:71Y/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^5V%R<F%N=',@
M27-S=65D('1O(%5N869F:6QI871E9"!%;G1I='D\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q,CQB<CY*=6YE(#(P,3(@
M3F]T97,O5V%R<F%N=',\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CY*=6YE(#(P,3(@3F]T97,O5V%R<F%N=',\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`Q.2P@,C`Q
M,CQB<CY*=6YE(#(P,3(@3F]T97,O5V%R<F%N=',@,7-T($ES<W5E/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,3DL(#(P,3(\8G(^
M2G5N92`R,#$R($YO=&5S+U=A<G)A;G1S(#)N9"!)<W-U93QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E=A<G)A
M;G1S($ES<W5E9"!T;R!5;F%F9FEL:6%T960@26YD:79I9'5A;',\8G(^3G5M
M8F5R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^5V%R<F%N=',@27-S=65D('1O(%5N<F5L871E9"!);F1I=FED
M=6%L(&9O<B!#;VYS=6QT:6YG(%-E<G9I8V5S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^5V%R<F%N=',@27-S
M=65D('1O(%5N<F5L871E9"!);F1I=FED=6%L(&9O<B!#;VYS=6QT:6YG(%-E
M<G9I8V5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@
M,S$L(#(P,3$\8G(^5V%R<F%N=',@27-S=65D($]F9FEC97)S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^5V%R
M<F%N=',@27-S=65D($]F9FEC97)S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^5V%R<F%N=',@27-S=65D($]F
M9FEC97)S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3$\8G(^5V%R<F%N=',@27-S=65D($]F9FEC97)S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^5V%R
M<F%N=',@27-S=65D('1O(%5N<F5L871E9"!%;G1I='D@9F]R($-O;G-U;'1I
M;F<@4V5R=FEC97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CY787)R86YT<R!)<W-U960@=&\@56YR96QA=&5D
M($5N=&ET>2!F;W(@0V]N<W5L=&EN9R!397)V:6-E<SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/E9E<W1E9"!N
M;VX@9F]R9F5I=&%B;&4@5FET84UE9"!787)R86YT<SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/E9E<W1E9"!N
M;VX@9F]R9F5I=&%B;&4@5FET84UE9"!787)R86YT<SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E9E<W1E9"!N
M;VX@9F]R9F5I=&%B;&4@5FET84UE9"!787)R86YT<SQB<CY.=6UB97(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CY697-T960@;F]N(&9O<F9E:71A8FQE(%9I=&%-960@5V%R<F%N=',\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CY697-T960@;F]N(&9O<F9E:71A8FQE(%9I=&%-960@5V%R<F%N=',\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`Q,RP@,C`Q,CQB
M<CY697-T960@;F]N(&9O<F9E:71A8FQE(%9I=&%-960@5V%R<F%N=',\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,SQB
M<CY-=6QT:7!L92!!9'9A;F-E(%)E=F]L=FEN9R!#<F5D:70@3F]T92`H4&QA
M=&\@5V%R<F%N="D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CY-=6QT:7!L92!!9'9A;F-E(%)E=F]L=FEN9R!#
M<F5D:70@3F]T92`H4&QA=&\@5V%R<F%N="D\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1F5B+B`R.2P@,C`Q,CQB<CY&96)R=6%R>2`R,#$R
M($YO=&5S+R!787)R86YT<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y&96(N(#(T+"`R,#$R/&)R/D9E8G)U87)Y(#(P,3(@3F]T97,O(%=A
M<G)A;G1S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,3,L(#(P,3(\8G(^5FET
M84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y
M($YO=&5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/DUR+B!&
M:6YI>FEO/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R/DUR+B!-
M:6QL:6=A;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$Q/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CY296EC
M:"!&86UI;'D@3&EM:71E9"!,4#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/DUI;FEM=6T\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY-87AI;75M
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^5V5I9VAT960@079E<F%G93QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY787)R86YT<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T
M+#(Y,RPT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@8V]N=')A8W1U86P@<F5M
M86EN:6YG(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<S
M('EE87)S(#$P(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!O
M9B!W87)R86YT<R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N-3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C0Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XR-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XT,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RXR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2XW.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YA;6]R=&EZ960@8V]S=',@;V8@
M=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3DY
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C:&%S960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@S+#,S,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X
M,RPS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C@S+#,S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L,S$T+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,34X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8L,C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S8L,C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@T+#(Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$X-"PR,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#DV.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#8X-2PS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Q-"PW,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,3,L-S$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&ER871I;VX@9&%T92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^2F%N(#,Q+`T*"0DR,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG
M(&1A=&4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^2G5N(#,P+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^3V-T(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A
M;'5E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`U+#`V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-C(L,3DV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$R-"PX-S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,S(L,C(X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#0R-"PY.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,S+#`T-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#DX,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#DX,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#4T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<Q,2PY-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-3`U+#(T-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PY.3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>2!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4N.#DE
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0U+C@T)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#0N.#$E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0N-S$E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"XV-"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"XW."4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,2XX,R4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#4N.30E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#$N,#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+C0T)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RXX.24\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"XR.24\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#0N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(')A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2XX.24\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XT,24\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N,#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XW-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N-S4E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW,B4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+CDQ)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C(S)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#@E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$N-38E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,N-#@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XX."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#DN,#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV:61E
M;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!D969E<G)E9"!F:6YA;F-I
M;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-3,R+#(R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-30W+#(Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(V,"PP,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X+#<Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!F:6YA;F-I;F<@
M8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V,"PP,C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#0U,2PY,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!P=7)C
M:&%S960@9F]R9F5I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#,S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5F%L=6%T:6]N(&UE=&AO9"!O9B!W87)R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=";&%C:RU38VAO
M;&5S($UO9&5L/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUC87-H(&-O;7!E;G-A=&EO;B!R96-O;F=I<V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U+#`V-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<L
M,#,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,V,"PU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,3@L,#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPQ-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPR.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPR
M.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS92US:&]R
M="!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34T+#`V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,V,"PU,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS-C`L-3(X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V4M;&]N9R!T97)M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`X+#$R
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4Y,RPQ,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU.3,L,3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(&)Y
M(')E;&%T:79E(&9A:7(@=F%L=64@8V%L8W5L871I;VX@;65T:&]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-C0Y+#@Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I
M;FEN9R!A;6]R=&EZ871I;VX@9&5F97)R960@9FEN86YC:6YG(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#$P,BPV.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#4Y+#8T-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!O9B!U;F%F9FEL:6%T960@:6YD:79I9'5A;',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V9E<W-I
M;VYA;"!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDL-S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C4V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!V97-T:6YG('!E<FEO9"!O9B!W
M87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)U1H92!787)R86YT<R!V97-T(&]V97(@82`T
M-"UM;VYT:"!P97)I;V0@8F5G:6YN:6YG(&]N($YO=F5M8F5R(#(Q+"`R,#$Q
M("AO<B`Q,RPV,S8@<VAA<F5S(&9O<B!M;VYT:',@,2TT,R!A;F0@,3,L-C4R
M('-H87)E<R!F;W(@;6]N=&@@-#0I+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=787)R86YT<R!V97-T960@
M870@=&AE(')A=&4@;V8@86X@86=G<F5G871E(&]F(#<V+#<Q-"!S:&%R97,@
M<&5R(&-A;&5N9&%R('%U87)T97(@96YD+CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9W)E96UE;G0@8V]V97)I;F<@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@;6]N=&AS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;F%N8VEN9R!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U+#DX,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IA=&EO;B!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(L-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3,L-34Q+#(V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#DR+#,V,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-RPR-#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DS-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-C$R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36EN:6UU;2!V;VQA=&EL:71Y(')A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS.2XQ,R4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!V
M;VQA=&EL:71Y(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2XQ
M-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36EN:6UU;2!R:7-K(&9R964@<F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N,S@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@<FES:R!F
M<F5E(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C8U)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:6YE(&]F(&-R961I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3<Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-SDL,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3DL,C(P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C$S+#<Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@=V%R<F%N=',@=F5S=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V,BPU
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N(&=U87)A;G1Y(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.30T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-2PP,S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,X
M+#$U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#DT-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#4L
M,#,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S."PQ-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?
M83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V,T
M-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE971S
M+U-H965T-3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5/5$%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-43T-+2$],1$524R<@15%52519("A$971A:6QS($YA<G)A=&EV
M92`R*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R<R!O9B!O<'1I;VYS(&]U<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RPR,#<L,C,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#@V."PS-#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y
M,"PU,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L('5N<F5C;V=N:7IE9"!E<W1I;6%T960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.3(Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0L,SDQ+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(T-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G;FEZ960@=V5I9VAT960M
M879E<F%G92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<Q('EE87(@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;B!E>&5R8VES92!P
M<FEC97,@*&EN(&1O;&QA<G,@<&5R('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&5X97)C:7-E('!R:6-E
M<R`H:6X@9&]L;&%R<R!P97(@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T+C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,#D@3&]N9R!497)M($EN8V5N=&EV
M92!#;VUP96YS871I;VX@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!P;&%N/"]T9#X-"B`@("`@("`@
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M97,L(&]R('1H92!!=V%R9',N(#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&%U=&AO
M<FEZ960@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV,S(L-S0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M;B!1=6%L:69I960@,C`Q,B!3=&]C:R!);F-E;G1I=F4@4&QA;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O9B!P
M;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4&QA;B!W87,@
M9&5S:6=N960@=&\@<V5R=F4@87,@86X@:6YC96YT:79E(&9O<B!R971A:6YI
M;F<@<75A;&EF:65D(&%N9"!C;VUP971E;G0@:V5Y(&5M<&QO>65E<RP@;V9F
M:6-E<G,L(&1I<F5C=&]R<RP@86YD(&-E<G1A:6X@8V]N<W5L=&%N=',@86YD
M(&%D=FES;W)S(&]F(&]U<B!C;VUP86YY+CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S
M(&%U=&AO<FEZ960@9F]R(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@:7-S
M=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8U,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F]N(%%U86QI9FEE9"`R,#$R(%-T;V-K($EN8V5N=&EV92!0;&%N('P@
M4F5S=')I8W1E9"!S=&]C:R!U;FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPT,C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F('-H87)E<R!P=7)C:&%S960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y697-T:6YG(&1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<R,#$T+3`T+3`Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,S+#4P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V
M8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U
M.3<T960Y+U=O<FMS:&5E=',O4VAE970U,2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15<R04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)5%D@
M*$1E=&%I;',I("A787)R86YT<RP@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.=6UB97(@;V8@
M<VAA<F5S('5N9&5R('=A<G)A;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@;W5T<W1A;F1I;F<L(&)E
M9VEN;FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,3DS
M+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#4W+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,S,R
M+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,#4W+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I<V5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH."PQ-#4L-#@V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&5X<&ER960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@8V%N8V5L;&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3$L,30R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!E;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#(Y,RPT.3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPQ.3,L-#DY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP
M-3<L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y697-T960@86YD($5X97)C:7-A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPW-C0L-S$P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT
M960@079E<F%G92!%>&5R8VES92!0<FEC93PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN
M9RP@8F5G:6YN:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BXW,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$N,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP+C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!E>&5R8VES960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@8V%N8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XR-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!E;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C8S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N
M9"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2XX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O
M;G1R86-T=6%L($QI9F4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@;W5T<W1A;F1I;F<L(&)E9VEN;FEN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#$P
M(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`Y(&UO;G1H<R`Q."!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S0@>65A<G,@,R!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S(#$P(&UO;G1H<R`R
M-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!O=71S=&%N9&EN9RP@96YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!Y96%R<R`Q,"!M;VYT:',@,C0@
M9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG-R!Y96%R<R`Q,"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N9"!%
M>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@
M>65A<G,@,3`@;6]N=&AS(#(T(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9V=R96=A=&4@
M26YT<FEN<VEC(%9A;'5E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&]U='-T86YD:6YG+"!B96=I;FYI
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3<L.3<Q+#DY
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPT.#,L-CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#(S,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PX.3$L,34P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT.#,L-CDQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!O=71S=&%N9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT."PY,S(L-S<W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L.3<Q+#DY-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#@S+#8Y
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F5S=&5D(&%N9"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T-BPX-#`L-34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V
M7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C
M-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T
M<R]3:&5E=#4R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%23)!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H1&5T86EL<R`Q*2`H5V%R
M<F%N=',L(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!F86ER('9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N.#,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1E<FT@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L
M87-S(&]F(%=A<G)A;G0@;W(@4FEG:'0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C@X)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N-S(E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XY,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0T+C(Y)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+C8T)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y+C$S)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5R;2`H:6X@
M>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%=A<G)A;G0@;W(@4FEG:'0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C$R)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,#0E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXT."4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T
M:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+C@Y)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T
M+C@Q)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4Q+C@S)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&5R;2`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R
M8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R
M:W-H965T<R]3:&5E=#4S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1%1!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H1&5T86EL<R`R
M*2`H4W1O8VL@3W!T:6]N<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI
M;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H
M87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP+C8U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N-C$E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XY,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(%9O;&%T:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+C,U)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+C<W)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+CDR)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP96-T960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)S4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<U('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E
M<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C<Q
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(N,C,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BXU-"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D(%9O;&%T:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0U+C<V)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+C`Q)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+C0X)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S8@>65A
M<G,@,R!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-B!Y96%R<R`S(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S(#,@;6]N=&AS
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C
M-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E
M-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970U-"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14DU
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TM(3TQ$15)3)R!%455)
M5%D@*$1E=&%I;',@,RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3G5M
M8F5R($]P=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!O=71S=&%N9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY.=6UB97(@3W!T:6]N<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T86YD:6YG+"!B96=I;FYI;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#<S,RPT.#@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PU.3`L
M,38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#4X,RPV-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#$R,2PR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PV.#(L,C$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE
M<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-2PT,C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PY,S$L-S@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DR+#`U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@17AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C4P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($-A;F-E;&QE9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C`X+#<U,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-BPQ,S4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!O=71S=&%N9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-2PV,S(L-S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-S,S+#0X.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#4Y,"PQ-C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!A;F0@97AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#(X,BPV
M,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY7
M96EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<L(&)E9VEN;FEN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I
M;VYS(&]U='-T86YD:6YG+"!E;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XT-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5F5S=&5D(&%N9"!E>&5R8VES86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@;W5T<W1A;F1I;F<L(&)E9VEN;FEN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,@."!M;VYT:',@
M,3(@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<W('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<Y('EE87)S(#D@;6]N=&AS(#$X(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG.2!Y96%R
M<R`X(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,@-R!M;VYT:',@-B!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^
M6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@;W5T<W1A;F1I;F<L(&5N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S<@>65A<G,@,B!M;VYT:',@,3(@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S
M(#@@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<R`W(&UO;G1H<R`V(&1A>7,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!A;F0@97AE<F-I
M<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<V('EE87)S
M(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06=G<F5G871E($EN=')I;G-I8R!686QU93PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS(&]U='-T86YD:6YG+"!B96=I;FYI
M;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8L.#`T+#$Q
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,30L,#8W+#8T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PY
M,C`L.3@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#<S-RPU,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$T+#$X."PT.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!O=71S=&%N
M9&EN9RP@96YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M."PX-S@L,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C8L.#`T+#$Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$T+#`V-RPV-#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E9E<W1E9"!A;F0@97AE<F-I<V%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#@L,S(Q+#DS,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@8V]L<W!A;CTS
M1#4^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE
M<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^
M#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^5&AI<R!I
M;F-L=61E<R`H:2D@5FET84UE9"!/<'1I;VYS(&=R86YT960@8F5T=V5E;B!/
M8W1O8F5R(#(P,#@@86YD($1E8V5M8F5R(#,Q+"`R,#$P(&9O<B!A;B!A9V=R
M96=A=&4@;V8@-RPV,SDL-S(R(%5N:71S+"!O9B!W:&EC:"`Q-BPP,#`@=V5R
M92!C86YC96QE9"!P<FEO<B!T;R!C;VYV97)S:6]N("AO<B!/<'1I;VYS(&9O
M<B`Y+#,U-RPU-C$@<VAA<F5S('!E<B!T:&4@0V]N=F5R<VEO;B!2871I;RDL
M("AI:2D@5FET84UE9"!/<'1I;VYS(&=R86YT960@8F5T=V5E;B!*86YU87)Y
M(#$L(#(P,3$@86YD($]C=&]B97(@,RP@,C`Q,2!F;W(@86X@86=G<F5G871E
M(&]F(#8R,2PP,#`@56YI=',@*&]R($]P=&EO;G,@9F]R(#<V,BPR,S4@<VAA
M<F5S('!E<B!T:&4@0V]N=F5R<VEO;B!2871I;RD@86YD("AI:6DI($]P=&EO
M;G,@9W)A;G1E9"!B971W965N($]C=&]B97(@-"P@,C`Q,2!A;F0@1&5C96UB
M97(@,S$L(#(P,3$@9F]R(&%N(&%G9W)E9V%T92!O9B`U-C(L-#(R('-H87)E
M<RX@5&AE('1E<FUS(&%N9"!C;VYD:71I;VYS(&]F('1H92!6:71A365D($]P
M=&EO;G,@=V5R92!R969L96-T960@:6X@=&AE(')E<&QA8V5M96YT($]P=&EO
M;G,@:6YC;'5D:6YG('1H92!N=6UB97(@;V8@<VAA<F5S('9E<W1E9"X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8S0V8S4P-F-?-#%E9E\T,C)C7V(W
M-C9?83!E-V$U.3<T960Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.2]7;W)K<VAE
M971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T3D%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/DE.0T]-12!405A%4R`H1&5T86EL<R!.87)R871I=F4I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9E9&5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S<L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C
M7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970U-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14Y,04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^24Y#3TU%(%1!
M6$53("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D
M($EN8V]M92!487@@07-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"PW-S,L-3,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#DR
M,"PX-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#<T."PT,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E(F86UP.T0@0W)E9&ET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-#<L-3$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@V+#,T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!D969E
M<G)E9"!I;F-O;64@=&%X(&%S<V5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-2PS,C$L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-BPQ,#<L,C`W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0X+#0P-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N
M(&%L;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34L
M,S(Q+#`T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@V+#$P-RPR,#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-S0X+#0P-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!);F-O;64@
M5&%X($%S<V5T<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R
M,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#4W+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%5TQ!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3D-/344@
M5$%815,@*$1E=&%I;',@,2D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9E9&5R86P@<W1A='5T;W)Y('1A>"!R871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T871E('1A>"!R871E+"!N970@;V8@9F5D97)A;"!T87@@8F5N969I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XX,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C4P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9&IU<W1M96YT(&EN('9A;'5A=&EO;B!A;&QO=V%N8V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,BXT,"4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3@N,C`E*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4N.#`E*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&5R;6%N96YT(&%N9"!O=&AE<B!D:69F97)E;F-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH."XT,"4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(N,S`E*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y+C(P)2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I
M<VEO;B`H0F5N969I="D@9F]R($EN8V]M92!487AE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R
M,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O
M<FMS:&5E=',O4VAE970U."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15951$D^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4D5,051%1"!005)42453("A$971A:6QS($YA<G)A
M=&EV92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0V
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0S/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,#0L(#(P,3$\8G(^06=R965M96YT(&%N9"!0;&%N
M(&]F($UE<F=E<B!W:71H(%9I=&%-960\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY"<FEA;B!"97)N:6-K/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^0G)I86X@0F5R;FEC:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/D)R:6%N($)E<FYI8VL\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY3=&]C
M:R!0=7)C:&%S92!!9W)E96UE;G0@5VET:"!097)N:7@@5&AE<F%P975T:6-S
M($Q,0SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/E-T;V-K(%!U<F-H87-E($%G<F5E;65N="!7:71H(%!E<FYI
M>"!4:&5R87!E=71I8W,@3$Q#/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^4W1O8VL@4'5R8VAA<V4@06=R965M
M96YT(%=I=&@@4&5R;FEX(%1H97)A<&5U=&EC<R!,3$,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY.;VXM869F
M:6QI871E9"!T:&ER9"!P87)T>3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y.;W8N(#$S+"`R,#$R/&)R/DUR+B!&:6YI>FEO/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,3,L(#(P,3(\8G(^37(N
M($UI;&QI9V%N/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO
M=BX@,3,L(#(P,3(\8G(^4F5I8V@@1F%M:6QY($QI;6ET960@3%`\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,CQB<CY6
M:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^3V-T+B`S,"P@,C`Q,3QB<CY6:71A365D(%!R;VUI<W-O
M<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,3QB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`Q,RP@,C`Q,CQB<CY6
M:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CY6:71A365D(%!R;VUI<W-O
M<GD@3F]T97,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T
M+B`P-"P@,C`Q,CQB<CY6:71A365D(%!R;VUI<W-O<GD@3F]T97,\8G(^0G)I
M86X@0F5R;FEC:SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$R/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB<CY"
M<FEA;B!"97)N:6-K/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R
M/DUR+B!&:6YI>FEO/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA<BX@,S$L(#(P,3$\8G(^5FET84UE9"!0<F]M:7-S;W)Y($YO=&5S/&)R
M/DUR+B!-:6QL:6=A;CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$Q/&)R/E9I=&%-960@4')O;6ES<V]R>2!.;W1E<SQB
M<CY296EC:"!&86UI;'D@3&EM:71E9"!,4#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/DYO=&5S($ES<W5E9"!T
M;R!-<BX@1FEN:7II;R!!;F0@37(N($UI;&QI9V%N/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^3F]T97,@27-S
M=65D('1O($UR+B!&:6YI>FEO/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D]C="X@,#0L(#(P,3(\8G(^3F]T97,@27-S=65D('1O($UR+B!-
M:6QL:6=A;CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6YE(&]F(&-R961I=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$W.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y.2PR,C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E('!R:6YC
M:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G
M871E(')E;6%I;FEN9R!P<FEN8VEP86P@86UO=6YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E<&%Y;65N=',@;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV.3$L.#0W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8W)U960@:6YT97)E<W0@<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$R+#@U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$W+#(U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS
M-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-3$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@<F5S97)V960@9F]R(&9U='5R92!I
M<W-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@
M;V8@;&]C:R!I;B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B=%86-H('-T;V-K:&]L9&5R(&%G<F5E9"!T:&%T(&1U<FEN9R!A
M(&QO8VLM=7`@<&5R:6]D(&9R;VT@=&AE(&1A=&4@;V8@=&AE(&QO8VLM=7`@
M86=R965M96YT<R!U;G1I;"`Q.`T*;6]N=&AS('1H97)E869T97(@=&AE>2!W
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;G-A8W1I;VX@86UO=6YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8S,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#8V
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5I=F%B;&5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&5G86P@9F5E(')E:6UB=7)S96UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T.2PY.#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,@<'5R8VAA<V5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$S
M+#<Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R8U]B-S8V7V$P93=A-3DW-&5D
M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-#9C-3`V8U\T,65F
M7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R:W-H965T<R]3:&5E=#4Y+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%25A!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"55-)
M3D534R!#3TY#14Y44D%424].4R`H1&5T86EL<R!.87)R871I=F4I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5P<&QI
M97(@0V]N8V5N=')A=&EO;B!2:7-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VYC96YT<F%T:6]N(%)I<VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDX+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92`M(%!R
M97-C<FEP=&EO;B!D:65T87)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYC96YT<F%T:6]N(%)I<VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<Y+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8S+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(%)E=F5N=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC
M96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;F-E;G1R871I;VX@4FES
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]N8V5N=')A=&EO;B!2:7-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A
M,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V
M8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O
M4VAE970V,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P139%044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,@*$1E=&%I;',@
M3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!$:7-C;&]S=7)E(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;VXM8V%N8V5L86)L92!O<&5R871I;F<@;&5A<V4@=&5R;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-C,@;6]N=&AS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO
M;G1H;'D@0F%S92!R96YT(&]F(&QE87-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,P+#$T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU;2!L96%S
M92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW
M-C8L,C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-S8V+#(U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y296YT86P@17AP96YS93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#@Y-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#$V.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#8L,S$U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(R
M+#<U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5N=&%L($EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S,BPY-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y
M-S1E9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?
M-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970V
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13-'04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M0T]-34E4345.5%,@04Y$($-/3E1)3D=%3D-)15,@*$1E=&%I;',I("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY&=71U<F4@;6EN:6UU;2!R96YT86P@<&%Y;65N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S$V+#`S.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<Q+#(T,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@R+#,W-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDS+#@T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`R+#<T.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PW-C8L,C4R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYC86YC96QA8FQE('-U8BUL
M96%S92!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X
M+#DU-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<R-RPR.38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?-#(R
M8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO5V]R
M:W-H965T<R]3:&5E=#8R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4C9!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY314Q%0U1%1"!154%25$523%D@1DE.04Y#24%,($1!
M5$$@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E%U87)T97)L>2!&:6YA;F-I86P@26YF;W)M871I;VX@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPX-C,L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(Y-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(L,#@Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2PU,S<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(T,2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,#,V+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M.#$Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-S(R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@."PW-S4L-3DX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#@Q."PP,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,#@X
M+#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1W)O<W,@<')O9FET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#,Y-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8T-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8Q-RPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$U-RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#@L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S(Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS.#8L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX,38L,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-CDL.3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M-#$L,#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@X+#,V,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@W+#8W,RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#`P.2PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+#,W
M-BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@U+#<R-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@T+#(U,RPP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PX-3`L,#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,3,L,CDP+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#(X+#0Q.2PS,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@S-2PQ,C`L,C,U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3(L.3$S
M+#,V-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQO<W,@<&5R(&-O;6UO;B!S:&%R92P@8F%S:6,@86YD(&1I;'5T
M960@*&EN(&1O;&QA<G,@<&5R('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H,"XP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XP-BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N
M,#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XQ-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XS."D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,C$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-#9C
M-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#D-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E
M-V$U.3<T960Y+U=O<FMS:&5E=',O4VAE970V,RYH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15)*
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U5"4T51545.5"!%5D5.5%,@
M*$1E=&%I;',@3F%R<F%T:79E*2`H4W1O8VL@3W!T:6]N<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2F%N+B`P-BP@,C`Q-#QB<CY3=6)S97%U96YT($5V96YT/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($=R
M86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3@S+#8W
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,3(Q+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#8X,BPR,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,Y,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$871E(&%W87)D<R!V97-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q-"TQ,BTS,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O
M;'-P86X],T0V/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;
M,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#4@=F%L:6=N/3-$=&]P
M/E1H:7,@:6YC;'5D97,@*&DI(%9I=&%-960@3W!T:6]N<R!G<F%N=&5D(&)E
M='=E96X@3V-T;V)E<B`R,#`X(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"!F;W(@
M86X@86=G<F5G871E(&]F(#<L-C,Y+#<R,B!5;FET<RP@;V8@=VAI8V@@,38L
M,#`P('=E<F4@8V%N8V5L960@<')I;W(@=&\@8V]N=F5R<VEO;B`H;W(@3W!T
M:6]N<R!F;W(@.2PS-3<L-38Q('-H87)E<R!P97(@=&AE($-O;G9E<G-I;VX@
M4F%T:6\I+"`H:6DI(%9I=&%-960@3W!T:6]N<R!G<F%N=&5D(&)E='=E96X@
M2F%N=6%R>2`Q+"`R,#$Q(&%N9"!/8W1O8F5R(#,L(#(P,3$@9F]R(&%N(&%G
M9W)E9V%T92!O9B`V,C$L,#`P(%5N:71S("AO<B!/<'1I;VYS(&9O<B`W-C(L
M,C,U('-H87)E<R!P97(@=&AE($-O;G9E<G-I;VX@4F%T:6\I(&%N9"`H:6EI
M*2!/<'1I;VYS(&=R86YT960@8F5T=V5E;B!/8W1O8F5R(#0L(#(P,3$@86YD
M($1E8V5M8F5R(#,Q+"`R,#$Q(&9O<B!A;B!A9V=R96=A=&4@;V8@-38R+#0R
M,B!S:&%R97,N(%1H92!T97)M<R!A;F0@8V]N9&ET:6]N<R!O9B!T:&4@5FET
M84UE9"!/<'1I;VYS('=E<F4@<F5F;&5C=&5D(&EN('1H92!R97!L86-E;65N
M="!/<'1I;VYS(&EN8VQU9&EN9R!T:&4@;G5M8F5R(&]F('-H87)E<R!V97-T
M960N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V,T-F,U,#9C7S0Q969?
M-#(R8U]B-S8V7V$P93=A-3DW-&5D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B]C-#9C-3`V8U\T,65F7S0R,F-?8C<V-E]A,&4W834Y-S1E9#DO
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M:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0Q+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970T,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0T+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#0W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T."YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#DN:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#4P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970U,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3(N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4S+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970U-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4V+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#4Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V,"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C$N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#8R+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970V,RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?
H8S0V8S4P-F-?-#%E9E\T,C)C7V(W-C9?83!E-V$U.3<T960Y+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2014</a></td>
        <td class="nump">$ 4,080<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2015</a></td>
        <td class="nump">1,997<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2016</a></td>
        <td class="nump">1,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2017</a></td>
        <td class="nump">1,997<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2018</a></td>
        <td class="nump">$ 1,997<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the next fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fifth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the fourth fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the third fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense expected to be recognized during the second fiscal year following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued payroll and commission costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">941,313</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">397,210</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">256,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,899</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Allowance for wholesale distributor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107,784</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued legal and accounting expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued lab research</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">536,574</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Accrued clinical trial costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Allowance for coupons and returns</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,002</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses<sup>(1)</sup></font></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">230,088</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">70,759</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">&#160;TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,601,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">833,654</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<div style="text-align: left; margin-left: 36pt; margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&#160;</div></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><sup>(1) </sup>In June 2008, we declared and paid a special
dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed
by certain shareholders at December 31, 2013 and 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncontrollingInterestAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of&#160;December&#160;31, 2013&#160;and&#160;December&#160;31,
2012:&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; background-color: white">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">December&#160;31,
    2013</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Gross<br />Carrying<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Weighted-<br />Average<br />Amortization<br />Period&#160;(yrs.)</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif"><b>Amortizing intangible assets:</b></font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; width: 40%"><font style="font-family: Times New Roman, Times, Serif">OPERA&#174; software patent</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">31,951</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">(499</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">31,452</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">15.8</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Development
    costs for corporate website</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(89,661</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,082</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.3</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif"><b>Non-amortizing
    intangible assets:</b></font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-left: 12pt; text-indent: -12pt"><font style="font-family: Times New Roman, Times, Serif">Hormone
    therapy drug candidate patents</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">572,726</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">572,726</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Multiple
    trademarks for vitamins/supplements</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">59,328</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">59,328</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 24pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">755,748</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(90,160</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">665,588</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">December&#160;31,
    2012</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Gross<br />Carrying<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Weighted-<br />Average<br />Amortization<br />Period&#160;(yrs.)</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 40%"><font style="font-family: Times New Roman, Times, Serif">OPERA
    &#174; software patent</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">23,722</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">0</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">23,722</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">0</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Development
    costs for corporate website</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(77,159</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">14,584</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.3</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Hormone
    therapy drug candidate patents</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,194</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,194</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Multiple
    trademarks for vitamins/supplements</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">21,055</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">21,055</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">316,714</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(77,159</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">239,555</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">Estimated amortization expense for the next
five years is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Year Ending December 31,</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Estimated Amortization</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2014</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">4,080</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,997</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating losses</a></td>
        <td class="nump">$ 14,773,537<span></span></td>
        <td class="nump">$ 5,920,861<span></span></td>
        <td class="nump">$ 748,404<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D Credit</a></td>
        <td class="nump">547,511<span></span></td>
        <td class="nump">186,346<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
        <td class="nump">15,321,048<span></span></td>
        <td class="nump">6,107,207<span></span></td>
        <td class="nump">748,404<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(15,321,048)<span></span></td>
        <td class="num">(6,107,207)<span></span></td>
        <td class="num">(748,404)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Income Tax Assets, net</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredIncomeTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DeferredIncomeTaxAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible loss carryforwards not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOtherLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, amount per share</a></td>
        <td class="nump">$ 0.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnclaimedDividends', window );">Unclaimed dividends</a></td>
        <td class="nump">$ 41,359<span></span></td>
        <td class="nump">$ 41,359<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnclaimedDividends">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of dividend which have been paid by the entity but not claimed by the shareholder</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_UnclaimedDividends</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DividendsPayableAmountPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><u>Summary of our Warrant activity and related information for
2011-2013</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares Under Warrants</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life in Years</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate Intrinsic Value</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2010</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt; width: 40%">Issued</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%">3,057,627</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 11%">0.36</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%">7.9</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 11%">3,483,691</td>
    <td style="text-align: left; width: 1%">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#9472;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2011</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,057,627</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.36</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7.9</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">3,483,691</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Issued</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">17,332,500</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.26</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.3</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">31,891,150</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(8,145,486</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.38</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(51,142</td>
    <td style="text-align: left; padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.24</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2012</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">12,193,499</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.63</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">17,971,994</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Issued</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,100,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2.72</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4.8</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">5,232,500</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#9472;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2013</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right">14,293,499</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.79</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3.9</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">48,932,777</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Vested and Exercisable at December 31, 2013</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right">13,764,710</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.81</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3.9</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">46,840,559</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock', window );">Schedule of weighted average fair value per share and assumptions used in the Black-Scholes Model of warants</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are
set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 90%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2013</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2012</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2011</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; width: 49%">Weighted average fair value</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 13%">2.83</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 13%">2.05</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 13%">0.16</td>
    <td style="text-align: left; width: 1%">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12</font></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">0.72-1.04</font></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">0.91-3.48</font></td>
    <td style="text-align: left">%</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89</font></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">44.64-44.81</font></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">39.13-51.83</font></td>
    <td style="text-align: left">%</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Term (in years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">5-10</font></td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.00</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.00</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.00</td>
    <td style="text-align: left">%</td></tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The assumptions
used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.61-2.23</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.91-2.54</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.77-46.01</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37.92-40.48</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.5-6.25</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt">Dividend yield</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option activity</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of activity under the 2009 and 2012 Plans and related
information for 2011-2013 follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Number of Shares Under Options</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life in Years</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Aggregate Intrinsic Value</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2010</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt; width: 40%">Granted<sup>(1)</sup></td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%">10,682,218</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 11%">0.16</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="text-align: right; width: 11%">7.6</td>
    <td style="text-align: left; width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 11%">14,188,484</td>
    <td style="text-align: left; width: 1%">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(92,057</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.19</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">&#9472;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2011</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">10,590,161</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.16</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7.6</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">14,067,649</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5,121,250</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2.80</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9.7</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,737,530</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,931,788</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">0.13</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#9472;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(46,135</td>
    <td style="text-align: left; padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2012</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">13,733,488</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.16</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7.7</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">26,804,117</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,583,677</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">3.31</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9.8</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">4,920,981</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Exercised</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(75,423</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 22pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(250</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 22pt">Cancelled</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right">(608,750</td>
    <td style="text-align: left; padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance at December 31, 2013</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right">15,632,742</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1.44</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7.2</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">58,878,132</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Vested and Exercisable at December 31, 2013</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: black 2.5pt double; text-align: right">11,282,627</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">.80</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">6.5</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">48,321,930</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)</sup>This includes (i) VitaMed Options
granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to
conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and
October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted
between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options
were reflected in the replacement Options including the number of shares vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of schedule of weighted average fair value per share and valuation assumptions of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ScheduleOfWeightedAverageFairValuePerShareAndValuationAssumptionsOfWarrantsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our deferred tax asset and liability as presented
in the accompanying consolidated financial statements consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 22pt; text-indent: -10pt">Net operating losses</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,773,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">5,920,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">748,404</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">R&#38;D Credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">547,511</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Total deferred income tax asset </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,321,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,107,207</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">748,404</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,321,048</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,107,207</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(748,404</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax rate reconciliation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 10pt; text-indent: -10pt">Federal statutory tax rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.8</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Permanent and other differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8.4</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(22.3</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29.2</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Provision (Benefit) for Income Taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>NOTE
2 &#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Principles of Consolidation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">We
maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses
related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting
from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no
limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per
depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured
limits.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal; letter-spacing: 0pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal; letter-spacing: 0pt"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal; letter-spacing: 0pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <font style="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Inventories</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">Inventories
represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using
the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed
in <u>Revenue Recognition</u>) are recorded as deferred costs and are included in inventory, until such time as the related deferred
revenue is recognized.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Fixed Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Equipment</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Leasehold
Improvements</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Intangible</u> </font><u>Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Patent
and Trademarks</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We have
adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350,
<i>Intangible-Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted
in the year ended December 31, 2013.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Impairment of Long-Lived Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property and
equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying
values may not be recoverable. Such events or circumstances include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         declines in an asset&#146;s market price;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         deterioration in an asset&#146;s physical condition;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         changes in the nature or extent of an asset&#146;s use or operation;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         adverse changes in the business climate that could impact an asset&#146;s value, including
                                         adverse actions or assessments by regulators; </td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">accumulation
                                         of costs significantly in excess of original expectations related to the acquisition
                                         or construction of an asset;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">current-period
                                         operating or cash flow losses combined with a history of such losses or a forecast that
                                         demonstrates continuing losses associated with an asset&#146;s use; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">expectations
                                         that it is more likely than not that an asset will be sold or otherwise disposed of significantly
                                         before the end of its previously estimated useful life.</td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&#146;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future
cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a
loss for the difference between the assets&#146; fair value and respective carrying value. We determine the fair value of the
assets using an &#147;income approach&#148; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected
selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships,
market conditions, and available external information about future trends. We believe our current assumptions and estimates are
reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting
in the need for an impairment charge in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts
payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered
Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short-
and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which
would be considered Level 3 inputs under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements
and Disclosures. </i> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets
and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities recorded in the consolidated
balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 36pt"></td><td style="width: 54pt; text-align: left"><b>Level 1</b></td><td style="text-align: justify">unadjusted quoted prices in active markets for identical
assets or liabilities;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td></td><td style="text-align: left"><b>Level 2</b></td><td style="text-align: justify">quoted prices for similar assets or liabilities in active
markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td></td><td style="text-align: left"><b>Level 3</b></td><td style="text-align: justify">unobservable inputs for the asset or liability.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, 2012, and 2011, we had
no assets or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="letter-spacing: 0pt"><u>Income
Taxes</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="letter-spacing: 0pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the advent of the Merger, we determined
that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because
of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4,
2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating
to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Share-Based Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2004, the FASB issued ASC 718,
<i>Compensation &#150; Stock Compensation</i>,<i> </i>or<i> </i>ASC 718. Under ASC 718, companies are required to measure the
compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial
statements over the period during which employees are required to provide services. Share-based compensation arrangements include
options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase
plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any,
over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,
an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the
expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of
the award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&#147;instruments&#148;)
issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC
505, <i>Equity Based Payments to Non-Employees</i>,<i> </i>or ASC 505<i>, </i>defines the measurement date and recognition period
for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b)
the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the
instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&#146;s requisite service period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Debt Discounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Revenue Recognition</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Over-the-Counter Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <font style="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</font>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Prescription Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">We sell our name
brand and generic prescription products </font>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product from
customers within a return period of six months prior to and following product expiration. Our prescription products currently have
a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot
reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue
on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products
are dispensed through patient prescriptions or expiration of the right of return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an effort
to maintain<i> </i>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program
is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We
estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary,
on a quarterly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Shipping and Handling Costs</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Advertising Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31,
2012, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Research and Development Expenses</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&#38;D, expenses
include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based
compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity
expenses include regulatory consulting and legal counsel. We charge internal R&#38;D activities and other activity expenses to
operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting
date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the
activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed
in future R&#38;D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively.
We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those
costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings Per Share</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS, in
accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and
diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We
compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options
and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our
Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these
periods because their effect would have been anti-dilutive due to the net loss reported by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Use
of Estimates</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Recently Issued Accounting Pronouncements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July, 2013, the FASB issued
Accounting Standards Update, or ASU, No. 2013-11, <i>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when
a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues
Task Force)</i>,<i> </i>or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation
of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.
An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating
loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized
tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new
recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning
after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2012, the FASB issued ASU No. 2012-02,
<i>Testing Indefinite-Lived Intangible Assets for Impairment</i>,<i> </i>or ASU 2012-02. ASU 2012-02 gives entities an option to
first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely
than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it
is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative
impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU
2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with
early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
<i>Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities</i>, or ASU 2011-11<i>.</i> ASU 2011-11 enhances
current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial
position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset
on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities
in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared
on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on
or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our
financial position or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassifications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain 2012 amounts have been reclassified to conform
to current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2013, future minimum rental payments are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center; border-bottom: Black 1pt solid; padding-left: 10pt">Years Ending December 31,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: center; padding-left: 0pt">2014</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">316,039</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 0pt">2015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,240</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 0pt">2016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 0pt">2017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">393,848</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 0pt">2018</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">302,748</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Total minimum lease payments</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,766,252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Noncancelable sub-lease income</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(38,956</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Net minimum lease payments</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,727,296</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsAndContingenciesTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_CommitmentsAndContingenciesTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>PREPAID EXPENSE (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent', window );">Prepaid R&amp;D costs</a></td>
        <td class="nump">$ 824,221<span></span></td>
        <td class="nump">$ 953,655<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsNoncurrent', window );">Prepaid manufacturing costs</a></td>
        <td class="nump">899,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidAccreditedCostsNoncurrent', window );">Accreted prepaid costs</a></td>
        <td class="nump">27,234<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">TOTAL PREPAID EXPENSE</a></td>
        <td class="nump">$ 1,750,455<span></span></td>
        <td class="nump">$ 953,655<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidAccreditedCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of accredited contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidAccreditedCostsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidManufacturingCostsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidResearchDevelopmentCostsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) (Stock Options)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">0.65%<span></span></td>
        <td class="nump">0.61%<span></span></td>
        <td class="nump">0.91%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
        <td class="nump">33.35%<span></span></td>
        <td class="nump">40.77%<span></span></td>
        <td class="nump">37.92%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years 6 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.71%<span></span></td>
        <td class="nump">2.23%<span></span></td>
        <td class="nump">2.54%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
        <td class="nump">45.76%<span></span></td>
        <td class="nump">46.01%<span></span></td>
        <td class="nump">40.48%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">6 years 3 months<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 54,191,260<span></span></td>
        <td class="nump">$ 1,553,474<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $26,555 and $42,048, respectively</a></td>
        <td class="nump">1,690,753<span></span></td>
        <td class="nump">714,425<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump">1,043,618<span></span></td>
        <td class="nump">1,615,210<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
        <td class="nump">2,477,715<span></span></td>
        <td class="nump">751,938<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">59,403,346<span></span></td>
        <td class="nump">4,635,047<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
        <td class="nump">61,318<span></span></td>
        <td class="nump">65,673<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expense</a></td>
        <td class="nump">1,750,455<span></span></td>
        <td class="nump">953,655<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
        <td class="nump">665,588<span></span></td>
        <td class="nump">239,555<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
        <td class="nump">135,686<span></span></td>
        <td class="nump">31,949<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
        <td class="nump">2,551,729<span></span></td>
        <td class="nump">1,225,159<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">62,016,393<span></span></td>
        <td class="nump">5,925,879<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">2,114,217<span></span></td>
        <td class="nump">1,641,366<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="nump">1,602,580<span></span></td>
        <td class="nump">1,144,752<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
        <td class="nump">3,601,189<span></span></td>
        <td class="nump">833,654<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">7,317,986<span></span></td>
        <td class="nump">3,619,772<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of debt discount of $0 and $1,102,680, respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,589,167<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued Interest</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">150,068<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-term liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,739,235<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">7,317,986<span></span></td>
        <td class="nump">7,359,007<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 250,000,000 shares authorized; 144,976,757 and 99,784,982 issued and outstanding, respectively</a></td>
        <td class="nump">144,977<span></span></td>
        <td class="nump">99,785<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
        <td class="nump">135,086,056<span></span></td>
        <td class="nump">50,580,400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(80,532,626)<span></span></td>
        <td class="num">(52,113,313)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">54,698,407<span></span></td>
        <td class="num">(1,433,128)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 62,016,393<span></span></td>
        <td class="nump">$ 5,925,879<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.10-17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest payable on debt, including, but not limited to, trade payables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph 5<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPayableCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and commission costs</a></td>
        <td class="nump">$ 941,313<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 397,210<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedFinancingCostsCurrent', window );">Accrued financing costs</a></td>
        <td class="nump">850,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
        <td class="nump">256,920<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">114,899<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
        <td class="nump">306,303<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">107,784<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
        <td class="nump">224,550<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">90,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedLabResearchCurrent', window );">Accrued lab research</a></td>
        <td class="nump">536,574<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
        <td class="nump">129,208<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
        <td class="nump">126,233<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">53,002<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump">230,088<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">70,759<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
        <td class="nump">$ 3,601,189<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 833,654<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AccruedClinicalTrialCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedFinancingCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for financing costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AccruedFinancingCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedLabResearchCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for lab research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AccruedLabResearchCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AllowanceForWholesaleDistributorFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_SalesDiscountsReturnsAndAllowancesGoods1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedProfessionalFeesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedSalariesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 710<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedVacationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECPAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (28,419,313)<span></span></td>
        <td class="num">$ (35,120,235)<span></span></td>
        <td class="num">$ (12,913,365)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount', window );">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(255,753)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">47,883<span></span></td>
        <td class="nump">27,484<span></span></td>
        <td class="nump">25,686<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump">10,262<span></span></td>
        <td class="nump">28,776<span></span></td>
        <td class="nump">29,159<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
        <td class="num">(15,493)<span></span></td>
        <td class="nump">40,548<span></span></td>
        <td class="nump">1,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">10,307,864<span></span></td>
        <td class="nump">7,390,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">6,716,504<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="nump">1,102,680<span></span></td>
        <td class="nump">1,604,240<span></span></td>
        <td class="nump">28,719<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="nump">3,207,238<span></span></td>
        <td class="nump">1,868,345<span></span></td>
        <td class="nump">190,513<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="nump">1,451,934<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">25,980<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock based expense for services</a></td>
        <td class="nump">636,917<span></span></td>
        <td class="nump">338,457<span></span></td>
        <td class="nump">22,630<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LoanGuarantyCosts', window );">Loan guaranty costs</a></td>
        <td class="nump">2,944<span></span></td>
        <td class="nump">45,036<span></span></td>
        <td class="nump">38,159<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(1,068,619)<span></span></td>
        <td class="num">(728,253)<span></span></td>
        <td class="num">(16,409)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
        <td class="nump">571,592<span></span></td>
        <td class="num">(1,027,137)<span></span></td>
        <td class="nump">29,996<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(1,386,319)<span></span></td>
        <td class="nump">42,281<span></span></td>
        <td class="num">(346,822)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
        <td class="num">(565,706)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">472,851<span></span></td>
        <td class="nump">1,334,855<span></span></td>
        <td class="nump">188,876<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Deferred revenue</a></td>
        <td class="nump">457,828<span></span></td>
        <td class="nump">1,144,752<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
        <td class="nump">2,875,320<span></span></td>
        <td class="nump">639,157<span></span></td>
        <td class="nump">594,535<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
        <td class="num">(150,068)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
        <td class="num">(20,768,069)<span></span></td>
        <td class="num">(12,737,326)<span></span></td>
        <td class="num">(4,966,596)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs, net of abandoned costs</a></td>
        <td class="num">(439,034)<span></span></td>
        <td class="num">(206,101)<span></span></td>
        <td class="num">(8,870)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDeposits', window );">Payment of security deposit</a></td>
        <td class="num">(103,737)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(40,790)<span></span></td>
        <td class="num">(66,405)<span></span></td>
        <td class="num">(28,766)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
        <td class="num">(583,561)<span></span></td>
        <td class="num">(272,506)<span></span></td>
        <td class="num">(37,636)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
        <td class="nump">78,650,353<span></span></td>
        <td class="nump">7,895,485<span></span></td>
        <td class="nump">1,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds bank line of credit</a></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">300,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
        <td class="nump">30,910<span></span></td>
        <td class="nump">191,000<span></span></td>
        <td class="nump">17,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from notes and loans payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,700,000<span></span></td>
        <td class="nump">2,684,160<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from notes and loans payable-related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of membership units, net of expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">707,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of bank line of credit</a></td>
        <td class="num">(500,000)<span></span></td>
        <td class="num">(300,000)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of notes payable - related party</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(200,000)<span></span></td>
        <td class="num">(100,696)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
        <td class="num">(4,691,847)<span></span></td>
        <td class="num">(1,850,000)<span></span></td>
        <td class="num">(200,000)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
        <td class="nump">73,989,416<span></span></td>
        <td class="nump">14,436,885<span></span></td>
        <td class="nump">4,707,714<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase in cash</a></td>
        <td class="nump">52,637,786<span></span></td>
        <td class="nump">1,427,053<span></span></td>
        <td class="num">(296,518)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
        <td class="nump">1,553,474<span></span></td>
        <td class="nump">126,421<span></span></td>
        <td class="nump">422,939<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
        <td class="nump">54,191,260<span></span></td>
        <td class="nump">1,553,474<span></span></td>
        <td class="nump">126,421<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">212,853<span></span></td>
        <td class="nump">17,253<span></span></td>
        <td class="nump">696<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancing', window );">Warrants issued for financing</a></td>
        <td class="nump">1,711,956<span></span></td>
        <td class="nump">2,509,537<span></span></td>
        <td class="nump">148,668<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForServices', window );">Warrants issued for services</a></td>
        <td class="nump">462,196<span></span></td>
        <td class="nump">1,532,228<span></span></td>
        <td class="nump">190,280<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest', window );">Warrants exercised in exchange for debt and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,102,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtConversionConvertedInstrumentNonCash', window );">Shares issued in exchange for debt and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,054,658<span></span></td>
        <td class="nump">849,137<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Notes payable issued for accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,123<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtConversionConvertedInstrumentNonCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DebtConversionConvertedInstrumentNonCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amount of effect of merger and recapitalization pursuant to execution of security exchange agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LoanGuarantyCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expense incurred for loan guaranty costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_LoanGuarantyCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amount of warrants ecercised in exchange for debt and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsExercisedInExchangeForDebtAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForFinancing">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued in the period for financing in a noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedForFinancing</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued in the period for services in a noncash transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueAdditions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherOperatingAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of notes issued in noncash investing and financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for deposits on goods and services during the period; excludes time deposits and deposits with other institutions, which pertain to financial service entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForDeposits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromShortTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 5<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLinesOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfCashFlowsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Supplier Concentration Risk</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="nump">98.00%<span></span></td>
        <td class="nump">76.00%<span></span></td>
        <td class="nump">95.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Revenue - Prescription dietary</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="nump">79.00%<span></span></td>
        <td class="nump">63.00%<span></span></td>
        <td class="nump">42.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Net Revenue</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="nump">64.00%<span></span></td>
        <td class="nump">28.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Deferred revenue</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
        <td class="nump">97.00%<span></span></td>
        <td class="nump">98.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKPAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Costs</a></td>
        <td class="nump">$ 11,739<span></span></td>
        <td class="nump">$ 19,480<span></span></td>
        <td class="nump">$ 65,944<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities', window );">Advance payments for future research and development activities</a></td>
        <td class="nump">$ 2,091,809<span></span></td>
        <td class="nump">$ 189,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
        <td class="nump">29,926,241<span></span></td>
        <td class="nump">25,926,987<span></span></td>
        <td class="nump">13,647,788<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment | Maximum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equipment | Minimum</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of advance payments made for future research and development activiites to be expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AdvancePaymentsForFutureResearchAndDevelopmentActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 35<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdvertisingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 16_ &#150; SUBSEQUENT EVENTS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">On January 6,
2014, options for 390,000 shares of stock were granted to certain members of our Board of Directors under the 2012 Plan for
their services to be rendered in 2014. The options were granted for a period of 10 years at an exercise price equal to the
closing price at the date of grant, and vest on December 31, 2014. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORY (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished Product</a></td>
        <td class="nump">$ 621,679<span></span></td>
        <td class="nump">$ 1,124,739<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw Material</a></td>
        <td class="nump">250,943<span></span></td>
        <td class="nump">380,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred Costs</a></td>
        <td class="nump">170,996<span></span></td>
        <td class="nump">110,471<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
        <td class="nump">$ 1,043,618<span></span></td>
        <td class="nump">$ 1,615,210<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCostsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNetAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">December
    31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2013</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2012</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"><font style="font: normal 10pt Times New Roman, Times, Serif">Finished
    product</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">621,679</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">1,124,739</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Raw
    material</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">250,943</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">380,000</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Deferred
    costs</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">170,996</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">110,471</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font: normal 10pt Times New Roman, Times, Serif">TOTAL
    INVENTORY</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">1,043,618</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">1,615,210</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>THE COMPANY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY</a></td>
        <td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>NOTE
1 &#150; THE COMPANY</u></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation,
or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized
on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless
the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as &#147;our company,&#148;
&#147;we,&#148; &#147;our,&#148; or &#147;us.&#148;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Nature of Business</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&#146;s healthcare product
company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on
conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy
pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of
and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and
vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or
in combination, with the aim of providing equivalent efficacy at lower doses, thereby enabling an enhanced side effect
profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables
the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture (through third
parties) and distribute branded and generic prescription prenatal vitamins as well as over-the-counter, or OTC, vitamins and
cosmetics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Agreement and Plan of Merger with VitaMed</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 18, 2011, we entered into an Agreement
and Plan of Merger with VitaMed and our newly formed wholly owned subsidiary. In connection with the acquisition, our subsidiary
merged with and into VitaMed with VitaMed surviving the merger. The merger became effective upon the filing of the Certificate
of Merger with the Secretary of State of the State of Delaware on October 4, 2011. In preparation for and prior to the closing
of the Merger, we completed the following required corporate actions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">a
                                         reverse split of our 16,575,209 issued and outstanding shares of our common stock, par
                                         value $0.001 per share, or the Common Stock, on a ratio of 1-for-100. As a result of
                                         the reverse split, each share of Common Stock outstanding on the July&#160;28, 2011 record
                                         date, without any action on the part of the holder thereof, became one one-hundredth
                                         of a share of Common Stock. The reverse split decreased the number of outstanding shares
                                         of our Common Stock by approximately 99%, resulting in 165,856 shares outstanding after
                                         the reverse split. The effectuation of the reverse split did not result in a change in
                                         the relative equity position or voting power of our shareholders;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">an
                                         increase in the number of shares of our Common Stock authorized for issuance to 250,000,000;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">a
                                         change in the name of our company to TherapeuticsMD, Inc.; and</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">an
                                         amendment to our 2009 Long Term Incentive Compensation Plan to increase the number of
                                         shares of our Common Stock reserved for issuance thereunder to 25,000,000.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the effective date of the merger, we acquired
100% of VitaMed in exchange for shares of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Exchange of Securities</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the effective date of the merger, all outstanding
membership units of VitaMed were exchanged for shares of our Common Stock. In addition, all outstanding options and warrants to
purchase VitaMed membership units were exchanged for and converted into options and warrants to purchase shares of our Common Stock.
Pursuant to the conversion ratio in the merger, we issued 58,407,331 shares of our Common Stock in exchange for the outstanding
VitaMed membership units, reserved an aggregate of 10,119,796 shares of our Common Stock for issuance upon the exercise of the
VitaMed options, and reserved an aggregate of 1,472,916 shares of our Common Stock for issuance upon the exercise of the warrants.
After giving effect to the reverse split, and taking into consideration the 58,407,331 shares issued in exchange for the membership
units, the number of shares of our Common Stock issued and outstanding as of the effective date of the merger was 58,573,187, of
which the former members of VitaMed owned approximately 99%. All shares of our Common Stock issued in exchange for the VitaMed
membership units and issuable upon exercise of the options and warrants were subject to a lock-up agreement for a period of 18
months from the effective date of the merger, and on a limited basis for 12 months thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6GAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
        <td class="nump">$ 26,555<span></span></td>
        <td class="nump">$ 42,048<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount on notes payable</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1,102,680<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="nump">250,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5074-111524<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 11 &#150; INCOME TAXES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For the years ended
December 31, 2013, 2012 and 2011, there was no provision for income taxes, current or deferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At December 31,
2013, we have a federal net operating loss carry forward of approximately $37,000,000 available to offset future taxable
income through 2033.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">At December 31,
2013, 2012, and 2011, we have state net operating loss carryforwards of approximately $35,000,000 available to offset future
losses through 2033. We established valuation allowances equal to the full amount of the deferred tax assets because of the
uncertainty of the utilization of the operating losses in future periods. We periodically assess the likelihood that we will
be able to recover the deferred tax assets. We consider all available evidence, both positive and negative,
including historical levels of income, expectations and risks associated with estimates of future taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our deferred tax asset and liability as presented
in the accompanying consolidated financial statements consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 22pt; text-indent: -10pt">Net operating losses</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,773,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">5,920,861</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">748,404</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">R&#38;D Credit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">547,511</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">186,346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Total deferred income tax asset </td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,321,048</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,107,207</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">748,404</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(15,321,048</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,107,207</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(748,404</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Deferred Income Tax Assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our provision for income taxes differs from
applying the statutory U.S. federal income tax rate to the income before income taxes. The primary differences result from deducting
certain expenses for financial statement purposes but not for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation between taxes computed at
the federal statutory rate and the consolidated effective tax rate is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; padding-left: 10pt; text-indent: -10pt">Federal statutory tax rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">35.0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">State tax rate, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0-</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Adjustment in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.4</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.8</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Permanent and other differences</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8.4</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(22.3</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29.2</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Provision (Benefit) for Income Taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 03, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 28, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">TherapeuticsMD, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000025743<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 278,462,272<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,017,060<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 12 &#150; RELATED PARTIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Loan Guaranty</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited
Limited Partnership. See NOTES 9 and 10 for more details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Loans from Affiliates</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory notes,
or the VitaMed Notes, in the aggregate principal amount of $500,000, of which $100,000 was sold to affiliates. In June 2012, the
affiliate notes were extended to October 15, 2012 (one held by Mr. Milligan for $50,000 and one for $50,000 held by BF Investments,
LLC, which is owned by Brian Bernick, a member of the board of directors of our company. On October 4, 2012 these VitaMed Promissory
Notes were paid in full including $5,341 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with original due dates of March 1, 2012. These
promissory notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio
was paid in full, including $888 in accrued interest. Mr. Milligan&#146;s VitaMed Promissory Note was extended to October 15,
2012. On October 4, 2012 this VitaMed Notes was paid in full including $1,519 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Lock Up Agreements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required by the terms of the merger agreement
with VitaMed dated July 18, 2011, we entered into Lock-Up Agreements with stockholders covering the aggregate of 70,000,000 shares
of our Common Stock issued pursuant to the merger or reserved for issuance pursuant to stock options and warrants. Each stockholder
agreed that during a lock-up period from the date of the lock-up agreements until 18 months thereafter they would not make or cause
any sale of our common stock. After the completion, each stockholder agreed not to sell or dispose of more than 2.5% of the stockholder&#146;s
aggregate Common Stock or shares reserved for issuance under stock options and warrants per quarter over the following 12-month
period, or the Dribble Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Purchases by Related Parties</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013, 2012, and 2011, we sold our products
to Dr. Brian Bernick, a director of our company, in the amounts of $0, $2,632 and $20,669, respectively, while $0, $1,272 and $0
of receivables related thereto remained outstanding at December 31, 2013, 2012 and 2011, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-weight: normal"><u>Agreements with Pernix Therapeutics,
LLC</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2012, Cooper C. Collins, President
and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. We closed a stock
purchase agreement with Pernix on October 5, 2011. From time to time, we have entered into agreements with Pernix in the normal
course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors.
During the years ended December 31, 2013, 2012, and 2011, we made purchases of approximately $0, $404,000 and $19,000, respectively,
from Pernix. At December 31, 2013, 2012, and 2011, there were amounts due Pernix of approximately $46,000, $308,000 and 19,000
outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, there were amounts due to
us from Pernix for legal fee reimbursement relating to a litigation matter pursuant to a license and supply agreement, in the amounts
of $249,981 and $0 for the periods ending December 31, 2013 and December 31, 2012, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-weight: normal"><u>Warrants
assigned to Related Party</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-weight: normal">In June 2012,
a warrant to purchase 100,000 shares of our Common Stock was assigned to the son of the Chairman of our board of directors by a
non-affiliated third party.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-weight: normal">&#160;</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYPAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
        <td class="nump">$ 8,775,598<span></span></td>
        <td class="nump">$ 3,818,013<span></span></td>
        <td class="nump">$ 2,088,177<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
        <td class="nump">1,959,597<span></span></td>
        <td class="nump">1,348,113<span></span></td>
        <td class="nump">947,112<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">6,816,001<span></span></td>
        <td class="nump">2,469,900<span></span></td>
        <td class="nump">1,141,065<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
        <td class="nump">19,014,837<span></span></td>
        <td class="nump">14,069,701<span></span></td>
        <td class="nump">6,406,197<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">13,551,263<span></span></td>
        <td class="nump">4,492,362<span></span></td>
        <td class="nump">107,241<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">58,145<span></span></td>
        <td class="nump">56,260<span></span></td>
        <td class="nump">54,845<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
        <td class="nump">32,624,245<span></span></td>
        <td class="nump">18,618,323<span></span></td>
        <td class="nump">6,568,283<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
        <td class="num">(25,808,244)<span></span></td>
        <td class="num">(16,148,423)<span></span></td>
        <td class="num">(5,427,218)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income and (expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
        <td class="nump">34,544<span></span></td>
        <td class="nump">3,001<span></span></td>
        <td class="nump">6,392<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">27,234<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Financing costs</a></td>
        <td class="num">(1,503,922)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,165,981)<span></span></td>
        <td class="num">(1,905,409)<span></span></td>
        <td class="num">(64,380)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LoanGuarantyCosts', window );">Loan guaranty costs</a></td>
        <td class="num">(2,944)<span></span></td>
        <td class="num">(45,036)<span></span></td>
        <td class="num">(38,159)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(10,307,864)<span></span></td>
        <td class="num">(7,390,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(6,716,504)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="num">(2,611,069)<span></span></td>
        <td class="num">(18,971,812)<span></span></td>
        <td class="num">(7,486,147)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes</a></td>
        <td class="num">(28,419,313)<span></span></td>
        <td class="num">(35,120,235)<span></span></td>
        <td class="num">(12,913,365)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (28,419,313)<span></span></td>
        <td class="num">$ (35,120,235)<span></span></td>
        <td class="num">$ (12,913,365)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (0.38)<span></span></td>
        <td class="num">$ (0.21)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding</a></td>
        <td class="nump">127,569,731<span></span></td>
        <td class="nump">91,630,693<span></span></td>
        <td class="nump">62,516,461<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LoanGuarantyCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expense incurred for loan guaranty costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_LoanGuarantyCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 2<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Beneficial Conversion Feature<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 40<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PREPAID EXPENSE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpensesDisclosureTextBlock', window );">PREPAID EXPENSE</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 6 &#150;PREPAID EXPENSE</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid R &#38; D costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">824,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">953,655</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid manufacturing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">899,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Accreted prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,234</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,750,455</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">953,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpensesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of prepaid expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PrepaidExpensesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 5 &#150; FIXED ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">December
    31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2013</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2012</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"><font style="font: normal 10pt Times New Roman, Times, Serif">Equipment</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">108,458</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">67,668</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Furniture
    and fixtures</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">46,625</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">46,625</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Leasehold
    improvements</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">11,980</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">155,083</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">126,273</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Accumulated
    depreciation</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">(93,765</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">(60,600</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font: normal 10pt Times New Roman, Times, Serif">TOTAL
    FIXED ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">61,318</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">65,673</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the years ended December
31, 2013, 2012, and 2011 was $45,145, $27,484 and $25,686, respectively. In December 2013, accumulated depreciation was reduced
by $11,980 associated with leasehold improvements of our previously leased office property.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Principles of Consolidation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed and BocaGreen. All material intercompany balances
and transactions have been eliminated in consolidation.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">We
maintain cash at financial institutions that at times may exceed federally insured limits. We have never experienced any losses
related to these funds. All of our non-interest bearing cash balances were fully insured at December 31, 2012 and 2011, resulting
from the temporary federal program in effect from December 31, 2010 through December 31, 2012. Under this program, there was no
limit to the amount of insurance for eligible accounts. Beginning January 1, 2013, insurance coverage reverted to $250,000 per
depositor at each financial institution, at which time our non-interest bearing cash balances again exceeded federally insured
limits.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal; letter-spacing: 0pt"><u>Trade
Accounts Receivable and Allowance for Doubtful Accounts</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal; letter-spacing: 0pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off as increase in allowance
for doubtful accounts when received. <font style="color: #252525">To the extent data we use to calculate these estimates does not
accurately reflect bad debts; adjustments to these reserves may be required.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Inventories</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">Inventories
represent packaged nutritional products and supplements and raw materials, which are valued at the lower of cost or market using
the average-cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed
in <u>Revenue Recognition</u>) are recorded as deferred costs and are included in inventory, until such time as the related deferred
revenue is recognized.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Fixed Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Equipment</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We state equipment at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expense as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line method
over the estimated useful lives of the related assets, which range from three to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Leasehold
Improvements</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We state
improvements at cost, net of accumulated depreciation. We compute depreciation using the straight-line method over the remaining
term of the lease.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Intangible</u> </font><u>Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Patent
and Trademarks</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">We have
adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350,
<i>Intangible-Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. Our first patent was granted
in the year ended December 31, 2013.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Impairment of Long-Lived Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review the carrying values of property and
equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying
values may not be recoverable. Such events or circumstances include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         declines in an asset&#146;s market price;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         deterioration in an asset&#146;s physical condition;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         changes in the nature or extent of an asset&#146;s use or operation;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">significant
                                         adverse changes in the business climate that could impact an asset&#146;s value, including
                                         adverse actions or assessments by regulators; </td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">accumulation
                                         of costs significantly in excess of original expectations related to the acquisition
                                         or construction of an asset;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">current-period
                                         operating or cash flow losses combined with a history of such losses or a forecast that
                                         demonstrates continuing losses associated with an asset&#146;s use; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">expectations
                                         that it is more likely than not that an asset will be sold or otherwise disposed of significantly
                                         before the end of its previously estimated useful life.</td></tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&#146;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future
cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected
timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a
loss for the difference between the assets&#146; fair value and respective carrying value. We determine the fair value of the
assets using an &#147;income approach&#148; based upon a forecast of all the expected discounted future net cash flows associated
with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected
selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships,
market conditions, and available external information about future trends. We believe our current assumptions and estimates are
reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting
in the need for an impairment charge in future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts
payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments and are considered
Level 1 assets under the fair value hierarchy. We use interest rates that are currently available to us for issuance of short-
and long-term debt with similar terms and remaining maturities to estimate the fair value of our short- and long-term debt, which
would be considered Level 3 inputs under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements
and Disclosures. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets
and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assets and liabilities recorded in the consolidated
balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; width: 100%; font-size: 10pt; margin-bottom: 0px">
<tr style="text-align: justify; vertical-align: top">
    <td style="width: 36pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 54pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Level 1</font></td>
    <td style="text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">unadjusted quoted prices in
    active markets for identical assets or liabilities;</font></td></tr>
<tr style="text-align: justify; vertical-align: top">
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="text-align: justify; vertical-align: top">
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">Level 2</font></td>
    <td style="text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">quoted prices for similar assets
    or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through
    market corroboration, for substantially the full term of the financial instrument; and</font></td></tr>
<tr style="text-align: justify; vertical-align: top">
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="text-align: justify; vertical-align: top">
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">Level 3</font></td>
    <td style="text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">unobservable inputs for the
    asset or liability.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, 2012, and 2011, we had
no assets or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="letter-spacing: 0pt"><u>Income
Taxes</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="letter-spacing: 0pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With the advent of the Merger, we determined
that VitaMed would become the sole focus of our company and previous business performed by our predecessor was discontinued. Because
of these events, deferred income taxes are determined by calculating the loss from operations of our company starting October 4,
2011.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for income taxes under the asset
and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis.
We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which
the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities
of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the
amount that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur. At December 31, 2013, 2012, and 2011 we had no uncertain income tax positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2013 and 2012, we had no tax positions relating
to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our tax returns are subject to review by the
Internal Revenue Service three years after they are filed. Currently, years filed after 2010 are subject to review.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Share-Based Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2004, the FASB issued ASC 718,
<i>Compensation &#150; Stock Compensation</i>,<i> </i>or<i> </i>ASC 718. Under ASC 718, companies are required to measure the
compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial
statements over the period during which employees are required to provide services. Share-based compensation arrangements include
options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase
plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any,
over the respective vesting periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,
an acceptable model in accordance with ASC 718, that requires the input of highly complex and subjective variables, including the
expected life of the award and our expected stock price volatility over a period equal to or greater than the expected life of
the award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Equity instruments (&#147;instruments&#148;)
issued to anyone other than employees are recorded on the basis of the fair value of the instruments, as required by ASC 718. ASC
505, <i>Equity Based Payments to Non-Employees</i>,<i> </i>or ASC 505<i>, </i>defines the measurement date and recognition period
for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b)
the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the
instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize the compensation expense for all
share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize
the compensation expense on a straight-line basis over the employee&#146;s requisite service period.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discounts</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Debt Discounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We generally amortize discounts over the life of the
related debt using the effective interest rate method.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Revenue Recognition</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, <i>Revenue Recognition</i>. We recognize revenue only when the price is fixed or determinable, persuasive evidence
of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Over-the-Counter Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We generate OTC revenue from product sales
primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of
loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include
shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive
the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. <font style="color: #252525">We
provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers.
</font>We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Prescription Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="color: #252525">We sell our name
brand and generic prescription products </font>primarily through drug wholesalers and retail pharmacies. We recognize revenue from
prescription product sales, net of sales discounts, chargebacks, and rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable product from
customers within a return period of six months prior to and following product expiration. Our prescription products currently have
a shelf life of 24 months from the date of manufacture. Given the limited history of our prescription products, we currently cannot
reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, we defer recognition of revenue
on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products
are dispensed through patient prescriptions or expiration of the right of return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain various rebate programs in an
effort to maintain<i> </i>a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate
program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end
user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Shipping and Handling Costs</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense all shipping and handling costs
as incurred. We include these costs in cost of sales on the accompanying consolidated financial statements.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt"><u>Advertising Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We expense advertising costs when incurred.
Advertising costs were $11,739, $65,944 and $19,480 during the years ended December 31, 2013, December 31, 2011 and December 31,
2012, respectively.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Research and Development Expenses</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&#38;D, expenses
include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research
sites, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based
compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity
expenses include regulatory consulting and legal counsel. We charge internal R&#38;D activities and other activity expenses to
operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting
date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the
activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed
in future R&#38;D activities were $2,091,809 and $189,375 for years ended December 31, 2013 and December 31, 2012, respectively.
We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those
costs applicable to the completion stage of a study as provided by CROs. Accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Earnings Per Share</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculate earnings per share, or EPS, in
accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and
diluted. We compute basic EPS based on the weighted-average number of shares of Common Stock outstanding during the period. We
compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive
shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options
and warrants. Potentially dilutive shares of our Common Stock representing 29,926,241, 25,926,987, and 13,647,788 shares of our
Common Stock for 2013, 2012, and 2011, respectively, were excluded from the calculation of diluted earnings per share for these
periods because their effect would have been anti-dilutive due to the net loss reported by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Use
of Estimates</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Newly Adopted Accounting Pronouncements</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Recently Issued Accounting Pronouncements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July, 2013, the FASB issued
Accounting Standards Update, or ASU, No. 2013-11, <i>Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when
a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues
Task Force)</i>,<i> </i>or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation
of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists.
An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating
loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized
tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new
recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning
after December 15, 2013. The amendments in ASU No. 2013-11 are not expected to have a material impact on our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2012, the FASB issued ASU No. 2012-02,
<i>Testing Indefinite-Lived Intangible Assets for Impairment</i>,<i> </i>or ASU 2012-02. ASU 2012-02 gives entities an option to
first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely
than not that the long-lived intangible asset are impaired. If, based on its qualitative assessment, an entity concludes that it
is more likely than not that the fair value of an indefinite lived intangible asset is less than its carrying amount, quantitative
impairment testing is required. However, if an entity concludes otherwise, quantitative impairment testing is not required. ASU
2012-02 is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with
early adoption permitted. ASU 2012-02 is not expected to have a material impact on our financial position or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11,
<i>Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities</i>, or ASU 2011-11<i>.</i> ASU 2011-11 enhances
current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial
position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset
on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities
in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared
on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on
or after January 1, 2013, and interim periods within those years. ASU 2011-11 is not expected to have a material impact on our
financial position or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Reclassifications</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Certain 2012 amounts have been reclassified to conform
to current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32704220&amp;loc=d3e8275-108329<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6387522&amp;loc=d3e8384-108330<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127066<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdvertisingCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2208565<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144471<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsFiniteLivedPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5144-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408196&amp;loc=d3e61069-111654<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Handling Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6514758<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915142&amp;loc=d3e60635-111653<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408413&amp;loc=d3e221937-122793<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Shipping Costs<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525344<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShippingAndHandlingCostPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 13 - BUSINESS CONCENTRATIONS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We purchase our products from several suppliers
with approximately 98%, 76%, and 95% of our purchases supplied from one vendor for the years ended December 31, 2013 2012, and
2011, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We sell our prescription dietary supplement
products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products
to retail pharmacies, hospitals, and other institutional customers. Revenue generated from sales to three customers, Cardinal Health,
Inc., Amerisource Bergen, and McKesson Corporation accounted for 79%, 63% and 42% of our recognized revenue for years ended December
31, 2013, 2012, and 2011, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2013 and
2012, 64% and 28% of our recognized revenue and 97% and 98% of our deferred revenue was generated from sales to only three
customers: AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. We did not sell to these customers
in prior years.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RisksAndUncertaintiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 9 &#150; NOTES PAYABLE</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Multiple Advance
Revolving Credit Note</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2013, we entered into a
business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the
Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal
amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the
Revolving Credit Note at our request, which advances were of a revolving nature and were able to be,made, repaid, and made
from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in
which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the
Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any,
was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each
of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid
$401,085, including accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31,
2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a
warrant to purchase 1,250,000 shares of our Common Stock at an exercise price $3.20 per share (see NOTE 10 for more
details).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Borrowing under Business Loan Agreement
and Promissory Note, as amended</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United Bank for a $300,000 bank line of credit for which personal guarantees and cash collateral were
required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers
of our Company, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of our Company.
The bank line of credit accrued interest at the rate of 3.02% per annum based on a year of 360 days and was due on March 1, 2012.
We negotiated a one-year extension with First United to the bank line of credit, which was executed on March 19, 2012. Under the
extension, borrowings bear interest at a rate of 2.35% and are due on March 1, 2013. On November 13, 2012, the outstanding balance
of $299,220 was repaid in full, and we amended the line of credit to reflect a $100,000 bank line of credit. In accordance with
the amended line of credit, the personal guarantee and cash collateral limited to $100,000 provided by the Reich Family Limited
Partnership remained in place, while the personal guarantees and cash collateral were removed for Mr. Finizio and Mr. Milligan.
In February 2013, we borrowed $100,000 from First United Bank under the amended bank line of credit. The amended bank line of credit
required a personal guarantee and cash collateral limited to $100,000, which was provided by Reich Family Limited Partnership.
On April 25, 2013, we re-paid $100,735, which represented the principal and interest that was due under the amended bank line of
credit. On May 1, 2013, the amended bank line of credit expired and was not renewed. Accordingly, the personal guarantee was canceled,
and the cash collateral was refunded to the Reich Family Limited Partnership. During the years ended December 31, 2013, 2012, and
2011, we paid $735, $7,366, and $5,650, respectively, of interest expense, which are included in interest expense on the accompanying
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance of Promissory Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February 2012, we issued 6%
promissory notes in the aggregate principal amount of $900,000, due March 1, 2012. As discussed below in <u>Issuance and Settlement
of February 2012 Notes</u>, these promissory notes were modified on February 24, 2012 through the issuance of secured promissory
notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Settlement of February 2012
Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 24, 2012, we issued promissory
notes, the February 2012 Notes, to an individual and an entity, or the Parties, both of which are stockholders of our company,
in the principal amount of $1,358,014 and $1,357,110, respectively, and granted warrants to purchase an aggregate of 9,000,000
shares of our Common Stock pursuant to the terms of a Note Purchase Agreement, dated February 24, 2012. We received an aggregate
of $1,000,000 of new funding from the Parties upon issuance of the February 2012 Notes and related warrants and surrender by the
Parties of certain promissory notes, which we previously issued in the aggregate amount of $1,700,000 plus the aggregate accrued
interest of $15,124 (collectively known as the &#147;Prior Notes&#148;). Under the February 2012 Notes, we borrowed an additional
$3,000,000 from the Parties during March, April, and May 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We granted 5,685,300 warrants in
consideration of the modification of the Prior Notes and 3,314,700 warrants with the February Funding. We determined that the
resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, <font style="font: 10pt Times New Roman, Times, Serif"><i>Modifications
and Extinguishments.&#160;</i></font>As such the modification was accounted for as an extinguishment and restructuring of
the debt, and the 5,685,300 warrants issued in consideration of the modification were expensed (see <u>Warrant Activity
During 2012 </u>in NOTE 10 for more details). The fair value of the Prior Notes was estimated by calculating the present
value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741,
resulting in a debt discount of $197,383 and recognized a loss on extinguishment of debt of $10,307,864, which represented
the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair
value as of the date of the modification on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we settled an aggregate amount
of $3,102,000 of principal and accrued interest of the February 2012 Notes in exchange for the exercise of warrants to purchase
8,145,486 shares of our Common Stock. As discussed below in <u>Issuance and Payment of June 2012 Notes</u>, the remaining balance
of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes, or the
June 2012 Notes (see NOTE 10 for more details).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of June 2012 Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 19, 2012, we issued secured promissory
notes, or the June 2012 Notes, to the Parties in the principal amounts of $2,347,128 and $2,344,719, respectively, pursuant to
the terms of a Note Purchase Agreement. In connection with the June 2012 Notes, the Parties surrendered the remaining balance of
the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively, which sums included principal and accrued
interest through June 19, 2012, and we received an aggregate of $2,000,000 of new funding from the Parties, or the June Funding.
The principal amount of each of the June 2012 Notes, plus any additional advance made to us thereafter, together with accrued interest
at the annual rate of 6%, was due in one lump sum payment on February 24, 2014. As security for our obligations under the June
2012 Notes, we entered into a Security Agreement and pledged all of our assets, tangible and intangible, as further described therein.
We also granted warrants to purchase an aggregate of 7,000,000 shares of our Common Stock in connection with the June Funding.
On March 21, 2013, we repaid $4,882,019, including accrued interest, leaving a balance of $21,595 in accrued interest as of March
31, 2013 on the June 2012 Notes. On April 25, 2013, the balance of accrued interest was paid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Additional Notes
in 2012</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August and September 2012, we issued 6%
promissory notes in the amount of $1,600,000 due on October 1, 2012, which due date was subsequently extended. These notes were
paid in full in October 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we issued a 6% promissory
note for $200,000 due on October 15, 2012. This note was paid in full in October 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Conversion of July 2011 Secured Notes </u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed issued two senior secured
promissory notes, or the Secured Notes, each in the amount of $500,000 and also entered into a security agreement under which VitaMed
pledged all of its assets to secure the obligation. The Secured Notes were assumed by us upon the merger and bore interest at the
rate of 6% per annum, were due on the one year anniversary thereof, and were convertible into shares of our Common Stock at our
option. We were permitted to satisfy the obligation underlying the Secured Notes by delivering such number of shares of our Common
Stock calculated by dividing the then-outstanding principal balance by the Share Price. For purposes of the Secured Notes, the
&#147;Share Price&#148; meant the lower of the most recent price at which we offered and sold shares of our Common Stock (not including
any shares of our Common Stock issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities)
or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, we reached an agreement
to convert the outstanding amount of the Secured Notes, representing principal and accrued interest through June 19, 2012, of $1,054,647
into an aggregate of 2,775,415 shares of our Common Stock at $0.38 per share. This resulted in a beneficial conversion feature
of $6,716,504 as recorded in other income and expense on the accompanying consolidated financial statements. For the years ended
December 31, 2012 and 2011, we recorded an aggregate of $33,204 and $21,453, respectively, as interest expense on the accompanying
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance of VitaMed Promissory Notes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2011, VitaMed issued promissory notes,
or the VitaMed Notes, in the aggregate principal amount of $500,000. In connection with the VitaMed Notes, we granted warrants
to purchase an aggregate of 613,718 shares of our Common Stock. The VitaMed Notes were assumed by us upon the merger and bore interest
at a rate of 4% per annum and were due at the earlier of (i) the six month anniversary of the date of issuance and (ii) such time
as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000, or the Funding. Upon
the closing of the Funding in July 2011, as more fully described above in <u>Conversion of July 2011 Secured Notes</u>, two of
the VitaMed Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Notes in the aggregate
of $300,000 were extended. In October 2011, one of the VitaMed Notes for $50,000 was paid in full, and, by mutual agreement, certain
of the VitaMed Notes in the aggregate amount of $100,000 were converted into 266,822 shares of our Common Stock at $0.38 per share,
which represented the fair value of the shares of our Common Stock on the date of conversion. In June 2012, a VitaMed Note held
by an unaffiliated individual was paid in full, including $2,160 in accrued interest. The remaining VitaMed Notes, held by Mr.
Milligan and by BF Investment Enterprises, Ltd., which is owned by Brian Bernick, a director of our company, in the aggregate amount
of $100,000, were extended to October 15, 2012. On October 4, 2012, we re-paid the outstanding VitaMed Notes in full, including
$5,341 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September and October 2011, VitaMed issued
convertible notes, or the VitaMed Convertible Notes, in the aggregate amount of $534,160. The VitaMed Convertible Notes bore interest
at the rate of 4% per annum and were due December 1, 2011. On November 18, 2011, we entered into Debt Conversion Agreements with
the holders of VitaMed Convertible Notes, pursuant to which we converted the principal and accrued interest of the VitaMed Convertible
Notes into 1,415,136 shares of our Common Stock at $0.38 per share, which represented the fair value of the shares of our Common
Stock on the date of conversion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 4% promissory notes
to Mr. Finizio and Mr. Milligan for an aggregate of $100,000 due March 1, 2012. These promissory notes were subsequently extended
by mutual agreement to June 1, 2012. In June 2012, we paid the promissory note held by Mr.&#160;Finizio in full, including $888
in accrued interest. Mr. Milligan&#146;s promissory note was extended to October 15, 2012. On October 4, 2012, we paid Mr. Milligan&#146;s
promissory note in full, including $1,519 in accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the years ended December 31, 2012 and 2011,
we recorded an aggregate of $6,344 and $2,390, respectively, as interest expense on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">63 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MonthlyBaseRentOfLeases', window );">Monthly Base rent of leases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 30,149<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments</a></td>
        <td class="nump">1,766,252<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,766,252<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental Expense</a></td>
        <td class="nump">180,894<span></span></td>
        <td class="nump">60,168<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">106,315<span></span></td>
        <td class="nump">122,752<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental Income</a></td>
        <td class="nump">$ 32,963<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total term (in months) of the company's outstanding lease obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_CapitalLeaseObligationsTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MonthlyBaseRentOfLeases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Base monthly rent of operating leases, as stipulated in leasing agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_MonthlyBaseRentOfLeases</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RentalIncomeNonoperating</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 7 &#150; INTANGIBLE ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="letter-spacing: -0.15pt">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The following table sets forth
the gross carrying amount and accumulated amortization of our intangible assets as of&#160;December&#160;31, 2013&#160;and&#160;December&#160;31,
2012:&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; background-color: white">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">December&#160;31,
    2013</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Gross<br />Carrying<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Weighted-<br />Average<br />Amortization<br />Period&#160;(yrs.)</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif"><b>Amortizing intangible assets:</b></font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; width: 40%"><font style="font-family: Times New Roman, Times, Serif">OPERA&#174; software patent</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">31,951</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">(499</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">31,452</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">15.8</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Development
    costs for corporate website</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(89,661</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">2,082</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">0.3</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif"><b>Non-amortizing
    intangible assets:</b></font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-left: 12pt; text-indent: -12pt"><font style="font-family: Times New Roman, Times, Serif">Hormone
    therapy drug candidate patents</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">572,726</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">572,726</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt"><font style="font-family: Times New Roman, Times, Serif">Multiple
    trademarks for vitamins/supplements</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">59,328</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">59,328</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -12pt; padding-left: 24pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">755,748</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(90,160</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">665,588</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">December&#160;31,
    2012</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Gross<br />Carrying<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Accumulated<br />Amortization</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Net<br />Amount</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Weighted-<br />Average<br />Amortization<br />Period&#160;(yrs.)</font></td>
    <td style="padding-bottom: 1pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Amortizing
    intangible assets:</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 40%"><font style="font-family: Times New Roman, Times, Serif">OPERA
    &#174; software patent</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">23,722</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">0</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">23,722</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; width: 11%"><font style="font-family: Times New Roman, Times, Serif">0</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Development
    costs for corporate website</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">91,743</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(77,159</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">14,584</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1.3</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Non-amortizing
    intangible assets:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Hormone
    therapy drug candidate patents</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,194</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">180,194</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Multiple
    trademarks for vitamins/supplements</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">21,055</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#151;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">21,055</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font-family: Times New Roman, Times, Serif">Total</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">316,714</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(77,159</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">239,555</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">The intangible asset related
to development costs for corporate website is amortized over 36 months, which is the prescribed life for software and website development
costs. The intangible asset related to OPERA&#174; is amortized using the straight-line method over the estimated remaining useful
life of 16 years, which is the life of the intellectual property patents.&#160;&#160;During the year ended December 31, 2013, there
was no impairment recognized. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">&#160;&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="background-color: white">Amortization expense was $13,001,
$28,776, $29,159 for the years ended December 31, 2013, 2012, and 2011, respectively. Estimated amortization expense for the next
five years is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 80%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Year Ending December
    31,</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">Estimated
    Amortization</font></td>
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; width: 81%"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font-family: Times New Roman, Times, Serif">4,080</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,997</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">2016</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,997</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">2017</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,997</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">2018</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,997</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 8 &#150; OTHER CURRENT LIABILITIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">December
    31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">2013</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">2012</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"><font style="font-family: Times New Roman, Times, Serif">Accrued
    payroll and commission costs</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font-family: Times New Roman, Times, Serif">941,313</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font-family: Times New Roman, Times, Serif">397,210</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    financing costs</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">850,000</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    vacation</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">256,920</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">114,899</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Allowance
    for wholesale distributor fees</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">306,303</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">107,784</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    legal and accounting expense</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">224,550</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">90,000</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    lab research</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">536,574</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Accrued
    clinical trial costs</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">129,208</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Allowance
    for coupons and returns</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">126,233</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">53,002</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt; font-size: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Other
    accrued expenses<sup>(1)</sup></font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">230,088</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">70,759</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font-family: Times New Roman, Times, Serif">&#160;TOTAL
    OTHER CURRENT LIABILITIES</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">3,601,189</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">833,654</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><sup>(1) </sup>In June 2008, we declared
and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which
$41,359 remained unclaimed by certain shareholders at December 31, 2013 and 2012.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>NOTE 10 &#150; STOCKHOLDERS&#146;
EQUITY</u></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><u>Preferred Stock</u></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">At December
31, 2013, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred
stock were outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><u>Common Stock</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">At December
31, 2013, we had </font>250,000,000 shares of Common Stock<font style="letter-spacing: -0.15pt"> authorized for issuance, of which
</font>144,976,757<font style="letter-spacing: -0.15pt"> shares of our Common Stock were issued and outstanding.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Issuances During 2013</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a shelf registration statement
previously filed with the Securities and Exchange Commission, or the SEC, on March 14, 2013, we entered into an underwriting agreement
with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating
to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share,
and the Jefferies Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting agreement
at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting
discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement,
we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The
offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional
1,954,587 shares of our Common Stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18,
2013 and received proceeds of approximately $3.1 million, net of expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2013, we entered into an underwriting
agreement with Stifel, Nicolaus &#38; Company, Incorporated, as the representative of the underwriters named therein, or the Stifel
Underwriters, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering
was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our Common Stock from us pursuant to the underwriting
agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting
underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2013 certain individuals exercised their
right to purchase shares of our Common Stock. Options to purchase an aggregate of 75,423 shares of our Common Stock were exercised
for approximately $31,000. These shares of our Common Stock were issued in part in reliance upon an exemption from the registration
provisions of the Securities Act of 1933, or the Act, provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Issuances During 2012</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2012, certain individuals exercised
their right to purchase shares of our Common Stock. These shares were issued in reliance upon an exemption from the registration
provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">                                                                                                                                                                                                                                                                                                                                                                                                               <tr style="vertical-align: top">
<td>&#160;</td><td><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">Options to purchase an aggregate
                                         of 1,691,393 shares of our Common Stock were exercised for $191,000.</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify">Using
                                         the cashless exercise feature, options to purchase an aggregate of 240,395 shares of
                                         our Common Stock were exercised.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During June 2012, we settled $3,102,000 in
principal and accrued interest of the February 2012 Notes in exchange for the Parties&#146; exercise of a portion of the related warrants
for an aggregate of 8,145,486 shares of our Common Stock. The shares were issued in reliance upon an exemption from the registration
provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder. During June 2012, we and
the Parties also agreed to convert a portion of the February 2012 Notes, and principal and accrued interest through June 19, 2012,
totaling $1,054,647, into 2,775,415 shares of our Common Stock at $0.38 per share. The shares were issued in reliance upon an exemption
from the registration provisions of the Act provided by Section 4(a)(2) and Rule 506 of Regulation D promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2012, we entered into a Securities
Purchase Agreement with multiple investors, relating to the issuance and sale of our Common Stock in a private placement. The private
placement closed on October 2, 2012, through which we sold an aggregate of 3,953,489 shares of our Common Stock at $2.15 per share,
for an aggregate purchase price of $8,500,001. In connection with the private placement, Jefferies served as our exclusive placement
agent. Jefferies&#146; compensation for the transaction was a cash fee of $552,500. We also paid legal fees and expenses of the
investors in the aggregate of $52,016, resulting in net proceeds to us from the private placement of $7,895,485. The shares were
issued in reliance upon the exemptions from registration under the Act provided by Section 4(a)(2) and Rule 506 of Regulation D
promulgated thereunder. The shares were issued directly by us and did not involve a public offering. The investors were &#147;accredited
investors&#148; as that term is defined in Rule 501 of Regulation D and acquired our Common Stock for investment only and not with
a present view toward, or for resale in connection with, the public sale or distribution thereof. Pursuant to the terms of the
Securities Purchase Agreement, we agreed to file a registration statement covering the resale of these shares, which we filed on
November 27, 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Issuances During 2011</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">In December
2011, </font>a former director of VitaMed, <font style="letter-spacing: -0.15pt">exercised options to purchase 92,057 shares of
our Common Stock for an aggregate exercise price of $17,250.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="letter-spacing: -0.15pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October and November 2011, we converted
principal and accrued interest in the aggregate of $849,137 into shares of our Common Stock totaling 20,266,822 and 1,415,136,
respectively (as more fully described in NOTE 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 5, 2011, we entered into a Stock
Purchase Agreement with Pernix Therapeutics, LLC, a Louisiana limited liability company, or Pernix. Pursuant to the terms of the
Stock Purchase Agreement, Pernix agreed to purchase 2,631,579 shares of our Common Stock at a purchase price of $0.38 per share
for a total purchase price of $1,000,000. Pernix is a related party. For further details, see NOTE 12</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 3, 2011, we effected a reverse split
of our 16,575,209 issued and outstanding shares of Common Stock on a ratio of 1- for -100, resulting in 165,856 shares issued and
outstanding thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Warrants </u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2013, we had warrants outstanding
to purchase an aggregate of 14,293,499 shares of our Common Stock with a weighted-average contractual remaining life of 3.9 years,
and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions,
including volatility of the stock price, the risk-free interest rate and the term of the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2013</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2013, we granted warrants to purchase
1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE
9). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised
prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the
date of the issuance using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. At
December 31, 2013, $260,022 was reported as deferred financing costs included in other current assets in the accompanying consolidated
balance sheet and is being amortized over the life of the Plato Note. As of December 31, 2013, $1,451,934 was recorded as financing
costs on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2013, we entered into a consulting agreement
with Sancilio &#38; Company, Inc., or SCI, to develop drug platforms to be used in hormone replacement drug products, or the Drug
Products. These services include support of our efforts to successfully obtain U.S. Federal Drug Administration, or FDA, approval
for the Drug Products, including a vaginal capsule for the treatment of vulvar and vaginal atrophy. In connection with the agreement,
SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant
to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI
a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-size: 10pt">1.</font></td><td style="text-align: justify"><font style="font-size: 10pt">283,333 shares were earned on May 11, 2013 upon successful filing
of the IND application with the FDA for the Drug Product for an estradiol-based product in a softgel vaginal capsule for the treatment
of vulvar and vaginal atrophy; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013. The
fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of the
vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the
entire $405,066 as non-cash compensation in the accompanying consolidated financial statements;</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-size: 10pt">&#160;</font></td><td style="text-align: justify"></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-size: 10pt">2.</font></td><td style="text-align: justify"><font style="font-size: 10pt">283,333 shares vested on June 30, 2013. The fair value of $462,196
for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility
of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. At December 31, 2013 we had $154,068 recorded as prepaid expense-short
term and $308,128 recorded as prepaid expense-long term in the accompanying consolidated financial statements. During the year
ended December 31, 2013, we recorded $77,034 as non-cash compensation in the accompanying consolidated financial statements; and</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-size: 10pt">&#160;</font></td><td style="text-align: justify"></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><font style="font-size: 10pt">3.</font></td><td style="text-align: justify"><font style="font-size: 10pt">283,334 shares will vest upon the receipt by us of any final FDA
approval of a Drug Product that SCI helped us design. It is anticipated that this event will not occur before December 2015.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2012</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2012, we issued an aggregate of
5,685,300 Warrants in connection with the modification of certain existing promissory notes, or the Modification Warrants, and
warrants for the purchase of an aggregate of 3,314,700 shares of our Common Stock in connection with the issuance of the February
2012 Notes, or the February 2012 Warrants (see NOTE 9). Both the Modification Warrants and the February 2012 Warrants are exercisable
at $0.38 per share. The Modification Warrants have a fair value of $10,505,247, and the February 2012 Warrants have a fair value
of $6,124,873. Fair value was determined on the date of the issuance using a term of five years; a volatility of 44.5%; risk free
rate of 0.89%; and a dividend yield of 0%. We recorded the fair value of the Modification Warrants as part of the loss on extinguishment
of debt in the accompanying consolidated financial statements. The relative fair value of the February 2012 Warrants of $859,647
was recorded as debt discount. As a result of the surrender of the February 2012 Notes on June 19, 2012, we expensed the remaining
unamortized debt discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2012, we issued an aggregate of 31,000
Warrants to five unaffiliated individuals for services rendered. These Warrants were valued on the date of the issuance using a
term of five years; a volatility of 44.81%; risk free rate of 1.04%; and a dividend yield of 0%; we recorded $29,736 as consulting
expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2012, we issued an aggregate of 1,300,000
Warrants to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided
are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug
development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing
efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property
and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and
(c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The
Warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility
of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2013, we had $360,528 reported as prepaid expense-short
term and $593,127 recorded as prepaid expense-long term. During the year ended December 31, 2013 and the year ended December 31,
2012, we recorded $360,528 and $218,045, respectively as non-cash compensation in the accompanying consolidated financial statements.
The contract will expire upon the commercial manufacture of a drug product. Based on the review, we have determined that the process
will take approximately five years. As a result, we are amortizing the $1,532,228 over five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we granted aggregate of 7,000,000
Warrants in connection with the issuance of the June 2012 Notes, or the June 2012 Warrants, (see NOTE 9). Of the June 2012 Warrants
issued, 6,000,000 are exercisable at $2.00 per share and 1,000,000 are exercisable at $3.00 per share. The fair value of the June
2012 Warrants of $9,424,982 was determined on the date of the issuance using a term of five years; a volatility of 44.64%; risk
free rate of 0.75%; and a dividend yield of 0%. The relative fair value of the June 2012 Warrants of $1,649,890 was determined
by using the relative fair value calculation method on the date of the issuance. Of the $1,649,890, $547,210 was amortized to interest
expense in 2012 and as a result of the repayment of the associated debt on March 21, 2013, we amortized the remaining unamortized
debt discount of $1,102,680 to interest expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2012, we issued an aggregate of 1,500
Warrants to three unaffiliated individuals for services rendered. The Warrants were valued on the date of the issuance using a
term of five years; a volatility of 44.78%; risk free rate of 0.72%; and a dividend yield of 0%. A total of $1,656 was recorded
as consulting expense in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Warrant Activity During 2011</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 500 Warrants with
a fair value of $338 to an unrelated individual for consulting services covered under a three-month agreement. The Warrants were
valued on the date of the issuance using a term of 10 years; volatility of 51.83%; risk free rate of 0.91%; and a dividend yield
of 0%. The Warrants vested immediately. As of December 31, 2011, of the $338 fair value, $15 was recorded as non-cash compensation
and $323 was recorded as prepaid expense on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2011, we issued 600,000 Warrants
with a fair value of $133,045 to an officer of our company for services performed. The Warrants were valued on the date of the
issuance using an exercise price of $0.38; a term of 10 years; volatility of 45.94%; risk free rate of 2.23%; and a dividend yield
of 0%. The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares
for month 44). For the years ended December 31, 2013, 2012 and 2011, we recognized $36,284, $36,284 and $7,158, as non-cash compensation
in the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2011, we issued 184,211 Warrants
with a fair value of $25,980 to an unrelated entity for consulting services covered under a two month agreement. The Warrants were
valued on the date of the issuance using an exercise price of $0.38; a term of five years; volatility of 41.04%; risk free rate
of 1.08%; and a dividend yield of 0%. For the year ended December 31, 2011, the $25,980 fair value was recorded as financing expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">In December 2011, VitaMed
entered into a two-year consulting agreement with an entity providing help to evaluate improvements to existing products and new
products as well as services, including research, design, compliance, scientific and regulatory affairs, and commercialization
of products. As compensation, the consultant received 800,000 fully vested and non forfeitableWarrants. The Warrants were valued
on the date of the issuance using an exercise price of $0.38; a term of 10 years; a volatility of 45.94%; risk free rate of 2.23%;
and a dividend yield of 0%. The Warrant vested immediately. The fair value of the warrants was $177,394 at the date of grant and
was amortized to research and development expense over the life of the agreement which is when the research and development activities
were performed. During the years ended December 31, 2013, 2012 and 2011, we recognized $71,688, $95,582 and $10,124, respectively,
in research and development expenses related to this agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2011, VitaMed also entered into a one-year
consulting agreement with the same consultant, whereby Consultant would assist in the design, development, and distribution efforts
of VitaMed&#146;s initial product offering. As compensation, the Consultant received 200,000 fully vested non forfeitable VitaMed Warrants
(or a Warrant for 245,485 shares pursuant to the Conversion Ratio). The VitaMed Warrant was valued on the date of the grant at
$12,548 using an exercise price of $0.41; a term of five years; a volatility of 39.44%; risk free rate of 1.56%; and a dividend
yield of 0%. The Warrant vested immediately. The fair value of the warrants was $12,548 at the date of grant and was amortized
to research and development expense over the life of the agreement which is when the research and development activities were performed.
During the years ended December 31, 2013, 2012 and 2011, we recognized $0, $6,936 and $5,612 respectively, in research and development
expenses related to this agreement. In June 2011, VitaMed issued promissory notes, or the VitaMed Notes, in the aggregate of $500,000
with 500,000 accompanying VitaMed Warrants (or Warrants for an aggregate of 613,718 shares of our Common Stock taking into account
the merger). The VitaMed Warrants were valued on the date of the issuance using an exercise price of $0.41; a term of five years;
a range of volatility from 39.13% to 39.15%; risk free rate ranging from 1.38-1.65%; and a dividend yield of 0%. The Warrants vested
immediately. Although the fair value was $30,993, using the appropriate accounting treatment, $28,719 was recorded as debt discount
and fully amortized during 2011 with the amortized amount recorded as interest expense on the accompanying consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2011, VitaMed entered into a business
loan agreement with First United for a $300,000 line of credit for which personal guarantees and cash collateral were required.
Personal guarantees and cash collateral limited to $100,000 each were provided by Mr. Finizio, Mr. Milligan, and Reich Family Limited
LP (See NOTE 9 for more details). In consideration for the personal guarantees and cash collateral, VitaMed issued an aggregate
of 499,998 VitaMed Warrants (or Warrants for an aggregate of 613,713 shares of our Common Stock taking into account the merger).
The ten-year Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end and have an exercise price of
$0.24 per share. On November 13, 2012, the outstanding balance was repaid in full and business loan agreement was amended to reflect
a $100,000 bank line of credit. As part of the amended line of credit, the personal guarantees and cash collateral were removed
for Mr. Finizio and Mr. Milligan. In accordance with the terms of the Warrants, Warrants previously issued to Mr. Finizio and Mr.
Milligan were amended to reflect the amount vested prior to the date of the amended line of credit (179,000 each). At December
31, 2013, an aggregate of 562,571 Warrants were vested. The Warrants, with a fair value of $93,969 ($86,139 after adjusting for
the effect of the amended line of credit ), were valued on the date of the issuance using a term of 10 years; a volatility of 47.89%;
risk free rate of 3.48%; and a dividend yield of 0%. For the years ended December 31, 2013, 2012 and 2011, $2,944, $45,036 and
$38,159, respectively was recorded as loan guaranty costs in other income and expense on the accompanying consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><u>Summary of our Warrant activity and related information for
2011-2013</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number
of Shares Under Warrants</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
Average Exercise Price</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Contractual
Life in Years</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
Intrinsic Value</td>
<td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2010</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 36%; padding-left: 22pt; text-indent: -10pt">Issued</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">3,057,627</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 11%; text-align: right">0.36</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 11%; text-align: right">7.9</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 3%">&#160;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 11%; text-align: right">3,483,691</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 22pt; text-indent: -10pt">Exercised</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 22pt; text-indent: -10pt">Expired</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#9472;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2011</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3,057,627</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">0.36</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">7.9</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">3,483,691</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 22pt; text-indent: -10pt">Issued</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">17,332,500</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1.26</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4.3</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">31,891,150</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 22pt; text-indent: -10pt">Exercised</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">(8,145,486</td>
<td style="text-align: left">)</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">0.38</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 22pt; text-indent: -10pt">Expired</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">(51,142</td>
<td style="padding-bottom: 1pt; text-align: left">)</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">0.24</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2012</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">12,193,499</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1.63</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">17,971,994</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 22pt; text-indent: -10pt">Issued</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,100,000</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">2.72</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4.8</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">5,232,500</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 22pt; text-indent: -10pt">Exercised</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 22pt; text-indent: -10pt">Expired</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#9472;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: right">&#9472;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance
at December 31, 2013</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">14,293,499</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1.79</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3.9</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">48,932,777</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Vested
and Exercisable at December 31, 2013</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right">13,764,710</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1.81</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">3.9</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 2.5pt">&#160;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">46,840,559</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2013, we had warrants outstanding
with exercise prices ranging from $0.24 to $3.20 per share. As of December 31, 2013, unamortized costs associated with warrants
totaled approximately $1,599,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2013, 2012 and 2011 are
set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-left: 10pt; text-indent: -10pt">Weighted average fair value</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0.16</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.72-1.04</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.91-3.48</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">44.64-44.81</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">39.13-51.83</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-10</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimated volatility is a measure of the
amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is
an average of the historical volatility of the stock prices of peer entities whose stock prices were publicly available. Our
calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We
used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during
2011-2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Options to Purchase Common Stock of the
Company</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2009, we adopted the 2009 Long Term Incentive
Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our
company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options
and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation
rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Prior to the merger, no awards had been issued
under the 2009 Plan. As of December 31, 2013 there were 13,632,742 shares of our Common Stock issued under the 2009 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 23, 2012, we adopted the 2012 Stock
Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as
an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of
our company. There are 10,000,000 shares of our Common Stock authorized for issuance thereunder. As of December 31, 2013, there
were 2,650,000 shares issued under the 2012 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The valuation methodology used to determine
the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions
including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions
used in the Black-Scholes Model during the years ended December 31, 2013 are set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2011</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.61-2.23</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">0.91-2.54</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40.77-46.01</font></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">37.92-40.48</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">5.5-6.25</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left; padding-left: 10pt; text-indent: -10pt">Dividend yield</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk-free interest rate assumption is based
upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated
volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award.
Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices
were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the
term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our
stock price. The average expected life is based on the contractual term of the option using the simplified method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of activity under the 2009 and 2012 Plans and related
information for 2011-2013 follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number
    of Shares Under Options</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
    Average Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
    Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
    Intrinsic Value</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2010</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#9472;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; padding-left: 22pt; text-indent: -10pt">Granted<sup>(1)</sup></td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">10,682,218</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">0.16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">7.6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">14,188,484</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 22pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92,057</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 22pt; text-indent: -10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#9472;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#9472;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2011</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,590,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,067,649</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 22pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,121,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,737,530</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 22pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,788</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 22pt; text-indent: -10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#9472;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(46,135</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">Balance at December 31, 2012</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,733,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">26,804,117</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 22pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,583,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,920,981</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 22pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,423</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 22pt; text-indent: -10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 22pt; text-indent: -10pt">Cancelled</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(608,750</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Balance
    at December 31, 2013</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,632,742</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">58,878,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt">Vested
    and Exercisable at December 31, 2013</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,282,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,321,930</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 25%"></div></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><sup>(1)</sup>This includes (i) VitaMed Options
granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to
conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and
October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted
between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options
were reflected in the replacement Options including the number of shares vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, our outstanding options
had exercise prices ranging from $0.10 to $4.67 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Share-based compensation expense for options
recognized in our results for the years ended December&#160;31, 2013, 2012, and 2011 ($3,200,655, $1,832,061, and $183,355, respectively)
is based on awards vested and we estimated no forfeitures. ASC 718-10 requires forfeitures to be estimated at the time of grant
and revised in subsequent periods if actual forfeitures differ from the estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2013, total unrecognized estimated
compensation expense related to unvested options granted prior to that date was approximately $3,921,000, which is expected to
be recognized over a weighted-average period of 1.3 years. No tax benefit was realized due to a continued pattern of operating
losses. At December 31, 2012 and 2011, total unrecognized estimated compensation expense related to unvested options granted prior
to that date was approximately $4,391,000 and $244,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2013, we issued a restricted stock
unit, or the RSU, under our 2012 Plan to an officer for the purchase of 50,000 shares of our Common Stock. The RSU will vest on
April 1, 2014 and has a fair value of $233,500. As of December 31, 2013, we recorded $53,428 of non-cash compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ERJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) (Stock Options)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jan. 06, 2014

</div>
          <div>Subsequent Event</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
        <td class="nump">2,583,677<span></span></td>
        <td class="nump">5,121,250<span></span></td>
        <td class="nump">10,682,218<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">390,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Exercise period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate', window );">Date awards vest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">2014-12-31<span></span></td>
      </tr>
      <tr>
        <td colspan="6"></td>
      </tr>
      <tr>
        <td colspan="6">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">This includes (i) VitaMed Options granted between October 2008 and December 31, 2010 for an aggregate of 7,639,722 Units, of which 16,000 were canceled prior to conversion (or Options for 9,357,561 shares per the Conversion Ratio), (ii) VitaMed Options granted between January 1, 2011 and October 3, 2011 for an aggregate of 621,000 Units (or Options for 762,235 shares per the Conversion Ratio) and (iii) Options granted between October 4, 2011 and December 31, 2011 for an aggregate of 562,422 shares. The terms and conditions of the VitaMed Options were reflected in the replacement Options including the number of shares vested.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the equity-based award vests, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateTimeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHMAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>THE COMPANY (Details Narrative)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 28, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 29, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed</div>
        </th>
        <th class="th">
          <div>Jul. 29, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed</div>
        </th>
        <th class="th">
          <div>Jul. 28, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed

</div>
          <div>Options</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed

</div>
          <div>Warrants</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="nump">99,784,982<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,856<span></span></td>
        <td class="nump">16,575,209<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
        <td class="text">1 for 100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 for 100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PercentageDecreaseInHoldingDueToMerger', window );">Percentage decrease in holding due to merger</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of holding acquired</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in exchange for outstanding membership units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,407,331<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future isssuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">70,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,119,796<span></span></td>
        <td class="nump">1,472,916<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DescriptionOfLockInPeriod', window );">Description of lock in period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18
months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder
agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares
reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble
Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DescriptionOfLockInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to description of lock in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DescriptionOfLockInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PercentageDecreaseInHoldingDueToMerger">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to percentage decrease in holding due to merger.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_PercentageDecreaseInHoldingDueToMerger</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityReverseStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EW2AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) (Warrants, USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesUnderWarrantAbstract', window );"><strong>Number of shares under warrant</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning</a></td>
        <td class="nump">12,193,499<span></span></td>
        <td class="nump">3,057,627<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants issued</a></td>
        <td class="nump">2,100,000<span></span></td>
        <td class="nump">17,332,500<span></span></td>
        <td class="nump">3,057,627<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(8,145,486)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants expired</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrants cancelled</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(51,142)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending</a></td>
        <td class="nump">14,293,499<span></span></td>
        <td class="nump">12,193,499<span></span></td>
        <td class="nump">3,057,627<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Vested and Exercisable</a></td>
        <td class="nump">13,764,710<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Warrants outstanding, beginning</a></td>
        <td class="nump">1.63<span></span></td>
        <td class="nump">0.36<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants', window );">Warrants issued</a></td>
        <td class="nump">2.72<span></span></td>
        <td class="nump">1.26<span></span></td>
        <td class="nump">0.36<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises', window );">Warrants exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures', window );">Warrants cancelled</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Warrants outstanding, ending</a></td>
        <td class="nump">1.79<span></span></td>
        <td class="nump">1.63<span></span></td>
        <td class="nump">0.36<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable', window );">Vested and Exercisable</a></td>
        <td class="nump">1.81<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLife', window );">Warrants outstanding, beginning</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeGrants', window );">Warrants issued</a></td>
        <td class="text">4 years 9 months 18 days<span></span></td>
        <td class="text">4 years 3 months 18 days<span></span></td>
        <td class="text">7 years 10 months 24 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLife', window );">Warrants outstanding, ending</a></td>
        <td class="text">3 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years 10 months 24 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable', window );">Vested and Exercisable</a></td>
        <td class="text">3 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Warrants outstanding, beginning</a></td>
        <td class="nump">$ 17,971,994<span></span></td>
        <td class="nump">$ 3,483,691<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue', window );">Warrants issued</a></td>
        <td class="nump">5,232,500<span></span></td>
        <td class="nump">31,891,150<span></span></td>
        <td class="nump">3,483,691<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Warrants outstanding, ending</a></td>
        <td class="nump">48,932,777<span></span></td>
        <td class="nump">17,971,994<span></span></td>
        <td class="nump">3,483,691<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Vested and Exercisable</a></td>
        <td class="nump">$ 46,840,559<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AggregateIntrinsicValueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average remaining contractual life of warrants outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRighstContractualLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average remaining contractual life of warrants granted in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRighstContractualLifeGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average remaining contractual life of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants exercised in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants cancelled or forfeited in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants granted in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exercise price of each class of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedAndExercisable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSharesUnderWarrantAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_NumberOfSharesUnderWarrantAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WeightedAverageExercisePriceAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WeightedAverageRemainingContractualLifeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of non-option equity instruments granted to participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 15 &#150; SELECTED QUARTERLY FINANCIAL
DATA (UNAUDITED)</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years&#160;2013&#160;and&#160;2012&#160;is
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2013
    Quarters</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-indent: -10pt; padding-left: 10pt; width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">(In
    thousands, except per share)</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">4th</font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Revenues</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,537</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,081</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,295</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,863</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    profit</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,157</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,617</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,646</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">2,396</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Net
    loss</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,376</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(6,009</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(7,673</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(8,361</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Loss
    per common share, basic and diluted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.05</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="14" style="border-bottom: black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2012
    Quarters</font></td>
    <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-indent: -10pt; padding-left: 10pt; width: 40%"><font style="font: 10pt Times New Roman, Times, Serif">(In
    thousands, except per share)</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">1<sup>st</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">2<sup>nd</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">3<sup>rd</sup></font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt; width: 2%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 11%"><font style="font: 10pt Times New Roman, Times, Serif">4th</font></td>
    <td style="text-align: left; padding-bottom: 1pt; width: 1%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Revenues</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">722</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">819</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,036</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,241</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Gross
    profit</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">386</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">447</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">729</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">908</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Net
    loss</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(13,290</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(11,850</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(4,253</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(5,727</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font: 10pt Times New Roman, Times, Serif">Loss
    per common share, basic and diluted</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.16</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.14</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.04</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(0.06</font></td>
    <td style="text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25249566&amp;loc=d3e1280-108306<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Equipment</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">108,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">67,668</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,625</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,980</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,273</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(93,765</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(60,600</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">TOTAL FIXED ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">61,318</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">65,673</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETRFO">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="4"></th>
        <th class="th" colspan="3"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>May 31, 2013

</div>
          <div>Sancilio &amp; Company Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Sancilio &amp; Company Warrants 1st Installments</div>
        </th>
        <th class="th">
          <div>May 11, 2013

</div>
          <div>Sancilio &amp; Company Warrants 1st Installments</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013

</div>
          <div>Sancilio &amp; Company Warrants 2nd Installments</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sancilio &amp; Company Warrants 2nd Installments</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sancilio &amp; Company Warrants 3rd Installments</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Modification Warrants</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012

</div>
          <div>Warrants Issued to Unaffiliated Individuals

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>May 31, 2012

</div>
          <div>Warrants Issued to Unaffiliated Entity</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Warrants Issued to Unaffiliated Entity</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrants Issued to Unaffiliated Entity</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes/Warrants</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>June 2012 Notes/Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes/Warrants 1st Issue</div>
        </th>
        <th class="th">
          <div>Jun. 19, 2012

</div>
          <div>June 2012 Notes/Warrants 2nd Issue</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Warrants Issued to Unaffiliated Individuals

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrants Issued to Unrelated Individual for Consulting Services</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrants Issued to Unrelated Individual for Consulting Services</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2011

</div>
          <div>Warrants Issued Officers</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Warrants Issued Officers</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrants Issued Officers</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrants Issued Officers</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrants Issued to Unrelated Entity for Consulting Services</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Warrants Issued to Unrelated Entity for Consulting Services</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Vested non forfeitable VitaMed Warrants</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>Vested non forfeitable VitaMed Warrants</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Vested non forfeitable VitaMed Warrants

</div>
          <div>Number</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Vested non forfeitable VitaMed Warrants</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Vested non forfeitable VitaMed Warrants</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Vested non forfeitable VitaMed Warrants</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Multiple Advance Revolving Credit Note (Plato Warrant)</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Feb. 24, 2012

</div>
          <div>February 2012 Notes/ Warrants</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Minimum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Maximum</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Weighted Average</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
        <td class="nump">$ 14,293,499<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
        <td class="text">3 years 10 months 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants (in dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.00<span></span></td>
        <td class="nump">3.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="nump">0.41<span></span></td>
        <td class="nump">0.24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.41<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.38<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.41<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.24<span></span></td>
        <td class="nump">3.20<span></span></td>
        <td class="nump">1.79<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnamortizedCostsOfWarrants', window );">Unamortized costs of warrants</a></td>
        <td class="nump">1,599,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">850,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">283,333<span></span></td>
        <td class="nump">283,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">283,334<span></span></td>
        <td class="nump">3,314,700<span></span></td>
        <td class="nump">31,000<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,000,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="nump">1,500<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="nump">600,000<span></span></td>
        <td class="nump">7,158<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="nump">184,211<span></span></td>
        <td class="nump">184,211<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,969<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,685,300<span></span></td>
        <td class="nump">3,314,700<span></span></td>
        <td class="nump">613,718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 31,
				 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jun. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">405,066<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">462,196<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,124,873<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,532,228<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,424,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">338<span></span></td>
        <td class="nump">338<span></span></td>
        <td class="nump">133,045<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,980<span></span></td>
        <td class="nump">25,980<span></span></td>
        <td class="nump">12,548<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,548<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,711,956<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,505,247<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,993<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45.89%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45.84%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44.50%<span></span></td>
        <td class="nump">44.81%<span></span></td>
        <td class="nump">44.71%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44.64%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44.78%<span></span></td>
        <td class="nump">51.83%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45.94%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41.04%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39.44%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47.89%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44.29%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45.89%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.41%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89.00%<span></span></td>
        <td class="nump">1.04%<span></span></td>
        <td class="nump">0.74%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.75%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.72%<span></span></td>
        <td class="nump">0.91%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2.23%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.08%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.56%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.48%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.88%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,532,228<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">547,210<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">260,022<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,719<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
        <td class="nump">260,022<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,451,934<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Number of shares purchased forfeit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">833,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights', window );">Valuation method of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Black-Scholes Model<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpenseRecognized', window );">Non-cash compensation recongised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">405,066<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">77,034<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">360,528<span></span></td>
        <td class="nump">218,045<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,158<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense-short term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">154,068<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">360,528<span></span></td>
        <td class="nump">360,528<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense-long term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">308,128<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">593,127<span></span></td>
        <td class="nump">593,127<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">323<span></span></td>
        <td class="nump">323<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod', window );">Fair value of warrants by relative fair value calculation method</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,649,890<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RemainingAmortizationOfFinancingCostsAndDiscounts', window );">Remaining amortization deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,102,680<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">859,647<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumbersOfUnaffiliatedIndividuals', window );">Number of unaffiliated individuals</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,736<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,656<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights', window );">Description of vesting period of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Warrants vest over a 44-month period beginning on November 21, 2011 (or 13,636 shares for months 1-43 and 13,652 shares for month 44).<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Warrants vested at the rate of an aggregate of 76,714 shares per calendar quarter end.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AgreementCoverPeriod', window );">Agreement covering period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FinancingExpense', window );">Financing expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,980<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AmortizationResearchAndDevelopmentExpense', window );">Amortization research and development expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,548<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
        <td class="nump">13,551,263<span></span></td>
        <td class="nump">4,492,362<span></span></td>
        <td class="nump">107,241<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">6,936<span></span></td>
        <td class="nump">5,612<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Minimum volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39.13%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Maximum volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39.15%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.38%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum risk free rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.65%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="nump">179,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,220<span></span></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedDuringPeriodShares', window );">Warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">613,713<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfWarrantsVested', window );">Number of warrants vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">562,571<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LoanGuarantyCosts', window );">Loan guaranty costs</a></td>
        <td class="nump">$ 2,944<span></span></td>
        <td class="nump">$ 45,036<span></span></td>
        <td class="nump">$ 38,159<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,944<span></span></td>
        <td class="nump">$ 45,036<span></span></td>
        <td class="nump">$ 38,159<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AgreementCoverPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item provides the agreement covering period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AgreementCoverPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AmortizationResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to amortization research and development expenseduring the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AmortizationResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpenseRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to non cash compensation expenses of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExpenseRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are expired in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of warrants or rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightFairValueOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refer to numbers of shares forfeit during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to valuation method of warrants or rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightValuationMethodOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the warrants or rights are vesting in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to description of warrants and rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DescriptionClassOfWarrantOrRightVestingPeriodOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to fair value of awards by a calculation method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_FairValueOfWarrantsByRelativeFairValueCalculationMethod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FinancingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to financing expense related to debt during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_FinancingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LoanGuarantyCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expense incurred for loan guaranty costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_LoanGuarantyCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfWarrantsVested">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to numbers of warrants vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_NumberOfWarrantsVested</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumbersOfUnaffiliatedIndividuals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to numbers of entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_NumbersOfUnaffiliatedIndividuals</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RemainingAmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to remaining amortization deferred financing costs during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_RemainingAmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnamortizedCostsOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to unamortized costs associated with warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_UnamortizedCostsOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item provides the weighted-average contractual remaining life of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Numbers of shares warrants for common stock issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedDuringPeriodShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCostsAndDiscounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28567-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
        <td class="nump">$ 10,262<span></span></td>
        <td class="nump">$ 28,776<span></span></td>
        <td class="nump">$ 29,159<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHRDI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid in Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2010</a></td>
        <td class="nump">$ 55,487<span></span></td>
        <td class="nump">$ 4,988,637<span></span></td>
        <td class="num">$ (4,079,713)<span></span></td>
        <td class="nump">$ 964,411<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2010</a></td>
        <td class="nump">55,487,321<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement', window );">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement</a></td>
        <td class="nump">166<span></span></td>
        <td class="num">(255,919)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(255,753)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares', window );">Effect of merger and recapitalization pursuant to execution of Security Exchange Agreement, shares</a></td>
        <td class="nump">165,879<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump">5,552<span></span></td>
        <td class="nump">1,701,448<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,707,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump">5,551,589<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Shares issued in exchange for debt</a></td>
        <td class="nump">21,682<span></span></td>
        <td class="nump">8,217,455<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,239,137<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued in exchange for debt, shares</a></td>
        <td class="nump">21,681,958<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump">92<span></span></td>
        <td class="nump">17,158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,250<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump">92,057<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options issued as compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">183,355<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">183,355<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">190,280<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">190,280<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties', window );">Warrants issued for loan guaranty costs-related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,969<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,969<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancingCosts', window );">Warrants issued for financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,362<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,362<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsFinancingCostRelatedParties', window );">Warrants issued as financing costs-related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,338<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,338<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsCompensationRelatedParty', window );">Warrants issued as compensation-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,158<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(12,913,365)<span></span></td>
        <td class="num">(12,913,365)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2011</a></td>
        <td class="nump">82,979<span></span></td>
        <td class="nump">15,198,241<span></span></td>
        <td class="num">(16,993,078)<span></span></td>
        <td class="num">(1,711,858)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2011</a></td>
        <td class="nump">82,978,804<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump">3,954<span></span></td>
        <td class="nump">7,891,531<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,895,485<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump">3,953,489<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Shares issued in exchange for debt</a></td>
        <td class="nump">2,775<span></span></td>
        <td class="nump">1,051,882<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,054,657<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued in exchange for debt, shares</a></td>
        <td class="nump">2,775,415<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump">1,932<span></span></td>
        <td class="nump">189,068<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">191,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump">1,931,788<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
        <td class="nump">8,145<span></span></td>
        <td class="nump">3,093,855<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,102,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
        <td class="nump">8,145,486<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options issued as compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,832,061<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,832,061<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,563,620<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,563,620<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancingCosts', window );">Warrants issued for financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,014,784<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,014,784<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsCompensationRelatedParty', window );">Warrants issued as compensation-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,284<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Cancellation of warrants issued for loan guaranty costs-related parties</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,830)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(7,830)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,716,504<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,716,504<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(35,120,235)<span></span></td>
        <td class="num">(35,120,235)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2012</a></td>
        <td class="nump">99,785<span></span></td>
        <td class="nump">50,580,400<span></span></td>
        <td class="num">(52,113,313)<span></span></td>
        <td class="num">(1,433,128)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2012</a></td>
        <td class="nump">99,784,982<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,784,982<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in private placement, net of cost</a></td>
        <td class="nump">45,117<span></span></td>
        <td class="nump">78,605,236<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">78,650,353<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in private placement, net of cost, shares</a></td>
        <td class="nump">45,116,352<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
        <td class="nump">75<span></span></td>
        <td class="nump">30,835<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,910<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
        <td class="nump">75,423<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices', window );">Warrants issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">867,262<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">867,262<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Employee Share Based Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,254,083<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,254,083<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancingCosts', window );">Warrants issued for financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,711,956<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,711,956<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedAsCompensationRelatedParty', window );">Warrants issued as compensation-related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,284<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,284<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(28,419,313)<span></span></td>
        <td class="num">(28,419,313)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2013</a></td>
        <td class="nump">$ 144,977<span></span></td>
        <td class="nump">$ 135,086,056<span></span></td>
        <td class="num">$ (80,532,626)<span></span></td>
        <td class="nump">$ 54,698,407<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2013</a></td>
        <td class="nump">144,976,757<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,976,757<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the effect of merger and recapitalization pursuant to the execution of a security exchange agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the merger and recapitalization pursuant to secuirty exchnage agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_EffectOfMergerAndRecapitalizationPursuantToExecutionOfSecurityExchangeAgreementShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedAsCompensationRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedAsCompensationRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedAsFinancingCostRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedAsFinancingCostRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedForFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_WarrantsIssuedForLoanGuarantyCostsRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 51<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32707879&amp;loc=d3e34017-109320<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other increase (decrease) in additional paid in capital (APIC).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to employee stock purchase programs during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568447-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4568740-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4I<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31814832&amp;loc=SL4590271-111686<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 4 &#150; OTHER CURRENT ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="width: 90%; border-collapse: collapse; font-size: 10pt; margin-left: 36pt">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">December
    31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2013</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font: normal 10pt Times New Roman, Times, Serif">2012</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 62%"><font style="font: normal 10pt Times New Roman, Times, Serif">Prepaid
    R&#38;D costs</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">1,267,588</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 15%"><font style="font: normal 10pt Times New Roman, Times, Serif">189,375</font></td>
    <td style="text-align: left; width: 1%"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Prepaid
    consulting</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">530,596</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">432,216</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Deferred
    financing costs</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">260,022</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Other
    receivable &#150; related party</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">249,981</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font-size: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Prepaid
    other</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">169,528</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">127,403</font></td>
    <td style="text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">Prepaid
    guaranty costs</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#9472;</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">2,944</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 22pt"><font style="font: normal 10pt Times New Roman, Times, Serif">TOTAL
    OTHER CURRENT ASSETS</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">2,477,715</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font: normal 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font: normal 10pt Times New Roman, Times, Serif">751,938</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font: normal 10pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCurrentAssetsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVUDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2011

</div>
          <div>Agreement and Plan of Merger with VitaMed</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Stock Purchase Agreement With Pernix Therapeutics LLC</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Stock Purchase Agreement With Pernix Therapeutics LLC</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Stock Purchase Agreement With Pernix Therapeutics LLC</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Non-affiliated third party</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2012

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Brian Bernick</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>VitaMed Promissory Notes

</div>
          <div>Reich Family Limited LP</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Notes Issued to Mr. Finizio And Mr. Milligan</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Notes Issued to Mr. Finizio</div>
        </th>
        <th class="th">
          <div>Oct. 04, 2012

</div>
          <div>Notes Issued to Mr. Milligan</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 179,000<span></span></td>
        <td class="nump">$ 179,000<span></span></td>
        <td class="nump">$ 179,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 299,220<span></span></td>
        <td class="nump">$ 300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="nump">$ 100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtInstrumentRemainingFaceAmount', window );">Aggregate remaining principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
        <td class="nump">4,691,847<span></span></td>
        <td class="nump">1,850,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Acrued interest paid</a></td>
        <td class="nump">212,853<span></span></td>
        <td class="nump">17,253<span></span></td>
        <td class="nump">696<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,160<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">888<span></span></td>
        <td class="nump">1,519<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future isssuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">70,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DescriptionOfLockInPeriod', window );">Description of lock in period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Each stockholder agreed that during a lock-up period from the date of the lock-up agreements until 18
months thereafter they would not make or cause any sale of our common stock. After the completion, each stockholder
agreed not to sell or dispose of more than 2.5% of the stockholder's aggregate Common Stock or shares
reserved for issuance under stock options and warrants per quarter over the following 12-month period, or the Dribble
Out Period. Upon the completion of the Dribble Out Period, the Agreements will terminate.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transaction amounts</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,632<span></span></td>
        <td class="nump">20,669<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">404,000<span></span></td>
        <td class="nump">19,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Receivables outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,272<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">46,000<span></span></td>
        <td class="nump">308,000<span></span></td>
        <td class="nump">19,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LegalFeeReimbursement', window );">Legal fee reimbursement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 249,981<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">613,718<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtInstrumentRemainingFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to balance amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DebtInstrumentRemainingFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DescriptionOfLockInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to description of lock in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DescriptionOfLockInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LegalFeeReimbursement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Refers to reimbursment of legal fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_LegalFeeReimbursement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOfficersOrStockholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 3<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueFromOfficersOrStockholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transactions with related party during the financial reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionAmountsOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PREPAID EXPENSE (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense, Current [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of prepaid expense</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="margin-left: 36pt; border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">December 31,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2013</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2012</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid R &#38; D costs</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">824,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">953,655</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Prepaid manufacturing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">899,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Accreted prepaid costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,234</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#9472;</font></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 22pt; text-indent: -10pt">TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,750,455</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">953,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of noncurrent assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssets</Role>
      <ShortName>FIXED ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpense</Role>
      <ShortName>PREPAID EXPENSE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - FIXED ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsTables</Role>
      <ShortName>FIXED ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - PREPAID EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseTables</Role>
      <ShortName>PREPAID EXPENSE (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CompanyDetailsNarrative</Role>
      <ShortName>THE COMPANY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - FIXED ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetailsNarrative</Role>
      <ShortName>FIXED ASSETS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - FIXED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsDetails</Role>
      <ShortName>FIXED ASSETS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - PREPAID EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseDetails</Role>
      <ShortName>PREPAID EXPENSE (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - INTANGIBLE ASSETS (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details )</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - OTHER CURRENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetailsNarrative</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - NOTES PAYABLE (Details Narrative 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayableDetailsNarrative1</Role>
      <ShortName>NOTES PAYABLE (Details Narrative 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 00000002 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jul. 29, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jul. 28, 2011'</Log>
    <Log type="Info">Process Flow-Through: 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>txmd-20131231.xml</File>
    <File>txmd-20131231.xsd</File>
    <File>txmd-20131231_cal.xml</File>
    <File>txmd-20131231_def.xml</File>
    <File>txmd-20131231_lab.xml</File>
    <File>txmd-20131231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FIXED ASSETS (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
        <td class="nump">$ 47,883<span></span></td>
        <td class="nump">$ 27,484<span></span></td>
        <td class="nump">$ 25,686<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Decrease accumulated depreciation</a></td>
        <td class="nump">$ 11,980<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Decrease amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>txmd_DecreaseAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>txmd_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><u>NOTE 14 &#150; COMMITMENTS AND CONTINGENCIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Operating Lease</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease administrative office space in Boca
Raton, Florida pursuant to a 63 month non-cancelable operating lease commencing on July 1, 2013 and expiring on September 30, 2018.
The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and
sales tax, for a total future minimum payments over the life of the lease of $1,899,414.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The straight line rental expense related to
our current lease totaled $180,894 for the six months ended December 31, 2013 offset by rent income of $32,963. The rental expense
related to our prior lease which expired June 30, 2013 totaled $60,168 for the six months ended June 30, 2013, and $106,315 and
$122,752 for the years ended December 31, 2012 and 2011, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2013, future minimum rental payments are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" align="center" style="width: 60%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Years
    Ending December 31,</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: center; width: 77%"><font style="font-family: Times New Roman, Times, Serif">2014</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; width: 18%"><font style="font-family: Times New Roman, Times, Serif">316,039</font></td>
    <td style="text-align: left; width: 1%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">2015</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">371,240</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">2016</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">382,377</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">2017</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">393,848</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif">2018</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">302,748</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Total
    minimum lease payments</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,766,252</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Noncancelable
    sub-lease income</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">(38,956</font></td>
    <td style="text-align: left; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif">)</font></td></tr>
<tr style="background-color: white; vertical-align: bottom">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif">Net
    minimum lease payments</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.5pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif">1,727,296</font></td>
    <td style="text-align: left; padding-bottom: 2.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td></tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
